2018”N“x –k—˘‘ĺŠwˆăŠw•”E‘ĺŠw•a‰@Œ¤‹†‹ĆŃW(HTML”Ĺ)


i’FŒ´–{‚ĹŒäŠm”F‰ş‚ł‚˘j



‰đ–UŠw (Źě’PˆĘ)

[Šwp˜_•ś]

110001. [Œ´’˜] A new targeted capture method using bacterial artificial chromosome (BAC) libraries as baits for sequencing relatively large genes. Koganebuchi K, Gakuhari T, Takeshima H, Sato K, Fujii K, Kumabe T, Kasagi S, Sato T, Tajima A, Shibata H, Ogawa M1, Oota H1: PLoS One 2018/7; 13 (7): e0200170. (ŹěŒł”V1, ‘ž“c”ŽŽ÷1: 1‰đ–U)

110002. [Œ´’˜] The prehistoric peopling of Southeast Asia. McColl H, Racimo F, Vinner L, Demeter F, Gakuhari T, Moreno-Mayar JV, van Driem G, Gram Wilken U, Seguin-Orlando A, de la Fuente Castro C, Wasef S, Shoocongdej R, Souksavatdy V, Sayavongkhamdy T, Saidin MM, Allentoft ME, Sato T, Malaspinas AS, Aghakhanian FA, Korneliussen T, Prohaska A, Margaryan A, de Barros Damgaard P, Kaewsutthi S, Lertrit P, Nguyen TMH, Hung HC, Minh Tran T, Nghia Truong H, Nguyen GH, Shahidan S, Wiradnyana K, Matsumae H, Shigehara N, Yoneda M, Ishida H, Masuyama T, Yamada Y, Tajima A, Shibata H, Toyoda A, Hanihara T, Nakagome S, Deviese T, Bacon AM, Duringer P, Ponche JL, Shackelford L, Patole-Edoumba E, Nguyen AT, Bellina-Pryce B, Galipaud JC, Kinaston R, Buckley H, Pottier C, Rasmussen S, Higham T, Foley RA, Lahr MM, Orlando L ?Sikora M, Phipps ME, Oota H1, Higham C, Lambert DM, Willerslev E: Science 2018/7; 361 (6397): 88-92. (‘ž“c”ŽŽ÷1: 1‰đ–U)

110003. [Œ´’˜] Abnormal nuclear morphology is independent of longevity in a zmpste24-deficient fish model of Hutchinson-Gilford progeria syndrome (HGPS). Tonoyama Y, Shinya M, Toyoda A, Kitano T, Oga A, Nishimaki T1, Katsumura T, Oota H2, Wan MT, Yip BWP, Helen MOL, Chisada S, Deguchi T, Au DWT, Naruse K, Kamei Y, Taniguchi Y: Comp Biochem Physiol C Toxicol Pharmacol 2018/7; 209: 54-62. (źę r”V1, ‘ž“c”ŽŽ÷2: 1Œ`‘ÔŒn, 2‰đ–U)

540001. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)]y“Á•Ę“Wul‘́v_”é‚Ö‚Ě’§íz“ę•śl‚ĚŽpƒQƒmƒ€‚Ş‚ ‚Ô‚čo‚ˇ. ‘ž“c”ŽŽ÷ (‰đ–U): ’Š“úV•ˇ 2018/5/27.

540002. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)]yƒTƒCƒGƒ“ƒX–ĘŒfÚzDNA’Ç‚˘ŒĂ‘ăl‚É”—‚é@“ę•śl“Œ“ěƒAƒWƒA‹NŒš‚Š. ‘ž“c”ŽŽ÷ (‰đ–U): “ú–{ŒoĎV•ˇ’ŠŠ§ 2018/9/2.

540003. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)]yƒfƒCƒ”ƒBƒbƒgEƒ‰ƒCƒN’˜uŒđŽG‚ˇ‚él—ށv‘•]zŒĂ‘ăDNA‚ŞŽŚ‚ˇl‚Ě—ˆ—đ. ‘ž“c”ŽŽ÷ (‰đ–U): “ú–{ŒoĎV•ˇ’ŠŠ§@2018/9/29.

[’˜@‘]

620001. [Šwp‘ (’P’˜)]yˆâ“`l—ŢŠw“ü–ĺ|ƒ`ƒ“ƒMƒXĽƒnƒ“‚ĚDNA‚͉˝‚đŒę‚é‚Šz‘ž“c”ŽŽ÷ (‰đ–U), ‚ż‚­‚ܐV‘ (’}–€‘–[), “Œ‹ž, 2018/5”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713001. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Human population history in the southwestern coastal region of Sea of Okhotsk, inferred from ancient genome analysis. Sato T, Adachi N, Kimura R, Yoneda M, Oota H1, Tajima A, Toyoda A, Matsumae H, Koganebuchi K, Shimizu KK, Hanihara T, Weber A, Kato H, Ishida H: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

713002. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Molecular mechanisms and evolutionary processes underlying genetic assimilation in the digestive tract of mdaka. Katsumura T, Sato S, Yamashita K, Oda S, Gakuhari T, Tanaka S, Imai T, Yosiura Y, Takeshima H, Hasiguchi Y, Mitani H, Ogawa M1, Takeuchi H, Oota H1: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (ŹěŒł”V1, ‘ž“c”ŽŽ÷1: 1‰đ–U)

713003. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) complex human histories of Northeast Asia revealed by correlaions between genes, language, and music. Matsumae H, Savage PE, Bickel B, Currie TE, Sato T, Tajima A, Stoneking M, Shimizu KK, Gillan M, Brown S, Oota H1: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

713004. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Whole genome analysis of the Jomon remain reveals deep lineage of East Eurasian populations. Gakuhari T, Sikora M, Rasmussen S, Allentoft M, Sato T, Kornrliussen T, Yonda M, Ishida H, Yamada Y, Shibata H, Nakagome S, Willerslev E, Oota H1: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

713005. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) The Transition to Farming in Eneolithic (Copper Age) Ukraine was Largely Driven by Population Replacement. Schmidt RW, Fernandes D, Karsten J, Harper T, Madden G, Ledogar S, Sokhatsky M, Oota H1, Pinhasi R: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

713006. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) A new targeted-capture method using bacteria artificial chromosome (BAC) as baits exclusively developed for sequencing relatively large loci of ancient DNA. Koganebuchi K, Gakuhari T, Takeshima H, Kasagi S, Sato T, Tajima A, Shibata H, Ogawa M1, Oota H1: The Society for Molecular Biology and Evolution, Annual Meeting (•ŞŽqś•¨Šw‚Ɛi‰ť‚̍‘ŰŠw‰ď2018”N”NŽŸ‘ĺ‰ď) (2018/7/8-12), Yokohama, Japan. (ŹěŒł”V1, ‘ž“c”ŽŽ÷1: 1‰đ–U)

713007. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Human genetic diversity and peopling history in East and Southeast Asia. Sawafuji R, Kimura R, Oota H1, Ishda H: PaleoAsia 2018 (The International Workshop, Cultural History of PaleoAsia) (2018/12/15-18), Kyoto, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

713008. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Genome-wide SNP analyses of ethnic groups in Thailand. Matsudaira K, Ishida T, Settheetham-Ishida W, Duangchan P, Pookajorn S, Tiwawech D, Nishida N, Verdu P, Oota H1: PaleoAsia 2018 (The International Workshop, Cultural History of PaleoAsia) (2018/12/15-18), Kyoto, Japan. (‘ž“c”ŽŽ÷1: 1‰đ–U)

723001. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒVƒƒTƒP’t‹›‚Ě‘Sg‘gD•W–{ěť‚Ć‚ť‚Ě‹łˆç“IŠˆ—p–@. źę r”V1, ´…ŒbŽq, Ÿ‘şŒ[Žj, ˛X–Ř—LŒŤ, ‰ŞˆŔ@ŒM, Ź‰ęŒú“ż, ”ö“cł“ń, ‘ž“c”ŽŽ÷2, ŹěŒł”V2 (1Œ`‘ÔŒn, 2‰đ–U): “ú–{—‰Č‹łˆçŠw‰ď‘ć68‰ń‘S‘‘ĺ‰ď (ŠâŽč‘ĺ‰ď) (2018/8/3-5), ŠâŽč.

723002. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LAMP–@‚đŽg—p‚ľ‚˝‰đ–U‘Ě‚É‚¨‚Ż‚錋Šj‹Ű‚̐v‘ŹŒŸ¸. ŽO‰Ył–ž1, Vˆä—Y‘ž1, ‹Ę–؉p–ž2, ‘ž“c”ŽŽ÷1, ŹěŒł”V1 (1‰đ–U, 2—Տ°‰đ–U‹łˆç): ‘ć124‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2019/3/27-29), VŠƒ.

723003. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒĂ‘ăƒQƒmƒ€‚Ş‰đ‚Ť–ž‚Š‚ˇƒzƒ‚EƒTƒsƒGƒ“ƒX‚ĚŠgŽU. ‘ž“c”ŽŽ÷ (‰đ–U): “ú–{l—Ţˆâ“`Šw‰ď‘ć63‰ń‘ĺ‰ď (2018/10/10-13), ‰Ą•l.

723004. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) A technical study of DNA extraction and analysis from feces and coprolites. Wakabayashi K, Uno M, Kumagai M, Sawafuji R, Gakuhari T, Inada K, Ajimoto M, Umezaki M, Yoneda M, ŹěŒł”V1, ‘ž“c”ŽŽ÷1 (1‰đ–U): ‘ć72‰ń“ú–{l—ŢŠw‰ď‘ĺ‰ď (2018/10/19-22), ŽO“‡.

723005. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒQƒmƒ€î•ń‚É‚ŕ‚Ć‚Ă‚­l—ŢŠw‚Ć•śŒn‰Č–Ú. ‘ž“c”ŽŽ÷ (‰đ–U): ‘ć72‰ń“ú–{l—ŢŠw‰ď‘ĺ‰ď (2018/10/19-22), ŽO“‡.

723006. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÉě’ÁE“ę•ślƒQƒmƒ€‚Š‚ç‚Ý‚˝“ŒƒAƒWƒAl—ޏW’c‚ĚŒ`ŹŽj. Šo’Ł—˛Žj, ’†žŽ Ž÷, Martin Sikora, Simon Rasmussen, Morten Allentoft, ˛“ĄäŠ°, Thorfinn Korneliussen, Bl‡naid N’ Chuinneag‡in, ź‘O‚Đ‚ë‚Ý, Ź‹ŕŸş‰Ŕ], Ryan Schmidt, –ÎŒ´Mś, •Ä“c@ő, –Ř‘ş—ş‰î, Î“c@”Ł, ‘ŽR’ő”V, ŽR“cNO, “c“‡@“Ö, ŽÄ“cO‹I, –L“c@“Ö, űŒ´P•F, Eske Willerslev, ‘ž“c”ŽŽ÷1 (1‰đ–U): ‘ć72‰ń“ú–{l—ŢŠw‰ď‘ĺ‰ď (2018/10/19-22), ŽO“‡.

723007. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒqƒgŠgŽU‚ÉŠÖ‚ˇ‚ég–`ŒŻˆâ“`Žq‰źŕh‚Ěƒƒ_ƒJ‚đ—p‚˘‚˝ŒŸŘ. Ÿ‘şŒ[Žj, ”ö“cł“ń, ă‰ŞŽj‹, ŽO’JŒ[Žu, ‘ž“c”ŽŽ÷1, ’|“ŕG–ž (1‰đ–U): ‘ć72‰ń“ú–{l—ŢŠw‰ď‘ĺ‰ď (2018/10/19-22), ŽO“‡.

723008. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ_ƒJÁ‰ťŠÇ‚Ĺ‚Ý‚ç‚ę‚éPlasticity-first evolution‚Ě•ŞŽqƒƒJƒjƒYƒ€‚Ć‚ť‚̏W’cˆâ“`Šw“IƒvƒƒZƒX. Ÿ‘şŒ[Žj, ˛“Ą@Ž, ŽR‰ş‰Ŕ“ß, ”ö“cł“ń, Šo’Ł—˛Žj, “c’†ăđĺ, “Ą’J˜aŽq, źę r”V1, Ąˆä@ł, ‹g‰YNŽő, •“‡O•F, ‹´ŒűN”V, ŽO’JŒ[Žu, ŹěŒł”V2, ’|“ŕG–ž, ‘ž“c”ŽŽ÷2 (1Œ`‘ÔŒn, 2‰đ–U): ‘ć124‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2019/3/27-29), VŠƒ.

723009. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Pelvic-fin brooding (• ƒrƒŒ•Űˆç) ‚ˇ‚éƒGƒo[ƒVƒƒ_ƒJ‚Ě”÷×Œ`‘ÔŠw“I‚ČŒŸ“˘. ź–Šr”V1, …–ě“W•q, Šâź‘éŽi, Ÿ‘şŒ[Žj, Kawilarang WA Maseng, ŽR•˝Žő’q, ”ö“cł“ń, Ź‰ęŒú“ż, ‘ž“c”ŽŽ÷2, ŹěŒł”V2 (1Œ`‘ÔŒn, 2‰đ–U): ‘ć124‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2019/3/27-29), VŠƒ.

732001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) “ę•ślƒQƒmƒ€‰đÍ‚Š‚猊‚˝ƒzƒ‚EƒTƒsƒGƒ“ƒX‚Ě“ŒƒAƒWƒA‚Ö‚ĚŠgŽU. ‘ž“c”ŽŽ÷ (‰đ–U): “Œ‹ž‘ĺŠw—Šw•”l—ŢŠw‰‰K^l—ŢŠwƒZƒ~ƒi[III (l—ŢŠw’k˜b‰ď), (2018/6/22), “Œ‹ž.

732002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yDNA‚Š‚ç‚ł‚Ž‚éŒĂ‘ă‚Ě“ú–{—ń“‡z”_kŽĐ‰ď‚̐l‚Ń‚Ć‚ĆDNAŒ¤‹†. ‘ž“c”ŽŽ÷ (‰đ–U): ‘ć62‰ńlŒĂŠwƒ[ƒ~ƒi[ƒ‹ (2018/6/29), “Œ‹ž.

732003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)‚Z‹łˆç‚Ɛl—ŢŠw. ‘ž“c”ŽŽ÷ (‰đ–U): ‚“™ŠwZ‹łˆçŒ¤‹†‰ď—‰Č (ś•¨) Œ¤‹†‰ď(2018/11/20), VŠƒ.

733001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒzƒ‚EƒTƒsƒGƒ“ƒX‚Ě“ŒƒAƒWƒA‚Ö‚ĚŠgŽU`ŒĂ‘ăƒQƒmƒ€‰đÍ‚Š‚ç‚Ě’­–]. ‘ž“c”ŽŽ÷ (‰đ–U): ƒpƒŒƒIƒAƒWƒA•ś‰ťŽjŠw‘ć5‰ńŒ¤‹†‘ĺ‰ď (2018/5/12-13), –źŒĂ‰Ž.

733002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒzƒ‚EƒTƒsƒGƒ“ƒX‚Ě“ŒƒAƒWƒA‚Ö‚ĚŠgŽU‚ÉŠÖ‚ˇ‚é“ě–k2Œo˜Hƒ‚ƒfƒ‹‚ĚŒŸŘ. ‘ž“c”ŽŽ÷ (‰đ–U): ƒpƒŒƒIƒAƒWƒA•ś‰ťŠwƒvƒƒWƒFƒNƒgŒv‰ćŒ¤‹†B02 2018”N“x”ljď‹c (2018/5/15-16), “Œ‹ž.

733003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) “ŒƒAƒWƒAE“Œ“ěƒAƒWƒA‚Ěƒqƒg‚Ěˆâ“`“I‘˝—lŤ‚Ć‚ť‚ĚŒ`Ź‰ß’ö. ŕV“Ą‚č‚Š‚˘, –Ř‘ş—ş‰î, ‘ž“c”ŽŽ÷1, Î“c@”Ł (1‰đ–U): ƒpƒŒƒIƒAƒWƒA•ś‰ťŽjŠw‘ć6‰ńŒ¤‹†‘ĺ‰ď (2018/11/17-18), “Œ‹ž.

733004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒ^ƒC‚̏­”–Ż‘°‚ĚƒQƒmƒ€–Ô—…“ISNPƒf[ƒ^‰đÍ. ź•˝ˆęŹ, Î“c‹M•ś, Wannapa Settheetham-Ishida, Phaiboon Duangchan, Surin Pookajorn, Danai Tiwawech, ź“c“މ›, Paul Verdu, ‘ž“c”ŽŽ÷1 (1‰đ–U): ƒpƒŒƒIƒAƒWƒA•ś‰ťŽjŠw‘ć6‰ńŒ¤‹†‘ĺ‰ď (2018/11/17-18), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-540001. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)]yƒTƒCƒGƒ“ƒXBOXz“ú–{l‚Ěƒ‹[ƒc’T‚é@DNA‚Ě30”N. ‘ž“c”ŽŽ÷ (‰đ–U): “Ç”„V•ˇ 2018/1/12.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723001. [Šw‰ď (‘S‘j] (ƒ|ƒXƒ^[) ƒƒ_ƒJ (Oryzias latipes) ‚Ě‘Sg‘gD•W–{‚Š‚猊‚é‘Ě“ŕŽó¸. ź–Šr”V1, ‘ĺX‹`—˛, Ÿ‘şŒ[Žj, ”ö“cł“ń, ‘ž“c”ŽŽ÷2, ŹěŒł”V2 (1Œ`‘ÔŒn, 2‰đ–U): “ú–{ś•¨‹łˆçŠw‰ď‘ć102‰ń‘S‘‘ĺ‰ď (2018/1/6-7), ŒF–{.

H29-732001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒRƒƒ“ƒe[ƒ^[) DNA‚Š‚ç‚Ý‚éW’c‚ĆŒÂ`‰Ť“ę, “ú–{, ƒAƒWƒA‚đ—á‚Ć‚ľ‚ā`. ‘ž“c”ŽŽ÷ (‰đ–U): ƒWƒ…ƒ“ƒN“°‘“X“ß”e“XƒTƒCƒGƒ“ƒXƒJƒtƒF (2018/3/3), “ß”e.


‰đ–UŠw (ăă’PˆĘ)

[Šwp˜_•ś]

110004. [Œ´’˜] Localization of EFA6 (exchange factor for ARF6) isoform D in steroidogenic testicular Leydig cells of adult mice. Chomphoo S, Pakkarato S, Sawatpanich T, Sakagami H1, Kondo H, Hipkaeo W: Acta Histochem 2018/4; 120 (3): 263-8. (ăă—ms1: 1‰đ–U)

110005. [Œ´’˜] Pull down assay for GTP-bound form of Sar1a reveals its activation during morphological differentiation. Urai Y, Yamawaki M, Watanabe N, Seki Y, Morimoto T, Tago K, Homma K, Sakagami H1, Miyamoto Y, Yamauchi J: Biochem Biophys Res Commun 2018/9; 503 (3): 2047-53. (ăă—ms1: 1‰đ–U)

110006. [Œ´’˜] Pallidin is a novel interacting protein for cytohesin]2 and regulates the early endosomal pathway and dendritic formation in neurons. Ito A1, Fukaya M2, Saegusa S, Kobayashi E, Sugawara T2, Hara Y2, Yamauchi J, Okamoto H3, Sakagami H2: J Neurochem 2018/10; 147 (2): 153-77. (ˆÉ“Ą—@Žq1, [’JšO2, ›Œ´Œ’”V2, Œ´@–FL2, ‰Ş–{_Žk3, ăă—ms2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰đ–U, 3–ƒŒ)

110007. [Œ´’˜] FIP4/Arfophilin]2 plays overlapping but distinct roles from FIP3/Arfophilin]1 in neuronal migration during cortical layer formation. Hara Y1, Fukaya M1, Sugawara T1, Sakagami H1: Eur J Neurosci 2018/11; 48 (9): 3082-96. (Œ´@–FL1, [’JšO1, ›Œ´Œ’”V1, ăă—ms1: 1‰đ–U)

110008. [Œ´’˜] New Features on the Expression and Trafficking of mGluR1 Splice Variants Exposed by Two Novel Mutant Mouse Lines. Naito R, Kassai H, Sakai Y, Schšnherr S, Fukaya M1, Schwarzer C, Sakagami H1, Nakao K, Aiba A, Ferraguti F: Front Mol Neurosci 2018; 11: 439. ([’JšO1, ăă—ms1: 1‰đ–U)

110009. [Œ´’˜] Involvement of SRF coactivator MKL2 in BDNF-mediated activation of the synaptic activity-responsive element in the Arc gene. Kikuchi K, Ihara D, Fukuchi M, Tanabe H, Ishibashi Y, Tsujii J, Tsuda M, Kaneda M, Sakagami H1, Okuno H, Bito H, Yamazaki Y, Ishikawa M, Tabuchi A: J Neurochem 2019/1; 148 (2): 204-18. (ăă—ms1: 1‰đ–U)

110010. [Œ´’˜] CMT type 2N disease-associated AARS mutant inhibits neurite growth that can be reversed by valproic acid. Tatsumi Y, Matsumoto N, Iibe N, Watanabe N, Torii T, Sango K, Homma K, Miyamoto Y, Sakagami H1, Yamauchi J: Neurosci Res 2019/2; 139: 69-78. (ăă—ms1: 1‰đ–U)

[Šw‰ďEŒ¤‹†‰ď“™]

723010. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) WestÇŒóŒQERettÇŒóŒQ‚ĚŒ´ˆöˆâ“`ŽqCDKL5‚Ě‘ŠŒÝě—p’`”’’Tő‚Ćloss-of-function‰đÍ‚É‚ć‚铝‡“I‹@”\‰đ–ž. “c’†‹PK, ‰œ“ck•, Ź—ѐ́, ‘şă‘ń“~, [’JšO1, ‚—YŒ[ŽO, “n糁@‹I, ”‹Œ´@•‘, ăă—ms1, …Œű@‰ë, ‹{ě@„, ^“çr–ç (1‰đ–U): ‘ć40‰ń“ú–{_Œo‰ČŠw‘ĺ‰ď (2018/7/20), ç—t.

723011. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SRF“]ŽĘŠˆŤ‰ťˆöŽqMKL1‚¨‚ć‚ŃMKL2‚̐V‹KR‘Ě‚Ě•]‰ż‚Ć‚ť‚Ě—˜—p‚É‚ć‚éƒVƒiƒvƒX‹ÇÝŤ‚̉đÍ. ‹ŕ“c^—Ę, ăă—ms1, ‘ĺ’Ë–Ť‹v, •Ÿ’n@Žç, ’Ă“cł–ž, “cŸş@–ž (1‰đ–U): ‘ć40‰ń“ú–{_Œo‰ČŠw‘ĺ‰ď (2018/7/20), ç—t.

723012. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) V‹Kcytohesin-2Œ‹‡•ŞŽqPallidin‚Ě×–E“ŕ‹ÇÝ‚Ć‚ť‚Ě‹@”\. [’JšO1, ˆÉ“Ą—@Žq, ‰Ş–{_Žk2, ăă—ms1 (1‰đ–U, 2–ƒŒ): ‘ć40‰ń“ú–{_Œo‰ČŠw‘ĺ‰ď (2018/7/21), ç—t.

733005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ”]”玿‘wŒ`Ź‚É‚¨‚Ż‚éArf Œ‹‡ƒ^ƒ“ƒpƒNŽżArfophilin-1‚Ć-2‚Ě‹@”\“IˇˆŮ. Œ´@–FL1, ăă—ms1 (1‰đ–U): “ú–{‰đ–UŠw‰ď‘ć106‰ńŠÖ“ŒŽx•”ŠwpW‰ď (2018/10/20), “Œ‹ž.

733006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ň‘‚É‚¨‚Ż‚éCytohesin 2 ‚Ě‹ÇÝ‰đÍ‚Ćáu’ɐ§Œä‚Ě‹@”\ŠÖ—^. ˆÉ“Ą—@Žq, [’JšO1, ‰Ş–{_Žk2, ăă—ms1 (1‰đ–U, 2–ƒŒ): “ú–{‰đ–UŠw‰ď‘ć106‰ńŠÖ“ŒŽx•”ŠwpW‰ď (2018/10/20), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110001. [Œ´’˜] Synaptic localisation of SRF coactivators, MKL1 and MKL2, and their role in dendritic spine morphology. Kaneda M, Sakagami H1, Hida Y, Ohtsuka T, Satou N, Ishibashi Y, Fukuchi M, Krysiak A, Ishikawa M, Ihara D, Kalita K, Tabuchi A: Sci Rep 2018/1; 8 (1): 727. (1ăă—ms: 1‰đ–U)

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723002. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) V‹Kcytohesin-2Œ‹‡•ŞŽqPallidin‚̏‰ŠúƒGƒ“ƒhƒ\[ƒ€—A‘—’˛ß‚ĆŽ÷ó“Ë‹NŒ`Ź§Œä‹@\. [’JšO1, ˆÉ“Ą—@Žq, ŽOŽ}M‘ž˜Y , Œ´@–FL1, ăă—ms1 (1‰đ–U) ‘ć123‰ń“ú–{‰đ–UŠw‰ď‘‰ď‘S‘ŠwpW‰ď (2018/3/30), “Œ‹ž.


ś—Šw (ěă’PˆĘ)

[Šwp˜_•ś]

110011. [Œ´’˜] Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure. Isonaka R1, Sullivan P, Jinsmaa Y, Corrales A, Goldstein DS: Clin Auton Res 2018/8; 28 (2): 223-30. (ˆé’†—š1: 1ś—)

110012. [Œ´’˜] Neurotropin abrogates lidocaine-induced suppression of neurite growth in cultured rat spinal neurons. Isonaka R1, Katakura T, Kawakami T1: Clin Res Trials 2018/9; 4 (5): 1-5. (ˆé’†—š1, ěă@—Ď1: 1ś—)

[Šw‰ďEŒ¤‹†‰ď“™]

723013. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽžŠúˆË‘ś“I‚ČƒAƒ“ƒhƒƒQƒ“‚̍ě—p‚É‚ć‚č—U”­‚ł‚ę‚é–ĄŠoŒ™ˆŤŠwKŒă‚̏Á‹Ž‹L‰ŻŠÖ˜A”]•”ˆĘ‚É‚¨‚Ż‚éƒVƒiƒvƒX‰Â‘YŤ. ˆźěŽ‡‰‘, “n•Óˆ¤Žq, âV“Ą—‰Ŕ, “ĄŒ´GŽq, ˛“Ą—ş•˝1, P‰Ş—m‰E, ‹{–{•“T (1ś—): ‘ć89‰ń“ú–{“Ž•¨Šw‰ď‘ĺ‰ď (2018/9/13), ŽD–y.

723014. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒZƒLƒZƒCƒCƒ“ƒR‚̍‚ŽŸ’ŽŠo—Ěˆć‚É‚¨‚Ż‚éƒR[ƒ‹ŽhŒƒŒă‚ĚZenk ‚¨‚ć‚Ńc-Fos ”­Œť‚Ěˆá‚˘. ˛“Ą—ş•˝1, “ĄŒ´GŽq, “n•Óˆ¤Žq, Matthijs A. Zandbergen, Johan J. Bolhuis, ‹{–{•“T (1ś—): ‘ć89‰ń“ú–{“Ž•¨Šw‰ď‘ĺ‰ď (2018/9/13), ŽD–y.

723015. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Analysis of androgen dependent synaptic plasticity related to extinction memory retention after conditioned taste aversion in mice using anterograde tracer. ‹{č@ˆ¤, ˆźěŽ‡‰‘, “n•Óˆ¤Žq, “ĄŒ´GŽq, ˛“Ą—ş•˝1, ‹{–{•“T (1ś—): “ú–{–Ą‚Ć“őŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/10/31), ‘ĺ‹{.

723016. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Age-dependent difference of neophobia and conditioned taste aversion in mice. ‹g“cĘ”T, ˆźěŽ‡‰‘, “n•Óˆ¤Žq, “ĄŒ´GŽq, ˛“Ą—ş•˝1, ‹{–{•“T (1ś—): “ú–{–Ą‚Ć“őŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/10/31), ‘ĺ‹{.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H28-310001. [Ç—á•ń] Autoimmunity-associated autonomic failure with sympathetic denervation. Goldstein DS, Holmes C, Sullivan P, Donadio V, Isonaka R1, Zhong E, Pourier B, Vernino S, Kopin IJ, Yehonatan Sharabi Y: Clin Auton Res 2017/2; 27 (1): 57-62. (ˆé’†—š1: 1ś—)

H29-110002. [Œ´’˜] Pure autonomic failure without synucleinopathy. Isonaka R1, Holmes C, Cook GA, Sullivan P, Sharabi Y, Goldstein DS: Clin Auton Res 2017/8; 27 (2): 97-101. (ˆé’†—š1: 1ś—)


ś—Šw (‚‹´’PˆĘ)

[Šwp˜_•ś]

110013. [Œ´’˜] Neutrophils Provide a Favorable IL-1-Mediated Immunometabolic Niche that Primes GLUT4 Translocation and Performance in Skeletal Muscles. Tsuchiya M, Sekiai S, Hatakeyama H1, Koide M, Chaweewannakorn C, Yaoita F, Tan-No K, Sasaki K, Watanabe M, Sugawara S, Endo Y Itoi E, Hagiwara Y, Kanzaki M: Cell Rep 2018/5; 23 (8): 2354-64. (”ŠŽR—TN1: 1ś—)

110014. [Œ´’˜] Roles of IL-1ƒż/ƒŔ in regeneration of cardiotoxin-injured muscle and satellite cell function. Chaweewannakorn C, Tsuchiya M, Koide M, Hatakeyama H1, Tanaka Y, Yoshida S, Sugawara S, Hagiwara Y, Sasaki K, Kanzaki M: Am J Physiol Regul Integr Comp Physiol 2018/7; 315 (1): R90-R103. (”ŠŽR—TN1: 1ś—)

110015. [Œ´’˜] Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ducts. Yasuoka Y1, Izumi Y, Nagai T, Fukuyama T2, Nakayama Y, Inoue H, Horikawa K, Kimura M, Nanami M, Yanagita K, Oshima T3, Yamazaki T, Uematsu T, Yamamura R, Kobayashi N, Shimada Y, Nagaba Y4, Nakanishi T, Yamashita T, Mukoyama M, Sato Y5, Kawahara K1, Nonoguchi H2: Biochem Biophys Res Commun 2018/9; 503 (4): 3121-7. (ˆŔ‰Ş—L‹IŽq1, •ŸŽR@—˛2, ‘ĺ“ˆ—F”ü3, ’ˇę@‘×3, ˛“Ą—Yˆę5, ‰ÍŒ´Ž‰ë1, –ěXŒű”ŽŽj2: 1ś—, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ś•¨•¨—Œn, 4t‘Ÿ“ŕ, 5ˆă—ÉqśŠw•”)

110016. [Œ´’˜] In Vivo Volume Dynamics of Dendritic Spines in the Neocortex of Wild-Type and Fmr1 KO Mice. Ishii K, Nagaoka A, Kishida Y, Okazaki H, Yagishita S, Ucar H, Takahashi N1, Saito N, Kasai H: eNeuro 2018/11; 5 (5). pii: ENEURO.0282-18.2018. doi: 10.1523/ENEURO.0282-18.2018. eCollection 2018 Sep-Oct. (‚‹´—ĎŽq1: 1ś—)

110017. [Œ´’˜] Strong stimulation triggers full fusion exocytosis and very slow endocytosis of the small dense core granules in carotid glomus cells. Tse A, Lee AK, Takahashi N1, Gong A, Kasai H, Tse FW: J Neurogenet 2018/9; 32 (3): 267-78. (‚‹´—ĎŽq1: 1ś—)

110018. [Œ´’˜] Cooperative actions of Tbc1d1 and AS160/Tbc1d4 in GLUT4-trafficking activities. Hatakeyama H1, Morino T, Ishii T, Kanzaki M: J Biol Chem 2019/1; 294 (4): 1161-72. (”ŠŽR—TN1: 1ś—)

510001. [‘ŕ] Three-Dimensional Tracking of Quantum Dot-Conjugated Molecules in Living Cells. Gardini L, Calamai M, Hatakeyama H1, Kanzaki M, Capitanio M, Pavone FS: Methods Mol Biol 2018; 1814: 425-48. (”ŠŽR—TN1: 1ś—)

520001. [‘ŕ] 2ŒőŽq—ă‹N‰ć‘œ–@‚đŠˆ—p‚ľ‚˝•Ş”ĺ‹@\‚̉đ–ž. ‚‹´—ĎŽq (ś—): –k—˘ˆăŠw 2018/6; 48 (1): 1-9.

522001. [uŔ]y“ÁW: ś‘Ě–Œ‚ĚƒoƒCƒIƒƒW[zIII. “Ž‘ԁ@ƒGƒNƒ\ƒTƒCƒg[ƒVƒX‚Ě•ŞŽq‹@\. ‚‹´—ĎŽq (ś—): ś‘̂̉Ȋw 2018/6; 69 (3): 227-32.

[Šw‰ďEŒ¤‹†‰ď“™]

712001. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Molecular configuration for primed exocytosis analyzed with 2-photon FLIM. Takahashi N1: Forefront of Neurotransmitter Release and Calcium Channel Signaling-A Symposium in honor of Sumiko Mochida- (2018/7/7), Tokyo, Japan. (‚‹´—ĎŽq1: 1ś—)

712002. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Imaging secretory cells and molecular configurations of exocytic proteins. Takahashi N1, Hatakeyama H1, Oshima T2, Morimoto Y, Kasai H: The 9th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2019) (2019/3/29), Kobe, Japan. (‚‹´—ĎŽq1, ”ŠŽR—TN1, ‘ĺ“ˆ—F”ü2, Žç–{—Sˆę, ‰Íźt˜Y: 1ś—, 2ś•¨•¨—Œn)

712003. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Mechanical forces of spine enlargement detected by presynaptic FRET/FLIM imaging. Kasai H, Ucar H, Noguchi J, Watanabe S, Yagishita S, Takahashi N1: The 9th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2019) (2019/3/30), Kobe, Japan. (‰Íźt˜Y, ƒEƒ`ƒƒƒ‹ƒnƒTƒ“, –ěŒű@, “n•Ó@œ¨, –ö‰ş@Ë, ‚‹´—ĎŽq1: 1ś—)

713009. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Fludrocortison stimulates erythropoietin (Epo) protein expression in the distal tubules of mouse kidney. Yasuoka Y1, Oshima T2, Izumi Y, Sato Y3, Takahashi N1, Nonoguchi H4, Kawahara K1: ƒAƒƒŠƒJt‘ŸŠw‰ď (Kidney Week 2018) (2018/10/26), San Diego, USA. (ˆŔ‰Ş—L‹IŽq1, ‘ĺ“ˆ—F”ü2, ň—Tˆę˜Y, ˛“Ą—Yˆę3, ‚‹´—ĎŽq1, –ěXŒű”ŽŽj4, ‰ÍŒ´Ž‰ë1: 1ś—, 2ś•¨•¨—Œn, 3ˆă—ÉqśŠw•”, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713010. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Potentiation of presynaptic functions by mechanical forces generated by spine enlargement. Ucar H, Watanabe S, Noguchi J, Yagishita S, Morimoto Y, Takahashi N1, Kasai H: Annual Meeting of Society of Neuroscience 2018 (2018/11/4), San Diego, USA. (ƒEƒ`ƒƒƒ‹ƒnƒTƒ“, “n•Ó@œ¨, –ěŒű@, –ö‰ş@Ë, Žç–{—Sˆę, ‚‹´—ĎŽq1, ‰Íźt˜Y: 1ś—)

713011. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Characterizations of the HCO3- transport activities of a choroid plexus-specific variant of NBC4. Fukuda H1, Takahashi N1: The 9th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2019) (2019/3/28), Kobe, Japan. (•Ÿ“c‰pˆę1, ‚‹´—ĎŽq1: 1ś—)

713012. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Low-Pi diet-induced metabolic acidosis with alkalinuria was reversed in the Pendrin KO mice. Yasuoka Y1, Oshima T2, Sato Y3, Nonoguchi H4, Takahashi N1, Kawahara K1: The 9th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2019) (2019/3/29), Kobe, Japan. (ˆŔ‰Ş—L‹IŽq1, ‘ĺ“ˆ—F”ü2, ň—Tˆę˜Y, ˛“Ą—Yˆę3, ‚‹´—ĎŽq1, –ěXŒű”ŽŽj4, ‰ÍŒ´Ž‰ë1: 1ś—, 2ś•¨•¨—Œn, 3ˆă—ÉqśŠw•”, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713013. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Heterotypic endosomal fusion as an initial trigger for insulin-induced GLUT4 translocation. Hatakeyama H1, Kanzaki M: The 9th Federation of the Asian and Oceanian Physiological Societies Congress (FAOPS2019) (2019/3/30), Kobe, Japan. (”ŠŽR—TN1: 1ś—)

722001. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒuŒő‹Zp‚đŠˆ—p‚ľ‚˝ś—ŠˆŤ•¨Žż•úo‹@\‚̉đÍ. ‚‹´—ĎŽq1, Žç–{—Sˆę, ‰Íźt˜Y (1ś—): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/25), “Œ‹ž.

723017. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝Šp“IŒőŠwƒCƒ[ƒWƒ“ƒOŒv‘Ş‚É‚ć‚č‰đ–ž‚ľ‚˝ƒ}ƒEƒX’P—ŁœŠi‹ŘüˆŰ‚É‚¨‚Ż‚éGLUT4—A‘—§Œä‚ĆƒCƒ“ƒXƒŠƒ“‰Šúě—p. ”ŠŽR—TN1, _č@“W (1ś—): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/27), “Œ‹ž.

723018. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž_•‰‰×ƒ}ƒEƒX‚É‚¨‚Ż‚éƒAƒ“ƒ‚ƒjƒA—A‘—ŠÖ˜Aˆâ“`Žq‚Ě”­Œť—ʉđÍ. ˆŔ‰Ş—L‹IŽq1, ‘ĺ“ˆ—F”ü2, ˛“Ą—Yˆę3, –ěXŒű”ŽŽj4, ‰ÍŒ´Ž‰ë1, ‚‹´—ĎŽq1 (1ś—, 2ś•¨•¨—Œn, 3ˆă—ÉqśŠw•”, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/10), VŠƒ.

723019. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pHŠ´ŽóŤ2EŒ^Kƒ`ƒƒƒlƒ‹ (TASK2) KOƒ}ƒEƒX‚É‚¨‚Ż‚éŽ_‰–ŠîƒCƒ“ƒoƒ‰ƒ“ƒX: ƒAƒ‹ƒJƒŠ•â[—Ă–@‚Ě“K—Ę•]‰ż. ‰ÍŒ´Ž‰ë1, ˆŔ‰Ş—L‹IŽq1, ‘ĺ“ˆ—F”ü2, ‚‹´—ĎŽq1, ˛“Ą—Yˆę3, ŒËP˜al, ŠÖŞ@T, ‹Ń’J‚Ü‚č‚ą, –ěXŒű”ŽŽj4 (1ś—, 2ś•¨•¨—Œn, 3ˆă—ÉqśŠw•”, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć22‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2019/1/13), ‰Ą•l.

732004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒuŒőƒCƒ[ƒWƒ“ƒO‚đ‹ěŽg‚ľ‚˝×–E“ŕ—A‘—§Œä‚Ě‘˝Šp“IŒv‘Ş. ”ŠŽR—TN (ś—): ƒjƒRƒ“ƒCƒ“ƒXƒeƒbƒN‹ZpŒŸ“˘‰ď (2018/4/4), “Œ‹ž.

732005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒuŒőƒCƒ[ƒWƒ“ƒO‚ÉŠî‚Ă‚­×–E“ŕ—A‘—§ŒäƒVƒXƒeƒ€‚Ě‘˝Šp“IŒv‘Ş. ”ŠŽR—TN (ś—): ‘ć7‰ńŒuŒőƒCƒ[ƒWƒ“ƒOƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€ (2018/6/8), ŽD–y.

732006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒuŒőƒCƒ[ƒWƒ“ƒO‚ÉŠî‚Ă‚­×–E“ŕ—A‘—§ŒäƒVƒXƒeƒ€‚ĚŒv‘Ş. ”ŠŽR—TN (ś—): ‘ć30‰ń–k—˘‘ĺŠwŽáŽčlab (2019/1/25), ‘Š–ÍŒ´.

732007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒCƒ“ƒXƒŠƒ“‰ž“šŤ“œ—A‘—’S‘ĚGLUT4‚Ě×–E“ŕ—A‘—§ŒäŒn‚̉Ž‹‰ťŒv‘Ş. ”ŠŽR—TN (ś—): Œ`‘Ô‰đÍƒ[ƒNƒVƒ‡ƒbƒv (2019/3/2), “Œ‹ž.

733007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’჊ƒ“H‚Ĺ—U”­‚ł‚ę‚˝‹tŕ“IƒAƒVƒh[ƒVƒX\ƒAƒ‹ƒJƒŠ”A‚ÍPendrin KOƒ}ƒEƒX‚Őłí‰ť‚ľ‚˝. ˆŔ‰Ş—L‹IŽq1, ‘ĺ“ˆ—F”ü2, ‚‹´—ĎŽq1, –ěXŒű”ŽŽj3, ‰ÍŒ´Ž‰ë1 (1ś—, 2ś•¨•¨—Œn, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć48‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2018/10/20), Vh.


ś‰ťŠw (ä’PˆĘ)

[Šwp˜_•ś]

110019. [Œ´’˜] The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. Miyazaki M, Otomo R, Matsushima-Hibiya Y, Suzuki H, Nakajima A, Abe N, Tomiyama A, Ichimura K, Matsuda K, Watanabe T, Ochiya T, Nakagama H, Sakai R1, Enari M: Cell Death Discov 2018/5; 4: 56. doi: 10.1038/s41420-018-0059-0. eCollection 2018. (ä@—˛ˆę1: 1ś‰ť)

110020. [Œ´’˜] Phosphorylation of SNAP-23 at Ser95 causes a structural alteration and negatively regulates Fc receptor-mediated phagosome formation and maturation in macrophages. Sakurai C, Itakura M1, Kinoshita D, Arai S, Hashimoto H, Wada I, Hatsuzawa K: Mol Biol Cell 2018/7; 29 (13): 1753-62. (”‘q@˝1: 1ś‰ť)

110021. [Œ´’˜] VAMP7 Regulates Autophagosome Formation by Supporting Atg9a Functions in Pancreatic ƒŔ-Cells From Male Mice. Aoyagi K, Itakura M1, Fukutomi T, Nishiwaki C, Nakamichi Y, Torii S, Makiyama T, Harada A, Ohara-Imaizumi M: Endocrinology 2018/11; 159 (11): 3674-88. (”‘q@˝1: 1ś‰ť)

[Šw‰ďEŒ¤‹†‰ď“™]

713014. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Identification and functional analysis of FGFR2 binding proteins in schirrous gastric cancer. Shirakihara T1, Sakai R1: 11th AACR-JCA Joint Conference : Breakthrough in Cancer Research (2019/2/9), Maui, Hawaii, USA. (”’–ŘŒ´‘ôĆ1, ä@—˛ˆę1: 1ś‰ť)

713015. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Identification and functional analysis of FGFR2 binding proteins in diffuse-type gastric carcinoma. Shirakihara T1, Sakai R1: AACR Annual Meeting 2019 (2019/3/30), Atlanta, Georgia, USA. (”’–ŘŒ´‘ôĆ1, ä@—˛ˆę1: 1ś‰ť)

723020. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”÷—Ę‘gD‚đ‘ÎŰ‚Ć‚ľ‚˝ƒyƒvƒ`ƒh[ƒ€‰đÍ–@‚ĚŠm—§‚Ɖž—p. ’†ě@÷, ŽR“c‘ń–ç, Šp“c‹MŽ÷, “Ą–{˜aŽŔ, ”‘q@˝1, ŹŽ›‹`’j (1ś‰ť): “ú–{Žż—Ę•ŞÍŠw‰ďE“ú–{ƒvƒƒeƒI[ƒ€Šw‰ď2018”N‡“Ż‘ĺ‰ď (2018/5/16), ‘ĺă.

723021. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) HTLV-1 ENV—R—ˆƒyƒvƒ`ƒh‚Ćƒjƒ…[ƒƒsƒŠƒ“1 b1ƒhƒƒCƒ“‚Ě•¨—‰ťŠw“I‘ŠŒÝě—p‰đÍ. “í@‰pŽ÷, “c’†r”V, ‰Í–ěr”V1, ×“c˜a’j, Žáź@Š], •lŒű@Œ÷ (1ś‰ť): ‘ć18‰ń“ú–{’`”’Žż‰ČŠw‰ď”N‰ď (2018/6/26), VŠƒ.

723022. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒLƒ‹ƒXˆÝ‚Ş‚ń‚ĆŠÔŽżüˆŰ‰č×–E‚Ě’źÚ“I‚Č‘ŠŒÝě—p‚ÉŠÖ‚í‚é•ŞŽq‹@\‚̉đ–ž. ‹{–{^Œá, ä@—˛ˆę1, ŽRŒű‰pŽ÷ (1ś‰ť): ‘ć27‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď (2018/7/19), ‰Ą•l.

723023. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒLƒ‹ƒXˆÝ‚Ş‚ń‚̐i“W‚ÉŠń—^‚ˇ‚éFGFŽó—e‘ĚŒ‹‡ƒ^ƒ“ƒpƒNŽż‚Ě’Tő‚Ć‹@”\‰đÍ. ”’–ŘŒ´‘ôĆ1, ä@—˛ˆę1 (1ś‰ť): ‘ć27‰ń“ú–{‚Ş‚ń“]ˆÚŠw‰ďŠwpW‰ďE‘‰ď (2018/7/19), ‰Ą•l.

723024. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VAMP7 regulates autophagosome formation by supporting Atg9a functions in pancreatic ƒŔ-cells. Â–ö‹¤‘ž, ”‘q@˝1, •Ÿ•yr”V, ź˜e’m˘”T, ’†“š—mŽq, ’š‹ŞŽi, –qŽR’q•F, Œ´“c˛G, Ąň”ü‰Ŕ (1ś‰ť): ‘ć91‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2018/9/25), ‹ž“s.

723025. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚Ń‚Ü‚ńŤˆÝ‚Ş‚ń‚É‚¨‚Ż‚éRhoA‚ĚƒXƒvƒ‰ƒCƒVƒ“ƒOˆŮí‚Ć‚ť‚ę‚É”ş‚¤”­Œť‹y‚ŃŠˆŤ‚̒ቺ. ‹{–{^Œá, ’†–VĘ‰Ô, [ŒŠŠó‘ăŽq, –öŒ´ŒÜ‹g, ä@—˛ˆę1, ŽRŒű‰pŽ÷ (1ś‰ť): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.

723026. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒLƒ‹ƒXˆÝ‚Ş‚ń‚̐i“W‚ÉŠÖ‚í‚éFGFR2Œ‹‡ƒ^ƒ“ƒpƒNŽż‚Ě’Tő‚Ć‹@”\‰đÍ. ”’–ŘŒ´‘ôĆ1, ä@—˛ˆę1 (1ś‰ť): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.

733008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Žó—e‘Ěƒjƒ…[ƒƒsƒŠƒ“1‚ÉŒ‹‡‚ˇ‚éV‹KHTLV-1ŠO”í“œ’`”’Žż”z—ń‚Ě“Ż’č. “í@‰pŽ÷, “c’†r”V, ‰Í–ěr”V1, ×“c˜a’j, Žáź@Š], •lŒű@Œ÷ (1ś‰ť): ‘ć57‰ńNMR“˘˜_‰ď (2018/9/18), ŽD–y.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110003. [Œ´’˜] Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. Yamamoto Y, Tomiyama A, Sasaki N, Yamaguchi H, Shirakihara T1, Nakashima K, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Sakai R, Namba H, Mori K: Biochem Biophys Res Commun 2018/1; 495 (1): 1292-9. (”’–ŘŒ´‘ôĆ1: 1ś‰ť)

H29-110004. [Œ´’˜] Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells. Miyamoto S, Nagamura Y, Nakabo A, Okabe A, Yanagihara K, Fukami K, Sakai R1, Yamaguchi H: Biochem Biophys Res Commun 2018/1; 495 (2): 1942-7. (ä@—˛ˆę1: 1ś‰ť)

H29-110005. [Œ´’˜] A novel neuropilin-1-binding sequence in the human T-cell lymphotropic virus type 1 envelope glycoprotein. Kusunoki H, Tanaka T, Kohno T1, Matsuhashi K, Hosoda K, Wakamatsu K, Hamaguchi I: Biochimica et Biophysica acta. Proteins and Proteomics 2018/2; 1866 (4): 541-8. (‰Í–ěr”V1: 1ś‰ť)


ś‰ťŠw (äݑă’PˆĘ)

[Šwp˜_•ś]

110022. [Œ´’˜] Localization of nectin-2ƒż at the boundary between the adjacent somata of the clustered cholinergic neurons and its regulatory role in the subcellular localization of the voltage-gated A-type K+ channel Kv4.2 in the medial habenula. Shiotani H1,2, Miyata M1, Itoh Y1, Wang S3, Kaito A3, Mizoguchi A3, Yamasaki M4, Watanabe M4, Mandai K1,5, Mochizuki H2, Takai Y1 (1Kobe University Graduate School of Medicine, 2Osaka University Graduate School of Medicine, 3Mie University Graduate School of Medicine, 4Hokkaido University, 5Kitasato University School of Medicine): J Comp Neurol 2018/6; 526 (9): 1527-49. (äݑ㌤“ń1,5: 5ś‰ť)

110023. [Œ´’˜] Involvement of l-afadin, but not s-afadin, in the formation of puncta adherentia junctions of hippocampal synapses. Maruo T1,2, Sakakibara S1, Miyata M1, Itoh Y1, Kurita S1, Mandai K1,3, Sasaki T2, Takai Y1 (1Kobe University Graduate School of Medicine, 2Tokushima University Graduate School of Medical Sciences, 3Kitasato University School of Medicine): Mol Cell Neurosci 2018/10; 92: 40-9. (äݑ㌤“ń3: 3ś‰ť)

110024. [Œ´’˜] Interaction of nectin-2ƒż with the auxiliary protein of the voltage-gated A-type K+ channel Kv4.2 dipeptidyl aminopeptidase-like protein at the boundary between the adjacent somata of clustered cholinergic neurons in the medial habenula. Shiotani H1,2, Miyata M1, Mizutani K1, Wang S3, Mizoguchi A3, Mochizuki H2, Mandai K1,4, Takai Y1 (1Kobe University Graduate School of Medicine, 2Osaka University Graduate School of Medicine, 3Mie University Graduate School of Medicine, 4Kitasato University School of Medicine): Mol Cell Neurosci 2019/1; 94: 32-40. (äݑ㌤“ń4: 4ś‰ť)

520002. [‘ŕ] ×–EŠÔÚ’…‚É‚¨‚Ż‚éƒAƒtƒ@ƒfƒBƒ“‚Ě‹@”\. äݑ㌤“ń (ś‰ť): –k—˘ˆăŠw 2018/12; 48 (2): 85-95.

[Šw‰ďEŒ¤‹†‰ď“™]

713016. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Observation of immunostained microtubules using three-dimensional super-resolution microscope with two-color annular wave plate. Iketaki Y, Bokor N, Okada D1, Kumagai H2: SPIE Structured Light 2018 (2018/4/24), Yokohama, Japan, Proceedings SPIE Vol., 10712. doi: 10.1117/12.2319154. (‰Ş“c‘ĺ•1, ŒF’J@Š°2: 1ś‰ť, 2ˆă—ÉqśŠw•”)

713017. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Afadin plays multiple roles in the structural and functional differentiations of hippocampal giant mossy fiber synapses. Maruo T, Mandai K1, Sasaki T, Takai Y: Cold Spring Harbor Asia Meeting, Latest Advances in Development & Function of Neuronal Circuits (2018/9/26), Awaji, Japan. (äݑ㌤“ń1: 1ś‰ť)

723027. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒgƒŒƒX‚É‚ć‚Á‚Ä—U“ą‚ł‚ę‚郊ƒ“Ž_‰ťƒ^ƒ“ƒpƒNŽż‚Ěƒ}ƒEƒX”]‚É‚¨‚Ż‚é‹ÇÝ. ŽRX‘D1, äݑ㌤“ń1 (1ś‰ť): ‘ć91‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2018/9/25), ‹ž“s.

732008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) _Œo‘gD‚É‚¨‚Ż‚é×–EŠÔÚ’…‚Ě•ŞŽq×–Eś•¨Šw“IŒ¤‹†. äݑ㌤“ń (ś‰ť): ‘ĺă‘ĺŠw’`”’ŽżŒ¤‹†Š•ŞŽq”­śŠwƒZƒ~ƒi[ (2018/5/2), ‘ĺă.


•ŞŽqˆâ“`Šw

[Šwp˜_•ś]

110025. [Œ´’˜] Dysregulated DNA methylation of GLA gene was associated with dysfunction of autophagy. Yanagisawa H, Hossain MA, Miyajima T, Nagao K1, Miyashita T1, Eto Y: Mol Genet Metab 2019/4; 126 (4): 460-5. doi: 10.1016/j.ymgme.2019.03.003. Epub 2019 Mar 7. (’ˇ”ö˜a‰E1, ‹{‰şr”V1: 1•ŞŽqˆâ“`)

521001. [‰đŕ]yƒŒƒNƒ`ƒƒ[zˆâ“`ŽqƒoƒŠƒAƒ“ƒg‚Ě•\‹L–@@‘ć3‰ń. ‹{‰şr”V (•ŞŽqˆâ“`): ‰Ć‘°ŤŽîᇠ2018/10; 18 (1): 12-4.

[Šw‰ďEŒ¤‹†‰ď“™]

722002. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •ę”ÁŠî’ę×–E‚Ş‚ńÇŒóŒQ (NBCCS) ‚̐ӔCˆâ“`Žq‚ÉŒŠ‚ç‚ę‚éˆâ“`Žq•ĎˆŮ‰đÍ. ‚ŽR‹g‰i1, ’ˇ”ö˜a‰E1, ‹TŽRFŽO1, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć50‰ń“ú–{—Տ°•ŞŽqŒ`‘ÔŠw‰ď‘‰ďEŠwpW‰ď (2018/9/7), “Œ‹ž.

723028. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒQƒmƒ€•ŇW‚đs‚Á‚˝•ę”ÁŠî’ę×–EŠŕÇŒóŒQ—R—ˆiPS×–E‚Ě×–Eś•¨Šw“I“ÁŤ‚̉đÍ. ’ˇ”ö˜a‰E1, “ĄˆäŽ‘Ľ (1•ŞŽqˆâ“`): ‘ć24‰ń“ú–{‰Ć‘°ŤŽîᇊw‰ďŠwpW‰ď (2018/6/9), _ŒË.

723029. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Generation of iPS cells as a model for NBCCS by using CRISPR/Cas9 System. ’ˇ”ö˜a‰E1, ‚ŽR‹g‰i1, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/28), ‘ĺă.

723030. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ę”ÁŠî’ę×–EŠŕÇŒóŒQŠłŽŇ—R—ˆ×–E‚đ—p‚˘‚˝Žîᇂ̍쐻. ’ˇ”ö˜a‰E1, ‰Á“Ąç¨, ‰Ł—m”ü, ‚ŽR‹g‰i1, ‹TŽRFŽO1, ”~ŕV–žO, “ĄˆäŽ‘Ľ, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/28), ‰Ą•l.

723031. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒEƒX‚ĚƒCƒ“ƒvƒŠƒ“ƒeƒBƒ“ƒOŒ^XőF‘Ě•sŠˆ‰ť‚É‚¨‚˘‚ÄRNF12‚ÍREX1‚Ě—}§‚É‚ć‚Á‚Ä•ƒ—R—ˆnon-coding RNA Tsix‚đ—}§‚ˇ‚é. ’†‘şˆŠ—˘, •Ÿ“c@“Ä, ’ˇ”ö˜a‰E1, ˆ˘‹v’ÉpŒ›, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/29), ‰Ą•l.

723032. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŸ˘‘ăƒV[ƒNƒGƒ“ƒT[‚đ—p‚˘‚˝GorlinÇŒóŒQŠłŽŇ‚É”­Ç‚ľ‚˝ŠeŽíŽîᇂ̈â“`Žq‰đÍ. Œ“—F—T‘ĺ, ‚ŽR‹g‰i1, ‰Ł—m”ü, “Ą’J˜aŽq, ’ˇ”ö˜a‰E1, ‹TŽRFŽO1, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/29), ‰Ą•l.

723033. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Fabry•a—ŤŠłŽŇ‚ĚƒI[ƒgƒtƒ@ƒW[•s‘S‚Í, •ĎˆŮƒAƒŒƒ‹‚ĚmRNA”­Œť—Ę‚Ćƒƒ`ƒ‹‰ť‚ÉŠÖ˜A‚ľ‚Ä‚˘‚˝. –öŕV”ä˜CŽq, ‹{“‡”CŽi, ’ˇ”ö˜a‰E1, ‹{‰şr”V1, Mohammad Arif Hossain, ĺʓĄ‹`Ÿ (1•ŞŽqˆâ“`): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/29), ‰Ą•l.

733009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) GorlinÇŒóŒQŠłŽŇ‚ĚŽîᇍזE‚É‚¨‚Ż‚éPTCH1‚Ěˆâ“`Žq•ĎˆŮ‰đÍ. Œ“—F—T‘ĺ, ‚ŽR‹g‰i1, ‰Ł—m”ü, “Ą’J˜aŽq, ’ˇ”ö˜a‰E1, ‹TŽRFŽO1, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€/‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) XőF‘Ě•sŠˆ‰ť‚ÉŠÖ‚í‚énon-coding RNA Xist‚Ě”­ŒťˆŰŽ‹@\‚̉đ–ž. ’†‘şˆŠ—˘, •Ÿ“c@“Ä, ˆ˘‹v’ÉpŒ›, ‹{‰şr”V1 (1•ŞŽqˆâ“`): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€/‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.


–ň—Šw

[Šwp˜_•ś]

110026. [Œ´’˜] Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1+ cells from bone marrow. Park K1, Amano H2, Ito Y2, Mastui Y3, Kamata M4, Yamazaki Y1, Takeda A1, Shibuya M, Majima M2: Anat Sci Int 2018/6; 93 (3): 372-83. (–p@Œ\ˆę1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, źˆäŒ[•v3, Š™“c^—Žq4, ŽRčˆŔ°1, •“c@Œ[1, ”n“ˆł—˛2: 1Œ`ŹE”üŠO, 2–ň—, 3ŒÄ‹zŠíŠO, 4t‘Ÿ“ŕ)

110027. [Œ´’˜] Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice. Nishizawa N1, Ito Y2, Eshima K3, Ohkubo H4, Kojo K5, Inoue T6, Raouf J, Jakobsson PJ, Uematsu S, Akira S, Narumiya S, Watanabe M5, Majima M2: J Hepatol 2018/6; 69 (1): 110-20. (źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‘ĺ‹v•Ű”Ž˘4, ŒĂé@Œ›5, ˆäă’qm6, “n粏š•F5, ”n“ˆł—˛2: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3–Ɖu, 4S‘ŸŒŒŠÇŠO, 5‰ş•”Á‰ťŠÇŠO, 6‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110028. [Œ´’˜] RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis. Inoue T1, Ito Y2, Nishizawa N3, Eshima K4, Kojo K5, Otaka F1, Betto T1, Yamane S1, Tsujikawa K, Koizumi W6, Majima M2: PLoS One 2018/11; 13 (11): e0200432. (ˆäă’qm1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ]“‡k“ń4, ŒĂé@Œ›5, ‘ĺ‚Žjš1, •Ęác•üL1, ŽRŞ‘‹IŽq1, Źň˜aŽO˜Y6, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4–Ɖu, 5‰ş•”Á‰ťŠÇŠO, 6Á‰ťŠí“ŕ)

110029. [Œ´’˜] Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. Kamata M1, Amano H2, Ito Y2, Fujita T, Otaka F3, Hosono K2, Kamata K, Takeuchi Y1, Yokomizo T, Shimizu T, Majima M2: PLoS One 2019/2; 14 (2): e0202842. (Š™“c^—Žq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ‘ĺ‚Žjš3, ×–ě‰Á“ŢŽq2, ’|“ŕN—Y1, ”n“ˆł—˛2: 1t‘Ÿ“ŕ, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110030. [Œ´’˜] RAMP1 attenuates immune-mediated hepatitis via recruiting regulatory T cells. Inoue T1, Inoue M2, Ito Y3, Otaka F1, Betto T1, Yamane S1, Koizumi W4, Majima M3: Kitasato Med J 2019/3; 49 (1): 9-15. (ˆäă’qm1, ˆäăŒőŽq2, ˆÉ“Ą‹`–ç3, ‘ĺ‚Žjš1, •Ęác•üL1, ŽRŞ‘‹IŽq1, Źň˜aŽO˜Y4, ”n“ˆł—˛3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3–ň—, 4Á‰ťŠí“ŕ)

110031. [Œ´’˜] Enhanced angiogenesis by recruitment of VEGFR1+ă•tCXCR4+ă•t cells from bone marrow during experimental colitis. Betto T1, Amano H2, Ito Y2, Eshima K3, Yoshida T4, Matsui Y5, Yamane S1, Inoue T1, Otaka F1, Kobayash K6, Shibuya M, Koizumi W7, Majima M2: Kitasato Med J 2019/3; 49 (1): 35-45. (•Ęác•üL1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‹g“c@Œ÷4, źˆäŒ[•v5, ŽRŞ‘‹IŽq1, ˆäă’qm1, ‘ĺ‚Žjš1, Ź—ѐ´“T6, Źň˜aŽO˜Y7, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4•a—, 5ŒÄ‹zŠíŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7Á‰ťŠí“ŕ)

110032. [Œ´’˜] The role of Angiotensin II type 1A receptor signaling in gastric ulcer healing. Yamane S1, Amano H2, Ito Y2, Betto T1, Inoue T1, Otaka F1, Koizumi W3, Majima M2: Kitasato Med J 2019/3; 49 (1): 52-63. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, •Ęác•üL1, ˆäă’qm1, ‘ĺ‚Žjš1, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ)

110033. [Œ´’˜] Vascular endothelial growth factor receptor 1 tyrosine kinase signaling facilitates healing of DSS-induced colitis by accumulation of Tregs in ulcer area. Betto T1, Amano H2, Ito Y2, Eshima K3, Yoshida T4, Matsui Y5, Yamane S1, Inoue T1, Otaka F1, Kobayashi K6, Koizumi W7, Shibuya M, Majima M2: Biomed Pharmacother 2019/3; 111: 131-41. (•Ęác•üL1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‹g“c@Œ÷4, źˆäŒ[•v5, ŽRŞ‘‹IŽq1, ˆäă’qm1, ‘ĺ‚Žjš1, Ź—ѐ´“T6, Źň˜aŽO˜Y7, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4•a—, 5ŒÄ‹zŠíŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7Á‰ťŠí“ŕ)

510002. [‘ŕ] CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization? Majima M1, Ito Y1, Hosono K1, Amano H1: Trends Pharmacol Sci 2019/1; 40 (1): 11-21. (”n“ˆł—˛1, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, “V–ě‰pŽ÷1: 1–ň—)

522002. [uŔ]y“ÁW : ś—ŠˆŤŽ‰ŽżŒ¤‹†‚ĚĹ‘Oüz˜`ś—ŠˆŤŽ‰ŽżŒ¤‹†, ƒƒNƒƒN‚ˇ‚éV“WŠJ. ”n“ˆł—˛ (–ň—): ‰ŠÇ‚ƖƉu 2018/5; 26 (5): 361.

522003. [uŔ]y“ÁW : ś—ŠˆŤŽ‰ŽżŒ¤‹†‚ĚĹ‘OüzŠĚ‹•ŒŒÄŸó—ŹŒă‚̩̏áŠQ‚đ§Œä‚ˇ‚鐜—ŠˆŤŽ‰Žż‚Ě–đŠ„. ˆÉ“Ą‹`–ç1, ”n“ˆł—˛1 (1–ň—): ‰ŠÇ‚ƖƉu 2018/5; 26 (5): 30-4.

[Šw‰ďEŒ¤‹†‰ď“™]

712004. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Role of lipid mediators in liver repair after liver injury in mice. Ito Y1, Majima M1: 10th International Symposium on Cell/Tissue Injury and Cytoprotection/Organoprotection (ISCTICO) (2018/6/28), Kyoto, Japan. (ˆÉ“Ą‹`–ç1, ”n“ˆł—˛1: 1–ň—)

713018. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) RAMP1 signaling in macrophages protects mice from concanavalin A-induced liver injury. Inoue T1, Ito Y2, Nishizawa N3, Otaka F1, Nakamoto S1, Tsuru S1, Hattori K4, Koizumi W5, Amano H2, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (ˆäă’qm1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ‘ĺ‚Žjš1, ’†–{CŽi1, ’Ă—Ż˘—˘1, •ž•”‹żŽq4, Źň˜aŽO˜Y5, “V–ě‰pŽ÷2, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4ŽY‰Č, 5Á‰ťŠí“ŕ)

713019. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Role of endogenous PGE2 in liver repair after hepatic ischemia/reperfusion. Ito Y1, Nishizawa N2, Eshima K3, Ohkubo H4, Inoue T5, Amano H1, Majima M1: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (ˆÉ“Ą‹`–ç1, źŕVL‹ą2, ]“‡k“ń3, ‘ĺ‹v•Ű”Ž˘4, ˆäă’qm5, “V–ě‰pŽ÷1, ”n“ˆł—˛1: 1–ň—, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3–Ɖu, 4S‘ŸŒŒŠÇŠO, 5‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713020. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Role of thromboxane prostanoid (TP) receptor in the facilitation of angiogenesis and the healing of gastric ulcers. Yamane S1, Amano H2, Betto T1, Inoue T1, Ito Y2, Shimizu Y3, Nishizawa N4, Narumiya S, Koizumi W3, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, •Ęác•üL1, ˆäă’qm1, ˆÉ“Ą‹`–ç2, ´…—T‹M3, źŕVL‹ą4, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

713021. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) VEGFR1-TK signaling protects exacerbation of dextran sulfate sodium-induced colitis in mice. Betto T1, Amano H2, Yamane S1, Inoue T1, Shimizu Y3, Ito Y2, Yoshida T4, Koizumi M, Koizumi W3, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (•Ęác•üL1, “V–ě‰pŽ÷2, ŽRŞ‘‹I1, ˆäă’qm1, ´…—T‹M3, ˆÉ“Ą‹`–ç2, ‹g“c@Œ÷4, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ, 4•a—)

722003. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒŠƒ“ƒpŠÇVś‚đ§Œä‚ˇ‚é_Œoƒyƒvƒ`ƒhCGRP‚Ě–đŠ„. ˆÉ“Ą‹`–ç1, ’Ă—Ż˘—˘2, ×–ě‰Á“ŢŽq1, “V–ě‰pŽ÷1, ”n“ˆł—˛1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć43‰ń“ú–{ƒŠƒ“ƒpŠw‰ď‘‰ď (2019/3/22), “Œ‹ž.

723034. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2 (PGE2)-EP3Žó—e‘ĚƒVƒOƒiƒ‹‚É‚ć‚éŠĚ‘gDC•œ‘Łiě—p. ’†–{CŽi1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, “n粏š•F4, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć33‰ń“ú–{ShockŠw‰ď‘‰ď (2018/6/29), “Œ‹ž.

723035. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) mPGES-1‚̓}ƒNƒƒtƒ@[ƒW‚É‚¨‚Ż‚éEP4ƒVƒOƒiƒ‹‚đ‰î‚ľ‚ÄŠĚ‹•ŒŒÄŠÁ—ŹáŠQŒă‚̩̏C•œ‚đ’x‰„‚ł‚š‚é. źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ’†–{CŽi3, ŒÜ\—’ˆę°3, “ĄŽR–FŽ÷3, ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “n粏š•F4 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/11), Ž­Ž™“‡.

723036. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒNƒbƒp[×–ERAMP1ƒVƒOƒiƒ‹‚̓Rƒ“ƒJƒiƒoƒŠƒ“ŠĚ‰Š‚đŒyŒ¸‚ł‚š‚é. ˆÉ“Ą‹`–ç1, ˆäă’qm2, ‘ĺ‚Žjš2, ’†–{CŽi2, Źň˜aŽO˜Y3, ”n“ˆł—˛1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Á‰ťŠí“ŕ): ‘ć32‰ńŠĚ—Ţ“´•Ç×–EŒ¤‹†‰ďŠwpW‰ď (2018/12/1), “Œ‹ž.

723037. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Prostaglandin E receptor subtype EP3 promotes liver repair after acute liver injury. ’†–{CŽi1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ‘ĺ‹v•Ű”Ž˘4, “n粏š•F5, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4S‘ŸŒŒŠÇŠO, 5‰ş•”Á‰ťŠÇŠO): ‘ć44‰ń“ú–{”÷ŹzŠÂŠw‰ď‘‰ď (2019/2/8), ‘ĺ‹{.

723038. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RAMP1 signaling in hepatic macrophages plays a critical role in immune-mediated hepatitis. ˆÉ“Ą‹`–ç1, ˆäă’qm2, ‘ĺ‚Žjš2, ”ü“‡—˜ş3, ‘ĺ‹v•Ű”Ž˘3, ”n“ˆł—˛1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3S‘ŸŒŒŠÇŠO): ‘ć92‰ń“ú–{–ň—Šw‰ď”N‰ď (2019/3/14), ‘ĺă.

723039. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) mPGES-1/PGE2/EP4 axis induces blood flow recovery via accumulation of regulatory T cells to ischemic muscle. “V–ě‰pŽ÷1, ]“‡k“ń2, ˆÉ“Ą‹`–ç1, R—ǐ×Y, Ź‹{@Žü, ”n“ˆł—˛1 (1–ň—, 2–Ɖu): ‘ć92‰ń“ú–{–ň—Šw‰ď”N‰ď (2019/3/14), ‘ĺă.

723040. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RAMP1 signaling in immune cells regulates lymphangiogenesis in the diaphragm during peritonitis. ’Ă—Ż˘—˘1, ˆÉ“Ą‹`–ç2, ×–ě‰Á“ŢŽq2, ź“cO”ü3, ‘ dçŠG3, ˆäă’qm1, ’†–{CŽi1, ‘ĺ‚Žjš1, ‰Ş–{_Žk3, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–ƒŒ): ‘ć92‰ń“ú–{–ň—Šw‰ď”N‰ď (2019/3/14), ‘ĺă.

723041. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Role of prostaglandin receptor EP4 in lymphangiogenesis in dextran sulfate sodium (DSS)-induced colitis. ×–ě‰Á“ŢŽq1, ˆÉ“Ą‹`–ç1, •Ęác•üL2, Ź‹{@Žü, ”n“ˆł—˛1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć92‰ń“ú–{–ň—Šw‰ď”N‰ď (2019/3/15), ‘ĺă.

733011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • –Œ‰Šƒ}ƒEƒX‚̉ĄŠu–ŒƒŠƒ“ƒpŠÇVś‚đ‘‹­‚ˇ‚éŽó—e‘ĚŠˆŤ’˛ß’`”’1 (RAMP1) ‚Ě–đŠ„. ’Ă—Ż˘—˘1, ˆÉ“Ą‹`–ç2, ˆäă’qm1, ×–ě‰Á“ŢŽq2, ź“cO”ü3, ‘ dçŠG3, ’†–{CŽi1, ‘ĺ‚Žjš1, •ž•”‹żŽq4, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–ƒŒ, 4ŽY‰Č): ‘ć139‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2018/10/20), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110006. [Œ´’˜] Inhibition of mPGES-1 protects the liver from ischemia/reperfusion injury through prostanoid EP2 receptor. Nishizawa N1, Ito Y2, Inoue T3, Nakamoto S3, Otaka F3, Tsuru S3, Hattori K3, Akira A, Watanabe M4, Majima M2: Kitasato Med J 2018/3; 48 (1): 26-34. (źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ˆäă’qm3, ’†–{CŽi3, ‘ĺ‚Žjš3, “s—Ż˘—˘3, •ž•”‹żŽq3, “n粏š•F4, ”n“ˆł—˛2: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO)


”÷ś•¨Šw

[Šwp˜_•ś]

110034. [Œ´’˜] Actinomadura barringtoniae sp. nov., an endophytic actinomycete isolated from the roots of Barringtonia acutangula (L.) Gaertn. Rachniyom H, Matsumoto A, Inahashi Y, Take A1, Takahashi Y, Thamchaipenet A: Int J Syst Evol Microbio 2018/5; 68 (5): 1584-90. (•@@W1: 1”÷ś•¨)

110035. [Œ´’˜] Streptomyces boninensis sp. nov., isolated from soil from a limestone cave in the Ogasawara Islands. Take A1, Inahashi Y,Omura S, Takahashi Y, Matsumoto A: Int J Syst Evol Microbiol 2018/5; 68 (5): 1795-9. (•@@W1: 1”÷ś•¨)

110036. [Œ´’˜] Hamuramicins A and B, 22-membered macrolides, produced by an endophytic actinomycete Allostreptomyces sp. K12-0794. Suga T, Kimura T, Inahashi Y, Iwatsuki M, Nonaka K, Take A1, Matsumoto A, Takahashi Y, Omura S, Nakashima T: J Antibiot (Tokyo) 2018/7; 71 (7): 619-25. (•@@W1: 1”÷ś•¨)

110037. [Œ´’˜] Identification and heterologous expression of the actinoallolide biosynthetic gene cluster. Inahashi Y, Shiraishi T, Take A1, Matsumoto A, Takahashi Y, Omura S, Kuzuyama T, Nakashima T: J Antibiot (Tokyo) 2018/8; 71 (8): 749-52. (•@@W1: 1”÷ś•¨)

110038. [Œ´’˜] Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells. Miyata N, Hayashi Y, Hayashi S1, Sato K, Hirai Y, Yamamoto H, Sugano K: Clin Transl Gastroenterol 2019/3; 10 (3): e00024. (—с@rŽĄ1: 1”÷ś•¨)

540051. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]y•˝Ź28-29”N“x‹łˆőƒvƒƒWƒFƒNƒgŒ¤‹†uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—˜—p‚ľ‚˝V‹KƒfƒBƒtƒBƒVƒ‹‹ŰŠ´őÇ‚ĚŽĄ—Ă–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: •˝Ź28”N“x`•˝Ź29”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, ‹¤“ŻŒ¤‹†ŽŇ: —с@rŽĄ1, –k—˘‰p˜Y2, ’†‘şłŽ÷2, “ŕ“cŒ’‘ž˜Y3, ‰Á“Ą‚Í‚é, –…”ö[•q, ŽRŒű–ž“ú”ü4, ]“c—Č‘ž˜Y4, ‹´–{r—ş4, ě“cˆíl4, ‘O‰ÔË‘ž˜Y4 (1”÷ś•¨, 2ˆă—ÉqśŠw•”, 3ŽŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č):uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—˜—p‚ľ‚˝V‹KƒfƒBƒtƒBƒVƒ‹‹ŰŠ´őÇ‚ĚŽĄ—Ă–@‚ĚŠJ”­vŒ¤‹†I—š•ń‘2018/4.

540052. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]y‰ČŠwŒ¤‹†”ď•â•‹ŕEŠî”ŐŒ¤‹† (C)uCŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘fˆâ“`Žq‚đ“`’B‚ˇ‚éƒtƒ@[ƒW‚̏hŽĺ”FŽŻ‹@\‚̉𖞂Ƃť‚̉ž—p (Œ¤‹†ŠúŠÔ: •˝Ź28”N“x`•˝Ź30”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, Œ¤‹†•Ş’SŽŇ: —с@rŽĄ1, ‰Á“Ą‚Í‚é, ‘ĺ‹{’ź–Ř, “ŕŽR~•˝, –…”ö[•q (1”÷ś•¨):uCŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘fˆâ“`Žq‚đ“`’B‚ˇ‚éƒtƒ@[ƒW‚̏hŽĺ”FŽŻ‹@\‚̉𖞂Ƃť‚̉ž—pv2017”N“xŽŔŽ{ó‹ľ•ń‘ 2018/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-16K08785/16K087852017hokoku/.

540053. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]y•˝Ź28-29”N“x‹łˆőƒvƒƒWƒFƒNƒgŒ¤‹†uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—˜—p‚ľ‚˝V‹KƒfƒBƒtƒBƒVƒ‹‹ŰŠ´őÇ‚ĚŽĄ—Ă–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: •˝Ź28”N“x`•˝Ź29”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, ‹¤“ŻŒ¤‹†ŽŇ: —с@rŽĄ1, –k—˘‰p˜Y2, ’†‘şłŽ÷2, “ŕ“cŒ’‘ž˜Y3, ‰Á“Ą‚Í‚é, –…”ö[•q, ŽRŒű–ž“ú”ü4, ]“c—Č‘ž˜Y4, ‹´–{r—ş4, ě“cˆíl4, ‘O‰ÔË‘ž˜Y4 (1”÷ś•¨, 2ˆă—ÉqśŠw•”, 3ŽŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—˜—p‚ľ‚˝V‹KƒfƒBƒtƒBƒVƒ‹‹ŰŠ´őÇ‚ĚŽĄ—Ă–@‚ĚŠJ”­v–k—˘‘ĺŠw‚ƍ‘—§Š´őÇŒ¤‹†Š‚É‚ć‚é‘ĺŠwŠÔ˜AŒg‹¤“ŻŒ¤‹†‹I—v 2018/5.

540004. [‚ť‚Ě‘ź] ‚­‚ˇ‚Ě–Ř. ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY 2018/7; 386: 14.

540054. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]yŒö‰vŕ’c–@l ŽO“‡ŠC‰_‹L”Oŕ’cE•˝Ź29”N“xŽO“‡ŠC‰_‹L”Oŕ’cŠwpŒ¤‹†§—ă‹ŕuƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—p‚˘‚˝CŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒXÇ‚̐V‹KŽĄ—Ă–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: •˝Ź29”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, ‹¤“ŻŒ¤‹†ŽŇF—с@rŽĄ1, ‰Á“Ą‚Í‚é, –…”ö[•q, “ŕŽR~•˝, ăŒű­´, “ŕ“cŒ’‘ž˜Y2 (1”÷ś•¨, 2ŽŠO):uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—p‚˘‚˝CŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒXÇ‚̐V‹KŽĄ—Ă–@‚ĚŠJ”­v•˝Ź30”N“x”NŽŸ•ń‘ 2018/7; p.44.

540055. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]yŒö‰vŕ’c–@l ŽO“‡ŠC‰_‹L”Oŕ’cE•˝Ź29”N“xŽO“‡ŠC‰_‹L”Oŕ’cŠwpŒ¤‹†§—ă‹ŕuƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—p‚˘‚˝CŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒXÇ‚̐V‹KŽĄ—Ă–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: •˝Ź29”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, ‹¤“ŻŒ¤‹†ŽŇ: —с@rŽĄ1, ‰Á“Ą‚Í‚é, –…”ö[•q, “ŕŽR~•˝, ăŒű­´, “ŕ“cŒ’‘ž˜Y2 (1”÷ś•¨, 2ŽŠO):uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—p‚˘‚˝CŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒXÇ‚̐V‹KŽĄ—Ă–@‚ĚŠJ”­v•˝Ź30”N“xŒ¤‹†•ń‘ 2018/7; p.1-4.

540056. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]y“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”‘‰ďE2018”N“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”ƒCƒ“ƒ^[ƒ‰ƒ{ƒZƒ~ƒi[E‘ć7‰ńƒtƒ@[ƒWŒ¤‹†‰ď‡“Ż‘ĺ‰ďŠJĂ•â•‹ŕ, •˝Ź30”N“xz˘˜bl: ăŒű‹`•F1, “ŕŽR~•˝ (1”÷ś•¨): •ń‘ 2018/9.

540057. [‚ť‚Ě‘ź] Œ¤‹†•ń‘)]yŒö‰vŕ’c–@l ‘ĺŽRŒ’Nŕ’cE•˝Ź28”N“x (‘ć43‰ń) ‘ĺŽRŒ’Nŕ’cŠwpŒ¤‹†•Ź‹ŕuƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚Ć—n‹Űy‘f‚đ—p‚˘‚˝ƒNƒƒXƒgƒŠƒWƒEƒ€EƒfƒBƒtƒBƒVƒ‹Š´őÇ‚̐V‹KŽĄ—Ă–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: •˝Ź29”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, Œ¤‹†‹Ś—ÍŽŇ: —с@rŽĄ1, ‰Á“Ą‚Í‚é, “ŕŽR~•˝, –…”ö[•q, ăŒű­´ (1”÷ś•¨): 2018”NE2017”N‡•š”Ĺ ”N•ń2018/12; No.43: p.31-3.

[Šw‰ďEŒ¤‹†‰ď“™]

713022. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Ability of disinfectant wipes to remove Clostridioides difficile spores. Hayashi S1, Sasahara T1, Ito M, Morisawa Y: The 9th International Congress of the Asia Pacific Society of Infection Control (2019/3/20), Danang, Vietnam. (—с@rŽĄ1, ůŒ´•Žu1: 1”÷ś•¨)

713023. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Bacterial transmission via medical adhesive tape. Ito M, Araki D, Ishii K, Ikeda N, Fukahori N, Morioka K, Sizuki R, Hayashi S1: The 9th International Congress of the Asia Pacific Society of Infection Control (2019/3/21), Danang, Vietnam. (—с@rŽĄ1: 1”÷ś•¨)

723042. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ‹–Œ‰ŠE•@‰ŠŠłŽŇ—R—ˆ Haemophilus influenzae ‚̐ś•¨Šw“IEˆâ“`“I‘Š“ŻŤ‚ɂ‚˘‚Ä. â–{‘Ľ•q, —с@rŽĄ1, Źě”ü•Ű (1”÷ś•¨): ƒtƒH[ƒTƒ€2018“Œ‹ž (‘ć55‰ń“ú–{ŠáŠ´őÇŠw‰ď) (2018/7/15), “Œ‹ž.

7231028. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A•¨‚ĚŞ‚ć‚č•Ş—Ł‚ł‚ę‚˝Micromonospora sp. KV-964 ‚̐ś—Ťó‚Ć•Ş—ŢŒ¤‹†. ’†‘ş—D”V‰î, ’r“căĈę, •@@W1, ‘ĺ‘ş@’q, ‚‹´—mŽq, ź–{ŒúŽq (1”÷ś•¨): 2018”N“x (‘ć33‰ń) “ú–{•úü‹ŰŠw‰ď‘ĺ‰ď (2018/9/12), “Œ‹ž.

7231029. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)gStreptomyces rosa subsp. notoensishOS-3966Š”‚ސśŽY‚ˇ‚éV‹K nanaomycin—މ‘Ě‚ÉŠÖ‚ˇ‚錤‹†. ź”ö—mF, ‹{–ě@—ĺ, –ěŒű‹g•F, •@@W1, ’†ź@~, d‘şŽŒČ, œAŁ—F–ő, ť’Ë•q–ž, ‚‹´—mŽq, ‘ĺ‘ş@’q, ’†“‡‘ôŽŠ (1”÷ś•¨): 2018”N“x (‘ć33‰ń) “ú–{•úü‹ŰŠw‰ď‘ĺ‰ď (2018/9/12), “Œ‹ž.

723043. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĹŒěŽt‚ŞŽg—p‚ˇ‚éˆă—Ă—pƒe[ƒv‚Ě×‹Ű‰˜ő‚ĆŠÇ—ó‹ľ‚ĚŒŸ“˘. ˆÉ“Ą“šŽq, r–Ř‘ĺ•ă, Îˆä˜aŽq, ’r“c‹IŽq, [–xMŽq, —é–Ř—ŠG, X‰Ş‹v”üŽq, —с@rŽĄ1 (1”÷ś•¨): ‘ć34‰ń“ú–{ŠÂ‹ŤŠ´őŠw‰ď‘‰ďEŠwpW‰ď (2019/2/23), _ŒË.

723044. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ°”÷ƒ‰ƒ}ƒ“‘˝•Ď—ĘƒXƒyƒNƒgƒ‹•Ş‰đ–@‚đ—p‚˘‚˝ ś—ŠˆŤ•¨Žżpenicillin‹y‚Ńavermectin‚Ě‹Ű‘Ě“ŕŒŸo. –xˆär•˝, ˆŔ“Ął_, •@@W1, Ashok Samuel, ’†“‡‘ôŽŠ, ź–{ŒúŽq, ‚‹´—mŽq, ’|ŽRtŽq (1”÷ś•¨): “ú–{‰ťŠw‰ď‘ć99t‹G”N‰ď (2019/3/16), •şŒÉ.

733012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •ł•ÖˆÚAŽĄ—Ă‚đs‚Á‚˝ƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒX (ƒNƒƒXƒgƒŠƒWƒEƒ€)EƒfƒBƒtƒBƒVƒ‹Š´őÇ—á‚É‚¨‚Ż‚é’°“ŕ”÷ś•¨‘p‚̉đÍ. ăŒű‹`•F1, Œă“Ą˜a‹`, –…”ö[•q, “ŕŽR~•˝, ”öč”šl, é‘ăN‹M, —с@rŽĄ1, ‘ĺ‹{’ź–Ř, ‰Á“Ą‚Í‚é (1”÷ś•¨): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733342. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ×–E•Çƒyƒvƒ`ƒhƒOƒŠƒJƒ“\‘˘‰đÍ–@‚ĚŠm—§. •@@W1, ’†“‡‘ôŽŠ, ˆî‹´—C‹N, ‰–ŒŠ˜a˜N, ‚‹´—mŽq, ‘ĺ‘ş@’q, ź–{ŒúŽq (1”÷ś•¨): ‘ć7‰ńƒtƒ@[ƒWŒ¤‹†‰ďA“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”ƒCƒ“ƒ^[ƒ‰ƒ{ƒZƒ~ƒi[‡“Ż‘ĺ‰ď (2018/8/31), ‘Š–ÍŒ´.

733013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒX (ƒNƒƒXƒgƒŠƒWƒEƒ€)EƒfƒBƒtƒBƒVƒ‹Š´őÇ‚ɑ΂ˇ‚é•ł•ÖˆÚA‚É‚¨‚Ż‚éƒqƒg’°“ŕ”÷ś•¨‘p‰đÍ. ăŒű‹`•F1, Œă“Ą˜a‹`, –…”ö[•q, “ŕŽR~•˝, ”öč”šl, é‘ăN‹M, —с@rŽĄ1, ‘ĺ‹{’ź–Ř, ‰Á“Ą‚Í‚é (1”÷ś•¨): ‘ć7‰ńƒtƒ@[ƒWŒ¤‹†‰ďE2018”N“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”ƒCƒ“ƒ^[ƒ‰ƒ{ƒZƒ~ƒi[‡“Ż‘ĺ‰ď (2018/8/31), ‘Š–ÍŒ´.

733014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒT[ƒWƒJƒ‹ƒe[ƒv‚Ě×‹Ű‰˜ő‚ĆŠÇ—ó‹ľ‚ĚŒŸ“˘. ˆÉ“Ą“šŽq, r–Ř‘ĺ•ă, Îˆä˜aŽq, ’r“c‹IŽq, [–xMŽq, —é–Ř—ŠG, X‰Ş‹v”üŽq, —с@rŽĄ1 (1”÷ś•¨): ‘ć84‰ń_“ŢěŒ§Š´őÇˆăŠw‰ď (2018/9/1), ‰Ą•l.

733015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆę”ʉ“S‹@‚đ—˜—p‚ľ‚˝V‹KƒEƒCƒ‹ƒX¸ť–@‚ĚŠm—§. “ߐ{ě’‰–í, “ŕŽR~•˝, “ŕŽRˆÉ‘ă, ŽŒ´—˛Žq, źč–ΓW, ăŒű‹`•F1, ‘şă—TM, …ăŒ\“ń˜Y, ăŒű‰ëO (1”÷ś•¨): ‘ć101‰ń“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”‘‰ď (2018/11/1), “Œ‹ž.

733016. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) BŒQ˜A˝‹…‹ŰŒŸ¸¸“xŒüă‚đ–ÚŽw‚ľ‚˝ƒtƒ@[ƒW—n‹Űy‘f‚Ě—˜—p. Ź•ű‰ë–ç, “ŕŽR~•˝, “ߐ{ě’‰–í, “ŕŽRˆÉ‘ă, ăŒű‹`•F1, źˆäGm, źč–ΓW, ‰Ô–؏G–ž, ăŒű‰ëO (1”÷ś•¨): ‘ć101‰ń“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”‘‰ď (2018/11/1), “Œ‹ž.

733343. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ďj] (ˆę”ʍu‰‰) ƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚đ—˜—p‚ľ‚˝V‹KƒfƒBƒtƒBƒVƒ‹‹ŰŠ´őÇ‚ĚŽĄ—Ă–@‚ĚŠJ”­. ăŒű‹`•F (”÷ś•¨): ‘ć31‰ń‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰ČŒ¤‹†ƒtƒH[ƒ‰ƒ€ (2018/11/22), ‘Š–ÍŒ´.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H28-540001. [‚ť‚Ě‘ź] uŽtA”CˆĽŽA. ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY2016/5; 366: 7.

H28-540002. [‚ť‚Ě‘ź] •˝Ź28”N“x•ś•”‰ČŠwČ‰ČŠwŒ¤‹†”ď•Ź‚đŽó‚Ż‚Ä. ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY2016/11; 371: 7.

H29-540002. [‚ť‚Ě‘ź] ‚­‚ˇ‚Ě‚Ť ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY2017/7; 377: 8.

H29-540003. [‚ť‚Ě‘ź] –kŠC“š”މ_–qęŽŔK‚ÉŽQ‰Á‚ľ‚Ä. ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY2017/11; 380: 12.

H29-540004. [‚ť‚Ě‘ź] •ŇWŒă‹L. ăŒű‹`•F (”÷ś•¨): –k—˘‘ĺŠwˆăŠw•”ƒjƒ…[ƒY2017/11; 380: 24.


Šńś’ŽŠw

[Šwp˜_•ś]

110039. [Œ´’˜] Trematode infections in farm animals and their vector snails in Saint Martin's Island, the southeastern offshore area of Bangladesh in the Bay of Bengal. Yasin MG, Alim MA, Anisuzzaman, Ahasan SA, Munsi MN, Chowdhury EH, Hatta T1, Tsuji N1, Mondal MMH: J Vet Med Sci 2018/4; 80 (4): 684-8. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)

110040. [Œ´’˜] Linguatula serrata, a food-borne zoonotic parasite, in livestock in Bangladesh: Some pathologic and epidemiologic aspects. Islam R, Anisuzzaman, Hossain MS, Alam Z, Islam A, Khan AHNA, Kabir ME, Hatta T1, Alim A, Tsuji N1: Vet Parasitol Reg Stud Reports 2018/8; 13: 135-40. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)

110041. [Œ´’˜] Glutathione S-transferases play a role in the detoxification of flumethrin and chlorpyrifos in Haemaphysalis longicornis. Hernandez EP, Kusakisako K, Talactac MR, Galay RL, Hatta T1, Fujisaki K, Tsuji N1, Tanaka T: Parasit Vectors 2018/9; 11 (1): 460. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)

110042. [Œ´’˜] Positive phototropism is accelerated in Biomphalaria glabrata snails by infection with Schistosoma mansoni. Maeda H, Hatta T1, Tsubokawa D1, Mikami F, Nishimaki T2, Nakamura T, Anisuzzaman, Matsubayashi M, Ogawa M3, da Costa CP, Tsuji N1: Parasitol Int 2018/10; 67 (5): 609611. (”Ş“cŠxŽm1, ’ؐě‘ĺŒĺ1, ź–Šr”V2, ŹěŒł”V3, ’ҁ@Ž—˜1: 1Šńś’Ž, 2Œ`‘ÔŒn, 3‰đ–U)

110043. [Œ´’˜] Novel Characteristics of Mitochondrial Electron Transport Chain from Eimeria tenella. Matsubayashi M, Inaoka DK, Komatsuya K, Hatta T1, Kawahara F, Sakamoto K, Hikosaka K, Yamagishi J, Sasai K, Shiba T, Harada S, Tsuji N1, Kita K: Genes (Basel) 201/1; 10 (1). pii: E29. doi: 10.3390/genes10010029. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)

[Šw‰ďEŒ¤‹†‰ď“™]

713024. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) RNAi mediated suppression of venestatin in the subcutaneous migration of Strongyloides venezuelensis. Tsubokawa D1, Hatta T1, Kikuchi T, Mikami F, Maruyama H, Tsuji N1: The International Congress of Parasitology (ICOPA 2018) (2018/8/23), Daegu, Korea. (’ؐě‘ĺŒĺ1, ”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)

723045. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ZŒŒ‹z’ŽÇ‚É‚¨‚Ż‚éI––“œ‰ťŽY•¨Žó—e‘Ě (RAGE) ‚Ě‹@”\‰đÍ. Źňčń‰Ě1, ’ؐě‘ĺŒĺ2, ”Ş“cŠxŽm2, ŽOă–[Žq3, ’†‘ş@Œ’, ŽR–{–ő•F, ’ҁ@Ž—˜2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šńś’Ž, 3—\–hˆăŠwŒn): ‘ć88‰ń“ú–{Šńś’ŽŠw‰ď‘ĺ‰ď (2019/3/15), ’ˇč.

723046. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒlƒYƒ~•Ú’ŽTrichuris muris ‚̐V‹KŠ”ěŹ‚ĚŽŽ‚Ý. Šâč@x, ŹŽR_ˆę1, •˝@Œ’‰î, ‰Š@ƒŒ˜ (1Šńś’Ž): ‘ć88‰ń“ú–{Šńś’ŽŠw‰ď‘ĺ‰ď (2019/3/16), ’ˇč.

723047. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •łü’Ž‚̏hŽĺ‘Ě“ŕˆÚs‚É‚¨‚Ż‚éI––“œ‰ťŽY•¨Žó—e‘Ě (RAGE) ‚Ě–đŠ„. ’ؐě‘ĺŒĺ1, ”Ş“cŠxŽm1, Źňčń‰Ě2, ŽOă–[Žq3, ŽR–{–ő•F, ŠŰŽRŽĄ•F, ’ҁ@Ž—˜1 (1Šńś’Ž, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—\–hˆăŠwŒn): ‘ć88‰ń“ú–{Šńś’ŽŠw‰ď‘ĺ‰ď (2019/3/16), ’ˇč.

733017. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒxƒlƒXƒ^ƒ`ƒ“ˆâ“`ŽqƒmƒbƒNƒ_ƒEƒ“‚É‚ć‚é•łü’Ž‚̏hŽĺ‘Ě“ŕˆÚs‚ւ̉e‹ż. ’ؐě‘ĺŒĺ1, ”Ş“cŠxŽm1, Źňčń‰Ě2, ŽOă–[Žq3, ’ҁ@Ž—˜1 (1Šńś’Ž, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—\–hˆăŠwŒn): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€/‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/9), ‘Š–ÍŒ´.

733018. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒxƒlƒXƒ^ƒ`ƒ“ˆâ“`ŽqƒmƒbƒNƒ_ƒEƒ“•łü’Ž‚đ—p‚˘‚˝Š´őŽŔŒą‚Ě“WŠJ. ’ؐě‘ĺŒĺ1, ”Ş“cŠxŽm1, Źňčń‰Ě2, ŽOă–[Žq3, ’ҁ@Ž—˜1 (1Šńś’Ž, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—\–hˆăŠwŒn): ‘ć26‰ń•ŞŽqŠńś’ŽŠwƒ[ƒNƒVƒ‡ƒbƒv/‘ć16‰ń•ŞŽqŠńś’ŽEƒ}ƒ‰ƒŠƒAŒ¤‹†ƒtƒH[ƒ‰ƒ€‡“Ż‘ĺ‰ď (2018/9/22), źŽRŽs.

733019. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) I––“œ‰ťŽY•¨Žó—e‘Ě (RAGE) Œ‡‘šƒ}ƒEƒX‚đ‚ŕ‚ż‚˘‚˝ĺž’ŽŠ´őŽŔŒą. ’ؐě‘ĺŒĺ1, Źňčń‰Ě2, ”Ş“cŠxŽm1, ŽOă–[Žq3, ŠŰŽRŽĄ•F, ’ҁ@Ž—˜1 (1Šńś’Ž, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—\–hˆăŠwŒn): ‘ć12‰ń徒ŽŒ¤‹†‰ď (2018/11/18), Ă‰Ş.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110007. [Œ´’˜] Characterization and expression analysis of a newly identified glutathione S-transferase of the hard tick Haemaphysalis longicornis during blood-feeding. Hernandez EP, Kusakisako K, Talactac MR, Galay RL, Hatta T1, Matsuo T, Fujisaki K, Tsuji N1, Tanaka T: Parasit Vectors 2018/2; 11 (1): 91. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’Ž)


•a—Šw (‘ş‰_’PˆĘ)

[Šwp˜_•ś]

110044. [Œ´’˜] Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma. Matsumoto T1, Nagashio R2, Ryuge S3, Igawa S3, Kobayashi M, Fukuda E, Goshima N, Ichinoe M1, Jiang SX, Satoh Y4, Masuda N, Murakumo Y1, Saegusa M1, Sato Y2: Pathol Int 2018/4; 68 (4): 232-40. (ź–{r‰p1, ’ˇ‰–@—ş2, —´‰ŘTˆę˜Y3, ˆäě@‘3, ˆęŒËš–ž1, ˛“Ą”Vr4, ‘ş‰_–FŽ÷1, ŽOŽ}@M1, ˛“Ą—Yˆę2: 1•a—, 2ˆă—ÉqśŠw•”, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO)

110045. [Œ´’˜] Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer. Yanagita K, Nagashio R1, Jiang SX, Kuchitsu Y, Hachimura K1, Ichinoe M2, Igawa S3, Fukuda E, Goshima N, Satoh Y4, Murakumo Y2, Saegusa M2, Sato Y1: Am J Pathol 2018/6; 188 (6): 1328-33. (’ˇ‰–@—ş1, ”Ť‘ş˜a’j1, ˆęŒËš–ž2, ˆäě@‘3, ˛“Ą”Vr4, ‘ş‰_–FŽ÷2, ŽOŽ}@M2, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2•a—, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO)

110046. [Œ´’˜] CD109 deficiency induces osteopenia with an osteoporosis-like phenotype in vivo. Mii S, Hoshino A, Enomoto A, Murakumo Y1, Ito M, Yamaguchi A, Takahashi M: Genes Cells 2018/7; 23 (7): 590-8. (‘ş‰_–FŽ÷1: 1•a—)

110047. [Œ´’˜] Prognostic significance of G6PD expression and localization in lung adenocarcinoma. Nagashio R1, Oikawa S, Yanagita K2, Hagiuda D2, Kuchitsu Y2, Igawa S3, Naoki K3, Satoh Y4, Ichinoe M5, Murakumo Y5, Saegusa M5, Sato Y1: Biochim Biophys Acta Proteins Proteom 2019/1; 1867 (1): 38-46. (’ˇ‰–@—ş1, –ö“cŒ›Œá2, ”‹ś“c‘ĺ‰î2, ‹€’Ă—L‹I2, ˆäě@‘3, —P–؍Ž•F3, ˛“Ą”Vr4, ˆęŒËš–ž5, ‘ş‰_–FŽ÷5, ŽOŽ}@M5, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO, 5•a—)

110048. [Œ´’˜] Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma. Hagiuda D, Nagashio R1, Ichinoe M2, Tsuchiya B1, Igawa S3, Naoki K3, Satoh Y4, Murakumo Y2, Saegusa M2, Sato Y1: Biomed Res 2019/2; 40 (1): 17-27. (’ˇ‰–@—ş1, ˆęŒËš–ž2, “y‰Žg1, ˆäě@‘3, —P–؍Ž•F3, ˛“Ą”Vr4, ‘ş‰_–FŽ÷2, ŽOŽ}@M2, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2•a—, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO)

510003. [‘ŕ] CD109 and squamous cell carcinoma. Qi R, Dong F, Liu Q, Murakumo Y1, Liu J: J Transl Med 2018/4; 16 (1): 88. (‘ş‰_–FŽ÷1: 1•a—)

[’˜@‘]

622001. [Šwp‘ (–|–óE•Ş’SŽˇ•M)]yƒƒrƒ“ƒX@Šî‘b•a—Šw@Œ´‘10”Łz‘ć20Í “ŕ•Ş”ĺŒn, p.795-845. ‘ş‰_–FŽ÷ (•a—), ŠÄ–ó: –Lš LĆ, ‚‹´‰ë‰p, ŠŰ‘Po”Ĺ, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

723048. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) GPIƒAƒ“ƒJ[Œ^’`”’CD109‚Ě”xG•˝ă”çŠŕ×–E‚É‚¨‚Ż‚é”­ŒťˆÓ‹`‚̉đÍ. ‘ş‰_–FŽ÷1, Žľ‰Y“Ţ“sŽŔ, ŸNˆä–ő‚1, ˆęŒËš–ž1 (1•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723049. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) REV7‚Ě”­Œť—}§‚͍RŠŕÜ’ďRŤăó×–EŽîᇂ̃VƒXƒvƒ‰ƒ`ƒ“Š´ŽóŤ‚đ‘‹­‚ˇ‚é. ŸNˆä–ő‚1, ’‡“c“TL, ‚‹´‰ë‰p, ‘ş‰_–FŽ÷1 (1•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723050. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šG•˝ă”çŠŕ‚É‚¨‚Ż‚éCD109‚Ě”­ŒťŒŸ“˘: Ú’…ˆöŽq‚Ć‚ĚŠÖ˜A. ˆęŒËš–ž1, ‘ş‰_–FŽ÷1, ”~‘ň“ÖŽq2 (1•a—, 2Œ`‘ÔŒn): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723051. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‘BŠŕ‚É‚¨‚Ż‚éNAP1L1‚Ě—\Œă—\‘ރ}[ƒJ[‚Ć‚ľ‚Ä‚Ě—L—pŤ‚ɂ‚˘‚Ä. ’ˇ‰–@—ş1, ”‹ś“c‘ĺ‰î2, ‹€’Ă—L‹I2, –ö“cŒ›Œá, ”Ť‘ş˜a’j1, “y‰Žg1, ˆęŒËš–ž3, ‘ş‰_–FŽ÷3, Ó@˘ˆŽ, ˛“Ą—Yˆę1 (1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723052. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) REV7‚Ě—}§‚͍RŠŕÜ’ďRŤăó×–EŽîᇂ̉ťŠw—Ă–@Š´ŽóŤ‚đ‘‹­‚ˇ‚é. ŸNˆä–ő‚1, ’‡“c“TL, ‚‹´‰ë‰p, ‘ş‰_–FŽ÷1 (1•a—): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.

723053. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DNA‘š‘ϐŤ‹@\‚ÉŠÖ—^‚ˇ‚éREV7ˆâ“`Žq‚Ě”­Œť’˛ß‹@\‚̉đÍ. ‘ş‰_–FŽ÷1, ŸNˆä–ő‚1 (1•a—): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.

723054. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚Ş‚ń×–EZŒ`‘Ԃ̐§Œä‹@\‚̉đ–ž. ‰Á“Ą‘ôĆ1, ‘ş‰_–FŽ÷1, Jenkins Robert, Sahai Erik (1•a—): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.


•a—Šw (ŽOŽ}’PˆĘ)

[Šwp˜_•ś]

110049. [Œ´’˜] Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma. Matsumoto T1, Nagashio R2, Ryuge S3, Igawa S3, Kobayashi M, Fukuda E, Goshima N, Ichinoe M1, Jiang SX, Satoh Y4, Masuda N, Murakumo Y1, Saegusa M1, Sato Y2: Pathol Int 2018/4; 68 (4): 232-40. (ź–{r‰p1, ’ˇ‰–@—ş2, —´‰ŘTˆę˜Y3, ˆäě@‘3, ˆęŒËš–ž1, ˛“Ą”Vr4, ‘ş‰_–FŽ÷1, ŽOŽ}@M1, ˛“Ą—Yˆę2: 1•a—, 2ˆă—ÉqśŠw•”, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO)

110050. [Œ´’˜] Immunophenotypic profile as a predictor of prognosis in advanced ovarian carcinoma. Yokoi A1, Matsumoto T2, Watanabe G, Tochimoto M, Saegusa M2: Hum Pathol 2019/3; 85: 210-20. (‰Ąˆäˆ¤1, ź–{r‰p2, ŽOŽ}@M2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—)

110051. [Œ´’˜] TGF-ƒŔ-mediated LEFTY/Akt/GSK-3ƒŔ/Snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas. Matsumoto T1, Yokoi A2, Hashimura M3, Oguri Y3, Akiya M1, Saegusa M1: Mol Carcinog 2018/8; 57 (8): 957-67. (ź–{r‰p1, ‰Ąˆäˆ¤2, ‹´‘ş”ü‹I3, ŹŒINŽq3, H’JšŽj1, ŽOŽ}@M1: 1•a—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn)

[Šw‰ďEŒ¤‹†‰ď“™]

712005. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) A functional role of LEFTY as a molecular marker for ovarian clear cell carcinom. Matsumoto T1, Akiya M1, Kawashima Y, Kodera Y, Yokoi A2, Oguri Y3, Hashimura M3, Saegusa M1: 9th Asia-Oceania Human Proteome Organization Conference (2018/5/18), Osaka, Japan. (ź–{r‰p1, H’JšŽj1, ‰Ąˆäˆ¤2, ŹŒINŽq3, ‹´‘ş”ü‹I3, ŽOŽ}@M1: 1•a—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn)

722004. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —‘‘ƒ–ž×–EŠŕ‚É‚¨‚Ż‚éLefty”­Œť‚Ć‚ť‚Ě—Ő°“IˆÓ‹`. ź–{r‰p1, H’JšŽj1, ě“‡—S‰î, ŹŽ›‹`’j, ‰Ąˆäˆ¤2, ŹŒINŽq3, ‹´‘ş”ü‹I3, ŽOŽ}@M1 (1•a—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn): ‘ć69‰ń“ú–{“d‹C‰j“ŽŠw‰ď‘‰ď (2018/8/8), ‘Š–ÍŒ´.

723055. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŠŕLBCŒŸ‘Ě‚Ěˆâ“`ŽqŒŸ¸‰ž—p‚ÖŒü‚Ż‚˝ŒŸ“˘|”|—{×–E‚đ—p‚˘‚˝‰đÍ|. ź”ö—R‹IŽq1, ‹g“c@Œ÷2, ŽR‰ş˜a–ç3, ŽOŒEŤŽj4, “ŕ“Ą‰ëm4, ŕV–ěáÁ—Žq, ‘ş‰_–FŽ÷2, ˛“Ą”Vr4 (1•a‘ԁEf—ĂŒn, 2•a—, 3•a—•”, 4ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/3), ŽD–y.

723056. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A possible case of IgG4-related disease in the brain. H’JšŽj1, Œ´@“ÖŽq2, •‚F—´‘ž˜Y3, ˛“ĄŸl4, ŒG•”rG4, ŽOŽ}@M1 (1•a—, 2–k—˘Œ¤‹†Š•a‰@, 3•úŽËü (‰ć‘œ), 4”]ŠO): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723057. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒ‚ĚŽq‹{“ŕ–ŒÇŤůN–E‚Š‚ç–ž×–EŠŕ‚Ě”­Šŕ‰ß’ö‚É‚¨‚Ż‚éTGF-ƒŔ/Nodal/LEFTYƒVƒOƒiƒ‹Œn‚Ě–đŠ„. ŽO‰Y—“ŢŽq1, ‹´‘ş”ü‹I2, ŹŒINŽq2, ŽOŽ}@M3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Œ`‘ÔŒn, 3•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723058. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒŠŕ‚Ěƒ^ƒ“ƒpƒN”­Œťƒvƒƒtƒ@ƒCƒ‹‚É‚ć‚éÄ”­E—\Œă—\‘ރVƒXƒeƒ€‚̍\’z. ‰Ąˆäˆ¤1, ź–{r‰p2, “n•Ó@‹, ‹´‘ş”ü‹I3, ŽOŽ}@M2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Œ`‘ÔŒn): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723059. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žq‹{“ŕ–ŒŠŕ‚ĚƒvƒƒQƒXƒeƒƒ“ (MPA) —Ă–@‚É‚¨‚Ż‚éLEFTY‚Ě‹@”\‰đÍ. ‹´‘ş”ü‹I1, –Ř“‡‘ĺ‹P, ‹´–{䝎Ŕ, ŹŒINŽq1, ŽOŽ}@M2 (1Œ`‘ÔŒn, 2•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723060. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒ‚ĚŽq‹{“ŕ–ŒÇ”X–E‚Ě”­Šŕ‰ß’ö‚É‚¨‚Ż‚éƒŔ-ƒJƒeƒjƒ“ˆŮí‚Ćˆâ“`Žq•sˆŔ’萍‚̉đÍ. —FLŠ˛‹v1, ź–{r‰p2, ŹŒINŽq3, ŽO‰Y—“ŢŽq1, ŽOŽ}@M2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Œ`‘ÔŒn): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.

723061. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Olfactomedin-4‚̉ŠÇŤ’°ŽžŠłŠÖ˜AŽîᇔ­ś‚É‚¨‚Ż‚é–đŠ„. ‰ĄŽR@Œd1, ‹g“c@Œ÷2, ‹´‘ş”ü‹I3, ŽOŽ}@M2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Œ`‘ÔŒn): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/23), ŽD–y.

723062. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TGFbeta-mediated LEFTY/Akt/GSK3b/snail modulates EMT/CSC properties in ovarian clear cell carcinoma. ź–{r‰p1, ‰Ąˆäˆ¤2, ‹´‘ş”ü‹I3, ŹŒINŽq3, H’JšŽj1, ŽOŽ}@M1 (1•a—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/23), ŽD–y.

723063. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) äP‰čŽî‚Ě’áŽ_‘fŠÂ‹Ť‚É‚¨‚Ż‚éHIF-1ƒż/AktˆË‘śŤ‚Ş‚ńŠ˛×–E‰ť‹@\‚ĚŘ–ž. Œ˘Ž”@‰~1, Œ´@“ÖŽq, ˆŔˆä”ü]2, ŽÄŒ´ˆę—z3, ŒG•”rG3, ŽOŽ}@M1 (1•a—, 2Œ`‘ÔŒn, 3”]ŠO): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/25), “Œ‹ž.


‰qśŠw

[Šwp˜_•ś]

110052. [Œ´’˜] Frequency of unsatisfactory cervical cytology smears in cancer screening of Japanese women: A systematic review and meta-analysis. Hosono S, Terasawa T, Katayama T, Sasaki S, Hoshi K1, Hamashima C: Cancer Sci 2018/4; 109 (4): 934-43. (Ż@‰Ŕ–F1: 1‰qś)

110053. [Œ´’˜] Employment sustainability after return to work among Japanese stroke survivors. Endo M, Haruyama Y, Muto G1, Yokoyama K, Kojimahara N, Yamaguchi N: Int Arch Occup Environ Health 2018/8; 91 (6): 717-24. (•“Ą@„1: 1‰qś)

110054. [Œ´’˜] Changes in thallium distribution in the scalp hair after an intoxication incident. Matsukawa T, Chiba M, Shinohara A, Matsumoto-Omori Y1, Yokoyama K.: Forensic Sci In. 2018/10; 291: 230-3. (‘ĺX—R‹I1: 1‰qś)

110055. [Œ´’˜] Application of the MM040 in the diagnosis of "sick house syndrome", a Japanese concept derived from sick building syndrome. Suto H, Miyajima E1, Sugiura Y2, Suzuki S, Yoshioka N, Nakashima H, Tsunoda M: Japanese J of Clinical Ecology 2018/10; 27 (1): 1-14. (‹{“‡]—˘Žq1, ™‰Y—R”üŽq2: 1‰qś, 2—\–hˆăŠwŒn)

110056. [Œ´’˜] Work Sustainability Among Male Cancer Survivors After Returning to Work. Endo M, Haruyama Y, Muto G1, Kiyohara K, Mizoue T, Kojimahara N, Yamaguchi N: J Epidemiol 2018; 28 (2): 88-93. (•“Ą@„1: 1‰qś)

110057. [Œ´’˜] Hospital-based screening to detect patients with cadmium nephropathy in cadmium-polluted areas in Japan. Sasaki T, Horiguchi H1, Arakawa A, Oguma E, Komatsuda A, Sawada K, Murata K, Yokoyama K, Matsukawa T, Chiba M, Omori Y1, Kamikomaki N: Environ Health Prev Med 2019/1; 24 (1): 8. doi: 10.1186/s12199-019-0762-3. (–xŒű•ş„1, ‘ĺX—R‹I1: 1‰qś)

110058. [Œ´’˜] Information exchange using a prescribed form and involvement of occupational health nurses promotes occupational physicians to collaborate with attending physicians for supporting workers with illness in Japan. Muto G1, Ishi-Nakamura R, Yokoyama K, Kitamura F, Omori Y1, Saito M, Endo M: Ind Health 2019/1; 57 (1): 10-21. (•“Ą@„1, ‘ĺX—R‹I1: 1‰qś)

110059. [Œ´’˜] Durations of first and second periods of depression-induced sick leave among Japanese employees: the Japan sickness absence and return to work (J-SAR) study. Endo M, Haruyama Y, Mitsui K, Muto G1, Nishiura C, Kuwahara K, Wada H, Tanigawa T: Ind Health 2019/2; 57 (1): 22-8. (•“Ą@„1: 1‰qś)

110060. [Œ´’˜] A cooperative support model for cancer therapy and employment balance: from focus-group interviews of health and business professionals. Takahashi M, Uetake C, Nakayama N, Eura A, Yamaguchi N, Kameda Y, Muto G1, Endo M, Kawamata K, Fujii T, Oka H, Matsudaira K: Ind Health 2019/2; 57 (1): 40-51. (•“Ą@„1: 1‰qś)

110061. [Œ´’˜] Toward the harmonization of work with treatment and prevention for patients with chronic respiratory failure. Wada H, Fukumoto S, Tamamura K, Muto G1, Ueki J, Tanigawa T: Ind Health 2019/2; 57 (1): 84-9. (•“Ą@„1: 1‰qś)

110062. [Œ´’˜] Promoting and inhibiting factors for the use of validated dietary assessment questionnaires in health check-up counseling: from occupational health nurses and dietitians' perspective. Katagiri R, Muto G1, Sasaki S: Ind Health 2019/2; 57 (1): 90-8. (•“Ą@„1: 1‰qś)

110063. [Œ´’˜] Development and Validation of Oral Bleeding Risk Scoring System (OBRS) for Predicting Post-tooth-extraction Bleeding in Patients Undergoing Treatment with Warfarin: A Single Centre Study. Fukuzawa S, Hoshi K1, Okamoto T, Ando T: Tokyo Women's Medical University Journal. Released February 07, 2019, Online. DOI: https://doi.org/10.24488/twmuj.2018001. (Ż@‰Ŕ–F1: 1‰qś)

520003. [‘ŕ]yƒVƒŠ[ƒY: ŠwpŒ¤‹†‚Š‚ç‚̏­Žq‰ť‘΍ô|“ú–{‰qśŠw‰ď‚Š‚ç‚Ě’ńŒž‚ÉŒü‚Ż‚āz­Žq‚—‘΍ô‚Ć‚ľ‚Ă̐E‹ĆśŠˆ‚ĆŒ’NEŽĐ‰ď–â‘č‚Ě—ź—§: ”D›sŤ•ŰŒě, ˆçŽ™‚Č‚ç‚Ń‚ÉŽž•aŽĄ—Âɑ΂ˇ‚éŽx‰‡. •“Ą@„1, ‰ĄŽR˜am, ‰““ĄŒšŽ÷ (1‰qś): “ú–{‰qśŠwŽGŽ 2018/5; 73 (2): 200-9.

520004. [‘ŕ] “ú–{‰qśŠw‰ď‚É‚¨‚Ż‚鏭Žq‰ť‘΍ô’ńŒž‚ÉŒü‚Ż‚Ä: “ú–{‰qśŠw‰ď­Žq‰ť‘΍ôƒ[ƒLƒ“ƒOƒOƒ‹[ƒv‚É‚ć‚é‚Ć‚č‚Ü‚Ć‚ß. –ě‘ş‹ąŽq, ŠĄ“c•c, r–Ř“ÖŽq, ź‰ŞÎŽq, •“Ą@„1, Šâˆä”üK, ‹Ń’J‚Ü‚č‚ą, ˆäă‚Ü‚čŽq, ’߃––ě‚ľ‚Ě‚Ô, –k–쏮”ü, ’Ň ^‹|, ”Ń“‡˛’mŽq, ă“c‰Ŕ‘ă, ă“‡’ʍ_, ŽRăp‘R‘ž˜Y, â“c´”ü, ˆÉ–؉ë”V, –öŕV—T”V, ‰Á“ĄšŽu, ‰ĄŽR˜am, Źňş•v, ‘ĺ’΍„–¤ (1‰qś): “ú–{‰qśŠwŽGŽ 2019/1; 74: 18034. doi: https://doi.org/10.1265/jjh.18034

522004. [uŔ]yŽY‹Ć•ŰŒ’‚Ć‘‡Œ’fzŽĄ—ÂƐE‹ĆśŠˆ‚Ě—ź—§Žx‰‡|˜AŒg‚É‚ć‚édÇ‰ť—\–h‚ĆFitness for Work. •“Ą@„1, ‰ĄŽR˜am, ‰““ĄŒšŽ÷, ‘ĺ‘O—˜“š, ”’“cç‰ŔŽq, ŞŽu–šŽq, •Ÿ“c@—m (1‰qś): ‘‡Œ’f 2018/5; 45 (2): 336-43.

522005. [uŔ]yŽY‹Ć•ŰŒ’‘“ŕŠÖ˜Aƒjƒ…[ƒXz‘ć88‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď•ń (3/22-3/24: “Œ‹ž). •“Ą@„1, ‰ĄŽR˜am, –k‘ş•ś•F, ×ě‚Ü‚äŽq (1‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2018/7; 41 (4): 65-9.

530001. [‚ť‚Ě‘ź (Editorial)] Harmonizing work with diseases treatment and prevention. Muto G1, Yokoyama K, Endo M, Fujino Y: Ind Health 2019/1; 57 (1): 1-2. (•“Ą@„1: 1‰qś)

540005. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ƒjƒRƒ`ƒ“‘ă‘Ö—Ă–@ (NRT) ‚É‚ć‚Á‚Ä‹Ö‰Œ‚Ĺ‚Ť‚é‚Š? [Nicotine replacement therapy versus control for smoking cessation (Cochrane Systematic Review - Intervention Version published: 31 May 2018. https://doi.org/10.1002/14651858.CD000146.pub5)]Nicotine replacement therapy versus control for smoking cessation)] Ż@‰Ŕ–F (‰qś): 2018/5. https://www.cochrane.org/ja/CD000146/nikotindai-ti-liao-fa-nrtniyotutejin-yan-dekiruka.

540006. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ‹Ö‰ŒƒRƒ“ƒeƒXƒg‚Í’†E’ˇŠú“I‚É‹Ö‰Œ‚ɑ΂ľ‚ÄŒř‰Ę‚Ş‚ ‚é‚Š? [Competitions for smoking cessation (Cochrane Systematic Review - Intervention Version published: 20 February 2019. https://doi.org/10.1002/14651858.CD013272)] Ż@‰Ŕ–F (‰qś): 2019/2. https://www.cochrane.org/ja/CD013272/jin-yan-kontesutohazhong-chang-qi-de-nijin-yan-nidui-sitexiao-guo-gaaruka.

540007. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ƒp[ƒgƒi[‚â‰Ć‘°, ‚Ü‚˝‚Í’‡ŠÔ‚É‚ć‚é1‘Î1‚ĚŽx‰‡‚đ‹­‰ť‚ˇ‚é‚ą‚Ć‚É‚ć‚Á‚Ä‹Ö‰Œ‚ސŹŒ÷‚ˇ‚é‚Š? [Enhancing partner support to improve smoking cessation (Cochrane Systematic Review - Intervention Version published: 13 August 2018. https://doi.org/10.1002/14651858.CD002928.pub4)]. Ż@‰Ŕ–F (‰qś): 2019/2. https://www.cochrane.org/ja/CD002928/patonayajia-zu-matahazhong-jian-niyoru1-dui-1-nozhi-yuan-woqiang-hua-surukotoniyotutejin-yan-gacheng.

540008. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y•˝Ź30”N“x@“ü‰@ŠłŽŇ•aE—đ’˛¸Šî‘b‰đÍ (2005”N“x`2016”N“x•aE—đƒf[ƒ^Žg—p)zŹ“‡Œ´“TŽq, —§“ššK, Ż@‰Ŕ–F1, –L“cÍG (1‰qś): “Ć—§s­–@l˜J“­ŽŇŒ’NˆŔ‘S‹@\, 2019/3. https://www.research.johas.go.jp/bs/doc/20190307.pdf.

540009. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y“Ć—§s­–@l˜J“­ŽŇŒ’NˆŔ‘S‹@\@˜JĐŽž•a“™ˆăŠwŒ¤‹†EŠJ”­, •‹yŽ–‹Ć (•˝Ź26”N“x`•˝Ź30”N“x) —Ěˆć–źu˜JĐŽž•a“™‚ĚŒ´ˆö‚Ɛf’fEŽĄ—Áv—ĚˆćzŒ¤‹†ŠJ”­ƒe[ƒ}: ‰^“ŽŠíŠOf—Ă‚ĚW–ń‰ť‚É‚ć‚鎥—ÐŹŃŒüă‚Ć‘ŠúŽĐ‰ď•œ‹A‚đ–ÚŽw‚ľ‚˝’Tő“IŒ¤‹†. ŽOă—eŽi, ŽR–{^ˆę, ‰Şč—TŽi, â–{“N–ç, ÎˆäŒj•ă, ˆäŒű_ˆę, Ż@‰Ŕ–F1, ‰Ş@Œh”V (1‰qś): ‘ć3Šú˜JĐŽž•a“™ˆăŠwŒ¤‹†u‰^“ŽŠíŠO‹@”\ÄŒš‚ÉŒW‚錤‹†EŠJ”­, •‹yvŒ¤‹†•ń‘i˜JĐŽž•a“™ˆăŠwŒ¤‹†EŠJ”­, •‹yvŒ¤‹†•ń‘ 2019/3; p.1-14.

540010. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y“Ć—§s­–@l˜J“­ŽŇŒ’NˆŔ‘S‹@\@˜JĐŽž•a“™ˆăŠwŒ¤‹†EŠJ”­, •‹yŽ–‹Ću˜JĐŽž•a“™‚ĚŒ´ˆö‚Ɛf’fEŽĄ—Áv—ĚˆćzŒ¤‹†ŠJ”­ƒe[ƒ}: ‰^“ŽŠíŠOf—Ă‚ĚW–ń‰ť‚É‚ć‚鎥—ÐŹŃŒüă‚Ć‘ŠúŽĐ‰ď•œ‹A‚đ–ÚŽw‚ľ‚˝’Tő“IŒ¤‹† (•˝Ź26”N“x`•˝Ź30”N“x). ŽOă—eŽi, ŽR–{^ˆę, ‰Şúą—TŽi, â–{“N–ç, ÎˆäŒj•ă, ˆäŒű_ˆę, Ż@‰Ŕ–F1, ‰Ş@Œh”V (1‰qś): ‘ć3Šú˜JĐŽž•a“™ˆăŠwŒ¤‹†u‰^“ŽŠíŠO‹@”\ÄŒš‚ÉŒW‚錤‹†EŠJ”­, •‹yvŒ¤‹†•ń‘ 2019/3; p.1-28.

[’˜@‘]

610001. [Šwp‘ (•Ş’SŽˇ•M)]yCadmium Toxicity@-New Aspects in Human Disease, Rice Contamination, and Cytotoxicity-z[Front Matter] Historical Lessons on Cadmium Environmental Pollution Problems in Japan and Current Cadmium Exposure Situation, p.3-19. Horiguchi H1: Editors: Himeno S and Aoshima K, Springer, Singapore, 2019”­s. (–xŒű•ş„1: 1‰qś)

610002. [Šwp‘ (•Ş’SŽˇ•M)]yCadmium Toxicity@-New Aspects in Human Disease, Rice Contamination, and Cytotoxicity-zCadmium exposure and its effects on the health status of rice farmers in Akita prefecture, p.75-83 Horiguchi H1: Editors: Himeno S and Aoshima K, Springer, Singapore, 2019”­s. (–xŒű•ş„1: 1‰qś)

620002. [Šwp‘ (•Ş’SŽˇ•M)]y•œEƒKƒCƒ_ƒ“ƒXŠˆ—pƒnƒ“ƒhƒuƒbƒNz‘ć2•” ƒŒƒrƒ…[‚­ƒNƒGƒXƒ`ƒ‡ƒ“@‘ć6Í ŽĺŽĄˆă‚âˆă—Ă‹@ŠÖ‚Ć‚Ě˜AŒg, p.36-47. •“Ą@„ (‰qś), Ó”C•ŇW: Ź“‡Œ´“TŽq, ŽÂŒ´o”ŐVŽĐ, “Œ‹ž, 2018/”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713025. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Analysis and prediction model of pattern of visits to medical institutions among working individuals with lifestyle-related diseases in Japan. Muto G1, Noda M, Endo M, Fukuda H, Katagiri R, Yokoyama K: 32nd International Congress on Occupational Health (ICOH 2018) (2018/4/29-5/4), Dublin, Ireland. (•“Ą@„1: 1‰qś)

713026. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) SYSTEMATIC REVIEW OF OVERDIAGNOSIS IN CERVICAL CANCER SCREENING: HOW SHOULD WE DEFINE OVERDIAGNOSIS IN CERVICAL CANCER SCREENING? Hamashima C, Terasawa T, Katayama T, Sasaki S, Hosono S, Hoshi K1: Preventing Overdiagnosis@2018 (2018/8/21), Copenhagen, Denmark. http://dx.doi.org/10.1136/bmjebm-2018-111070.92 BMJ EVIDENCE-BASED MEDICINE, Vol 23, Suppl 2. (Ż@‰Ŕ–F1: 1‰qś)

713027. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Frequency of unsatisfactory cervical cytology smears in cancer screening of healthy Japanese women: A meta-analysis. Hosono S1,2, Terasawa T3, Katayama T4, Sasaki S5, Hoshi K6, Hamashima C7 (1Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, 2All Japan Labour Welfare Foundation, Tokai Clinic, Nagoya, Aichi, Japan, 3Section of General Internal Medicine, Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan, 4Department of Statistics and Computer Science, College of Nursing Art and Science, University of Hyogo, Hyogo, Japan, 5St. Luke's International Hospital Affiliated Clinic, Center for Preventive Medicine, Tokyo, Japan, 6Department of Hygiene, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, 7Division of Cancer Screening Assessment and Management, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan): 17th Biennial Meeting of the International Gynecologic Cancer Society (2018/9/16), kyoto, Japan. https://igcs2018.com/scientific-information/interactive-program#.XERId1X7SUk. (Ż@‰Ŕ–F6: 6‰qś)

713028. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Information exchange using a prescribed form and involvement of occupational health nurses promotes occupational physicians to collaborate with attending physicians for supporting workers with illness in Japan. Yokoyama K, Muto G1, Ishii-Nakamura R, Kitamura F, Omori Y1, Saito M, Endo M: 15th International Congress of Behavioral Medicine (2018/11/14-17), Santiago, Chile. (•“Ą@„1, ‘ĺX—R‹I1: 1‰qś)

713029. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Analysis& development of a predictive model of visiting behavior to physicians in high-risk individuals of lifestyle-related diseases: a longitudinal study using claims & annual health check-up data. Muto G1, Goto A, Katagiri R, Endo M, Yokoyama K: 15th International Congress of Behavioral Medicine (2018/11/14-17), Santiago, Chile. (•“Ą@„1: 1‰qś)

723064. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ü‰@ŠłŽŇ•aE—đ’˛¸‚É‚¨‚Ż‚é“ü‰@ŠúŠÔ‚Ć“ü‰@‰ń”‚̕ωť. Ź“‡Œ´“TŽq1, Ż@‰Ŕ–F2, —§“ššK3, –L“cÍG4 (1“Œ‹ž—Žqˆă‘ĺ, 2‰qś, 3“ŒŠC‘ĺŠw, 4’†‘˜JĐ•a‰@): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/18), ŒF–{.ŽY‹Ć‰qśŠwŽGŽ 2018/5; 60 (—ŐŽž‘Š§†): 313.

723065. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —Տ°ŠÂ‹ŤˆăŠwŠO—ˆŠłŽŇ‚É‚¨‚Ż‚鋡‹`‚ĚƒVƒbƒNƒnƒEƒXÇŒóŒQC‰ťŠw•¨Žż‰ß•qÇŠY“–ŽŇ‚ĚŽŔ‘Ô. ‹{“‡]—˘Žq1, Šp“cłŽj, —é–Ř‘Žq, {“Ą‘ĺ‹M, ™‰Y—R”üŽq2, â•”@v (1‰qś, 2—\–hˆăŠwŒn): ‘ć27‰ń“ú–{—Տ°ŠÂ‹ŤˆăŠw‰ďŠwpW‰ď (2018/7/7), ŽOd.

723066. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ’Nf’f‚Ć•ŰŒ’Žw“ąĽŒ’NŽx‰‡3. •“Ą@„ (‰qś): ‘ć28‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2018/9/14-16), “Œ‹ž.

723067. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eˆć50–œlƒf[ƒ^‚É‚ć‚郁ƒ^ƒ{ƒnƒCƒŠƒXƒNŽŇ‚ĚŒ’fŒăŽó—Ís“Ž—\‘ރ‚ƒfƒ‹‚ĚŠJ”­‚ĆŽŔ‘HEŒ’NŒo‰c‚É‚ć‚éƒwƒ‹ƒXƒAƒEƒgƒJƒ€‚Ö‚ĚŠń—^‚̉”\Ť. •“Ą@„1, •Đ‹Ë—ČŽq, Œă“Ą@‰ˇ, ‰ĄŽR˜am, Îˆä—“Ţ, •Ÿ“c@—m, ‘ĺX—R‹I1, ‰““ĄŒšŽ÷, ƒJƒƒ`ƒCƒ`ƒ[ (1‰qś): ‘ć28‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2018/9/14-16), “Œ‹ž.

723068. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Beyond UHC for maximize utilization: a prediction model of NCD patients in Japan. •“Ą@„1, Goto A, Katagiri R, Fukuda H, Endo M, Yokoyama K (1‰qś): ‘ć77‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2018/10/24-26), ŒSŽR.

723069. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 40Î–˘–žŒ’fŽófŽŇ‚Ě4”NŠÔ‚̐śŠˆKŠľ‚̕ωť‚ŞŒŒˆł, Ž‰Žż, “œ”A•aŒŸ¸ˆŮí‚É—^‚Ś‚é‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‹{“‡]—˘Žq1, ‹g“c@‹I, ŒÜ\—’ŒhŽq, ‰Ÿ“cŹ•S‡, –î“ßűPM—Y, ‘ĺˆä“cłl, –ě“c‹g˜a (1‰qś): “ú–{‘‡Œ’fˆăŠw‰ď‘ć47‰ń‘ĺ‰ď (2019/2/1), ‰Ą•l.

723070. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰””˜˜I‚É‚ć‚éƒAƒXƒgƒƒTƒCƒg‚ĚŽó—e‘Ě‚ĚƒJƒ‹ƒVƒEƒ€‰ž“š‚ւ̉e‹ż. ‘ĺX—R‹I1, ăŒE—T“ń, źěŠx‹v, ‰ĄŽR˜am, –xŒű•ş„1 (1‰qś): ‘ć89‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2019/2/3), –źŒĂ‰Ž.

723071. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒJƒhƒ~ƒEƒ€‰˜ő’nˆćZ–Ż‚É‚¨‚Ż‚郁ƒ^ƒƒ`ƒIƒlƒCƒ“ŽYś”\‚Ɛt”A×ŠÇ‹@”\áŠQ‚Ć‚ĚŠÖŒW. –xŒű•ş„1, ŹŒF‰xŽq, ‘ĺX—R‹I1, ’†“ˆŽs, âV“ĄGr, Ź•˝@Ži, ‰ĄŽR˜am, ç—t•SŽq, źěŠx‹v, Źź“c“Ö, ‘ş“cŸŒh, “ŕ“cł”ü: ‘ć89‰ń“ú–{‰qśŠw‰ď‘‰ď (2019/2/3), –źŒĂ‰Ž, “ú–{‰qśŠwŽGŽ 2019; 74: S167.

723072. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Th2Œ^‰ŠÇ (—}§ˆöŽqTRAF6cK0/ƒAƒjƒTƒLƒXŠ´ő) ‚É‚ć‚é’°“ŕ×‹Ű‚ւ̉e‹ż. •“Ą@„1, ”ň’e–ě^–ç, ”öč‹MŽm, O“c—Ę“ń, ’†‘ş—T”V, ‰ĄŽR˜am, •Đ‹Ë—ČŽq, ‘ĺX—R‹I1, –xŒű•ş„1, Ź—Ń—˛Žu (1‰qś): ‘ć89‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2019/2/1-3), –źŒĂ‰Ž.

731001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) H“cŒ§–k’nˆć‚̍zŽR‚Ě—đŽj‚Ɛl‚Ö‚ĚŒ’N‰e‹ż. –xŒű•ş„ (‰qś): ‘ć37‰ńś‘Ě‚Ć‹ŕ‘ŽE‰ťŠw•¨Žż‚ÉŠÖ‚ˇ‚錤‹†‰ď (ƒ`ƒ‡[ƒNƒg[ƒN2018) (2018/8/27), H“c.

732009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€)yH•i’†‚̏d‹ŕ‘Ž—ނ̐l‘Ě’~Ď‚ĆŒ’N‰e‹ż Up-To-Datez’X…ŠÇ—ŽŔŽ{‰ş‚̏H“cŒ§ƒJƒhƒ~ƒEƒ€‰˜ő’nˆć‚É‚¨‚Ż‚é•Äě”_‰Ć‚Ö‚ĚŒ’N‰e‹ż‹y‚Ń•Ä’†ƒJƒhƒ~ƒEƒ€‚Ćƒq‘f”Z“x‚ĚŒťó. –xŒű•ş„ (‰qś): ƒtƒH[ƒ‰ƒ€2018 ‰qś–ňŠwEŠÂ‹ŤƒgƒLƒVƒRƒƒW[ (2018/9/11), ˛˘•Ű.

732010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰)y“˘˜_Žĺ‘č: H•i‚ĚˆŔ‘SŠm•Ű‚ÉŒü‚Ż‚˝ƒ~ƒlƒ‰ƒ‹EŒł‘f‚ÉŠÖ‚ˇ‚éĹ‹ß‚Ě“ŽŒüzH•i‚Š‚ç‚ĚƒJƒhƒ~ƒEƒ€”˜˜I‚ĚŒ’NƒŠƒXƒN‚ɂ‚˘‚Ä‚ĚÄŒŸ“˘. –xŒű•ş„ (‰qś): ‘ć16‰ńH•iˆŔ‘SƒtƒH[ƒ‰ƒ€ (2018/12/7), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110008. [Œ´’˜] Insulin-like Effects of Mt. Fuji Subsoil Water which Conta ins Vanadium on Cultured Cells: Insight from Japan. Sorimachi K, Ohmori Y1, Matsukawa T, Yokoyama K, Ohhira S: Current Traditional Medicine 2017; 3 (3): 178-89. (‘ĺX—R‹I1: 1‰qś)

H29-110009. [Œ´’˜] Prenatal mercury exposure and birth weight. Vigeh M, Nishioka E, Ohtani K, Omori Y1, Matsukawa T, Koda S, Yokoyama K: Reprod Toxicol 2018/3; 76: 78-83. (‘ĺX—R‹I1: 1‰qś)

H29-540005. [‚ť‚Ě‘ź (Plain language summary–|–ó)] —źe‚â—{ˆçŽŇ‚ւ̉î“ü‚É‚ć‚Á‚ÄŽq‚Ç‚ŕ‚Ěƒ^ƒoƒR‚̉Œ‚Ö‚Ě”˜˜I‚đŒ¸‚ç‚š‚é‚Š? [Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke (Cochrane Systematic Review - Intervention Version published: 31 January 2018. https://doi.org/10.1002/14651858.CD001746.pub4)] Ż@‰Ŕ–F (‰qś): 2018/1. https://www.cochrane.org/ja/CD001746/liang-qin-yayang-yu-zhe-henojie-ru-niyotutezi-domonotabakonoyan-henopu-lu-wojian-raseruka.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-713001. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Influences on microbiome diversity and plasma metabolomes due to TRAF6 signal, a pivotal regulator of regulatory T cells against Th2 skewing in autoinflammation mice. Muto G1: 3rd Annual MIT-Harvard Microbiome Symposium (2018/3/21), Boston, USA. (•“Ą@„1: 1‰qś)

H29-723002. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Th2Œ^‰ŠÇ (ƒAƒŒƒ‹ƒM[EŽŠŒČ–Ɖu) —}§ˆöŽqTRAF6ƒVƒOƒiƒ‹‚Ě’°“ŕ×‹Ű‘p‚ւ̉e‹ż‚ĚŒŸ“˘. •“Ą@„1, ”öč‹MŽm, ”ň‘Ë–ě^–ç, ’JŒű‘Pm, O“c—Ę“ń, ’†‘ş—T”V, ‘ĺX—R‹I1, ‰ĄŽR˜am, Ź—Ń—˛Žu (1‰qś): ‘ć88‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2018/3/22-24), “Œ‹ž.

H29-723003. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇ‰ť—\–h‚ĚŠĎ“_‚Š‚ç‚ĚŽž•a‚ƏA˜J—ź—§‚ĚŽŔ‘Ô‚Ć, ˆă—Ă/Œ’f‹@ŠÖ|Eˆć (C2C) ˜AŒg‚É‚ć‚éFitness for Work‚̐„i. •“Ą@„ (‰qś): ‘ć88‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2018/3/22-24), “Œ‹ž.


ŒöO‰qśŠw

[Šwp˜_•ś]

110064. [Œ´’˜] Associations among job demands and resources, work engagement, and psychological distress: fixed-effects model analysis in Japan. Oshio T1, Inoue A1, Tsutsumi A1: J Occup Health 2018/5; 60 (3): 254-62. (Ź‰–—˛Žm1, ˆäă˛b1, ’ç@–žƒ1: 1ŒöO‰qś)

110065. [Œ´’˜] Interaction effect of job insecurity and role ambiguity on psychological distress in Japanese employees: a cross-sectional study. Inoue A1, Kawakami N, Eguchi H1, Tsutsumi A1: Int Arch Occup Environ Health 2018/5; 91 (4): 391-402. (ˆäă˛b1, ]Œű@Ž1, ’ç@–žƒ1: 1ŒöO‰qś)

110066. [Œ´’˜] Parental Socioeconomic Status and Weight Faltering in Infants in Japan. Kachi Y1, Fujiwara T, Yamaoka Y, Kato T: Front Pediatr 2018/5; 6: 127. doi: 10.3389/fped.2018.00127. eCollection 2018. (‰Â’m—IŽq1: 1ŒöO‰qś)

110067. [Œ´’˜] Association Between Cortisol to DHEA-s Ratio and Sickness Absence in Japanese Male Workers. Hirokawa K, Fujii Y, Taniguchi T, Takaki J, Tsutsumi A1: Int J Behav Med 2018/6; 25 (3): 362-7. (’ç@–žƒ1: 1ŒöO‰qś)

110068. [Œ´’˜] Effect of the National Stress Check Program on mental health among workers in Japan: A 1-year retrospective cohort study. Imamura K, Asai Y, Watanabe K, Tsutsumi A1, Shimazu A, Inoue A1, Hiro H, Odagiri Y, Yoshikawa T, Yoshikawa E, Kawakami N: J Occup Health 2018/7; 60 (4): 298-306. (’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

110069. [Œ´’˜] Associations of non-standard employment with cardiovascular risk factors: findings from nationwide cross-sectional studies in Japan. Ando E, Kachi Y1, Kawakami N, Fukuda Y, Kawada T: Ind Health 2018/7; 56 (4): 336-45. (‰Â’m—IŽq1: 1ŒöO‰qś)

110070. [Œ´’˜] Psychosocial factors at work and inflammatory markers: protocol for a systematic review and meta-analysis. Eguchi H1, Watanabe K, Kawakami N, Ando E, Arima H, Asai Y, Inoue A1, Inoue R, Iwanaga M, Imamura K, Kobayashi Y, Nishida N, Otsuka Y, Sakuraya A, Tsuno K, Shimazu A, Tsutsumi A1: BMJ Open 2018/8; 8 (8): e022612. (]Œű@Ž1, ˆä@˛b1, ’ç@–žƒ1: 1ŒöO‰qś)

110071. [Œ´’˜] WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of exposure to long working hours and of the effect of exposure to long working hours on stroke. Descatha A, Sembajwe G, Baer M, Boccuni F, Di Tecco C, Duret C, Evanoff BA, Gagliardi D, Ivanov ID, Leppink N, Marinaccio A, Magnusson Hanson LL, Ozguler A, Pega F, Pell J, Pico F, PrŸss-†stŸn A, Ronchetti M, Roquelaure Y, Sabbath E, Stevens GA, Tsutsumi A1, Ujita Y, Iavicoli S: Environ Int 2018/10; 119: 366-78. (’ç@–žƒ1: 1ŒöO‰qś)

110072. [Œ´’˜] WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of exposure to long working hours and of the effect of exposure to long working hours on ischaemic heart disease. Li J, Brisson C, Clays E, Ferrario MM, Ivanov ID, Landsbergis P, Leppink N, Pega F, Pikhart H, PrŸss-†stŸn A, Rugulies R, Schnall PL, Stevens G, Tsutsumi A1, Ujita Y, Siegrist J: Environ Int 2018/10; 119: 558-69. (’ç@–žƒ1: 1ŒöO‰qś)

110073. [Œ´’˜] Distribution of autistic traits and their association with sociodemographic characteristics in Japanese workers. Suzuki T, Miyaki K, Eguchi H1, Tsutsumi A1: Autism 2018/11; 22 (8): 907-14. (]Œű@Ž1, ’ç@–žƒ1: 1ŒöO‰qś)

110074. [Œ´’˜] Gender differences in the effects of job insecurity on psychological distress in Japanese workers: a population-based panel study. Kachi Y1, Hashimoto H, Eguchi H1: Int Arch Occup Environ Health 2018/11; 91 (8): 991-9. (‰Â’m—IŽq1, ]Œű@Ž1: 1ŒöO‰qś)

110075. [Œ´’˜] Mental health of working-age populations in Japan who provide nursing care for a person at home: A cross-sectional analysis. Eguchi H1, Wada K: J Occup Health 2018/11; 60 (6): 458-66. (]Œű@Ž1: 1ŒöO‰qś)

110076. [Œ´’˜] Association of workplace social capital with psychological distress: results from a longitudinal multilevel analysis of the J-HOPE Study. Eguchi H1, Tsutsumi A1, Inoue A1, Hikichi H, Kawachi I: BMJ Open 2018/12; 8 (12): e022569. (]Œű@Ž1, ’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

110077. [Œ´’˜] The effect of alternative scoring procedures on the measurement properties of a self-administered depression scale: An IRT investigation on the CES-D scale. Iwata N, Tsutsumi A1, Wakita T, Kumagai R, Noguchi H, Watanabe N: European Journal of Psychological Assessment 2019/1; 35 (1): 55-62. (’ç@–žƒ1: 1ŒöO‰qś)

110078. [Œ´’˜] Characteristics of self-reported daily life note (LN) users in return-to-work judgment for workers on sick leave due to mental health conditions, and usefulness of the tool. Kusumoto A, Kajiki S, Fujino Y, Namba K, Nagata T, Nagata M, Tsutsumi A1, Mori K: Ind Health 2019/2; 57 (1): 70-8. (’ç@–žƒ1: 1ŒöO‰qś)

110079. [Œ´’˜] Organizational Justice and Refraining from Seeking Medical Care Among Japanese Employees: A 1-Year Prospective Cohort Study. Inoue A1, Tsutsumi A1, Eguchi H1, Kawakami N: Int J Behav Med 2019/2; 26 (1): 76-84. (ˆäă˛b1, ’ç@–žƒ1, ]Œű@Ž1: 1ŒöO‰qś)

110080. [Œ´’˜] Association between working hours, work engagement, and work productivity in employees: A cross-sectional study of the Japanese Study of Health, Occupation, and Psychosocial Factors Relates Equity. Okazaki E, Nishi D, Susukida R, Inoue A1, Shimazu A, Tsutsumi A1: J Occup Health 2019/3; 61 (2): 182-8. (ˆäă˛b1, ’ç@–žƒ1: 1ŒöO‰qś)

110081. [Œ´’˜] Effect Modification by Attention Deficit Hyperactivity Disorder (ADHD) Symptoms on the Association of Psychosocial Work Environments With Psychological Distress and Work Engagement. Nagata M, Nagata T, Inoue A1, Mori K, Matsuda S: Front Psychiatry 2019/3; 10: 166. (ˆäă˛b1: 1ŒöO‰qś)

120001. [Œ´’˜] ƒXƒgƒŒƒXƒ`ƒFƒbƒN§“xŽ{sŠJŽn1”N“x‚ĚŽŔŽ{ó‹ľ, —L—pŤ‚¨‚ć‚щۑč: ˜J“­ŽŇ‚Ö‚ĚƒCƒ“ƒ^[ƒlƒbƒg’˛¸. óˆä—T”ü, Ą‘şK‘ž˜Y, ’ç@–žƒ1, “‡’Ă–žl, ˆäă˛b1, œA@Ž“T, Ź“cŘ—DŽq, ‹gě@“O, ‹gě‰xŽq, ěă@Œ›l (1ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/4; 25 (2): 257-71.

120002. [Œ´’˜] “ď•aŠłŽŇ‚É‚¨‚Ż‚鎥—Ă‚ĆA˜J‚Ě—ź—§Žx‰‡. ]Œű@Ž (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/7; 25 (3): 325-34.

120003. [Œ´’˜] ”ńŹ×–E”xŠŕ‚ɑ΂ˇ‚éRŠŕÜŽĄ—Ă‚ĚŽx•Ľ‚˘ˆÓŽvŠz‚ÉŠÖ‚ˇ‚éˆÓŽŻ’˛¸. –x“cM”V, ]Œű@Ž1, ‹ŕŽq@–Ň (1ŒöO‰qś): “ú–{ŒÄ‹zŠíŠw‰ďŽ 2018/7; 7 (4): 204-11.

120004. [Œ´’˜] ť‘˘‹Ć’jŤ˜J“­ŽŇ‚É‚¨‚Ż‚éAUDIT‚đŽg—p‚ľ‚˝—LŠQ‚ČƒAƒ‹ƒR[ƒ‹Žg—pƒŠƒXƒN•]‰ż‚Ćƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ĚŠÖŒW. œ\•y”ü“ŢŽq, Œ´@rĆ, žY@Šx•ś, ’ç@–žƒ1 (1ŒöO‰qś): ˜J“­‰ČŠw 2019/2; 95 (1): 1-9.

120005. [Œ´’˜] ]‹ĆˆőŽQ‰ÁŒ^EęŠÂ‹Ť‰ü‘P‚̏€”ő—vˆö‚ĚŒŸ“˘: Basic Organizational Development for Your workplace (BODY) ƒ`ƒFƒbƒNƒŠƒXƒg‚ĚŠJ”­. Ź—Ń—R‰Ŕ, “n•Ó˜aL, ‘ĺ’ˑאł, ]Œű@Ž1, ěăŒ›l (1ŒöO‰qś): ŽY‹Ć‰qśŠwŽGŽ 2019/3; 61 (2): 43-58.

520005. [‘ŕ] ƒXƒgƒŒƒXƒ`ƒFƒbƒN§“x‚ĹŽg—p‚ł‚ę‚éE‹ĆŤƒXƒgƒŒƒX’˛¸•[‚Ě‘Ă“–Ť. ’ç@–žƒ (ŒöO‰qś): ƒXƒgƒŒƒX‰ČŠw 2018/10; 32 (3): 187-99.

521002. [‰đŕ] (1) ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/4; 25 (2): 283.

521003. [‰đŕ] (2) ‰ß˜JŽ€“™–hŽ~‘΍ô„i–@. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/4; 25 (2): 284.

522006. [uŔ]y“ÁW: ‰ß˜JŽ€–hŽ~Šw‰ď‚ŞŒť‘ă“ú–{‚É’ń‹N‚ˇ‚é‚ŕ‚́z10. ƒXƒgƒŒƒXƒ`ƒFƒbƒN“ą“ü‚ĚˆÓ‹`. ’ç@–žƒ (ŒöO‰qś): PROGRESS IN MEDICINE 2018/4; 38 (4): 399-404.

522007. [uŔ]y˜AÚ: ‘ć51‰ńzŒ’f‹@ŠÖ‚ÉŠú‘Ň‚ˇ‚é‚ŕ‚́^ƒ†[ƒU[‚ĚŽ‹“_‚Š‚ç. ]Œű@Ž (ŒöO‰qś): ˜J“­‰qśŠÇ— 2018/4; 29 (2): 65-6.

522008. [uŔ]y“ÁW: Eę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXzŸEę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXŠTŠĎ@Eę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚ĚŠTŠĎ‚Ć–@—ß/Žwj. ’ç@–žƒ (ŒöO‰qś): f’f‚ĆŽĄ—Ă 2018/5; 106 (5): 544-50.

522009. [uŔ]y“ÁW: ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§‚É‚¨‚Ż‚éƒXƒgƒŒƒXz“ÁW‚É‚ć‚š‚Ä. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/7; 25 (3): 287.

522010. [uŔ]y“ÁW: ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§‚É‚¨‚Ż‚éƒXƒgƒŒƒXz“ď•aŠłŽŇ‚É‚¨‚Ż‚鎥—Ă‚ĆA˜J‚Ě—ź—§. ]Œű@Ž (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/7; 25 (3): 325-34.

522011. [uŔ]yŽY‹ĆƒJƒEƒ“ƒZƒŠƒ“ƒO‚ĚŒťę‚Š‚çz‘ć165‰ń@u‘gD“IŒöłv‚ŞŒ’N‚É—^‚Ś‚é‰e‹ż.u‘gD“IŒöłv‚ŞŒ’N‚É—^‚Ś‚é‰e‹ż ˆäă˛b (ŒöO‰qś): ˆŔ‘SƒXƒ^ƒbƒt 2018/9; 2314: 32-3.

522012. [uŔ]y“ÁW: ‘ć21‰ń“ú–{¸_•ŰŒ’E—\–hŠw‰ďŠwpW‰ď (“ß”eŽs) ‚ć‚čzƒXƒgƒŒƒXƒ`ƒFƒbƒN‚ĚƒGƒrƒfƒ“ƒX. ’ç@–žƒ (ŒöO‰qś): —\–h¸_ˆăŠw 2019/3; 3 (1): 86-94.

522013. [uŔ]y“ÁW: ŒÇ—§‚ˇ‚éEę, ‚Â‚Č‚Ş‚č‡‚¤Eęz“­‚­l‚˝‚ż‚ĚŽQ‰Á‚ˇ‚éŒÂl‚Ć‘gD‚ĚŠˆŤ‰ťŽč–@|Eę‚Ěƒ\[ƒVƒƒƒ‹EƒLƒƒƒsƒ^ƒ‹‚ĆƒWƒ‡ƒuEƒNƒ‰ƒtƒeƒBƒ“ƒO|. ]Œű@Ž (ŒöO‰qś): ˜J“­‚̉Ȋw 2018/9; 73 (9): 8-12.

522014. [uŔ]y˜AÚ: —ź—§Žx‰‡zŽĄ—Ă’†‚̏]‹Ćˆő‚Ě”\—Í‚đŠˆ‚Š‚ˇ! Work Ability‚ƏA˜JŒp‘ąŽx‰‡. ]Œű@Ž (ŒöO‰qś): ƒrƒWƒlƒXƒKƒCƒh 2018/9; 859: 68-76.

522015. [uŔ]yƒJƒŒƒ“ƒgƒgƒsƒbƒNƒXz áŠQŽŇŒŮ—p. ]Œű@Ž (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/11; 25 (4): 447-8.

522016. [uŔ]yŒ’N12ƒ•ŒŽNo383zŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡‚É‚¨‚Ż‚éŠé‹Ć‚Ćˆă—Ă‹@ŠÖ‚̏î•ńŒđŠˇ‚̐i‚ß•ű. ]Œű@Ž (ŒöO‰qś): ˜J“­ˆŔ‘S‰qś‚Š‚Č‚Ş‚í 2018/12; 63 (12): 12-4.

540011. [‚ť‚Ě‘ź]y“ÁW‚É‚ć‚š‚āzŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§‚É‚¨‚Ż‚éƒXƒgƒŒƒX. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/7; 25 (3): 287.

540012. [‚ť‚Ě‘ź] Decent work for all. ’ç@–žƒ (ŒöO‰qś): _“ŢěŒ§ˆăŽt‰ď•ń 2018/7; 828: 11-3.

540013. [‚ť‚Ě‘ź (•śŒŁĐ‰î)]y•śŒŁĐ‰îz‘ސE‚Ć”F’m‹@”\‚Ć‚ĚŠÖ˜A. ˆäă—äŽq, ˆäă˛b1, ]Œű@Ž1, ‰Â’m—IŽq1, ’ç@–žƒ1 (1ŒöO‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2018/7; 41 (4): 112-5.

540014. [‚ť‚Ě‘ź] •ŇWŒă‹L. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2018/7; 25 (3).

540115. [‚ť‚Ě‘ź (ŠŞ“ŞŒž)]yŠŞ“ŞŒž: ˜ëáՁz‘ŰŒđ—ŹE‘Ű‹Ś—Í‚ŞŘ‚čŠJ‚­ŽY‹ĆˆŔ‘S•ŰŒ’‚Ě–˘—ˆ. ’ç@–žƒ (ŒöO‰qś): ˜J“­‚̉Ȋw 2018/8; 73 (8): 1.

[’˜@‘]

610003. [Šwp‘ (•Ş’SŽˇ•M)]yPrinciples and Concepts of Behavioral Medicine: A Global HandbookzTheory in Behavioral Medicine, p.181-214. Dekker J, Brosschot JF, Schwarzer R, Tsutsumi A1, Editors: Fisher E, Cameron L, Christensen AJ, Ehlert U, Guo Y, Oldenburg B, Snoek F Springer-Verlag, New York, USA, 2018/10”­s. (’ç@–žƒ1: 1ŒöO‰qś)

620003. [Šwp‘ (•Ş’SŽˇ•M)]yŽY‹Ć•ŰŒ’‚Ě•ĄŽGƒf[ƒ^‚đW‚ß‚Ä ‚Ü‚Ć‚ß‚Ä “`‚Ś‚é ƒƒU (ŽY‹Ć•ŰŒ’‚ĆŠĹŒě2018”Nt‹G‘Š§)z‘ć2Í Žá—t‚ł‚ń‚ĆŠw‚Ô! ƒf[ƒ^Šˆ—p‚Ť‚Ů‚ń‚́u‚Ťv@Ÿ2 ƒf[ƒ^‚Ě‚Ü‚Ć‚ß•ű (1) “Œv•ŞÍ‚ĚŠî–{ (4`8), p.56-61. Ÿ4 ƒf[ƒ^‚ĚŒŠ‚š•ű, “`‚Ś•ű (7), p.101-3. ‘ć4Í Žá—t‚ł‚ń‚Ş’§í! Šw‰ď”­•\‚đ–ÚŽw‚ť‚¤@ƒRƒ‰ƒ€ (8) ˆę”ʉť‰Â”\Ť‚ĆŒ¤‹†‚ĚŒŔŠE, p.153. Ÿ2 Šw‰ď”­•\‘O‚Ɂ@Šů‘ś‚Ě•ń‚âćsŒ¤‹†‚𒲂ׂé(2), p.156-9. ]Œű@Ž (ŒöO‰qś), •Ň’˜: ˜a“ckŽĄ, ’Ă–ě“Ţ”ü, MCƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/4/”­s.

620004. [Šwp‘ (•Ş’SŽˇ•M)]yŽq‚Ç‚ŕ‚Ě•n˘‚ƐHŠiˇ: ‚¨• ‚˘‚Á‚Ď‚˘H‚ׂł‚š‚˝‚˘z‘ć‚RÍ •n˘‚Ş‚ŕ‚˝‚炡Žq‚Ç‚ŕ ‚Ě”ě–žŠiˇ, p.53-83. ‰Â’m—IŽq1 (1ŒöO‰qś), •Ň: ˆ˘•”@Ę, ‘şŽRLŽq, ‰Â’m—IŽq1, éí@çŽq, ‘ĺŒŽ‘“X, “Œ‹ž, 2018/4”­s.

620005. [Šwp‘ (•Ş’SŽˇ•M)]yƒWƒFƒlƒ‰ƒŠƒXƒg‹łˆçƒRƒ“ƒ\[ƒVƒAƒ€@consortium vol.10zII. ŽĐ‰ď‰uŠw‚ÉŠÖ˜A‚ľ‚˝Žć‚č‘g‚݁EŒ¤‹†‚Ć‘‡f—Á@E‹ĆŤƒXƒgƒŒƒX‚ɑ΂ˇ‚éŽć‚č‘g‚Ý, p.132-7. ’ç@–žƒ (ŒöO‰qś), •Ň: ‰Ą—ŃŒ’ˆę, ƒCƒ`ƒ[EƒJƒƒ`, ƒJƒC‘—Ń, ‚ł‚˘‚˝‚ÜŽs, 2018/5”­s.

620006. [Šwp‘ (•Ş’SŽˇ•M)]yŽY‹ĆˆăŠw‚ĚƒvƒŠƒ“ƒVƒvƒ‹`‘ĺŘ‚Č‚ą‚Ɓ|ŽY‹ĆˆăŠwU‹ťŕ’c40Žü”N‹L”OŽ|zV. Ž‹Šp: Žĺ—vƒe[ƒ}‚̍ĄŒă‚ÉŒü‚Ż‚ā@E‹ĆŤƒXƒgƒŒƒX‚Ě‘Ş’č‚Ć•]‰ż, p.174-6. Ź“cŘ—DŽq, ˆäă˛b1 (1ŒöO‰qś), •Ň: ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹•ŇWˆĎˆő‰ď, ŕ’c–@lŽY‹ĆˆăŠwU‹ťŕ’c, “Œ‹ž, 2018/5”­s.

620007. [Šwp‘ (•Ş’SŽˇ•M)]yŽY‹ĆˆăŠw‚ĚƒvƒŠƒ“ƒVƒvƒ‹`‘ĺŘ‚Č‚ą‚Ɓ|ŽY‹ĆˆăŠwU‹ťŕ’c40Žü”N‹L”OŽ|zV. Ž‹Šp: Žĺ—vƒe[ƒ}‚̍ĄŒă‚ÉŒü‚Ż‚ā@‚ą‚ę‚Š‚ç‚ĚŽY‹ĆˆăEŽY‹Ć•ŰŒ’Šˆ“Ž‚Ě‚˝‚ß‚Ě˜J“­ˆŔ‘S‰qś“Œv, p.193-5. ’ç@–žƒ (ŒöO‰qś), •Ň: ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹•ŇWˆĎˆő‰ď, ŕ’c–@lŽY‹ĆˆăŠwU‹ťŕ’c, “Œ‹ž, 2018/5”­s.

620008. [Šwp‘ (•Ş’SŽˇ•M)] U‚č•Ô‚č@Œťó‚ƍs“Ž‰ČŠw‹łˆç, p.29-32. ’ç@–žƒ (ŒöO‰qś), ŠÄC: ˆę”ĘŽĐ’c–@l“ú–{ˆăŠw‹łˆçŠw‰ď, •Ň: “ú–{ˆăŠw‹łˆçŠw‰ď@Šw‰ďL•ńEî•ńŠî”ŐˆĎˆő‰ď, ŽÂŒ´o”ŐVŽĐ, “Œ‹ž, 2018/7”­s.

620009. [Šwp‘ (•Ş’SŽˇ•M)]yNEW—\–hˆăŠwEŒöO‰qśŠw ‰ü’ů‘ć4”Łz4•” ŠÂ‹Ť‚ĆŒ’N@‘ć3Í ŽY‹Ć‰qś@H Eę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX, p.252-6. ’ç@–žƒ (ŒöO‰qś), ŠÄC: ŠÝ@—ćŽq, •Ň: Źňş•v, ”nę‰€–ž, Ą’†—Yˆę, •—с@‹œ, “ě]“°, “Œ‹ž, 2018/11”­s.

620010. [Šwp‘ (•Ş’SŽˇ•M)]yQ&A‚ĹŠw‚Ôƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg@‚Ĺ‚Ť‚éEę‚̂‚­‚č‚Š‚˝zŠé‹Ć‘gD‚ĚŒöł‚Ćƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚ɂ͂ǂ̂悤‚ČŠÖŒW‚Ş‚ ‚č‚Ü‚ˇ‚Š? p.58-9. ˆäă˛b (ŒöO‰qś), •ŇW‘ă•\: “‡’Ă–žl, •Ň: Žsě‰Ŕ‹, ]Œű@Ž1, ‘ĺ’ˑאł, ŽíŽsN‘ž˜Y, ź@‘ĺ•ă, ‹ŃŒË“TŽq, Œ´—Y“ń˜Y, •˝ź—˜–ƒ, ‹ŕ„o”Ĺ, “Œ‹ž, 2018/12”­s.

620011. [Šwp‘ (•Ş’SŽˇ•M)]yQ•A‚ĹŠw‚Ôƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg@‚Ĺ‚Ť‚éEę‚̂‚­‚č‚Š‚˝z‘ćII•” ŽŔ‘H•Ň: Q&A|‚˘‚´‚Ć‚˘‚¤‚Ć‚Ť–đ‚É—§‚Â67‚Ěƒqƒ“ƒgW@‘ć1Í ƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚Ć‚Í‚Č‚ń‚ž‚낤?@Q-7 ƒ[ƒNƒGƒ“ƒQƒCƒWƒƒ“ƒg‚͂ǂ̂悤‚Č•a‹C (ŽžŠł) ‚ĆŠÖŒW‚Ş‚ ‚č‚Ü‚ˇ‚Š, Q-8 ƒ[ƒNƒGƒ“ƒQƒCƒWƒƒ“ƒg‚ÍŒŒ‰tŒŸ¸‚Ě’l‚ĆŠÖŒW‚Ş‚ ‚č‚Ü‚ˇ‚Š?, p.40-3. Q-14u‚S‘ĺŒo‰cŽ‘Œš (ƒqƒgEƒ‚ƒmEƒJƒlEî•ń)v‚ƁuŽdŽ–‚ĚŽ‘Œšv‚͉˝‚Şˆá‚˘‚Ü‚ˇ‚Š?, p.56-7. ‘ć2Í ƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚đŽć‚č“ü‚ę‚悤!@Q-25 Šé‹Ć‚ĚŒo‰c—”O‚̓[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚ɂǂ̂悤‚ȉe‹ż‚đ‹y‚Ú‚ľ‚Ü‚ˇ‚Š?, p.82-3. ‘ć4Í ƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚Í‚ą‚ą‚Ĺ‚ŕ–𗧂Â!@Q-67 ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡‚đi‚ß‚éă‚Ĺƒ[ƒNEƒGƒ“ƒQƒCƒWƒƒ“ƒg‚ĚŠT”O‚͂ǂ̂悤‚ÉŠˆ—p‚Ĺ‚Ť‚Ü‚ˇ‚Š?, p.184-5. ]Œű@Ž1 (1ŒöO‰qś), •ŇW‘ă•\: “‡’Ă–žl, •Ň: Žsě‰Ŕ‹, ]Œű@Ž1, ‘ĺ’ˑאł, ŽíŽsN‘ž˜Y, ź@‘ĺ•ă, ‹ŃŒË“TŽq, Œ´—Y“ń˜Y, •˝ź—˜–ƒ, ‹ŕ„o”Ĺ, “Œ‹ž, 2018/12”­s.

620012. [Šwp‘ (•Ş’SŽˇ•M)]yu‚Í‚˝‚ç‚­v‚đŽx‚Ś‚é!@Eę~ˆË‘śÇEƒAƒfƒBƒNƒVƒ‡ƒ“ 1”Łz‘ć2Í Eę‚É‚¨‚Ż‚éƒAƒ‹ƒR[ƒ‹‚Ě–â‘č@1. ˜JĐ, E‹ĆŤƒXƒgƒŒƒX, ƒXƒgƒŒƒXƒ`ƒFƒbƒN§“x‚Ć‚ĚŠÖ˜A, p.36-40. ˆäă˛b1,œA@Ž“T (1ŒöO‰qś), •Ň: ”óŒű@i, œA@Ž“T, “ěŽR“°, “Œ‹ž, 2019/1”­s.

620013. [Šwp‘ (•Ş’SŽˇ•M)]yŽĐ‰ďEŠÂ‹Ť‚ĆŒ’N ŒöO‰qśŠw 2019”N”ŁzCHAPTER 9 ¸_•ŰŒ’‘΍ô, p.97-104. ’ç@–žƒ (ŒöO‰qś), •Ň: –öě@—m, ”ö“‡r”V, ˆăŽ•–ňo”ĹŠ”ŽŽ‰ďŽĐ, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712006. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Public Health Challenges in Japan -Occupational Health and Infection-. Eguchi H1: 15th Joint Symposium Robert Koch Institute and The Kitasato Institute Kitasato University (2018/11/14), ‘Š–ÍŒ´Žs. (]Œű@Ž1: 1ŒöO‰qś)

713030. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Which stress-related factors affect the mental health of nuclear emergency workers over a long period? Hiro H, Hino A, Mafune K, Inoue A1, Shigemura J, Yamada M, Okubo T: 32nd International Congress on Occupational Health (2018/4/29), Dublin, Ireland. (ˆäă˛b1: 1ŒöO‰qś)

713031. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Workplace incivility among health care workers and its health outcomes: mental health and physical complaints. Tsuno K, Ando E, Inoue A1, Kurioka S, Kawakami N, Miyashita K: 32nd International Congress on Occupational Health (2018/4/29), Dublin, Ireland. (ˆäă˛b1: 1ŒöO‰qś)

713032. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Collecting and organizing basic occupational health data for international comparisons. Tsutsumi A1, Kajiki S, Muto T, Shimazu A, Okahara S, Ohdo K, Yoshikawa T, Mishiba T, Inoue A1: 32nd International Congress on Occupational Health (2018/5/2), Dublin, Ireland. (’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

713033. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The Stress Check Program: an evaluation of the first-year implementation of the new national workplace mental health program in Japan. Kawakami N, Imamura K, Asai Y, Watanabe K, Tsutsumi A1, Shimazu A, Inoue A1, Hiro H, Odagiri Y, Yoshikawa T, Yoshikawa E: 32nd International Congress on Occupational Health (2018/5/2), Dublin, Ireland. (’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

713034. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Predicting lost productive time and medical cost due to poor psychosocial working conditions: a one-year prospective study. Kawakami N, Imamura K, Baba T, Asai Y, Tsutsumi A1, Shimazu A, Inoue A1, Hiro H, Odagiri Y, Yoshikawa T, Yoshikawa E: 32nd International Congress on Occupational Health (2018/5/2), Dublin, Ireland. (’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

713035. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The influence of workplace social capital on HbA1c levels among Japanese workers: a 2-year prospective cohort study (J-HOPE). Eguchi H1, Tsutsumi A1, Inoue A1, Kawachi I: 32nd International Congress on Occupational Health (2018/5/2), Dublin, Ireland. (]Œű@Ž1, ’ç@–žƒ1, ˆäă˛b1: 1ŒöO‰qś)

713036. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Combined effects of overtime work hours and exercise habit on psychological distress: a cross-sectional study among Japanese white-collar workers. Hino A, Wakida Y, Noguchi Y, Ido H, Inoue A1, Mafune K, Hiro H: 32nd International Congress on Occupational Health (2018/5/2), Dublin, Ireland. (ˆäă˛b1: 1ŒöO‰qś)

713037. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Development of teaching materials to improve the knowledge and skills that medical students should possess to prevent suicide. Tsutsumi A1, Chiba H2, Moriya R2, Inoue A1, Shimazu A: 15th International Congress of Behavioral Medicine (2018/11/15), Santiago, Chile. (’ç@–žƒ1, ç—tG‹B2, Žç‰Ž—˜‰Ŕ2, ˆäă˛b1: 1ŒöO‰qś, 2ˆăŠw‹łˆç)

713038. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Work-related psychosocial risk factors and hepatic abnormalities among Japanese male workers. Otsuka Y, Nakata A, Inoue A1, Eguchi H1, Sakurai K: 15th International Congress of Behavioral Medicine (2018/11/16), Santiago, Chile. (ˆäă˛b1, ]Œű@Ž1: 1ŒöO‰qś)

721001. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ŽY‹Ć•ŰŒ’ŠĹŒěE‚ÉŠú‘Ň‚ˇ‚é˜_•ś“Še. ’ç@–žƒ (ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/19), ŒF–{.

722005. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’†ŹŠé‹Ć‚É‚¨‚Ż‚鎥—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡‚̐„i‚Ě‚˝‚ß‚É. ]Œű@Ž (ŒöO‰qś): ‘ć28‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2018/9/15), “Œ‹ž.

722006. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)ySNSŽž‘ă‚ĚŽáŽŇ‚ɑ΂ˇ‚éV‚˝‚ČŽŠŽE‘΍ô‚̍\’z`ŔŠÔŽ–Œ‚ĚÄ”­–hŽ~‚đŽ‹–ě‚É“ü‚ę‚ā`zˆăŠwś‚đ‘ÎŰ‚Ć‚ľ‚˝ŽŠŽE—\–h‹łˆçƒvƒƒOƒ‰ƒ€‚ĚŠJ”­‚ĆŽŔ‘H. ’ç@–žƒ1, ˆäă˛b1, Žç‰Ž—˜‰Ŕ2, ç—tG‹B2, Ź“cŒ´K, “‡’Ă–žl (1ŒöO‰qś, 2ˆăŠw‹łˆç): ‘ć77‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2018/10/24), •Ÿ“‡, “ú–{ŒöO‰qśŽGŽ 2018; 65 (10) “Á•Ę•˜^: p.82.

722007. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) kĐŒă‚ĚŽŠŽEEƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX‘΍ô`Œ¤‹†Ź‰Ę‚Š‚ç‹ď‘Ě“I‚Č‘Îô‚ց`. ’ç@–žƒ1, ˆÉ“ĄOl, ‘ĺ•˝“N–ç, –ě‘ş‹ąŽq (1ŒöO‰qś): ‘ć77‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2018/10/26), •Ÿ“‡, “ú–{ŒöO‰qśŽGŽ 2018; 65 (10) “Á•Ę•˜^: p.166-168.

722008. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽY‹ĆƒXƒgƒŒƒX—Ěˆć‚É‚¨‚Ż‚éę–ĺEE‹@ŠÖŠÔ‚Ě˜AŒg„i‚ÉŒü‚Ż‚ā|‰qśEŒöO‰qś‚Ě‹łˆçŒ¤‹†E‚Ě—§ę‚Š‚ç|. ˆäă˛b (ŒöO‰qś): ‘ć26‰ń“ú–{ŽY‹ĆƒXƒgƒŒƒXŠw‰ď (2018/11/30), “Œ‹ž.

722009. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) [ƒVƒ“ƒ|ƒWƒXƒgEŔ’ˇ] —ź—§Žx‰‡‚ƍs“ŽˆăŠw@‰îŒě‚ĆŽdŽ–‚Ě—ź—§. ’ç@–žƒ (ŒöO‰qś): ‘ć25‰ń“ú–{s“ŽˆăŠw‰ďŠwp‘‰ď (2018/12/9), “ż“‡, ‘ć25‰ń“ú–{s“ŽˆăŠw‰ďŠwp‘‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018; p.32.

722010. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) uEę‚É‚¨‚Ż‚éƒXƒgƒŒƒXƒ}ƒl[ƒWƒƒ“ƒgvE‹ĆŤƒXƒgƒŒƒX‚̐śŠˆKŠľ•a‚Ö‚ĚƒCƒ“ƒpƒNƒg. ’ç@–žƒ (ŒöO‰qś): ‘ć53‰ń“ú–{Źl•a (śŠˆKŠľ•a) Šw‰ďŠwpW‰ď (2019/1/13), “Œ‹ž.

722011. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) u–\˜I‘Ş’č‚ĚŒŔŠE‚Ö‚Ě’§ívƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXEƒXƒgƒŒƒX‚̉uŠw‚É—p‚˘‚éŽw•W. ’ç@–žƒ (ŒöO‰qś): ‘ć29‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2019/1/31), “Œ‹ž.

722012. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ’†ŹŠé‹Ć‚É‚¨‚Ż‚é—ź—§Žx‰‡‚ĚŽŔŰ|ˆęl‚Ĺ‚ŕ‘˝‚­‚Ě•ű‚ÉŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§‚Ě‹@‰ď‚đ’ń‹Ÿ‚ˇ‚é‚˝‚߂Ɂ|. ]Œű@Ž (ŒöO‰qś): ‘ć89‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2019/2/3), –źŒĂ‰Ž, “ú–{‰qśŠwŽGŽ 2019/2; 74 (Suppl): pS111-2.

723073. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˜J“­ŽŇ‚É‚¨‚Ż‚éuPokemon GOv‚ƐS—“IƒXƒgƒŒƒX”˝‰ž‚Ć‚ĚŠÖ˜A: Œă‚ëŒü‚ŤƒRƒz[ƒgŒ¤‹†. “n•Ó˜aL, ěăŒ›l, Ą‘şK‘ž˜Y, ˆäă˛b1, “‡’Ă–žl, ‹gě@“O, œA@Ž“T, óˆä—T”ü, Ź“cŘ—DŽq, ‹gě‰xŽq, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/17), ŒF–{.

723074. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eę‚Ĺ‚ĚŠ´ŽÓ‚ƏăŽiE“Ż—ť‚ĚŽx‰‡CƒpƒtƒH[ƒ}ƒ“ƒXCS—“IƒXƒgƒŒƒX”˝‰ž‚ĚŠÖ˜A‚ɂ‚˘‚Ä. ‹îŁ@—D, ěăŒ›l, Ą‘şK‘ž˜Y, ˆäă˛b1, “‡’Ă–žl, ‹gě@“O, œA@Ž“T, óˆä—T”ü, Ź“cŘ—DŽq, ‹gě‰xŽq, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/17), ŒF–{.

723075. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ź‹K–ÍŽ–‹Ćę‚É‚¨‚Ż‚éŽQ‰ÁŒ^EęŠÂ‹Ť‰ü‘P‚Ě•W€“IŽč–@‚ĚŠJ”­`”äŠr‘ΏƮŽŒą`. “ú–ěˆŸ–íŽq, ˜e“c—SŽŔ, –ěŒű—T•ă, ˆäŒË°, ˆäă˛b1, ^‘D_‰î, œA@Ž“T (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/17), ŒF–{.

723076. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šé‹Ć‚É‚¨‚Ż‚é‘gD“IŒöł‚ޘJ“­ŽŇ‚ĚŽóf—}§‚É‹y‚Ú‚ˇ‰e‹ż: 1”NŠÔ‚Ě‘OŒü‚ŤƒRƒz[ƒgŒ¤‹†. ˆäă˛b1, ěăŒ›l, ]Œű@Ž1, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/17), ŒF–{.

723077. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œo‰c—”O‚̐Z“§‚ޘJ“­ŽŇ‚̐S—“IƒXƒgƒŒƒX‚É—^‚Ś‚é‰e‹ż. ]Œű@Ž1, ˆäă˛b1, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/17), ŒF–{.

723078. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠŽĄ‘̐Eę‚É‚¨‚Ż‚éOSHMS’č’…‚ĆˆŔ‘S‰qśŽw•W‚⊈“Ž‚ւ̉e‹ż•]‰ż@‘ć24•ń. “n•Ó—TW, b“c–ÎŽ÷, ˛X–Ř‹B, ź—tŽjŽq, ˆÉ“ĄşD, ŒF’JM“ń, Œ´@–M•v, ’ç@–žƒ1, ŠŰŽRłŽĄ, ŽRŒűGŽ÷ (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/18), ŒF–{.

723079. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ú–{Œę”ĹƒT[ƒoƒ“ƒgƒŠ[ƒ_[ƒVƒbƒvŽÚ“x (“ú–{Œę”ĹSLS) ‚ĚˆöŽq\‘˘‹y‚ѐM—ŠŤ‚ĚŒŸ“˘. Ź—Ń—R‰Ŕ, “n•Ó˜aL, ]Œű@Ž1, ‘ĺ’ˑאł, “ď”gŽs, Ą‘şK‘ž˜Y, ěăŒ›l (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/18), ŒF–{, ŽY‹Ć‰qśŠwŽGŽ 2018; 60 (—ŐŽž‘Š§†): 318.

723080. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šé‹ĆŠO˜J“­‰qś‹@ŠÖ‚É‚¨‚Ż‚鎥—ÂƐE‹ĆśŠˆ‚Ě—ź—§Žx‰‡‚ɂ‚˘‚Ä‚ĚƒCƒ“ƒ^ƒrƒ…[’˛¸•ŞÍ. XŒűŽŸ˜Y, éꌴ—RŽq, ]Œű@Ž1, ˆäă˛b1, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/19), ŒF–{.

723081. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) _“ŢěŒ§‰ş‚É‚¨‚Ż‚éŽY‹Ć•ŰŒ’Šˆ“Ž’˛¸ (1) ŽY‹Ćˆă‘I”Có‹ľ‚ĆŠú‘Ň‚ˇ‚éŽY‹Ćˆă‹Ć–ą“ŕ—e. –žŠÔ‹ÎŽq, —é–ŘŠě‘ă”ü, ç—tGˆę, ’‡‘ş@€, •˝@vG, ‹{–{‹P˜a, ]Œű@Ž1, ŒĂ‰Í@‘×, –kŒ´‰Ŕ‘ă, “n•”^‹|, ‰Á‰ę‚Ü‚ą‚Ć (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/19), ŒF–{, ŽY‹Ć‰qśŠwŽGŽ 2018; 60 (—ŐŽž‘Š§†): 500.

723082. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) _“ŢěŒ§‰ş‚É‚¨‚Ż‚éŽY‹Ć•ŰŒ’Šˆ“Ž’˛¸ (2) `ƒXƒgƒŒƒXƒ`ƒFƒbƒNE’ˇŽžŠÔ˜J“­‚Ć‘Îô. ‰Á‰ę‚Ü‚ą‚Ć, •˝@vG, ŒĂ‰Í@‘×, –žŠÔ‹ÎŽq, ]Œű@Ž1, –kŒ´‰Ŕ‘ă, —é–ŘŠě‘ă”ü, ç—tGˆę, ’‡‘ş@€, ‹{–{‹P˜a, “n•”^‹| (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/19), ŒF–{, ŽY‹Ć‰qśŠwŽGŽ 2018; 60 (—ŐŽž‘Š§†): 501.

723083. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) _“ŢěŒ§‰ş‚É‚¨‚Ż‚éŽY‹Ć•ŰŒ’Šˆ“Ž’˛¸ (3) `ÝEŽŇŽ€–S‚Ě’˛¸`. ‹{–{‹P˜a, –kŒ´‰Ŕ‘ă, “n•”^‹|, –žŠÔ‹ÎŽq, ]Œű@Ž1, ‰Á‰ę‚Ü‚ą‚Ć, —é–ŘŠě‘ă”ü, •˝@vG, ç—tGˆę, ’‡‘ş@€, ŒĂ‰Í@‘× (1ŒöO‰qś): ‘ć91‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2018/5/19), ŒF–{, ŽY‹Ć‰qśŠwŽGŽ 2018; 60 (—ŐŽž‘Š§†): 501.

723084. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ź‹K–ÍŽ–‹Ćę‚É‚¨‚Ż‚銈—Í‚ ‚éEę‚Ă‚­‚č‚Ě‚˝‚ß‚ĚDŽ–—á‚Ě—ŢŒ^‰ť. “ú–ěˆŸ–íŽq, ‘ĺ{‰ę~, ™–ě”ü—R‹I, ˜e“c—SŽŔ, –ěŒű—T•ă, ˆäŒË°, “c’†L–ž, ˆäă˛b1, ^‘D_‰î, œA@Ž“T (1ŒöO‰qś): ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2018/6/30), “Œ‹ž.

723085. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽOÎˆČă‚Ĺ•Űˆç‰€E—c’t‰€‚É“ü‰€‚ľ‚Ä‚˘‚Č‚˘Žq‚Ç‚ŕ‚̎ЉďEg‘Ě“I”wŒi—vˆö‚Ě•ŞÍ. ‰Â’m—IŽq1, ‰Á“Ął•F (1ŒöO‰qś): “ú–{Ô‚ż‚á‚ńŠw‰ď‘ć18‰ńŠwpW‰ď (2018/7/7-8), “Œ‹ž.

723086. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šé‹ĆŠO˜J“­‰qś‹@ŠÖ‚É‚¨‚Ż‚鎥—ÂƐE‹ĆśŠˆ‚Ě—ź—§Žx‰‡‚ɂ‚˘‚Ä‚ĚƒAƒ“ƒP[ƒg’˛¸•ŞÍ. XŒűŽŸ˜Y, éꌴ—RŽq, ‘ĺ‹´ŽjŽq, ]Œű@Ž1, ˆäă˛b1, ‘ü–ě@—S, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć59‰ń“ú–{lŠÔƒhƒbƒNŠw‰ďŠwp‘ĺ‰ď (2018/8/31), VŠƒ.

723087. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡‚ÉŠÖ‚ˇ‚鎖‹ĆŠ“ŕƒ‹[ƒ‹‚̍쐬‹y‚ŃŽ–‹ĆŠ“ŕŒ¤C‚ĚŽŔŽ{‚Ć—ź—§Žx‰‡‚̑̐§‚̏[ŽŔ“x‚Ć‚ĚŠÖ˜A. ]Œű@Ž1, ’ç@–žƒ1, ˆäă˛b1, ‰Â’m—IŽq1 (1ŒöO‰qś): ‘ć28‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2018/9/16), “Œ‹ž. ‘ć28‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ďu‰‰W 2018; p.233.

723088. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ú–{‚Ě’†‚”NŽŇ‚É‚¨‚Ż‚é‚Ş‚ńŽĄ—Ă‚ĚA˜J‚ւ̉e‹ż|’†‚”NŽŇc’f’˛¸9”NŠÔ‚Ě•ŞÍ‚Š‚ç|. ]Œű@Ž1, “c•Ł‹M‘ĺ (1ŒöO‰qś): ‘ć77‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2018/10/26), •Ÿ“‡.

723089. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 3`5Î‚Ĺ•Űˆç‰€E—c’t‰€‚É’Ę‚Á‚Ä‚˘‚Č‚˘Žq‚Ç‚ŕ‚̎ЉďEŒoĎEŒ’N–Ę‚Ě“Á’Ľ. ‰Â’m—IŽq1, ‰Á“Ął•F (1ŒöO‰qś): ‘ć77‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2018/10/24-26), •Ÿ“‡.

723090. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eę‚Ěƒ\[ƒVƒƒƒ‹EƒLƒƒƒsƒ^ƒ‹‚Ć—ŁEˆÓŽv‚Ć‚ĚŠÖ˜A: ‰Ą’fŒ¤‹†. ”Ń“c^Žq, ěăŒ›l, ˆŔ“ĄŠG”üŽq, ˆäă˛b1, ŒI‰ŞZŽq, ’Ă–ě“Ţ”ü (1ŒöO‰qś): ‘ć26‰ń“ú–{ŽY‹ĆƒXƒgƒŒƒXŠw‰ď (2018/11/30), “Œ‹ž.

731002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Ă—{EA˜J—ź—§Žx‰‡Žw“ą—ż‚ĚŠˆ—p‚Š‚ç`ˆă—ÂƐEę‚ĹŽx‚Ś‚éŽdŽ–‚ĆŽĄ—Ă‚Ě—ź—§Žx‰‡‚đl‚Ś‚é`. ]Œű@Ž (ŒöO‰qś): ‘ć77‰ń“ú–{ŽY‹Ć‰qśŠw‰ď“Œ–k’n•ű‰ď (2018/7/28), ĺ‘ä.

732011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒ“ƒP[ƒg‚đ‚ˇ‚é‘O‚É’m‚Á‚Ä‚¨‚Ť‚˝‚˘‚ą‚Ć. ˆäă˛b (ŒöO‰qś): śŠU‹łˆçˆĎˆő‰ďŽáŽčŒ¤‹†ŽŇ‚̉ď (2018/5/17), ŒF–{.

732012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žq‚Ç‚ŕ‚Ě•n˘‚ĆŒ’NŠiˇ|ŽĐ‰ď‰uŠw‚Š‚ç‚ĚƒAƒvƒ[ƒ`|. ‰Â’m—IŽq (ŒöO‰qś): “ú–{Šwp‰ď‹c ‘ć3‰ńŽáŽč‰ČŠwŽŇƒTƒ~ƒbƒg (2018/6/4), “Œ‹ž.

732013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒXƒgƒŒƒXƒ`ƒFƒbƒN‚ĚŠˆ—p. ’ç@–žƒ (ŒöO‰qś): ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—‹Ś‰ďŠÖ“ŒbM‰z’n•ű•”‰ďŒ¤‹†W‰ď (2018/8/2), “Œ‹ž‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—‹Ś‰ďŠÖ“ŒbM‰z’n•ű•”‰ďŒ¤‹†W‰ďƒvƒƒOƒ‰ƒ€ 2018; p.20-3.

732014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) “­‚Ť‚Č‚Ş‚çŽqˆç‚Ä‚ľ‚˝‚­‚Č‚é!? ‚¨“ž­ô‚ĚƒXƒXƒ. ‰Â’m—IŽq (ŒöO‰qś): •˝Ź30”N“xu’j—‹¤“ŻŽQ‰ć„iƒtƒH[ƒ‰ƒ€v (2018/9/1), é‹Ę.

733020. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽŠŽE—\–h‚ɑ΂ľ‚Ĉă—Ă, •ŰŒ’, •ŸŽƒ, S—“™‚̐ę–ĺ‰Ć‚đ–ÚŽw‚ˇŠwś‚Ş—L‚ˇ‚é‚ׂŤ’mŽŻ‚Ć‹ZpŒüă‚Ě‚˝‚ß‚Ě‹łŢŠJ”­‚ÉŠÖ‚ˇ‚錤‹†. ’ç@–žƒ1, ˆäă˛b1, Žç‰Ž—˜‰Ŕ2, ç—tG‹B2, “‡’Ă–žl, Ź“cŒ´K, ŠOŽR_”V (1ŒöO‰qś, 2ˆăŠw‹łˆç): •˝Ź30”N“xŽŠŽE‘΍ô„iƒŒƒA[ƒ‹ (2019/2/14), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[’˜@‘]

H28-610001. [Šwp‘ (•Ş’SŽˇ•M)]yPsychosocial Factors at Work in the Asia Pacific From Theory to PracticezGuidelines for Primary Prevention for Mental Health at Wrok, p.61-75. Tsutsumi A1, Shimazu A: Editors: Shimazu A, Bin Nordin R, Dollard M, Oakman J, Springer International Publishing Switzerland, 2016/9”­s. (’ç@–žƒ1: 1ŒöO‰qś)


–@ˆăŠw

[Šwp˜_•ś]

120006. [Œ´’˜] –k—˘‘ĺŠwˆăŠw•”–@ˆăŠw‚É‚¨‚Ż‚é“ű—cŽ™“Ë‘RŽ€—á‚Ě–@ˆăŠw“IŒŸ“˘. ˛“Ą•śŽq1, “ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1 (1–@ˆă): “ú–{SIDSE“ű—cŽ™“Ë‘RŽ€—\–hŠw‰ďŽGŽ 2018/12; 18 (1): 24-8.

220001. [€Œ´’˜] ŽŸ˘‘ăƒV[ƒPƒ“ƒT[‚đ—p‚˘‚˝S‹ŘÇ‚Ěˆâ“`Žq‰đÍ. ‘şăçŽq1, “ü]@Â1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1 (1–@ˆă, 2Œ`‘ÔŒn): “ú–{DNA‘˝Œ^ 2018/7; 26: 184-6.

220002. [€Œ´’˜]y‹Zp•ńzŠCˆć‚É‚¨‚Ż‚é•Y—ŹŽ€‘Ě: ŠC“ďęŠ‚Ć“úŽž‚ŞŠm‚Š‚ČŽ–—á‚ĚŽűW. ‘O“c—Y‘ĺ, ŹŕV@‘ć, Š_“ŕNG, Š_–{—R•z, ‰iŔGˆę, Šâă‘G, “c’†—f˜Y, ’†–ěŽjâM, ‘ĺč‹`ˆę, Œ´@ŞŽ÷, ˛“Ą—I•˝, ’†ě^‰î, ŒË“c‹ĹŽq, ‰Ş‘ş‰ë–ç, –{“c˜a•F, ˆî”g—T”V, ŁŒË—Ç‹v, ˛“Ą•śŽq1, ‘ĺŕVŽ‘Ž÷ (1–@ˆă): –@‰ČŠw‹Zp 2019/1; 24 (1): 99-106.

310001. [Ç—á•ń] Fulminant group A streptococcal infection without gangrene in the extremities: Analysis of five autopsy cases. Kato S, Yanazaki M, Hayashi K, Satoh F1, Isobe I, Tsutsumi Y: Pathol Int. 2018/7; 68 (7): 419-24. (˛“Ą•śŽq1: 1–@ˆă)

310002. [Ç—á•ń] Extensive gastric necrosis secondary to acute gastric dilatation: A case report. Murakami C1, Irie W1, Sasaki C1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: Leg Med (Tokyo) 2019/2; 36: 85-8. (‘şăçŽq1, “ü]@Â1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1: 1–@ˆă, 2Œ`‘ÔŒn)

[Šw‰ďEŒ¤‹†‰ď“™]

713039. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A case of autopsy in which paternity was denied by X-STR. Murakami C1, Irie W1, Sasaki C1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: 24th Congress of the International Academy of Legal Medicine (IALM) & ‘ć102ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2018/6/6), •Ÿ‰Ş. (‘şăçŽq1, “ü]@Â1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1: 1–@ˆă, 2Œ`‘ÔŒn)

713040. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Statistical Study of Impurity Peaks for Analysis of Alcohol using Gas Chromatography. Sasaki C1, Murakami C1, Irie W1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: 24th Congress of the International Academy of Legal Medicine (IALM) & ‘ć102ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2018/6/6), •Ÿ‰Ş. (˛X–ؐçŽőŽq1, ‘şăçŽq1, “ü]@Â1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1: 1–@ˆă, 2Œ`‘ÔŒn)

713041. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Carboxyhaemoglobin saturation in the body blood`Significance of the laterality in the heart blood`. Irie W1, Murakami C1, Sasaki C1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: 24th Congress of the International Academy of Legal Medicine (IALM) & ‘ć102ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2018/6/8), •Ÿ‰Ş. (“ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1: 1–@ˆă, 2Œ`‘ÔŒn)

723091. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ€ÇŒ^—n˜A‹ŰŠ´őÇ‚É‚Ä‹}Ž€‚ľ‚˝VśŽ™–UŒŸ—á. ˛“Ą•śŽq1, “ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2 (1–@ˆă, 2Œ`‘ÔŒn): ‘ć1‰ń“ú–{–@ˆă•a—Šw‰ďŠwp‘S‘W‰ď (2018/9/1-2), ‚ź.

723092. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DSMSƒvƒƒWƒFƒNƒg|ƒuƒ‰ƒCƒ“ƒhƒeƒXƒg|: ‘ć5‰ńƒuƒ‰ƒCƒ“ƒhƒeƒXƒg‚ĚŽŔŽ{Œ‹‰Ę‚ƍlŽ@. ˛X–ؐçŽőŽq1, ˛“Ą•śŽq1 (1–@ˆă): ‘ć43‰ń“ú–{ˆă—pƒ}ƒXƒXƒyƒNƒgƒ‹Šw‰ď”N‰ď (2018/9/6), ŽD–y.

723093. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć“VŤŇ’Œ‘¤œ^Ç‚đ‡•š‚ľ‚˝ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚Ě—cŽ™–UŒŸ—á. ˛“Ą•śŽq1, “ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2 (1–@ˆă, 2Œ`‘ÔŒn): ‘ć25‰ń“ú–{SIDSE“ű—cŽ™“Ë‘RŽ€—\–hŠw‰ďŠwpW‰ď (2019/2/23), ‰ŞŽR.

731003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “ü—’†‚Ě‹}Ž€‚Ć—\–h‘΍ô‚ɂ‚˘‚Ä. ˛“Ą•śŽq (–@ˆă): ‘ć44‰ń–k—˘ˆăŠw‰ď‘‰ď (2018/11/17), ‘Š–Í‘ĺ–ě.

733021. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”xĂ–Ź‚ƍśS–[ŽüˆÍ‚ĚŽŠ—Ľ_Œo‚Ě”z—ń‚̖Ɖu‘gD‰ťŠw“IŒŸ“˘ “ü—’†‚Ě‹}Ž€—á‚Ć‘ÎĆÇ—á‚Ć‚Ě”äŠr. ˛“Ą•śŽq1, “ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ‘ĺŕVŽ‘Ž÷ (1–@ˆă, 2Œ`‘ÔŒn): ‘ć87‰ń“ú–{–@ˆăŠw‰ďŠwpŠÖ“Œ’n•űW‰ď (2018/10/6), “Œ‹ž.

733022. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ŻŽžŠú‚ɕʁX‚Ě—vˆö‚ĹŽ€–S‚ľ‚˝“Ż‹ŒZ’í‚Ě–UŒŸ—á. “ü]@Â1, ‘şăçŽq1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˛“Ą•śŽq1 (1–@ˆă, 2Œ`‘ÔŒn): ‘ć87‰ń“ú–{–@ˆăŠw‰ďŠwpŠÖ“Œ’n•űW‰ď (2018/10/6), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110010. [Œ´’˜] Double suicide in modern Japan (in Kanagawa prefecture): Comparison with those in post-war Japan and other countries. Satoh F1, Osawa M: Med Sci Law 2018/2; 58 (2): 97-101. (˛“Ą•śŽq1: 1–@ˆă)


ŽŔŒą“Ž•¨Šw

[Šwp˜_•ś]

110082. [Œ´’˜] Craniofacial abnormality with skeletal dysplasia in mice lacking chondroitin sulfate N-acetylgalactosaminyltransferase-1. Ida-Yonemochi H, Morita W, Sugiura N, Kawakami R, Morioka Y, Takeuchi Y, Sato T1, Shibata S, Watanabe H, Imamura T, Igarashi M, Ohshima H, Takeuchi K: Sci Rep 2018/11; 8 (1): 17134. (˛“ĄrĆ1: 1ŽŔ“Ž)

110083. [Œ´’˜] Differential behavioral phenotypes of dopamine D1 receptor knockdown mice at the embryonic, postnatal, and adult stages. Okubo T1, Sato A2, Okamoto H3, Sato T1, Sasaoka T: Int J Dev Neurosci 2018/5; 66: 1-8. (‘ĺ‹v•Ű’ź1, ˛“Ą’ŠŽq2, ‰Ş–{_Žk3, ˛“ĄrĆ1: 1ŽŔ“Ž, 2ś•¨•¨—Œn, 3–ƒŒ)

[Šw‰ďEŒ¤‹†‰ď“™]

723094. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ˆ˘•”@Šw, ě‘ş–źŽq, ꎓĄ“މp, Ź“c‰Ŕ“ŢŽq, ěŠÔćŕ–@, “ŕŽRŸ, ˆ˘•”ŒőŽő, “c’†@–Ť, ŽR–{”ü‹u, _•ŰKO, ˛“ĄrĆ2, “ĄŕVM‹`, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž): ‘ć41‰ń“ú–{_Œo‰ČŠw‘ĺ‰ď (2018/7/26), _ŒË.

723095. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ꎓĄ“މp, •Ÿ“cŽľ•ä, ˆ˘•”@Šw, ě‘ş–źŽq, Ź“c‰Ŕ“ŢŽq, ˛“ĄrĆ2, “ĄŕVM‹`, ŽRŒű@u, “cˆä’†ˆę‹M, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/30), ‰Ą•l.

733023. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ꎓĄ“މp, •Ÿ“cŽľ•ä, ˆ˘•”@Šw, ě‘ş–źŽq, Ź“c‰Ŕ“ŢŽq, ˛“ĄrĆ2, ‰Ş–{_Žk3, “ĄŕVM‹`, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž, 3–ƒŒ): ‘ć59‰ńVŠƒś‰ťŠw§˜b‰ď (2018/6/2), ’ˇ‰Ş.

733024. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) TDP-43×–E“ŕ‹ÇÝƒXƒCƒbƒ`§Œä‚É‚ć‚é‹ŘˆŢkŤ‘¤őd‰ťÇƒ‚ƒfƒ‹‚̍쐬. ˛“ĄrĆ1, ’†‘şŠ˛ş2 (1ŽŔ“Ž, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): •˝Ź30”N“x”]Œ¤‹†Š‹¤“Ż—˜—p‹¤“ŻŒ¤‹† (ů‰Ş”ǁEč‘ş”Ç) ‡“ŻƒZƒ~ƒi[ (2018/12/18), VŠƒ.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110011. [Œ´’˜] Ripply3 is required for the maintenance of epithelial sheets in the morphogenesis of pharyngeal pouches. Tsuchiya Y, Mii Y, Okada K, Furuse M, Okubo T1, Takada S: Dev Growth Differ 2018/2; 60 (2): 87-96. (‘ĺ‹v•Ű’ź1: 1ŽŔ“Ž)


–ƉuŠw

[Šwp˜_•ś]

110084. [Œ´’˜] Role of T-bet, the master regulator of Th1 cells, in the cytotoxicity of murine CD4+ T cells. Eshima K1, Misawa K, Ohashi C, Iwabuchi K1: Microbiol Immunol 2018/5; 62 (5): 348-56. (]“‡k“ń1, ŠâŸş˜a–ç1: 1–Ɖu)

110085. [Œ´’˜] Role of Natural Killer T Cells in the Development of Obesity and Insulin Resistance: Insights From Recent Progress. Satoh M1, Iwabuchi K1: Front Immunol 2018/6; 9: 1314. (˛“Ą@‰ë1, ŠâŸş˜a–ç1: 1–Ɖu)

110086. [Œ´’˜] Characterization of T cell receptors in a novel murine model of nickel-induced intraoral metal contact allergy. Nakasone Y, Kumagai K, Matsubara R, Shigematsu H, Kitaura K, Suzuki S, Satoh M1, Hamada Y, Suzuki R: PLoS One 2018/12; 13 (12): e0209248. (˛“Ą@‰ë1: 1–Ɖu)

522017. [uŔ]y“ÁW: MHCƒNƒ‰ƒXIbS‘ŠŤT×–EŒ¤‹†‚̐V“WŠJz‚Í‚ś‚ß‚É. ŠâŸş˜a–ç (–Ɖu): ˆăŠw‚Ě‚ ‚ä‚Ý 2018/4; 265 (4): 42.

522018. [uŔ]y“ÁW: –ƉuŒn‚đ‰î‚ľ‚˝ƒVƒXƒeƒ€˜AŠÖ: PíŤ‚ĚˆŰŽ‚Ć”j’]zV. –Ɖu‚Ć‘ăŽÓ@NKT×–E‚ĆŽ‰–b‘gD. ŠâŸş˜a–ç1, ˛“Ą@‰ë1 (1–Ɖu): ś‘̂̉Ȋw 2019/3-4; 70 (2): 130-4.

[Šw‰ďEŒ¤‹†‰ď“™]

713042. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The regulatory function of NKT cells in experimental autoimmune uveoretinitis. Kato T, Satoh M1, Iwabuchi K1: the 3rd International Conference on Innate Lymphoid Cells (ILC2018) (2018/11/30), Tokyo, Japan. (˛“Ą@‰ë1, ŠâŸş˜a–ç1 : 1–Ɖu)

713043. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) NKT cell - adipocyte interaction have an important role in adipose tissue inflammation. Satoh M1, Iwabuchi K1: the 3rd International Conference on Innate Lymphoid Cells (ILC2018) (2018/11/30), Tokyo, Japan. (˛“Ą@‰ë1, ŠâŸş˜a–ç1 : 1–Ɖu)

713044. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The protective role of MAIT cell in allergic contact dermatitis. Imahashi N, Satoh M1, Iwabuchi K1: the 3rd International Conference on Innate Lymphoid Cells (ILC2018) (2018/11/30), Tokyo, Japan. (˛“Ą@‰ë1, ŠâŸş˜a–ç1: 1–Ɖu)

713045. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The effect of invariant NKT cell activation by ƒż-galactosylceramide in the heart. Yoshino K, Satoh M1, Iwabuchi K1: the 3rd International Conference on Innate Lymphoid Cells (ILC2018) (2018/11/30), Tokyo, Japan. (˛“Ą@‰ë1, ŠâŸş˜a–ç1: 1–Ɖu)

722013. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰ŠÇŤŽžŠł‚É‚¨‚Ż‚éNKT×–E‚Ě–đŠ„‚Ć‚ť‚̐§Œä. ŠâŸş˜a–ç (–Ɖu): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/23), ŽD–y.

723096. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) NADPH oxidase (NOX2) ”ńˆË‘ś“ID’†‹…NETosis—U“ą‚Ćƒ~ƒgƒRƒ“ƒhƒŠƒAROSŽYś‚ĚŠÖ˜A‚ɂ‚˘‚Ä. ’|“ŕŒb”üŽq1, ’|“ŕN—Y2 (1–Ɖu, 2t‘Ÿ“ŕ): ‘ć46‰ń“ú–{—Տ°–ƉuŠw‰ď‘‰ď (2018/11/8), Œyˆä‘ň.

723097. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Functional analyses of cortical thymic epithelial cells in NF-ƒČB-inducing kinase (NIK)-mutated, alymphoplasia mice. ]“‡k“ń1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723098. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The protective role of MR1/MAIT cell in allergic contact dermatitis. Imahashi N, ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723099. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Amelioration of relapse model of experimental autoimmune uveoretinitis with NKT cell ligand. Kato T, ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723100. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CD1d-positive antigen presenting cells in the heart. Yoshino K, ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723101. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Modulation of NKT-cell function in mice fed on high fat diet (HFD). ‰HŞŒőŽi1, ˛“Ą@‰ë2, ŠâŸş˜a–ç2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723102. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) NKT cells control insulin sensitivity by interacting with adipocytes and macrophages. ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/10), •Ÿ‰Ş.

723103. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The associateon of NADPHoxidase-independent NETosis with acceleration of mitochondrial ROS production. ’|“ŕŒb”üŽq1, ’|“ŕN—Y2, Iizuka M, ŠâŸş˜a–ç1 (1–Ɖu, 2t‘Ÿ“ŕ): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/11), •Ÿ‰Ş.

723104. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Lymphocyte-dependent accumulation of myeloid-derived suppressor cell (MDSC)-like CD11b+/Gr-1+ cells in the periphery of NF-ƒČB-inducing kinase (NIK) mutant mice. Ohashi C, ]“‡k“ń1, ‘ĺ‹´çq2, ŠâŸş˜a–ç1 (1–Ɖu, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć47‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2018/12/12), •Ÿ‰Ş.

723105. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒ}ƒEƒXŽŔŒą“IŽŠŒČ–ƉuŤ–Ô–Œ‚Ô‚Ç‚¤–Œ‰ŠÄ”Rƒ‚ƒfƒ‹‚ĚNKT×–E‚đ‰î‚ľ‚˝‰ŠÇ§Œä. ‰Á“Ą‘žŠě, ˛“Ą@‰ë1, –kŽsL‹`, ’JŒű@Ž, Luc Van Kaer, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć2‰ń“ú–{ƒx[ƒ`ƒFƒbƒg•aŠw‰ď (2018/12/14), ‰Ą•l.

732015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠeŽí•a‘Ԑ§Œä‚É‚¨‚Ż‚éNKT×–E‚Ě‚Í‚˝‚ç‚Ť. ŠâŸş˜a–ç1, ˛“Ą@‰ë1 (1–Ɖu): ‘ć62‰ń“ú–{–ňŠw‰ďŠÖ“ŒŽx•”‘ĺ‰ď (2018/9/15), “Œ‹ž.

733025. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚Ž‰–bH•‰‰×‚É‚¨‚Ż‚éNKT×–E‚Ě‹@”\‰đÍ. ‰HŞŒőŽi1, ˛“Ą@‰ë1,2, ŠâŸş˜a–ç1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) NKT×–E‚đ‰î‚ľ‚˝ŽŠŒČ–ƉuŤ‚Ô‚Ç‚¤–Œ‰Š‚Ě—}§ƒƒJƒjƒYƒ€. ‰Á“Ą‘žŠě1, ˛“Ą@‰ë1,2, –kŽsL‹`3, ŠâŸş˜a–ç1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu, 3–kŠC“šˆă—Ă‘ĺŠw): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ÚGŤ”畆‰Š‚É‚¨‚Ż‚éMAIT×–E‚Ě‹@”\‰đÍ. Ą‹´Ž–ç1, ˛“Ą@‰ë1,2, ŠâŸş˜a–ç1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) NF-ƒČB-inducing kinase (NIK) •ĎˆŮƒ}ƒEƒX‚É‚¨‚Ż‚鍜‘—R—ˆ—}§×–E (MDSC) —l×–E‚Ě’~Ď‚ɂ‚˘‚Ä. ‘ĺ‹´çq1, ]“‡k“ń1,2, ŠâŸş˜a–ç1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8), ‘Š–ÍŒ´.

733029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) NKT×–E‚É‚ć‚é’°“ŕ×‹Ű‘p‚̐§Œä. ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć7‰ńƒtƒ@[ƒWŒ¤‹†‰ďE2018”N“ú–{×‹ŰŠw‰ďŠÖ“ŒŽx•”ƒCƒ“ƒ^[ƒ‰ƒ{ƒZƒ~ƒi[‡“Ż‘ĺ‰ď (2018/9/1), ‘Š–ÍŒ´.


’nˆćŽ™“ś¸_‰Čˆă—ĂŠw


Äśˆă—ĂŒ`ŹŠO‰ČŠw


’nˆć‘‡ˆă—ĂŠw


‰ŠÇŤ’°ŽžŠł‹łˆçE—Տ°Œ¤‹†Šw


ŹŽ™|ŹŽ™zŠÂŠí’nˆćˆă—ĂŠw


Á‰ťŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110087. [Œ´’˜] Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. Naganuma M, Aoyama N, Tada T, Kobayashi K1,2, Hirai F, Watanabe K, Watanabe M, Hibi T3,4: J Gastroenterol 2018/4; 53 (4): 494-506. (Ź—ѐ´“T1,2, “ú”ä‹I•ś3,4: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4–k—˘Œ¤‹†Š•a‰@)

110088. [Œ´’˜] Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W1, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A: Gastric Cancer 2018/5; 21 (3): 429-38. (Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ)

110089. [Œ´’˜] Efficacy and Long-Term Outcomes of Side-by-Side Self-Expandable Metal Stent Placement Using a 2-Channel Endoscope for Unresectable Malignant Hilar Biliary Obstruction Occurring After Billroth II Reconstruction (with Video). Okuwaki K1, Yamauchi H1, Kida M1,2, Imaizumi H1, Iwai T1, Matsumoto T1, Kawaguchi Y1, Uehara K1, Nakatani S1, Koizumi W1: Dig Dis Sci 2018/6; 63 (6): 1641-6. (‰œ˜e‹ť‰î1, ŽR“ŕ_Žj1, –Ř“cŒőL1,2, Ąň@O1, Šâˆä’m‹v1, ź–{‚–ž1, ěŒű—C•ă1, ăŒ´ˆę”ż1, ’†’JŞŒá1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110090. [Œ´’˜] Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802). Ishido K1, Tanabe S1,2, Azuma M1, Katada C1, Wada T1, Yano T1, Koizumi W1: Surg Endosc 2018/6; 32 (6): 2939-47. (ÎŒËŒŞŽŸ1, “c糁@‘1,2, “Œ@’q1, Œ˜“ce—˜1, ˜a“c‘ń–ç1, –î–ě‹MŽj1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110091. [Œ´’˜] Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K1, Yoshimura N, Hibi T2,3: Dig Dis Sci 2018/7; 63 (7): 1910-9. (‰ĄŽR@ŒO1, “ú”ä‹I•ś2,3: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110092. [Œ´’˜] Consensus guidelines on the optimal management in interventional EUS procedures: results from the Asian EUS group RAND/UCLA expert panel. Teoh AYB, Dhir V, Kida M1,2, Yasuda I, Jin ZD, Seo DW, Almadi M, Ang TL, Hara K, Hilmi I, Itoi T, Lakhtakia S, Matsuda K, Pausawasdi N, Puri R, Tang RS, Wang HP, Yang AM, Hawes R, Varadarajulu S, Yasuda K, Ho LKY: Gut 2018/7; 67 (7): 1209-28. (–Ř“cŒőL1,2: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110093. [Œ´’˜] Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Hisamatsu T1, Kunisaki R1, Nakamura S1, Tsujikawa T1, Hirai F1, Nakase H1, Watanabe K1, Yokoyama K1,2, Nagahori M1, Kanai T1, Naganuma M1, Michimae H1, Andoh A1, Yamada A1, Yokoyama T1, Kamata N1, Tanaka S1, Suzuki Y1, Hibi T1,3,4, Watanabe M1 (1CERISIER Trial group): Intest Res 2018/7; 16 (3): 494-8. (‰ĄŽR@ŒO1,2, “ú”ä‹I•ś1,3,4: 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4–k—˘Œ¤‹†Š•a‰@)

110094. [Œ´’˜] Aprepitant, palonosetron, with dexamethasone to prevent nausea and vomiting induced by cisplatin-based chemotherapy for hepatocellular carcinome. Wada N1, Hidaka H1, Kondo M, Nakazawa T1, Uojima H1, Kubota K1, Tanaka Y1, Shibuya A1,2, Irie K, Morimoto M, Suzuki M, Tanaka K, Koizumi W1: Kitasato Med J 2018/9; 48 (2): 81-7. (˜a“cŽ‹v1, “ú‚@‰›1, ’†ŕV‹MG1, ‹›“ˆ°‹I1, ŒE“cK‰î1, “c’†ŒŤ–ž1, a’J–ž—˛1,2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ĂŠÇ—)

110095. [Œ´’˜] A Prospective Multicenter Study of a Fully Covered Metal Stent in Patients with Distal Malignant Biliary Obstruction: WATCH-2 Study. Kogure H, Ryozawa S, Maetani I, Nakai Y, Kawakami H, Yasuda I, Mochizuki H, Iwano H, Maguchi H, Kida M1,2, Kubota K, Mukai T, Hasebe O, Igarashi Y, Hanada K, Irisawa A, Ito K, Itoi T, Isayama H: Dig Dis Sci 2018/9; 63 (9): 2466-73. (–Ř“cŒőL1,2: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110096. [Œ´’˜] Analysis of the diagnostic yield of endoscopic ultrasonography-guided fine-needle aspiration in patients with a suspected pancreatic malignancy. Yang L, Iwai T1, Kida M1,2, Yamauchi H1, Okuwaki K1, Imaizumi H1, Kaneko T1, Hasegawa R1, Miyata E1, Koizumi W1: Rev Esp Enferm Dig 2018/9; 110 (9): 544-50. (Šâˆä’m‹v1, –Ř“cŒőL1,2, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Ąň@O1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110097. [Œ´’˜] Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis. Uojima H1, Hidaka H1, Tanaka Y1, Inoue T2, Onoue M1, Wada N1, Kubota K1, Nakazawa T1, Shibuya A1,3, Fujikawa T, Nakayama T1, Yamanoue H, Sung JH, Kako M, Koizumi W1: J Gastroenterol Hepatol 2018/11; 33 (11): 1889-96. (‹›“ˆ°‹I1, “ú‚@‰›1, “c’†ŒŤ–ž1, ˆäă’qm2, ”öă”üŒb1, ˜a“cŽ‹v1, ŒE“cK‰î1, ’†ŕV‹MG1, a’J–ž—˛1,3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—)

110028. [Œ´’˜] RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis. Inoue T1, Ito Y2, Nishizawa N3, Eshima K4, Kojo K5, Otaka F1, Betto T1, Yamane S1, Tsujikawa K, Koizumi W6, Majima M2: PLoS One 2018/11; 13 (11): e0200432. (ˆäă’qm1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ]“‡k“ń4, ŒĂé@Œ›5, ‘ĺ‚Žjš1, •Ęác•üL1, ŽRŞ‘‹IŽq1, Źň˜aŽO˜Y6, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4–Ɖu, 5‰ş•”Á‰ťŠÇŠO, 6Á‰ťŠí“ŕ)

110098. [Œ´’˜] A multi-institution consensus on how to perform EUS-guided biliary drainage for malignant biliary obstruction. Guo J, Giovannini M, Sahai AV, Saftoiu A, Dietrich CF, Santo E, Fusaroli P, Siddiqui AA, Bhutani MS, Bun Teoh AY, Irisawa A, Arturo Arias BL, Achanta CR, Jenssen C, Seo DW, Adler DG, Kalaitzakis E, Artifon E, Itokawa F, Poley JW, Mishra G, Ho KY, Wang HP, Okasha HH, Lachter J, Vila JJ, Iglesias-Garcia J, Yamao K, Yasuda K, Kubota K, Palazzo L, Sabbagh LC, Sharma M, Kida M1,2, El-Nady M, Nguyen NQ, Vilmann P, Garg PK, Rai P, Mukai S, Carrara S, Parupudi S, Sridhar S, Lakhtakia S, Rana SS, Ogura T, Baron TH, Dhir V: Endosc Ultrasound 2018/11-12; 7 (6): 356-65. (–Ř“cŒőL1,2: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110099. [Œ´’˜] Relationship between response to lusutrombopag and splenic volume. Uojima H1, Arase Y, Itokawa N, Atsukawa M, Satoh T2, Miyazaki K3, Hidaka H1, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R2, Koizumi W1: World J Gastroenterol 2018/12; 24 (46): 5271-9. (‹›“ˆ°‹I1, ˛“Ą—˛Ži2, ‹{ř“_“ń3, “ú‚@‰›1, –x]—Lję2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ÉqśŠw•”, 3—AŒŒE×–EˆÚA)

110100. [Œ´’˜] Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H1, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M: Invest New Drugs 2018/12; 36 (6): 1072-84. (“ú‚@‰›1: 1Á‰ťŠí“ŕ)

110101. [Œ´’˜] Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H1, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T: J Gastroenterol 2018/12; 53 (12): 1276-84. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110102. [Œ´’˜] Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis. Tanaka Y1, Masaki T, Uojima H1, Ohtake T, Fujikawa T, Yamanouchi Y, Wada N1, Kubota K1, Hidaka H1, Nakazawa T1, Shibuya A1,2, Aoyama T, J.H.Sung, Kako M, Kobayashi S, Takeuchi Y, Koizumi W1: Renal Replacement Therapy 2018; Article number: 51. (“c’†ŒŤ–ž1, ‹›“ˆ°‹I1, ˜a“cŽ‹v1, ŒE“cK‰î1, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛1,2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ĂŠÇ—)

110103. [Œ´’˜] Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Nishina T, Azuma M1, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I: Gastric Cancer 2019/1; 22 (1): 138-46. (“Œ@’q1: 1Á‰ťŠí“ŕ)

110104. [Œ´’˜] Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N1, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W1: Gastric Cancer 2019/1; 22 (1): 155-63. (’†ŽR¸“T1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ)

110105. [Œ´’˜] Short-term outcomes of multicenter prospective cohort study of gastric endoscopic resection: 'Real-world evidence' in Japan. Suzuki H1, Takizawa K1, Hirasawa T1, Takeuchi Y1, Ishido K1, Hoteya S1, Yano T1, Tanaka S1, Endo M1, Nakagawa M1, Toyonaga T1, Doyama H1, Hirasawa K1, Matsuda M1, Yamamoto H1, Fujishiro M1, Hashimoto S1, Maeda Y1, Oyama T1, Takenaka R1, Yamamoto Y1, Naito Y1, Michida T1, Kobayashi N1, Kawahara Y1, Hirano M1, Jin M1, Hori S1, Niwa Y1, Hikichi T1, Shimazu T1, Ono H1, Tanabe S1,2,3, Kondo H1, Iishi H1, Ninomiya M1 (1Ichiro Oda for J-WEB/EGC group): Dig Endosc 2019/1; 31 (1): 30-9. (ÎŒËŒŞŽŸ1,2, “c糁@‘1,2,3: 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă)

110106. [Œ´’˜] Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M1,2, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N: Hepatol Res 2019/1; 49 (1): 105-10. (“n粐^˛1,2: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110107. [Œ´’˜] Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients. Uojima H1, Kobayashi S, Hidaka H1, Kinbara T, Fujikawa T, Nakayama T, Yamanoue H, Kanemaru T, Hashimotoh T, Hyun Sung J, Kako M, Koizumi W1: Ann Hepatol 2019/1-2; 18 (1): 109-15. (‹›“ˆ°‹I1, “ú‚@‰›1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ)

110108. [Œ´’˜] Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M1, Chen LT, Kang YK: Ann Oncol 2019/2; 30 (2): 250-8. (“Œ@’q1: 1Á‰ťŠí“ŕ)

110109. [Œ´’˜] A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis. Kobayashi K1,2, Suzuki Y, Watanabe K, Oda K, Mukae M, Yamada A, Yamagami H, Nishimura A, Okamoto H: J Clin Pharmacol 2019/2; 59 (2): 271-9. (Ź—ѐ´“T1,2: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ)

110110. [Œ´’˜] Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H1, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K: J Gastroenterol Hepatol 2019/2; 34 (2): 364-9. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110030. [Œ´’˜] RAMP1 attenuates immune-mediated hepatitis via recruiting regulatory T cells. Inoue T1, Inoue M2, Ito Y3, Otaka F1, Betto T1, Yamane S1, Koizumi W4, Majima M3: Kitasato Med J 2019/3; 49 (1): 9-15. (ˆäă’qm1, ˆäăŒőŽq2, ˆÉ“Ą‹`–ç3, ‘ĺ‚Žjš1, •Ęác•üL1, ŽRŞ‘‹IŽq1, Źň˜aŽO˜Y4, ”n“ˆł—˛3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3–ň—, 4Á‰ťŠí“ŕ)

110031. [Œ´’˜] Enhanced angiogenesis by recruitment of VEGFR1+ă•tCXCR4+ă•t cells from bone marrow during experimental colitis. Betto T1, Amano H2, Ito Y2, Eshima K3, Yoshida T4, Matsui Y5, Yamane S1, Inoue T1, Otaka F1, Kobayash K6, Shibuya M, Koizumi W7, Majima M2: Kitasato Med J 2019/3; 49 (1): 35-45. (•Ęác•üL1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‹g“c@Œ÷4, źˆäŒ[•v5, ŽRŞ‘‹IŽq1, ˆäă’qm1, ‘ĺ‚Žjš1, Ź—ѐ´“T6, Źň˜aŽO˜Y7, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4•a—, 5ŒÄ‹zŠíŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7Á‰ťŠí“ŕ)

110032. [Œ´’˜] The role of Angiotensin II type 1A receptor signaling in gastric ulcer healing. Yamane S1, Amano H2, Ito Y2, Betto T1, Inoue T1, Otaka F1, Koizumi W3, Majima M2: Kitasato Med J 2019/3; 49 (1): 52-63. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, •Ęác•üL1, ˆäă’qm1, ‘ĺ‚Žjš1, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ)

110033. [Œ´’˜] Vascular endothelial growth factor receptor 1 tyrosine kinase signaling facilitates healing of DSS-induced colitis by accumulation of Tregs in ulcer area. Betto T1, Amano H2, Ito Y2, Eshima K3, Yoshida T4, Matsui Y5, Yamane S1, Inoue T1, Otaka F1, Kobayashi K6,7, Koizumi W7, Shibuya M, Majima M2: Biomed Pharmacother 2019/3; 111: 131-41. (•Ęác•üL1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‹g“c@Œ÷4, źˆäŒ[•v5, ŽRŞ‘‹IŽq1, ˆäă’qm1, ‘ĺ‚Žjš1, Ź—ѐ´“T6,7, Źň˜aŽO˜Y7, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4•a—, 5ŒÄ‹zŠíŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7Á‰ťŠí“ŕ)

110111. [Œ´’˜] A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M1, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N: Gastric Cancer 2019/3; 22 (2): 344-54. (“Œ@’q1: 1Á‰ťŠí“ŕ)

210001. [€Œ´’˜] Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Hisamatsu T1, Kunisaki R1, Nakamura S1, Tsujikawa T1, Hirai F1, Nakase H1, Watanabe K1, Yokoyama K1,2, Nagahori M1, Kanai T1, Naganuma M1, Michimae H1, Andoh A1, Yamada A1, Yokoyama T1, Kamata N1, Tanaka S1, Suzuki Y1, Hibi T1,3,4, Watanabe M1 (1CERISIER Trial group): Intest Res 2018/7; 16 (3): 494-8. (‰ĄŽR@ŒO1,2, “ú”ä‹I•ś1,3,4: 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4–k—˘Œ¤‹†Š•a‰@)

310003. [Ç—á•ń] Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Uojima H1, Murakami S, Nakatani S1, Hidaka H1, Takeuchi A1, Tanaka Y1, Inoue T2, Yamane K2, Kubota K1, Nakazawa T1, Shibuya A1,3, Tanaka Y, Koizumi W1: Intern Med 2018/4; 57 (7): 951-6. doi: 10.2169/internalmedicine.9671-17. Epub 2017 Dec 8. (‹›“ˆ°‹I1, ’†’JŞŒá1, “ú‚@‰›1, ’|“ŕ“ÖŽq1, “c’†ŒŤ–ž1, ˆäă’qm2, ŽRŞŒhŽq2, ŒE“cK‰î1, ’†ŕV‹MG1, a’J–ž—˛1,3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—)

310004. [Ç—á•ń] Endoscopic ultrasound-guided antegrade metal stent placement using the stent-in-stent technique in a patient with malignant hilar biliary obstruction. Yamauchi H1, Kida M1,2, Miyazawa S1, Okuwaki K1, Iwai T1, Imaizumi H1, Koizumi W1: Endosc Ultrasound 2018/5-6; 7 (3): 204-6. (ŽR“ŕ_Žj1, –Ř“cŒőL1,2, ‹{ŕVŽu˜N1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

310005. [Ç—á•ń] Long-lasting patent fistula after EUS-guided choledochoduodenostomy in a patient with refractory benign biliary stricture. Iwai T1, Kida M1,2, Yamauchi H1, Kaneko T1, Okuwaki K1, Imaizumi H1, Koizumi W1: VideoGIE 2018/5; 3 (6): 193-5. (Šâˆä’m‹v1, –Ř“cŒőL1,2, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ‰œ˜e‹ť‰î1, Ąň@O1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

310006. [Ç—á•ń] Temporary non-flared fully covered self-expandable metal stent placement for refractory benign choledochojejunal anastomotic stricture. Yamauchi H1, Tadehara M1, Kida M1,2: Dig Endosc 2018/7; 30 (4): 541-2. (ŽR“ŕ_Žj1, äřŒ´Ť—Ç1, –Ř“cŒőL1,2: 1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

310007. [Ç—á•ń] A giant trichobezoar extracted by laparoscopic and endoscopic cooperative surgery (LECS). Kurosu T1, Tanabe S1,2, Hasegawa R1, Yano T1, Wada T1, Ishido K1, Azuma M1, Katada C1, Koizumi W1, Moriya H3, Yamashita K3,4: Endosc Int Open 2018/12; 6 (12): E1413-6. (•{‹M_1, “c糁@‘1,2, ’ˇ’Jě—Í–ç1, –î–ě‹MŽj1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, “Œ@’q1, Œ˜“ce—˜1, Źň˜aŽO˜Y1, X’JGŒő3, ŽR‰şŒpŽj3,4: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

320001. [Ç—á•ń] –Ó’°”S–Œ‰şŽîᇂɑ΂ľ‚Ä”S–Œ‰ş‘w”—Łp‚đŽ{s‚ľ‚˝1—á. “c糔ü“Ţ1, ěŠÝ‰Á“Ţ1, âV“Ą—FĆ, ź–{ˆçG1, Œ}@”üK1, ‰ĄŽR@ŒO1, ˛“c”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1, H’JšŽj2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă•a—): Progress of Digestive Endoscopy 2018/5; 92 (1): 130-1.

320002. [Ç—á•ń] č÷—ą‹…œ‹Ž—Ă–@‚Ş‘tŒ÷‚ľ‚˝ƒXƒeƒƒCƒhƒiƒC[ƒuŹŽ™’×ᇐŤ‘ĺ’°‰Š‚Ě1—á. ŽOŽ}—zˆę1,2, ”üŒ´Ă1, ‹ŕ@–ž“N1,2, ‰Á“Ą@Ę1,2, ŒK”ö’čm1, ŽO‹´—˜‰ˇ1, źŒłŽ›ŽâX1,2, ‘ĺˆä“cłl1,2 (1‘Š–Í–ě•a‰@Á, 2Á‰ťŠí“ŕ): Progress of Digesive Endscopy 2018/6; 92 (1): 136-7.

320003. [Ç—á•ń] ’ź’°_Œo“ŕ•Ş”ĺŽîá‡2•a•Ď‚ɑ΂ľ“ŕŽ‹‹ž“IŘœp‚đŽ{s‚ľ‚˝1—á. –kě”Ž”V1,2, źŽR@—ł1,2, –kŒ´@Œž1, Ž›“cšO1, ‰Íźčű‘ž˜Y1, ‹e’nG•F1,2, —˘“š“N•F1,2, ŽRčDŠě1,2, –ě“o@˝1,2, źŒ´@C1 (1•˝’Ë‹¤Ď•a‰@, 2Á‰ťŠí“ŕ): Progress of Digestive Endoscopy 2018/12; 93 (1): 143-5.

522019. [uŔ] “–‰@‚É‚¨‚Ż‚é‘ĺ’°“ŕŽ‹‹ž‘}“ü˘“ď—á‚ĚŒťó‚Ć‘Îô. Œ}@”üK1, Ź—ѐ´“T1,2, ˛“c”ü˜a1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{‘ĺ’°ŒŸ¸Šw‰ďŽ 2018/4; 34 (2): 55-61 (111-7).

522020. [uŔ]y“ÁWII. Á‰ťŠíŽžŠł‚É‚¨‚Ż‚鐍ˇˆă—Ă‚đl‚Ś‚éz‰ŠÇŤ’°ŽžŠł‚ƐŤˇ|‰ŠÇŤ’°ŽžŠł—ŤŠłŽŇ‚đf‚é‚Ć‚Ť‚Ɂ|. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Á‰ťŠíEŠĚ‘Ÿ“ŕ‰Č 2018/5; 3 (5): 517-9.

522021. [uŔ] ’´‰š”g“ŕŽ‹‹ž‚É‚ć‚é”S–Œ‰ş•a•Ď‚̐f’f. –Ř“cŒőL1,2, ěŒű—C•ă1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ŹňŽüŽq1, ‰œ˜e‹ť‰î1, ‹{ŕVŽu˜N1, Šâˆä’m‹v1, ‹e’nG•F1, “n•Ó–€–ç1, Ąň@O1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŽGŽ 2018/5; 60 (5): 1116-31.

522022. [uŔ]y“ÁW: ‚Ç‚¤‚ˇ‚éäXůN–EzŠe˜_ II. ‹}ŤäX‰ŠŒă‚ĚůN–EŤ•a•Ď (PPC‚ĆWON)@’´‰š”g“ŕŽ‹‹ž‰ş‰źŤůN–EƒhƒŒƒi[ƒW. Šâˆä’m‹v1, –Ř“cŒőL1,2, Ąň@O1, ‰œ˜e‹ť‰î1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Á‰ťŠí“ŕŽ‹‹ž 2018/5; 30 (5): 645-52.

522023. [uŔ]y˜AÚ: EUS, EUS-FNA f’fEŽĄ—Á|Tips & TrickszƒRƒ“ƒxƒbƒNƒXŒ^EUS‚É‚ć‚é’_äX•W€’Šo–@ (1). –Ř“cŒőL1,2, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, ‹e’nG•F1, Ąň@O1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): —ŐଏÁ‰ťŠí“ŕ‰Č 2018/6; 33 (6): 680-6.

522024. [uŔ]y˜AÚ: EUS, EUS-FNA f’fEŽĄ—Á|Tips & TrickszƒRƒ“ƒxƒbƒNƒXŒ^EUS‚É‚ć‚é’_äX•W€’Šo–@ (2). –Ř“cŒőL1,2, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, ‹e’nG•F1, Ąň@O1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): —ŐଏÁ‰ťŠí“ŕ‰Č 2018/7; 33 (8): 1067-72.

522025. [uŔ]y“ÁWII: ŠĚd•Ď‚ĚŽĄ—Ă–ň|‚ǂ̂悤‚ÉŽg‚˘‚ą‚Č‚ˇ‚Š?zƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“III (ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“) ťÜ. “ú‚@‰›1, ‹›“ˆ°‹I1, š •Ş–ΔŽ1 (1Á‰ťŠí“ŕ): Á‰ťŠíEŠĚ‘Ÿ“ŕ‰Č 2018/9; 4 (3): 254-60.

522026. [uŔ]y“ÁW: ƒAƒ‹ƒR[ƒ‹‚Ć‹CŠÇH“š‰ČzƒAƒ‹ƒR[ƒ‹‚ƐH“šŠŕ. Œ˜“ce—˜1, “c糁@‘1,2, ŽR‰ş @‘ń3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3Ž¨•@ˆôAE“ŞčňŠO): “ú–{‹CŠÇH“š‰ČŠw‰ď‰ď•ń 2018/10; 69 (5): 297-304.

522027. [uŔ]y“ÁW: ’×ᇐŤ‘ĺ’°‰Š‚Ě“ŕ‰Č“IŽĄ—Á|i‚ß•ű‚ĆŒŠ‹É‚ß•űz’×ᇐŤ‘ĺ’°‰ŠŽĄ—Ă‚É‚¨‚Ż‚éV–ňƒgƒtƒ@ƒVƒ`ƒjƒu, ƒxƒhƒŠƒYƒ}ƒu‚̉”\Ť. ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): Á‰ťŠí‚Ě—Ő° 2018/11; 21 (4): 275-81.

522028. [uŔ]y“ÁW: ’_äXƒhƒŒƒi[ƒWupdatez2. äXƒhƒŒƒi[ƒW@Še˜_ äXŽüˆÍ‰t‘Ě’™—Ż‚ɑ΂ˇ‚éEUSƒKƒCƒh‰şƒhƒŒƒi[ƒW. Šâˆä’m‹v1, –Ř“cŒőL1,2, Ąň@O1, ‰œ˜e‹ť‰î1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Á‰ťŠí“ŕŽ‹‹ž 2018/11; 30 (11): 1584-91.

522029. [uŔ]y“ÁW: ŠĚáŠQ‚Ć‹ĂŒĹü—nŒnzŠĚd•Ď‚É‚¨‚Ż‚é–ĺ–ŹŒŒđÇ‚Ě•a‘Ô‚ĆŽĄ—Ă. “ú‚@‰›1, ˜a“cŽ‹v1 (1Á‰ťŠí“ŕ): Thrombosis Medicine 2018/12; 8 (4): 262-8.

522030. [uŔ]yŽĺ‘č: EUS‚É‚ć‚éÁ‰ťŠÇŽžŠł‚̐f’f|Œťó‚ƍŐV‚Ě˜b‘čz‘ĺ’°Šŕ‚ĚEUSf’f. Ź—ѐ´“T1,2, âV“Ą—FĆ2, ź–{ˆçG2, ěŠÝ‰Á“Ţ2, Œ}@”üK2, ‰ĄŽR@ŒO2, ˛“c”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ˆÝ‚Ć’° 2018/12; 53 (13): 1737-46.

522031. [uŔ]y“ÁW: ŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠłzŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠł‚Ć‚˘‚¤‘O‚Ɂ@Ą–Ť‰ş—Ÿ‚ւ̐f’f“IƒAƒvƒ[ƒ`. ˛“c”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ŽĄ—Ă 2019/2; 101 (2): 138-45.

522032. [uŔ]y“ÁW: ŠĚŤ”]ÇŽĄ—Ă‚Ě•Ď‘JŠĚŤ”]Ç‚ĚĹ‹ß‚Ěl‚Ś•űzƒVƒƒƒ“ƒgŤŠĚŤ”]Ç‚ĚŽĄ—Á|IVR (B-RTO)|. ’†ŕV‹MG1, “c’†ŒŤ–ž1, ‹›“ˆ°‹I1, “ú‚@‰›1, š •Ş–ΔŽ1 (1Á‰ťŠí“ŕ): ŠĚ’_äX 2019/3: 78 (3): 419-26.

522033. [uŔ]y“ÁW: ƒGƒLƒXƒp[ƒg‚Ö‚Ě“š|‰ş•”Á‰ťŠÇz‘ĺ’°@2. f’f–@@’´‰š”g“ŕŽ‹‹ž (EUS) ‚ĚƒRƒc‚Ɛf’f–@. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2019/2; 31 (2): 217-23.

[’˜@‘]

610004. [Šwp‘ (•Ş’SŽˇ•M)]yAdvanced Therapeutic Endoscopy for Pancreatico-Biliary DiseaseszPresent Status and Future Perspectives of Endoscopic Ultrasonography-Guided Fine Needle Aspiration (EUS-FNA), p.103-8. Kida M1, Iwai T1, Imaizumi H1: Editors: Mine T, Fujita R, Springer Japan, 2018/”­s. (–Ř“cŒőL1, Šâˆä’m‹v1, Ąň@O1: 1Á‰ťŠí“ŕ)

610005. [Šwp‘ (•Ş’SŽˇ•M)]yClinical Investigation of Portal Hypertension <1st ed. 2019>zPart 3 Complications of portal hypertension: Gastrointestinal varices@17. Conservative Treatment: Pharmacological Therapy, p.195-202. Hidaka H1, Editor: Obara K, Springer, 2019/2. (“ú‚@‰›1: 1Á‰ťŠí“ŕ)

620014. [Šwp‘ (•Ş’SŽˇ•M)]yĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@Á‰ťŠíŽžŠł@f’fEŽĄ—ĂŽwjzVÍ ŽĄ—Ă–@‘˜_@ă•”Á‰ťŠÇŽžŠł@“ŕŽ‹‹žŽĄ—Á@“ŕŽ‹‹ž“IŘœp, p.176-8. źŽR@—ł1,2, Œă“Ą“c‘ěŽu3 (1•˝’Ë‹¤Ď•a‰@, 2Á‰ťŠí“ŕ, 3“ú–{‘ĺŠwˆăŠw•”“ŕ‰ČŠwŒnÁ‰ťŠíŠĚ‘Ÿ“ŕ‰ČŠw•Ş–ě), ‘•ŇW: ˛X–Ř—T, •Ň: –؉ş–Fˆę, ‰şŁě“O, “n•Ó@Žç, ’†ŽR‘“X, “Œ‹ž, 2018/7”­s.

620015. [Šwp‘ (•Ş’SŽˇ•M)]yĹVƒKƒCƒhƒ‰ƒCƒ“€‹’@Á‰ťŠíŽžŠł@f’fEŽĄ—ĂŽwjzVÍ ŽĄ—Ă–@‘˜_@ă•”Á‰ťŠÇŽžŠł@“ŕŽ‹‹žŽĄ—Á@H“šEˆÝĂ–ŹáŽŽĄ—Ă, p.178-81. “ú‚@‰›1, š •Ş–ΔŽ1 (1Á‰ťŠí“ŕ), ‘•ŇW: ˛X–Ř—T, •Ň: –؉ş–Fˆę, ‰şŁě“O, “n•Ó@Žç, ’†ŽR‘“X, “Œ‹ž, 2018/7”­s.

620016. [Šwp‘ (•Ş’SŽˇ•M)]yu‘‚í‚Š‚čv“ŕŽ‹‹žŠÖ˜AƒKƒCƒhƒ‰ƒCƒ“2018 (Á‰ťŠí“ŕŽ‹‹ž9ŒŽ‘‘ĺ†)zŠe˜_ VI. Á‰ťŠí‘S”Ę‚É‚¨‚ć‚Ô‚ŕ‚́@…@‰ŠÇŤ’°ŽžŠł (IBD) f—ĂƒKƒCƒhƒ‰ƒCƒ“2016, …A’×ᇐŤ‘ĺ’°‰ŠEƒNƒ[ƒ“•a@f’fŠî€EŽĄ—ĂŽwj, p.1257-64. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2018/9”­s.

620017. [Šwp‘ (‹¤’˜)]yŹŕu‹t“]ƒzƒXƒsƒ^ƒ‹v‚ĹŠw‚ԁ@ˆă—ĂŒo‰cƒtƒŒ[ƒ€ƒ[ƒN“ü–ĺza’J–ž—˛1,2 (1ˆă—ĂŠÇ—, 2Á‰ťŠí“ŕ), •Ň: a’J–ž—˛1,2, “úŒoBPŽĐ, “Œ‹ž, 2018/10”­s.

620018. [Šwp‘ (•Ş’SŽˇ•M)]y’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě‚ˇ‚ׂĂނ킊‚é@f—Ăƒnƒ“ƒhƒuƒbƒNz‘ć2Í ’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě—Ő°f’f@2 ‰ć‘œf’f@A. Á‰ťŠÇ‘˘‰eŒŸ¸, p.26-9. Ź—ѐ´“T1,2, ‰ĄŽR@ŒO2, ‹v•Ű“c (˛“c) ”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), ŠÄC: —é–؍N—Y, •Ň: ”Ń’Ë•ś‰l, “c’†ł‘Ľ, ź“c—˛G, ć’[ˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

620019. [Šwp‘ (•Ş’SŽˇ•M)]y’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě‚ˇ‚ׂĂނ킊‚é@f—Ăƒnƒ“ƒhƒuƒbƒNz‘ć5Í ŽĄ—Ă–@@Še˜_1 –ň•¨—Ă–@@A. 5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_ťÜ, p.108-10. Ź—ѐ´“T1,2, ‰ĄŽR@ŒO2, ‹v•Ű“c (˛“c) ”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), ŠÄC: —é–؍N—Y, •Ň: ”Ń’Ë•ś‰l, “c’†ł‘Ľ, ź“c—˛G, ć’[ˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

620020. [Šwp‘ (•Ş’SŽˇ•M)]y’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě‚ˇ‚ׂĂނ킊‚é@f—Ăƒnƒ“ƒhƒuƒbƒNz‘ć5Í ŽĄ—Ă–@@Še˜_2 ‰h—{—Ă–@, p.140-2. Ź—ѐ´“T1,2, ‰ĄŽR@ŒO2, ‹v•Ű“c (˛“c) ”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), ŠÄC: —é–؍N—Y, •Ň: ”Ń’Ë•ś‰l, “c’†ł‘Ľ, ź“c—˛G, ć’[ˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

620021. [Šwp‘ (•Ş’SŽˇ•M)]y’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě‚ˇ‚ׂĂނ킊‚é@f—Ăƒnƒ“ƒhƒuƒbƒNz‘ć6Í Ç—á‚Š‚çŠw‚ԁ@2) ŽĄ—Ă‚ÉŠÖ‚ˇ‚éÇ—á@Ç—á35 pŒăÄ”­‚đ‚­‚č•Ô‚ľ‚˝’°ŠÇƒx[ƒ`ƒFƒbƒg•a (•s‘SŒ^) ‚Ě1—á, p.216-7. Ź—ѐ´“T1,2, ‰ĄŽR@ŒO2, ‹v•Ű“c (˛“c) ”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), ŠÄC: —é–؍N—Y, •Ň: ”Ń’Ë•ś‰l, “c’†ł‘Ľ, ź“c—˛G, ć’[ˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

620022. [Šwp‘ (•Ş’SŽˇ•M)]y’°ŠÇƒx[ƒ`ƒFƒbƒg•a‚Ě‚ˇ‚ׂĂނ킊‚é@f—Ăƒnƒ“ƒhƒuƒbƒNz‘ć7Í “ÁŽę—áE“úíśŠˆ‚ĚƒPƒAEŽw“ą@1. ”DPEoŽYEŽö“ű, p.222-4. Ź—ѐ´“T1,2, ‰ĄŽR@ŒO2, ‹v•Ű“c (˛“c) ”ü˜a2, Źň˜aŽO˜Y2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), ŠÄC: —é–؍N—Y, •Ň: ”Ń’Ë•ś‰l, “c’†ł‘Ľ, ź“c—˛G, ć’[ˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

620023. [Šwp‘ (•Ş’SŽˇ•M)]y“ÁW: ƒGƒLƒXƒp[ƒg‚Ö‚Ě“š|’_EäX (Á‰ťŠí“ŕŽ‹‹ž3ŒŽ‘‘ĺ†)zEUSŠÖ˜A@ŽĄ—ĂŽč‹Z@äXůN–EƒhƒŒƒi[ƒW‚ĆƒlƒNƒƒZƒNƒgƒ~[|“K‰ž‚Ě‘I‘đ, ‹ô”­Ç‚đ‹N‚ą‚ł‚Č‚˘ƒRƒc|, p.516-21. Šâˆä’m‹v1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711001. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) EUS-FNA/B sample processing to increase the diagnostic yield. Iwai T1: 16th Korean Sosiety of Gastorointestinal Endoscopy EUS Hands-on Work shop & WISE 2018 (2018/6/23), Korea. (Šâˆä’m‹v1: 1Á‰ťŠí“ŕ)

711002. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Teaching & Distribution of EUS/EUS-FNA. Kida M1: ’†‘“ŕŽ‹‹žŠw‰ď‘‰ď (2018/8/25), Nanjing, China. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

711003. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Collaboration of EUS-FNA and ERCP/PTBD. Kida M1: 1 st Oriental Conference on Gastrointestinal Endoscopy the 21 st Chinese S ymposium on E ndoscopic U ltrasonography (2018/10/12), Shanghai, Chaina. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

711004. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) How to differentiate Pancreatic Masses. Kida M1: 1 st Oriental Conference on Gastrointestinal Endoscopy the 21 st Chinese S ymposium on E ndoscopic U ltrasonography (2018/10/12), Shanghai, Chaina. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

711005. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Cytapheresis in Patients with Ulcerative Colitis. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć6‰ń’†‘‘ĺ˜A‰ŠÇŤ’°ŽžŠłŠw‰ď (2018/11/30), ‘ĺ˜A, ’†‘.

711006. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) The Current Situation and The Appropriate Usage of Cytapheresis in Patients with UC in Japan. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć6‰ń’†‘‘ĺ˜A‰ŠÇŤ’°ŽžŠłŠw‰ď (2018/12/1), ‘ĺ˜A, ’†‘.

712007. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Interventional EUS - EUS PFC/WON Drainage -. Kida M1: AEG INTERVENTIONAL EUS HANDS-ON TRAINING COURSE (2018/5/25), Ho Chi Minh, Vietnam. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712008. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) EUS-Injection • Ablation Therapy & Future Direction. Kida M1: AEG INTERVENTIONAL EUS HANDS-ON TRAINING COURSE (2018/5/25), Ho Chi Minh, Vietnam. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712009. [Šw‰ď (‘Ű)] (ƒ[ƒNƒVƒ‡ƒbƒv) From Multidisciplinary team to treatment II A Case of Crohn's disease. Yokoyama K1: AOCC 2018 THE 6th ANNUAL MEETING OF ASIAN ORGANIZATION FOR CROHN'S & CLOITIS (2018/6/21), Chaina. (‰ĄŽR@ŒO1: 1Á‰ťŠí“ŕ)

712010. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) EUS guided tissue acquisition - Limitation & How to increase yield -. Kida M1: AEG Workshop Delieh (2018/6/23), Delieh. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712011. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) EUS Instruments and Devices for Interventional EUS. Kida M1: AEG Workshop Delieh (2018/6/23), Delieh. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712012. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Therapeutic EUS. Kida M1: “ě•űÁ‰ťŠí“ŕŽ‹‹ž‘ŰŠw‰ď (2018/7/13), Guangzhou, Chaina. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712013. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) How to differentiate Panc. Masses? Kida M1: DEST ‘ä˜p“ŕŽ‹‹žŠw‰ď (2018/7/28), Taipei, Taiwan. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712014. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) EUS PFC Drainage/Necrosectomy. Kida M1: APSDE TTT Workshop Vietnam (2018/10/4), Ho Chi Minh, Vietnam. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712015. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) How to find early stage pancreatic cancer: the Japanese way. Kida M1: 4th EUS-ERCP Connection (2018/11/16), Turin, Italy. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712016. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) endoscopy Live Demo. Kida M1: Taipei Veterans General Hospital ERCP/EUS Live Demo (2018/12/17), Taipei, Taiwan. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

712017. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Cholangiogram / Pancreatogram. Kida M1: 2019 DEST Certification Course of Therapeutic ERCP (2019/2/24), Taipei, Taiwan. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

713018. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) RAMP1 signaling in macrophages protects mice from concanavalin A-induced liver injury. Inoue T1, Ito Y2, Nishizawa N3, Otaka F1, Nakamoto S1, Tsuru S1, Hattori K4, Koizumi W5, Amano H2, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (ˆäă’qm1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ‘ĺ‚Žjš1, ’†–{CŽi1, ’Ă—Ż˘—˘1, •ž•”‹żŽq4, Źň˜aŽO˜Y5, “V–ě‰pŽ÷2, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4ŽY‰Č, 5Á‰ťŠí“ŕ)

713020. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Role of thromboxane prostanoid (TP) receptor in the facilitation of angiogenesis and the healing of gastric ulcers. Yamane S1, Amano H2, Betto T1, Inoue T1, Ito Y2, Shimizu Y3, Nishizawa N4, Narumiya S, Koizumi W3, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, •Ęác•üL1, ˆäă’qm1, ˆÉ“Ą‹`–ç2, ´…—T‹M3, źŕVL‹ą4, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

713021. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) VEGFR1-TK signaling protects exacerbation of dextran sulfate sodium-induced colitis in mice. Betto T1, Amano H2, Yamane S1, Inoue T1, Shimizu Y3, Ito Y2, Yoshida T4, Koizumi M, Koizumi W3, Majima M2: 18th World Congress of Basic and Clinical Pharmacology (2018/7/1), Kyoto, Japan. (•Ęác•üL1, “V–ě‰pŽ÷2, ŽRŞ‘‹I1, ˆäă’qm1, ´…—T‹M3, ˆÉ“Ą‹`–ç2, ‹g“c@Œ÷4, Źň˜aŽO˜Y3, ”n“ˆł—˛2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3Á‰ťŠí“ŕ, 4•a—)

713046. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Usefulness of Measuring Serum Infliximab Concentrations during Treatment with Infliximab for Ulcerative Colitis. Yokoyama K1, Kawagishi K1, Kobayashi K1,2, Koizumi W1: IBD and Liver: East Meets West (2018/9/7), Kyoto. (‰ĄŽR@ŒO1, ěŠÝ‰Á“Ţ1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

713047. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) A phase I study of the combination chemotherapy of IRISOX (irinotecan/S-1/oxaliplatin) in gemcitabine-refractory pancreatic cancer. Miyata E1, Okuwaki K1, Imaizumi H1,2, Kida M1,3, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Adachi K4, Tadehara M4, Koizumi W1: ESMO 2018 Congress (2018/10/19-23), Munich, Germany. (‹{“c‰pŽĄ1, ‰œ˜e‹ť‰î1, Ąň@O1,2, –Ř“cŒőL1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, ˆŔ’B@‰ő4, äřŒ´Ť—Ç4, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘Š–Í–ě•a‰@, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713048. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Analysis of BRCAness with MLPA in pancreatic ductal adenocarinoma patients using FFPE sample obtained via EUS-FNAB. Okuwaki K1, Imaizumi H1,2, Masutani H3, Yoshida T4, Kida M1,5, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Miyata E1, Adachi K3, Koizumi W1: ESMO 2018 Congress (2018/10/19-23), Munich, Germany. (‰œ˜e‹ť‰î1, Ąň@O1,2, Ą’JŠ°ˆČ3, ‹g“c@Œ÷4, –Ř“cŒőL1,5, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, ˆŔ’B@‰ő3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘Š–Í–ě•a‰@, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4•a—, 5–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713049. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Risk factors for acute bleeding and delayed bleeding after endoscopic submucosal dissection in patients with early gastric cancer. Tabnabe S1,2: UEG Week2018 (2018/10/20-24), Vienna, Austria. (“c糁@‘1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ)

713050. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Endoscopic treatment of Bile duct stones in patients with surgically altered anatomy. Kida M1, Yamauchi H1, Miyata E1, Hasegawa R1, Kaneko T1, Okuwaki K1, Iwai T1, Imaizumi H1: UEG Week2018 ‘ć26‰ń‰˘BÁ‰ťŠí•aTŠÔ (2018/10/22), Vienna, Austria. (–Ř“cŒőL1, ŽR“ŕ_Žj1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1: 1Á‰ťŠí“ŕ)

713051. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Newly Developed Model for training EUS-FNA and Pseudocyst Drainage procedure. Kida M1, Hasegawa R1, Miyata E1, Kaneko T1, Yamauchi H1, Okuwaki K1, Iwai T1, Imaizumi H1: UEG Week2018 ‘ć26‰ń‰˘BÁ‰ťŠí•aTŠÔ (2018/10/23), Vienna, Austria. (–Ř“cŒőL1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1: 1Á‰ťŠí“ŕ)

713052. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Characteristics and prevention of early mortality in patients with hepatocellular carcinoma. Watanabe M1,2, Yokomori H1,3: GASTRO 2018 (2018/12/7), BangKok, Thailand. (“n粐^˛1,2, ‰ĄXOş1,3: 1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ, 3‘‡f—Ă)

713053. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Long-term outcomes of adalimumab in patients with Crohn's Disease Can a doubled dose of adalimumab improve outcomes? Kanazawa Jun1, Yokoyama K1, Matsumoto Y1, Kawagishi K1, Mukae M1, Kubota M1, Kobayashi K1,2, Koizumi W1: 14th Congress of European Crohn's and Colitis Organisation (2019/3/8), Copenhagen, Denmark. (‹ŕŕV@1, ‰ĄŽR@ŒO1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, Œ}@”üK1, ‹v•Ű“c”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

721002. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ƒNƒ[ƒ“•aŽĄ—Ă‚É‚¨‚Ż‚é’ˇŠúŽžŠłƒRƒ“ƒgƒ[ƒ‹‚Ě‚˝‚ß‚Ě“Kłƒ}ƒlƒWƒƒ“ƒg. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): abbbvie ƒCƒ“ƒ^[ƒlƒbƒgƒZƒ~ƒi[ (2018/10/9), “Œ‹ž.

721003. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‹ÇŠťÜ‚đŽg‚˘‚ą‚Č‚ť‚¤! ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): JDDW2018 (2018/11/1), _ŒË.

721004. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) “ú–{‘ĺ’°ăč–ĺ•aŠw‰ď‚Ě—Ď—Žwj‚ÉŒW‚í‚é\ż‚ɂ‚˘‚Ä. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/9), “Œ‹ž.

721005. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) Biologics‚ĚŒř‰ĘĹ‘剝‚ÉŒü‚Ż‚˝ŽĄ—Ð헪. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/10), “Œ‹ž.

721006. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‘‚Ś‘ą‚Ż‚é’×ᇐŤ‘ĺ’°‰Š`Ą‚ą‚ť‚Ý‚ń‚ȂŐf‚é‚˝‚߂Ɂ`. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć15‰ń“ú–{Á‰ťŠÇŠw‰ď‘‰ďŠwpW‰ď (2019/2/2), ˛‰ę.

722014. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒ`[ƒ€ˆă—Ă‚ĹŽć‚č‘g‚ŢIBD‚ĚShared Decision Making. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/19), “Œ‹ž.

722015. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ŠĚd•Ď‡•šÇ‘΍ô|upto-date 2018|. ‹›“ˆ°‹I (Á‰ťŠí“ŕ): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/19), “Œ‹ž.

722016. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) NBIŠg‘ĺ“ŕŽ‹‹ž‚đ—p‚˘‚˝’†‰şˆô“Ş•\ÝŠŕ‚ĚƒŠƒ“ƒpß“]ˆÚ—\‘Ş. Œ˜“ce—˜1, ‰Ş–{—ˇl2, ˆęŒËš–ž3 (1Á‰ťŠí“ŕ, 2Ž¨•@ˆôAE“ŞčňŠO, 3•a—): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/10), “Œ‹ž.

722017. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ŠĚ–ĺ•”ˆŤŤ’_ŠÇ‹ˇó‚É‚¨‚Ż‚é‹ŕ‘ŽƒXƒeƒ“ƒg‚̐ŹŃ‚Ćre-intervention‚ĚŒŸ“˘. Šâˆä’m‹v1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/11), “Œ‹ž.

722018. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) äX‰źŤůN–EEŠ´őŤWON ‚ɑ΂ˇ‚é“ŕŽ‹‹žŽĄ—Ă. –Ř“cŒőL1,2, ŠŁ@˜a˜Y3 (1Á‰ťŠí“ŕ‰Č, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3“Ą“c•ŰŒ’‰qś‘ĺŠwâ•śŽí•ńúş˜đ•a‰@Á‰ťŠí“ŕ‰Č): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/12), “Œ‹ž.

722019. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) pŒăÄŒš’°ŠÇŠłŽŇ‚ɑ΂ˇ‚éƒVƒ‡[ƒgƒ^ƒCƒvƒVƒ“ƒOƒ‹ƒoƒ‹[ƒ“ŽŽŹ’°‹ž‚đ—p‚˘‚˝ERCP‚É‚¨‚Ż‚é“ž’BŽ¸”sˆöŽq‚ĚŒŸ“˘. ŽR“ŕ_Žj1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/12), “Œ‹ž.

722020. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ŠĚŽžŠł—Ěˆć‚É‚¨‚Ż‚éV‚ľ‚˘R‹ĂŒĹ—Ă–@. “ú‚@‰› (Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/14), ‘ĺă.

722021. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) –ĺ–Źˆł˜´iÇ‚É”ş‚¤äBŽî‚Ş—^‚Ś‚郋ƒXƒgƒƒ“ƒ{ƒpƒN“Š—^Œă‚ĚŒŒŹ”‘‰Á‚ÉŠÖ‚ˇ‚錟“˘. ˜a“cŽ‹v1, ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/14), ‘ĺă.

722022. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ŠĚd•Ď‚Ě• …ŽĄ—Ð헪. ‹›“ˆ°‹I (Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/15), ‘ĺă.

722023. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠĚŤ•‚ŽîŠłŽŇ‚ɑ΂ˇ‚鐅EƒiƒgƒŠƒEƒ€—˜”AÜ•š—p—Ă–@‚ÉŠÖ‚ˇ‚é‘OŒü‚ŤŒŸ“˘: a randomised pilot study. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰ęŒĂ@áÁ (1Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/15), ‘ĺă.

722024. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) –ĺ–ŹŒŒđŠłŽŇ‚ɑ΂ˇ‚éƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“ťÜ“Š—^‚Ě‘tŒř‚ÉŠń—^‚ˇ‚éˆöŽq‚ĚŒŸ“˘. “ú‚@‰›1, š •Ş–ΔŽ1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/20), ‘ĺă.

722025. [Šw‰ď (‘S‘)] (‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) ŠĚŤ”]Ç‚ɑ΂ˇ‚郌ƒ{ƒJƒ‹ƒjƒ`ƒ“ + ƒŠƒtƒ@ƒLƒVƒ~ƒ“•š—p—Ă–@‚Ě—L—pŤ. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/20), ‘ĺă.

722026. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠĚŤ• …‡•šŠĚd•ĎŠłŽŇ‚É‚¨‚˘‚Ä, ƒgƒ‹ƒoƒvƒ^ƒ““Š—^Œă‚Ě”A’†ƒiƒgƒŠƒEƒ€”rŸ•—ʂ̕ωť. ‹›“ˆ°‹I1, “ú‚@‰›1, ˜a“cŽ‹v1, “c’†ŒŤ–ž1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/21), ‘ĺă.

722027. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) äBŽî‚Ş—^‚Ś‚郋ƒXƒgƒƒ“ƒ{ƒpƒO“Š—^Œă‚ĚŒŒŹ”‘‰Á‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, Ž…ě“T•v, rŁ‹gF, “ú‚@‰›1, Œúěł‘Ľ, ‰ÁěŒšO (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/21), ‘ĺă.

722028. [Šw‰ď (‘S‘)] (—v–]‰‰‘č) ”ń‘㏾ŤŠĚd•Ď‚É‚¨‚Ż‚é‹Ř“÷—ĘŒ¸­‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰ęŒĂ@áÁ, “Ąě’qÍ, “c’†ŒŤ–ž1, ˜a“cŽ‹v1, ŒE“cK‰î1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/21), ‘ĺă.

722029. [Šw‰ď (‘S‘)] (‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) –ŤŠĚŽžŠł‚É‚¨‚Ż‚錌Ź”ÂŒ¸­‚É‚¨‚Ż‚éäB‘Ÿ‘ĚĎ‚ĆRŒŒŹ”R‘Ě‚ĚŒŸ“˘. ˜a“cŽ‹v1, “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/21), ‘ĺă.

722030. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) –ŤŠĚŽžŠł‚É”ş‚¤ŒŒŹ”ÂŒ¸­Ç‚ɑ΂ˇ‚é, ƒgƒƒ“ƒ{ƒ|ƒGƒ`ƒ“Žó—e‘ĚƒAƒSƒjƒXƒg“Š—^Œă‚̕ωť‚ÉŠÖ‚ˇ‚é‘OŒü‚Ť‘˝Ž{Ý‹¤“ŻŒ¤‹†. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰ęŒĂ@áÁ2 (1Á‰ťŠí“ŕ, 2Ă“슙‘q‘‡•a‰@EÁ‰ťŠí•aƒZƒ“ƒ^[ ): JDDW 2018 (2018/11/1), _ŒË.

722031. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) “ŕŽ‹‹ž“I“EœŒă‚Ě‘ĺ’°T1 (SM) Šŕ‚ɑ΂ˇ‚é’ljÁ’°Řœ“K‰žŠî€‚Ě‘Ă“–Ť‚ĚŒŸ“˘. Œ}@”üK1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): JDDW 2018 (2018/11/1), _ŒË.

722032. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) “Şčň•”•\ÝŠŕ‚ɑ΂ˇ‚éŒoŒű“IŽčp‚ĚˆŔ‘SŤ‚Ć—LŒřŤ‚ÉŠÖ‚ˇ‚錟“˘|“Şčň•”•\ÝŠŕ‘S‘“o˜^’˛¸|. •“Ą@Šw1, Œ˜“ce—˜2, —с@—˛ˆę3 (1‹ž“s‘ĺ•‘Ž•a‰@EŽîᇓŕ‰Č, 2Á‰ťŠí“ŕ, 3‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@E“Şčň•”ŠO‰Č): JDDW 2018 (2018/11/1), _ŒË.

722033. [Šw‰ď (‘S‘)] (ƒZƒ~ƒi[) ‹ÇŠťÜ‚đŽg‚˘‚ą‚Č‚ť‚¤! ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): JDDW 2018 (2018/11/1), _ŒË.

722034. [Šw‰ď (‘S‘)] (ƒZƒ~ƒi[) ŠĚd•Ď‚̍‡•šÇ‘΍ô & OTSUKA Award 2018. ‹›“ˆ°‹I (Á‰ťŠí“ŕ): JDDW 2018 (2018/11/2), _ŒË.

722035. [Šw‰ď (‘S‘)] (ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€) ‚Ý‚ń‚ȂŐf‚é’×ᇐŤ‘ĺ’°‰Š. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): JDDW 2018 (2018/11/2), _ŒË.

722036. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’ÁĂ‘Oƒ`ƒFƒbƒNƒŠƒXƒg‚É‚ć‚é“ŕŽ‹‹žf—Ă‚Ě’ÁĂ‘OŠłŽŇ•]‰ż‚ĚŽć‚č‘g‚Ý. ÎŒËŒŞŽŸ1, “c糁@‘1,2, •Šâ­”V3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3–ƒŒ): JDDW 2018 (2018/11/3), _ŒË.

722037. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚éV‹KRTNF-ƒżR‘̐ťÜgolimumab‚Ě—LŒřŤ‚ɂ‚˘‚Ä. ‰ĄŽR@ŒO1, ěŠÝ‰Á“Ţ1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/9), “Œ‹ž.

722038. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) “–‰@‚É‚¨‚Ż‚éCrohn•a‚ɑ΂ˇ‚éƒAƒ_ƒŠƒ€ƒ}ƒu‚Ě’ˇŠúŽĄ—ÐŹŃ. ‹ŕŕV@1, Ź—ѐ´“T1,2, ‰ĄŽR@ŒO1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/9), “Œ‹ž.

723106. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) \“ńŽw’°“ű“Ş‚ĚŒ`‘Ô•Ş—Ţ‚ÉŠî‚Ă‚­’_ŠÇ‘}ŠÇ˘“ď—á‚̐„’č. “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, Ąň@O1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ’†’JŞŒá1, ăŒ´ˆę”ż1, Ą’JŠ°ˆČ2, ěŒű—C•ă1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ź–{‚–ž1, Šâˆä’m‹v1, –Ř“cŒőL1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/10), “Œ‹ž.

723107. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ăč–ĺŠÇL“W•a•Ď‚ɑ΂ˇ‚é‘ĺ’°”S–Œ‰ş‘w”—Łp‚ĚŒŸ“˘. –Ř”Ś‚ ‚â“ß1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c (˛“c) ”ü˜a1, ź–{ˆçG1, Œ}@”üK1, ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/10), “Œ‹ž.

723108. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) EUS-BD‚Ě“ą“ü‰Šú‚̐ŹŃ. ‹ŕŽq@‹œ1, Ąň@O1, –Ř“cŒőL1,2 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/10), “Œ‹ž.

723109. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) pŒăÄŒš’°ŠÇ‚đ—L‚ˇ‚鍂—îŽŇ‚ɑ΂ˇ‚é“ŕŽ‹‹ž“I’_ŠÇŒ‹ÎŽĄ—Ă‚ĚˆŔ‘SŤ‚Ć—LŒřŤ. ‹{“c‰pŽĄ1, ŽR“ŕ_Žj1, –Ř“cŒőL1 (1Á‰ťŠí“ŕ): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/11), “Œ‹ž.

723110. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘ĺ’°‘}“ü˘“ď—á‚ɑ΂ˇ‚é×Œa‘ĺ’°“ŕŽ‹‹ž‚Ě—L—pŤ‚ĚŒŸ“˘. Œ}@”üK1, ‹v•Ű“c (˛“c) ”ü˜a1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, Źň˜aŽO˜Y1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/11), “Œ‹ž.

723111. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) EUS‚Ĺ”­ŒŠ‚ľ“ž‚˝Segmental arterial mediolysis‚Ě—Ő°ŒoŒą. Îčƒ˜Y1, “Œ@’q1, ˜a“c‘ń–ç1, –î–ě‹MŽj1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, “c糁@‘1,2, ƒEƒbƒhƒnƒ€ƒX—ćŽq3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3•úŽËü (‰ć‘œ): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/11), “Œ‹ž.

723112. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’_ŠÇ“ŕEäXŠÇ“ŕ–Ŕ“üƒXƒeƒ“ƒg‚É‚¨‚Ż‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO. ’ˇ’Jě—Í–ç1, –Ř“cŒőL1, ˆŔ’B@‰ő2, ’†’JŞŒá1, äřŒ´Ť—Ç2, ‹{“c‰pŽĄ1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/12), “Œ‹ž.

723113. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚é•\ÝŤ”ń“ű“Ş•”\“ńŽw’°Žîᇠ(SNADET) ‚ɑ΂ˇ‚é“ŕŽ‹‹žŽĄ—Ă‚ĚŒŸ“˘. Î‹´@˜Đ1, ÎŒËŒŞŽŸ1, “c糁@‘1,2, ‹v•Ű“c—z3, ˜a“c‘ń–ç1, “n粍WŽŻ1, “Œ@’q1, Œ˜“ce—˜1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć95‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/5/12), “Œ‹ž.

723114. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠĚƒTƒ‹ƒRƒyƒjƒAf’fŠî€‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚é‘OŒü‚ŤŒŸ“˘. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰ęŒĂ@áÁ (1Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/15), ‘ĺă.

723115. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠĚ×–EŠŕ‚ɑ΂ľƒ\ƒ‰ƒtƒFƒjƒu‚đ“ą“ü‚ľ’ˇŠúś‘ś‚ľ‚˝Ç—á‚Ě“Á’Ľ. “c’†ŒŤ–ž1, ’†ŕV‹MG1, ŽRŞŒhŽq2, ˜a“cŽ‹v1, ˆäă’qm2, ŒE“cK‰î1, ‹›“ˆ°‹I1, Ź–ěO“ń1, “n粐^˛1, “ú‚@‰›1, a’J–ž—˛1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/15), ‘ĺă.

723116. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘㏾Šú‚ć‚č”ń‘㏾ŠúŠĚd•Ď‚É‚¨‚Ż‚éM2BPGi ’l‚̕ωť‚ÉŠÖ‚ˇ‚錟“˘. ”öăŠG”ü, ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć54‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2018/6/15), ‘ĺă.

723117. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –ĺ–Źˆł˜´iÇ‚É”ş‚¤äBŽî‚Ş—^‚Ś‚郋ƒXƒgƒƒ“ƒ{ƒpƒN“Š—^Œă‚ĚŒŒŹ”‘‰Á‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, ‹{ř“_“ń2, “cŽ›”͍s3, ‰Ľ@‘c˝3, “ú‚@‰›1 (1Á‰ťŠí“ŕ, 2—AŒŒE×–EˆÚA, 3ŒŒ‰t“ŕ): ‘ć40‰ń“ú–{ŒŒđŽ~ŒŒŠw‰ďŠwpW‰ď (2018/6/29), ŽD–y.

723118. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “Ť—ǐŤ’_ŠÇ‹ˇó‚ɉü—ÇŒ^‘SƒJƒo[‹ŕ‘ŽƒXƒeƒ“ƒg‚đ—p‚˘‚˝’_ŠÇ\“ńŽw’°•Ť‡p‚Ě—L—pŤ. äřŒ´Ť—Ç1, Šâˆä’m‹v2, –Ř“cŒőL2,3, ‹{“c‰pŽĄ2, ’ˇ’Jě—Í–ç2, ‹ŕŽq@‹œ2, ŽR“ŕ_Žj2, ‰œ˜e‹ť‰î2, Ąň@O2, Źň˜aŽO˜Y2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć49‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2018/6/30), ˜a‰ĚŽR.

723119. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) VWHO•Ş—Ţ2017‚đ—p‚˘‚˝pancreatic neuroendocrine carcinoma‚ĚÄŒŸ“˘. “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ’†’JŞŒá1, ăŒ´ˆę”ż1, Ą’JŠ°ˆČ2, ěŒű—C•ă1, ‹{“c‰pŽĄ1, ź–{‚–ž1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, Šâˆä’m‹v1, Ąň@O1, –Ř“cŒőL1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć49‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2018/6/30), ˜a‰ĚŽR.

723120. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŽŠŒČ–ƉuŤäX‰ŠŠ°‰đŒă‚ÉˆŮŽžŤ‚ĚŒă• –ŒüˆŰÇ‚É‚ć‚čtṐú”j‚𐜂ś‚˝1—á. ’†’JŞŒá1, Šâˆä’m‹v1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Ąň@O1, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć49‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2018/6/30), ˜a‰ĚŽR.

723121. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŽŠ‘R’E—ŽŒ^äXŠÇƒXƒeƒ“ƒg—Ż’uŒă, äXŠÇ‹ˇó‚đ—ˆ‚ľäX‰Š‚đˆř‚Ť‹N‚ą‚ľ‚˝ˆę—á. ˆŔ’B@‰ő1, ŽR“ŕ_Žj2, –Ř“cŒőL2,3, ‹{“c‰pŽĄ2, ’ˇ’Jě—Í–ç2, ‹ŕŽq@‹œ2, ‰œ˜e‹ť‰î2, Šâˆä’m‹v2, Ąň@O2, Źň˜aŽO˜Y2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć49‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2018/6/30), ˜a‰ĚŽR.

723122. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠĚd•Ď‚Ě—\Œă‚ÉŠÖ‚ˇ‚éMac-2Œ‹‡ƒ^ƒ“ƒpƒN“œ˝CüˆŮŤ‘Ě‚Ě—L—pŤ. ‹›“ˆ°‹I1, “ú‚@‰›1, “c’†ŒŤ–ž1 (1Á‰ťŠí“ŕ): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/21), ‘ĺă.

723123. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éš‹‰şŒP—űHŠm—§Œă‚ĚŽć‚č‘g‚Ý. ˛“ĄěŠěŽq1, –ö“c“މ›Žq1, ‹n•Łƒ1, Îˆä—mŽq1, ‘ĺ–ě@—˛1,2 (1ˆÉ¨Œ´‹Ś“Ż•a‰@, 2Á‰ťŠí“ŕ): ‘ć67‰ń“ú–{”_‘şˆăŠw‰ďŠwp‘‰ď (2018/10/10), “Œ‹ž, “ú–{”_‘şˆăŠw‰ďŽGŽ 2018; 67 (3): 376.

723124. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘ŠúˆŤŤŽîᇔS–Œ‰ş‘w”—ŁpƒpƒX‚Ě•ŞÍ, f—Ă•ńV‰ü’č‚đ“Ľ‚Ü‚Ś‚Ä. ˛X–Ř‚Ü‚č‚ 1, ‘ĺ–ě@—˛1,2, ‹{č@‘1, –öěšŽj1, ŒĂ’J@’1, ź“c”ü•ä1 (1ˆÉ¨Œ´‹Ś“Ż•a‰@, 2Á‰ťŠí“ŕ): ‘ć19‰ń“ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ďŠwpW‰ď (2018/10/12), ”ŸŠŮ, “ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ďŽ 2018; 20 (3): 421.

723125. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’ź’°benign fibroblastic polyp‚Ě1—á. –Ř”Ś‚ ‚â“ß1, źŽR@—ł1, –kě”Ž”V1, Ž›“cšO1, ‰Íźčű‘ž˜Y1, ‹e’nG•F1, —˘“š“N•F1, ŽRčDŠě1, –ě“o@˝1 (1•˝’Ë‹¤Ď•a‰@Á‰ťŠí“ŕ‰Č): ‘ć67‰ń‹¤ĎˆăŠw‰ď (2018/10/17), •Ÿ‰Ş.

723126. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒNƒ[ƒ“•a‚̏Ź’°‹ˇó‚ɑ΂ˇ‚é“ŕŽ‹‹ž“Iƒoƒ‹[ƒ“Šg’Łp‚ĚŽĄ—ÐŹŃ. ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ź–{ˆçG1, Œ}@”üK1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): JDDW 2018 (2018/11/2), _ŒË.

723127. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) CŒ^–ŤŠĚ‰Š“§Í—á‚ɑ΂ˇ‚éƒOƒŒƒJƒvƒŒƒrƒ‹/ƒsƒuƒŒƒ“ƒ^ƒXƒrƒ‹‚Ě—LŒřŤ‚ĆˆŔ‘SŤ. “c’†ŒŤ–ž1, ‹›“ˆ°‹I1, ˜a“cŽ‹v1, ŽRŞŒhŽq1, ˆäă’qm2, ŒE“cK‰î1, “n粐^˛1,3, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛1,4, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4ˆă—ĂŠÇ—): JDDW 2018 (2018/11/2), _ŒË.

723128. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) –ŤCŒ^ŠĚ‰Š‚ɑ΂ˇ‚é’źÚě—pŒ^RƒEƒCƒ‹ƒX–ň“Š—^Œă‚ĚŒŒŹ”ÂŒ¸­Ç‰ü‘P‚ÉŠÖ‚ˇ‚錟“˘. ˜a“cŽ‹v1, ‹›“ˆ°‹I1, ŽRŞŒhŽq1, ˆäă’qm2, ŒE“cK‰î1, “c’†ŒŤ–ž1, ’†ŕV‹MG1, a’J–ž—˛1,3, “ú‚@‰›1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—): JDDW 2018 (2018/11/2), _ŒË.

723129. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éŠĚŤ”]Ç‚ɑ΂ˇ‚郊ƒtƒ@ƒLƒVƒ~ƒ“‚ĚŽg—pŒoŒą. ŠâčGˆę˜Y1, ‹›“‡°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): JDDW 2018 (2018/11/2), _ŒË.

723130. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) —ǐŤ’_ŠÇ‹ó’°•Ť‡•”‹ˇó‚ɑ΂ˇ‚é“ŕŽ‹‹ž“Iƒoƒ‹[ƒ“Šg’Łp‚̐ŹŃ. –Š@Ž‹M1, ŽR“ŕ_Žj1, –Ř“cŒőL1,2, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JDDW 2018 (2018/11/3), _ŒË.

723131. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ÇŒóŤäXŽüˆÍ‰t‘Ě’™—Ż‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŒoÁ‰ťŠÇƒXƒeƒ“ƒg‚Ě’ˇŠú—Ż’u‚É”ş‚¤‹ô”­Ç‚ĚŒŸ“˘. •{‹M_1, ’ˇ’Jě—Í–ç1, ŽR“ŕ_Žj1, –Ř“cŒőL1,2, Šâˆä’m‹v1, ‹{“c‰pŽĄ1, ‹ŕŽq@‹œ1, ‰œ˜e‹ť‰î1, Ąň@O1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JDDW 2018 (2018/11/3), _ŒË.

723132. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “ű“Ş•”‚ć‚čŒű‘¤‚̏\“ńŽw’°‹ˇó—á‚Ĺ‚ĚŒo“ű“Ş“IƒhƒŒƒi[ƒW‚ĆEUS-HGS‚Ě”äŠr. ‹ŕŽq@‹œ1, –Ř“cŒőL1,2, Ąň@O1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JDDW 2018 (2018/11/3), _ŒË.

723133. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šEˆô“Ş•\ÝŠŕ‚ɑ΂ˇ‚é“ŕŽ‹‹ž”S–Œ‰ş‘w”—Łp (ESD). Œ˜“ce—˜1, “c糁@‘1,2, ŽR‰ş@‘ń3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3Ž¨•@ˆôAE“ŞčňŠO): ‘ć70‰ń“ú–{‹CŠÇH“š‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2018/11/8), •iě.

723134. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’×ᇐŤ‘ĺ’°‰ŠdÇ—á‚ɑ΂ľ‚ÄTacrolimus‚ĆGolimumab‚Ě•š—p—Ă–@‚Ş‘tŒ÷‚ľ‚˝1—á. •˝—ÇŽŃŒŽ1, ‰ĄŽR@ŒO1, ěŠÝ‰Á“Ţ1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723135. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Šˆ“ŽŠú’×ᇐŤ‘ĺ’°‰Š‚ĚŽĄ—ĂŒř‰Ę”ť’č‚É—L—p‚Č“ŕŽ‹‹žƒXƒRƒA‚ɂ‚˘‚Ä. ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723136. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Infliximab‚É‚ć‚é–ňÜŤ”x‰Š‚đ”­Ç‚ľ‚˝’×ᇐŤ‘ĺ’°‰Š‚Ě1—á. ˆÉ“Ą—˛Žm1, ‰ĄŽR@ŒO1, •˝—ÇŽŃŒŽ1, ěŠÝ‰Á“Ţ1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723137. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒTƒ‹ƒRƒyƒjƒAš‹‰şáŠQ‚É‚ć‚éŒo•@‰h—{‚Ě‚Ý‚Š‚çKTƒoƒ‰ƒ“ƒXƒ`ƒƒ[ƒg‚đ—p‚˘‚ÄŒoŒűŰŽć‚ĚˆÚs‚ɐŹŒ÷‚ľ‚˝1—á. –ö“c“މ›Žq1, Îˆä—mŽq1, ŹŽRŽě”ü1, Žŕ–Ř‹|ˆË1, ‰Ş‘şˆę‹P1, ˛“ĄěŠěŽq1, ‘ĺ–ě@—˛1,2 (1ˆÉ¨Œ´‹Ś“Ż•a‰@, 2Á‰ťŠí“ŕ): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/14), “Œ‹ž.

723138. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éŘœ•s”\EÄ”­ˆÝŠŕ‚ɑ΂ľnab-PTX+RAM•š—p—Ă–@‚ĚŽĄ—ÐŹŃ. Î‹´ ˜Đ1, “Œ@’q1, ‹v•Ű“c—z1, “n粍WŽŻ1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, “c糁@‘1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/2/28), Ă‰Ş.

723139. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éŘœ•s”\EÄ”­ˆÝ‚Ş‚ń‚ɑ΂ˇ‚éƒjƒ{ƒ‹ƒ}ƒu‚ĚŽĄ—ÐŹŃ. ”öă”üŒb1, ÎŒËŒŞŽŸ1, ‹v•Ű“c—z1, ‹ß“Ą—Y‹I2, “n•ÓWŽŻ1, ˜a“c‘ń–ç1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ă‰Ş.

723140. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚Ĺ‚ĚESDŒăፍ­‹ß–T‚ĚˆŮŽž‘˝”­•a•Ď‚ɑ΂ˇ‚錟“˘. –kŒ´@Œž1, ÎŒËŒŞŽŸ1, “c糁@‘1,2, ‹v•Ű“c—z1, ‹ß“Ą—Y‹I3, “n•ÓWŽŻ1, ˜a“c‘ń–ç1, “Œ@’q1, Œ˜“ce—˜1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ă‰Ş.

723141. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚ĹŒoŒą‚ľ‚˝ˆÝ’ę‘BŒ^ˆÝŠŕ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Îčƒ˜Y1, ˜a“c‘ń–ç1, H’JšŽj2, “n粍WŽŻ1, ÎŒËŒŞŽŸ1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3, ‹g“c@Œ÷2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2•a—, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ă‰Ş.

731004. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚Ě“ŕ‰ČŽĄ—Ăup to date. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): IBD Biologics Seminar (2018/4/3), L“‡.

731005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚̐f’f‚ĆŽĄ—Ă‚ĚĹVî•ń. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ‘ĺ˜aŽsˆăŽt‰ď“ŕ‰Čˆă‰ďŠwpu‰‰‰ď (2018/4/24), ‘ĺ˜a.

731006. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ‚Ý‚ń‚ȂŐf‚é’×ᇐŤ‘ĺ’°‰Š. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć3‰ńˆÉ¨č˛”gIBDŽĄ—Ă˜AŒg§˜b‰ď (2018/5/18), ‚č.

731007. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ƒXƒeƒ‰[ƒ‰Ň‚ĚŽg—pÇ—á‚ĆŒo‰ß. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): STELARAŇ Expert meeting for BIO User's (2018/5/25), ’Ź“c.

731008. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚Ě“ŕ‰ČŽĄ—Âɂ‚˘‚Ä. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ’nˆć–ňÜŽt‰ďƒZƒ~ƒi[ (2018/5/30), ‘ĺ˜a.

731009. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ‚Ý‚ń‚ȂŐf‚é’×ᇐŤ‘ĺ’°‰Š. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): źŽO‰ÍIBDƒZƒ~ƒi[ (2018/6/2), –L“c.

731010. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•ĘŠé‰ć) ’×ᇐŤ‘ĺ’°‰Š‚Ě1—á. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć50‰ńIBD Club Jr.Œ¤‹†‰ď (2018/6/9), •iě.

731011. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) IBD—Ěˆć‚É‚¨‚Ż‚éSDM‚̏d—vŤ‚ɂ‚˘‚Ä. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Shared Decision Making in IBD (2018/7/7), “Œ‹ž.

731012. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ‚Ý‚ń‚ȂŐf‚é’×ᇐŤ‘ĺ’°‰Š. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Œ§–kIBDŽĄ—Ămeeting (2018/7/12), “Č–Ř.

731013. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰ŠŽĄ—Ă‚É‚¨‚Ż‚é”S–ŒŽĄ–ü`–Ú•W‚ĆŒťŽŔ`. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć32‰ń‘ĺăƒNƒ[ƒ“•aŽĄ—ĂŒ¤‹†‰ď (2018/7/20), ‘ĺă.

731014. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) IBDf—Á@ŠłŽŇ‚ł‚ń‚Ěƒ‚ƒ`ƒx[ƒVƒ‡ƒ“‚đă‚°‚é‚˝‚ß‚É. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Žü“ě’n‹ćŠwpu‰‰‰ď (2018/7/21), ŽRŒű.

731015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰ŠEƒNƒ[ƒ“•a‚Ě‰ć‘œf’f|—މŽžŠł‚Ć‚ĚŠÓ•Ę‚đŠÜ‚ß‚Ä. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ‘ć318‰ń‘ĺ˜aŽsˆÝE‘ĺ’°ŒŸfƒJƒ“ƒtƒ@ƒŒƒ“ƒXE‘ć284‰ń‘ĺ˜aŽsÁ‰ťŠí•aŒ¤‹†‰ď (2018/9/7), ‘ĺ˜a.

731016. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) IBD‚Ěƒtƒ@[ƒXƒgƒ^ƒbƒ`. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Œ§‰›E‘Š–ÍŒ´’n‹ćIBDˆă—Ă˜AŒgu‰‰‰ď (2018/9/20), ‘Š–ÍŒ´Žs.

731017. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚Ě–ň•¨ŽĄ—Ăup to date. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Ž­Ž™“‡ Biologics Seminar on UC (2018/9/28), Ž­Ž™“‡.

731018. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰ŠŽĄ—Ă‚Ěup to date`5-ASAťÜ‚đ‚Ç‚¤Žg‚¤‚Š`. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): IBD Expert Meeting (2018/10/24), ĺ‘ä.

731019. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰ŠŽĄ—Ă‚Ěup to date`5‚`‚r‚`ťÜ‚đ‚Ç‚¤Žg‚¤‚Š`. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): Œ§–k‰ŠÇŤ’°ŽžŠłƒZƒ~ƒi[ (2018/11/15), ˆďé.

731020. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•ĘŠé‰ć) –ŤŠĚŽžŠł‚É‘ą”­‚ľ‚˝RGPIIb/IIIaR‘ĚŽYśB ×–E—zŤ—á‚ɑ΂ˇ‚郋ƒXƒgƒƒ“ƒ{ƒpƒN‚ĚŽĄ—ĂŒř‰Ę. ˜a“cŽ‹v1, ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć42‰ń“ú–{ŠĚ‘ŸŠw‰ď“Œ•”‰ď (2018/12/8), “Œ‹ž.

731021. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) IBDf—Á@ŠłŽŇ‚ł‚ń‚Ěƒ‚ƒ`ƒx[ƒVƒ‡ƒ“‚đă‚°‚é‚˝‚ß‚É. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): IBD Regional Advocate meeting (2018/12/20), ’Ă.

731022. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ‘‚Ś‚Ä‚˘‚éƒNƒ[ƒ“•a‚ɂ‚˘‚Ä’m‚낤! ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć17‰ń‚Š‚Č‚Ş‚í–ňÜŽtŠwp‘ĺ‰ď (2019/1/20), ‰Ą•l.

731023. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚é–ň•¨—Ă–@‚̍ŐV‚ĚƒgƒsƒbƒNƒX. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć45‰ń‘Š–ÍŒ´ˆă—Ă–ňŠwƒtƒH[ƒ‰ƒ€ (2019/2/27), ‘Š–ÍŒ´.

731024. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŠJ‹Ćˆă‚É‚¨‚Ż‚鐜•¨ťÜ‚ĚŠî–{. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ‘ć2‰ńź“‡“ŕŽ‹‹ž§˜b‰ď (2019/3/2), “Œ‹ž.

731025. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “ú–{l’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝Vedolizumab‚Ě‘ć1‘ŠŽŽŒą‚ɂ‚˘‚Ä‚ĚŒ‹‰Ę•ń. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ěčE‰Ą•l–kź•”Á‰ťŠíƒZƒ~ƒi[@ƒGƒ“ƒ^ƒCƒrƒIV”­”„‹L”O (2019/3/13), ‰Ą•l.

732016. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) “–‰@‚ĚäXÎÇ‚ɑ΂ˇ‚é“ŕŽ‹‹žŽĄ—Ă‚ĚŽŔŰ. ‹{“c‰pŽĄ1, Šâˆä’m‹v1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

732017. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) Šˆ“ŽŠú’×ᇐŤ‘ĺ’°‰Š‚ĚŽĄ—ĂŒř‰Ę”ť’č‚É—L—p‚Č“ŕŽ‹‹žƒXƒRƒA‚ɂ‚˘‚Ä. ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

732018. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) “–‰@‚É‚¨‚Ż‚éHHLOŒŸő‚ĚŒťó. ˜a“c‘ń–ç1, “c糁@‘1,2, ’†‘şł•F3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3–ňŠw•”): ‘ć51‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2018/11/10), _“ސě.

732019. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“ťÜ‚ĚŒŒđ—n‰đ‚Ě‘tŒ÷‚ÉŠń—^‚ˇ‚éˆöŽq‚ĚŒŸ“˘. “ú‚@‰›1, š •Ş–ΔŽ1,2 (1Á‰ťŠí“ŕ, 2V•S‡ƒ–‹u‘‡•a‰@): ‘ć42‰ń“ú–{ŠĚ‘ŸŠw‰ď“Œ•”‰ď (2018/12/7), “Œ‹ž.

732020. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘㏾ŤŠĚd•Ď‚É‚¨‚Ż‚é‹Ř“÷—ĘŒ¸­‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰ęŒĂ@áÁ2 (1Á‰ťŠí“ŕ, 2Ă“슙‘q‘‡•a‰@): ‘ć42‰ń“ú–{ŠĚ‘ŸŠw‰ď“Œ•”‰ď (2018/12/7), “Œ‹ž.

732021. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’×ᇐŤ‘ĺ’°‰ŠŠÖ˜AŽîᇂɑ΂ˇ‚éNBIŠg‘ĺ“ŕŽ‹‹žf’f‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Œ}@”üK1, Ź—ѐ´“T1,2, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

732022. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) ESDŽĄ—͢“ď‚Č‘ŠúˆÝŠŕ‚ɑ΂ˇ‚éEMR‚Ě—L—pŤ‚ĆˆŔ‘SŤ. ‹v•Ű“c—z1, “c糁@‘1,2, ÎŒËŒŞŽŸ1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

732023. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) Œű‘¤—˛‹N‚ĚŒ`‘Ô‚Š‚ç‚Ý‚˝trainee‚Ćtrainer‚É‚¨‚Ż‚é’_ŠÇ‘}ŠÇ˘“ď—á‚̐„’č. “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, –Ř“cŒőL1,2 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

732024. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’ÁĂ‘Oƒ`ƒFƒbƒNƒŠƒXƒg‚É‚ć‚é“ŕŽ‹‹žf—Ă‚Ě’ÁĂ‘OŠłŽŇ•]‰ż‚ĚŽć‚č‘g‚Ý. ÎŒËŒŞŽŸ1, “c粁@‘1,2, •Šâ­”V3, Œ´@—D‰Ô4, ŠÝ–Ř‚ ‚ä‚Ý4, “Ą“c–ƒ”üŽq4, ŒĂŻ´”ü4, ŽO‰Y”ü•Ű5, rˆä—L”ü6 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3–ƒŒ, 4ŠĹŒě•”, 5“ŕŽ‹‹žƒZƒ“ƒ^[, 6ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.

732025. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŹäXŠŕ‚̐f’f‚É‚¨‚Ż‚éEUS‚Ě—L—pŤ. –Š@Ž‹M1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.

733030. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ŠĚ“Ž–Ź‰ťŠwÇđ—Ă–@Œă‚É, ‹}Ť—nŒŒ‚Ĺ”­ś‚ľ‚˝Clostridium perfringens”sŒŒÇ‚Ě1—á. ”öă”üŒb1, ‹›“ˆ°‹I1, “ú‚@‰›1, ŒE“cK‰î1, ˜a“cŽ‹v1, “c’†ŒŤ–ž1, ˆäă’qm2, ’†ŕV‹MG1, a’J–ž—˛1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć349‰ń—á‰ď (2018/4/28), “Œ‹ž.

733031. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (Œ¤CˆăƒZƒbƒVƒ‡ƒ“) ‘ĺŒ`—LŒsŤˆÝ‰ßŒ`ŹŤƒ|ƒŠ[ƒv‚đ”wŒi‚Ć‚ľ’E•Ş‰ť‚̉ߒö‚ĆƒŠƒ“ƒpŠÇZ‚𔺂Á‚˝SMZˆÝŠŕ‚Ěˆę—á. ŽOŕV—C‰î1, “n粐^˛1,2, ‘ĺ’ˏr˜a1,2, ‹ŕŕV@1,2, ăŒ´ˆę”ż1,2, ěŒű—C•ă1,2, “cŒ´‹v”üŽq1, –Ř“cŒőL1,2 (1–k—˘‘ĺƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć349‰ń—á‰ď (2018/4/28), “Œ‹ž.

733032. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ‹‘ĺŠĚ×–EŠŕ‚ɑ΂ľ‚ÄBeads TACE (Transarterial chemoembolizaion) ‚𒆐S‚Ć‚ľ‚˝WŠw“IŽĄ—Ă‚Ş—L—p‚Ĺ‚ ‚Á‚˝1—á. –kŒ´@Œž1, ŒE“cK‰î1, “ú‚@‰›1, ’†ŕV‹MG1, “c’†ŒŤ–ž1, ‹›“ˆ°‹I1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ): “ú–{“ŕ‰ČŠw‰ď‘ć641‰ńŠÖ“Œ’n•ű‰ď (2018/5/12), “Œ‹ž.

733033. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ˆÝŠŕ‚É‚¨‚Ż‚éS-1‚ĚŽg—pŒoŒą. –Ř”Ś‚ ‚â“ß1, —˘“š“N•F2, Ž›“cšO2, –kě”Ž”V2, ‰Íźčű‘ž˜Y2, ‹e’nG•F2, źŽR@—ł2, ŽRčDŠě2 (1Á‰ťŠí“ŕ, 2•˝’Ë‹¤Ď•a‰@): ‘ć6‰ńKDOG meeting (2018/5/19), “Œ‹ž.

733034. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) RŒŒđ–ň•ž—pŽŇ‚ɑ΂ˇ‚éÁ‰ťŠí“ŕŽ‹‹žf—ĂƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚˘‚ā|’Ç•â2017‚đ“Ľ‚Ü‚Ś‚ā|. ‹v•Ű“c (˛“c) ”ü˜a (Á‰ťŠí“ŕ): ‘ć62‰ń_“ސě‘ĺ’°ŽžŠłŒ¤‹†‰ď (2018/6/12), ‰Ą•l.

733035. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ŒŔ‹ÇŤ‘ĺ’°ƒAƒ~ƒƒCƒh[ƒVƒX‚Ě1—á. ź‰şš—T1, Œ}@”üK1, Ź—ѐ´“T1,2, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Źň˜aŽO˜Y1, H’JšŽj3, ŽOŽ}@M3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3•a—): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

733036. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) White Globe Appearance‚đ”F‚ßLSBE“ŕ‚É”­ś‚ľ‚˝Barrett'sH“š‘BŠŕ‚Ě1—á. Œ´“c—m•˝1, “c糁@‘1,2, ’†’JŞŒá1, ˜a“c‘ń–ç1, “n•ÓWD1, ÎŒËŒŞŽŸ1, “Œ@’q1, Œ˜“ce—˜1, ‹g“c@Œ÷3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3•a—): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

733037. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) Žá”N—Ť‚Ĺ’_ůN—˛‹NŤ•a•Ď‚đŒ_‹@‚ÉäX’_ŠÇ‡—ŹˆŮí‚Ɛf’f‚ľ• o‹ž‰ş’_ůN“Eop‚É‚Ähyperplastic polyp‚đ”F‚ß‚˝1—á. Î‹´@˜Đ1, ‹ŕŽq@‹œ1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, –Ř“cŒőL1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

733038. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ’ź’°_Œo“ŕ•Ş”ĺŽîá‡2•a•Ď‚ɑ΂ľ“ŕŽ‹‹ž“IŘœp‚đŽ{s‚ľ‚˝1—á. –kě”Ž”V1, źŽR@—ł1, –kŒ´@Œž1, Ž›“cšO1, ‰Íźčű‘ž˜Y1, ‹e’nG•F1, —˘“š“N•F1, ŽRčDŠě1, –ě“o@˝1, źŒ´@C1 (1•˝’Ë‹¤Ď•a‰@): ‘ć106‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/6/16), “Œ‹ž.

733039. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒ|ƒXƒ^[) ŒăŠú‚—îŽŇ‚ɑ΂ˇ‚éŠĚ×–EŠŕŽĄ—Ă‚ĚŒŸŘ. “n粐^˛1,2, ‚‹´’ől1,3, ‰Ş“c•—Ď1, ‰ĄXOş1,4 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‘‡f—Ă): ‘ć54‰ń“ú–{ŠĚŠŕŒ¤‹†‰ď (2018/6/28), ‹v—Ż•Ä.

733040. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒ|ƒXƒ^[) ŠĚ×–EŠŕ‚ɑ΂ľŒo”ç“Iƒ‰ƒWƒI”gÄŽÜp‚ĚŽ{sŒă‚ÉBiliary CastÇŒóŒQ‚đ”F‚ß‚˝ˆę—á. ˜a“cŽ‹v (Á‰ťŠí“ŕ‰Č): ‘ć54‰ń“ú–{ŠĚŠŕŒ¤‹†‰ď (2018/6/29), ‹v—Ż•Ä.

733041. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ‘ĺ’°T1Šŕ‚̐[’B“xf’f‚É‚¨‚Ż‚é’´‰š”g“ŕŽ‹‹ž‚Ě—Ő°“I—L—pŤ. Œ}@”üK1, Ź—ѐ´“T1,2, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Źň˜aŽO˜Y1, “n粏š•F3, ŽOŽ}@M4 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO, 4•a—): ‘ć89‰ń‘ĺ’°ŠŕŒ¤‹†‰ď (2018/7/5), VŠƒ.

733042. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) LSBE“ŕ‚É”­ś‚ľWhite Globe Appearance‚đ”F‚ß‚˝ƒoƒŒƒbƒgH“š‘BŠŕ‚Ě1—á. Œ´“c—m•˝1, “c糁@‘1,2, ’†’JŞŒá1, ˜a“c‘ń–ç1, “n•ÓWD1, ÎŒËŒŞŽŸ1, “Œ@’q1, Œ˜“ce—˜1, ‹g“c@Œ÷3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3•a—): ‘ć63‰ń_“ŢěŒ§Á‰ťŠí•aŒ¤‹†‰ď (2018/7/7), ‰Ą•l.

733043. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ’ź’°benign fibroblastic polyp‚Ě1—á. –Ř”Ś‚ ‚â“ß1, źŽR@—ł1, –kě”Ž”V1, Ž›“cšO1, ‰Íźčű‘ž˜Y1, ‹e’nG•F1, —˘“š“N•F1, ŽRčDŠě1, –ě“o@˝1 (1•˝’Ë‹¤Ď•a‰@Á‰ťŠí“ŕ‰Č): ‘ć63‰ń_“ŢěŒ§Á‰ťŠí•aŒ¤‹†‰ď (2018/7/7), ‰Ą•l.

733044. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) f’f‚É‹ę—ś‚ľ‚˝Œă• –ŒŽîᇂĚ1—á. “y‹“í‘ž˜Y1, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć350‰ń—á‰ď (2018/7/14), “Œ‹ž.

733045. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) SAPHOÇŒóŒQ‚É’×ᇐŤ‘ĺ’°‰Š‚đ‡•š‚ľ‚˝‚—îŽŇ‚Ě1—á. âV“ĄŒöĆ1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, Źň˜aŽO˜Y1, Ź—ѐ´“T1,2, ˜a“c’B•F3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3äPŒ´•aEŠ´ő“ŕ): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć350‰ń—á‰ď (2018/7/14), “Œ‹ž.

733046. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) Ź’°Œ´”­ŒŒŠÇ“÷Žî‚Ě1Řœ—á. ŠâčGˆę˜Y1, Ź—ѐ´“T1,2, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, Œ}@”üK1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Źň˜aŽO˜Y1, ŽR—œ‚L3, ‹g“c@Œ÷4 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO, 4•a—): “ú–{“ŕ‰ČŠw‰ď‘ć643‰ńŠÖ“Œ’n•ű‰ď (2018/7/15), “Œ‹ž.

733047. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) Žá”N—Ť‚É”­Ç‚ľf’f‚É‹ę—ś‚ľ‚˝ŠĚ‹@”\áŠQ‚Ě1—á. ŠâčGˆę˜Y1, “ú‚@‰›1, ˜a“cŽ‹v1, ‹›“ˆ°‹I1, ŒE“cK‰î1, “c’†ŒŤ–ž1, ’†ŕV‹MG1, a’J–ž—˛1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2ˆă—ĂŠÇ—): “ú–{“ŕ‰ČŠw‰ď‘ć644‰ńŠÖ“Œ’n•ű‰ď (2018/9/8), “Œ‹ž.

733048. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (Žĺ‘艉‘č) “–‰@‚É‚¨‚Ż‚éHHLOŒŸő‚ĚŒťó. ˜a“c‘ń–ç1, “c糁@‘1,2, ’†‘şł•F3, “Œ@’q1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3–ňŠw•”): ‘ć27‰ńÁ‰ťŠíŽžŠł•a‘ÔŽĄ—ĂŒ¤‹†‰ď (2018/9/15), ‚’m.

733049. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) Beads TACE (Transarterial chemoembolization) ‚𒆐S‚Ć‚ľ‚˝WŠw“IŽĄ—Ă‚Ş—LŒř‚Ĺ‚ ‚Á‚˝‹‘ĺŠĚ×–EŠŕ‚Ě1—á. –kŒ´@Œž1, ŒE“cK‰î1, ˜a“cŽ‹v1, ‹›“ˆ°‹I1, “c’†ŒŤ–ž1, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛1,2, “c糁@‘1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2ˆă—ĂŠÇ—, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć27‰ńÁ‰ťŠíŽžŠł•a‘ÔŽĄ—ĂŒ¤‹†‰ď (2018/9/15), ‚’m.

733050. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (Œ¤CˆăƒZƒbƒVƒ‡ƒ“) ’š”§ˆÝ‰Š‚̏ŠŒŠ‚đ’ć‚ľ‚˝ƒNƒ[ƒ“•a‚Ě1—á. “c糔ü“Ţ1, “c糁@‘1,2, ‰ĄŽR@ŒO1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c—z3, “n粍WD1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, “Œ@’q1, Œ˜“ce—˜1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć27‰ńÁ‰ťŠíŽžŠł•a‘ÔŽĄ—ĂŒ¤‹†‰ď (2018/9/15), ‚’m.

733051. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ‘ĺ’°Šŕ, ŠĚ“]ˆÚ‚ɑ΂ľ‚ÄXELOX, ƒxƒoƒVƒYƒ}ƒu“Š—^Œă‚É”­Ç‚ľ‚˝ŒŒđŤ”÷ŹŒŒŠÇÇ‚ɑ΂ľ, ŒŒŸ÷ŒđŠˇ—Ă–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á. –Š@Ž‹M1, “Œ@’q1, ‹v•Ű“c—z2, ‹ß“Ą—Y‹I2, “n•ÓWŽŻ1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, Źň˜aŽO˜Y1, “c糁@‘1,3 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć351‰ń—á‰ď (2018/9/22), “Œ‹ž.

733052. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) 䉖ňŠĂ‘“’‚É‚ć‚é–ňÜŤ‹NˆöŤŽŠŒČ–ƉuŤŠĚ‰Š, Œ´”­Ť’_`Ť’_ŠÇ‰ŠƒI[ƒo[ƒ‰ƒbƒvÇŒóŒQ‚Ěˆę—á. áÁ•”—Dě1,2, “n粐^˛1,2, –Ř“cŒőO1,2, ěŒű—C•ă1,2, ăŒ´ˆę”ż1,2, •˝—ÇŽŃŒŽ1,2, ‰ĄXOş1,3 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ, 3‘‡f—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ď‘ć351‰ń—á‰ď (2018/9/22), “Œ‹ž.

733053. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) Šg‘ĺŠĚś—tŘœp‚đŽ{s‚ˇ‚é‚ŕÄ”­‚ľ‚˝ŠĚŒ´”­•˝ŠŠ‹Ř“÷Žî‚Ěˆę—á. Œ´“c—m•˝1, “c’†ŒŤ–ž1, ˜a“cŽ‹v1, ŒE“cK‰î1, ˆäă’qm2, ŽRŞŒhŽq1, ‹›“ˆ°‹I1, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂŠÇ—): ‘ć51‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2018/11/10), _“ސě.

733054. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ŒŒ´Rp53R‘̏㏸‚ޏăsŒ‹’°ŠŕESDŒă‚ĚÄ”­‚Ě”­ŒŠŒ_‹@‚Ć‚Č‚Á‚˝1—á. źŒ´‰ŔŘ1, ‹v•Ű“c (˛“c) ”ü˜a1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, Œ}@”üK1, ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1, ’†‘ş—˛r3, ‘ĺ•”@˝4 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO, 4–k—˘Œ¤‹†Š•a‰@): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć352‰ń—á‰ď (2018/12/1), “Œ‹ž.

733055. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ‹}Ť• Ç‚đ’ć‚ľ‚˝Źl’°ŠÇ–ŒƒŠƒ“ƒpŠÇŽî‚Ě1—á. –Ř”Ś‚ ‚â“ß1, źŽR@—ł1, –kě”Ž”V1 ,Ž›“cšO1, ‰ÍźŒ°‘ž˜Y1, ‹e’nG•F1, —˘“š“N•F1, ŽRčDŠě1, źŒ´@C1 (1•˝’Ë‹¤Ď•a‰@): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć352‰ń—á‰ď (2018/12/1), “Œ‹ž.

733056. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒ|ƒXƒ^[) ś•¨Šw“IťÜ‚ŞŒ´ˆö‚ĆŽv‚í‚ę‚é–ňÜŤ”x‰Š‚đ—ˆ‚ľ‚˝’×ᇐŤ‘ĺ’°‰Š‚Ě1—á. ˆÉ“Ą—˛Žm1, ‰ĄŽR@ŒO1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, Œ}@”üK1, ‹v•Ű“c”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{“ŕ‰ČŠw‰ď‘ć647‰ńŠÖ“Œ’n•ű‰ď (2018/12/8), “Œ‹ž.

733057. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) p‘Of’f‚ލ˘“ď‚Ĺ‚ ‚Á‚˝äX“Ş•”ŽîᇂĚ1—á. ź‰şš—T1, –Ř“cŒőL1,2, ’ˇ’Jě—Í–ç1, ‹{“c‰pŽĄ1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1, Źň˜aŽO˜Y1, ŠC’Ă‹MŽj3, ŒGŒł—Y‰î3 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

733058. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) äXŠÇŠŕ‚É—ŢŽ—‚ľ‚˝’´‰š”g“ŕŽ‹‹ž‰ć‘œ‚đ’ć‚ľ‚˝äX_Œo“ŕ•Ş”ĺŽîᇂĚ1—á. ‹Ę’u–žŠ°1, ‰œ˜e‹ť‰î1, •{‹M_1, –Š@Ž‹M1, “n•Ó^ˆč1, ’†’JŞŒá1,2, ‹{“c‰pŽĄ1, ź–{‚–ž1,2, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, Šâˆä’m‹v1, Ąň@O1,3, –Ř“cŒőL1,4, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2ˆÉ¨Œ´‹Ś“Ż•a‰@, 3JCHO‘Š–Í–ě•a‰@, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

733059. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ’´‰š”g“ŕŽ‹‹ž (EUS) ‚É‚Ä‹ô”­“I‚É”­ŒŠ‚ł‚ę‚˝äX_Œo“ŕ•Ş”ĺŽîᇂĚ1—á. –kŒ´@Œž1, ‹ŕŽq@‹œ1, –Ř“cŒőL1,2, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ŽR“ŕ_Žj1, ‰œ˜e‹ť‰î1, Šâˆä˜a‹v1, Ąň@O1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

733060. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (Œ¤CˆăƒZƒbƒVƒ‡ƒ“) EUS-FNA‚É‚Ä•a—f’f‚đ“ž‚˝‘˝”­Ťœ‘ŽîäX“]ˆÚ‚Ě1—á. ˛–ě’BĆ1, –Š@Ž‹M1, ‰œ˜e‹ť‰î1, źŒ´‰ŔŘ1, ‹{“c‰pŽĄ1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ŽR“ŕ_Žj1, Šâˆä’m‹v1, –Ř“cŒőL1,2 (1Á‰ťŠí“ŕ, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/15), “Œ‹ž.

733061. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) “ŕŽ‹‹ž“I“ű“ŞŘœp‚ɂĐf’f‚ľ“ž‚˝“ű“Ş•”_Œo“ŕ•Ş”ĺŽîᇂĚ1—á. •˝—ÇŽŃŒŽ1, ěŒű—C•ă1,2, áÁ•”—Dě1, ăŒ´ˆę”ż1,2, ‘ĺ’ˏr˜a1, “cŒ´‹v”üŽq1, “n粐^˛1,2, –Ř“cŒőL1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.

733062. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) EUS‚ސf’f‚É—L—p‚Ĺ‚ ‚Á‚˝TS1äXŠŕ‚Ě1—á. áÁ•”—Dě1, ăŒ´ˆę”ż1,2, •˝—ÇŽŃŒŽ1, ěŒű—C•ă1,2, ‘ĺ’ˏr˜a1, “cŒ´‹v”üŽq1, “n粐^˛1,2, –Ř“cŒőL1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.

733063. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) L“‡Šż•ű‚Ě‚Ý‚ĹŠ°‰đˆŰŽE”S–ŒŽĄ–ü‚đ”F‚ß‚é’×ᇐŤ‘ĺ’°‰Š‚Ě1Ç—á. ŽOŽ}—zˆę1,2, Ąň@O1,2, Îčƒ˜Y1,2, ‹ŕ@–ž“N1,2, ‰Á“Ą@Ę1,2, ŒK”ö’čm1, ŽO‹´—˜‰ˇ1, źŒłŽ›ŽâX1,2, ‘ĺˆä“cłl1,2 (1‘Š–Í–ě•a‰@, 2Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.

733064. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚éƒ[ƒ“ƒ^ƒR[ƒg҂̎g—pŒoŒą. Œ´“c—m•˝1, ‰ĄŽR@ŒO1, Œ}@”üK1, ź–{ˆçG1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): CD ƒ[ƒNƒVƒ‡ƒbƒv (2019/2/7), ‘Š–ÍŒ´.

733065. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ƒjƒ{ƒ‹ƒ}ƒu‚É‚ć‚é•›t•s‘S‚đ”­Ç‚ľ‚˝—Տ°ŒoŒą. ƒă‘ž˜Y1, “Œ@’q1, ”öă”üŒb1, ÎŒËŒŞŽŸ1, ‹v•Ű“c—z1, ‹ß“Ą—Y‹I2, “n糍WD1, ˜a“c‘ń–ç1, Œ˜“ce—˜1, “c糁@‘1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć353‰ń—á‰ď (2019/2/23), “Œ‹ž.

733066. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) ’†‹K–Í•a‰@‚É‚¨‚Ż‚鉊ÇŤ’°ŽžŠł‚Ěƒ`[ƒ€ˆă—Ă‚Ć’nˆćˆă—Ă˜AŒg. ŽOŽ}—zˆę1,2, Ąň@O1,2, Ąň‹Mś1, –î“ŕŒ´’qŽq1, ŽR“ŕ‹M—Y1, ’r“cG”ü1, ”öč—F”ü1, ‚‹´@—É3, ‹{â—ł”n3, Îˆä—˛Ži4, •ĐŽR‘쎢4, ŽR‰ş‰ëŽq1, ‹ŕ@–ž“N1,2, Îčƒ˜Y1,2, ‘ĺˆä“cłl1, –ě“c‹g˜a1 (1‘Š–Í–ě•a‰@, 2Á‰ťŠí“ŕ, 3t‘Ÿ“ŕ, 4ŒŒ‰t“ŕ): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć18‰ń_“ސěŽx•”ŠwpW‰ď (2019/3/9), _“ސě


‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č@Á‰ťŠí“ŕ‰ČŠw
Šń•uŔu‰ŠÇŤ’°ŽžŠł—Տ°Œ¤‹†uŔv

[Šwp˜_•ś]

110112. [Œ´’˜] Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. Teratani T, Tomita K, Suzuki T, Furuhashi H, Irie R, Nishikawa M, Yamamoto J, Hibi T1,2, Miura S, Minamino T, Oike Y, Hokari R, Kanai T: J Clin Invest 2018/4; 128 (4): 1581-96. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110113. [Œ´’˜] Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Watanabe K1, Matsumoto T1, Hisamatsu T1, Nakase H1, Motoya S1, Yoshimura N1, Ishida T1, Kato S1, Nakagawa T1, Esaki M1, Nagahori M1, Matsui T1, Naito Y1, Kanai T1, Suzuki Y1, Nojima M1, Watanabe M1, Hibi T1,2,3 (1DIAMOND study group): Clin Gastroenterol Hepatol 2018/4; 16 (4): 542-9.e1. (“ú”ä‹I•ś1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110114. [Œ´’˜] Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Kobayashi T1,2, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K3, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T1,2: Intest Res 2018/4; 16 (2): 168-77. (Ź—с@‘ń1,2, ‰ĄŽR@ŒO3, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@, 3Á‰ťŠí“ŕ)

110115. [Œ´’˜] Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T1,2: Intest Res 2018/4; 16 (2): 233-45. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110116. [Œ´’˜] Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Ogata H, Yokoyama T, Mizushima S, Hagino A, Hibi T1,2: Intest Res 2018/4; 16 (2): 255-66. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110117. [Œ´’˜] Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. Tanaka H1, Kamata N1, Yamada A1, Endo K1, Fujii T1, Yoshino T1, Sugaya T1, Yokoyama Y1, Bamba S1, Umeno J1, Yanai Y1, Ishii M1, Kawaguchi T1, Shinzaki S1, Toya Y1, Kobayashi T1,2,3, Nojima M1, Hibi T1,2,3 (1ADJUST study group): J Gastroenterol Hepatol 2018/5; 33 (5): 1031-8. (Ź—с@‘ń1,2,3, “ú”ä‹I•ś1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110118. [Œ´’˜] Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T1,2: Inflamm Intest Di. 2018/7; 2 (4): 228235. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110119. [Œ´’˜] Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's disease. Umeno J1, Esaki M1, Hirano A1, Fuyuno Y1, Ohmiya N1, Yasukawa S1, Hirai F1, Kochi S1, Kurahara K1, Yanai S1, Uchida K1, Hosomi S1, Watanabe K1, Hosoe N1, Ogata H1, Hisamatsu T1, Nagayama M1, Yamamoto H1, Abukawa D1, Kakuta F1, Onodera K1, Matsui T1, Hibi T1,2,3, Yao T1, Kitazono T1, Matsumoto T1 (1CEAS study group): J Gastroenterol 2018/8; 53 (8): 907-15. (“ú”ä‹I•ś1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110120. [Œ´’˜] Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. Komoto S, Matsuoka K, Kobayashi T1,2, Yokoyama Y, Suzuki Y, Hibi T1,2, Miura S, Hokari R: J Gastroenterol Hepatol 2018/8; 33 (8): 1485-91. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110121. [Œ´’˜] Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T1,2: PLoS One 2018/8; 13 (8): e0201956. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110122. [Œ´’˜] NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severeadverse events in Japanese patients with inflammatory bowel disease: a multicenter study. Kakuta Y1, Kawai Y1, Okamoto D1, Takagawa T1, Ikeya K1, Sakuraba H1, Nishida A1, Nakagawa S1, Miura M1, Toyonaga T1, Onodera K1, Shinozaki M1, Ishiguro Y1, Mizuno S1, Takahara M1, Yanai S1, Hokari R1, Nakagawa T1, Araki H1, Motoya S1, Naito T1, Moroi R1, Shiga H1, Endo K1, Kobayashi T1,2,3, Naganuma M1, Hiraoka S1, Matsumoto T1, Nakamura S1, Nakase H1, Hisamatsu T1, Sasaki M1, Hanai H1, Andoh A1, Nagasaki M1, Kinouchi Y1, Shimosegawa T1, Masamune A1, Suzuki Y1 (1MENDEL study group): J Gastroenterol 2018/9; 53 (9): 1065-78. (Ź—с@‘ń1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110123. [Œ´’˜] A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. Okabayashi S, Kobayashi T1,2, Nakano M, Toyonaga T, Ozaki R, Tablante MC, Kuronuma S, Takeuchi O, Hibi T1,2: Inflamm Bowel Dis 201/10; 24 (11): 2404-12. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110124. [Œ´’˜] Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T1,2, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T1,2: Intest Res 2018/10; 16 (4): 609-18. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110125. [Œ´’˜] 5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T1,2, Kanai T: Intest Re 2018/10; 16 (4): 635-40. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110126. [Œ´’˜] Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: A nationwide survey data in Japan. Komoto S, Higashiyama M, Watanabe C, Suzuki Y, Watanabe M, Hibi T1,2, Takebayashi T, Asakura K, Nishiwaki Y, Miura S, Hokari R: J Gastroenterol Hepatol 2018/11; 33 (11): 1839-43. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110127. [Œ´’˜] Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. Hosoe N, Nakano M, Takeuchi K, Endo Y, Matsuoka K, Abe T, Omori T, Hayashida M, Kobayashi T1,2, Yoshida A, Mizuno S, Nakazato Y, Naganuma M, Kanai T, Watanabe M, Ueno F, Suzuki Y, Hibi T1,2, Ogata H: Inflamm Bowel Dis 2018/11; 24 (12): 2641-7. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110128. [Œ´’˜] Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. Ozaki R, Kobayashi T1,2, Okabayashi S, Nakano M, Morinaga S, Hara A, Ohbu M, Matsuoka K, Toyonaga T, Saito E, Hisamatsu T, Hibi T1,2: J Crohns Colitis 2018/11; 12 (11): 1288-94. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110129. [Œ´’˜] Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. Sagami S, Kobayashi T1,2, Hibi T1,2: Inflamm Intest Dis 2018/11; 3 (1): 1-10. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110130. [Œ´’˜] Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Okabayashi S, Kobayashi T1,2, Hibi T1,2: Inflamm Intest Dis 2018/11; 3 (1): 25-31. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110131. [Œ´’˜] The Burden of Diverticular Disease and Its Complications: West versus East. Imaeda H, Hibi T1,2: Inflamm Intest Dis 2018/12; 3 (2): 61-8. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110132. [Œ´’˜] Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. Yagisawa K, Kobayashi T1,2, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T1,2: Intest Res 2019/1; 17 (1): 87-93. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110133. [Œ´’˜] Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T1,2, Hibi T1,2, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH: BMJ Open 2019/1; 9 (1): e024222. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110134. [Œ´’˜] Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study). Hisamatsu T1, Matsumoto T1, Watanabe K1, Nakase H1, Motoya S1, Yoshimura N1, Ishida T1, Kato S1, Nakagawa T1, Esaki M1, Nagahori M1, Matsui T1, Naito Y1, Kanai T1, Suzuki Y1, Nojima M1, Watanabe M1, Hibi T1,2,3 (1DIAMOND study group): J Crohns Colitis 2019/2. doi: 10.1093/ecco-jcc/jjz030. [Epub ahead of print] (“ú”ä‹I•ś1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110135. [Œ´’˜] Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. Sagami S, Kobayashi T1,2, Kikkawa N, Umeda S, Nakano M, Toyonaga T, Okabayashi S, Ozaki R, Hibi T1,2: PLoS One 2019/2; 14 (2): e0212404. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

110136. [Œ´’˜] Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T1,2: PLoS One 2019/2; 14 (2): e0212989. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

320004. [Ç—á•ń] Œ‹ŠjƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚މAŤ‚Ĺ‚ ‚Á‚˝‚É‚ŕ‚Š‚Š‚í‚炸RTNF-ƒżR‘̐ťÜ“ą“üŒă‚É”xŒ‹Šj‚đ”­Ç‚ľ‚˝ƒNƒ[ƒ“•a‚Ě1—á. Œ´@—E•ă, Ź—с@‘ń1,2, ‰Ş—ѐT“ń, ’†–ě@‰ë, ˛ăW‘ž˜Y, ”öúą@—Ç, ’†ŽR‘‘•˝, —é–Ř—Y‰î, íź@—ß, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): “ú–{Á‰ťŠí•aŠw‰ďŽGŽ 2018/11; 115 (11): 996-1003.

522034. [uŔ]y“ÁW:•a‘Ô‚Š‚çl‚Śo‚ł‚ę‚˝IBDŽĄ—Â̐i•ŕz4. IL12/23‘jŠQÜ. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): INTESTINE 2018/5; 22 (3): 245-9.

522035. [uŔ] RTNF-ƒżR‘Ě‚ĚŽ~‚ß. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): IBDƒjƒ…[ƒX 2018/7; 64: 3.

522036. [uŔ]y“ÁW: ‚í‚Ş‘‚ĚIBD‚̐V‹KŽĄ—Ă–ň‚đ–Ô—…‚ˇ‚é!zƒSƒŠƒ€ƒ}ƒu. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): IBD Research 2018/9; 12 (3): 147-50.

522037. [uŔ]y“ÁW: ‘ĺ’°ŽžŠł|•a‘Ô‚ÉŠî‚Ă‚­ŽŔ’nf—Ă‚đ–ÚŽw‚ľ‚ā|z‰ŠÇŤ’°ŽžŠł‚Ě“ŕ‰ČŽĄ—Ă. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): Medical Practice 2018/12; 35 (12): 1914-8.

[’˜@‘]

620024. [Šwp‘ (•Ş’SŽˇ•M)]y‰ŠÇŤ’°ŽžŠł‚ĚŒŸ¸Ef’f2 (“ú–{—Őଠ76ŠŞ‘Š§†3)zI. ‘˜_@‰ŠÇŤ’°ŽžŠł‚ĚŒťó, ˘ŠE‚Ć“ú–{, p.7-12. “ú”ä‹I1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@), “ú–{—Ő଎Đ, “Œ‹ž, 2018/4”­s.

620025. [Šwp‘ (•Ş’SŽˇ•M)]y‰ŠÇŤ’°ŽžŠł‚ĚŒŸ¸Ef’f2 (“ú–{—Őଠ76ŠŞ‘Š§†3)zV. ‰ŠÇŤ’°ŽžŠł‚ĚŒŸ¸Ef’f@2. ‰ŠÇŤ’°ŽžŠł‚̐f’f‚É‚¨‚Ż‚錌‰tŒŸ¸‹y‚Ń×‹ŰŠw“IŒŸ¸, p. 173-7. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@), “ú–{—Ő଎Đ, “Œ‹ž, 2018/4”­s.

620026. [Šwp‘ (•Ş’SŽˇ•M)]y‰ŠÇŤ’°ŽžŠł‚ĚŒŸ¸Ef’f2 (“ú–{—Őଠ76ŠŞ‘Š§†3)zVI. ‰ŠÇŤ’°ŽžŠł‚Ě“ŕ‰Č“IŽĄ—Á@3. ‰ŠÇŤ’°ŽžŠłŽĄ—Ă–ň‚ĚŽg‚˘•ű‚Ć“ÁŤ@ (8) RIL-12 p40R‘Ě: ƒEƒXƒeƒLƒkƒ}ƒu, p. 345-9. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@), “ú–{—Ő଎Đ, “Œ‹ž, 2018/4”­s.

620027. [Šwp‘ (•Ş’SŽˇ•M)]y‚ŕ‚Á‚Ć‚¤‚Ü‚­‚˘‚­! •af˜AŒg‚́u“`‚Ś•űv(“ŕ‰Č2018”N9ŒŽ‘‘ĺ†)z‘ćIIÍ <f—ÉȕĘ>ƒRƒ“ƒTƒ‹ƒg‚Ěƒ|ƒCƒ“ƒg@C. Á‰ťŠí‰Č‚ÖƒRƒ“ƒTƒ‹ƒg@2. ‰ŠÇŤ’°ŽžŠł, p.527-30. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@), “ě]“°, “Œ‹ž, 2018/9”­s.

620028. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠíŽžŠłĹV‚ĚŽĄ—Ă2019-2020zIIIÍ Á‰ťŠÇŽžŠł@[C. ’°]@6. ’×ᇐŤ‘ĺ’°‰Š, p.202-7. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@), •Ň: Ź’r˜a•F, ŽR–{”Ž“ż, ŁŒË‘×”V, “ě]“°, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712018. [Šw‰ď (‘Ű)] (Scientific Session)yChairzIBD around the world. Hibi T1,2: ECCO2019 (2019/3/8), Copenhagen, Denmark. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713054. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Challenging case II. Kobayashi T1,2: The 6th Annual Meeting of Asian Organization for Crohn's & Colitils (AOCC) 2018 (2018/6/22), Shanghai, China. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713055. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Mechanism-based treatment strategy for IBD: How to use new medicines properly "JAK inhibitors". Kobayashi T1,2: FALK symposium 212 (2018/9/7), Kyoto, Japan. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713056. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Emerging Therapies in IBD "New kids on the block" the role of small molecules in IBD. Kobayashi T1,2: The 3rd APAGE Clinical IBD Forum Cebu 2018 (2018/9/22), Cebu, Philippines. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713057. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Accuracy of Doppler transabdominal ultrasound in assessing disease severity and extent in IBD. Sagami S, Kobayashi T1,2, Kanazawa T, Aihara K, Morikubo H, Ozaki R, Okabayahi S, Matsubayashi M, Fuchigami A, Kiyohara H, Nakano M, Hibi T1,2: ECCO 2019 (2019/3/7), Copenhagen, Denmark. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713058. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). Hisamatsu T1, Kato S1, Kunisaki R1, Matsuura M1, Nagahori M1, Motoya S1, Esaki M1, Fukata N1, Inoue S1, Sugaya T1, Sakuraba H1, Hirai F1, Watanabe K1, Kanai T1, Naganuma M1, Nakase H1, Suzuki Y1, Watanabe M1, Hibi T1,2,3, Nojima M1, Matsumoto T1 (1DIAMOND2 Study Group): ECCO2019 (2019/3/7), Copenhagen, Denmark. (“ú”ä‹I•ś1,2,3: 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

713059. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Safety and effectiveness of adalimumab treatment in 1523 patients with ulcerative colitis: Results from a prospective, multi-centre ,observational study. Ogata H, Hagiwara T, Ito Y, Kawaberi T, Kobayashi M, Hibi T1,2: ECCO2019 (2019/3/7), Copenhagen, Denmark. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713060. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T1,2, Geert G, D'Haens R, Tuttle J, Krueger K, Friedrich S, Durante M, Arora V, Feagan B: ECCO2019 (2019/3/8), Copenhagen, Denmark. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713061. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study. G. D'Haens, S. Danese, M. Davies, Watanabe M, Hibi T1,2: ECCO2019 (2019/3/8), Copenhagen, Denmark. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

713062. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. G. Geert R. D'Haens, W. J. Sandborn, M. Ferrante, B. R. Bhandari, E. Berliba, Hibi T1,2, J. Tuttle, J. B. Canavan, S. Friedrich, M. Durante, V. Arora, B. Feagan: ECCO2019 (2019/3/9), Copenhagen, Denmark. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@)

722039. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)y“Á•Ę”­ŒžzBeyond The anti-TNF-ƒż antibody treatment. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/21), “Œ‹ž.

722040. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yCAP‚̍ĄŒă‚̉ۑč, ‚—îŽŇ‚â”DPŠłŽŇ‚Č‚Ç‚Ě“ÁŽęÇ—á‚ɑ΂ˇ‚éCAP‚Ě—LŒřŤ‚ĆˆŔ‘SŤz’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚é”’ŒŒ‹…œ‹Ž—Ă–@‚Ě’ˇŠú—\Œă’˛¸—Տ°Œ¤‹†. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć39‰ń“ú–{ƒAƒtƒFƒŒƒVƒXŠw‰ďŠwp‘ĺ‰ď (2018/10/26), ‰ŞŽR.

722041. [Šw‰ď (‘S‘)] (International session)yRecent progress in IBD ResearchzMucin depletion is a histological risk factor for clinical relapse in ulcerative colitis with endoscopically normal mucosa. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): JDDW 2018 (2018/11/1), _ŒË.

722042. [Šw‰ď (‘S‘)] (ƒrƒMƒi[ƒYƒZƒ~ƒi[) ’°ŠÇ–Ɖu‚ĚŠî‘b‚Ć—Ő°. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć46‰ń“ú–{—Տ°–ƉuŠw‰ď‘‰ď (2018/11/8), Œyˆä‘ň.

723142. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚éƒAƒ_ƒŠƒ€ƒ}ƒu‚ĚŽŔ—Տ°‚Ĺ‚ĚˆŔ‘SŤ‚Ć—LŒřŤ‚ĚŒŸ“˘: “Á’čŽg—pŹŃ’˛¸@’†ŠÔ‰đÍ•ń. •ű°•F, ě‡—S”ü, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/19), “Œ‹ž.

723143. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) fŽ@ƒf[ƒ^ƒx[ƒX‚đ—p‚˘‚˝–{–M‚É‚¨‚Ż‚é’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚éRTNF-ƒżR‘̐ťÜ‚ĚŽg—pŽŔ‘Ô‰đÍ. Ź—с@‘ń1,2, ‰F“cWm, œA‹L‘ , ‰F“cěŠG—˘, •őŽR’q‰Ŕ, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/19), “Œ‹ž.

723144. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒCƒ“ƒtƒŠƒLƒVƒ}ƒuEƒoƒCƒIƒVƒ~ƒ‰[‚̉ŠÇŤ’°ŽžŠł‚đ‘ÎŰ‚Ć‚ľ‚˝“Á’čŽg—pŹŃ’˛¸‚Ě’†ŠÔ•ń. ’†ě—Ď•v, źě´L, Ź—с@‘ń1,2, óˆä@“N, ŽL“‡—R‹K‘Ľ, —é–؍N•v, “n•Ó@Žç, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/19), “Œ‹ž.

723145. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†“™Ç–”‚͏dÇ‚Ě“ú–{l’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚Ě“ą“üEˆŰŽ—Ă–@‚É‚¨‚Ż‚éƒxƒhƒŠƒYƒ}ƒu‘ć3‘ŠŽŽŒą. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć104‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2018/4/20), “Œ‹ž.

723146. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Mucin depletion is a histological risk factor for clinical relapse in ulcerative colitis with endoscopically nomal mucosa. Ź—с@‘ń1,2, ”öč@—Ç, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć60‰ń“ú–{Á‰ťŠí•aŠw‰ď‘ĺ‰ď (JDDW 2018) (2018/11/1), _ŒË.

723147. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Filgotinib decreases systemic and mucosal markers of inflammation associated with endoscopic improvement in active Crohn's disease patients. “ú”ä‹I•ś1,2, W Sandborn, B Feagan, R Galien, L Goyal, W Li, A Mirza, A Serone, C Tasset, A V Aa, J Woo, S Vermeire (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć60‰ń“ú–{Á‰ťŠí•aŠw‰ď‘ĺ‰ď (JDDW 2018) (2018/11/2), _ŒË.

723148. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Effect of disease duration and location on clinical remission in Crohn's disease patients treated with filgotinib:post-hoc analysis. “ú”ä‹I•ś1,2, S Vermeire, A V Aa, C Jamoul, C Tasset, P Harrison, Geert D' Haens (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć60‰ń“ú–{Á‰ťŠí•aŠw‰ď‘ĺ‰ď (JDDW 2018) (2018/11/2), _ŒË.

723149. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_•s‘Ď’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚Ě—Ő°“I“Á’Ľ. ´Œ´—T‹M1, Ź—с@‘ń1,2, ŸşăˆťŽq1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/9), “Œ‹ž.

723150. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)y2nd Japan-Korea Exchange Evening Symposium -Multidisciplinary approach to IBD care in Asia-: Ži‰ďzƒNƒ[ƒ“•aăč–ĺ•a•Ď‚đ—L‚ˇ‚銳ŽŇ‚Ö‚ĚƒAƒvƒ[ƒ`. “ú”ä‹I•ś1,2, “ńŒŠŠě‘ž˜Y (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723151. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒNƒ[ƒ“•a‚đ‘ÎŰ‚Ć‚ľ‚˝ƒAƒ_ƒŠƒ€ƒ}ƒuEƒAƒUƒ`ƒIƒvƒŠƒ“‚Ě•š—pŒř‰Ę‚ÉŠÖ‚ˇ‚é‘OŒü‚ŤŒ¤‹† (DIAMOND study). ź–{Žĺ”V, ’‡Ł—TŽu, “n•ÓŒ›ŽĄ, ‹vź—ˆę, –{’J@‘, –쓇łŠ°, “n•Ó@Žç, —é–؍N•v, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723152. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Mirikizumab (IL-23ťÜ) ‚Ě“ú–{l‚đŠÜ‚Ţ’×ᇐŤ‘ĺ’°‰Š (UC) ŠłŽŇ‚Ĺ‚Ě‘ć‡U‘ŠŽŽŒą‚Ě—LŒřŤ‹y‚ŃˆŔ‘SŤ. –{’J@‘, William J. Sandborn, Mark Ferrante, Bal Raj Bhandari, Geert R. D'Haens, Elina Berliba, Brian G. Feagan, Ko Nakajo, Satoi Y, Janelle Laskowski, Stuart Friendrich, Michael Durante, Jay Tuttle, “n•Ó@Žç, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘Œ¤‹†Š•a‰@): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723153. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚ĚŠˆ“ŽŤ•]‰ż‚É‚¨‚Ż‚é• •”’´‰š”gŒŸ¸‚̐¸“x. ‹ŕ‘ň“O—Y, ˛ăW‘ž˜Y1, Ź—с@‘ń1,2, ‘ŠŒ´‰Ŕ“ߎq, —с@‹K—˛, X‹v•Ű‘ń1, ź—ѐ^‰›1, ŸşăˆťŽq1, ´Œ´—T‹M1, ”öč@—Ç, ‰Ş—ѐT“ń, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723154. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚é5-ASAťÜ‚Ćƒ`ƒIƒvƒŠƒ“ťÜ‚Ě‘ŠŒÝě—p‚ÉŠÖ‚ˇ‚錤‹†. X‹v•Ű‘ń1, Ź—с@‘ń1,2, ”öč@—Ç, ´Œ´—T‹M1, ŸşăˆťŽq1, ź—ѐ^‰›1, ˛ăW‘ž˜Y1, ’†–ě@‰ë1, ‹vź—ˆę, “ú”ä‹I•ś1,2 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć9‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2018/11/22), ‹ž“s.

723155. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńŠˆ“ŽŠú’×ᇐŤ‘ĺ’°‰ŠŠłŽŇƒ‚ƒjƒ^ƒŠƒ“ƒO‚É‚¨‚Ż‚éCapsule Scoring of Ulcerative Colitis (CSUC) ‚ĚˆÓ‹`. ź—ѐ^‰›1, Ź—с@‘ń1,2, ‰Ş—ѐT“ń, ŸşăˆťŽq1, ”öč@—Ç, ˛ăW‘ž˜Y1, ´Œ´—T‹M1, X‹v•Ű‘ń1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć12‰ń“ú–{ƒJƒvƒZƒ‹“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2019/2/3), ˛‰ę.

723156. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒJƒvƒZƒ‹“ŕŽ‹‹ž‚É‚ć‚é’×ᇐŤ‘ĺ’°‰Š‚̉ŠÇ•]‰żƒXƒRƒA: Capsule Scoring of Ulcerative Colitis (CSUC) ‚Ć‚ť‚ĚValidation. ×]’źŽ÷, ’†–ě@‰ë1, ’|“ŕ@Œ’, ‰““Ą@–L, ź‰ŞŽ‘P, ‘ĺX“S•˝, —Ń“c^—, …–ěT‘ĺ, ’ˇŔ@˝, Ź—с@‘ń1,2, ‹g“c“ÄŽj, ’†—˘Œ\G, ‹ŕˆä—˛“T, “ú”ä‹I•ś1,2, —é–؍N•v, ă–ě•śş, “n•Ó@Žç, •ű°•F (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć12‰ń“ú–{ƒJƒvƒZƒ‹“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2019/2/3), ˛‰ę.

733067. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒNƒ[ƒ“•a‚Ě‘ĺ’°“ŕŽ‹‹ž‘Oˆ’u’†‚ÉMRƒGƒ“ƒeƒƒOƒ‰ƒtƒB[‚đ’ljÁ‚ˇ‚é‚Əăć‚šŒř‰Ę‚ÍŠú‘Ň‚Ĺ‚Ť‚é‚Š? ˛ăW‘ž˜Y1, Ź—с@‘ń1,2, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć107‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/16), “Œ‹ž.


zŠÂŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110137. [Œ´’˜] The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J1, Sugishita N, Shimizu S, Atarashi H, Inoue H: Int J Cardiol 2018/5; 258: 126-32. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110138. [Œ´’˜] Clinical Usefulness of Wearable Cardioverter Defibrillator (WCD) and Current Understanding of Its Clinical Indication in Japan. Niwano S1, Sekiguchi Y, Ishii Y, Iwasaki Y, Kato R, Okamura H, Takagi M, Kurita T, Nitta T: Circ J 2018/5; 82 (6): 1481-6. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

110139. [Œ´’˜] Portal congestion and intestinal edema in hospitalized patients with heart failure. Ikeda Y1, Ishii S1, Yazaki M2, Fujita T1, Iida Y1, Kaida T1, Nabeta T1, Nakatani E, Maekawa E1, Yanagisawa T1, Koitabashi T1, Inomata T1,3, Ako J1: Heart Vessels 2018/7; 33 (7): 740-51. ’r“c—S‹B1, Îˆär•ă1, –îč–ƒ—R2, “Ą“c“S•˝1, ”Ń“c—Sˆę˜Y1, b”ă“c–L“ń1, “ç“c@Œ’1, ‘OěŒb”ü1, –öŕV’q‹`1, Ź”‹´r”ü1, ’––”FŒł1,3, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘Œ¤‹†Š•a‰@)

110140. [Œ´’˜] Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. Ako J1, Hibi K, Kozuma K, Miyauchi K, Morino Y, Shinke T, Tsujita K, Uno K, Kawabata Y, Hiro T: J Cardiol 2018/7; 71 (6): 583-9. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110141. [Œ´’˜] Importance of Early Diagnosis of Cardiac Sarcoidosis in Patients with Complete Atrioventricular Block. Kaida T1, Inomata T1,2, Minami Y1, Yazaki M3, Fujita T1, Iida Y1, Ikeda Y1, Nabeta T1, Ishii S1, Naruke T1, Maekawa E1, Koitabashi T1, Ako J1: Int Heart J 2018/7; 59 (4): 772-8. (b”ă“c–L“ń1, ’––”FŒł1,2, “ě@ŽŒŤ1, –îč–ƒ—R3, “Ą“c“S•˝1, ”Ń“c—Sˆę˜Y1, ’r“c—S‹B1, “ç“c@Œ’1, Îˆär•ă1, Ź–с@’1, ‘OěŒb”ü1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2–k—˘Œ¤‹†Š•a‰@, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110142. [Œ´’˜] Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation. Igarashi T1, Niwano S1, Niwano H, Yoshizawa T1, Nakamura H1, Fukaya H1, Fujiishi T1, Ishizue N1, Satoh A1, Kishihara J1, Murakami M1, Ako J1: Heart Vessels 2018/10; 33 (10): 1258-65. (ŒÜ\—’Œš1, ’ë–ěTˆę1, ‹gŕV’qŽĄ1, ’†‘ş—m”Í1, [’J‰p•˝1, “ĄÎŽě”ü1, Î––ŹĆ1, ŠÝŒ´@~1, ‘şă‰ë”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110143. [Œ´’˜] Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial. Kuroda K1, Shinke T1, Otake H1, Kinutani H1, Iijima R1, Ako J1,2, Okada H1, Ito Y1, Ando K1, Anzai H1, Tanaka H1, Ueda Y1, Takiuchi S1, Nishida Y1, Ohira H1, Kawaguchi K1, Kadotani M1, Niinuma H1, Omiya K1, Morita T1, Zen K1, Yasaka Y1, Inoue K1, Ishiwata S1, Ochiai M1, Hamasaki T1, Urasawa K1, Kataoka T1, Yoshiyama M1, Fujii K1, Inoue T1, Kawata M1, Yokoi H1, Nakamura M1 (1NIPPON investigators): Heart Vessels 2018/8; 33 (8): 837-45. (ˆ˘ŒĂĆ1,2: 2zŠÂŠí“ŕ)

110144. [Œ´’˜] Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma. Fujiwara T, Takeda N, Hara H, Morita H, Kishihara J, Inuzuka R, Yagi H, Maemura S, Toko H, Harada M, Ikeda Y, Kumagai H, Nomura S, Takimoto E, Akazawa H, Ako J1, Komuro I: Eur J Hum Genet 2018/8; 26 (8): 1151-8. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110145. [Œ´’˜] Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. Yasuda S, Kaikita K, Ogawa H, Akao M, Ako J1, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K: Int J Cardiol 2018/8; 265: 108-12. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110146. [Œ´’˜] Early Safety and Efficacy of Sapien 3 20 mm Transcatheter Heart Valve Implantation in Small Japanese Body Size. Meguro K1, Kakizaki R1, Hashimoto T1, Yanagisawa T1, Koitabashi T1, Kitamura T2, Ako J1: Heart Surg Forum 2018/8; 21 (5): E341-4. (–ڍ•Œ’‘ž˜Y1, Š`č—Ç‘ž1, ‹´–{‘ń–í1, –öŕV’q‹`1, Ź”‹´r”ü1, –k‘ş@—Ľ2, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO)

110147. [Œ´’˜] Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation. Yoshizawa T1, Niwano S1, Niwano H, Tamaki H2, Nakamura H1, Igarashi T1, Oikawa J1, Satoh A1, Kishihara J1, Murakami M1, Fukaya H1, Ako J1: International Heart Journal 2018/9; 59 (5): 1077-85. (‹gŕV’qŽĄ1, ’ë–ěTˆę1, ‹Ę–؉p–ž2 ’†‘ş—m”Í1, ŒÜ\—’Œš1, ‹yě@~1, ˛“Ą@—z1, ŠÝŒ´@~1, ‘şă‰ë”ü1, [’J‰p•˝1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2—Տ°‰đ–U‹łˆç)

110148. [Œ´’˜] Endothelial Dysfunction Is Associated with Cognitive Impairment of Elderly Cardiovascular Disease Patients. Fujiyoshi K1, Yamaoka-Tojo M2, Minami Y1, Kutsuna T, Obara S, Kakizaki R1, Nemoto T1, Hashimoto T1, Namba S1, Shimohama T1, Tojo T1, Ako J1: Int Heart J 2018/9; 59 (5): 1034-40. (“Ą‹g˜a”Ž1, “ŒžŠ”ü“ŢŽq2, “ě@ŽŒŤ1, Š`č—Ç‘ž1, Ş–{Ć˘Žu1, ‹´–{F–ž1, “ď”g‘–퍁1, ‰ş•lF˜Y1, “ŒžŠ‘ĺ‹P1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”)

110149. [Œ´’˜] Modifiable factors associated with prolonged door to balloon time in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Noguchi M, Ako J1, Morimoto T, Homma Y, Shiga T, Obunai K, Watanabe H: Heart Vessel. 2018/10; 33 (10): 1139-48. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110150. [Œ´’˜] Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation. Igarashi T1, Niwano S1, Niwano H, Yoshizawa T1, Nakamura H1, Fukaya H1, Fujiishi T1, Ishizue N1, Satoh A1, Kishihara J1, Murakami M1, Ako J1: Heart Vessels 2018/10; 33 (10): 1258-65. (ŒÜ\—’Œš1, ’ë–ěTˆę1, ‹gŕV’qŽĄ1, ’†‘ş—m”Í1, [’J‰p•˝1, “ĄÎŽě”ü1, Î––ŹĆ1, ˛“Ą@—z1, ŠÝŒ´@~1, ‘şă‰ë”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110151. [Œ´’˜] Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. Harada-Shiba M, Ako J1, Arai H, Hirayama A, Murakami Y, Nohara A, Ozaki A, Uno K, Nakamura M: Atherosclerosis 2018/10; 277: 362-8. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110152. [Œ´’˜] Unexpected Measurement Error in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. Katamine M1, Minami Y2, Yanagisawa T2, Meguro K2, Shimohama T2, Tojo T2, Ako J2: JACC Cardiovasc Interv 2018/11; 11 (21): e179-80. (•Đ•ôłáŠ1, “ě@ŽŒŤ2, –öŕV’q‹`2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

110153. [Œ´’˜] Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Sato N1,2, Minami Y2, Shimohama T2, Kameda R2, Tojo T2, Ako J2: Health Sci Rep 2018/12; 2 (1): e105. (˛“ĄL—m1,2, “ě@ŽŒŤ2, ‰ş•lF˜Y2, ‹T“c@—Ç2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‹~–˝, 2zŠÂŠí“ŕ)

110154. [Œ´’˜] Impact of underlying plaque type on strut coverage in the early phase after drug-eluting stent implantation. Kakizaki R1, Minami Y1, Hashikata T1, Nemoto T1, Hashimoto T1, Fujiyoshi K1, Meguro K1, Shimohama T1, Tojo T1, Ako J1: Coron Artery Dis 2018/12; 29 (8): 624-31. (Š`č—Ç‘ž1, “ě@ŽŒŤ1, ”˘•űŒ’G1, Ş–{Ć˘Žu1, ‹´–{‘ń–í1, “Ą‹g˜a”Ž1, –ڍ•Œ’‘ž˜Y1, ‰ş•lF˜Y1, “ŒžŠ‘ĺ‹P1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110155. [Œ´’˜] Dilated cardiomyopathy with re-worsening left ventricular ejection fraction. Nabeta T1, Inomata T1,2, Ishii S1, Yazaki M3, Fujita T1, Iida Y1, Ikeda Y1, Maekawa E1, Naruke T1, Koitabashi T1, Ako J1: Heart Vessels 2019/1; 34 (1): 95-103. (“ç“c@Œ’1, ’––”FŒł1,2, Îˆär•ă1, –îč–ƒ—R3, “Ą“c“S•˝1, ”Ń“c—Sˆę˜Y1, ’r“c—S‹B1, ‘OěŒb”ü1, Ź–с@’1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2–k—˘Œ¤‹†Š•a‰@, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110156. [Œ´’˜] Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease. Hashimoto T1, Minami Y1, Kakizaki R1, Nemoto T1, Fujiyoshi K1, Meguro K1, Shimohama T1, Tojo T1, Ako J1: J Clin Lipidol 2019/1-2; 13 (1): 194-200. (‹´–{‘ń–í1, “ě@ŽŒŤ1, Š`č—Ç‘ž1, Ş–{Ć˘Žu1, “Ą‹g˜a”Ž1, –ڍ•Œ’‘ž˜Y1, ‰ş•lF˜Y1, “ŒžŠ‘ĺ‹P1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110157. [Œ´’˜] Arrhythmogenic cardiac alternans in heart failure is suppressed by late sodium current blockade by ranolazine. Fukaya H1, Plummer BN, Piktel JS, Wan X, Rosenbaum DS, Laurita KR, Wilson LD: Heart Rhythm 2019/2; 16 (2): 281-89. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110158. [Œ´’˜] Burden of Implanted-Device-Detected Atrial High-Rate Episode Is Associated With Future Heart Failure Events - Clinical Significance of Asymptomatic Atrial Fibrillation in Patients With Implantable Cardiac Electronic Devices. Nishinarita R1, Niwano S2, Fukaya H2, Oikawa J2, Nabeta T2, Matsuura 1, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Horiguchi A1, Nakamura H2, Ishizue N2, Kishihara J2, Satoh A2, Ako J2: Circ J 2019/3; 83 (4): 736-42. (źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ‹yě@~2, “ç“c@Œ’2, ź‰Y@Œł1, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, Î––ŹĆ2, ŠÝŒ´@~2, ˛“Ą@—z2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

110159. [Œ´’˜] Linagliptin Suppresses Electrical and Structural Remodeling in the Isoproterenol Induced Myocardial Injury Model. Ishizue N1, Niwano S1, Niwano H, Oikawa J1, Nakamura H1, Hashikata T1, Igarashi T1, Fujiishi T1, Yoshizawa T1, Kishihara J1, Satoh A1, Fukaya H1, Ako J1: Int Heart J 2019/3; 60 (2): 411-8. (Î––ŹĆ1, ’ë–ěTˆę1, ‹yě@~1, ’†‘ş—m”Í1, ”˘•űŒ’G1, ŒÜ\—’Œš1, “ĄÎŽě”ü1, ‹gŕV’qŽĄ1, ŠÝŒ´@~1, ˛“Ą@—z1, [’J‰p•˝1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

310008. [Ç—á•ń] Improved hemodynamics following endovascular treatment for acquired aortic coarctation: A case report. Nagata T1, Ikeda Y1, Ishii S1, Kishihara J1, Ohkubo H2, Mishima T2, Kitamura T2, Miyaji K2, Ako J1: J Cardiol Cases 2018/7; 18 (4): 138-40. (‰i“c‹MŽq1, ’r“c—S‹B1, Îˆär•ă1, ŠÝŒ´@~1, ‘ĺ‹v•Ű”Ž˘2, ”ü“‡—˜ş2, –k‘ş@—Ľ2, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO)

310009. [Ç—á•ń] Intra-isthmus atrial flutter visualized with ultra-high resolution mapping. Fukaya H1, Nishinarita R2, Igarashi G1, Ako J1: J Cardiovasc Electrophysiol 2018/11; 29 (11): 1579-580. ([’J‰p•˝1, źŹ“c—ş2, ŒÜ\—’Œš1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310010. [Ç—á•ń] Unexpected Measurement Error in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. Katamine M1, Minami Y2, Yanagisawa T2, Meguro K2, Shimohama T2, Tojo T2, Ako J2: JACC Cardiovasc Interv 2018/11; 11 (21): e179-80. (•Đ•ôłáŠ1, “ě@ŽŒŤ2, –öŕV’q‹`2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

520006. [‘ŕ]y“ÁW: THEME@DOAC‚Ć‚˘‚¤–˝‘čz›Special Articles@EDOAC‚ĆƒtƒŒƒCƒ‹ŠłŽŇ. ’ë–ěTˆę (zŠÂŠí“ŕ): Cardio-Coagulation 2018/8; 5 (2): 84-8.

522038. [uŔ]y“ÁW: zŠÂŠíŽžŠłf—Ă50”N‚đU‚č•Ô‚Á‚ā|S‹ŘŽžŠł‚É‚¨‚Ż‚é‚í‚Ş‘‚Ě•ŕ‚݁|z3. “ŕ‰Č“IŽĄ—Ă (–ň•¨). ’––”FŒł1,2 (1zŠÂŠí“ŕ, 2–k—˘Œ¤‹†Š•a‰@): S‘Ÿ 2018/6; 50 (6): 602-6.

522039. [uŔ]y—Տ°uŔzŽüŽYŠúS‹ŘÇ. Ź”‹´r”ü (zŠÂŠí“ŕ): ’´‰š”gŒŸ¸‹Zp 2018/6; 43 (3): 287-95.

522040. [uŔ]y“ÁW: zŠÂŠíŽžŠł‚É‚¨‚Ż‚éƒfƒBƒx[ƒgzŽĄ‚ˇ@8. DESŒă‚ĚDAPT‚Í‚˘‚‚܂őą‚Ż‚é‚ׂŤ‚Š. ‰ş•lF˜Y1, ‹T“c@—Ç1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): Heart View 2018/9; 22 (10): 49-55.

522041. [uŔ]y“ÁW: ‹•ŒŒŤSŽžŠłf—Ă‚ĚŒťÝ‚Ć–˘—ˆ|X‚Č‚é—\Œă‰ü‘P‚đ–ÚŽw‚ˇŽŔ’nf—Á|zŽĄ—Ă: ƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚˘‚˝‹•ŒŒŤSŽžŠłŽĄ—Ă‚ĚŽŔŰuŽŠ“K‚ȍRŒŒŹ”—Ö@‚Ƃ͉˝‚Šv. ‰Á“ĄĘ”ü1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): Medical Practice 2018/10; 35 (9): 1427-32.

522042. [uŔ]yŽ¸”s‚ľ‚˝Ç—áEŽ¸”s‚ľ‚ť‚¤‚É‚Č‚Á‚˝Ç—á‚Š‚çŠw‚Ú‚¤! ‚Č‚şŽ¸”s‚ľ‚˝‚Ě‚Š? ‚Ç‚¤‚ˇ‚ę‚΂悊‚Á‚˝‚Ě‚Š?zS‹ŘÇ•Ň. Ź”‹´r”ü SƒGƒR[ 2018/10; 19 (10): 980-8.

522043. [uŔ]y“ÁW: ƒJƒe[ƒeƒ‹ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‡•šS–[×“Ž‚É‚¨‚Ż‚éR‹ĂŒĹ—Ă–@zS–[×“Ž‡•šŠĽ“Ž–ŹŽžŠłŠłŽŇ‚̕“IŽĄ—Ă. ‰ş•lF˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): Cardio-Coagulation 2018/12; 5 (4): 15-22.

522044. [uŔ]y“ÁW: ‚—îŽŇ‚É‚¨‚Ż‚éRŒŒđER‹ĂŒĹ—Ă–@zSeminar 7. ŠĽ“Ž–ŹŽžŠł‚ƐS–[×“Ž‚đ‡•š‚ľ‚Ä‚˘‚éę‡‚̍RŒŒđ–ň‚ĚŽg‚˘•ű. ‰ş•lF˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ˜V”NˆăŠw 2019/2; 57 (2): 139-44.

522045. [uŔ]y“ÁW: ŒŒđŽ~ŒŒ‚Ě—Ő°|Œ¤Cˆă‚Ě‚˝‚ß‚É [‘ć2”Ĺ] (Œă•Ň)zDAPT‚ĆDOAC•š—p—Ă–@‚ĚŒp‘ąŽžŠÔ. [’J‰p•˝1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): “ú–{ŒŒđŽ~ŒŒŠw‰ďŽ 2019/2; 30 (1): 116-21.

522046. [uŔ]y“ÁW: RŒŒđ—Ă–@‚ĚƒWƒŒƒ“ƒ}@—\–h‚ˇ‚ׂŤ‚ÍŒŒđ‚Š, oŒŒ‚Š?zĄR‹ĂŒĹ–ň‚Ě“ÁŤ‚đ—‰đ‚ˇ‚é@ŒoŒűXaˆöŽq‘jŠQ–ň‚Ě“K‰ž‚ĆŽg—p–@. [’J‰p•˝1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): Medicina 2019/2; 56 (2): 281-6.

530002. [‚ť‚Ě‘ź (Editorials)] Is female sex always a risk for bleeding? Fukaya H1, Ako J1: Jpn Circ J 2018/6; 82 (7): 1743-5. ([’J‰p•˝1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

[’˜@‘]

620029. [Šwp‘ (•Ş’SŽˇ•M)]y‚—îŽŇˆă—Ăƒnƒ“ƒhƒuƒbƒN@‚—îŽŇˆă—Ă‚É‚¨‚Ż‚éƒ_ƒCƒo[ƒVƒeƒB‚ւ̑Ήž (—Տ°ŽGŽ“ŕ‰Č2018”N4ŒŽ‘‘ĺ†z‘ćIXÍ ‚—îŽŇ‚É‚¨‚Ż‚é–ňÜŽg—p‚Ě’ˆÓ“_@1. R‹ĂŒĹ–ňERŒŒŹ”–ň, p.908-12. ‘şź—T‰î1, “ě@ŽŒŤ2, [’J‰p•˝2, ‰ş•lF˜Y2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ), “ě]“°, “Œ‹ž, 2018/4”­s.

620030. [Šwp‘ (•Ş’SŽˇ•M)]yŽŔ—͐S“d}|u“Ç‚ß‚év‚Ě‚ť‚̐ć‚ց|z‘ć6Í S“d}”ť“ǁ|u“Ç‚ß‚év‚Ě‚ť‚̐ć‚ց|@ăŽşŤ•sŽ–Ź, p.188-239. ’ë–ěTˆę (zŠÂŠí“ŕ), ˆę”ĘŽĐ’c–@l“ú–{•sŽ–ŹS“dŠw‰ď, “Œ‹ž, 2018/7”­s.

620031. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@7) Ž¸_E‹N—§Ť’ጌˆł, p.30-7. ‘OěŒb”ü1 (1zŠÂŠí“ŕ), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620032. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zII “ŕ•”áŠQŒnŽĺ—vŒŸ¸@2. ŒŒ‰tEś‰ťŠwŒŸ¸: Šî€’l‚ĆˆŮí’l‚Ě–ÚˆŔˆę——, p.166-71. ‘OěŒb”ü1 (1zŠÂŠí“ŕ), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620033. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zII “ŕ•”áŠQŒnŽĺ—vŒŸ¸@4. SƒGƒR[}, p.174-86. ‘OěŒb”ü1 (1zŠÂŠí“ŕ), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620034. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zII “ŕ•”áŠQŒnŽĺ—vŒŸ¸@5. S‘ŸƒJƒe[ƒeƒ‹ŒŸ¸, p.187-94. ‘OěŒb”ü1 (1zŠÂŠí“ŕ), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620035. [Šwp‘ (•Ş’SŽˇ•M)]y[zŠÂŠíf—ĂƒUEƒx[ƒVƒbƒN] ‹}ŤŠĽÇŒóŒQzĄƒXƒeƒ“ƒgŒŒđÇ (Stent thrombosis), p.36-51. ‰ş•lF˜Y (zŠÂŠí“ŕ), •Ň: ˆ˘ŒĂĆ, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/9”­s.

620036. [Šwp‘ (•Ş’SŽˇ•M)]yƒ`ƒFƒbƒNƒV[ƒg‚ĹŠĹŒěƒŒƒxƒ‹‚đŠm”F@ƒi[ƒX‚Ě–đŠ„‚Ş‚ľ‚Á‚Š‚č‚Ý‚Ś‚é&ƒ`[ƒ€‚Ě’†‚Ĺ“Ž‚Ż‚é@‚ˇ‚˛‚­‚í‚Š‚é!@S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO 2018H‹G‘Š§)z‘ć1Í ƒJƒeŽş‚É“ü‚é‘O‚É’m‚Á‚Ä‚¨‚ą‚¤@4 ƒJƒe‚ÉŽQ‰Á‚ˇ‚éƒXƒ^ƒbƒt‚Í’N?@‘˝EŽí˜AŒg‚Ĺ‚Ěƒi[ƒX‚Ě–đŠ„‚Í?, p.20-4. ‘şź—T‰î1, •˝@KŒb2 (1zŠÂŠí“ŕ, 2ŠĹŒě•”), ŠÄC: ˆ˘ŒĂĆ1, ƒƒf˛ƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620037. [Šwp‘ (•Ş’SŽˇ•M)]yŒŒđ‚𐧂ˇ‚é‚ŕ‚̂͐S‘Ÿ‚𐧂ˇ! ŒŒđzŠÂŠíŠwQ&A@R‹ĂŒĹ—Ă–@ERŒŒŹ”—Ö@‚ĚƒNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“‚É“š‚Ś‚ézPart.1 SŒŒŠÇƒCƒxƒ“ƒg‚đ—\–h‚ˇ‚éRŒŒŹ”—Ö@@CQ5 őPCIŒă‚̍RŒŒŹ”–ň2Ü•š—pŠúŠÔ‚͂ǂ̂悤‚É‚˘‚˝‚ç‚悢‚Ĺ‚ľ‚傤‚Š? ‚ť‚ĚŒă, ’PÜ‚đŽc‚ˇę‡‚ɂ‚˘‚Ä‚ŕ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.12-5. ‰ş•lF˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ), •Ň: ˆÉ“Ą@_, •śŒő“°, “Œ‹ž, 2019/3”­s.

620038. [Šwp‘ (•Ş’SŽˇ•M)]y‚ˇ‚˛‚­‚í‚Š‚é! S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO2018”NH‹G‘Š§)z[‘ć1Í ƒJƒeŽş‚É“ü‚é‘O‚É’m‚Á‚Ä‚¨‚ą‚¤]@7. ƒJƒeŽĄ—Ă‚Ě‘O‚ɍs‚¤ŒŸ¸‚ɂ͉˝‚Ş‚ ‚é‚Ě?, p.34-8. Ź”‹´r”ü (zŠÂŠí“ŕ), ŠÄC: ˆ˘ŒĂĆ, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620039. [Šwp‘ (•Ş’SŽˇ•M)]y‚ˇ‚˛‚­‚í‚Š‚é! S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO2018”NH‹G‘Š§)z[‘ć1Í ƒJƒeŽş‚É“ü‚é‘O‚É’m‚Á‚Ä‚¨‚ą‚¤]@11. Š´őÇ‘΍ô‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.59-63. –ě“cçt (zŠÂŠí“ŕ), ŠÄC: ˆ˘ŒĂĆ, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620040. [Šwp‘ (•Ş’SŽˇ•M)]y‚ˇ‚˛‚­‚í‚Š‚é! S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO2018”NH‹G‘Š§)z[‘ć3Í ‚ł‚ , ƒJƒeŽş‚É“ü‚낤!]@(2) ƒJƒe‘O‚ĚƒPƒA@1. ŠłŽŇ‚ł‚ń‚Ě“üŽş`ƒhƒŒ[ƒsƒ“ƒO, p.156-66. ‰ş•lF˜Y (zŠÂŠí“ŕ), ŠÄC: ˆ˘ŒĂĆ, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620041. [Šwp‘ (•Ş’SŽˇ•M)]y‚ˇ‚˛‚­‚í‚Š‚é! S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO2018”NH‹G‘Š§)z[‘ć4Í V‚ľ‚˘ƒJƒe[ƒeƒ‹ŽĄ—Ă]@1. ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Á‚Ä‚Č‚ń‚Ĺ‚ˇ‚Š?, p.210-9. [’J‰p•˝ ŠÄC: ˆ˘ŒĂĆ, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620042. [Šwp‘ (•Ş’SŽˇ•M)]y‚ˇ‚˛‚­‚í‚Š‚é! S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO2018”NH‹G‘Š§)z[‘ć4Í V‚ľ‚˘ƒJƒe[ƒeƒ‹ŽĄ—Ă]@2. TAVI‚Á‚Ä‚Č‚ń‚Ĺ‚ˇ‚Š?, p.220-6. –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ), ŠÄC: ˆ˘ŒĂĆ, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620043. [Šwp‘ (•Ş’SŽˇ•M)]y—Տ°ƒVƒiƒŠƒI‚ÉŠî‚Ă‚­ŠO—ˆf—ĂƒXƒLƒ‹ƒAƒbƒv@‚ą‚ń‚ČŠO—ˆŠłŽŇ‚ł‚ń, ćś‚Č‚ç‚Ç‚¤‚ľ‚Ü‚ˇ‚Š? (Heart View 2018”N11ŒŽ‘Š§†)z2. •Ů–ŒÇ@a. ƒtƒŒƒCƒ‹‚Ć‘§Ř‚ę‚Şi‚Ý•ŕs˘“ď‚Ć‚Č‚č‚‚‚ ‚é’´‚—îASŠłŽŇ, p.41-6. –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ), ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/10”­s.

620044. [Šwp‘ (•Ş’SŽˇ•M)]y—Տ°ƒVƒiƒŠƒI‚ÉŠî‚Ă‚­ŠO—ˆf—ĂƒXƒLƒ‹ƒAƒbƒv@‚ą‚ń‚ČŠO—ˆŠłŽŇ‚ł‚ń, ćś‚Č‚ç‚Ç‚¤‚ľ‚Ü‚ˇ‚Š? (Heart View 2018”N11ŒŽ‘Š§†)z7. •sŽ–Ź@e. ŠŽ‘S–[ŽşƒuƒƒbƒN‚ĹDDDƒy[ƒXƒ[ƒJ‚đAž‚Ý, ‰“ŠuŠú‚ɐS‹@”\‚̒ቺ‚đŽw“E‚ł‚ę‚˝–łÇóŠłŽŇ, p.190-5. Ź”‹´r”ü (zŠÂŠí“ŕ), ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/10”­s.

620045. [Šwp‘ (•Ş’SŽˇ•M)]yS•s‘S (‘ć‚Q”Ĺ) ’†|ĹV‚ĚŠî‘bE—Տ°Œ¤‹†‚̐i•ŕ|(“ú–{—ŐŕŹ77ŠŞ‘Š§†1)zIX. ŽĄ—Â̐i•ŕ@1. ƒKƒCƒhƒ‰ƒCƒ“@(1) ACC/AHAƒKƒCƒhƒ‰ƒCƒ“, p.11-7. Ź”‹´r”ü (zŠÂŠí“ŕ), “ú–{—Ő଎Đ, “Œ‹ž, 2019/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712019. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Current understanding of the indication of Wearable Cardioverter Defibrillator. Niwano S1: International Cardiac Electrophysiology Meeting 2018 (2018/6/29), Chiba, Japan. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

712020. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Role of Wearable Cardioverter Defibrillator (WCD) in Acute Phase Care of Patients at High SCD Risk. Niwano S1: Great Wall International Congress of Cardiology 2018 (2018/10/13), Beijing, China. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

712021. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Experience of Clinical Usage of Wearable Cardioverter Defibrillator (WCD) in Japan. Niwano S1: APHRS 2018|11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/18), Taipei, Taiwan. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

712022. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Suppressive Effect of DPP4-Inhibitor for the Atrial Remodeling in a Canine AF Model. Niwano S1: APHRS 2018|11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/19), Taipei, Taiwan. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

713063. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Thrombus burden is significantly less in drug-eluting stent than in bare metal stent at three-weeks follow-up after ST-segment elevation myocardial infarction: an optical coherence tomography study. Sato N, Minami Y1, Shimohama T1, Kameda R1, Tojo T1, Ako J1: Transcatheter Cardiovascular Therapeutics Asian Pacific 2018 (2018/4/28), Seoul, Korea. (“ě@ŽŒŤ1, ‰ş•lF˜Y1, ‹T“c@—Ç1, “ŒžŠ‘ĺ‹P1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713064. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Acute Coronary Syndrome Triggered by Exercise; Calcified Nodule as an Underlying Lesion. Kato A1, Minami Y2, Meguro K2, Shimohama T2, Tojo T2, Ako J2: APSC congress 2018 (2018/5/17), Taipei, Taiwan. (‰Á“ĄĘ”ü1, “ě@ŽŒŤ2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713065. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) How to Manage Cancer Patients with Ischemic Heart Disease? Ako J1: APSC congress 2018 (2018/5/19), Taipei, Taiwan. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713066. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Relationship of atrial fibrillation pattern and heart failure in patients without prior heart failure hospitalization. Nabeta T1, Oikawa J1, Ishii S1, Naruke T1, Iida Y1, Fujita T1, Kaida T1, Noda C1, Yamaoka-Tojo M2, Ako J1: APSC congress 2018 (2018/5/17-20), Taipei, Taiwan. (“ç“c@Œ’1, ‹yě@~1, Îˆär•ă1, Ź–с@’1, ”Ń“c—Sˆę˜Y1, “Ą“c“S•˝1, b”ă“c–L“ń1, –ě“cçt1, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”)

713067. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Burden of Device-Detected Atrial High-Rate Episode Relates to Heart Failure Events. Nishinarita R1, Niwano S2, Fukaya H2, Oikawa J2, Nabeta T2, Arakawa Y1, Horiguchi A1, Nakamura H2, Kishihara J2, Sato A2, Ako J2: Internatinall Cardiac Electrocardiology Meeting 2018 (2018/6/29), Chiba, Japan. (źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ‹yě@~2, “ç“c@Œ’2, rě—Y‹I1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, ŠÝŒ´@~2, ˛“Ą@—z2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713068. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Optimal PCI and Healing. Ako J1: TOPIC2018 (2018/7/13), Tokyo, Japan. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713069. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Daily Heart Rate Variability Predicts Heart Failure Events in Patients with Permanent Atrial Fibrillation. Oikawa J1, Fukaya H1, Nabeta T1, Arakawa Y2, Horiguchi A2, Nishinarita R2, Nakamura H1, Satoh A1, Kishihara J1, Ishii S1, Noda C1, Yamaoka-Tojo M3, Niwano S1, Ako J1: Ammual Scentific Congress of European Society of Cardiology 2018 (2018/8/25), Munich, German. (‹yě@~1, [’J‰p•˝1, “ç“c@Œ’1, rě—Y‹I2, –xŒű@ˆ¤2, źŹ“c—ş2, ’†‘ş—m”Í1, ˛“Ą@—z1, ŠÝŒ´@~1, Îˆär•ă1, –ě“cçt1, “ŒžŠ”ü“ŢŽq3, ’ë–ěTˆę1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”)

713070. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Suppressive effect of Canagliflozin on atrial remodelling In canine atrial fibrillation Model. Nishinarita R1, Niwano S2, Niwano H, Fukaya H2, Matsuura G1, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Horiguchi A1, Nakamura H2, Igarashi T2, Ishizue N2, Nabeta T2, Fujiishi T2, Yoshizawa T2, Oikawa J2, Satoh A2, Murakami M2, Ako J2: Ammual Scentific Congress of European Society of Cardiology 2018 (2018/8/26), Munich, German. (źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ź‰Y@Œł1, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, ŒÜ\—’Œš2, Î––ŹĆ2, “ç“c@Œ’2, “ĄÎŽě”ü2, ‹gŕV’qŽĄ2, ‹yě@~2, ˛“Ą@—z2, ‘şă‰ë”ü2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713071. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Burden of Device-Detected Atrial High-Rate Episode Relates to Heart Failure Events. Nishinarita R1, Niwano S2, Fukaya H2, Oikawa J2, Nabeta T2, Arakawa Y1, Horiguchi A1, Nakamura H2, Kishihara J2, Sato A2, Ako J2: Ammual Scentific Congress of European Society of Cardiology 2018 (2018/8/28), Munich, German. (źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ‹yě@~2, “ç“c@Œ’2, rě—Y‹I1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, ŠÝŒ´@~2, ˛“Ą@—z2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713072. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Fibrillation cycle length predicts recurrence after catheter ablation in patients with persistent atrial fibrillation. Fukaya H1, Kishihara J1, Niwano S1, Arakawa Y2, Nishinarita R2, Horiguchi A2, Nakamura H1, Oikawa J1, Satoh A1, Ako J1: Ammual Scentific Congress of European Society of Cardiology 2018 (2018/8/25-29), Munich, German. ([’J‰p•˝1, ŠÝŒ´@~1, ’ë–ěTˆę1, rě—Y‹I2, źŹ“c—ş2, –xŒű@ˆ¤2, ’†‘ş—m”Í1, ‹yě@~1, ˛“Ą@—z1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713073. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Clinical and economic values of innovative biologics for cardiovascular disease and what are the appropriate ways to assess their value. Ako J1: ISPOR Asia Pacific 2018 (2018/9/11), Tokyo, Japan. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713074. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) S-ICD or TV-ICD; our selection of the defibrillation devices. Kobayashi S1, Kishihara J2, Niwano S2, Matsuura G1, Arakawa Y1, Shirakawa Y1, Nishinarita R1, Horiguchi A1, Ishizue N2, Oikawa J2, Igarashi G2, Fukaya H2, Ako J2: APHRS 2018|11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/18), Taipei, Taiwan. (Ź—ŃŽü•˝1, ŠÝŒ´@~2, ’ë–ěTˆę2, ź‰Y@Œł1, rě—Y‹I1, ”’ě—TŠî1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ2, ‹yě@~2, ŒÜ\—’Œľ2, [’J‰p•˝2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713075. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Additional Posterior Wall Isolation causes Gastric Hypoperistalsis in the Catheter Ablation for Atrial Fibrillation. Oikawa J1, Fukaya H1, Kishihara J1, Satoh A1, Wada T, Matsuura G2, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Horiguchi A2, Nishinarita R2, Ishizue N1, Igarashi G1, Katada C3, Tanabe S3,4, Niwano S1, Ako J1: APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/18), Taipei, Taiwan. (‹yě@~1, [’J‰p•˝1, ŠÝŒ´@~1, ˛“Ą@—z1, ź‰Y@Œł2, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, –xŒű@ˆ¤2, źŹ“c—ş2, Î––ŹĆ1, ŒÜ\—’Œľ1, Œ˜“ce—˜3, “c糁@‘3,4, ’ë–ěTˆę1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Á‰ťŠí“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă)

713076. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The day-to-day variation of J-wave as a Predictor for Life-Threatening Arrhythmias in patient with Implantable Cardioverter Defibrillator. Ishizue N1, Niwano S1, Fukaya H1, Matsuura G2, Arakawa Y2, Kobayashi S2, Nishinarita R2, Horiguchi A2, Oikawa J1, Igarashi G1, Kishihara J1, Ako J1: APHRS 2018|11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/19), Taipei, Taiwan. (Î––ŹĆ1, ’ë–ěTˆę1, [’J‰p•˝1, ź‰Y@Œł2, rě—Y‹I2, Ź—ŃŽü•˝2, źŹ“c—ş2, –xŒű@ˆ¤2, ‹yě@~1, ŒÜ\—’Œľ1, ŠÝŒ´@~1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713077. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Wearable Cardioverter Defibrillator: our initial 4-year experience with 32 cases. Horiguchi A1, Kishihara J2, Fukaya H2, Niwano S2, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Nishinarita R1, Nakamura H2, Ishizue N2, Igarashi G2, Oikawa J2, Satoh A2, Ako J2: APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/19), Taipei, Taiwan. (–xŒű@ˆ¤1, ŠÝŒ´@~2, [’J‰p•˝2, ’ë–ěTˆę2, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, źŹ“c—ş1, ’†‘ş—m”Í2, Î––ŹĆ2, ŒÜ\—’Œľ2, ‹yě@~2, ˛“Ą@—z2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713078. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Successful catheter ablation of triggered PVCs in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation. Kishihara J1, Fukaya H1, Niwano S1, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Nishinarita R2, Horiguchi A2, Nakamura H1, Ishizue N1, Igarashi G1, Oikawa J1, Satoh A1, Ako J1, Sekiguchi Y, Nogami A: APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/19), Taipei, Taiwan. (ŠÝŒ´@~1, [’J‰p•˝1, ’ë–ěTˆę1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, źŹ“c—ş2, –xŒű@ˆ¤2, ’†‘ş—m”Í1, Î––ŹĆ1, ŒÜ\—’Œľ1, ‹yě@~1, ˛“Ą@—z1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713079. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Medical survey of patients with syncopal episodes in emergency medical service in Kitasato university hospital. Nishinarita R1, Niwano S2, Fukaya H2, Matsuura G1, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Horiguchi A1, Nakamura H2, Ishizue N2, Kishihara J2, Oikawa J2, Satoh A2, Aoyama N3, Ako J2: APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/20), Taipei, Taiwan. (źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ź‰Y@Œł1, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, Î––ŹĆ2, ŠÝŒ´@~2, ‹yě@~2, ˛“Ą@—z1, ÂŽR’ź‘P3, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‘‡f—Ă)

713080. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Two cases of idiopathic outflow tract ventricular tachycardia in perinatal period. Shirakawa Y1, Kishihara J2, Fukaya H2, Niwano S2, Matsuura G1, Arakawa Y1, Kobayashi S1, Nishinarita R1, Horiguchi A1, Ishizue N2, Oikawa J2, Igarashi G2, Ako J2: APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session (2018/10/20), Taipei, Taiwan. (”’ě—TŠî1, ŠÝŒ´@~2, [’J‰p•˝2, ’ë–ěTˆę2, ź‰Y@Œł1, rě—Y‹I1, Ź—ŃŽü•˝1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ2, ‹yě@~2, ŒÜ\—’Œľ2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713081. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Flow-mediated dilation is associated with the severity of coronary artery disease. Nemoto T1, Minami Y2, Yamaoka-Tojo M3, Sato T1, Muramatsu Y1, Kakizaki R1, Hashimoto T1, Fujiyoshi K2, Meguro K2, Shimohama T2, Tojo T2, Ako J2: AHA2018 (2018/11/10), Chicago, USA. (Ş–{Ć˘Žu1, “ě@ŽŒŤ2, “ŒžŠ”ü“ŢŽq3, ˛“Ąrˆň1, ‘şź—T‰î1, Š`č—Ç‘ž1, ‹´–{‘ń–í1, “Ą‹g˜a”Ž2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3ˆă—ÉqśŠw•”)

713082. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Optical Coherence Tomography Guided Percutaneous Coronary Intervention is not Associated with Decline in Kidney Function. Nemoto T1, Minami Y2, Sato T1, Muramatsu Y1, Kakizaki R1, Fujiyoshi K2, Hashimoto T1, Oikawa J2, Meguro K2, Shimohama T2, Tojo T2, Ako J2: AHA2018 (2018/11/10), Chicago, USA. (Ş–{Ć˘Žu1, “ě@ŽŒŤ2, ˛“Ąrˆň1, ‘şź—T‰î1, Š`č—Ç‘ž1, “Ą‹g˜a”Ž2, ‹´–{‘ń–í1, ‹yě@~2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713083. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Triple Drug Therapy: Who Really Needs a Triple Threat? Ako J1: AHA2018 (2018/11/11), Chicago, USA. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

721007. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) WPWÇŒóŒQ‚ĚƒAƒuƒŒ[ƒVƒ‡ƒ“. ’ë–ěTˆę (zŠÂŠí“ŕ): EPƒTƒ}[ƒZƒ~ƒi[2018 (2018/6/17), “Œ‹ž.

721008. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) śŽş—Źo˜H‹ˇó‡•š—á‚Ĺ‚Ě”DP‚Ě–â‘č“_‚ĆŠÇ—. Ź”‹´r”ü1, –]ŒŽƒŽq2, ‰Á“Ą—˘ŠG3,4, ‰œ•xr”V4, Îˆäł_5, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2ŽY‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4–ƒŒ, 5ŹŽ™): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/7-9), ‘ĺă.

721009. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰)yƒP[ƒX‚ÉŠw‚ԁzŠg’Ł•s‘S‚̊ӕʐf’f `S‹ŘŽžŠł‚đ‹^‚¤‘O‚ÉŒŠ‹É‚߂鎞Šł‚Ƃ́H ƒI[ƒvƒjƒ“ƒOƒI[ƒo[ƒrƒ…[‚Ć‚Ü‚Ć‚ß. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/7-9), ‘ĺă.

721010. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ’፶S‹@”\‚đ‡•š‚ľ‚˝ ƒtƒ@ƒ[Žl’ĽÇS“ŕC•œpŒă‚̐ŹlŠú‚É‚¨‚Ż‚閝ŤS•s‘S‚ɑ΂ˇ‚鎥—Ð헪‚ɂ‚˘‚Ä. Ź”‹´r”ü1, “Ą“c“S•˝1, ŒSŽRŒbŽq1, ‘OěŒb”ü1, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO): ‘ć9‰ń“ú–{S‘Ÿ•Ů–ŒÇŠw‰ď (2018/12/14-15), ‹ž“s.

721011. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) Ç—á’ńŽŚ. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

721012. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‘ĺ“Ž–Ź‹ˇóÇ‚É‹‚ß‚ç‚ę‚éSƒGƒR[}•]‰ż. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć83‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2019) (2019/3/29-31), ‰Ą•l.

722043. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) zŠÂŠí“ŕ‰Čˆă‚Ě–Ú‚Š‚猊‚˝Ž‰Žż’ቺ—Ă–@PCSK9‘jŠQÜ‚Ć‚˘‚¤‘I‘đŽˆ. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć91‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠwp‘‰ď (2018/4/27), ‹{č, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/4; 94 (1): 301.

722044. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) WCD for Prevention of SCD after Infected ICD Removal. ’ë–ěTˆę (zŠÂŠí“ŕ): ‘ć65‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

722045. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“: ƒŠ[ƒh”˛‹Ž‚͐ϋɓI‚ÉŽŔŽ{‚ˇ‚ׂŤ. [’J‰p•˝ (zŠÂŠí“ŕ): ‘ć11‰ńA‚Śž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2019/2/16), “Œ‹ž.

723157. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) f’fŠî€‚̉ü’ů‚É”ş‚¤ƒTƒ‹ƒRƒCƒh[ƒVƒXf—Ă‚É‚¨‚Ż‚éSƒGƒR[}ŒŸ¸‚Ě–đŠ„‚Ě•Ď‰ť. Ź”‹´r”ü1, ‘OěŒb”ü1, b”ă“c–L“ń1, ŒSŽRŒbŽq1, –ڍ•Œ’‘ž˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ˆę”ĘŽĐ’c–@l“ú–{SƒGƒR[}Šw‰ď ‘ć29‰ńŠwpW‰ď (2018/4/26-28), ŠâŽč.

723158. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žčpí—ނɉe‹ż‚ˇ‚é“ű“ޏóüˆŰ’eŤŽî‚Ě‘˝—lŤ. ‘OěŒb”ü1, Ź”‹´r”ü1, b”ă“c–L“ń1, ŒSŽRŒbŽq1, –k‘ş@—Ľ2, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO): “ú–{’´‰š”gˆăŠw‰ď‘ć91‰ńŠwpW‰ď (2018/6/8-10), _ŒË, ’´‰š”gˆăŠw 2018/6; 45 (Suppl): S820.

723159. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –ŤŠúSŽžŠłŠłŽŇ‚É‚¨‚Ż‚鎉Žż‘ăŽÓ‚ĚŠÇ—‚Ć“Ž–Źd‰ť‚ĚŒpŽž“I•Ď‰ť: Ťˇ‚É‚ć‚é‰e‹ż‚ĚŒŸ“˘. ÂŽRW‘ž1, “ŒžŠ”ü“ŢŽq2, –ě“cçt3, ‰“Œ´^ˆę, ´…ŠG—˘, ŠÖŞŒb”üŽq, ‚‹´—R”ü, ź‰i“Ä•F2, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ): ‘ć54‰ń“ú–{zŠÂŠí•a—\–hŠw‰ďŠwpW‰ď (2018/6/22), ŽD–y. (YIAƒZƒbƒVƒ‡ƒ“‚Ƀmƒ~ƒl[ƒg)

723160. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ú–{‚É‚¨‚Ż‚鏬ŒűŒa‚ĚŒoƒJƒe[ƒeƒ‹“I‘ĺ“Ž–Ź•Ů—Ż’upƒfƒoƒCƒX‚̐ŹŃ‚Ć‚ť‚Ě”äŠr. ‹´–{‘ń–í1, –öŕV’q‹`2, ˆ˘ŒĂĆ2, –k‘ş@—Ľ3: JTVT registry research proposal 2018 investigators (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3S‘ŸŒŒŠÇŠO): ‘ć9‰ń“ú–{ŒoƒJƒe[ƒeƒ‹S‘Ÿ•ŮŽĄ—ĂŠw‰ďŠwpW‰ď JTVT2018 (2018/7/8), ‘ĺă.

723161. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‰~EŠJ‘ś‚É‚ć‚é‰EśƒVƒƒƒ“ƒg‚ĆŠĚ”xÇŒóŒQ‚đ‡•š‚ľ‚˝FallotŽl’ĽÇS“ŕC•œpŒă‚̏dÇ‰ES•s‘S‚Ěˆę—á. “Ą“c“S•˝1, Ź”‹´r”ü1, ‘OěŒb”ü1, ŒSŽRŒbŽq1, –ڍ•Œ’‘ž˜Y1, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/7-9), ‘ĺă, “ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď´˜^ 2018/9; 66: EP-141.

723162. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ACSŠłŽŇ‚É‚¨‚Ż‚éŒľŠiŽ‰ŽżŠÇ—. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć50‰ń“ú–{“Ž–Źd‰ťŠw‰ď‘‰ďEŠwpW‰ď (2018/7/12), ‘ĺă.

723163. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œo”ç“I‘ĺ“Ž–Ź•Ů’uŠˇpŒă‚Ě‹}ŤŠú‚Ɖ“ŠuŠú‚É‚¨‚Ż‚é‰^“Ž‘Ď—e”\‚̕ωť. ‘OěŒb”ü1, _’JŒ’‘ž˜Y2, “c’†L–í3, Žsě‹M•ś3, –ěčN•˝3, ź‘ň—Ç‘ž3, ŕ_čL–ž3, ™–ě‰Á“ŢŽq4, ŒÜ\—’ˆŸŠóŽq4, –ڍ•Œ’‘ž˜Y1, –ě“cçt1, ‰ş•lF˜Y1, “ŒžŠ”ü“ŢŽq2, ‘“c@‘ě2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4ŠĹŒě•”): ‘ć24‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2018/7/14), ‰Ą•l.

723164. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Real World Antithrombotic Therapy in Atrial Fibrillation Patients with a History of Percutaneous Coronary Intervention Before and After the Launch of Direct Oral Anticoagulants. –xŒű@ˆ¤1, [’J‰p•˝2, ‹yě@~2, rě—Y‹I1, źŹ“c—ş1, ’†‘ş—m”Í2, ŠÝŒ´@~2, ˛“Ą@—z2, ’ë–ě—TŒb, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć65‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

723165. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Atypical Approach for the Catheter Ablation of Paroxysmal Atrial Tachycardia with a Bilateral Femoral Vein Occlusion and Persistent Left Superior Vena Cava. rě—Y‹I1, [’J‰p•˝2, ź‰Y@Œł1, Ź—ŃŽü•˝1, ”’ě—TŠî1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ1, ‹yě@~2, ŒÜ\—’Œľ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć65‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

723166. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Recovery of Left Ventricular Function after Atrial Fibrillation Ablation was Observed only in Patients with Left Ventricular Dysfunction with Unknown Cause. ŠÝŒ´@~1, [’J‰p•˝1, ’ë–ěTˆę1, źŹ“c—ş2, –xŒű@ˆ¤2, ’†‘ş—m”Í1, ‹yě@~1, ˛“Ą@—z1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć65‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

723167. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Burden of Device-Detected Atrial High Rate Episode (AHRE) is associated with Heart Failure Events. źŹ“c—ş1, ’ë–ěTˆę2, [’J‰p•˝2, ź‰Y@Œł1, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í2, ŒÜ\—’Œš2, Î––ŹĆ1, “ĄÎŽě”ü2, ‹gŕV’qŽĄ2, ‹yě@~2, ˛“Ą@—z2, ‘şă‰ë”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć65‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

723168. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Longitudinal stent deformation due to strut entrapment into protruding plaque in tortuous calcified lesion. ‰Á“ĄĘ”ü1, “ě@ŽŒŤ2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć27‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠwpW‰ď (CVIT 2018) (2018/8/2), _ŒË.

723169. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Longitudinal Measurement Error in Optical Coherence Tomography Due to Deep Breath During Pullback. •Đ•ôłáŠ1, “ě@ŽŒŤ2, –öŕV’q‹`2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, “ŒžŠ‘ĺ‹P2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć27‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠwpW‰ď (CVIT 2018) (2018/8/2), _ŒË.

723170. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ACSŠłŽŇ‚É‚¨‚Ż‚éŒľŠiŽ‰ŽżŠÇ—. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć27‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠwpW‰ď (CVIT 2018) (2018/8/2), _ŒË.

723171. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PCI‚̍‡•šÇ|ƒXƒeƒ“ƒgŒŒđÇ|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć27‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠwpW‰ď (CVIT 2018) (2018/8/3), _ŒË.

723172. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}ŤśS•s‘S‚̉Á—Ă’†‚É‚˝‚ą‚‚ڌ^S‹ŘÇ‚̐f’f‚ނ‚˘‚˝1—á. ‹gŕV’qŽĄ1, ’ë–ěTˆę1, [’J‰p•˝1, âV“Ą‘ĺŽ÷1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/9), ‘ĺă.

723173. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PCSK9‚đ‚Ç‚¤Žg‚¤‚Š. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/7), ‘ĺă.

723174. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –łÇŒóŤ‚É”­ŒŠ‚ł‚ę‚˝‰E–[”S‰tŽí‚Ě1—á. âV“Ą‘ĺŽ÷1, ‹gŕV’qŽĄ1, [’J‰p•˝1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć66‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2018/9/8), ‘ĺă.

723175. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EvolutR—Ż’uŽžŒă”ź‚ɃfƒoƒCƒX‚ލśŽş“ŕ‚Ƀ_ƒCƒu‚ľ‚˝Ç—á. –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ): ƒXƒgƒ‰ƒNƒ`ƒƒ[ƒNƒ‰ƒuEƒWƒƒƒpƒ“@ƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“2018 (2018/9/29), ‰ŞŽR.

723176. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Horizontal AortaÇ—á‚ɍ˝œ‰ş“Ž–ŹƒAƒvƒ[ƒ`‚ĹŽŠŒČŠg’ŁƒfƒoƒCƒX‚đ—Ż’u‚ľ‚˝ˆę—á. –ڍ•Œ’‘ž˜Y1, Š`č—Ç‘ž2, ‹´–{‘ń–í2, –k‘ş@—Ľ3, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3S‘ŸŒŒŠÇŠO): ƒXƒgƒ‰ƒNƒ`ƒƒ[ƒNƒ‰ƒuEƒWƒƒƒpƒ“@ƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“2018 (2018/9/29), ‰ŞŽR.

723177. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’፶S‹@”\‚đ’悡‚éƒtƒ@ƒ[Žl’ĽÇS“ŕC•œpŒă‰“ŠuŠú‚É”x“Ž–Ź•Ů’uŠˇp‚ɐŹŒ÷‚ľ‚˝ˆę—á. Ź”‹´r”ü1, “Ą“c“S•˝1, ‘O‘şŒ’“ń2, ‘ĺ–Ř‘ě–¤2, –îč–ƒ—R1, ’r“c—S‹B1, “ç“c@Œ’1, ŒSŽRŒbŽq1, ‘OěŒb”ü1, Ź–с@’1, ‹{’n@ŠÓ3, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3S‘ŸŒŒŠÇŠO): ‘ć22‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2018/10/11-13), “Œ‹ž.

723178. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĽ“Ž–ŹŽžŠł‚ĆƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—Ă. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć33‰ń“ú–{“œ”A•a‡•šÇŠw‰ď (2018/10/20), “Œ‹ž.

723179. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚ć‚萳í‰ť‚ľ‚˝śS‹@”\‚Ş, S–[×“Ž‚ĚÄ”­Œă‹}Œƒ‚ČÄˆŤ‰ť‚đ‚Ť‚˝‚ľ‘˝Œ^SŽş•p”‚đ‚Ť‚˝‚ľ‚˝Ž‘ąŤS–[×“Ž‚Ěˆę—á. [’J‰p•˝1, ŠÝŒ´@~1, ź‰Y@Œł2, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, źŹ“c—ş2, –xŒű@ˆ¤2, ’†‘ş—m”Í1, Î––ŹĆ1, ‹yě@~1, ŒÜ\—’ŠŢ1, ˛“Ą@—z1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć30‰ńƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2018 (2018/11/9-11), ‰Ť“ę.

723180. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LDL‚Í‚ˇ‚ׂĂ̊łŽŇ‚đ70mg/dl–˘–ž‚É‚ˇ‚é‚ׂŤ‚ž. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ARIA2018 (2018/11/23), •Ÿ‰Ş.

723181. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ“Ž–ŹŠg’Ł‚𔺂Á‚˝‘ĺ“Ž–Ź“ńë•ŮÇ—á‚Ě”DP—á. Ź”‹´r”ü1, “Ą“c“S•˝1, ‘O‘şŒ’ŽĄ2, ŒSŽRŒbŽq1, ‘OěŒb”ü1, –]ŒŽƒŽq3, ŠC–ěM–ç3, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŽY‰Č): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723182. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽOë•Ů’uŠˇpŒă‚ÉŠĚ•s‘S‚Ě‹}Ť‘ˆŤ‚đ”F‚ß‚˝ƒGƒuƒXƒ^ƒCƒ“•a‚Ěˆę—á. “Ą“c“S•˝1, Ź”‹´r”ü1, Î––ŹĆ1, ‘OěŒb”ü1, ŒSŽRŒbŽq1, •Ÿź‘ô^2, âV–؍G•ś3, ‹{–{—˛Ži2, ćčG–ž3,4, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO, 3ŹŽ™, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723183. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –ĺ–Źˆł˜´iÇ‚đ‡•š‚ľ‚˝S“ŕC•œpŒăƒtƒ@ƒ[Žl’ĽÇ‚̐isŤŒŒs“Ž‘Ô‘ˆŤ‚ɑ΂ˇ‚鎥—Ð헪‚đ”@‰˝‚ɍl‚Ś‚é‚Š? “Ą“c“S•˝1, Ź”‹´r”ü1, ‘OěŒb”ü1, ŒSŽRŒbŽq1, ‹{–{—˛Ži2, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723184. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ES–[“ŕ‚É–Œ—l\‘˘•¨‚đ”F‚ß‚˝“ńŽŸEŒ^S–[’†ŠuŒ‡‘šÇ‚Ěˆę—á. ŒSŽRŒbŽq1, Ź”‹´r”ü1, ‘OěŒb”ü1, “Ą“c“S•˝1, ‹{–{—˛Ži2, –k‘ş@—Ľ2, ‹{’n@ŠÓ2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723185. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –Ťœ‘Ť”’ŒŒ•a‚Ć”x“Ž–ŹŤ”x‚ŒŒˆł‚đ‡•š‚ľ‚˝ƒtƒ@ƒ[Žl’ĽÇpŒă‚Ěˆę—á. ‘O‘şŒ’ŽĄ1, Ź”‹´r”ü1, “Ą“c“S•˝1, ŒSŽRŒbŽq1, ‘OěŒb”ü1, âV–؍G•ś2, ‹{–{—˛Ži3, ‹{’n@ŠÓ3, ćčG–ž2,4, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2ŹŽ™, 3S‘ŸŒŒŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723186. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Early Safety and Efficacy of SAPIEN 3 20 mm Transcatheter Heart Valve Implantation (ŒoƒJƒe[ƒeƒ‹“Iś‘Ě•ŮSapien3 20mm•Ů‚Ě‘Šú‚̐ŹŃ). –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ): PCR Tokyo valves 2019 (2019/2/16), “Œ‹ž.

731026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ĺ‹ß‚Ě•sŽ–ŹŽĄ—Á|–ň•¨ŽĄ—Ă‚ĚˆĘ’u‚Ă‚Ż|. ’ë–ěTˆę (zŠÂŠí“ŕ): The 4th Circle of Lifestyle Related Diseases (2018/4/18), ěč.

731027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) S–[×“Ž‚̍RŒŒđŽĄ—Á|‘ć4‚ĚNOAC‚đŒ}‚Ś‚˝—Տ°Œťę‚Ě‘I‘đ|. ’ë–ěTˆę (zŠÂŠí“ŕ): ˆę‹{“ŕ‰Čˆă‰ďŠwpu‰‰‰ď (2018/7/21), –źŒĂ‰Ž.

731028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) S–[×“Ž‚̍RŒŒđŽĄ—Ă-‘ć4‚ĚNOAC‚đŒ}‚Ś‚˝—Տ°Œťę‚Ě‘I‘đ-. ’ë–ěTˆę (zŠÂŠí“ŕ): ˛“yŒ´’n‹ćˆăŽt‰ďŠwpu‰‰‰ď (2018/9/19), ‹{č.

731029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) S–[×“Ž‚Ě–ň•¨ŽĄ—Á|ƒAƒbƒvƒXƒgƒŠ[ƒ€‚̍čl‚đŠÜ‚߂ā|. ’ë–ěTˆę (zŠÂŠí“ŕ): •sŽ–Ź Up to Date 2018 in ç—t (2018/10/26), ç—t.

733068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Optimal PCI and Medical Therapy. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‹ß‹ESŒŒŠÇŽĄ—ĂƒWƒ‡ƒCƒ“ƒgƒ‰ƒCƒu (KCJL) 2018 (2018/4/14), ‘ĺă.

733069. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ACSŠłŽŇ‚É‚¨‚Ż‚éŒľŠiŽ‰ŽżŠÇ—. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć248‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/6/9), “Œ‹ž.

733070. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) S–[×“Ž‚đ‡•š‚ľ‚˝ŠĽ“Ž–ŹŽžŠłŠłŽŇ‚̍RŒŒđ—Ă–@‚đ‚ǂ̂悤‚ɍl‚Ś‚é‚Š? ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć25‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ď (CVIT) ’†‘EŽl‘’n•ű‰ď (2018/9/1), ‰ŞŽR.

733071. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠĽ“Ž–ŹáŽ‚Ö‚Ěprimary PCI‚É‚Ä’˜–ž‚Čmalapposition‚đ‚Ť‚˝‚ľ‚˝ˆę—á. ˛“ĄL—m, “ě@ŽŒŤ1, Î“cO‹B, ‰ş•lF˜Y1, “ŒžŠ‘ĺ‹P1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć53‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/10/20), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110012. [Œ´’˜] A High Level of Blood Urea Nitrogen Is a Significant Predictor for In-hospital Mortality in Patients with Acute Myocardial Infarction. Horiuchi Y1, Aoki J1, Tanabe K1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Yasuda S1, Noguchi T1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Uematsu M1, Hirata K1, Shibata Y1, Nakai M1, Nishimura K1, Miyamoto Y1, Ishihara M1 (1J-MINUET investigators): Int Heart J 2018/3; 59 (2): 263-71. (ˆ˘ŒĂĆ1,2: 2zŠÂŠí“ŕ)

H29-540006. [‚ť‚Ě‘ź (ƒRƒƒ“ƒg)]yV•x˜_•ś‚ɑ΂ˇ‚éEditorial CommentzS‹ŘŠQ—á‚É‚¨‚Ż‚éR•sŽ–Ź–ň‚ĚĂ•sŽ–Źě—p. ’ë–ěTˆę (zŠÂŠí“ŕ): S‘Ÿ 2018/1; 50 (1): 88-9.

[’˜@‘]

H29-620001. [Šwp‘ (•Ş’SŽˇ•M)]yICDECRT‚̍l‚Ś•ű, Žg‚˘•űz5 ŠÇ—EŒo‰ßŠĎŽ@@…B—Տ°ă‚Ěƒ|ƒCƒ“ƒgQ&A@Q1 ”ńŽ‘ąŤSŽş•p” (NSVT) ‚ĚŠÇ—@Answer…@, p.189. Q2?‹šŠs“ŕƒCƒ“ƒs[ƒ_ƒ“ƒXƒ‚ƒjƒ^ (OptiVol) ‚Ě“ÁŤ‚ĆŠˆ—p–@@Answer…@, p.192. Q3 “úíśŠˆ‚Ć’ˆÓŽ–€@Answer…@, p.195. ’ë–ěTˆę (zŠÂŠí“ŕ), •Ň: ´…ş•F, ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-713002. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) 6 Months vs. 18 Months DAPT: NIPPON Trial. Ako J1: KSIC2018 (2018/1/13), Seoul, Korea. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

H29-721001. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ACHDSƒGƒR[@up to date ‘ĺ“Ž–Ź•Ů‹ˇó‚Ć”DP‚ƐSƒGƒR[. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć20‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2018/1/28), “Œ‹ž.

H29-723004. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Dual Antithrombotic Therapy withDabigatran after PCI for Atrial Fibrillation:
East Asian and JapaneseSubgroup Analysis of RE-DUAL PCI Trial. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć82‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2018/3/24), ‘ĺă.


_Œo“ŕ‰ČŠw

[Šwp˜_•ś]

110160. [Œ´’˜] Novel De Novo KCND3 Mutation in a Japanese Patient with Intellectual Disability, Cerebellar Ataxia, Myoclonus, and Dystonia. Kurihara M, Ishiura H, Sasaki T, Otsuka J, Hayashi T, Terao Y, Matsukawa T, Mitsui J, Kaneko J1, Nishiyama K1, Doi K, Yoshimura J, Morishita S, Shimizu J, Tsuji S: Cerebellum 2018/4; 17 (2): 237-42. (‹ŕŽq~‘ž˜Y1, źŽR˜a—˜1: 1_Œo“ŕ)

110161. [Œ´’˜] Pathological and immunoblot analysis of phosphorylated TDP-43 in sporadic amyotrophic lateral sclerosis with pallido-nigro-luysian degeneration. Uchino A1, Ogino M, Takahashi-Fujigasaki J, Oonuma S, Kanazawa N2, Kajita S3, Ichinoe M3, Hasegawa M, Nishiyama K1, Murayama S: Neuropathology 2018/4; 38 (2): 171-8. (“ŕ–쏲Žq1, ‹ŕŕV’ź”ü2, Š“cç”ü”T3, ˆęŒËš–ž3, źŽR˜a—˜1: 1_Œo“ŕ, 2•a‘ԁEf—ĂŒn, 3•a—)

110162. [Œ´’˜] Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Spatola M, Sabater L, Planagumˆ J, Mart’nez-Hernandez E, ArmanguŽ T, PrŸss H, Iizuka T1, Capar— Oblitas RL, Antoine JC, Li R, Heaney N, Tubridy N, Munteis Olivas E, Rosenfeld MR, Graus F, Dalmau J: Neurology 2018/5; 90 (22): e1964-72. (”Ń’Ë‚_1: 1_Œo“ŕ)

110163. [Œ´’˜] Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation - SAMURAI-NVAF Study. Yoshimura S1, Koga M1, Sato S1, Todo K1, Yamagami H1, Kumamoto M1, Itabashi R1, Terasaki T1, Kimura K1, Yagita Y1, Shiokawa Y1, Kamiyama K1, Okuda S1, Okada Y1, Takizawa S1, Hasegawa Y1, Kameda T1, Shibuya S1, Nagakane Y1, Ito Y1, Matsuoka H1, Takamatsu K1, Nishiyama K1,2, Fujita K1, Kamimura T1, Ando D1, Ide T1, Yoshimoto T1, Shiozawa M1, Matsubara S1, Yamaguchi Y1, Kinoshita N1, Matsuki T1, Takasugi J1, Tokunaga K1, Higashida K1, Homma K1, Kario K1, Arihiro S1, Toyoda K1 (1SAMURAI Study Investigators): Circ J 2018/6; 82 (7): 1935-42. (źŽR˜a—˜1,2: 2_Œo“ŕ)

110164. [Œ´’˜] Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders: 190 cases. Kaneko J1, Kanazawa N2, Tominaga N, Kanekoa A, Suga H1, Usui R1, Ishima D1, Kitamura E1, Akutsu T1, Yoshida K, Nishiyama K1, Iizuka T1: J Neurol Sci 2018/7; 390: 26-32. (‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, {‰ę—TŽ÷1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, –k‘ş‰p“ń1, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1, ”Ń’Ë‚_1: 1_Œo“ŕ, 2•a‘ԁEf—ĂŒn)

110165. [Œ´’˜] Prodromal headache in anti-NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity. Tominaga N1, Kanazawa N2, Kaneko A1, Kaneko J1, Kitamura E1, Nakagawa H, Nishiyama K1, Iizuka T1: Brain Behav 2018/7; 8 (7): e01012. (•x‰i“Ţ•Ű”ü1, ‹ŕŕV’ź”ü2, ‹ŕŽq@Œú1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, źŽR˜a—˜1, ”Ń’Ë‚_1: 1_Œo“ŕ, 2•a‘ԁEf—ĂŒn)

110166. [Œ´’˜] The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial. Oki R1, Izumi Y1, Nodera H1, Sato Y1, Nokihara H1, Kanai K1, Sonoo M1, Urushitani M1, Nishinaka K1, Atsuta N1, Kohara N1, Shimizu T1 Kikuchi H1, Oda M1, Ikeda K1, Nagai M1,2, Komai K1, Kojima Y1, Kuzume D1, Isose S1, Shimohama S1, Abe K1, Ito H1, Noda K1, Ishihara T1, Morita M1, Shimohata T1, Teramukai S1, Kagimura T1, Noma K1, Yanagawa H1, Kuwabara S1, Kaji R1 (1JETALS): JMIR Res Protoc 2018/12; 7 (12): e12046. (‰iˆä^‹MŽq1,2: 2_Œo“ŕ)

110167. [Œ´’˜] Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation. Tokunaga K1, Koga M1, Itabashi R1, Yamagami H1, Todo K1, Yoshimura S1, Kimura K1, Sato S1, Terasaki T1, Inoue M1, Shiokawa Y1, Takagi M1, Kamiyama K1, Tanaka K1, Takizawa S1, Shiozawa M1, Okuda S1, Okada Y1, Kameda T1, Nagakane Y1, Hasegawa Y1, Shibuya S1, Ito Y1, Matsuoka H1, Takamatsu K1, Nishiyama K1,2, Kario K1, Yagita Y1, Fujita K1, Ando D1, Kumamoto M1, Arihiro S1, Toyoda K1 (1SAMURAI Study Investigators): J Am Heart Assoc 2019/2; 8 (3): e010593. (źŽR˜a—˜1,2: 2_Œo“ŕ)

522047. [uŔ]y“ÁW: ’†•_ŒoŒn’E‘ŽžŠł‚ĚĹ‘Oü|RMOGR‘Ě‚ĚŠÖ—^‚đl‚Ś‚ézRMOGR‘ĚŠÖ˜AŽžŠł@—Տ°‘œ: ‘ź‚ĚŽŠŒČR‘Ě‚Ć‚Ě•š‘ś—á. ”Ń’Ë‚_ (_Œo“ŕ): Clinical Neuroscience 2018/11; 36 (11): 1356-8.

522048. [uŔ]y‘ć35‰ń“ú–{_ŒoŽĄ—ĂŠw‰ď‘‰ď“ÁW1zƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒŒƒNƒ`ƒƒ[: ŽŠŒČ–ƉuŤ”]‰Š‚É‚¨‚Ż‚鑁Šúf’f‚Ć‘ŠúŽĄ—Ă‚Ěd—vŤ. ”Ń’Ë‚_ (_Œo“ŕ): _ŒoŽĄ—ĂŠw 2018/12; 35 (3): 231-6.

540016. [‚ť‚Ě‘ź (’Z•ń)] ‰Â‹tŤ”]ŒŒŠÇškÇŒóŒQ‚đ‡•š‚ľ, ‚­‚ŕ–Œ‰şoŒŒ‚Ć”][Ç‚đ“ŻŽž”­Ç‚ľ‚˝ś‘O‘ĺ”]“Ž–Ź‰đ—Ł‚Ě1—á. ‰Oˆä@—É1, ˆ˘‹v’Ă“ń•v1, ˆä“‡‘ĺ•ă1, –k‘ş‰p“ń1, ‹ŕŽq~‘ž˜Y1, ’†‘şŠ˛ş, –ö“c“ÖŽq1, ‹ŕŽq@Œú1, ‹ß“Ą—TŽq, {‰ę—TŽ÷1, ‚‹´˜aš, ‰iˆärs1, ŽR–{‘ĺ•ă1, źŽR˜a—˜1 (1_Œo“ŕ): ”]‘˛’† 2019/3: 41 (2): 120-3.

[Šw‰ďEŒ¤‹†‰ď“™]

713084. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Clinical findings, IgG subclass, and antibody effects in encephalitis associated with metabotropic glutamate receptor 5 (mGluR5) antibodies. Spatola M, Sabater L, Planaguma J, Iizuka T1, Pruss, Martinez Hernandez E, Armangue T, Rosenfeld MR, Graus F, Dalmau J: The 70th Annual AAN Annual Meeting (2018/4/26), Los Angeles, USA. (”Ń’Ë‚_1: 1_Œo“ŕ)

722046. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) ŽŠŒČ–ƉuŤ”]‰Š‚Ě—Ő°ƒXƒyƒNƒgƒ‰ƒ€‚ĚŠg‚Ş‚č: ŽŠŒČ–ƉuŤ”]‰Š‚É‚¨‚Ż‚鎊ŒČR‘Ě‚Ć—Ő°‘œ‚ĚƒI[ƒo[ƒrƒ…[. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23), ŽD–y.

722047. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) International Education Course: Movement Disorders in General Neurology. 2. Movement disorders in autoimmune diseases. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/24), ŽD–y.

722048. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒVƒ“ƒ|ƒWƒEƒ€: ‚Ä‚ń‚Š‚ńŤŽžŠł‚Ć‹~‹}@2. Cryptogenic NORSE‚ĚŽžŠłŠT”OC•a‘ԁCŽĄ—Ă. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć32‰ń“ú–{_Œo‹~‹}Šw‰ďŠwpW‰ď (2018/6/30), ‘Š–ÍŒ´.

722049. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹}Ť”­ěŤ‚ĚˆŮí‰^“ŽÇ: RNMDAŽó—e‘Ě”]‰Š‚¨‚ć‚Ń‚ť‚̗މŽžŠł‚É‚¨‚Ż‚éˆŮí‰^“Ž‚Ě—Ő°ÇŒó. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć12‰ńƒp[ƒLƒ“ƒ\ƒ“•aE‰^“ŽáŠQŽžŠłƒRƒ“ƒOƒŒƒX (2018/7/5), ‹ž“s.

722050. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒVƒ“ƒ|ƒWƒEƒ€3: –ƉuŤ_ŒoŽžŠł‚Ěemerging topicsuŽŠŒČ–ƉuŤ”]‰Š‚Ě‘˝—lŤv. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć30‰ń“ú–{_Œo–ƉuŠw‰ďŠwpW‰ď (2018/9/21), ŒSŽR.

722051. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’m‚Á‚Ä‚¨‚Ť‚˝‚˘”]‰Š‚ĆŽŠŒČR‘Ě‚ÉŠÖ‚ˇ‚铤’mŽŻ. ”Ń’Ë‚_ (_Œo“ŕ): ‘ć36‰ń“ú–{_ŒoŽĄ—ĂŠw‰ďŠwpW‰ď (2018/11/25), “Œ‹ž.

722052. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”]‘˛’†‚Ěˆâ“`ŠwAŠó­‚Č”]ŒŒŠÇáŠQFMELAS‚Ě”]‘˛’†—l”­ě‚Ě‘˝—lŤF‚ť‚Ě—Ő°“I“Á’Ľ‚Ć•a‘Ԑś— ”Ń’Ë‚_ (_Œo“ŕ): ‘ć44‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (2019/3/22), ‰Ą•l.

723187. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis. ‹ŕŽq@Œú1, ”Ń’Ë‚_1, ‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, {‰ę—TŽ÷1, •x‰i“Ţ•Ű”ü1, ˆä“‡‘ĺ•ă1, –k‘ş‰p“ń1, Hattori K, Ugawa Y, Kuzume D, źŽR˜a—˜1 (1_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23), ŽD–y.

723188. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) OPTNˆâ“`Žq•ĎˆŮ‚É‚ć‚éALS-FTD‚ĚŽo–…—á. ě˜Q@•ś1, ‰iˆä^‹MŽq1, –ö“c“ÖŽq2, ‹ŕŕV’ź”ü3, ŽOŽ}@M4, źŽR˜a—˜1 (1_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a‘ԁEf—ĂŒn, 4•a—): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23), ŽD–y.

723189. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éRHMGCRR‘Ě—zŤ‰óŽ€Ťƒ~ƒIƒpƒ`[4—á‚Ě—Uˆö‚Ć—Ő°‘œ‚ĚŒŸ“˘. ´…’G, ‰iˆä^‹MŽq1, ‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, •x‰i“Ţ•Ű”ü1, ě˜Q@•ś1, ˆ˘‹v’Ă“ń•v1, ”Ń’Ë‚_1, ź–ěˆęŽO, źŽR˜a—˜1 (1_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23), ŽD–y.

723190. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RNMDAŽó—e‘̍R‘Ě‚ĆRMOGR‘Ě‚ ‚邢‚͍RAQP4R‘Ě‚Ěd•Ą‚ľ‚˝4—á‚Ě—Ő°“IŒŸ“˘. ‹ŕŽq~‘ž˜Y1, ”Ń’Ë‚_1, ‹ŕŽq@Œú1, •x‰i“Ţ•Ű”ü1, ‹ŕŕV’ź”ü2, Š‹–Ú‘ĺ•ă, •ŒŠ—S”üŽq, ‰Fě‹`ˆę, źŽR˜a—˜1 (1_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/24), ŽD–y.

723191. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”]’ę“Ž–Ź‚Ě‹ˇó•”ˆĘ‚ÉŠÖ‚ˇ‚é•úŽËüŠw“IŒŸ“˘. ˆ˘‹v’Ă“ń•v1, ˛“Ą@—I1, ˆ˘•”—L‹N1, {‰ę—TŽ÷1, ‹ŕŽq@Œú1, ‰iˆärs1, ‚‹´˜aš2, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ´…’G, ‹ŕŽq~‘ž˜Y1, –{‹˝@—I1, –k‘ş‰p“ń1, ”Ń’Ë‚_1, źŽR˜a—˜1 (1_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/24), ŽD–y.

723192. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}ŤŠú”]oŒŒ‚ɍ‡•š‚ˇ‚é‹}ŤŠú–łÇŒóŤ”][Ç‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‰iˆärs1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ´…’G, ‹ŕŽq~‘ž˜Y1, –{‹˝@—I1, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1_Œo“ŕ): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/24), ŽD–y.

723193. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Autoimmune neurological disorders with antibodies against neuronal cell surface antigens: 54 cases. ”Ń’Ë‚_1, ‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, •x‰i“Ţ•Ű”ü1, ‹ŕŽq@Œú1, {‰ę—TŽ÷1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, –k‘ş‰p“ń1, źŽR˜a—˜1 (1_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/25), ŽD–y.

723194. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) IL-6 may not be involved in altered cortical susceptibility to CSD in Zucker fatty rat. –k‘ş‰p“ń1, ”Ń’Ë‚_1, ‹ŕŕV’ź”ü2, źŽR˜a—˜1 (1_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23-26), ŽD–y.

723195. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”­Ç4.5ŽžŠÔˆČ“ŕ‚Ě‘O•űzŠÂŒnŽĺŠ˛”]“Ž–Ź•ÂÇÇ‚ɑ΂ˇ‚錌đ‰ńŽű—Ă–@’P“Ć‚Ě—LŒřŤ. –Ř‘ş•śŤ1, {‰ę—TŽ÷1, ‹ŕŽq@Œú1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ‹ŕŽq~‘ž˜Y1, –{‹˝@—I1, ´…’L, –k‘ş‰p“ń1, ˆ˘‹v’Ă“ń•v1, ŽR–{‘ĺ•ă2, źŽR˜a—˜1 (1_Œo“ŕ, 2”]ŠO): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23-26), ŽD–y.

723196. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RAch-RR‘Ě—zŤdÇ‹Ř–ł—͏ǂɂ¨‚Ż‚éR‘̉ż‚Ć—Ő°Çó‚Ě‘ŠŠÖŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. –{‹˝@—I1, {‰ę—TŽ÷1, ‹ŕŽq@Œú1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1_Œo“ŕ): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23-26), ŽD–y.

723197. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DOAC“ŕ•ž’†‚É”­Ç‚ľ‚˝SŒ´Ť”]ÇđÇ‚Ě—\Œă‚ĚŒŸ“˘. ˛“Ą@—I1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, –k‘ş‰p“ń1, ŽR–{‘ĺ•ă2, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1_Œo“ŕ, 2”]ŠO): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/23-26), ŽD–y.

723198. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘Šú‚ÉCryptogenic NORSE‚đ—\‘Ş‚ˇ‚éă‚ĹC-NORSE score‚Í—L—p‚Š? ‹ŕŽq@Œú1, ”Ń’Ë‚_1, ‹ŕŽq~‘ž˜Y1, Ź–ěŕV—T–ç2, ‹ŕŕV’ź”ü3, źŽR˜a—˜1 (1_Œo“ŕ, 2—ŐŒŸ•”, 3•a‘ԁEf—ĂŒn): ‘ć30‰ń“ú–{_Œo–ƉuŠw‰ďŠwpW‰ď (2018/9/20), ŒSŽR.

723199. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RƒOƒŠƒVƒ“Žó—e‘̍R‘Ě‚đ—L‚ˇ‚éPERM‚Ě—Ő°“I“Á’Ľ‚Ć‚ť‚Ě•a‘Ô: 3—á•ń. ‹ŕŽq~‘ž˜Y1, ”Ń’Ë‚_1, ˆ˘•”—L‹N1, ‹ŕŽq@Œú1, {‰ę—TŽ÷1, •x‰i“Ţ•Ű”ü1, Ź–ěŕV—T–ç2, ‹ŕŕV’ź”ü3, źŽR˜a—˜1 (1_Œo“ŕ, 2—ŐŒŸ•”, 3•a‘ԁEf—ĂŒn): ‘ć30‰ń“ú–{_Œo–ƉuŠw‰ďŠwpW‰ď (2018/9/21), ŒSŽR.

723200. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RIgLON5R‘ĚŠÖ˜AŽžŠł‚ĆŠÓ•Ę‚đ—v‚ľ‚˝MM2-Ž‹°Œ^CJD‚Ě–UŒŸ—á. –{‹˝@—I1, ”Ń’Ë‚_1, ‹ŕŽq@Œú1, {‰ę—TŽ÷1, “ŕ–쏲Žq1, ‘şŽR”É—Y, źŽR˜a—˜1 (1_Œo“ŕ): ‘ć23‰ń“ú–{_ŒoŠ´őÇŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2018/10/19-20), “Œ‹ž.

723201. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Á”­Ť”ěŒúŤd–Œ‰Š‚ɉ‹tŤ”]ŒŒŠÇškÇŒóŒQ‚đ‡•š‚ľ, —‹–—l“Ş’É‚đ’ć‚ľ‚˝1—á. –Ř‘ş•śŤ1, ˆä“‡‘ĺ•ă1, ‰Oˆä@—É1, –k‘ş‰p“ń1, ”Ń’Ë‚_1, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1_Œo“ŕ): ‘ć46‰ń“ú–{“Ş’ÉŠw‰ď‘‰ď (2018/11/16), _ŒË.

723202. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ěŒúŤd–Œ‰Š‚É‚¨‚Ż‚錌’†MMP-3‚Ě•Ď“Ž (3—á‚ĚŒŸ“˘). –k‘ş‰p“ń1, –Ř‘ş•śŤ1, ‹ŕŽq@Œú1, {‰ę—TŽ÷1, ’†‘şŠ˛ş2, ˆä“‡‘ĺ•ă1, ‹ŕŕV’ź”ü3, ”Ń’Ë‚_1, źŽR˜a—˜1 (1_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a‘ԁEf—ĂŒn): ‘ć46‰ń“ú–{“Ş’ÉŠw‰ď‘‰ď (2018/11/16-17), _ŒË.

723203. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ÄŸó—Ź—Ă–@Œă‚Ě”]’ę“Ž–Ź•ÂÇŠŽ‘SÄŠJ’ʂƐS–[×“Ž‚Ć‚ĚŠÖŒW. ˆ˘‹v’Ă“ń•v1, ‹ŕŽq@Œú1, {‰ę—TŽ÷1, ‰iˆärs1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ‹ŕŽq~‘ž˜Y1, –{‹˝@—I1, –k‘ş‰p“ń1, ”Ń’Ë‚_1, ŽR–{‘ĺ•ă2, źŽR˜a—˜1 (1_Œo“ŕ, 2”]ŠO): STROKE2019 (2019/3/22), _“ސě.

731030. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŠŒČ–ƉuŤ”]‰Š‚É‚¨‚Ż‚éf’f‚¨‚ć‚ŃŽĄ—Ïă‚Ě—ŻˆÓ“_. ”Ń’Ë‚_ (_Œo“ŕ): –ƉuŤ_ŒoŽžŠłŠwpu‰‰‰ď (2018/12/7), “Œ‹ž.

731031. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŠŒČ–ƉuŤ‚Ä‚ń‚Š‚ń‚Ć‚ť‚̗މŽžŠłFf’f‚ĆŽĄ—Ă. ”Ń’Ë‚_ (_Œo“ŕ): ‚ł‚˘‚˝‚Ü‚Ä‚ń‚Š‚ńŽĄ—Ăƒ~[ƒeƒCƒ“ƒO (2019/1/17), ‰Y˜a.

731032. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) RNMDAŽó—e‘Ě”]‰Š‚𒆐S‚Ć‚ˇ‚鎊ŒČ–ƉuŤ‚Ä‚ń‚Š‚ń, ‚¨‚ć‚ѐV‹K”­Ç“Ť‚Ä‚ń‚Š‚ńdĎŒ^”]‰Š (Cryptogenic NORSE) ‚É‚¨‚Ż‚é—Տ°E–ƉuŠw“IŒŸ“˘ <Œ¤‹†–JÜŽóÜ‹L”O•ń>. ”Ń’Ë‚_ (_Œo“ŕ): Œö‰vŕ’c–@l‚Ä‚ń‚Š‚ńŽĄ—ĂŒ¤‹†U‹ťŕ’c@‘ć30‰ńŒ¤‹†•ń‰ď (2019/3/1), ‘ĺă.

732026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Cryptogenic new-onset refractory status epilepticus (C-NORSE): R‚Ä‚ń‚Š‚ń–ňˆČŠO‚É‹}ŤŠú‚É‚Ĺ‚Ť‚é‚ą‚Ć‚Í‚Č‚˘‚Š? ”Ń’Ë‚_ (_Œo“ŕ): źĂŒ§‰›_Œo“ŕ‰Čƒlƒbƒgƒ[ƒN (2018/6/5), ŠC˜V–ź.

732027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) –ƉuŤŽžŠł‚É‚¨‚Ż‚éˆŮí‰^“Ž. ”Ń’Ë‚_ (_Œo“ŕ): •˝Ź30”N“x“ú–{_ŒoŠw‰ď“ŒŠCE–k—¤’n‹ćśŠU‹łˆçu‰‰‰ď (2019/3/3), –źŒĂ‰Ž.

733072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —ź‘¤ŤŠááىş‚‚Ĺ”­Ç‚ľ‚˝RƒOƒŠƒVƒ“Žó—e‘̍R‘Ě—zŤ‚ĚPERM‚Ě54Î’jŤ. ˆ˘•”—L‹N1, ‹ŕŽq~‘ž˜Y1, ”Ń’Ë‚_1, –k‰’‹v—Y, {‰ę—TŽ÷1, ‚‹´˜aš2, ‹ŕŽq@Œú1, źŽR˜a—˜1 (1_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć225‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2018/6/2), “Œ‹ž.

733073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ”]”玿‚É“Á’Ľ“I‚Č‰ć‘œŠŒŠ‚đŽŚ‚ł‚¸, ‘Šú‚Š‚ç_Œo‹@”\‰ń•œ‚đ”F‚ß‚˝cryptogenic NORSE‚Ě25Î—Ť—á. ”’’š“”V, ˆť–쐅Ž÷, ăŒŽ’źŽ÷, “ŕ–x@•ŕ, Žsě–퐜Žq, ”Ń’Ë‚_1, ç—tŒú˜Y (1_Œo“ŕ): ‘ć227‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2018/12/2), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723005. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TrousseauÇŒóŒQ‚ɑ΂ˇ‚ért-PAĂ’—Ă–@‚¨‚ć‚ŃŒŒŠÇ“஡—Ă‚Ě—LŒřŤ. {‰ę—TŽ÷1, ‹ŕŽq~‘ž˜Y1, ‰Oˆä@—É1, ’†‘şŠ˛ş2, –ö“c“ÖŽq2, ˆä“‡‘ĺ•ă1, ŽR–{‘ĺ•ă3, ˆ˘‹v’Ă“ń•v1, ”Ń’Ë‚_1, źŽR˜a—˜1 (1_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3”]ŠO): ‘ć43‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (STROKE2018) (2018/3/15-18), •Ÿ‰Ş.

H29-723006. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”­Ç6ŽžŠÔˆČ“ŕ‚Ě“ŕŒz“Ž–Ź•ÂÇÇ‚Ö‚ĚŒŒđ‰ńŽű—Ă–@‚É‚¨‚Ż‚éƒXƒeƒ“ƒgŒ^‚Ć‹zˆřŒ^ƒfƒoƒCƒX‚Ĺ‚Ě—\Œă‚Ě”äŠrŒŸ“˘. ˆä“‡‘ĺ•ă1, ˆ˘‹v’Ă“ń•v1, ‰Oˆä@—É1, {‰ę—TŽ÷1, ‹ŕŽq~‘ž˜Y1, ´…’G, –{‹˝@—I1, –k‘ş‰p“ń1, ‹{â˜aO2, ŽR–{‘ĺ•ă2, źŽR˜a—˜1 (1_Œo“ŕ, 2”]ŠO): ‘ć43‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (STROKE2018) (2018/3/16), •Ÿ‰Ş.

H29-723007 [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒđ‰ńŽű—Ă–@pŒă‚̉ߊҗŹ‚É‚ć‚čˆę‰ßŤ‚É‘źl‚ĚŽč’ĽŒó‚đ”F‚ß‚˝SŒ´Ť”]ÇđÇ‚Ě1Ç—á. –Ř‹–‘ń”n1, ˆä“‡‘ĺ•ă1, ‹ŕŽq@Œú1, –ö“c“ÖŽq1, ŽR–{‘ĺ•ă2, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1_Œo“ŕ, 2”]ŠO): ‘ć43‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (STROKE2018) (2018/3/15-18), •Ÿ‰Ş.


ŒŒ‰t“ŕ‰ČŠw

[Šwp˜_•ś]

110168. [Œ´’˜] Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Matsuda A1, Kawabata H1, Tohyama K1, Maeda T1, Araseki K1, Hata T1, Suzuki T1,2, Kayano H1, Shimbo K1, Usuki K1, Chiba S1, Ishikawa T1, Arima N1, Nohgawa M1, Ohta A1, Miyazaki Y1, Nakao S1, Ozawa K1, Arai S1, Kurokawa M1, Mitani K1, Takaori-Kondo A1 (1Japanese National Research Groupon Idiopathic Bone Marrow Failure Syndromes): Leuk Res 2018/11; 74: 137-43. (—é–Ř—˛_1,2: 2ŒŒ‰t“ŕ)

520007. [‘ŕ] Źl–ŤD’†‹…Œ¸­Çf—Ă‚ĚŽQĆƒKƒCƒh. ‰ĄŽR‘׋v1, ‚ŒŠş—Ç1, X@N—Y1, ˛“ĄM–ç1, —é–Ř—˛_1,2, ŒÜŠł•F1, ŹŒ´@’ź1, ‹{č‘׎i1, ÔŽi_ˆę1, ç—t@Ž 1 (1“ú–{ˆă—ĂŒ¤‹†ŠJ”­‹@\E“ŤŽžŠłŽŔ—p‰ťŒ¤‹†Ž–‹ĆuŹl–ŤD’†‹…Œ¸­Ç‚̐f—ĂƒKƒCƒhƒ‰ƒCƒ“ěŹ‚ÉŒü‚Ż‚˝—\Œă’ǐՒ˛¸vŒ¤‹†”Ç, 2ŒŒ‰t“ŕ): —Տ°ŒŒ‰t 2018/7; 59 (7): 845-57.

521004. [‰đŕ] MDS‚ĆCMML‚ɑ΂ˇ‚éƒAƒUƒVƒ`ƒWƒ“EƒŒƒiƒŠƒhƒ~ƒh•š—p—Ă–@. –x•Ä—Cˆę1, —é–Ř—˛_1 (1ŒŒ‰t“ŕ): ŒŒ‰t“ŕ‰Č 2018/5; 76 (5): 694-9.

522049. [uŔ]y“ÁW: —Տ°ŒŒ‰tŠw|ĹVî•ń‚ƍĄŒă‚Ě“W–]2018 (ÔŒŒ‹…ŒnŽžŠł)z|ƒI[ƒo[ƒrƒ…[. —é–Ř—˛_ (ŒŒ‰t“ŕ): —Տ°ŒŒ‰t 2018/6; 59 (6): 701-2.

522050. [uŔ]y“ÁW: “KŘ‚Č•nŒŒf—Ă‚Ěƒ|ƒCƒ“ƒgzę–ĺˆă‚ÉĐ‰î‚ˇ‚ׂŤ•nŒŒ|Đ‰î‚ˇ‚ׂŤƒ^ƒCƒ~ƒ“ƒO‚ĆŠÓ•ĘŒŸ¸. —é–Ř—˛_ (ŒŒ‰t“ŕ): “ú–{ˆăŽt‰ďŽGŽ 2018/7; 147 (4): 713-7.
2018/7

522051. [uŔ]y“ÁW ÔŒŒ‹…‘˘ŒŒ‚ĚƒƒJƒjƒYƒ€‚Ć‚ť‚ĚˆŮí|Ĺ‹ß‚̐i•ŕ|z9. Œă“VŤˆâ“`Žq•ĎˆŮ‚É‚ć‚éÔŒŒ‹…‘˘ŒŒˆŮí. —é–Ř—˛_ (ŒŒ‰t“ŕ): ŒŒ‰tƒtƒƒ“ƒeƒBƒA 2018/9; 28 (9): 1361-6.
2018/9

522052. [uŔ]y“ÁW: —AŒŒ2018|ŒŔ‚č‚ ‚鎑Œš‚đˆŔ‘S‚ɁC—LŒř‚ÉŠˆ—p‚ˇ‚é‚˝‚߂Ɂz<—AŒŒ‚É”ş‚¤’x”­Ť‚Ě—LŠQŽ–Ű>@“S‰ßčÇ. —é–Ř—˛_ (ŒŒ‰t“ŕ): “ŕ‰Č 2018/10; 122 (4): 787-92.
2018/10

522053. [uŔ]y“ÁW: œ‘ˆŮŒ`ŹÇŒóŒQiMDSj‚Ě•Ş—ŢE•a‘ԁEŽĄ—Ă‚Ć—\Œă‚ĚĹ‘Oüz4. ’჊ƒXƒNœ‘ˆŮŒ`ŹÇŒóŒQ‚ɑ΂ˇ‚鎥—Ă. —é–Ř—˛_ (ŒŒ‰t“ŕ): ŒŒ‰tƒtƒƒ“ƒeƒBƒA 2018/12; 28 (12): 1719-26.
2018/12

522054. [uŔ]y“ÁW ŒŒ‰tŽžŠł‚ĚŒŸ¸f’f‚̐i•ŕz2. •nŒŒ‚̊ӕʐf’f‚ĚŒťó. —é–Ř—˛_ (ŒŒ‰t“ŕ): ŒŒ‰tƒtƒƒ“ƒeƒBƒA 2019/3; 29 (3): 325-32.

530003. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)] 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T1, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. Renal Replacement Therapy 2017; 3: 36. DOI 10.1186/s41100-017-0114-y. (—é–Ř—˛_1: 1ŒŒ‰t“ŕ)

[’˜@‘]

620046. [Šwp‘ (•Ş’SŽˇ•M)yEBMŒŒ‰tŽžŠł‚ĚŽĄ—Ă2019-2020zII. ÔŒŒ‹…ŒnŽžŠł@7. MDS‚ɑ΂ˇ‚éV‹KŽĄ—Ă–ňŠJ”­‚ĚŒťó, p.53-7. —é–Ř—˛_ (ŒŒ‰t“ŕ), •Ň: ‹ŕ‘q@÷, –؍菹O, —é–Ř—Ľ˜N, _“c‘PL, ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/10”­s.

620047. [Šwp‘ (•Ş’SŽˇ•M)]y“§ÍŠłŽŇ‚̏d—vŒŸ¸•ŒŸ¸’l50 (“§ÍƒPƒA 2018“~‹G‘Š§)z‘ć1ÍŒŒ‰tŒŸ¸@9. –ԏóÔŒŒ‹…/•˝‹ĎÔŒŒ‹…—eĎ (MCV). p.46-9. —é–Ř—˛_ (ŒŒ‰t“ŕ), •Ň: ˆÉ’O‹V—F, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018/12”­s.

620048. [Šwp‘ (•Ş’SŽˇ•M)yĄ“ú‚̏ˆ•ű@‰ü’ů‘ć6”Łz‘ć9Í ŒŒ‰tE‘˘ŒŒŠíŽžŠł@17. ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX (“S‰ßčÇ), p.414-5. —é–Ř—˛_ (ŒŒ‰t“ŕ), •Ň: ‰Y•”ť•v, “‡“c˜aK, ě‡áÁˆę, “ě]“°, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722053. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) yWHO•Ş—Ţ2017‚̉ü’č“_-f’f‚Ö‚ĚŠˆ—p‚đ–ÚŽw‚ľ‚āz1œ‘ˆŮŒ`ŹÇŒóŒQ|f’f‚Ěƒ|ƒCƒ“ƒg|. —é–Ř—˛_ (ŒŒ‰t“ŕ): ‘ć19‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ďŠwpW‰ď (2018/7/22), ‘ĺ‹{, “ú–{ŒŸ¸ŒŒ‰tŠw‰ďŽGŽ ŒŸ¸‚ĆŒŒ‰t2019/2; 20 (1): 99-109.

723204. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Źl–ŤD’†‹…Œ¸­Ç‚Ě—\Œă’ǐՒ˛¸. ‰ĄŽR‘׋v, ŹŒ´@’ź, ŒÜŠł•F, —é–Ř—˛_1, ‚ŒŠş—Ç, ‹{úą‘׎i, ÔŽi_ˆę, ç—t@Ž  (1ŒŒ‰t“ŕ): ‘ć115‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ď (2018/4/13-15), ‹ž“s, “ú–{“ŕ‰ČŠw‰ďŽ 2018; 107 (Suppl): 219.

723205. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Characteristics of palliative home care for hematological tumors in comparison with solid tumors. ‘ĺ‹´W‘ž, Î“c@—˛1, ‰ĽçŽq2, ‘ĺ‹´Žu•Ű, ‰Ľ@‘c˝3, ‹{ř“_“ń1, —é–Ř—˛_3 (1—AŒŒE×–EˆÚA, 2t‘Ÿ“ŕ, 3ŒŒ‰t“ŕ): ‘ć80‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2018/10/12-14), ‘ĺă, —Տ°ŒŒ‰t 2018; 59 (9): 406 (1540).

723206. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MCV and reticulocyte count at diagnosis predict prognosis of MDS patients with low blast percentages. ě’[@_, ‰P‹nŒ›—S, V“°^‹I, ’ĘŽR@ŒO, ź“c@W, rŠÖ‚Š‚â‚Ě, ”g‘˝’qŽq, —é–Ř—˛_1, Š–ěGˆę, V•Ű@Œh, ç—t@Ž , Îě—˛”V, –k–ěrs, ’źě‹§°, ‹{č‘׎i, •ě•ô•v, rˆär–ç, ŽO’JŒŚŽq, ‚ÜWŽj (1ŒŒ‰t“ŕ): ‘ć80‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2018/10/12-14), ‘ĺă, —Տ°ŒŒ‰t 2018; 59 (9): 456 (1590).

723207. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A nation-wide study of adult chronic neutropenia in Japan: 2nd report. ‰ĄŽR‘׋v, ŹŒ´@’ź, ŒÜŠł•F, —é–Ř—˛_1, ‚ŒŠş—Ç, ‹{č‘׎i, ÔŽi_ˆę, ç—t@Ž  (1ŒŒ‰t“ŕ): ‘ć80‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2018/10/12-14), ‘ĺă, —Տ°ŒŒ‰t 2018; 59 (9): 492 (1626).

723208. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Expression of adhesion molecules in intravascular lymphoma: histopathological review of our cases. Ź‘qTŽi1, H’JšŽj2, –x•Ä—Sˆę1, ‹g“c@Œ÷2, ‰Ľ@‘c˝1, “cŽ›”͍s1, Î“c@—˛3, “š‰ş—Y‰î1, ‰ĄŽR^Šě1, Š™“c_–Ť1, ‹{ř“_“ń3, ‘ş‰_–FŽ÷2, —é–Ř—˛_1 (1ŒŒ‰t“ŕ, 2•a—, 3—AŒŒE×–EˆÚA): ‘ć80‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2018/10/12-14), ‘ĺă, —Տ°ŒŒ‰t 2018; 59 (9): 521 (1655).

733074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —ŹŽY‚đŒ_‹@‚É”­Ç‚ľ‚˝TAFRO-like SLE‚Ě1—á. “š‰ş—Y‰î1, ‰Ľ@‘c˝1, ]”¨Wˆę1, ‰HŽRŒdˆČ2, –x•Ä—Cˆę1, ‰ĄŽR^Šě1, “cŽ›”͍s1, Î“c@—˛3, Š™“c_–Ť1, ‹{ř“_“ń3, —é–Ř—˛_1 (1ŒŒ‰t“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—AŒŒE×–EˆÚA): ‘ć9‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/7/14), Š‘ň, —Տ°ŒŒ‰t 2018; 59 (11): 2504.

733075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒCƒuƒ‹ƒ`ƒjƒu“Š—^’†‚ÉŒJ‚č•Ô‚ľ’ÜŽüˆÍ‰Š, “÷‰čŒ`Ź‚đ‚Ť‚˝‚ľ, RśÜŽĄ—Âʼnü‘P‚ľ‚˝Ç—á. ]”¨Wˆę1, Î“c@—˛2, “š‰ş—Y‰î1, ‰HŽRŒdˆČ3, –x•Ä—Cˆę1, “cŽ›”͍s1, Š™“c_–Ť1, ‰Ľ@‘c˝1, –x]—Lję4, ‹{úą_“ń2, —é–Ř—˛_1 (1ŒŒ‰t“ŕ, 2—AŒŒE×–EˆÚA, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/3/23), “Œ‹ž, —Տ°ŒŒ‰t 2019; 60 (5): 537.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-732002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) MDS‚Ě•a‘ԂƐf—Á|Ĺ‹ß‚Ě˜b‘č|. —é–Ř—˛_ (ŒŒ‰t“ŕ): ‘ć125‰ń“ú–{ŒŒ‰tŠw‰ď“Œ–k’n•ű‰ď (2018/2/18), ĺ‘ä.


ŒÄ‹zŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110169. [Œ´’˜] Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. Yagasaki K, Komatsu H, Soejima K, Naoki K1, Kawada I, Yasuda H, Hamamoto Y: Asia Pac J Oncol Nurs 2018/4-6; 5 (2): 172?7. (—P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110170. [Œ´’˜] Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma. Kobayashi M, Nagashio R1, Saito K, Aguilar-Bonavides C, Ryuge S2, Katono K2, Igawa S2, Tsuchiya B1, Jiang SX, Ichinoe M3, Murakumo Y3, Saegusa M3, Satoh Y4, Sato Y1: Hum Pathol 2018/4; 74: 148-55. (’ˇ‰–@—ş1, —´‰ŘTˆę˜Y2, ă‰“–ěŒ’2, ˆäě@‘2, “y‰Žg1, ˆęŒËš–ž3, ‘ş‰_–FŽ÷3, ŽOŽ}@M3, ˛“Ą”Vr4, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2ŒÄ‹zŠí“ŕ, 3•a—, 4ŒÄ‹zŠíŠO)

110171. [Œ´’˜] Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Kobayashi K1, Nakachi I1, Naoki K1,2, Satomi R1, Nakamura M1, Inoue T1, Tateno H1, Sakamaki F1, Sayama K1, Terashima T1, Koh H1, Abe T1, Nishino M1, Arai D1, Yasuda H1, Kawada I1, Soejima K1, Betsuyaku T1 (1Keio Lung Oncology Group (KLOG)): Clin Lung Cancer 2018/5; 19 (3): e349-58. (—P–؍Ž•F1,2: 2ŒÄ‹zŠí“ŕ)

110172. [Œ´’˜] Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. Fukui T1, Okuma Y1, Nakahara Y1, Otani S1, Igawa S1, Katagiri M2, Mitsufuji H3, Kubota M1, Hiyoshi Y1, Ishihara M1, Kasajima M1, Sasaki J1,4, Naoki K1: Clin Lung Cancer 2018/5. pii: S1525-7304(18)30103-7. (•Ÿˆä•ü–ç1, ‘ĺŒF—F—œŽq1, ’†Œ´‘P˜N1, ‘ĺ’JçŽq1, ˆäě@‘1, •Đ‹Ë^l2, ŽO“Ą@‹v3, ‹v•Ű“cŸ1, “ú‹gNO1, ÎŒ´–˘ŠóŽq1, Š}“‡^Žu1, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110173. [Œ´’˜] Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer. Yanagita K, Nagashio R1, Jiang SX, Kuchitsu Y, Hachimura K1, Ichinoe M2, Igawa S3, Fukuda E, Goshima N, Satoh Y4, Murakumo Y2, Saegusa M2, Sato Y1: Am J Pathol 2018/6; 188 (6): 1328-33. (’ˇ‰–@—ş1, ”Ť‘ş˜a’j1, ˆęŒËš–ž2, ˆäě@‘3, ˛“Ą”Vr4, ‘ş‰_–FŽ÷2, ŽOŽ}@M2, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2•a—, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO)

110174. [Œ´’˜] Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. Igawa S1, Shirasawa M1, Ozawa T1, Nishinarita N1, Okuma Y1, Ono T1, Sugimoto A1, Kurahayashi S1, Sugita K1, Sone H1, Fukui T1, Mitsufuji H2, Kubota M1, Katagiri M3, Sasaki J1,4, Naoki K1: Thorac Cancer 2018/8; 9 (8): 967-73. (ˆäě@‘1, ”’ŕVš”V1, ŹŕV‹M—T1, źŹ“cŮŽq1, ‘ĺŒF—F—œŽq1, Ź–ě‘ו˝1, ™–{@—•1, ‘q—ѐT‘ž˜Y1, ™“cŒi—C1, ‘]Ş‰p”V1, •Ÿˆä•ü–ç1, ŽO“Ą@‹v2, ‹v•Ű“cŸ1, •Đ‹Ë^l3, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110175. [Œ´’˜] Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study. Sone H1, Igawa S1, Kasajima M1, Ishihara M1, Hiyoshi Y1, Hosotani S1, Ohe S1, Ito H1, Kaizuka N1, Manaka H1, Fukui T1, Mitsufuji H2, Kubota M1, Katagiri M3, Sasaki J1,4, Naoki K1: Thorac Cancer 2018/10; 9 (10): 1279-84. (‘]Ş‰p”V1, ˆäě@‘1, Š}“‡^Žu1, ÎŒ´–˘ŠóŽq1, “ú‹gNO1, ×’J^Ži1, ‘ĺ]r‘ž˜Y1, ˆÉ“ĄO‹I1, ŠL’ːéŽ÷1, ŠÔ’†”Ž–ç1, •Ÿˆä•ü–ç1, ŽO“Ą@‹v2, ‹v•Ű“cŸ1, •Đ‹Ë^l3, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110176. [Œ´’˜] Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Shirasawa M1, Fukui T1, Kusuhara S1, Hiyoshi Y1, Ishihara M1, Kasajima M1, Nakahara Y1, Otani S1, Igawa S1, Yokoba M2, Mitsufuji H3, Kubota M1, Katagiri M2, Sasaki J1,4, Naoki K1: Cancer Manag Res. 2018/11; 21 (10): 6039?47. (”’ŕVš”V1, •Ÿˆä•ü–ç1, “팴­ˆę˜Y1, “ú‹gNO1, ÎŒ´–˘ŠóŽq1, Š}“‡^Žu1, ’†Œ´‘P˜N1, ‘ĺ’JçŽq1, ˆäě@‘1, ‰Ąęł“T2, ŽO“Ą@‹v3, ‹v•Ű“cŸ1, •Đ‹Ë^l2, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110177. [Œ´’˜] Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. Igawa S1, Nishinarita N1, Takakura A1, Ozawa T1, Harada S2, Kusuhara S1, Niwa H1, Hosotani S1, Sone H1, Nakahara Y1, Fukui T1, Mitsufuji H3, Yokoba M4, Kubota M1, Katagiri M4, Sasaki J1,5, Naoki K1: Cancer Manag Res. 2018/12; 14 (10): 7013?9. (ˆäě@‘1, źŹ“cŮŽq1, ‚‘q@W1, ŹŕV‹M—T1, Œ´“c^–ç2, “팴­ˆę˜Y1, ’O‰H‰p”V1, ×’J^Ži1, ‘]Ş‰p”V1, ’†Œ´‘P˜N1, •Ÿˆä•ü–ç1, ŽO“Ą@‹v3, ‰Ąęł“T4, ‹v•Ű“cŸ1, •Đ‹Ë^l4, ˛X–ŘŽĄˆę˜Y1,5, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŠĹŒěŠw•”, 4ˆă—ÉqśŠw•”, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110178. [Œ´’˜] Postoperative pulmonary function changes according to the resected lobe: a 1-year follow-up study of lobectomized patients. Yokoba M1, Ichikawa T, Harada S2, Naito M3, Satoh Y3, Katagiri M1: J Thorac Dis 2018/12; 10 (12): 6891-902. (‰Ąęł“T1, Œ´“c^–ç2, “ŕ“Ą‰ëm3, ˛“Ą”Vr3, •Đ‹Ë^l1: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŒÄ‹zŠíŠO)

110047. [Œ´’˜] Prognostic significance of G6PD expression and localization in lung adenocarcinoma. Nagashio R1, Oikawa S, Yanagita K2, Hagiuda D2, Kuchitsu Y2, Igawa S3, Naoki K3, Satoh Y4, Ichinoe M5, Murakumo Y5, Saegusa M5, Sato Y1: Biochim Biophys Acta Proteins Proteom 2019/1; 1867 (1): 38-46. (’ˇ‰–@—ş1, –ö“cŒ›Œá2, ”‹ś“c‘ĺ‰î2, ‹€’Ă—L‹I2, ˆäě@‘3, —P–؍Ž•F3, ˛“Ą”Vr4, ˆęŒËš–ž5, ‘ş‰_–FŽ÷5, ŽOŽ}@M5, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŒÄ‹zŠí“ŕ, 4ŒÄ‹zŠíŠO, 5•a—)

110179. [Œ´’˜] Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study. Agemi Y, Shimokawa T, Sasaki J1,2, Miyazaki K, Misumi Y, Sato A, Aida S, Ishii M, Nakamura Y, Naoki K2, Okamoto H: PLoS One 2019/1; 14 (1): e0210499. (˛X–ŘŽĄˆę˜Y1,2, —P–؍Ž•F2: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ŒÄ‹zŠí“ŕ)

110180. [Œ´’˜] Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K1, Soejima K: Lung Cancer 2019/1; 127: 146-52. (—P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110181. [Œ´’˜] Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia. Shirasawa M1, Fukui T1, Kusuhara S1, Hiyoshi Y1, Nakahara Y1, Nishinarita N1, Igawa S1, Naoki K1: BMC Cancer 2019/2; 19 (1): 163. (”’ŕVš”V1, •Ÿˆä•ü–ç1, “팴­ˆę˜Y1, “ú‹gNO1, ’†Œ´‘P˜N1, źŹ“cŮŽq1, ˆäě@‘1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

310011. [Ç—á•ń] A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation. Niwa H1, Nakahara Y1, Sasaki J1,2, Masuda N1: BMJ Case Rep 2018/6; 2018. pii: bcr-2017-219770. (’O‰H‰p”V1, ’†Œ´‘P˜N1, ˛X–ŘŽĄˆę˜Y1,2, ‰v“c“TK1: 1ŒÄ‹zŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

[’˜@‘]

620049. [Šwp‘ (•Ş’SŽˇ•M)]yƒGƒrƒfƒ“ƒX‚Ɋ‚˘‚˝Šŕ‰ťŠw—Ă–@ƒnƒ“ƒhƒuƒbƒN 2018z‘ć1Í ”xŠŕ|”ńŹ×–E”xŠŕ@CDDP + CPT-11—Ă–@, p.119-21. ÎŒ´–˘ŠóŽq1, ˆäě@‘1 (1ŒÄ‹zŠí“ŕ), ‘ŠÄC: ‘ĺ’Á@“Ö, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ, ‘ĺă, 2018/6”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713085. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Phase II Study of Amrubicin Monotherapy in Elderly or Poor-Risk Patients with Extensive Disease of Small Cell Lung Cancer. Igawa S1, Fukui T1, Shirasawa M1, Ozawa T1, Sone H1, Kusuhara S1, Nishinarita N1, Hiyoshi Y1, Kubota M1, Mitsufuji H2, Sasaki J1,3, Katagiri M4, Naoki K1: The IASLC 19th World Conference on Lung Cancer (2018/9/24), Toronto, Canada. (ˆäě@‘1, •Ÿˆä•ü–ç1, ”’ŕVš”V1, ŹŕV‹M—T1, ‘]Ş‰p”V1, “팴­ˆę˜Y1, źŹ“cŮŽq1, “ú‹gNO1, ‹v•Ű“cŸ1, ŽO“Ą@‹v2, ˛X–ŘŽĄˆę˜Y1,3, •Đ‹Ë^l4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆă—ÉqśŠw•”)

713086. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Survival update in Randomized Phase II trial of S-1/Cisplatin (SP) or Docetaxel/Cisplatin (DP) with Concurrent Thoracic Radiotherapy for Inoperable Stage III NSCLC1. Takiguchi Y, Kubota K, Kishi K, Shimokawa T, Saito H, Igawa S1, Yamada K, Kato T, Okamoto H: ESMO 2018 ‘ć43‰ń‰˘B—Տ°Žîᇊw‰ď (2018/10/20), Munich, Germany. (ˆäě@‘1: 1ŒÄ‹zŠí“ŕ)

723209. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ϐŤ‰ťŒă‚̍ĐśŒŸ‘gD‚đ—p‚˘‚˝ƒNƒŠƒjƒJƒ‹ƒV[ƒNƒGƒ“ƒX‚ŞŽĄ—Ă‘I‘đ‚É—L—p‚Ĺ‚ ‚Á‚˝ALK”xŠŕ‚Ě1—á. ‘]Ş‰p”V1, •Ÿˆä•ü–ç1, ˛X–ŘŽĄˆę˜Y1,2, ’†Œ´‘P˜N1, źŹ“cŮŽq1, ™“cŒi—C1, Ź–ě‘ו˝1, âˆä˜aŽq, ź”ö˜al, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ˆăŠwśEŒ¤Cˆă‚Ě“ú–{“ŕ‰ČŠw‰ď‚ą‚Ć‚Í‚ś‚ß 2018‹ž“s (‘ć115‰ń“ú–{“ŕ‰ČŠw‰ď‘‰ďEu‰‰‰ď) (2018/4/14), ‹ž“s.

723210. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x—tŘœpŒă”xŠŕŠłŽŇ‚É‚¨‚Ż‚épŒă1”NŠÔ‚ĚŒÄ‹z‹@”\ŒŸ¸‚̉ń•œ‚ɂ‚˘‚Ä. ‰Ąęł“T1, Žsě@‹B, Œ´“c^–ç2, źŹ“cŮŽq3, ŽO“Ą@‹v4, ‹v•Ű“cŸ3, ˛“Ą”Vr5, —P–؍Ž•F3, •Đ‹Ë^l1 (1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŒÄ‹zŠí“ŕ, 4ŠĹŒěŠw•”, 5ŒÄ‹zŠíŠO): ‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2018/4/27), ‘ĺă.

723211. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‰ŠŽĄ—Ă‚É‚¨‚Ż‚éR‹Ű–ň“Š—^‚ތċC’†…‘f”Z“x‚É—^‚Ś‚é‰e‹ż. Š}“‡^Žu1, ‹v•Ű“cŸ1, ”’ŕVš”V1, ŹŕV‹M—T1, źŹ“cŮŽq1, ’†Œ´‘P˜N1, ˆäě@‘1, ‰Ąęł“T2, Ź—Ń‚ą‚¸Œb2, Ź‹v•ŰŒŞˆę2, ˛X–ŘŽĄˆę˜Y1,3, •Đ‹Ë^l2, Ź—эO—S2, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2018/4/28), ‘ĺă.

723212. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇ‚Ü‚˝‚ÍPS•s—Ç‚Č–˘ŽĄ—Ði“WŒ^Ź×–E”xŠŕ‚É‚¨‚Ż‚éAMR’PÜ‚Ě”ńƒ‰ƒ“ƒ_ƒ€‰ť‘ćII‘ŠŽŽŒą. ”’ŕVš”V1, ˆäě@‘1, Š}“‡^Žu1, ‰Ąęł“T2, •Ÿˆä•ü–ç1, ‘ĺ’JçŽq1, ÎŒ´–˘ŠóŽq1, “ú‹gNO1 źŹ“cŮŽq1, ’†Œ´‘P˜N1, ŽO“Ą@‹v3, ‹v•Ű“cŸ1, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2018/4/29), ‘ĺă.

723213. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—î‚Ü‚˝‚ÍPS•s—ǐi“WŒ^Ź×–E”xŠŕŠłŽŇ‚ɑ΂ˇ‚éƒAƒ€ƒ‹ƒrƒVƒ“’PÜ—Ă–@Œă‚Ěƒvƒ‰ƒ`ƒi•š—p—Ă–@‚É‚ć‚é2ŽŸ‰ťŠw—Ă–@‚ĚŒř‰Ę‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ”’ŕVš”V1, ˆäě@‘1, “팴­ˆę˜Y1, Œ´“c^–ç2, źŹ“cŮŽq1, ‘]Ş‰p”V1, ‘ĺŒF—F—œŽq1, Ź–ě‘ו˝1, ‘q—ѐT‘ž˜Y1, ™“cŒi—C1, Š}“‡^Žu1, ‹v•Ű“cŸ1, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć58‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2018/4/29), ‘ĺă.

723214. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EGFRˆâ“`Žq•ĎˆŮ—zŤis”ńŹ×–E”xŠŕ‚ĹT790M‘gDÄśŒŸ‰A‰e, ƒŠƒLƒbƒhƒoƒCƒvƒV[—zŤŠłŽŇ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. “팴­ˆę˜Y1, ˆäě@‘1, ”’ŕVš”V1, Š}“‡^Žu1, ÎŒ´–˘ŠóŽq1, Œ´“c^–ç2, ‘q—ѐT‘ž˜Y1, ™“cŒi—C1, •Ÿˆä’q–ç1, ŽO“Ą@‹v3, ‹v•Ű“cŸ1, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŠĹŒěŠw•”): ‘ć41‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2018/5/25), “Œ‹ž.

723215. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ťŠw—Ă–@‚â•úŽËü—Ă–@‚Ş”ńŹ×–E”xŠŕ‚ĚPD-L1”­Œť‚É‚¨‚ć‚Ú‚ˇ‰e‹ż. ’†Œ´‘P˜N1, •Ÿˆä•ü–ç1, ‘ĺŒF—F—œŽq1, ‘]Ş‰p”V1, ŽO“Ą@‹v2, ‰Ąęł“T3, •Đ‹Ë^l3, ‹v•Ű“cŸ1, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć41‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2018/5/25), “Œ‹ž.

723216. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éEGFRˆâ“`Žq•ĎˆŮ—zŤ”xŠŕ‚ĚT790MŒŸo‚É‚Ţ‚Ż‚˝‘gDÄśŒŸ‚̐ŹŃ. ÎŒ´–˘ŠóŽq1, ˆäě@‘1, ”’ŕVš”V1, ‘]Ş‰p”V1, ™–{@—•1, Œ´“c^–ç2, “팴­ˆę˜Y1, “ú‹gNO1, ‘ĺ’JçŽq1, ŽO“Ą@‹v3, ‘ş‰_–FŽ÷4, ‹v•Ű“cŸ1, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŠĹŒěŠw•”, 4•a—): ‘ć41‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2018/5/25), “Œ‹ž.

723217. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Efficacy and Risk of Chemotherapy for Extensive Disease- Small Cell Lung Cancer Patients with Interstitial Pneumonia. Ź–ě‘ו˝1, ™“cŒi—C1, ”’ŕVš”V1, •Ÿˆä•ü–ç1, “ú‹gNO1, ÎŒ´–˘ŠóŽq1, ŹŕV‹M—T1, ˆäě@‘1, ‰Ąęł“T2, ŽO“Ą@‹v3, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”): ‘ć16‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2018/7/19), _ŒË.

723218. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –˘ŽĄ—Ă‚ĚPS•s—Ç‚ŕ‚ľ‚­‚͍‚—îŽŇi“WŒ^Ź×–E”xŠŕŠłŽŇ‚Ö‚ĚƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“/ƒGƒgƒ|ƒVƒh‚ĆƒAƒ€ƒ‹ƒrƒVƒ“’PÜ‚Ě”äŠrŒŸ“˘. ŹŕV‹M—T1, ˆäě@‘1, ”’ŕVš”V1, Š}“‡^Žu1, ‘q—ѐT‘ž˜Y1, Ź–ě‘ו˝1, ‘]Ş‰p”V1, źŹ“cŮŽq1, •Ÿˆä•ü–ç1, ‹v•Ű“cŸ1, •Đ‹Ë^l2, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”): ‘ć16‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2018/7/21), _ŒË.

723219. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŽżŤ”x‰Š‡•š”ńŹ×–E”xŠŕŠłŽŇ‚Ö‚ĚƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“+ƒiƒuƒpƒNƒŠƒ^ƒLƒZƒ‹‚ɂ‚˘‚Ä‚ĚŒŸ“˘. źŹ“cŮŽq1, ˆäě@‘1, ‚‘q@W1, ‘]Ş‰p”V1, ×’J^Ži1, ‘ĺ]r‘ž˜Y1, ˆÉ“ĄO‹I1, ŠL’ːéŽ÷1, ŠÔ’†”Ž–ç1, ‘q—ѐT‘ž˜Y1, “팴­ˆę˜Y1, ’O‰H‰p”V1, ’†Œ´‘P˜N1, •Ÿˆä•ü–ç1, ‰Ąęł“T2, ŽO“Ą@‹v3, ‹v•Ű“cŸ1, ˛X–ŘŽĄˆę˜Y1,4, •Đ‹Ë^l2, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2018/11/29), “Œ‹ž.

723220. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŞŽĄ“I”xŘœp‚đŽó‚Ż‚˝”x‘BŠŕŠłŽŇ‚É‚¨‚Ż‚éŽîᇑgD’†‚ĚMitofilin”­Œť‚Ć—\Œă‚ĚŠÖ˜A. “ú‹gNO1, —´‰ŘTˆę˜Y1, ˆäě@‘1, “팴­ˆę˜Y1, ˆÉ“ĄO‹I1, ‘]Ş‰p”V1, ŽO“Ą@‹v2, ‹v•Ű“cŸ1, ˛X–ŘŽĄˆę˜Y1,3, •Đ‹Ë^l4, ˛“Ą”Vr5, ˛“Ą—Yˆę4, ‘ş‰_–FŽ÷6, ŽOŽ}@M6, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆă—ÉqśŠw•”, 5ŒÄ‹zŠíŠO, 6•a—): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď. (2018/11/29), “Œ‹ž.

723221. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EGFRˆâ“`Žq•ĎˆŮ—zŤis”ńŹ×–E”xŠŕ‚É‚¨‚Ż‚éT790M‘gDÄśŒŸ‰AŤ, ŒŒŸ÷—zŤŠłŽŇ‚ĚƒIƒVƒƒ‹ƒ`ƒjƒu—Տ°Œř‰Ę. ŠÔ’†”Ž–ç1, ÎŒ´–˘ŠóŽq1, “팴­ˆę˜Y1, ˆäě@‘1, ”’ŕVš”V1, ŹŕV‹M—T1, ŽO“Ą@‹v2, ‹v•Ű“cŸ1, ‘ş‰_–FŽ÷3, ŽOŽ}@M3, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3•a—): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2018/12/1), “Œ‹ž.

723222. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŠŕ”]“]ˆÚ•a•Ď‚ɑ΂ˇ‚éƒKƒ“ƒ}ƒiƒCƒtŽĄ—ĂŒă‚ɐ_ŒoäP‰čŽî‚đ”F‚ß‚˝ˆę—á. Šz‰ędŹ, —P–؍Ž•F1, ˆŔ“c_”V, ě“cˆę˜Y, ”öŒ´Œ’‘ž˜Y, •›“‡Œ¤‘˘, •Ę–đ’qŽq (1ŒÄ‹zŠí“ŕ): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2018/11/29-12/1), “Œ‹ž.

733076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒyƒ“ƒuƒƒŠƒYƒ}ƒu‚É‚ć‚é–ňÜŤ‰ş‚‘Ě‹@”\’ቺÇ‚đ‚Ť‚˝‚ľ‚˝”xŠŕ‚Ě2—á. ŠL’ːéŽ÷1, •Ÿˆä•ü–ç1, ”’ŕVš”V1, Ź–ě‘ו˝1, ŹŕV‹M—T1, źŹ“cŮŽq1, ˆäě@‘1, ‹v•Ű“cŸ1, —P–؍Ž•F1, ’†Œ´‘P˜N1 (1ŒÄ‹zŠí“ŕ): ‘ć643‰ń“ú–{“ŕ‰ČŠw‰ďŠÖ“Œ’n•ű‰ď (2018/7/15), “Œ‹ž.

733077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”ń“ÁˆŮ“I‚Č‰ć‘œŠŒŠ‚ć‚čˆŤŤ_ŒoŒ´ŤŽîᇂđ‹^‚Á‚˝_ŒoâŽî‚Ě1—á. ‘ĺ]r‘ž˜Y1, ”’ŕVš”V1, źŹ“cŮŽq1, ŹŕV‹M—T1, “팴­ˆę˜Y1, ÎŒ´–˘ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, •Ÿˆä•ü–ç1, ˆäě@‘1, ‹v•Ű“cŸ1, ˛X–ŘŽĄˆę˜Y1,2, •Đ‹Ë^l3, ŽO“Ą@‹v4, —P–؍Ž•F1, —с@ËŽq5, ‰–ŒŠ@˜a5, ˛“Ą”Vr5, H’JšŽj6, ŽOŽ}@M6 (1ŒÄ‹zŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ˆă—ÉqśŠw•”, 4ŠĹŒěŠw•”, 5ŒÄ‹zŠíŠO, 6•a—): ‘ć183‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2018/12/15), “Œ‹ž.

733078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”x–ěZ‰e‚̏Á‘ނƖƉuf’fŒŸ¸‚É‚ć‚čf’f‚ľ‚˝ƒgƒLƒ\ƒJƒ‰Ç‚Ěˆę—á. ×’J^Ži1, ˆÉ“ĄO‹I1, ŠL’ːéŽ÷1, ‘ĺ]r‘ž˜Y1, ŹŕV‹M—T1, •Ÿˆä•ü–ç1, ˆäě@‘1, ŽO“Ą@‹v2, ‹v•Ű“cŸ1, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”): ‘ć233‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠÖ“Œ’n•ű‰ď (2019/2/23), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110013. [Œ´’˜] Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma. Kobayashi M, Nagashio R1, Saito K, Aguilar-Bonavides C, Ryuge S2, Katono K2, Igawa S2, Tsuchiya B, Jiang SX, Ichinoe M3, Murakumo Y3, Saegusa M3, Satoh Y4, Sato Y1: Human Pathology 2018/1; 74: 148-55. (’ˇ‰–@—ş1, —ł‰ŘTˆę˜Y2, ă‰“–ěŒ’2, ˆäě@‘2, ˆęŒËš–ž3, ‘ş‰_–FŽ÷3, ŽOŽ}@M3, ˛“Ą”Vr4, ˛“Ą—Yˆę1: 1ˆă—ÉqśŠw•”, 2ŒÄ‹zŠí“ŕ, 3•a—, 4ŒÄ‹zŠíŠO)


“ŕ•Ş”ĺ‘ăŽÓ“ŕ‰ČŠw

[Šwp˜_•ś]

110182. [Œ´’˜] Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Takada T1, Masaki T2, Hoshiyama A2, Toki T2, Kamata Y1, Shichiri M1: Nephrology (Carlton) 2018 /9; 23 (9): 883-6. (‚“c“NG1, ł–ŘŽkl2, ŻŽRˆťŽq2, “yŠň‘ě–ç2, Š™“c—T“ń1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110183. [Œ´’˜] Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. Inoue M1, Hayashi A2, Taguchi T1, Arai R3, Sasaki S1, Takano K2, Inoue Y4, Shichiri M2: J Diabetes Investig 2018/11. doi: 10.1111/jdi.12980. [Epub ahead of print] (ˆäăŒőŽq1, —с@“N”Í2, “cŒű@•ü1, Vˆä—œˆß“ß3, ˛X–ŘŽŃ–ç‰Á1, ‚–ěK˜H2, ˆäă—D‰î4, Žľ—˘áÁ‹`2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3—ŐŒŸŠw, 4•úŽËü (‰ć‘œ))

110184. [Œ´’˜] Identification of the salusin-ƒŔ receptor using proteoliposomes embedded with endogenousmembrane proteins. Shichiri M1, Nonaka D, Lee LJ, Tanaka K: Sci Rep 2018/12; 8 (1) :17865. (Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110185. [Œ´’˜] A novel strategy to identify autoantigens by proteomic analysis of plasma IgG-bound proteins. Toki T1, Kodera Y, Konno R, Hirata Y, Saito T, Shichiri M2: Journal of Electrophoresis 2019/1; 63 (1): 15-24. (“yŠň‘ě–ç1, Žľ—˘áÁ‹`2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

120007. [Œ´’˜] “–Ž{Ý‚É‚¨‚Ż‚éRGADR‘Ě—zŤ‚Ě”DP“œ”A•a‚¨‚ć‚Ń”DP’†‚Ě–ž‚ç‚Š‚Č“œ”A•a”D•w‚Ě•p“x‚ÉŠÖ‚ˇ‚錟“˘. —é–Ř‚Ü‚čd1, Žsě—‹Žt1, Źň’mŽq1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): “œ”A•a‚Ć”DP 2019; 19 (1): 37-41.

320005. [Ç—á•ń] ”DP’†Šú‚Ü‚Ĺƒrƒ‹ƒ_ƒOƒŠƒvƒ`ƒ“‚đ•ž—p‚ľ•Ş•Ř‚ľ‚˝“œ”A•a‡•š”DP‚Ě1—á. “Ąˆä—˘]1, ”’ě—‰i1, ‰Í‡š—FŠó2, Žsě—‹Žt1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “œ”A•a‚Ć”DP 2019; 19 (1): 63-7.

522055. [uŔ]y“ÁW: äX_Œo“ŕ•Ş”ĺŽîᇁ|f’f‚ĆŽĄ—Ă‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg|z‹@”\Ť_Œo“ŕ•Ş”ĺŽîá‡‚Ě“ŕ•Ş”ĺÇó‚ĚŽĄ—Ă. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ŠĚ’_äX 2019/1; 78 (1): 109-14.

530004. [‚ť‚Ě‘ź (Šw‰ď´˜^)] Glycemic Fluctuation and the Risk of Hypoglycemia Unawareness Associated with Hemodialysis in Type 2 Diabetic Renal Failure Hayashi A1, Momozono A2, Kawai S2, Masaki T2, Yoshino S2, Ogawa A1, Takano K1, Shichiri M1: Diabetes 2018/7; 67 (Suppl 1): 535-P. (—Ń“N@”Í1, “‰€@–ž2, ‰Í‡š—FŠó2, ł–ŘŽkl2, ‹g–쉑”ü2, ŹěŒ°Žj1, ‚–ěK˜H1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

[’˜@‘]

620050. [Šwp‘ (•Ş’SŽˇ•M)y•a‹C‚Ć‚­‚ˇ‚č2018|Šî‘b‚ĆŽŔ‘H Expert's Guide|(–ň‹Ç2018”N‘Š§Vol.69, No.4)z10. ‘ăŽÓŒn‚Ě•a‹C‚Ć‚­‚ˇ‚č@A ‘ăŽÓŒnŽžŠł@“œ”A•a (‡•šÇ‚đŠÜ‚Ţ), p. 862-74. —с@“N”Í1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ), “ěŽR“°, “Œ‹ž, 2018/4”­s.

620051. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ•Ş”ĺ‘ăŽÓ‰Čę–ĺˆăŒ¤CƒKƒCƒhƒuƒbƒNz‘ć11Í ‘˝‘BŤ“ŕ•Ş”厞Šł, ˆâ“`ŤŽžŠł@4. ƒCƒ“ƒXƒŠƒm[ƒ}, p.535-6. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ), •Ň: “ú–{“ŕ•Ş”ĺŠw‰ď, f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2018/5”­s.

620052. [Šwp‘ (•Ş’SŽˇ•M)]yäXEÁ‰ťŠÇNET‚̐f’f‚ĆŽĄ—ĂƒŒƒWƒƒ“zIIÍ •a‘Ô•Ę‚ÉŒŠ‚˝ŽĄ—Ð헪‚Ě—§‚Ä•ű (f’f`ŽĄ—Ă)@1. “]ˆÚ‚đ—L‚ˇ‚é‹@”\ŤäXNET@C. ƒOƒ‹ƒJƒSƒm[ƒ}, VIPŽYśŽîá‡, ƒ\ƒ}ƒgƒXƒ^ƒ`ƒm[ƒ}, ƒJƒ‹ƒ`ƒmƒCƒhÇŒóŒQ, p.20-4. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ), •Ň: n‰Ş@”Í, ‰œâ‘ńŽu, ˆăŠw‚ĆŠĹŒěŽĐ, “Œ‹ž, 2018/6”­s.

620053. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚̏ˆ•ű ‰ü’ů‘ć6”Łz7Í “ŕ•Ş”ĺE‘ăŽÓŽžŠł@16. Ź’ˇƒzƒ‹ƒ‚ƒ“•Ş”ĺ•s‘SÇ, p.320-2. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ), •Ň: ‰Y•”ť•v, “‡“c˜aK, ě‡áÁˆę, “ě]“°, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713087. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Glycemic Fluctuation and the Risk of Hypoglycemia Unawareness Associated with Hemodialysis in Type 2 Diabetic Renal Failure. Hayashi A1, Momozono A2, Kawai S2, Masaki T2, Yoshino S2, Ogawa A1, Takano K1, Shichiri M1: American Diabetes Association 78th Scientific Sessions (2018/6/22-26), Orlando, USA, Diabetes 67 (Suppl 1)F535-P. (—с@“N”Í1, “‰€@–ž2, ‰Í‡š—FŠó2, ł–ŘŽkl2, ‹g–쉑”ü2, ŹěŒ°Žj1, ‚–ěK˜H1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713088. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) REDUCED CENTRAL FAT MASS WITH ONCE-WEEKLY SOMAPACITAN IN ADULT GROWTH HORMONE DEFICIENCY (AGHD): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND OPEN ACTIVE-CONTROLLED STUDY. Takano K1, Johannsson G, Rasmussen MH, HŒkonsson IH, Biller BMK: 9th International Congress of the Growth Hormone Research & IGF Societies (2018/9/15), Seattle, USA. (‚–ěK˜H1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

713089. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The impact of implementation of a medication algorithm for drug-na•ve patients with type 2 diabetes mellitus in an academic teaching hospital in Japan. Iwasawa A, Suzuki A1, Hayashi A1, Atsuda K: ASHP MIDYEAR2018 (2018/12/2-6), Anaheim, CA, USA. (Session-Board# 4-063, 2018) (—é–Řă–ź1, —с@“N”Í1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

722054. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) SGLT2‘jŠQ–ň‚Ĺ’BŹ‚Ĺ‚Ť‚é‚ą‚Ć. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć22‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2019/1/12), ‰Ą•l.

722055. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) GLP-1ƒAƒiƒƒO‚̍ě—p‚Ć—Ő°‰ž—p. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć22‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2019/1/13), ‰Ą•l.

723223. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ź‘¤•›toŒŒ‚đ‚Ť‚˝‚ľf’f‚ĆŽĄ—Ă‚É“ďa‚ľ‚˝TAFROÇŒóŒQ‚Ě1—á. ’ç@‹M‘ĺ1, Žsě—‹Žt1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć91‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠwp‘‰ď (2018/4/26-28), ‹{č, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018; 94 (1): 428.

723224. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒtƒ‰ƒbƒVƒ…ƒOƒ‹ƒR[ƒXƒ‚ƒjƒ^ƒŠƒ“ƒO‚đ—p‚˘‚˝ƒCƒ“ƒXƒŠƒ“ƒOƒ‰ƒ‹ƒMƒ“U100‚Š‚çU300‚ւ̐؂č‘Ö‚Ś‚É‚ć‚é’ZŠú“IŒŒ“œ“Ž‘ԕωť‚ÉŠÖ‚ˇ‚錟“˘. “IęŒ’‘ž1, —с@“N”Í1, Vˆä—œˆß“ß2, ‘ş“cH•ä1, ‰Í‡š—FŠó3, –öŕV^ŽŔ1, “yŠň‘ě–ç3, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2—ŐŒŸŠw, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S235.

723225. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÚAŒăV‹K”­Ç“œ”A•a (NODAT) ‚ĆˆÚA‘OŒoŒűŒŒ“œ•‰‰×ŽŽŒą (OGTT) Œ‹‰Ę‚ĚŠÖŒWŤ‚ĚŒŸ“˘. â“Œ@Œd1, —с@“N”Í2, ‰Ťčiˆę˜Y2, “cŒű@•ü1, ‹g“c•üŽq3, Îˆä‘ĺ•ă4, ‹g“cˆęŹ4,5, ‚–ěK˜H2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3‰h—{•”, 4”ĺ”AŠí, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S255.

723226. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•a‚É‚¨‚Ż‚éV‹K•a‘Ô—\‘ރoƒCƒIƒ}[ƒJ[‚Ć‚ľ‚Ä‚ĚŒŒ´ƒż2-ƒ}ƒNƒƒOƒƒuƒŠƒ“Žl—Ę‘Ě‚Ě—Ő°“IˆÓ‹`. ‹g–쉑”ü1, ‚“c“NG2, “Ą–{˜aŽŔ, ‰Í‡š—FŠó1, —с@“N”Í2, Š™“c—T“ń2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S260.

723227. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńƒAƒ‹ƒR[ƒ‹ŤŽ‰–bŤŠĚŽžŠł (NAFLD) ‡•š2Œ^“œ”A•aŠłŽŇ‚ɑ΂ˇ‚éƒJƒiƒOƒŠƒtƒƒWƒ“‚ĚŒř‰Ę‚ĚŒŸ“˘. ˆäăŒőŽq1, —с@“N”Í2, ˛X–ŘŽŃ–ç‰Á1, ŹěŒ°Žj2, ‰Ťčiˆę˜Y2, Žsě—‹Žt2, Š™“c—T“ń2, ‚–ěK˜H2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S299.

723228. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é“œ”A•aŠáÇŠłŽŇ‚̐f—Ă‚ÉŠÖ‚ˇ‚éŠá‰Č‚Ć‚Ě˜AŒgó‹ľ‚ĚŒŸ“˘. Źň’mŽq1, —с@“N”Í1, Źă–ž—˘ŠG1, —é–Ř‚Ü‚čd1, Žsě—‹Žt1, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S324.

723229. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 2Œ^“œ”A•aŒŒ‰t“§ÍŠłŽŇ (T2HD) ‚É‚¨‚Ż‚铧ÍŒă’ጌ“œ‚đ’悡‚銳ŽŇ‚Ě—Ő°“I“Á’Ľ. —с@“N”Í1, “‰€@–ž2, ł–ŘŽkl2, ‹g–쉑”ü2, ŹěŒ°Žj1, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž, “œ”A•a 2018; 61: S381.

723230. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠŒČŠÇ—ó‹ľ‚É‚ć‚čT1‰ńGLP-1Žó—e‘Ěě“Ž–ň‚É•ĎX‚ľ‚˝2Œ^“œ”A•a“§Í (T2DMHD) ŠłŽŇ‚Ö‚ĚŒř‰Ę. •–ö—T”ü, ŕV“c”üŽŃŽq, ‹g‰Ş“Ţ’ĂŽq, ’‡@~Žq, Îˆäç˛Žq, ‰Á“Ą@Œ‹, –ě’n‹ŕŽq, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‘ĺ‹v•Ű[l, —с@“N”Í1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29-7/1), _ŒË.

723231. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žá”Nœ‘e頏ǂÉGH•â[‚đs‚Á‚˝3—á. “cŒű@•ü1, ‚–ěK˜H2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć45‰ń“ú–{_Œo“ŕ•Ş”ĺŠw‰ďŠwpW‰ď (2018/10/27-28), “Œ‹ž.

723232. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) GH•â[‚Ĺ‘Ź‚â‚Š‚ÉŽ‰–bŠĚ, ‘Ě‘gŹ‚މü‘P‚ľ‚˝“ŞŠWˆô“ŞŽîpŒă‚Ěˆę—á. “cŒű@•ü1, Š™“c—T“ń2, ‚–ěK˜H2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć28‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2018/11/2-3), •Ÿ‰Ş, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/9; 94: 625.

723233. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒgzŠÂŒŒŸ÷’†ƒvƒƒŒƒjƒ“‚Ě•ŞŽq‘śÝ—lŽŽ‚Ć‚ť‚Ě”Z“x. “Ą–{˜aŽŔ, ‰Í‡š—FŠó1, ‹g–쉑”ü1, â“Œ@Œd1, Š™“c—T“ń2, ŹŽ›‹`’j, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć28‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2018/11/2-3), •Ÿ‰Ş, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/9; 94: 632.

723234. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SŒŒŠÇŽžŠłƒŠƒXƒNˆöŽq‚Ć‚ľ‚Ä‚ĚŒŒ´ƒż2-ƒ}ƒNƒƒOƒƒuƒŠƒ“‚ĚˆÓ‹`. ‹g–쉑”ü1, “Ą–{˜aŽŔ, ‚“c“NG2, ‰Í‡š—FŠó1, Źě“Ő˜Y, —с@“N”Í2, Š™“c—T“ń2, ŹŽ›‹`’j, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć28‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2018/11/2-3), •Ÿ‰Ş, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/9; 94: 661.

723235. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) R‘̉AŤ‚ĚBasedow•a‚ɑ΂ľ‚Ä, Žčp‚đŽ{s‚ľ‚˝1—á. ’ç@‹M‘ĺ1, ł–ŘŽkl2, ŹěŒ°Žj1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć28‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2018/11/2-3), •Ÿ‰Ş, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/9; 94 (2): 690.

723236. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RƒCƒ“ƒXƒŠƒ“R‘Ě—zŤÇ—á‚É‚¨‚Ż‚鎞Šł“ÁˆŮ“IŹ•Ş‚Ě’Tő. “yŠň‘ě–ç1, ˛X–ŘŽŃ–ç‰Á1, “‰€@–ž1, “Ą–{˜aŽŔ, —с@“N”Í2, Žsě—‹Žt2, Š™“c—T“ń2, ŹŽ›‹`’j, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć28‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2018/11/2-3), •Ÿ‰Ş, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/9; 94: 721.

723237. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž‚𔺂¤“œ‘ăŽÓˆŮí‡•š”D•w‚Ě”DP’†‚Ě‘Ěd•Ď‰ť‚ĆŽüŽYŠú—\Œă‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Žsě—‹Žt1, —é–Ř‚Ü‚čd1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l, “œ”A•a‚Ć”DP 2018; 18 (3): S-84.

723238. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŠƒuƒŒPro‚đ—p‚˘‚˝”DP“œ”A•aŠÇ—‚̉”\Ť. —с@“N”Í1, “Ąˆä—˘]1, —é–Ř‚Ü‚čd1, ˛X–ŘŽŃ–ç‰Á2, “‰€@–ž2, Žsě—‹Žt1, Žç‰Ž’B”ü3, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ’NŠÇ—ƒZ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l, “œ”A•a‚Ć”DP 2018; 18 (3): S-93.

723239. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) GDM”D•w‚É‚¨‚Ż‚éf’fŽž75OGTT‚ĚŒŒ“œƒs[ƒN‚Ěƒ^ƒCƒ~ƒ“ƒO‚ĆŽüŽYŠú—\Œă‚ĚŠÖ˜A‚ɂ‚˘‚Ä‚ĚŒŸ“˘. —é–Ř‚Ü‚čd1, Žsě—‹Žt1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l, “œ”A•a‚Ć”DP 2018; 18 (3): S-111.

723240. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽYŒă‚Ě“œ‘ăŽÓˆŮí‚Ě•]‰ż‚Í75g OGTT‚ł悢‚Š`Ž‘ąŒŒ“œ‘Ş’č‚đ—p‚˘‚˝ŒŸ“˘`. ˛X–ŘŽŃ–ç‰Á1, —с@“N”Í2, “Ąˆä—˘]2, —é–Ř‚Ü‚čd2, “‰€@–ž1, Žsě—‹Žt2, Žç‰Ž’B”ü3, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3Œ’NŠÇ—ƒZ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l, “œ”A•a‚Ć”DP 2018; 18 (3): S-111.

733079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒAƒ‹ƒhƒXƒeƒƒ“‰ßčŽYś‚đ•š”­‚ľ‚˝Œă• –Œ_ŒoâŽî‚Ě1—á. ’J@—TŽŠ1, ‰Á“Ą—R‹NŽq, ‰Ťčiˆę˜Y1, ˛X–ŘŽŃ–ç‰Á2, ‘ş“cH•ä1, ‰Í‡š—FŠó2, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{“ŕ‰ČŠw‰ď‘ć643‰ńŠÖ“Œ’n•ű‰ď (2018/7/15), “Œ‹ž.

733080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äXEÁ‰ťŠÇ_Œo“ŕ•Ş”ĺŽîᇂɂ‚˘‚Ä’m‚Á‚Ä‚¨‚Š‚Č‚Ż‚ę‚΂Ȃç‚Č‚˘Ĺ‹ß‚Ě—Ő°ă‚̐i•ŕ. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć19‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠÖ“ŒbM‰zŽx•”ŠwpW‰ď (2018/9/7-8), “Œ‹ž, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/12; 94 (3): 806.

733081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰şŽˆ[•”Ă–ŹŒŒđÇ‚ÖƒŠƒoƒƒLƒTƒoƒ“ŠJŽnŒă‚ɉş‚‘Ě‘˛’†‚đ’ć‚ľ‚˝ƒvƒƒ‰ƒNƒ`ƒm[ƒ}‚Ěˆę—á. “cŒű@•ü1, Š™“c—T“ń2, ‚–ěK˜H2, Žľ—˘áÁ‹`2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć19‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠÖ“ŒbM‰zŽx•”ŠwpW‰ď (2018/9/7-8), “Œ‹ž, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2018/12; 94 (3): 876.

733082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “œ”A—pŒŒ‰t“§ÍŠłŽŇ‚É‚¨‚Ż‚éCGMŽŔŽ{‚Ě—Ő°“IˆÓ‹``“§ÍŒă’ጌ“œ‚Ě”­ś•p“x‚ĚŒŸ“˘`. —с@“N”Í1, “‰€@–ž2, ł–ŘŽkl2, ‹g–쉑”ü2, ŹěŒ°Žj1, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć18‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć16‰ń1Œ^“œ”A•aŒ¤‹†‰ď (2018/9/29-30), _ŒË, ‘ć18‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć16‰ń1Œ^“œ”A•aŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018; p.45.

733083. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Sensor Augmented Pump 620G‚Š‚ç640G‚ւ̐؂č‘Ö‚Ś‚É‚ć‚錌“œ“Ž‘Ԃ̕ωť`ƒXƒ}[ƒgƒK[ƒh‚ĚŒř‰Ę‚ĚŒŸ“˘`. ´…‡–ç1, —с@“N”Í1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć18‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć16‰ń1Œ^“œ”A•aŒ¤‹†‰ď (2018/9/29-30), _ŒË, ‘ć18‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć16‰ń1Œ^“œ”A•aŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018; p.50.

733084. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚ŒŒ“œ‹Ů‹}Ç‚É“œ”A•aŤ•‘“Ľ•a‚đ”ş‚ľ‚˝‚—î2Œ^“œ”A•a‚Ě1—á. —é–؍V–ź1, —é–Ř—z•F1, ‘唊NG1, ´…‡–ç1, ’ç@‹M‘ĺ1, Žsě—‹Žt1, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć56‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/1/26), ‰Ą•l.

733085. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 2Œ^“œ”A•aŒo‰ß’†‚ɃAƒ[ƒoŤ‘ĺ’°‰Š‚đ”­Ç‚ľ, RGADR‘Ě‚Ş—zŤ‰ť‚ľ‚˝1—á. ‘唊NG1, —с@“N”Í1, —é–؍V–ź1, ´…‡–ç1, “IęŒ’‘ž1, Žsě—‹Žt1, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć56‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/1/26), ‰Ą•l.

733086. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “œ”A•aŤƒPƒgƒAƒVƒh[ƒVƒX‚Ĺ‚ ‚é‚É‚ŕŠÖ‚í‚炸ƒAƒ‹ƒJƒŒƒ~ƒA‚đ’ć‚ľ‚˝1Œ^“œ”A•a‚Ěˆę—á. ´…‡–ç1, Žsě—‹Žt1, “cŒű@•ü2, —é–؍V–ź1, ‘唊NG1, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć56‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/1/26), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-540007. [‚ť‚Ě‘ź (Šw‰ď´˜^)] ƒCƒ“ƒXƒŠƒ“ƒ|ƒ“ƒvŽg—p“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éCarbo-count, Bolus wizard‚ĚŒŒ“œ“Ž‘Ԃɑ΂ˇ‚éŒř‰Ę‚ĚŒŸ“˘. ‚–ěK˜H (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): “ú–{•a‘Ô‰h—{Šw‰ďŽ 2018/1; 21 (Suppl): S-101.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723008. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒCƒ“ƒXƒŠƒ“ƒ|ƒ“ƒvŽg—p“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éCarbo-count, Bolus wizard‚ĚŒŒ“œ“Ž‘Ԃɑ΂ˇ‚éŒř‰Ę‚ĚŒŸ“˘. —с@“N”Í1, ”’ě—‰i1, ˆäăŒőŽq2, “‰€@–ž2, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć21‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2018/1/12-14), ‹ž“s, “ú–{•a‘Ô‰h—{Šw‰ďŽ 2018; 21 (Suppl): S-101.

H29-733001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’˜–ž‚ȍ‚NaŒŒÇ, Z“§ˆł•Ď‰ť‚É‚ć‚萜‚ś‚˝Z“§ˆł’E‘ÇŒóŒQCŽ‹°‰ş•”Ť•›tEŤ‘B‹@”\’ቺÇE•”•ŞŒ^’†•Ť”A•öÇ‚̉ń•œŒo‰ß‚đŠĎŽ@‚ľ‚˝ˆę—á. “IęŒ’‘ž1, ‰Í‡š—FŠó2, ”’ě—‰i1, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć52‰ń_“ސě“ŕ•Ş”ĺE‘ăŽÓƒZƒ~ƒi[ (2018/2/17), ‰Ą•l.


t‘Ÿ“ŕ‰ČŠw

[Šwp˜_•ś]

110186. [Œ´’˜] Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. Kamata M1, Amano H2, Ito Y2, Fujita T, Otaka F3, Hosono K2, Kamata K, Takeuchi Y1, Yokomizo T, Shimizu T, Majima M2: PLoS One 2019/2; 14 (2): e0202842. (Š™“c^—Žq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, ‘ĺ‚Žjš3, ×–ě‰Á“ŢŽq2, ’|“ŕN—Y1, ”n“ˆł—˛2: 1t‘Ÿ“ŕ, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310012. [Ç—á•ń] An autopsy case of TAFRO syndrome with membranoproliferative glomerulonephritis-like lesions. Hashimoto K1, Sano T1, Honma Y1, Ida M1, Tominaga H1, Sawada A1, Abe T1, Takahashi H1, Shimada Y1, Masaki T1, Kamata M1, Naito S1, Aoyama T1, Takeuchi Y1, Akiya M2, Inukai M2, Nakata N: CEN Case Rep 2019/2; 8 (1): 48-54. (‹´–{ŒbŽq1, ˛–ě@—˛1, –{ŠÔ—F—1, ˆä“c^śŽq1, •x‰i‘ĺŽu1, ŕV“c@Ę1, ˆ˘•”“N–ç1, ‚‹´@—y1, “‡“c–F—˛1, ł–Ř‹M‹ł1, Š™“c^—Žq1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1, H’JšŽj2, Œ˘Ž”@‰~2: 1t‘Ÿ“ŕ, 2•a—)

320006. [Ç—á•ń] ŒuŒőR‘̐őF–@‚ĹFull-House-Pattern‚đ”F‚ß, ŽŠŒČR‘̉AŤ‚đ’ć‚ľ‚˝ƒƒTƒ“ƒMƒEƒ€‘BŤt‰Š‚Ěˆę—á. źŽRŒiŽq1, Š™“c•‡”ü1, ‹{â—ł”n1, ŽRč‘ń–ç1, –{ŠÔ—F—˘1, ˆä“c^śŽq1, ‹´–{ŒbŽq1, ˆ˘•”“N–ç1, ł–Ř‹M‹ł1, Š™“c^—Žq1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1, é@ŒŞ•ă, ŽRŒű@—T (1t‘Ÿ“ŕ): t‰ŠÇ—ጤ‹† 2018/2; 34: 135-54.

[Šw‰ďEŒ¤‹†‰ď“™]

723241. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é‘˝”­Ť”X–Et‚ĚŒťó‚Ɖۑč. ÂŽR“ŒŒÜ1, ˆ˘•”“N–ç1, ł–Ř‹M‹ł1, Š™“c•‡”ü1, Š™“c^—Žq1, “ŕ“Ął‹g1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/9), VŠƒ.

723242. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œŽ‰ŽżGM3‚̓lƒtƒŠƒ“R‘Ě‚É‚ć‚é×–EáŠQ‚đłí‰ť‚ˇ‚é. “ŕ“Ął‹g1, ě“‡‰iŽq1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/10), VŠƒ.

723243. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œŽ‰Žż‚đ—˜—p‚ľ‚˝–Ťt‘Ÿ•a‚ɑ΂ˇ‚éV‹K‘n–ňƒV[ƒY‚Ě’ńˆÄ. ě“‡‰iŽq1, “ŕ“Ął‹g1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): BIO tech 2018 (2018/6/28), “Œ‹ž.

723244. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒNƒŠƒIƒtƒBƒ‹ƒgƒŒ[ƒVƒ‡ƒ“‚ĆƒXƒeƒƒCƒh—Ă–@‚Ş‘tŒř‚ľ‚˝ƒNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ‚Ě1—á. ŕV“c@Ę1, ł–Ř‹M‹ł1, źŽRŒiŽq1, –{ŠÔ—F—1, ‹{â—ł”n1, ŽRč‘ń–ç1, ˆä“c^śŽq1, •x‰i‘ĺŽu1, ˆ˘•”“N–ç1, ‹´–{ŒbŽq1, ‚‹´@—É1, ’|“ŕ˜a”Ž1, Š™“c•‡”ü1, Š™“c^—Žq1, ‘ş–ě‡–ç1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË.

732028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) –Ťt‘Ÿ•a‚ɑ΂ˇ‚éV‹K‘n–ňƒV[ƒY‚Ě’Tő. ě“‡‰iŽq1, “ŕ“Ął‹g1 (1t‘Ÿ“ŕ): ’áE’†•ŞŽq‘n–ň„iƒvƒ‰ƒbƒgƒtƒH[ƒ€ (2018/11/9), “Œ‹ž.

733087. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) tˆÚAŒă‚Ě• o“ŕPTLD 2—á. ŕV“c@Ę1, Îˆä‘ĺ•ă2, źŽRŒiŽq1, –Ȋс@ăÄ2, “V–ě“”V2, Žu‘ş‘sˆę˜N2, Šâ‘şłŽk2 (1t‘Ÿ“ŕ, 2”ĺ”AŠí): ‘ć29‰ń_“ސěˆÚAˆăŠw‰ď (2018/6/2), ‰Ą•l.

733088. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”DPŽž‚Ƀlƒtƒ[ƒ[ÇŒóŒQ‚đ’ć‚ľ, oŽYŒă‚ɐt‹@”\‘ˆŤ‚đ”F‚ß‚˝”źŒŽ‘ĚŒ`ŹŤIgAtÇ‚Ěˆę—á. ‰i‰Ş–˘—ˆ1, ˛–ě@—˛1, ŸN—с@r1, ˆä“c^śŽq1, ŕV“c@Ę1, •x‰i‘ĺŽu1, Š™“c•‡”ü1, ł–Ř‹M‹ł1, ŽđˆäŒ’Žj1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć70‰ń_“ސět‰ŠŒ¤‹†‰ď (2018/9/1), ‰Ą•l.

733089. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”xŠŕ‚Ö‚Ě•úŽËüŽĄ—Ă‚Ć‹¤‚Ƀlƒtƒ[ƒ[ÇŒóŒQ‚ŞŠ°‰đ‚ľ‚˝–ŒŤtÇ‚Ěˆę—á. •x‰i‘ĺŽu1, ˛–ě@—˛1, ŸN—с@r1, ‰i‰Ş–˘—ˆ1, ˆä“c^‰›Žq1, ŕV“c@Ę1, ł–Ř‹M‹ł1, ŽđˆäŒ’Žj1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć48‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2018/10/21), Vh.

733090. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) RƒlƒtƒŠƒ“R‘Ě‚đ—p‚˘‚˝Ž…‹…‘ĚŒř‰Ęƒ‚ƒfƒ‹‚ĚŠm—§‚ÉŒü‚Ż‚˝Šî‘b“IŒŸ“˘. ŒK…—Ź~, ‘ĺ’Źh•˝, ‰Ă‘ş”ü—˘, ‰Ą“c@—ƒ, Ž›–{Œ[—S, Ź“ˆ@—y, Mary Ann Suico, Žń“Ą@„, ě“‡‰iŽq1, “ŕ“Ął‹g1 (1t‘Ÿ“ŕ): ‘ć35‰ń“ú–{–ňŠw‰ď‹ăBŽx•”‘ĺ‰ď (2018/11/17), ’ˇč.

733091. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”x‰Š‹…‹ŰŤ”sŒŒÇ‚đŒ_‹@‚É•›t”玿‹@”\’ቺ‚ɊׂÁ‚˝ŒŒ‰t“§ÍŠłŽŇ‚Ěˆę—á. ŸN—с@r1, ˛–ě@—˛1, ‰i‰Ş–˘—ˆ1, ˆä“c^‰›Žq1, ŕV“c@Ę1, •x‰i‘ĺŽu1, ł–Ř‹M‹ł1, ŽđˆäŒ’Žj1, Š™“c•‡”ü1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć96‰ń_“ސětŒ¤‹†‰ď (2018/11/18), ‰Ą•l.

733092. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ˆę”ĘŒű‰‰) “Á”­ŤŒŒŹ”ÂŒ¸­Ç (ITP), D’†‹…Œ¸­Ç‚đ‡•š‚ľ‚˝IgG4ŠÖ˜AŒÄ‹zŠíŽžŠł‚Ě1—á. ‹{â—ł”n1, –î“ŕŒ´’qŽq2, ‚‹´@—É1, Îčƒ˜Y3, ŽOŽ}—zˆę2, •ĐŽR‘쎢2, Îˆä—˛Ži4, ŽR“ŕ‹M—Y2, Ąč‹Mś2, Ąň@O2 (1t‘Ÿ“ŕ, 2‘Š–Í–ě•a‰@, 3Á‰ťŠí“ŕ, 4ŒŒ‰t“ŕ): “ú–{“ŕ‰ČŠw‰ď‘ć647‰ńŠÖ“Œ’n•ű‰ď (2018/12/8), “Œ‹ž.


äPŒ´•aEŠ´ő“ŕ‰ČŠw

[Šwp˜_•ś]

110187. [Œ´’˜] Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes. Hoshiyama T1, Matsueda Y, Tono T1, Arinuma Y1, Nagai T1, Hirohata S: Mod Rheumatol 2018/5; 28 (3): 506-12. (ŻŽR—˛s1, “Œ–ěr—m1, —LŔ—ǍK1, ‰iˆä—§•v1: 1äPŒ´•aĽŠ´ő“ŕ)


“ű‘BEbó‘BŠO‰ČŠw

[Šwp˜_•ś]

110188. [Œ´’˜] Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y1, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies S, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ: Cell Rep 2018/8; 24 (6): 1434-44.e7. (Źâ–ůŒŤ1: 1“ű‘BEbó‘BŠO)

110189. [Œ´’˜] Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y1, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M: Breast Cancer Res Treat 2018/10; 171 (3): 675-83. (Źâ–ůŒŤ1: 1“ű‘BEbó‘BŠO)

110190. [Œ´’˜] Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. Kosaka Y1, Minatani N, Tanaka Y2, Shida A, Kikuchi M1, Nishimiya H1, Waraya M1, Katoh H1, Sato T3, Sengoku N1, Tanino H, Yamashita K4,5, Watanabe M3: Mol Clin Oncol 2018/11; 9 (5): 566-74. (Źâ–ůŒŤ1, “c’†—uŽq2, ‹e’r^—Žq1, ź‹{—mŽj1, ˜m’J”ü“Ţ1, ‰Á“Ą@O1, ˛“Ąr˜Y3, ĺÎ‹I•F1, ŽR‰şŒpŽj4,5, “n粏š•F3: 1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5ă•”Á‰ťŠÇŠO)

120008. [Œ´’˜] S—“IƒXƒgƒŒƒX‚ĚŒyŒ¸‚ÉŒü‚Ż‚˝ƒˆƒK‚ƐS—‹łˆç‚Ě‘g‚ݍ‡‚í‚š‚ĚŽŽ‚Ý. Â–ؐł•˝1, Źâ–ůŒŤ2, ĺÎ‹I•F2, ‹e’r^—Žq2, ˛“Ą–ŤŽq, ĺU•Ŕ@Ÿ, ”’ˆä‹łŽq3, “c‹v•Ű”üç‘ă, ˆäăŸ•v4, ‹{‰Ş@“™4, Šâ–ž—D”ü1 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3ŠĹŒě•”, 4¸_): –k—˘ˆăŠw 2018/12; 48 (2): 105-12.

320007. [Ç—á•ń] “űŠÇ“ŕ“ű“ŞŽî‚Ć‚ľ‚ÄŒo‰ßŠĎŽ@‚ł‚ę‚Ä‚˘‚˝“űŠŕ‚Ě1—á. ˜m’J”ü“Ţ1, —с@‹žŽq1, Œ˘Ž”@‰~2, ŽR–{Œöˆę3, ‰HœAŒ’m, ‰Ÿ“cŹ•S‡1, Źâ–ůŒŤ1, ĺÎ‹I•F1, “n粏š•F4 (1“ű‘BEbó‘BŠO, 2•a—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): Šŕ‚ƉťŠw—Ă–@ 2019/1; 46 (1): 106-8.

[Šw‰ďEŒ¤‹†‰ď“™]

713090. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Functional and therapeutic significance of ESR1 gene fusions in breast cancer. J T Lei, J Shao, J Zhang, M Iglesia, D W Chan, J Cao, M Anurag, P Singh, X He, Kosaka Y1, R Matsunuma, R Crowder, J Hoog, C Phommaly, R Goncalves, S Romalho, R M R Peres, N Punturi, C Schmidt, A Bartram, E Jou, W V Lai, O Hampton, A Rogers, E Tobias, P Parikh, S R Davies, S Li, C X Ma, V Suman, K K Hunt, M A Watson, K A Hoadley, E A Thompson, X Chen, S M Kavuri, C J Creighton, C A Maher, C M Perou, S Haricharan, M J Ellis: American Association for Cancer Research (AACR) Annual Meeting 2018 (2018/4/14-18), Chicago, IL, USA. (Źâ–ůŒŤ1: 1“ű‘BEbó‘BŠO)

713091. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4: J-CAT trial). Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y1, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N: The 2018 CTRC-AACR San Antonio Breast Cancer Symposium (2018/12/5), SanAntonio, TX, USA. (Źâ–ůŒŤ1: 1“ű‘BEbó‘BŠO)

713092. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) BRCAness as a prognostic marker in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: A multicenter retrospective study. Kosaka Y1, Yamamoto Y, Nishimiya H1, Ibusuki-Yamamoto M, Hirota Y, Tanino H, Iwase H, Nakamura S, Akashi-Tanaka S: The 2018 CTRC-AACR San Antonio Breast Cancer Symposium (2018/12/8), SanAntonio, TX, USA. (Źâ–ůŒŤ1, ź‹{—mŽj1: 1“ű‘BEbó‘BŠO)

722056. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ER‰AŤHER2—zŤ“űŠŕ‚É‚¨‚Ż‚ébasal marker‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚錤‹†. •ž•”ł–ç, ‘Š—LjŔş, ‚“cł‘×, ‘ĺˆä‹ą‘ă, •ZšŽj, ‘ĺ’J˛ˆę˜Y, ˆäăŒŤˆę, ‚”öM‘ž˜Y, ˛“ĄMş, ŽR‰ş”NŹ, Źâ–ůŒŤ1, •Z@ŒŁ, X“c’qŽ‹, Šâ“cLŽĄ, ŒËˆä‰ë˜a (1“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/16), ‹ž“s.

723245. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O‚É”ńZŤ“űŠÇŠŕ‚Ć”ť’f‚ľ‚˝“űŠŕŽčpÇ—á‚̐f’f‚Ć—\Œă. ‹e’r^—Žq1, Źâ–ůŒŤ1, “c’†—uŽq2, M‘žşŽq3, ź‹{—mŽj1, ‰Á“Ą@O1, ĺÎ‹I•F1, “n粏š•F4 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a—, 4‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723246. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isÄ”­“űŠŕ‚ɑ΂ˇ‚éEribulin“Š—^‚Ě—LŒřŤEˆŔ‘SŤ‚ɂ‚˘‚Ä. “c’†—uŽq1, Źâ–ůŒŤ2, ‹e’r^—Žq2, M‘žşŽq3, ź‹{—mŽj2, ‰Á“Ą@O2, ĺÎ‹I•F2, ‘ •Ŕ@Ÿ, “n粏š•F4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3•a—, 4‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723247. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bó‘B“ű“ŞŠŕ‚É‚¨‚Ż‚éHOPXˆâ“`Žqƒvƒƒ‚[ƒ^[—Ěˆćƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. ‘ĺň—z‰î1, ‰Á“Ą@O2, ŽR‰şŒpŽj3,4, ŒÜ\—’ˆę°1, Ź›¸Œc‘ž1, ‹e’r^—Žq2, M‘žşŽq5, Źâ–ůŒŤ2, ĺÎ‹I•F2, “n粏š•F6 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5•a—, 6‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/6), “Œ‹ž.

723248. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’jŤIntraductal papillary carcinoma‚Ě1—á. Źâ–ůŒŤ (“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/16), ‹ž“s.

723249. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ǐŤŽîᇓEo•W–{‚Ĺ”­ŒŠ‚ł‚ę‚˝”ńZŤŹ—tŠŕ‚ĚÇ—á. ă–ě‘ˆę˜Y, ’†ŒF‘¸Žm, ‚‹´“Ţ, ’ˇ“cG–¤, ĺÎ‹I•F1, –{ŠÔ@Œb (1“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s.

723250. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “űŠŕ‚É‚¨‚Ż‚éGCNT2ˆâ“`Žqƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. “c’†—uŽq1, Źâ–ůŒŤ2, ‹e’r^—Žq2, ‰Ą“cŒő‰›1, ‰Á“Ą@O2, ĺÎ‹I•F2, ŽR‰şŒpŽj3,4, “n粏š•F5 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s.

723251. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’jŤ“ű–[‚É”­Ç‚ľ‚˝Myofibroblastoma‚Ě1—á. ‰Ą“cŒő‰›1, ĺÎ‹I•F2, ‰Ş–{Œő‹FŽq3, “c’†—uŽq1, ‹e’r^—Žq2, ź‹{—mŽj2, ‰Á“Ą@O2, Źâ–ůŒŤ2, Š“cç”ü”T4, “n粏š•F5 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3ă•”Á‰ťŠÇŠO, 4•a—, 5‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s.

723252. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O‰ťŠw—Ă–@‚đŽ{s‚ľ‚˝triple negative “űŠŕÇ—á‚É‚¨‚Ż‚éBRCAness‚¨‚ć‚ŃAndrogen Receptor‚ÉŠÖ‚ˇ‚錟“˘. Źâ–ůŒŤ1, ź‹{—mŽj1, ‰Ą“cŒő‰›2, ‹e’r^—Žq1, ‰Á“Ą@O1, Š“cç”ü”T3, ’J–ě—Tˆę, ĺÎ‹I•F1, “n粏š•F4 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a—, 4‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s.

723253. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “űŠŕ‰„‘“]ˆÚ‚đ—ˆ‚ľ‚˝1—á. ‰Ş–{Œő‹FŽq1, ‹e’r^—Žq2, ‰Ą“cŒő‰›2, “c’†—uŽq3, ź‹{—mŽj2, Źâ–ůŒŤ2, ‰Á“Ą@O2, ĺÎ‹I•F2, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO, 2“ű‘BEbó‘BŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s.

723254. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Š{œ‰óŽ€‚É‚ć‚éŒűo“ŕoŒŒ‚ɑ΂ľTAE‚đŽ{s‚ľ‚˝1—á. ”Ń’Ë”ü, ˆäă€l, “ń“nM], •˝ěk‘ĺ, ‘ĺX’qŽq, ‘ëě­˜a, –x“cˆťŽq, Ä“Ąś˜N, ‹ŕˆäˆč‘ă, ‹e’r^—Žq1, ĺÎ‹I•F1 (1“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723255. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒB‚ĹƒJƒeƒSƒŠ[4‚Ü‚˝5‚Ɛf’f‚ľ‚˝“ű‘BÇ‚ĚŒŸ“˘. —с@‹žŽq1, ˜m’J”ü“Ţ1, ‰HœAŒ’m, ŽR–{Œöˆę2, ĺÎ‹I•F1, Œ˘Ž”@‰~3, ‘ě˜ad4, “n粏š•F5 (1“ű‘BEbó‘BŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3•a—, 4•úŽËü (Žîá‡), 5‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723256. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒ“ƒ‚ƒOƒ‰ƒtƒB[ (MMG) —ǐŤÎŠD‰ťŠŒŠ‚ĚŒŸf‚𒆐S‚Ć‚ľ‚˝Œo‰ßŠĎŽ@. ĺÎ‹I•F (“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723257. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ű‘BŒ´”­ˆŤŤƒŠƒ“ƒpŽî‚Ě2—á. ˜m’J”ü“Ţ1, —с@‹žŽq1, Źâ–ůŒŤ1, Œ˘Ž”@‰~2, ŽR–{Œöˆę3, ‰Ÿ“cŹ•S‡1, ‰HœAŒ’m, ‹e’r^—Žq1, ĺÎ‹I•F1, “n粏š•F4 (1“ű‘BEbó‘BŠO, 2•a—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723258. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) WŠw“IŽĄ—Ă‚É‚ć‚č—ǍD‚ČŒo‰ß‚đ“ž‚Ä‚˘‚é—ź‘¤“űŠŕpŒăS”X“]ˆÚ‚Ě1—á. ĺÎ‹I•F1, “Ą–ěŽjD2, “c’†—uŽq3, ‹e’r^—Žq1, Źâ–ůŒŤ1, ‰Á“Ą@O1, “n粏š•F2 (1“ű‘BEbó‘BŠO, 2‰ş•”Á‰ťŠÇŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723259. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒeƒŒƒIƒKƒCƒh‰şƒ}ƒ“ƒ‚ƒg[ƒ€śŒŸ‚đŽ{s‚ľ‚˝”÷×ÎŠD‰ť•a•Ď‚ĚŒŸ“˘. ‹e’r^—Žq1, Źâ–ůŒŤ1, ‰Ş–{Œő‹FŽq2, ‰Ą“cŒő‰›3, “c’†—uŽq3, ź‹{—mŽj1, ‰Á“Ą@O1, ĺÎ‹I•F1, —é–Řˆ¤Žq, ’†‘ş—ÇŒb, “n•Ó‚ ‚ä‚Ý, “n粏š•F4 (1“ű‘BEbó‘BŠO, 2ă•”Á‰ťŠÇŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s.

723260. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’_ůN‰ŠŒo‰ß’†‚ÉŒŸo‚ľˆÝŠŕ‰“ŠuŠú“]ˆÚ‚Ć‚ł‚ę‚˝’Ž‚‹y‚яŹ’°•a•Ď. X@’ĺ_, ––ƒ—˘ŠG, ’Ź“c’źŽq, ’†ŽRLˆę, Źâ–ůŒŤ1, ‚˛Œ°”V, źŽR•Ű”äŒĂ, ’†ěˆę (1“ű‘BEbó‘BŠO): ‘ć43‰ń“ú–{’´‰š”gŒŸ¸Šw‰ďŠwpW‰ď (2018/6/3), ‘ĺă.

723261. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”z‹ôŽŇ‘¤‚Ě‰ĆŒn‚É‚ŕƒŠƒXƒN—vˆö‚Ş”F‚ß‚ç‚ęˆâ“`“IƒŠƒXƒN•]‰ż‚É‹ę—ś‚ľ‚˝HBOC‚Ě1—á. r–؏Ž”ü, ˜m’J”ü“Ţ1, Źâ–ůŒŤ1, Ź•ő^—Žq, ‚“cŽj’j2 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć42‰ń“ú–{ˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒOŠw‰ďŠwpW‰ď (2018/6/30), ĺ‘ä.

723262. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ű‚Ş‚ńŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝ƒˆƒK‚ƐS—‹łˆç“I‰î“ü‚ĚŽŽ‚Ý. ˛“Ą–ŤŽq, Â–ؐł•˝, Źâ–ůŒŤ1, ĺÎ‹I•F1, ‹e’r^—Žq1, ĺU•Ŕ@Ÿ, ”’ˆä‹łŽq2, “c‹v•Ű”üç‘ă2, ˆäăŸ•v3, Šâ–ž—D”ü4 (1“ű‘BEbó‘BŠO, 2ŠĹŒě•”, 3¸_, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć31‰ń“ú–{ƒTƒCƒRƒIƒ“ƒRƒƒW[Šw‰ď‘‰ď (2018/9/21-22), Îě.

723263. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Differential prognostic relevance of promoter DNA methylation of CDO1 gene and HOPX gene in primary breast cancer. “c’†—uŽq1, ŽR‰şŒpŽj2,3, Źâ–ůŒŤ4, Œ´“cG‹P1, ‰Ą“c˜aŽq1, ‹e’r^—Žq4, ź‹{—mŽj4, ‰Á“Ą@O4, ĺÎ‹I•F4, “n粏š•F5 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5‰ş•”Á‰ťŠÇŠO): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/27), ‘ĺă.

723264. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) BRCA1/2ˆâ“`Žq‹¤•ĎˆŮ‚Ě‚Ý‚ç‚ę‚˝HBOC‚Ě1—á. ˜m’J”ü“Ţ1, Źâ–ůŒŤ1, r–؏Ž”ü, ‚“cŽj’j2 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć63‰ń‘ĺ‰ď (2018/10/11), ‰Ą•l.

723265. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éƒpƒ‹ƒ{ƒVƒNƒŠƒuŽg—pÇ—á‚ĚŒŸ“˘. ‹e’r^—Žq1, Źâ–ůŒŤ1, ‰Ş–{@—¤2, ćс@—T—ş2, “c’†—uŽq3, ź‹{—mŽj1, ‰Á“Ą@O1, ĺÎ‹I•F1, “n粏š•F2 (1“ű‘BEbó‘BŠO, 2‰ş•”Á‰ťŠÇŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/18), ‰Ą•l.

723266. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}‘Ź‘‘ĺ‚đ”F‚ߏ€‹Ů‹}Žčp‚Ş•K—v‚Ĺ‚ ‚Á‚˝“ű‘B”S‰tŠŕ‚Ě1—á. ‰Ş–{@—¤1, ‹e’r^—Žq2, Źâ–ůŒŤ2, ź‹{—mŽj2, ĺÎ‹I•F2, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO, 2“ű‘BEbó‘BŠO): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/19), ‰Ą•l.

723267. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒzƒ‹ƒ‚ƒ“Žó—e‘Ě—zŤCHER2‰AŤ, Ki67‚’l‚̐ZŤ“űŠÇŠŕ‚ɍĔ­‚ÉŠÖ‚ˇ‚錟“˘. ćс@—T—ş1, ź‹{—mŽj2, “c’†—uŽq3, ‹e’r^—Žq2, ‰Á“Ą@O2, Źâ–ůŒŤ2, ĺÎ‹I•F2, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO, 2“ű‘BEbó‘BŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/19), ‰Ą•l.

733093. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œ´”­“űŠŕ‚É‚¨‚Ż‚éGCNT2ˆâ“`Žqƒƒ`ƒ‹‰ť‚Ě—Ő°•a—Šw“IˆÓ‹`. “c’†—uŽq1, ŽR‰şŒpŽj2,3, Œ´“cG‹P1, ‰Ą“c˜aŽq1, ’†–{CŽi1, “Y–ěF•ś1, “ĄŽR–FŽ÷1, ‰Ą“cŒő‰›1, Źâ–ůŒŤ4, “n粏š•F4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5‰ş•”Á‰ťŠÇŠO): ‘ć38‰ń“ú–{•ŞŽqŽîᇃ}[ƒJ[Œ¤‹†‰ď (2018/9/26), ‘ĺă.


ˆę”ʁEŹŽ™EŠĚ’_äXŠO‰ČŠw

[Šwp˜_•ś]

110191. [Œ´’˜] The potentiality of laparoscopic partial liver excisional biopsy using analysis of the liver surface based on preoperative 3D simulation imaging: A case report. Ei S, Itano O, Yoshida H, Ojima H, Shimoda M, Uchida H, Maeda S, Kumamoto Y1, Aiko S: Int J Surg Case Rep 2018; 45: 33-7. (ŒGŒł—Y‰î1: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

110027. [Œ´’˜] Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice. Nishizawa N1, Ito Y2, Eshima K3, Ohkubo H4, Kojo K5, Inoue T6, Raouf J, Jakobsson PJ, Uematsu S, Akira S, Narumiya S, Watanabe M5, Majima M2: J Hepatol 2018/6; 69 (1): 110-20. (źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ]“‡k“ń3, ‘ĺ‹v•Ű”Ž˘4, ŒĂé@Œ›5, ˆäă’qm6, “n粏š•F5, ”n“ˆł—˛2: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3–Ɖu, 4S‘ŸŒŒŠÇŠO, 5‰ş•”Á‰ťŠÇŠO, 6‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110192. [Œ´’˜] Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma. Nakamoto S1, Kumamoto Y2, Igarashi K1, Fujiyama Y1, Nishizawa N2, Ei S2, Tajima H2, Kaizu T2, Watanabe M3, Yamashita K4,5: PLoS One 2018/10; 13 (10): e0205864. (’†–{CŽi1, ŒGŒł—Y‰î2, ŒÜ\—’ˆę°1, “ĄŽR–FŽ÷1, źŕVL‹ą2, ‰i@Žœ‹ł2, “c“‡@O2, ŠC’Ă‹MŽj2, “n粏š•F3, ŽR‰şŒpŽj4,5: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5ă•”Á‰ťŠÇŠO)

110193. [Œ´’˜] Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma. Kumamoto Y1, Kaizu T1, Tajima H1, Nishizawa N1, Ei S1, Igarashi K2, Watanabe M3: Mol Clin Oncol 2018/10; 9 (4): 362-8. (ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Ž ‹ł1, ŒÜ\—’ˆę°2, “n粏š•F3: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO)

110194. [Œ´’˜] Patients' preoperative background causes gastric stasis after laparoscopy-assisted pylorus-preserving gastrectomy. Nishizawa N1, Hosoda K2, Moriya H2, Mieno H2, Ema A2, Ushiku H2, Ishii S2, Tanaka T2, Washio M2, Yokoi K3, Harada H4, Watanabe M3, Yamashita K2,5: Asian J Endosc Surg 2018/11; 11 (4): 337-45. (źŕVL‹ą1, ×“c@Œj2, X’JGŒő2, ŽOd–ě_˜N2, ]ŠÔ@—ć2, ‹‹vGŽ÷2, Îˆä@’q2, “c’†r“š2, ˜h”ö^—ˆ¤2, ‰ĄˆäŒ\Œĺ3, Œ´“cG‹P4, “n粏š•F3, ŽR‰şŒpŽj2,5: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110195. [Œ´’˜] Expression of Kita-Kyushu Lung Cancer Antigen-1 as detected by a novel monoclonal antibody in gastric cancer. Takahashi Y1, Fukuyama T, Futawatari N, Ichiki Y, Ohmiya H, Chuman M, Yamashita T, Hiki N2, Kumamoto Y1, Yamazaki H3, Nonoguchi H, Nishi Y, Kobayashi N: Anticancer Research 2019/11; 39 (11): 6259-63. (‚‹´’ől1, ”äŠé’źŽ÷2, ŒGŒł—Y‰î1, ŽRč@“™3: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3•a—)

110196. [Œ´’˜] Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a K-ras gene mutation in pancreatic ductal adenocarcinoma. Nishizawa N1, Kumamoto Y1, Katoh H2, Ushiku H3, Yokoi K4, Tanaka T3, Ishii S4, Igarashi K5, Tajima H1, Kaizu T1, Yoshida T6, Saegusa M6, Watanabe M4, Yamashita K3,7: Oncol Lett 2019/2; 17 (2): 2141-50. (źŕVL‹ą1, ŒGŒł—Y‰î1, ‰Á“Ą@O2, ‹‹vGŽ÷3, ‰ĄˆäŒ\Œĺ4, “c’†r“š3, Îˆä@’q4, ŒÜ\—’ˆę°5, “c“‡@O1, ŠC’Ă‹MŽj1, ‹g“c@Œ÷6, ŽOŽ}@M6, “n粏š•F4, ŽR‰şŒpŽj3,7: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2“ű‘BEbó‘BŠO, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO, 5‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 6•a—, 7V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

320008. [Ç—á•ń] ˆÝŠŕŠĚ“]ˆÚ‚ɑ΂ľ• o‹ž‰şŠĚ•”•ŞŘœ‚đŽ{s‚ľ‚˝1—á. Œă“Ą‘ě–ç1, ŠC’Ă‹MŽj2, “n粏š•F3, ŒGŒł—Y‰î2, “c“‡@O2, ‰Í–”@Š°, źŽR@—ş, ’†–{CŽi1 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO): “ú–{—Տ°ŠO‰ČŠw‰ďŽGŽ 2018/5; 79 (5): 1164.

320009. [Ç—á•ń] ×ŒaççŽq‚đ•š—p‚ľ• o‹ž‰ş‚ɐ؏œ‚ľ‚Ś‚˝• o_Œo‘p—R—ˆ_ŒoâŽî‚Ě1—á. â–{ƒˆę1, ŠC’Ă‹MŽj1, źŕVL‹ą1, “c“‡@O1, ŒGŒł—Y‰î1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ďŽGŽ 2019/3; 24 (2): 109-15.

522056. [uŔ]y“ÁW: ä`ƒwƒ‹ƒjƒA: Žčp‚Ćˆł”—z–Č‹…‚É‚ć‚éˆł”—–@. ŽR–{—T‹P1, “c’†@Œ‰1,2, •“cŒ›Žq, ’Ç–ŘGé1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ŹŽ™ŠO‰Č 2018/4; 50 (4): 381-4.

522057. [uŔ]y“ÁW: ‚ą‚ą‚ŞŠë‚Č‚˘ŹŽ™f—Ă‚ĚƒsƒbƒgƒtƒH[ƒ‹: “úíf—Õҁz‘lŒaƒwƒ‹ƒjƒA—ŢŽčp: ‘lŒa–@. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ŹŽ™ŠO‰Č 2018/8; 50 (8): 822-5.

522058. [uŔ]y“ÁW: ŠeŽíÁ‰ťŠÇƒXƒg[ƒ}ěŹ‚Ě“K‰ž‚ƏpŽŽE‡•šÇz‰“ˆĘ‘¤’°ŠÇ’“ü‚Ě‚˝‚ß‚Ě•Ş—ŁŽŽƒXƒg[ƒ}. “c’†@Œ‰1,2, ŽR–{—T‹P1, ’Ç–ŘGé1 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ŹŽ™ŠO‰Č 2018/9; 50 (9): 915-9.

’˜@‘]

620054. [Šwp‘ (•Ş’SŽˇ•M)]yä`‚ĚŠO‰Č@ŹŽ™‚Ěä`ŽžŠłŽĄ—Ă‚Ćä`‚đ—˜—p‚ľ‚˝ŽčpzII. ŽžŠłŠe˜_@ä`ƒwƒ‹ƒjƒA/ˆł”——Ă–@@ŽŔŰ‚ĚŽč‹Z‚ĆŽĄ—ÐŹŃ: –Č‹…, p.26-9. ŽR–{—T‹P1, “c’†@Œ‰1,2, •“cŒ›Žq1, ’Ç–ŘGé1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ŠÄC: “cŒű’qÍ, ŕ_“c‹g‘Ľ, •Ň: “yŠň@˛, ‰œŽRGb, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/8”­s.

620055. [Šwp‘ (•Ş’SŽˇ•M)]yä`‚ĚŠO‰Č@ŹŽ™‚Ěä`ŽžŠłŽĄ—Ă‚Ćä`‚đ—˜—p‚ľ‚˝ŽčpzIII. ä`‚đ—˜—p‚ľ‚˝Žčp@ä`‚Š‚ç‚ĚŽčp‚މ”\‚ČŽžŠłEŽčp@—‘‘ƒŽîáŽ, p.242-6. “c’†@Œ‰1,2, •“cŒ›Žq2, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO), ŠÄC: “cŒű’qÍ, ŕ_“c‹g‘Ľ, •Ň: “yŠň@˛, ‰œŽRGb, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/8”­s.

620056. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇ•Ť‡–@ƒoƒCƒuƒ‹z3Í ŠĚ’_äX—Ěˆć@8. äX‹ó’°•Ť‡–@|Š`“cŽŽ•Ť‡, p. 181-3. ŒGŒł—Y‰î (ˆę”ʁEŹŽ™EŠĚ’_äXŠO), ŠÄC: –k“‡­Ž÷, •Ň: ‹{ŕVŒő’j, ’|“ŕ—T–ç, ˆăŠw‘‰@, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713093. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Gross TypeA esophageal atresia with congenital tracheal diverticulum. Yamamoto Y1, Tanaka K1,2, Takeda N, Oiki H1, Goto T1, Watanabe M3: Pacific Association of Pediatric Surgeons 51th Annual Scientific Meeting (2018/5/13), Sapporo, Japan. (ŽR–{—T‹P1, “c’†@Œ‰1,2, •“cŒ›Žq, ’Ç–ŘGé1, Œă“Ą‘ě–ç1, “n粏š•F3: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3‰ş•”Á‰ťŠÇŠO)

722057. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) How to manage the bleeding or bile leakage in laparoscopic liver resection (LLR). ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “c“‡@O1, ‰i@Ž ‹ł1, źŕVL‹ą1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

722058. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘”rŸ•oˆâŽcÇ‚̏‰ŠúŽĄ—Ă‚É‚¨‚Ż‚é”r”AŠÇ—‚ɂ‚˘‚Ä. ŽR–{—T‹P1, “c’†@Œ‰1,2, ’Ç–ŘGé1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć34‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďH‹GƒVƒ“ƒ|ƒWƒEƒ€ (2018/10/27), “Œ‹ž.

723268. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒ’Eo‚𔺂¤—Ž™‘lŒaƒwƒ‹ƒjƒA‚É‘ŠúŽčp‚Í•K—v‚Š. ’Ç–ŘGé1, “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2018/5/30), VŠƒ.

723269. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝH“š‹t—ŹÇ‚ɑ΂ˇ‚é‹t—Ź–hŽ~Žčp‚Ě—L—pŤ. “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2018/5/30), VŠƒ.

723270. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć“VŤH“š•Â˝Ç‚É‚¨‚Ż‚ép‘O‹CŠÇ“ŕŽ‹‹žŒŸ¸‚ĚˆÓ‹`. “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2018/5/30), VŠƒ.

723271. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć“VŤH“š•Â˝Ç‚Ɛć“VŤSŽžŠł‚̍‡•š‚ɂ‚˘‚Ä. ŽR–{—T‹P1, “c’†@Œ‰1,2, •“cŒ›Žq, ’Ç–ŘGé1, “n粏š•F3 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2018/6/1), VŠƒ.

723272. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —LÇóÁ‰ťŠÇd•ĄÇ‚ĚŒŸ“˘. “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P1, ’Ç–ŘGé1 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć32‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2018/6/2), ‚‚­‚Î.

723273. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •Ą”ŒÂ‚Ě‹…Œ`ƒlƒIƒWƒ€ŽĽÎ‚đŒëˆů‚ľ, ˆÝ‹ó’°ú’Ę‚đ‚Ť‚˝‚ľ‚˝1—á. ’Ç–ŘGé1, “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć32‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2018/6/2), ‚‚­‚Î.

723274. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Values of NLR, PNI and mGPS for predicting postoperative morbidity in patients with biliary carcinomas. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Žœ‹ł1, ŒÜ\—’ˆę°2, “n粏š•F3 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO): ‘ć30‰ń“ú–{ŠĚ’_äXŠO‰ČŠw‰ďŠwpW‰ď (2018/6/8), ‰Ą•l.

723275. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ConversionŽčp‚đŽ{s‚ľ‚˝isäXŠŕÇ—á‚É‚¨‚Ż‚éPLR (Platelet to lymphocyte ratio) ‚Ć—\Œă‚Ě‘ŠŠÖ. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Žœ‹ł1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć49‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2018/6/29), ˜a‰ĚŽR.

723034. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2 (PGE2)-EP3Žó—e‘ĚƒVƒOƒiƒ‹‚É‚ć‚éŠĚ‘gDC•œ‘Łiě—p. ’†–{CŽi1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, “n粏š•F4, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć33‰ń“ú–{ShockŠw‰ď‘‰ď (2018/6/29), “Œ‹ž.

723276. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˘‰eCT‚ŞŒ_‹@‚Ć‚Č‚č”­Ç‚ľ‚˝VśŽ™‰óŽ€Ť’°‰Š‚Ě1—á. “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P1, ’Ç–ŘGé1, ’†źG•F2,3, ™›Ž@Šw3, ŽRŒűˆť”T3 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3ŹŽ™): ‘ć54‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2018/7/8), “Œ‹ž.

723035. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) mPGES-1‚̓}ƒNƒƒtƒ@[ƒW‚É‚¨‚Ż‚éEP4ƒVƒOƒiƒ‹‚đ‰î‚ľ‚ÄŠĚ‹•ŒŒÄŠÁ—ŹáŠQŒă‚̩̏C•œ‚đ’x‰„‚ł‚š‚é. źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ’†–{CŽi3, ŒÜ\—’ˆę°3, “ĄŽR–FŽ÷3, ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “n粏š•F4 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/11), Ž­Ž™“‡.

723277. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ťŠw—Ă–@‚É‚ć‚čConversionŽčp‚đŽ{s‚ľ‚˝isäXŠŕÇ—á‚Ě—Ő°Žîᇊw“IŒŸ“˘‚ĆNLR (Neutrophil to lymphocyte ratio) ‚ĚˆÓ‹`. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Ž ‹ł1, ŒÜ\—’ˆę°2, ’†–{CŽi2, “n粏š•F3 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723278. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é‘ĺ’°Šŕ“ŻŽžŤŠĚ“]ˆÚÇ—á‚É‚¨‚Ż‚é• o‹ž‰şŒ´”­‘ƒŠĚ“]ˆÚ‘ƒ“ŻŽžŘœp‚Ě‘Ă“–Ť‚ĚŒŸ“˘. ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, ’†–{CŽi2, źŕVL‹ą1, “c“‡@O1, ŒGŒł—Y‰î1, “n粏š•F3 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/13), Ž­Ž™“‡.

723279. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŠƒ“ƒpŠÇĂ–Ź•Ť‡‚É‚Ä‘ĺ‘Ú‚Š‚ç‚Ě“ű‚Ń‚Ě˜Ro‚ޏÁŽ¸‚ľ‚˝ƒŠƒ“ƒpŠÇŠďŒ`‚Ě1—á. “c’†@Œ‰1,2, ŽR–{—T‹P1, ’Ç–ŘGé1, ˛‹vŠÔP (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć15‰ń“ú–{ŒŒŠÇŽîŒŒŠÇŠďŒ`Šw‰ďŠwpW‰ď (2018/7/21), ‘ĺă.

723280. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş”ö‘¤äXŘœ‚Ĺ‚ĚNeedlescopicsurgery‚ĚŒŸ“˘. “c“‡@O1, ŒGŒł—Y‰î1, ‰i@Ž ‹ł1, źŕVL‹ą1, ŠC’Ă‹MŽj1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): 7th Reduced Port Surgery Forum 2018 in Sapporo (2018/8/3), ŽD–y.

723281. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şŠĚŘœ‚É‚¨‚Ż‚éReducedPortSurgery (RPS) ‚ĚŽŽ‚Ý. ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “c“‡@O1, ‰i@Ž ‹ł1, źŕVL‹ą1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): 7th Reduced Port Surgery Forum 2018 in Sapporo (2018/8/4), ŽD–y.

723282. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĚ”öó—t‹‘ĺ”X–EŤ•a•Ď‚ɑ΂ľ• o‹ž‰şspiegel—tŘœ‚đˆŔ‘S‚ɐ‹s‚ľ‚Ś‚˝1—á. ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, źŕVL‹ą1, “c“‡@O1, ŒGŒł—Y‰î1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): 7th Reduced Port Surgery Forum 2018 in Sapporo (2018/8/4), ŽD–y.

723283. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒlƒIƒWƒ€ŽĽÎŒëˆů‚É‚ć‚éˆÝ‹ó’°ú’ʂɑ΂ľ‚āC• o‹ž‰ş‚ÉˆŮ•¨“EoCúE•”•Â˝‚đs‚Á‚˝1—á. ’Ç–ŘGé1, “c’†@Œ‰1,2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/6), •Ÿ‰Ş.

723284. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Cantlie line‚Š‚ç‚Í‚ś‚Ü‚é• o‹ž‰şŠĚŘœ. ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “c“‡@O1, ‰i@Ž ‹ł1, źŕVL‹ą1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/7), •Ÿ‰Ş.

723285. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é• o‹ž‰ş• •Çፍ­ƒwƒ‹ƒjƒAC•œp‚ĚŒŸ“˘. ‰Ş–{ŒőŠóŽq1, ŠC’Ă‹MŽj2, “c“‡@O2, ‰i@Ž ‹ł2, źŕVL‹ą2, ŽO‰YŒ[šć3, ’†‘ş—˛r3, ŒGŒł—Y‰î2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723286. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PMN‚ɑ΂ˇ‚é• o‹ž‰şäX‘Ě”ö•”Řœ‚̐ŹŃ. źŕVL‹ą1, “c“‡@O1, ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723287. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă• •”ŽčpŠů‰—đ‚Ě‚ ‚éÇ—á‚É‚¨‚Ż‚é• o‹ž‰şŠĚŘœp‚Ě’ZŠúŹŃ‚ĆŽčp‚Ěƒ|ƒCƒ“ƒg. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Ž ‹ł1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723288. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é• o‹ž‰şŠĚŘœp‚ĚŽčpŹŃ‚Ć“K‰žŒŔŠE‚ĚŒŸ“˘. ‰i@Ž ‹ł1, ŠC’Ă‹MŽj1, źŕVL‹ą1, “c“‡@O1, ŒGŒł—Y‰î1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723289. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äXŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş”ö‘¤äXŘœp. “c“‡@O1, ŒGŒł—Y‰î1, ‰i@Ž ‹ł1, źŕVL‹ą1, ŠC’Ă‹MŽj1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723036. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Prostaglandin E receptor subtype EP3 promotes liver repair after acute liver injury. ’†–{CŽi1, ˆÉ“Ą‹`–ç2, źŕVL‹ą3, ‘ĺ‹v•Ű”Ž˘4, “n粏š•F5, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4S‘ŸŒŒŠÇŠO, 5‰ş•”Á‰ťŠÇŠO): ‘ć44‰ń“ú–{”÷ŹzŠÂŠw‰ď‘‰ď (2019/2/8), ‘ĺ‹{.

733094. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ä`ŒĘóŘŠJpŒăä`“ˏoÇ‚ɑ΂ˇ‚éä`Œ`Źp. “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć4‰ń“ú–{ŹŽ™‚Ö‚ťŒ¤‹†‰ď (2018/4/6), “Œ‹ž.

733095. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŠJ• ‚É‚ć‚鏬Ž™‚ĚˆÝᑑ˘Ýp. ’Ç–ŘGé1, “c’†@Œ‰1,2, •“cŒ›Žq, ŽR–{—T‹P2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć32‰ń“ú–{ŹŽ™ƒXƒg[ƒ}E”rŸ•E‘nŠÇ—Œ¤‹†‰ď (2018/6/30), “Œ‹ž.

733096. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘˝”‰ńŠJ• pŒă‚Ě–ü’…‚É‚ć‚čdÇäX‰ŠE’°ŠÇ‰óŽ€‚đ‹N‚ą‚ľ‚˝Œă, ˆÝ‹ó’°•Ť‡p‚đŽ{s‚ľ‚˝SotosÇŒóŒQ‚Ěˆę—á. •“cŒ›Žq, “c’†@Œ‰1,2, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć34‰ń_“ŢěŒ§ŹŽ™ŠĚEÁ‰ťŠíŽžŠłŒ¤‹†‰ď (2018/9/8), ‰Ą•l.

733097. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ć“VŤ‹ó’°•Â˝Ç‚Əoś‘Of’f‚ł‚ę‚˝’°‰ń“]ˆŮíÇE’†’°Ž˛”P“]‚Ě1—á. ‰Ş–{@—¤1, “c’†@Œ‰2,3, ŽR–{—T‹P3, ’Ç–ŘGé3 (1‰ş•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć53‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/10/13), “Œ‹ž.

733098. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) VśŽ™ƒƒbƒPƒ‹ŒeŽşúE‚Ě1—á. ‹ŕ“c’—Ç1, ŽR–{—T‹P2, ’Ç–ŘGé2, “c’†@Œ‰2,3, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć53‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/10/13), “Œ‹ž.

733099. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘”rŸ•oŠO”˝ÇCäSŒ‡‘šÇ‚ɑ΂ľ‚ÄŽq‹{äNă÷•Ť‡‚É‚ÄŒoŒŒ˜H‚đŠm•Ű‚ľ‚˝1—á. ’Ç–ŘGé1, “c’†@Œ‰1,2, ŽR–{—T‹P1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć38‰ń“ú–{ŹŽ™“ŕŽ‹‹žŠO‰ČEŽčpŽč‹ZŒ¤‹†‰ď (2018/10/25), “Œ‹ž.

733100. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —\–h“IR‹Ű–ň“Š—^‚É‚ć‚č’†SĂ–ŹƒJƒe[ƒeƒ‹Š´őÇ‚đ‰ń”đ‚ľ‚Ä‚˘‚é1—á. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć48‰ń“ú–{ŹŽ™ŠO‰Č‘ăŽÓŒ¤‹†‰ď (2018/10/25), “Œ‹ž.

733101. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰AŒs”A“šC”A“š‹ˇó, HŒ^äNă÷äTᑂ𔺂Á‚˝”ĺ”AśB“´ŠďŒ`‚̏—Ž™2—á. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’Ç–ŘGé2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć75‰ń’ź’°ăč–ĺŠďŒ`Œ¤‹†‰ď (2018/10/26), “Œ‹ž.

733102. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “űŽ™‘Šú‚ĚŠŠ’Eƒwƒ‹ƒjƒA‚ɑ΂ˇ‚鎥—Ă•űj. ’Ç–ŘGé1, “c’†@Œ‰1,2, ŽR–{—T‹P1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć10‰ń_“ސěƒwƒ‹ƒjƒAŒ¤‹†‰ď (2018/12/1), ‰Ą•l.

733103. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰AŒs”A“šC”A“š‹ˇóCHŒ^äNă÷äTᑂ𔺂Á‚˝”ĺ”AśB“´ŠďŒ`‚̏—Ž™2—á. ăź—Rš1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’Ç–ŘGé1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć153‰ń_“ŢěŒ§—Տ°ŠO‰ČˆăŠw‰ďW’k‰ď (2018/12/22), ‰Ą•l.

733104. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • o‹ž‰ş‘’_ŠÇŠg’ŁÇŽčp“ą“ü‚ÉŒü‚Ż‚Ä. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰i@Ž ‹ł1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć8‰ń• o‹ž‰ş’_“šŽčpŒ¤‹†‰ď (2019/2/16), ‰Ť“ę.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110014. [Œ´’˜] Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma. Kumamoto Y1, Kaizu T1, Tajima H1, Nishizawa N1, Ei S1, Igarashi K2, Watanabe M3: Mol Clin Oncol 2018/1; 9 (4): 362-8. (ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‰i@Žœ‹ł1, ŒÜ\—’ˆę°2, “n粏š•F3: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO)

H29-110006. [Œ´’˜] Inhibition of mPGES-1 protects the liver from ischemia/reperfusion injury through prostanoid EP2 receptor. Nishizawa N1, Ito Y2, Inoue T3, Nakamoto S3, Otaka F3, Tsuru S3, Hattori K3, Akira A, Watanabe M4, Majima M2: Kitasato Med J 2018/3; 48 (1): 26-34. (źŕVL‹ą1, ˆÉ“Ą‹`–ç2, ˆäă’qm3, ’†–{CŽi3, ‘ĺ‚Žjš3, “s—Ż˘—˘3, •ž•”‹żŽq3, “n粏š•F4, ”n“ˆł—˛2: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO)

H29-320001. [Ç—á•ń] • o‹ž‰ş’_”X“Eop9”NŒă‚É—Ž‰şŒ‹Î‚É‚ć‚é• o“ŕ”^ᇁE• •Ç”^ᇂ𔭏ǂľ, ŠJ• Žčp‚đ—v‚ľ‚˝1—á. “‡’Á@Ť, ŒGŒł—Y‰î1, ‰i‰ŞNŽu, ˆÉ–ě˜a”n, “ĄŽR–FŽ÷, “c“‡@O1, ŠC’Ă‹MŽj1, ’†‘ş—˛r2, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): _“ސěˆăŠw‰ďŽGŽ 2018/1; 45 (1): 1-7

H29-320002. [Ç—á•ń] • o‹ž‰şŠĚŠO‘¤‹ćˆćŘœp‚đŽ{s‚ľ‚˝ŠĚ“ŕŒ‹ÎÇ‚Ě1—á. ’†”nŠî”Ž1, ŠC’Ă‹MŽj2, ‘ěG‹P, ‹ŕŽR–F˜Y, “c’†—uŽq3, ‰Í–”@Š°, źŽR@—ş, “c“‡@O2, ŒGŒł—Y‰î2, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): _“ސěˆăŠw‰ďŽGŽ 2018/1; 45 (1): 25.

H29-320003. [Ç—á•ń] ‰ťŠw—Ă–@Ž{sŒă‚É‘ĺ’°ŠŕŠĚ“]ˆÚ‚Ş‹^‚í‚ę‚˝1—á. “Ą”örˆň, źŽR@—ş, ‘ĺ•”@˝, ‰Í–”@Š°, “c“‡@O1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): “ú–{—Տ°ŠO‰ČŠw‰ďŽGŽ 2018/3; 79 (3); 658-9.

H29-522001. [uŔ]y“ÁW: “O’ę‰đŕ! äX“ޏ\“ńŽw’°Řœ‚ĚŽčpŽč‹ZzĄŽčpŽč‹Z@äXÁ‰ťŠÇ•Ť‡|Š`“c–@. ŒGŒł—Y‰î (ˆę”ʁEŹŽ™EŠĚ’_äXŠO): —Տ°ŠO‰Č 2018/3; 73 (3): 310-3.


ă•”Á‰ťŠÇŠO‰ČŠw

[Šwp˜_•ś]

110197. [Œ´’˜] Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer. Araki I1, Washio M1, Yamashita K1,2, Hosoda K1, Ema A1, Mieno H1, Moriya H1, Katada N, Kikuchi S3, Watanabe M4: Surg Today 2018/5; 48 (5): 478-85. (r–Řˆę•ş‘ž1, ˜h”ö”ü“Ţ1, ŽR‰şŒpŽj1,2, ×“c@Œj1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, ‹e’rŽj˜Y3, “n粏š•F4: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 34•a‰@˜AŒg‹łˆç, 4‰ş•”Á‰ťŠÇŠO)

110198. [Œ´’˜] Carcinosarcoma of the esophagus: A report of 6 cases associated with zinc finger E-box-binding homeobox 1 expression. Harada H1, Hosoda K2, Moriya H2, Mieno H2, Ema A2, Washio M2, Kikuchi M2, Kosaka Y3, Watanabe M4, Yamashita K2,5: Oncol Lett 2019/1; 17 (1): 578-86. (Œ´“cG‹P1, ×“c@Œj2, X’JGŒő2, ŽOd–ě_˜N2, ]ŠÔ@—ć2, ˜h”ö^—ˆ¤2, ‹e’r^—Žq2, Źâ–ůŒŤ3, “n粏š•F4, ŽR‰şŒpŽj2,5: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ă•”Á‰ťŠÇŠO, 3“ű‘BEbó‘BŠO, 4‰ş•”Á‰ťŠÇŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110199. [Œ´’˜] Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. Aoyama T, Yoshikawa T, Ida S, Cho H, Sakamaki K, Ito Y, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Oshima T, Nunobe S, Hiki N1: J Cancer 2019/1; 10 (5): 1070-6. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110200. [Œ´’˜] Laparoscopic endoscopic cooperative surgery (LECS) for the gastrointestinal tract: Updated indications. Hiki N1, Nunobe S: Ann Gastroenterol Surg 2019/2; 3 (3): 239-46. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

310013. [Ç—á•ń] Expression of KK-LC-1, a cancer/testis antigen, at non-tumour sites of the stomach carrying a tumour. Fukuyama T, Futawatari N, Yamamura R, Yamazaki T, Ichiki Y, Ema A1, Ushiku H1, Nishi Y, Takahashi Y1,2, Otsuka T2,3, Yamazaki H2,4, Koizumi W3, Yasumoto K, Kobayashi N: Sci Rep 2018/4; 8 (1): 6131. (]ŠÔ@—ć1, ‹‹vGŽ÷1, ‚‹´’ől1,2, ‘ĺ’ˏr˜a2,3, ŽRč@“™2,4, Źň˜aŽO˜Y3: 1ă•”Á‰ťŠÇŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3Á‰ťŠí“ŕ, 4•a—)

310014. [Ç—á•ń] Esophagogastric junction cancer successfully treated by laparoscopic proximal gastrectomy and lower esophagectomy with intrathoracic double-flap technique: A case report. Hosoda K1, Yamashita K1,2, Moriya H1, Washio M1, Mieno H1, Ema A1, Watanabe M3: Asian J Endosc Surg 2018/5; 11 (2): 160-4. (×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ˜h”ö^—ˆ¤1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, “n粏š•F3: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO)

320010. [Ç—á•ń] –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚É‚ć‚Á‚Đś‚ś‚˝1Œ^“œ”A•a‚ɃJ[ƒ{ƒJƒEƒ“ƒg–@‚Ş—LŒř‚Ĺ‚ ‚Á‚˝Š{‰ş‘BŠŕ‚Ě1—á. ‰|“cŽ •ä, ŒF’JŒúŽu, –]ŒŽG”ü, ’†űMFŽu, ˆä“c@’q, •ő@^Ži, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): JSPEN 2019/2; 1 (1): 33-7.

510004. [‘ŕ] Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Yamashita K1,2, Hosoda K2, Nishizawa N3, Katoh H4, Watanabe M5: Cancer Sci 2018/12; 109 (12): 3695-706. (ŽR‰şŒpŽj1,2, ×“c@Œj2, źŕVL‹ą3, ‰Á“Ą@O4, “n粏š•F5: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4“ű‘BEbó‘BŠO, 5‰ş•”Á‰ťŠÇŠO)

520008. [‘ŕ] ă•”Á‰ťŠÇŠŕ‚É‚¨‚Ż‚é•ŞŽqˆŮí. ×“c@Œj1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): –k—˘ˆăŠw 2018/12; 48 (2): 77-84.

522059. [uŔ]yƒƒ{ƒbƒgŽx‰‡‰şŽčp‚ĚĹ‘Oüz[Še˜_] ˆÝŠŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡‰şˆÝŘœp. ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ˆăŠw‚Ě‚ ‚ä‚Ý 2018/10; 267 (1): 76-82.

’˜@‘]

620057. [Šwp‘ (•Ş’SŽˇ•M)]yH“šŠŕ (‘ć2”Ĺ)|Šî‘bE—Տ°Œ¤‹†‚̐i•ŕ| (“ú–{—ŐŕŹ76ŠŞ‘Š§†8)zVIII. H“šŠŕ‚ĚŽĄ—Á@4. ‰ťŠw—Ă–@@(1) p‘OEpŒă•â•‰ťŠw—Ă–@, p.360-9. ×“c@Œj1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), “ú–{—Ő଎Đ, “Œ‹ž, 2018/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713094. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Shot-Term Outcomes of Laparoscopy-Assisted Proximal Gastrectomy Using the Double-Flap Technique as Compared with the OrVil Technique. Hosoda K1, Yamashita K1,2, Moriya H1, Mieno H1, Ema A1, Washio M1, Watanabe M3: 26th International Congress of the European Association for Endoscopic Surgery (2018/5/31), London, UK. (×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ˜h”ö^—ˆ¤1, “n粏š•F3: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO)

713095. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Robotic Distal Gastrectomy with Lymph Node Dissection for Gastric Cancer. Yamashita K1,2, Hosoda K2, Mieno H2, Ema A2: CLINICAL CONGRESS2018 (2018/10/25), Boston, USA. (ŽR‰şŒpŽj1,2, ×“c@Œj2, ,ŽOd–ě_˜N2, ]ŠÔ@—ć2: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO)

722059. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Preoperative chemotherapy for Siewert type II esophagogastric junction cancer. ×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ˜h”ö^—ˆ¤1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

722060. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚“xisˆÝŠŕ‚ɑ΂ˇ‚éDCS—Ă–@Œă‚̐؏œŹŃ. ×“c@Œj1, ŽOd–ě_˜N1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, X’JGŒő1, “Œ@’q3, “c糁@‘3,4, Źň˜aŽO˜Y3, “n粏š•F5 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă, 5‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

722061. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) • o‹ž‰şˆÝ‘S“E‚É‚¨‚Ż‚éOrVil–@‚Ć”äŠr‚ľ‚˝FEEA‚É‚ć‚éH“š‹ó’°•Ť‡. ×“c@Œj1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć43‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2018/6/23), “Œ‹ž.

722062. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) A phase II trial of robotic distal gastrectomy for stage IA gastric cancer. ×“c@Œj1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): JDDW 2018 (2018/11/2), _ŒË.

722063. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆÝŘœp‘OŒo’°‰h—{—Ă–@‚ĚˆÓ‹`. ˆä“c@’q, ”äŠé’źŽ÷1, ź”öG”ü, ŒF’JŒúŽu, •ő@^Ži (1ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/14), “Œ‹ž.

722064. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —Տ°‰h—{‘ăŽÓę–ĺ—Ă–@Žm (‰źĚ) §“x‚ĚŠT—Ş. ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ď (2019/2/15), “Œ‹ž.

722065. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —Տ°‰h—{‘ăŽÓę–ĺ—Ă–@Žm”F’čŽč‘ą‚Ť‚ɂ‚˘‚Ä (Žb’č”F’č‚đŠÜ‚Ţ). ”Ń“‡ł•˝1, “ç’JŒ\G2, ”äŠé’źŽ÷3 (1‘ĺă‘Ű‚Ş‚ńƒZƒ“ƒ^[, 2ç—tŒ§‚Ş‚ńƒZƒ“ƒ^[, 3ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ď (2019/2/15), “Œ‹ž.

723290. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕpŒă‚ĚS-1 compliance‚ɉe‹ż‚đ‹y‚Ú‚ˇŽüpŠúˆöŽq‚ĚŒŸ“˘`S-1 compliance‚ĚŒüă‚đ–ÚŽw‚ľ‚ā`. ×“c@Œj1, ]ŠÔ@—ć1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723291. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕE‘ĺ’°‚Ş‚ń‚É‚¨‚Ż‚éd—v‚Č—\Œă—\‘ރ}[ƒJ[‚Ĺ‚ ‚éŠŕ“ÁˆŮ“ICysteine dioxygenase type 1 (CDO1) ˆâ“`Žq‚ĚDNAƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. ×“c@Œj1, Œ´“cG‹P2, ŽR‰şŒpŽj1,3, Ź›¸Œc‘ž2, ‰ĄˆäŒ\Œá4, ˜h”ö^—ˆ¤, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723292. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şˆÝ‘S“Ep‚É‚¨‚Ż‚éH“š‹ó’°•Ť‡–@‚ĚŒŸ“˘. ×“c@Œj1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, Œ´“cG‹P3, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723293. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ’°Šŕ‚É‚¨‚Ż‚éCDO1ˆâ“`Žq‚Ěƒƒ`ƒ‹‰ťˆŮí‚Ćƒ~ƒgƒRƒ“ƒhƒŠƒA–Œ“dˆĘ‚Ö‚Ěě—p‚đ‰î‚ľ‚˝‰ťŠw—Ă–@Š´ŽóŤ‚ɂ‚˘‚Ä. Ź›¸Œc‘ž1, ŽR‰şŒpŽj2,3, ‰ĄˆäŒ\Œĺ4, ‰Ą“c˜aŽq1, ‘ĺň—z‰î1, ŒÜ\—’ˆę°1, “c’†r“š4, ‰Á“Ą@O5, “n粏š•F4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/6), “Œ‹ž.

723294. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹›œˆÝ•Çú’Ę‚É‚ć‚éŠĚ”^ᇂɑ΂ľC• o‹ž‰şˆŮ•¨œ‹Žp‚đŽ{s‚ľ‚˝1—á. ×“c@Œj1, ‹ŕ“c’—Ç2, ˜h”ö^—ˆ¤1, Œă“Ą‘ě–ç3, ‰i‰ŞNŽu, Œ´“cG‹P4, ]ŠÔ@—ć1, X’JGŒő1, “n粏š•F2, ŽR‰şŒpŽj1,5 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć43‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2018/6/22), “Œ‹ž.

723295. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŘœŒă\“ńŽw’°’f’[leak‚É‚ć‚é• o“ŕoŒŒ‚ɏp’†ŒoƒJƒe[ƒeƒ‹“Ž–ŹÇđ‚đŽ{s‚ľ‚˝ˆę—á. ×“c@Œj1, “ĄŽR–FŽ÷2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽR‰şŒpŽj1,3, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć43‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2018/6/23), “Œ‹ž.

723296. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şˆÝ‘S“E‚É‚¨‚Ż‚éOrVil–@‚Ć”äŠr‚ľ‚˝FEEA‚É‚ć‚éH“š‹ó’°•Ť‡. ×“c@Œj1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć43‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2018/6/23), “Œ‹ž.

723297. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) T3H“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚鎥—Ð헪. ×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723298. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰“Šu“]ˆÚStage IVH“šŠŕ‚É‚¨‚Ż‚éƒRƒ“ƒo[ƒWƒ‡ƒ“Žčp‚̉”\Ť‚ĚŒŸ“˘. ×“c@Œj1, ‹‹vGŽ÷1, ŽR‰şŒpŽj1,2, Œ´“cG‹P3, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723299. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚鎥—Ð헪. ×“c@Œj1, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723300. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šG•˝ă”çŠŕ‚É‚¨‚Ż‚éHDAC‘jŠQÜ (OBP-801) ‚ĚŠ´ŽóŤ‹K’čˆöŽqŒó•â‚Ě“Ż’č. ×“c@Œj1, ‘ĺň—z‰î2, ŽR‰şŒpŽj1,3, ŒÜ\—’ˆę°2, Ź›¸Œc‘ž2, ˜h”ö^—ˆ¤, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723301. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) čň•”H“šŠŕ‚Ě“Á’Ľ‚ĆŽĄ—Ð헪. ×“c@Œj1, X’JGŒő1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723302. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) BarrettH“šŠŕ‚É‚¨‚Ż‚écysteine dioxygenase type 1ˆâ“`Žq‚Ěƒƒ`ƒ‹‰ťˆŮí‚Ć—Ő°“IˆÓ‹`. ×“c@Œj1, Ź›¸Œc‘ž2, ŽR‰şŒpŽj1,3, ‹‹vGŽ÷1, ‘ĺň—z‰î2, ŒÜ\—’ˆę°2, ŽOd–ě_˜N1, X’JGŒő1, “c糁@‘4,5, “n粏š•F6 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4Á‰ťŠí“ŕ, 5V˘‹Iˆă—ÁEć’[ˆă—Ă, 6‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/29), ‰F“s‹{.

723303. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) GERDÇ—á‚ɑ΂ˇ‚é• o‹ž‰şŽčpŒă‚̐H“š‰^“Ž‹@”\‰ü‘P‚ÉŠÖ‚ˇ‚錟“˘. ×“c@Œj1, ˜h”ö^—ˆ¤1, Œ´“cG‹P2, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “nç˛ š•F3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/29), ‰F“s‹{.

723304. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇE”ń‚—îŽŇH“šŠŕ‚ɑ΂ˇ‚鍪ŽĄ“IŽĄ—Ă‚É‚¨‚Ż‚鎥—ÐŹŃ‚ĚŒŸ“˘. ×“c@Œj1, Œ´“cG‹P2, ŽR‰şŒpŽj1,3, Œ˜“ce—˜4, ŹXłŽq5, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F6 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4Á‰ťŠí“ŕ, 5•úŽËü (Žîá‡), 6‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/29), ‰F“s‹{.

723305. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŠŕ“ŻŽžŤ‘ź‘ŸŠíd•ĄŠŕ Induction Chemotherapy Œă‚ĚŽĄ—Ð헪. ×“c@Œj1, ]ŠÔ@—ć1, X’JGŒő1, Œ´“cG‹P2, Œ˜“ce—˜3, ŹXłŽq4, ˜h”ö^—ˆ¤1, ŽOd–ě_˜N1, “n粏š•F5, ŽR‰şŒpŽj1,6 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Á‰ťŠí“ŕ, 4•úŽËü (Žîá‡), 5‰ş•”Á‰ťŠÇŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/29), ‰F“s‹{.

723306. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“š—ŢŠî’ę×–EŠŕ (BSC) ‚Ě—Ő°•a—Šw“I“Á’Ľ‚Ć–â‘č“_. ×“c@Œj1, ‘Œű@Ši2, X’JGŒő1, ŽOd–ě_˜N1, ŽR‰şŒpŽj1,3, Ä“c–F‹v, ‘’nM–ç, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2•úŽËü (Žîá‡), 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/29), ‰F“s‹{.

723307. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒgŠŕ‚É‚¨‚Ż‚éOBP-801Š´ŽóŤ‹K’čˆöŽq‚Ě“Ż’č. ‘ĺ’Ë—z‰î, ŽR‰şŒpŽj1,2, ŒÜ\—’ˆę°3, Ź›¸Œc‘ž3, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, ×“c@Œj1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/11), Ž­Ž™“‡.

723308. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚“xisˆÝŠŕ‚ɑ΂ˇ‚éDCS—Ă–@Œă‚̐؏œŹŃ. ŽOd–ě_˜N1, ŽR‰şŒpŽj1,2, ˜h”ö^—ˆ¤, ]ŠÔ@—ć1, X’JGŒő1, ×“c@Œj1, “Œ@’q3, Źň˜aŽO˜Y3, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/11), Ž­Ž™“‡.

723309. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ• –Œ”dŽí‚̐V‹Kf’f–@‚ĆŽĄ—Ă“W–]. ]ŠÔ@—ć1, ŽR‰şŒpŽj1,2, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ŽOd–ě_˜N1, X’JGŒő1, ×“c@Œj1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723310. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Řœ•s”\isˆÝŠŕ‚ɑ΂ˇ‚éDocetaxel+CDDP+S-1(DCS) conversion surgery. ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, Œ´“cG‹P3, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1 ×“c@Œj1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723311. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ’°‚ĚŠŕ‰ť‚É‚¨‚Ż‚éHOPXƒŔˆâ“`Žq‚Ěƒvƒƒ‚[ƒ^[—Ěˆć‚Ěƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. ‰Ą“c˜aŽq1, ŽR‰şŒpŽj2,3, “c’†—uŽq1, Œ´“cG‹P1, ‘ĺň—z‰î1, Ź›¸Œc‘ž1, “c’†r“š4, ‰ĄˆäŒ\Œá4 “n粏š•F4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723312. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ź’°Šŕp‘O‰ťŠw•úŽËü—Ă–@‚ĚŽĄ—ĂŒř‰Ę—\‘Ş. Ź›¸Œc‘ž1, ŽR‰şŒpŽj2,3, ‰ĄˆäŒ\Œĺ1, “c’†r“š4, ‘ĺň—z‰î1, ŒÜ\—’ˆę°1, ŽR—œ‚L4, ˛“Ą•˜Y4, ’†‘ş—˛r4, “n粏š•F4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723313. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕE‘ĺ’°Šŕ‚É‚¨‚Ż‚é—\Œă—\‘ރ}[ƒJ[‚Ĺ‚ ‚éŠŕ“ÁˆŮ“ICysteine dioxygenase type 1 (CDO1) ˆâ“`Žq‚ĚDNAƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. ×“c@Œj1, Œ´“cG‹P2, Ź›¸Œc‘ž2, ‰ĄˆäŒ\Œĺ2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F2, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/29), ‘ĺă.

723314. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 80ÎˆČă‚—îŽŇˆÝŠŕ‚ĚŽčpŹŃ‚ĆŒťó. ×“c@Œj1, ]ŠÔ@—ć1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŽOd–ě_˜N1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/18), ‰Ą•l.

723315. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O‰ťŠw—Ă–@Žž‘ă‚ĚcStage II/III H“šG•˝ă”çŠŕ‚ɑ΂ˇ‚éčň•”ƒŠƒ“ƒpßŠs´‚ĚˆÓ‹`. ×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, Œ˜“ce—˜3, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ, 4‰ş•”Á‰ťŠÇŠO): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/19), ‰Ą•l.

723316. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) GERDÇ—á‚ɑ΂ˇ‚é• o‹ž‰ş‹t—Ź–hŽ~Žčp (LARS) ‚ĚˆÓ‹`. ×“c@Œj1, ˜h”ö^—ˆ¤1, Œ´“cG‹P2, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, “n粏š•F3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): JDDW 2018 (2018/11/2), _ŒË.

723317. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šG•˝ă”çŠŕ‚É‚¨‚Ż‚éSOX2 ƒ˘Np63ˆâ“`Žq‘•‚ĚˆÓ‹`‚ÉŠÖ‚ˇ‚錟“˘. ×“c@Œj1, ‘ĺň—z‰î2, ŽR‰şŒpŽj1,3, Œ´“cG‹P2, ŒÜ\—’ˆę°2, Ź›¸Œc‘ž2, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, ‰Á“Ą@O4, “n粏š•F5 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4“ű‘BEbó‘BŠO, 5‰ş•”Á‰ťŠÇŠO): JDDW 2018 (2018/11/3), _ŒË.

723318. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡ˆÝŠŕŽčp‚Ě“Á’Ľ‚ƍĄŒă‚̉ۑč. ×“c@Œj1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/22), “Œ‹ž.

723319. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Řœ•s”\isˆÝŠŕ‚ɑ΂ˇ‚éDocetaxel + CDDP + S-1 (DCS) —Ă–@Œă‚̐؏œ—á‚ÉŠÖ‚ˇ‚錟“˘. ×“c@Œj1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, Œ´“cG‹P2, ]ŠÔ@—ć1, ŽOd–ě_˜N1, X’JGŒő1, ŽR‰şŒpŽj1,3, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/23), “Œ‹ž.

723320. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) cStage II/IIIH“šŠŕ•â•—Ă–@i•ŕ‚ĆŽĄ—Ă•Ď‘J. ×“c@Œj1, ŽR‰şŒpŽj1,2, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, “Œ@’q3, ÎŽR”ŽžŠ4, “n粏š•F5 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ, 4•úŽËü (Žîá‡), 5‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/23), “Œ‹ž.

723321. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) NOMI‚Ě“Ž’—Ă–@Œă‚̏Á‰ťŠÇoŒŒ‚ɑ΂ľ‚Ä‹~–˝‚ľ“ž‚˝ˆę—á. ×“c@Œj1, ’r‘ş‹ž”V‰î2, ŠŰŽRł—T3, ‹‹vGŽ÷1, â–{ƒˆę4, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, ŽR‰şŒpŽj1,5 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/24), “Œ‹ž.

723322. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 80ÎˆČă‚—îŽŇˆÝŠŕ‚ĚŠO‰ČŽĄ—ÐŹŃ‚Ć‚ť‚ĚŒť‹ľ. ]ŠÔ@—ć1, ×“c@Œj1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŽOd–ě_˜N1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/6), •Ÿ‰Ş.

723323. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹šo‹ž‰şH“šŘœpŽž‚É‚¨‚Ż‚é• ‰çˆĘ‚Ě“ą“ü‚ɂ‚˘‚Ä. ‹‹vGŽ÷1, ×“c@Œj1, X’JGŒő1, ˜h”ö^—ˆ¤, ]ŠÔ@—ć1, ŽOd–ě_˜N1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723324. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ŠúˆÝŠŕ‚ɑ΂ˇ‚é• o‹ž•â•‰ş—H–ĺ•Ű‘śˆÝŘœp (LAPPG). ˜h”ö^—ˆ¤1, ×“c@Œj1, Œ´“cG‹P2, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723325. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şˆÝŘœ‚É‚¨‚Ż‚é, #6, #8aŠs´•”ˆĘ‚ɉž‚ś‚˝ƒfƒoƒCƒX‚ĚŽg‚˘•Ş‚Ż. ŽOd–ě_˜N1, ×“c@Œj1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723326. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş•Ź–呤ˆÝŘœp‚É‚¨‚Ż‚éŠĎ‰šŠJ‚Ť–@‚̏pŒă’ZŠúŹŃ. ×“c@Œj1, ŽOd–ě_˜N1, ˜h”ö^—ˆ¤, ]ŠÔ@—ć1, ‹‹vGŽ÷1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/7), •Ÿ‰Ş.

723327. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒŠŕpŒă‡•šÇ‚ÉŠÖ˜A‚ˇ‚é—Տ°•a—Šw“IˆöŽq‚ĚŒŸ“˘‚Ɖh—{‰î“ü‚̉”\Ť. ‰|“cŽ •ä1, ŒF’JŒúŽu2, ź”öG”ü1, ‰Ş–ěˆŸŽq1, ŽRŒű@Ę1, ˆÉ’O—D‹MŽq1 ’†‰ŽŒb—œ1, ‚–Ř‹v”ü1, ě–źD1, ˆÉ‘ň—R‹IŽq1, ’†ŕ_FŽu1, ˆä“c@’q2, •ő@^Ži2, ”öźŒö•˝3, ”äŠé’źŽ÷2,4 (1‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@‰h—{ŠÇ—•”ENST, 2‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@Á‰ťŠíŠO‰Č, 3‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@•wl‰Č, 4ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/14), “Œ‹ž.

723328. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ¸—ʉh—{Žw“ą‚đŽ{s‚ľ‚˝“űŠŕŠÖ˜AăŽˆƒŠƒ“ƒp•‚ŽîŠłŽŇ‚É‚¨‚Ż‚é‘Ě‘gŹ‚̕ωť. ˆÉ’O—D‹MŽq1, •ő@^Ži1, ‰Ź’J˜NŽq2, ‰Ş–ěˆŸŽq1, ź”öç•ä3, “c’[@‘3, ź”öG”ü1, ˆä“c@’q4, ŒF’JŒúŽu4, ’†ŕ_FŽu1, •Đ‰Ş–ž”ü2, ă–ě‹M”V2, ‰F’Ă–Ř‹vmŽq5, ‘ĺ–ě^Ži2, ”äŠé’źŽ÷1,6 (1‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@‰h—{ŠÇ—•”ENST, 2‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@“ű‘BŠO‰Č, 3‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@ƒŠƒ“ƒp•‚ŽîŽĄ—ĂŽş, 4‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@Á‰ťŠíŠO‰Č, 5‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@•wl‰Č, 6ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/14), “Œ‹ž.

723329. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Şčň•”Šŕ‰ťŠw•úŽËü—Ă–@ŠłŽŇ‚É‚¨‚Ż‚éˆŔĂŽžƒGƒlƒ‹ƒM[‘ăŽÓ—Ę, ‰h—{ó‘Ԃ̐„ˆÚ‚ÉŠÖ‚ˇ‚錟“˘. ě–ź‰ÁD1, ‰|“cŽ •ä1, Ž™‹ĘŽě—2, ç—t—ćŽq2, â“c‘•c2, ‘O“‡ˆŸ”ü2, “Ą–Ř—R‰ŔŽq2, ×“c–ž”ü3, ŒF’JŒúŽu4, ’†ŕ_FŽu1, •ő@^Ži4, ˆä“c@’q4, ”äŠé’źŽ÷4,5 (1‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@‰h—{ŠÇ—•”, 2‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@ŠĹŒě•”, 3“Œ‹žˆă—Ă•ŰŒ’‘ĺŠwˆă—Ă•ŰŒ’Šw•”ˆă—Éh—{Šw‰Č, 4‚Ş‚ńŒ¤‹†‰ď—L–ž•a‰@Á‰ťŠíƒZƒ“ƒ^[, 5ă•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/15), “Œ‹ž.

723330. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pŒă‹}‘Ź‚ČŒo‰ß‚Ĺ• –Œ”dŽí‚đ‚Ť‚˝‚ľ‚˝‘ŠúˆÝŠŕ‚Ě1—á. ×“c@Œj1, ‰Ş–{@—¤2, ŽR‰şŒpŽj1,3, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ćс@—T—ş2 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/2/28), Ŕ’Ă.

723331. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŠŕŞŽĄŘœpŒă‚ĚˆÝŠÇŠŕ‚ɑ΂ľ‚Ä• o‹ž‰şˆÝŠÇŘœp‚đŽ{s‚ľ‚˝ˆę—á. ×“c@Œj1, “Ą”örˆň2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, ŽR‰şŒpŽj1,3, “n粏š•F2 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/2/28), Ŕ’Ă.

723332. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şˆÝ‘S“E (LATG) Ž{sÇ—á‚ĚŒŸ“˘, ƒZƒ“ƒ`ƒlƒ‹ƒiƒrƒQ[ƒVƒ‡ƒ“ (SN) •š—pŽčp‚đ‘z’č‚ľ‚Ä. ×“c@Œj1, ˜h”ö^—ˆ¤1, “Y–ěF•ś2, Œ´“cG‹P2, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/2/28), Ŕ’Ă.

723333. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡ˆÝŘœp‚ĚŽčpŽč‹Z‚Ć’ZŠúŹŃ. ×“c@Œj1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

723334. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CDO1ˆâ“`Žqƒƒ`ƒ‹‰ť‚đ—˜—p‚ľ‚˝‚Š´“xˆÝŠŕ• …DNAôň×–Ef‚ĚŠJ”­. ×“c@Œj1, “Y–ěF•ś2, ŽR‰şŒpŽj1,3, Œ´“cG‹P2, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

723335. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚“xisˆÝŠŕ‚ɑ΂ˇ‚éDocetaxel { CDDP { S-1 (DCS) —Ă–@Œă‚̐؏œŹŃ. ×“c@Œj1, ‹‹vGŽ÷1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ˜h”ö^—ˆ¤1, “Œ@’q2, “c糁@‘2,3, ŽR‰şŒpŽj1,4, Źň˜aŽO˜Y2, “n粏š•F5 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă, 5‰ş•”Á‰ťŠÇŠO): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

723336. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇˆÝŠŕ‚ĚŠO‰ČŽĄ—ÐŹŃ. ×“c@Œj1, ŽR‰şŒpŽj1,2, ]ŠÔ@—ć1, ŽOd–ě_˜N1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

723337. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ‚É‚¨‚Ż‚é—\Œă—\‘ރ}[ƒJ[‚Ć‚ľ‚Ä‚ĚMutL homolog 1 (MLH1) ƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. ×“c@Œj1, Œ´“cG‹P2, ŽR‰şŒpŽj1,3, “Y–ěF•ś2, ˜h”ö^—ˆ¤, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F4 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

723338. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚鎥—Ð헪. ×“c@Œj1, r–Řˆę•ş‘ž1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, ŽOd–ě_˜N1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć91‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2019/3/1), Ŕ’Ă.

733105. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŹŽ™ŠĚˆÚAŒă‚̉“ŠuŠú‚É‚Ý‚ç‚ę‚˝‰Á—î‚É‚ć‚é‚ĆŽv‚í‚ę‚éŠĚáŠQ‚Ě1—á. ‰i@Ž ‹ł1, ŒĂ“cˆę“ż, ’†“‡ßŽq2,3, źŕVL‹ą1, “c“‡@O1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1, “n粏š•F4, ‘ĺ•”@˝5 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ŠĹŒě•”, 3ˆÚAˆă—ĂŽx‰‡Žş, 4‰ş•”Á‰ťŠÇŠO, 5–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń_“ސěˆÚAˆăŠw‰ď (2018/6/2), _“ސě, _“ސěˆăŠw‰ďŽGŽ 2018/7; 45 (2): 260-1.

733106. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 80ÎˆČă‚—îŽŇˆÝŠŕ‚Ě“ŕŽ‹‹žŠO‰ČŽĄ—ÐŹŃ‚ĆŒťó. ]ŠÔ@—ć1, ×“c@Œj1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŽOd–ě_˜N1, X’JGŒő1, ŽR‰şŒpŽj1,2, “n粏š•F3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO): ‘ć47‰ń_“ŢěŒ§Á‰ťŠíŠO‰ČŒ¤‹†‰ď (2018/6/16), _“ސě.

733107. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Long Non-Coding RNA and Treatment Resistance in Human Cancer. ŽR‰şŒpŽj1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO): ‘ć10‰ń“ú–{RNAiŒ¤‹†‰ďE‘ć5‰ń“ú–{×–EŠOŹ–EŠw‰ďJSEV (2018/8/31), L“‡.

733108. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 80ÎˆČă‚—îŽŇˆÝŠŕ‚ĚŠO‰ČŽĄ—ÐŹŃ‚Ć‚ť‚ĚŒť‹ľ. ]ŠÔ@—ć1, ×“c@Œj1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŽOd–ě_˜N1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć27‰ńÁ‰ťŠíŽžŠł•a‘ÔŽĄ—ĂŒ¤‹†‰ď (2018/9/15), ‚’m.

733109. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šŕ“ÁˆŮ“Iƒƒ`ƒ‹‰ťˆČă‚đ—˜—p‚ľ‚˝ŽcˆÝŠŕ‚Ě’ZŠú”­Ç—\‘Ş. Ź›¸Œc‘ž1, ŽR‰şŒpŽj2,3, ‰Á“Ą@O4, ‘ĺň—z‰î1, ŒÜ\—’ˆę°1, źŕVL‹ą5, Œ´“cG‹P1, ‰Ą“c˜aŽq1, “c’†—uŽq1, ’†–{CŽi1, “n粏š•F6 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 6‰ş•”Á‰ťŠÇŠO): ‘ć38‰ń“ú–{•ŞŽqŽîᇃ}[ƒJ[Œ¤‹†‰ď (2018/9/26), ‘ĺă.

733110. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’_ůNŽžŠł‚É‚¨‚Ż‚éCD01ˆâ“`Žqƒvƒƒ‚[ƒ^[—ĚˆćDNAƒƒ`ƒ‹‰ť‚ĚŒŸ“˘. ŒÜ\—’ˆę°1, ŽR‰şŒpŽj2,3, ‰Á“Ą@O4, Ź›¸Œc‘ž1, źŕVL‹ą5, “c“‡@O5, ŠC’Ă‹MŽj5, ŒGŒł—Y‰î5, “n粏š•F6 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 6‰ş•”Á‰ťŠÇŠO): ‘ć38‰ń“ú–{•ŞŽqŽîᇃ}[ƒJ[Œ¤‹†‰ď (2018/9/26), ‘ĺă.

733111. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽcˆÝŠŕ‚É‚¨‚Ż‚é”­ś—\‘Ş‚É‚¨‚Ż‚郁ƒ`ƒ‹‰ť‚̉ž—p. ŽR‰şŒpŽj1,2, ×“c@Œj2, ŽOd–ě_˜N2, ]ŠÔ@—ć2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, “n粏š•F3 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć48‰ńˆÝŠO‰ČEpŒăáŠQŒ¤‹†‰ď (2018/11/9), Îě.

733112. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚“xisˆÝŠŕ‚ɑ΂ˇ‚éNAC-DCSŒă‚̐؏œŹŃ. ŽOd–ě_˜N1, ×“c@Œj1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ]ŠÔ@—ć1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć48‰ńˆÝŠO‰ČEpŒăáŠQŒ¤‹†‰ď (2018/11/10), Îě.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110015. [Œ´’˜] Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. Hosoda K1, Yamashita K1,2, Tsuruta H, Moriya H1, Mieno H1, Ema A1, Washio M1, Watanabe M3: Oncol Lett 2018/1; 15 (1): 1200-10. (×“c@Œj1, ŽR‰şŒpŽj1,2, X’JGŒő1, ŽOd–ě_˜N1, ]ŠÔ@—ć1, ˜h”ö^—ˆ¤1, “n粏š•F3: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO)

H29-110016. [Œ´’˜] Lauren histology and lymphatic permeation are critical prognostic factors in Borrmann type I gastric cancer. Yamashita K1,2, Katada N, Hosoda K2, Mieno H2, Moriya H,2 Kikuchi S3, Watanabe M4: International Surgery 2018/1-2; 103 (1-2): 95-104. (ŽR‰şŒpŽj1,2, ×“c@Œj2, ŽOd–ě_˜N2, X’JGŒő2, ‹e’rŽj˜Y3, “n粏š•F4: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO, 34•a‰@˜AŒg‹łˆç, 4‰ş•”Á‰ťŠÇŠO)

H29-110017. [Œ´’˜] Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy. Hosoda K1, Yamashita K1,2, Ushiku H1, Ema A1, Moriya H1, Mieno H1, Washio M1, Watanabe M3: Oncol Lett 2018/2; 15 (2): 1853-60. (×“c@Œj1, ŽR‰şŒpŽj1,2, ‹‹vGŽ÷1, ]ŠÔ@—ć1, X’JGŒő1, ŽOd–ě_˜N1, ˜h”ö^—ˆ¤1, “n粏š•F3: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO)

[Šw‰ďEŒ¤‹†‰ď“™]

H29-713003. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Identification the molecular mechanisms that explain a novel histone deacetylase inhibitor OBP-801 sensitivity in human cancer. Ooizumi Y1, Yamashita K2,3, Yokota K1, Igarashi K1, Kojima K1, Katoh H4, Yamanashi T5, Sato T5, Nakamura T5, Watanabe M5: Society Surgical Oncology 2018 (SSO2018) (2018/3/21), Chicago, USA. (‘ĺň—z‰î1, ŽR‰şŒpŽj2,3, ‰Ą“c˜aŽq1, ŒÜ\—’ˆę°1, Ź›¸Œc‘ž1, ‰Á“Ą@O4, ŽR—œ‚L5, ˛“Ą•˜Y5, ’†‘ş—˛r5, “n粏š•F5: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5‰ş•”Á‰ťŠÇŠO)


‰ş•”Á‰ťŠÇŠO‰ČŠw

[Šwp˜_•ś]

110201. [Œ´’˜] Laparoscopic surgery for locally advanced T4 colon cancer: the long-term outcomes and prognostic factors. Yamanashi T1, Nakamura T1, Sato T1, Naito M1, Miura H1, Tsutsui A1, Shimazu M1, Watanabe M1: Surg Today 2018/5; 48 (5): 534-44. (ŽR—œ‚L1, ’†‘ş—˛r1, ˛“Ą•˜Y1, “ŕ“Ął‹K1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO)

110202. [Œ´’˜] Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer. Kojima K1, Nakamura T2, Ohbu M, Katoh H3, Ooizumi Y1, Igarashi K1, Ishii S4, Tanaka T2, Yokoi K2, Nishizawa N5, Yokota K1, Kosaka Y3, Sato T2, Watanabe M2, Yamashita K4,6: PLoS One 2018/5; 13 (5): e0194785. (Ź›¸Œc‘ž1, ’†‘ş—˛r2, ‰Á“Ą@O3, ‘ĺň—z‰î1, ŒÜ\—’ˆę°1, Îˆä@’q4, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, źŕVL‹ą5, ‰Ą“c˜aŽq1, Źâ–ůŒŤ3, ˛“Ąr˜Y2, “n粏š•F2, ŽR‰şŒpŽj4,6: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO, 3“ű‘BEbó‘BŠO, 4ă•”Á‰ťŠÇŠO, 5ˆę”ʏŹŽ™EŠĚ’_äXŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110203. [Œ´’˜] Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer. Kojima K1, Nakamura T2, Ooizumi Y1, Igarashi K1, Tanaka T2 Yokoi K2, Ishii S3, Nishizawa N4, Katoh H5, Kosaka Y5, Sato T1, Watanabe M2, Yamashita K3,6: PLoS One 2019/1; 14 (1): e0211108. (Ź›¸Œc‘ž1, ’†‘ş—˛r2, ‘ĺň—z‰î1, ŒÜ\—’ˆę°1, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, Îˆä@’q3, źŕVL‹ą4, ‰Á“Ą@O5, Źâ–ůŒŤ5, ˛“Ąr˜Y2, “n粏š•F2, ŽR‰şŒpŽj3,6: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʏŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110204. [Œ´’˜] Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy. Yokoi K1, Harada H2, Yokota K2, Ishii S3, Tanaka T1, Nishizawa N4, Shimazu M1, Kojo K1, Miura H1, Yamanashi T1, Sato T1, Nakamura T1, Watanabe M1, Yamashita K3,5: Ann Surg Oncol 2019/2; 26 (2): 406-14. (‰ĄˆäŒ\Œĺ1, Œ´“cG‹P2, ‰Ą“c˜aŽq2, Îˆä@’q3, “c’†r“š1, źŕVL‹ą4, “‡’Á@Ť1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ąr˜Y1, ’†‘ş—˛r1, “n粏š•F1, ŽR‰şŒpŽj3,5: 1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʏŹŽ™EŠĚ’_äXŠO“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110205. [Œ´’˜] Risk factors for and countermeasures against postoperative infection associated with the placement of implantable central venous ports. Nakamura T1, Sato T1, Torii S2, Takayama Y3, Watanabe M1: Kitasato Med J 2019/3; 49 (1): 21-5. (’†‘ş—˛r1, ˛“Ą•˜Y1, ’šˆäWŽO2, ‚ŽR—zŽq3, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO, 2ˆă—ĂˆŔ‘S, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110206. [Œ´’˜] Strategy to avoid local recurrence in patients with locally advanced rectal cancer. Nakamura T1, Sato T1, Hayakawa K2, Koizumi W3, Kumagai Y4, Watanabe M1: Radiat Oncol 2019/3; 14 (1): 53. doi: 10.1186/s13014-019-1253-9. (’†‘ş—˛r1, ˛“Ą•˜Y1, ‘ě˜ad2, Źň˜aŽO˜Y3, ŒF’J—Y“ń4, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO, 2•úŽËü (Žîá‡), 3Á‰ťŠí“ŕ, 4—Տ°Œ¤‹†EŠé‰ć^ƒvƒƒWƒFƒNƒg)

320011. [Ç—á•ń] ‘ĺ–ÔŒ´”­–˘•Ş‰ť‘˝Œ`“÷Žî‚Ě1—á. ŠŰŽRł—T, “ŕ“Ął‹K1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): “ú–{—Տ°ŠO‰ČŠw‰ďŽ 2018/6; 79 (6): 1305-8.

521005. [‰đŕ] pŒă’°•ÂÇ‚ɑ΂ˇ‚é• o‹ž‰şŘœ‚Ě—L—pŤ. ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): “ú–{• •”‹~‹}ˆăŠw‰ďŽGŽ 2018/11; 38 (6): 965-70.

522060. [uŔ]y‘ć33‰ń–k—˘ŽîᇃtƒH[ƒ‰ƒ€z‚—îŽŇ‚ɑ΂ˇ‚é‘ĺ’°ŠŕŽĄ—Ă‚Ě–â‘č“_‚Ć‚ť‚ĚŽć‚č‘g‚Ý. “›ˆä“ÖŽq1, ’†‘ş—˛r1, “‡’Á@Ť1, ŽO‰YŒ[Žő1, ŽR—œ‚L1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): –k—˘ˆăŠw 2018/6; 48 (1): 41-4.

522061. [uŔ]y“ÁW: ‚ ‚˝‚ç‚ľ‚˘@ŠO‰Č‹ÇŠ‰đ–U‘S}|ƒ‰ƒ“ƒhƒ}[ƒN‚Ć‚ť‚̏o‚ľ•űzĄ‰ş•”Á‰ťŠÇ@‰ĄsŒ‹’°Šŕ‚ɑ΂ˇ‚é• o‹žŽčp‚É•K—v‚Č‹ÇŠ‰đ–U|ƒŠƒ“ƒpßŠs´”͈͌ˆ’č‚𒆐S‚Ɂ|. ˛“Ą•˜Y1, ’†‘ş—˛r1, ŽR—œ‚L1, ŽO‰YŒ[Žő1, “›ˆä“ÖŽq1, “‡’Á@Ť1, ŒĂé@Œ›1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): —Տ°ŠO‰Č 2018/10; 73 (11): 87-92.

522062. [uŔ]y“ÁW: ƒƒ{ƒbƒgŽx‰‡‰şŽčp‚ĚĹ‘OüzˆÝŠŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡‰şˆÝŘœp ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ˆăŠw‚Ě‚ ‚ä‚Ý 2018/10; 267 (1): 76-82.

’˜@‘]

620058. [Šwp‘ (•Ş’SŽˇ•M)]y“ÁW: ‚ą‚ę‚ź’Bl‚Ě‹Z!@ĹV‚̏Á‰ťŠí“ŕŽ‹‹žŠO‰ČŽčp (Á‰ťŠíŠO‰Č2018”N4ŒŽ‘Š§†)zII Œ‹’°E’ź’°Eăč–ĺ‚Ě‹žŽ‹‰şŽčp@9. • o‹ž‰ş‘¤•űƒŠƒ“ƒpßŠs´p, p.686-93. ŽR—œ‚L1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO), ‚ւ邡o”Ĺ, “Œ‹ž, 2018/4”­s.

620059. [Šwp‘ (•Ş’SŽˇ•M)]yH“šŠŕ (‘ć2”Ĺ)|Šî‘bE—Տ°Œ¤‹†‚̐i•ŕ| (“ú–{—ŐŕŹ76ŠŞ‘Š§†8)zVIII. H“šŠŕ‚ĚŽĄ—Á@4. ‰ťŠw—Ă–@@(1) p‘OEpŒă•â•‰ťŠw—Ă–@, p.360-9. ×“c@Œj1, “n粏š•F2, ŽR‰şŒpŽj1,3 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), “ú–{—Ő଎Đ, “Œ‹ž, 2018/10”­s.

620060. [Šwp‘ (•Ş’SŽˇ•M)]y‘nŠ§40Žü”N‹L”O“ÁW: “ŕŽ‹‹žŠO‰Č‚̐i•ŕ (Á‰ťŠíŠO‰Č‘ć41ŠŞ‘ć13†)z Še•Ş–ě‚É‚¨‚Ż‚é—đŽj‚Ć–˘—ˆ@3. Œ‹’°Šŕ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚̐i•ŕ, p.1765-73. “n粏š•F (‰ş•”Á‰ťŠÇŠO), ‚ւ邡o”Ĺ, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713096. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A new therapeutic strategy that could control local recurrence for locally advanced rectal cancer. Nakamura T1, Sato T1, Yamanashi T1, Miura H1, Tsutsui A1, Shimazu M1, Watanabe M1: American Society of Colon& Rectal Surgeons 2018(ASCRS2018) (2018/5/22), Nashville, USA. (’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO)

713097. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Laparoscopic surgery for locally advanced right-sided pT4a colon cancer: clinical outcomes and prognostic factors. Yamanashi T1, Nakamura T1, Sato T1, Naito N1, Miura H1, Tsutsui A1, Shimazu M1, Watanabe M1: 26th International congress of the European Association for Endoscopic Surgery (E.A.E.S) (2018/5/31), London, UK. (ŽR—œ‚L1, ’†‘ş—˛r1, ˛“Ą•˜Y1, “ŕ“Ął‹K1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO)

713098. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Treatment outcome of laparoscopic surgery afterneoadjuvant chemoradiotherapy for lower advanced rectal cancer. Shimazu M1, Miura H1, Tsutsui A1, Yamanashi T1, Sato T1, Naito N1, Nakamura T1, Watanabe M1: 26th International congress of the European Association for Endoscopic Surgery (E.A.E.S) (2018/5/31), London, UK. (“‡’Á@Ť1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, ŽR—œ‚L1, ˛“Ą•˜Y1, “ŕ“Ął‹K1, ’†‘ş—˛r1, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO)

722066. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ÇŠis’ź’°Šŕ‚ɑ΂ˇ‚ép‘O‰ťŠw•úŽËü—Ă–@. ˛“Ą•˜Y1, ’†‘ş—˛r1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ŒĂé@Œ›1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723339. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pT4Œ‹’°Šŕ‚ɑ΂ˇ‚é• o‹ž‰şŽčp|ŽĄ—ÐŹŃ‚Ć—\Œă—\‘ވöŽq‚ĚŒŸ“˘|. ŽR—œ‚L1, ’†‘ş—˛r1, “‡’Á@Ť1, “›ˆä“ÖŽq1, ŽO‰YŒ[šć1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5), “Œ‹ž.

723340. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ÇŠis’ź’°Šŕ‚ɑ΂ˇ‚ép‘O‰ťŠw•úŽËüŽĄ—ĂŒă‚Ě—\ŒăˆöŽq. ’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, Ź‘q’źl1, “ŕ“Ął‹K1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/6), “Œ‹ž.

723341. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ÇŠis‰ş•”’ź’°Šŕ‚ɑ΂ˇ‚ép‘O‰ťŠw•úŽËü—Ă–@ (NCRT) ‚đ—p‚˘‚˝ŽĄ—Ð헪`Žčp‚̉ń”đ‚͉”\‚Š`. ˛“Ą•˜Y1, ’†‘ş—˛r1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, ‰i‰ŞNŽu, ‰Ą“cŒő‰›2, â–{ƒˆę3, ŠŰŽRł—T4, Œă“Ą‘ě–ç4, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3“ű‘BEbó‘BŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/7), “Œ‹ž.

723342. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ‹’°ŠŕpStage III‚ĚŽĄ—ÐŹŃ. ŽO‰YŒ[šć1, “‡’Á@Ť1, ŽR—œ‚L1, “›ˆä“ÖŽq1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/7), “Œ‹ž.

723343. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ş•”’ź’°Šŕ‚ɑ΂ˇ‚éTaTME|“–‰Č‚É‚¨‚Ż‚éŽčpŽč‹Z‚ĆŽĄ—ÐŹŃ|. ŽR—œ‚L1, ’†‘ş—˛r1, “‡’Á@Ť1, “›ˆä“ÖŽq1, ŽO‰YŒ[šć1, “ŕ“Ął‹K1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723344. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Stage IV‘ĺ’°Šŕ‚É‚¨‚Ż‚éč‹’•”ˆĘ•ĘŽĄ—ÐŹŃ. ŽO‰YŒ[šć1, ˛“Ą•˜Y1, “‡’Á@Ť1, “›ˆä“ÖŽq1, ŽR—œ‚L1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/12), Ž­Ž™“‡.

723345. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†SĂ–Źƒ|[ƒg‚̏pŒă‡•šÇ‚ĆŽĄ—ÐŹŃ. ’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, “ŕ“Ął‹K1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/13), Ž­Ž™“‡.

723346. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ÇŠis’ź’°Šŕ‚ɑ΂ľp‘O‰ťŠw•úŽËüŽĄ—ĂŒă‚ÉWatch-and-wait approach‚Ć‚ľ‚˝8—á‚ĚŒŸ“˘. “‡’Á@Ť1, ’†‘ş—˛r1, “›ˆä“ÖŽq1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ŒĂé@Œ›1, Ź‘q’źl1, “ŕ“Ął‹K1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2018/7/13), Ž­Ž™“‡.

723347. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) i‰ť‚ˇ‚é”牺–„‚ߍž‚ÝŒ^’†SĂ–Źƒ|[ƒg. ’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŒĂé@Œ›1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/19), ‰Ą•l.

723348. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”牺–„‚ߍž‚ÝŒ^’†SĂ–Źƒ|[ƒg‘˘ÝŒă‚̍‡•šÇ‚Ć‚ť‚Ě‘Îô. ’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć16‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘ĺ‰ď (JDDW 2018) (2018/11/2), _ŒË.

723349. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pT4ś‘¤Œ‹’°Šŕ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚ĚŒŸ“˘. ŽR—œ‚L1, ’†‘ş—˛r1, “‡’Á@Ť1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/9), “Œ‹ž.

723350. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’čŒ^‰ť‚ľ‚˝• o‹ž‰şŒ‹’°ŠŕŽčp‚Ě’ZŠúE’ˇŠúŹŃ. ’†‘ş—˛r1, ˛“Ą•1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ŒĂé@Œ›1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć73‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2018/11/10), “Œ‹ž.

723351. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O‰ťŠw•úŽËüŽĄ—Ă‚đŽ{s‚ľ‚˝‹ÇŠis’ź’°Šŕ‚Ě’ˇŠúŹŃ. ’†‘ş—˛r1, ˛“Ą•˜Y1, “ŕ“Ął‹K1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ŒĂé@Œ›1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/22), “Œ‹ž.

723352. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ź’°d•ĄŠŕ• –Œ”dŽí‚đ”F‚ß‚˝Ź’°Œ^ƒNƒ[ƒ“•a‚Ěˆę—á. ‰Ą“c˜aŽq1, ’†‘ş—˛r2, “‡’Á@Ť2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ˛“Ą•˜Y2, “n粏š•F2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/22), “Œ‹ž.

723353. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ’°ŒeŽş‰Š‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚Ě—L—pŤ. ŠŰŽRł—T1, ’†‘ş—˛r2, “‡’Á@Ť2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ˛“Ą•˜Y2, “n粏š•F2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć80‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2018/11/23), “Œ‹ž.

723354. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’čŒ^‰ť‚ľ‚˝• o‹ž‰şŒ‹’°ŠŕŽčp‚Ě’ZŠúŹŃ. ’†‘ş—˛r1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ŒĂé@Œ›1, “‡’Á@Ť1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/7), •Ÿ‰Ş.

723355. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒJ‚č•Ô‚ˇŒ‹’°ŒeŽşoŒŒ‚ɑ΂ľÄTAEŒă‚É’°ŠÇ‰óŽ€‚Ć‚Č‚č• o‹ž‰şŽčp‚đŽ{s‚ľ‚˝1—á. ”‹Œ´çŒb1, ’†‘ş—˛r1, “‡’Á@Ť1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/7), •Ÿ‰Ş.

723356. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş‘ĺ’°Řœ‚đŽ{s‚ľ‚˝ƒXƒe[ƒWIIŒ‹’°Šŕ‚ĚÄ”­ƒŠƒXƒNˆöŽq. ŒĂé@Œ›1, “‡’Á@Ť1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723357. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ź’°Šŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡• o‹ž‰şŽčp‚Ě“ą“ü. ŽR—œ‚L1, ’†‘ş—˛r1, “‡’Á@Ť1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, “ŕ“Ął‹K1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723358. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pStage II, IIIäBœ^‹Č•”Šŕ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚ĚŽĄ—ÐŹŃ. ŽO‰YŒ[šć1, ˛“Ą•˜Y1, “‡’Á@Ť1, ŒĂé@Œ›1, ŽR—œ‚L1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

733113. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹Zp”F’čŽć“ž‚ɑ΂ˇ‚é‰äX‚ĚŽć‚č‘g‚Ý (‘ĺ’°—Ěˆć). ŽO‰YŒ[šć1, “‡’Á@Ť1, “›ˆä“ÖŽq1, ŽR—œ‚L1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć72‰ńŽčpŽč‹ZŒ¤‹†‰ď (2018/5/11), “ż“‡.

733114. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹łˆç‚đŽó‚Ż‚Ä‚˘‚é—§ę‚Š‚çl‚Ś‚é• o‹ž‰ş‘ĺ’°ŠŕŽčp. “‡’Á@Ť1, ŒĂé@Œ›1, “›ˆä“ÖŽq1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ’†‘ş—˛r1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): ‘ć72‰ńŽčpŽč‹ZŒ¤‹†‰ď (2018/5/11), “ż“‡.

733115. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ź’°Šŕ• –Œ”dŽí‚đ”F‚ß‚˝Ź’°Œ^ƒNƒ[ƒ“•a‚Ěˆę—á. ‰Ą“c˜aŽq1, ’†‘ş—˛r2, “‡’Á@Ť2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ˛“Ą•˜Y2, “n粏š•F2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO): ‘ć47‰ń_“ސě‘ĺ’°ăč–厞Šł§˜b‰ď (2018/5/15), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-320004. [Ç—á•ń] ’°dĎ‚đ”­Ç‚ľ‚˝Ź’°ŒŒŠÇŽ‰–bŽî‚Ě1—á. “‡’Á@Ť1, ’†‘ş—˛r1, XŁłŽ÷, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): “ú–{• •”‹~‹}ˆăŠw‰ďŽGŽ 2018/1; 38 (1): 133-6.

H29-522002. [uŔ]y“ÁW: ‹}Ť• Ç‚ĚŠO‰ČŽčp2018ziNŤ’°•ÂÇ‚ɑ΂ˇ‚é• o‹žŽčp. “›ˆä“ÖŽq1, ’†‘ş—˛r1, “‡’Á@Ť1, ŽR—œ‚L1, ˛“Ą•˜Y1, “n粏š•F1 (1‰ş•”Á‰ťŠÇŠO): Žčp 2018/3; 72 (3): 2018/3; 72 (3): 271-6.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-713004. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Laparoscopic surgery for locally advanced T4 colon cancer: long-term outcomes and prognostic factors. Nakamura T1, Sato T1, Naito M1, Yamanashi T1, Miura H1, Tsutsui A1, Watanabe M1: Society Surgical Oncology 2018 (SSO2018) (2018/3/21), Chicago, USA. (’†‘ş—˛r1, ˛“Ą•˜Y1, “ŕ“Ął‹K1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “›ˆä“ÖŽq1, “n粏š•F1: 1‰ş•”Á‰ťŠÇŠO)


S‘ŸŒŒŠÇŠO‰ČŠw

[Šwp˜_•ś]

110207. [Œ´’˜] Conventional repair of total anomalous venous drainage without primary sutureless technique: surgical tips to prevent pulmonary vein obstruction. Sughimoto K, Miyaji K1, Oka N1, Torii S1,2, Kitamura T1: Gen Thorac Cardiovasc Surg 2018/7; 66 (7): 405-10. (‹{’n@ŠÓ1, ‰Ş@“ż•F1, ’šˆäWŽO1,2, –k‘ş@—Ľ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

110208. [Œ´’˜] Flow Energy Loss as a Predictive Parameter for Right Ventricular Deterioration Caused by Pulmonary Regurgitation After Tetralogy of Fallot Repair. Shibata M1, Itatani K2, Hayashi T3, Honda T4, Kitagawa A4, Miyaji K1, Ono M5: Pediatr Cardiol 2018/8; 39 (4): 731-42. (ŽÄ“c@u1, –{“c@’4, –kě“ÄŽj4, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2‹ž“sˆă‰Č‘ĺŠw, 3‘—§Źˆçˆă—ĂŒ¤‹†ƒZƒ“ƒ^[, 4ŹŽ™, 5“Œ‹ž‘ĺŠw)

110209. [Œ´’˜] Sternal semi-closure using a bioresorbable osteosynthesis device: a new method for delayed sternal closure. Tanaka Y1, Miyamoto T1, Naito Y, Yoshitake S, Sasahara A1, Miyaji K1: Surg Today 2018/8; 48 (8): 748-55. (“c’†—C‹M1, ‹{–{—˛Ži1, ůŒ´‘–L1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

110210. [Œ´’˜] Samurai cannulation (direct true-lumen cannulation) for acute Stanford Type A aortic dissection. Kitamura T1, Torii S1,2, Kobayashi K1, Tanaka Y1, Sasahara A1, Ohtomo Y1, Horikoshi R1, Miyaji K1: Eur J Cardiothorac Surg 2018/9; 54 (3): 498-503. (–k‘ş@—Ľ1, ’šˆäWŽO1,2, Ź—ŃŒ’‰î1, “c’†—C‹M1, ůŒ´‘–L1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

110211. [Œ´’˜] Mid-term result of atrioventricular valve replacement in patients with a single ventricle. Sughimoto K, Hirata Y, Hirahara N, Miyata H, Suzuki T, Murakami A, Miyaji K1, Takamoto S: Interact Cardiovasc Thorac Surg 2018/12; 27 (6): 895-900. (‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

110212. [Œ´’˜] Cerebral oximetry for cardiac surgery: a preoperative comparison of device characteristics and pitfalls in interpretation. Kobayashi K1, Kitamura T1, Kohira S2, Torii S1,3, Mishima T1, Ohkubo H1, Tanaka Y1, Sasahara A1, Fukunishi T1, Ohtomo Y1, Horikoshi R1, Murai Y1, Miyaji K1: J Artif Organs 2018 /12; 21 (4): 412-8. (Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, ŒĂ•˝@‘2, ’šˆäWŽO1,3, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—C‹M1, ůŒ´‘–L1, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‘şˆä—C‘ž1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S)

110213. [Œ´’˜] Repeat surgical intervention after aortic repair for acute Stanford type A dissection. Kitamura T1, Torii S1,2, Kobayashi K1, Tanaka Y1, Sasahara A1, Araki H1, Ohtomo Y1, Horikoshi R1, Miyaji K1: Gen Thorac Cardiovasc Surg 2018/12; 66 (12): 692-9. (–k‘ş@—Ľ1, ’šˆäWŽO1,2, Ź—ŃŒ’‰î1, “c’†—C‹M1, ůŒ´‘–L1, r‹Lt“Ţ1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

110214. [Œ´’˜] Markers of peripheral perfusion during high-flow regional cerebral perfusion for aortic arch repair. Sughimoto K1, Kohira S1, Hayashi H, Torii S1,3, Kitamura T1, Horai T1, Miyaji K1: J Thorac Cardiovasc Surg 2018/12; 156 (6): 2251-7. (™–{Wˆę1, ŒĂ•˝@‘2, ’šˆäWŽO1,3, –k‘ş@—Ľ1, •ó—ˆ“N–ç1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S)

210002. [€Œ´’˜]yIMAGES IN CARDIAC SURGERYzPapillary fibroelastoma of the left ventricular apex excised using a videoscopic technique. Tanaka Y1, Kitamura T1, Kobayashi K1, Ohtomo Y1, Miyaji K1: J Card Surg 2018/5; 33 (5): 277-9. (“c’†—C‹M1, –k‘ş@—Ľ1, Ź—ŃŒ’‰î1, ‘ĺ—F—EŽ÷1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

220003. [€Œ´’˜]y—Տ°ŒoŒązAž‚ÝŒ^•â•lHS‘Ÿ‚ĚƒfƒoƒCƒXŠ´ő‘΍ô‚Ě‚˝‚ß‚Ě‘ĺ–ԏ[“Up. Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—C‹M1, ůŒ´‘–L1, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‘şˆä—C‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‹š•”ŠO‰Č 2018/10; 71 (11): 924-8.

220004. [€Œ´’˜] “–‰@‚É‚¨‚Ż‚é•~’n“ŕ‹Ö‰Œ‰ťŽŔŒť‚Ö‚ĚƒvƒƒZƒX‚ɂ‚˘‚Ä. ‹{–{—˛Ži (S‘ŸŒŒŠÇŠO): “ú–{ŹŽ™‹Ö‰ŒŒ¤‹†‰ďŽGŽ 2018/10; 8 (2): 74-7.

310015. [Ç—á•ń] Total arch replacement using the Gelweave Lupiae graft for an aneurysm arising from Kommerell's diverticulum with an aberrant left subclavian artery and right-sided aortic arch. Tanaka Y1, Kitamura T1, Irisawa Y1, Miyaji K1: Interact Cardiovasc Thorac Surg 2018/8; 27 (2): 307-9. (“c’†—C‹M1, –k‘ş@—Ľ1, “üŕV—F•ă1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310016. [Ç—á•ń] Cardiac hemangioma with epicardial infiltration. Inoue T1, Kitamura T1, Torii S1,2, Miyaji K1: J Thorac Dis 2018/9; 10 (9): E704-6. (ˆäă’“š1. –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

310017. [Ç—á•ń] [Article in Japanese] Omental Flap for the Device Infection of the HeartMate II. Kobayashi K1, Kitamura T1, Torii S2, Mishima T1, Ohkubo H1, Tanaka Y1, Sasahara A1, Fukunishi T1, Ohtomo Y1, Horikoshi R1, Murai Y1, Miyaji K1: Kyobu Geka 2018/10; 71 (11): 924-8. (Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—C‹M1, ůŒ´‘–L1, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‘şˆä—C‘ž1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

310018. [Ç—á•ń] Isolated Mitral Valve Replacement was Effective in Patient with Hypertrophic Obstructive Cardiomyopathy and Concomitant Mitral Regurgitation;Report of a Case. Matsushiro T1, Fujimatsu T, Miyaji K1: Kyobu Geka 2019/2; 72 (2): 149-52. (ź‘ă‘ě–ç1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

320012. [Ç—á•ń] ‘m–X•Ů•Â˝•s‘SÇ‚đ‡•š‚ľ‚˝•ÂÇŤ”ě‘ĺŒ^S‹ŘÇ‚É•Ů’uŠˇp‚Ě‚Ý‚ĹśŽş—Źo˜H‹ˇó‚đ‰đœ‚ľ‚Ś‚˝1—á. ź‘ă‘ě–ç1, “Ąź—˜_2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2–k“l•a‰@): ‹š•”ŠO‰Č 2019/2; 72 (2): 149-52.

530005. [‚ť‚Ě‘ź] Correction to: Cerebral oximetry for cardiac surgery: a preoperative comparison of device characteristics and pitfalls in interpretation. Kobayashi K1, Kitamura T1, Kohira S2, Torii S1,3, Mishima T1, Ohkubo H1, Tanaka Y1, Sasahara A1, Fukunishi T1, Ohtomo Y1, Horikoshi R1, Murai Y1, Miyaji K1: J Artif Organs 2018/12; 21 (4): 419. (Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, ŒĂ•˝@‘2, ’šˆäWŽO1,3, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—C‹M1, ůŒ´‘–L1, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‘şˆä—C‘ž1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S)

530006. [‚ť‚Ě‘ź (ƒRƒƒ“ƒg)]yComment on: Preferences Regarding Transfer of Patients With Congenital Heart Disease Who Attend Children's Hospital. (Circ J 2019/3; 83 (4): 824-30.)zSelf-Efficacy and Physical Activity Level Holds Important Implications for Transfer of Adult Congenital Heart Disease. Miyamoto T1: Circ J 2019/3; 83 (4): 715-7. (‹{–{—˛Ži1: 1S‘ŸŒŒŠÇŠO)

[’˜@‘]

620061. [Šwp‘] (•Ş’SŽˇ•M)yS‘ŸE‘ĺ“Ž–ŹŠO‰ČŽčp@Šî–{EƒRƒcEŠ¨Šz‘ć20Í ŠĽ“Ž–Źá‘Žčp@1 ŠĽ“Ž–Źá‘‚̐f’f‚ĆŽčpƒeƒNƒjƒbƒN, p.336-8. –k‘ş@—Ľ (S‘ŸŒŒŠÇŠO), •Ň: ŹâáÁˆę, ˆăŠw‘‰@, “Œ‹ž, 2018/7”­s.

620062. [Šwp‘ (’P’˜)]yś–˝‚ƐŠ–ź‚Ć‚Ěo‰ď‚˘|‘ŮŽ™f’fEŽĄ—Ă‚đ’m‚Á‚Ä‚˘‚Ü‚ˇ‚Š?z‹{–{—˛Ži (S‘ŸŒŒŠÇŠO), Œś“~ŽÉƒ‹ƒlƒbƒTƒ“ƒXVŽĐ, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713099. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Heart surgery in patients on dialysis: who is at high risk? Kitamura T1, Torii S1,2, Mishima T1, Ohkubo H1, Kobayashi K1, Ohtomo Y1, Miyaji K1: The 26th Annual Meeting of Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2018/5/24-27), Moscow, Russia. (–k‘ş@—Ľ1, ’šˆäWŽO1,2, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, Ź—ŃŒ’‰î1, ‘ĺ—F—EŽ÷1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S)

713100. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Different biodegradation rates of tissue-engineered vascular grafts in small and large animal models. Fukunishi T1: The 26th Annual Meeting of Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2018/5/24-27), Moscow, Russia. (•Ÿź‘ô^1: 1S‘ŸŒŒŠÇŠO)

713101. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Expenence of Emergncy Thoracic Endovascular Aortic Repair. Ohkubo H1: The Asia-Pacific Angiology Academic Alliance (APA) Conference and 2018 International Annual Congress of Macau Medical Science & Technology Research Association (2018/5/25-27), Macau, China. (‘ĺ‹v•Ű”Ž˘1: 1S‘ŸŒŒŠÇŠO)

713102. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Usefulness of FABPAB (Flow-adjustable bilateral pulmonary artery banding) in neonatal complex congenital heart disease. Miyamoto T1: 12th International Joint Meeting on Cardiovascular Diseases Meet the Expert Symposium (IJM) 2018 (2018/6/7-9), DŸsseldorf, Germany. (‹{–{—˛Ži1: 1S‘ŸŒŒŠÇŠO)

713103. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A Novel Extruded Polyglycerol (Sebacate) and Polyglycolic Acid Vascular Graft Forms a Neoartery. Fukunishi T1, Lui C, Ong CS, Zhang H, Smoot C, Winner S, Harris J, Gabriele P, Santhanam L, Berkowitz D, Vricella L, Lu S, Hibino N. The 16th Biennial Meeting of International Society of Applied Cardiovascular Biology (ISACB) (2018/9/16-19), Bordeaux, France. (•Ÿź‘ô^1: 1S‘ŸŒŒŠÇŠO)

713104. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Risk factors for liver diseases after fontan operation. Oka N1, Miyamoto T1, Tomoyasu T1, Hayashi H1, Miyaji K1: The32th Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS) (2018/10/18-20), Milan Italy. (‰Ş@“ż•F1, ‹{–{—˛Ži1, —F•Ű‹M”Ž1, —с@GŒ›1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

713105. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Direct True Lumen Cannulation ("Samurai" Cannulation) for Acute Stanford Type A Aortic Dissection. Kitamura T1, Miyaji K1: The 55th Annual Meeting of Society of Thoracic Surgeons (STS) (2019/1/27-29), San Diego, USA. (–k‘ş@—Ľ1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

721013. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) S‘ŸƒfƒoƒCƒXŒđŠˇp‚Ěpitfall. ’šˆäWŽO1,2 (1ˆă—ĂˆŔ‘SŠw‹łˆç, 2S‘ŸŒŒŠÇŠO): ‘ć11‰ńAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2019/2/16), •iě.

723359. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹlŠJSp’†‚Ě”]‹ÇŠŽ_‘f–O˜a“x‘Ş’č’l‚Ě‹@Ší‚É‚ć‚鍷. Ź—ŃŒ’‰î1, ŒĂ•˝@‘2, –k‘ş@—Ľ1, ’šˆäWŽO1,3, •˝“cŒő”Ž, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—S‹M1, ůŒ´‘–L1, ĺŒ’Ži˜N1, r‹Lt“Ţ1, –x‰z—m1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5-7), “Œ‹ž, “ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď´˜^W 2018/3; 118: 975.

723360. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”j—ôŤ• •”‘ĺ“Ž–ŹáŽ‚ɑ΂ˇ‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ŕ‘}p‚Ě18—á. ‘ĺ‹v•Ű”Ž˘1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, Ź—ŃŒ’‰î1, “c’†—C‹M1, ůŒ´‘–L1, r‹Lt“Ţ1, ‘ĺ—F—E‹C1, –x‰z—m1, ‘şˆä—C‘ž1,•˝“cŒő”Ž, ’šˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć46‰ń“ú–{ŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/9-11), ŽRŒ`, “ú–{ŒŒŠÇŠO‰ČŠw‰ďŽGŽ 2018/5; 27 (Suppl): P7-7.

723361. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘¤•›ŒŒs˜H‚Ě“Ž–ŹáŽ‚đ‡•š‚ľ‚˝Źl’PƒŒ^‘ĺ“Ž–ŹkóÇ‚ɑ΂ľ‚Ä2Šú“IŒŒŠÇ“஡—Ă‚đŽ{s‚ľ‚˝1—á. ‘şˆä—C‘ž1, ‘ĺ‹v•Ű”Ž˘1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, Ź—ŃŒ’‰î1, “c’†—C‹M1, ůŒ´‘–L1, r‹Lt“Ţ1, ‘ĺ—F—E‹C1, –x‰z—m1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć46‰ń“ú–{ŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/9-11), ŽRŒ`, “ú–{ŒŒŠÇŠO‰ČŠw‰ďŽGŽ 2018/5; 27 (Suppl): O19-6.

723362. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é• •”debranch TEVAR‚Ě2—á. ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “c’†—C‹M1, ůŒ´‘–L1, ‘ĺ—F—EŽ÷1, –x‰z—m1, Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć46‰ń“ú–{ŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/9-11), ŽRŒ`, “ú–{ŒŒŠÇŠO‰ČŠw‰ďŽGŽ 2018/5; 27 (Suppl): P23-4.

723363. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S‘ŸŒŒŠÇŠO‰ČŠłŽŇ‚É‚¨‚Ż‚é• •”“ŕ‘ŸŽ‰–b–ĘĎ‚ÍœŠi‹Ř–§“x‚ĆŠÖ˜A‚ˇ‚é. ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F1,2, –k‘ş@—Ľ3, ŕ_čL–ž4, ź‘ň—Ç‘ž4, –ěčN•˝4, “c’†L–í4, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ): ‘ć54‰ń“ú–{zŠÂŠí•a—\–hŠw‰ďŠwpW‰ď (2018/6/22-23), ŽD–y, “ú–{zŠÂŠí•a—\–hŠw‰ďŽ 2018/6; 53 (2): 185.

723364. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) śS’áŒ`ŹÇŒóŒQ‚ɑ΂ˇ‚éŠO‰ČŽĄ—Ă —ź‘¤”x“Ž–ŹiNp‚ƐVśŽ™ƒm[ƒEƒbƒhŽčp‚̉“ŠuŹŃ‚Ě”äŠrŒŸ“˘. ‰Ş@“ż•F1, ‹{’n@ŠÓ1, ‹{–{—˛Ži1, —F•Ű‹M”Ž1, —с@GŒ›1, Ź—Ń•x’j2 (1S‘ŸŒŒŠÇŠO, 2ŒQ”nŹŽ™ˆă—ĂƒZƒ“ƒ^[): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723365. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ăS‘ŸŒ^‘”xĂ–ŹŠŇ—ŹˆŮíÇC•œp‚É‚¨‚Ż‚郉ƒeƒ‰ƒ‹ƒAƒvƒ[ƒ`‚Ě—L—pŤ. ‰Ş@“ż•F1, ‹{–{—˛Ži1, —F•Ű‹M”Ž1, —с@GŒ›1, Ź—Ń•x’j2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ŒQ”nŹŽ™ˆă—ĂƒZƒ“ƒ^[): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723366. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHS”x’†D’†‹…/ƒŠƒ“ƒp‹…”ä‚͏ŹŽ™ŠJSpŒă‹}ŤtŠQ‚Ě—\‘ވöŽq‚ƂȂ肤‚é‚Š? ůŒ´‘–L1, ŒĂ•˝@‘2, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –x‰z—m1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ME•”): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723367. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Pulmonary coarctation‚ɑ΂ˇ‚é‘Ě”x’Z—Žčp‚Ć”x“Ž–ŹŒ`Źp“ŻŽžŽčp‚Ě—LŒřŤ. •Ÿź‘ô^1, ‹{’n@ŠÓ1, ‘ĺ—F—EŽ÷1, ‚—œ@Šw2, Ö–؍G•ś2, ›–{Œ’Ži2, ćčG–ž2,3, Îˆäł_2 (1S‘ŸŒŒŠÇŠO, 2ŹŽ™, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723368. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MICS MVP‚É‚¨‚Ż‚é‹šŠsG•˝ŒW”. –k‘ş@—Ľ1, Ź—ŃŒ’‰î1, ’šˆäWŽO1,2, •Ÿź‘ô^1, r–؏t“Ţ1, –x‰z—m1, –L“c^Žő1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć3‰ń“ú–{’áNPS‘ŸŽčpŠw‰ďŠwpW‰ď Japan MICS Summit 2018 (2018/7/7), ‘ĺă.

723369. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}ŤStanford AŒ^‘ĺ“Ž–Ź‰đ—ŁpŒă‚É‚¨‚Ż‚éÄŽčpÇ—á‚ĚŒŸ“˘. –x‰z—m1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{–{—˛Ži1, ”ü“‡—˜ş1, Ź—ŃŒ’‰î1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, –L“c^Žő1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.145.

723370. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “§ÍŠłŽŇ‚̐S‘Ÿ‘ĺ“Ž–ŹŽčp‚É‚¨‚Ż‚郊ƒXƒNƒtƒ@ƒNƒ^[. –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{–{—˛Ži1, ”ü“‡—˜ş1, Ź—ŃŒ’‰î1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, –x‰z—m1, –L“c^Žő1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.171.

723371. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰đ—ŁŤ‘ĺ“Ž–ŹáŽ‚ɑ΂ˇ‚éTEVAR ‚ĚŽĄ—ÐŹŃ‚ɑ΂ˇ‚錟“˘. “Ą‰Şrˆę˜Y1, źˆäŒŞ‘ž1, ’†‘ş—D”ň1, –x‰z—m1, ‘ĺ‹v•Ű”Ž˘1, Ź—ŃŒ’‰î1, ”ü“‡—˜ş1, •ó—ˆ“N–ç1, •Űâ@–Î2, –k‘ş@—Ľ1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2‘—§‘Űˆă—ĂŒ¤‹†ƒZƒ“ƒ^[): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.174.

723372. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć“VŤSŽžŠł‚ɑ΂ˇ‚éNO‹z“ü—Ă–@ (iNO). ‹{’n@ŠÓ (S‘ŸŒŒŠÇŠO): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.197.

723373. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) śŠĽ“Ž–Ź”x“Ž–Ź‹NŽnÇ‚ɑ΂ˇ‚éSpiral-Cuff–@. ‰Ş@“ż•F1, —F•Ű‹M”Ž1, —с@GŒ›1, Î“°”ŽŒh1, ‹{–{—˛Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.213.

723374. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ“Ž–Ź‹|’áŒ`Ź‚𔺂¤‘ĺ“Ž–ŹkóE—Ł’f‚ɑ΂ˇ‚鉺s‘ĺ“Ž–Ź|ăs‘ĺ“Ž–Ź’[‘¤•Ť‡‚É‚ć‚é‘ĺ“Ž–ŹÄŒš‚ĚŒŸ“˘|. ‹{’n@ŠÓ1, ‹{–{—˛Ži1, •Ÿź‘ô^1, –L“c^Žő1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, Ź—ŃŒ’‰î1, “Ą‰Şrˆę˜Y1, –x‰z—m1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.214.

723375. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘”xĂ–ŹŠŇ—ŹˆŮípŒă”xĂ–Ź‹ˇó‚đ‰ń”đ‚ˇ‚é‚ɂ́|SŠOŒ^TAPVC ‚ɑ΂ˇ‚鑍”xĂ–ŹŠ˛|ś–[’źÚ•Ť‡–@. ‹{’n@ŠÓ1, ‰Ş@“ż•F1, ‹{–{—˛Ži1, •Ÿź‘ô^1, –L“c^Žő1, ’šˆäWŽO1,2, –k‘ş@—Ľ1, Ź—ŃŒ’‰î1, “Ą‰Şrˆę˜Y1, –x‰z—m1, źˆäŒŞ‘ž1, ’†‘ş—D”ň1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.214.

723376. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VśŽ™ŠJSpŒă‚̍˜”w•”‘gDŽ_‘f–O˜a“xƒ‚ƒjƒ^[‚Ě—L—pŤ. –L“c^Žő1, ŒĂ•˝@‘2, ‹{–{—˛Ži1, •Ÿź‘ô^1, –k‘ş@—Ľ1, ’šˆäWŽO1,3, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, –x‰z—m1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.217.

723377. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŠJSp’źŒă‚Ě‹}ŤŒÄ‹záŠQ‚É‚¨‚Ż‚ép‘OˆöŽq‚ĚŒŸ“˘. •Ÿź‘ô^1, ‹{’n@ŠÓ1, ŒĂ•˝@‘2, ‹{–{—˛Ži1, –L“c^Žő1, –k‘ş@—Ľ1, ’šˆäWŽO1,3, Ź—ŃŒ’‰î1, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, –x‰z—m1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1 (1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.222.

723378. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†SĂ–ŹƒJƒe[ƒeƒ‹‘}“ü (CVC) Žž‚̍‡•šÇƒ[ƒ‚đ–ÚŽw‚ľ‚Ä. ’šˆäWŽO1,2 (1ˆă—ĂˆŔ‘SŠw‹łˆç, 2S‘ŸŒŒŠÇŠO): ‘ć13‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2018/11/24), –źŒĂ‰Ž.

723379. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹlŠúEbstein•a‚ɑ΂ˇ‚éŠO‰Č“IŽĄ—ĂŒoŒą. ‹{–{—˛Ži1, “Ą“c“S•˝2, Ź”‹´r”ü2, •Ÿź‘ô^1, źˆäŒŞ‘ž1, ’†‘ş—D”ň1, 沓c^Žő1, Î“°”ŽŒh1, řw“cšŽq3, ‚—œ@Šw3, âV–؍G•ś3, ›–{Œ’Ži3, ćčG–ž3,4, ˆ˘ŒĂĆ2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2zŠÂŠí“ŕ, 3ŹŽ™, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723380. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S‘ŸŽčp‚É‚¨‚Ż‚é”]‹ÇŠŽ_‘f–O˜a“x: ‹@Ží•Ę‘Ş’č’l‚̏p‘O”äŠr‚Ć‹•ŒŒ•]‰ż‚É‚¨‚Ż‚钍ˆÓ“_. Ź—ŃŒ’‰î1, ŒĂ•˝@‘2, –k‘ş@—Ľ1, ’šˆäWŽO1,3, ‹{–{—˛Ži1, ”ü“‡—˜ş1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, –x‰z—m1, –L“c^Žő1, ’†‘ş—D”ň1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ME•”, 3ˆă—ĂˆŔ‘S): ‘ć49‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2019/2/11-13), ‰ŞŽR, “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2019/2; 49: PP-134.

723381. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Consideration for indications and procedures in adult congenital heart disease. •Ÿź‘ô^1, źˆäŒŞ‘ž1, Î“°”ŽŒh1, ‘şˆä—C‘ž1, –L“c^Žő1, ’†‘ş—D”ň1, –x‰z—m1, r‹Lt“Ţ1, “Ą‰Şrˆę˜Y1, ‘ĺ‹v•Ű”Ž˘1, ˆäăMK1, Ź—ŃŒ’‰î1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć21‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2019/1/11-13), ‰ŞŽR.

723382. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ––˝Œ^[•”Ă–ŹŒŒđÇ‚ɑ΂ˇ‚鎥—Ð헪. “Ą‰Şrˆę˜Y1, ‘ĺ‹v•Ű”Ž˘1, ”ü“‡—˜ş1, ‘şˆä—C‘ž1, Î“°”ŽŒh1, r‹Lt“Ţ1, ˆäăMK1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć49‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2019/2/11-13), ‰ŞŽR, “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2019/2; 49: PR36-1.

723383. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) śS’áŒ`ŹÇŒóŒQ‚ɑ΂ˇ‚éŽčpí—Ş‚ĚŒŸ“˘. ‰Ş@“ż•F1, —F•Ű‹M”Ž1, —с@GŒ›1, źˆäŒŞ‘ž1, ‹{–{—˛Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć49‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2019/2/11-13), ‰ŞŽR, “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2019/2; 49: PR12-3.

723384. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă‘ĺĂ–ŹŠÂ—ŹŒ^•”•Ş”xĂ–ŹŠŇ—ŹˆŮíÇ‚ɑ΂ˇ‚éDouble decker•Ď–@ (ƒƒtƒg–@). •Ÿź‘ô^1, ‹{–{—˛Ži1, ‰Ş@“ż•F1, —F•Ű‹M”Ž1, —с@GŒ›1, źˆäŒŞ‘ž1, Î“°”ŽŒh1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć49‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2019/2/11-13), ‰ŞŽR, “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2019/2; 49: PP-023.

723385. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éDamus-Kaye-Stansel•Ť‡Ž{sŒă”x“Ž–Ź•Ů‹t—Ź‚ĚŒŸ“˘. —с@GŒ›1, ‰Ş@“ż•F1, —F•Ű‹M”Ž1, Î“°”ŽŒh1, ‹{–{—˛Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć49‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2019/2/11-13), ‰ŞŽR, “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2019/2; 49: PP-022.

733116. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ“Ž–Ź•Ů‹ˇó, “Ž–ŹŠÇŠJ‘ś, ‹š•”‘ĺ“Ž–ŹáŽ‚̐ŹlÇ—á‚ɑ΂ˇ‚é1Šú“IŽčp. ŒŐŠâ‚ß‚Ž‚Ý, –k‘ş@—Ľ1, –x‰z—m1, ’šˆäWŽO1,2, ‹{–{—˛Ži1, Ź—ŃŒ’‰î1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, źˆäŒŞ‘ž1, –L“c^Žő1, ’†‘ş—D”ň1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć177‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/6/23), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/6; 177: 6.

733117. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}Ť‘ĺ“Ž–Ź‰đ—Ł (AŒ^) ‚̏pŒă3“ú–Ú‚ÉNOMI ‚đ”­Ç, “Ž’—Ă–@‚đŽ{s‚ľ‹~–˝‚ľ‚Ś‚˝Ç—á. ’†“‡Œő‹M1, ź‰iŒc—ő1, ŹŒ´–M‹`2, ćс@łŠî2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ŠC˜V–ź‘‡•a‰@): ‘ć177‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/6/23), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/6; 177: 16.

733118. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) pŒă‹}ŤśS•s‘S‚ɑ΂ľ‚Đ‚’źĂ–Ź’EŒŒ\śS•â•zŠÂ‚Ĺ‹~–˝‚ľ‚Ś‚˝‘”xĂ–ŹŠŇ—ŹˆŮí‚Ě1—á. –L“c^Žő1, •Ÿź‘ô^1, ‘ĺ—F—EŽ÷1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ”ü“‡—˜ş1, Ź—ŃŒ’‰î1, ‘ĺ‹v•Ű”Ž˘1, ůŒ´‘–L1, –x‰z—m1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć177‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/6/23), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/6; 177: 34.

733119. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹|•”‘ĺ“Ž–Ź‰đ—ŁpŒăˆŸ‹}ŤŠú‚É”ń•ÂÇŤ’°ŠÇ‹•ŒŒ‚đ”­Ç‚ľ‹~–˝‚ľ“ž‚˝1—á. ’†‘ş—D”ň1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{–{—˛Ži1, ”ü“‡—˜ş1, Ź—ŃŒ’‰î1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, –x‰z—m1, –L“c^Žő1, źˆäŒŞ‘ž1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć178‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/11/3), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/11; 178: 9.

733120. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ“Ž–Ź•Ů’uŠˇpŒă8”N‚ĹŒ`Ź‚ł‚ę‚˝ăs‘ĺ“Ž–Ź‰źŤ“Ž–ŹáŽ‚Ě1—á. ź‰iŒc—ő1, ’†“‡Œő‹M1, ŹŒ´–M‹`2, ćс@łŠî2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ŠC˜V–ź‘‡•a‰@): ‘ć178‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/11/3), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/11; 178: 26.

733121. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –łäBÇŒóŒQ, ‘”xĂ–ŹŠŇ—ŹˆŮíÇ, ’áoś‘̏dŽ™‚Ě2—á. –L“c^Žő1, •Ÿź‘ô^1, ‹{–{—˛Ži1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ”ü“‡—˜ş1, Ź—ŃŒ’‰î1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, –x‰z—m1, źˆäŒŞ‘ž1, ’†‘ş—D”ň1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć178‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/11/3), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2018/11; 178: 29.

733122. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}Ť‘ĺ“Ž–Ź‰đ—Ł (AŒ^) pŒă‚ÉäB”j—ô‚đ‚Ť‚˝‚ľ‚˝Š™óÔŒŒ‹…Ç‚Ěˆę—á. –L“c^Žő1, ’†“‡Œő‹M1, ź‰iŒc—ő1, ŹŒ´–M‹`2, ćс@łŠî2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ŠC˜V–ź‘‡•a‰@): ‘ć179‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/3/2), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2019/3; 179: 13.

733123. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ăs‘ĺ“Ž–Źƒ‰ƒbƒsƒ“ƒOpŒă‰“ŠuŠú‚̏ăs‘ĺ“Ž–ŹŠg‘ĺ. “cŠ—S‹I1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ‹{–{—˛Ži1, ”ü“‡—˜ş1, ˆäăMK1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, •Ÿź‘ô^1, r‹Lt“Ţ1, ‘şˆä—C‘ž1, Î“°”ŽŒh1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć179‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/3/2), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2019/3; 179: 22.

733124. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) BTƒVƒƒƒ“ƒg‚đ—p‚˘‚˝NorwoodŒ^Žčp‚đs‚Á‚˝‰EŽş’áŒ`Ź, ŠŽ‘S‘ĺŒŒŠÇ“]ˆĘ, ‘ĺ“Ž–Ź—Ł’fÇ‚Ě1—á. ‘şˆä—C‘ž1, •Ÿź‘ô^1, ‹{–{—˛Ži1, –k‘ş@—Ľ1, ’šˆäWŽO1,2, ”ü“‡—˜ş1, ˆäăMK1, ‘ĺ‹v•Ű”Ž˘1, “Ą‰Şrˆę˜Y1, r‹Lt“Ţ1, Î“°”ŽŒh1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ĂˆŔ‘S): ‘ć179‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/3/2), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2019/3; 179: 29.


ŒÄ‹zŠíŠO‰ČŠw

[Šwp˜_•ś]

110215. [Œ´’˜] Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens. Matsuo Y1, Yoshida T2, Yamashita K3, Satoh Y1: Cancer Cytopathol 2018/12; 126 (12): 1011-21. (ź”ö—R‹IŽq1, ‹g“c@Œ÷2, ŽR‰ş˜a–ç3, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2•a—, 3•a—•”)

110216. [Œ´’˜] Relevance of Intraoperative Pleural Lavage Cytology and Histologic Subtype in Lung Adenocarcinoma. Mikubo M1, Naito M1, Matsui Y1, Shiomi K1, Ichinoe M2, Yoshida T2, Satoh Y1: Ann Thorac Surg 2018/12; 106: 1654?60. (ŽOŒEŤŽj1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˆęŒËš–ž2, ‹g“c@Œ÷2, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2•a—)

310019. [Ç—á•ń] Pulmonary torsion after open esophagectomy for esophageal cancer: a case report and review. Shiomi K1, Yamashita K2, Arai M3, Ito S3, Hayashi S1, Ono M1, Naito M1, Mikubo M1, Matsui Y1, Satoh Y1: J Thorac Dis 2018/6; 10 (6): E462-8. (‰–ŒŠ@˜a1, ŽR‰şŒpŽj2, VˆäłN3, ˆÉ“Ą‘s•˝3, —с@ËŽq1, Ź–ěŒłŽk1, “ŕ“Ą‰ëm1, ŽOŒEŤŽj1, źˆäŒ[•v1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3–ƒŒ)

310020. [Ç—á•ń] Thoracoscopic surgery using omental flap for bronchopleural fistula. Endoh H, Yamamoto R, Nishizawa N, Satoh Y1: Surg Case Rep 2019/1; 5 (1): 5. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

320013. [Ç—á•ń] ‘OcŠuůN–EóƒŠƒ“ƒpŠÇŽî‚Ě1Řœ—á: ‰ć‘œf’f‚ÉŠÖ‚ˇ‚é•śŒŁ“IlŽ@. ‹Ęě@’B1, ‹ß“Ą‘אl1, Ź–ěŒłŽk1, ŽRčGŒp1, źˆäŒ[•v1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): “úŒÄŠO‰ďŽ 2018/7; 32 (5): 640-6.

320014. [Ç—á•ń] RƒŠƒ“Ž‰ŽżR‘ĚÇŒóŒQ‚đ‡•š‚ľ‚˝”xŠŕ2Řœ—á‚ĚŒŸ“˘. ‹ß“Ą‘אl1, ‹Ęě@’B1, ‰€“c@‘ĺ1, źˆä Œ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): “úŒÄŠO‰ďŽ 2019/1; 33 (1): 12-20.

320015. [Ç—á•ń] ‰ť”^Ť‹š˝ŠÖß‰Š‚É‚ć‚é‹š•Ç, cŠu”^ᇂɑ΂ľŠO‰Č“IƒhƒŒƒi[ƒWp‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á. ŽRčGŒp1, ‹ß“Ą‘אl1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): “úŒÄŠO‰ďŽ 2019/1; 33 (1): 95-100.

521006. [‰đŕ]y˜AÚ: 1–‡‚ĚƒVƒF[ƒ}z‘ĺ‚Ť‚ȏăcŠuŽîᇂɑ΂ˇ‚鍽œăâ|ƒAƒvƒ[ƒ`‚̉ž—p. ˛“Ą”Vr (ŒÄ‹zŠíŠO): ‹š•”ŠO‰Č 2018/6; 71 (6): 424.

540017. [‚ť‚Ě‘ź (’Z•ń)] ‰EŽŠ‘R‹C‹špŒă‚É‹š…’™—Ż‚Ĺ”­Ç‚ľ‚˝‹š–Œ’†”çŽî‚Ě1—á. ŽOŒEŤŽj1, âŒű@”E1, ‰€“c@‘ĺ1, ‹g“c@Œ÷2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): “ú—Ő×‰ďŽ 2018/7; 57 (4): 233-4.

[’˜@‘]

620063. [Šwp‘ (•ŇW)]yŒÄ‹zŠíŠO‰ČƒeƒLƒXƒg ‘ć3üz•Ň: “ú–{ŒÄ‹zŠíŠO‰ČŠw‰ď^ŒÄ‹zŠíŠO‰Čę–ĺˆă‡“ŻˆĎˆő‰ď (˛“Ą”Vr (ŒÄ‹zŠíŠO)), “ě]“°, “Œ‹ž, 2018/6”­s.

620064. [Šwp‘ (ŠÄCE•ŇW)]y’†”çŽîᇎ戵‚˘‹K–ńz ˛“Ą”Vr (ŒÄ‹zŠíŠO), •Ň: Î–ȁE’†”çŽîŒ¤‹†‰ď, “ú–{’†”çŽîŒ¤‹†‹@\, “ú–{”xŠŕŠw‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/11

620065. [Šwp‘ (•Ş’SŽˇ•M)]y”xŠŕf—ĂƒKƒCƒhƒ‰ƒCƒ“ 2018”N”Ł@‘ć5”Ł@ˆŤŤ‹š–Œ’†”çŽîE‹š‘BŽîᇊ܂ށz×–Ef”ť’čŠî€‰ü’ůˆĎˆő‰ďˆĎˆő’ˇ: ˛“Ą”Vr (ŒÄ‹zŠíŠO), •Ň: “ú–{”xŠŕŠw‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712023. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Cytologic Criteria in the Revision of the General Rule for Clinical and Pathological Record of Lung Cancer in Japan. Satoh Y1: 19th National Congress & Annual Scientific Meeting Indonesia (2018/9/20), Suravaya, Indonesia. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

712024. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) The clinical impact of a morphologic micropapillary pattern in lung adenocarcinoma. Satoh Y1: 19th National Congress & Annual Scientific Meeting Indonesia (2018/9/22), Suravaya, Indonesia. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

713106. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Ciliated muconodular papillary tumors of the lung: a case report. Maruyama R1, Mikubo M1, Kakinuma H2, Yoshida T3, Satoh Y1: 17th Japan-Korea Joint Meeting for Diagnostic Cytopathology (2018/9/8), Busan, Japan. (ŠŰŽR—ˆ‹P1, ŽOŒEŤŽj1, Š`ŔœA–M2, ‹g“c@Œ÷3, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2•a—•”, 3•a—)

713107. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Relevance of results of intraoperative pleural lavage cytology and histological subtype in lung adenocarcinoma. Mikubo M1, Maruyama R1, Matsushima K1, Hayashi S1, Naito M1, Matsui Y1, Shiomi K1, Ichinoe M2, Yoshida T2, Satoh Y1: 19th World Conference on Lung Cancer (2018/9/23-26), Toronto, Canada. (ŽOŒEŤŽj1, ŠŰŽR—ˆ‹P1, ź“‡Œ\Œá1, —с@ËŽq1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˆęŒËš–ž2, ‹g“c@Œ÷2, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2•a—)

713108. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Interesting Cases of lung tumor. Satoh Y1: 19th National Congress & Annual Scientific Meeting Indonesia (2018/9/20), Suravaya, Indonesia. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

721014. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) Postgraduate Course Žc‘ś”xŘœ. ˛“Ą”Vr (ŒÄ‹zŠíŠO): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3), “Œ‹ž.

723386. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‘BŠŕ‚É‚¨‚Ż‚é”÷Ź“ű“ޏó\‘˘‚Ě‹šo“ŕôň×–Ef‚É—^‚Ś‚é‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ŽOŒEŤŽj1, ‹Ęě@’B1, ‹ß“Ą‘אl1, ŽRčGŒp1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˆęŒËš–ž2, ‹g“c@Œ÷2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/5-7), “Œ‹ž.

723387. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RƒŠƒ“Ž‰ŽżR‘ĚÇŒóŒQ‚đ‡•š‚ľ‚˝”xŠŕ2Řœ—á‚ĚŒŸ“˘. ‹ß“Ą‘אl1, ‹Ęě@’B1, ź“‡Œ\Œá1, —с@ËŽq1, ‰€“c@‘ĺ2, ŽRčGŒp1, ŽOŒEŤŽj1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć35‰ń“ú–{ŒÄ‹zŠíŠO‰ČŠw‰ď‘‰ď (2018/5/17-18), ç—t.

723388. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‘BŠŕŽčp‚É‚¨‚Ż‚é”÷Ź“ű“ޏó\‘˘‚ĚŒŸő‚ĚˆÓ‹`. ŽOŒEŤŽj1, ‹Ęě@’B1, ‹ß“Ą‘אl1, ŽRčGŒp1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˆęŒËš–ž2, ‹g“c@Œ÷2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘ć35‰ń“ú–{ŒÄ‹zŠíŠO‰ČŠw‰ď‘‰ď (2018/5/17-18), ç—t.

723389. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŒ´”­•@Œ^ßŠOŤNK/T×–EŤƒŠƒ“ƒpŽî‚Ě1—á. ’†ŽR•üH, ˛“ĄŒ›r, ŠâźO•ś, ˆäoL–ç, ź—Yˆę‹M, Î‹TœAŽ÷, Â–ö‘ĺŽ÷, ‰–ŕV@“N, ˛“Ą”Vr1, ›–ě—SK (1ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/1-3), ŽD–y.

723390. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹š‘B‘BŠŕ (NOS) ‚ĆABŒ^‹š‘BŽî‚Š‚ç\Ź‚ł‚ę‚鍬‡Œ^‹š‘BŠŕ‚Ě1Ç—á. ŠâźO•ś, ’†ŽR•üH, ˛“ĄŒ›r, ˆäoL–ç, Â–ö‘ĺŽ÷, ‰–ŕV@“N, Î‹TœAŽ÷, ˛“Ą”Vr1, Îě—Yˆę (1ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/1-3), ŽD–y.

723391. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ő̐Z‚𔺂¤”xŠŕ‚ɑ΂ˇ‚éŠO‰ČŽĄ—Ă‚ĚŒŸ“˘. “ŕ“Ą‰ëm1, ŠŰŽR—ˆ‹P1, ź“‡Œ\Œá1, —с@ËŽq1, ŽRčGŒp1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž.

723392. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷‚̍‚ˆŮŒ^“x”A˜Hă”çŠŕ‚ĚŒo‰ß’†‚ɏŹ×–EŠŕ‚̏oŒť‚đ”F‚ß‚˝1—á. ˆäoL–ç, ’†ŽR•üH, ŠâźO•ś, ’†ŽRŒPŽq, ˛“ĄŒ›r, ź”öˆę‹M, Â–ö‘ĺŽ÷, ‰–ŕV@“N, Î‹TœAŽ÷, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć57‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2018/11/17-18), ‰Ą•l.

723393. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŠŕ‰tó‰ť×–EfŒŸ‘Ě‚đ—p‚˘‚˝EGFRˆâ“`ŽqŒŸ¸‚ĚŒŸ“˘. ŽOŒEŤŽj1, ŠŰŽR—ˆ‹P1, ź“‡Œ\Œá1, —с@ËŽq1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ‹g“c@Œ÷2, ‘ş‰_–FŽ÷2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2018/11/29-12/1), “Œ‹ž.

723394. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆŤŤƒŠƒ“ƒpŽî‚đŠů‰‚ÉŽ‚ÂŒ´”­Ť”xŠŕ‚ɑ΂ľŘœp‚đŽ{s‚ľ‚˝12—á‚ĚŒŸ“˘. ź“‡Œ\Œá1, ŠŰŽR—ˆ‹P1, —с@ËŽq1, “ŕ“Ą‰ëm1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2018/11/29-12/1), “Œ‹ž.

733125. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’Ĺ‘Ě‚¨‚ć‚Ń‹š•Ç‡•šŘœ‚𔺂Á‚˝śă—t”xŠŕ‚Ě1Řœ—á. ŠŰŽR—ˆ‹P1, ź“‡Œ\Œá1, —с@ËŽq1, “ŕ“Ą‰ëm1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć177‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/6/23), “Œ‹ž.

733126. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚É“ďa‚ľ‚˝cŠu’E•Ş‰ťŒ^Ž‰–b“÷Žî‚Ě1—á. ź“‡Œ\Œá1, “ŕ“Ą‰ëm1, ŠŰŽR—ˆ‹P1, —с@ËŽq1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˆęŒËš–ž2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘ć183‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2018/12/15), “Œ‹ž.

733127. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹CŠÇŽx“ŕi“W‚𔺂Á‚˝śă—tG•˝ă”çŠŕ‚ɑ΂ľ‚Ä•ĄŽG‹CŠÇŽxŒ`Źp (type B) ‚đŽ{s‚ľ‚˝1—á. ŠŰŽR—ˆ‹P1, źˆäŒ[•v1, ź“‡Œ\Œá1, —с@ËŽq1, “ŕ“Ą‰ëm1, ŽOŒEŤŽj1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć179‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/3/2), “Œ‹ž.


”]_ŒoŠO‰ČŠw

[Šwp˜_•ś]

110217. [Œ´’˜] Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Kanamori M, Maekawa M, Shibahara I, Saito R, Chonan M, Shimada M, Sonoda Y, Kumabe T1, Watanabe M, Mano N, Tominaga T: Brain Tumor Pathol 2018/4; 35 (2): 90-6. (ŒG•”rG1: 1”]ŠO)

110218. [Œ´’˜] Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. Hide T1, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu JI, Mukasa A, Yano S: EBioMedicine 2018/4; 30: 94-104. (G‘ńˆę˜Y1: 1”]ŠO)

110219. [Œ´’˜] Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system. Shibahara I1, Hanihara M1, Watanabe T, Dan M1, Sato S1, Kuroda H1, Inamura A1, Inukai M2, Hara A2, Yasui Y3, Kumabe T1: J Neurooncol 2018/4; 137 (2): 417-27. (ŽÄŒ´ˆę—z1, űŒ´Œől1, ’h@@[1, ˛“ĄŸl1, •“c”Ž‹I1, ˆî‘ş˛‹I1, Œ˘Ž”@‰~2, Œ´@“ÖŽq2, ˆŔˆä”ü]3, ŒG•”rG1: 1”]ŠO, 2•a—, 3Œ`‘ÔŒn)

110220. [Œ´’˜] Clinical Features of Precocious, Synchronous, and Metachronous Brain Metastases and the Role of Tumor Resection. Shibahara I1, Kanamori M, Watanabe T, Utsunomiya A, Suzuki H, Saito R, Sonoda Y, Jokura H, Uenohara H, Tominaga T: World Neurosurg 2018/5; 113: e1-e9. (ŽÄŒ´ˆę—z1: 1”]ŠO)

110221. [Œ´’˜] Usefulness of Oblique Coronal Computed Tomography and Magnetic Resonance Imaging in the Endoscopic Endonasal Approach to Treat Skull Base Lesions. Yano S, Shinojima N, Kitajima M, Uetani H, Hide T1, Mukasa A: World Neurosurg 2018/5; 113: e10-9. (G‘ńˆę˜Y1: 1”]ŠO)

110222. [Œ´’˜] Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. Kayama T1, Sato S1, Sakurada K1, Mizusawa J1, Nishikawa R1, Narita Y1, Sumi M1, Miyakita Y1, Kumabe T1,2, Sonoda Y1, Arakawa Y1, Miyamoto S1, Beppu T1, Sugiyama K1, Nakamura H1, Nagane M1, Nakasu Y1, Hashimoto N1, Terasaki M1, Matsumura A1, Ishikawa E1, Wakabayashi T1, Iwadate Y1, Ohue S1, Kobayashi H1, Kinoshita M1, Asano K1, Mukasa A1, Tanaka K1, Asai A1, Nakamura H1, Abe T1, Muragaki Y1, Iwasaki K1, Aoki T1, Watanabe T1, Sasaki H1, Izumoto S1, Mizoguchi M1, Matsuo T1, Takeshima H1, Hayashi M1, Jokura H1, Mizowaki T1, Shimizu E1, Shirato H1, Tago M1, Katayama H1, Fukuda H1, Shibui S1 (1Japan Clinical Oncology Group): J Clin Oncol 2018/6: JCO2018786186. doi: 10.1200/JCO.2018.78.6186. (ŒG•”rG1,2: 2”]ŠO)

110223. [Œ´’˜] A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-ƒČB. Ozawa T, Arora S, Szulzewsky F, Juric-Sekhar G, Miyajima Y, Bolouri H, Yasui Y, Barber J, Kupp R, Dalton J, Jones TS, Nakada M, Kumabe T1, Ellison DW, Gilbertson RJ, Holland EC: Cell Rep 2018/6; 23 (13): 3787-97. (ŒG•”rG1: 1”]ŠO)

110224. [Œ´’˜] Indications for salvage surgery during treatment for intracranial germ cell tumors. Kanamori M, Kumabe T1, Watanabe M, Chonan M, Saito R, Yamashita Y, Ogawa Y, Sonoda Y, Tominaga T: J Neurooncol 2018/7; 138 (3): 601-607. (ŒG•”rG1: 1”]ŠO)

110225. [Œ´’˜] JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonƒŔ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. Wakabayashi T1, Natsume A1, Mizusawa J1, Katayama H1, Fukuda H1, Sumi M1, Nishikawa R1, Narita Y1, Muragaki Y1, Maruyama T1, Ito T1, Beppu T1, Nakamura H1, Kayama T1, Sato S1, Nagane M1, Mishima K1, Nakasu Y1, Kurisu K1, Yamasaki F1, Sugiyama K1, Onishi T1, Iwadate Y1, Terasaki M1, Kobayashi H1, Matsumura A1, Ishikawa E1, Sasaki H1, Mukasa A1, Matsuo T1, Hirano H1, Kumabe T1,2, Shinoura N1, Hashimoto N1, Aoki T1, Asai A1, Abe T1, Yoshino A1, Arakawa Y1, Asano K1, Yoshimoto K1, Shibui S1 (1Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG): J Neurooncol 2018/7; 138 (3): 627-36. (ŒG•”rG1,2: 2”]ŠO)

110226. [Œ´’˜] A new targeted capture method using bacterial artificial chromosome (BAC) libraries as baits for sequencing relatively large genes. Koganebuchi K, Gakuhari T, Takeshima H, Sato K, Fujii K, Kumabe T1, Kasagi S, Sato T, Tajima A, Shibata H, Ogawa M, Oota H: PLoS One 2018/7; 13 (7): e0200170. (ŒG•”rG1: 1”]ŠO)

110227. [Œ´’˜] Employment status and termination among survivors of pediatric brain tumors: a cross-sectional survey. Sato I, Higuchi A, Yanagisawa T, Murayama S, Kumabe T1, Sugiyama K, Mukasa A, Saito N, Sawamura Y, Terasaki M, Shibui S, Takahashi J, Nishikawa R, Ishida Y, Kamibeppu K: Int J Clin Oncol 2018/10; 23 (5): 801-11. (ŒG•”rG1: 1”]ŠO)

110228. [Œ´’˜] Safe Stereotactic Biopsy for Basal Ganglia Lesions: Avoiding Injury to the Basal Perforating Arteries. Sato S1, Dan M1, Hata H2, Miyasaka K1, Hanihara M3, Shibahara I1, Inoue Y4, Kumabe T1: Stereotact Funct Neurosurg 2018/10; 96 (4): 244-8. (˛“ĄŸl1, ’h@@[1, `@”Ž•ś2, ‹{â˜aO1, űŒ´Œől3, ŽÄŒ´ˆę—z1, ˆäă—D‰î4, ŒG•”rG1: 1”]ŠO, 2•úŽËü•”, 3ŽR—œ‘ĺŠw, 4•úŽËü (‰ć‘œ))

110229. [Œ´’˜] Safe Stereotactic Biopsy for Basal Ganglia Lesions: Avoiding Injury to the Basal Perforating Arteries. Sato S1, Dan M1, Hata H2, Miyasaka K1, Hanihara M, Shibahara I1, Inoue Y3, Kumabe T1: Stereotact Funct Neurosurg 2018; 96 (4): 244-8. (˛“ĄŸl1, ’h@@[1, `@”Ž•ś2, ‹{â˜aO1, ŽÄŒ´ˆę—z1, ˆäă—D‰î3, ŒG•”rG1: 1”]ŠO, 2•úŽËü•”, 3•úŽËü (‰ć‘œ))

110230. [Œ´’˜] Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI. Shibahara I1, Saito R, Osada Y, Kanamori M, Sonoda Y, Kumabe T1, Mugikura S, Watanabe M, Tominaga T: J Neurooncol 2019/1; 141 (2): 337-45. (ŽÄŒ´ˆę—z1, ŒG•”rG1: 1”]ŠO)

110231. [Œ´’˜] Idiopathic spinal cord herniation: consideration of its pathogenesis based on the histopathology of the dura mater. Shimizu S1,2, Kobayashi Y2, Oka H1,3, Kumabe T1: Eur Spine J 2019/2; 28 (2): 298-305. (´…@ú1,2, Ź—Ń—m‰î2, ‰Ş@GG1,3, ŒG•”rG1: 1”]ŠO, 2‰Ą•lŽs—§”]‘˛’†E_ŒoŇ’ĹƒZƒ“ƒ^[, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110232. [Œ´’˜] A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T1, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A1, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M: Neuro Oncol 2019/2; 21 (3): 348-59. (ŒG•”rG1: 1”]ŠO)

120009. [Œ´’˜] “ąoĂ–Ź‚Şá‘‚ĆˆŮ‚Č‚é‘ß‚ōd–Œ‚đŠŃ’Ę‚ˇ‚éŇ‘d–Œ“ŽĂ–Źá‘: Žčp‚đ•ĄŽG‰ť‚ˇ‚é”ń“TŒ^“I‘–s. ´…@ú1,2, ‘ĺŕVŹ”V1, –]ŒŽ’O1, ŠĂ—˜˜aŒő2, ‹ß“Ą—łŽj1, ŒG•”rG1: 1”]ŠO, 2‰Ą•lŽs—§”]‘˛’†E_ŒoŇ’ĹƒZƒ“ƒ^[): J Spine Res 2018/7; 9 (7): 1143-8.

120010. [Œ´’˜] ŹŽ™”]ŽîᇎĄ—Ă‚ĚW–ń‰ť‚đ‚Ç‚¤‚ˇ‚ˇ‚ß‚é‚Š: ‘S‘ƒAƒ“ƒP[ƒg’˛¸Œ‹‰Ę‚ć‚č. “n•Ó—SŽq, űŒ´Œől1, źě@—ş, ŒG•”rG1 (1”]ŠO): ŹŽ™‚Ě”]_Œo 2018/7; 43 (3): 314-27.

120011. [Œ´’˜] _ŒoŠÇ•Â˝áŠQ—\–h‚ÉŠÖ‚ˇ‚éˆă—ÐE‚Ě—tŽ_”F’m—Ś. ‹ß“ĄŒúś, ‘˝“cŽ•F, Žt“cMl1, ˆÉ’nr‰î, ˆÉ“Ą’mŒh, ‹{“ŕ˛l (1”]ŠO): “úˆăŽGŽ 2019/1; 147 (10): 2051-6.

310021. [Ç—á•ń] New Radiologic Findings of Hypertrophic Olivary Degeneration in 2 Patients with Brainstem Lymphoma. Sato S1, Shibahara I1, Inoue Y2, Hide T1, Kumabe T1: World Neurosurg 2019/3; 123: 464-8.e1. (˛“ĄŸl1, ŽÄŒ´ˆę—z1, ˆäă—D‰î2, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO, 2•úŽËü (‰ć‘œ))

320016. [Ç—á•ń] Šg‘ĺŒXŒü‚đŽŚ‚ˇ–łÇŒóŤăˆß‰ş‹×–EŤŻ×–EŽî‚ɑ΂ˇ‚éŽčp‰î“üŒˆ’č‚É‚¨‚Ż‚éŽîᇗeĎ‰đÍ‚Ě—L—pŤ. ŽÄŒ´ˆę—z1, űŒ´Œől, ŒG•”rG1 (1”]ŠO): ŹŽ™‚Ě”]_Œo 2018/12; 43 (4): 481-6.

320017. [Ç—á•ń] ‹žŽ‹‰şŽčŞŠÇ‰đ•úp‚É‚¨‚Ż‚é•s‘SŠJ•ú‚Ɣ牺’f’[_ŒoŽîŒ`Ź‚Ş•Ą‡Ť‹ÇŠáu’ɏnjóŒQ‚𐜂ś‚˝1—á. ´…@ú1, ‘ĺŕVŹ”V, ’h@@[1, “c’†@—, –]ŒŽ’O, Ş–{@[2, ‰Ş@GG1,3, ŒG•”rG1 (1”]ŠO, 2Œ`ŹE”üŠO, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ”]_ŒoŠO‰Č 2018/12; 46 (12): 1093-101.

520009. [‘ŕ] ƒJƒ‹ƒ€ƒXƒ`ƒ“”]“ŕ—Ż’u—pÜ (ƒMƒŠƒAƒfƒ‹Ň) ‚É‚ć‚鏉”­äP‰čŽî‚ĚŽĄ—ÐŹŃ. ŒG•”rG1, ŽÄŒ´ˆę—z1, âV“Ą—ł‘ž (1”]ŠO): ”]_ŒoŠO‰Č 2018/5; 46 (5): 367-76.

520010. [‘ŕ] _ŒoäPŽî“EoŽž‚̐[•”×“Ž–Ź‘š‚É‚ć‚é‹•ŒŒ‡•šÇ‚Ć‚ľ‚Ẳ^“Ž–ƒáƒ. ŒG•”rG (”]ŠO): ”]‘˛’†‚ĚŠO‰Č 2018/7; 46 (3): 189-94.

520011. [‘ŕ] –TˆĆ•”Žîᇎčp‚É‚¨‚Ż‚éICG“ŕŽ‹‹ž‚Ě—L—pŤ. G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ”]_ŒoŠO‰Č‘Ź•ń 2019/3; 29 (3): 270-7.

522063. [uŔ]y‹łŒP“IÇ—á‚ÉŠw‚ÔƒVƒŠ[ƒYzŠJ“ޏp‚Őś‚ś‚˝–Č•ĐˆâŽc‚đŒo‰ßŠĎŽ@‚Ć‚ľ‚˝2Ç—á: ‰ńŽűŽčp‚̐Ľ”ń. ´…@ú1, áÁ–ě@—B, ŒG•”rG1, •y‰i’î“ń, ’†ŽRŒŤŽi, ŽR–{—E•v (1”]ŠO): ”]_ŒoŠO‰Č 2018/6; 46 (6): 529-33.

522064. [uŔ]y‹łŒP“IÇ—á‚ÉŠw‚ÔƒVƒŠ[ƒYzŠJ“ޏp‚Őś‚ś‚˝–Č•ĐˆâŽc‚đŒo‰ßŠĎŽ@‚Ć‚ľ‚˝2Ç—á: ‰ńŽűŽčp‚̐Ľ”ń. ´…@ú1, áÁ–ě@—B, ŒG•”rG1, •y‰i’î“ń, ’†ŽRŒŤŽi, ŽR–{—E•v (1”]ŠO): ”]_ŒoŠO‰Č 2018/6; 46 (6): 529-33.

522065. [uŔ]y“ÁW: Ň’ŐҐ‘ŠO‰Č‚É‚¨‚Ż‚郂ƒjƒ^ƒŠƒ“ƒOz˜ĺ•”öÝŤ“ń•ŞŇ’ĹŽčp‚É‚¨‚Ż‚ép’†_Œoś—Šw“IŽč‹Z. Žt“cMl (”]ŠO): Ň’ŐҐ‘ƒWƒƒ[ƒiƒ‹ 2018/7; 31 (7): 653-66.

522066. [uŔ]y“ÁW: ŹŽ™”]_ŒoŠO‰ČŽžŠł‚̉ۑč‚Ć“W–]zöÝŤ“ń•ŞŇ’Ĺ. ‹g“Ą˜a‹v, ‘ĺX‹`”Í, Ź–ö@ň, Žt“cMl1, ŽOš MŒ[ (1”]ŠO): ”]_ŒoŠO‰ČƒWƒƒ[ƒiƒ‹ 2018/9; 27 (9): 662-9.

522067. [uŔ]y“ÁW: VśŽ™ŠO‰ČŽžŠł‚̐¸_Eg‘Ě”­ˆçzŇ‘‘–ŒáŽŠłŽ™‚̐¸_‰^“Ž”­’B. Žt“cMl (”]ŠO): ŹŽ™ŠO‰Č 2019/1; 51 (1): 94-9.

[’˜@‘]

620066. [Šwp‘ (•Ş’SŽˇ•M)]yƒvƒ‰ƒCƒ€”]_ŒoŠO‰Č@4 ƒOƒŠƒI[ƒ}z‘ćIÍ 1. ƒOƒŠƒI[ƒ}Žčp‚̍l‚Ś•ű, 2. “Eo‹ŤŠEŒˆ’č, 3. ŒŒŠÇ‰ˇ‘ś, 4. Ž~ŒŒE“Eo, p.2-31. ŒG•”rG1 (1”]ŠO), ŠÄC: –Ř“ŕ”Ž”V, Ä“Ą‰„l, •Ň: ŒG•”rG1, ŽO—֏‘“X, “Œ‹ž, 2018/4”­s.

620067. [Šwp‘ (•Ş’SŽˇ•M)]yƒvƒ‰ƒCƒ€”]_ŒoŠO‰Č 4 ƒOƒŠƒI[ƒ}z‘ćIIÍ ŽčpŽx‰‡‘•’u@4. p’†CT/MRI, p.50-6. ‘şŠ_‘P_, ŒG•”rG1, ’h@@[1 (1”]ŠO), ŠÄCF–Ř“ŕ”Ž”V, Ä“Ą‰„l , •Ň: ŒG•”rG1, ŽO—֏‘“X, “Œ‹ž, 2018/4”­s.

620068. [Šwp‘ (•Ş’SŽˇ•M)]yƒvƒ‰ƒCƒ€”]_ŒoŠO‰Č 4 ƒOƒŠƒI[ƒ}z‘ćIIIÍ •”ˆĘ•ĘƒOƒŠƒI[ƒ}“Eo•ű–@@10. ”]Š˛•”, p.253-62. Žt“cMl1, ˆäŒ´@“N, ‰ŹŒ´‰pŽ÷ (1”]ŠO), ŠÄCF–Ř“ŕ”Ž”V, Ä“Ą‰„l , •Ň: ŒG•”rG1, ŽO—֏‘“X, “Œ‹ž, 2018/4”­s.

620069. [Šwp‘ (•Ş’SŽˇ•M)]yVNS NOW 15@”]Š˛E”][•”‚ĚŽčp@ŽčpƒAƒvƒ[ƒ`‚ĚŠî–{‚ĆŽčp‚̍l‚Ś•űzŠî’ęŠjƒOƒŠƒI[ƒ}‚ĚŽčp|ƒŒƒ“ƒYŠjƒOƒŠƒI[ƒ}‚ɑ΂ˇ‚étranssylvian & transinsular approach|, p.78-86. ŒG•”rG1, ˛“ĄŸl1 (1”]ŠO), •Ň: Ä“Ą‰„l, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/9”­s.

620070. [Šwp‘ (•Ş’SŽˇ•M)]y”]Š˛E”][•”‚ĚŽčp@ŽčpƒAƒvƒ[ƒ`‚ĚŠî–{‚ĆŽčp‚̍l‚Ś•űzŠî’ęŠjƒOƒŠƒI[ƒ}‚ĚŽčp|ƒŒƒ“ƒYŠjƒOƒŠƒI[ƒ}‚ɑ΂ˇ‚étranssylvian & transinsular approach|, p.78-86. ŒG•”rG1, ˛“ĄŸl1 (1”]ŠO), ’S“–•ŇWˆĎˆő: Ä“Ą‰„l, •ŇWˆĎˆő: X“c–ž•v, ˆÉ’B@ŒM, ‹e“cŒ’ˆę˜Y, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, ‘ĺă, 2018/9”­s.

620071. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ_ƒo[‚Ć“Ž‰ć‚ĹŠw‚Ô”][•”ƒAƒvƒ[ƒ`zI ”]Žş‚Ö‚ĚƒAƒvƒ[ƒ`@A. ‘¤”]Žş@2. Paramedian high parietal approach@1) Žčp, p.16-20. ‰Ş@GG1,2 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), ŠÄC: ‹g“cˆęŹ3 (3Œcœä‹`m‘ĺŠw), •Ň: ˆäě–[•v4, ‰Ş@GG1,2, HŒłŽĄ˜N5, Šâ—§N’j6 (4“‡ŞŒ§—§’†‰›•a‰@, 5“Œ‹žˆă‰Č‘ĺŠw, 6ç—t‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰@), ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/10”­s.

620072. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ_ƒo[‚Ć“Ž‰ć‚ĹŠw‚Ô”][•”ƒAƒvƒ[ƒ`zI ”]Žş‚Ö‚ĚƒAƒvƒ[ƒ`@A. ‘¤”]Žş@2. Paramedian high parietal approach@2) ƒJƒ_ƒo[, p.21-6. ‰Ş@GG1,2 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), ŠÄC: ‹g“cˆęŹ3 (3Œcœä‹`m‘ĺŠw), •Ň: ˆäě–[•v4, ‰Ş@GG1,2, HŒłŽĄ˜N5, Šâ—§N’j6 (4“‡ŞŒ§—§’†‰›•a‰@, 5“Œ‹žˆă‰Č‘ĺŠw, 6ç—t‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰@), ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/10”­s.

620073. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ_ƒo[‚Ć“Ž‰ć‚ĹŠw‚Ô”][•”ƒAƒvƒ[ƒ`zI ”]Žş‚Ö‚ĚƒAƒvƒ[ƒ`@A. ‘¤”]Žş@3. Interhemispheric precuneus approach@2) ƒJƒ_ƒo[, p.38-42. ‰Ş@GG1,2 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), ŠÄC: ‹g“cˆęŹ3 (3Œcœä‹`m‘ĺŠw), •Ň: ˆäě–[•v4, ‰Ş@GG1,2, HŒłŽĄ˜N5, Šâ—§N’j6 (4“‡ŞŒ§—§’†‰›•a‰@, 5“Œ‹žˆă‰Č‘ĺŠw, 6ç—t‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰@), ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/10”­s.

620074. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ_ƒo[‚Ć“Ž‰ć‚ĹŠw‚Ô”][•”ƒAƒvƒ[ƒ`zI ”]Žş‚Ö‚ĚƒAƒvƒ[ƒ`@B. ‘ćŽO”]Žş@2. Transchoroidal fissure approach@1) Žčp, p.59-62. ‰Ş@GG1,2 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), ŠÄC: ‹g“cˆęŹ3 (3Œcœä‹`m‘ĺŠw), •Ň: ˆäě–[•v4, ‰Ş@GG1,2, HŒłŽĄ˜N5, Šâ—§N’j6 (4“‡ŞŒ§—§’†‰›•a‰@, 5“Œ‹žˆă‰Č‘ĺŠw, 6ç—t‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰@), ’†ŠOˆăŠwŽĐŽĐ, “Œ‹ž, 2018/10”­s.

620075. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ_ƒo[‚Ć“Ž‰ć‚ĹŠw‚Ô”][•”ƒAƒvƒ[ƒ`zIV [•””’ŽżüˆŰ‚đl—ś‚ľ‚˝ŠO‰ČŽčp@1. Žčp@3) “‡•”, p.187-91. ŒG•”rG1 (1”]ŠO), ŠÄC: ‹g“cˆęŹ2 (2Œcœä‹`m‘ĺŠw), •Ň: ˆäě–[•v3, ‰Ş@GG1,4, HŒłŽĄ˜N5, Šâ—§N’j6 (3“‡ŞŒ§—§’†‰›•a‰@, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 5“Œ‹žˆă‰Č‘ĺŠw, 6ç—t‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰@), ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711007. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Short and long-term risks of posterior instrumentation in children and when to remove it. Morota N1: The 3rd European Society for Pediatric Neurosurgery Hands-on workshop on craniovertebral junction surgery (2019/7/1), Lyon, France. (Žt“cMl1: 1”]ŠO)

711008. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Surgery for craniovertebral junction in children. Morota N1: The 10th Chinese Pediatric Neurosurgical Forum (2018/7/13), Haikou, Chaina. (Žt“cMl1: 1”]ŠO)

711009. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Surgical strategy for germ cell tumors in the anterior half of the third ventricle. Morota N1: The 10th Chinese Pediatric Neurosurgical Forum (2018/7/14), Haikou, Chaina. (Žt“cMl1: 1”]ŠO)

711010. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Brainstem surgery with the use of intraoperative neurophysiological procedures. Morota N1: The 10th Chinese Pediatric Neurosurgical Forum (2018/7/14), Haikou, Chaina. (Žt“cMl1: 1”]ŠO)

711011. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Surgery of spinal lipomas based on the new classification system. Morota N1: World Federation of Neurological Surgery and Asian Congress of Neurosurgery, Education Seminor in Myanmar (2018/9/22), Yangon, Myanmar. (Žt“cMl1: 1”]ŠO)

711012. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Posterior fossa surgery: Tokyo experience. Morota N1: The 46th Annual Meeting of the International Society for Pediatric Neurosurgery (2018/10/7), Tel Aviv, Israel. (Žt“cMl1: 1”]ŠO)

712025. [Šw‰ď (‘Ű)] (‹łˆçu‰‰) Cortical Stimulation Mapping: How we do it. Kumabe T1: Second International Brain Mapping Course (2018/4/27), New Orleans, USA. (ŒG•”rG1: 1”]ŠO)

712026. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Usefulness of ICG endoscope in endonasal skull base surgery. Hide T1: 2nd Asian Congress of Neurological Surgeons Endoscopic Cadaver and Live Surgery seminar (2019/7/15), Tumen, Russia. (G‘ńˆę˜Y1: 1”]ŠO)

712027. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Surgical strategy for craniopharyingimas: neuroendoscopic and microscopic hybrid surgery. Oka H1: Prague Neurosurgerical Week 2018 (2018/9/1), Prague, Czech. (‰Ş@GG1: 1”]ŠO)

713109. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Tumor microenvironment after biodegradable BCNU wafer implantation. Special consideration on immune system. Kumabe T1: 22nd International Conference on Brain Tumor Research and Therapy (ICBTRT) (2018/6/26), Norway. (ŒG•”rG1: 1”]ŠO)

713110. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Surgery for spinal lipoma based on a new classification system. Morota N1: The 46th Annual Meeting of the International Society for Pediatric Neurosurgery (2018/10/8), Tel Aviv, Israel. (Žt“cMl1: 1”]ŠO)

721015. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) BCNU wafers‚ĆŽîᇔ÷ŹŠÂ‹Ť. ŒG•”rG (”]ŠO): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/11), ĺ‘ä.

722067. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) Ž‹°Ežś‘O•”EŒă•”‘яó‰ńE”]—Ŕ–c‘ĺ•”Eź‰Ę‘ĚŽîᇓEo‚É‚¨‚Ż‚é“ŕ‘ĺ”]Ă–Ź‰ˇ‘ś. ŒG•”rG1, ŽÄŒ´ˆę—z1, űŒ´Œől, ŠÚ‰Ş@’B, ˆî‘ş˛‹I, ’h@@[1, ‹{â˜aO1, ˛“ĄŸl1 (1”]ŠO): ‘ć27‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (2018/4/13), “Ţ—Ç.

722068. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ƒƒbƒPƒ‹o‹ß–TŽîᇂւ̒§í. ‹v{”ü^—1, ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ˛“ĄŸl1, ‹{â˜aO1, ŒG•”rG1 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć27‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (2018/4/14), “Ţ—Ç.

722069. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŹŽ™…“ޏǂɑ΂ˇ‚é“ŕŽ‹‹ž“I‘ćŽO”]Žş’ęŠJ‘‹pŹŒ÷‚Ě—\‘ވöŽq‚Ć‚ľ‚Ä‚ĚTrans Ependymal Flow. ’Ă“c‹ąŽĄ, ˆäŒ´@“N, Žt“cMl1 (1”]ŠO): ‘ć46‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2018/6/8), “Œ‹ž.

722070. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) p’†‹…ŠC–Č‘Ě”˝ŽËƒ‚ƒjƒ^ƒŠƒ“ƒO: ˜ĺ•”Žčp‚̏p’†_Œoś—Šw“IŽč‹Z. Žt“cMl1, ˆäŒ´@“N, ’Ă“c‹ąŽĄ (1”]ŠO): ‘ć33‰ń“ú–{Ň‘ŠO‰ČŠw‰ď (2018/6/14), “Ţ—Ç.

722071. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) “ŞŠWˆô“ŞŽîŽčpí—Ş: ŠJ“ޏp‚Ć“ŕŽ‹‹žŽčp‚ĚŽg‚˘•Ş‚Ż. ‰Ş@GG1,2, ‹v{”ü^—1,2, ‹ß“ĄGŽĄ1,2, ’h@@[1, ŒG•”rG1, ƒyƒ‹ƒlƒcƒL[EƒAƒNƒZƒ‹, ƒŠƒ…[ƒfƒBƒbƒNEƒfƒCƒ^[ (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć23‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2018/9/14), ˜a‰ĚŽR.

722072. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) AT/RT‚ĚŽĄ—ÐŹŃ‚ÍŒüă‚ľ‚Ä‚˘‚é‚Š? “Á‚ÉŽčp‚Ě–đŠ„‚É‚Â‚˘‚Ä. ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ‹v{”ü^—1,2, ’h@@[1, ŒG•”rG1, ƒyƒŠ[EƒA[ƒŠ[, ƒVƒƒƒCƒgƒnƒEƒA[Eƒo[ƒ“ƒh (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć23‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2018/9/14), ˜a‰ĚŽR.

722073. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‰şŽˆ‰^“Žđ“ú‰ˇ‘ś‚Ě‚˝‚ß‚Ě‘Sg–ƒŒ‰ş“d‹Cś—Šw“I‰^“Ž‹@”\ƒ}ƒbƒsƒ“ƒOEƒ‚ƒjƒ^ƒŠƒ“ƒO. ŒG•”rG1, ŽÄŒ´ˆę—z1, ‹{â˜aO1, ‹v{”ü^—1,2, ˛“ĄŸl1 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć23‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2018/9/14), ˜a‰ĚŽR.

722074. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ƒƒbƒPƒ‹o‹ß–TŽîᇂւ̒§í. ‹v{”ü^—1,2, ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ŒG•”rG1 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć23‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2018/9/15), ˜a‰ĚŽR.

722075. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) Olig2 positive Oligodendrocytes lineage cells induce chemo-radioresisitant characteristics at the tumor border in glioblastomas. G‘ńˆę˜Y1, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu J, Mukasa A (1”]ŠO): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/25), “Œ‹ž.

722076. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) äP‰čŽî×–E‚̓IƒŠƒSƒfƒ“ƒhƒƒTƒCƒg‚âƒ}ƒNƒƒtƒ@[ƒW‚Ć”÷ŹŠÂ‹Ť‚đŒ`Ź‚ľŽĄ—Ă’ďRŤ‚đŠl“ž‚ˇ‚é. G‘ńˆę˜Y1, ŒÔŒ´‹`O2, ’†‘ş‰p•v3, –q–ěŒhŽj3, –î–ě–Εq3, ŽÄŒ´ˆę—z1, ŒG•”rG1, •Š}Wä3 (1”]ŠO, 2ŒF–{‘ĺŠw×–E•a—, 3ŒF–{‘ĺŠw”]_ŒoŠO‰Č): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/10), ĺ‘ä.

722077. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‰ŠúŽĄ—ĂŒă10”NˆČăŒo‰ß‚ľ‚˝“ŞŠW“ŕăóŽî‚Ě‹@”\—\Œă. ‹ŕX­”V1, âV“Ą—ł‘ž1, ”ђˁ@“2, ź”öŒc”V2, ”ž‘qrŽi3, ˛‹vŠÔ“Ä4, ă”W‚Žu5, ‰€“c‡•F6, ŒG•”rG7, —é–Ř‹§Žq2, •y‰i’î“ń1 (1“Œ–k‘ĺŠw”]_ŒoŠO‰Č, 2“Œ–k‘ĺŠw‚ŽŸ‹@”\áŠQŠw, 3“Œ–k‘ĺŠw•úŽËüf’fŠw•Ş–ě, 4“Œ–k‘ĺŠw¸__ŒoŠw•Ş–ě, 5“Œ–k‘ĺŠw‹łˆçŠw•”, 6ŽRŒ`‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 7”]ŠO): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/11), ĺ‘ä.

722078. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) Ä”­äP‰čŽî‚ɑ΂ˇ‚éŒÂ•Ę‰ťƒyƒvƒ`ƒhƒƒNƒ`ƒ“: ‘ć3‘ŠŽĄŒą‚Š‚猊‚Ś‚˝ĄŒă‚Ě•űŒüŤ. ˆÉ“Ą‹ąŒĺ1, Ź“c‘PF2, rě–F‹P3, ŽRč•ś”V4, źě@—ş5, Â–Ř—F˜a6, ‹ŕX­”V7, ‰iŞŠî—Y8, ŒG•”rG9, œAŁ—Yˆę10, Žsě’qŒp11, Ź—э_”V12, “ĄŠŞ‚Œő13, ŒÜ“‡‹v—z14, ’|“‡G—Y15, Ž›č•F16 (1‹v—Ż•Ä‘ĺŠwƒƒNƒ`ƒ“ƒZƒ“ƒ^[, 2‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@”]Ň‘ŽîᇉČ, 3‹ž“s‘ĺŠw”]_ŒoŠO‰Č, 4L“‡‘ĺŠw”]_ŒoŠO‰Č, 5é‹Ęˆă‰Č‘ĺŠw‘Űˆă—ĂƒZƒ“ƒ^[”]EŇ‘ŽîᇉČ, 6‹ž“sˆă—ĂƒZƒ“ƒ^[”]_ŒoŠO‰Č, 7“Œ–k‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 8ˆÇ—Ń‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 9”]ŠO, 10“Ą“cˆă‰Č‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 11‰ŞŽR‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 12–kŠC“š‘ĺŠw”]_ŒoŠO‰Č, 13é‹Ęˆă‰Č‘ĺŠw”]_ŒoŠO‰Č, 14ŽRŒű‘ĺŠw”]_ŒoŠO‰Č, 15‹{č‘ĺŠw”]_ŒoŠO‰Č, 16‹v—Ż•Ä‘ĺŠw”]_ŒoŠO‰Č): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/12), ĺ‘ä.

722079. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ”]ŠO‰ČŽ¨•@‰Č‡“ŻŽčpÇ—á‚É‚¨‚Ż‚é“ŞŠWŠç–ĘŽčp‚Š‚çŒo•@“I“ŕŽ‹‹žŽčp‚Ö‚Ě“]Šˇ‚ƍH•v. G‘ńˆę˜Y1, Ž]Šň“OŽĄ2, –î–ě–Εq3, ‹{–{r•ă4, ŽR‰ş@‘ń4 (1”]ŠO, 2–źŒĂ‰ŽŽs—§‘ĺŠwˆăŠw•”Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰Č, 3ŒF–{‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 4Ž¨•@ˆôAE“ŞčňŠO): ‘ć25‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2018/10/27), VŠƒ.

722080. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) Œ°”÷‹ž”]_ŒoŠO‰ČŽž‘ă‚Š‚çŠOŽ‹‹ž”]_ŒoŠO‰ČŽž‘ă‚Ö‚Ě’§í. ‰Ş@GG1,2, ‹v{”ü^—1,2, ‹ß“ĄGŽĄ1,2, ƒAƒNƒZƒ‹Eƒyƒ‹ƒlƒcƒL[3 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ƒ}ƒCƒ“ƒc‘ĺŠw”]_ŒoŠO‰Č): ‘ć25‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2018/10/27), VŠƒ.

722081. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘ćŽO”]Žş“ŕEˆĆă•”Žîᇂւ̎Ą—Ð헪C‘˝•űŒüƒAƒvƒ[ƒ`‚̏K“ž‚Ć“ŕŒ°”÷‹ž”]_ŒoŠO‰ČŽž‘ă‚Š‚çŠOŽ‹‹žŠO‰ČŽž‘ă‚Ö‚Ě’§íŽ‹‹žŽčp‚̏d—vŤ. ‰Ş@GG (”]ŠO): ‘ć24‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2018/11/9), ‰Ą•l.

722082. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‹ô‘R”­ŒŠ‚ł‚ę‚˝’áˆŤŤ“x_ŒoäPŽî‚Ć‚Ý‚Č‚ł‚ę‚é•a•Ď‚ɑ΂ˇ‚éŽčp‰î“üŽžŠúŒˆ’č‚Ě–â‘č“_. ŒG•”rG1, ŽÄŒ´ˆę—z1, ‹{â˜aO1, ’h@@[1, ˛“ĄŸl1, G‘ńˆę˜Y1 (1”]ŠO): ‘ć36‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2018/12/3), Ź“cŒ´.

722083. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) Œ°”÷‹ž”]_ŒoŠO‰ČŽž‘ă‚Š‚çŠOŽ‹‹ž”]_ŒoŠO‰ČŽž‘ă‚Ö‚Ě’§í. ‰Ş@GG1,2, ‹v{”ü^—1,2, ‹ß“ĄGŽĄ1,2, ƒAƒNƒZƒ‹Eƒyƒ‹ƒlƒcƒL[3 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ƒ}ƒCƒ“ƒc‘ĺŠw”]_ŒoŠO‰Č): ‘ć36‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2018/12/3), Ź“cŒ´.

722084. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œă“ŞŠWâ|”]Š˛•”ŠO‘¤•a•ĎƒAƒvƒ[ƒ`‚É‚¨‚Ż‚éHorizontal fissure”—Ł‚Ě—L—pŤ. ‰Ş@GG1, ‹v{”ü^—1 (1”]ŠO): ‘ć21‰ń“ú–{_ŒoŒ¸ˆłpŠw‰ď (2019/1/24), “Œ‹ž.

722085. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ’źŒa4 mm ICG“ŕŽ‹‹ž‚Ě—L—pŤ‚Ɖ”\Ť. G‘ńˆę˜Y1, ‹{âO˜a1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1, ŒG•”rG1 (1”]ŠO): ‘ć29‰ń“ú–{ŠÔ”]‰ş‚‘ĚŽîᇊw‰ď (2019/2/23), ‘ĺă.

723395. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĺ”]Šî’ęŠj•”Žîᇂɑ΂ˇ‚é‰Â‹y“I“Eop: Trans-Sylvian & Trans-insular approach. ŽÄŒ´ˆę—z1, ’h@@[1, ‹{â˜aO1, ˛“ĄŸl1, ŒG•”rG1 (1”]ŠO): ‘ć27‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (2018/4/13), “Ţ—Ç.

723396. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œ°”÷‹ž”]_ŒoŠO‰ČŽž‘ă‚Š‚çŠOŽ‹‹ž”]_ŒoŠO‰ČŽž‘ă‚Ö‚Ě’§í. ‰Ş@GG1,2, ‹v{”ü^—1,2, ‹ß“ĄGŽĄ1,2, Perneczky Axel3 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ƒ}ƒCƒ“ƒc‘ĺŠw”]_ŒoŠO‰Č): ‘ć27‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (2018/4/13), “Ţ—Ç.

723397. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œă“ŞŠWâ|”]Š˛•”ŠO‘¤•a•ĎƒAƒvƒ[ƒ`‚É‚¨‚Ż‚éHorizontal fissure”—Ł‚Ě—L—pŤ. ‹v{”ü^—1,2, ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ˛“ĄŸl1, ‹{â˜aO1, ŒG•”rG1 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć27‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (2018/4/14), “Ţ—Ç.

723398. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Oligodendrocyte progenitor cells and macrophages/microglia produce glioma stem cell niches at the tumor border. G‘ńˆę˜Y1, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu J, Mukasa A, Yano S (1”]ŠO): ‘ć16‰ńŠ˛×–EƒVƒ“ƒ|ƒWƒEƒ€ (2018/6/1), •Ÿ‰Ş.

723399. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńÇŒóŒQŤ–îó–D‡‘Šú–ü‡Ç‚ĚŒZ’í—á. Ş–{–˘, ˆäŒ´@“N, ‹Ę“cˆęŒh, ’Ă“c‹ąŽĄ, Žt“cMl1, ˛‹vŠÔ, âV“Ą@´ (1”]ŠO): ‘ć46‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2018/6/8), “Œ‹ž.

723400. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”˝•œŤ”A˜HŠ´ő‚Ĺ”­Ç‚ľ‚˝Ň‘d–ŒŠO‚­‚ŕ–ŒůN–E‚Ěˆę—á. ”Ń“‡ˆťŽq, ˆäŒ´@“N, ’Ă“c‹ąŽĄ, Žt“cMl1 (1”]ŠO): ‘ć46‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2018/6/8), “Œ‹ž.

723401. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ň‘IŽnŘœ‚É‚ć‚éŒW—Ż‰đœp‚ĚŽčp“K‰ž‚ĆŽĄ—ĂŒř‰Ę. ’Ă“c‹ąŽĄ, ˆäŒ´@“N, Žt“cMl1 (1”]ŠO): ‘ć46‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2018/6/8), “Œ‹ž.

723402. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™”]_ŒoŠO‰ČŽčp‚̏p‘O‰Ć‘°ŕ–ž“ŕ—e‚ĚŒŸ“˘‹y‚яpŽŻ•Ęŕ–žƒ}ƒjƒ…ƒAƒ‹‚ւ̉ü’ů. ’|‘şiŽq, “cŒű‰Ŕ”g, ’†–{‹M”V, •Ä’J‹ąŽq, ˆäŒ´@“N, Žt“cMl1 (1”]ŠO): ‘ć46‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2018/6/8), “Œ‹ž.

723403. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œo•@“ŕŽ‹‹ž‰ş‘O“ŞŠW’ęŽčp‚É‚¨‚Ż‚鐑‰t˜R—\–h‚Ćƒsƒbƒgƒz[ƒ‹. G‘ńˆę˜Y1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq, ˛“ĄŸl1, ŒG•”rG1 (1”]ŠO): ‘ć31‰ń“ú–{“ŞŠW’ęŠO‰ČŠw‰ď (2019/7/12), “Œ‹ž.

723404. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) šk_Œo‰č×–EŽî‚ɑ΂ˇ‚éŒo•@“I“ŕŽ‹‹žŽčp. G‘ńˆę˜Y1, Ž]Šň“OŽĄ, “n粁@‹B, –î–ě–Εq, ŒG•”rG1 (1”]ŠO): ‘ć30‰ń“ú–{“ŞŠW’ęŠO‰ČŠw‰ď (2018/7/13), “Œ‹ž.

723405. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’†”]Rosette-forming glioneruronal tumor‚Ě2—á‚Ć—Ő°“I‹y‚Ń•ŞŽq•a—Šw“I‰đÍ. ŽÄŒ´ˆę—z1, ’h@@[1, ‹{â˜aO1, ˛“ĄŸl1, G‘ńˆę˜Y1, ‹`‰ŞFŽq2, •˝ŒËƒŽq3, ’†–ě‰ĂŽq4, Žs‘şKˆę4, ŒG•”rG1 (1”]ŠO, 2‘—§Źˆçˆă—ĂƒZƒ“ƒ^[•a—f’f•”, 3ŒQ”n‘ĺŠwˆăŠw•”•t‘Ž•a‰@•a—•”, 4‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[”]_ŒoŠO‰Č): ‘ć19‰ń“ú–{•ŞŽq”]_ŒoŠO‰ČŠw‰ď (2018/8/24), ‘ĺă.

723406. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) _ŒoäPŽî“EopW’†C—ű’†‚̏pŽŇ‚É‚¨‚Ż‚鑤“Ş—t“ŕ‘¤äP‰čŽî‚ɑ΂ˇ‚é“Eop. ŽÄŒ´ˆę—z1, ŒG•”rG1 (1”]ŠO): ‘ć23‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2018/9/15), ˜a‰ĚŽR.

723407. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’†”]Rosette-forming glioneuronal tumor‚Ě2—á‚Ć—Ő°“I‹y‚Ń•ŞŽq•a—Šw“I‰đÍ. ŽÄŒ´ˆę—z1, ’h@@[1, ‹{â˜aO1, ˛“ĄŸl1, G‘ńˆę˜Y1, ‹`‰ŞFŽq2, •˝ŒËƒŽq3, ’†–ě‰ĂŽq4, Žs‘şKˆę4, ŒG•”rG1 (1”]ŠO, 2‘—§Źˆçˆă—ĂŒ¤‹†ƒZƒ“ƒ^[•a—f’f•”, 3ŒQ”n‘ĺŠwˆăŠw•”•‘Ž•a‰@•a—•”, 4‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/26), “Œ‹ž.

723408. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’˜‚ľ‚˘’†•_ŒoŒn”dŽí‚É‚Ä”­Ç‚ľ–UŒŸ‚ŏ‰‚ß‚ÄŠm’čf’f‚Ş“ž‚ç‚ę‚˝‚—îŽŇ’†ŠÔŒ^ź‰Ę‘ĚŽŔŽżŽîᇠ(PPTID) ‚Ě1—á. ‹{â˜aO1, ŽÄŒ´ˆę—z1, ŠÚ‰Ş@’B2, ˆî‘ş˛‹I, H’JšŽj3, Œ˘Ž”@‰~3, ŽOŽ}@M3, ŒG•”rG1 (1”]ŠO, 2ŽR—œ‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 3•a—): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/26), “Œ‹ž.

723409. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‰ŠúŽĄ—ĂŒăCR‚đˆŰŽ‚ľ13”NŠÔ‚đŒo‚Ä”]“]ˆÚ‚ľ‚˝Žq‹{ŒzŠŕ‚ĚˆęÇ—á. ˆî‘ş˛‹I, ŽÄŒ´ˆę—z1, ’h@@[1, ‹{â˜aO1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/26), “Œ‹ž.

723410. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒXƒeƒƒCƒh‚Ş’˜Œř‚ľ‚˝‘ćŽO”]Žş‹ß–T“÷‰čŽîŤ•a•Ď‚Ěˆę—á. ‹ß“ĄGŽĄ1,2, ‹v{”ü^—1,2, ŽRč@“™2,3, ‰Ş@GG1,2 (1”]ŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a—): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/26), “Œ‹ž.

723411. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) AT/RT‚Í‚Ç‚ą‚܂ʼn𖞂ł‚ę‚é‚悤‚É‚Č‚Á‚˝‚Š? ŠT”O’ńĽ‚Š‚ç20”N‚Ě•Ď‘J. ‰Ş@GG1,2, ‹v{”ü^—1,2, ’h@@[1, ‹ß“ĄGŽĄ1,2, ŒG•”rG1, ƒyƒŠ[EƒA[ƒŠ[3, ƒVƒƒƒCƒgƒnƒEƒA[Eƒo[ƒ“ƒh4 (1”]ŠO, 22–k—˘ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ƒJƒŠƒtƒHƒ‹ƒjƒA‘ĺŠwƒTƒ“ƒtƒ‰ƒ“ƒVƒXƒRZ•a—, 4ƒƒCƒˆ[ƒNƒŠƒjƒbƒN•a—): ‘ć36‰ń“ú–{”]Žîᇕa—Šw‰ď (2018/9/26), “Œ‹ž.

723412. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. G‘ńˆę˜Y1, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu J, Mukasa A, Yano S (1”]ŠO): ‘ć77‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2018/9/28), ‘ĺă.

723413. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”][Ç‚đ”­Ç‚ľ‚˝ŒŒđ‰ť”]“Ž–ŹáŽ‚Ö‚ĚŽĄ—Ă•űjÇ—á•ń‚Ć•śŒŁƒŒƒrƒ…[. •“c”Ž‹I1, –]ŒŽ’O1, ´…@‹Ĺ1,2, ŒG•”rG2 (1‰Ą•lŽs—§”]‘˛’†E_ŒoŇ’ĹƒZƒ“ƒ^[”]_ŒoŠO‰Č, 2”]ŠO): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/10), ĺ‘ä.

723414. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰”­äP‰čŽî‚ɑ΂ˇ‚é“EopEƒMƒŠƒAƒfƒ‹—Ż’uŒă•úŽËüEƒeƒ‚ƒ]ƒƒ~ƒh•š—p—Ă–@‚ĚŽĄ—ÐŹŃ. ‹{â˜aO1, ŽÄŒ´ˆę—z1, ’h@@[1, áÁ–ě@—B2, ’ˇ“ě‰ëŽu3, ˛“Ą—Yˆę4, ‹TŽRšK5, ‘ĺ‰z—Tl, űŒ´Œől6, ˆî‘ş–žŒ›7, ŠÚ‰Ş@’B6, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2ÎŠŞÔ\Žš•a‰@”]_ŒoŠO‰Č, 3‹{éŒ§—§‚Ş‚ńƒZƒ“ƒ^[”]_ŒoŠO‰Č, 4ŠâŽčˆă‰Č‘ĺŠw”]_ŒoŠO‰Č, 5]“ě•a‰@”]_ŒoŠO‰Č, 6ŽR—œ‘ĺŠwˆăŠw•””]_ŒoŠO‰Č, 7ŽRŒű‘ĺŠwˆăŠw•””]_ŒoŠO‰Č): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/10), ĺ‘ä.

723415. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰Â‹y“I“Eo‚đ‘O’ń‚Ć‚ľ‚˝‰đ–UŠw“IŽîᇑśÝ•”ˆĘ‚Š‚ç‚Ě‘¤“Ş—täP‰čŽî•Ş—Ţ. ŽÄŒ´ˆę—z1, űŒ´Œől2, ’h@@[1, ‹{â˜aO1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2ŽR—œ‘ĺŠwˆăŠw•””]_ŒoŠO‰Č): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/10), ĺ‘ä.

723416. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œ¸ˆłŠJ“ޏp‚É‚¨‚Ż‚é–â‘č“_[Ž¨‰îŒă•űŘŠJ‚Ə]—ˆ–@‚Ć‚Ě”äŠr[. ŹňŠ°”V1,2, ŽR–{‘ĺ•ă2, ŽÄŒ´ˆę—z2, G‘ńˆę˜Y2, ˛“ĄŸl2, ’h@@[2, ‹{â˜aO2, ó—˜@–ő1, ŒG•”rG2 (1‹~–˝, 2”]ŠO): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/10), ĺ‘ä.

723417. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) AT/RT‚Í‚Ç‚ą‚Ü‚ĹŽĄ—Ă‚Ĺ‚Ť‚é‚悤‚É‚Č‚Á‚˝‚Š? ŠT”O’ńĽ‚Š‚ç20”N‚Ě•Ď‘J. ‰Ş@GG1,2, ‹v{”ü^—1,2, ‹ß“ĄGŽĄ1,2, ŒG•”rG2, ƒA[ƒŠ[EƒyƒŠ[3, ƒo[ƒ“ƒhEƒVƒƒƒCƒgƒnƒEƒA4 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO, 3ƒJƒŠƒtƒHƒ‹ƒjƒA‘ĺŠwƒTƒ“ƒtƒ‰ƒ“ƒVƒXƒRZ•a—, 4ƒƒCƒˆ[ƒNƒŠƒjƒbƒN•a—): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/11), ĺ‘ä.

723418. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒƒbƒPƒ‹o‹ß–TŽîᇂւ̒§í. ‹v{”ü^—1,2, ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ŒG•”rG2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/11), ĺ‘ä.

723419. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒđ‰ńŽű‚đ—v‚ˇ‚é’´‹}ŤŠú”][ÇŠłŽŇ‚ɑ΂ˇ‚éProgressive CT angiography‚É‚ć‚é•ÂÇ•”ˆČ‰“•`o. ŽR–{‘ĺ•ă1, ‹{â˜aO1, ’h@@[1, ‰Oˆä@—É2, ˆä“‡‘ĺ•ă2, •“c”Ž‹I1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1, m–؁@~1, ŒG•”rG1 (1”]ŠO, 2_Œo“ŕ): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/11), ĺ‘ä.

723420. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) p’†MEPƒ‚ƒjƒ^ƒŠƒ“ƒO‚É‚¨‚Ż‚é‰A‹ÉŽhŒƒ‚̍ě—p‹@˜‚ɂ‚˘‚Ä. ˛“ĄŸl1, Ź–ěŕV—T–ç2, ŽÄŒ´ˆę—z1, ŹňŠ°”V1,3, ŒG•”rG1 (1”]ŠO, 2—ŐŒŸ•”, 3‹~–˝): “ú–{”]_ŒoŠO‰ČŠw‰ď‘ć77‰ńŠwp‘‰ď (2018/10/12), ĺ‘ä.

723421. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]“ŽĂ–ŹŠďŒ`”j—ô‚É‚ć‚éd“Ä‚Č”]“ŕoŒŒ‚ɑ΂ˇ‚é‹}ŤŠú_Œo“ŕŽ‹‹ž‰şŒŒŽîœ‹Žp. ŹňŠ°”V1,2, ŽR–{‘ĺ•ă1, G‘ńˆę˜Y1, ó—˜@–ő2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć25‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2018/10/26), VŠƒ.

723422. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒđ‰ńŽű‚đ—v‚ˇ‚é’´‹}ŤŠú”][ÇŠłŽŇ‚ɑ΂ˇ‚éProgressive CT angiography‚É‚ć‚é•ÂÇ•”ˆČ‰“•`o. ŽR–{‘ĺ•ă1, ˆä“‡‘ĺ•ă2, ‹{â˜aO1, ‰Oˆä@—É2, •“c”Ž‹I1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1,3, m–؁@~1, ŒG•”rG1 (1”]ŠO, 2_Œo“ŕ, 3‹~–˝): ‘ć34‰ńNPO–@l“ú–{”]_ŒoŒŒŠÇ“஡—ĂŠw‰ďŠwp‘‰ď (2018/11/23), ĺ‘ä.

723423. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) TemozolomideŽž‘ă‚ĚäP‰čŽî‚ɑ΂ˇ‚é•úŽËü‘S”]ĆŽË‚ĚŒř‰Ę. âV“Ą—ł‘ž1, ‹ŕX­”V1, ‰€“c‡•F2, ŒG•”rG3, •y‰i’î“ń1 (1“Œ–k‘ĺŠw”]_ŒoŠO‰Č, 2ŽRŒ`‘ĺŠw”]_ŒoŠO‰Č, 3”]ŠO): ‘ć36‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2018/12/3), Ź“cŒ´.

723424. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‰”­äP‰čŽî‚ɑ΂ˇ‚é“EopEƒMƒŠƒAƒfƒ‹—Ż’uŒă•úŽËüEƒeƒ‚ƒ]ƒƒ~ƒh•š—p—Ă–@‚ĚŽĄ—ÐŹŃ. ‹{â˜aO1, ŽÄŒ´ˆę—z1, ’h@@[1, áÁ–ě@—B, ’ˇ“ě‰ëŽu, ˛“Ą—Yˆę, ‹TŽRšK, ‘ĺ‰z—Tl, űŒ´Œől, ŠÚ‰Ş@’B, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć36‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2018/12/3), Ź“cŒ´.

723425. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”][Ç‚đ”­Ç‚ľ‚˝ŒŒđ‰ť”]“Ž–ŹáŽ‚Ö‚ĚŽĄ—Ă•űj: Ç—á•ń‚Ć•śŒŁƒŒƒrƒ…[. •“c”Ž‹I1, ´…@ú1, –]ŒŽ’O, ŒG•”rG1 (1”]ŠO): ‘ć44‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (2019/3/22), ‰Ą•l.

723426. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Half-tied stay suture: ”]“Ž–Ź’[‘¤ƒoƒCƒpƒXp‚É‚¨‚˘‚ĉB‚ę‚˝•Ť‡Œű‚đŽ‹”F‚ˇ‚éH•v. ´…@ú1, ‘ĺŕVŹ”V, ŹňŠ°”V1, –]ŒŽ’O, ŒG•”rG1 (1”]ŠO): ‘ć48‰ń“ú–{”]‘˛’†‚ĚŠO‰ČŠw‰ďŠwpW‰ď (2019/3/23), ‰Ą•l.

731033. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‚Ä‚ń‚Š‚ńŽĄ—Ă. ‰Ş@GG (”]ŠO): ‚Ä‚ń‚Š‚ńŽĄ—ĂƒtƒH[ƒ‰ƒ€ (2018/7/31), ă”ö.

731034. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆŤŤ_ŒoäPŽî‚Ɛ[•”Ă–ŹŒŒđE”xÇđÇ. ŒG•”rG (”]ŠO): ‘ć24‰ń‹v—Ż•Ä”]_ŒoŠO‰ČƒZƒ~ƒi[ (2018/9/7), ‹v—Ż•Ä.

731035. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ú’ĘŽ}‚̉đ–U. ŒG•”rG (”]ŠO): ‘ć29‰ń_“ސě”]_ŒoŠO‰ČŽčpŽč‹ZŒ¤‹†‰ď (2018/9/22), ‰Ą•l.

731036. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‚Ä‚ń‚Š‚ńf—ĂƒAƒbƒvƒf[ƒg. ‰Ş@GG (”]ŠO): ‘ć7‰ńé‹Ę‚Ä‚ń‚Š‚ńŽĄ—ĂŠwpu‰‰‰ď (2018/11/20), ‚ł‚˘‚˝‚Ü.

731037. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŹŽ™ázk‚ɑ΂ˇ‚éƒoƒNƒƒtƒFƒ“‘’—Ă–@. Žt“cMl (”]ŠO): ’ˇ–ěŒ§dSŽŇˆă—Ă˜A—‹Ś‹c‰ď (2018/12/8), z–K.

731038. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŹŽ™_Œo‚Ć”]_ŒoŠO‰Č‚̐ړ_|”­śE‰đ–UE—Տ°ś—‚ÉŠî‚Ă‚˘‚˝ŹŽ™_ŒoŠO‰Č|. Žt“cMl (”]ŠO): ‘ć73‰ń‘˝–€ŹŽ™_Œo§˜b‰ď (2019/1/19), •{’†.

733128. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ’ág’ˇ‚đŒ_‹@‚É”­ŒŠ‚ł‚ę‚˝“ŞŠWˆô“ŞŽî‚Ě6Î’jŽ™—á. G‘ńˆę˜Y (”]ŠO): ‘ć25‰ń‚Š‚Č‚Ş‚íŠÔ”]‰ş‚‘ĚŽžŠłƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/6/22), ‰Ą•l.

733129. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠO‘¤Œă“Ş–@‚É‚¨‚Ż‚é“ந“š‰đ•ú‚Ć“ŕŽ¨“š“ŕŽîᇓEo. ‹v{”ü^—1,2, ‰Ş@GG1,2, ‹ß“ĄGŽĄ1,2, ŒG•”rG2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘ć27‰ń“ú–{’Ž_ŒoŽîᇌ¤‹†‰ď (2018/6/23), “Œ‹ž.

733130. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”]—ŔŒ`Ź•s‘SEŽ‰–bŽî‚ÉCalcifying pseudoneoplasms of the neuroaxis (CAPNON) ‚đ‡•š‚ľ‚˝ˆę—á. ’h@@[1, Œ˘Ž”@‰~2, ‹{â˜aO1, ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2•a—): ‘ć136‰ń“ú–{”]_ŒoŠO‰ČŠw‰ďŠÖ“ŒŽx•”‰ď (2018/9/8), “Œ‹ž.

733131. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) —ź‘¤‘O’ë_ŒoâŽî‚𔺂í‚Č‚˘Šáâ|“ŕ_ŒoâŽî‚ɂĐf’f‚ł‚ę‚˝shwannomatosis‚Ěˆę—á. ‹{â˜aO1, ŽÄŒ´ˆę—z1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć137‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď ŠÖ“ŒŽx•”‰ď (2018/12/8), “Œ‹ž.

733132. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) Ž‹°äP‰čŽî‚ĆŠÓ•Ę‚đ—v‚ľ‚˝”ńŒ‹ŠjŤRŽ_‹ŰÇ‚Ěˆę—á: ADC’l‚Ě—L—pŤ‚ĆASL‰ć‘œŠŒŠ. ‰Ž“c˜a‹MŽq1, ‹{â˜aO1, ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć137‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď ŠÖ“ŒŽx•”‰ď (2018/12/8), “Œ‹ž.

733133. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒIƒŠ[ƒuŠj”ě‘ĺ•ĎŤ‚𐜂ś‚˝”]Š˛•”ˆŤŤƒŠƒ“ƒpŽî‚Ě2—á. ˛“ĄŸl1, ŽÄŒ´ˆę—z1, ‹{â˜aO1, ŹňŠ°”V1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć30‰ń_“ސě”]_ŒoŠO‰ČŽčpŽč‹ZŒ¤‹†‰ď (2019/1/12), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H28-310002. [Ç—á•ń] Therapeutic Potential of Everolimus on Core Autism Symptoms and Increasing Serum Ceruloplasmin and Transferrin Levels in a Pubescent Boy with Tuberous Sclerosis. Yui K, Imataka G, Okanishi T, Oka H1, Kawasaki Y: J Neonat Pediatr Med 2017/3; 3 (1): DOI: 10.4172/2572-4983.1000128. (‰Ş@GG1: 1”]ŠO)

H29-110018. [Œ´’˜] Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Kurogi R, Nishimura K, Nakai M, Kada A, Kamitani S, Nakagawara J, Toyoda K, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Matsuda S, Yoshimura S, Okuchi K, Suzuki A, Nakamura F, Onozuka D, Ido K, Kurogi A, Mukae N, Nishimura A, Arimura K, Kitazono T, Hagihara A, Iihara K; J-ASPECT Study Collaborators (Collaborators: Kumabe T1): Neurology 2018/3; 90 (13): e1143-9. (ŒG•”rG1: 1”]ŠO)

H29-120001. [Œ´’˜] _ŒoŠÇ•Â˝áŠQ: —tŽ_ŰŽć‚É‚ć‚é—\–h. ‹ß“ĄŒúś, Žt“cMl1, ‰Şˆä‚˘‚­‚ć, ŽR–{Œ›˜N, ‹ß“ĄŒúĆ, “n糒q”V (1”]ŠO): ƒrƒ^ƒ~ƒ“ 2018/1; 92 (1): 1-17.


ŹŽ™‰ČŠw

[Šwp˜_•ś]

110233. [Œ´’˜] Clinically diverse phenotypes and genotypes of patients with branchio-oto-renal syndrome. Unzaki A, Morisada N, Nozu K, Ye MJ, Ito S, Matsunaga T, Ishikura K1, Ina S, Nagatani K, Okamoto T, Inaba Y, Ito N, Igarashi T, Kanda S, Ito K, Omune K, Iwaki T, Ueno K, Yahata M, Ohtsuka Y, Nishi E, Takahashi N, Ishikawa T, Goto S, Okamoto N, Iijima K: J Hum Genet 2018/5; 63 (5): 647-56. (Î‘qŒ’Ži1: 1ŹŽ™)

110234. [Œ´’˜] Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Shima Y1, Nakanishi K1, Sako M1, Saito-Oba M1, Hamasaki Y1, Hataya H1, Honda M1, Kamei K1, Ishikura K1,2, Ito S1, Kaito H1, Tanaka R1, Nozu K1, Nakamura H1, Ohashi Y1, Iijima K1, Yoshikawa N1 (1Japanese Study Group of Kidney Disease in Children (JSKDC)): Pediatr Nephrol 2019/5; 34 (5): 837-46. (Î‘qŒ’Ži1,2: 2ŹŽ™)

110235. [Œ´’˜] Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents. Kamei K, Miyairi I, Ishikura K1, Ogura M, Shoji K, Funaki T, Ito R, Arai K, Abe J, Kawai T, Onodera M, Ito S: J Pediat. 2018/5; 196: 217-22.e1. (Î‘qŒ’Ži1: 1ŹŽ™)

110236. [Œ´’˜] Renal replacement therapy for children throughout the world: the need for a global registry. Ploos van Amstel S, Noordzij M, Warady BA, Cano F, Craig JC, Groothoff JW, Ishikura K1, Neu A, Safouh H, Xu H, Jager KJ, Schaefer F: Pediatr Nephrol 2018/5; 33 (5): 863-71. (Î‘qŒ’Ži1: 1ŹŽ™)

110237. [Œ´’˜] Cardiac Ventricular Contractile Responses to Chronically Increased Afterload Secondary to Right Ventricular Outflow Obstruction in Patients With Tetralogy of Fallot. Sugamoto K1, Kurishima C, Iwamoto Y, Ishido H, Masutani S, Ushinohama H, Sagawa K, Ishikawa S, Nakano T, Kado H, Senzaki H1,2: Am J Cardiol 2018/5; 121 (9): 1090-3. (›–{Œ’Ži1, ćčG–ž1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110238. [Œ´’˜] Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Kamei K, Ogura M, Sato M, Ito S, Ishikura K1: Pediatr Nephrol 2018/6; 33 (6): 1013-8. (Î‘qŒ’Ži1: 1ŹŽ™)

110239. [Œ´’˜] Long-term outcome of congenital nephrotic syndrome after kidney transplantation in Japan. Hamasaki Y, Muramatsu M, Hamada R, Ishikura K1, Hataya H, Satou H, Honda M, Nakanishi K, Shishido S: Clin Exp Nephrol 2018/6; 22 (3): 719-26. (Î‘qŒ’Ži1: 1ŹŽ™)

110240. [Œ´’˜] Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients. Terano C, Ishikura K1, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M: Nephrology (Carlton) 2018/6; 23 (6): 539-45. (Î‘qŒ’Ži1: 1ŹŽ™)

110241. [Œ´’˜] Coagulopathy as a complication of kidney biopsies in paediatric systemic lupus erythematosus patients with antiphospholipid syndrome. Nagata H, Sato M, Ogura M, Yoshikawa T, Yamamoto K, Matsumura S, Kano Y, Saida K, Sako M, Kamei K, Yoshioka T, Ogata K, Ito S, Ishikura K1: Nephrology (Carlton) 2018/6; 23 (6): 592-6. (Î‘qŒ’Ži1: 1ŹŽ™)

110242. [Œ´’˜] Trends in the neurodevelopmental outcomes among preterm infants from 2003-2012: a retrospective cohort study in Japan. Nakanishi H1,2,3, Suenaga H1, Uchiyama A1, Kono Y1, Kusuda S1 (1Neonatal Research Network, Japan): J Perinatol 2018/7; 38 (7): 917-28. (’†źG•F1,2,3: 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ŹŽ™)

110243. [Œ´’˜] Ensuring safe drug administration to pediatric patients with renal dysfunction: a multicenter study. Harada R, Ishikura K1, Shinozuka S, Mikami N, Hamada R, Hataya H, Morikawa Y, Omori T, Takahashi H, Hamasaki Y, Kaneko T, Iijima K, Honda M: Clin Exp Nephrol 2018/8; 22 (4): 938-46. (Î‘qŒ’Ži1: 1ŹŽ™)

110244. [Œ´’˜] Strong Association of the HLA-DR/DQ Locus with Childhood Steroid-Sensitive Nephrotic Syndrome in the Japanese Population. Jia X1, Horinouchi T1, Hitomi Y1, Shono A1, Khor SS1, Omae Y1, Kojima K1, Kawai Y1, Nagasaki M1, Kaku Y1, Okamoto T1, Ohwada Y1, Ohta K1, Okuda Y1, Fujimaru R1, Hatae K1, Kumagai N1, Sawanobori E1, Nakazato H1, Ohtsuka Y1, Nakanishi K1, Shima Y1, Tanaka R1, Ashida A1, Kamei K1, Ishikura K1,2, Nozu K1, Tokunaga K1, Iijima K1 (1Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan): J Am Soc Nephrol 2018/8; 29 (8): 2189-99. (Î‘qŒ’Ži1,2: 2ŹŽ™)

110245. [Œ´’˜] Validation of estimated glomerular filtration rate equations for Japanese children. Gotoh Y1, Uemura O1, Ishikura K1,2, Sakai T1, Hamasaki Y1, Araki Y1, Hamda R1, Honda M1 (1Pediatric CKD Study Group in Japan in conjunction with the Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology): Clin Exp Nephrol 2018/8; 22 (4): 931-7. (Î‘qŒ’Ži1,2: 2ŹŽ™)

110246. [Œ´’˜] Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial). Hama T1, Nakanishi K1, Ishikura K1,2, Ito S1, Nakamura H1, Sako M1, Saito-Oba M1, Nozu K1, Shima Y1, Iijima K1, Yoshikawa N1 (1Japanese Study Group of Kidney Disease in Children (JSKDC)): BMC Nephrol 201/9; 19 (1): 223. (Î‘qŒ’Ži1,2: 2ŹŽ™)

110247. [Œ´’˜] Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice. Nakanishi H1,2, Morikawa S, Kitahara S, Yoshii A, Uchiyama A, Kusuda S, Ezaki T: Med Mol Morphol 2018/9; 51 (3): 166-75. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

110248. [Œ´’˜] Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Shima Y1, Nakanishi K1, Kaku Y1, Ishikura K1,2, Hataya H1, Matsuyama T1, Honda M1, Sako M1, Nozu K1, Tanaka R1, Iijima K1, Yoshikawa N1 (1Japanese Pediatric IgA Nephropathy Treatment Study Group): Pediatr Nephrol 2018/11; 33 (11): 2103-12. (Î‘qŒ’Ži1,2: 2ŹŽ™)

110249. [Œ´’˜] Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). Horinouchi T, Sako M, Nakanishi K, Ishikura K1, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K: BMC Nephrol 2018/11; 19 (1): 302. (Î‘qŒ’Ži1: 1ŹŽ™)

110250. [Œ´’˜] Loss of miR-144 signaling interrupts extracellular matrix remodeling after myocardial infarction leading to worsened cardiac function. He Q, Wang F, Honda T1, James J, Li J, Redington A: Sci Rep 2018/11; 8 (1): 16886. (–{“c@’1: 1ŹŽ™)

110251. [Œ´’˜] Persistent pulmonary hypertension of the newborn in extremely preterm infants: a Japanese cohort study. Nakanishi H1,2,3, Suenaga H1, Uchiyama A1, Kusuda S1 (1Neonatal Research Network, Japan): Arch Dis Child Fetal Neonatal Ed 2018/11; 103 (6): F554-61. (’†źG•F1,2,3: 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ŹŽ™)

110252. [Œ´’˜] Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Kamei K, Ishikura K1, Sako M, Ito S, Nozu K, Iijima K: Pediatr Nephrol 2018 Dec 18. doi: 10.1007/s00467-018-4166-1. [Epub ahead of print] (Î‘qŒ’Ži1: 1ŹŽ™)

110253. [Œ´’˜] Topiramate Blood Levels During Polytherapy for Epilepsy in Children. Toki T1, Iwasaki T1, Ishii M1: Am J Ther 2019/1-2; 26 (1): e18-24. (“yŠň@•˝1, Šâčr”V1, Îˆäł_1: 1ŹŽ™)

110254. [Œ´’˜] Experience with the use of a sheet-shaped body vibrometer in infants admitted to the neonatal intensive care unit. Kenmochi M1, Kogere T, Kaneko M1, Ishida S1, Yamaguchi A1, Ooka M1, Yokozeki Y1, Senzaki H1,2: J Transl Sci 2019/2; 5: 1-3. (çݎ@Šw1, ‹ŕŽq‰ë‹I1, Î“c@Ži1, ŽRŒűˆť”T1, ‘剪–ƒ—1, ‰ĄŠÖ—Sˆę˜Y1, ćčG–ž1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110255. [Œ´’˜] Necessity of performing voiding cystourethrography for children with unilateral multicystic dysplastic kidney. Yamamoto K, Kamei K, Sato M, Ogura M, Suzuki M, Hasegawa Y, Ueoka K, Ito S, Ishikura K1: Pediatr Nephrol 2019/2; 34 (2): 295-9. (Î‘qŒ’Ži1: 1ŹŽ™)

110256. [Œ´’˜] Acute and chronic remote ischemic conditioning attenuate septic cardiomyopathy, improve cardiac output, protect systemic organs, and improve mortality in a lipopolysaccharide-induced sepsis model. Honda T1, He Q, Wang F, Redington AN: Basic Res Cardiol 2019/3; 114 (3): 15. (–{“c@’1: 1ŹŽ™)

110257. [Œ´’˜] Thyroid Function in Patients With a Fontan Circulation. Kuwata S1, Takanashi M1, Hashimoto M1, Iwamoto Y, Ishido H, Masutani S, Saiki H1, Sugamoto K1, Senzaki H1,2: Am J Cardiol 2019/3; 123 (6): 979-83. (řw“cšŽq1, ‚—œ@Šw1, ‹´–{‚Ü‚ä1, âV–؍G•ś1, ›–{Œ’Ži1, ćčG–ž1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

120012. [Œ´’˜] ć“VŤSŽžŠł‡•š”DP•ę‘ĚBNP’l‚ĆŽ™‚ĚŒÄ‹záŠQ, zŠÂ“Ž‘Ô‚Ć‚ĚŠÖŒW. Î“c@Ži1, “ŕŽR@‰ˇ, Ąˆä@Œ›, ––‰i‰p˘, ‘ĺ–ěGŽq, Žń—˘‹žŽq, ‘–{Œ’ˆę, ŒË’ĂŒÜŒŽ, ’†źG•F1,2, “í“c@‘ (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŽGŽ 2018/5; 54 (1): 33-8.

120013. [Œ´’˜]uŹŽ™–Ťt‘Ÿ•aŠłŽŇ‚É‚¨‚Ż‚éˆÚsˆă—Âɂ‚˘‚Ä‚Ě’ńŒžv‚ƁuŽvtŠúEÂ”NŠú‚ĚŠłŽŇ‚Ě‚˝‚ß‚ĚCKDf—ĂƒKƒCƒhv‚Ě”F’m“x, —‰đ“x, Šˆ—p“x‚ÉŠÖ‚ˇ‚éƒAƒ“ƒP[ƒg’˛¸‚Ě•ń. ˛ŒĂ‚Ü‚ä‚Ý, ŽO‰YŒ’ˆę˜Y, ˆ°“c@–ž, Î‘qŒ’Ži1, ˆäă@•×, Œă“Ą–F[, ŹźNG, dź@—˛, ™ŽR@Ä, Ž›–ěçŽq, ’†ź_ˆę, ź”ö–­D, ”Ś’J_Žj, “ĄŒłşˆę, ŒüŽR­Žu, ‹g–î–M•F, –{“c‰ëŒh, Šâ–쐳”V, •ž•”ŒłŽj (1ŹŽ™): “ú–{t‘ŸŠw‰ďŽ 2018/7; 60 (7): 972-7.

310022. [Ç—á•ń] Typhoid fever complicated by sepsis and disseminated intravascular coagulateon in a 7-year-old boy. Nishida T1, Ebato T1, Kawada K1, Takechi S1, Kitsuta K1, Ando H1, Sugamoto K1, Senzaki H1,2: Kitasato Med J 2018/9; 48 (2): 132-6. (ź“cŽŽj1, ]”gŒËF•ă1, ě“cF‘ž1, •’ms•ă1, ‹k“cˆęŽ÷1, ˆŔ“Ą@Žő1, ›–{Œ’Ži1, ćčG–ž1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

310023. [Ç—á•ń] Azathioprine-induced Agranulocytosis and Severe Alopecia After Kidney Transplantation Associated With a NUDT15 Polymorphism: A Case Report. Saida K, Kamei K, Ogura M, Matsumura S, Kano Y, Sato M, Andoh A, Ishikura K1: Transplant Proc 2018/12; 50 (10): 3925-7. (Î‘qŒ’Ži1: 1ŹŽ™)

320018. [Ç—á•ń] t‹@”\áŠQ‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝bó‘B‹@”\’ቺÇ‚Ě1—á. ŽR–{‚Š‚¸‚Č, Ž›–ěçŽq, ŕ_“c@—¤, ‹´–{~–ç, •“c—Ǐ~, Œ´“c—ÁŽq, Î‘qŒ’Ži1, ’ˇ’Jěs—m, ”Ś’J_Žj, –{“c‰ëŒh (1ŹŽ™): “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2018/11; 31 (2): 167-71.

320019. [Ç—á•ń] “Ť“Ş’É, ázšdĎ‚đ‹N‚ą‚ľ‚˝NP-SLE‚Ě10Î‚̏—Ž™. ]”gŒËF•ă1, “Ą–{‚Ü‚ä1, îŒ´‹`l1, •űš•˝1, â“Œ—R‹I1, Îˆäł_1 (1ŹŽ™): ŹŽ™ƒŠƒEƒ}ƒ` 2018; 9 (1): 40-4.

320020. [Ç—á•ń] PKD1‚Ě•Ą‡ƒwƒeƒÚ‡‘Ě•ĎˆŮ‚đŽŚARPKD‚Ć—ŢŽ—‚ľ‚˝—Տ°‘œ‚đ’ć‚ľ‚˝’jŽ™—á. ‹TˆäGˆę, ˆîŠ_Gl, X@’”J, “ĄŠŰ‘ń–ç, ‘hŒ´‰f˝, ŕ_č—SŽq, ŽłŒË´ˆę˜Y, ‹`‰ŞFŽq, •űŒŞ‘ž˜Y, ‰Ş“c–ƒ—, Ź–¸‰ë•v, ˛“Ą@•‘, ‘q‹´_Ž÷, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{ŹŽ™t•s‘SŠw‰ďŽGŽ 2018; 38: 152-5.

320021. [Ç—á•ń] ś‘̐tˆÚAŒă––Šút•s‘S‚ɐt‘ă‘Ö—Ă–@‚đs‚Ś‚Č‚Š‚Á‚˝Œ‹ßŤd‰ťÇ‚Ě1—á. Ź‘Š—ČŽq, ‹TˆäGˆę, —]’J’¨”V, ‰Á”[—DŽĄ, Ź–¸‰ë•v, ‹v•Ű“c‰ë–ç, ‰–“c—jŽq, “c’†‹ąŽq, ‘O“c_—˜, –ؐ{@Ę, “Č’JŽĄŽq, —é–؁@Ę, Î•@¸, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{ŹŽ™t•s‘SŠw‰ďŽGŽ 2018; 38: 242-4.

320022. [Ç—á•ń] ‹Nˆö‹Ű“Ż’č‚Ü‚Ĺ‚ÉŽžŠÔ‚đ—v‚ľf’f‚É‹ę—ś‚ľ‚˝”ń’čŒ^RŽ_‹ŰŤ• –Œ‰Š‚Ě4Î’jŽ™—á. Î˜a@ăÄ, ‹TˆäGˆę, Ź–¸‰ë•v, źŒ’‘ž˜N, ‰œ’Ă”ü‰Ä, ź‘ş‘sŽj, ˛“Ą@•‘, ź“cŠ˛Žq, ‰F“c˜aG, ŻŽiŒ’‰î, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{ŹŽ™PDEHDŒ¤‹†‰ďŽGŽ 2018; 30: 33-5.

320023. [Ç—á•ń] ŒŒˆł‚ĚŠÇ—‚É“ďa‚ľ‚˝‚ƒŒƒjƒ“Ť‚ŒŒˆł‚ĚDenys-DrashÇŒóŒQ‚Ě1Î—Ž™—á. ‹TˆäGˆę, Dě‹M‹v, ‰i“c—TŽq, źŒ’‘ž˜N, Î˜a@ăÄ, ‰œ’Ă”ü‰Ä, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, —é–Ř–œ—˘, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{ŹŽ™PDEHDŒ¤‹†‰ďŽGŽ 2018; 30: 55-7.

520012. [‘ŕ] ŹŽ™–Ťt‘Ÿ•a (ŹŽ™CKD) ‚̍ŐV‚Ě’mŒŠ. Î˜a@ăÄ, Î‘qŒ’Ži1 (1ŹŽ™): ŹŽ™‰Č 2018/9; 59 (9): 1315-23,

520013. [‘ŕ] • –Œ“§Í‚Š‚猌‰t“§Í‚ֈڍs‚ľ‚˝‘˝“ŽŒXŒü‚É‚ ‚銳ŽŇ‚ĚŠĹŒě. ź“cŠ˛Žq, •űŽu•ä, ’†ŽR”ü•äŽq, Î˜a@ăÄ, Ź–¸‰ë•v, ‹TˆäGˆę, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{ŹŽ™PDEHDŒ¤‹†‰ďŽGŽ 2018; 30: 66-8.

520014. [‘ŕ] –Ɖu—}§–ň“ŕ•ž’†‚ĚŠłŽŇ‚Ö‚ĚŽă“ŐśƒƒNƒ`ƒ“ÚŽí‚ĚŒťó‚ƍĄŒă‚̐헪E‰Ű‘č. ‹TˆäGˆę, ‹{“ü@—ó, ŻŽiŒ’‰î, ‰Í‡—˜Ž, VˆäŸ‘ĺ, ˆÉ“Ą—ćŽq, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ’†‘şG•ś, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): “ú–{—Տ°tˆÚAŠw‰ďŽGŽ 2018; 6 (2): 163-72.

521007. [‰đŕ] ŹŽ™, ć“VŤSŽžŠł‚É‚¨‚Ż‚ézŠÂŠíf—Â̐i•ŕ‚Ɖۑč: Œ`‘ԏC•œ‚Š‚çzŠÂC•œ‚ĚŽž‘ă‚Ö. Ö–؍G•ś1, •ô”öŒb—œ1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): zŠÂŠíę–ĺˆă (Journal of JCS Cardiologists) 2018/8; 27: 107-10.

522068. [uŔ]y“ÁW: —\–h2018z•Ş•ŘT”•Ę‚É‚Ý‚˝Ž™‚Ě’ZŠúE’ˇŠú—\Œă. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ŽüŽYŠúˆăŠw 2018/4; 48 (4): 411-6.

522069. [uŔ]y‘“ÁW: ˆă—Ă“IƒPƒA‚đ•K—v‚Ć‚ˇ‚éŽq‚Ç‚ŕ‚Ć‹¤‚ɐś‚Ť‚éz[Ž–—á‚Š‚çŠw‚ԍݑîˆÚsŠú‚¨‚ć‚Ń‚ť‚ĚŒă‚ĚŽx‰‡]@…@ŒÄ‹zŠÖ˜A@‹CŠÇŘŠJ, Ý‘îlHŒÄ‹zŠÇ—‚ĚŠT—v‚ĆŠĎŽ@ƒ|ƒCƒ“ƒg. “ě–ě‰ (ŹŽ™): ŹŽ™ŠĹŒě 2018/5; 41 (5): 576-81.

522070. [uŔ]y“ÁW: ŹŽ™f—ĂƒKƒCƒhƒ‰ƒCƒ“‚Ě“Ç‚Ý‰đ‚Ť•ű|ƒKƒCƒhƒ‰ƒCƒ“‚Ě”wŒi, Žg‚˘•ű‚𒆐S‚Ɂz[Še˜_: ŹŽ™ŠÖ˜AŠw‰ď (•Ş–ě) ‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Ö‚ĚŽć‚č‘g‚Ý] t‘Ÿ—Ěˆć (“ú–{ŹŽ™t‘Ÿ•aŠw‰ď). ˛“Ą@•‘, Î‘qŒ’Ži1 (1ŹŽ™): ŹŽ™“ŕ‰Č 2018/5; 50 (5): 824-7.

522071. [uŔ]y“ÁW: VśŽ™‚ĚŒŸ¸’lƒAƒZƒXƒƒ“ƒg ‹ęŽč‚ČŒŒƒKƒX‚ŕ‚ľ‚Á‚Š‚čƒ}ƒXƒ^[!z10. ‹ęŽčŽ•ž! Ç—ጟ“˘ƒhƒŠƒ‹. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2018/5; 37 (5): 457-62.

522072. [uŔ]y“ÁW: ‚¨‚ł‚Ś‚˝‚˘f—ĂƒKƒCƒhƒ‰ƒCƒ“‚Ěƒcƒ{zI. f—ĂƒKƒCƒhƒ‰ƒCƒ“‘˜_@’m‚Á‚Ä‚¨‚Ť‚˝‚˘‘“ŕŠO‚ĚƒKƒCƒhƒ‰ƒCƒ“. ›–{Œ’Ži1, çݎ@Šw1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ŹŽ™‰Čf—Ă 2018/7; 81 (7): 835-40.

522073. [uŔ]y“ÁW: Ź‡•a“‚É‚¨‚Ż‚鏬Ž™ŠĹŒěz[ŠÇ—ŽŇ&ˆăŽt‚ĚŽ‹“_]@…BŹŽ™‰Čˆă‚ĚŽ‹“_‚Š‚ç‚Ý‚˝Ź‡•a“‚ĚŒťó‚Ɖۑč. “ě–ě‰ (ŹŽ™): ŹŽ™ŠĹŒě 2018/8; 41 (8): 1134-6.

522074. [uŔ]y“ÁW: ŹŽ™t•s‘S|ˆÚsŠúˆă—Ă‚ĚŠÇ—z4. ŹŽ™––Šút•s‘S‚É‚¨‚Ż‚é‰h—{—Ă–@. Ź–¸‰ë•v, Î‘qŒ’Ži1 (1ŹŽ™): —Տ°“§Í 2018/8; 34 (9): 1097-102.

522075. [uŔ]y“ÁWNICUĹ‘Oü: ‰Ć‘°‚Ö‚Ěŕ–ž‚ÉŽg‚Ś‚é!@VśŽ™‚ĚŒŸ¸EŒŸ¸’l@‚Ü‚é‚í‚Š‚čŠî–{ƒ}ƒXƒ^[z(4) ƒGƒR[ŒŸ¸. Î“c@Ži (ŹŽ™): NEONATAL CARE 2018/11; 31 (11): 108-13.

522076. [uŔ]y“ÁW: ‰Ć‘°‚Ö‚Ěŕ–ž‚ÉŽg‚Ś‚é! VśŽ™‚ĚŒŸ¸EŒŸ¸’l‚Ü‚é‚í‚Š‚čŠî–{ƒ}ƒXƒ^[z[˜˜_]. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ƒlƒIƒlƒCƒ^ƒ‹ƒPƒA 2018/11; 31 (11): 1013.

522077. [uŔ]y“ÁW: ‰Ć‘°‚Ö‚Ěŕ–ž‚ÉŽg‚Ś‚é! VśŽ™‚ĚŒŸ¸EŒŸ¸’l‚Ü‚é‚í‚Š‚čŠî–{ƒ}ƒXƒ^[z[‘˜_]@Šî–{‚ĚŒŸ¸@ƒoƒCƒ^ƒ‹ƒTƒCƒ“ (S””, ŒÄ‹z”, ŒŒˆł, ‘̉ˇ). ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ƒlƒIƒlƒCƒ^ƒ‹ƒPƒA 2018/11; 31 (11): 1014-20.

522078. [uŔ]y“ÁW: ŽüŽYŠú“ŕ•Ş”厞Šł‚Ě•KC’mŽŻz•›t@”ÓŠúzŠÂ•s‘S (f’f‚ĆŽĄ—Ă, ƒŠƒXƒN—vˆö, —\Œă). ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ŽüŽYŠúˆăŠw 2018/11; 48 (11): 1521-5.

522079. [uŔ]y“ÁW: ƒlƒtƒ[ƒ[ÇŒóŒQ|MCNS/FSGS‚̍ŐV’mŒŠz[ŽĄ—Ă‚ĚƒGƒrƒfƒ“ƒX‚Ć‚ť‚̍\’z] ƒKƒCƒhƒ‰ƒCƒ“‚ĚĐ‰î: ŠCŠO‚Ć“ú–{‚Ě”äŠr-ŹŽ™. ˛“Ą@•‘, Î‘qŒ’Ži1 (1ŹŽ™): t‚Ć“§Í 2018/12; 85 (6): 795-800.

522080. [uŔ]y“ÁW: ƒlƒtƒ[ƒ[ÇŒóŒQ|MCNS/FSGS‚̍ŐV’mŒŠz[‡•šÇ‘΍ô‚ĆƒGƒrƒfƒ“ƒX] –Ɖu—}§–ň“ŕ•ž’†‚ĚŠłŽŇ‚Ö‚ĚŽă“ŐŤƒƒNƒ`ƒ“ÚŽí. ‹TˆäGˆę, ‹{“ü@—ó, ŻŽiŒ’‰î, ‰Í‡—˜Ž, VˆäŸ‘ĺ, ˆÉ“Ą—ćŽq, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ’†‘şG•ś, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): t‚Ć“§Í 2018/12; 85 (6): 864-8.

530007. [‚ť‚Ě‘ź (Letter to the editor)] Creatinine-based estimated glomerular filtration rate for children younger than 2 years. Uemura O, Ishikura K1, Gotoh Y, Honda M: Clin Exp Nephrol 2018/4; 22 (2): 483-4. (Î‘qŒ’Ži1: 1ŹŽ™)

540018. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)] ƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­CKDf—ĂƒKƒCƒhƒ‰ƒCƒ“2018. ‰Ş“c_ˆę1, ˆŔ“c‹XŹ,1 ˆŽ@_ˆę1, ˆÉ“ĄFŽj1, —v@L–ç1, _“c‰pˆę˜Y1, ›–ě‹`•F1, Žl•űŒŤˆę1, ŽÄŠ_—LŒá1, “y’J@Œ’1, ’߉Ž˜a•F1, ’ˇ“c‘ž•1, Ź“cˆę‰q1, “ěŠwłb1, •ž•”ŒłŽj1, ŕ_–ě‚s1, “ĄŒłşˆę1, ŽçŽR•qŽ÷1, ŽRăp–MO1, ŽR–{—Ë•˝1, Žá™ŽO“ŢŽq1, ˆ°“c@–ž1, ‰Pˆääˆę1, ě‘ş˜aŽq1, –k‘şŒ’ˆę˜Y1, Ą“cP•v1, —é–Ř—S‰î1, ’߉ޏGˆę1, ź”ö–­D1, “Ąˆä’ź•F1, “ĄˆäG‹B1, ˜a“cŒ’•F1, ‰ĄŽR@m1, Â–؍ŽŒ›1, HŽR‘ĺˆę˜Y1, r–ؐMˆę1, —L”n‹v•x1, Îě‰p“ń1, Î‘qŒ’Ži1,2, Î’ˊ쐢L1, Î–{‘ěŽk1, Î–{@—V1, ˆäŠÖ–M•q1, ”‹´”ü’Ð˘1, ˆę‰Ş‘Žq1, Žsěˆę˝1, Žsě‘ĺ‰î1, ˆäăG“ń1, Ąˆä—˜”ü1, Ą‘şG–ž1, Šâ“c‹ą‹X1, Šâ’ÍD—˛1, ‰Pˆär–ž1, “ŕ“cŒ[Žq1, ]ě‰ë”Ž1, ‘ĺŒ´Mˆę˜Y1, ‘ĺX‹ł—Y1, ‰Ş“c—ŒbŽq1, ‰œ“c—Y‰î1, ”öŠÖ‹MĆ1, Ź”¨—zŽq1, b”ă•˝N1, ‰Á“Ą‹K—˜1, ‹ŕčŒ[‘˘1, ‹ŕŽq‰ŔŒŤ1, Š—ŕVG–ĺ1, ěŒű••F1, ěčK•F1, ě“‡Œ\‰î1, ‰Í–ět“Ţ1, ‹e’n@Š¨1, –ŘŒ´ł•v1, –Ř‘ş—Ç‹I1, ŒI“c‹X–ž1, Ź’rŒ’‘ž˜Y1, ŹňŒŤ—m1, Ź“‡’qˆŸ—˘1, Œă“Ąr‰î1, ŸŒł—˛—Y1, ŒĂ”g‘ Œ’‘ž˜Y1, ŹźOK1, ‹îę‘ĺ•ô1, âV“Ą’m‰h1, Žđˆäs’ź1, âŒű—I‰î1, —˘’†OŽu1, ŽŠŒŠ‰Á“ŢŽq1, ´…ş”Ž1, ´…‚ł‚â‚Š1, ”’ˆäŹ•S‡1, V‘ň^‹I1, ™ŽR˜aŠ°1, —é–؁@’q1, —é–؁@m1, “ŠŽR˜aG1, Łě—T‰Ŕ1, ‚‹´˜a–ç1, “c’†Œ’ˆę1, “c’†“N—m1, Šp“c—ş–ç1, ’ß“c—I–Ř1, ’†‘q•şŒÉ1, ’ˇŕVNs1, ’†ź_ˆę1, ’ˇ•lł•F1, ’†‰Ž—ˆĆ1, –ź”gł‹`1, V”¨Šo–ç1, ź@Tˆę1, ź˜eGŽ÷1, ’ˇ’JěËŽq1, ’ˇ’Jě‚Ý‚Ç‚č1, ‰Ô“c@Œ’1, —с@GŽ÷1, Œ´“c—ÁŽq1, •H“c@Šw1, •˝–ě‘ĺŽu1, •˝‹´~ˆę1, •˝ŠÔÍ˜Y1, •˝ŽR_ˆę1, [ě‰ëŽj1, •Ÿ“cŒ°O1, “Ąˆä—ǍK1, “Ąč‹Bˆę˜Y1, ŒĂ‰Ž•ś•F1, Ż–ěƒˆę1, ×“‡NG1, –{“cŒŞŽŸ˜Y1, ‘“c‹M”Ž1, źˆä_•ă1, źŒG—S‘ž1, ź‘ş‰pŽ÷1, ŽOˆäˆŸŠóŽq1, ŽO‰YŒ’ˆę˜Y1, ŽOŒË•”—Ď‘ĺ1, ‹{—˘ŒŤ˜a1, ‹{–{@‘1, ŽO—֍šD1, ’JŕV‰ë•F1, –î“c—Y‰î1, ŽR–{‹`_1, “n糌ö—Y1 (1“ú–{t‘ŸŠw‰ďCKDf—ĂƒKƒCƒhEƒKƒCƒhƒ‰ƒCƒ“‰ü’ůˆĎˆő‰ď, 2ŹŽ™): “ú–{t‘ŸŠw‰ďŽ 2018/8; 60 (8): 1037-93.

540019. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)] X‰iŒ¤‹†•Ź‹ŕŒ¤‹†•ń‘. ]”gŒËF•ă (ŹŽ™): 2018.

[’˜@‘]

610006. [Šwp‘ (•Ş’SŽˇ•M)]yAmerican Heart Association Scientific Sessions 2017 Highlihtszp.11, 13. Senzaki H1,2, ƒAƒbƒ”ƒB‡“Ż‰ďŽĐ, 2018/5”­s. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

620076. [Šwp‘ (•Ş’SŽˇ•M)]yŹŽ™‚ĚŽĄ—ĂŽwj (ŹŽ™‰Čf—ĂVol.81‘Š§†z15. VśŽ™@‘ŽYŽ™”ÓŠúzŠÂ•s‘S, p.967-9. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2018/4”­s.

620077. [Šwp‘ (•Ş’SŽˇ•M)]yƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚­CKDf—ĂƒKƒCƒhƒ‰ƒCƒ“2018z‰Ş“c_ˆę, ˆŔ“c‹XŹ, ˆŽ@_ˆę, ˆÉ“ĄFŽj, —v@L–ç, _“c‰pˆę˜Y, ›–ě‹`•F, Žl•űŒŤˆę, ŽÄŠ_—LŒá, “y’J@Œ’,@’߉Ž˜a•F, ’ˇ“c‘ž•, Ź“cˆę‰q, “ěŠwłb, •ž•”ŒłŽj, ŕ_–ě‚s, “ĄŒłşˆę, ŽçŽR•qŽ÷, ŽRăp–MO, ŽR–{—Ë•˝, Žá™ŽO“ŢŽq, ˆ°“c@–ž, ‰Pˆääˆę, ě‘ş˜aŽq, –k‘şŒ’ˆę˜Y, Ą“cP•v, —é–Ř—S‰î, ’߉ޏGˆę, ź”ö–­D, “Ąˆä’ź•F, “ĄˆäG‹B, ˜a“cŒ’•F, ‰ĄŽR@m, Â–؍ŽŒ›, HŽR‘ĺˆę˜Y, r–ؐMˆę, —L”n‹v•x, Îě‰p“ń, Î‘qŒ’Ži1, Î’ˊ쐢L, Î–{‘ěŽk, Î–{@—V, ˆäŠÖ–M•q, ”‹´”ü’Ð˘, ˆę‰Ş‘Žq, Žsěˆę˝, Žsě‘ĺ‰î, ˆäăG“ń, Ąˆä—˜”ü, Ą‘şG–ž, Šâ“c‹ą‹X, Šâ’ÍD—˛, ‰Pˆär–ž, “ŕ“cŒ[Žq, ]ě‰ë”Ž, ‘ĺŒ´Mˆę˜Y, ‘ĺX‹ł—Y,@‰Ş“c—ŒbŽq, ‰œ“c—Y‰î, ”öŠÖ‹MĆ, Ź”¨—zŽq, b”ă•˝N, ‰Á“Ą‹K—˜, ‹ŕčŒ[‘˘, ‹ŕŽq‰ŔŒŤ, Š—ŕVG–ĺ, ěŒű••F, ěčK•F, ě“‡Œ\‰î, ‰Í–ět“Ţ, ‹e’n@Š¨, –ŘŒ´ł•v, –Ř‘ş—Ç‹I, ŒI“c‹X–ž, Ź’rŒ’‘ž˜Y, ŹňŒŤ—m, Ź“‡’qˆŸ—˘, Œă“Ąr‰î, ŸŒł—˛—Y, ŒĂ”g‘ Œ’‘ž˜Y, ŹźOK, ‹îę‘ĺ•ô, âV“Ą’m‰h, Žđˆäs’ź, âŒű—I‰î, —˘’†OŽu, ŽŠŒŠ‰Á“ŢŽq, ´…ş”Ž, ´…‚ł‚â‚Š, ”’ˆäŹ•S‡, V‘ň^‹I, ™ŽR˜aŠ°, —é–؁@’q, —é–؁@m, “ŠŽR˜aG, Łě—T‰Ŕ, ‚‹´˜a–ç, “c’†Œ’ˆę, “c’†“N—m, Šp“c—ş–ç, ’ß“c—I–Ř, ’†‘q•şŒÉ, ’ˇŕVNs, ’†ź_ˆę, ’ˇ•lł•F, ’†‰Ž—ˆĆ, –ź”gł‹`, V”¨Šo–ç, ź@Tˆę, ź˜eGŽ÷, ’ˇ’JěËŽq, ’ˇ’Jě‚Ý‚Ç‚č, ‰Ô“c@Œ’, —с@GŽ÷, Œ´“c—ÁŽq, •H“c@Šw, •˝–ě‘ĺŽu, •˝‹´~ˆę, •˝ŠÔÍ˜Y, •˝ŽR_ˆę, [ě‰ëŽj, •Ÿ“cŒ°O, “Ąˆä—ǍK, “Ąč‹Bˆę˜Y, ŒĂ‰Ž•ś•F, Ż–ěƒˆę, ×“‡NG, –{“cŒŞŽŸ˜Y, ‘“c‹M”Ž, źˆä_•ă, źŒG—S‘ž, ź‘ş‰pŽ÷, ŽOˆäˆŸŠóŽq, ŽO‰YŒ’ˆę˜Y, ŽOŒË•”—Ď‘ĺ, ‹{—˘ŒŤ˜a, ‹{–{@‘, ŽO—֍šD, ’JŕV‰ë•F, –î“c—Y‰î, ŽR–{‹`_, “n糌ö—Y (1ŹŽ™), •Ň: “ú–{t‘ŸŠw‰ď, “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2018/6”­s.

620078. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@ŽOS–[S, p.252-3. ‹ŕŽq‰ë‹I1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620079. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@’PSŽş, p.253-4. ‹´–{‰č‹v”ü1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620080. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@śS’áŒ`ŹÇŒóŒQ, p.254-5. “c‘ş—C•˝1, ›–{Œ’Ži1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620081. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@•sŽ–ŹŒ´Ť‰EŽşˆŮŒ`Ź, p.255. ‚—œ@Šw1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620082. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@ƒ~ƒgƒRƒ“ƒhƒŠƒAS‹ŘÇ, p.255-6. ”’ˆäG’ź1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620083. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@ć“VŤ‘m–X•Ů•Â˝•s‘SÇ, p.256-7. ‚—œ@Šw1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620084. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕ‰ČŠw‘ ‰ü’č‘ć9”Ĺ Vol.3 zŠÂŠíŽžŠłz11. ć“VŤSŽžŠł@ć“VŤCł‘ĺŒŒŠÇ“]ˆĘÇ, p.257. Œ´ŒűŒ[”V‰î1, ›–{Œ’Ži1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), ‘•ŇW: “ěŠwłb, •Ň: •Ÿ“cŒbˆę, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620085. [Šwp‘ (•Ş’SŽˇ•M)]yHow to Follow-up Q&A|2018ƒAƒbƒvƒf[ƒg (ŽüŽYŠúˆăŠw9ŒŽ‘‘ĺ†)z<—\Œă>@’´‘ŽYŽ™‚Ě’ˇŠú—\Œă, p.1109-13. ‘剪–ƒ—1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2018/9”­s.

620086. [Šwp‘ (•Ş’SŽˇ•M)]yŹŽ™ŽžŠł‚̐f’fŽĄ—ĂŠî€ (ŹŽ™“ŕ‰Č2018”N50ŠŞ‘Š§†)zXI. Á‰ťŠíŽžŠł@177. ’`”’˜RoŤˆÝ’°Ç, p.396-7. “Ą•‹`l (ŹŽ™), ‹¤•Ň:uŹŽ™“ŕ‰ČvuŹŽ™ŠO‰Čv•ŇWˆĎˆő‰ď, “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2018/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711013. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Trends in the neonatal intensive care and neurodevelopmental outcomes among preterm infants from 2003-2012: A retrospective cohort study in Neonatal Research Network, Japan (NRNJ). Nakanishi H1,2: The 2nd Korea-Japan-Taiwan Joint Congress on Neonatology (2018/5/24), Soul, Korea. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

711014. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Respiratory Syncytial Virus (RSV) infection management with Palivizumab for preterm infants in Japan. Nakanishi H1,2: The 25th Annual Spring Meeting of the Korean Society of Neonatology (2018/5/25), Soul, Korea. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

712028. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Current status of Neonatal Care in Japan. Nakanishi H1,2: Advanced Medical and Medicine Forum (2018/7/24), Jakarta, Indonesia. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

713111. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) comprehensive analysis of massive peripheral blood mononuculear cell in. Ebato T1: The 12th International Kawasaki Disease Symposium (2018/6/12-15), Yokohama. (]”gŒËF•ă1: 1ŹŽ™)

713112. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Trends in Morbidity and Mortality in 22-24 Weeks gestational Age from 2003-2012: A retrospective Cohort Study in Japan. Yamaguchi A1, Ishida S1, Ooka M1, Kemmochi M1, Nakanishi H1,2: Federation of Asia and Oceania Perintal Societies (FAOPS 2018) (2018/9/23-26), Philippine. (ŽRŒűˆť”T1, Î“c@Ži1, ‘剪–ƒ—˘1, çݎ@Šw1, ’†źG•F1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

713113. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Adrenal suppression after prednisolone treatment in children with idiopathic nephrotic syndrome: a multicenter prospective study. Harada R, Kikunaga K, Kamei K, Hamada R, Nagata H, Ando T, Ishikura K1: ASN Kidney Week 2018 (2018/10/23-28), San Diego, USA. (Î‘qŒ’Ži1: 1ŹŽ™)

713114. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Favorable Pulmonary Vascular Bed Before Fontan Surgery Secures Favorable Fontan Hemodynamics. Kuwata S1, Saiki H1, Takanashi M1, Sugamoto K1, Senzaki H1,2: American Heart Association (AHA) Scientific Sessions 2018 (2018/11/10-12), Chicago, USA. (řw“cšŽq1, âV–؍G•ś1, ‚—œ@Šw1, ›–{Œ’Ži1,ćčG–ž1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

713115. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Remote ischemic preconditioning attenuates lipopolysaccharide-induced septic cardiomyopathy by regulating circulating inflammatory mediators. Honda T1, He Q, Wang F, Schulte C, Moore V, Redington AN: American Heart Association (AHA) Scientific Sessions 2018 (2018/11/10-12), Chicago, USA. (–{“c@’1: 1ŹŽ™)

721016. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‘ŽYŽ™‚ɑ΂ˇ‚éNO‹z“ü—Ă–@ (iNO) ‚Ě“ú–{‚ĚŒťó‚ƍĄŒă‚Ě“W–]. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć63‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2018/11/23), “Œ‹ž.

721017. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ’PSŽşzŠÂ‚Ě”xŒŒŠÇ°•]‰ż. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć30‰ńJPICŠwpW‰ď (2019/1/26), é‹Ę.

722086. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒyƒ‰ƒ“ƒpƒlƒ‹‚ĚŒŒ’†”Z“x‘Ş’č`ĹV‚Ě’mŒŠ`. Šâčr”V (ŹŽ™): ‘ć60‰ń“ú–{ŹŽ™_ŒoŠw‰ďŠwpW‰ď (2018/5/31-6/2), –‹’Ł, ”]‚Ć”­’B 2018; 50: s267.

722087. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ŹŽ™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ@–{–M‚Ě—Ő°Œ¤‹†‚Ɛf—ĂƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ů. Î‘qŒ’Ži (ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

722088. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‚ŒŒˆł‚ƐtáŠQ@ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ ŹŽ™tŽžŠł‚ƍ‚ŒŒˆł‹Ů‹}Ç@PRES‚𒆐S‚É. Î‘qŒ’Ži (ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

722089. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‘ź‰@‚ŏC•œ˘“ď‚Ɛf’f‚ł‚ę‚˝Ź‡Œ^‘”xĂ–ŹŠŇ—ŹˆŮíÇ‚ɑ΂ˇ‚é•Ş•ŘŒv‰ć‚ƐS“ŕC•œ. ‚—œ@Šw1, âV–؍G•ś1, ”’ˆäG’ź1, řw“cšŽq1, ›–{Œ’Ži1, ‘ĺ—F—EŽ÷2, •Ÿź‘ô^2, ‹{–{—˛Ži2, ‹{’n@ŠÓ2, Îˆäł_1, ćčG–ž1,3 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

722090. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹z—Šw—Ă–@‚đ‚Ç‚ń‚ČÇ—á‚É, ‚˘‚‚â‚é? ‰˝‚đ‚ˇ‚é? ŹŽ™ŒÄ‹z—Šw—Ă–@‚đˆ•ű‚ľ‚悤@‘‡•a‰@‚Ě—§ę‚Š‚ç. “ě–ě‰ (ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

722091. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) ‚ą‚Ç‚ŕ‚́g‚Ä‚˛‚킢h‚Ä‚ń‚Š‚ń. Šâčr”V (ŹŽ™): ‘ć52‰ń“ú–{‚Ä‚ń‚Š‚ńŠw‰ďŠwpW‰ďEŽs–ŻŒöŠJuŔ (2018/10/27), ‰Ą•l.

722092. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) PDAˆË‘śŤ‘̏zŠÂ‚ĚŽĄ—Ð헪. âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, ›–{Œ’Ži1, ÎŒË”Ž—˛, ‘’J@‘, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ńJPICŠwpW‰ď (2019/1/24), é‹Ę.

723427. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ěč•a‚É‚¨‚Ż‚éPBMCs‚Ě–Ô—…“I‰đÍ. ]”gŒËF•ă (ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723428. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) KMT2Dˆâ“`ŽqˆŮí‚É”ş‚¤KabukiÇŒóŒQ‚̖ƉuŠw“IƒAƒvƒ[ƒ`‚Ć‚ť‚Ě•a‘Ô‚ĚŒŸ“˘. ]”gŒËF•ă (ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723429. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –Ɖu•s‘SÇ‚ĆŽŠŒČ–ƉuŽžŠł‚đ‡•š‚ľ‚˝‰Ě•‘ŠęÇŒóŒQ‚ĚKMT2Dˆâ“`ŽqˆŮí‚É‚ć‚é•a‘Ô‰đÍ. ]”gŒËF•ă1, â“Œ—R‹I1, `Œ’ˆę˜Y, ‰E“c‰¤‰î, ŠÝ–{—mŽq, ‚“cŽj’j, Îˆäł_1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş, “ú–{ŹŽ™‰ČŠw‰ďŽGŽ 2018; 122: p.240.

723430. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –łä°–ŒŒ^ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‹Ű‚É‚ć‚é”í•ď‰ť‹š…‡•š”x‰Š‚đ‚Ť‚˝‚ľ‚˝21trisomyÇ—á. ‹ŕŽq‰ë‹I1, â“Œ—R‹I1, Îˆäł_1, ›Ŕ‰h‰î (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş, “ú–{ŹŽ™‰ČŠw‰ďŽGŽ 2018; 122: p.415.

723431. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘˝”­Ťœ•a•Ď‚đ’ć‚ľ‚˝–ŤÄ”­Ť‘˝”­Ťœ‘‰Š‚Ě2—á. ŠÖŒË—Y‹M, ’†ŠÚŽ–ç, ˆÉ“ĄGˆę, Ź–¸‰ë•v, Î‘qŒ’Ži1, ‹{›˝@ŽĄ, –ěâr‰î, ŒE“c@–ž, Î•@¸ (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723432. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠwZŒŸ”A‚đŒ_‹@‚É”­ŒŠ‚ł‚ęt‹@”\áŠQ‚đ’ć‚ľ‚˝”ě–žŠÖ˜AtÇ‚Ě14Î’jŽ™—á. Š˜]’q‰ŔŽq, ‹TˆäGˆę, ź‘ş‘sŽj, aěŽK, ŽO’J@‘u, ’Ň“c—RŠě, Źš —T˜a, –ě‘ş’qÍ, “Ą“cŠîŽ‘, ’†ě‹IŽq, Î‘qŒ’Ži1, •–؍N•x (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723433. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) NUP107‚Ě•Ą‡ƒwƒeƒ•ĎˆŮ‚đ”F‚ß‚˝–łÇŒóŤ’`”’”A‚Ě3Î—Ž™. ‹TˆäGˆę, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, źŒ’‘ž˜N, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ’†źŒ[‘ž, –ě’ĂŠ°‘ĺ, ”Ń“‡ˆę˝, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723434. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ăŽˆ‚̩֐ߍSk‚Ĺ”­ŒŠ‚ł‚ę, ‘ŠúŽĄ—Ă‚Ş‘tŒ÷‚ľ‚˝­ŠÖßŒ^Žá”NŤ“Á”­ŤŠÖß‰Š‚Ě3—á. ˆŔ‰Í“ŕ—I, Ź–¸‰ë•v, Î‘qŒ’Ži1, ˆÉ“ĄGˆę, Î•@¸ (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723435. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’°ŠÇoŒŒŤ‘ĺ’°‹ŰŠ´őÇ‚É‚ć‚é—nŒŒŤ”A“ĹÇÇŒóŒQ‚É”ş‚¤‹}Ť”]Ç‚Ě—\Œă‚ĚŒŸ“˘. źŒËF”Ž, ź‘ş“Ţ•ä, “n糑ž˜Y, ˆäŽčŒ’‘ž˜Y, ’†ě@‘, ‹{“ü@—ó, Î‘qŒ’Ži1, ‹v•Ű“c‰ë–ç (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723436. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –Ɖu—}§–ň“ŕ•ž’†‚ĚŠłŽŇ‚Ö‚ĚŽă“ŐśƒƒNƒ`ƒ“ÚŽí‚ĚŒťó‚ƍĄŒă‚̐헪E‰Ű‘č. ‹TˆäGˆę, ‹{“ü@—ó, ŻŽiŒ’‰î, ˛ŒĂ‚Ü‚ä‚Ý, ’†‘şG•ś, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723437. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™Šú”­ÇSTEC-HUS‚ĆaHUS‚̐f’fŽž—Տ°‘œ‚¨‚ć‚Ń—\Œă‚Ě”äŠr. ŕ_“c@—¤, o—ˆšD, “ě@—T‰Ŕ, ˆäŒű’q—m, ‘ĺX‹ł—Y, ꎓĄˆťŽq, “ż‰iFŽj, ‹e‰i‰ŔD, ŽOă’ź˜N, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, Î‘qŒ’Ži1, ”Ś’J_Žj, –{“c‰ëŒh (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723438. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ‘S‘‰uŠw’˛¸ (JP-SHINE study). ˛“Ą@•‘, Î‘qŒ’Ži1, Ž›–ěçŽq, ‹e‰i‰ŔD, Ź–q •ś‘ă, ÎX ^Œá, ŕ_č —SŽq, ˆŔ“Ą ‚Žu, ˆÉ“Ą Gˆę, –{“c ‰ëŒh (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723439. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‹}Œƒ‚Ȑt‹@”\’ቺ‚É‚ć‚čVśŽ™Šú‚É“§Í“ą“ü‚ÉŽŠ‚Á‚˝Denys-DrashÇŒóŒQ‚Ě5—á. źŒ’‘ž˜N, Ź–¸‰ë•v, Î˜a@ăÄ, ź‘ş‘sŽj, ‰œ’Ă”ü‰Ä, ˛“Ą@•‘, ˛ŒĂ‚Ü‚ä‚Ý, ‹TˆäGˆę, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723440. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) 3Œ^BartterÇŒóŒQ (3Œ^BS) ‚Ě2—á‚ĆGitelmanÇŒóŒQ (GS) ‚Ě2—á: —Տ°f’f‚ĚŒŔŠE‚ɂ‚˘‚Ä. ŽO‰Y^—Žq, ‰Á”[—DŽĄ, ˆÉ“Œ@—•, ‘Oě‹ML, Ź–¸‰ë•v, ‹TˆäGˆę, –ě’ĂŠ°‘ĺ, ŒE“c@–ž, Î•@¸, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/21), •Ÿ‰Ş.

723441. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) PGťÜ‚ōś”x“Ž–Ź‚ĚŒŒ—Ź‚Ş•Ű‚˝‚ę‚˝ć“VŤŒÇ—§Ťś”x“Ž–ŹŒ‡‘šÇ‚Ě1—á. ě“cF‘ž1, çݎ@Šw1, âV–؍G•ś1, ŽRŒűˆť”T1, ‘剪–ƒ—1, Îˆäł_1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/20-22), •Ÿ‰Ş.

723442. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĺŠw•a‰@‚É‚¨‚Ż‚édÇSgáŠQÝ‘îˆă—ĂŽx‰‡‚ĚŽŽ‚݁@ŹŽ™Ý‘îŽx‰‡ƒZƒ“ƒ^[‚Ě•K—vŤ. Œ´ŒűŒ[”V‰î1, Šâčr”V1, •C“c‚ł‚â‚Š, ”’ˆäG’ź1, “yŠň@•˝1, –ěX“c–L1, Î“c—Ď–ç, ”’ˆäGK1, Îˆäł_1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/20-22), •Ÿ‰Ş, “ú–{ŹŽ™‰ČŠw‰ďŽGŽ 2018; 122 (2): 529.

723443. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒJƒe[ƒeƒ‹Žč‹Z‚É‚ć‚č”x“Ž–Ź•Â˝—l‚É‚Č‚Á‚˝dÇ”x“Ž–Ź•Ů‹ˇó‚Ě2—á. ‚—œ@Šw1, řw“cšŽq1, –kě“ÄŽj1, ˆŔ“Ą@Žő1, âV–؍G•ś1, –Ř‘şƒl1, •x“c@‰p, Îˆäł_1 (1ŹŽ™): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/20-22), •Ÿ‰Ş.

723444. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”x“Ž–Ź•Ů’uŠˇp‘O‚̉EŽş—Źo˜H‹ˇó‚ޏpŒă‚̐S‹@”\‚É—^‚Ś‚é‰e‹ż. –kě“ÄŽj1, âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, ‹{’n@ŠÓ2, Îˆäł_1 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO): ‘ć121‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2018/4/20-22), •Ÿ‰Ş, “ú–{ŹŽ™‰ČŠw‰ďŽGŽ 2018/4; 122 (2): 251.

723445. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‹ŰŤ”í•ď‰ť‹š…‚̏ŹŽ™—á. ‚‹´@F, â“Œ—R‹I1, ›Ŕ‰h‰î (1ŹŽ™): ‘ć66‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď (2018/5/31-6/2), ‰ŞŽR, “ú–{‰ťŠw—Ă–@Šw‰ďŽGŽ 2018; 66 (Suppl A): 335.

723446. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‹}Œƒ‚ČŒo‰ß‚đ‚˝‚Ç‚Á‚˝ƒCƒ“ƒtƒ‹ƒGƒ“ƒUAŒ^Š´ő‚É”ş‚¤‹}Ť‰óŽ€Ť”]Ç‚Ě1—Ž™—á. “c‘ş—C•˝1, ˆŔ“Ą@Žő1, ”’ˆäG’ź1, ]”gŒËF•ă1, ‹ŕŽq’‰O1, –ěX“c–L1, Îˆäł_1 (1ŹŽ™): ‘ć32‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2018/6/2-3), ˆďé.

723447. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒQƒmƒ€ƒƒCƒhŠÖ˜A‰đÍ‚É‚ć‚鏬Ž™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ‚Ěriskhaplotype“Ż’č. –x”V“ŕ’qŽq, –ě’ĂŠ°‘ĺ, Î‘qŒ’Ži1, ”Ń“‡ˆę˝ (1ŹŽ™): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/8-10), VŠƒ.

723448. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒŠƒcƒLƒVƒ}ƒuŒă–Ɖu—}§–ň‚đŒp‘ą‚ľ‚˝“Ťƒlƒtƒ[ƒ[ÇŒóŒQ‚ł̖Ɖu—}§–ň’†Ž~ŒăÄ”­‚ÉŠń—^‚ˇ‚éˆöŽq‚ĚŒŸ“˘. ‹TˆäGˆę, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, źŒ’‘ž˜N, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/8-10), VŠƒ.

723449. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒŠƒcƒLƒVƒ}ƒu”˝•œ“Š—^‚É‚ć‚čƒAƒiƒtƒBƒ‰ƒLƒV[‚đ’ć‚ľ‚˝1—á. źě‹ĹŽq (ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29), •Ÿ“‡.

723450. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚ĹŠÇ—‚ł‚ę‚˝ć“VŤƒlƒtƒ[ƒ[ÇŒóŒQ, “űŽ™ƒlƒtƒ[ƒ[ÇŒóŒQ49—á‚Ě—Ő°Œo‰ß‚ĚŒŸ“˘. ˆäŒű’q—m, ŕ_“c@—¤, “ě@—T‰Ŕ, o—ˆšD, ‘ĺX‹ł—Y, ꎓĄˆťŽq, “ż‰iFŽj, ‹e‰i‰ŔD, ŽOă’ź˜N, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723451. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚ĹŒoŒą‚ľ‚˝WT1ŠÖ˜AtÇ34—á‚Ěˆâ“`ŽqˆŮí‚Ć—Ő°‘œ. ŕ_“c@—¤, Î‘qŒ’Ži1, ‘ĺX‹ł—Y, ŽOă’ź˜N, Ž›–ěçŽq, Œ´“c—ÁŽq, źˆä‘Pˆę, ˛“Ą—T”V, Œă“Ą”ü˜a, ŕ_č—SŽq, ”Ś’J_Žj, •űŒŞ‘ž˜Y, ’†ź_ˆę, ’ˇ’Jěs—m, ŽłŒË´ˆę˜Y, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723452. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™‰”­ƒlƒtƒ[ƒ[ÇŒóŒQ‚É‚¨‚Ż‚鍂ŒŒˆł‚Ě—Ő°‘œ. âV“ĄˆťŽq, Œ´“c—ÁŽq, “ě@—T‰Ŕ, o—ˆšD, ˆäŒű’q—m, ‘ĺX‹ł—Y, “ż‰iFŽj, ‹e‰i‰ŔD, Ž›–ěçŽq, ŕ_“c@—¤, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723453. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™Šú”­ÇtŽžŠłŠłŽŇ‚ĚŽžŠł—‰đ, ŽŠ—§“x‚͐ŹlŠú”­ÇŠłŽŇ‚Ć“Ż“™‚Ĺ‚ ‚é. Ž›–ěçŽq, ”Ś’J_Žj, ‹v•Ű“c˜j, ‹e‰i‰ŔD, ŽOă’ź˜N, Œ´“c—ÁŽq, ŕ_“c@—¤, ŕ_č—SŽq, Î‘qŒ’Ži1, ™ˆäÍ“ń, ź”öN‰p, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723454. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒŠƒcƒLƒVƒ}ƒuŒă–Ɖu—}§–ň‚đŒp‘ą‚ľ‚˝“Ťƒlƒtƒ[ƒ[ÇŒóŒQ‚ł̖Ɖu—}§–ň‚ĚŽŠ“K’†Ž~ŽžŠú‚¨‚ć‚Ń’†Ž~ŒăÄ”­‚ÉŠń—^‚ˇ‚éˆöŽq‚ĚŒŸ“˘. ‹TˆäGˆę, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, źŒ’‘ž˜N, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723455. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) automated peritoneal dialysis (APD) ‚É‚¨‚Ż‚鏜…—Ę“–‚˝‚č‚ĚƒiƒgƒŠƒEƒ€œ‹Ž—ʂɂ‚˘‚Ä‚ĚŒŸ“˘. “ż‰iFŽj, ŕ_“c@—¤, o—ˆšD, “ě@—T‰Ŕ, ‘ĺX‹ł—Y, ꎓĄˆťŽq, ˆäŒű’q—m, ‹e‰i‰ŔD, Ž›–ěçŽq, ŽOă’ź˜N, Œ´“c—ÁŽq, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723456. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ––Šút•s‘S‚ÉŽŠ‚Á‚˝ć“VŤt”A˜HˆŮí (CAKUT) ŠłŽŇ‚ĚŒo‰ß|Syndromic‚ĆNon-syndromic‚Ě”äŠr|. ‹e‰i‰ŔD, ŕ_“c@—¤, “ě@—T‰Ŕ, o—ˆšD, ˆäŒű’q—m, ‘ĺX‹ł—Y, ꎓĄˆťŽq, “ż‰iFŽj, ŽOă’ź˜N, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723457. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒXƒeƒƒCƒh’ďRŤƒlƒtƒ[ƒ[ÇŒóŒQ‚ĚŠů‰‚Ş‚ ‚é“Ťƒlƒtƒ[ƒ[ÇŒóŒQ‚ɑ΂ˇ‚éB×–E‰ń•œŒă‚ĚƒŠƒcƒLƒVƒ}ƒu—\–h“I’ljÁ“Š—^. ‰œ’Ă”ü‰Ä, ‹TˆäGˆę, ź‘ş‘sŽj, ˛“Ą@•‘, źŒ’‘ž˜N, Î˜a@ăÄ, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723458. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) 8Î‚ĹƒXƒeƒƒCƒh’ďRŤƒlƒtƒ[ƒ[ÇŒóŒQ‚đ”­Ç‚ľŒă‚ÉNPHS1•Ą‡ƒwƒeƒÚ‡‘Ě•ĎˆŮ‚Ş”ť–ž‚ľ‚˝—Ž™—á. ‹TˆäGˆę, –ě’ĂŠ°‘ĺ, ’†źŒ[‘ž, ’ˇ–ě’q“ß, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, źŒ’‘ž˜N, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ˆÉ“ĄGˆę, ”Ń“‡ˆę˝, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723459. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒQƒmƒ€ƒƒCƒhŠÖ˜A‰đÍ‚É‚ć‚鏬Ž™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ‚Ěrisk haplotype“Ż’č. –x”V“ŕ’qŽq, Jia Xiaoyuan, lŒŠ—SŠî, Î‘qŒ’Ži1, ‹TˆäGˆę, ŕ_“c@—¤, Šs@‹`ˆű, “ĄŠŰ‹G‰Â, ‰Ş–{F”V, ‘ĺ˜a“c—tŽq, “c’†—ş“ń˜Y, Œă“Ą–F[, ŠL“Ą—TŽj, –ě’ĂŠ°‘ĺ, “ż‰iŸŽm, ”Ń“‡ˆę˝ (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723460. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) IgG’ž’…‚Ě—L–ł‚É‚ć‚éC3tÇ‚Ě—\Œă‚ĚŒŸ“˘. ‘ĺX‹ł—Y, ŕ_“c@—¤, o—ˆšD, “ě@—T‰Ŕ, ˆäŒű’q—m, ꎓĄˆťŽq, “ż‰iFŽj, ‹e‰i‰ŔD, ‰œ“c—Y‰î, ŽOă’ź˜N, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723461. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠwZŒŸ”A‚đŒ_‹@‚É”­ŒŠ‚ł‚ęt‹@”\áŠQ‚đ’ć‚ľ‚˝”ě–žŠÖ˜AtÇ‚Ě14Î’jŽ™—á. Š˜]’q‰ŔŽq, ‹TˆäGˆę, ź‘ş‘sŽj, aěŽK, ŽO’J@‘u, ’Ň“c—RŠě, ŽR–{‚Š‚¸‚Č, Źš —T˜a, –ě‘ş’qÍ, “Ą“cŠîŽ‘, ’†ě‹IŽq, Î‘qŒ’Ži1, •–؍N•x (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723462. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ˆâ“`Šw“IŒŸ¸‚É‚ć‚čŠm’čf’f‚ł‚ę, ŽŸŽq‚̏oś‘Of’f‚ŞŒŸ“˘‚ł‚ę‚˝ˆâ“`ŤtŽžŠł‚Ě2‰ĆŒn. ‰Á”[—DŽĄ, źŒ’‘ž˜N, Î˜a@ăÄ, ‰œ’Ă”ü‰Ä, ź‘ş‘sŽj, ˛“Ą@•‘, Ź–¸‰ë•v, ‹TˆäGˆę, •ŸŒ´N”V, –ě’ĂŠ°‘ĺ, ’r“c^—Žq, ‘q‹´_Ž÷, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723463. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒlƒtƒ[ƒ[ó‘Ô‚ÉŽŠ‚Á‚˝ŹŽ™dÇŽ‡”Á•aŤt‰Š (HSPN) ‚ɑ΂ˇ‚étśŒŸ“K‰ž|ŒŒ´ƒAƒ‹ƒuƒ~ƒ“’l‚Š‚ç‚Ý‚˝tśŒŸ‰î“üŽžŠú‚ĚŒŸ“˘|. ‘ĺ’J—E‹I, ˆäŒű’q—m, “ż‰iFŽj, “ě@—T‰Ŕ, o—ˆšD, ‘ĺX‹ł—Y, ꎓĄˆťŽq, ‹e‰i‰ŔD, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_“c@—¤, ŕ_č—SŽq, ”Ś’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723464. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒđŤ”÷ŹŒŒŠÇáŠQ (TMA) ‚đ‡•š‚ľ‚˝ƒXƒeƒƒCƒh’ďRŤƒlƒtƒ[ƒ[ÇŒóŒQ‚Ě1Î’jŽ™—á. źŒ’‘ž˜N, Ź–¸‰ë•v, Î˜a@ăÄ, ‰Á”[—DŽĄ, Ë“c@ŒŞ, ‰œ’Ă”ü‰Ä, ź‘ş‘sŽj, ˛“Ą@•‘, ˛ŒĂ‚Ü‚ä‚Ý, ‹TˆäGˆę, ’ˇ“c“š•v, ‹`‰ŞFŽq, •űŒŞ‘ž˜Y, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2018/6/29-30), •Ÿ“‡.

723465. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”x“Ž–Ź•ŞŠň•”‹ˇóÇ‚ɑ΂ˇ‚éŒo”ç“I”x“Ž–ŹŒ`Źp‚Ě—LŒřŤ‚Ć”x“Ž–Ź•Â˝•s‘S‚ĚŠÖ˜A. řw“cšŽq1, âV–؍G•ś1, ‚—œ@Šw1, –kě“ÄŽj1, –Ř‘şƒl1, ćčG–ž1,2, Îˆäł_1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723466. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ű—cŽ™ŠúTOF‚̏ăs‘ĺ“Ž–ŹStiffness‚ɉe‹ż‚đ—^‚Ś‚éˆöŽq‚ĚŒŸ“˘. řw“cšŽq1, âV–؍G•ś1, ‚—œ@Šw1, –kě“ÄŽj1, –Ř‘şƒl1, ›–{Œ’Ži1, ćčG–ž1,2, Îˆäł_1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723467. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰^“ŽŽž‚Ě‹š’É‚Ĺ”­ŒŠ‚ł‚ę‚˝ŹŽ™Šú”­ÇŠĽškŤ‹ˇSÇ‚Ě2—á. ‚—œ@Šw1, âV–؍G•ś1, řw“cšŽq1, –kě“ÄŽj1, –Ř‘şƒl1, ›–{Œ’Ži1, ćčG–ž1,2, Îˆäł_1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ďEŠwpW‰ď (2018/7/5-7), ‰Ą•l.

723468. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒoƒ‹ƒTƒ‹ƒoŽč‹Z‚É‚ć‚é•˝‹ĎzŠÂ[–žˆł„’č. âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, Îˆäł_1, ƒŒƒbƒhƒtƒB[ƒ‹ƒh ƒ}[ƒKƒŒƒbƒg, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/6), ‰Ą•l.

723469. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TOFpŒăPS‚¨‚ć‚ŃPR‚̉EŽşŽűk”\‚ւ̉e‹ż`ś—Šw“IŒŠ’n‚Š‚ç‚̍Įčp“K‰žŠî€‚̍lŽ@`. ›–{Œ’Ži1, ź‘ş@s, Šâ–{—mˆę, âV–؍G•ś1, ÎŒË”Ž—˛, ‘’J@‘, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/6), ‰Ą•l.

723470. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒtƒHƒ“ƒ^ƒ“zŠÂ‚É‚¨‚Ż‚éĂ–Ź‚¤‚ÁŒŒ‚ĆŒă•‰‰×‘‹­‚ĚŠÖ˜A. âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, ›–{Œ’Ži1, Îˆäł_1, ‘’J@‘, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/6), ‰Ą•l.

723471. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x“Ž–Ź’áŒ`ŹÇ—á‚ɑ΂ˇ‚é‰EŽş—Źo˜HÄŒšpŒă‚Ě–â‘č“_. âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, –kě“ÄŽj1, –Ř‘şƒl1, Îˆäł_1, ‘’J@‘, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2018/7/7), ‰Ą•l.

723472. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ű—cŽ™”­Ç“Ť“€áŒ—l”ç]‚Ě2Ç—á. ]”gŒËF•ă1, â“Œ—R‹I1 (1ŹŽ™): ‘ć42‰ń“ú–{ŹŽ™”畆‰ČŠw‰ďŠwp‘ĺ‰ď (2018/7/15), “Œ‹ž.

723473. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) V“üEˆőƒtƒHƒ[ƒAƒbƒvŒ¤C‚É‚¨‚Ż‚é‘˝EŽí˜AŒg‰‰K (IPW) ‚ĚŽŔ‘H‚Ɖۑč. â“Œ—R‹I1, ŽR–{G–ž, Œ´“c•qŒb, ă@•ä, Ž›ŽR‰xŽq, Ź—ŃáÁ‹I, ç—tG‹B2, Žç‰Ž—˜‰Ŕ2 (1ŹŽ™, 2ˆăŠw‹łˆç): ‘ć50‰ń“ú–{ˆăŠw‹łˆçŠw‰ď‘ĺ‰ď (2018/8/3-4), “Œ‹ž, ˆăŠw‹łˆç 2018; 49 (Suppl): 166.

723474. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–ˆă—ĂŒ^áŠQŽ™ (ŽŇ) “üŠŽ{Ý‚É‚¨‚Ż‚élHŒÄ‹zŠí‚ĚŒťó‚Ɖۑč. “ě–ě‰ (ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723475. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) NPŤ”x‰Š‹…‹ŰŠ´őÇ (invasive pneumococcal disease: IPD) ‚É‚ć‚č30ŽžŠÔ‚ĹŽ€–S‚ľ‚˝ˆę—á. ´…^”ż, “ě–ě‰1 (1ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723476. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚•p“xlHŠˇ‹C—Ă–@ (HFO) ‚Ş”x‚ĚƒŠƒNƒ‹[ƒgƒƒ“ƒg‚É—L—p‚Ĺ‚ ‚Á‚˝ˆę—á. ‘ĺ‹ČłŽ÷, “ě–ě‰1 (1ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723477. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Ň‘Ť‹ŘˆŢkÇ1Œ^‚ɑ΂ˇ‚éƒkƒVƒlƒ‹ƒZƒ“‘’‚ĚŒÄ‹z‹@”\Œř‰Ę. ‘ĺę”ż”T‰Ŕ, “ě–ě‰1 (1ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723478. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) táŠQ‚Ě—L–ł‚É‚ć‚鏬Ž™ŠĚˆÚA—á‚Ě’ˇŠút—\Œă: 471—á‚̉đÍ. ˛“Ą@•‘, Î‘qŒ’Ži1, •“cšŠ°, ˛X–ŘŒ’Œá, “ŕ“c@–Đ, •˝“c‹`O, •Ÿ“cW–ç, ă–{–ő‰î, Š}Œ´ŒQś (1ŹŽ™): ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2018/10/3-5), “Œ‹ž.

723479. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠĚˆÚAŒă“Żˆęƒhƒi[‚É‚ć‚étˆÚA‚É‚¨‚Ż‚éRƒhƒi[R‘Ě‚ĚˆÓ‹`. ˛“Ą@•‘, Ź–¸‰ë•v, ‹TˆäGˆę, Î‘qŒ’Ži1, •Ÿ“cW–ç, ă–{–ő‰î, Š}Œ´ŒQś (1ŹŽ™): ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2018/10/3-5), “Œ‹ž.

723480. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Lacosamide‚đ“ŕ•ž‚ľ‚˝‚Ä‚ń‚Š‚ń13Ç—á‚É‚¨‚Ż‚éĹ‚ŒŒ´’†”Z“x‚Ě—L—pŤ. Šâčr”V1, ”’ˆäG’ź1, Î“c—Ď–ç, “yŠň@•˝1, –ěX“c–L1, ”’ˆäGK1 (1ŹŽ™): ‘ć52‰ń“ú–{‚Ä‚ń‚Š‚ńŠw‰ďŠwpW‰ď (2018/10/25-27), ‰Ą•l. ‚Ä‚ń‚Š‚ńŒ¤‹† 2018; 36 (2): 493.

723481. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘SgŒ^Žá”Nś“Á”­śŠÖß‰Š‚É‚Ý‚ç‚ę‚éŠĚ‹@”\áŠQ‚Ě•a—Šw“IŒŸ“˘. ]”gŒËF•ă1, â“Œ—R‹I1 (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/27), “Œ‹ž.

723482. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚鐏lˆÚsŠúŽx‰‡ƒ`[ƒ€Šˆ“Ž‚ĚŒťó@ŹŽ™ƒŠƒEƒ}ƒ`ŤŽžŠł‚Ě“Á’Ľ‚ĆŽć‚č‘g‚݂ɂ‚˘‚Ä. â“Œ—R‹I1, –ěX“c–L1, ]”gŒËF•ă1, ‘ĺ’ˁ@2, âV“Ą‘Žq2 (1ŹŽ™, 2ŠĹŒě•”): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž, ƒvƒƒOƒ‰ƒ€E´˜^W 2018; p.81.

723483. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘SgŒ^Žá”NŤ“Á”­ŤŠÖß‰Š‚É‚Ý‚ç‚ę‚éŠĚ‹@”\áŠQ‚Ě•a—Šw“IŒŸ“˘. ]”gŒËF•ă1, â“Œ—R‹I1 (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž, ƒvƒƒOƒ‰ƒ€E´˜^W 2018; p.110.

723484. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒXƒeƒƒCƒh‚𒆎~‚ľ‚Ś‚˝ŹŽ™Šú”­Ç‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX‚Ě10—á. źŒ’‘ž˜N, Ź–¸‰ë•v, Î˜a@ăÄ, ‰œ’Ă”ü‰Ä, ‹ŕX@“§, ˛“Ą@•‘, ˛ŒĂ‚Ü‚ä‚Ý, ‹TˆäGˆę, ˆÉ“ĄGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž.

723485. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) RMDA5R‘Ě—zŤŽá”NŤ”畆‹Ř‰Š‚ĚŠŽŽĄŒă‚ɍŹ‡ŤŒ‹‡‘gD•a‚đ”­Ç‚ľ‚˝1—Ž™—á. Ź–¸‰ë•v, ˆÉ“ĄGˆę, ‹ŕX@“§, źŒ’‘ž˜N, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, ˛“Ą@•‘, ‹TˆäGˆę, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž.

723486. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™ƒŠƒEƒ}ƒ`ŤŽžŠłŠłŽŇ‚É‚¨‚Ż‚郁ƒgƒgƒŒƒLƒT[ƒg‚Ě•›ě—p’˛¸‚¨‚ć‚Ń—tŽ_ťÜ‚Ě—\–hŒř‰Ę‚ĚŒŸ“˘. ŒÎé—R‰Ŕ, ˜lŠÔ—œŒb, Ź–¸‰ë•v, Î‘qŒ’Ži1, ˆÉ“ĄGˆę, ŽR’J–žł (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž.

723487. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‹}ŤS•s‘S‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝‚ˆŔ“Ž–Ź‰Š‚Ě12Î—Ž™—á. ‹ŕXŒ[‘ž, źŒ’‘ž˜N, Î˜a@ăÄ, Ź–¸‰ë•v, Î‘qŒ’Ži1, ˆÉ“ĄGˆę (1ŹŽ™): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/26-28), “Œ‹ž.

723488. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚鐏lˆÚsŠúŽx‰‡ƒ`[ƒ€Šˆ“Ž‚ĚŒťó|ŹŽ™ƒŠƒEƒ}ƒ`ŤŽžŠł‚Ě“Á’Ľ‚ĆŽć‚č‘g‚݂ɂ‚˘‚ā|. â“Œ—R‹I1,2, –ěX“c–L1, ]”gŒËF•ă1, ‘ĺ’ˁ@3, ꎓĄ‘Žq3 (1ŹŽ™, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ŠĹŒě•”): ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2018/10/27), “Œ‹ž, ‘ć28‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.110.

723489. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”źŒŽ‘ĚŒ`ŹŤt‰Š‚đ’ć‚ľ‚˝C3t‰Š‚Ě4Î—Ž™. ‹TˆäGˆę, ˛“Ą@•‘, ‹ŕX@“§, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, źŒ’‘ž˜N, Ź–¸‰ë•v, ŕVˆärG, ‰œ“c—Y‰î, ‹`‰ŞFŽq, •űŒŞ‘ž˜Y, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć40‰ń“ú–{ŹŽ™t•s‘SŠw‰ďŠwpW‰ď (2018/11/8-9), ‹{č.

723490. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ć“VŤt”A˜HˆŮí‚Ě—Ő°‘œ‚Ćˆâ“`Žq•ĎˆŮ‚ĚŠÖ˜AŤ: ’PŽ{Ý64—á‚̉đÍ. Î˜a@ăÄ, ˛“Ą@•‘, źŒ’‘ž˜N, ‹ŕX@“§, ‰œ’Ă”ü‰Ä, Ź–¸‰ë•v, ˛ŒĂ‚Ü‚ä‚Ý, ‹TˆäGˆę, ˆÉ“ĄGˆę, ”Ń“‡ˆę˝, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć40‰ń“ú–{ŹŽ™t•s‘SŠw‰ďŠwpW‰ď (2018/11/8-9), ‹{č.

723491. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –łÇóŤ’`”’”A‚̐¸¸‚ĹWT1ˆâ“`ŽqˆŮí‚Ş”ť–ž‚ľ‚˝17Î—Ž™—á. ‹ŕX@“§, ‹TˆäGˆę, źŒ’‘ž˜N, ‰œ’Ă”ü‰Ä, Î˜a@ăÄ, ˛“Ą@•‘, Ź–¸‰ë•v, ˆÉ“ĄGˆę, ’†źŒ[‘ž, –ě’ĂŠ°‘ĺ, ”Ń“‡ˆę˝, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć40‰ń“ú–{ŹŽ™t•s‘SŠw‰ďŠwpW‰ď (2018/11/8-9), ‹{č.

723492. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@NICU‚É‚¨‚Ż‚éVLBW‚ɑ΂ˇ‚éR‹Ű–ň‚Ě“KłŽg—p‚ĚŽć‚č‘g‚Ý. çݎ@Šw1, ŽRŒűˆť”T1, Î“c@Ži1, ‘剪–ƒ—1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć50‰ń“ú–{ŹŽ™Š´őÇŠw‰ď‘‰ďEŠwpW‰ď (2018/11/10-11), •Ÿ‰Ş.

723493. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒwƒpƒŠƒ“–ł“Y‰Á‚Ĺ‚Ěsec one coating PIƒJƒe[ƒeƒ‹‚ĚŽg—pŒoŒą. ŽRŒűˆť”T1, çݎ@Šw1, Î“c@Ži1, ‘剪–ƒ—1, ‰ĄŠÖ—Sˆę˜Y1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2018/11/22-24), “Œ‹ž.

723494. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) —Տ°‘œ‚Š‚ç‹Áœą•a‚Ɛf’f‚ľ‚˝MD‘o‘Ů‚Ě1Ž™—á. çݎ@Šw1, ŽRŒűˆť”T1, Î“c@Ži1, ‘剪–ƒ—1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2018/11/22-24), “Œ‹ž.

723495. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹É’áoś‘̏dŽ™‚ĆŒ’íŽ™‚̍ŔˆĘƒŠ[ƒ`“Žě‚É‚¨‚Ż‚é‘ĚŠ˛‰^“Ž‚Ě•ŞÍ. –ě‘ş—DŽq, ‘剪–ƒ—1, çݎ@Šw1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2018/11/22-24), “Œ‹ž.

723496. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”DP’†Šú‘O”ź‚É2:1–[ŽşƒuƒƒbƒN‚đ”F‚ß‚˝ć“VŤQT‰„’ˇÇŒóŒQ. řw“cšŽq1, âV–؍G•ś1, ‹´–{‰č‹v”ü1, ‚—œ@Šw1, ŽRŒűˆť”T1, —с@—§\, ‰Á“Ąˆ¤Í, ›–{Œ’Ži1, –x•ÄmŽu, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć23‰ń“ú–{ŹŽ™S“dŠw‰ďŠwpW‰ď (2018/11/30-12/1), “Ţ—Ç.

723497. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒtƒHƒ“ƒ^ƒ“p‘OƒRƒCƒ‹Çđp‚Ě—Ő°“IˆÓ‹`. âV–؍G•ś1, řw“cšŽq1, ‚—œ@Šw1, Šâ–{—mˆę, ›–{Œ’Ži1, ÎŒË”Ž—˛, ‘’J@‘, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ńJPICŠwpW‰ď (2019/1/24), é‹Ę.

723498. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) p’†”x“Ž–ŹƒXƒeƒ“ƒg—Ż’u‚Ě“K‰ž‚Ć–â‘č“_. ‚—œ@Šw1, âV–؍G•ś1, řw“cšŽq1, •Ÿź‘ô^2, –Ř‘şƒl1, ›–{Œ’Ži1, ‹{–{—˛Ži2, ‹{’n@ŠÓ2, ćčG–ž1,3 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ńJPICŠw‰ďŠwpW‰ď (2019/1/24-26), é‹Ę.

723499. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –Ɖu—}§–ň‚␜•¨Šw“IťÜŽg—p‰ş‚ł̐śƒƒNƒ`ƒ“ÚŽí‘S‘ŽŔ‘Ô’˛¸. ‹TˆäGˆę, ‹{“ü@—ó, ŻŽiŒ’‰î, ˛ŒĂ‚Ü‚ä‚Ý, ’†‘şG•ś, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/13-15), ‘ĺă.

723500. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ź‰@‚ŏC•œ˘“ď‚Ć”ť’f‚ł‚ę‚˝Ź‡Œ^‘”xĂ–ŹŠŇ—ŹˆŮíÇ`_“î‚Čƒ`[ƒ€\’z‚̏d—vŤ`. âV–؍G•ś1, řw“cšŽq1, ‘吟—fŽq2, ‹ŕˆä—Y“ń2, –]ŒŽƒŽq2, ”’ˆäG’ź1, ‚—œ@Šw1, ›–{Œ’Ži1, ™›Ž@Šw1, •Ÿź‘ô^3, ‹{’n@ŠÓ3, Îˆäł_1, ćčG–ž1,4 (1ŹŽ™, 2ŽY‰Č, 3S‘ŸŒŒŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć25‰ń“ú–{‘ŮŽ™S‘Ÿ•aŠw‰ďŠwpW‰ď (2019/2/15), ‘ĺă.

723501. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”DP’†Šú‘O”ź‚É2 : 1–[ŽşƒuƒƒbƒN‚đ”F‚ß‚˝ć“VŤQT‰„’ˇÇŒóŒQ. řw“cšŽq1, âV–؍G•ś1, ‹ŕˆä—Y“ń2, ‹´–{‰č‹v”ü1, ‚—œ@Šw1, ŽRŒűˆť”T1, —с@—§\, ›–{Œ’Ži1, ™›Ž@Šw1, –x•ÄmŽu, ćčG–ž1,3 (1ŹŽ™, 2ŽY‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć25‰ń“ú–{‘ŮŽ™S‘Ÿ•aŠw‰ďŠwpW‰ď (2019/2/15), ‘ĺă.

731039. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŹŽ™zŠÂŠíf—Ă‚Ě—đŽj‚ƍĄŒă. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć343‰ńŠ‘ňŹŽ™‰Čˆă‰ďŠwpu‰‰‰ď (2018/5/22), Š‘ň.

731040. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‰ESŽş‚đf‚é`‰E–[‰EŽş, ‰EŽş”x“Ž–Ź, ‰EŽşśŽşŠÖ˜A‚Ć‚Ć‚ŕ‚Ɂ`. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć111‰ń–k—˘zŠÂŠíƒZƒ~ƒi[ (2018/6/28), ‘Š–ÍŒ´.

731041. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) SŽžŠłHˆę”ʏŹŽ™“úíf—Ă‚Ĺ‚ĚTips. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć1‰ń–k—˘ŹŽ™Ç—ጟ“˘‰ď (2018/7/11), ‘Š–ÍŒ´.

731042. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆę”ʏŹŽ™‰Čˆă‚Ě‚˝‚߂̐S‹@”\•]‰ż‚ƏzŠÂŠÇ—. ćčG–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć22‰ń•Ÿ“‡Œ§ŹŽ™zŠÂŠíŒ¤‹†‰ď (2018/11/24), •Ÿ“‡.

732029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) R‚Ä‚ń‚Š‚ń–ň‚ɂ‚˘‚ā`—Տ°ˆă‚Š‚ç–ňÜŽt‚ł‚ń‚É‚¨“`‚Ś‚ľ‚˝‚˘‚ą‚Ɓ`. Šâčr”V (ŹŽ™): ŠC˜V–źŽs–ňÜŽt‰ďŽĺĂEPharamaceutical careŒ¤C‰ď (2018/5/20), ŠC˜V–ź.

732030. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŹŽ™‚Ě‚Ä‚ń‚Š‚ń`—Տ°ˆă‚Š‚ç, ‚Ä‚ń‚Š‚ńŠłŽ™‚ÉŠÖ‚í‚é‘ĺl‚ĚŠF—l‚Ö. Šâčr”V (ŹŽ™): “ú–{‚Ä‚ń‚Š‚ń‹Ś‰ď_“ŢěŒ§Žx•”u‰‰‰ď (2018/6/24), ‰Ą•l.

732031. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ‚Ä‚ń‚Š‚ń”­ě‚ɂ‚˘‚ā|‘‚­ŒŠ‚‚Ż‚Ä, ‘Ώˆ‚ˇ‚é‚˝‚߂Ɂ|. Šâčr”V (ŹŽ™): •˝Ź30”N“xŔŠÔŽsŹ˜A‹Ś‘ć2‰ńEˆőŒ¤C‰ď (2018/7/20), ŔŠÔ.

732032. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒyƒ‰ƒ“ƒpƒlƒ‹‚ĚŒŒ’†”Z“x‘Ş’č: ĹV‚Ě’mŒŠ. Šâčr”V (ŹŽ™): Epilepsy Internet Live Seminar (2018/7/20), “ú–{‹´.

732033. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒ‹ƒtƒBƒiƒ~ƒh‚đ“ŕ•ž‚ľ‚˝Lennox-GastautÇŒóŒQ‚Ě13—á‚ĚŒŸ“˘`TDM‚Ě‘¤–Ę‚Š‚ç`. Šâčr”V (ŹŽ™): _“ސě‚Ä‚ń‚Š‚ńŽĄ—Ăƒlƒbƒgƒ[ƒN (2018/7/27), ‰Ą•l.

732034. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŠwZ‚É‚¨‚Ż‚é“KŘ‚ȐH•¨ƒAƒŒƒ‹ƒM[EƒAƒiƒtƒBƒ‰ƒLƒV[‘Ήž‚ĚÝ‚č•ű. â“Œ—R‹I (ŹŽ™): –k–{Žs‹łˆçˆĎˆő‰ďŠwZ‹łˆç‰ŰŽĺĂ@H•¨ƒAƒŒƒ‹ƒM[EƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‘ΉžŒ¤C‰ď1 (2018/8/10), –k–{.

732035. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŠwZ‚Ĺ‹N‚Ť‚é‚Ä‚ń‚Š‚ń”­ěŽž‚̑Ήž‚ɂ‚˘‚ā`‚ť‚ĚŽž, ‹łˆő‚Ć‚ľ‚Ä‚Ĺ‚Ť‚é‚ą‚Ć. Šâčr”V (ŹŽ™): “Ą‘ňŽs‹łˆçˆĎˆő‰ďŽĺĂ‹łˆőŒ¤C‰ď (2018/8/17), “Ą‘ň.

732036. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒyƒ‰ƒ“ƒpƒlƒ‹‚ĚŽg—pŒoŒą`ŒŒ’†”Z“x‘Ş’č‚ĚˆÓ‹``. Šâčr”V (ŹŽ™): é“ŒŹŽ™_Œo§˜b‰ď (2018/8/22), ‘ĺă.

732037. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) V‹KR‚Ä‚ń‚Š‚ń–ň‚ĚŽg‚˘•Ş‚Ż`ƒyƒ‰ƒ“ƒpƒlƒ‹‚ĚˆĘ’u•t‚Ż‚ĆŽg‚˘•ű`. Šâčr”V (ŹŽ™): ‘ć3‰ń“š–kŹŽ™_ŒoƒGƒLƒXƒp[ƒgƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2018/9/18), ˆŽě.

732038. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) TDM‚đ“Ľ‚Ü‚Ś‚˝R‚Ä‚ń‚Š‚ń–ň•¨ŽĄ—Á`ƒyƒ‰ƒ“ƒpƒlƒ‹‚ĚˆĘ’u•t‚Ż‚ĆŽg‚˘•ű`. Šâčr”V (ŹŽ™): “Œ‹ž—Ăˆç§˜b‰ď (2018/11/10), ’˛•z.

732039. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒAƒŒƒ‹ƒM[‚ÉŠÖ‚ˇ‚éĹVî•ń. â“Œ—R‹I (ŹŽ™): ƒyƒXƒgƒRƒ“ƒgƒ[ƒ‹‹Ś‰ď‹ZpŒüă•”‰ď (2019/3/19), ‰Y˜a.

733134. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –{–M‚̏ŹŽ™–Ťt‘Ÿ•a (ŹŽ™CKD). Î‘qŒ’Ži (ŹŽ™): ‰Ť“ꏬŽ™t‘Ÿ•aƒtƒH[ƒ‰ƒ€2018 (2018/7/14), ‰Ť“ę.

733135. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘Ť‹ŘˆŢkÇIŒ^‚Ě“űŽ™—á‚ɑ΂ˇ‚éƒkƒVƒlƒ‹ƒZƒ“‚ĚŽg—pŒoŒą. ”’ˆäG’ź1, –ěX“c–L1, “yŠň@•˝1, Šâčr”V1 (1ŹŽ™): ‘ć353‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ސě’n•ű‰ď (2018/9/15), ‰Ą•l.

733136. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 22-24TŽ™‚É‚¨‚Ż‚閝Ť”xŽžŠł‚Ě”­Ç•p“x‚Ɛ_ŒoŠw“I—\Œă‚Ě•Ď‘J: 2003-2012”N‚É‚¨‚Ż‚éŽüŽYŠúVśŽ™ƒlƒbƒgƒ[ƒNƒf[ƒ^ƒx[ƒX‚đ—p‚˘‚˝Œă•űŽ‹“IƒRƒz[ƒgŒ¤‹†. ŽRŒűˆť”T1, çݎ@Šw1, Î“c@Ži1, ‘剪–ƒ—1, ‰ĄŠÖ—Sˆę˜Y1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć31‰ń“ú–{VśŽ™–Ť”xŽžŠłŒ¤‹†‰ď (2018/10/20), é‹Ę.

733137. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) NICU‘މ@Ž™‚̏AŠwó‹ľ. çݎ@Šw (ŹŽ™): ‘Š–ÍŒ´Žs“Á•ĘŽx‰‡‹łˆçŒ¤‹†‰ď (2018/10/22), ‘Š–ÍŒ´.

733138. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) VśŽ™Šú‚ɐf’fE‰Á—Ă‚ľ‚˝ć“VŤŒÇ—§Ťś”x“Ž–ŹŒ‡‘šÇ‚̏pŒăŒo‰ß. ‚—œ@Šw1, ě“cF‘ž1, řw“cšŽq1, âV–؍G•ś1, ›–{Œ’Ži1, çݎ@Šw1, ‹{–{—˛Ži2, ‹{’n@ŠÓ2, ćčG–ž1,3 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć14‰ń_“ŢěŒ§ŹŽ™zŠÂŠíŒ¤‹†‰ď (2018/10/27), ‰Ą•l.

733139. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “–‰@PICU‚É‚¨‚Ż‚鏬Ž™dÇŠłŽŇŒ}‚Ś”Ŕ‘—‚ĚŽŔ‘Ô. •ô”öŒb—œ1, ˆŔ“Ą@Žő1, “c‘ş—C•˝1, Š@L–ç2, ‹ŕŽq’‰O1, ćčG–ž1,3 (1ŹŽ™, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ŹŽ™dÇÇ—ጟ“˘‰ď (2018/11/2), _“ސě.

733140. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “–‰@PICU‚É‚¨‚Ż‚鏬Ž™dÇŠłŽŇŒ}‚Ś”Ŕ‘—‚ĚŽŔ‘Ô. •ô”öŒb—œ1, ˆŔ“Ą@Žő1, “c‘ş—C•˝1, Š@L–ç2, ‹ŕŽq’‰O1, ćčG–ž1,3 (1ŹŽ™, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć354‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2018/11/17), _“ސě.

733141. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚éIgAtÇ‚ĚŽĄ—Ă–@‚ĚŒŸ“˘. ]”gŒËF•ă (ŹŽ™): ‘ć431‰ń‘Š–ÍŒ´ŽsˆăŽt‰ďŹŽ™‰Čˆă‰ď (2018/11/21), ‘Š–ÍŒ´.

733142. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “űŽ™Œ^Ň‘Ť‹ŘˆŢkÇ‚ĚƒkƒVƒlƒ‹ƒZƒ“—Ă–@‚Ć‘Šú”­ŒŠ‚É‚Ţ‚Ż‚Ä. ”’ˆäG’ź (ŹŽ™): ‘ć431‰ń‘Š–ÍŒ´ŽsˆăŽt‰ďŹŽ™‰Čˆă‰ďŒŽ—፧˜b‰ď (2018/11/21), ‘Š–ÍŒ´.

733143. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ěč•a‚É‚¨‚Ż‚é10%ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ťÜ“Š—^Ç—á‚ɂ‚˘‚Ä. –Ř‘şƒl1, X@‘PŽ÷1, â“Œ—R‹I1 (1ŹŽ™): ‘ć10‰ńé‹ĘƒWƒ…ƒjƒAƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2019/1/25), é‹Ę.

733144. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‰Č‚É‚¨‚Ż‚é“Ž•¨‰îÝˆă—Ă, “Ž•¨‚ĚƒAƒŒƒ‹ƒM[‚ɂ‚˘‚Ä. â“Œ—R‹I (ŹŽ™): ˆă—ÎҁEˆă—Ă‹@ŠÖ‰^‰cŽŇ‚Ě‚˝‚߂́u“Ž•¨‰îÝ—Ă–@vuK‰ď (2019/1/26-27), “Œ‹ž.

733145. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚Ä‚ń‚Š‚ń‚ĚˆÚsŠúˆă—Á`ŹŽ™‰Č‚ƐŹl‰Č‚Ě˜AŒg”­“W‚ÉŒü‚Ż‚ā`. Šâčr”V (ŹŽ™): ’šŽć‘ĺŠwEˆăŽt‰ď‹¤Ă ‚Ä‚ń‚Š‚ńƒZƒ~ƒi[ in•ÄŽq`‚ć‚č‚悢f—ÁE˜AŒg‚đ–ÚŽw‚ľ‚ā` (2019/2/7), •ÄŽq.

733146. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒpƒ“ƒP[ƒLƒVƒ“ƒhƒ[ƒ€‚Ě2Ç—á@ƒ_ƒjRŒ´—ʂ̉đÍ. â“Œ—R‹I (ŹŽ™): ‘ć13‰ńé‹ĘƒAƒŒƒ‹ƒM[§˜b‰ď (2019/2/9), é‹Ę.

733147. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‚Ä‚ń‚Š‚ń–ň•¨ŽĄ—Ă‚É‚¨‚Ż‚éV‚˝‚Č‘I‘đŽˆ`ƒrƒ€ƒpƒbƒg҂ւ̊ú‘ҁ`. Šâčr”V (ŹŽ™): ‚Ä‚ń‚Š‚ńwebƒZƒ~ƒi[ (2019/2/27), ˜Z–{–Ř.

733148. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Therapeutic drug monitoring‚ÉŠî‚Ă‚˘‚˝R‚Ä‚ń‚Š‚ń–ň‚ĚŽg‚˘•ű|perampanel‚ĚˆĘ’u‚Ă‚Ż|. Šâčr”V (ŹŽ™): ˆăŽt‰ďŽĺĂ‘˝–€ŹŽ™‚Ä‚ń‚Š‚ńƒZƒ~ƒi[ (2019/3/8), ‘˝–€.

733149. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽŔ—Տ°‚É‚¨–𗧂ĉş‚ł‚˘!@‚Ä‚ń‚Š‚ń–ň•¨ŽĄ—Ă‚É‚¨‚Ż‚éŠî–{‚Ć“¤’mŽŻ. Šâčr”V (ŹŽ™): Epilepsy symposium in Sagamihara (2019/3/19), ‘Š–ÍŒ´.

733150. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽŔ—Տ°‚É‚¨–𗧂Ă­‚ž‚ł‚˘!@‚Ä‚ń‚Š‚ń–ň•¨—Ă–@‚É‚¨‚Ż‚éŠî–{‚Ć“¤’mŽŻ. Šâčr”V (ŹŽ™): _“ŢěŒ§‚Ä‚ń‚Š‚ńˆă—ÁEŽĐ‰ď˜AŒg‹Ś‹c‰ďŽĺĂŽs–ŻŒöŠJuŔ in Ź“cŒ´ (2019/3/24), Ź“cŒ´.

733151. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚ą‚Ç‚ŕ‚Ě‚Ä‚ń‚Š‚ń`“ŕ•žŽĄ—Ă‚Ě‹^–â‚â•sˆŔ‚đ‰đŒˆ‚ˇ‚é‚˝‚߂Ɂ`. Šâčr”V (ŹŽ™): _“ŢěŒ§‚Ä‚ń‚Š‚ńˆă—ÁEŽĐ‰ď˜AŒg‹Ś‹c‰ďŽĺĂŽs–ŻŒöŠJuŔ in Ź“cŒ´ (2019/3/24), Ź“cŒ´.

733152. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰^“ŽŽž‚Ě‹š’É‚Ĺ”­ŒŠ‚ł‚ę‚˝ŹŽ™Šú”­ÇŠĽškŤ‹ˇSÇ‚Ě3—á. ‚—œ@Šw1, âV–؍G•ś1, řw“cšŽq1, –{“c@’1, ›–{Œ’Ži1, X@‘PŽ÷1, ćčG–ž1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć356‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2019/3/30), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H17-522001. [uŔ]y“ÁW: ŹŽ™‚Ě–ň•¨—Ă–@‚ĆTDMzŹŽ™‚ÉŽg—p‚ł‚ę‚éR‚Ä‚ń‚Š‚ń–ň‚ĚŽĄ—Ă“IˆĘ’u‚Ă‚Ż‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. Šâčr”V (ŹŽ™): –ň‹Ç 2006/2; 57 (2): 198-201.

H29-110019. [Œ´’˜] The Effectiveness of Lamotrigine and Its Blood Levels for Pediatric Epilepsy. Iwasaki T1, Toki T1, Nonoda Y1, Ishii M1: Am J Ther 2017/9-10; 24 (5): e524-31. (Šâčr”V1, “yŠň@•˝1, –ěX“c–L1, Îˆäł_1: 1ŹŽ™)

H29-110020. [Œ´’˜] Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Sato M, Kamei K, Ogura M, Ishikura K1, Ito S: Clin Exp Nephrol 2018/2; 22 (1): 110-6. (Î‘qŒ’Ži1: 1ŹŽ™)

H29-110021. [Œ´’˜] Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: A multicenter randomized controlled trial. Morikawa Y1, Miura M1, Furuhata MY1, Morino S1, Omori T1, Otsuka M1, Chiga M1, Obonai T1, Hataya H1, Kaneko T1, Ishikura K1,2, Honda M1, Hasegawa Y1 (1Tokyo Pediatric Clinical Research Network): Pediatr Pulmonol 2018/3; 53 (3): 358-65. (Î‘qŒ’Ži1,2: 2ŹŽ™)

H29-522003. [uŔ]y“ÁWNICUĹ‘Oü: ŒŸ¸‚Š‚玥—ÁEƒPƒA‚Ü‚Ĺ VśŽ™‚̏zŠÂŠíŽžŠł@—\Œă‰ü‘P‚Ěƒvƒ‰ƒXƒƒ“!z(1) –˘nŽ™“Ž–ŹŠÇŠJ‘śÇ (PDA)@Ef’f‚ĆŽĄ—Ă–@‚Ěƒ|ƒCƒ“ƒg. Î“c@Ži (ŹŽ™): NEONATAL CARE 2018/2; 31 (2): 108-13.

H29-522004. [uŔ]y“ÁWNICUĹ‘Oü: ŒŸ¸‚Š‚玥—ÁEƒPƒA‚Ü‚Ĺ VśŽ™‚̏zŠÂŠíŽžŠł@—\Œă‰ü‘P‚Ěƒvƒ‰ƒXƒƒ“!z(1) –˘nŽ™“Ž–ŹŠÇŠJ‘śÇ (PDA)@Ef’f‚ĆŽĄ—Ă–@‚Ěƒ|ƒCƒ“ƒg. Î“c@Ži (ŹŽ™): NEONATAL CARE 2018/2; 31 (2): 108-13.

[’˜@‘]

H27-620001. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚̏ŹŽ™ŽĄ—ĂŽwj (‘ć16”Ĺ)z9. –ƉuŽžŠł, äPŒ´•a@IgAŒŒŠÇ‰Š (Henoch-SchoƒEƒ€ƒ‰ƒEƒgnleinŽ‡”Á•a), p.289-90. â“Œ—R‹I (ŹŽ™), ‘•ŇW: …Œű@‰ë, Žs‹´@Œő, čŽR@O, f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2019/9”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

H28-723001. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť‚Ä‚ń‚Š‚ńŠłŽ™‚¨‚ć‚ŃŽá”NŠłŽŇ‚É‚¨‚Ż‚éclobazam”A’†”Z“x‚ÉŠî‚Ă‚­•âł’l‚Ě—L—pŤ. Šâčr”V1, –ěX“c–L1, “yŠň@•˝1, Î“c—Ď–ç, ”’ˆäGK, Îˆäł_1 (1ŹŽ™): ‘ć50‰ń“ú–{‚Ä‚ń‚Š‚ńŠw‰ďŠwpW‰ď (2016/10/7-9), Ă‰Ş.

H29-723009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‚É‚Ý‚ç‚ę‚銴őÇ‚Š‚琏l‚É‚ŕœëŠł‚ˇ‚銴őÇ‚Ö: Œťó‚Ć—\–h‘΍ô‚đl‚Ś‚é. â“Œ—R‹I (ŹŽ™): ‰@“ੴő‘΍ô‹łˆçu‰‰‰ď (2018/1/12), –k–{.

H29-723010. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™ƒŠƒEƒ}ƒ`ŤŽžŠłŠłŽ™‚É‚¨‚Ż‚郁ƒgƒgƒŒƒLƒT[ƒg‚Ě•›ě—p’˛¸‚¨‚ć‚Ń—tŽ_ťÜ‚Ě—\–hŒř‰Ę‚ĚŒŸ“˘. ŒÎé—R‰Ŕ, ˜lŠÔ—œŒb, —é–Ř–G‰Ä, Ô‰HŽO‹M, Ź–¸‰ë•v, ˆÉ“ĄGˆę, Î‘qŒ’Ži1, Îě—mˆę (1ŹŽ™): “ú–{–ňŠw‰ď‘ć138”N‰ď (2018/3/25-28), ‹ŕ‘ň.

ŽY‰ČŠw^•wl‰ČŠw

[Šwp˜_•ś]

110258. [Œ´’˜] A Yolk Sac Larger Than 5 mm Suggests an Abnormal Fetal Karyotype, Whereas an Absent Embryo Indicates a Normal Fetal Karyotype. Yoneda S, Shiozaki A, Yoneda N, Sameshima A, Ito M, Shima T, Nakashima A, Yoshino O1,2, Kigawa M, Takamori R, Shinagawa Y, Saito S: J Ultrasound Med 2018/5; 37 (5): 1233-41. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

110259. [Œ´’˜] CD11c+ M1-like macrophages (Mƒłs) but not CD206+ M2-like Mƒł are involved in folliculogenesis in mice ovary. Ono Y, Nagai M, Yoshino O1,2, Koga K3 Nawaz A, Hatta H, Nishizono H, Izumi G, Nakashima A, Imura J, Tobe K, Fujii T, Osuga Y, Saito S: Sci Rep 2018/5; 8 (1): 8171. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

110260. [Œ´’˜] The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan. Mikami M, Ikeda M, Sato H1, Iwase H1, Enomoto T, Kobayashi Y, Katabuchi H: J Gynecol Oncol 2018/7; 29 (4): e46. (˛“Ą‰p‹M1, ŠâŁtŽq1: 1•wl)

110261. [Œ´’˜] Usefulness of labor induction in pregnancies complicated by preeclampsia. Kawano S1, Kato R2, Okutomi T3, Ohnishi Y1, Kanai Y1, Mochizuki J1, Amano K1, Unno N1: Kitasato Med J 2018/9; 48 (2): 88-95. (‰Í–ěĆŽq1, ‰Á“Ą—˘ŠG2, ‰œ•xr”V3, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, “V–ě@ŠŽ1, ŠC–ěM–ç1: 1ŽY‰Č, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3–ƒŒ)

110262. [Œ´’˜] 17OHP-C in patients with spontaneous preterm labor and intact membranes: is there an effect according to the presence of intra-amniotic inflammation? Yoneda S, Yoneda N, Shiozaki A, Yoshino O1,2, Ueno T, Niimi H, Kitajima I, Tamura K, Kawasaki Y, Makimoto M, Yoshida T, Saito S: Am J Reprod Immunol 2018/9; 80 (3): e12867. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

110263. [Œ´’˜] The Clinical Features of Recurrent Endometrial Cancer in Japan: Chemotherapy Instead of Radiotherapy as Postoperative Adjuvant Treatment. Iwase H1, Furukawa S1, Hirasawa T, Asai S, Ohara T, Hosonuma S, Endo S1, Tazo Y1, Sato H1, Takada T1, Arai M1, Ikeda M, Shida M, Yoshioka N, Tozawa-Ono A, Suzuki N, Mikami M, Onda T1: Int J Gynecol Cance. 2018/10; 28 (8): 1616-23. (ŠâŁtŽq1, ŒĂěł‹`1, ‰““Ą^ˆę1, “cŽG—L‹I1, ˛“Ą‰p‹M1, ‚“c‹ąb1, VˆäłG1, ‰ś“c‹MŽu1: 1•wl)

110264. [Œ´’˜] Trophoblast-Specific Conditional Atg7 Knockout Mice Develop Gestational Hypertension. Aoki A, Nakashima A, Kusabiraki T, Ono Y, Yoshino O1,2, Muto M, Kumasawa K, Yoshimori T, Ikawa M, Saito S: Am J Pathol 2018/11; 188 (11): 2474-86. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

120014. [Œ´’˜] ”S‰tŤ—‘‘ƒŽîᇂɂ¨‚Ż‚éRac•sŠˆ‰ťˆöŽqFilGAP”­Œť‚Ć—\Œă‚Ć‚ĚŠÖ˜A‚ĚŒŸ“˘. ˛“ĄŠG—“Ţ1, ŽOŽ}@M2, ‹´‘ş”ü‹I3, Œ´@“ÖŽq2, ‰““Ą^ˆę4, ŒĂěł‹`4, “cŽG—L‹I4, ‚“c‹ąb4, VˆäłG4, ŠâŁtŽq4, ‘ž“cˆŔ—˛5, ‰ś“c‹MŽu4 (1•a‘ԁEf—ĂŒn, 2•a—, 3Œ`‘ÔŒn, 4•wl, 5—Šw•”): –k—˘ˆăŠw 2018/12; 48 (2): 121-9.

120015. [Œ´’˜] •˝Ź29”N“x@_“ސěŽY‰Č•wl‰ČŠw‰ď@•wl‰ČˆŤŤŽîᇓo˜^WŒv•ń. Ŕč—ߎq, ‹g“c@_, ˛“Ą”ü‹IŽq, ™‰Y@ŒŤ, ‘ĺŒ´@Ž÷, ‚“c‹ąb1, Vˆä@“w1, –Ř”ŇvŽœ, ˛X–؍N, •ÄŽR„ˆę, —с@NŽq, •˝ŕV@–Ň, X‰Ş@Š˛, ˆéč‘žˆę, “n粖LŽĄ, ŽOăŠ˛’j, ‰Á“Ą‹vˇ, ’†–ěáÁ˛’j, ŠC–ěM–ç2, ‚‹´P’j (1•wl, 2ŽY‰Č): _“ސěŽY‰Č•wl‰ČŠw‰ďŽ 2019/2; 55 (2): 16-23.

310024. [Ç—á•ń] Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments. Yoshino O1,2, Minamisaka T, Ono Y, Tsuda S, Samejima A, Shima T, Nakashima A, Koga K, Osuga Y, Saito S: J Obstet Gynaecol Res 2018/9; 44 (9): 1850-8. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

320024. [Ç—á•ń] D’†‹…‘‘˝‚đŒ_‹@‚Ć‚ľ‚Đf’f‚ÉŽŠ‚Á‚˝G-CSFŽYśŽq‹{čň•”‘BŠŕ‚Ě1Ç—á. ˛“Ą‰p‹M1, ŠâŁtŽq1, ‰““Ą^ˆę1, ŒĂěł‹`1, “cŽG—L‹I1, ‚“c‹ąb1, VˆäłG1, ‰ś“c‹MŽu1 (1•wl): “ú–{•wl‰ČŽîᇊw‰ďŽGŽ 2019/1; 37 (1): 9-17.

521008. [‰đŕ]y–ł’É•Ş•Ř‚ÉŠÖ‚ˇ‚éŒúś˜J“­ČŒ¤‹†”Ç’ńŒž‚ɂ‚˘‚āz“ú–{ŽY‰Č–ƒŒŠw‰ď@–ł’É•Ş•Ř‚ĚˆŔ‘SŤŠm•Ű‚Ě‚˝‚ß‚ĚŠˆ“Ž‚ÉŠÖ‚ˇ‚é•ń. ŠC–ěM–ç (ŽY‰Č): •Ş•Ř‚Ć–ƒŒ 2018/11; 100: 1-7.

522081. [uŔ]y“ÁW: —ŤƒAƒXƒŠ[ƒg‚Ěƒwƒ‹ƒXƒPƒAz—ŤƒAƒXƒŠ[ƒg‚Ě”DP‚ÉŠÖ‚ˇ‚鏔–â‘č. ”\Ł‚ł‚â‚Š, ‹g–ě@C1,2: (1ŽY‰Č, 2•wl): ŽY‰Č‚Ć•wl‰Č 2018/4; 85 (4): 449-53.

522082. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€: ŽY•wl‰Č—Ěˆć‚É‚¨‚Ż‚éˆă—ĂˆŔ‘S (•˝Ź29”N“x‰Ć‘°Œv‰ćE•ę‘Ě•ŰŒě–@Žw“ąŽŇuK‰ď)zŽY‰Č–ƒŒ‚É‚¨‚Ż‚éˆă—ĂˆŔ‘S. ŠC–ěM–ç (ŽY‰Č): “ú–{ˆăŽt‰ďŽGŽ 2018/5; 147 (2): 325-8.

522083. [uŔ]y“ÁW: •wl‰Č‚Ş‚ń|Œ¤‹†E—Տ°‚̐V“WŠJz[—‘‘ƒŠŕE—‘ŠÇŠŕE• –ŒŠŕ]@ă”琍—‘‘ƒŠŕE—‘ŠÇŠŕE• –ŒŠŕ: Žčp—Ă–@‚Ěƒ^ƒCƒ~ƒ“ƒO. ‰ś“c‹MŽu (•wl): ˆăŠw‚Ě‚ ‚ä‚Ý 2018/7; 266 (1): 102-7.

522084. [uŔ]yCurrent Organ Topics: Gynecologic Cancer •wl‰ČŠŕ •wl‰ČŠŕ‚ĚŽčp—Ă–@zII. —‘‘ƒŠŕ‰‰ńŽĄ—Ă‚É‚¨‚Ż‚éPDS‘ÎNAC-IDS‚Ě”äŠr. ‰ś“c‹MŽu (•wl): Šŕ‚ƉťŠw—Ă–@ 2019/2; 46 (2): 236-9.

522085. [uŔ]y“ÁW: —‘‘ƒ‚Ş‚ńŞˆł‚Ö‚Ěƒ}ƒCƒ‹ƒXƒg[ƒ“z2. —‘‘ƒ‚Ş‚ń‰‰ń‰ťŠw—Ă–@‚ÉŠÖ‚ˇ‚é—Տ°ŽŽŒą. ‰ś“c‹MŽu (•wl): ŽY•wl‰Č‚ĚŽŔŰ 2019/3; 68 (3): 249-55.

530008. [‚ť‚Ě‘ź (Correspondence)] Unpaid doctors in Japanese university hospitals. Shibuya K, Unno N1: Lancet 2019/3; 393: 1096-7. (ŠC–ěM–ç1: 1ŽY‰Č)

[’˜@‘]

620087. [Šwp‘ (•Ş’SŽˇ•M)]yŽŔ‘H —Տ°śB–ƉuŠwzII Še˜_@1. —Ť•s”DÇEART‚ƖƉu@2. —‘–E”­ˆç‚Ć”r—‘, p.150-5. ‹g–ě@C1,2, Ź–ě—m•ă, âV“Ą@Ž  (1ŽY‰Č, 2•wl), •Ň: ŽÄŒ´_Í, ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2018/5”­s.

620088. [Šwp‘ (•ŇW)]yV‘ĚŒn ŠĹŒěŠw‘S‘@Žž•a‚̐Ź‚č—§‚ż‚Ɖń•œ‚Ě‘Łi@Žž•a‚ĆŽĄ—Á@tE”ĺ”AŠí/—ŤśBŠíz•Ň: “z“cŒ´‹I‹v—Y, —v@L–ç, ‰ś“c‹MŽu1 (1•wl), ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽĐ, “Œ‹ž, 2018/11”­s.

620089. [Šwp‘ (•ŇW)]yV‘ĚŒn ŠĹŒěŠw‘S‘@ę–ĺ•Ş–ěII ŹlŠĹŒěŠw@—ŤśBŠíz•Ň: ‰ś“c‹MŽu1, ’|‘ş’őŽq (1•wl), ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽĐ, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713116. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) An etiology of endometriosis, from the point of autonomic nerve system. Yoshino O1,2, Kobayashi M, Osuga Y, Saito S: 4th Congress of the Society of Endometriosis and Uterine Disorders (2018/4/26), Italy. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

713117. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. Onda, T1, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Takehara K, Miyamoto K, Wakabayashi M, Okamoto A, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Omatsu K, Watanabe Y, Yamamoto K, Yaegashi N, Kamura T, Yoshikawa H: American Society of Clinical Oncology Annual meeting (ASCO 2018) (2018/6/1-5), Chicago, USA. (‰ś“c‹MŽu1: 1•wl)

713118. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311). Kitagawa R, Ishikawa M, Shibata T, Miyamoto K, Kobayashi H, Onda T1, Takekuma M, Takahashi F, Yokota H, Tanikawa M, Mizuno M, Oishi T, Aoki Y, Nishio S, Iwata T, Yaegashi N: American Society of Clinical Oncology Annual meeting (ASCO 2018) (2018/6/1-5), Chicago, USA. (‰ś“c‹MŽu1: 1•wl)

713119. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) A case of uterine endometrial clear cell carcinoma (CCC) occurred 10 years after concurrent chemoradiotherapy (CCRT) for uterine cervical cancer. Tazo Y1, Iwase H1, Endo S1, Furukawa S1, Takada T1, Arai M1, Onda T1: 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) (2018/9/14-16), Kyoto, Japan. (“cŽG—L‹I1, ŠâŁtŽq1, ‰““Ą^ˆę1, ŒĂěł‹`1, ‚“c‹ąb1, VˆäłG1, ‰ś“c‹MŽu1: 1•wl)

713120. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) Clinical features of patients with brain metastases from gynecologic malignancies. Furukawa S1, Iwase H1, Endo S1, Tazo Y1, Sato H1, Takada T1, Arai M1, Onda T1: 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) (2018/9/14-16), Kyoto, Japan. (ŒĂěł‹`1, ŠâŁtŽq1, ‰““Ą^ˆę1, “cŽG—L‹I1, ˛“Ą‰p‹M1, ‚“c‹ąb1, VˆäłG1, ‰ś“c‹MŽu1: 1•wl)

722093. [Šw‰ď (‘S‘)] (Šw‰ď§—ăÜ“Á•Ęu‰‰) ƒzƒ‹ƒ‚ƒ“‚É‚ć‚čI–­‚ɐ§Œä‚ł‚ę‚鐜BŒťŰ‚É–Ł‚š‚ç‚ę‚Ä. ‹g–ě@C1,2: (1ŽY‰Č, 2•wl): : ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/12), ĺ‘ä.

722094. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ĐŠQŽžŹŽ™ŽüŽYŠúƒŠƒGƒ]ƒ“‚Ě–đŠ„. ŠC–ěM–ç (ŽY‰Č): ‘ć45‰ń“ú–{ŽY•wl‰Čˆă‰ďŠwpW‰ď (2018/10/7), ‘ĺă.

722095. [Šw‰ď (‘S‘)] (Žs–ŻŒöŠJuŔ) ˆŔ‘S‚ĹˆŔS‚Č–ł’É•Ş•Ř‚Ě•‹y‚Ě‚˝‚ß‚É. ŠC–ěM–ç (ŽY‰Č): ‘ć122‰ń“ú–{ŽY‰Č–ƒŒŠw‰ďŠwpW‰ďƒTƒeƒ‰ƒCƒgŠé‰ć@Žs–ŻŒöŠJuŔ (2018/11/4), ‰Ą•l.

722096. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ˆăŽt‚Ě“­‚Ť•ű‰üŠv‚ĆŽüŽYŠúˆă—Ă. ŠC–ěM–ç (ŽY‰Č): ‘ć63‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2018/11/22), “Œ‹ž.

722097. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žq‹{“ŕ–ŒÇŠłŽŇ‚Ě’°“ŕ×‹Ű‘p‚ł͐§ŒäŤT×–E—U“ą‚ɏd—v‚Č—Ž_ŽYś‹Ű‚ŞŒ¸Žă‚ľ‚Ä‚˘‚é. ‹g–ě@C1,2, ŽR“c‘ńŽi, ŽÂŽR@Œ’, Ź–ě—m•ă, ˆÉ“Œ‰ë”ü, Ź—с@–r, âV“Ą@Ž  (1ŽY‰Č, 2•wl): ‘ć40‰ń“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ďŠwpu‰‰‰ď (2019/1/20), “Œ‹ž.

723502. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ”DP‰Šú‚É‚¨‚Ż‚éregular (intact) hCG, hCGƒŔƒTƒuƒ†ƒjƒbƒg‘Ş’č‚ĚˆÓ‹`. Šâ’[r•ă1, ě“ŕ”Žl1, –{“c‰ëŽq2, ‰ş“c—˛m1, ‰ś“c‹MŽu1, ŠC–ěM–ç3 (1•wl, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŽY‰Č): ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/12), ĺ‘ä.

723503. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) —U”­–ƒŒ•Ş•Ř‚đs‚Á‚˝‘o‘Ů”DPÇ—á‚Ě•Ş•Ř“]‹A‚ÉŠÖ‚ˇ‚錟“˘. ’†‹ŕ˜NŽq1, –]ŒŽƒŽq1, ‹g‘ş‰ĂL1, •ž•”‹żŽq1, ŠÖŒű˜aŠé1, źŕVW‘ă1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/12), ĺ‘ä.

723504. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) –{–M‚É‚¨‚Ż‚鍂—î•wl‰ČˆŤŤŽîᇂɑ΂ˇ‚鎥—Ă‚ĚŽŔ‘Ô‚đ–ž‚ç‚Š‚É‚ˇ‚é‚˝‚ß‚ĚƒAƒ“ƒP[ƒg’˛¸ (Japan Clinical Oncology Group (JCOG) •wl‰ČŽîᇃOƒ‹[ƒv). ‰ˇňě^—R, ‰ś“c‹MŽu1, ŽO‹´@‹Ĺ, źŒł@—˛, ‰Ť@–ž“T, “ż‰i‰pŽ÷, ŕVč@—˛, ‚–ě_–M, “c‘ă_“ż, ŽRŒű@‘, –ě‘şOs, Ž›”ö‘׋v, ‹e’r@˜N, Ž­“‡‘ĺ–ő, ‰Ş—Ż‰ë•v, “n—˜‰p“š, ”nę@’ˇ, ”ސ™—˜ŽĄ, Ÿ–“”Í”V, ‹“ˆŒöś, ÎěŒő–ç, ”ޏdŠ~Lś (1•wl): ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/12), ĺ‘ä.

723505. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) —U”­–ł’É•Ş•Ř‚Ě•Ş•Ř‘ć1Šú‚É‚¨‚Ż‚éƒIƒLƒVƒgƒVƒ“‚Ě“Š—^—Ę‚Ć•Ş•Ř“]‹A. –]ŒŽƒŽq1, ‹ŕˆä—Y“ń1, ‘吟—fŽq1, ŠÖŒű˜aŠé1, źŕVW‘ă1, ’†‹ŕ˜NŽq1, Îě—˛ŽO1, ‹g‘ş‰ĂL1, •ž•”‹żŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/13), ĺ‘ä.

723506. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ‘ĺ‹K–͐kĐ”­śŽž‚É‚¨‚Ż‚éŽüŽYŠú•ęŽqˆă—ĂƒZƒ“ƒ^[‚Ě‹Ć–ąŒp‘ąŒv‰ć (BCP) ěŹ‚ÉŒü‚Ż‚˝“–‰@‚ĚŽć‚č‘g‚Ý. •ž•”‹żŽq1, –]ŒŽƒŽq1, ’†‹ŕ˜NŽq1, źŕVW‘ă1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć70‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/5/13), ĺ‘ä.

723507. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ŒŒŠÇŤ•‚Žî‚𔺂¤ƒRƒŠƒ“Ťĺ@–ƒ]‡•š”DP‚ĚŽüŽYŠúŠÇ—. ’†‹ŕ˜NŽq1, ‹g‘ş‰ĂL1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć54‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2018/7/8), “Œ‹ž.

723508. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) “œ”A•a‡•š”D•w‚Ě”DP‘OŒŒ“œŠÇ—‚ĚŽŔ‘Ô. –]ŒŽƒŽq1, ‘吟—fŽq1, çݎ@Šw2, ŽRŒűˆť”T2, ‘剪–ƒ—2, ‹g‘ş‰ĂL1, ’†‹ŕ˜NŽq1, źŕVW‘ă1, ŠÖŒű˜aŠé1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č, 2ŹŽ™): ‘ć54‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2018/7/8), “Œ‹ž.

723509. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Žq‹{‘ĚŠŕ• o‹žŽčpŒă‚ĚäNă÷‹žŒŸ¸Žž‚É‹ô‘RäNă÷Šŕ‚Ş”­ŒŠ‚ł‚ę‚˝ˆęÇ—á. ŒĂěł‹`1,2, ’†‘şŠîŠ°1,2, HŽRŠG—˘Žq1, ÎˆäŠG从q1,3, ˆÉ“ĄŽŔ1, Ş’ÍK•ä1,3, ‹v“ˆ‘Ľs1, ŽO–Ř–ž“ż1,3 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2•wl, 3ŽY‰Č): ‘ć58‰ń“ú–{ŽY‰Č•wl‰Č“ŕŽ‹‹žŠw‰ďŠwpu‰‰‰ď (2018/8/4), “‡Ş.

723510. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚éˆŮŠŤ”DPÇ—á‚ĚŒŸ“˘. ’†‘şŠîŠ°1,2, ź“‡ƒˆę1, ˆÉ“ĄŽŔ1, HŽRŠG—˘Žq1, ŒĂěł‹`1,2, ÎˆäŠG从q1,3, Ş’ÍK•ä1,3, ŽO–Ř–ž“ż1,3 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2•wl, 3ŽY‰Č): ‘ć58‰ń“ú–{ŽY‰Č•wl‰Č“ŕŽ‹‹žŠw‰ďŠwpu‰‰‰ď (2018/8/4), “‡Ş.

723511. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒŽîá‡‚ĆŠÓ•Ę‚Ş˘“ď‚Ĺ‚ ‚Á‚˝Œă• –ŒŽîá‡. Ş’ÍK•ä1,2, ’†‘şŠîŠ°1,3, ź“‡ƒˆę1, ˆÉ“ĄŽŔ1, HŽRŠG—˘Žq1, ŒĂěł‹`1,3, ÎˆäŠG从q1,2, ŽO–Ř–ž“ż1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ŽY‰Č, 3•wl): ‘ć58‰ń“ú–{ŽY‰Č•wl‰Č“ŕŽ‹‹žŠw‰ďŠwpu‰‰‰ď (2018/8/4), “‡Ş.

723512. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ”DP’†‚ÉŽlŽˆ’Zk‚Ć’Z˜]œ‚Ɛt”A˜HŒnˆŮí‚đ’ć‚ľ,ośŒă‚ÉJeuneÇŒóŒQ‚Ɛf’f‚ľ‚˝ˆę—á. ‹g‘ş‰ĂL1, –]ŒŽƒŽq1, ŠÝ–{—mŽq, ‘吟—fŽq1, r–؏Ž”ü, ŠC–ěM–ç1, ‰E“c‰¤‰î, `Œ’ˆę˜Y, ‚“cŽj’j2 (1ŽY‰Č, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć63‰ń‘ĺ‰ď (2018/10/12), ‰Ą•l.

723513. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) –ł’É•Ş•Ř‚ĚˆŔ‘SŤŒüă‚Ě‚˝‚ß‚É –ł’É•Ş•ŘŽćˆľŽ{Ý‚É‹‚ß‚ç‚ę‚é‚ą‚Ɓ|u–ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ďv‚Ě”­‘Ť‚ÉŰ‚ľ‚ā|. ŠC–ěM–ç (ŽY‰Č): ‘ć122‰ń“ú–{ŽY‰Č–ƒŒŠw‰ďŠwpW‰ď (2018/11/23), •lź.

723514. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žq‹{“ŕ–ŒÇ‚Ć‘ŽY. ‹g–ě@C1,2 (1ŽY‰Č, 2•wl): ‘ć40‰ń“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ďŠwpu‰‰‰ď (2019/1/19), “Œ‹ž.

723515. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ‘ĺ‹K–͐kĐ‚É”ő‚Ś‚˝’nˆćŽüŽYŠúˆă—Ñ̐§Ž”ő‚ĚŒŸ“˘. •ž•”‹żŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć24‰ń“ú–{ĐŠQˆăŠw‰ď‘‰ďEŠwpW‰ď (2019/3/18), •ÄŽq.

731043. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –ł’É•Ş•Ř‚ĚˆŔ‘S‘΍ôˆŔ‘SŠÇ—‘̐§‚̍\’z‚ÉŒü‚Ż‚Ä. ŠC–ěM–ç (ŽY‰Č): ‘ć3‰ń_“ސ얳’É•Ş•ŘŒ¤‹†‰ď (2018/5/31), ‰Ą•l.

731044. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆăŽt‚Ě“­‚Ť•ű‰üŠv‚Ć’nˆć•Ş•ŘŠÂ‹Ť‚ĚŠm•Ű. ŠC–ěM–ç (ŽY‰Č): ‘ć6‰ńVŠƒŒ§ƒyƒŠƒlƒCƒ^ƒ‹Œ¤‹†‰ď (2018/6/9), VŠƒ.

732040. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľăٍu‰‰) Žq‹{‹ŘŽîEŽq‹{‘B‹ŘÇŽĄ—Ă‚Ö‚ĚƒXƒgƒ‰ƒeƒW[. ‹g–ě@C1,2 (1ŽY‰Č, 2•wl): –kMŽY•wl‰Čˆă‰ď (2019/1/24), ’ˇ–ě.

732041. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žs–ŻŒöŠJuŔ) –ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ď (JALA) ”­‘Ť‚Ü‚Ĺ‚ĚŒoˆÜ‚Ć”­‘ŤŒă‚ĚŠˆ“Ž. ŠC–ěM–ç (ŽY‰Č): –ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ď@Žs–ŻŒöŠJuŔ|–ł’É•Ş•Ř‚ĚˆŔ‘SŤŒüă‚Ě‚˝‚߂Ɂ| (2019/3/24), “Œ‹ž.

732042. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žs–ŻŒöŠJuŔ) –ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ď (JALA) î•ńŒöŠJ•Ş‰Č‰ď Šˆ“Ž•ń. ŠC–ěM–ç (ŽY‰Č): –ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ď@Žs–ŻŒöŠJuŔ|–ł’É•Ş•Ř‚ĚˆŔ‘SŤŒüă‚Ě‚˝‚߂Ɂ| (2019/3/24), “Œ‹ž.

733153. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) 2017”N“x•ę‘Ě”Ŕ‘—ó‹ľ•ń. ‘吟—fŽq (ŽY‰Č): Œ§‰›E–k‘ŠŽüŽYŠú‹~‹}ŒŸ“˘‰ď (2018/5/24), ‘Š–ÍŒ´.

733154. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŒŒŤ—r…‚đ”F‚ß‹Ů‹}’鉤ŘŠJp‚đs‚Á‚˝ˆę—á. ‰Ş–ě‚Ý‚¸‚Ť, ’ˇ“ě‹LŽuŽq, ě’[–[ŠG, ’†‹ŕ˜NŽq1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć51‰ń“ú–{•Ş•ŘŠÄŽ‹Œ¤‹†‰ď (2018/6/2), “Œ‹ž.

733155. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) —ŹŽYŽčp‚̏p‘OŒŸ¸‚đŒ_‹@‚ÉTAFROÇŒóŒQ‚̐f’f‚ÉŽŠ‚Á‚˝1—á. ŽRč@—D1, źŕVW‘ă1, ź“‡ƒˆę1, ‹g‘ş‰ĂL1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć135‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/6/17), “Œ‹ž.

733156. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽY‰Č‘ĺ—ʏoŒŒ‚ɑ΂ˇ‚éƒtƒBƒuƒŠƒmƒQƒ“ťÜ‚ĚŽg—pŒoŒą. ŒÜ\”¨mŽu1, ‘吟—fŽq1, ‹g‘ş‰ĂL1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć379‰ńŽl…‰ď (2018/6/27), “Œ‹ž.

733157. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”DP‰Šú‚ɐ[•”Ă–ŹŒŒđÇ‚đ”­Ç‚ľ‚˝5Ç—á‚Ě—Ő°”wŒi. Ź“‡@ˆč1, ‘吟—fŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ’†‹ŕ˜NŽq1, •ž•”‹żŽq1, ‹g‘ş‰ĂL1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć422‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/7/7), ‰Ą•l.

733158. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽYŒăoŒŒ‚Ĺ”Ŕ‘—‚ł‚ę‚˝Ç—á‚ÉŠÖ‚ˇ‚錟“˘. ŒÜ\”¨mŽu1, ‘吟—fŽq1, ‹g‘ş‰ĂL1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć422‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/7/7), ‰Ą•l.

733159. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) _“ŢěŒ§ŽY‰Č•wl‰Čˆă‰ď ăO–ѐŤŽžŠł“o˜^Ž–‹Ć WŒv•ń. ˛X–؍N, ‘ĺŒ´@Ž÷, Vˆä@“w1, ˆéč‘žˆę, –Ř”ŇvŽœ, –Γc”Žs, ™‰Y@ŒŤ, ‚“c‹ąb1, ’‡‘ňŒo•v, Ŕč—ߎq, —с@NŽq, •˝ŕV@–Ň, ‹{é‰xŽq, X‰Ş@Š˛, •ÄŽR„ˆę, “n糖LŽĄ, ‰Á“Ą‹vˇ, ŽOăŠ˛’j, ’†–ěáÁ˛’j, ŠC–ěM–ç2, ‚‹´P’j (1•wl, 2ŽY‰Č): ‘ć422‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/7/7), ‰Ą•l.

733160. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) •˝Ź29”N“x _“ސěŽY‰Č•wl‰ČŠw‰ď •wl‰ČˆŤŤŽîᇓo˜^WŒv•ń. Ŕč—ߎq, ‹g“c@_, ˛“Ą”ü‹IŽq, ™‰Y@ŒŤ, ‘ĺŒ´@Ž÷, ‚“c‹ąb1, Vˆä@“w1, –Ř”ŇvŽœ, ˛X–؍N, •ÄŽR„ˆę, —с@NŽq, •˝ŕV@–Ň, X‰Ş@Š˛, ˆéč‘žˆę, “n粖LŽĄ, ŽOăŠ˛’j, ‰Á“Ą‹vˇ, ’†–ěáÁ˛’j, ŠC–ěM–ç2, ‚‹´P’j (1•wl, 2ŽY‰Č): ‘ć422‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/7/7), ‰Ą•l.

733161. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”~“ō‡•š”DP‚Ě3—á. ź“‡ƒˆę1, HŽRŠG—˘Žq1, ’†‘şŠîŠ°1,2, ÎˆäŠG从q1,3, Ş’ÍK•ä1,3, ‹v“‡‘Ľs1, ŽO–Ř–ž“ż1,3 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2•wl, 3ŽY‰Č): ‘ć93‰ńé‹ĘŽY‰Č•wl‰ČŠw‰ďŠwpW‰ď (2018/7/7), é‹Ę.

733162. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ˆăŽt‚Ě“­‚Ť•ű‰üŠv ŒŸ“˘‚ĚŒťó. ŠC–ěM–ç (ŽY‰Č): ‘ć38‰ńˆă—Ă‚đl‚Ś‚éˆăŠwŽŇ‰ď‹c (2018/7/29), ‰Ą•l.

733163. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –ł’É•Ş•Ř‚ĚˆŔ‘SŤŠm•Ű‚Ě•űô‚ɂ‚˘‚Ä. ŠC–ěM–ç (ŽY‰Č): •˝Ź30”N“x‘ć1‰ń‹{čŒ§ˆăŽt‰ď•ę‘Ě•ŰŒě–@Žw’čˆăŽtŒ¤C‰ď (2018/8/18), ‹{č.

733164. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘O˜riN—Ö‚đ’ć‚ľ‚˝—r–ŒőÇŒóŒQ‚Ě1—á. ŽÄ–؏r•˝1, ‹g‘ş‰ĂL2, ‘吟—fŽq2, Îě—˛ŽO2, ŠÖŒű˜aŠé2, ’†‹ŕ˜NŽq2, •ž•”‹żŽq2, ‹ŕˆä—Y“ń2, –]ŒŽƒŽq2, ŠC–ěM–ç2 (1Œ¤Cˆă, 2ŽY‰Č): ‘ć423‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/9/1), ěč.

733165. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) oś‘Of’f‚ł‚ę‚˝ę‹Œaƒwƒ‹ƒjƒA‚Ěˆę—á. ‹g‘ş‰ĂL1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ’†‹ŕ˜NŽq1, źŕVW‘ă1, –]ŒŽƒŽq1, ŠC–ěM–ç1 (1ŽY‰Č): “ú–{’´‰š”gˆăŠw‰ď ‘ć30‰ńŠÖ“ŒbM‰z’n•ű‰ďŠwpW‰ď (2018/10/27), “Œ‹ž.

733166. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ŽY•wl‰Čˆă‚Ě“­‚Ť•ű‰üŠv. ŠC–ěM–ç (ŽY‰Č): ‹ž“sŽüŽYŠúƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2018/11/10), ‹ž“s.

733167. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é“ŕŽ‹‹žŽ‹‰şŽčp‚ĚŒŸ“˘. ’†‘şŠîŠ°1,2, Ş’ÍK•ä1,3, HŽRŠG—˘Žq1, ÎˆäŠG从q1,3, ‹v“ˆ‘Ľs1, ŽO–Ř–ž“ż1,3 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2•wl, 3ŽY‰Č): ‘ć94‰ńé‹ĘŽY‰Č•wl‰ČŠw‰ďEé‹ĘŒ§ŽY•wl‰Čˆă‰ď•˝Ź 30 ”N“xŒăŠúŠwpW‰ď (2018/11/10), ‚ł‚˘‚˝‚Ü.

733168. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠO‰A•”•a•Ď‚đŒ_‹@‚É”­ŒŠ‚ł‚ę‚˝”~“Ĺ‚Ěˆę—á. –L“cš”ü1, ŠâŁtŽq2, ‰““Ą^ˆę2, “cŽG—L‹I2, ‚“c‹ąb2, VˆäłG2, ‰ś“c‹MŽu2 (1Œ¤Cˆă, 2•wl): ‘ć424‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/11/11), •˝’Ë.

733169. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆŤŤ“]‰ť‚𔺂¤—‘‘ƒŹnŠďŒ`Ží‚Ě2—á. ŸNˆä@—v1, VˆäłG2, ‰““Ą^ˆę2, “cŽG—L‹I2, ‚“c‹ąb2, ŠâŁtŽq2, ‰ś“c‹MŽu2 (1Œ¤Cˆă, 2•wl): ‘ć424‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2018/11/11), •˝’Ë.

733170. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ŠŽ‘S’†ŠuŽq‹{‚̉E‘¤Žq‹{‚É”­ś‚ľ‚˝Žq‹{‘ĚŠŕ‚Ěˆę—á. ˆ˘•”@‰1, “cŽG—L‹I1, ˆÉ“ĄŽŔ1, ‰““Ą^ˆę1, ‚“c‹ąb1, VˆäłG1, ŠâŁtŽq1, ‰ś“c‹MŽu1 (1•wl): ‘ć136‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď ‘‰ďEŠwpW‰ď (2018/11/24), “Œ‹ž.

733171. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) “řĘ“]ˆÚ‚đ”F‚ß‚˝—‘‘ƒŠŕ“÷Žî‚Ěˆę—á. ŁŒËšŒŽ1, “cŽG—L‹I2, ˆÉ“ĄŽŔ2, ‰““Ą^ˆę2, ‚“c‹ąb2, VˆäłG2, ŠâŁtŽq2, ‰ś“c‹MŽu2 (1Œ¤Cˆă, 2•wl): ‘ć136‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď ‘‰ďEŠwpW‰ď (2018/11/24), “Œ‹ž.

733172. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) “–‰@‚ĹŒoŒą‚ľ‚˝ăO–ѐŤŽžŠł11—á‚ĚŒŸ“˘. ŒÜ“‡—T”V1, ÎˆäŠG从q1,2, HŽRŠG—˘Žq1, ź“‡ƒˆę1, Ş’ÍK•ä1,2, ‹v“ˆ‘Ľs1, ŽO–Ř–ž“ż1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ŽY‰Č): ‘ć136‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď ‘‰ďEŠwpW‰ď (2018/11/24), “Œ‹ž.

733173. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é–EóŠď‘ŮÇ—á‚ĚhCG’ቺ•s—Ç—á‚ÉŠÖ‚ľ‚Ä‚ĚŒŸ“˘. ŒÜ“‡—T”V1, ÎˆäŠG从q1,2, HŽRŠG—Žq1, ź“‡ƒˆę1, Ş’ÍK•ä1,2, ‹v“ˆ‘Ľs1, ŽO–Ř–ž“ż1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ŽY‰Č): ‘ć136‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/11/24), “Œ‹ž.

733174. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”DP20TˆČ~‚ÉŽĄ—Ă“IčňŠÇ–Dkp‚đs‚Á‚˝11Ç—á‚Ě•Ş•Ř“]‹A. Žž”CňŒÎ1, –]ŒŽƒŽq1, ŽRč@—D1, Îě—˛ŽO1, ‘吟—fŽq1, ŠÖŒű˜aŠé1, ’†‹ŕ˜NŽq1, •ž•”‹żŽq1, ‹g‘ş‰ĂL1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć136‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď ‘‰ďEŠwpW‰ď (2018/11/25), “Œ‹ž.

733175. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽY•wl‰Čˆă‚É‚Ć‚Á‚Ä‚Ě“­‚Ť•ű‰üŠv‚Ƃ́|‘˜_‚Š‚çŠe˜_EŽŔ‘H‚ց|. ŠC–ěM–ç (ŽY‰Č): ‘ć380‰ńŽl…‰ď (2018/11/28), “Œ‹ž.

733176. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)gˆă—Ă‚ĚŽżEˆŔ‘S‚ĚŠm•Űh‚ƁgˆăŽt‚ĚŒ’N‚Ö‚Ě”z—śh|‚ť‚Ě—ź—§‚đ‚ß‚´‚ľ‚Ä. ŠC–ěM–ç (ŽY‰Č): ˆę”ĘŽĐ’c–@l“ú–{ˆăŠw‰ď˜A‡ŽĺĂ@ˆăŽt‚Ě“­‚Ť•ű‰üŠv‚đl‚Ś‚é@‹Î–ąˆă‚Ě˜J“­ŠÂ‹ŤŒŸ“˘ˆĎˆő‰ď‚Š‚ç‚Ě’ńŒžĐ‰î‚ƍs­EŠeŠw‰ďE’c‘Ě“™‚Ć‚ĚƒtƒH[ƒ‰ƒ€ (2018/12/1), “Œ‹ž.

733177. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yƒtƒH[ƒ‰ƒ€: ƒ^ƒXƒNƒVƒtƒeƒBƒ“ƒO‚Ć•a‰@‹@”\‚̏W–ń‰ťEˆăŽt‚ĚŒđ‘㐧“™‚ɂ‚˘‚ÄŒťę‚Ĺ‚Ç‚¤i‚ß‚é‚Š?z—ŤˆăŽt‚Ć˜J“­ŠÂ‹Ť. ŠC–ěM–ç (ŽY‰Č): ˆę”ĘŽĐ’c–@l“ú–{ˆăŠw‰ď˜A‡ŽĺĂ Žs–ŻŒöŠJƒtƒH[ƒ‰ƒ€ (2019/3/2), “Œ‹ž.

733178. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”DP17T‚É”j…‚ľŽĄ—Ă•űj‚ĚŒˆ’č‚É‹ę—ś‚ľ‚˝ˆę—á. •˝–ě“Žq1, ‹g‘ş‰ĂL2, •ž•”‹żŽq2, ’†‹ŕ˜NŽq2, ŠÖŒű˜aŠé2, Îě—˛ŽO2, ‘吟—fŽq2, ‹ŕˆä—Y“ń2, –]ŒŽƒŽq2, ŠC–ěM–ç2 (1Œ¤Cˆă, 2ŽY‰Č): ‘ć425‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2019/3/16), ‰Ą•l.

733179. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) HIVŠ´ő”DP‚Ěˆę—á. ‰““Ą—ŕ‰—“Ţ1, ‘吟—fŽq2, ź“‡ƒˆę2, ‹g‘ş‰ĂL2, •ž•”‹żŽq2, ’†‹ŕ˜NŽq2, ŠÖŒű˜aŠé2, Îě—˛ŽO2, ‹ŕˆä—Y“ń2, –]ŒŽƒŽq2, ŠC–ěM–ç2 (1Œ¤Cˆă, 2ŽY‰Č): ‘ć425‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2019/3/16), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110022. [Œ´’˜] In which preterm labor-patients is intravenous maintenance tocolysis effective? Yoneda S, Yoneda N, Fukuta K, Shima T, Nakashima A, Shiozaki A, Yoshino O1,2, Kigawa M, Yoshida T, Saito S: J Obstet Gynaecol Res 2018/3; 44 (3): 397-407. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

H29-110023. [Œ´’˜] Bradykinin system is involved in endometriosis-related pain through endothelin-1 production. Yoshino O1,2, Yamada-Nomoto K, Kobayashi M, Andoh T, Hongo M, Ono Y, Hasegawa-Idemitsu A, Sakai A, Osuga Y, Saito S: Eur J Pain 2018/3; 22 (3): 501-10. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

H29-110024. [Œ´’˜] Low Bone Mineral Density in Elite Female Athletes With a History of Secondary Amenorrhea in Their Teens. Nose-Ogura S, Yoshino O1,2, Dohi M, Kigawa M, Harada M, Kawahara T, Osuga Y, Saito S: Clin J Sport Med 2018/3. doi: 10.1097/JSM.0000000000000571. [Epub ahead of print] 2018. (‹g–ě@C1,2: 1ŽY‰Č, 2•wl)

[’˜@‘]

H29-620002. [Šwp‘ (•Ş’SŽˇ•M)]yŽ„‚ĚŽĄ—Ă [2017-18”N“x”Ĺ]z20. •wl‰ČŽžŠł@ŒŽŒoE“ŕ•Ş”ĺ‚ĚˆŮí@[07] ‹@”\ŤŽq‹{oŒŒ, p.1450-1. ‹g–ě@C1,2, âV“Ą@Ž  (1ŽY‰Č, 2•wl), ŠÄC: ‰Ž“c‹’j, –k‘ş‘yˆę˜Y, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2017/7”­s.

H29-620003. [Šwp‘ (•Ş’SŽˇ•M)]y•wl‰Č‚Ş‚ń (‘ć2”Ĺ)|ĹV‚ĚŒ¤‹†“ŽŒü|(“ú–{—ŐŕŹ76ŠŞ‘Š§†2)zVI. —‘‘ƒ‚Ş‚ń@3. —‘‘ƒŠŕ‚ĚŽĄ—Á@(7) p‘O‰ťŠw—Ă–@, p.618-24. ‰ś“c‹MŽu (•wl), “ú–{—Ő଎Đ, “Œ‹ž, 2018/3”­s.


ŽŒ`ŠO‰ČŠw

[Šwp˜_•ś]

110265. [Œ´’˜] Long-term clinical and radiographic results of the cementless Spotorno stem in Japanese patients: A more than 15-year follow-up. Zang J, Uchiyama K1, Moriya M1, Li Z, Fukushima K1, Yamamoto T, Takahira N2, Takaso M1, Liu J, Feng W: J Orthop Surg (Hong Kong) 2018/1-4; 26 (1): 2309499017750310. (“ŕŽRŸ•ś1, X’JŒőr1, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110267. [Œ´’˜] In Vivo Release of Vancomycin from Calcium Phosphate Cement. Uchida K1, Sugo K, Nakajima T, Nakawaki M2, Takano S2, Nagura N2, Takaso M1, Urabe K1,3: Biomed Res Int 2018/5; 2018: 4560647. (“ŕ“cŒ’‘ž˜Y1, ’†˜e[Í2, ‚–쏸‘ž˜Y2, –ź‘q’źd2, ‚‘ŠťŽm1, č•”@Œ›1,3: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110268. [Œ´’˜] Relationship between synovial inflammatory cytokines and progression of osteoarthritis after hip arthroscopy: Experimental assessment. Fukushima K1, Inoue G1, Uchida K1, Fujimaki H, Miyagi M1, Nagura N2, Uchiyama K1, Takahira N3, Takaso M1: Journal of Orthopaedic Surgery 2018/5; 26 (2): 1-6. (•Ÿ“‡Œ’‰î1, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, ‹{éłs1, –ź‘q’źd2, “ŕŽRŸ•ś1, ‚•˝ŽL3, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”)

110269. [Œ´’˜] Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis. Takano S1, Uchida K2, Inoue G2, Matsumoto T2, Aikawa J2, Iwase D2, Mukai M1, Miyagi M2, Takaso M2: BMC Musculoskelet Disord 2018/6; 19 (1): 204. (‚–쏸‘ž˜Y1, “ŕ“cŒ’‘ž˜Y2, ˆäă@Œş2, ź–{ŒőŒ\2, ‘Šě@~2, ŠâŁ@‘ĺ2, Œ}@@Šw1, ‹{éłs2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

110270. [Œ´’˜] Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia. Mukai M1, Uchida K2, Takano S1, Iwase D2, Aikawa J2, Inoue G2, Miyagi M2, Takaso M2: Lipids Health Dis 2018/6; 17 (1): 137. (Œ}@@Šw1, “ŕ“cŒ’‘ž˜Y2, ‚–쏸‘ž˜Y1, ŠâŁ@‘ĺ2, ‘Šě@~2, ˆäă@Œş2, ‹{éłs2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

110271. [Œ´’˜] Histological analysis and biomechanical evaluation of fatty infiltration after rotator cuff tear and suprascapular nerve injury in a rat model. Sasaki Y. Ochiai N, Nakajima A, Sasho T, Kenmoku T1, Yamaguchi T, Kijima T, Hashimoto E, Sasaki Y, Ohtori S: Journal of Orthopaedic Science 2018/9; 23 (5): 834?41. (ŒŠ–Ú’q‹I1: 1ŽŠO)

110272. [Œ´’˜] Effects of the Elbow Flexion Angle on the Radial Nerve Location around the Humerus: A Cadaver Study for Safe Installation of a Hinged External Fixator. Sukegawa K1, Kuniyoshi K, Suzuki T, Matsuura Y, Onuma K1, Kenmoku T1, Takaso M1: J Hand Surg Asian Pac Vol 2018/9; 23 (3): 388-94. (•ě_Žm1, ŹŔŒŤŽĄ1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1: 1ŽŠO)

110273. [Œ´’˜] Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis. Aikawa J1, Uchida K1, Takano S2, Inoue G1, Iwase D1, Miyagi M1, Mukai M2, Shoji S, Sekiguchi H, Takaso M1: Lipids Health Dis 2018/9; 17 (1): 215. (‘Šě@~1, “ŕ“cŒ’‘ž˜Y1, ‚–쏸‘ž˜Y2, ˆäă@Œş1, ŠâŁ@‘ĺ1, ‹{éłs1, Œ}@@Šw2, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110274. [Œ´’˜] Is staged operation using external fixation needed for all proximal tibial fractures? Kawamura T1, Minehara H2, Matsuura T1, Shoji S3, Tazawa R3, Ohtake Y1, Takaso M1, Suzuki T: œÜ 2018/9; 40 (4): 1062-7. (‰Í‘ş@’ź1, •ôŒ´Gš2, ź‰YWł1, ŻŽi^‘ž˜Y3, “cŕV@—Č3, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1: 1ŽŠO, 2‹~–˝, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110275. [Œ´’˜] Scaption kinematics of reverse shoulder arthroplasty do not change after the sixth postoperative month. Matsuki K, Sugaya H, Hoshika S, Takahashi N, Kenmoku T1, Banks SA: Clin Biomech (Bristol, Avon) 2018/10; 58: 1-6. (ŒŠ–Ú’q‹I1: 1ŽŠO)

110276. [Œ´’˜] Radiographic and Clinical Outcomes From the Use of S2 Alar Screws in Surgery for Adult Spinal Deformity. Nakazawa T1, Inoue G1, Imura T1, Miyagi M1, Saito W1, Shirasawa E1, Uchida K1, Takahira N2, Takaso M1: Global Spine J 2018/10; 8 (7): 668-75. (’†ŕVr”V1, ˆäă@Œş1, ˆä‘ş‹M”V1, ‹{éłs1, âV“Ą@˜j1, ”’ŕV‰hŽ÷1, “ŕ“cŒ’‘ž˜Y1, ‚•˝ŽL2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110277. [Œ´’˜] Intracapsular cuneiform osteotomy compared with in-situ pinning for the management of slipped capital femoral epiphysis. Zang J, Uchiyama K1, Moriya M1, Li Z, Fukushima K1, Yamamoto T, Liu J, Feng W, Takahira N2, Takaso M1: J Pediatr Orthop B 2018/11; 27 (6): 491-5. (“ŕŽRŸ•ś1, X’JŒőr1, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110278. [Œ´’˜] Relationship between spinal sagittal alignment and acetabular coverage: a patient-matched control study. Fukushima K1, Miyagi M1, Inoue G1, Shirasawa E1, Uchiyama K1, Takahira N2, Takaso M1: Arch Orthop Trauma Surg 2018/11; 138 (11): 1495-9. (•Ÿ“‡Œ’‰î1, ‹{éłs1, ˆäă@Œş1, ”’ŕV‰hŽ÷1, “ŕŽRŸ•ś1, ‚•˝ŽL2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110279. [Œ´’˜] Clinical usefulness of multiplex PCR-lateral flow for the diagnosis of orthopedic-related infections. Minegishi Y1, Uchiyama K2, Sakurai K3, Ibe S, Kanda H, Nihonyanagi S4, Nakamura M5, Ikeda S1, Takaso M2: Mod Rheumatol 2018 Nov 5:1-7. (•őŠÝ—m“ń˜Y1, “ŕŽRŸ•ś2, ŸNˆäŒc‘˘3, “ń–{–öL4, ’†‘şłŽ÷5, ’r“cM‰î1, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3—ŐŒŸ•”, 4Š´őŠÇ—Žş, 5ˆă—ÉqśŠw•”)

110280. [Œ´’˜] Double-layered antibiotic-loaded cement spacer as a novel alternative for managing periprosthetic joint infection: an in vitro study. Ikeda S1, Uchiyama K2, Minegishi Y1, Ohno K, Nakamura M3, Yoshida K3, Fukushima K2, Takahira N3, Takaso M2: J Orthop Surg Res 2018/12; 13 (1): 322. (’r“cM‰î1, “ŕŽRŸ•ś2, •ôŠÝ—mŽŸ˜Y1, ’†‘şłŽ÷3, ‹g“c˜aO3, •Ÿ“‡Œ’‰î2, ‚•˝ŽL3, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ÉqśŠw•”)

110281. [Œ´’˜] The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients. Miyagi M1, Fujimaki H, Naruse K1, Suto K, Inoue G1, Nakazawa T1, Imura T1, Saito W1, Uchida K1, Shirasawa E1, Takahira N2, Takaso M1: J Orthop Sci 2019/1; 24 (1): 153-8. (‹{éłs1, ŹŁŒÉŽĄ1, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, âV“Ą@˜j1, “ŕ“cŒ’‘ž˜Y1, ”’ŕV‰hŽ÷1, ‚•˝ŽL2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110282. [Œ´’˜] Nerve growth factor continuously elevates in a rat rotator cuff tear model. Nagura N1, Kenmoku T2, Uchida K2, Nakawaki M2, Inoue G2, Takaso M2: J Shoulder Elbow Surg 2019/1; 28 (1): 143-8. (–ź‘q’źd1, ŒŠ–Ú’q‹I2, “ŕ“cŒ’‘ž˜Y2, ’†˜e[Í2, ˆäă@Œş2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

120016. [Œ´’˜] lH•GŠÖß‘S’uŠˇp‚Ěáu’ɐ§ŒäE•GŠÖß‹@”\‰ń•œEt‹@”\ˆŰŽ‚ɑ΂ˇ‚éŒo”ç‹zŽűŒ^’Á’ɏľ‰ƒ–ň‚Ě—LŒřŤ. č•”@Œ›1, –ڍ•’qN, ŹŁNŽĄ1, •˝ě‹IŽq1, “ŕ–쐳—˛1 (1ŽŠO): —Տ°ŽGŽ ŽŒ`ŠO‰Č 2018/5; 69 (5): 420-3.

120017. [Œ´’˜] ƒƒbƒLƒ“ƒO‹@\‚đ—L‚ˇ‚éƒXƒ‰ƒCƒh‰„’ˇ|ƒEƒTƒM‰şŽˆäF‚đ—p‚˘‚˝‹­“xŽŽŒą|. ŠâŁ@‘ĺ1, ź”ö@—˛, ź”ö@“Ä, “ŕ“cŒ’‘ž˜Y1, ŠÖŒű—T”V, –ÚŽž—LŠóŒb1, ‘Šě@~1, “ŒŽR—玥1, ŹŔŒŤŽĄ1, ‚‘ŠťŽm1 (1ŽŠO): “ú–{ŹŽ™ŽŒ`ŠO‰ČŠw‰ďŽGŽ 2018/9; 27 (1): 118-21.

120018. [Œ´’˜] ƒZƒƒ“ƒgƒŒƒXlHŒŇŠÖßƒVƒFƒ‹‚̏‰ŠúŒĹ’萍‚Ě•]‰ż. Ź“‡ç—T, Žđˆä—˜“Ţ1, ‹g“c˜aO1, •Ÿ“‡Œ’‰î2, ’†–ě‰ë–ç, ‚•˝ŽL1, “ŕŽRŸ•ś2, ”nŸş´Ž‘, Ž•˝­L1 (1ˆă—ÉqśŠw•”, 2ŽŠO): —Տ°ƒoƒCƒIƒƒJƒjƒNƒX 2018/10; 39: 43-7.

220005. [€Œ´’˜] ĹV‚ĚƒAƒLƒŒƒX‚Ż‚ń’f—ô‚ɑ΂ˇ‚鎥—Ă. •˝ě‹IŽq1, č•”@Œ›1 (1ŽŠO): é‹ĘŒ§ˆăŽt‰ďŽ 2018/10; 823: 49-51.

320025. [Ç—á•ń] ‰şŽˆ“ŽĂ–ŹŠďŒ`‚𔺂Á‚˝•ĎŒ`ŤŒŇŠÖßÇ‚ɑ΂ľlHŒŇŠÖß‘S’uŠˇp‚đŽ{s‚ľ‚˝1—á. ‘ĺ’|—IĆ1, “ŕŽRŸ•ś1, X’JŒőr1, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): “Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ďŽGŽ 2018/12; 30 (4): 562-6.

521009. [‰đŕ] ŽŒ`ŠO‰Č—Ěˆć‚É‚¨‚Ż‚鐜‘ĚŢ—ż|Š´ő‚Ě—\–h‚ĆŽĄ—Á|. ’r“cM‰î1, “ŕŽRŸ•ś2, •őŠÝ—mŽŸ˜Y1, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): Ţ—ż‚̉Ȋw‚ƍHŠw 2018/6; 55 (3): 84-7.

521010. [‰đŕ]yVocabularyzƒAƒhƒŒƒmƒƒfƒ…ƒŠƒ“. ‚–쏸‘ž˜Y1, “ŕ“cŒ’‘ž˜Y2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): —Տ°ŽGŽ ŽŒ`ŠO‰Č 2018/8; 69 (9): 938.

522086. [uŔ] lHŒŇŠÖßŽčp‚É‚¨‚Ż‚éŽčp•”ˆĘŠ´ő‚Ě—\–h`Ĺ‹ß‚Ě’mŒŠ`. “ŕŽRŸ•ś1, ‚‘ŠťŽm1 (1ŽŠO): —Տ°–ƒŒ 2018/8; 42 (8): 1125-9.

522087. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(1) ŒŇŠÖß‚Ě•K{‰đ–U’mŽŻ. (2) •ĎŒ`ŤŒŇŠÖßÇ. ‚•˝ŽL (ˆă—ÉqśŠw•”ŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 756-63.

522088. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(3) ‘ĺ‘ڍœŒz•”œÜ. •Ÿ“‡Œ’‰î (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 764-5.

522089. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(4) ‘ĺ‘ڍœ“]Žq•”œÜ. ‰Í‘ş@’ź (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 766-7.

522090. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(5) ‘ĺ‘ڍœœŠ˛•”œÜ. •ôŒ´Gš1,2 (1‹~–˝, 2ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 768-9.

522091. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`zŸTopics1 ŒŇŠÖß‹ž‚Ş‘‚Ś‚Ä‚Ť‚Ä‚˘‚é? •Ÿ“‡Œ’‰î (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 773.

522092. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(7) œ”Ő—ÖœÜ. (8) Š°œ‰PœÜ. ź‰YWł (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 744-9.

522093. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(9) ”­ˆçŤŒŇŠÖßŒ`Ź•s‘S. “ŕŽRŸ•ś (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 780-2.

522094. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`zŸTopics2 ”­ˆçŤŒŇŠÖßŒ`Ź•s‘S? ć“VŤŒŇŠÖß’E‰P? ŠâŁ@‘ĺ (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 873.

522095. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(10) lHŒŇŠÖß‘S’uŠˇp (‘O•ű–@). •Ÿ“‡Œ’‰î (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 784-5.

522096. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(11) lHŒŇŠÖß‘S’uŠˇp (Œă•ű–@). (12) lHœ“Ş’uŠˇp. X’JŒőr (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 876-91.

522097. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(13) ‘ĺ‘ڍœ“]Žq•”œÜ‚̍œÚ‡p. ‰Í‘ş@’ź (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 792-4.

522098. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(14) ‘ĺ‘ڍœœŠ˛•”œÜ‚̍œÚ‡p. •ôŒ´Gš (‹~–˝): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 795-7.

522099. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(15) ”­ˆçŤŒŇŠÖßŒ`Ź•s‘S‚Ě•Ű‘śŽĄ—Ă. (16) ”­ˆçŤŒŇŠÖßŒ`Ź•s‘S‚ĚŽčpŽĄ—Ă. “ŕŽRŸ•ś (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 798-803.

522100. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(18) Žq‚Ç‚ŕ‚ĚŒŇŠÖß‚ĚŠĹŒě. ŠâŁ@‘ĺ (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 808-9.

522101. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`zŸTopics3 Ĺ‹ß‚ĚŒŇŠÖßŽĄ—Ă‚Ě˜b‘č. •Ÿ“‡Œ’‰î (ŽŠO): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 817.

522102. [uŔ]yŽăƒVƒ“ƒ|ƒWƒEƒ€: ’ĹŠÔ”ÂŒ¤‹†‚ĚĹ‘Oüz’ŊԔ•ϐŤ‚Ćáu’É. ‹{éłs (ŽŠO): —Տ°ŽŒ`ŠO‰Č 2018/11; 53 (11): 945-50.

522103. [uŔ]y“ÁW: ˜’ÉŽĄ—Ă‚ĚĹ‘OüzVi. ˜’ÉŽĄ—Ă‚ĚĄŒă‚ĚŠú‘ҁ@Ň’ĹŽžŠł‚ɑ΂ˇ‚é“ŻŽíœˆÚA. ˆäă@Œş1, ‹{éłs1, âV“Ą@˜j1, ˆä‘ş‹M”V1, ’†ŕVr”V1, ”’ŕV‰hŽ÷1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1 (1ŽŠO): ŠÖßŠO‰Č 2018/11; 37 (12): 1368-71.

522104. [uŔ]y“ÁW: ƒƒRƒ‚‚̍ŐV‰ć‘œf’fzƒNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“…A: ‹Ř“÷—Ę‚Ě‘Ş’č•ű–@‚ɂ͂ǂ̂悤‚Č‚ŕ‚Ě‚Ş‚ ‚č‚Ü‚ˇ‚Š? ‹{éłs (ŽŠO): Loco Cure 2018/11; 4 (4): 357-9.

540020. ‚ť‚Ě‘ź (Šw‰ď´˜^)]y‘ć37‰ń“ú–{‰^“ŽŠíˆÚAEÄśˆăŠwŒ¤‹†‰ďz‘ĺ‘ڍœ“ŕ‘¤č÷ŠJ•úœÜ‚É‚ć‚Á‚Đś‚ś‚˝L”͈͍œ“Œ‡‘š‚ɑ΂ľ‚Ä“ŻŽíœˆÚA‚ĆŽŠ‰Ć”|—{“×–EˆÚAp‚đ•š—p‚ľ‚˝1—á. č•”@Œ›1, •˝ě‹IŽq1 (1ŽŠO): ˆÚA 2019/3; 53 (6): 381.

[’˜@‘]

620090. [Šwp‘ (•Ş’SŽˇ•M)]yƒXƒ|[ƒcŒŇŠÖß’Ɂ|f’f‚ĆŽĄ—Á|(Monthly Book Orthopaedics‘ć31ŠŞ6†)zFAI (femoroacetabular impingement) ‚̐f’f‚ƉuŠw, p.15-20. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, “ŕŽRŸ•ś1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”), •Ň: “ŕ“c@Žu, ‘S“ú–{•a‰@o”ʼnď, “Œ‹ž, 2018/6”­s.

620091. [Šwp‘ (•Ş’SŽˇ•M)]y‘gDˆÚAText Book|‘gDˆÚAˆăE‘gDˆÚAƒR[ƒfƒBƒl[ƒ^[‚É‚Ţ‚Ż‚ā|z‘ć11Í Še‘gD‚̮̍ćE•Ű‘śE‹Ÿ‹‹@II Še‘gD‚̮̍ć‚ĆˆÚA“K‰žEˆÚApE—Տ°Œř‰Ę@œE“Ex‘Ń, p.155-60. č•”@Œ› (ŽŠO), ŠÄC: “ú–{‘gDˆÚAŠw‰ď, •Ň: “ú–{‘gDˆÚAŠw‰ď‹łˆçˆĎˆő‰ď, ‚ւ邡o”Ĺ, “Œ‹ž, 2018/7”­s.

620092. [Šwp‘ (•Ş’SŽˇ•M)]yŽŒ`ŠO‰ČŽčp•”ˆĘŠ´ő‘΍ôƒ}ƒjƒ…ƒAƒ‹ (Monthly Book Orthopaedics‘Š§†)zII. Surgical Site Infection (SSI) ‚ւ̑Ήž@RMRSA–ň‚ĚŽg‚˘•ű: DAP|ŽŒ`ŠO‰Č—ĚˆćpŒăŠ´őÇ (lHŠÖßŽüˆÍŠ´ő‚đŠÜ‚Ţ) ‚ɑ΂ˇ‚éDAP‚Ě—LŒřŤ‚ĆˆŔ‘SŤ|, p.162-8. “ŕŽRŸ•ś1, ‰Ô–؏G–ž, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”), ‘S“ú–{•a‰@o”ʼnď, “Œ‹ž, 2018/10”­s.

620093. [Šwp‘ (•Ş’SŽˇ•M)]ylHŒŇŠÖßÄ’uŠˇpƒeƒNƒjƒbƒN‚đ’b‚Ś‚é (Monthly Book Orthopaedics‘ć31ŠŞ13†)zIV. ‘ĺ‘ڍœƒXƒeƒ€ŽüˆÍœÜ‚ɑ΂ˇ‚élHŒŇŠÖßÄ’uŠˇp@‹‘ĺœŒ‡‘š‚𔺂¤ƒXƒeƒ€ŽüˆÍœÜ‚ɑ΂ˇ‚é“ŻŽíœ‚đ—p‚˘‚˝Ä’uŠˇp, p.71-9. “ŕŽRŸ•ś1, ‰Ô–؏G–ž, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”), •Ň: “ŕŽRŸ•ś1, ‘S“ú–{•a‰@o”ʼnď, “Œ‹ž, 2018/12”­s.

620094. [Šwp‘ (•Ş’SŽˇ•M)]yŽŒ`ŠO‰Č “úíf—Ă‚ĚƒGƒbƒZƒ“ƒX Ň’ŁzIII ŽžŠł•ĘŽĄ—Ă–@@[Œz’Ĺ]@Œz•”’É, p.166-78. ˆäă@Œş (ŽŠO), •Ň: Ž–ěœÄˆę, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2019/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711015. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Banked bone allograft in Orthopaedic Surgery. Urabe K1: 17th International Conference of Asia Pacific Association of Surgical Tissue Banks (APASTB) 2018 (2018/8/29), Selangor, Malaysia. (č•”@Œ›1: 1ŽŠO)

711016. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) HipAlign Supine‚đ—p‚˘‚˝ALS-THA|Šî‘b‚Š‚çŽčp‚ޏo—ˆ‚é‚悤‚É‚Č‚é‚܂Ł|. Uchiyama K1: ZimmerBiomet ƒJƒ_ƒo[ƒgƒŒ[ƒjƒ“ƒO (2018/11/2), Bangkok, Thailand. (“ŕŽRŸ•ś1: 1ŽŠO):

712029. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Strategies to reduce the incidence of pedicle screw loosening, cage subsidence, and pseudarthrosisafter fusion surgery in patients with osteoporosis. Inoue G1: Spine across the sea 2018 (2018/8/1), Hawaii. (ˆäă@Œş1: 1ŽŠO)

713121. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Comparison of the Open Palm and Digit Technique with the Mixed Method of Partial Open Technique or Complete Wound Closure Technique According to the Degree of Dermal Contracture in Dupuytren's Contracture. Sukegewa K1, Otake Y1, Yokozeki Y1, Kobayashi A, Takaso M1: Annnual Meeting of American Association for Surgery of the Hand (2018/9/13), Boston, USA. (•ě_Žm1, ‘ĺ’|—IĆ1, ‰ĄŠÖ—YŽi1, ‚‘ŠťŽm1: 1ŽŠO)

713122. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) An anatomical cadaver study for safe installation of a hinged external fixator of the elbow: Effects of the elbow flexion angle on the radial nerve course around the humerus. Sukegawa K1, Onuma K1, Otake Y1, Kuroda A1, Yokozeki Y1, Takaso M1: The 73rd Annual Meeting of the American Society for Surgery of the Hand (ASSH) (2018/9/13-15), Boston, USA. (•ě_Žm1, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, •“cW‹`1, ‰ĄŠÖ—YŽi1, ‚‘ŠťŽm1: 1ŽŠO)

713123. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Treatment of post-traumatic pronation-supination disorder of the forearm using tendon and fascia allografting. Sukegawa K1, Onuma K1, Otake Y1, Kuroda A1, Yokozeki Y1, Takaso M1: The 73rd Annual Meeting of the American Society for Surgery of the Hand (ASSH) (2018/9/13-15), Boston, USA. (•ě_Žm1, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, •“cW‹`1, ‰ĄŠÖ—YŽi1, ‚‘ŠťŽm1: 1ŽŠO)

713124. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Relationship between synovial inflammatory cytokines and progression of osteoarthritis after hip arthroscopy: Experimental assessment. Fukushima K1, Inoue G1, Uchida K1, Fujimaki H, Miyagi M1, Nagura N2, Uchiyama K1, Takahira N3, Takaso M1: Hip preservation society annual meeting 2018 (2018/10/4), Melbourne, Australia. (•Ÿ“‡Œ’‰î1, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, “ĄŠŞŽőŽq, ‹{éłs1, –ź‘q’źd2, “ŕŽRŸ•ś1, ‚•˝ŽL3, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”)

721018. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) “ŤlHŒŇŠÖßŽüˆÍŠ´őÇ (PJI) ‚ɑ΂ˇ‚鎥—Ă–@‚̍H•v. “ŕŽRŸ•ś1, •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/16), “Œ‹ž.

722098. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –Ť˜’ɏǂɑ΂ˇ‚é–ň•¨ŽĄ—Ă‚Š‚çl‚Ś‚éŇ’ĹŽžŠłŽĄ—Ă‚É‚¨‚Ż‚é”ď—p‘ÎŒř‰ĘŒ¤‹†‚ĚˆÓ‹`. ŠC“n‹MŽi, Ž“c÷ŽĄ, źŽRKO, ŽR‰ş•q•F, ěă@Žç, “cŒű•q•F, ”g˜C_F, ĄŠ˜Žj˜Y, ŽRčłŽu, ˆäă@Œş1, ‘şă‰pŽ÷, ź“cN‘ž˜Y, ‹{˜Ž‹v, ŽR“c@G, V’J@•ŕ (1ŽŠO): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/12), _ŒË.

722099. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Surgical strategy for treatment of groin pain in young patients with borderline dysplasia. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‰ĄŠÖ—YŽi1, “y‰Ž^•ä1, “ŕŽRŸ•ś1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{ŠÖß‹žE•GEƒXƒ|[ƒcŽŒ`ŠO‰ČŠw‰ď (JOSKAS2018) (2018/6/14), •Ÿ‰Ş.

722100. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) œŘ‚č‚đ•š—p‚ľ‚˝Œă•ű’P“ĆƒAƒvƒ[ƒ`‚Ĺ‚Ě‹¸łŒĹ’čp. ˆäă@Œş (ŽŠO): Global Alignment Seminar 2018 (2018/9/1), “Œ‹ž.

722101. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) lHŠÖßŽüˆÍŠ´ő‚É‚¨‚Ż‚éPCR–@‚đ—p‚˘‚˝Œ´ˆö‹ŰŽí“Ż’č‚ĚŽŽ‚Ý. “ŕŽRŸ•ś1, ŸNˆäŒc‘˘2, _“cG”ü3, •őŠÝ—mŽŸ˜Y4, ’r“cM‰î4, X’JŒőr1, •Ÿ“‡Œ’‰î1, Žë–ě—Lě2,5, mˆäŒŠ‰pŽ÷6, ‚•˝ŽL7, ‚‘ŠťŽm1 (1ŽŠO, 2—ŐŒŸ•”, 3–k—˘‘ĺ’˃oƒCƒIƒƒfƒBƒJƒ‹ƒAƒbƒZƒCŒ¤‹†Š, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5—ŐŒŸŠw, 6•xŽR‘ĺ‘ĺŠw‰@ˆăŠw–ňŠwŒ¤‹†•”, 7ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S1616.

722102. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 40ÎˆČ‰ş‚̐isŠúE––Šú•ĎŒ`ŤŒŇŠÖßÇ‚ɑ΂ˇ‚éŠO”˝, Chiari‡•šŽčp‚Ě“K‰ž‚ƍH•v. “ŕŽRŸ•ś1, ‚•˝ŽL2, •Ÿ“‡Œ’‰î1, X’JŒőr1, •őŠÝ—mŽŸ˜Y3, ’r“cM‰î3, ‘ĺ‹´Œc‹v1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/27), –źŒĂ‰Ž.

722103. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ŤŠEŒ^Š°œ‰PŒ`Ź•s‘S (borderline dysplasia) ‚Ě’č‹`‚Ɛf’f. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, “ŕŽRŸ•ś1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/27), –źŒĂ‰Ž.

722104. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒp[ƒLƒ“ƒ\ƒ“•a‚ɑ΂ˇ‚éŇ’ĹŽčp‚ĚŒŸ“˘. ˆäă@Œş1, âV“Ą@˜j1, ˆä‘ş‹M”V1, ‹{éłs1, ”’ŕV‰hŽ÷1, ě‹v•Ű•ŕ2, ’†ŕVr”V1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć21‰ń“ú–{’áNPŇ’ĹŠO‰ČŠw‰ďŠwpW‰ď (2018/11/30), “Œ‹ž.

722105. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) THA‹Â‰çˆĘ‘O‘¤•űƒAƒvƒ[ƒ` (ALS). ‚•˝ŽL1, “ŕŽRŸ•ś2, •Ÿ“‡Œ’‰î2 (1ˆă—ÉqśŠw•”, 2ŽŠO): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/15), “Œ‹ž.“ú–{lHŠÖßŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2019; 49th: 232.

722106. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) THAŽčp‚É‚¨‚Ż‚éŽOŽŸŒłƒ‚ƒfƒ‹‚̉ž—p. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, “ŕŽRŸ•ś1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/15), “Œ‹ž.

722107. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) lHŒŇŠÖßŽüˆÍŠ´ő‚ɑ΂ˇ‚é“ńŠú“IŽĄ—Á|R‹Ű–ňŠÜ—LƒZƒƒ“ƒgƒXƒy[ƒT‚É‚ć‚é“ńŠú“IÄ’uŠˇp|. “ŕŽRŸ•ś1, ’r“cM‰î2, •őŠÝ—mŽŸ˜Y2, •Ÿ“‡Œ’‰î1, X’JŒőr1, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/16), “Œ‹ž.

723516. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽvtŠú“Á”­Ť‘¤œ^ÇŠłŽŇ‚É‚¨‚Ż‚鑤œ^‚Ć‘Ě‘gŹ‚ĚŠÖŒW‚ÉŠÖ‚ˇ‚錟“˘|”Ä—pŤ‚̍‚‚˘V‹K‘¤œ^Ç‰î“ü–@Šm—§‚đ–ÚŽw‚ľ‚ā|. ‹{éłs1, âV“Ą@˜j1, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ˆî–ŃˆęG, ‘ĺ’š¸Ži, ‚‘ŠťŽm1 (1ŽŠO): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/12), _ŒË.

723517. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒeƒƒCƒhŤœ‘e頏NJłŽŇ‚É‚¨‚Ż‚鍘’É‚Ć‹Ř“÷—Ę‚ĚŒŸ“˘. ŹŽR’q‹v1, ˆäă@ăÄ1, ‹{éłs1, “c“‡Gˆę˜Y1, ‘ş“cK—S2, ě‹v•Ű•ŕ2, A‘—RˆÉ1, ‰ĄŠÖ—YŽi1, “ĄŠŞŽőŽq, Îˆä‘ĺ•ă1, ‘ĺ’š¸Ži, ˆî–ŃˆęG, “ŕ“cŒ’‘ž˜Y1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/12), _ŒË.

723518. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒp[ƒLƒ“ƒ\ƒ“•a‚𔺂¤ŹlŇ’Œ•ĎŒ`ŠłŽŇ‚ɑ΂ˇ‚鋸łŒĹ’čpŒăÄŽčpÇ—á‚ĚŒŸ“˘. ”’ŕV‰hŽ÷1, ˆäă@Œş1, âV“Ą@˜j1, ‹{éłs1, ˆä‘ş‹M”V1, ’†ŕVr”V1, Šz‰ę—BŽŠ, Žđˆä‘ĺ•ă, ‰Á“Ą—TK, žwŽR–ž•F, “c’†^O, ˛“Ąłl, “n•Ó‰ë•F, ‚‘ŠťŽm1 (1ŽŠO): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/13), _ŒË.

723519. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”˛“B‚đŽ{s‚ľ‚˝‹š˜’Ĺ”j—ôœÜ‚ɑ΂ˇ‚éŒo”ç“IŒă•űŒĹ’čp‚ĚŒoŽž“I‰ć‘œ•]‰ż. ě‹v•Ű•ŕ1, âV“Ą@˜j2, ‹{éłs2, ”’ŕV‰hŽ÷2, ˆäă@Œş2, ’†ŕVr”V2, ˆä‘ş‹M”V2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/14), _ŒË.

723520. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’x”­Ť’Ĺ‘Ěˆł’ׂɑ΂ˇ‚éŽčpŽĄ—ÐŹŃ@pŒă˜’É‚Š‚猊‚˝‰đÍ. Šz‰ę—BŽŠ, Žđˆä‘ĺ•ă, ‰Á“Ą—TK, žwŽR–ž•F, “c’†^O, ˛“Ąłl, “n•Ó‰ë•F, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, ‹{éłs1, âV“Ą@˜j1, ”’ŕV‰hŽ÷1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć47‰ń“ú–{Ň’ŐҐ‘•aŠw‰ďŠwpW‰ď (2018/4/14), _ŒË.

723521. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńś‘Ě“ŻŽí’°ăřx‘Ń‚đ—p‚˘‚˝ŠOŤ‘O˜r‰ńůáŠQ‚ĚŽĄ—ĂŒoŒą|ŠOŤžôŽÚœ–ü‡Ç‚Ě2—á|. •ě_Žm1, ŹŔŒŤŽĄ1, ŒŠ–Ú’q‹I1, ‘ĺ’|—IĆ1, •“cW‹`1, ‰ĄŠÖ—YŽi1, A‘—RˆÉ1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć61‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2018/4/26), “Œ‹ž.

723522. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DupuytrenSk‚ɑ΂ˇ‚éŠO‰Č“IŽĄ—Ă–@‚ĚŒŸ“˘. ŹŔŒŤŽĄ1, •ě_Žm1, ‘ĺ’|—IĆ1, •“cW‹`1, ‰ĄŠÖ—YŽi1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć61‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2018/4/26), “Œ‹ž.

723523. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†ŠÔ‘}“ü•¨‚É”ńś‘Ě“ŻŽí’°ăřx‘Ń‚đ—p‚˘‚ÄŽĄ—Ă‚ľ‚˝ŠOŤžôŽÚœ–ü‡Ç‚ĚŽĄ—ĂŒoŒą. A‘—RˆÉ1, •ě_Žm1, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, •“cW‹`1, “ŕ“cŒ’‘ž˜Y1, ‚“c@Œ¤2, ‰ĄŠÖ—YŽi1, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć91‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/24), _ŒË.

723524. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă˜rœ‹ßˆĘ•”œÜ‚ɑ΂ˇ‚é‹tsŤ‘“ŕ“B‚ĚŽĄ—ĂŒoŒą. “ŕ–쐳—˛1, •˝ě‹IŽq1, ŹŁNŽĄ1, č•”@Œ›1 (1ŽŠO): ‘ć91‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/25), _ŒË.

723525. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŇŠÖß’É‚ĆŒŇŠÖß‹žŽ‹ŠŒŠ, ŠŠ–Œ“ŕ‰ŠÇŤƒTƒCƒgƒJƒCƒ“”­Œť‚ĚŠÖ˜A. •Ÿ“‡Œ’‰î1, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, ‹{éłs1, “ŕŽRŸ•ś1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć91‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2018/5/27), _ŒË.

723526. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •GŠÖßL“W§ŒŔ‚đ‚Ť‚˝‚ľ‚˝‹U’É•—Œ‹ß‚Ě1—á. ŹŁNŽĄ1, •˝ě‹IŽq1, “ŕ–쐳—˛1, ‚‹´ł“T1, č•”@Œ›1 (1ŽŠO): ‘ć10‰ń“ú–{ŠÖß‹žE•GEƒXƒ|[ƒcŽŒ`ŠO‰ČŠw‰ď (JOSKAS2018) (2018/6/15), •Ÿ‰Ş.

723527. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŇŠÖßŠO—ˆ‚É‚¨‚Ż‚éCĐ‰î•a–ź‚Ɛf’f•a–ź‚̍ˇˆŮ‚ĚŒŸ“˘. ‰ĄŠÖ—YŽi1, •Ÿ“‡Œ’‰î1, –Š@„Ž÷1, “ŕŽRŸ•ś1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{ŠÖß‹žE•GEƒXƒ|[ƒcŽŒ`ŠO‰ČŠw‰ď (JOSKAS2018) (2018/6/15), •Ÿ‰Ş.

723528. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŇŠÖßMRI‚É‚¨‚Ż‚éBone Marrow Edema (BME) ‚ÉŠÖ‚ˇ‚錟“˘. ŹŽR’q‹v1, •Ÿ“‡Œ’‰î1, –Š@„Ž÷1, “ŕŽRŸ•ś1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{ŠÖß‹žE•GEƒXƒ|[ƒcŽŒ`ŠO‰ČŠw‰ď (JOSKAS2018) (2018/6/15), •Ÿ‰Ş.

723529. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă˜rœ‹ßˆĘ•”œÜ‚ɑ΂ˇ‚é‹tsŤ‘“ŕ“B‚ĚŽĄ—ĂŒoŒą. “ŕ–쐳—˛1, •˝ě‹IŽq1, ŹŁNŽĄ1, č•”@Œ›1, Žđˆä—˜“Ţ2 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć44‰ń“ú–{œÜŽĄ—ĂŠw‰ď (2018/7/6), ‰ŞŽR.

723530. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Neer type II˝œ‰“ˆĘ’[œÜ‚ɑ΂ˇ‚é•Ű‘ś—Ă–@‚ĆŽčp—Ă–@‚Ě”äŠr. “ŕ–쐳—˛1, •˝ě‹IŽq1, ŹŁNŽĄ1, č•”@Œ›1 (1ŽŠO): ‘ć44‰ń“ú–{œÜŽĄ—ĂŠw‰ď (2018/7/6), ‰ŞŽR.

723531. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŠÖßŽüˆÍŠ´ő‚̐f’f‚É‚¨‚Ż‚éŠÖß‰tCRP‘Ş’č‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. •őŠÝ—mŽŸ˜Y1, “ŕŽRŸ•ś2, ’r“cM‰î1, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć41‰ń“ú–{œEŠÖßŠ´őÇŠw‰ď (2018/7/6), ‘ĺă.´˜^W@p.94.

723532. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒgƒVƒŠƒYƒ}ƒuŽg—pŠłŽŇ‚ɐś‚ś‚˝lHŒŇŠÖßŽüˆÍŠ´ő‚Ě2—á. “ŕŽRŸ•ś1, X’JŒőr1, •őŠÝ—mŽŸ˜Y2, ’r“cM‰î2, •Ÿ“‡Œ’‰î1, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć41‰ń“ú–{œEŠÖßŠ´őÇŠw‰ď (2018/7/7), ‘ĺă, ‘ć41‰ń“ú–{œEŠÖßŠ´őÇŠw‰ď´˜^W 2018; p.139.

723533. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŒ`ŠO‰ČŽžŠł‚ɑ΂ˇ‚é“ŻŽíäFEčՑшڐA‚ĚŒťó. ˆäă@Œş1, •ě_Žm1, ŹŔŒŤŽĄ1, ŒŠ–Ú’q‹I1, ŠâŁ@‘ĺ1, Š}Œ´‚Ý‚Ç‚č, ‘ĺ’JŒö‹M, “ŕ“cŒ’‘ž˜Y1, č•”@Œ›1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć17‰ń“ú–{‘gDˆÚAŠw‰ď‘‰ďEŠwpW‰ď (2018/8/25), ç—t.

723534. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹Â‰çˆĘƒ|[ƒ^ƒuƒ‹ƒiƒrƒQ[ƒVƒ‡ƒ“‚̐¸“x•]‰ż‚Ćƒ‰[ƒjƒ“ƒOƒJ[ƒu. âV“ĄLŽ÷1, “ŕŽRŸ•ś1, •Ÿ“‡Œ’‰î1, X’JŒőr1,2, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2•‰Í“ŕ•a‰@, 3ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S1657.

723535. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŒŇŠÖß’uŠˇp‚É‚¨‚Ż‚épŒăŠ´ő—\–hƒZƒtƒ@ƒ]ƒŠƒ““Š—^‚Ě—LŒřŤ‚ĚŒŸŘ. ’r“cM‰î1, “ŕŽRŸ•ś2, •őŠÝ—mŽŸ˜Y1, Źź•q˛3, —F“c‹g‘Ľ4, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3–ňÜ•”, 4–ňŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S1680.

723536. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŠÖßŽüˆÍŠ´ő‚̐f’f‚É‚¨‚Ż‚é”’ŒŒ‹…ƒGƒXƒeƒ‰[ƒ[ŽŽŒą‚Ě•K—vŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. •őŠÝ—mŽŸ˜Y1, “ŕŽRŸ•ś2, ’r“cM‰î1, ’†‘şłŽ÷3, ‘O‰ÔË‘ž˜Y3, –k—˘‰p˜Y3, ‚•˝ŽL3, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S1680.

723537. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŒŇŠÖßŽüˆÍŠ´ő‚É‚¨‚Ż‚éŠO‰Č“IŽĄ—Ă‚ĚŒř‰Ę”ť’č‚Ɋ֐߉t’†ƒż-defensin”Z“x‘Ş’č‚Í—L—p‚Š? •őŠÝ—mŽŸ˜Y1, “ŕŽRŸ•ś2, ’r“cM‰î1, ’†‘şłŽ÷3, ‘O‰ÔË‘ž˜Y3, –k—˘‰p˜Y3, ‚•˝ŽL3, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S1681.

723538. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒoƒ“ƒRƒ}ƒCƒVƒ“ŠÜ—LƒŠƒ“Ž_ƒJƒ‹ƒVƒEƒ€ƒZƒƒ“ƒg‚̐ś‘Ě“ŕƒoƒ“ƒRƒ}ƒCƒVƒ“™•ú“ÁŤ‚ĚŒŸ“˘. č•”@Œ›1, “ŕ“cŒ’‘ž˜Y1 (1ŽŠO): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.

723539. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OE‰Šú•ĎŒ`ŤŒŇŠÖßÇ‚É‚¨‚Ż‚éTNFƒż‚đ‰î‚ľ‚˝áu’ÉŽä‹NƒƒJƒjƒYƒ€‚ĚŒŸ“˘. •Ÿ“‡Œ’‰î1, –ź‘q’źd2, “ŕ“cŒ’‘ž˜Y1, ˆäă@Œş1, ‹{éłs1, ‚–쏸‘ž˜Y2, ’†˜e[Í2, ‘ĺŠŃ—TŽq3, “ŕŽRŸ•ś1, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a‘ԁEf—ĂŒn, 4ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.

723540. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Complex elbow instability‚ĚŽčp—Ă–@‚ɑ΂ˇ‚é‰đ–UŠw“IŒ¤‹†. •ě_Žm1, š ‹gˆęŽ÷, —é–ؐ’Ş, ź‰Y—C‰î, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, ‰ĄŠÖ—YŽi1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/11), “Ţ—Ç.

723541. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ŰŒŻ“K—pŠOŒŸ¸‚ŕŠÜ‚ß‚˝lHŠÖßŽüˆÍŠ´őf’fƒvƒƒgƒR[ƒ‹ěŹ‚ĚŽŽ‚Ý. •őŠÝ—mŽŸ˜Y1, “ŕŽRŸ•ś2, ’r“cM‰î1, ’†‘şłŽ÷3, ‘O‰ÔË‘ž˜Y3, ě“cˆíl1, –k—˘‰p˜Y3, ‚•˝ŽL3, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć33‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2018/10/12), “Ţ—Ç.“ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2018; 92 (8): S2008.

723542. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ăřœƒRƒ“ƒ|[ƒlƒ“ƒgŒ`ó‚Ě‘Šˆá‚ŞăřœƒRƒ“ƒ|[ƒlƒ“ƒgŠO‘¤•ĎˆĘ‚É—^‚Ś‚é‰e‹ż. •˝ě‹IŽq (–k—˘ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć46‰ń“ú–{ŠÖß•aŠw‰ď (2018/11/9), ‰ŞŽR.

723543. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Palm size Navigation‚đ—p‚˘‚˝‹Â‰çˆĘTHA. –Ľ“csG1, ˆÉ“Ą‰ë”V2, ŠâŘŒ’‘ž˜Y3, “ŕŽRŸ•ś4, ‹ŕŽĄ—L•F5, ěč‰ëŽj6, _“cÍ’j7, _–ě“N–ç8, FŠ™@—ş9, ç—t‘ĺ‰î10, ’ˇ’Jěł—T11, “Ą‘ă‚–ž12, ŽO’J@–Î13 (1‘ĺăŽs‘ĺ ‘ĺŠw‰@ˆăŠwŒ¤‹†‰Č ŽŒ`ŠO‰ČŠw, 2•Ÿ“‡Œ§ˆă‘ĺ ŠOÄŒšŠw, 3”’’ë•a‰@ ŽŒ`ŠO‰Č, 4ŽŠO, 5Œc‰ž‘ĺ ˆă ŽŒ`ŠO‰ČŠw, 6]“ěŒúś•a‰@ ŽŒ`ŠO‰Č, 7‡“V“°‘ĺ ˆă Ă‰Ş•a‰@ŽŒ`ŠO‰Č, 8ŕՋŚˆă‘ĺ é‹Ęˆă—ĂƒZ ‘ć“ńŽŒ`ŠO‰Č, 9‘ĺăŽs‘ĺ ‘ĺŠw‰@ˆăŠwŒ¤‹†‰Č ŽŒ`ŠO‰ČŠw, 10“Œ–k‘ĺ ˆă ŽŒ`ŠO‰Č, 11ŽOd‘ĺ ‘ĺŠw‰@ˆăŠwŒ¤‹†‰Č ŽŒ`ŠO‰ČŠw, 12‚’Εa‰@ ŽŒ`ŠO‰Č, 13ěčˆă‘ĺ ŽŒ`ŠO‰ČŠw): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/15), “Œ‹ž, “ú–{lHŠÖßŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2019; p.249.

723544. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ăřœƒRƒ“ƒ|[ƒlƒ“ƒg‚ĚƒZƒƒ“ƒgŒĹ’č‚É‚ć‚éˆĘ’u‚ĚˆÚ“Ž‚ƍœˆÚA‚É‚ć‚é‚ť‚̐§Œä. •C“c‹M‰ë, ŹŁNŽĄ1, •˝ě‹IŽq1 (1–k—˘ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/15), “Œ‹ž.

723545. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) E1ƒ‰ƒCƒi[‚đ—p‚˘‚˝THAŒă‚Ě–€–ŐŒv‘ށ`‹ŕ‘Žœ“Ş‚ĆCeramicœ“Ş‚Ě‘OŒü‚Ť–łěˆ×‰ť‘˝Ž{Ý‹¤“ŻŒ¤‹† ‘ć4•ń`. ‹ŕŽq”Ž“ż1, ‘ĺ‹´OŽk2, –؉ş_ˆę3, “ŕŽRŸ•ś4, ‹ŕŽĄ—L•F5 (1–k—˘Œ¤‹†Š•a‰@, 2‘ĺă•{Ďś‰ď’†’Ă•a‰@ ŽŒ`ŠO‰Č, 3•Ÿ‰Ş‘ĺˆă ŽŒ`ŠO‰Č, 4ŽŠO, 5Œc‰ž‘ĺˆă ŽŒ`ŠO‰ČŠw): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/16), “Œ‹ž.“ú–{lHŠÖßŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2019; 49th: 315.

723546. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 10”NˆČă‚Ě’ˇŠúŒŒ‰t“§ÍŠłŽŇ‚É‚¨‚Ż‚éƒZƒƒ“ƒgƒŒƒXƒXƒeƒ€‚ĚŒĹ’čŤ‚ĚŒŸ“˘. ŽR–{‹–ž1, “ŕŽRŸ•ś2, Źň‰pŽ÷1, ‰““ĄˆŸšŽq1, ‚•˝ŽL3, m–Ř‹vĆ1 (1šƒ}ƒŠƒAƒ“ƒiˆă‘ĺˆă ŽŒ`ŠO‰Č, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć49‰ń“ú–{lHŠÖßŠw‰ď (2019/2/16), “Œ‹ž.“ú–{lHŠÖßŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2019; p.507.

723547. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Š°œ‰P”핢‚ĆŇ’Ĺœ”Ő–îó–ĘƒAƒ‰ƒCƒƒ“ƒg‚Ć‚ĚŠÖ˜A‚ĚŒŸ“˘. •Ÿ“‡Œ’‰î1, ‹{éłs1, ˆäă@Œş1, ”’ŕV‰hŽ÷1, ‘ĺ’|—IĆ1, “ŕŽRŸ•ś1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): ‘ć9‰ń“ú–{ŹlŇ’Œ•ĎŒ`Šw‰ď (2019/3/2), “Œ‹ž.

723548. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) OLIF + Œă•űŒĹ’č‚É‚¨‚Ż‚éI”‘š‚ÉŠÖ‚ˇ‚錟“˘. ˆäă@Œş1, âV“Ą@˜j1, ‹{éłs1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ě‹v•Ű•ŕ2, ’†ŕVr”V1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć9‰ń“ú–{ŹlŇ’Œ•ĎŒ`Šw‰ď (2019/3/2), “Œ‹ž.

731045. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖßŽüˆÍŠ´ő‚̐f’f‚ĆŽĄ—Ă. “ŕŽRŸ•ś (ŽŠO): ‘Š–ÍŒ´Žs‘ĺ˜aŽsŽŒ`ŠO‰Čˆă‰ď‡“ŻŠwpu‰‰‰ď (2018/4/14), ‘Š–Í‘ĺ–ě.

731046. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”ńś‘Ě“ŻŽíœˆÚA‚Ě•K—vŤ‚ƍœƒoƒ“ƒN‚̐ݗ§. “ŕŽRŸ•ś (ŽŠO): ‘ć50‰ń–kŠC“šŒŇŠÖßŒ¤‹†‰ď (2018/6/9), ŽD–y.

731047. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‹–‚ł‚ę‚éDelay, ‹–‚ł‚ę‚´‚éDelay ‘ć2’e|Complex Elbow Instability|—Տ°‰đ–U‚𒆐S‚Ɂ|. •ě_Žm (ŽŠO): ‘ć14‰ńç—tăŽˆƒZƒ~ƒi[ (2018/6/30), ç—t.

731048. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽčE•IŠÖßŽžŠł‚ĆŠO‚̐f’f‚ĆŽĄ—Á`Ĺ‹ß‚Ě’mŒŠ‚đŠÜ‚߂ā`. •ě_Žm (ŽŠO): ‘ć127‰ń‘Š–ÍŒ´ŽsˆăŽt‰ďŽŒ`ŠO‰Čˆă‰ďŠwpu‰‰‰ď (2018/7/5), ‘Š–ÍŒ´.

731049. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Diagnosis for femoroacetabular impingement (FAI) in Japan. •Ÿ“‡Œ’‰î (ŽŠO): ‘ć14‰ń“ú–{ŒŇŠÖß‹žŒ¤‹†‰ď (2018/9/1), •Ÿ‰Ş.

731050. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Œ‹‰Ę‚Š‚çÄl‚ˇ‚éŇ’ĹŽčp’áNP‰ť‚ĚŽŽ‚Ý. ˆäă@Œş (ŽŠO): ‘ć11‰ńŠÖ“ŒMIStŒ¤‹†‰ď (2018/9/1), “Œ‹ž.

731051. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “úíŠO—ˆ‚É‚¨‚Ż‚é, ‘lŒa•”’ɂ̐f—Ă. •Ÿ“‡Œ’‰î (ŽŠO): ‰Ą•l–k•”–k—˘ŽŒ`ŠO‰Čˆă‰ď (2018/9/26), V‰Ą•l.

731052. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖßŽüˆÍŠ´ő§ˆł‚Ö‚Ě’§í. “ŕŽRŸ•ś (ŽŠO): ‘ć13‰ńM”Z’ŹŠ´őÇŒ¤‹†‰ď (2018/9/27), M”Z’Ź.

731053. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŠÖßŽüˆÍŠ´őEœ‘‰Š‚ɑ΂ˇ‚éŠO‰Č“IŽĄ—Ă‚ĆR‹Ű–ňŽĄ—Ă‚ĚŽŔŰ. “ŕŽRŸ•ś (ŽŠO): 2018”N‘ć2‰ńR‹Ű‰ťŠw—Ă–@EŠ´ő§Œäę–ĺ–ňÜŽt—{ŹŒ¤‹†‰ď (2018/10/6), Vh.

731054. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖß’uŠˇp‚ƍœ‘e頏Ç. “ŕŽRŸ•ś (ŽŠO): ‘ć6‰ńĂ“ě’n‹ćŽŒ`ŠO‰ČƒZƒ~ƒi[ (2018/10/31), “Ą‘ň.

731055. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖßŽüˆÍŠ´őg0 (ƒ[ƒ)g‚Ö‚Ě’§í. “ŕŽRŸ•ś (ŽŠO): ŽŒ`ŠO‰ČŽčp‚đl‚Ś‚é‰ď (2018/11/5), ˆŽě.

731056. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖßŽüˆÍMRSAŠ´ő‚É‚¨‚Ż‚éV‚˝‚ČŽĄ—Ð헪. “ŕŽRŸ•ś (ŽŠO): é–kMRSAŠ´őÇƒZƒ~ƒi[ (2018/12/13), “Œ‹ž.

731057. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ꋌa•”’É‚đ[‚­f‚é-Dysplasia, FAI‚đŠÜ‚ß‚Ä-. •Ÿ“‡Œ’‰î (ŽŠO): GIFU Advanced Joint Seminar (2019/2/9), Šň•Œ.

731058. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) HipAlign Supine‚đ—p‚˘‚˝ALS-THA‚ƓŤlHŒŇŠÖßŽüˆÍŠ´őÇ (PJI) ‚ɑ΂ˇ‚鎥—Ă. “ŕŽRŸ•ś (ŽŠO): Banetsu Active Career Meeting (2019/2/23), VŠƒ.

731059. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) lHŒŇŠÖßŽüˆÍŠ´ő‚Ě—\–hEf’fEŽĄ—Ă. “ŕŽRŸ•ś (ŽŠO): ‘ć3‰ńĂ‰ŞŒ§“Œ•”ŽŒ`ŠO‰Č“ŤŠ´őÇŒ¤‹†‰ď (2019/3/6), Ă‰Ş.

731060. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “úíŠO—ˆ‚É‚¨‚Ż‚éꋌa•”’ɂ̐f—Ă. •Ÿ“‡Œ’‰î (ŽŠO): ‘ć10‰ńŒN’Ă–ŘX’ÐŽŒ`ŠO‰Čˆă‰ďŠwpW‰ď (2019/3/14), –؍X’Ă.

731061. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) lHŒŇŠÖßƒXƒeƒ€ŽüˆÍœÜ‚ɑ΂ˇ‚鎥—Ă•űj’´‚•ŞŽq—Ęƒ|ƒŠƒGƒ`ƒŒƒ“ťƒP[ƒuƒ‹‚đ—p‚˘‚˝ŒĹ’č–@. “ŕŽRŸ•ś (ŽŠO): “ú–{œÜŽĄ—ĂŠw‰ď@•˝Ź30”N“xŒ¤C‰ď@‘ć13‰ńƒx[ƒVƒbƒNƒR[ƒXE‘ć10‰ńƒAƒhƒoƒ“ƒXƒR[ƒX (2018/9/23), _ŒË.

732043. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŽŒ`ŠO‰Č—ĚˆćŠó­Š´őÇ‚ĚŽĄ—Á|ƒmƒJƒ‹ƒWƒAŠ´őÇ‚𒆐S‚Ɂ|. “ŕŽRŸ•ś (ŽŠO): ‘ć10‰ń“Œ‹ž“ŤŠ´őÇŒ¤‹†‰ď (2018/11/10), “Œ‹ž.

733180. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šî‘bŽžŠł‚âŠO—đ‚Ě‚Č‚˘Ç—á‚ɐś‚ś‚˝, ListerŒ‹ß•”‚̍œž™‚É‚ć‚é’ˇ•ęŽwL‹ŘäF”牺’f—ô‚Ě1—á. “Ą–쏯‘ž˜Y1, ŹŔŒŤŽĄ1, •ě_Žm1, ‘ĺ’|—IĆ1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć689‰ńŠÖ“ŒŽŒ`ĐŠQŠO‰ČŠw‰ďŒŽ—á‰ď (2018/6/23), “Œ‹ž.

733181. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) lHŠÖß’uŠˇp‚É‚¨‚Ż‚鎄‚̍H•v: lH•GŠÖß’uŠˇp‚É‚¨‚Ż‚é“ŻŽí‘gDˆÚA‚Ě•š—p. ‘Šě@~1, ŠâŁ@‘ĺ1, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, “ŒŽR—玥1, ‚–쏸‘ž˜Y2, Œ}@@Šw2, ‚‘ŠťŽm1, č•”@Œ›1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć163‰ń_“ސ쐎Œ`ĐŠQŠO‰ČŒ¤‹†‰ď (2018/7/21), ‰Ą•l.

733182. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Pain DETECT‚ŞŒŇŠÖßO‘šŠłŽŇ‚ĚŽĄ—Ă•űj‚ĚŒˆ’č‚É—L—p‚Ĺ‚ ‚Á‚˝3Ç—á. •Ÿ“‡Œ’‰î1, ’†˜e[Í2, ˆäă@Œş1, “ŕŽRŸ•ś1, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): Hip Forum 2018 (2018/7/27), ‹ŕ‘ň.

733183. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) CRŒ^‚s‚j‚`‚É‚¨‚Ż‚épŒă‹ü‹ČŠp“x•s—Ç—áˆöŽq‚ĚŒŸ“˘. •˝ě‹IŽq (–k—˘ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć67‰ń“Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ď (2018/9/22), H“c.

733184. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) AŒQƒŔ—n˜A‹Ű‚É‚ć‚é•ęŽw‰óŽ€Ť“î•”‘gDŠ´őÇ‚ĚŽĄ—ĂŒoŒą. ě‹v•Ű•ŕ1, •ě_Žm2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ‰ĄŠÖ—YŽi2, A‘—RˆÉ2, ˆäă@ăÄ2, ŒŠ–Ú’q‹I2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć24‰ń_“ސěăŽˆŠO‰ČŒ¤‹†‰ď (2018/10/13), ‰Ą•l.

733185. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”˝“]‚ľ‚˝ś‘¤—ô—Łœ•Đ‚𔺂Á‚˝žôœŽčŞŠÖß”w‘¤’E‰PœÜ‚Ě1—á. ‘ĺ’|—IĆ1, •ě_Žm1, ŹŔŒŤŽĄ1, –ÚŽž—LŠóŒb1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć24‰ń_“ސěăŽˆŠO‰ČŒ¤‹†‰ď (2018/10/13), ‰Ą•l.

733186. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šî‘bŽžŠł‚âŠO—đ‚Ě‚Č‚˘’jŤ‚ɐś‚ś‚˝’ˇ•ęŽwL‹Ř”牺’f—ô‚Ě1—á. “Ą–쏯‘ž˜Y1, ŹŔŒŤŽĄ1, •ě_Žm1, ‘ĺ’|—IĆ1, ŒŠ–Ú’q‹I1, Ź—Ń–žł, ‚‘ŠťŽm1 (1ŽŠO): ‘ć24‰ń_“ސěăŽˆŠO‰ČŒ¤‹†‰ď (2018/10/13), ‰Ą•l.

733187. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠO‘¤”źŒŽˆŸ‘S“EpŒă‚Ě•ĎŒ`Ť•GŠÖßÇ‚ɑ΂ľ“ŻŽí”źŒŽˆÚAp‚đs‚Á‚˝1—á. ŹŁNŽĄ1, •˝ě‹IŽq1 (1–k—˘ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): –k‘Ť—§ŒSŽsˆăŽt‰ďˆăŠw‰ď (2018/10/20), é‹ĘŒ§.

733188. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) lH•GŠÖß‘S’uŠˇpŒă‚É•GŠÖß”ńŒ‹ŠjŤRŽ_‹ŰÇ‚Ć”ť–ž‚ľ‚˝ŠÖßƒŠƒEƒ}ƒ`‚Ě1—á. ‹{“c@Ž÷1, •ě_Žm1, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, ŒŠ–Ú’q‹I1, ŠâŁ@‘ĺ1, “ě’J@~, ‚‘ŠťŽm1 (1ŽŠO): ‘ć691‰ńŠÖ“ŒŽŒ`ĐŠQŠO‰ČŠw‰ďŒŽ—á‰ď (2018/12/15), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110025. [Œ´’˜] Degradation of Cylindrical Poly-Lactic Co-Glycolide/Beta-Tricalcium Phosphate Biocomposite Anchors After Arthroscopic Bankart Repair: A Prospective Study. Matsuki K, Sugaya H, Takahashi N, Kawasaki T, Yoshimura H, Kenmoku T1: Orthopedics 2018/3; 4 1(3): e348-53. (ŒŠ–Ú’q‹I1: 1ŽŠO)

H29-521001. [‰đŕ]yŽŒ`ƒgƒsƒbƒNƒXz•ĎŒ`Ť•GŠÖßÇŠŠ–Œ‘gD‚É‚¨‚Ż‚éCOX-2/PGE2‚đ‰î‚ľ‚˝ƒJƒ‹ƒVƒgƒjƒ“ˆâ“`ŽqŠÖ˜Aƒyƒvƒ`ƒhƒVƒOƒiƒŠƒ“ƒO‚̐§Œä‚Ćáu’É‚Ö‚ĚŠÖ—^. “ě’J@~1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1 (1ŽŠO): —Տ°ŽGŽ ŽŒ`ŠO‰Č 2018/3; 69 (3): 230.

H29-522005. [uŔ]y“ÁW: ŒŇŠÖß‚𒆐S‚Ć‚ľ‚˝ŽOŽŸŒłƒAƒ‰ƒCƒƒ“ƒg hip-spine‚Ćhip-kneezŒŇŠÖß’É‚Ć˜’É‚ĚŠÖ˜A‚Ć•a‘Ô. ‹{éłs (ŽŠO): ŠÖßŠO‰Č 2018/1; 37 (2): 174-8.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723011. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†ŠÔ‘}“ü•¨‚É“ŻŽí’°ăřx‘Ń‚đ—p‚˘‚ÄŽĄ—Ă‚ľ‚˝ŠOŤžôŽÚœ–ü‡Ç‚ĚŽĄ—ĂŒoŒą. •ě_Žm1, ŹŔŒŤŽĄ1, ŒŠ–Ú’q‹I1, ‘ĺ’|—IĆ1, •“cW‹`1, “ŕ“cŒ’‘ž˜Y1, ‰ĄŠÖ—YŽi1, ‚“c@Œ¤2, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć30‰ń“ú–{•IŠÖßŠw‰ďŠwpW‰ď (2018/2/16), “Œ‹ž.

H29-732003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€)yœ‘e頏ǎĄ—Ă‚É‚¨‚Ż‚étreat-to-target (T to T)zœ‘e頏ǎĄ—Ă‚É‚¨‚Ż‚étreat-to-target: œ‘e頏ǎĄ—Ă‚É‚¨‚Ż‚鍜Œ`Ź‘ŁiÜ‚ĚˆĘ’u‚Ă‚Ż. ‹{éłs1, “ĄŠŞŽőŽq, ŹŁNŽĄ1, “c“‡Gˆę˜Y1, ‘ş“cK—C2, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć58‰ńŠÖ“ŒŽŒ`ĐŠQŠO‰ČŠw‰ď (2018/3/17), “Œ‹ž.

H29-733002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Žč‚Š‚ç‘O˜r‹ßˆĘ•”‚É”g‹y‚ľ‚˝”ńŒ‹ŠjŤRŽ_‹ŰÇ (Mycobacterium arupense) ‚Ě1—á. •ě_Žm1, ‰ĄŠÖ—YŽi1, ‘ĺ’|—IĆ1, ŹŔŒŤŽĄ1, ˆäă@ăÄ1, @d‹żŽq1, ˜a“c’B•F2, ‚•˝ŽL3, ‚‘ŠťŽm1 (1ŽŠO, 2äPŒ´•aEŠ´ő“ŕ, 3ˆă—ÉqśŠw•”): ‘ć32‰ń“Œ“ú–{ŽčŠO‰ČŒ¤‹†‰ď (2018/2/3), “Œ‹ž.


Œ`ŹŠO‰ČE”ü—eŠO‰ČŠw

[Šwp˜_•ś]

110026. [Œ´’˜] Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1+ cells from bone marrow. Park K1, Amano H2, Ito Y2, Mastui Y3, Kamata M4, Yamazaki Y1, Takeda A1, Shibuya M, Majima M2: Anat Sci Int 2018/6; 93 (3): 372-83. (–p@Œ\ˆę1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, źˆäŒ[•v3, Š™“c^—Žq4, ŽRčˆŔ°1, •“c@Œ[1, ”n“ˆł—˛2: 1Œ`ŹE”üŠO, 2–ň—, 3ŒÄ‹zŠíŠO, 4t‘Ÿ“ŕ)

120019. [Œ´’˜] “ú–{l‚đ‘ÎŰ‚Ć‚ľ‚˝ƒqƒAƒ‹ƒƒ“Ž_”畆[“UÜ‚đ—p‚˘‚˝Šç–Ę‚Ě‚ľ‚펥—Ă‚É‚¨‚Ż‚éŒř‰Ę‚ĆˆŔ‘SŤ. ŒĂŽR“o—˛1, ‘Ť—§^—R”ü1, Vé@Œ›1, ”Ń”ö—ç”ü1, ˆÉ’O@˛1, Ąň–žŽq1, ŠŒ´•üŒb1, ‰Í–ě‘ž˜Y1, Ź–öˆß—™Žq1, ˛“Ą‰p–ž1, •“c@Œ[2, “c’†ˆŸŠóŽq1, ’Ř“ŕ—˜]Žq1, ’†–kMş1, ź‘ş@—Y1, “n粐çt1 (1ŽŠ—R‚Ş‹uƒNƒŠƒjƒbƒN, 2Œ`ŹE”üŠO): “ú–{”ü—eŠO‰ČŠw‰ď‰ď•ń 2018; 40 (4): 119-35.

320026. [Ç—á•ń] ‰şŠ{“Ş‹zŽű‚𔺂¤œŠiŤ‰şŠ{Œă‘ŢÇ‚É‘Î‚ľ‚ÄŠ{‹¸łŽčp‚đŽ{s‚ľ‚˝2—á. ŒN’ˍKŽq1, ŽRčˆŔ°1, ™–{‰Ŕ1, XŽR˜a‚Ě1, ™–{F”V1, ÎěS‰î1, Î“n–ő•v, •“c@Œ[1 (1Œ`ŹE”üŠO): –k—˘ˆăŠw 2018/6; 48 (1): 33-40.

[’˜@‘]

620095. [Šwp‘ (•ŇW)]y–Ń”Ż|ƒKƒCƒhƒ‰ƒCƒ“2017‚đ“Ľ‚Ü‚Ś‚˝ŽĄ—Ăupdate|z•Ň: •“c@Œ[ (Œ`ŹE”üŠO), Ž˝“°o”Ĺ, “Œ‹ž, 2018/4”­s.

620096. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj 2019”N”Łz‘˜_@2. ’†“ŐŤŽžŠł@ƒwƒr™ů (ƒ}ƒ€ƒV, ƒnƒu), p.156-7. Ş–{@[ (Œ`ŹE”üŠO), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2019/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712030. [Šw‰ď (‘Ű)] (‹łˆçu‰‰) Rhinoplasty Using Diced Cartilage Wrapped with Fascia. Takeda A1, Nakamura H1, Iwakawa S1, Ishikawa S1, Nemoto M1: 18Th International Congress of Plastic and Reconstruction Surgery in Shanghai (2019/3/16), Shanghai, China. (•“c@Œ[1, ’†‘şGŒő1, Šâě‚ł‚¨‚č1, ÎěS‰î1, Ş–{@[1: 1Œ`ŹE”üŠO)

713125. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Biological differences of human mesenchymal cells derived from different bone tissues and comprehensive gene expression analysis. Yamazaki Y1, Sugimoto Y1, Moriyama K1, Baba K2, Sone Y3, Sugimoto T1, Iwata T, Onizuka S, Takeda A1: Society For Biomaterials 2018 Annual Meeting (2018/4/12), Atlanta, USA. (ŽRčˆŔ°1, ™–{‰Ŕ1, XŽR˜a‚Ě1, ”nęŽq2, ‘]Ş—R”üŽq3, ™–{F”V1, •“c@Œ[1: 1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ĂŒn)

713126. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Umbilical cord blood derived fibrin net and platelet-rich-plasma have potency in osteogenic regenerative medicine. Baba K1, Yamazaki Y2, Sone Y3, Sugimoto Y2, Moriyama K2, Sugimoto T2, Kumazawa K4, Takeda A2: Society For Biomaterials 2018 Annual Meeting (2018/4/11-14), Atlanta, USA. (”nęŽq1, ŽRčˆŔ°2, ‘]Ş—R”üŽq3, ™–{‰Ŕ2, XŽR˜a‚Ě2, ™–{F”V2, ŒFŕVŒ›ˆę4, •“c@Œ[2: 1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO, 3•a‘ԁEf—ĂŒn, 4‹~–˝)

713127. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Examination of Exosome purification method derived from culture supernatant of the mesenchymal cells from human ilium bone(hBMCs) which we chose and the bone differentiation inducibility. Sugimoto Y1, Yamazaki Y1, Moriyama K1, Baba K2, Sone Y3, Sugimoto T1, Kumazawa K4, Takeda A1: Society For Biomaterials 2018 Annual Meeting (2018/4/11-14), Atlanta, USA. (™–{‰Ŕ1, ŽRčˆŔ°1, XŽR˜a‚Ě1, ”nęŽq2, ‘]Ş—R”üŽq3, ™–{F”V1, ŒFŕVŒ›ˆę4, •“c@Œ[1: 1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ĂŒn, 4‹~–˝)

713128. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) Frontalis musculocutaneous flap for coverage of temporal skin defect with facial nerve paralysis. Watou J1, Takeda A1, Hyodo T1, Iwakawa S1, Taguchi N1, Shimomura M1, Ugajin K1, Shinozaki T1: 14th KJPRS (2018/6/3), Pyeongchang, Korea. (˜a“‚ƒ•˝1, •“c@Œ[1, •ş“Ş“O–ç1, Šâě‚ł‚¨‚č1, “cŒűŹ”ü1, ‰ş‘şŽŔ‹MŽq1, ‰F‰ę_Š”ü1, ŽÂč’qŒö1: 1Œ`ŹE”üŠO)

713129. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Filler-induced granulomatous reaction of nose: a case report. Takeda A1, Iwakawa S1, Shimomura M1, Taguchi N1, Moriyama K1: 14th KJPRS (2018/6/3), Pyeongchang, Korea. (•“c@Œ[1, Šâě‚ł‚¨‚č1, ‰ş‘şŽŔ‹MŽq1, “cŒűŹ”ü1, XŽR˜a‚Ě1: 1Œ`ŹE”üŠO)

713130. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Cryopreserved Umbilical cord derived Mesenchymal Stromal Cells have Osteogenic@potency as the source of osteogenic regenerative medicine. Baba K1, Yamazaki Y2, Sone Y3, Sugimoto Y2, Moriyama K2, Sugimoto T2, Kumazawa K4, Takeda A2: 14th KJPRS (‘ć14‰ńŠŘ“úŒ`ŹŠO‰ČŠw‰ď) (2018/6/3-5), PyeongChang, Korea. (”nęŽq1, ŽRčˆŔ°2, ‘]Ş—R”üŽq3, ™–{‰Ŕ2, XŽR˜a‚Ě2, ™–{F”V2, ŒFŕVŒ›ˆę4, •“c@Œ[2: 1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO, 3•a‘ԁEf—ĂŒn, 4‹~–˝)

713131. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A patient with IgG4-related Mikulicz's disease involving enlarged lacrimal glands. Moriyama K1, Baba K2, Ishiguro M, Takeda A1: 14th KJPRS (‘ć14‰ńŠŘ“úŒ`ŹŠO‰ČŠw‰ď) (2018/6/3-5), PyeongChang, Korea. (XŽR˜a‚Ě1, ”nęŽq2, •“c@Œ[1: 1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713132. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Co-culture of Umbilical Cord derived Mesenchymal Stem Cells (UCMSCs) and Bone Marrow derived Mesenchymal Stem Cells (BMMSCs) /Chondrocytes improved the Osteogenic/Chondrogenic differentiation. Baba K1, Yamazaki Y2, Sone Y3, Sugimoto Y2, Moriyama K2, Sugimoto T2, Kumazawa K4, Takeda A2: 5th TERMIS World Congress (‘ć5‰ń‘Ű‘gDHŠwEÄśˆă—ĂŠw‰ď ˘ŠE‰ď‹c2018) (2018/9/4-7), Kyoto, Japan. (”nęŽq1, ŽRčˆŔ°2, ‘]Ş—R”üŽq3, ™–{‰Ŕ2, XŽR˜a‚Ě2, ™–{F”V2, ŒFŕVŒ›ˆę4, •“c@Œ[2: 1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO, 3•a‘ԁEf—ĂŒn, 4‹~–˝)

713133. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) Cost of inpatients with foot problems covered by health insurance in Japn and measures against long hospital stay. Watou J1, Kashiwagi S1: The 20th congress of the International Association of Rural Health ane Medicine (2018/10/10-12), Tokyo, Japan. (˜a“‚ƒ•˝1, ”–ؐT–ç1: 1Œ`ŹE”üŠO)

713134. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) Use of NPWT for Skin Graft Fixation Over Uneven Skull Defects. Kashiwagi S1: 18Th International Congress of Plastic and Reconstruction Surgery in Shanghai (2019/3/16), Shanghai, China. (”–ؐT–ç1: 1Œ`ŹE”üŠO)

713135. [Šw‰ď (‘Ű)] (ˆę”ʉ‰‘č) Filler-induced Granulomatous Reaction of Nose. Nakamura H1: 18Th International Congress of Plastic and Reconstruction Surgery in Shanghai (2019/3/16), Shanghai, China. (’†‘şGŒő1: 1Œ`ŹE”üŠO)

722108. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –k—˘‘ĺŠw•a‰@Œ`ŹŠO‰ČE”ü—eŠO‰Č‚É‚¨‚Ż‚鉺‘ځC‘Ť•”œ‘‰Š‚ĚŽĄ—ÐŹ. Ş–{@[1, ”–ؐT–ç1, ŒFŕVŒ›ˆę2, ƒ’r“Ţ’ĂŽq1, ‹g’|r—T, XŽR˜a‚Ě1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/11), •Ÿ‰Ş.

722109. [Šw‰ď (‘S‘) (ƒVƒ“ƒ|ƒWƒEƒ€) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŒűŠW—ôŽĄ—Á|Œ`ŹŠO‰Čˆă‚ĆŒžŒę’ŽŠoŽm‚Ě˜AŒg|. ™–{F”V1, ‰Ş•”‘•c, ŽRčˆŔ°1, ŒN’ˍKŽq1, ŒE“cçť, ™–{‰Ŕ1, –q@“ÖŽq2, ‘ĺŒ´‘ěĆ2, Î“n–ő•v, ă–슰Žq, —é–ŘŒbŽq, ÎěS‰î1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2018/5/24), ‘ĺă.

722110. [Šw‰ď (‘S‘) (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠO•@ÄŒš‚ĚAesthetic mind. •“c@Œ[1, ‰ş‘şŽŔ‹MŽq1, “cŒűŹ”ü1, Šâě‚ł‚¨‚č1, XŽR˜a‚Ě1 (1Œ`ŹE”üŠO): ‘ć36‰ń“ú–{“ŞŠWŠ{Šç–ĘŠO‰ČŠw‰ďŠwpW‰ď (2018/10/11), ŽD–y.

723549. [Šw‰ď (‘S‘) (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é_ŒoâŽîÇ—á‚ĚŒŸ“˘`“Á‚É’´‰š”gŒŸ¸‚ɂ‚˘‚ā`. ”–ؐT–ç1, “cŒűŹ”ü1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723550. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) —ÖŠsŒ`‘Ô‚đl—ś‚ľ‚čs‚Á‚˝‰şŠ{œ’P“ĆŽčp‚É‚ć‚éŠ{•ĎŒ`ÇŽĄ—Ă. •ş“Ş“O–ç1, ™–{F”V1, ŒN’ˍKŽq1, ŽRčˆŔ°1, ’†–kMş2, •{ěr•F3, •“c@Œ[1 (1Œ`ŹE”üŠO, 2ŽŠ—R‚Ş‹uƒNƒŠƒjƒbƒN, 3‚Ó‚Š‚틸łŽ•‰Č): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723551. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) Ž¨‰î‚Š‚ç•@’Œ‚Ö‚Ě•Ą‡‘gDˆÚA‚đs‚Á‚˝O—ô•@•ĎŒ`‚Ě2—á. ÎěS‰î1, ™–{F”V1, ™–{‰Ŕ1, ŒN’ˍKŽq1, ŽRčˆŔ°1, •ş“Ş“O–ç1, Šâě‚ł‚¨‚č1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723552. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) —ŤŠO‰A•”“ű–[ŠOƒpƒWƒFƒbƒg•a‚̐؏œ’f’[—zŤ—á‚ĚŒŸ“˘. ƒ’r“Ţ’ĂŽq1, H–{•ôŽ1, ‰ş‘şŽŔ‹MŽq1, “cŒűŹ”ü1, XŽR˜a‚Ě1, •ş“Ş“O–ç1, Šâě‚ł‚¨‚č1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723553. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) ‰Ć‘°ŤƒAƒ~ƒƒCƒhƒ|ƒŠƒjƒ…[ƒƒpƒ`[‚É‚ć‚éŠç–ʐ_Œo–ƒáƒ‚ɑ΂ľ‚ĐÓIÄŒšp‚đŽ{s‚ľ‚˝ ˆę—á . ‰ş‘şŽŔ‹MŽq1, ÎěS‰î1, ™–{F”V1, ™–{‰Ŕ1, •ş“Ş“O–ç1, Šâě‚ł‚¨‚č1, “cŒűŹ”ü1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723554. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) ƒeƒBƒbƒVƒ…EƒGƒLƒXƒpƒ“ƒ_[–@‚Ě‚Ý‚Ĺ‘SŘœ‚ľ‚˝‹‘ĺF‘fŤ•ę”Á‚Ě’ˇŠúŒo‰ß. Šâě‚ł‚¨‚č1, ‰ş‘şŽŔ‹MŽq1, “cŒűŹ”ü1, ŁčWˆę˜Y1, ‰F‰ę_Š”ü1, ˜a“‚ƒ•˝1, ŽÂč’qŒö1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723555. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) Anomalous articulation‚Ě1—á. ‰F‰ę_Š”ü1, Ş–{@[1, ”–ؐT–ç1, ƒ’r“Ţ’ĂŽq1, ˜a“‚ƒ•˝1, ŽÂč’qŒö1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć61‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/4/12), •Ÿ‰Ş.

723556. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’Ü•ĎŒ`‚𔺂Á‚˝’ÜŽüˆÍŽîᎂɑ΂ˇ‚éŽčpŹŃ. Ş–{@[1, ”–ؐT–ç1, ŒFŕVŒ›ˆę2, ‰ş‘şŽŔ‹MŽq1, “cŒűŹ”ü1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć61‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2018/4/27), “Œ‹ž.

723557. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”ç•Ů‚É‚ć‚éÄŒš‚đ—v‚ľ‚˝ăŽˆfriction injury‚Ě1—á. Ş–{@[1, ˜a“‚ƒ•˝1, ŒFŕVŒ›ˆę2, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć44‰ń“ú–{”MŠw‰ď‘‰ďEŠwpW‰ď (2018/5/17), “Œ‹ž.

723558. [Šw‰ď (‘S‘) (ˆę”ʍu‰‰) ”M‚Ě‹ÇŠ•Ű‘ś—Ă–@|‰Šúf—Ă‚Š‚疝ŤŠú‚܂Ł|. Ş–{@[ (Œ`ŹE”üŠO): ‘ć44‰ń“ú–{”MŠw‰ď‘‰ďEŠwpW‰ď (2018/5/18), “Œ‹ž.

723559. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) •Đ‘¤OŠ{ŒűŠW—ôŠłŽŇ‚É‚¨‚Ż‚éFurlow•Ď–@‚đ—p‚˘‚˝ŒűOŒűŠW“ŻŽžŒ`Źp‚Ě–ÍŒ^•]‰ż. Î“n–ő•v1, ‹´–{KŽĄ, “Œ‚ä‚č‚ , ‚‹´ˆę˝1, ŽRčˆŔ°2, ™–{F”V2, ŁčWˆę˜Y2, •“c@Œ[2 (1‚˘‚ľ‚í‚˝‹¸łŽ•‰Č, 2Œ`ŹE”üŠO): ‘ć42‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2018/5/24), ‘ĺă.

723560. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) “]ˆÚŽ•‚ƉߊW™ů‡‚𔺂Á‚˝•Đ‘¤OŠ{ŒűŠW—ô‚Ě‹¸łŽĄ—ÏI—šÇ—á. ‚‹´ˆę˝1, Î“n–ő•v1, ŁčWˆę˜Y2, ‹´–{KŽĄ, ŽRčˆŔ°2, ŒN’ˍKŽq2, ™–{F”V2, •“c@Œ[2 (1‚˘‚ľ‚í‚˝‹¸łŽ•‰Č, 2Œ`ŹE”üŠO): ‘ć42‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2018/5/24), ‘ĺă.

723561. [Šw‰ď (‘S‘) (ˆę”ʍu‰‰) Ray amputation‚đs‚Á‚˝‰EŽŚŽwˆŤŤ•FŽî‚Ěˆę—á. ‰ş‘şŽŔ‹MŽq1, ”–ؐT–ç1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć34‰ń“ú–{”畆ˆŤŤŽîᇊw‰ďŠwp‘ĺ‰ď (2018/7/5), •lź.

723562. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) ŒűŠWŒ`Źp‚đŽ{s‚ľ‚˝ƒGƒ}ƒkƒGƒ‹ÇŒóŒQ (22trisomy) ‚Ě1—á. ŒN’ˍKŽq1, ™–{F”V1, ÎěS‰î1, ŽRčˆŔ°1, ™–{‰Ŕ1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć36‰ń“ú–{“ŞŠWŠ{Šç–ĘŠO‰ČŠw‰ďŠwpW‰ď (2018/10/11), ŽD–y.

723563. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ÿó—Ź‚đ•š—p‚ľ‚˝‹ÇŠ‰Aˆł•Â˝—Ă–@; Negative Pressure Wound Therapy (NPWT) ‚ĚŽĄ—ĂŒoŒą. ”nęŽq1, ”–ؐT–ç2, Ź—яťŽq, ”öŕV­Šě, ‘ĺ’؉Á“ŢŽq, Î•‹§Žj, •“c@Œ[2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO): ‘ć66‰ń“ú–{E‹ĆEĐŠQˆăŠw‰ďŠwp‘ĺ‰ď (2018/10/20-21), ˜a‰ĚŽR.

723564. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ĐŠQŽž‚É‚¨‚Ż‚鏈•űⳋLÚ‚ÉŠÖ‚ˇ‚é’˛¸. ”–ؐT–ç1, ”nęŽq2 (1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć66‰ń“ú–{E‹ĆEĐŠQˆăŠw‰ďŠwp‘ĺ‰ď (2018/10/20-21), ˜a‰ĚŽR.

723565. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) ƒhƒ‰ƒCƒ\ƒPƒbƒg‚ɑ΂ˇ‚éG-CSFťÜƒWƒFƒ‹‚É‚ć‚鎥—ĂŒoŒą. “nŠŃ@Œ\, ŹŽRç‰Ŕ, “n粑ĺ’q, ’†“‡‰ps, –NŽĄ, ŒN’ˍKŽq1, ŠâˆärŒ›, Œő“ĄŒ’Ži (1Œ`ŹE”üŠO): ‘ć63‰ń“ú–{ŒűoŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/11/2), –‹’Ł.

723566. [Šw‰ď (‘S‘) (ƒ|ƒXƒ^[) “–‰Č‚ĹŒoŒą‚ľ‚˝ƒGƒ}ƒkƒGƒ‹ÇŒóŒQ (22trisomy) ‚Ě1—á. ŒN’ˍKŽq1, ™–{F”V1, ÎěS‰î1, ŽRčˆŔ°1, ™–{‰Ŕ1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć63‰ń“ú–{ŒűoŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/11/3), –‹’Ł.

723567. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹¤”|—{‚Ĺ“ž‚ç‚ę‚˝ä`‘ŃŠÔ—tŒn×–E—R—ˆÄś“‚Ě‘gDŠw“I•]‰ż. ”nęŽq1, ŽRčˆŔ°2, ™–{‰Ŕ2, XŽR˜a‚Ě2, ™–{F”V2, ŒFŕVŒ›ˆę3, •“c@Œ[2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO, 3‹~–˝): ‘ć18‰ń“ú–{Äśˆă—ĂŠw‰ď‘‰ď (2019/3/21), _ŒË.

723568. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) œ‘gD—R—ˆŠÔ—tŒn×–E‚Ě•Ş‰ť”\E‘B”\E˜V‰ťŒťŰ‚ĚŠm”F`20”NE15”NE10”NE5”NE1”N‚Ě•Ű‘śŒŸ‘Ě‚đ—p‚˘‚ā`. ™–{‰Ŕ1, ŽRčˆŔ°1, XŽR˜a‚Ě1, ™–{F”V1, ŒFŕVŒ›ˆę2, ”nęŽq3, ‘]Ş—R”üŽq4, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ĂŒn): ‘ć18‰ń“ú–{Äśˆă—ĂŠw‰ď‘‰ď (2019/3/22), _ŒË.

723569. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Š{œ—R—ˆ‚¨‚ć‚Ń’°œ—R—ˆŠÔ—tŒn×–E‚Ě‘˝•Ş‰ť”\‚̍ˇˆŮ‚ɂ‚˘‚Ä. XŽR˜a‚Ě1, ŽRčˆŔ°1, ™–{‰Ŕ1, ™–{F”V1, ŒFŕVŒ›ˆę2, ”nęŽq3, ‘]Ş—R”üŽq4, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ĂŒn): ‘ć18‰ń“ú–{Äśˆă—ĂŠw‰ď‘‰ď (2019/3/23), _ŒË.

731062. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –Ń”ŻŽĄ—Ă‚É‚¨‚Ż‚é“ŕ‰Č“IEŠO‰Č“IŽĄ—Ð헪. •“c@Œ[ (Œ`ŹE”üŠO): ŠÖ“ŒŒ`ŹŠO‰ČŠw‰ď‘ć291‰ń“Œ‹ž’n•ű‰ď (2018/7/7), “Œ‹ž.

733189. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ű–[ÄŒš‚ĚŽć‚č‘g‚Ý: ŒťóE‰Ű‘čE˜AŒg. ÎěS‰î (Œ`ŹE”üŠO): ‘ć3‰ń_“ސě“ű–[ÄŒšŒ¤‹†‰ď (2018/8/25), ‰Ą•l.

733190. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šç–ʍœ—R—ˆ‚¨‚ć‚Ń’°œ—R—ˆŠÔ—tŒn×–E‚Ě‘˝•Ş‰ť”\‚̍ˇˆŮ‚ɂ‚˘‚Ä. XŽR˜a‚Ě1, ™–{‰Ŕ1, ŽRčˆŔ°1, ™–{F”V1, ŒFŕVŒ›ˆę2, ”nęŽq3, ‘]Ş—R”üŽq4, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ĂŒn): ‘ć21‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2018/10/8), ‘Š–ÍŒ´.

733191. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) œ—R—ˆŠÔ—tŒn×–E‚Ě•Ş‰ť”\@‘B”\E˜V‰ťŒťŰ‚ĚŠm”F`20”NE15”NE10”NE5”NE1”N‚Ć•Ű‘ś‚ł‚ę‚˝‚ŕ‚Ě‚đ”äŠr‚ľ‚Ä. ™–{‰Ŕ1, ŽRčˆŔ°1, XŽR˜a‚Ě1, ™–{F”V1, ŒFŕVŒ›ˆę2, ”nęŽq3, ‘]Ş—R”üŽq4, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ĂŒn): ‘ć21‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2018/10/8), ‘Š–ÍŒ´.

733192. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰şŠ{œŠÖß“Ë‹NœÜ‚ɑ΂ˇ‚éHigh perimandibular approach‚đ—p‚˘‚˝ŠĎŒŒ“IŽ•œp‚ĚŒoŒą. ŽÂč’qŒö1, ŒN’ˍKŽq1, ™–{F”V1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć21‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2018/10/8), ‘Š–ÍŒ´.

733193. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒCƒ“ƒeƒOƒ‰Žg—pŒoŒą‚Ě1—á. ’†‘şGŒő (Œ`ŹE”üŠO): ‘ć21‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2018/10/8), ‘Š–ÍŒ´.

733194. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰şŠ{“Ş‹zŽű‚𔺂¤œŠiŤ‰şŠ{Œă‘ŢÇ‚É‘Î‚ľ‚ÄŠ{‹¸łŽčp‚đŽ{s‚ľ‚˝2—á. ŒN’ˍKŽq1, ŽRčˆŔ°1, ™–{‰Ŕ1, XŽR˜a‚Ě1, ™–{F”V1, ÎěS‰î1, Î“n–ő•v, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć21‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2018/10/8), ‘Š–ÍŒ´.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-733003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) MPŠÖß‹­’źÇ‚Ě1—á. Ş–{@[ (Œ`ŹE”üŠO): ‘ć12‰ńŠÖ“ŒăŽˆć“VˆŮíÇ—ጟ“˘‰ď (2018/1/18), “Œ‹ž.

H29-733004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”ç•Ů‚É‚ć‚éÄŒš‚đ—v‚ľ‚˝ăŽˆfriction injury‚Ě1—á. Ş–{@[1, ˜a“‚ƒ•˝1, ŒFŕVŒ›ˆę2, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć26‰ń“ú–{”MŠw‰ďŠÖ“Œ’n•ű‰ď (2018/1/20), “Œ‹ž.


”畆‰ČŠw

[Šwp˜_•ś]

110283. [Œ´’˜] Hair-Follicle-Associated Pluripotent (HAP) Stem Cells Encapsulated on Polyvinylidene Fluoride Membranes (PFM) Promote Functional Recovery from Spinal Cord Injury. Obara K1, Tohgi N1, Shirai K1, Mii S1, Hamada Y2, Arakawa N, Aki R1, Singh SR, Hoffman RM, Amoh Y1: Stem Cell Reviews and Reports 2019/1; 15: 59-66. (ŹŒ´GĆ1, “Œ‹V“ß’ĂŽq1, ”’ˆä‹ž”ü1, ŽOˆäƒá1, •l“c—SŽq2, ˆŔĺY—Lję1, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ĂŒn)

110284. [Œ´’˜] The unique tropism of Mycobacterium leprae to the nasal epithelial cells can be explained by the mammalian cell entry protein 1A. Fadlitha VB, Yamamoto F, Idris I, Dahlan H, Sato N1, Aftitah VB, Febriyanda A, Fujimura T1, Takimoto H: PLoS Negl Trop Dis 2019/3; 13 (3): e0006704. (˛“Ą’źĆ1, “Ą‘ş‹ż’j1: 1”畆)

210003. [€Œ´’˜] Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review. Obara K1, Masuzawa M1, Amoh Y1: J Dermatol 2018/5; 45 (5): 587-91. (ŹŒ´GĆ1, ‘ŕV^ŽŔŽq1, “V‰HN”V1: 1”畆)

310025. [Ç—á•ń] A case of primary cutaneous peripheral T-cell lymphoma, not otherwise specified, with cytotoxic phenotype showing multiple ulcers on the entire body. Obara K1, Mii S1, Amoh Y1: J Cutan Pathol 2019/2; 46 (2): 148-51. (ŹŒ´GĆ1, ŽOˆäƒá1, “V‰HN”V1: 1”畆)

320027. [Ç—á•ń] Monoclonal gammopathy of undertermined significance (MUGS) ‚É”ş‚¤‘SgƒAƒ~ƒƒCƒh[ƒVƒX. ă“c‹ŞŽm1, “ŕŠC—F—, “n糐^L, ”’ˆä‹ž”ü1 (1”畆): ”畆•af—Ă 2019/4; 41 (4): 317-20.

510005. [‘ŕ] Hair Follicle-Associated Pluripotent(HAP) Stem Cells. Hoffman RM, Amoh Y1: Prog Mol Biol Transl Sci 2018/11; 160: 23-8. (“V‰HN”V1: 1”畆)

510006. [‘ŕ] Nerve Growth and Interaction in Gelfoam Histoculture: A Nervous System Organoid. Hoffman RM, Mii S1, Duong J, Amoh Y1: Methods Mol Biol 2018; 1760: 163-86. (ŽOˆäƒá1, “V‰HN”V1: 1”畆)

510007. [‘ŕ] Beating Heart Cells from Hair-Follicle-Associated Pluripotent (HAP) Stem Cells. Hoffman RM, Amoh Y1: Methods Mol Biol 2018; 1842: 241-54. (“V‰HN”V1: 1”畆)

[’˜@‘]

620097. [Šwp‘ (•Ş’SŽˇ•M)]y–Ń”Ż|ƒKƒCƒhƒ‰ƒCƒ“2017‚đ“Ľ‚Ü‚Ś‚˝ŽĄ—Ăupdate|z‘ćVÍ ’m‚Á‚Ä‚¨‚­‚ׂŤ–Ń‚ĚŠî‘b@2. –Ń•ď‚̍\‘˘‚Ć–ŃŽüŠú, p.168-77. “V‰HN”V1 (1”畆), •Ň: •“c@Œ[2 (2Œ`ŹE”üŠO), Ž˝“°o”Ĺ, “Œ‹ž, 2018/4”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713136. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The unique tropism of Mycobacterium leprae to the nasal epithelial celle can be explained by the mammalian cell entry protein 1A. Viesta baby Fadlitha, Sato N1, Andini Febriyanda, Vienza Beby Aftitah, Irfan Idris, Takimoto H, Fujimura T1: ˆăŠwś•¨Šw“dŽqŒ°”÷‹ž‹ZpŠw‰ď‘ć34‰ńŠwpu‰‰‰ď‚¨‚ć‚Ń‘‰ďEJoint meeting 7th International Symposium on Electron Microscopy in Medicine and Biology 2018 (2018/5/18), “Œ‹ž. (˛“Ą’źĆ1, “Ą‘ş‹ż’j1: 1”畆):

723570. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŠƒ“ƒpŠÇ“÷Žî‚ÍŒŒŠÇ“÷Žî‚Ěvariant‚Ć‚ľ‚Ä‹ć•Ę‚ł‚ę‚é‚ׂŤ‚Š: “–‰Č‚É‚¨‚Ż‚郊ƒ“ƒpŠÇ“÷Žî20—á‚ĚŒŸ“˘. ‘ŕV^ŽŔŽq1, “Œ‹V“ß’ĂŽq1, •l“c—SŽq2, X@^—, ÎˆäłŽq, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ĂŒn): ‘ć117‰ń“ú–{”畆‰ČŠw‰ď‘‰ď (2018/6/1), L“‡.

723571. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žá”N”­Ç‚Ĺ”­Ç‚ľ”畆‚Ö‚Ě’˜–ź‚ȐΊD’ž’…‚đ‚Ť‚˝‚ľ‚˝‘SgŤ‹­”çÇ‚Ě1—á. ˆŔĺY—Lję1, ”–ˆä—˜‘ĺ1, ‘ŕV^ŽŔŽq1, ”’ˆä‹ž”ü1, Vˆä@’B, źŽ}@—S2, ”–ؐT–ç3, “V‰HN”V1 (11”畆, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`ŹE”üŠO): ‘ć48‰ń“ú–{”畆–ƉuƒAƒŒƒ‹ƒM[Šw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/16-18), “Ţ—Ç.

733195. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •Ą”­Ť‘яóáv]‚Ě2—á‚ƍlŽ@. a’J—ş‘ž1, ‹{ŕV—ŒbŽq1, –î–ěŽu‚¸‚Š1, “n‰ď@W, ”’ˆä‹ž”ü1, “V‰HN”V1 (1”畆): “ú–{”畆‰ČŠw‰ď‘ć881‰ń“Œ‹ž’n•ű‰ď (2018/9/8), “Œ‹ž.

733196. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰ş‘ÚŽĺ‘Ě‚Ég”Á‚𐜂ś‚˝ƒyƒ‰ƒOƒ‰‚Ě1—á. ă“c‹ŞŽm1, Œj@—F—1, ”’ˆä‹ž”ü1 (1”畆): ‘ć82‰ń“ú–{”畆‰ČŠw‰ď“Œ•”Žx•”Šwp‘ĺ‰ď (2018/10/6-7), ˆŽě.

733197. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ipilimumab‰‰ń“Š—^Œä‚ɉş‚‘̉Š, ”dŽíŤŒŒŠÇ“ŕ‹ĂŒĹÇŒóŒQ (DIC) ‚đ”­Ç‚ľ‚˝ˆŤŤ•FŽî‚Ě1—á. t–ŘĘŒŠ1, ŽOˆäƒá1, –î–ěŽu‚¸‚Š1, âV“Ą‹ąŽq1, ŹŒ´GĆ1, ”’ˆä‹ž”ü1, “V‰HN”V1 (1”畆): ‘ć82‰ń“ú–{”畆‰ČŠw‰ď“Œ‹žŽx•”Šwp‘ĺ‰ď (2018/12/1-2), “Œ‹ž.

733198. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰óŽ€Ť—V‘–Ťg”Á‚ć‚čäX_Œo“ŕ•Ş”ĺŽîᇂ̐f’f‚ÉŽŠ‚Á‚˝2—á‚Ě”äŠr. ‘ŕV^ŽŔŽq1, “Œ‹V“ß’ĂŽq1, Žé‘VŽ›“TŽq1, “c•ÓŒ’ˆę1, Žsě—‹Žt2, Š™“c—T“ń2, “c“‡@O3, ‰œ˜e‹ť‰î4, •Ÿ“c‹ąŽq, ŽÄŽR—ĽŽq, “V‰HN”V1 (1”畆, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4Á‰ťŠí“ŕ): ‘ć82‰ń“ú–{”畆‰ČŠw‰ď“Œ‹žŽx•”Šwp‘ĺ‰ď (2018/12/1-2), “Œ‹ž.

733199. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’áŽ_‘fŠÂ‹Ť‚É‚¨‚Ż‚é–ѕ×–E‚Š‚ç‚̐S‹Ř×–E‚Ö‚Ě•Ş‰ť‚ĚŒŸ“˘. ”’ˆä‹ž”ü1, •l“c—SŽq2, rěLŽq, ŽRč—•Žq, “Œ‹V“ß’ĂŽq1, ˆŔĺY—Lję1, ŽOˆäƒá1, Robert M Hoffman, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ĂŒn): ‘ć26‰ń–Ń”Ż‰ČŠwŒ¤‹†‰ď (2018/12/8), ‘ĺŽč’Ź.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H28-110001. [Œ´’˜] Hypoxia Enhances Differentiation of Hair Follicle-Associated-Pluripotent (HAP) Stem Cells to Cardiac-Muscle Cells. Shirai K1, Hamada Y2, Arakawa N, Yamazaki A, Tohgi N1, Aki R1, Mii S1, Hoffman RM, Amoh Y1: J Cell Biochem 2017/3; 118 (3): 554-8. (”’ˆä‹ž”ü1, •l“c—SŽq2, “Œ‹V“ß’ĂŽq1, ˆŔĺY—Lję1, ŽOˆäƒá1, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ĂŒn)

[Šw‰ďEŒ¤‹†‰ď“™]

H29-713005. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Implanted Hair-follicle-associated pluripotent (HAP) stem cells encapsulated in polyvinylidene fluoride membrane cylinders promote effective recovery of peripheral nerve injury. Obara K1, Yamazaki A, Tohgi N1, Shirai K1, Mii S1, Hamada Y2, Arakawa N, Aki R1, Robert M Hoffman, Amoh Y1: ‘ć10‰ń‘Ű–Ń”ŻŒ¤‹†Šw‰ď (2017/10/31-11/3), ‹ž“s. (ŹŒ´GĆ1, “Œ‹V“ß’ĂŽq1, ”’ˆä‹ž”ü1, ŽOˆäƒá1, •l“c—SŽq2, ˆŔĺY—Lję1, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ĂŒn)

H29-733005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) MGUS (Monoclonal gammopathy of undetermined significance) ‚É”ş‚¤‘SgŤƒAƒ~ƒƒCƒh[ƒVƒX. ă“c‹ŞŽm1, Œj@—F—1, ”’ˆä‹ž”ü1, “n糐^L (1”畆): ‘ć68‰ń“ú–{”畆‰ČŠw‰ď’†•”Žx•”Šwp‘ĺ‰ď (2017/10/6-7), ‹ž“s.

H29-733006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’×ᇂđ’ć‚ľ‚˝–łF‘fŤŠî’ę×–EŠŕ‚Ě1—á. Œj@—F—1, ă“c‹ŞŽm1, ”’ˆä‹ž”ü1 (1”畆): ‘ć875‰ń“ú–{”畆‰ČŠw‰ď@“Œ‹ž’n•ű‰ď (2017/11/11), “Œ‹ž.

H29-733007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Á‰ťŠÇ•a•Ď, t•a•Ď‚đ‡•š‚ľ‚˝IgAŒŒŠÇ‰Š‚Ě1—á. ‹ŕŽR‚Ü‚č‚Š1, ŽOˆäƒá1, t–ŘĘŒŠ1, ”’ˆä‹ž”ü1, “V‰HN”V1, ł–Ř‹M‹ł2, ˆÉč‘Žu (1”畆, 2t‘Ÿ“ŕ): ‘ć876‰ń“ú–{”畆‰ČŠw‰ď@“Œ‹ž’n•ű‰ď (2017/12/16), “Œ‹ž.


”ĺ”AŠí‰ČŠw

[Šwp˜_•ś]

110285. [Œ´’˜] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Matsubara N, Yamada Y, Tabata KI1, Satoh T1, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S: Clin Genitourin Cancer 2018/4; 16 (2): 142-8. (“c”¨Œ’ˆę1, ˛“ĄˆĐ•ś1: 1”ĺ”AŠí)

110286. [Œ´’˜] Histologic variants associated with biological aggressiveness and poor prognosis in patients treated with radical cystectomy. Koguchi D1, Matsumoto K1, Ikeda M1, Taoka Y1, Hirayama T1, Murakami Y1, Utsunomiya T, Matsuda D, Okuno N, Irie A1, Iwamura M1: Jpn J Clin Oncol 2019/4; 49 (4): 373-8. (‚Œű@‘ĺ1, ź–{˜aŤ1, ’r“cŸb1, “c‰Ş‰ŔŒ›1, •˝ŽR‹M”Ž1, ‘şă‘א´1, “ü]@Œ[1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110287. [Œ´’˜] Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study. Ikeda M1, Matsumoto K1, Hirayama T1, Koguchi D1, Murakami Y1, Matsuda D1, Okuno N, Utsunomiya T, Taoka Y1, Irie A1, Iwamura M1: Clin Genitourin Cancer 2018/6; 16 (3): e669-75. (’r“cŸb1, ź–{˜aŤ1, •˝ŽR‹M”Ž1, ‚Œű@‘ĺ1, ‘şă‘א´1, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, ‰F“s‹{‘ńŽĄ, “c‰Ş‰ŔŒ›1, “ü]@Œ[1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110288. [Œ´’˜] Impact of body mass index on the oncological outcomes of patients with upper and lower urinary tract cancers treated with radical surgery: A multi-institutional retrospective study. Murakami Y1, Matsumoto K1, Ikeda M1, Utsunomiya T, Hirayama T1, Koguchi D1, Matsuda D1, Okuno N, Taoka Y1, Irie A1, Iwamura M1: Asia Pac J Clin Oncol 2018/8; 14 (4): 310-7. (‘şă‘א´1, ź–{˜aŤ1, ’r“cŸb1, ‰F“s‹{‘ńŽĄ, •˝ŽR‹M”Ž1, ‚Œű@‘ĺ1, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, “c‰Ş‰ŔŒ›1, “ü]@Œ[1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110289. [Œ´’˜] Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Fujita T1, Hirayama T1, Ishii D1, Matsumoto K1, Yoshida K1,2, Iwamura M1: Mol Clin Oncol 2018/10; 9 (4): 394-8. (“Ą“c“N•v1, •˝ŽR‹M”Ž1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1: 1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110290. [Œ´’˜] Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi-institutional retrospective study. Koguchi D1, Matsumoto K1, Ikeda M1, Taoka Y1, Hirayama T1, Murakami Y1, Utsunomiya T, Matsuda D1, Okuno N, Irie A1, Iwamura M1: Asia Pac J Clin Oncol 2018/10; 14 (5): e420-7. (‚Œű@‘ĺ1, ź–{˜aŤ1, ’r“cŸb1, “c‰Ş‰ŔŒ›1, •˝ŽR‹M”Ž1, ‘şă‘א´1, ‰F“s‹{‘ńŽĄ, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, “ü]@Œ[1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110291. [Œ´’˜] Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study. Tsumura H1, Ishiyama H2, Tabata KI1, Sekiguchi A2, Kawakami S2, Satoh T1, Kitano M, Iwamura M1: Prostate 2019/4; 79 (5): 506-14. doi: 10.1002/pros.23757. Epub 2018 Dec 26. (’Ă‘şGN1, ÎŽR”ŽžŠ2, “c”¨Œ’ˆę1, ŠÖŒűˆŠˆß2, ěăłŒĺ2, ˛“ĄˆĐ•ś1, –k–ě‰ëŽj, Šâ‘şłŽk1: 1”ĺ”AŠí, 2•úŽËü (Žîá‡))

110292. [Œ´’˜] Robot-assisted laparoscopic radical cystectomy is a safe and effective procedure for patients with bladder cancer compared to laparoscopic and open surgery: Perioperative outcomes of a single-center experience. Matsumoto K1, Tabata KI1, Hirayama T1, Shimura S1, Nishi M1, Ishii D1, Fujita T1, Iwamura M1: Asian J Surg 2019/1; 42 (1): 189-96. (ź–{˜aŤ1, “c”¨Œ’ˆę1, •˝ŽR‹M”Ž1, Žu‘ş‘sˆę˜N1, ź@ˇG1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110293. [Œ´’˜] TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy. Nomura M1, Matsumoto K1, Shimizu Y, Ikeda M1, Amano N1, Nishi M1, Ryo A, Nagashio R2, Sato Y2, Iwamura M1: Cancer Biomark 2019/2; 24 (1): 91-6. (–ě‘ş@Œb1, ź–{˜aŤ1, ’r“cŸb1, “V–ě“”V1, ź@ˇG1, ’ˇ‰–@—ş2, ˛“Ą—Yˆę2, Šâ‘şłŽk1: 1”ĺ”AŠí, 2ˆă—ÉqśŠw•”)

210004. [€Œ´’˜] National database of patients treated with radical cystectomy provides a current standard and comparison for future technologies. Matsumoto K1: Transl Androl Urol 2018/5; 7 (Suppl 2): S240-1. (ź–{˜aŤ1: 1”ĺ”AŠí)

320028. [Ç—á•ń] ’ˇŠúŒo‰ßŠĎŽ@’†äNă÷”AŠÇˆÚs•”Ä”­Ť”A˜Hă”çŠŕ‚ɑ΂ľ‚Ä, ”AŠÇ•”•ŞŘœpEäNă÷”AŠÇV•Ť‡p‚đŽ{s‚ľ‚˝1—á. Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, “c”¨Œ’ˆę1, “Ą“c“N•v1, Šâ‘şłŽk1 (1”ĺ”AŠí): ”ĺ”AŠí‹I—v 2018/4; 64 (4): 157-60.

520015. [‘ŕ] tˆÚA‚ÉŠÖ‚ˇ‚é’˛¸ (•˝Ź29”N“x) ‚Ě•ŞÍŒ‹‰Ę‚ɂ‚˘‚Ä. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): _“ŢěŒ§“§ÍŽ{Ý˜A—‹Ś‹c‰ď•ń 2018; 33: 14-7.

522105. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€1: ”A˜HŒ‹Î‚Ě”jÓŽĄ—Á|r-TUL, f-TUL, PNL, mini-PNL, ECIRS‚ť‚ę‚ź‚ę‚ĚŽĄ—Ă–@‚Ş‘ćˆę‘I‘đ‚Ć‚ľ‚Đ„‘E‚ł‚ę‚é ”A˜HŒ‹Î‚Ć‚Í?z4. r-TUL‚¨‚ć‚Ńf-TUL‚Ě—L—pŤ‚Ć‚ť‚ĚĹ“K‚Č”A˜HŒ‹ÎÇ—á‚Ě“K‰ž‘I‘đ‚ɂ‚ŤŒŸ“˘. •ĘŠ‰pŽĄ1, ”nę—Dl, rě@F (1”ĺ”AŠí): ”ĺ”AŠíŠO‰Č 2018/5; 31 (—ŐŽž‘Š§†): 626.

522106. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€6: ƒƒ{ƒbƒgŽx‰‡t•”•ŞŘœp (RAPN); “ą“ü‚Š‚牞—p‚܂Łz1. ƒƒ{ƒbƒgŽx‰‡t•”•ŞŘœp (RAPN) “ą“ü‚Ě‚˝‚ß‚Ě€”ő. “Ą“c“N•v1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ”ĺ”AŠíŠO‰Č 2018/5; 31 (—ŐŽž‘Š§†): 676-7.

522107. [uŔ]y“ÁW:  ‚Ě“`ł@Žčp‚đ‹É‚ß‚˝‚˘‚ ‚Č‚˝‚ցzĄ• o‹ž‰şŽčp@• o‹ž‰şt᱌`Źp‚É‚¨‚Ż‚é–D‡–@. Šâ‘şłŽk (”ĺ”AŠí): —Տ°”ĺ”AŠí‰Č 2018/8; 72 (9): 696-9.

522108. [uŔ]y“ÁW2: ’´‚—îŽŇ‘O—§‘B”ě‘ĺÇ‚ւ̑ΉžzŽčp“K‰ž‚ĆŽčp–@. •˝ŽR‹M”Ž1, ÝŠy•q–ç, Šâ‘şłŽk1 (1”ĺ”AŠí): Prostate Journal 2018/10; 5 (2): 255-61.

522109. [uŔ]y“ÁW‚܂邲‚Ć Šî‘b`ĹV‚Ü‚Ĺ‚ˇ‚ׂĂނ킊‚é! ‘O—§‘B‚Ş‚ńUp-to-datez<‘O—§‘B‚Ş‚ń‚ĚŽĄ—Ă–@ Up-to-date>@‘O—§‘B‚Ş‚ń‚ĚŽčp: ƒƒ{ƒbƒgŽx‰‡Žčp‚¨‚ć‚Ń• o‹ž‰şŽčp. “c”¨Œ’ˆę (”ĺ”AŠí): ”ĺ”AŠíCare&Cure Uro-Lo 2019/2; 24 (1): 42-4.

540021. [‚ť‚Ě‘ź (´˜^)]y‘ć82‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď‹L˜^Wzr-TUL‹y‚Ń f-TUL‚Ě—L—pŤ‚Ć‚ť‚ĚĹ“K‚Č”A˜HŒ‹ÎÇ—á‚Ě“K‰ž‘I‘đ‚ɂ‚ŤŒŸ“˘. •ĘŠ‰pŽĄ1, ”nę—Dl, rě@F (1”ĺ”AŠí): ”ĺ”AŠíŠO‰Č 2018/6; 31 (—ŐŽž‘Š§): 626.

540022. [‚ť‚Ě‘ź (‰ď•ń)] ‘˛‹Ćś‚É‘I‚΂ę‚é‹łˆçŒ¤C•a‰@‚đ–ÚŽw‚ľ‚Ä. Šâ‘şłŽk (”ĺ”AŠí): –k—˘‘ĺŠwˆăŠw•”“Ż‘‹‰ď‰ď•ń 2018/9; 79: 11.

540023. [‚ť‚Ě‘ź (ƒvƒƒOƒ‰ƒ€)] ‘ć20‰ń–k—˘ˆÚAŽs–ŻƒZƒ~ƒi[‚ĚŠJĂ‚ÉŰ‚ľ‚Ä. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): KITASATOˆÚAŽs–ŻƒZƒ~ƒi[ƒvƒƒOƒ‰ƒ€ 2018/10; 20: 2.

540024. [‚ť‚Ě‘ź (ƒvƒƒOƒ‰ƒ€)] ‘ć20‰ń–k—˘ˆÚAŽs–ŻƒZƒ~ƒi[`’ˇŠúś’…Žž‘ă‚đŒ}‚Ś‚ā`. Îˆä‘ĺ•ă (”ĺ”AŠí): KITASATOˆÚAŽs–ŻƒZƒ~ƒi[ƒvƒƒOƒ‰ƒ€ 2018/10; 20: 8.

[’˜@‘]

610007. [Šwp‘ (•Ş’SŽˇ•M)]yHormone Therapy and Castration Resistance of Prostate CancerzLocal Therapy in Combination with Androgen Deprivation Therapy for Metastatic Prostate Cancer, p.189-99. Tsumura H1, Tabata K1, Iwamura M1, Editors: Arai Y, Ogawa O, Springer, Singapore, 2018/5. (’Ă‘şGN1, “c”¨Œ’ˆę1, Šâ‘şłŽk1: 1”ĺ”AŠí)

620098. [Šwp‘ (•Ş’SŽˇ•M)]yŒăŠúŒ¤Cˆă‚Ş‚¨‚ł‚Ś‚Ä‚¨‚Ť‚˝‚˘”ĺ”AŠíŽčpTOP30@“K‰ž”ť’č‚ĆŽüpŠúŠÇ— (”ĺ”AŠíŠO‰Č Vol.31 “Á•Ę†)z• o‹žŽčp@LPP (• o‹ž‰şt᱌`Źp), p.128-35. ź@ˇG1, Šâ‘şłŽk1 (1”ĺ”AŠí), ˆăŠw}‘o”Ĺ, é‹Ę, 2018/4”­s.

620099. [Šwp‘ (•Ş’SŽˇ•M)]yUrologic& Surgery Next 1@• o‹žŽčpzI • o‹žŽčp‚ĚŠî–{Žĺ‹`, p.2-9. Šâ‘şłŽk (”ĺ”AŠí), •Ň: rˆä—zˆę, ‚‹´@Œĺ, ŽR–{VŒá, “y’J‡•F, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/4”­s.

620100. [Šwp‘ (•Ş’SŽˇ•M)]y”ĺ”AŠí“ŕŽ‹‹žŽčp‚Ě‚ˇ‚×‚Ä (—Տ°”ĺ”AŠí‰Č 72 (4) ‘Š§†)z”AŠÇEäNă÷‚ĚŽčp@• o‹ž‰şt᱌`Źp, p.112-8. Šâ‘şłŽk1, ź@ˇG1 (1”ĺ”AŠí), •Ň: ‘ĺ‰ĆŠîŽk, ‹ß“ĄKq, Ź“‡ËŒh, ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620101. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj@Ž„‚Í‚ą‚¤‚ľ‚ÄŽĄ—Ă‚ľ‚Ä‚˘‚é@2019”N”Łz19. ”ĺ”AŠí‰ČŽžŠł@äNă÷ŒeŽş, äNă÷áŽ, p.1197-8. Šâ‘şłŽk (”ĺ”AŠí), •Ň: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2019/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711017. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Current Status of Kidney Transplantation in Japan. Ishii D1: Lao Society of Nephrology (2019/3/23), Vientiane, Laos. (Îˆä‘ĺ•ă1: 1”ĺ”AŠí)

713137. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) COMPARISON OF THE EFFECTS OF PRE-DILUTION AND POST-DILUTION ON-LINE HEMODIAFILTRATION ON INFLAMMATORY MARKERS, LYMPHOCYTES AND PLETELES. Sakurai K, Saito T, Yamauchi F, Hosoya H, Kurihara Y, Yoshida K1,2, Ishii D2, Kokubo K3: 55th ERA-EDTA Congress (2018/5/26), Copenhagen, Denmark. (‹g“cˆęŹ1,2, Îˆä‘ĺ•ă1, Ź‹v•ŰŒŞˆę3: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ˆă—ÉqśŠw•”)

713138. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) COMPARISON OF THE EFFECTS OF PRE-DILUTION AND POST-DILUTION ON-LINE HEMODIAFILTRATION ON THE CELL SURFACE MARKER OF PLATELETS AND CYTOKINES. Sakurai K, Saito T, Yamauchi F, Hosoya H, Kurihara Y, Wakabayashi Y, Yoshida K1,2, Ishii D2, Iwamura M2, Kokubo K3: 55th ERA-EDTA Congress (2018/5/26), Copenhagen, Denmark. (‹g“cˆęŹ1,2, Îˆä‘ĺ•ă2, Šâ‘şłŽk2, Ź‹v•ŰŒŞˆę3: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ˆă—ÉqśŠw•”)

713139. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) A meta-analysis on attitudes towards organ donation of undergraduate nurse students. Tsubaki M, Tougo S, Kobayashi M, Arakawa S, Ito Y, Yoshida K1,2: 55th ERA-EDTA Congress (2018/5/26), Copenhagen, Denmark. (‹g“cˆęŹ1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí)

713140. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The urine loss ratio as a predictor of urinary continence after robot assisted laparoscopic radical prostatectomy A prospective study. Murakami Y1, Tabata KI1, Tsumura H1, Hirayama T1, Matsumoto K1, Takenami T2, Ikeda T, Iwamura M1: 36th World Congress of Endourology (2018/9/22), Paris, France. (‘şă‘א´1, “c”¨Œ’ˆę1, ’Ă‘şGN1, •˝ŽR‹M”Ž1, ź–{˜aŤ1, ’|˜Q–Ż]2, Šâ‘şłŽk1: 1”ĺ”AŠí, 2–ƒŒ)

713141. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A real time compensation technique for a cold spot using a combination of trans rectal ultrasonography and intraoperative computed tomography in patients treated with interstitial permanent prostate brachytherapy. Tsumura H1, Ishiyama H2, Satoh T1, Hayakawa T2, Kawakami S2, Murakami Y1, Sekiguchi A2, Tabata K1, Iwamura M1: 11th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer (2019/2/9), Kyoto. (’Ă‘şGN1, ÎŽR”ŽžŠ2, ˛“ĄˆĐ•ś1, ‘ě–L˜a2, ěăłŒĺ2, ‘şă‘א´1, ŠÖŒűˆŠˆß2, “c”¨Œ’ˆę1, Šâ‘şłŽk1: 1”ĺ”AŠí, 2•úŽËü (Žîá‡))

713142. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199. Antonarakis ES, Goh J, Gross-Goupil M, Vaishampayan U, Piulats J, de Wit R, Alanko T, Fukasawa S, Tabata K1, Feyerabend S, Berger R, Wu H, Kim J, Poehlein C, de Bono JS: ASCO GU 2019 (2019/2/14), San Francisco, USA. (“c”¨Œ’ˆę1: 1”ĺ”AŠí)

721019. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) tˆÚA‚Š‚猊‚˝ˆÚAˆă—Ăƒ`[ƒ€ě‚č`ˆÚAˆă—ĂŽx‰‡Žş‚Ě–đŠ„`. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ď@ŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W p.14.

722111. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) t᱌`Źp`‰ŠÇ‚Ş‹­‚˘‚Ć‚Ť‰˝‚đ‹C‚đ‚‚Ż‚é`. ź@ˇG1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć27‰ń“ú–{ŹŽ™”ĺ”AŠí‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/6/26), ‹ŕ‘ň.

722112. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚAŒă‚Ě“§ÍÄ“ą“ü, ÄtˆÚA. ‹g“cˆęŹ1,2, Îˆä‘ĺ•ă2, –ěŒű•ś”T3, ’r“cŹ]2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ŠĹŒě•”): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË.

722113. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) t‘ă‘Ö—Ă–@‚É‚¨‚Ż‚étˆÚA‚Ě—§ę. ŽsŠŰ’źŽk, ‘Šě@Œú, ‹g“cˆęŹ1,2, “c‘q’q”V (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË.

722114. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠłŽŇŠÇ—‚Ć“§Íˆ•ű. Žáˆä—zŠó, ˆ˘•”“Ţ’Ă”ü, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

722115. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) • –Œ“§Í‚Š‚çtˆÚA‚Ö, tˆÚA‚Š‚ç• –Œ“§Í‚Ö. ‹g“cˆęŹ1,2, Îˆä‘ĺ•ă2, –ěŒű•ś”T3, ’r“cŹ]2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ŠĹŒě•”): ‘ć24‰ń“ú–{• –Œ“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/10/7), “ż“‡.

722116. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ‘O—§‘B‚Ş‚ń‚Ě–ň•¨—Ă–@‚ĆFNƒ}ƒlƒWƒƒ“ƒg. “c”¨Œ’ˆę (”ĺ”AŠí): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/19), ‰Ą•l.

722117. [Šw‰ď (‘S‘)] (ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€) –D‡‘€ě‚̍H•v. ź@ˇG1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/28), ĺ‘ä.

722118. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‘gD“ŕĆŽË—Ă–@ (I-125). ˛“ĄˆĐ•ś, ÎŽR”ŽžŠ2, ’Ă‘şGN1, “c”¨Œ’ˆę1, ‘şă‘א´1, ěăłŒĺ2, ‘ě–L˜a2, ŠÖŒűˆŠˆß2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2•úŽËü (Žîá‡)): ‘ć34‰ń‘O—§‘BƒVƒ“ƒ|ƒWƒEƒ€ (2018/12/9), “Œ‹ž.

722119. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “§ÍŰ“ą“üŽž‚ĚƒAƒNƒZƒX. Îˆä‘ĺ•ă1, ‹g“cˆęŹ1,2 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/15), ‘ĺă.

722120. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{‚É‚¨‚Ż‚é•v•wŠÔtˆÚA‚ĚŒťó‚Ć–â‘č“_. ‹g“cˆęŹ1,2, –ěŒű•ś”T3, Îˆä‘ĺ•ă2, ’r“cŹ]2, ˆä‘ş—[•P3 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ŠĹŒě•”): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/15), ‘ĺă.

723572. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) • o‹ž‰ş‘O—§‘B‘S“EœpŒă‚̐ś‰ťŠw“IÄ”­‚É‚¨‚Ż‚郊ƒ“ƒpŠÇZ‚ĚˆÓ‹`. “c”¨Œ’ˆę1, ’Ă‘şGN1, –ź–؏l, –Ȋс@ăÄ1, Ÿ–”—mŽ÷1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1, •˝ŽR‹M”Ž1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723573. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠJ• C•œp‚đ—v‚ľ‚˝ŽY•wl‰ČŽčpŠÖ˜A”AŠÇ‘š‚ĚŒŸ“˘. •˝ŽR‹M”Ž1, ź@ˇG1, ’Ă‘şGN1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723574. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) isŤt×–EŠŕ‚ɑ΂ˇ‚éƒ\ƒ‰ƒtƒFƒjƒuŽĄ—Ă‚É‚¨‚Ż‚é‘˝Œ`g”Á”­ŒťŠëŒŻˆöŽq‚ĚŒŸ“˘. “Ą“c“N•v1, •˝ŽR‹M”Ž1, ź@ˇG1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723575. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚é• o‹ž‰ş‘O—§‘B‘S“Eœp (LRP) ‚Ćƒƒ{ƒbƒgŽx‰‡• o‹ž‰ş‘O—§‘B‘S“Eœp (RALP) ‚É‚¨‚Ż‚é’ZŠúŽčpŹŃ, ŽüpŠú‡•šÇ‚Ě”äŠr. ‘şă‘א´1, ‰Š@‰p–Î, ‚“cŽĄŽq1, Žá“c•”—zŽi1, “y‹´łl1, ě‘ş•ä1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723576. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) äNă÷Šŕ‚Ĺ‚Ě•a—‘gD•Ş—Ţ‚đ—p‚˘‚˝—Տ°•a—Šw“IˆöŽq‚¨‚ć‚Ń—\Œă‚ÉŠÖ‚ˇ‚錟“˘. ‚Œű@‘ĺ1, ź–{˜aŤ1, ’r“cŸb1, “c‰Ş‰ŔŒ›1, ‰F“s‹{‘ńŽĄ, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, “ü]@Œ[1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723577. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) äNă÷Šŕ‚É‚¨‚Ż‚éCD155”­Œť‚Ć—Ő°•a—ŠwˆöŽq‚Ć‚Ě”äŠrŒŸ“˘. ”‹Œ´ł”Ž1, ź–{˜aŤ1, •˝ŽR‹M”Ž1, –ź–؏l, “c‰Ş‰ŔŒ›1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, ˛“Ą—Yˆę2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2ˆă—ÉqśŠw•”): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723578. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) äNă÷Šŕ‚É‚¨‚Ż‚錌´Epiplakin‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. –]ŒŽ N•˝1, ź–{˜aŤ1, –ö“cŒ›Œá, ź ˇG1, “c”¨Œ’ˆę1, ‰F“s‹{‘ńŽĄ, ˛“Ą—Yˆę2, ‹g“cˆęŹ1,3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2ˆă—ÉqśŠw•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723579. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) äNă÷äSᑂ𐶂ś‚˝ŽY•wl‰ČpŒăÇ—á‚ĚŒŸ“˘. Ÿ–”—mŽ÷1, ź@ˇG1, •˝ŽR‹M”Ž1, Ź—Ń“Žq1, –Ȋс@ăÄ1, “V–ě“”V1, –ź–؏l, ’Ă‘şGN1, Îˆä‘ĺ•ă1, “c”¨Œ’ˆę1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723580. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 2 cmˆČă‚̐tŒ‹Î‚ɑ΂ˇ‚éf-TUL‚ĚŽĄ—ÐŹŃ. ”nę—Dl, rě@F, •ĘŠ‰pŽĄ1, ‘ĺ“Œ‹MŽu, ‰z“c’|˜N, ’O‰H’ź–ç, Ÿˆä­”Ž, Źź“c–ž—˘ (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723581. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Œ‹ÎŤtṐt‰ŠŒă‚ĚŒ‹ÎŽĄ—Ă‚É‚¨‚Ż‚é—Տ°“IŒŸ“˘. ‘OŽR—Ç‘ž, •˝–ěC•˝1, ŽR“c‘׎j, ź“c‘ĺ‰î (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/19), ‹ž“s.

723582. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŞŽĄ“IäNă÷‘S“EœŽOpŽŽ‚É‚¨‚Ż‚éŽüpŠúŹŃ‚Ě”äŠrŒŸ“˘. ź–{˜aŤ1, “c”¨Œ’ˆę1, •˝ŽR‹M”Ž1, ź@ˇG1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/20), ‹ž“s.

723583. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ă•””A˜Hă”çŠŕ‚ɑ΂ˇ‚éŠJ• p‚Ć• o‹ž‰şp‚É‚¨‚Ż‚é—Տ°•a—Šw“IˆöŽq‚ĚŒŸ“˘. Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, ’r“cŸb1, ‚Œű@‘ĺ1, “c‰Ş‰ŔŒ›1, •˝ŽR‹M”Ž1, ‘şă‘א´1, ‰F“s‹{‘ńŽĄ, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, “ü]@Œ[1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/20), ‹ž“s.

723584. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘O—§‘BŠŕN1‚É‚¨‚Ż‚éHigh-dose-rate brachytherapy: ŽĄ—ĂŒř‰Ę‚ĆÄ”­—\‘Ş‚ĚŒŸ“˘. ’Ă‘şGN1, “c”¨Œ’ˆę1, ÎŽR”ŽžŠ2, Ÿ–”—mŽ÷1, Ź—Ń“Žq1, –ź–؏l, —§‰Ô‹MŽj1, –k–ě‰ëŽj, “Ą“c“N•v1, ˛“ĄˆĐ•ś, ‘ě˜ad2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2•úŽËü (Žîá‡)): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/20), ‹ž“s.

723585. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “]ˆÚŤ‹Ž¨’ďRŤ‘O—§‘BŠŕ‚ɑ΂ˇ‚éRa-223‚ĚŽĄ—ĂŒoŒą. Ş–{—Žq, “c”¨Œ’ˆę1, Ź—Ń“Žq1, —§‰Ô‹MŽj1, ‹ŕŽqŽu•Ű1, ’Ă‘şGN1, ˛“ĄˆĐ•ś, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/20), ‹ž“s.

723586. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠO—ˆ‚É‚¨‚Ż‚é’PƒŤäNă÷‰Š‚ɑ΂ˇ‚éƒZƒtƒ@ƒNƒƒ‹‚É‚ć‚鏉ŠúŽĄ—Ă‚ĚŒŸ“˘. “y‹´łl1, •˝–ěC•˝1, ‘şă‘א´1, ‚Œű@‘ĺ1, Îˆä~ˆę˜Y (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/20), ‹ž“s.

723587. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŞŽĄ“It”AŠÇ‘S“EpŒă‚ĚÄ”­E“]ˆÚ‚ɑ΂ˇ‚é‹~Ď‰ťŠw—Ă–@‚ĚŽĄ—ÐŹŃ. ’r“cŸb1, ź–{˜aŤ1, •˝ŽR‹M”Ž1, ‚Œű@‘ĺ1, ‘şă‘א´1, ź“c‘ĺ‰î1, ‰œ–ě‹I•F, ‰F“s‹{‘ńŽĄ, “c‰Ş‰ŔŒ›1, “ü]@Œ[1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723588. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) tSolitary fibrous tumor (SFT) ‚Ě1—á. ‚“cŽĄŽq1, ‰œ–ě‹I•F, Žá“c•”—zŽi1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723589. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) tᱏŹ×–EŠŕ‚Ě1—á. Žt”ö”ɍF1, “c‰Ş‰ŔŒ›1, ”‹Œ´ł”Ž1, “ě“c@—@1, “Ą“c“N•v1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723590. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘O’uŠˇOn-line HDF‚ĆHD‚Ĺ‚Ě‘Ě“ŕƒAƒ~ƒmŽ_‘rŽ¸—}§Œř‰Ę‚ĚŒŸ“˘. •ş“Ą@“§, ‰Y•Órˆę˜Y, Žáˆä—zŠó, –k‘ş@^, ”ň“c”ü•ä, ‘q“cN‹v, Îˆä‘ĺ•ă1, ‰““Ą’‰—Y, ”nęŽu˜Y, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723591. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éƒJƒoƒWƒ^ƒLƒZƒ‹‚ĚŽg—pŒoŒą. –]ŒŽN•˝1, •âáÁ“ń1, ‘呐@—m, “Ąé‹M‹ł, “c”¨Œ’ˆę1, ’Ă‘şGN1, ˛“ĄˆĐ•ś, ‰F“s‹{‘ńŽĄ, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723592. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚̐ćs“ItˆÚA‚Ć’ZŠú“§ÍŒătˆÚA‚ĚŒŸ“˘. Îˆä‘ĺ•ă1, “V–ě“”V1, —§‰Ô‹MŽj1, •˝ŽR‹M”Ž1, “Ą“c“N•v1, Šâ‘şłŽk1, ‹g“cˆęŹ1,2 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723593. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “Ť‚Ě”AŠÇoŒŒ‚ɑ΂ľ, ŒŒŠÇ‘˘‰e‚É‚Ä– óŒŒŠÇŽî‚Ɛf’f‚Ĺ‚Ť, ŽĄ—Ă‚ľ“ž‚˝ˆę—á. â“c—T‰î1, –Ȋс@ăÄ1, ŠŰ@“T•v, Žu‘ş‘sˆę˜N1, Îě@–í1, ˆŔ“Ą–š”ü1, ź@’źŽq, źŠŞ@”Ž, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723594. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isŤäNă÷Šŕ‚ɑ΂ˇ‚éäNă÷‘S“EpŒă‚Ě•â•‰ťŠw—Ă–@‚Ě—L—pŤ‚ĚŒŸ“˘: ‘˝Ž{Ý‹¤“ŻŒ¤‹†. ‹ŕ’J~Žu, ź–{–ž•F, ě‡„l, ’r“cŸb1, ‹{ěm•˝, “cŒű@œa, “ŕ“Ąť—T, ‘ĺ’ː^Žj, ’†ź‘׈ę, “Œ@„Ži, —é–ŘŠî•ś, ŒĂ‰ę•ś—˛, ‹ß“Ą@–ő, ‰ŞŞ’J—˜ˆę, “c’†—Ç“T, ‹v•ÄtŠě, ’†ě@“O (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723595. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”r”AŽŠ—§Žw“ą—ż‚Ɋ‚­”rŸ•ƒPƒA‰ńf‚ĚŽŔŰ‚Ć‚ť‚Ě–â‘č“_‚ɂ‚˘‚Ä. ‘ĺě‚ ‚łŽq, “Ąé‹M‹ł, •˝ˆäËŽi, ‚“cŽĄŽq1, ’†–ě‚Ü‚ä‚ç (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723596. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éThuliumLaser‚đ—p‚˘‚˝Œo”A“š“I‘O—§‘BŠjop‚Ě—Ő°“IŒŸ“˘. Žá“c•”—zŽi, ‘ĺŽR“N•˝1, ‚“cŽĄŽq1, ‰œ–ě‹I•F (1”ĺ”AŠí): ‘ć106‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (2018/4/21), ‹ž“s.

723597. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‚—îŽŇ‚É‚¨‚Ż‚鍪ŽĄ“I‘O—§‘B“Eœp‚̏pŒă”AŽ¸‹Ö‚ɑ΂ˇ‚élŒű”A“šŠ‡–ń‹ŘAžp. •˝ŽR‹M”Ž1, Ÿ–”—mŽ÷1, –Ȋс@ăÄ1, —§‰Ô‹MŽj1, •âáÁ“ń1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć31‰ń“ú–{˜V”N”ĺ”AŠí‰ČŠw‰ď (2018/5/12), •Ÿˆä.

723598. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éCMVŠ´ő‚ĆmTOR‘jŠQ–ňŽg—p‚ĚŒŸ“˘. –Ȋс@ăÄ1, Îˆä‘ĺ•ă1, “V–ě“”V1, Žu‘ş‘sˆę˜N1, ŕV“c@Ę2, –ěŒű•ś”T3, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2t‘Ÿ“ŕ, 3ŠĹŒě•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ńtˆÚA–Ɖu—Ă–@ƒZƒ~ƒi[ (2018/6/16), “Œ‹ž.

723599. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘˝”­Ťt”^ᇂɑ΂ľ‚Đt“Eœp‚đŽ{s‚ľ‚˝1—á. Ź—Ń“Žq1, ź@ˇG1, Ÿ–”—mŽ÷1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć27‰ń“ú–{ŹŽ™”ĺ”AŠí‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/6/27), ‹ŕ‘ň.

723600. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) HutchŒeŽş‚𔺂¤äNă÷”AŠÇ‹t—Ź‚ɑ΂ľ, ‹CäNă÷‚ľ‚˝äNă÷”AŠÇV•Ť‡p‚đŽ{s‚ľ‚˝1—á. ź@ˇG1, Ź—Ń“Žq1, Ÿ–”—mŽ÷1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć27‰ń“ú–{ŹŽ™”ĺ”AŠí‰ČŠw‰ď‘‰ďEŠwpW‰ď (2018/6/28), ‹ŕ‘ň.

723601. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) • o‹ž‰ş‚É“Eœ‚ľ‚˝•›t‹ß–TŹnŠďŒ`Žî‚Ě1—á. ’Ă‘şGN1, “Ą“c“N•v1, •˝ŽR‹M”Ž1, ź@ˇG1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ď‘‰ď (2018/6/28), ŽD–y.

723602. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠłŽŇ‚ĚƒZƒ‹ƒtƒPƒAŒüă‚Ěˆ×‚ĚŽx‰‡•ű–@‚Ě“ˆę‰ť‚đ–ÚŽw‚ľ‚Ä. —Ž‡^Šó, ”ŞŒŽń“ú‰Ŕ‘ă, —Ž‡—˘“Ţ, ‚‹´_—Y, ‹g“cˆęŹ1,2, ‚‹´—Tˆę˜Y (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË.

723603. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “§ÍƒNƒŠƒjƒbƒN‚É‚¨‚Ż‚éf—ĂŠÖ˜A•ś‘‚Ě“dŽq•Ű‘ś‚Ɖ@ŠO•ŰŠÇ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. â–{“Ţ–źŽq, ŽR’†—˘‰Ŕ, “n糗FŽq, ŕ_čG—ćŽq, ˆ˘•”“Ţ’Ă”ü, Žáˆä—zŠó, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË.

723604. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒKƒ“ƒ}ü–Ĺ‹Űˆ—‚É‚ć‚éDEHPƒtƒŠ[“§Í—pŒŒ‰t‰ń˜HƒZƒbƒg‚Ě—Ő°•]‰ż. •Űč@˝, •˝–ě’¨‹v, ’Ł‘ň^ˆ¤, ‚‹´—Tˆę˜Y, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

723605. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰“ÔŠOü—Ă–@ (Far Infrared radiation Therapy: FIT) ‚Ě‘Ť’ę•”ŒŒ—ŹŠFŁ‚É‚¨‚Ż‚éŒř‰Ę. ŽR–{Žá—t, ŠC˜VŒ´Œd, —é–؉ԓŢ, ŕ_čG—ćŽq, ˆ˘•”“Ţ’Ă”ü, Žáˆä—zŠó, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

723606. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”Ä—pe-learningƒVƒXƒeƒ€‚ĆAI‰šş‡ŹƒVƒXƒeƒ€‚đŠˆ—p‚ľ‚˝Ý‘‰t“§ÍŒ¤C—p‹łŢěŹ‚ĚŽŽ‚Ý. ˆ˘•”“Ţ’Ă”ü, Žáˆä—zŠó, ‘ĺÎ’źŽq, ŽR’†—˘‰Ŕ, •ş“ށ@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

723607. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ“ƒ{ƒWƒA‚Ĺ‚ĚW’†ƒZƒ~ƒi[ŠJĂ‚É‚ć‚éŒť’nˆăŠwś‹y‚ŃŽáŽčˆăŽt‚ɑ΂ˇ‚é‹łˆçŽx‰‡. ŽR‰Y@„, ŹŒ´‹M, —é–؉ԓŢ, ˆ˘•”“Ţ’Ă”ü, ŽR’†—˘‰Ŕ, Žáˆä—zŠó, •ş“Ą@“§, ‹g“cˆęŹ1,2, ěźGŽ÷ (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

723608. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ“ƒ{ƒWƒAt‘ŸŠw‰ďŠwp‘‰ďŠJĂŽx‰‡Šˆ“Ž‚ɂ‚˘‚Ä. ŠC˜VŒ´Œd, Žáˆä—zŠó, ˆ˘•”“Ţ’Ă”ü, ŕ_čG—ćŽq, Œ´“cŽŽ}, •ş“Ą@“§, ‹g“cˆęŹ1,2, ěźGŽ÷ (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/30), _ŒË.

723609. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‰“ÔŠOü—Ă–@ (Far Infrared radiation Therapy: FIT) ‚ŞAVF‚É—^‚Ś‚é‰e‹ż . ŠC˜VŒ´Œd, ŽR–{Žá—t, —é–؉ԓŢ, ŕ_čG—ćŽq, ˆ˘•”“Ţ’Ă”ü, Žáˆä—zŠó, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/7/1), _ŒË.

723610. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) t•s‘Sˆă—Ï]Ž–ŽŇ‚Ö‚Ěî•ń’ń‹Ÿ‚ÉŽć‚č‘g‚ސt•s‘Sƒ`[ƒ€ˆă—Ă‹Ś‹c‰ď (Kicos) ‚Ě“WŠJ. ’r“cŹ]1, –ěŒű•ś”T2, ˆÉ“Ą’qŒbŽq, ‰Í–ě@Œb, ŹâŽu•Ű, ‹´‹l@—ş, ź‘şŽ‘˘, Îč—T–ç, Îˆä‘ĺ•ă1, Žáˆä—zŠó1, ‹g“cŽ–@, ‹g“cˆęŹ1,3 (1”ĺ”AŠí, 2ŠĹŒě•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/7/1), _ŒË.

723611. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”Ä—pƒlƒbƒgƒ[ƒNƒJƒƒ‰‚đŠˆ—p‚ľ‚˝Ý‘‰t“§ÍŽx‰‡EˆŔ‘SŠÇ—ƒVƒXƒeƒ€\’z‚ĚŽŽ‚Ý. Žáˆä—zŽ÷, ˆ˘•”“Ţ’Ă”ü, ŽR’†—˘‰Ŕ, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/7/1), _ŒË.

723612. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŒŁtˆÚA‚ĚŒŸ“˘. Îˆä‘ĺ•ă1, ‹g“cˆęŹ1,2, źŽRŒiŽq3, “V–ě“”V1, –Ȋс@ăÄ1, Žu‘ş‘sˆę˜N1, Žáˆä—zŠó, –ěŒű•ś”T4, ’r“cŹ]1, ’|“ŕN—Y3, Šâ‘şłŽk1 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3t‘Ÿ“ŕ, 4ŠĹŒě•”): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/7/1), _ŒË.

723613. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝”­äNă÷Œ‹Î‚¨‚ć‚Ń‹‘ĺ”A“šŒ‹Î‚Ěˆę—á. –Ȋс@ăÄ1, ŠŰ@“T•v, ˆŔ“Ą–š”ü1, Îě@–í1, Šâ‘şłŽk1 (1”ĺ”AŠí): “ú–{”A˜HŒ‹ÎÇŠw‰ď‘ć28‰ńŠwpW‰ď (2018/8/25), ‘ĺă.

723614. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚Ĺ‚Ě“ą“üŠúƒGƒxƒƒŠƒ€ƒX•š—pƒvƒƒgƒR[ƒ‹‚ĚŒŸ“˘. Îˆä‘ĺ•ă1, –Ȋс@ăÄ1, “V–ě“”V1, Žu‘ş‘sˆę˜N1, ’r“cŹ]1, –ěŒű•ś”T2, ‰““Ą’‰—Y, Šâ‘şłŽk1, ’|“ŕN—Y3, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3t‘Ÿ“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2018/10/4), “Œ‹ž, ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď—ŐŽž† 2018; 53 (—ŐŽž†): 410.

723615. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŒŁtˆÚA“o˜^ƒVƒXƒeƒ€‚É‚ć‚é–â‘č‚ƑΉžô. ’r“cŹ]1, Îˆä‘ĺ•ă1, ŽR•Ó°”ü2, –ěŒű•ś”T3, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2—ŐŒŸ•”, 3ŠĹŒě•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2018/10/4), “Œ‹ž, ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď—ŐŽž† 2018; 53 (—ŐŽž†): 474.

723616. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒVƒƒƒ“ƒg‹}Ť•ÂÇ‚ĚŒŸŘ. ŒK“c”䍻], ă‘ş@ŒO, Îˆä‘ĺ•ă1, óˆä—FŠî, ’†“ˆ^ˆę, –{‹´˛’mŽq, ’|“ŕN—Y2, ‹g“cˆęŹ1,3, ‹g“c@ŕˆ (1”ĺ”AŠí, 2t‘Ÿ“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć22‰ń“ú–{ƒAƒNƒZƒXŒ¤‹†‰ďŠwpW‰ďE‘‰ď (2018/10/13), L“‡.

723617. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒIƒŠƒSƒƒ^ƒXƒ^ƒVƒX‚ɑ΂ˇ‚é‘O—§‘BŠŕ–§••ŹüŒš—Ă–@‚Ć“]ˆÚĆŽË‚Ě—LŒřŤ‚ĆˆŔ‘SŤ‚ĚŒŸ“˘. ’Ă‘şGN1, “c”¨Œ’ˆę1, ÎŽR”ŽžŠ2, ‘şă‘א´1, “Ą“c“N•v1, –k–ě‰ëŽj, ˛“ĄˆĐ•ś, ‘ě˜ad2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2•úŽËü (Žîá‡)): ‘ć56‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2018/10/18), ‰Ą•l.

723618. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹‘吸‘ƒŽîᇂĚ2—á. •ĘŠ‰pŽĄ1, ě‘ş•ä1, Žá“c•”—zŽi1, ‰œ–ě‹I•F (1”ĺ”AŠí): ‘ć72‰ń‘—§•a‰@‘‡ˆăŠw‰ď (2018/11/9), _ŒË.

723619. [Šw‰ď (‘S‘)] (‘‰ďÜƒfƒWƒ^ƒ‹ƒ|ƒXƒ^[) Secondary UPJO‚ɑ΂ˇ‚édismembered, non-dismembered pyeloplasty‚ĚŒŸ“˘. ź@ˇG1, Îˆä‘ĺ•ă1, •˝ŽR‹M”Ž1, “Ą“c“N•v1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/27), ĺ‘ä.

723620. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡‰ş‘O—§‘B‘S“Eœp‚É‚¨‚Ż‚éŠg‘ĺƒŠƒ“ƒpßŠs´‚ĚŒŸ“˘. “c”¨Œ’ˆę1, ’Ă‘şGN1, ‘şă‘א´1, •˝ŽR‹M”Ž1, ź@ˇG1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/28), ĺ‘ä.

723621. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹ž‰ş‘O—§‘B‘S“EœpŒă‚Ě”r”AEŤ‹@”\ŠÖ˜AQOL‚ĚŒŸ“˘. ’Ă‘şGN1, “c”¨Œ’ˆę1, ‘şă‘א´1, •˝ŽR‹M”Ž1, Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/28), ĺ‘ä.

723622. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹ž‰ş‘O—§‘B‘S“EœpŒă”A‹Ö§‚É‚¨‚Ż‚éMRIœ”Ő’ę‰đ–UŠwˆöŽq‚ĚŒŸ“˘. ‘şă‘א´1, “c”¨Œ’ˆę1, ’Ă‘şGN1, Žu‘ş‘sˆę˜N1, “V–ě“”V1, –Ȋс@ăÄ1, Ÿ–”—mŽ÷1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/28), ĺ‘ä.

723623. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şŞŽĄ“It“Eœp‚É‚¨‚Ż‚éƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚đŽg—p‚ľ‚˝pŒăáu’ÉŠÇ—‚ĚŒŸ“˘. “Ą“c“N•v1, •˝ŽR‹M”Ž1, ź@ˇG1, ’Ă‘şGN1, Îˆä‘ĺ•ă1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/28), ĺ‘ä.

723624. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”A•Â‚𐜂ś‚˝‘O—§‘B”ě‘ĺÇ‚ɑ΂ˇ‚éŒo”A“š“I‘O—§‘BŠjop (HoLEP). •˝ŽR‹M”Ž1, ÝŠy•q–ç, “V–ě“”V1, Žu‘ş‘sˆę˜N1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/29), ĺ‘ä.

723625. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) HoLEP‚É‚¨‚Ż‚é”ĺ”AŠí‰Čf—ÏŠ‚Ć”ĺ”AŠí‰Č•a‰@‚Ć‚Ě˜AŒg‘̐§\’z‚ĚŽŽ‚Ý. ‘ĺŽR“N•˝1, ŽRŒű@‘, “żŒőłs, ‘ˆä‘Ľş, Î“c—T‘Ľ, a’JH•F, ™“c@“Ö, …‰iŒő”Ž (1”ĺ”AŠí): ‘ć32‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2018/11/29), ĺ‘ä.

723626. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ~ƒƒƒ“ƒ}[‚̐tˆÚAˆă—Ïé’ń‹Ÿ‚Ě•ń. ’r“cŹ]1, rě–@Žq2, Ź‹v•ŰŒŞˆę3, Îˆä‘ĺ•ă1, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć3‰ń‘Ű—Տ°ˆăŠw‰ďŠwpW‰ď (2018/12/8), “Œ‹ž.

723627. [Šw‰ď (‘S‘)] (ƒfƒWƒ^ƒ‹ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éThulium Laser‚đ—p‚˘‚˝Œo”A“š“I‘O—§‘BŠjop‚Ě—Ő°“IŒŸ“˘. Žá“c•”—zŽi1, ě‘ş•ä1, •ĘŠ‰pŽĄ1, ‰œ–ě‹I•F (1”ĺ”AŠí): ‘ć31‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2018/12/8), •Ÿ‰Ş.

723628. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş‘O—§‘B‘S“Eœp, ƒƒ{ƒbƒgŽx‰‡• o‹ž‰ş‘O—§‘B‘S“Eœp‚É‚¨‚Ż‚éŘœ’f’[‚ĚŒŸ“˘. ‚“cŽĄŽq1, “c”¨Œ’ˆę1, ‘şă‘א´1, •˝ŽR‹M”Ž1, ’Ă‘şGN1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć11‰ń“ú–{ƒƒ{ƒbƒgŠO‰ČŠw‰ďŠwpW‰ď (2019/1/26), –źŒĂ‰Ž.

723629. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŁt“o˜^ŠłŽŇ‚ĚŽv‚˘‚ÉŠń‚č“Y‚Á‚˝28”N‚ĆˆÚAŒ[”­Šˆ“Ž‚ĹŒŠ‚Ś‚˝‚ą‚Ć. ’r“cŹ]1, Îˆä‘ĺ•ă1, –ěŒű•ś”T2, ‹g“c•üŽq3, Šâ‘şłŽk1, ‰““Ą’‰—Y, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3‰h—{•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/14), ‘ĺă.

731063. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “–‰@‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ň‚Ě•›ě—p‘΍ô. ź–{˜aŤ (”ĺ”AŠí): ”A˜Hă”çŠŕƒZƒ~ƒi[ (2018/4/11), ‘Š–ÍŒ´.

731064. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) t×–EŠŕ–ň•¨—Ă–@‚É‚¨‚Ż‚éAEƒ}ƒlƒWƒƒ“ƒg. “Ą“c“N•v (”ĺ”AŠí): _“ŢěŒ§‰›RCCu‰‰‰ď (2018/4/27), ŠC˜V–ź.

731065. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) tˆÚA‚É‚¨‚Ż‚éƒ`[ƒ€ˆă—Ă. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć3‰ńŠÖźt‘ŸƒZƒ~ƒi[ (2018/6/1), ‘ĺă.

731066. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) t×–EŠŕ‚̐f’f‚ĆŽĄ—Ă. “Ą“c“N•v (”ĺ”AŠí): ‘Š–ÍŒ´ŽsˆăŽt‰ď’nˆćˆă—ĂŒ¤‹†‰ď (2018/6/12), ‘Š–ÍŒ´.

731067. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) M1‘O—§‘BŠŕ‚ɑ΂ˇ‚é‹ÇŠŽĄ—Ă‚ĚƒXƒXƒ`ASCO2018‚̍ŐV’mŒŠ‚đŒđ‚Ś‚ā`. “c”¨Œ’ˆę (”ĺ”AŠí): ˆ¤“†GUƒtƒH[ƒ‰ƒ€ (2018/6/21), “Œ‹ž.

731068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –k—˘‘ĺŠw•a‰@ˆÚAˆă—ĂŽx‰‡Žş‚ɂ‚˘‚Ä. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć5‰ńMeeting for Optimized Kidney Transplantation (2018/6/23), “Œ‹ž.

731069. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‰ßŠˆ“ŽäNă÷‚̍ŐVŽĄ—Âɂ‚˘‚Ä. •˝ŽR‹M”Ž (”ĺ”AŠí): ‘Š–ÍŒ´•af˜AŒg (2018/7/18), ‘Š–ÍŒ´.

731070. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “ú–{l‚ĚHNPC‚ɑ΂ˇ‚鎥—Ă‚đÄl‚ˇ‚é. “c”¨Œ’ˆę (”ĺ”AŠí): ‘Š–ÍŒ´EźĂƒGƒŠƒAHNPCu‰‰‰ď (2018/9/7), ‘Š–ÍŒ´.

731071. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) M1‘O—§‘BŠŕ‚ɑ΂ˇ‚鎥—Ð헪:‹ÇŠŽĄ—Ă‚Í—LŒř‚Š? “c”¨Œ’ˆę (”ĺ”AŠí): ‘ć4‰ńWestern Tokyo GU Conference (2018/11/22), “Œ‹ž.

732044. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‘O—§‘B‚Ş‚ńPSAŒŸf‚Ě•‹y‚Ć—\Œă‚ւ̉e‹ż. ’Ă‘şGN (”ĺ”AŠí): ‘ć45‰ńŠÖ“Œ”_‘şˆăŠw‰ďŠwp‘‰ď (2018/7/14), •˝’Ë.

732045. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) “–‰@‚Ĺ‚Ěƒƒ{ƒbƒgŽx‰‡t•”•ŞŘœp (RAPN) •W€pŽŽ‚ĚŠm—§‚ÉŒü‚Ż‚Ä. Îˆä‘ĺ•ă1, “Ą“c“N•v1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/13), “Œ‹ž.

732046. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ ) M1‘O—§‘BŠŕ‚Ě‹ÇŠ—Ă–@`Ľ‚Ć‚ˇ‚é—§ę‚Š‚ç`. “c”¨Œ’ˆę1, ’Ă‘şGN1, ‘şă‘א´1, ź–{˜aŤ1, Šâ‘şłŽk 1 (1”ĺ”AŠí): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/14), “Œ‹ž.

733200. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äNă÷‘S“Eœp+‰ń’°“ąŠÇ‘˘ÝpŽ{s‚ÉŽŠ‚Á‚˝äNă÷äTᑂ̈ę—á. –Ȋс@ăÄ1, “c‰Ş‰ŔŒ›1, ‚Œű@‘ĺ1, “ě“c@—@1, ŽRč@“™2, ŽO–Ř–ž“ż3 (1”ĺ”AŠí, 2•a—, 3ŽY‰Č): ‘ć77‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď é‹Ę’n•ű‰ď (2018/4/4), ‚ł‚˘‚˝‚Ü.

733201. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆÚAŒă‘Šú‚É“Ž–Ź•ÂÇ‚đ—ˆ‚ľ‚˝ś‘̊ԐtˆÚAÇ—á‚ĚŒŸ“˘. Îˆä‘ĺ•ă1, “V–ě“”V1, —§‰Ô‹MŽj1, Žu‘ş‘sˆę˜N1, –ěŒű•ś”T2, Šâ‘şłŽk1, ‹g“cˆęŹ1,3, ’|“ŕ˜a”Ž4, ’|“ŕN—Y4, ˛X–؏G˜Y, —͐ΒC–ç (1”ĺ”AŠí, 2ŠĹŒě•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4t‘Ÿ“ŕ): ‘ć34‰ńtˆÚAEŒŒŠÇŠO‰ČŒ¤‹†‰ď (2018/5/26), Ž­Ž™“‡.

733202. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) tˆÚAŒă‚Ě• o“ŕPTLD2—á. ŕV“c@Ę, Îˆä‘ĺ•ă1, źŽRŒiŽq, –Ȋс@ăÄ1, “V–ě“”V1, Žu‘ş‘sˆę˜N1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć29‰ń_“ސěˆÚAˆăŠw‰ď (2018/6/2), ‰Ą•l.

733203. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éRa-223‚̏‰ŠúŽg—pŒoŒą. ě‘ş•ä1, Žá“c•”—zŽi, •ĘŠ‰pŽĄ, ‰œ–ě‹I•F (1”ĺ”AŠí): –k—˘‘ĺŠw•a‰@@•a˜AŒg‚̉ď (2018/6/7), ‘Š–ÍŒ´.

733204. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ‚Ť‚ČäNă÷ŒeŽş‚𔺂¤äNă÷”AŠÇ‚ɑ΂ˇ‚é‹CäNă÷‰şäNă÷”AŠÇV•Ť‡p. ź@ˇG1, •˝ŽR‹M”Ž1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć15‰ń”ĺ”AŠí‰ČÄŒšÄśŒ¤‹†‰ď (2018/6/16), “ß”e.

733205. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éCMVŠ´ő‚ĆmTOR‘jŠQ–ňŽg—p‚ĚŒŸ“˘. –Ȋс@ăÄ1, Îˆä‘ĺ•ă1, “V–ě“”V1, Žu‘ş‘sˆę˜N1, ŕV“c@Ę2, –ěŒű•ś”T3, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2t‘Ÿ“ŕ, 3ŠĹŒě•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ƒ~ƒ]ƒŠƒrƒ“Œ¤‹†‰ď (2018/6/16), “Œ‹ž.

733206. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚錋ÎŽĄ—Âɂ‚˘‚Ä. •ĘŠ‰pŽĄ1, ě‘ş•ä1, Žá“c•”—zŽi1, ‰œ–ě‹I•F (1”ĺ”AŠí): ‘ć4‰ń‚ł‚Ş‚Ý”ĺ”AŠí’nˆć˜AŒg‚̉ď (2018/6/20), _“ސě.

733207. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ¸‘ƒ”P“]‚ɑ΂ľ, ¸‘ƒ”’–Œ–Ĺ’ŁŘŠJp‚đs‚Á‚˝2—á. ’†‘ş^—˜]1, “V–ě“”V1, Ÿ–”—mŽ÷1, Žu‘ş‘sˆę˜N1, Îˆä‘ĺ•ă1, •˝ŽR‹M”Ž1, ‚“cŽĄŽq1, ‘şă‘א´1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć94‰ń_“ŢěŒ§”ĺ”AŠí‰Čˆă‰ď (2018/6/23), ěč.

733208. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚É‹ę—ś‚ľ‚˝–aŽ×–EŒ^t×–EŠŕ‚Ěˆę—á. Žt”ö”ɍF1, “c‰Ş‰ŔŒ›1, “ě“c@—@1, —§‰Ô‹MŽj1 (1”ĺ”AŠí): ‘ć79‰ń“ú–{”ĺ”AŠí‰ČŠw‰ďé‹Ę’n•ű‰ď (2018/6/23), ‚ł‚˘‚˝‚Ü.

733209. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒnƒCƒŠƒXƒN‘O—§‘BŠŕ‚ɑ΂ˇ‚éŠOĆŽË‚˝‚ń“xŽĄ—Ă‚ĆŠOĆŽË•š—pHDR brachytherapy‚ĚŽĄ—ÐŹŃ‚Ě”äŠr. ‘şă‘א´1, ’Ă‘şGN1, “c”¨Œ’ˆę1, “Ą“c“N•v1, ˛“ĄˆĐ•ś, –k–ě‰ëŽj, ÎŽR”ŽžŠ2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2•úŽËü (Žîá‡)): ‘ć35‰ń_“ŢěŒ§‘O—§‘BŽîᇌ¤‹†‰ď (2018/7/7), ‰Ą•l.

733210. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŒŁtˆÚA“o˜^’ˇŠú‘Ň‹@ŠłŽŇ‚Ě‹CŽ‚ż‚ÉŠÖ‚í‚Á‚˝28”NŠÔ. ’r“cŹ]1, Îˆä‘ĺ•ă1, –ěŒű•ś”T2, ‰““Ą’‰—Y, ‹g“cˆęŹ1,3 (1”ĺ”AŠí, 2ŠĹŒě•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć29‰ń“ú–{ƒTƒCƒRƒlƒtƒƒƒW[Œ¤‹†‰ď (2018/7/7), “Œ‹ž.

733211. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ź’°úE‚É‚ć‚č’˛ßŘœp‚đ—v‚ľ‚˝tˆÚAŒăŹ’°Œ´”­PTLD‚Ěˆę—á. Îˆä‘ĺ•ă1, –Ȋс@ăÄ1, Žu‘ş‘sˆę˜N1, “V–ě“”V1, Šâ‘şłŽk1, Š™“c_–Ť2, “›ˆä“ÖŽq3, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŒŒ‰t“ŕ, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć27‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ď (2018/7/21), ŽD–y.

733212. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘˝”­Ťt”^ᇂɑ΂ľt“EœpŒă‚ɑΑ¤”AŠÇ‚ÉŒ‹Î‚đ”F‚ß‚˝ˆę—á. ‰––ě@—T1, ź@ˇG1, Ÿ–”—mŽ÷1, Žu‘ş‘sˆę˜N1, “V–ě“”V1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć58‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď
_“ސě’n•ű‰ď (2018/9/6), ‰Ą•l.

733213. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒnƒCƒŠƒXƒNmHNPC‚ɑ΂ˇ‚éƒAƒrƒ‰ƒeƒƒ“‚ĚŽg—pŒoŒą. ‘şă‘א´1, ’Ă‘şGN1, “c”¨Œ’ˆę1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘Š–ÍŒ´EźĂƒGƒŠƒAHNPCu‰‰‰ď (2018/9/7), ‘Š–ÍŒ´.

733214. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) ŠOŒa‚ĚˆŮ‚Č‚éƒAƒNƒZƒXƒV[ƒX‚đŽg—p‚ľ‚˝fTUL‚ĚŽüpŠúŹŃ‚ÉŠÖ‚ˇ‚錟“˘. ‚Œű@‘ĺ1, “y‹´łl1, •˝–ěC•˝1, ‘şă‘א´1, Îˆä~ˆę˜Y (1”ĺ”AŠí): ‘ć68‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď’†•”‘‰ď (2018/10/6), –źŒĂ‰Ž.

733215. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äNă÷ŠŕÇ—á‚É‚¨‚Ż‚錌´DJ-1”­Œť‚ĚŒŸ“˘. •˝–ěC•˝1, ź–{˜aŤ1, •˝ŽR‹M”Ž1, ź@ˇG1, ’Ă‘şGN1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, ˛“Ą—Yˆę2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2ˆă—ÉqśŠw•”): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/13), “Œ‹ž.

733216. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äNă÷‘S“Eœp•W–{‚É‚¨‚Ż‚éTROY”­Œť‚ĚŒŸ“˘. –ě‘ş@Œb1, ź–{˜aŤ1, ’r“cŸb1, “V–ě“”V1, “c”¨Œ’ˆę1, ź^—RŽq, —Ŕ@–žG, ‹g“cˆęŹ1,2, ˛“Ą—Yˆę3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆă—ÉqśŠw•”): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/13), “Œ‹ž.

733217. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒnƒCƒŠƒXƒN‘O—§‘BŠŕ‚ɑ΂ˇ‚éŠOĆŽË’P“ĆŽĄ—Ă‚ĆŠOĆŽË•š—pHDR brachytherapy‚ĚŽĄ—ÐŹŃ‚Ě”äŠr. ‘şă‘א´1, ’Ă‘şGN1, “c”¨Œ’ˆę1, ’†‘ş^—˜]1, “V–ě“”V1, “Ą“c“N•v1, ˛“ĄˆĐ•ś, –k–ě‰ëŽj, ÎŽR”ŽžŠ2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2•úŽËü (Žîá‡)): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/14), “Œ‹ž.

733218. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) ’´‰š”gÓÎŠí‚Ş—LŒř‚Ĺ‚ ‚Á‚˝‘˝”­äNă÷Œ‹Î‚¨‚ć‚Ń‹‘ĺ”A“šŒ‹Î‚Ěˆę—á. –Ȋс@ăÄ1, â“c—T‰î1, ˆŔ“Ą–š”ü1, Îě@–í1, ŠŰ@“T•v, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć83‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2018/10/14), “Œ‹ž.

733219. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰‰ńŽĄ—Ă‚Š‚ç20”NŒă‚ɍĔ­‚đ”F‚ß‚˝“]ˆÚŤ¸‘ƒŠŕ‚Ě1—á. Žt”ö”ɍF1, “c”¨Œ’ˆę1, Žu‘ş‘sˆę˜N1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć95‰ń_“ŢěŒ§”ĺ”AŠí‰Čˆă‰ď (2018/11/10), ‰Ą•l.

733220. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) BCGäNă÷“ŕ’“ü—Ă–@‚Ě“ą“ü—Ă–@‚Ć“ą“üˆŰŽ—Ă–@‚Ě”äŠrŒŸ“˘. ź–{˜aŤ1, •˝ŽR‹M”Ž1, ’r“cŸb1, ’Ă‘şGN1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć11‰ńBCG’“ü—Ă–@Œ¤‹†‰ď (2018/11/16), “Œ‹ž.

733221. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ź’°úE‚đ”F‚ß‚˝PTLD‚Ě1Ç—á. “V–ě“”V1, Îˆä‘ĺ•ă1, Žu‘ş‘sˆę˜N1, Šâ‘şłŽk1, Š™“c_–Ť2, “›ˆä“ÖŽq3, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŒŒ‰t“ŕ, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć15‰ń‘ŸŠí•s‘SŠłŽŇ‚ɑ΂ˇ‚éŠO‰ČEŠÇ—Œ¤‹†‰ď (2018/11/17), “Œ‹ž.

733222 [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • –Œ“§ÍƒJƒe[ƒeƒ‹‚Ě—‘ŠÇŃŠŞ—‚É‚ć‚é•ÂÇ‚Ě1—á. Ÿ–”—mŽ÷1, —§‰Ô‹MŽj1, “ě“c@—@1, “c‰Ş‰ŔŒ›1 (1”ĺ”AŠí): ‘ć80‰ń“ú–{”ĺ”AŠí‰ČŠw‰ďé‹Ę’n•ű‰ď (2018/11/17), ‚ł‚˘‚˝‚Ü.

733223. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) HIVŠ´őŠłŽŇ‚ɐś‘̐tˆÚAp‚đŽ{s‚ľ‚˝1Ç—á. “V–ě“”V1, Îˆä‘ĺ•ă1, –Ȋс@ăÄ1, ě‘ş•ä1, ŕV“c@Ę2, ’|“ŕN—Y2, ˜a“c’B•F3, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2t‘Ÿ“ŕ, 3äPŒ´•aEŠ´ő“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć96‰ń_“ސětŒ¤‹†‰ď/‘ć34‰ń_“ŢěŒ§“§ÍŽ{Ý˜A—‹Ś‹c‰ď ‡“ŻŒ¤‹†‰ď (2018/11/18), ‰Ą•l.

733224. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) M1‘O—§‘BŠŕ‚ɑ΂ˇ‚é‹ÇŠŽĄ—Ă. “c”¨Œ’ˆę (”ĺ”AŠí): Prostate Cancer Seminar 2018 (2018/11/21), ‰Ą•l.

733225. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘O—§‘B”ě‘ĺÇ‚É‚ć‚鎥—Ă‚ĚŒťó. ě‘ş•ä1, Žá“c•”—zŽi1, •ĘŠ‰pŽĄ1, ‰œ–ě‹I•F (1”ĺ”AŠí): ‘ć5‰ń‚ł‚Ş‚Ý”ĺ”AŠí’nˆć˜AŒg‚̉ď (2018/11/22), _“ސě.

733226. [Šw‰ď ( ’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠÔŽżŤ”x‰Š‚Ć‘ĺ’°‰Š‚đ‘ą”­‚ľ‚Ä”F‚ß‚˝ƒyƒ“ƒuƒƒŠƒYƒ}ƒu“Š—^‚Ě1Ç—á. ‰––ě@—T1, Îˆä‘ĺ•ă1, â“c—T‰î1, Žu‘ş‘sˆę˜N1, “V–ě“”V1, •˝ŽR‹M”Ž1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć59‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď_“ސě’n•ű‰ď (2019/2/7), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-520001. [‘ŕ] tˆÚA‚ÉŠÖ‚ˇ‚é’˛¸ (•˝Ź28”N“x) ‚Ě•ŞÍŒ‹‰Ę‚ɂ‚˘‚Ä. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): _“ŢěŒ§“§ÍŽ{Ý˜A—‹Ś‹c‰ď•ń 2017; 32: 15-8.

H29-522006. [uŔ]y“ÁW: ‚܂邲‚Ć ”ĺ”AŠí‚Ş‚ń‚̉ťŠw—Ă–@E•ŞŽq•W“I—Ă–@E–Ɖu—Ă–@z<‹Ž¨’ďRŤ‘O—§‘B‚Ş‚ń>@14. V‹Kƒzƒ‹ƒ‚ƒ“Ü (ƒAƒrƒ‰ƒeƒƒ“EƒGƒ“ƒUƒ‹ƒ^ƒ~ƒh) ‚Ě•›ě—pƒRƒ“ƒgƒ[ƒ‹. “c”¨Œ’ˆę1, Šâ‘şłŽk1 (1”ĺ”AŠí): ”ĺ”AŠíCare&Cure Uro-Lo 2017/10; 22 (5): 73-8.

[’˜@‘]

H29-620004. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj 2018”N”Ł@Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚éz‘˜_@19. ”ĺ”AŠí‰ČŽžŠł@”ĺ”AŠí‰Č—Ěˆć‚Ě• o‹ž‰şŽčp, p.1147-8. Šâ‘şłŽk (”ĺ”AŠí), •Ň: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2018/1”­s.


Šá‰ČŠw

[Šwp˜_•ś]

110294. [Œ´’˜] Validating Variational Bayes Linear Regression Method With Multi-Central Datasets. Murata H, Zangwill LM, Fujino Y, Matsuura M, Miki A, Hirasawa K1, Tanito M, Mizoue S, Mori K, Suzuki K, Yamashita T, Kashiwagi K, Shoji N2, Asaoka R: Invest Ophthalmol Vis Sci 2018/4; 59 (5): 1897-904. (•˝ŕVˆę–@1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110295. [Œ´’˜] Etiology and outcomes of secondary surgical intervention for dissatisfied patients after pseudophakic monovision. Kato S, Ito M, Shimizu K1,2, Kamiya K1: Int Ophthalmol 2018/6; 38 (3): 1003-9. (_’J˜aF1, ´…Œö–ç1,2: 1Šá‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[)

110296. [Œ´’˜] Evaluation of the Effects of the Occlu-Pad for the Management of Anisometropic Amblyopia in Children. Iwata Y1, Handa T2, Ishikawa H2, Goseki T3, Shoji N3: Curr Eye Res 2018/6; 43 (6): 785-7. (Šâ“c@—y1, ”ź“c’m–ç2, Îě@‹Ď2, ŒăŠÖ—˜–ž3, ŻŽiMs3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č)

110297. [Œ´’˜] Mapping the Central 10‹ Visual Field to the Optic Nerve Head Using the Structure-Function Relationship. Fujino Y1, Murata H, Matsuura M1, Yanagisawa M, Shoji N2, Inoue K, Yamagami J, Asaoka R: Invest Ophthalmol Vis Sci 2018/6; 59 (7): 2801-7. (“Ą–ě—F—˘1, ź‰YŤl1, ŻŽiMs2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č)

110298. [Œ´’˜] Relationship between central and peripheral corneal astigmatism in elderly patients. Kawamorita T1, Hosikawa R2, Kamiya K1, Shoji N2: Optical Review 2018/6; 25 (3): 336-9. (ěŽç“c‘ńŽu1, Šąě—˘ŠG2, _’J˜aF1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110299. [Œ´’˜] Effect of visual target blurring on accommodation under distance viewing. Iwata Y1, Handa T2, Ishikawa H2: Optical Review 2018/6; 25 (3): 380-2. (Šâ“c@—y1, ”ź“c’m–ç2, Îě@‹Ď2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”)

110300. [Œ´’˜] A Case of Microscopic Amblyopia Successfully Treated using Occlu-Pad. Iwata Y1, Hnanda T2, Ishikawa H2: EC ophthalmology 2018/6; 9 (6): 404-7. (Šâ“c@—y1, ”ź“c’m–ç2, Îě@‹Ď2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”)

110301. [Œ´’˜] Intentional Undercorrection by Implantation of Posterior Chamber Phakic Intraocular Lens With A Central Hole (Hole ICL) For Early Presbyopia. Takahashi M1, Kamiya K2, Shoji N1, Kato S, Igarashi A, Shimizu K: Biomed Res Int 2018/6; 2018: 6158520. (‚‹´ł‰p1, _’J˜aF2, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110302. [Œ´’˜] Is the Ethambutol Administration Triggering Factor for Onset of Leber's Hereditary Optic Neuropathy?: a Case Report. Nakazawa M1, Ishikawa H2, Goseki T1, E, Shoji N1: _ŒoŠá‰Č 2018/6; 35 (2): 239-43. (’†ŕV—S‘Ľ1, Îě@‹Ď2, ŒăŠÖ—˜–ž1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110303. [Œ´’˜] Evaluation of a Relative Afferent Pupillary Defect using the RAPDxŇ Device Before and After Treatment in Patients with Optic Nerve Disease. Satou T, Ishikawa H1, Goseki T2, Asakawa K1: Neuroophthalmology 2018/6; 42 (3): 146-9. (Îě@‹Ď1, ŒăŠÖ—˜–ž2, óě@ŒŤ1: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110304. [Œ´’˜] Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. Kato COS, Shimizu K, Kamiya K1, Ishikawa H1, Igarashi1 A: Sci Rep 2018/6; 8 (1): 9003 (5 pages). (_’J˜aF1, Îě@‹Ď1: 1ˆă—ÉqśŠw•”)

110305. [Œ´’˜] Improving the structure-function relationship in glaucomatous and normative eyes by incorporating photoreceptor layer thickness. Matsuura M1, Fujino Y1, Kanamoto T, Murata H, Yanagisawa M, Hirasawa K2, Inoue T, Shoji N3, Inoue K, Yamagami J, Asaoka R: Sci Rep 2018/7; 8 (1): 10450. (ź‰YŤl1, “Ą–ě—F—˘1, •˝ŕVˆę–@2, ŻŽiMs3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č)

110306. [Œ´’˜] Time Course of Changes in Simulated Keratometry and Total Corneal Refractive Power after Corneal Collagen Cross-Linking for Progressive Keratoconus. Takahashi M1, Kamiya K2, Kono Y1, Shoji N1: Biomed Res Int 2018/8; 2018: 2620784. (‚‹´ł‰p1, _’J˜aF2, ‰Í–ě—Y—ş1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110307. [Œ´’˜] Comparison of Simulated Keratometry and Total Refractive Power for Keratoconus According to the Stage of Amsler-Krumeich Classification. Kamiya K1, Kono Y2, Takahashi M2, Shoji N2: Sci Rep 2018/8; 8 (1): 12436. (_’J˜aF1, ‰Í–ě—Y—ş2, ‚‹´ł‰p2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110308. [Œ´’˜] Evaluation of Pupil Fields Using a Newly Developed Head-mounted Perimeter in Healthy Subjects. Asakawa K1, Nanno M, Ishikawa H1, Shoji N2: J Glaucoma 2018/9; 27 (9): 807-15. (óě@ŒŤ1, Îě@‹Ď1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110309. [Œ´’˜] Effects of Divergence with Base-in Prisms on Near Visual Function. Kawai M1, Nishikawa N, Ishiko S, Yoshida A: _ŒoŠá‰Č 2018/9; 35 (3): 357-62. (‰Í‡ˆ¤ŽŔ1: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110310. [Œ´’˜] Compressive Lesions of the Optic Chiasm: Subjective Symptoms and Visual Field Diagnostic Criteria. Takahashi M1, Goseki T1, Ishikawa H2, Goukon H3, Hirasawa K2, Shoji N1: Neuroophthalmology 2018/9; 42 (6): 343-8. (‚‹´ŽŔŠóŽq1 ŒăŠÖ—˜–ž1, Îě@‹Ď2, ‹˝‰E‹ß”ŽN3, •˝ŕVˆę–@2, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110311. [Œ´’˜] Prospective Randomized Multicenter Comparison of the Clinical Outcomes of V4c and V5 Implantable Collamer Lenses: A Contralateral Eye Study. Kojima T, Kitazawa Y, Nakamura T, Takahashi M1, Kamiya K1, Ichikawa K, Igarashi A, Shimizu K: J Ophthalmol 2018/9; 2018: 7623829 (6 pages). (‚‹´ł‰p1, _’J˜aF1: 1ˆă—ÉqśŠw•”)

110312. [Œ´’˜] Posterior Chamber Phakic Intraocular Lens Implantation in Eyes with an Anterior Chamber Depth of Less Than 3 mm: A Multicenter Study. Kamiya K1, Shimizu K, Igarashi A, Kitazawa Y, Kojima T, Nakamura T, Ichikawa K: Sci Rep 2018/9; 8 (1): 13322 i7pages). (_’J˜aF1: 1ˆă—ÉqśŠw•”)

110313. [Œ´’˜] Causes, background, and characteristics of binocular diplopia in the elderly. Kawai M1, Goseki T2, Ishikawa H3, Hoshina M, Shoji N2: Jpn J Ophthalmol 2018/11; 62 (6): 659-66. (‰Í‡ˆ¤ŽŔ1, ŒăŠÖ—˜–ž2, Îě@‹Ď3, ŻŽiMs2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”)

110314. [Œ´’˜] Changes in Corneal Biomechanics and Intraocular Pressure Following Cataract Surgery. Hirasawa K1, Nakakura S, Nakao Y, Fujino Y2, Matsuura M2, Murata H, Kiuchi Y, Asaoka R: Am J Ophthalmol 2018/11; 195: 26-35. (•˝ŕVˆę–@1, “Ą–ě—F—˘2, ź‰YŤl2: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110315. [Œ´’˜] Variability in monocular and binocular fixation during standard automated perimetry. Hirasawa K1, Kobayashi K, Shibamoto A, Tobari H, Fukuda Y, Shoji N2: PLoS One 2018/11; 13 (11): e0207517. (•˝ŕVˆę–@1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110316. [Œ´’˜] Factors influencing subjective symptoms in dry eye disease. Kobashi H, Kamiya K1, Sambe T, Nakagawa R: Int J Ophthalmol 2018/12; 11 (12): 1926-31. (_’J˜aF1: 1ˆă—ÉqśŠw•”)

110317. [Œ´’˜] Central Islands and Visual Outcomes of Phototherapeutic Keratectomy Using the Photorefractive Keratectomy Mode. Kamiya K1, Takahashi M2, Igarashi A, Shoji N2: Cornea 2019/1; 38 (1): 89-92. (_’J˜aF1, ‚‹´ł‰p2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110318. [Œ´’˜] Relationship between the Vertical Asymmetry of the Posterior Pole of the Eye and the Visual Field Damage in Glaucomatous Eyes. Hirasawa K1, Yamashita T, Fujino Y2, Matsuura M2, Yanagisawa M, Kii Y, Sakamoto T, Murata H,Asaoka R: Ophthalmology Glaucoma 2019/1-2; 2 (1): 28-35. (•˝ŕVˆę–@1, “Ą–ě—F—˘2, ź‰YŤl2: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110319. [Œ´’˜] Using Deep Learning and Transfer Learning to Accurately Diagnose Early-Onset Glaucoma From Macular Optical Coherence Tomography Images. Asaoka R, Murata H, Hirasawa K1, Fujino Y2, Matsuura M2, Miki A, Kanamoto T, Ikeda Y, Mori K, Iwase A, Shoji N3, Inoue K, Yamagami J, Araie M: Am J Ophthalmol 2019/2; 198: 136-45. (•˝ŕVˆę–@1, “Ą–ě—F—˘2, ź‰YŤl2, ŻŽiMs3: 1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Šá‰Č)

110320. [Œ´’˜] The Influence of Trabectome Surgery on Corneal Endothelial Cells. Kasahara M1, Shoji N1, Matsumura K: J Glaucoma 2019/2; 28 (2): 150-3. (Š}Œ´łs1, ŻŽiMs1: 1Šá‰Č)

110321. [Œ´’˜] Quantitative Analysis of Objective Forward Scattering and Its Relevant Factors in Eyes with Cataract. Kamiya K1, Fujimura F1, Kawamorita T1, Takahashi M2, Ando W2, Iida Y2, Shoji N2: Sci Rep 2019/2; 9 (2): 3167 (5pages). (_’J˜aF1, “Ą‘ş•‡˛Žq1, ěŽç“c‘ńŽu1, ‚‹´ł‰p2, ˆŔ“Ą˜a‰ĚŽq2, ”Ń“c‰Ă•F2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110322. [Œ´’˜] A Multicenter Study on Early Outcomes of Small-Incision Lenticule Extraction for Myopia. Kamiya K1, Takahashi M2, Nakamura T, Kojima T, Toda I, Kariya M: Sci Rep 2019/3; 9 (1): 4067 (7pages). (_’J˜aF1, ‚‹´ł‰p2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110323. [Œ´’˜] The Role of Zinc in Ethambutol-induced Neuroretinopathy:Functional and Morphologic Assessment in a Rabbit Model. Palisoc E1,2, Asakawa K3, Uga S3, Mashimo K2, Ishikawa H3 (1Manila Central University College of Medicine): _ŒoŠá‰Č 2019/3; 36 (1): 95-105. (óě@ŒŤ3, áÁ‰ş‹I”ü‘ă2, Îě@‹Ď3: 2Šá‰Č, 3ˆă—ÉqśŠw•”)

120020. [Œ´’˜]yŠw‰ďŒ´’˜: ‘ć71‰ń“ú–{—Տ°Šá‰ČŠw‰ďu‰‰W [2]zƒAƒCƒgƒ‰ƒbƒJ[‚đ—p‚˘‚˝d“x”]Ť–ƒáƒŠłŽŇ‚ĚŽ‹‰^“ŽŤŠáU‚Ě•Ş—Ţ. —é–ŘŒŤŽĄ1, Vˆä“cF—T1,2, ˛“Ą@Ži1, ‚‹´—RŽk1, –ěă‹Žu1, Œ´@’źl1, “ĄŽR—R‹IŽq1 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”Ž‹‹@”\—Ă–@Šw‰Č, 2Šá‰Č): —Տ°Šá‰Č 2018/4; 72 (4): 543-50.

120021. [Œ´’˜]yŠw‰ďŒ´’˜: ‘ć71‰ń“ú–{—Տ°Šá‰ČŠw‰ďu‰‰W [4]z’´‰š”gś‘ĚŒ°”÷‹ž‚Ć‘OŠá•”ŒőŠąÂ’f‘wŒv‚ĹŠĎŽ@‚ł‚ę‚˝…ť‘ĚŒ`ó‚Ě”äŠr. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO3, “ŕ“ĄŽ‹v3, ˆé’JŽ‹P4, •Đ‰Ş“”Ž4, ’†‘ş—Fş4, Žsěˆę•v3,5 (1Šá‰Č–žŠá‰@, 2Šň•Œ“úÔ•a‰@Šá‰Č, 3’†‹žŠá‰Č, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5Šá‰Č): —Տ°Šá‰Č 2018/6; 72 (6): 875-82.

120022. [Œ´’˜]yŠw‰ďŒ´’˜: ‘ć71‰ń“ú–{—Տ°Šá‰ČŠw‰ďu‰‰W [5]z’˛ß‚É”ş‚¤…ť‘Ě‚ĚŒ`ó‰đÍ. Î“c@‹Ĺ1, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č): —Տ°Šá‰Č 2018/7; 72 (7): 1009-12.

120023. [Œ´’˜]yŠw‰ďŒ´’˜: ‘ć71‰ń“ú–{—Տ°Šá‰ČŠw‰ďŠwp‰‰K [6]zŠ´ŠoŤŠOŽÎŽ‹‚Ě”­śƒƒJƒjƒYƒ€‚ĚŒ¤‹†@•ĐŠáŤ‰Š”Á•”ŽžŠł‚É‚¨‚Ż‚鎋—Í, ŠáˆĘ, —źŠáŽ‹‹@”\, Ž‹–ě‚ĚŒŸ“˘. ‘ĺŔ@Šw1,2, Vˆä“cF—T2,3, Œ´@’źl2, “ĄŽR—R‹IŽq2, ”–ˆä‹I•v1, “ŕŠC@’Ę1 (1ˆă—Ă–@l–ž“ż‰ď‘‡Vě‹´•a‰@Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3Šá‰Č): —Տ°Šá‰Č 2018/8; 72 (8): 1091-7.

120024. [Œ´’˜] —§‘ĚŽ‹‰ž“š‘Ź“x‚É‚¨‚Ż‚éŒy“x—Ž‹‚̉e‹ż. Œ‹éŠxŽu1, ”ź“c’m–ç2, Šâ“c@—y2, ”Ń“c‰Ă•F3, ŻŽiMs3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2018/9; 35 (9): 1295-8.

120025. [Œ´’˜] –ňÜŠ´ŽóŤŽŽŒą‚őϐŤ‚đŽŚ‚ľ‚˝‚É‚ŕ‚Š‚Š‚í‚炸ƒŒƒ{ƒtƒƒLƒTƒVƒ““_Šá‚Ş’˜Œř‚ľ‚˝ƒmƒJƒ‹ƒWƒAŠp–Œ‰Š‚Ě1—á. ”Ń“cŤŒł1, Žq“‡—Ç•˝1,2, Ź–ě@‹Ş1, X@—mÄ1,2, –ěŒű‚ä‚Š‚č1, Šâč‘ô–ç1, ‹{“c˜a“T1 (1‹{“cŠá‰Čˆă‰@, 2Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2018/11; 35 (11): 1545-9.

120026. [Œ´’˜]yŠw‰ďŒ´’˜: ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ďu‰‰W [1] (u‰‰5-4)zŠÜ…—Ś‚đ‚‚­‚ľ‚˝‘a…ŤƒAƒNƒŠƒ‹Šá“ŕƒŒƒ“ƒY‚É‚¨‚Ż‚épŒă’ˇŠú‚Ě•\–ĘŽU—. –؉ş—Yl1, Žq“‡—Ç•˝1,2, –{–Vłl1, “ěŒcˆę˜Y1, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): —Տ°Šá‰Č 2019/3; 73 (3): 291-5.

120027. [Œ´’˜] Šá‹…Œ‹–Œ‚É”­Ç‚ľ‚˝–łF‘fŤŒ‹–ŒˆŤŤ•FŽî‚Ě1—á. ŒĂě—F‘ĺ1, ŽO“c‘ş–ƒ—˘2, ’ˇ’JěˆŸ—˘1, Ź“‡—˛Ži3, ‰Á‰ę’BŽu1, Žsěˆę•v4,5 (1JCHO’†‹ž•a‰@, 2Šň•ŒÔ\Žš•a‰@, 3Œcœä‹`m‘ĺŠw, 4’†‹žŠá‰Č, 5Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2019/3; 36 (3): 403-6.

120028. [Œ´’˜] ƒ|ƒPƒ‚ƒ“ƒXƒeƒŒƒIƒeƒXƒg‚ĚŽg—pŒoŒą. ‘–ö—R‹G1, Šâ“c@—y2, Žđ“őä—T2 (1‚ł‚ą‚¤Šá‰Č, 2ˆă—ÉqśŠw•”): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2019/3; 36 (3): 411-4.

120029. [Œ´’˜] SMILEpŒă‚ÉŠp–ŒŠg’ŁÇ‚đ”­Ç‚ľ‚˝1Ç—á. •ÄŽR@—Č1, _’J˜aF1, ‚‹´ł‰p1, ŻŽiMs1 (1Šá‰Č): IOL&RS 2019/3; 33 (1): 124-9.

310026. [Ç—á•ń] Cataract surgery in a patient with an angle gamma due to macular heterotopia. Hoshikawa R1, Iida Y2, Kawamorita T1, Shoji N2: Am J Ophthalmol Case Rep 2018/10; 12: 97-100. (Šąě—˘ŠG1, ”Ń“c‰Ă•F2, ěŽç“c‘ńŽu1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

320029. [Ç—á•ń] ’ˇŠúŒo‰ßŠĎŽ@‚މ”\‚Ĺ‚ ‚Á‚˝Ž÷•Xó–Ô–ŒŒŒŠÇ‰Š‚Ě1—á. ‰Í‡ˆ¤ŽŔ1, ŒăŠÖ—˜–ž2, Îě@‹Ď3, ŻŽiMs2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2018/9; 35 (3): 317-23.

320030. [Ç—á•ń] Vort-Ź–ö-Œ´“c•aŒo‰ß’†‚É”­Ç‚ľ‚˝Adie“ľE‚Ć–Ź—–ŒŒŒ—Ź‚ĚŒŸ“˘|ƒŒ[ƒU[ƒXƒyƒbƒNƒ‹ƒtƒ[ƒOƒ‰ƒtƒB[‚đ—p‚˘‚ā|. “n•ÓŒ¤l1, ź–{@’ź1, ŽÄ@—F–ž1, •x“c‹§•F1, XŽRŽŃ”ż1, Îě@‹Ď2, –x@—Tˆę1 (1“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 2ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2018/12; 35 (4): 418-23.

320031. [Ç—á•ń] ƒvƒŠ[ˆŮí‚𔺂¤“ŕŽÎŽ‹‚É”{—Ę‹¸łŠpŽčp‚Ş‘tŒ÷‚ľ‚˝ˆę—á. Š—ś^—˘1, ŒăŠÖ—˜–ž2, Žs粋`Í1,2, ŒN“‡^ƒ1, Œü–ě˜a—Y1,2 (1_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN, 2Šá‰Č): _ŒoŠá‰Č 2018/12; 35 (4): 424-9.

320032. [Ç—á•ń]yCase Report2zpŒă‹üÜŒëˇ‚𐜂ś‚˝Ç—á. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ĹVŠá‰Čî•ńOphthalmology Update 2018”N‘W•Ň 2019/1; p.10-2.

410001. [—Տ°ŽŽŒą] Improvement of Adherence with Occlu-Pad Therapy for Pediatric Patients with Amblyopia. Totsuka S1, Handa T2, Ishikawa H2, Shoji N1: Biomed Res Int 2018/11; 2018: 2394562 (5 pages). (ŒË’ˁ@Œĺ1, ”ź“c’m–ç2, Îě@‹Ď2, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

510008. [‘ŕ] Phototransduction in a rabbit model with retinitis pigmentosa. óě@ŒŤ1, Îě@‹Ď1 (1ˆă—ÉqśŠw•”): Austin J Clin Ophthalmol 2018/8; 5 (3): 1095 (5pages).

520016. [‘ŕ] 2017”N“xJSCRS‰ďˆőƒAƒ“ƒP[ƒg. ˛“ĄłŽ÷1, —с@@Œ¤1, ŞŠÝˆę”T1, _’J˜aF1,2, ƒrƒbƒZƒ“‹{“‡OŽq1 (1JSCRSƒAƒ“ƒP[ƒg’˛¸ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv, 2ˆă—ÉqśŠw•”): IOL&RS 2018/9; 32 (3): 421-41.

520017. [‘ŕ]yReview2z”’“ŕáŽčp: Ĺ‹ß‚Ě˜b‘č. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ĹVŠá‰Čî•ńOphthalmology Update 2018”N‘W•Ň 2019/1; p.8-10.

521011. [‰đŕ]yƒGƒLƒXƒp[ƒg‚ÉŠw‚Ô: Šá‰ČŽčp‚ĚŽż–â” zQhole ICLŽčp‚ĚƒRƒc‚⒍ˆÓ“_‚đ‹ł‚Ś‚ĉş‚ł‚˘. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰ČŽčp 2018/4; 31 (2): 256-7.

521012. [‰đŕ]yƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[zƒGƒLƒXƒp[ƒg‚É•ˇ‚­. ’š‹GŹ1, ”Ń“c‰Ă•F1, ‘O“c’ź”V2, X@—mÄ1,3 (1Šá‰Č, 2ŒÎčŠá‰Č, 3‹{“cŠá‰Č•a‰@): IOL&RS 2018/6; 32 (2): 324-30.

521013. [‰đŕ]y‹@ŠíE–ňÜĐ‰îz29. 3D Visual Function Trainer-ORTe. ”ź“c’m–ç (ˆă—ÉqśŠw•”): Šá‰Č 2018/9; 60 (9): 949-52.

521014. [‰đŕ]y‹@ŠíE–ňÜĐ‰îz31. ƒgƒ‰ƒxƒNƒg[ƒ€. Š}Œ´łs1, ŻŽiMs1 (1Šá‰Č): Šá‰Č 2018/11; 60 (12): 1503-6.

521015. [‰đŕ] V‚ľ‚˘ŒŸ¸‹@Ší‚Ě“Ç‚Ý•ű@ƒRƒ“ƒgƒ‰ƒXƒgŠ´“xŒŸ¸. “Ą‘ş•‡˛Žq (ˆă—ÉqśŠw•”): IOL&RS 2018/12; 32 (4): 670-4.

521016. [‰đŕ]y‹@ŠíE–ňÜĐ‰îz34. SpotTMVision Screener. ˛“Ą@Ži1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č): Šá‰Č 2019/2; 61 (2): 171-8.

521017. [‰đŕ]yŠá‰Čˆă‚ĚŽčˆř‚Ťz<929> ŽüpŠú‚̍R‹Ű“_Šá–ňŽg—p. Žq“‡—Ç•˝1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): “ú–{‚ĚŠá‰Č 2019/2; 90 (2): 155-6.

521018. [‰đŕ] FLACS‚Í•K—v‚Š”Ű‚Š: •s—v”h. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): IOL&RS 2019/3; 33 (1): 137-41.

521019. [‰đŕ]yĹV‹@ŠíƒŠƒ|[ƒg HellozIntroduction. ŒăŠÖ—˜–ž (Šá‰Č): _ŒoŠá‰Č 2019/3; 36 (1): 87.

521020. [‰đŕ]yĹV‹@ŠíƒŠƒ|[ƒg Helloz”­ˆÄŽŇ‚Ě—§ę‚Š‚ç. ”ź“c’m–ç (ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2019/3; 36 (1): 89-90.

521021. [‰đŕ]yĹV‹@ŠíƒŠƒ|[ƒg HellozUser's Comment. Šâ“c@—y1, Îě@‹Ď2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2019/3; 36 (1): 90-4.

522110. [uŔ]y“ÁW: ƒCƒ`‚Š‚ç‚Í‚ś‚ß‚é_ŒoŠá‰Čf—Áz”ń“TŒ^“IŽ‹_Œo‰Š‚Ć‚Í. Šâ˛^‹|1,2, ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): OCULISTA 2018/4; 61: 6-14.

522111. [uŔ]y“ÁW: ƒCƒ`‚Š‚ç‚Í‚ś‚ß‚é_ŒoŠá‰Čf—Áz“ľEˆŮí‚Ě‚Ý‚Š‚˝‚Ć‹Ů‹}ŽžŠł. —´ˆä‰‘Žq1, ŒăŠÖ—˜–ž1 (1Šá‰Č): OCULISTA 2018/4; 61: 55-60.

522112. [uŔ]y“ÁW: ŽŔ‘HI”’“ŕá“ďÇ—áŽčp‚É’§‚ށzŹ“ľEEIFIS. ”Ń“c‰Ă•F (Šá‰Č): OCULISTA 2018/5; 62: 19-24.

522113. [uŔ]yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYƒZƒ~ƒi[zƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYˆ•ű‚ł‚ç‚Č‚éˆę•ŕ43. ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ĚŒőŠw“ÁŤ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2018/5; 35 (5): 645-6.

522114. [uŔ]y—ΓŕáƒZƒ~ƒi[z216. Ší‹ď‚đ—Ż’u‚ˇ‚é—Źo˜HÄŒšp. ŻŽiMs (Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2018/635 (6): 793-4.

522115. [uŔ]y‹łˆçƒZƒ~ƒi[: ‚ł‚ , Œ¤‹†‚đŽn‚߂悤z…ť‘́E”’“ŕá‚ĚŠáŒőŠwŒ¤‹†“ü–ĺ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): “ú–{”’“ŕáŠw‰ďŽ 2018/6; 30: 77-9.

522116. [uŔ] ‰~Šp–Œ‚ɑ΂ˇ‚éŠá“ŕƒŒƒ“ƒY“x”ŒvŽZ. _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2018/6; 32 (2): 208-14.

522117. [uŔ]yÇ—á‚Š‚çŠw‚Ô”’“ŕáŽčp‚ĚŽŔ‘HƒŒƒNƒ`ƒƒ[: p‘O•Ň6zíÝ‹Ű‚Ě“ŽŒüEŒ¸‹Ű‰ť. Žq“‡—Ç•˝1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): —Տ°Šá‰Č 2018/7; 72 (7): 930-3.

522118. [uŔ]y“ÁW: “úíf—ÂŖ𗧂ŠáŒőŠw‚Ě’mŽŻz‹üÜ‹¸ł–@‚ĆŠáŒőŠw: ‹üÜ‹¸łŽčp‚ĚŠáŒőŠw. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): OCULISTA 2018/7; 64: 20-6.

522119. [uŔ]y“ÁW: “úíf—ÂŖ𗧂ŠáŒőŠw‚Ě’mŽŻzŒŸ¸‚ĆŠáŒőŠw: “úíf—ÂŖ𗧂ŽűˇEŽU—‰đÍ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): OCULISTA 2018/7; 64: 43-52.

522120. [uŔ]y“ÁW: ‚ŕ‚Á‚Ć’m‚č‚˝‚˘ƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[zƒIƒ‹ƒ\ƒPƒ‰ƒgƒƒW[‚̍‡•šÇ. ‰F’ĂŒŠ‹`ˆę1,2 (1‰F’ĂŒŠŠá‰Čˆă‰@, 2Šá‰Č): OCULISTA 2018/9; 66: 46-58.

522121. [uŔ]y“ÁW: ‚ł‚­‚Á‚Ćƒ|ƒCƒ“ƒg‚މŸ‚ł‚Ś‚ç‚ę‚é!@”’“ŕá‚ĚŒŸ¸EŽčpEƒPƒA‘‚í‚Š‚čƒ}ƒjƒ…ƒAƒ‹z ”’“ŕáŠłŽŇ‚ł‚ń‚ĚŒŸ¸‚Ěƒ|ƒCƒ“ƒg. ”Ń“c‰Ă•F (Šá‰Č): Šá‰ČƒPƒA 2018/9; 20 (9): 851-9.

522122. [uŔ] “ÁW: ICL‚Ě’ˇŠú—Տ°ŹŃ. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): IOL&RS 2018/9; 32 (3): 389-95.

522123. [uŔ] “ÁW: ICLƒAƒbƒvƒf[ƒg2018uICL‚ĚŒőŠw‚¨‚ć‚Ń—Ź‘Ě—ÍŠw“ÁŤv. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): IOL&RS 2018/9; 32 (3): 396-9.

522124. [uŔ] “ÁW: ICL‘“ŕ‘˝Ž{Ý‹¤“ŻŒ¤‹†`ŒyE’†“™“x‹ßŽ‹‚¨‚ć‚Ń‹­“x‹ßŽ‹‚Ě”äŠr`. _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2018/9; 32 (3): 411-6.

522125. [uŔ]y“ÁW: ˜VŽ‹‚Ě‚ˇ‚ׂāz˜VŽ‹‚ĚŠî‘b. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): OCULISTA 2018/10; 67: 1-6.

522126. [uŔ]y“ÁW: ˜VŽ‹‚Ě‚ˇ‚ׂāzƒŒ[ƒVƒbƒNƒ‚ƒmƒrƒWƒ‡ƒ“. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): OCULISTA 2018/10; 67: 22-8.

522127. [uŔ]y“ÁW: ˜VŽ‹‚Ě‚ˇ‚ׂāz˜VŽ‹‚ɑ΂ľ‚Ä‚ĚICL. ‚‹´ł‰p (Šá‰Č): OCULISTA 2018/10; 67: 29-36.

522128. [uŔ]y“ÁW: ˜VŽ‹‚Ě‚ˇ‚ׂāzIOLƒ‚ƒmƒrƒWƒ‡ƒ“. ˆÉ“Ą”üšŠG1, ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): OCULISTA 2018/10; 67: 63-9.

522129. [uŔ]y“ÁW1: ‰~Šp–Œ‚̐V‚ľ‚˘ŽĄ—Áz‰~Šp–Œ‚ɑ΂ˇ‚éƒg[ƒŠƒbƒN—L…ť‘ĚŠá“ŕƒŒƒ“ƒYEƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰ČŽčp 2018/10; 31 (4): 500-4.

522130. [uŔ]y“ÁW2: Šá‰ČŽčpŒă‚ĚŽ‹‹@”\‚đl‚Ś‚éz‹üÜ‹¸łŽčp. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): Šá‰ČŽčp 2018/10; 31 (4): 519-22.

522131. [uŔ]y“ÁW: ƒJƒ‰[ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚̍Ą‚đ’m‚ézƒJƒ‰[ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ÉŠÖ‚ˇ‚éf—Ă‚Ě‚ ‚č•ű. ‰F’ĂŒŠ‹`ˆę1,2 (1‰F’ĂŒŠŠá‰Čˆă‰@, 2Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2018/11; 35 (11): 1479-88.

522132. [uŔ]y“ÁW: ƒ~ƒGƒŠƒ“ƒIƒŠƒSƒfƒ“ƒhƒƒTƒCƒgƒOƒŠƒRƒvƒƒeƒCƒ“ (MOG) ‚ĆŽžŠł‚Ć‚ĚŠÖ‚í‚čzRMOGR‘Ě—zŤŽ‹_Œo‰Š|‘S‘’˛¸‚Š‚ç‚í‚Š‚Á‚˝‚ą‚Ɓ|. ŒăŠÖ—˜–ž1,2 (1Šá‰Č, 2RMOGR‘Ě—zŤŽ‹_Œo‰Š’˛¸”ÇŽ––ą‹Ç): _ŒoŠá‰Č 2018/12; 35 (4): 389-97.

522133. [uŔ]y“ÁW: Šp–Œ‚Š‚琅ť‘Ě‚Ü‚Ĺ‚Ě‘OŠá•”‰đÍ‚ĆŠá“ŕƒŒƒ“ƒY‚ĚˆĘ’u—\‘ށz‘OŠá•”OCT‚đ—p‚˘‚˝…ť‘ĚŒ`‘ÔŒv‘Ş‚ĆpŒăŠá“ŕƒŒƒ“ƒYˆĘ’u‚ĚŠÖŒWŤ. ˛“Ą@Ži1, íœAr‘ž˜Y2,3, ´…Œö–ç2,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”Ž‹‹@”\—Ă–@Šw‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 3Šá‰Č): IOL&RS 2018/12; 32 (4): 600-5.

522134. [uŔ]y“ÁW: Šá‹ž, ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY, ‹üÜ‹¸łŒŸ¸‚ĚŒŸ¸‚Í‚Ç‚¤‚ˇ‚é? Ĺ‘Ź—‰đ! ‹üÜŒŸ¸‚ĚŠî–{&‰ž—pz[1] ‹üÜˆŮí‚Ć‚Í (‹ßŽ‹, ‰“Ž‹, —Ž‹). ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): Šá‰ČƒPƒA 2018/12; 20 (12): 6-15.

522135. [uŔ]y“ÁW: Šá‹ž, ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY, ‹üÜ‹¸łŒŸ¸‚ĚŒŸ¸‚Í‚Ç‚¤‚ˇ‚é? Ĺ‘Ź—‰đ! ‹üÜŒŸ¸‚ĚŠî–{&‰ž—pz[2] ‹üÜŒŸ¸@(1) ‘źŠo“I‹üÜŒŸ¸. Šąě—˘ŠG (ˆă—ÉqśŠw•”): Šá‰ČƒPƒA 2018/12; 20 (12): 16-23.

522136. [uŔ] ‚í‚Š‚č‚₡‚˘—Տ°uŔ: _ŒoŠá‰Č‚ĚŒťÝ‚Ć10”NŒă. Îě@‹Ď (ˆă—ÉqśŠw•”): “ú–{‚ĚŠá‰Č 2019/1; 90 (1): 29-33.

522137. [uŔ]y‹üÜ‹¸łŽčpƒZƒ~ƒi[|ƒXƒLƒ‹ƒAƒbƒvuŔ|z224. PiXL‚É‚ć‚éŒy“x‹ßŽ‹ŽĄ—Ă. _’J˜aF (ˆă—ÉqśŠw•”): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2019/1; 36 (1): 65-6.

522138. [uŔ]y“ÁW: Žĺ‘i‚Š‚çˆř‚­ŠááَžŠłf—Ăƒ}ƒjƒ…ƒAƒ‹z4.ŠJ‚Ť‚Â炢III (‚Ż‚˘‚ę‚ńE‚܂΂˝‚Ť‚Ş‘˝‚˘). “ě‰_‚Í‚é‚Š1, ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): OCULISTA 2019/1; 70: 19-24.

522139. [uŔ]y“ÁW: ’˛ß‹@”\: Šî‘b‚Š‚ç—Տ°‚܂Łz5. ‹ßŒŠ”˝‰ž ‘Ş’č‘•’u‚Ć•ű–@ (Instruments and methods for measuring near response). óě@ŒŤ (ˆă—ÉqśŠw•”): Šá‰Č 2019/3; 61 (3): 253-9.

522140. [uŔ]y“ÁW: Brush up ŠáŠ´őÇ|f’f‚ĆŽĄ—ẨˇŒĚ’mV|zŠáŠ´őÇtopicsŽüpŠú‚̍R‹Ű–ň‚Í‚˘‚‚â‚ß‚é‚ׂŤ‚Š Žq“‡—Ç•˝1,2 (‹{“cŠá‰Č•a‰@, 2Šá‰Č): OCULISTA 2019/3; 72: 95-101.

530009. [‚ť‚Ě‘ź (Letter to the Editor)]yLetter to the Editorz Investigated the Thickness of the Neural Layer in the Macula of the Retina in Individuals with Amblyopia. ŒË’ˁ@Œĺ1, ŒăŠÖ—˜–ž1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): Annals of Case Reports 2018/6; 2018 (7) Issue 4: DOI: 10.29011/2574-7754/100085 (2pages).

530010. [‚ť‚Ě‘ź (Letter to the editor)] Pupil fields in a patient with early-onset postgeniculate lesion. Asakawa K1, Ishikawa H1: Graefes Arch Clin Exp Ophthalmol 2019/2; 257 (2): 441-3. (óě@ŒŤ1, Îě@‹Ď1: 1ˆă—ÉqśŠw•”)

540025. [‚ť‚Ě‘ź (ŠO‘Ž—v——)] ‰Šú˜VŽ‹Ç—á‚ɑ΂ˇ‚éŠŃ’ʍE•t‚ŤŒă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚É‚ć‚郂ƒmƒrƒWƒ‡ƒ“. _’J˜aF1, ‚‹´ł‰p2, ‚‹´‰ÄŽŔ2, ŻŽiMs2, ´…Œö–ç2,3 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3ŽR‰¤•a‰@): “ú–{”’“ŕáŠw‰ďŽ 2018/6; 30: 88.

540026. [‚ť‚Ě‘ź (ĄŒŽ‚Ě•\Ž†)]yĄŒŽ‚Ě•\Ž†zÉŽq‘Ě’Eo. ‰i–ěKˆę1, —é–؍N”V2 (1Šá‰Č, 2“ŒŠC‘ĺŠw): —Տ°Šá‰Č 2018/6; 72 (6): 754.

540027. [‚ť‚Ě‘ź (˜˜_)]y“ÁW: _ŒoŠá‰Č–Ô (Neuro-Ophthalmology Network)z˜˜_. Îě@‹Ď (ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2018/6; 35 (2): 151.

540028. [‚ť‚Ě‘ź (‘Î’k)] NEXTŠá‰Č‚đ—\‘Ş‚ˇ‚é`‘ć7‰ń`10”NŒă‚Ě‹üÜ‹¸ł. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰Čˆăƒ}ƒ‹ƒ`ƒtƒ@ƒCƒ“ƒ_[ 2018/7; 34: 2-3.

540029. [‚ť‚Ě‘ź (ƒgƒsƒbƒNƒX)] ƒgƒsƒbƒNƒX: ‹üÜ‹¸łŽčp‘OŒü‚Ť‘˝Ž{Ý‹¤“ŻŒ¤‹†. _’J˜aF1, ŒÜ\—’ÍŽj1,2, —с@@Œ¤3, ŞŠÝˆę”T4, ˛“ĄłŽ÷5, ƒrƒbƒZƒ“‹{“‡OŽq6 (1ˆă—ÉqśŠw•”, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 3—ŃŠá‰Čˆă‰@, 4Œcœä‹`m‘ĺŠw, 5ƒTƒgƒEŠá‰Č, 6“Œ‹žŽ•‰Č‘ĺŠw…“š‹´•a‰@): Šá‰ČŽčp 2018/7; 31 (3): 392-96.

540030. [‚ť‚Ě‘ź (ƒŒƒ|[ƒg)]ySpecial Reportz‹üÜ‹¸łŽčp‚ĚŒťó. _’J˜aF (ˆă—ÉqśŠw•”): ˆă—Ïî•ńŽƒVƒ…ƒlƒ‰[ (Schneller) 2018/10; 108: 3-6.

540031. [‚ť‚Ě‘ź] “ÁW‚É‚ ‚˝‚Á‚Ä. _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2018/9; 32 (3): 388.

540032. [‚ť‚Ě‘ź]y“ÁW: ˜VŽ‹‚Ě‚ˇ‚ׂāz•ŇWŠé‰ć‚É‚ ‚˝‚Á‚ācc. _’J˜aF (ˆă—ÉqśŠw•”): OCULISTA 2018/10; 67: ‘O•t1.

540033. [‚ť‚Ě‘ź (ĄŒŽ‚Ě•\Ž†)]yĄŒŽ‚Ě•\Ž†z‰Š”Á‰~E. ˆŔ“Ą˜a‰ĚŽq (Šá‰Č): —Տ°Šá‰Č 2018/11; 72 (12): 1497.

540034. [‚ť‚Ě‘ź (ĄŒŽ‚Ě•\Ž†)]yĄŒŽ‚Ě•\Ž†z…ť‘Ě—Z‰đ. ŽRŒű@ƒ (Šá‰Č): —Տ°Šá‰Č 2018/12; 72 (13): 1625.

540035. [‚ť‚Ě‘ź (ŠŞ“ŞŒž)]gƒIƒƒRƒ“h‚đŒŸŘ‚ľ‚Ü‚š‚ń‚Š? _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2018/12; 32 (4): 567.

540036. [‚ť‚Ě‘ź] –@l‚Š‚ç‚Ě‚¨’m‚ç‚š@lś100”NŽž‘ă. Žsěˆę•v1,2,3 (1JSCRS•›—Ž–’ˇ, 2’†‹žŠá‰Č, 3Šá‰Č): IOL&RS 2018/12; 32 (4): 732-3.

540037. [‚ť‚Ě‘ź (ƒgƒsƒbƒNƒX)] ƒgƒsƒbƒNƒX: ƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰ČŽčp 2019/1; 32 (1): 75-8.

540038. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)]yˆă—ÁEŒ’NzƒRƒ“ƒ^ƒNƒg ˜VŠá‚ɃtƒBƒbƒg. ŻŽiMs (Šá‰Č): “ú–{ŒoĎV•ˇ 2018/12/24; 2018: 13.

540039. [‚ť‚Ě‘ź (•ŇW)]yAbstractsz—Γŕá (•ŇW) ŻŽiMs (Šá‰Č): ĹVŠá‰Čî•ńOphthalmology Update 2018”N‘W•Ň 2019/1; p.19-21.

[’˜@‘]

620102. [Šwp‘ (•Ş’SŽˇ•M)]y‘ć112‰ńˆăŽt‘‰ĆŽŽŒą–â‘č‰đŕ‘zA-10 ‰““_50‡p‹ß“_25‡p‚Ć‚Č‚éŠá‚Ě’˛ß—Í, p.11. A-29 ’˛ßŤ“ŕŽÎŽ‹‚ւ̑Ήž, p.44-5. A-52 ƒAƒ‹ƒJƒŠŠáŠO‚̏‰Šú‘Ήž, p.89-90. B-14 ŽU“ľ‚ľ‚čs‚¤ŒŸ¸, p.147-8. C-31 ‰Á—”Á•ĎŤ‚ĚƒŠƒXƒN—vˆö, p.225-6. D-1 ”’“ŕáŽčp‚ÉŠÖ‚ˇ‚éˆę”Ę“I’mŽŻ, p.283. D-13 ƒEƒCƒ‹ƒXŤ‚ĚŠpŒ‹–ŒŽžŠł, p.293. D-34 —ŹsŤŒ‹–Œ‰ŠŠłŽŇ‚ւ̐śŠˆŽw“ą, p.330-1. E-27 “œ”A•a–Ô–ŒÇ‚ւ̑Ήž, p.428430. F-62 Œ‹–Œ‰şoŒŒ‚ւ̑Ήž, p.531-2. ŒăŠÖ—˜–ž1, Žs粋`Í1,2 (1Šá‰Č, 2_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN), •Ň: ˆăŽt‘‰ĆŽŽŒą–â‘č‰đŕ‘•ŇWˆĎˆő‰ď, ƒeƒRƒ€o”ĹŽ–‹Ć•”, “Œ‹ž, 2018/4”­s.

620103. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\ŠwƒGƒLƒXƒp[ƒg@ŒőŠwEŠá‹žz‘ć1•” ŒőŠw@‘ć2Í Šô‰˝ŒőŠw@VII ŒŸ¸—p‹ď‚ĚŒőŠw, p.26-31. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”), •Ň: ź–{•x”üŽq, Ź—эŽ•F, Îˆä—SŽq, ‹Ę’u–ž–ě, ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620104. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\ŠwƒGƒLƒXƒp[ƒg@ŒőŠwEŠá‹žz‘ć2•” ŒőŠw“IŒŸ¸@‘ć11Í ‘źŠo“I‹üÜŒŸ¸@I ƒI[ƒgƒŒƒtƒ‰ƒNƒgƒ[ƒ^, II ƒPƒ‰ƒgƒ[ƒ^, III Šp–ŒŒ`ó‰đÍ‘•’u, p.115-26. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”), •Ň: ź–{•x”üŽq, Ź—эŽ•F, Îˆä—SŽq, ‹Ę’u–ž–ě, ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620105. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\ŠwƒGƒLƒXƒp[ƒg@ŒőŠwEŠá‹žz‘ć2•” ŒőŠw“IŒŸ¸@‘ć14Í Ž‹–ěŒŸ¸, p.176-81. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”), •Ň: ź–{•x”üŽq, Ź—эŽ•F, Îˆä—SŽq, ‹Ę’u–ž–ě, ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620106. [Šwp‘ (•Ş’SŽˇ•M)]yŽĺ‘i‚ƏŠŒŠ‚Š‚ç‚Ý‚˝Šá‰Čcommon disease (Šá‰Č2018”N9ŒŽ—ŐŽž‘Š§†)zI Žĺ‘i‚Š‚ç‚Ý‚˝f’f‚̐i‚ß•ű@13 ŠJáٍ˘“ď, p.1047-9. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), •Ň: ”Ń“‡—TK, •x“c„Ži, ’Ř“cˆę’j, Œă“Ą@_, ŽG‰ęŽiŽě–ç, –ĺ”V‰€ˆę–ž, ŽO‘ş@ŽĄ, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/9”­s.

620107. [Šwp‘ (•Ş’SŽˇ•M)]yŽĺ‘i‚ƏŠŒŠ‚Š‚ç‚Ý‚˝Šá‰Čcommon disease (Šá‰Č2018”N9ŒŽ—ŐŽž‘Š§†)zII ŠŒŠ‚Š‚ç‚Ý‚˝f’f‚̐i‚ß•ű@1 ŠááفEŠáâ|E—Ü“šE—ÜŠí@4) Šá‹…“ˏo/Š×‰š/•ÎˆĘ, p.1100-4. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), •Ň: ”Ń“‡—TK, •x“c„Ži, ’Ř“cˆę’j, Œă“Ą@_, ŽG‰ęŽiŽě–ç, –ĺ”V‰€ˆę–ž, ŽO‘ş@ŽĄ, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/9”­s.

620108. [Šwp‘ (•Ş’SŽˇ•M)]yŽĺ‘i‚ƏŠŒŠ‚Š‚ç‚Ý‚˝Šá‰Čcommon disease (Šá‰Č2018”N9ŒŽ—ŐŽž‘Š§†)zII ŠŒŠ‚Š‚ç‚Ý‚˝f’f‚̐i‚ß•ű@5 ŠpŒ‹–Œ@4) Šp–ŒŒ`óˆŮí, p.1221-4. _’J˜aF (ˆă—ÉqśŠw•”), •Ň: ”Ń“‡—TK, •x“c„Ži, ’Ř“cˆę’j, Œă“Ą@_, ŽG‰ęŽiŽě–ç, –ĺ”V‰€ˆę–ž, ŽO‘ş@ŽĄ, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/9”­s.

620109. [Šwp‘ (•Ş’SŽˇ•M)]y7”N‘O‚ĚíŽŻ‚ÍŒťÝ‚Ě”ńíŽŻ|Šá‰Čf—Ă‚ĚĹV•W€ (—Տ°Šá‰Č10ŒŽ‘Š§†)z1. ‹üÜ/’˛ß‚ĚˆŮíE”’“ŕá@[Special Lecture] —L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚̍ŐV“ŽŒü, p.50-2. _’J˜aF (ˆă—ÉqśŠw•”), •Ň: ´…Oˆę, ”n“ˆşś, ‘“cŠ°ŽŸ˜Y, ‘ĺ–ědş, ‹Ęˆä@M, ŽO‘î—{ŽO, ź“c‹P•v, …—Ź’‰•F, Ş–؁@ş, ‰ş‘ş‰Ăˆę, ˆăŠw‘‰@, “Œ‹ž, 2018/10”­s.

620110. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ą‚Ş’m‚č‚˝‚˘&Ą‚ł‚畡‚Ż‚Č‚˘‚É“š‚Ś‚é@Šá‰ČŽžŠłf’fEŽĄ—Ăƒ}ƒjƒ…ƒAƒ‹z‘ć1Í f’f•Ň@I. Žĺ‘i‚Š‚ç‚Ý‚˝ŠÓ•Ęf’f@A. Šá‚Ş’É‚˘, p.2-3. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‘ŠŒ´@ˆę, “ě]“°, “Œ‹ž, 2018/10”­s.

620111. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ą‚Ş’m‚č‚˝‚˘&Ą‚ł‚畡‚Ż‚Č‚˘‚É“š‚Ś‚é@Šá‰ČŽžŠłf’fEŽĄ—Ăƒ}ƒjƒ…ƒAƒ‹z‘ć1Í f’f•Ň@I. Žĺ‘i‚Š‚ç‚Ý‚˝ŠÓ•Ęf’f@B. ‚Ü‚Ô‚ľ‚­‚袂é, p.4-5. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‘ŠŒ´@ˆę, “ě]“°, “Œ‹ž, 2018/10”­s.

620112. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ą‚Ş’m‚č‚˝‚˘&Ą‚ł‚畡‚Ż‚Č‚˘‚É“š‚Ś‚é@Šá‰ČŽžŠłf’fEŽĄ—Ăƒ}ƒjƒ…ƒAƒ‹z‘ć2Í ŽĄ—Õҁ@C. Šp–Œ‚ĚŽžŠł@4. lHŠp–Œ‚Ć‚Í?, p.184-6. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‘ŠŒ´@ˆę, “ě]“°, “Œ‹ž, 2018/10”­s.

620113. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ą‚Ş’m‚č‚˝‚˘&Ą‚ł‚畡‚Ż‚Č‚˘‚É“š‚Ś‚é@Šá‰ČŽžŠłf’fEŽĄ—Ăƒ}ƒjƒ…ƒAƒ‹z‘ć2Í ŽĄ—Õҁ@L. Š´őÇ@1. Šp–Œ’×ᇂ͂ǂ¤ŽĄ—Ă‚ˇ‚é‚Š?, p.276-80. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‘ŠŒ´@ˆę, “ě]“°, “Œ‹ž, 2018/10”­s.

620114. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ą‚Ş’m‚č‚˝‚˘&Ą‚ł‚畡‚Ż‚Č‚˘‚É“š‚Ś‚é@Šá‰ČŽžŠłf’fEŽĄ—Ăƒ}ƒjƒ…ƒAƒ‹z‘ć2Í ŽĄ—Õҁ@P. ‹üÜ‹¸łŽčp@1. PRK, LASIK, SMILE, ICL‚Č‚Ç‹üÜ‹¸łŽčp‚Ě“Á’Ľ‚Ć“K‰ž, p.307-11. _’J˜aF (ˆă—ÉqśŠw•”), •Ň: ‘ŠŒ´@ˆę, “ě]“°, “Œ‹ž, 2018/10”­s.

620115. [Šwp‘ (•Ş’SŽˇ•M)]y1ŽžŠÔ‚Ĺ‚í‚Š‚ébó‘BŠáÇ“ü–ĺƒpƒ“ƒtƒŒƒbƒgz22. ŽÎŽ‹Žčp‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.40-1. ŒăŠÖ—˜–ž (Šá‰Č), •Ň: Ž­“ˆ—FŒh, Ž­“ˆ—FŒh, “Œ‹ž, 2018/10”­s.

620116. [Šwp‘ (•Ş’SŽˇ•M)]y1ŽžŠÔ‚Ĺ‚í‚Š‚ébó‘BŠáÇ“ü–ĺƒpƒ“ƒtƒŒƒbƒgz23. ŽÎŽ‹ŽčpŒă‚ĚƒPƒA‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.41-2. ŒăŠÖ—˜–ž (Šá‰Č), •Ň: Ž­“ˆ—FŒh, Ž­“ˆ—FŒh, “Œ‹ž, 2018/10”­s.

620117. [Šwp‘ (•Ş’SŽˇ•M)]y1ŽžŠÔ‚Ĺ‚í‚Š‚ébó‘BŠáÇ“ü–ĺƒpƒ“ƒtƒŒƒbƒgz27. Žčp‚ÍŒ’N•ŰŒŻ‚Ě“K‰ž‚Ş‚ ‚é‚Ě‚Ĺ‚ľ‚傤‚Š, p.47. ŒăŠÖ—˜–ž (Šá‰Č), •Ň: Ž­“ˆ—FŒh, Ž­“ˆ—FŒh, “Œ‹ž, 2018/10”­s.

620118. [Šwp‘ (•Ş’SŽˇ•M)]y‰Á—ŽžŠł‚ւ̑ΉžQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č ‘ć35ŠŞ—ŐŽž‘nŠ§†)zII ‹ßŽ‹, —Γŕá@Q6’†‚”NŽŇ‚ŋߎ‹‚ސis‚ˇ‚錴ˆö‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, 127-30. _’J˜aF (ˆă—ÉqśŠw•”), •Ň: ‰Ş“cƒAƒiƒxƒ‹‚ ‚â‚ß, ‘ĺ–ě‹žŽq, ˛“Ą”ü•Ű, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2018/11”­s.

620119. [Šwp‘ (•Ş’SŽˇ•M)]y‰Á—ŽžŠł‚ւ̑ΉžQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č ‘ć35ŠŞ—ŐŽž‘nŠ§†)zIII ŽÎŽ‹, ”’“ŕá, _ŒoŠá‰Č@1. ŽÎŽ‹@Q1 ”’“ŕáŽčpŒă‚Ě•ĄŽ‹‚ւ̑Ήž‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.148-52. Ź–ě—˘‹KŽq1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č), •Ň: ‰Ş“cƒAƒiƒxƒ‹‚ ‚â‚ß, ‘ĺ–ě‹žŽq, ˛“Ą”ü•Ű, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2018/11”­s.

620120. [Šwp‘ (•Ş’SŽˇ•M)]y‰Á—ŽžŠł‚ւ̑ΉžQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č ‘ć35ŠŞ—ŐŽž‘nŠ§†)zIII ŽÎŽ‹, ”’“ŕá, _ŒoŠá‰Č@2. ”’“ŕá@Q1 p‘OŒ¸‹Ű‚¨‚ć‚ŃŽüpŠú‚̕ې´‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.171-3. Žq“‡—Ç•˝1,2, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‰Ş“cƒAƒiƒxƒ‹‚ ‚â‚ß, ‘ĺ–ě‹žŽq, ˛“Ą”ü•Ű, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2018/11”­s.

620121. [Šwp‘ (•Ş’SŽˇ•M)]y‰Á—ŽžŠł‚ւ̑ΉžQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č ‘ć35ŠŞ—ŐŽž‘nŠ§†)zIII ŽÎŽ‹, ”’“ŕá, _ŒoŠá‰Č@3. _ŒoŠá‰Č@Q3 ‚—îŽŇ‚̍bó‘BŠáÇ‚Ě“Á’Ľ‚ĆŽĄ—Ă•űj‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.215-8. Šâ˛^‹|1,2, ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), •Ň: ‰Ş“cƒAƒiƒxƒ‹‚ ‚â‚ß, ‘ĺ–ě‹žŽq, ˛“Ą”ü•Ű, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2018/11”­s.

620122. [Šwp‘ (•Ş’SŽˇ•M)]y‰Á—ŽžŠł‚ւ̑ΉžQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č ‘ć35ŠŞ—ŐŽž‘nŠ§†)zIII ŽÎŽ‹, ”’“ŕá, _ŒoŠá‰Č@3. _ŒoŠá‰Č@Q4 ‚—îŽŇ‚Ě“ľEˆŮí‚̊ӕʐf’f‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.219-22. —´ˆä‰‘Žq (Šá‰Č), •Ň: ‰Ş“cƒAƒiƒxƒ‹‚ ‚â‚ß, ‘ĺ–ě‹žŽq, ˛“Ą”ü•Ű, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2018/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713143. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A Sense of Distance and Augmented Reality for Stereoscopic Vision. Takeda K, Ishihara K, Kawamorita T1: WCX 2018 SAE World Congress Experience (2018/4/11), Detroit,USA. (ěŽç“c‘ńŽu1: 1ˆă—ÉqśŠw•”)

713144. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Effectiveness of barrier-free display on accommodation. Kawamorita T1, Miyazaki K, Yamazaki T, Takahashi S, Nakatani M, Miyaji S, Handa T1, Shoji N2: ARVO2018 (2018/5/1), Hawaii, USA. (ěŽç“c‘ńŽu1, ”ź“c’m–ç1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

713145. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Evaluating the usefulness of MP-3 microperimetry in glaucoma patients. Matsuura M1,2, Murata H1, Fujino Y1,2, Hirasawa K3, Yanagisawa M1, Shoji N2, Asaoka R1: 23rd International Visual Field & Imaging Symposium (2018/5/10), Ishikawa, Japan. (ź‰YŤl1,2, “Ą–ě—F—˘1,2, •˝ŕVˆę–@3, ŻŽiMs2: 1“Œ‹ž‘ĺŠw, 2Šá‰Č, 3Moorfield Eye Hospital NHS Fundation Trust)

713146. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Mapping the Central 10 Degrees Visual Field to the Optic Nerve Head using the Structure Function Relationship. Fujino Y1,2, Murata H1, Matsuura M1,2, Yanagisawa M1, Shoji N2, Inoue K, Yamagami J, Asaoka R1: 23rd International Visual Field & Imaging Symposium (2018/5/10), Ishikawa, Japan. (“Ą–ě—F—˘1,2, ź‰YŤl1,2, ŻŽiMs2: 1“Œ‹ž‘ĺŠw, 2Šá‰Č)

713147. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[)yŔ’ˇzPoster 4/ Oral 6 Session@New Perimetry Chairman. Shoji N1: 23rd International Visual Field & Imaging Symposium (2018/5/12), Ishikawa, Japan. (ŻŽiMs1: 1Šá‰Č)

713148. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Evaluation of pupil fields using a newly developed perimeter in glaucoma patients. Totsuka K1, Asakawa K2, Kasahara M1, Matsumura K1, Ishikawa H2, Shoji N1: 23rd International Visual Field & Imaging Symposium (2018/5/12), Ishikawa, Japan. (ŒË’˘aŽq1, óě@ŒŤ2, Š}Œ´łs1, ź‘şˆęO1, Îě@‹Ď2, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

713149. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Effect of non-measurement eyes on the result of measurement eyes by the monocular visual field tests under binocular open view. Goukon H1,2, Fujimura F3, Kasahara M1, Matsumura K1, Shoji N1: 23rd International Visual Field & Imaging Symposium (2018/5/12), Ishikawa, Japan. (‹˝‰E‹ß”ŽN1,2, “Ą‘ş•‡˛Žq3, Š}Œ´łs1, ź‘şˆęO1, ŻŽiMs1: 1Šá‰Č, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”)

713150. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Progression of visual field loss before and after trabeculectomy. Kanayama S1: 13th EGS Congress (2018/5/21), Florence, Italy. (‹ŕŽRr‰î1: 1Šá‰Č)

713151. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Large Angle Exotropia and the Legend of the Surgical Dose-Response Curve. Li L1, Goseki T1,2, Suh SY1, Pineles SL1, Isenberg SJ1, Demer JL1 (1Stein Eye Institute, David Geffen School of Medicine, UCLA): AAPOS 2019 ‘ć45‰ń•Ä‘ŹŽ™Šá‰ČŠw‰ď‹c/American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 43th Annual Meeting (2019/3/28), San Diego, USA. (ŒăŠÖ—˜–ž1,2: 2Šá‰Č)

713152. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) High Prevalence of Sagging Eye Syndrome in Adults with Binocular Diplopia. Goseki T1, Suh Soh Youn, Laura Robbins, Stacy L Pineles, Federico G Velez, Joseph L Demer: AAPOS 2019 ‘ć45‰ń•Ä‘ŹŽ™Šá‰ČŠw‰ď‹c American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 45th Annual Meeting (2019/3/30), San Diego, USA. (ŒăŠÖ—˜–ž1: 1Šá‰Č)

713153. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Combined Inferior Rectus Recession and Lower Eyelid Retractor Release in Thyroid Eye Disease. De Andrade LM1, Velez FG1, Rootman DB1, Goldberg RA1, Putthirangsiwong B1, Goseki T1,2, Demer JL1, Pineles SL1 (1Stein Eye Institute, David Geffen School of Medicine, UCLA): AAPOS 2019 ‘ć45‰ń•Ä‘ŹŽ™Šá‰ČŠw‰ď‹c/American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 44th Annual Meeting (2019/3/30), San Diego, USA. (ŒăŠÖ—˜–ž1,2: 2Šá‰Č)

721020. [Šw‰ď (‘S‘)] (“Á•Ę•ń) JSCRSƒAƒ“ƒP[ƒg’˛¸ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv•ń@‰ďˆőƒAƒ“ƒP[ƒg‚Š‚çŠw‚Ô‹üÜ‹¸łŽčp‚̏pŽŽ‚Ě•Ď‘J‚ĆŒťó. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

722121. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇzŽ‹_Œo‰Š‚ĚŠî‘bE—Տ°Œ¤‹†Ĺ‘Oü The latest basic and clinical study for refractory optic neuriris. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

722122. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰ä‚ލ‘‚̓ŤŽ‹_Œo‰Š‚̉uŠw’˛¸Œ‹‰Ę‚Ɛf—ĂƒKƒCƒhƒ‰ƒCƒ“ Nationwide epidemiologiacal survey of refractory optic neuritis in Japan. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

722123. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ŽüpŠúR‹Ű“_Šá–ň‚ƑϐŤ‰ť Perioperative antimicrobial eye drops and resistance. Žq“‡—Ç•˝1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/21), ‘ĺă.

722124. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) •aŠú‚Š‚ç‚݂鎥—Ăƒ}ƒlƒWƒƒ“ƒg|Ĺ“K‰đ‚Í‚Č‚É‚Š?|‰Šú‚Š‚ç’†Šú‚É‚¨‚Ż‚éƒ}ƒlƒWƒƒ“ƒg. ŻŽiMs (Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/21), ‘ĺă.

722125. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yŔ’ˇzIOL“x”ŒvŽZ‚đ‹É‚ß‚é Mastering Intraocular Lens Power Calculation. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722126. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) LASIK, Šp–Œ”’”Á‚Č‚Ç, Šp–Œƒtƒ‰ƒbƒgŠá‚ĚIOL“x”ŒvŽZ Intraocular lens power calculation for the flattened cornea. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722127. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) ƒXƒeƒB[ƒvŠáE‰~Šp–ŒŠá‚ĚIOL“x”ŒvŽZ Intraocular lens power calculation in eyes with steep cornea and keratoconus. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722128. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[zŽ‹_ŒoŽžŠł: f’f‚ĚŒˆ‚ߎč How to diagnose optic nerve disorders. ŻŽiMs (Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722129. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[z—Γŕá: ŒŸ¸‚ĚŒˆ‚ߎč Diagnosis with glaucoma examination. ŻŽiMs (Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722130. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[, ƒ‚ƒfƒŒ[ƒ^[z—Γŕá: ŽĄ—Ă‚ĚŒˆ‚ߎč Glaucoma : Decisive evidence treatment. ŻŽiMs (Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

722131. [Šw‰ď (‘S‘)] (uK‰ď) ‹üÜ‹¸łŽčpE‘“ŕŠO‚ĚŒťó‚ƍĄŒă‚Ě“W–]. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (“ú–{Šá‰ČŠw‰ď‹üÜ‹¸łŽčpuK‰ď) (2018/4/22), ‘ĺă.

722132. [Šw‰ď (‘S‘)] (Special Project)yŔ’ˇz2018JPS Special Project: uŠî‘b‚Š‚ç—Տ°‚Ü‚Ĺ‘S‚Ä‚Ş‚Â‚Č‚Ş‚éŽ‹–ě‚Ć‰ć‘œ‚Ě‹łˆçƒZƒ~ƒi[`‚ą‚ę‚Ĺ‚ ‚Č‚˝‚ŕŽ‹–ěE‰ć‘œƒ}ƒCƒXƒ^[!`vuSpecial Project 4uŠáŽžŠł‚Š‚çŠw‚ÔŽ‹–ě‚ĆOCTv. ŻŽiMs (Šá‰Č): ‘ć7‰ń“ú–{Ž‹–ěŠw‰ďŠwpW‰ď (2018/5/12), ‹ŕ‘ň.

722133. [Šw‰ď (‘S‘)] (ƒI[ƒvƒ“ƒtƒH[ƒ‰ƒ€) “ú–{‚ĚƒXƒ^ƒ“ƒ_[ƒh‚͐˘ŠE‚ĚƒXƒ^ƒ“ƒ_[ƒh‚Š?@JSCRSƒAƒ“ƒP[ƒg’˛¸Œ‹‰Ę‚ĆŠCŠO‚Ě”äŠr (Do Japanese standards Match International Standards?-Comparison Between Results of JSCRS Surveys and Standards in the World). _’J˜aF (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722134. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒ‚ƒfƒŒ[ƒ^[zŽŸ‚ÉŒq‚Ž‹üÜ‹¸ł–@@ƒ‚ƒfƒŒ[ƒ^[. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722135. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) isŤ‰~Šp–Œ‚ɑ΂ˇ‚éƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. ‚‹´ł‰p (Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722136. [Šw‰ď (‘S‘)] (JSCRSƒvƒ‰ƒNƒeƒBƒX)yƒ‚ƒfƒŒ[ƒ^[zƒg[ƒŠƒbƒN@ƒ‚ƒfƒŒ[ƒ^[. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722137. [Šw‰ď (‘S‘)] (JSCRSƒvƒ‰ƒNƒeƒBƒX) ƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY‚ĚŽčp‚ĚŽŔŰ. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722138. [Šw‰ď (‘S‘)] (JSCRSƒvƒ‰ƒNƒeƒBƒX) ŠáŒőŠwŒ¤‹†“ü–ĺ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722139. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzCCC‚đ‹É‚ß‚é! Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722140. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzuV‚ľ‚˘”j”X‚ľ‚É‚­‚˘’´‰š”gƒ`ƒbƒvv‚É‚ć‚é’´‰š”g”’“ŕáŽčp. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722141. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŒƒ|[ƒg) NX70CH‚ĚŽg—pŒoŒą. ‹g“c‘Ľ•F1, Žsěˆę•v2,3 (1Šň•ŒÔ\Žš•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722142. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) pŒăŠú‘Ň’l‚ލ‚‚Ü‚éVƒVƒXƒeƒ€@ƒCƒ[ƒWƒKƒCƒhƒVƒXƒeƒ€‚ɏ]‚Á‚˝”’“ŕá‹üÜ‹¸łŽčp. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

722143. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[z‚Ý‚ń‚Č‚Ĺl‚Ś‚é”’“ŕáŽčp: QOV‚É‚ą‚ž‚í‚낤. ”Ń“c‰Ă•F (Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

722144. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[EuŽtz˘ŠE‚̍ŐVƒgƒŒƒ“ƒh‚đ’m‚낤!gWhat's New in 2018h. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

722145. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Šp–ŒŽžŠł‚đ—L‚ˇ‚éÇ—á. ”Ń“c‰Ă•F (Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

722146. [Šw‰ď (‘S‘)] (Ž‹”\ŒP—űŽmƒvƒƒOƒ‰ƒ€)yƒ‚ƒfƒŒ[ƒ^[zł‚ľ‚˘ŒŸ¸Œ‹‰Ę‚đ“ą‚­‚˝‚ß‚ĚŽ„‚̍H•v. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

722147. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[EuŽtzyORT‚É‚ć‚éORT‚Ě‚˝‚ß‚ĚICzŒv‘ށ@‚Ĺ‚Ť‚Č‚­‚袂Á‚˝Žž‚ĚŽ„‚Ě‰đŒˆô. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

722148. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzyORT‚É‚ć‚éORT‚Ě‚˝‚ß‚ĚICzŒv‘ށ@‚Ĺ‚Ť‚Č‚­‚袂Á‚˝Žž‚ĚŽ„‚Ě‰đŒˆô. Šąě—˘ŠG (Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

722149. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO@Šî‘b‚Š‚çĹV‚Ě˜b‘č‚Ü‚Ĺ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

722150. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŒƒ|[ƒg) isŤ‰~Šp–Œ‚ɑ΂ľ‚ăgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚đŽ{s‚ľ‚˝2—á. _’J˜aF1, ‚‹´ł‰p2, ‹ŕŽRr‰î2, ŻŽiMs2, X@—mÄ2,3, ‹{“c˜a“T3 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3‹{“cŠá‰Č•a‰@): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

722151. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) AŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘fťÜƒ{ƒgƒbƒNƒXuKEŽŔ‹ZƒZƒ~ƒi[uŽÎŽ‹vŽžŠł•Ň. ŒăŠÖ—˜–ž (Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

722152. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ˆ•űŹŒ÷—Ś94%‚đŽŔŒť‚ˇ‚éŒőŠw•”Eˆ•ű–@‚ĚŒőŠw“IlŽ@`ƒƒ“ƒf[ƒAƒLƒ…ƒrƒ…[-ƒ‚ƒCƒXƒg-ƒ}ƒ‹ƒ`ƒtƒH[ƒJƒ‹`. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ƒtƒH[ƒTƒ€2018“Œ‹ž (‘ć61‰ń“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ď‘‰ď) (2018/7/15), “Œ‹ž.

722153. [Šw‰ď (‘S‘)] (ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠî‘buŔ) Šî‘b‚Š‚çŠw‚Ô‰“‹ß—ź—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY, ‚ť‚Ě••ŐŤ‚Ć‘˝—lŤ`ŒŠ‚Ś‚éŽd‘g‚Ý‚Š‚珈•ű‚ĚƒRƒc‚܂Ł`. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ƒtƒH[ƒTƒ€2018“Œ‹ž (‘ć61‰ń“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ď‘‰ď) (2018/7/16), “Œ‹ž.

722154. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ’†“ŐŤŽ‹_ŒoÇ‚Ě—Ő°. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć45‰ń“ú–{“ŐŤŠw‰ďŠwp”N‰ď (2018/7/18), ‘ĺă.

722155. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒqƒgś‘ĚŠá‚É‚¨‚Ż‚鐅ť‘Ě‘O–ĘŒ`ó‚̉đÍ: ‰Á—î‹y‚Ń”’“ŕá”­Ç‚É‚ć‚é‰e‹ż. Žsě@Œc1, ”n“ˆ´”@2, ‰Á“ĄKm3, ŽđˆäKO3, “´ˆäŠG—˘3, ‹Ę’u–ž–ě4, Žsě—ćŽq3, Žsěˆę•v3,5 (1Šň•ŒÔ\Žš•a‰@Šá‰Č, 2Šá‰Č–žŠá‰@, 3’†‹žŠá‰Č, 4’nˆćˆă—Єi‹@\’†‹ž•a‰@, 5Šá‰Č): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

722156. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) Ž‹‹@”\‚ɉe‹ż‚ˇ‚é—lX‚ČˆöŽq‚ĚŒŸŘ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

722157. [Šw‰ď (‘S‘)] (Special Symposium) —L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚ĚŒőŠw“ÁŤ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/8), VŠƒ.

722158. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ’†ŠÔ“§Œő‘Ě‚ĚÄŒš`Šp–Œ‚Š‚çÉŽq‘̂܂Ł`. X@—mÄ1,2 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/8), VŠƒ.

722159. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) ”’“ŕáŽčpŒă‚Ě‹üÜ‚đ‹É‚߂悤@’m‚Á‚Ä‚¨‚Ť‚˝‚˘IOL“x”ŒvŽZŽŽ‚Ě‘I‘đ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/9), VŠƒ.

722160. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Äl!Šá“ŕƒŒƒ“ƒY‚ĚŒőŠw“ÁŤ. ”ź“c’m–ç (ˆă—ÉqśŠw•”): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/9), VŠƒ.

722161. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) Šá‹žECL‚ĚŠáŒőŠw‚Əˆ•ű‚ĚƒRƒc (˜VŠá‚𒆐S‚É). ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/9), VŠƒ.

722162. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Rates of Visual Field Loss in Primary Open-Angle Glaucoma and Primary Angle-Closure Glaucoma. “Ą–ě—F—˘1,2 (1“Œ‹ž‘ĺ, 2Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

722163. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzŒŠ“Ś‚ľ‚˝‚­‚Č‚˘is‚ĚƒTƒCƒ“`Šá’ę‚Š‚ç, Ž‹–ě‚Š‚ç. ŻŽiMs (Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

722164. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇzƒVƒ“ƒ|ƒWƒEƒ€7@MIGS: ŘŠJ, —Ż’u, ‚ť‚ę‚Ć‚ŕ? ŻŽiMs (Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

722165. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒgƒ‰ƒxƒNƒg[ƒ€Žčp@Trabectome surgery. Š}Œ´łs (Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

722166. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) —ΓŕáĹVŽĄ—Á@‘@ˆŰ’Œ‘ѐ؏œpŒă‚âƒgƒ‰ƒxƒNƒg[ƒ€Œă‚̓Ç—á‚ɑ΂ˇ‚éCYCLO G6‚ĚŽĄ—ÐŹŃ. ź‘şˆęO (Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

722167. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šp–ŒŽžŠł‚ĚŽU—. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722168. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) RMB_ŒoŠá‰Č•×‹­‰ď. ’†”nGŽ÷1, ””ˆä@‘2, ”öč•őś3, ŽRă–žŽq4,5, Žá‘q‰ë“o4, ‘ĺÎ–žś6, ‹´–{‰ël7, ‘O‹v•Ű’ms8, “c‘şOˆę˜Y9, ‘ĺ‹v•Ű^Ži10 (1‹{č‘ĺ, 2ˆ¤’mi“ż‘ĺ, 3”öčŠá‰Č, 4ˆäăŠá‰Č•a‰@, 5Šá‰Č, 6‹ž“s‘ĺ, 7’†‘ş‹L”O•a‰@, 8ŽO‘îŠá‰Č•a‰@, 9‘ĺ•Ş‘ĺ, 10‚¨‚¨‚­‚ÚŠá‰ČƒNƒŠƒjƒbƒN): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722169. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽŔ‘H‚Š‚çŠw‚Ô—L…ť‘ĚŠá“ŕƒŒƒ“ƒY. ´…Œö–ç1,2, _’J˜aF3, Žsěˆę•v1,4, ’†‘ş—Fş5, –kŕV˘Žu”Ž6 (1Šá‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 3ˆă—ÉqśŠw•”, 4’†‹žŠá‰Č, 5–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 6_ŒË_“ސěƒAƒCƒNƒŠƒjƒbƒN): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722170. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ‘OŠá•”ŽžŠłƒgƒŠƒA[ƒW`ŽĄ—Ă‚Ěƒ^ƒCƒ~ƒ“ƒO‚đ“Ś‚ł‚Č‚˘‚˝‚߂Ɂ`. ‘Š”n„ŽŠ1, čŒł@’¨2, —é–؁@’3,4, Žq“‡—Ç•˝5,6, ‘ĺ‰Ć‹`‘Ľ1, ŽRŒű„Žj7 (1‘ĺă‘ĺ, 2“ú–{‘ĺ, 3“Œ–M‘ĺE‘ĺX, 4‚˘‚ľ‚Ă‚żŠá‰Č, 5‹{“cŠá‰Č, 6Šá‰Č, 7“Œ‹žŽ•‘ĺEŽsě): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722171. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzDysphotopsia: ”’“ŕáŽčpŒă‚ĚQOV‚đl‚Ś‚é. ´…Œö–ç1,2,3 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722172. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Dysphotopsia: ”’“ŕáŽčpŒă‚ĚQOV‚đl‚Ś‚éuDysphotopsia‚ĚŠáŒőŠwv. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722173. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Dysphotopsia: ”’“ŕáŽčpŒă‚ĚQOV‚đl‚Ś‚éu”­ś•p“x‚Ć‘Îˆ–@‚ɂ‚˘‚āv. ŒÜ\—’ÍŽj1,2,3 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

722174. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzThe 24th VISION TIMES SEMINAR (˘“ď‚đć‚č‰z‚Ś‚鐸_‹Ř—Í). ´…Œö–ç1,2,3 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

722175. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzThe 24th VISION TIMES SEMINAR (˘“ď‚đć‚č‰z‚Ś‚鐸_‹Ř—Í). ”Ń“c‰Ă•F (Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

722176. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) NTGŽĄ—Âɑ΂ˇ‚鎥—Ă‹­‰ťEŽčpí—Ş. ŻŽiMs (Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/13), “Œ‹ž.

722177. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šáâ|ƒvƒŠ[‚ĆŒă“V“ŕŽÎŽ‹. ŒăŠÖ—˜–ž1,2 (1Šá‰Č, 2Stein Eye Institute, USA): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/13), “Œ‹ž.

722178. [Šw‰ď (‘S‘)] (uK‰ď) ‹üÜ‹¸łŽčpE‘“ŕŠO‚ĚŒťó‚ƍĄŒă‚Ě“W–]. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/14), “Œ‹ž.

722179. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰)yŔ’ˇzŹŒ÷‚ˇ‚é”’“ŕá—\–hEŽĄ—Ð헪. _’J˜aF1, ěŽç“c‘ńŽu1 (1ˆă—ÉqśŠw•”): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722180. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[)yŔ’ˇzƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[. ŻŽiMs (Šá‰Č): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď@ƒWƒ‡ƒCƒ“ƒgƒZƒ~ƒi[ (2018/10/20), _“ސě.

722181. [Šw‰ď (‘S‘)] (ľ‘ҍu“™)yŔ’ˇz_ŒoŠá‰Č—Ěˆć‚̐V‚ľ‚˘ŒŸ¸‹@Ší. Îě@‹Ď (ˆă—ÉqśŠw•”): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722182 [Šw‰ď (‘S‘)] (ľ‘ҍu“™) Hello!!|‘źŠo“IŽ‹‹@”\•]‰ż‚ĚŽž‘ă‚ց|. ”ź“c’m–ç (ˆă—ÉqśŠw•”): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722183. [Šw‰ď (‘S‘)] (ľ‘ҍu“™) Hello‚Ě—Ő°ŹŃ. Šâ“c@—y (ˆă—ÉqśŠw•”): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722184. [Šw‰ď (‘S‘)] (ľ‘ҍu“™) ZEISS CLARUS 500, Optos‚Ć‚Ě”äŠr@ƒtƒHƒgƒOƒ‰ƒtƒ@[‚ĚŽ‹“_‚Š‚ç. ‰i–ěKˆę (Šá‰Č): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722185. [Šw‰ď (‘S‘)] (ľ‘ҍu“™)yŔ’ˇzŠá‰Čˆă—Ă‚ĆAI. ”Ń“c‰Ă•F (Šá‰Č): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722186. [Šw‰ď (‘S‘)] (ľ‘ҍu“™) lH’m”\‚đ—p‚˘‚˝‰~Šp–Œ‚ĚŽŠ“Žf’f. _’J˜aF (ˆă—ÉqśŠw•”): The 22nd IRSJ (2018)E‘ć18‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2018/10/20), _“ސě.

722187. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇzƒVƒ“ƒ|ƒWƒEƒ€“O’ꓢ˜_!: Visual pathway disorder. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

722188. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŽi‰ďzƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[2u“O’ę‰đ–ž@Ž‹_Œo‰Šv. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

722189. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yƒpƒlƒŠƒXƒgzƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[2u“O’ę‰đ–ž@Ž‹_Œo‰Šv. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

722190. [Šw‰ď (‘S‘)] (‘Š’kÇ—á) ŠO‚ĚŠÖ—^‚Ş‹^‚í‚ęf’f‚É‹ę—ś‚ľ‚˝7Î’jŽ™‚ĚŽ‹_ŒoÇ‚Ě1—á. —´ˆä‰‘Žq1, Îě@‹Ď2, ’r“c“N–ç1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

722191. [Šw‰ď (‘S‘)] (‘Š’kÇ—á) Ž‹_Œo‰ŠŽĄ—ĂŒă‚É‹}‘Ź‚ɐis‚ľ‚˝‹SŤŽ‹–싡ó. ź–{@’ź1, •x“c‹§•F1, Îě@‹Ď2 (1“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 2ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723630. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’˛ß‚É”ş‚¤…ť‘ĚŒ`ó‚Ć“ľEŒa‚̕ωť. Î“c@‹Ĺ1, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723631. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒőŠwƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚ć‚éWatercleftsŠá‚ĚŽ‹‹@”\•]‰ż. ŠÖ@—S‰î1, ěŽç“c‘ńŽu2, ŽO“c“N‘ĺ1, –k@@•‘1, ’J‘ş’ź‹I1, ‹v•Ű]—1, ˛X–Ř—m1 (1‹ŕ‘ňˆă‘ĺ, 2ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723632. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚ŞŽü•Ó•”Šp–Œ“ŕ”ç×–EŒ`‘Ô‚Ö‹y‚Ú‚ˇ‰e‹ż‚ĚŒŸ“˘. ‹˝‰E‹ß”ŽN1, _’J˜aF2, ‚‹´ł‰p1, ‹ŕŽRr‰î1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723633. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) [‘wŠwK‚đ—˜—p‚ľ‚˝Šá’ęŽĘ^‚É‚ć‚é—ΓŕáŽŠ“ŽƒXƒNƒŠ[ƒjƒ“ƒOƒAƒ‹ƒSƒŠƒYƒ€ŠJ”­. ’Š‰Ş@—ş1, ŽÄ“c’źl2, ŽO‹´Œ[‘˝2, “Ą–ě—F—˘1,3, ź‰YŤl1,3, ‘ş“c”ŽŽj1, ’JŒËłŽ÷4 (1“Œ‹ž‘ĺ, 2Queue, 3Šá‰Č, 4ź]Ô\Žš•a‰@): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723634. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒőŠąÂŽŽ‘OŠá•”Œ`ó‰đÍ‚đ—˜—p‚ľ‚˝ŒőŠąÂŽŽŠáŽ˛‘Ş’č‚É‚¨‚Ż‚éŒv‘ŞŒëˇ‚ĚŒŸ“˘. ˛“ĄM”V1,2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723635. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) BarrettŽŽ‚đ—p‚˘‚˝‰~Šp–Œ‚ɑ΂ˇ‚é”’“ŕáŽčp‚Ě—\‘ސŤ‚ĚŒŸ“˘. ”Ń“‡@Œh1, _’J˜aF2, ŻŽiMs1, X@—mÄ1,3, ‹{“c˜a“T3, ŽRŒű„Žj4, “‡č@4, “n•Ó^–î5, ‘O“c’ź”V5 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‹{“cŠá‰Č•a‰@, 4“Œ‹žŽ•‘ĺEŽsě, 5‘ĺă‘ĺ): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723636. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĄ—Ă“IƒŒ[ƒU[Šp–ŒŘœ (PTK) pŒă‚Ě”’“ŕáŽčp‚É‚¨‚Ż‚é—\‘ސŤ‚ĚŒŸ“˘. •ÄŽR@—Č1,2, _’J˜aF3, ”Ń“‡@Œh2, ‰Í–ě—Y—ş4, ‚‹´ł‰p2, ŻŽiMs2 (1ŠC˜V–ź‘‡•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4“ŒŽĹ—ŃŠÔ•a‰@): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723637. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[‚É‚¨‚Ż‚é, R‚Ş‚ńÜS-1‚É‚ć‚é—Ü“šáŠQ103–ź‚Ě‘Š‡. ”–؍LĆ1,2 (1Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723638. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –˘AŠwŽ™Šá‰ČŒŸf‚É‚¨‚Ż‚éŒőŠwŽŽŠáŽ˛’ˇ‘Ş’č‘•’u“ą“ü‚ĚŽŽ‚Ý. ˛“Ą@Ži1, ˆÉ“Ą”üšŠG1, ‚‹´—RŽk1, –ěă‹Žu1, Žlƒm‹{—C”n1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723639. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ƒ{ƒcƒŠƒkƒX’ŽËŽž‚Ěáu’ɂɑ΂ˇ‚éƒGƒ€ƒ‰ƒNƒŠ[ƒ€?‚ĚŒř‰Ę. ‰Í–{‚Đ‚ë”ü1, Žá‘q‰ë“o1, Šâ˛^‹|1,2, ˆř“crˆę1, “cK”ü1, ŽRă–žŽq1,2, —é–؉xŽq1, ˆäăŒŤŽĄ1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/19), ‘ĺă.

723640. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lecithin cholesterol acyltransferase (LCAT) Œ‡‘šÇ‚Ěˆâ“`Žq‰đÍ. Ź–ě@‹Ş1, Šâč‘ô–ç1,2, Žq“‡—Ç•˝1,3, X@—mÄ1,3, ‹g‘ş–žŽq2, ˆŔ“Ą‹§G2, ‰Ş–{—TŽk2, ‚“ˆ@”Ž2, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Ž­Ž™“‡‘ĺE_Œo“ŕ‰ČE˜V”N•aŠw, 3Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723641. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ĄŽ‹‚𔺂¤‚—îŽŇ‚ĚŠáâ|ƒv[ƒŠ[•Ď‰ť. ‰Í‡ˆ¤ŽŔ1, ŒăŠÖ—˜–ž2, Îě@‹Ď3, ŻŽiMs2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723642. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —L…ť‘ĚŒă–[ƒŒƒ“ƒYp‘OŒă‚Ě“Ž‘ĚŽ‹—́E—§‘ĚŽ‹EŠáˆĘ‚ĚŒŸ“˘. ‰Á“ĄŽŃ–1, ´…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, ěŽç“c‘ńŽu3 (1ŽR‰¤•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723643. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕápŒă‚É‚¨‚Ż‚éDysphotopsia”­śˆöŽq‚ĚŒŸ“˘. ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2, íœAr‘ž˜Y1,2, ‰Á“ĄŽŃ–1, ˆÉ“Ą”üšŠG3, ěŽç“c‘ńŽu4 (1ŽR‰¤•a‰@, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 4ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723644. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Small Incision Lenticule Extraction‚̏pŒă3”N‚̐ŹŃ. ŕV–ŘˆťŽq1, ’ˇ’JěˆŸ—˘2, Ź“‡—˛Ži3, ’†‘ş—Fş4, •Đ‰Ş“”Ž4, Žsěˆę•v5,6 (1‘ĺ—Y‰ď‘ćˆę•a‰@, 2JCHO’†‹ž•a‰@, 3Œcœä‘ĺ, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5’†‹žŠá‰Č, 6Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723645. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Anti-Central Islands Program‚đ—p‚˘‚˝ƒŒ[ƒU[ŽĄ—Ă“IŠp–ŒŘœp‚̏pŒăŹŃ. ‚‹´ł‰p1, _’J˜aF2, ‹´–{“ÄŽj3, ‹ŕŽRr‰î1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3ŒQ”n‘ĺ): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723646. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) łí…ť‘Ě‚Ć”’“ŕá…ť‘Ě‚É‚¨‚Ż‚é‰đ–UŠw“I‚ČŒX‚Ť‚Ě”äŠr. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO3, “ŕ“ĄŽ‹v3, •Đ‰Ş“”Ž4, ’†‘ş—Fş4, ‹Ę’u–ž–ě5, Žsěˆę•v3,6 (1Šá‰Č–žŠá‰@, 2Šň•ŒÔ\Žš•a‰@, 3’†‹žŠá‰Č, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5JCHO’†‹ž•a‰@, 6Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723647. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Šá‰Č—p3ŽŸŒł‰f‘œƒVƒXƒeƒ€‚Ć‘OŠá•”OCT‚đ—p‚˘‚˝“ŕŽ‹‹ž‰ş‹÷Šp–ü’…‰đ—Łp‚ĚŒŸ“˘. ‚–Ř—E‹M1, ó–ě@—ş1, “n糎OŒP2,3, ‰Á‰ę’BŽu1 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723648. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) 2-ƒIƒNƒ`ƒ‹ƒVƒAƒmƒAƒNƒŠƒŒ[ƒg‚đ—p‚˘‚Äŕh‰ß–EC•œ‚đs‚˘CASIA2‚É‚ÄŒo‰ßŠĎŽ@‚ľ‚˝1Ç—á. ó–ě@—ş1, ’ˇ’JěˆŸ—˘1, “n糎OŒP2,3 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/20), ‘ĺă.

723649. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ΓŕáŠłŽŇ‚É‚¨‚Ż‚éƒwƒbƒhƒ}ƒEƒ“ƒgŒ^Ž‹–ěŒv‚É‚ć‚é“ľEŽ‹–ě‘Ş’č‚Ě—L—pŤ. ŒË’˘aŽq1, óě@ŒŤ2, Š}Œ´łs1, ź‘şˆęO1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

723650. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Corvis ST‚É‚ć‚éŠp–ŒŠ×‰šŒ`ó‚ĆŒ´”­ŤŠJ•ú‹÷Šp—ΓŕáŽ‹–ěis‚Ć‚ĚŠÖ˜A‚̉đÍ. Â–؏rˆę˜Y1, ‘ş“c”ŽŽj1, ź‰YŤl2, •˝ŕVˆę–@2,3, ’†”öŠě—˛4, ’†‘qr—S5, –Ř“ŕ—Ç–ž4, ’Š‰Ş@—ş1 (1“Œ‹ž‘ĺ, 2Šá‰Č, 3Moorfields Eye Hosp NHS Foundation Trust and UnivColl, 4L“‡‘ĺ, 5ƒcƒJƒUƒL•a‰@): ‘ć122‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2018/4/22), ‘ĺă.

723651. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) OA‚đ—p‚˘‚˝ƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY‚̏pŒăŹŃ‚ĚŒŸ“˘. ŕV–ŘˆťŽq1, ‰Á“ĄKm2, ‚–Ř–ƒ—˘3, Žsě@Œc3, “´ˆä—˘ŠG2, ‹Ę’u–ž–ě4, Ź“‡—˛Ži5, Žsěˆę•v2,6 (1‘ĺ—Y‰ď‘ćˆę•a‰@, 2’†‹žŠá‰Č, 3Šň•ŒÔ\Žš•a‰@, 4’†‹ž•a‰@, 5Œcœä‘ĺ, 6Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723652. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´‰š”gś‘ĚŒ°”÷‹ž‚Ć‘OŠá•”ŒőŠąÂŒv‚ĹŠĎŽ@‚ľ‚˝ƒqƒg…ť‘ĚŒ`ó‚Ě”äŠr. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO3, “ŕ“ĄŽ‹v3, •Đ‰Ş“”Ž4, ’†‘ş—Fş4, ‹Ę’u–ž–ě5, Žsěˆę•v3,6 (1Šá‰Č–žŠá‰@, 2Šň•ŒÔ\Žš•a‰@, 3’†‹žŠá‰Č, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5’†‹ž•a‰@, 6Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723653. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) łíŠá‚É‚¨‚Ż‚é3‹@ŽíŠÔ‚É‚ć‚é‹÷ŠpŠÔ‹——Ł‚Ě‘Ş’č’lEÄŒťŤ‚Ě”äŠrŒŸ“˘. Ö“Ą@Ę1, _’J˜aF2, “Ą‘ş•‡˛Žq2, ‚‹´ł‰p1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723654. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 3‹@Ží‚đ—p‚˘‚˝‹÷ŠpŠÔ‹——Ł‚ĆŠp–Œ…•˝Œa‚Ě”äŠrŒŸ“˘. ŽRěç‰Ŕ1, _’J˜aF2, “Ą‘ş•‡˛Žq2, Ö“Ą@Ę1, ‚‹´ł‰p1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723655. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) łíŠá‚É‚¨‚Ż‚é5‹@ŽíŠÔ‚É‚ć‚é‘O–[[“x‚Ě‘Ş’č’lE‘Ş’čÄŒťŤ‚Ě”äŠrŒŸ“˘. “Ą‘ş•‡˛Žq1, _’J˜aF1, Ö“Ą@Ę2, ŽRěç‰Ŕ2, ‚‹´ł‰p2, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723656. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OŠá•”ŒőŠąÂ’f‘wŒv‚đ—p‚˘‚˝Šá“ŕƒŒƒ“ƒY‚ĚŒ`ó‚Ć‘fŢ‚É‚ć‚é”’“ŕápŒăŒĹ’čˆĘ’u‚Ě•Ď. ˛“ĄM”V1,2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723657. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OŠá•”ƒpƒ‰ƒ[ƒ^‚ƏpŒăŠá“ŕƒŒƒ“ƒYˆĘ’u‚Ě‘ŠŠÖ‚ĆIOL“x”ŒvŽZŽŽ. ˛“Ą@Ži1,2, ´…Œö–ç1,2,3, íœAr‘ž˜Y1,2,3, ŒÜ\—’ÍŽj1,2,3, ‰Á“ĄŽŃ–2, •Ű‰Č”üŠó2, —`…@Šw1,2,3, Žl”V‹{—C”n1, Vˆä“cF—T1,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺ, 2ŽR‰¤•a‰@, 3Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723658. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕápŒă‚Ě1ƒs[ƒX, 3ƒs[ƒXIOL‚ĚˆĘ’u•Ď‰ťE‹üÜŒëˇ‚Ě”äŠr. íœAr‘ž˜Y1,2, ´…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, —`…@Šw1,2, ‰Á“ĄŽŃ–1, •Ű‰Č”üŠó1 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723659. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šp–Œ‹Č—Ś‚Ě‘ĺ‚Ť‚ČÇ—á‚É‚¨‚Ż‚éŠá“ŕƒŒƒ“ƒY“x”ŒvŽZ‚Ě—\‘ސŤ‚ĚŒŸ“˘. ”Ń“‡@Œh1, ”Ń“c‰Ă•F1, Î“c@‹Ĺ1, ]•—Ft1, ŻŽiMs1 (1Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/29), “Œ‹ž.

723660. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Refractive Lenticule ExtractionpŒă’ˇŠúŹŃ‚ĚŒŸ“˘. ‹ŕŽRr‰î1, _’J˜aF2, ‚‹´ł‰p1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723661. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝Ž{Ý‹¤“ŻŒ¤‹†‚É‚ć‚éSmall Incision Lenticule Extraction (SMILE) ‚Ě‘Šú—Տ°ŹŃ‚ĚŒŸ“˘. _’J˜aF1, ‚‹´ł‰p2, ’†‘ş—Fş3, Ź“‡—˛Ži4, ŒË“cˆčŽq5, ŠĄ’J–ƒ˜C6 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 4Œcœä‘ĺ, 5“ěÂŽRƒAƒCƒNƒŠƒjƒbƒN, 6Vh‹ßŽ‹ƒNƒŠƒjƒbƒN): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723662. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šp–Œ‘S‹üÜ—Í‚đ—p‚˘‚˝ŽĄ—Ă“IƒŒ[ƒU[Šp–ŒŘœ (PTK) pŒă‚Ě”’“ŕáŽčp‚Ě—\‘ސŤ. •ÄŽR@—Č1,2, _’J˜aF3, ”Ń“‡@Œh2, ‰Í–ě—Y—ş2, ‚‹´ł‰p2, ŻŽiMs2 (1ŠC˜V–ź‘‡•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723663. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p’†”g–ĘŽűˇ‰đÍ‘•’u‚̐„§“x”‚Əp‘O‚ɏ€”ő‚ľ‚˝IOL“x”‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. Žsě@Œc1, Ź“‡—˛Ži1,2, “c’†–FŽ÷3, ŽO“c‘ş–ƒ—˘1, “´ˆä—˘ŠG3, ŽđˆäKO3, “ŕ“ĄŽ‹v3, ‹Ę’u–ž–ě4, Žsěˆę•v3,4,5 (1Šň•ŒÔ\Žš•a‰@, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4’†‹ž•a‰@, 5Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723664. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Laser in situ keratomileusis (LASIK) ŽčpŠů‰Šá‚ɑ΂ˇ‚é”’“ŕáŽčpŒă‚É”­Ç‚ľ‚˝Interface fluid syndrome (IFS) Ç—á. ‹g“c—zŽq1, …–ě‘׎q1,2, ’ˇ’JěˆŸ—˘1,3, ˆé’JŽ‹P1, Ź“‡—˛Ži1,4, ’†‘ş—Fş1, Žsěˆę•v2,3,5 (1–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 2’†‹žŠá‰Č, 3’†‹ž•a‰@, 4Œcœä‘ĺ, 5Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723665. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Šp–ŒŒ`ó‰đÍŽw•W‚ĆˆŮ‚Č‚é‘Ş’čŒa‚ĚŠp–Œ‹üÜ—Í‚Ć‚ĚŠÖ˜AŤ. –ěă‹Žu1, ˛“Ą@Ži1, ˆÉ“Ą”üšŠG1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723666. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) —L…ť‘ĚŒă–[ƒŒƒ“ƒY‘}“üp4”NŒă‚̐ŹŃ. ’ˇ’JěˆŸ—˘1, Ź“‡—˛Ži2, ź“c’m–ç3, —L’|ˆŸ‹G‘ă3, ’†‘ş—Fş3, ‰Á‰ę’BŽu1, Žsěˆę•v4,5 (1’†‹ž•a‰@, 2Œcœä‘ĺ, 3–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 4’†‹žŠá‰Č, 5Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/6/30), “Œ‹ž.

723667. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OůNŘŠJ•ű–@•Ę‚Ě‘O”XŘŠJ‰ˆř’Ł‹­“x‚Ě”äŠr. ŽO“c‘ş–ƒ—˘1, Ź“‡—˛Ži2, ŕV–ŘˆťŽq3, Žsě@Œc1, “´ˆä—˘ŠG4, “c’†–FŽ÷4, Žsěˆę•v4,5 (1Šň•ŒÔ\Žš•a‰@, 2Œcœä‘ĺ, 3‘ĺ—Y‰ď•a‰@, 4’†‹žŠá‰Č, 5Šá‰Č): ‘ć33‰ńJSCRSŠwp‘‰ď (2018/7/1), “Œ‹ž.

723668. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Virtual Reality (VR) Ž‹’Ž‚É‚ć‚é‹ßŒŠ”˝‰ž‚ĆŽŠ—Ľ_Œo‚É—^‚Ś‚é‰e‹ż. Œ´@’źl1, –ěă‹Žu1, Š™“c‘׏˛1, ˜e‚Ü‚Ç‚Š1, ŒÜ\—’Ę‰Ä1, ‰ş“c—V–˘1, ’|ěŽjD1, “c’†G@1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠwŽ‹‹@”\—Ă–@Šw‰Č, 2Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723669. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Šá’ęŽĘ^‚đ—p‚˘‚˝‘źŠo“IŠO•ű‰ńůŠp“x‚ĚŒŸ“˘. ‰Í‡ˆ¤ŽŔ1, ŒăŠÖ—˜–ž2, Îě@‹Ď3, ”ź“c’m–ç3, ŻŽiMs2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723670. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚é”’“ŕápŒă‚Ě•ĄŽ‹‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ź‹˝Ř1, ŒăŠÖ—˜–ž1, ŒË’ˁ@Œĺ1, ŻŽiMs1 (1Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723671. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) OCT-angiography‚đ—p‚˘‚˝ŽăŽ‹Šů‰Šá‚É‚¨‚Ż‚é–Ô–ŒŒŒŠÇ–§“x‚Ě•]‰ż. ŒË’ˁ@Œĺ1, ŒăŠÖ—˜–ž1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723672. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)yŔ’ˇzŹŽ™‹üÜŒŸ¸. Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺ, 2Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723673. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –˘AŠwŽ™‚É‚¨‚Ż‚éSpoy Vision Screener‚̐M—ŠŤ‚Ɛ„§Šî€’l‚ĚŒŸŘ. ˛“Ą@Ži1, ‚‹´—RŽk1, ˆÉ“Ą”üšŠG1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺ, 2Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723674. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) •˝Ź29”N“x‘Š–ÍŒ´ŽsAŠwŽžŒ’Nf’fŽžŽ‹—ÍŒŸ¸‚ĚŽŔ’n•ń. “Ą‘ş•‡˛Žq1, ”ź“c’m–ç1, ŒË’ˁ@Œĺ2, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723675. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ƒ|ƒPƒ‚ƒ“ƒXƒeƒŒƒIƒeƒXƒg‚đ—p‚˘‚˝ŹŽ™‚É‚¨‚Ż‚é—§‘ĚŽ‹•]‰ż‚Ě—L—pŤ. ŽRěç‰Ŕ1, ”ź“c’m–ç2, ŒË’ˁ@Œĺ1, ŒăŠÖ—˜–ž1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723676. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Occul-pad‚đ—p‚˘‚˝’ʉ@Œ^ŽăŽ‹ŒP—ű‚É‚ć‚éŒP—űŽžŠÔ•ŞŽU‚ĚŒř‰Ę. Šâ“c@—y1, Îě@‹Ď1, ŒăŠÖ—˜–ž2, ”ź“c’m–ç1, Žđ“őä—T3, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3‚ł‚ą‚¤Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723677. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Ž‹ü‰đÍ‘•’u‚É‚ć‚錒íŹŽ™‚ĚŐ“ŽŤŠá‹…‰^“Ž‚̐öŽžŒv‘Ş. Žl”V‹{—C”n1, —é–ŘŒŤŽĄ1, ‚‹´—RŽk1, Ź–ě‹|ŠG2, Vˆä“cF—T1,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺ, 2–žŽĄ‘ĺ, 3Šá‰Č): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723678. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ŠOŤ“ŕ’ź‹Ř’f—ô‚ɑ΂ľź“c–@•Ď–@‚đŽ{s‚ľ‚˝ˆę—á. ’†ŕV—S‘Ľ1, ŒăŠÖ—˜–ž1, —´ˆä‰‘Žq1, ’r“c“N–ç1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć74‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2018/7/6), ‰ŞŽR.

723679. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č)yŔ’ˇz”’“ŕáŽ‹‹@”\. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

723680. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ”’“ŕáŠá‚É‚¨‚Ż‚é‘źŠo“I‘O•űŽU—‚Ě’č—Ę‚ĆŠÖ˜AˆöŽq‚ĚŒŸ“˘. _’J˜aF1, “Ą‘ş•‡˛Žq1, ěŽç“c‘ńŽu1, ‚‹´ł‰p2, ˆŔ“Ą˜a‰ĚŽq2, Ö“Ą@Ę2, ”Ń“c‰Ă•F2, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

723681. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ŒőŠw•”‘SŽüƒVƒƒ[ƒvƒGƒbƒWŒ`óŠá“ŕƒŒƒ“ƒY‚É‚¨‚Ż‚épŒă3”NŠÔ‚ĚŒă”­”’“ŕá—}§Œř‰Ę‚ĚŒŸ“˘. ‚“cŒc‘ž1, ”Ş–Ř—I•ă1, X@—mÄ1,2, “ěŒcˆę˜Y1, ‰Á“Ą@‘3, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č, 3“Œ‹ž‘ĺŠw): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

723682. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ƒqƒgś‘ĚŠá‚É‚¨‚Ż‚鐅ť‘̐ԓš•”‚ĚˆĘ’u‚đ“Á’股‚é•ű–@. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO3, “ŕ“ĄŽ‹v3, •Đ‰Ş“”Ž4, ’†‘ş—Fş4, ‹Ę’u–ž–ě5, Žsěˆę•v3,6 (1Šá‰Č–žŠá‰@, 2Šň•ŒÔ\Žš•a‰@, 3’†‹žŠá‰Č, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5JCHO’†‹ž•a‰@, 6Šá‰Č): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

723683. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“)yŔ’ˇzƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/21), ‹ŕ‘ň.

723684. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[, ZEPTO, CCC‚É‚¨‚Ż‚é‘O”XŘŠJ‰‚Ě‘gDŠw“IŒŸ“˘. ŽO“c‘ş–ƒ—˘1, Ź“‡—˛Ži2, “c’†–FŽ÷1, Žsě@Œc3, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œc‰ž‹`m‘ĺŠw, 3Šň•ŒÔ\Žš•a‰@, 4Šá‰Č): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/22), ‹ŕ‘ň.

723685. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ”’“ŕáŠá‚ĚŽŠ“ŽŽÔ‰^“]‚ÉŠÖ‚ˇ‚éŽĺŠĎ•]‰ż‚ĆŽ‹‹@”\‚ĚŠÖŒW. ěŽç“c‘ńŽu1, ˆŔ“Ą˜a‰ĚŽq2, _’J˜aF1, ”Ń“c‰Ă•F2, ź‰Yí•v3, ”ź“c’m–ç1, Îě@‹Ď1, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3ŽŔ‘H—Žq‘ĺŠw): ‘ć57‰ń“ú–{”’“ŕáŠw‰ď‘‰ď/‘ć44‰ń…ť‘ĚŒ¤‹†‰ď (2018/7/22), ‹ŕ‘ň.

723686. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) •ĐŠáŽŐ•Â‰ş‚É”ş‚¤’†‹——Ł‹y‚Ń‹ß•űŽ‹Žž‚Ě‹üÜ’l•Ď‰ť. ’†Vˆä“c—I‘ž1, ”ź“c’m–ç2, ěŽç“c‘ńŽu2, Šâ“c@—y2, ŻŽiMs3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/8), VŠƒ.

723687. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) Ž‹–쐧ŒŔ‚É”ş‚¤ŽŠŠo“I‹üÜ’l•Ď‰ť‚ĚŒŸ“˘. Œ‹éŠxŽu1, ”ź“c’m–ç2, ěŽç“c‘ńŽu2, Šâ“c@—y2, ŻŽiMs3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č): ‘ć54‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2018/9/8), VŠƒ.

723688. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) —ΓŕáŠá‚É‚¨‚Ż‚éŒăŠá•”Œ`ó‚ĆŽ‹–ěáŠQ‚Ěă‰ş”ń‘Ώ̐Ť‚ĚŠÖŒW (Relationship between the shape of posterior pole of an eye and visual field damage in glaucoma eyes). ŽR‰ş‚–ž1, •˝ŕVˆę–@2,3,4, “Ą–ě—F—˘2,3, ź‰YŤl2,3, –öŕV”üˆßŽq3, Šěˆä—TĆ1, â–{‘דń1, ‘ş“c”ŽŽj3, ’Š‰Ş@—ş3 (1Ž­Ž™“‡‘ĺ, 2Šá‰Č, 3“Œ‹ž‘ĺ, 4Moorfields Eye Hosp): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

723689. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Improving the structure-function relationship by incorporating photoreceptor layer thickness. ź‰YŤl1,2, “Ą–ě—F—˘1,2, Kanamoto T3, Murata H1, Yanagisawa M1, •˝ŕVˆę–@2,4, Inoue T1, Inoue K5, Yamagami J6, Asaoka R1 (1“Œ‹ž‘ĺ, 2Šá‰Č, 3Hiroshima Memorial Hosp, 4Moorfields Eye Hosp, 5Inouye Eye Hosp, 6JR Tokyo Gen Hosp): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

723690. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œo–Ń—l‘̝G•˝•”ƒƒ“ƒOƒ`ƒ…[ƒuƒVƒƒƒ“ƒg‘}“üŒă‚̏ɮq‘̛Ɠڂɑ΂ˇ‚é“ŕŽ‹‹ž‰şÉŽq‘̐؏œ (Endoscope-assisted vitrectomy for management of glaucoma implants occluded by vitreous incarceration). ź“c‘וă1, “n糎OŒP2,3, ó–ě@—ş1, ‰Á‰ę’BŽu1, Žsěˆę•v2,3 (1’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

723691. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) p‘OŠáˆł20 mmHg–˘–ž‚ĚÇ—á‚ɑ΂ˇ‚éTrabectomeŽčp (Trabectome surgery for the cases whose preoperative intraocular pressure was less than 20 mmHg). ˆäă‰Ŕ–źŽq1, Š}Œ´łs1, ź‘şˆęO1, ‰Í–ě—Y—ş1, ’Ň‘ň’C•F1, —´ˆä‰‘Žq1, ]•—Ft1, ŻŽiMs1 (1Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/14), VŠƒ.

723692. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒ‰ƒ^ƒmƒvƒƒXƒg{ƒJƒ‹ƒeƒIƒ[ƒ‹‚Š‚烉ƒ^ƒmƒvƒƒXƒg/ƒJƒ‹ƒeƒIƒ[ƒ‹”z‡“_Šá–ň‚Ö‚Ě•ĎX‚É‚ć‚é’ˇŠú“Š—^ (Long-term efficacy of switching to Latanoprost/Carteolol fixed combination from an unfixed). łˆä’qŽq1,2, ˆäăŒŤŽĄ1, ‰–ě”üŘŽq1, Šâ˛^‹|1,3, Î“c‹ąŽq2, •x“c„Ži2 (1ˆäăŠá‰Č•a‰@, 2“Œ–M‘ĺE‘ĺ‹´, 3Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723693. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) TrabectomeŽčp‚É‚ć‚鎋–ěáŠQ‚̐is—}§Œř‰Ę (Effect to inhibit progression of visual field disturbance by the Trabectome surgery). ‚‹´‰ÄŽŔ1, Š}Œ´łs1, ’Ň‘ň’C•F1, ‰Í–ě—Y—ş1, ˆäă‰Ŕ–źŽq1, —´ˆä‰‘Žq1, ]•—Ft1, ź‘şˆęO1, ŻŽiMs1 (1Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723694. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) p‘OŠáˆł•Ę‚É•Ş‚Ż‚˝Trabectome ŽčpŒă‚ĚŽ‹–ěáŠQ‚̐is‘Ź“x (Progress speed of visual field defects according to the preoperative IOP after Trabectome surgery). ‰Í–ě—Y—ş1, Š}Œ´łs1, ‚‹´‰ÄŽŔ1, ’Ň‘ň’C•F1, ˆäă‰Ŕ–źŽq1, —´ˆä‰‘Žq1, ]•—Ft1, ź‘şˆęO1, ŻŽiMs1 (1Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723695. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ”’“ŕáŽčp•š—püˆŰ’Œ‘ѐ؏œp‚̏pŒă‹üÜŒëˇ (Refractive error of Trabeculectomy with Cataract surgery). ‰z’n—šŽq, Š}Œ´łs1, ”Ń“c‰Ă•F1, ź‘şˆęO1, ŻŽiMs1 (1Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723696. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ŠáˆłƒRƒ“ƒgƒ[ƒ‹•s—Ç—á‚ɑ΂ˇ‚éCYCLO G6‚Ě’ZŠúŠáˆł‰ş~Œř‰Ę (Short term effect of intraocular pressure by CYCLO G6). ’Ň‘ň’C•F1, ŻŽiMs1, ź‘şˆęO1, Š}Œ´łs1, ]•—Ft1, —´ˆä‰‘Žq1, ‰Í–ě—Y—ş1, ˆäă‰Ŕ–źŽq1 (1Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723697. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) …ť‘ĚˆŸ’E‰P‚𔺂¤ŠOŤ—Γŕá‚ɑ΂ľTrabectome ‚đs‚Á‚˝ˆę—á (A case of traumatic glaucoma with subluxated lens treated by Trabectome). ó–ě@—ş1, ŽO“c‘ş—El1, “n糎OŒP2,3 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć29‰ń“ú–{—ΓŕáŠw‰ď (2018/9/15), VŠƒ.

723698. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠááŮázšŠłŽŇ‚Ě“]“|Ž–ŒĚó‹ľ‚¨‚ć‚ѐśŠˆ•sŽŠ—R“x‚ĚŒŸ“˘. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć5‰ń“ú–{ƒ{ƒcƒŠƒkƒXŽĄ—ĂŠw‰ďŠwp‘ĺ‰ď (2018/9/21), “Œ‹ž.

723699. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰Ć“eŠOŠá‹Ř‚Ö‚Ěƒ{ƒcƒŠƒkƒX“Ĺ‘f’ŽË‚ŞŠp–Œ’mŠo_Œo‚Ö—^‚Ś‚é‰e‹ż. ’†ŕV—S‘Ľ1, Îě@‹Ď2, ŒăŠÖ—˜–ž1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć5‰ń“ú–{ƒ{ƒcƒŠƒkƒXŽĄ—ĂŠw‰ďŠwp‘ĺ‰ď (2018/9/21), “Œ‹ž.

723700. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ‚Ť‚ČŠOŽÎˆĘŠp“x‚ɑ΂ˇ‚é’PĹ“_Šá“ŕƒŒƒ“ƒY‚É‚ć‚郂ƒmƒrƒWƒ‡ƒ“–@‚ĚŒŸ“˘. ‰Á“ĄŽŃ–1, ´…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, —`…@Šw1,2, íœAr‘ž˜Y1,2, ˆÉ“Ą”üšŠG1 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723701. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÜ…—Ś‚đ‚‚­‚ľ‚˝‘a…ŤƒAƒNƒŠƒ‹Šá“ŕƒŒƒ“ƒY‚É‚¨‚Ż‚épŒă’ˇŠú‚Ě•\–ĘŽU—. –؉ş—Yl1, Žq“‡—Ç•˝1,2, –{–Vłl1, “ěŒcˆę˜Y1, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723702. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹@ŠBŠwK‚đ—p‚˘‚˝‰~Šp–Œ‚̐f’f”\‚ĚŒŸ“˘ (‘ć1•ń: ‘OŠá•”ŒőŠąÂ’f‘wŒv‚É‚ć‚錟“˘). _’J˜aF1, ˆť’Ë—S“ń2, ‰Á“Ą—Y‘ĺ2, “Ą‘ş•‡˛Žq1, ‚‹´ł‰p3, ŻŽiMs3, X@—mÄ3,4, ‹{“c˜a“T4 (1ˆă—ÉqśŠw•”, 2ƒNƒŒƒXƒRŽĐ, 3Šá‰Č, 4‹{“cŠá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723703. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CorvisST‚đ—p‚˘‚˝CBI‚É‚ć‚é‰~Šp–Œf’f‚Ě—L—pŤ‚ĚŒŸ“˘. Žu‰ę@—D1, Ź“‡—˛Ži1,2, ’ˇ’JěˆŸ—˘1, ź“c’m–ç2, ’†‘ş—Fş2, ‰Á‰ę’BŽu1, Žsěˆę•v1,3 (1’†‹ž•a‰@, 2–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 3Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723704. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) IOLƒ}ƒXƒ^[700҂ɂĒˆÓŠŤ‹NŽw•W‚Ş•\ŽŚ‚ł‚ę‚éÇ—á‚É‚¨‚Ż‚é”’“ŕápŒă‹üÜŒëˇ. ‘ěG‹P1, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, âV“Ą@Ę1, ŽRěç‰Ŕ1, ŻŽiMs1 (1Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723705. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Šá“ŕƒŒƒ“ƒY‘}“üŠá‚É‚¨‚Ż‚鎊Šo‹üÜ’l‚Ć—‡ŠáŽ‹—Í‚Ě•Ş•z. ‰ĄŠÖ—S‰ŔŽq1, ”Ń“c‰Ă•F1, Šąě—˘ŠG2, ”Ń“‡@Œh1, ]•—Ft1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723706. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Šp–Œ‹Č—Ś‚¨‚ć‚ъᎲ’ˇ•Ę‚Ě—\‘Ş‘O–[[“x. Î“cGr1, –k@@•‘1, ěŽç“c‘ńŽu2, ŽO“c“N‘ĺ1, ˆÉˆä@Ę1, ŽÄ“c“މ›Žq1, ‹{‰ş‹v”Í1, a’JŒb—1, ‹v•Ű]—1, ˛X–Ř—m1 (1‹ŕ‘ňˆă‘ĺ, 2ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/11), “Œ‹ž.

723707. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) TrabectomeŽčp—źŠáŽ{s—á‚É‚¨‚Ż‚鍶‰E‚̐ŹŃ‚Ě”äŠrŒŸ“˘. Š}Œ´łs1, ź‘şˆęO1, ]•—Ft1, —´ˆä‰‘Žq1, ‰Í–ě—Y—ş1, ’Ň‘ň’C•F1, ˆäă‰Ŕ–źŽq1, ŻŽiMs1 (1Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723708. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) •aŒ^•Ę‚É•Ş‚Ż‚˝TrabectomeŽčpŒă‚ĚŽ‹–ěáŠQis‘Ź“x‚ĚŒŸ“˘. ’Ň‘ň’C•F1, ŻŽiMs1, ź‘şˆęO1, Š}Œ´łs1, ]•—Ft1, —´ˆä‰‘Žq1, ˆäă‰Ŕ–źŽq1, ‰Í–ě—Y—ş1, ‚‹´‰ÄŽŔ1 (1Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723709. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇzˆę”ʍu‰‰@Ŕ’ˇ. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723710. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isŤ‰~Šp–Œ‚ɑ΂ˇ‚éƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ě‘ŠúŹŃ. ‚‹´ł‰p1, _’J˜aF2, ‰Í–ě—Y—ş1, âV“Ą@Ę1, ‘ěG‹P1, ŻŽiMs1, X@—mÄ1,3, ‹{“c˜a“T3 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‹{“cŠá‰Č•a‰@): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723711. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒYICL‚Ě’ˇŠúŹŃ. ’†‘ş—Fş1, ‹g“c—zŽq1, ˆé’JŽ‹P1, ™ŽRN—Y1, Ź“‡—˛Ži1,2, Žsěˆę•v3,4 (1–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723712. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒŠƒbƒgƒXƒLƒƒƒ“‚đ—p‚˘‚˝ÚGŒ^‚É‚ć‚éŠp–Œ“ŕ”ç×–E‚Ě•”ˆĘ•Ę•]‰ż. —›@^ę¤1, X@—mÄ1,2, –{–Vłl1, ”ö•ű”ü—R‹I1, “ěŒcˆę˜Y1, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723713. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) V‚ľ‚˘ELP—\‘ŞŒvŽZŽŽ‚ĆŒőü’ǐՖ@‚É‚ć‚éIOL“x”ŒvŽZŽŽ‚ĚŒŸŘ. ˛“Ą@Ži1,2, ´…Œö–ç1,2,3, íœAr‘ž˜Y1,2,3, ŒÜ\—’ÍŽj1,2,3, ‰Á“ĄŽŃ–2, •Ű‰Č”üŠó2, —`…@Šw1,2,3, Žl”V‹{—C”n1, Vˆä“cF—T1,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺEŽ‹‹@”\—Ă–@Šw‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 3Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723714. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šp–ŒƒXƒeƒB[ƒvŠá‚ɑ΂ˇ‚éBarrettŽŽ‚Ě—\‘ސŤ‚ĚŒŸ“˘. ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ]•—Ft1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723715. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇzˆę”ʍu‰‰@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/12), “Œ‹ž.

723716. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ”’“ŕápŒăŠá“ŕƒŒƒ“ƒYŒđŠˇŽčp‚ĚŒŸ“˘. ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2, —`…@Šw1,2, íœAr‘ž˜Y1,2, ‰Á“ĄŽŃ–1 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/13), “Œ‹ž.

723717. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ’´‰š”gś‘ĚŒ°”÷‹ž‚Ć‘OŠá•”ŒőŠąÂŒv‚đŽg—p‚ľ‚˝Šá“ŕƒŒƒ“ƒY’†S•”Œú‚ĚŒv‘Ş. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO3, “ŕ“ĄŽ‹v3, •Đ‰Ş“”Ž4, ˆé’JŽ‹P4, ’†‘ş—Fş4, ‹Ę’u–ž–ě5, Žsěˆę•v3,6 (1Šá‰Č–žŠá‰@, 2Šň•ŒÔ\Žš•a‰@, 3’†‹žŠá‰Č, 4–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 5JCHO’†‹ž•a‰@, 6Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/13), “Œ‹ž.

723718. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šá“ŕƒŒƒ“ƒY–D’…p‚É‚¨‚Ż‚éŠá“ŕƒŒƒ“ƒYŒĹ’čˆĘ’u‚ƏpŒă‹üÜŒëˇ. ”Ń“c‰Ă•F1, ˛“ĄM”V1, ‰ĄŠÖ—S‰ŔŽq1, –ö“c’q•F1, ŻŽiMs1 (1Šá‰Č): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/13), “Œ‹ž.

723719. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆŮ‚Č‚éƒXƒŠ[ƒs[ƒXŠá“ŕƒŒƒ“ƒY‚̏pŒăŒĹ’čˆĘ’u‚Ć‘OŠá•”OCT‚É‚ć‚éŒv‘Ş’l‚Ě‘ŠŠÖŤ‚Ě”äŠr. ˛“ĄM”V1,2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć72‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2018/10/14), “Œ‹ž.

723720. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒKƒ€™đš‚É‚ć‚é”ć‚ę–Ú—}§Œř‰Ę‚ĚŒŸŘ. ›–ě@”Í1, ˆŔ“Ą’q‹ł1, óě@ŒŤ2, ‘ĺŕVŒŞ“ń1 (1ƒƒbƒe’†‰›Œ¤‹†Š, 2ˆă—ÉqśŠw•”): “ú–{™đšŠw‰ď‘ć29‰ńŠwp‘ĺ‰ď (2018/10/13), ź–{.

723721. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Ž‹ü’Ǐ]‘•’u‚đ—p‚˘‚˝‘źŠo“I9•űŒüŠáˆĘ‘Ş’č‚ĚŽŽ‚Ý. Šâ“c@—y1,2, ”ź“c’m–ç1, Îě@‹Ď1, ŻŽiMs3 (1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723722. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) f’f‚É‹ę—ś‚ľ‚˝ŠOŤŽ‹Ž‹őáŠQ‚Ě1—á. •y‰Ş•q–ç1, –]ŒŽ—˛’j2, Îě@‹Ď3 (1‰Ą{‰ęŽs—§Žs–Ż•a‰@Šá‰Č, 2‰Ą{‰ęŽs—§Žs–Ż•a‰@•úŽËü‰Č, 3ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723723. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Ä”­‚đŒJ‚č•Ô‚ľƒRƒ“ƒgƒ[ƒ‹•s—Ç‚ČRMOGR‘Ě—zŤŽ‹_Œo‰Š‚Ě1—á. ‚‹´—m•˝1,2, ŽRă–žŽq3,4, Šâ˛^‹|3,4, ˆäăŒŤŽĄ3, Žá‘q‰ë“o3, ‚‹´—˜K5,6 (1TMG‚ ‚ł‚Šˆă—ĂƒZƒ“ƒ^[, 2“Œ‹ž—Žqˆă‰Č‘ĺŠw•a‰@, 3ˆäăŠá‰Č•a‰@, 4Šá‰Č, 5“Œ–k‘ĺŠwˆăŠw•”_Œo“ŕ‰Č, 6‘—§•a‰@‹@\•Ä‘ň•a‰@): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723724. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒGƒ^ƒ“ƒuƒg[ƒ‹“ŕ•ž‚Ş—Uˆö‚ƍl‚Ś‚ç‚ę‚˝”ń“TŒ^“I‚ČƒŒ[ƒxƒ‹ˆâ“`ŤŽ‹_ŒoÇ‚Ě1—á. ’†ŕV—S‘Ľ1, Îě@‹Ď2, âV“ĄŽi˜N1, â–{‘דń1, –Řč‡ˆę˜Y3, ź‘ş‰hˆę3 (1Ž­Ž™“‡‘ĺŠw, 2ˆă—ÉqśŠw•”, 3ş˜a‘ĺŠw“Ą‚Ş‹uƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723725. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ú–{lLeberˆâ“`ŤŽ‹_ŒoÇ‚ɑ΂ˇ‚éƒCƒfƒxƒmƒ““Š—^1”NŒă‚ĚŒo‰ß: ĹI•ń. Îě—Tl1, ‘“c—mˆę˜Y2, ŒÜ–Ą@•ś1, •~“‡ŒhŒĺ2, ŒăŠÖ—˜–ž3, Îě@‹Ď4, –Ń’Ë„Žu5, ŽO‘ş@ŽĄ1 (1•şŒÉˆă‰Č‘ĺŠw, 2“Œ‹žŽœŒb‰ďˆă‰Č‘ĺŠw, 3Šá‰Č, 4ˆă—ÉqśŠw•”, 5“Œ‹žˆă‰Č‘ĺŠw): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723726. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) LSFG‚đ—p‚˘‚˝Ž‹_Œo‰Š‹^‚˘Ç—á‚É‚¨‚Ż‚éUhthoff’ĽŒóoŒť‘OŒă‚ĚŠáŒŒ—Ź‘Ş’č. ŕ_“ޏŽq1, ź–{@’ź1, ‰Á“ĄŒjŽq1, •x“c‹§•F1, Œ÷“—tŽq1, –x@—Tˆę1, Îě@‹Ď2 (1“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 2ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723727. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) –k—˘‘ĺŠw•a‰@Šá‰Č‚É‚¨‚Ż‚éLeberˆâ“`ŤŽ‹_ŒoÇ‚̐f—Ă˜^‚đ—p‚˘‚˝Œă‚ëŒü‚ŤŒ¤‹†. ŔŕV—E‹P1, ’†ŕV—S‘Ľ2, ŒË’ˁ@Œĺ1, Îě@‹Ď3, ŸNˆäŒc‘˘4, ˆŔ–{—´”n4, ŻŽiMs1 (1Šá‰Č, 2Ž­Ž™“‡‘ĺŠw•a‰@, 3ˆă—ÉqśŠw•”, 4—ŐŒŸ•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723728. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) mt4171C>A•ĎˆŮ‚đ’ć‚ľ‚˝ƒŒ[ƒxƒ‹ˆâ“`ŤŽ‹_ŒoÇ‚Ě1—á. ‹´’J@—Ő1, ŽRă–žŽq1,2, Šâ˛^‹|1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, ź–{@’ź3, ˆŔ–{—´”n4, ŸNˆäŒc‘˘4, Îě@‹Ď5 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č, 3“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 4—ŐŒŸ•”, 5ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723729. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ö•šŠáU‚đ—L‚ˇ‚é•ĐŠáŽăŽ‹‚ɑ΂ľ‚ÄOcclu-pad‚É‚ć‚éŒP—ű‚Ş‘tŒ÷‚ľ‚˝2—á. ŒË’ˁ@Œĺ1, ”ź“c’m–ç2, ŒăŠÖ—˜–ž1, Îě@‹Ď2, ŻŽiMs1(1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723730. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Ž‹üŒv‘Ş‘•’u‚đ—p‚˘‚˝Šá‹…‰^“Ž‚Ě’č—Ę‚Ć]—ˆŒŸ¸‚Ě”äŠr. ĺŒ´Žľd1, Îě@‹Ď1, ŒŠ•tŽé—˘1, “n糗zŘ1 (1ˆă—ÉqśŠw•”): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723731. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”ń’ˇŠáŽ˛Šá‚ĹŠá‰Č‹‡‹üÇŒóŒQ‚ĚŠÓ•Ę‚Şl‚Ś‚ç‚ę‚˝6Ç—á‚ĚMRI‚Ě”äŠrŒŸ“˘. Šâ˛^‹|1,2, ‰Í–{‚Đ‚ë”ü1, ŽRă–žŽq1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/14), _ŒË.

723732. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]Ň‘‰tŒ¸­Ç‚ĚŽ‹‹@”\ˆŮí. ŽRă–žŽq1,2, Šâ˛^‹|1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, Îě@‹Ď3, ‚‹´_ˆę4 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4ŽR‰¤•a‰@”]ŠO‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723733. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[)yŔ’ˇzŽ‹‹@”\E“ľE. ŒăŠÖ—˜–ž (Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723734. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‚Zś‚É‚¨‚Ż‚éƒXƒ}[ƒgƒtƒHƒ“‚ĚŽg—p‚É‚ć‚é’˛ßˆŮí‚Ć—}§‚ĚŠÖ˜A‚ĚŒŸ“˘. ”“c^‹GŽq1, —é–Ř••q1, ‘ü–ě@T1, ›Œ´@—Č1, Ź–ě—˘‹KŽq2, Œ´@’źl2,3, Vˆä“cF—T2,3,4 (1”@…‰ď—é–ŘŠá‰Č‹gŹ˜H, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw•a‰@, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”, 4Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723735. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒXƒ}[ƒgƒtƒHƒ“’ˇŽžŠÔŽg—p‚É‚ć‚鍂Zś‚Ě’˛ß‹@”\‚ւ̉e‹ż. Ź–ě—˘‹KŽq1, Œ´@’źl1,2, Vˆä“cF—T1,2,3, ”“c^‹GŽq4, ‘ü–ě@T4, ›Œ´@—Č4, —é–Ř••q4 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”Ž‹‹@”\—Ă–@Šw‰Č, 3Šá‰Č, 4”@…‰ď—é–ŘŠá‰Č‹gŹ˜H): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723736. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[)yŔ’ˇz‘SgŽžŠłEŠáâ|. ”–؍LĆ1,2 (1Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

723737. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) —źŠá‚Ě“ű“ŞŽî’Ż‚Ĺ”­ŒŠ‚ł‚ę‚˝d–Œ“ŽĂ–Źá‘‚Ě1—á. ’ß“cŘ“E1, Žs粋`Í1,2, Œ´@’źl2,3, ŒN“‡^ƒ1, Š—ś^—˘1, ŒË’˘aŽq1, Œü–ě˜a—Y1,2 (1_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”Ž‹‹@”\—Ă–@Šw‰Č): ‘ć56‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2018/12/15), _ŒË.

731072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Γŕá‚Ě’ˇŠúŠÇ—‚ĆŽčp. ŻŽiMs (Šá‰Č): é‹ĘŒ§Šá‰Čˆă‰ďE‚ł‚˘‚˝‚ܐԏ\Žš•a‰@Šá‰Č‡“Ż§˜b‰ď (2018/4/7), é‹Ę.

731073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ç—á‚Š‚çl‚Ś‚é_ŒoŠá‰ČŽžŠł‚̐f’fEŽĄ—Ă, ę–ĺŽ{ÝĐ‰î‚Ö‚Ěƒ^ƒCƒ~ƒ“ƒO. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć11‰ń‹I‚̍‘ŠáŽžŠłŒ¤‹†‰ď (2018/5/26), ˜a‰ĚŽR.

731074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “Á•Ęu‰‰I Ŕ’ˇ. ‰F’ĂŒŠ‹`ˆę1,2 (1_“ŢěŒ§Šá‰Čˆă‰ď•›‰ď’ˇ, 2Šá‰Č): ‘ć131‰ń_“ŢěŒ§Šá‰ČW’k‰ď (2018/5/27), _“ސě.

731075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆęŽč–@”’“ŕáŽčp‚Ě‚ˇ‚ˇ‚ß. ”Ń“c‰Ă•F (Šá‰Č): ‘ć19‰ńŠá‰ČŽčp‚ĚŽ›Žq‰Ž`ÉŽq‘ĚƒT[ƒWƒƒƒ“‚đ–ÚŽw‚ˇŠF‚ł‚ń‚ց` (2018/5/31), “Œ‹ž.

731076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ç—á‚Š‚çŠw‚ÔŽ‹_ŒoŽžŠł. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć12‰ń_ŒoŠá‰ČƒRƒƒLƒEƒ€`×á‚̉ď` (2018/6/2), •şŒÉ.

731077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŸ˘‘ă‚ĚŽ‹–ěŒvƒwƒbƒhƒ}ƒEƒ“ƒgŒ^Ž‹–ěŒvimo (ƒAƒCƒ‚)`‚ť‚̉”\Ť‚Ɖۑč`. ‹˝‰E‹ß”ŽN (Šá‰Č): ‘ć12‰ń‚ł‚Ş‚ÝŠá‰ČŒ¤‹†‰ď (2018/6/22), _“ސě.

731078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰2@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć12‰ń‚ł‚Ş‚ÝŠá‰ČŒ¤‹†‰ď (2018/6/22), _“ސě.

731079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰2@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć18‰ń_“ސěŠá‰ČƒZƒ~ƒi[ (2018/7/5), _“ސě.

731080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŠÇ—‚É‚¨‚Ż‚鎥—Ă‚Ě‘Šú“ą“ü. ŻŽiMs (Šá‰Č): ‘ć33‰ńŽOdŒ§Šá‰ČƒZƒ~ƒi[ (2018/7/8), ŽOd.

731081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) _ŒoŠá‰ČŽžŠł‚̐f’fEŽĄ—Ă, ę–ĺŽ{ÝĐ‰î‚Ö‚Ěƒ^ƒCƒ~ƒ“ƒO. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć12‰ń’šŽćŒ§Šá‰ČƒtƒH[ƒ‰ƒ€ (2018/7/21), ’šŽć.

731082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –[…—Źo‚ĚŽĺŒo˜H‚đŠˆ—p‚ˇ‚éMIGS. ŻŽiMs (Šá‰Č): ‘ć3‰ń—Γŕá‰ˇŒĚ’mV‚̉ď (2018/9/1), –kŠC“š.

731083. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Γŕáf’f‚ĚĹ‹ß‚Ě˜b‘č: PRG‚ĆMIGS. ŻŽiMs (Šá‰Č): ‘ć258‰ńŽ­Ž™“‡Œ§Šá‰ČW’k‰ď (2018/9/8), Ž­Ž™“‡.

731084. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŒőŠw“I‘¤–Ę‚Š‚çŒę‚éŽÎŽ‹ŽăŽ‹. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć29‰ńŹŽ™Šá‰Č (ŽÎŽ‹EŽăŽ‹) Ç—ጟ“˘‰ďE•×‹­‰ď (2018/9/13), _“ސě.

731085. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”’“ŕáŽĄ—Ð헪. ”Ń“c‰Ă•F (Šá‰Č): ‘ć10‰ńŠá‰ČŽžŠłŒ¤‹†‰ď (2018/9/27), _“ސě.

731086. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

731087. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Γŕá‚̐f’f‚ĆŽĄ—Ă‚Ě”ť’f. ŻŽiMs (Šá‰Č): ‘ć16‰ń•şŒÉŒ§Šá‰ČƒI[ƒvƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/6), _ŒË.

731088. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Šá’ęŽĘ^ŽB‰e‚ĚQ&A. ‰i–ěKˆę (Šá‰Č): ‘ć22‰ńÂXŒ§Ž‹”\ŒP—űŽm‚̉ď•×‹­‰ď (2018/11/17), ÂX.

731089. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Γŕáf—Ă‚ĚĹ‹ß‚Ě˜b‘č: PPG‚ĆMIGS. ŻŽiMs (Šá‰Č): ‘ć192‰ńé‹žŠá‰ČŠwpW‰ď (2018/11/17), é‹Ę.

731090. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰@Ŕ’ˇ. ŻŽiMs (Šá‰Č): —ΓŕáƒJƒ“ƒtƒ@ƒŒƒ“ƒX`f—Ă‚ĚĹ‘Oü` (2018/11/30), “Œ‹ž.

731091. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

731092. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŠłŽŇ‚Ě–ž‘Ť“x‚Š‚çl‚Ś‚é”’“ŕáŽĄ—Ð헪. ”Ń“c‰Ă•F (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

731093. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŽčpŽĄ—Ă. ŻŽiMs (Šá‰Č): ‘ć11‰ń‚’mOPHTALMICƒZƒ~ƒi[ (2019/1/19), ‚’m.

731094. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰II@Ŕ’ˇ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć15‰ńĂ“ěŠá‰Č‹äŠy•” (2019/2/14), _“ސě.

731095. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –k—˘‘ĺ–Ô–Œ”Ç‚ĚŒť‹ľ‚Ć, –Ô–Œ—ôE‚ɑ΂ˇ‚é—\–h“IŒő‹ĂŒĹ‚ɂ‚˘‚Ä. –ö“c’q•F (Šá‰Č): ‘ć9‰ń’Ź“cŽs•af˜AŒgƒAƒbƒvƒf[ƒgƒZƒ~ƒi[ (2019/2/15), “Œ‹ž.

731096. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ž‹_ŒoŽžŠł‚̐f•ű‚ƍŐV‚Ě˜b‘č. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć15‰ńé‹Ę—Տ°Šá‰ČƒZƒ~ƒi[ (2019/2/15), é‹Ę.

731097. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰I@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć1‰ńSENJU Glaucoma Seminar (2019/2/27), _“ސě.

731098. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘ŠúŽĄ—Ă‚Ě“ą“ü`PRG‚ĆMIGS. ŻŽiMs (Šá‰Č): Kowa Ophthalmology Forum (2019/3/2), ‰Ť“ę.

732047. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Γŕá–ň•¨ŽĄ—Ă‚Š‚çŽčp‚Ö. ŻŽiMs (Šá‰Č): ‘ć12‰ń‹ăBŠá‰ČƒAƒJƒfƒ~[ (2018/4/14), •Ÿ‰Ş.

732048. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) –Ô–ŒÉŽq‘ĚŽčp‚ɂ‚˘‚Ä. –ö“c’q•F (Šá‰Č): ‹ť˜a‘n–ň (Š”) ŽĐ“ŕu‰‰‰ď (2018/5/11), _“ސě.

732049. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Žó‚Ż‚é‘O‚É’m‚Á‚Ä‚¨‚Ť‚˝‚˘ŽĄ—Ă‚Ě˜b`”’“ŕáŽčp. ”Ń“c‰Ă•F (Šá‰Č): _“ސ쎕‰Č‘ĺ•t‘Ž‰Ą•lƒNƒŠƒjƒbƒNŽs–ŻŒöŠJuŔ (2018/6/2), _“ސě.

732050. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Γŕá–ň•¨ŽĄ—Ă‚ĆMIGS. ŻŽiMs (Šá‰Č): ‘ć12‰ńŽl‘Eyeƒ‰ƒ“ƒhƒZƒ~ƒi[ (2018/6/2), ‚ź.

732051. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ŠOŤ–ł“řĘE–ł…ť‘ĚŠá‚ɑ΂ľŒă”X‚Éoptic capture‚đŽ{s‚ľ‚˝ˆę—á. ‰ĄŠÖ—S‰ŔŽq (Šá‰Č): ‘ć11‰ńƒRƒ‹ƒjƒAƒtƒFƒCƒRƒZƒ~ƒi[ (2018/6/14), _“ސě.

732052. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (•×‹­‰ď) ƒAƒhƒoƒCƒU[Dr.Šé‰ć. ”Ń“c‰Ă•F (Šá‰Č): ŽĐŠOuŽt•×‹­‰ď (çŽő) (2018/6/15), _“ސě.

732053. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ƒgƒ‰ƒxƒNƒg[ƒ€Žčp. Š}Œ´łs (Šá‰Č): ‘ć1‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2018/6/16), “Œ‹ž.

732054. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ‘˝Ž{Ý‹¤“ŻŒ¤‹†‚Ć—VŠw‚ĚƒXƒXƒ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć1‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2018/6/16), “Œ‹ž.

732055. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (•×‹­‰ď) —ΓŕáŽĄ—Âɂ‚˘‚Ä. Š}Œ´łs (Šá‰Č): ƒtƒ@ƒCƒU[ (Š”) ŽĐ“ŕ•×‹­‰ď (2018/6/21), _“ސě.

732056. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) Ç—á’ńŽŚu‰Š”Áă–ŒpŒă‚ɉŠ”Á•‚Žî‚đ—ˆ‚ľ‚˝Ç—á‚ĚŒŸ“˘v. t–ؐ’G (Šá‰Č): ‘ć13‰ń_“ސ쉊”ÁŒ¤‹†‰ď (2018/6/23), _“ސě.

732057. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒŠƒXƒg) ƒe[ƒ}u–Ô–ŒŽžŠł‚̐f’f‚¨‚ć‚ŃŽĄ—Ă‘I‘đŽˆvƒpƒlƒŠƒXƒg. –ö“c’q•F (Šá‰Č): ‘ć13‰ń_“ސ쉊”ÁŒ¤‹†‰ď (2018/6/23), _“ސě.

732058. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (•×‹­‰ď) ƒAƒhƒoƒCƒU[Dr.Šé‰ć. Š}Œ´łs (Šá‰Č): ŽĐŠOuŽt•×‹­‰ď (çŽő) (2018/6/28), _“ސě.

732059. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕu‰‰‰ď) –˘nŽ™–Ô–ŒÇ. ’r“c“N–ç (Šá‰Č): ƒAƒ‹ƒRƒ“ƒtƒ@[ƒ}ŽĐ“ŕu‰‰‰ď (2018/7/17), _“ސě.

732060. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹üÜ‹¸ł‚ć‚ŕ‚â‚ܘb. _’J˜aF (ˆă—ÉqśŠw•”): Refractive Surgery Update Seminar 2018 in Kyoto@”’“ŕá&ƒŠƒtƒ‰ƒNƒeƒBƒu (2018/7/21), ‹ž“s.

732061. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) …ť‘̂̉Á—î•Ď‰ť‚ĆŽ‹‹@”\. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): 2018ŠáŒőŠwƒ`ƒ…[ƒgƒŠƒAƒ‹ƒZƒ~ƒi[ (2018/7/28), “Œ‹ž.

732062. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (•×‹­‰ď) ”’“ŕáŽčp‚ɂ‚˘‚Ä. ”Ń“c‰Ă•F (Šá‰Č): ‘ĺ’ːť–ňˆăŽtľăٕ׋­‰ď (2018/8/24), _“ސě.

732063. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕu‰‰‰ď) ƒOƒ‰ƒiƒeƒbƒN‚ĚŽg—pŒoŒą‚ɂ‚˘‚Ä. ŽO‘îr”V1,2 (1‰Ą{‰ęŽs—§‚¤‚í‚Ü‚ż•a‰@, 2Šá‰Č): ‹ť˜a‘n–ň ‡Š ŽĐ“ŕu‰‰‰ď (2018/8/28), _“ސě.

732064. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) Ą, Ž„‚ލl‚Ś‚éROCK‘jŠQ–ň@ƒfƒBƒXƒJƒbƒT[. Š}Œ´łs (Šá‰Č): _“ŢěŒ§Ŕ’k‰ďuROCK‘jŠQ–ň‚ĚˆĘ’u‚Ă‚Ż‚đl‚Ś‚év(2018/9/20), _“ސě.

732065. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) Expert Panel Discussion `Cataract Surgery`@ƒpƒlƒŠƒXƒg. ”Ń“c‰Ă•F (Šá‰Č): ‘ć10‰ńŠá‰ČŽžŠłŒ¤‹†‰ď (2018/9/27), _“ސě.

732066. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ‹łˆçu‰‰@Ŕ’ˇ. –ö“c’q•F (Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

732067. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ƒXƒeƒB[ƒvŠp–ŒŠáE‰~Šp–ŒŠá‚É‚¨‚Ż‚éŠá“ŕƒŒƒ“ƒY“x”ŒvŽZ. ”Ń“‡@Œh (Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

732068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕu‰‰‰ď) –˘nŽ™–Ô–ŒÇ‚ɂ‚˘‚Ä. ’r“c“N–ç (Šá‰Č): ‹ť˜a‘n–ň (Š”) ŽĐ“ŕu‰‰‰ď (2018/10/9), _“ސě.

732069. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕu‰‰‰ď) ŹŽ™Šá‰Č‚ɂ‚˘‚Ä. ’r“c“N–ç (Šá‰Č): ‘ĺ’ːť–ň (Š”) ŽĐ“ŕ•×‹­‰ď (2018/10/23), _“ސě.

732070. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Šá‚Š‚çl‚Ś‚éŒđ’ĘˆŔ‘S. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć2‰ń‚ß‚Ş‚Ý‚Ě‰ď (2018/10/28), _“ސě.

732071. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰I@Ŕ’ˇ. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć9‰ńĂźŠá‰ČƒAƒJƒfƒ~[ (2018/11/1), _“ސě.

732072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ŕ’k‰ď) Ŕ’k‰ď@Ži‰ď. ŻŽiMs (Šá‰Č): Ŕ’k‰ď: —ΓŕáŽĄ—Ă‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg (2018/11/10), “Œ‹ž.

732073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzƒZƒ~ƒi[@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć1‰ńƒOƒ‰ƒEƒRƒXMIGSƒZƒ~ƒi[ (2018/11/10), “Œ‹ž.

732074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) đĄ‚ĚŽ‹_ŒoŽžŠł‚Ě˜b‘č. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć12‰ńƒIƒtƒTƒ‹ƒ~ƒbƒNƒtƒH[ƒ‰ƒ€ (2018/11/17), •xŽR.

732075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕu‰‰‰ď) Šp–ŒˆÚAp‚Ć”’“ŕáŽčp‚ɂ‚˘‚Ä. ‘ŠŕV‘ĺ•ă1,2 (1ŠC˜V–ź‘‡•a‰@, 2Šá‰Č): ‹ť˜a‘n–ň (Š”) ŽĐ“ŕu‰‰‰ď (2018/11/28), _“ސě.

732076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰1@Ŕ’ˇ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć58‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2018/12/13), _“ސě.

732077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć58‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2018/12/13), _“ސě.

732078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕŒ¤C‰ď) ”’“ŕá‚ɂ‚˘‚Ä’m‚Á‚Ä‚¨‚Ť‚˝‚˘‚ą‚Ć. ”Ń“‡@Œh (Šá‰Č): ‘ĺ’ːť–ňŽĐ“ŕŒ¤C‰ď (2018/12/21), “Œ‹ž.

732079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (TVƒtƒH[ƒ‰ƒ€) MIGS‚É‚¨‚Ż‚éƒgƒ‰ƒxƒNƒg[ƒ€Žčp‚ĚˆĘ’u‚Ă‚ŻEŽg‚˘•Ş‚Ż. ŻŽiMs (Šá‰Č): OTSUKA OPHTHALMIC SURGERY VIDEO LIVE (2019/1/10), “Œ‹ž.

732080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Šw‰ď•ń@ESCRS@2018. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć15‰ń‰~Šp–ŒŒ¤‹†‰ďŠwpƒ~[ƒeƒBƒ“ƒO (2019/2/2), _“ސě.

732081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —ΓŕáŽčpƒAƒbƒvƒf[ƒg`MIGS (Micro Invasive Glaucoma Surgery)`. Š}Œ´łs (Šá‰Č): ‘ĺ˜aŽsŠá‰Čˆă‰ďŠwpu‰‰‰ď (2019/2/5), _“ސě.

732082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ƒKƒ`ƒtƒ“_Šá‰t0.3%‚̐ťÜ“Á’Ľ‚ɂ‚˘‚Ä. ŻŽiMs (Šá‰Č): çŽőť–ňƒAƒhƒoƒCƒU[Dr. (2019/2/5), _“ސě.

732083. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰1@Ŕ’ˇ. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć6‰ń_“ސ쏬Ž™Šá‰ČE_ŒoŠá‰ČƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/2/7), _“ސě.

732084. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2@Ŕ’ˇ. ‰F’ĂŒŠŒ’ˆę1,2 (1_“ŢěŒ§Šá‰Čˆă‰ď•›‰ď’ˇ, 2Šá‰Č): ‘ć6‰ń_“ސ쏬Ž™Šá‰ČE_ŒoŠá‰ČƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/2/7), _“ސě.

732085. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçuŔ) _ŒoŠá‰ČŽžŠł|”wŒă‚ɉB‚ę‚鎞Šł‚đŒŠ“Ś‚ł‚Č‚˘‚˝‚߂Ɂ|. Îě@‹Ď (ˆă—ÉqśŠw•”): “ú–{Šá‰Čˆă‰ď‘ć76‰ńśŠU‹łˆçuŔ (2019/2/16), “Œ‹ž.

732086. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć4‰ńŽ‹Šoś—ŠwŠî‘bƒZƒ~ƒi[ (2019/2/17), _“ސě.

732087. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzľ‘ҍu‰‰@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć4‰ńŽ‹Šoś—ŠwŠî‘bƒZƒ~ƒi[ (2019/2/17), _“ސě.

732088. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—á•ń) ŠO‚ĚŠÖ—^‚Ş‹^‚í‚ę‚˝ŹŽ™Ž‹_Œo‰Š‚Ě2Ç—á. ’r“c“N–ç (Šá‰Č): ‘ć11‰ń_“ސěƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2019/2/23), _“ސě.

732089. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (•Â‰ď‚ĚŽŤ) •Â‰ď‚ĚŽŤ. ‰F’ĂŒŠŒ’ˆę1,2 (1_“ŢěŒ§Šá‰Čˆă‰ď•›‰ď’ˇ, 2Šá‰Č): ‘ć11‰ń_“ސěƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2019/2/23), _“ސě.

732090. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçƒZƒ~ƒi[) AIŽž‘ă‚ĚORT–˘—ˆ—\‘z}. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć2‰ń–k—˘‘ĺŠwŽ‹Šo‹@”\—Ă–@ŠwęU‘˛Œă‹łˆçƒZƒ~ƒi[ (2019/2/28), _“ސě.

732091. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Šá’ęŽĘ^ŽB‰e‚ĚQ&A. ‰i–ěKˆę (Šá‰Č): ‘ć8‰ń_“ŢěŒ§Ž‹”\ŒP—űŽm‚̉ď (2019/3/9), _“ސě.

732092. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ă‰ş’Ž‹–ƒáƒ‚đ’ć‚ľ‚˝•Đ‘¤Ť’†”][Ç‚Ě1Ç—á. •y‰Ş•q–ç1,2 (1‰Ą{‰ęŽs—§Žs–Ż•a‰@, 2Šá‰Č): ‘ć11‰ń“ŒŠC“šŠá‰ČŒ¤‹†‰ď (2019/3/9), _“ސě.

732093. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) “–ƒNƒŠƒjƒbƒN‚É‚¨‚Ż‚é–Ô–ŒĂ–Ź•ÂÇÇ (RVO) ‚ɑ΂ˇ‚鎥—Ð헪. Žs粋`Í1,2 (1_“ސ쎕‰Č‘ĺŠw•t‘Ž‰Ą•lƒNƒŠƒjƒbƒN, 2Šá‰Č): ‘ć11‰ń“ŒŠC“šŠá‰ČŒ¤‹†‰ď (2019/3/9), _“ސě.

732094. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰1@Ŕ’ˇ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć59‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2019/3/14), _“ސě.

732095. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2@Ŕ’ˇ ŻŽiMs (Šá‰Č): ‘ć59‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2019/3/14), _“ސě.

732096. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —ΓŕáŠÇ—‚É‚¨‚Ż‚鎥—Ă‚Ě‘Šú“ą“ü. ŻŽiMs (Šá‰Č): ŽD–yŠá‰ČW’k‰ď (2019/3/16), ŽD–y.

732097. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) <—Γŕá‚̍ŐVŒŸ¸> ‘OŠá•”OCT‚ĚŠˆ—p–@. Š}Œ´łs (Šá‰Č): ‘ć17‰ń‚¨‚Á‚ľ‚傢Šá‰ČŽčp‚̉ď (2019/3/16), ”Ž‘˝.

732098. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yƒI[ƒKƒiƒCƒU[z—Î‚ĚƒLƒYƒi…@ ŒŸ¸Ef’f‚Ő[‚ß‚é`‰˝‚Í‚Ć‚ŕ‚ ‚ę‹÷ŠpŒŸ¸!`ƒI[ƒKƒiƒCƒU[. ŻŽiMs (Šá‰Č): —΂ĚăJ2019 (2019/3/17), “Œ‹ž.

732099. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ˜VŠáŒ¤‹†‰ď@˜VŠáŽĄ—ĂNEW Topics@ICL‚É‚ć‚é˜VŽ‹‹¸ł. _’J˜aF (ˆă—ÉqśŠw•”): Tokyo Ophthalmology Summit 2019 (‘ć2‰ń“Œ‹žŠá‰ČƒTƒ~ƒbƒg2019) (2019/3/17), “Œ‹ž.

732100. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçuŔ) _ŒoŠá‰ČŽžŠł|”wŒă‚ɉB‚ę‚鎞Šł‚đŒŠ“Ś‚ł‚Č‚˘‚˝‚߂Ɂ|. Îě@‹Ď (ˆă—ÉqśŠw•”): “ú–{Šá‰Čˆă‰ď‘ć76‰ńśŠU‹łˆçuŔ (2019/3/30), •Ÿ‰Ş.

733227. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʉ‰‘č6`11@Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć10‰ń_“ސěŠá‰ČŠw‰ď (2018/5/27), _“ސě.

733228. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ƒGƒ^ƒ“ƒuƒg[ƒ‹“ŕ•ž‚ŞŒ´ˆö‚ĹƒŒ[ƒxƒ‹ˆâ“`ŤŽ‹_ŒoÇ‚đ”­Ç‚ľ‚˝‚ƍl‚Ś‚ç‚ę‚˝ˆę—á. ’†ŕV—S‘Ľ1, Îě@‹Ď2, ŒăŠÖ—˜–ž1, ŻŽiMs1, –Řč‡ˆę˜Y3, ź‘ş‰hˆę3 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3ş˜a‘ĺŠw“Ą‚Ş‹uƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@): ‘ć10‰ń_“ސěŠá‰ČŠw‰ď (2018/5/27), _“ސě.

733229. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚đŽ{s‚ľ‚˝ƒyƒ‹[ƒVƒhŠp–Œ•ĎŤ‚Ěˆę—á. ‚‹´ł‰p1, _’J˜aF2, ‹ŕŽRr‰î1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć10‰ń_“ސěŠá‰ČŠw‰ď (2018/5/27), _“ސě.

733230. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Šá“ŕƒŒƒ“ƒY‘}“üŠá‚É‚¨‚Ż‚鎊Šo‹üÜ’l‚Ć—‡ŠáŽ‹—Í. ‰ĄŠÖ—S‰ŔŽq1, ”Ń“c‰Ă•F1, ‹ŕŽRr‰î1, ”Ń“‡@Œh1, ]•—Ft1, ˆäă‰Ŕ–źŽq1, ŻŽiMs1 (1Šá‰Č): ‘ć10‰ń_“ސěŠá‰ČŠw‰ď (2018/5/27), _“ސě.

733231. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) CYCLO G6‚Ě’ZŠúŹŃ. ’Ň‘ň’C•F1, ź‘şˆęO1, Š}Œ´łs1, ’r“c“N–ç1, ]•—Ft1, —´ˆä‰‘Žq1, ŻŽiMs1 (1Šá‰Č): ‘ć10‰ń_“ސěŠá‰ČŠw‰ď (2018/5/27), _“ސě.

733232. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) TrabectomeŽčp—źŠáŽ{s—á‚É‚¨‚Ż‚鍶‰E‚̐ŹŃ‚Ě”äŠr. Š}Œ´łs (Šá‰Č): ‘ć5‰ńJapan ROCK Conference (2018/8/26), “Œ‹ž.

733233. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʉ‰‘č@Ŕ’ˇ. ”Ń“c‰Ă•F (Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733234. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) —ôEŒ´ś–Ô–Œ”—Ł‚ɑ΂ˇ‚éÉŽq‘ĚŽčpŒă‚ɉŠ”Á•‚Žî‚𐜂ś‚˝Ç—á‚ĚŒŸ“˘. ‚‹´‰ŘŽq1, t–ؐ’G1, ”Ń“‡@ˆť1, –ö“c’q•F1, ŻŽiMs1 (1Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733235. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Ĺ“_[“xŠg’ŁŒ^Šá“ŕƒŒƒ“ƒYTecnis symfony‘}“üŠłŽŇ‚ɑ΂ľ‚ÄŠá“ŕƒŒƒ“ƒYŒđŠˇ‚đs‚Á‚˝2—á. Šąě—˘ŠG1, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, ‰Í–ě—Y—ş1, ŻŽiMs1 (1Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733236. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) iStentŽčp‚Ě’ZŠúŹŃ. ‰Í–ě—Y—ş1, Š}Œ´łs1, ź‘şˆęO1, ’Ň‘ň’C•F1, ]•—Ft1, —´ˆä‰‘Žq1, ˆäă‰Ŕ–źŽq1, ŻŽiMs1 (1Šá‰Č): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733237. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ŠO‚ĚŠÖ—^‚Ş‹^‚í‚ęf’f‚É‹ę—ś‚ľ‚˝7Î’jŽ™‚ĚŽ‹_Œo‰Š. —´ˆä‰‘Žq1, Îě@‹Ď2, ’r“c“N–ç1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733238. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) V‚˝‚Čƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚ĚŽŽ‚Ý. ‚‹´ł‰p1, _’J˜aF2, ‰Í–ě—Y—ş1, ˆŔ“Ą˜a‰ĚŽq1, âV“Ą@Ę1, ‘ěG‹P1, ŻŽiMs1, X@—mÄ1,3, ‹{“c˜a“T3 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‹{“cŠá‰Č•a‰@): ‘ć54‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2018/10/4), _“ސě.

733239. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰)yŔ’ˇzˆę”ʍu‰‰@Ŕ’ˇ. ”Ń“c‰Ă•F (Šá‰Č): —ΓŕáƒJƒ“ƒtƒ@ƒŒƒ“ƒX`f—Ă‚ĚĹ‘Oü` (2018/11/30), “Œ‹ž.

733240. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠC˜V–ź‘‡•a‰@‚É‚¨‚Ż‚éƒ~ƒPƒ‹ƒi‚ĚŽg—pŒoŒą‚̍lŽ@. •ÄŽR@—Č (Šá‰Č): —ΓŕáƒJƒ“ƒtƒ@ƒŒƒ“ƒX`f—Ă‚ĚĹ‘Oü` (2018/11/30), “Œ‹ž.

733241. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) MIGS‚É‚¨‚Ż‚éŽg—p“_Šá–ň‚ĆŽčpŹŃ. Š}Œ´łs (Šá‰Č): —ΓŕáƒJƒ“ƒtƒ@ƒŒƒ“ƒX`f—Ă‚ĚĹ‘Oü` (2018/11/30), “Œ‹ž.

733242. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʉ‰‘č@Ŕ’ˇ. –ö“c’q•F (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

733243. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) “–‰@‚É‚¨‚Ż‚é—ΓŕáŽčpÇ—á‚ĚŒo‰ß•ń. ‰Í–ě—Y—ş (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

733244. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ‹ŕ‘Ž•Đ‚É‚ć‚éŠá‹…”j—ô‚đ‚Ť‚˝‚ľ‚˝1—á. ŠFě—FŒ› (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

733245. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ‰“Ž‹—}§ŽĄ—Ă“IŠp–ŒŘœp (Hyperopia Correcting-PTK) ‚Ş‘tŒ÷‚ľ‚˝1—á. ‘ěG‹P (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

733246. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ŠO‚ĚŠÖ—^‚Ş‹^‚í‚ę‚˝10Î’jŽ™‚̍RMOGR‘Ě—zŤŽ‹_Œo‰Š‚Ě1—á. ’r“c“N–ç (Šá‰Č): ‘ć16‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2019/1/17), _“ސě.

733247. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”’“ŕáŽčpŒă‚Ě‘˝Ĺ“_ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚É‚ć‚é˜VŽ‹‹¸ł. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć7‰ń–ł…ť‘ĚŠáŽčpŽĄ—ĂŒ¤‹†‰ď (IOL“ńŽŸ‘}“ü‚̉ď) (2019/3/16), “Œ‹ž.

733248. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰)yŔ’ˇzˆę”ʍu‰‰@‘ć“ń•”@Ŕ’ˇ. ”Ń“c‰Ă•F (Šá‰Č): ‘ć7‰ń–ł…ť‘ĚŠáŽčpŽĄ—ĂŒ¤‹†‰ď (IOL“ńŽŸ‘}“ü‚̉ď) (2019/3/16), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-540008. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y•˝Ź27 (2015) ”N“x` •˝Ź29 (2017) ”N“x Œúś˜J“­‰ČŠwŒ¤‹†”ď•â•‹ŕ Žž•aEáŠQ‘΍ôŒ¤‹†•Ş–ě “ďŽĄŤŽžŠł“™­ôŒ¤‹† (“ŤŽžŠł­ôŒ¤‹†)z_Œo–ƉuŠw“IŽ‹“_‚É‚ć‚é“ŤŽ‹_Œo‰Š‚̐f’fŠî€ěŹ (H27-““™ (“ď)-ˆę”Ę-023). Œ¤‹†‘ă•\ŽŇ: Îě@‹Ď1, Œ¤‹†•Ş’SŽŇ: ŽO‘ş@ŽĄ, ‹g•yŒ’Žu, •~“‡ŒhŒĺ, •˝‰Ş”ü‹I ’†”nGŽ÷,–Ń’Ë„Ži, ’†‘ş@˝, ŒăŠÖ—˜–ž2, “c’†œ¨Žq, Œ¤‹†‹Ś—ÍŽŇ: ŽRă–žŽq2, Ż@‰Ŕ–F3, áÁ‰ş‹I”ü‘ă2, ˆÉ“Ą@Œő (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3‰qś): •˝Ź27 (2015) ”N“x` •˝Ź29 (2017) ”N“x Œúś˜J“­‰ČŠwŒ¤‹†”ď•â•‹ŕ Žž•aEáŠQ‘΍ôŒ¤‹†•Ş–ě “ďŽĄŤŽžŠł“™­ôŒ¤‹†(“ŤŽžŠł­ôŒ¤‹†) ‘Š‡Œ¤‹†•ń‘ 2018/3.


Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠw

[Šwp˜_•ś]

110324. [Œ´’˜] A retrospective study of treatment for curative synchronous double primary cancers of the head and neck and the esophagus. Okamoto T1, Katada C2, Komori S3, Yamashita K4, Miyamoto S1, Kano K1, Seino Y1, Hosono H1, Matsuba H, Moriya H5, Sugawara M6, Azuma M2, Ishiyama H3, Tanabe S7, Hayakawa K3, Koizumi W2, Okamoto M1, Yamashita T1: Auris Nasus Larynx 2018/10; 45 (5): 1053-60. (‰Ş–{—ˇl1, Œ˜“ce—˜2, ŹXłŽq3, ŽR‰şŒpŽj4, ‹{–{r•ă1, ‰Á”[Fˆę1, ´–ě—R”y1, ×–ě_Žm1, X’JGŒő5, ›Œ´[L6, “Œ@’q2, ÎŽR”ŽžŠ3, “c糁@‘7, ‘ě˜ad3, Źň˜aŽO˜Y2, ‰Ş–{–ql1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ, 3•úŽËü (Žîá‡), 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5ă•”Á‰ťŠÇŠO, 6–ňÜ•”, 7V˘‹Iˆă—ÁEć’[ˆă—Ă)

110325. [Œ´’˜] Classification of tumors by imaging diagnosis and preoperative fine-needle aspiration cytology in 120 patients with tumors in the parapharyngeal space. Matsuki T1, Miura K, Tada Y, Masubuchi T, Fushimi C, Kanno C, Takahashi H, Kamata S, Okamoto I, Miyamoto S1, Yamashita T1: Head Neck 2019/5; 41 (5): 1277-81. doi: 10.1002/hed.25552. Epub 2019 Jan 8. (ź–؁@’1, ‹{–{r•ă1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO)

120030. [Œ´’˜] ‰îŒě˜VlŽ{Ý“üŠŽŇ‚Ě•â’ŽŠíŽŽ’Ž ‘ć“ń•ń|•â’ŽŠí‘•—p‚ĚŒř‰Ę|. ˆäă—ŠG1, —é–ŘŒbŽq2, ”~Œ´KŒb1, `@ŽáŘ2, ´…@•˝, ˛–ě@”Ł2, ‰Ş–{–ql1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2ˆă—ÉqśŠw•”): Audiology Japan 2018/6; 61 (3): 187-1894.

120031. [Œ´’˜] ‰îŒě˜VlŽ{Ý“üŠŽŇ‚Ě•â’ŽŠíŽŽ’Ž ‘ćŽO•ń|•â’ŽŠí“K‡‚ĆŽŽ’Ž‚ĚŒ‹‰Ę|. ”~Œ´KŒb1, —é–ŘŒbŽq2, ˆäă—ŠG1, `@ŽáŘ2, ´…@•˝, ˛–ě@”Ł2, ‰Ş–{–ql1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2ˆă—ÉqśŠw•”): Audiology Japan 2018/6; 61 (3): 195-202.

120032. [Œ´’˜] Ž‘ą‚ˇ‚é•˝táŠQ‚É‚¨‚Ż‚é–k—˘‘ĺŠw•űŽŽ‚ß‚Ü‚˘ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ć‚ť‚Ě•]‰ż. —Ž‡@“Ö1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): Equilibrium Res 2019/2; 78 (1): 16-22.

120033. [Œ´’˜] ŒűoŠŕŘœŒăÄŒš‚É‚¨‚Ż‚éăœ‰ş‹Ř”ç•Ů‚Ě—L—pŤ|‘O˜r”ç•Ů, ‘OŠO‘¤‘ĺ‘Ú”ç•Ů‚Ć‚Ě”äŠr|. ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Ş–{—ˇl1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): “Şčň•”ŠO 2019/2; 28 (3): 293-300.

120034. [Œ´’˜] ~‰şŤ‰óŽ€ŤcŠu‰Š‚đ‚Ť‚˝‚ľ‚˝[čň•”Š´őÇ‚Ě—Ő°“IŒŸ“˘. –Ř‘şŽé—˘1, ‹{–{r•ă1, ×–ě_Žj1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): “ú–{‹CŠÇH“š‰ČŠw‰ď‰ď•ń 2019/2; 70 (1): 9-16.

120035. [Œ´’˜] ƒJƒjƒ…[ƒŒŽhŒƒ‚É‚ć‚é‹CŠÇ‹ˇó‚ɑ΂ľŽ­–쎎ş–ĺ•Â˝p‚đŽ{s‚ľ‚˝Ç—á. ´–ě—R”y1, Ž­–ě^l1, ×–ě_Žj1, ‘ĺŒ´‘ěĆ1, ŒĂ–ŘČŒá1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): “Şčň•”ŠO‰Č 2019; 28 (3): 301-6.

520018. [‘ŕ] “Şčň•”ÄŒš‚É‚¨‚Ż‚é‹ÇŠ”ç•Ů‚Ě–đŠ„. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@ˆôA‰Č“W–]2018/12; 61 (6): 300-9.

521022. [‰đŕ] GorlinÇŒóŒQ (•ę”ÁŠî’ę×–EŠŕÇŒóŒQ). V“c‹`—m1, —é–Ř—§r1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@ˆôA‰Č—Տ° 2019/3; 112 (3): 144-5.

522141. [uŔ]y“ÁW: Žčp‚É•K—v‚Č‰ć‘œf’f|ŒűoEˆô“Ş•Ňz[ˆô“Ş] ‰şˆô“Ş—œóŠ×‰šá‘“Eop. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): JOHNS 2018/5; 34 (5): 639-44.

522142. [uŔ]y˜AÚ: ŠO—ˆf—Ă‚É‚¨‚Ż‚鎄‚̏ˆ’uzˆôA“Ş‚Ěˆ’u2: Œű“ŕ‰Š‚ɑ΂ˇ‚鏈’u. ´–ě—R”y1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): JOHNS 2018/6; 34 (6): 795-9.

522143. [uŔ]yHPVƒƒNƒ`ƒ“‚đ‰ü‚߂čl‚Ś‚é|ÚŽíŠŠ§‚̍ĩJ‚ÉŒü‚Ż‚ā|z2. ’†ˆô“Ş‚Ş‚ń‚̉uŠw‚ĆŽĄ—Ă. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): ŽY•wl‰Č‚ĚŽŔŰ 2018.9; 67 (9): 949-54.

522144. [uŔ]y“ÁW:ŒŠ“Ś‚ľ‚Ä‚Í‚Č‚ç‚Č‚˘Ž¨•@ˆôA‰ČŽžŠł@‚ą‚ń‚ČÇ—á‚É‚Í—v’ˆÓ!zĄŒűoEˆôA“ށE“Şčň•”—Ěˆć@ˆŸ‹}Ťbó‘B‰Š‚ž‚ĆŽv‚Á‚Ä‚˘‚˝‚ç‹}Ť‰ť”^Ťbó‘B‰Š‚ž‚Á‚˝! ´–ě—R”y1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰Č 2018/11; 90 (12): 1058-61.

522145. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€5: ’†ˆô“Ş‘¤•ÇŠŕ‚ĚŽĄ—Ð헪z’†ˆô“Ş‘¤•ÇŠŕŽĄ—Ă‚É‚¨‚Ż‚éŒoŒű“IŽčp‚Ě–đŠ„. ŽR‰ş@‘ń1, ‹{–{r•ă1, ´–ě—R”y1, ‰Ş–{—ˇl1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1 (1Ž¨•@ˆôAE“ŞčňŠO): “Şčň•”Šŕ 2018/12; 44 (3): 263-8.

522146. [uŔ]y“ÁW: ‚í‚Š‚č‚₡‚­“`‚Ś‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒgzA“ށE‹CŠÇŽčp‚É‚¨‚Ż‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg@‹CŠÇE‹CŠÇŽxˆŮ•¨œ‹Žp. ‘ĺŒ´‘ěĆ1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): JOHNS 2019/2; 35 (2): 223-5.

530011. [‚ť‚Ě‘ź (Letter to the editor)] ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media. Ohta N, Ueki S, Konno Y, Hirokawa M, Kubota T, Tomioka-Matsutani S, Suzuki T, Ishida Y, Kawano T, Miyasaka T, Takahashi T, Suzuki T1, Ohno I, Kakehata S, Fujieda S: Allergol Int 2018/7; 67 (3): 414-6. (—é–Ř—§r1: 1Ž¨•@ˆôAE“ŞčňŠO)

[’˜@‘]

620123. [Šwp‘ (•Ş’SŽˇ•M)]yŽ¨•@ˆôA‰Č‚É‚¨‚Ż‚éVśŽ™E“ű—cŽ™EŹŽ™‚Ö‚Ě“Š–ň|update|(ENTONI No218‘Š§†)zIII. Ž¨•@ˆôA‰ČŽžŠł‚ɑ΂ˇ‚é–ň•¨—Ă–@@14. čň•”ƒŠƒ“ƒpß‰Š, [čň•”Š´őÇ, ˆôŒă”^á‡, p. 149-55. ‘ĺŒ´‘ěĆ (Ž¨•@ˆôAE“ŞčňŠO), •Ň: Žç–{—ĎŽq, ‘S“ú–{•a‰@o”ʼnď, “Œ‹ž, 2018/4”­s.

620124. [Šwp‘ (•Ş’SŽˇ•M)]yŠłŽŇE‰Ć‘°‚Ö‚Ěŕ–žƒKƒCƒh@ł‚ľ‚­“`‚Ś, ”[“ž‚đˆř‚Ťo‚ľ, ”ť’f‚đ‘Ł‚ˇ‚˝‚ß‚É (Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰Č2018”N4ŒŽ‘Š§†zII. ‚ß‚Ü‚˘‚ĆŠç–ʐ_Œo–ƒáƒ‚Ě‚ą‚Ɓ@ˆăŽtEˆă—ĂŽŇ‚Š‚çŕ–ž‚ľ‚Ä‚¨‚Ť‚˝‚˘‚ą‚Ɓ@“ŤƒƒjƒG[ƒ‹•a‚ɑ΂ˇ‚鐜ŠˆŽw“ą, p.96-7. ’ˇŔ‰p–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Ž¨•@ˆôAE“ŞčňŠO), ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620125. [Šwp‘ (•Ş’SŽˇ•M)]yuƒCƒ‰ƒXƒgv‚ß‚Ü‚˘‚ĚŒŸ¸ ‰ü’ů‘ć3”ŁzVII ‚ß‚Ü‚˘E•˝táŠQ‚đ‚Ť‚˝‚ˇŽžŠł‚ĚŠTŠĎ@A ––˝‘O’ëŒnŽžŠł@3 “ந‰Š, p.104-5. ’ˇŔ‰p–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Ž¨•@ˆôAE“ŞčňŠO), •Ň: ˆę”ĘŽĐ’c–@l “ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď, f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2018/6”­s.

620126. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŽĄ—ĂŽwj (‘ć4”Ĺ)zŽžŠł•Ń@6 A“ށE‹CŠÇEH“šEčň•”ŽžŠł@25. ‹h‹t, p.435-5. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO), ŠÄC: XŽR@Š°, •Ň: ‘ĺXFˆę,“ĄŽ}dŽĄ, Ź“‡”ŽŒČ, ’–Œ´G“T, ˆăŠw‘‰@, “Œ‹ž, 2018/6”­s.

620127. [Šwp‘ (•Ş’SŽˇ•M)]y‚݂݁E‚͂ȁE‚̂ǐf’f@‚ą‚ę‚ž‚Ż‚͍s‚Á‚Ä‚Ů‚ľ‚˘Œˆ‚ߎč‚ĚŒŸ¸ (ENTONI No.223‘‘ĺ†)zI. Ž¨ŽžŠłE’ŽŠoŽžŠł@5. •â’ŽŠí‚đŠŠ‚ß‚é‚ׂŤ‚Š|ˆę‘¤Ť“ď’Ž‚ĆŒy“x“ď’Ž‚ւ̑Ήž|, p. 22-8. –q@“ÖŽq(“ÁWŽ¨•@ˆôAE“ŞčňŠO), •Ň: â“cr•ś, ‘S“ú–{•a‰@o”ʼnď, “Œ‹ž, 2018/9”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713154. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Prognosticators kinematic characteristics of deglutition sfter esophagectomy with gastric tube reconstruction. Seino Y1, Moriya H2, Yamashita T1: 12th Congress of the European Laryngological Society (2018/5/16-19), London, UK. (´–ě—R”y1, X’JGŒő2, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO, 2ă•”Á‰ťŠÇŠO)

713155. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Outcomes of Autologous Buccal Fat injection Laryngoplasty in Unilateral Vocal Cord Paralysis. Hosono H1, Seino Y1, Yamashita T1: 12th Congress of the European Laryngological Society (2018/5/16-19), London, UK. (×–ě_Žj1, ´–ě—R”y1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO)

722192. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ’´‚—ŽĐ‰ď‚É‚¨‚Ż‚é’ŽŠoáŠQ‚Ě–â‘č“_. ˛–ě@”Ł (ˆă—ÉqśŠw•”): ‘ć44‰ń“ú–{ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“áŠQŠw‰ďŠwpu‰‰‰ď (2018/5/12), ‘Š–ÍŒ´.

722193. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ’†ˆô“ށE‰şˆô“ŞŠŕ‚ĚŒoŒű“IŽĄ—Ă. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): ‘ć119‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/6/2), ‰Ą•l.

722194. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) •›•@oƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ě—Ő°‘œ|fungus ball, ZŒ^, AFRS‚ɂ‚˘‚ā|. —é–Ř—§r (Ž¨•@ˆôAE“ŞčňŠO): ‘ć92‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď/‘ć66‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď‡“ŻŠw‰ď (2018/6/2), ‰ŞŽR.

722195. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’†ˆô“Ş‘¤•ÇŠŕŽĄ—Ă‚É‚¨‚Ż‚éŒoŒű“IŽčp‚Ě–đŠ„. ŽR‰ş@‘ń1, ‹{–{r•ă1, ´–ě—R”y1, ‰Ş–{—ˇl1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

722196. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y’†ˆô“Ş‘¤•ÇŠŕ‚ĚŽĄ—Ð헪z’†ˆô“Ş‘¤•ÇŠŕ‚É‚¨‚Ż‚éŒoŒű“IŽčp‚Ě–đŠ„. ŽR‰ş@‘ń1, ‹{–{r•ă1, ´–ě—R”y1, ‰Ş–{—ˇl1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/15), “Œ‹ž.

722197. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yA“ŞŠŕ‚̍A“މˇ‘śŽĄ—Á|“K‰ž‚ĆŒŔŠE‚ɂ‚˘‚ā|zA“ވŸ‘S“Eop (supracricoid laryngectomy) ‚Ě“K‰ž‚ĆŒŔŠE‚ɂ‚˘‚Ä. ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć31‰ń“ú–{A“Ş‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2019/3/8), ‹v—Ż•Ä.

723738. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •@ƒAƒŒƒ‹ƒM[ŠłŽŇ‚É‚¨‚Ż‚é•@•Â‚Ć“úíśŠˆŽxá“x‚ĚŠÖŒW. ‘ĺ–ŘŠ˛•ś (Ž¨•@ˆôAE“ŞčňŠO): ‘ć119‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/5/31), ‰Ą•l.

723739. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O“ą“ü‰ťŠw—Ă–@‚É‚ć‚č•a—Šw“IŠŽ‘S‘tŒ÷‚Ş“ž‚ç‚ę‚˝“Şčň•”ŠŕÇ—á‚ĚŒŸ“˘. ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Ş–{—ˇl1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

723740. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ş–ĺŠŕT2Ç—á‚ɑ΂ˇ‚éS-1•š—p‰ťŠw•úŽËü—Ă–@‚ĚŽĄ—ÐŹŃ. —é–ŘˆťŽq1, ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

723741. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éTPF“ą“ü‰ťŠw—Ă–@‚ĚŽĄ—ÐŹŃ. ’ç@ăĕ˝1, ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Á”[Fˆę1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

723742. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é“ŕŽ‹‹ž‚đ—p‚˘‚˝ŒoŒű“IŘœp‚̏pŽŽ•ĘŒŸ“˘. ‰Á”[Fˆę1, Œ˜“ce—˜2, ‰Ş–{—ˇl1, ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

723743. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é“Şčň•”Šŕ‚ɑ΂ˇ‚éNivolumab“Š—^Ç—áÇ—á‚ĚŒŸ“˘. ź–؁@’1, ‹{–{r•ă1, ´–ě—R”y1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2018/6/14), “Œ‹ž.

723744. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DŽ_‹…Ť’†Ž¨‰Š‚É‚¨‚Ż‚éeosinophil extracellular DNA trap cell death (EETosis). ‘ž“cL’j, A–؏dŽĄ, ’ˇät‘ĺŽm, —é–Ř—§r1, —é–Ř—S•ă, ‚—œ–F’, “ĄŽ}dŽĄ (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć67‰ń“ú–{ƒAƒŒƒ‹ƒM[Šw‰ďŠwp‘ĺ‰ď (2018/6/23), –‹’Ł.

723745. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒVƒF[ƒOƒŒƒ“ÇŒóŒQ‚ɍ‡•š‚ľ‚˝ˆŮŽžŤ—ź‘¤ŤƒKƒ}Žî—á. ‹{–{r•ă1, —é–ŘˆťŽq1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć80‰ńŽ¨•@ˆôA‰Č—Տ°Šw‰ď‘‰ďEŠwpu‰‰‰ď (2018/6/29), ‰Ą•l.

723746. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚鏬Ž™ˆô“ŞŠO69—á‚ĚŒŸ“˘. ”g‘˝–ě‰l‘ž1, ‘ĺŒ´‘ěĆ1, –q@“ÖŽq1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć13‰ń“ú–{ŹŽ™Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/7/13), ‰Ą•l.

723747. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Mycobacterium avium ‚É‚ć‚é—ź‘¤čň•”ƒŠƒ“ƒpß‰Š‚đ‚Ť‚˝‚ľ‚˝1—cŽ™—á. ‘ĺŒ´‘ěĆ1, –q@“ÖŽq1, ”g‘˝–ě‰l‘ž1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć13‰ń“ú–{ŹŽ™Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/7/13), ‰Ą•l.

723748. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •@ƒAƒŒƒ‹ƒM[ŠłŽŇ‚É‚¨‚Ż‚鍂’ŁH‰–…‚É‚ć‚é•@oôňŒř‰Ę. ‘ĺ–ŘŠ˛•ś1, —é–Ř—§r1, ‹gŽR—F“ń, ‚–ě@čń (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć6‰ń“ú–{Ž¨•@ˆôA‰ČŠ´őÇEƒGƒAƒƒ]ƒ‹Šw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/7), ‹ŕ‘ň.

723749. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •@ƒAƒŒƒ‹ƒM[ŠłŽŇ‚É‚¨‚Ż‚鍂’ŁH‰–…‚É‚ć‚é•@oôňŒř‰Ę. ‘ĺ–ŘŠ˛•ś1, —é–Ř—§r1, ‹gŽR—F“ń, ‚–ě@čń (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć6‰ń“ú–{Ž¨•@ˆôA‰ČŠ´őÇEƒGƒAƒƒ]ƒ‹Šw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/8), ‹ŕ‘ň.

723750. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éG“ŽüˆÍ”^ᇏǗá‚ĚŒŸ“˘. “Ąě’ź–ç1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć6‰ń“ú–{Ž¨•@ˆôA‰ČŠ´őÇEƒGƒAƒƒ]ƒ‹Šw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/8), ‹ŕ‘ň.

723751. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹CŠÇE‚đ—L‚ˇ‚éš‹‰şáŠQŠłŽŇ‚Ěš‹‰şƒŠƒnƒrƒŠ‚Ć‹CŠÇEŠÇ—. ´–ě—R”y1, —é–Ř—§r1, ‰Ş•”‘•c, ă“cˆťŽq, “’–{@“ľ, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć24‰ń“ú–{ŰHš‹‰şƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwp‘ĺ‰ď (2018/9/9), ĺ‘ä.

723752. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž•Œ´ŤŠp‰ť‚Ě‚¤–E‚ɑ΂ľ‚ÄESS‚đŽ{s‚ľ‚˝GorlinÇŒóŒQ‚Ě1—á. V“c‹`—m, —é–Ř—§r1, ŽR‰ş@‘ń1, ‘ĺ–ŘŠ˛•ś1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć57‰ń“ú–{•@‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/27), ˆŽě.

723753. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž•Œ´ŤŠp‰ť‚Ě‚¤–E‚ɑ΂ľ‚ÄESS‚đŽ{s‚ľ‚˝GorlinÇŒóŒQ‚Ě1—á. V“c‹`—m, —é–Ř—§r1, ŽR‰ş@‘ń1, ‘ĺ–ŘŠ˛•ś1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć57‰ń“ú–{•@‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/28), ˆŽě.

723754. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •@•ÂŠłŽŇ‚É‚¨‚Ż‚é“úí‚Ě•@o‹ÇŠ—Ă–@‚Ě‘I‘đ‚ɂ‚˘‚Ä. ‘ĺ–ŘŠ˛•ś1, ‘ĺ‹´Œ’‘ž˜Y1, ‹{‰şŒ\ˆę1, ’†‘ş‹gŹ1, —é–Ř—§r1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć57‰ń“ú–{•@‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/9/29), ˆŽě.

723755. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ʏŠƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“—˜—p‚—îŽŇ‚Ě•â’ŽŠíŽŽ’Ž. —é–ŘŒbŽq1, ˆäă—ŠG2, ”~Œ´KŒb2, `@ŽáŘ1, ´…@•˝, ˛–ě@”Ł1, ’†ě‹Mm2, ŽR‰ş@‘ń2 (1ˆă—ÉqśŠw•”, 2Ž¨•@ˆôAE“ŞčňŠO): ‘ć63‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/10/18), _ŒË.

723756. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é•â’ŽŠí‘•—pŽŇ‚ĚƒtƒBƒbƒeƒ“ƒOó‹ľ‚Ě•ŞÍ. ŒĂ–ŘČŒá1, ˛–ě@”Ł2, –q@“ÖŽq1, ˆäă—ŠG1, ”~Œ´KŒb1, Œ´@—R‹I2, —é–ŘŒbŽq2, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2ˆă—ÉqśŠw•”): ‘ć63‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/10/18), _ŒË.

723757. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă•”Á‰ťŠí“ŕŽ‹‹žŒŸ¸‚É‚¨‚Ż‚鉺ˆô“ŞŠĎŽ@‚Ĺ‚Ěƒoƒ‹ƒTƒ}ƒEƒX‚Ě—L—pŤ‚ĚŒŸ“˘. ×–ě_Žj1, Œ˜“ce—˜2, –Ř‘şŽé—˘1, ’ç@ăĕ˝1, ‰Á”[Fˆę1, ´–ě—R”y1, ‹{–{r•ă1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ): ‘ć70‰ń“ú–{‹CŠÇH“š‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2018/11/8), •iě.

723758. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “நáŠQ‚ĆƒXƒgƒŒƒX‚ĚŠÖ˜AŤ‚̉𖞁|IP3Žó—e‘Ětype-1 KOƒ}ƒEƒX‚ĚBoettcher×–E‚Ě×–E“ŕŒ`‘Ô‚ĚŒŸ“˘|. ’ˇŔ‰p–ž1,2, Ö“Ą—Yˆę˜Y, ’†ě‹M”V2, —Ž‡@“Ö2, “ż‘Œú“ń, ŒäŽqŽÄŽ•F (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Ž¨•@ˆôAE“ŞčňŠO): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 451.

723759. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éVEMP‚đ—p‚˘‚˝‹…‘Ě”XE—‘Œ`”X‚Ě‹@”\’ቺ‚É‚ć‚éÇó‚ĚŒŸ“˘. “c‘şš–ç1, —Ž‡@“Ö1, ’†ě‹M”V1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 451.

723760. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”­ÇŠú•Ę‚É•Ş‚Ż‚˝ƒƒjƒG[ƒ‹•a‚Ě—ź‘¤‚Ě’Ž—Í•Ď“Ž•‚ɂ‚˘‚Ä‚ĚŒŸ“˘. V“c‹`—m, ’†ě‹M”V1, —Ž‡@“Ö1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 462.

723761. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é’x”­Ť“ŕƒŠƒ“ƒp…Žî‚Ě—Ő°“IŒŸ“˘. ’†‘ş‹gŹ1, —Ž‡@“Ö1, ’†ě‹M”V1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 466.

723762. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒjƒG[ƒ‹•a‚ĆŒŒˆł‚ĚŒXŒü. ’†ě‹M”V1, —Ž‡@“Ö1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 474.

723763. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éŒđ’ĘŽ–ŒĚŒă‚Ě‚ß‚Ü‚˘‚Ě—Ő°“IŒŸ“˘. —Ž‡@“Ö1, ’†ě‹M”V1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć77‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2018/11/29), ŽRŒű, —\eW: Equilibrium Res 2018; 77 (5): 480.

723764. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šg‘ĺA“Ş‘S“EoŒă‚ɃIƒgƒKƒC‰ş”ç•Ů‚É‚ć‚éˆô“ލČš‚đs‚Á‚˝‚—îisş–ĺăŠŕ‚Ě2—á. ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć29‰ń“ŞčňŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2019/1/25), ĺ‘ä.

723765. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –j‹Ř”S–Œ•ŮE–j•”Ž‰–b‘Ě•Ů‚É‚ć‚éÄŒš‚đs‚Á‚˝’†ˆô“ޏă•ÇŠŕ‚Ě1—á. –ŕŽR•Ű1, ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Ş–{—ˇl1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć29‰ń“ŞčňŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2019/1/25), ĺ‘ä.

723766. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A“ŞŠŕf’f‚É‚¨‚Ż‚éŠg‘ĺNBIŠĎŽ@‚Ě—L—pŤ|Šg‘ĺNBIŠĎŽ@‚Ć”’FŒő‚Ć”ńŠg‘ĺNBIŠĎŽ@‚Ć‚Ě”äŠr|. ×–ě_Žj1, Œ˜“ce—˜2, –Ř‘şŽé—˘1, ’ç@ăĕ˝1, ‰Á”[Fˆę1, ´–ě—R”y1, ‹{–{r•ă1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ): ‘ć31‰ń“ú–{A“Ş‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2019/3/7), ‹v—Ż•Ä.

723767. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚Ĺ‚Ěˆę‘¤Ťş‘Ń–ƒáƒ‚ɑ΂ˇ‚鐺‘Ń“ŕŽŠ‰ĆŽ‰–b’“üp‚ĚŽć‚č‘g‚Ý. –Ř‘şŽé—˘1, ×–ě_Žj1, ´–ě—R”y1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć31‰ń“ú–{A“Ş‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2019/3/7), ‹v—Ż•Ä.

723768. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •úŽËü—Ă–@Œă‚Ě“Şčň•”‚Ş‚ńŠłŽŇ‚ŞŒoŒűŽŠ—§‚đ‰Ę‚˝‚ľ‚Ä‚ŕH‚ׂç‚ę‚Č‚˘‚Ć‘i‚Ś‚éS—“I—vˆö‚ĚŒŸ“˘. “’–{@“ľ, ěŠÔŒ’”V•, ‹g–ěáÁ—Žq, ´–ě—R”y1, ŽR‰ş@‘ń1, ‰Ş•”‘•c, ă“cˆťŽq (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{š‹‰şˆăŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2019/3/8), ‹v—Ż•Ä.

723769. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹CŠÇE‚đ—L‚ˇ‚éš‹‰şáŠQŠłŽŇ‚Ěš‹‰şƒŠƒnƒrƒŠ‚Ć‹CŠÇEŠÇ—. ´–ě—R”y1, —é–Ř—§r1, ‰Ş•”‘•c, ă“cˆťŽq, “’–{@“ľ, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć42‰ń“ú–{š‹‰şˆăŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2019/3/8), ‹v—Ż•Ä.

731099. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “Şčň•”Šŕ‚ɑ΂ˇ‚é’áNP‰ť‚ĚŽŽ‚Ý. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): ‘ć147‰ńŒä’ƒƒm…Ž¨•@ˆôAE“Şčň‰ČŽĄ—ĂŒ¤‹†‰ď (2018/5/10), “Œ‹ž.

731100. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “Şčň•”Šŕ‚Ě’áNPŽĄ—Ă‚đ–ÚŽw‚ľ‚Ä. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): •˝Ź30”N“xŒcŽ¨‰ďŠwpu‰‰‰ď (2018/5/19), “Œ‹ž.

731101. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •@ƒAƒŒƒ‹ƒM[‚Ć•›•@oŽžŠł`V‹KRƒqƒXƒ^ƒ~ƒ“–ň‚đŠÜ‚߂ā`. —é–Ř—§r (Ž¨•@ˆôAE“ŞčňŠO): ‘Š–ÍŒ´ŽsŽ¨•@‰Čˆă‰ďŠwpu‰‰‰ď (2018/11/22), ‘Š–ÍŒ´.

731102. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒƒjƒG[ƒ‹•a‚̐f’f‚ĆŽĄ—Ă. ’ˇŔ‰p–ž1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Ž¨•@ˆôAE“ŞčňŠO):“ú–{Ž¨•@ˆôA‰ČŠw‰ď_“ŢěŒ§’n•ű•”‰ďŠwpW‰ď (2019/1/19), ‰Ą•l.

731103. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‡–°Žž–łŒÄ‹z‚É‚¨‚Ż‚é•@ŒÄ‹z‚ĚŠÖ—^. ‘ĺ–ŘŠ˛•ś (Ž¨•@ˆôAE“ŞčňŠO): ‘ć32‰ń‡–°ŒÄ‹záŠQŒ¤‹†‰ďŽ¨•@ˆôA‰Č•”‰ď (2019/2/16), •iě.

732101. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçƒZƒ~ƒi[) “–‰Č‚É‚¨‚Ż‚鏬Ž™ˆô“ŞŠO69—á‚ĚŒŸ“˘. ”g‘˝–ě‰l‘ž (Ž¨•@ˆôAE“ŞčňŠO): ‘ć12‰ń‘Š–ÍŒ´DRIAOMSu‰‰‰ď (2018/5/24), ’Ź“c.

732102. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (WebƒZƒ~ƒi[) “Şčň•”ŠO‰Čˆă“IŽ‹“_‚Š‚猊‚˝ŞŽĄ•s”\Šŕ‚É‚¨‚Ż‚éƒjƒ{ƒ‹ƒ}ƒu‚Ě—§‚żˆĘ’u|‚Ç‚Ě—l‚ČŘ—á‚ÉŽg‚¤‚ׂŤ‚Š|. ‹{–{r•ă (Ž¨•@ˆôAE“ŞčňŠO): ƒIƒvƒW[ƒ{40minƒŒƒNƒ`ƒƒ[ (“Şčň•”Šŕ) (2018/7/18), –k—˘.

732103. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (WebƒZƒ~ƒi[) “–‰@‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜŽĄ—Ă‚ĚŽŔŰ. ‹{–{r•ă (Ž¨•@ˆôAE“ŞčňŠO): ‘˝–€“Şčň•”ŽîᇃGƒŠƒAWebƒZƒ~ƒi[ (2018/9/14), —§ě.

732104. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçƒZƒ~ƒi[) ‰Á—î‚Ć‚ß‚Ü‚˘E•˝táŠQ. —Ž‡@“Ö (Ž¨•@ˆôAE“ŞčňŠO): •˝Ź30”N“xŽs–Ż‘ĺŠw (–k—˘‘ĺŠwƒR[ƒX) (2018/10/24), ‘Š–ÍŒ´.

732105. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€)yA“މˇ‘śŽĄ—Ă‚ĚŽ¸”s—á‚ÉŠw‚ԁzŠOŘŠJA“Ş•”•ŞŘœŒă‚ĚŽ¸”s—á. ‹{–{r•ă1, ´–ě—R”y1, ź–؁@’1, ‰Ş–{—ˇl1, ‰Á”[Fˆę1, ’ç@ăĕ˝1, —é–ŘˆťŽq1, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć11‰ńA“Ş‹@”\‰ˇ‘śŽĄ—ĂŒ¤‹†‰ď (2018/10/27), •iě.

733249. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éA“ŞŠŕT2NOÇ—á‚ĚŽĄ—ÐŹŃ. —é–ŘˆťŽq (Ž¨•@ˆôAE“ŞčňŠO): ‘ć18‰ń_“ސ쓪čň•”ŠŕƒtƒH[ƒ‰ƒ€ (2018/4/11), ‰Ą•l.

733250. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ç—á‚Š‚ç‚Ý‚˝š‹‰ş‘˘‰eŒŸ¸ (VF) ‚ĚŽg—p–@‚ƑΉž–@. ´–ě—R”y (Ž¨•@ˆôAE“ŞčňŠO): ‘ć23‰ń“úŽ¨•@_“ސ욋‰şŒ¤‹†‰ď (2018/5/12), ‰Ą•l.

733251. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‹CŠÇŘŠJ‚ɂ‚˘‚Ä. ‘ĺŒ´‘ěĆ (Ž¨•@ˆôAE“ŞčňŠO): ‘Š–ÍŒ´Ž¨•@‰Čˆă‰ďŠwpu‰‰‰ď (2018/6/21), ‘Š–ÍŒ´.

733252. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “Şčň•”Šŕ‚ĆŽĄ—Ă‚É”ş‚¤Œű“ŕ‰Š‚ɑ΂ˇ‚銿•ű–ň‚ĚŽĄ—ĂŒř‰Ę. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): Kampo Oncology Seminar `‚Ş‚ńŽĄ—Ă‚ÉŠż•ű–ň‚đ‚Ç‚¤Žć‚č“ü‚ę‚é‚Š` (2018/7/27), “Œ‹ž.

733253. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šż•ű‚ĚŒťó: ‚Ş‚ńŽxŽ—Ă–@‚ĆŠż•ű`”ź‰ÄŕbS“’‚ĚƒGƒrƒfƒ“ƒX`. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): Š”ŽŽ‰ďŽĐƒcƒ€ƒ‰‘n‹Ć125Žü”N‹L”Ou‰‰‰ď|KAMPO‚Ĺ–˘—ˆ‚Ö ? (2018/9/1), “Œ‹ž.

733254. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •úŽËüŽĄ—ĂŒă‚ĚÄ”­‰şˆô“ŞŠŕ‚ɑ΂ľ‚ÄELPS‚Ĺ‹~Ď‚ľ‚Ś‚˝ˆę—á. Œ´“c—YŠî1, ´–ě—R”y1, Œ˜“ce—˜2, ‹{–{r•ă1, ‰Á”[Fˆę1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ): “ú–{Ž¨•@ˆôA‰ČŠw‰ď_“ŢěŒ§’n•ű•”‰ď‘ć184‰ńŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠwpu‰‰‰ď (2018/9/1), ‰Ą•l.

733255. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚ß‚Ü‚˘‚Ě‚ˇT‚ß. —Ž‡@“Ö (Ž¨•@ˆôAE“ŞčňŠO): ‘Š–ÍŒ´Žs–ňÜŽt‰ďŠwpu‰‰‰ď (2018/9/18), ‘Š–ÍŒ´.

733256. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@EŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰Č‚Ĺ‚ĚƒVƒ_ƒgƒŒƒ“Eƒ~ƒeƒBƒLƒ…ƒAŽĄ—Ă‚ÉŠÖ‚ľ‚Ä. —é–Ř—§r (Ž¨•@ˆôAE“ŞčňŠO): ‘Š–ÍŒ´ƒAƒŒƒ‹ƒQƒ“•×‹­‰ď (2018/10/4), ‘Š–ÍŒ´.

733257. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ç—á‚Š‚猊‚˝š‹‰ş“ŕŽ‹‹žŒŸ¸ (VE) ‚ĚŽg—p–@‚ƑΉž–@. ´–ě—R”y (Ž¨•@ˆôAE“ŞčňŠO): ‘ć25‰ń“úŽ¨•@_“ސ욋‰şŒ¤‹†‰ď (2018/10/13), ‰Ą•l.

733258. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) š‹‰şáŠQŠłŽŇ‚̏‰Šú‘Ήž–@. ‰iˆä_–¤ (Ž¨•@ˆôAE“ŞčňŠO): ‘ć25‰ń“úŽ¨•@_“ސ욋‰şŒ¤‹†‰ď (2018/10/13), ‰Ą•l.

733259. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚Ş‚ńŽxŽ—Ă–@‚É‚¨‚Ż‚銿•ű–ň‚Ě–đŠ„. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): ÷ŽRŠż•űŒ¤‹†‰ďŠwpu‰‰‰ď (2018/10/30), –źŒĂ‰Ž.

733260. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‹CŠÇŘŠJ‚ĚŠÇ—. ‘ĺŒ´‘ěĆ (Ž¨•@ˆôAE“ŞčňŠO): ‘Š–ÍŒ´—Ăˆç‰€30Žü”N‹L”OŒöŠJuŔ (2018/11/11), ‘Š–ÍŒ´.

733261. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šż•ű–ň‚đ—p‚˘‚˝“Şčň•”ŠŕŽxŽ—Ă–@`“Şčň•”ŠŕŽĄ—Ă‚Ě’áNP‰ť‚ĚŽŽ‚݁`. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): –k—¤Ž¨•@ˆôA‰ČŠż•űŒ¤‹†‰ď (2018/11/21), Îě.

733262. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “Şčň•”Šŕ‚É‚¨‚Ż‚éCD109”­Œť‚ĚŒŸ“˘. ’ç@ăĕ˝ (Ž¨•@ˆôAE“ŞčňŠO): Educational Seminar in KANAGAWA (2018/11/29), Œú–Ř.

733263. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é•â’ŽŠí‘•—pŽŇ‚ĚŽŔŽ¨‘}“ü—˜“ž‚Əˆ•űƒ^[ƒQƒbƒg‚Ě”äŠr. ŒĂ–ŘČŒá1, ˛–ě@”Ł2, –q@“ÖŽq1, ”g‘˝–ě‰l‘ž1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2ˆă—ÉqśŠw•”): “ú–{Ž¨•@ˆôA‰ČŠw‰ď_“ŢěŒ§’n•ű•”‰ď‘ć185‰ńŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠwpu‰‰‰ď (2018/12/1), ‰Ą•l.

733264. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ňŽĄ—Ă. –ŕŽR•Ű (Ž¨•@ˆôAE“ŞčňŠO): ‘ć36‰ń–k—˘ŽîᇃtƒH[ƒ‰ƒ€ (2019/2/22), –k—˘.

733265. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) čň•”ÎŠD‰ť•a•Ď‚É‚ć‚鍀•”d’ź‚đ—ˆ‚ľ‚˝3Ç—á. “Ąě’ź–ç1, ´–ě—R”y1, ŒĂ–ŘČŒá1, ”g‘˝–ě‰l‘ž1, ’ç@ăĕ˝1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): “ú–{Ž¨•@ˆôA‰ČŠw‰ď_“ŢěŒ§’n•ű•”‰ď‘ć186‰ńŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠwpu‰‰‰ď (2019/3/23), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-120002. [Œ´’˜] ‰îŒě˜VlŽ{Ý“üŠŽŇ‚Ě•â’ŽŠíŽŽ’Ž ‘ćˆę•ń|•â’ŽŠí‘•—p‚ĚŒř‰Ę|. —é–ŘŒbŽq1, ˆäă—ŠG2, ”~Œ´KŒb2, `@ŽáŘ1, ´…@•˝, ˛–ě@”Ł1, ‰Ş–{–ql, ŽR‰ş@‘ń2 (1ˆă—ÉqśŠw•”, 2Ž¨•@ˆôAE“ŞčňŠO): Audiology Japan 2018/2; 61 (1): 90-6.

H29-520002. [‘ŕ] “Şčň•”‚Ş‚ń‚ĚŽxŽ—Ă–@‚É‚¨‚Ż‚銿•ű–ň‚ĚŽg‚˘•ű. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): “ú–{Ž¨•@ˆôA‰ČŠw‰ď‰ď•ń 2018/1; 121 (1): 22-30.

H29-522007. [uŔ]y“ÁW: ‚ą‚ń‚Č‚Ć‚Ť‚Ç‚¤‚ˇ‚é?@p’†EpŒă‚Ěƒgƒ‰ƒuƒ‹‘Ήžzsˆô“ށEA“ށE“Şčň•”—Ěˆćt@ŒoŒű“IŽîᇐ؏œ’†‚ÉᑍE‚ސś‚ś‚˝. ´–ě—R”y1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰Č 2018/1; 90 (1): 50-3.

H29-522008. [uŔ]y“ÁW: ‚Ş‚ńŽĄ—Ăˆă‚É•ˇ‚­@ŽŔ’n—Տ°‚É•K—v‚Čáu’Ɋɘa‚Ě’mŽŻz‰ťŠw•űŽËü—Ă–@‚É‚ć‚éŒűo‚âH“š‚̒ɂ݁E‹ę’É‚ĚŠÉ˜a. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO): ‚Ş‚ńŠłŽŇ‚Ć‘ÎÇ—Ă–@ 2018/3; 27 (1): 7-12.

[’˜@‘]

H29-620005. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj2018”N”Ł@Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚éz‘˜_@25. Ž¨•@ˆôA‰ČŽžŠł@‰şˆô“ŞŠŕ, p. 1544-5. ŽR‰ş@‘ń (Ž¨•@ˆôAE“ŞčňŠO), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2018/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723012. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒJƒjƒ…[ƒŒŽhŒƒ‚É‚ć‚é‹CŠÇ‹ˇó‚ɑ΂ľŽ­–쎎ş–ĺ•Â˝p‚đŽ{s‚ľ‚˝Ç—á. ´–ě—R”y (Ž¨•@ˆôAE“ŞčňŠO): ‘ć28‰ń“ú–{“Şčň•”ŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2018/1/25), “Č–Ř.


¸_‰ČŠw

[Šwp˜_•ś]

110326. [Œ´’˜] Relationships of white matter hyperintensity with arterial stiffness and lifestyle in patients with mild cognitive impairment. Arai H1, Takahashi M1, Nakajima K1, Oishi S1, Miyaoka H1: Kitasato Med J 2018/9; 48 (2): 73-80. (Vˆä‹v–Ť1, ‚‹´@Œb1, ’†“‡Œ[‰î1, ‘ĺÎ@’q1, ‹{‰Ş@“™1: 1¸_)

110327. [Œ´’˜] Prediction of changes in functional ability of inpatients with schizophrenia using logarithmic and linear regression modelling. Kawaguchi T, Matsunaga A1, Watanabe A, Suzuki M, Asano E, Shirakihara Y, Shimizu S, Sawayama T2, Fukuda M1, Miyaoka H2: Hong Kong Journal of Occupational Therapy 2018/10; 31 (2): 76-85. (ź‰i“Ä•F1, ŕVŽR@“§2, •Ÿ“c—Ď–ç1, ‹{‰Ş@“™2: 1ˆă—ÉqśŠw•”, 2¸_)

120036. [Œ´’˜] ŹlASD‚É‚¨‚Ż‚éP-FƒXƒ^ƒfƒB‚đ—p‚˘‚˝W’cˆę’v“x (GCR) ‚ĆASD“ÁŤ‚Ć‚ĚŒŸ“˘. •űŒcŽO˜Y, ˆäăŸ•v1, ‘ęŕV‹B–î, ˛ŽR‰p”ü, ’ÍčS–ç, Aź”ü”ż, ‹{‰Ş@“™1 (1¸_): ¸_ˆăŠw 2019/2; 61 (2): 205-11.

220006. [€Œ´’˜]yˆä”V“Ş•a‰@Œ¤‹†Šî‹ŕ•Ź˜_•śz¸_‰ČŠO—ˆ‰fŠłŽŇ‚É‚¨‚Ż‚éQT‰„’ˇ‚Ě—L–ł‚ÉŠÖ‚ˇ‚é’˛¸•ń. ŸNˆäGŽ÷1, ‘ĺÎ@’q1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1 (1¸_): •˝Ź29”N“xŒö‰vŕ’c–@lˆä”V“Ş•a‰@Œ¤‹†‹I—v 2018/12; p.47-50.

220007. [€Œ´’˜]y“Á•ĘŠé‰ć: ˜AŒgŽŔ–ąŽŇ‚É‚ŕ’m‚Á‚Ä‚Ů‚ľ‚˘!z“œ”A•aŠłŽŇ‚É”F’mÇ‚Ş”­Ç‚ˇ‚é‚ą‚Ć‚É‚ć‚Á‚Đś‚ś‚éƒPƒA‚ւ̉e‹ż‚Ć‚ť‚Ě‰đŒˆô. ‰ş‘ş—TŒŠŽq1, ›I@‘P‹M1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ’nˆć˜AŒg “ü‘މ@‚ĆÝ‘îŽx‰‡ 2019/1-2; 11 (6): 104-11.

320033. [Ç—á•ń] ŽŠ•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚ÉŠÖ˜A‚ľ‚˝dÇ’ŽŠo‰ß•q‚ĚŽĄ—Á|ƒAƒŠƒsƒvƒ‰ƒ][ƒ‹‚Ɖš”˜˜I‚đŽŽ‚Ý‚˝ˆę—á|. ˆäăŸ•v1, _’Jr‰î2, ‹g—Ń—˜•ś1, ‹{‰Ş@“™1 (1¸_, 2’nˆćŽ™“ś¸_): Ž™“śÂ”N¸_ˆăŠw‚Ć‚ť‚Ě‹ßÚ—Ěˆć 2018/4; 59 (2): 199-207.

320034. [Ç—á•ń] ”][Ç‚Ć”]“Ž–ŹáŽ‚đ‡•š‚ľ‚˝‚¤‚•aŠłŽŇ‚ɏCłŒ^“d‹C‚Ż‚˘‚ę‚ń—Ă–@‚Ş—LŒř‚ž‚Á‚˝1—á|‚ć‚čˆŔ‘S‚ČŽĄ—Ă–@‚ĚŠm—§‚ÉŒü‚Ż‚ā|. “‡–ě•ü–ç1, ‰ÄŽR@‘ě2, ŕVŽRŒb”g1, ‘ĺÎ@’q1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ¸__ŒoŠwŽGŽ 2018/8; 120 (8): 633-9.

320035. [Ç—á•ń] ’ˇŠúŒo‰ß‚Ě’†‚ʼnń•œ‚Ş“ž‚ç‚ę‚˝ƒAƒ‹ƒR[ƒ‹ŤƒRƒ‹ƒTƒRƒtÇŒóŒQ‚Ěˆę—á. ›I@‘P‹M1, ‘ĺÎ@’q1, ˆäă•üŽq1, “‡–ě•ü–ç1, ’Š‘q’•ś2, ‘ęŕV‹B–î1, ŕVŽR@“§1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_, 2’nˆćŽ™“ś¸_): ¸_‰ČŽĄ—ĂŠw 2019/3; 34 (3): 337-42.

522147. [uŔ]y“ÁW: Š“žŠiˇŽž‘ă‚Ě–ň•¨ŽĄ—ÁgŒoĎ“I•‰’S‚đŒyŒ¸‚ľ‚˝‚˘hŠłŽŇ‚Ě‘i‚Ś‚É‚˘‚Š‚ɉž‚Ś‚é‚ŠzĄf—Ă‚Ěƒvƒ‚ލl‚Ś‚éŒoĎ“I•‰’S‚đŒ¸‚ç‚ˇ‚˝‚ß‚Ě‘I‘đŽˆ
E‚¤‚•a. ‹{‰Ş@“™ (¸_): –ň‹Ç 2018/4; 69 (5): 50-3.

522148. [uŔ]yDoctor & Patient Communicationz”F’mÇ‚Ş‚ ‚Á‚Ä‚ŕˆŔS‚ľ‚Ä•é‚ç‚š‚é‚˝‚ß‚Ě“`‚Ś•ű. ‘ĺÎ@’q (¸_): ¸_‰Č—Տ°Regato 2018/4; 4 (1): 32-3.

522149. [uŔ]y“ÁW: ADHD‚Ć‚ť‚ĚŽü•Ó|Ž™“ś‚Š‚çÂ”NŠú‚܂Ł|zADHDf—ĂŽŔ‘H‚É‚¨‚Ż‚é‘O’ń‚Ć—ŻˆÓ“_|f’fEŽĄ—Ă‚ĚŒë‚č‚đ”đ‚Ż‚é‚˝‚߂Ɂ|. ˆäăŸ•v (¸_): —Տ°¸_ˆăŠw 2018/5; 47 (5): 593-8.

522150. [uŔ]y“ÁW2: •ĎŠvŠú‚đŒ}‚Ś‚鐸_ˆă—ÂƐ¸_ŽžŠł‚đ‡•š‚ˇ‚銳ŽŇ‚ĚŽx‰‡E˜AŒgz’nˆćˆÚsŽx‰‡‚ÉŠˆ‚Š‚ˇ¸_‰Č’nˆć˜AŒgƒpƒX‚̍쐬‚Ɖ^—p. ‘ĺÎ@’q (¸_): ’nˆć˜AŒg “ü‘މ@‚ĆÝ‘îŽx‰‡ 2018/5; 11 (2): 49-53.

522151. [uŔ]y“Á•ĘŠé‰ć: Žq‚Ç‚ŕ‚Ě‚ą‚ą‚ë‚Ć”]z”­’B‚̂‚܂¸‚Ť‚Ć‚ą‚ą‚ëE”]|áŠQ‚Ě—‰đ@Žq‚Ç‚ŕ‚̐SgÇEg‘̏Ǐó|‚ą‚ą‚ë‚Ě”­’B‰Ű‘č‚Š‚ç”]‰ČŠw‚Ü‚Ĺ. ˆäăŸ•v (¸_): ‚ą‚ą‚ë‚̉Ȋw 2018/6; 200: 81-6.

522152. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć17‰ńz‚˘‚í‚ä‚éu•¨“‚ç‚ę–Ď‘zv‚Ě‚ ‚é”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/6; 38 (6): 689-93.

522153. [uŔ]yDoctor & Patient Communicationz”F’mÇ‚Ş‚ ‚Á‚Ä‚ŕˆŔS‚ľ‚Ä•é‚ç‚š‚é‚˝‚ß‚Ě“`‚Ś•ű. ‘ĺÎ@’q (¸_): ¸_‰Č—Տ°Regato 2018/7; 4 (2): 34-5.

522154. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć18‰ńz‚˘‚í‚ä‚éuŽš“i–Ď‘zv‚Ě‚ ‚é”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/7; 38 (7): 797-801.

522155. [uŔ] f—Ă‚Ěƒvƒ‚ލl‚Ś‚éŒoĎ“I•‰’S‚đŒ¸‚ç‚ˇ‚˝‚ß‚Ě‘I‘đŽˆ@5. ‚¤‚•a. ‰ş‘ş—TŒŠŽq1, ‹g‘şƒ•F, ’†‘ş‹N–ç, ă“c”ü˛], ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ’nˆć˜AŒg “ü‘މ@‚ĆÝ‘îŽx‰‡ 2018/7-8; 11 (3): 53-7.

522156. [uŔ]y“ÁWI: ¸_ˆăŠw‹łˆç‚̍ĄŒăz¸_‰Čę–ĺˆă‹łˆç. “V•Ű‰p–ž (¸_): ¸_‰Č 2018/8; 33 (2): 118-22.

522157. [uŔ]yƒvƒ`EƒAƒ‹ƒR[ƒ‹ˆË‘ś‚É‹C‚Ă‚­ ’N‚É‚Ĺ‚ŕ‚Ĺ‚Ť‚éƒAƒ‹ƒR[ƒ‹Žg—páŠQ‚ւ̑Ήžz<ę–ĺˆă‚É‚ć‚éd“x‚ĚƒAƒ‹ƒR[ƒ‹Žg—páŠQŠłŽŇ‚Ö‚ĚŽĄ—Ă>@3. “Ž‹@‚Ă‚Ż–ʐڂ͎ŔŰ‚ǂ̂悤‚Č‚ŕ‚Ě‚Š‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. ŕVŽR@“§ (¸_): ƒ‚ƒ_ƒ“ƒtƒBƒWƒVƒƒƒ“ 2018/8; 38 (8): 836-9.

522158. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć19‰ńz–°‚ę‚Č‚˘”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/8; 38 (8): 905-9.

522159. [uŔ]y“ÁW: Ži–@‚đl—ś‚ľ‚˝¸_‰Čˆă—Ă‚ĆŽx‰‡|”­’BáŠQ‚Š‚ç‹ß”N‚ĚƒgƒsƒbƒN‚ƂȂ鐸_áŠQ‚܂Ł|zƒMƒƒƒ“ƒuƒ‹áŠQ. Š—ś—TŽi (¸_): ¸_‰ČŽĄ—ĂŠw 2018/8; 33 (8): 917-22.

522160. [uŔ]yƒJƒŒƒ“ƒgEƒgƒsƒbƒNƒXzƒJƒWƒm‚ĆƒMƒƒƒ“ƒuƒ‹“™ˆË‘śÇ‘΍ôŠî–{–@. ’Š‘q’•ś(¸_): ¸_‰ČŽĄ—ĂŠw 2018/8; 33 (8): 1015-20.

522161. [uŔ]y“ÁWI: ¸_‰Čˆă—Ă’ń‹Ÿ‘̐§‚Ě‹@”\‹­‰ťzg‘ĚŽžŠł‚đ‡•š‚ˇ‚鐸_ŽžŠł‚Ě‚ ‚él‚ɑ΂ˇ‚éˆă—Ă’ń‹Ÿ‘̐§‚̍\’z. ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ¸_‰Č 2018/9; 33 (3): 219-26.

522162. [uŔ] “˘˜_: –łŽ‹‚ł‚ę‚Ä‚Ť‚˝ƒ_ƒCƒGƒbƒg‚Ć‘‰‚š‚ˇ‚Ź‚ĚŠëŒŻŤ|‘‰‚š‚ˇ‚Źƒ‚ƒfƒ‹‹ÖŽ~–@‚ÉŒü‚Ż‚ā|. ‰i“c—˜•F, ŽR‰ş’B‹v, ŽR“c@P, …Œ´—S‹N, …“cˆę˜Y, –ěŠÔrˆę, “c’†@‘, ›Á@ŕvm, ˜a“c—Ç‹v, ‰Ş–{•S‡, —é–ŘáÁ—, ‹{‰Ş@“™1 (1¸_): ¸__ŒoŠwŽGŽ 2018/9; 120 (9): 741-51.

522163. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć19‰ńz‚˘‚í‚ä‚éuœpœjv‚đŽw“E‚ł‚ę‚˝”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/9; 38 (9): 1012-6.

522164. [uŔ]y“Á•ĘŠé‰ć:u•‚Ż‚āv‚ŞŒž‚Ś‚Č‚˘|‰‡•‚Ɖ‡•Šó‹zu‚ą‚Ě‚Ü‚Ü‚ś‚á‚Ü‚¸‚˘‚Ż‚Ç, •Ď‚í‚č‚˝‚­‚Č‚˘v|–Ŕ‚¤l‚Ě”w’†‚đ‚Ç‚¤‰Ÿ‚ˇ‚Š. ŕVŽR@“§ (¸_): ‚ą‚ą‚ë‚̉Ȋw 2018/10; 202: 22-6.

522165. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć20‰ńzˆŮ‚Č‚é——R‚đ‚°‚ç‚ę—ˆ‰@‚ľ‚˝”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/10; 38 (10): 1098-102.

522166. [uŔ]y“ÁW: “ŕ•Ş”ĺE‘ăŽÓŤŽžŠł‚ĚƒGƒ}[ƒWƒFƒ“ƒV[z‹´–{”]Ç. œA‰ŞF—z(¸_): Źl•a‚ƐśŠˆKŠľ•a 2018/10; 48 (10): 1090-9.

522167. [uŔ]y“ÁW: ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ďz‘ĺ‰ď’ˇu‰‰: ŽY‹Ć¸_•ŰŒ’‚̉ۑč|“§–ž‰ť‚Ć•W€‰ť‚ĚŠĎ“_‚Š‚ç. ‹{‰Ş@“™ (¸_): ŽY‹Ć¸_•ŰŒ’ 2018/11; 26 (4): 311-4.

522168. [uŔ]y“ÁW: ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ďz8. ”­’BáŠQ‚̐ł‚ľ‚˘—‰đ. ˆäăŸ•v (¸_): ŽY‹Ć¸_•ŰŒ’ 2018/11; 26 (4): 346-9.

522169. [uŔ] Ž™“ś¸_‰Čˆă‚Š‚ç‚Ý‚˝Žq‚Ç‚ŕ‚ĆSNS‚Ě–â‘č. ˆäăŸ•v (¸_): ŠwZ‰^‰c 2018/11; 60 (8): 12-5.

522170. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć21‰ńzˆŔ’č‚ľ‚Ä‚˘‚é‚悤‚É‚Ý‚Ś‚é”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/11; 38 (11): 1196-200.

522171. [uŔ]y“ÁW: ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ďz‹łˆçu‰‰VI˜^: ”­’BáŠQ‚̐ł‚ľ‚˘—‰đ. ˆäăŸ•v (¸_): ŽY‹Ć¸_•ŰŒ’ 2018/11; 26 (4): 346-9.

522172. [uŔ]y“ÁW: ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ďz‹łˆçu‰‰VIII˜^: Eˆć‚É‚¨‚Ż‚éƒMƒƒƒ“ƒuƒ‹‚Ě–â‘č. Š—ś—TŽi (¸_): ŽY‹Ć¸_•ŰŒ’ 2018/11; 26 (4): 356-9.

522173. [uŔ]y“ÁW: ŰHáŠQ‚̍Ą“ú“I—‰đ‚ĆŽĄ—ĂIIzŰHáŠQŠłŽŇ‚ވę”Ę‹~‹}‚â‘ź‰Č‚É“ü‰@‚ľ‚Ä‚Ť‚˝ę‡‚ɍl‚Ś‚é‚ą‚Ć, ‚Č‚ˇ‚ׂŤ‚ą‚Ć. Vˆä‹v–Ť (¸_): ¸_‰ČŽĄ—ĂŠw 2018/12; 33 (12): 1425-9.

522174. [uŔ]y“ÁW: ŰHáŠQ‚̍Ą“ú“I—‰đ‚ĆŽĄ—ĂIIzŰHáŠQŠłŽŇ‚ވę”Ę‹~‹}‚â‘ź‰Č‚É“ü‰@‚ľ‚Ä‚Ť‚˝ę‡‚ɍl‚Ś‚é‚ׂŤ‚ą‚Ć, ‚Č‚ˇ‚ׂŤ‚ą‚Ć. Vˆä‹v–Ť (¸_):¸_‰ČŽĄ—ĂŠw 2018/12; 33 (12): 1425-9.

522175. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć22‰ńz‰îŒě‚ł‚ę‚é‚ą‚Ć‚đ‹‘”Ű‚ˇ‚é”F’mÇ‚Ě‚ ‚él‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2018/12; 38 (12): 1279-83.

522176. [uŔ]y“ÁWII: “‡Œ^ƒŠƒ][ƒg (IR)EƒJƒWƒm‰đ‹Ö‚ɂ‚˘‚čl‚Ś‚éz•a‰@‚É–K‚ę‚éƒMƒƒƒ“ƒuƒ‹áŠQŠłŽŇ‚Í•Ď‚í‚Á‚˝‚Ě‚Š. ’Š‘q’•ś (¸_): ¸_‰Č 2018/12; 33 (6): 525-9.

522177. [uŔ]y“ÁW: ¸_‰Č‚É‚¨‚Ż‚鉓Šuf—Ẩ”\Ťz[Ŕ’k‰ď] ¸_‰Č‚É‚¨‚Ż‚鉓Šu (ƒIƒ“ƒ‰ƒCƒ“) f—Ẩ”\Ť. ŠÝ–{‘׎m˜Y, Œ´@šŒá, —Ž‡F•ś, ĺ”gƒˆę, ‹{‰Ş@“™1 (1¸_): ¸_‰ČŽĄ—ĂŠw 2019/2; 34 (2): 213-22.

522178. [uŔ]y”F’mÇ‚̐f’f‚Ć‚Ć‚ŕ‚ÉŠłŽŇ‚ł‚ń‚É“`‚Ś‚˝‚˘‚ą‚Ć: ‘ć23‰ńz‰Ć‚É‹A‚é‚ĆŒJ‚č•Ô‚ˇ”F’mÇ‚Ě‚ ‚él‚É“`‚Ś‚˝‚˘‚ą‚Ć. ‘ĺÎ@’q (¸_): Modern Physician 2019/2; 39 (2): 228-32.

540040. [‚ť‚Ě‘ź] ŽY‹Ć•ŰŒ’‘“ŕŠÖ˜Aƒjƒ…[ƒX|‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď. ‹{‰Ş@“™ (¸_): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2018/11; 41 (6): 65-9.

[’˜@‘]

620128. [Šwp‘ (–|–ó)]yƒ‰ƒ^[ Ž™“śÂ”N¸_ˆăŠw [Œ´‘‘ć6”Ĺ]zPart 4 —Տ°ÇŒóŒQ: _Œo”­’B, î, s“Ž, g‘́|”]‚ÉŠÖ‚ˇ‚é—Տ°ÇŒóŒQ D g‘́|”]‚ÉŠÖ‚ˇ‚é—Տ°ÇŒóŒQ@‘ć69Í Ť•Ęˆá˜a‚Ćƒpƒ‰ƒtƒBƒŠƒA (ŤšnDáŠQ), p.1247-67. ˆäăŸ•v (¸_), ŠÄ–ó: ’ˇ”öŒ\‘˘, Ž‰Ć@•, Ź–ě‘P˜Y, ‹g“cŒhŽq, –žÎ‘“X, “Œ‹ž, 2018/4”­s.

620129. [Šwp‘ (‹¤’˜)]y‘ĺl‚Ě”­’BáŠQ‚Á‚Ä‚ť‚¤‚˘‚¤‚ą‚Ć‚ž‚Á‚˝‚Ě‚Š@‚ť‚ĚŒăz‹{‰Ş@“™1, “ŕŽR“o‹I•v (1¸_), ˆăŠw‘‰@, “Œ‹ž, 2018/7”­s.

620130. [Šwp‘ (•Ş’SŽˇ•M)]yŠO—ˆE•a“‚Ĺ‚ć‚­‚݂鐸_Çó ‘Ήžƒ}ƒjƒ…ƒAƒ‹ (ŒŽŠ§–ňŽ–2018”N7ŒŽ‘Š§†)z‘ć1Í ‰Ÿ‚ł‚Ś‚Ä‚¨‚Ť‚˝‚˘Œü¸_–ň‚ĚŠî–{@2. Œü¸_–ň‚Ě“Á’Ľ‚ĆŽg‚˘•ű@…E‚ť‚Ě‘ź‚Ě–ňÜ (”F’mÇEŽü•ÓÇóŽĄ—Ă–ň, Šż•ű–ň‚Č‚Ç), p. 60-5. ‘ĺÎ@’q (¸_), •Ň: ź‘şŸŽĄ, ‚ś‚Ů‚¤, “Œ‹ž, 2018/7”­s.

620131. [Šwp‘ (•Ş’SŽˇ•M)]yVƒAƒ‹ƒR[ƒ‹E–ň•¨Žg—páŠQ‚̐f’fŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“z‘ć2Í Ç—á•Ę‰Šú‘Ήž•Ň@I. ƒAƒ‹ƒR[ƒ‹Žg—páŠQ‚Ö‚Ě‰Šú‘Ήž (“ŕ‰ČŒn)@10. ‰Ć‘°‚Ş–{l‚đ˜A‚ę‚Ä‚Ť‚˝ę‡, p.58-9. ŕVŽR@“§ (¸_), ŠÄC: VƒAƒ‹ƒR[ƒ‹E–ň•¨Žg—páŠQ‚̐f’fŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“ěŹˆĎˆő‰ď, •Ň: ”óŒű@i, âV“Ą—˜˜a, “’–{—m‰î, V‹ťˆăŠwo”ĹŽĐ, “Œ‹ž, 2018/9”­s.

620132. [Šwp‘ (•ŇW)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‹{‰Ş@“™1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620133. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć1Í: “‡Ž¸’˛Ç@Q2. “‡Ž¸’˛Ç‚ĚŠłŽŇ‚Ş–Ď‘z‚ɍś‰E‚ł‚ęg‘Ě“IŽĄ—Ă‚đ‹‘”Ű‚ľ‚Ä‚˘‚Ü‚ˇ. ‚Ç‚¤‚ľ‚˝‚ç‚悢‚Ĺ‚ľ‚傤‚Š? p.16-7. ŸNˆäGŽ÷1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620134. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć3Í: _ŒoÇŒ—@Q41. S‹CÇ‚ĚŠłŽŇ‚ł‚ń‚Ş‚˝‚Ń‚˝‚ŃŒŸ¸‚đ‹‚ß‚Ä‚ą‚ç‚ę‚Ü‚ˇ. ‚ǂ̂悤‚ɑΉž‚ľ‚˝‚ç‚悢‚Ĺ‚ľ‚傤‚Š? p.98-9. ‹{’n‰p—Y1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620135. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć5Í: ”­’BáŠQEŽ™“śŽvtŠú@Q60. ASD‚É‚Ý‚ç‚ę‚銴Šo‚̉ߕq‚ł, “ÝŠ´‚ł‚Ć‚Í, ‹ď‘Ě“I‚ɂǂ̂悤‚ȏǏó‚đŽw‚ˇ‚Ě‚Ĺ‚ľ‚傤‚Š? p.138-9. _’Jr‰î1 (1’nˆćŽ™“ś¸), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M (1¸_), Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620136. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć6Í: ”F’mÇ@Q64. Œy“x”F’máŠQ‚Ć”ť’f‚ł‚ę‚˝ŠłŽŇ‚ł‚ń‚Š‚ç, ”F’mÇ‚É‚Č‚ç‚Č‚˘‚˝‚ß‚Ě•ű–@‚ɂ‚˘‚Đq‚Ë‚ç‚ę‚Ü‚ľ‚˝. ‚Ç‚¤‰ń“š‚ľ‚˝‚ç‚悢‚Ĺ‚ľ‚傤‚Š? p.148-9. ‘ĺÎ@’q1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620137. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć6Í: ”F’mÇ@Q69. MMSE‚âHDS-R‚đ‰˝“x‚ŕs‚¤‚Ɛł‚ľ‚˘•]‰ż‚Ş‚Ĺ‚Ť‚Č‚­‚Č‚é‚Ě‚Ĺ‚ľ‚傤‚Š? p.158-9. ‘ęŕV‹B–î1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620138. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć6Í: ”F’mÇ@Q70. ”~“ĹŒŒ´”˝‰ž‚Ş—zŤ‚Ĺ‚ľ‚˝. ‚Ç‚¤”ť’f‚ˇ‚ׂŤ‚Ĺ‚ˇ‚Š? p.160-1. ›I@‘PF1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620139. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć6Í: ”F’mÇ@Q71. ”F’mÇ‚̊ӕʐf’f‚đ‚Š‚Š‚č‚‚Ż‚Ě“ŕ‰Čˆă‚Š‚çˆË—Š‚ł‚ę‚Ü‚ľ‚˝. ‚ǂ̂悤‚Č–âfEŒŸ¸‚đ‚ˇ‚ę‚΂悢‚Ĺ‚ľ‚傤‚Š? p.162-3. œA‰ŞF—z1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620140. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć8Í: ˆË‘śÇ@Q81. ŽŘ‹ŕ‚Ş‚ ‚é‚Ě‚ÉƒMƒƒƒ“ƒuƒ‹‚Ş‚â‚ß‚ç‚ę‚Č‚˘‚Ć‚˘‚¤l‚Ş‚Ť‚Ü‚ľ‚˝. ‚Ç‚¤‘Ήž‚ˇ‚é‚Ě‚Ş–]‚Ü‚ľ‚˘‚Ĺ‚ľ‚傤‚Š? p.186-7. Š—ś—TŽi1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620141. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć11Í: ŒŸ¸@Q94. S—ŒŸ¸‚ĚŒ‹‰Ę‚𕡂˘‚˝ŠłŽŇ‚ł‚ń‚Ş, •”‰Ž‚É–ß‚Á‚Ä‚Š‚獆‹ƒ‚ł‚ę‚Ä‚˘‚˝‚ť‚¤‚Ĺ‚ˇ. ‚ą‚ĚŒă‚ĚƒtƒHƒ[‚͂ǂ̂悤‚É‚ˇ‚ę‚΂悢‚Ĺ‚ľ‚傤‚Š? p.218-9. •űŒcŽO˜Y1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620142. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć12Í: –ň•¨—Ă–@@Q95. Œü¸_–ň‚Ĺ’ˆÓ‚ˇ‚ׂŤ–ň•¨‘ŠŒÝě—p‚Í‚Č‚ń‚Ĺ‚ľ‚傤? p.222-3. œA‰ŞF—z1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

620143. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ&A (¸_‰ČŽĄ—ĂŠw‘ć33ŠŞ‘Š§†)z‘ć13Í: Cł“d‹C‚Ż‚˘‚ę‚ń–@ (mECT)@Q104. ECTŒă‚ĚŒp‘ąEˆŰŽ—Ă–@‚͂ǂ̂悤‚É‚ˇ‚ę‚΂˘‚˘‚Ĺ‚ˇ‚Š? p.242-3. ŕVŽRŒb”g1 (1¸_), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q1, ‰ęŒĂ—E‹P, ’†‘O@‹M, Ż˜a‘“X, “Œ‹ž, 2018/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713156. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Safety of Methylphenidate Use in Treating an ADHD Child with Familial Long QT Syndrome Inoue K1: ‘ć23‰ń‘ŰŽ™“śÂ”N¸_ˆăŠw‰ď‹c (IACAPAP2018) (2018/7/23), Prague, Czech Republic. (ˆäăŸ•v1: 1¸_)

721021. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ”­’BáŠQ‚𐳂ľ‚­—‰đ‚ˇ‚é. ˆäăŸ•v (¸_): ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2018/7/1), ”’‹ŕ.

721022. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ŽŠŽEŠé}‚Ĺ”Ŕ‘—‚ł‚ę‚銳ŽŇ‚Ě—Ő°“I“Á’Ľ‚Ć‹~‹}E¸_‰Č‚Ć‚Ě˜AŒg‚̉ۑč. Vˆä‹v–Ť (¸_): ‘ć46‰ń“ú–{‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/11/19-21), ‰Ą•l.

722198. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ‘ĺl‚Ě”­’BáŠQ‚Ɛ¸_ŽžŠł‚ĚŠÓ•Ę‚Ć‡•š. ‹{‰Ş@“™ (¸_): ‘ć59‰ń“ú–{SgˆăŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2018/6/8), –źŒĂ‰Ž.

722199. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘ĺl‚ĚŽŠ•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚̐f’f•â•‚É—L—p‚ȐS—ŒŸ¸‚Ć—ŻˆÓ“_. ˆäăŸ•v (¸_): ‘ć114‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ď (2018/6/22), _ŒË.

722200. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Eę‚ł̑ΐlŠÖŒW‰Ű‘č‚đ‰đŒˆ‚ˇ‚é‚˝‚ß‚ĚSST. ‚‹´@Œb (¸_): ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2018/6/30), “Œ‹ž.

722201. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ”­’BáŠQ‚𐳂ľ‚­—‰đ‚ˇ‚é. ˆäăŸ•v (¸_): ‘ć25‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2018/7/1), “Œ‹ž.

722202. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ŽŠŽEŠé}‚Ĺ”Ŕ‘—‚ł‚ę‚銳ŽŇ‚Ě—Ő°“I“Á’Ľ‚Ć‹~‹}E¸_‰Č‚Ć‚Ě˜AŒg‚̉ۑč. Vˆä‹v–Ť (¸_): ‘ć46‰ń“ú–{‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/11/21), ‰Ą•l.

722203. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —lX‚ČˆË‘śEšn•Č‚ɑ΂ˇ‚é”F’ms“Ž—Ă–@: ‚ť‚ę‚ź‚ę‚Ě“Á’Ľ‚Ć‚ť‚Ě‹¤’Ę“_‚Ć‘Šˆá“_. ŕVŽR@“§1, ‹´–{@–], ŒĂ–ěŒĺŽu, ’†‘ş‰pŽi (1¸_): ‘ć18‰ń“ú–{”F’m—Ă–@E”F’ms“Ž—Ă–@Šw‰ď (2018/11/24), ‰ŞŽR.

723770. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ¸_‰Č•a““ü‰@’†‚ĚŠłŽŇ‚É‚¨‚Ż‚鎊ŽEŠé}‚Ě“Á’Ľ‚Ć‘Îô. ’†‘şŒł”ü1, ‘ĺÎ@’q1, ˆäă•üŽq1, ‘ęŕV‹B–î1, ŽRŒű–žŽq, ŒFâ^—R”ü, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_): ‘ć114‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ď (2018/6/21), _ŒË.

723771. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) î•sˆŔ’萍ƒp[ƒ\ƒiƒŠƒeƒBáŠQ“ü‰@ŠłŽŇ‚Ě“]‹AŠÖ˜A—vˆö‚ÉŠÖ‚ˇ‚錟“˘. Vˆä‹v–Ť1, ‘ĺÎ@’q1, âV“Ął”Í1, ˆäăŸ•v1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1 (1¸_): ‘ć114‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ď (2018/6/22), _ŒË.

723772. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw“Œ•a‰@ƒMƒƒƒ“ƒuƒ‹áŠQę–ĺŠO—ˆ‚đŽóf‚ľ‚˝ŠłŽŇ‚Ě“]‹A. ’Š‘q’•ś1, Š—ś—TŽi2, ‘ĺÎ@’q2, ‹{‰Ş@“™2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2¸_): ‘ć114‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ď (2018/6/22), _ŒË.

723773. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “‡Ž¸’˛Ç–ň•¨ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“‚Ć‚¤‚•aŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“‚Ě‹łˆçŒř‰Ę‚Ě•]‰ż|EGUIDEƒvƒƒWƒFƒNƒg‚Š‚ç‚Ě•ń. ‘ĺÎ@’q1, ‘ęŕV‹B–î1, ›I@‘P‹M1, ˆî“c@Œ’, “n•Ótˆę˜Y, ‹´–{—ş‘ž, ‹{‰Ş@“™1 (1¸_): ‘ć114‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ď (2018/6/23), _ŒË.

723774. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”F’mÇŽĄ—Ă–ň’†Ž~Œă‚ĚŽĄ—ĂŒo‰ß‚ÉŠÖ‚ˇ‚éˆęlŽ@. —é–Ř—´‘ž˜Y1, ›I@‘P‹M1, ‘ęŕV‹B–î1, ’†‘ş“Ţ“Ţ, Vˆä‹v–Ť1, ‘ĺÎ@’q1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_): ‘ć33‰ń“ú–{˜V”N¸_ˆăŠw‰ď (2018/6/30), •Ÿ“‡, ˜V”N¸_ˆăŠwŽGŽ 2018/6; 29 (‘Š§-II): 198.

723775. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žá”NŒ^ƒAƒ‹ƒcƒnƒCƒ}[Œ^”F’mÇ‚É‚¨‚Ż‚é‘ĺ”]”’Žż•a•Ď‚Ć“Ž–Źd‰ťEśŠˆKŠľ‚ĚŠÖ˜A. Vˆä‹v–Ť1, ‚‹´@Œb1, ‘ĺÎ@’q1, ’†“‡Œ[‰î1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1 (1¸_): ‘ć33‰ń“ú–{˜V”N¸_ˆăŠw‰ď (2018/6/29-30), •Ÿ“‡.

723776. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ć2‰ńwf—Ăˆă—Ă‚ĆƒpƒX‚đŠw‚ԁx‰Ť“ę‚Ĺ‚ĚŒ¤C‰ď‰ď‹c•ń. ‰ş‘ş—TŒŠŽq, ‘ĺÎ@’q1, ’†‘ş‹N–ç, ’‡’n‹MO, ŽOŒ´”üá, ‹{‰Ş@“™1 (1¸_): ‘ć19‰ń“ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ďŠwpW‰ď (2018/10/12), ”ŸŠŮ.

723777. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ¸_ˆă—Ẩۑč‚ĆƒNƒŠƒjƒJƒ‹ƒpƒX—L—pŤ‚Ö‚ĚlŽ@`’ß‰ŞŽs‘ą•ń`. ‰ş‘ş—TŒŠŽq, ‘ĺÎ@’q1, ’†‘ş‹N–ç, ŽOŒ´”üá, ’‡’n‹MO, ‹{‰Ş@“™1 (1¸_): ‘ć19‰ń“ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ďŠwpW‰ď (2018/10/12), ”ŸŠŮ.

723778. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŽŠ•ÂÇEd“x’m“IáŠQ‚ÉŒŽŒo‘O•s‰ő‹C•ŞáŠQ‚Ş•š‘ś‚ľ‚˝ˆę—á. ˆäăŸ•v1,2, _’Jr‰î2, ‹{‰Ş@“™1,2 (1¸_, 2’nˆćŽ™“ś¸_): ‘ć59‰ń“ú–{Ž™“śÂ”N¸_ˆăŠw‰ď‘‰ď (2018/10/12), “Œ‹ž.

723779. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw¸__Œo‰ČŽ™“śEŽvtŠú•”–ĺ‚É‚¨‚Ż‚鏉fŠłŽŇ‚Ě“ŽŒü‚ÉŠÖ‚ˇ‚éŒă•űŽ‹“IŒ¤‹†. _’Jr‰î1, ’†“‡N•ă1, ˆäăŸ•v1,2, ‹{‰Ş@“™1,2 (1’nˆćŽ™“ś¸_, 2¸_): ‘ć59‰ń“ú–{Ž™“śÂ”N¸_ˆăŠw‰ď‘‰ď (2018/10/12), “Œ‹ž.

723780. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw¸__Œo‰ČŽ™“śEŽvtŠú•”–ĺ‚É‚¨‚Ż‚é•s“oZŠłŽŇ‚Ě—Ő°“I“Á’Ľ‚ÉŠÖ‚ˇ‚éŒă•űŽ‹“IŒ¤‹†. _’Jr‰î1, ’†“‡N•ă1, ˆäăŸ•v1,2, ‹{‰Ş@“™1,2 (1’nˆćŽ™“ś¸_, 2¸_): ‘ć59‰ń“ú–{Ž™“śÂ”N¸_ˆăŠw‰ď‘‰ď (2018/10/12), “Œ‹ž.

723781. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •˝Ź29”N“x_“ŢěŒ§‘Š–ÍŒ´Žs‚É‚¨‚Ż‚éƒtƒ@ƒ~ƒŠ[ƒOƒ‹[ƒvƒJƒ“ƒtƒ@ƒŒƒ“ƒXŽ–‹Ć‚Ě•ń. Š™“cˆťŽq, ™ŽR‹ĘŒb, ˆäăŸ•v1 (1¸_): ‘ć59‰ń“ú–{Ž™“śÂ”N¸_ˆăŠw‰ď‘‰ď (2018/10/13), “Œ‹ž.

723782. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ¸_‰Č•a“‚É“ü‰@‚ľ‚˝_ŒoŤ–łH—~ÇŠłŽŇ‚Ě—Ő°“I“Á’Ľ‚ɂ‚˘‚Ä. Vˆä‹v–Ť1, ŸNˆäGŽ÷1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ‘ć22‰ń“ú–{ŰHáŠQŠw‰ďŠwpW‰ď (2018/11/8), –źŒě.

723783. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇzÂtŠú‚Ě“ńŽŸáŠQ‚É‚ć‚鏭—“I‘Ţ‹p|Œy“x”­’BáŠVŽŇ‚̍m’č“IŽŠŒČˆ¤‚ĚŠl“ž‚Ě‚˝‚ß‚ĚƒGƒ“ƒpƒƒƒ“ƒg|. ˆäăŸ•v (¸_): ‘ć36‰ń“ú–{Â”NŠú¸_—Ă–@Šw‰ď‘‰ď (2018/12/2), ‘ĺă.

723784. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰Ć‘°Ť‚ĚQT‰„’ˇ‚Ş‚Ý‚ç‚ę‚˝ADHDŽ™“ś‚Ö‚Ěƒƒ`ƒ‹ƒtƒFƒjƒf[ƒg™•úů‚ĚŽg—p. ˆäăŸ•v (¸_): “ú–{ADHDŠw‰ď ‘ć10‰ń‘‰ď (2019/3/3), ěč.

731104. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆË‘śÇ‚Ć‹~‹}ˆă—Ă. Vˆä‹v–Ť (¸_): ‘ć69‰ńGHPŒ¤‹†‰ď (2018/8/4), “Œ‹ž.

732106. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ‘‡f—Ă‚É‚¨‚Ż‚鎙“śEŽvtŠúŠłŽŇ‚ւ̑Ήž. ˆäăŸ•v (¸_): ‘ć46‰ń_“ŢěŒ§SgˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/4/21), ‰Ą•l.

732107. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ę’ɁE‹ę”Y‚Ě•]‰ż‚ƑΉž. ‹{’n‰p—Y (¸_): ‘ć35‰ń–k—˘ŽîᇃtƒH[ƒ‰ƒ€ (2018/9/7), ‘Š–ÍŒ´.

733266. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠóŽ€”O—ś‚đ—L‚ˇ‚é‘ĺŠwś‚Ö‚Ě‹łˆő‚ĚŠÖ‚í‚č‚Ɛ¸_‰Čˆă—Ă. ŹŕV@Šî1, Vˆä‹v–Ť1, —é–Ř—´‘ž˜Y1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ‘ć46‰ń_“ŢěŒ§SgˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/4/21), ‰Ą•l.

733267. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —‘‘ƒ‘BŽîpŒă‚ÉŒśŠoE–Ď‘zó‘Ô‚đ’ć‚ľ‚˝RNMDAŽó—e‘Ě”]‰Š‚Ěˆę—á. ×“c‘厥1, Vˆä‹v–Ť1, ŽRŒű—F‹I—Y1, ”Ń’Ë‚_2, œA‰ŞF—z1, ‘ĺÎ@’q1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_, 2_Œo“ŕ): ‘ć47‰ń_“ŢěŒ§SgˆăŠw‰ďEŠwpW‰ď (2018/9/15), ‰Ą•l.

733268. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ¨–Ŕó‘Ô‚Ş‘J‰„‚ľ‚Ä‹š…’™—Ż‚É‚ć‚莥—Ă‚É“ďa‚ľ‚˝“‡Ž¸’˛Ç‚Ěˆę—á. ŽRŒű—F‹I—Y1, Vˆä‹v–Ť1, ×“c‘厥1, —é–Ř—´‘ž˜Y1, Î“c‹§G1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ‘ć48‰ń _“ŢěŒ§SgˆăŠw‰ď‘‰ďEŠwpW‰ď (2019/3/23), ‰Ą•l.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H21-120001. [Œ´’˜] ¸_‰Čg‘̍‡•šÇ•a““ü‰@ŠłŽŇ‚Ě—Ő°“I“Á’Ľ‚ɂ‚˘‚Ä. ‘“c—ł‘ĺ1, Vˆä‹v–Ť1, ŽR–{ŒŤŽi1, ‹{‰Ş@“™1 (1¸_): _“ŢěŒ§¸_ˆăŠw‰ďŽGŽ 2009/3; 58: 3-9.

H28-522001. [uŔ]y“ÁW: ƒpƒ‹ƒX”g“d‹C‚Ż‚˘‚ę‚ń—Ă–@‚͐ł‚ľ‚­s‚í‚ę‚Ä‚˘‚é‚Šzu“d‹C‚Ż‚˘‚ę‚ń—Ă–@ (ECT) „§Ž–€‰ü’ů”Łv‚É‘Ľ‚č•W€‰ť‚ƉŽ‹‰ť‚đ’Ç‹‚ľ‚˝ƒpƒX‰ü’ů. ŕVŽRŒb”g1, ‰ş‘ş—TŒŠŽq1, ‰ÄŽR@‘ě, –{“c—], “‡–ě•ü–ç1, ‹{’nLŒá1, ‘ĺÎ@’q1, –ě‘ş”ü‹I, ŠÖX‘쉛, “c‘ş‘ń–˛, —é–ؐ­@, ´@„Žm, ŽRŒű–žŽq, ŒË“c‰ë–ç2, ’|˜Q–Ż]2, ‹{‰Ş@“™1 (1¸_, 2–ƒŒ): ¸_‰ČŽĄ—ĂŠw 2016/12; 31 (12): 1529-35.

H29-540009. [‚ť‚Ě‘ź (´˜^)]y‘ć113‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ďz¸_‰Č•a““ü‰@’†‚ĚŠłŽŇ‚É‚¨‚Ż‚鎊ŽEŠé}‚Ě“Á’Ľ‚Ć‘Îô. ’†‘şŒł”ü1, ‘ĺÎ@’q1, ˆäă•üŽq1, ‘ęŕV‹B–î1, ŽRŒű–žŽq, ŒFâ^—R”ü, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_): ¸__ŒoŠwŽGŽ 2017/6; 119 (Suppl): S382.

H29-540010. [‚ť‚Ě‘ź (´˜^)]y‘ć113‰ń“ú–{¸__ŒoŠw‰ďŠwp‘‰ďzî•sˆŔ’萍ƒp[ƒ\ƒiƒŠƒeƒBáŠQ“ü‰@ŠłŽŇ‚Ě“]‹AŠÖ˜A—vˆö‚ÉŠÖ‚ˇ‚錟“˘. Vˆä‹v–Ť1, ‘ĺÎ@’q1, âV“Ął”Í1, ˆäăŸ•v1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1 (1¸_): ¸__ŒoŠwŽGŽ 2017/6; 119 (Suppl): S543

[’˜@‘]

H29-620006. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@1. ¸_ˆăŠw‚Ɛg‘̏Ǐó‚Ć‚ĚŠÖ˜A, p.10-3. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620007. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@1. ¸_ŽžŠłŠT˜_@2. Ž•‰ČSgÇ‚Ɛ¸_ˆăŠw, p.14-8. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620008. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@1. ¸_ŽžŠłŠT˜_@2. Ž•‰ČSgÇ‚Ɛ¸_ˆăŠw, p.14-8. ‹{‰Ş@“™1, ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620009. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@2. Ž•‰ČSgÇ‚Ɛ¸_ˆăŠw, p.14-8. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620010. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@2. _ŒoÇŒ—@1. g‘Ě•\ŒťŤáŠQ, p.19-23. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620011. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@2. _ŒoÇŒ—@2. “]ŠˇŤáŠQE‹•‹UŤáŠQEź•a, p.24-6. ‹{‰Ş@“™1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620012. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@2. _ŒoÇŒ—@3. _ŒoŤáŠQ, p.27-8. 4. g‘̏XŒ`áŠQ, p.29-30. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620013. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@3. ‹C•ŞáŠQŒ—@3. ‹C•ŞáŠQ, p.31-5. ”Ń“c—@‹X1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620014. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@4. “‡Ž¸’˛ÇŒ—@1. “‡Ž¸’˛Ç, p.36-7. ™‘ş@–G1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620015. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@4. “‡Ž¸’˛ÇŒ—@2. ƒZƒlƒXƒgƒpƒ`[, p.38-9. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620016. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@5. ”F’mÇ@1. ¸_‰Č‚Š‚ç‚Ý‚˝”F’mÇ, p.40-3. ›I@‘P‹M1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620017. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@6.‘ΐlŠÖŒW‚É’ˆÓ‚ˇ‚ׂŤŽžŠł@1. ƒp[ƒ\ƒiƒŠƒeƒBáŠQ, p.47-9. ‹´–{@Ž÷1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620018. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@6.‘ΐlŠÖŒW‚É’ˆÓ‚ˇ‚ׂŤŽžŠł@2. ”­’BáŠQŒ—, p.50-4. _’Jr‰î1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620019. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@6.‘ΐlŠÖŒW‚É’ˆÓ‚ˇ‚ׂŤŽžŠł@3. ’m“IáŠQ, p.55-6. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620020. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@7. ˆË‘ś‚ÉŠÖ‚ˇ‚鎞Šł@1. ƒAƒ‹ƒR[ƒ‹ˆË‘śÇ, p.57-8. ŸNˆäGŽ÷1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620021. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@7. ˆË‘ś‚ÉŠÖ‚ˇ‚鎞Šł@2. ŰHáŠQ, p.59-60. Vˆä‹v–Ť1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620022. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@8. –ň•¨‚ÉŠÖ˜A‚ľ‚˝–â‘č@1. ¸_‰ČŽĄ—Ă–ň‚ÉŠÖ˜A‚ľ‚˝–â‘č|–ňÜ‚Ě•›ě—p|, p.61-71. œA‰ŞF—z1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620023. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć1Í ¸_ŽžŠł‚ĆŽ•‰ČŽĄ—Á@9. ‚ť‚Ě‘źA¸_‰Čˆă—Ă‚ÉŠÖ˜A‚ľ‚˝–â‘č@1. ¸_‰ČƒŠƒGƒ]ƒ“f—Ă, p.72-3. 2. ‚Ş‚ńŠłŽŇ‚̐S—, p.74-7. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620024. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć2Í ‚ą‚ą‚ë‚Ě•a‹C‚đl—ś‚ˇ‚ׂŤŒűoŠÖ˜AÇó‚ĆŽ•‰ČŽĄ—Á@1. Š´Šo‚Ě–â‘č@4. ŒűoŠŁ‘‡Š´, p.99-102. ˜a‹C—T”V, ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620025. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć2Í ‚ą‚ą‚ë‚Ě•a‹C‚đl—ś‚ˇ‚ׂŤŒűoŠÖ˜AÇó‚ĆŽ•‰ČŽĄ—Á@2. ŒűL‚Ě–â‘č@1. ŒűL‚Ş‹C‚É‚Č‚é, p.121-5. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620026. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć3Í ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚ĆƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg@2. ˆă—Ă‚đi‚ß‚éƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“, p.171-4. ‹{’n‰p—Y1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

H29-620027. [Šwp‘ (•Ş’SŽˇ•M)]y—אڈăŠwƒVƒŠ[ƒY@‚ą‚ą‚ë‚Ě•a‹C‚ĆŽ•‰ČŽĄ—Áz‘ć3Í ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚ĆƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg@3. ˆă—Ă‚đi‚ß‚éƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg, p.175-8. ‹{’n‰p—Y1, ‹{‰Ş@“™1 (1¸_), ŠÄ’˜: ‹{‰Ş@“™1, ˜a‹C—T”V, •Ň’˜: ‹{’n‰p—Y1, ˆË“c“N–ç, ƒfƒ“ƒ^ƒ‹ƒ_ƒCƒ„ƒ‚ƒ“ƒhŽĐ, “Œ‹ž, 2018/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-733008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒEƒ}‚ւ̐ڐG‚ރqƒg‚Ě”]Šˆ“Ž, S—ó‘Ô‚¨‚ć‚ŃƒXƒgƒŒƒX‚É‹y‚Ú‚ˇ‰e‹ż. ź‰Yť‰›, ‹Ŕ’돎Žq, –ŘŒË—tŸ, —é–؁@•ü, ŽR–{G–ž1, ‚‹´@Œb1, â“Œ—R‹I2 (1¸_, 2ŹŽ™): ‘ć54‰ń“ú–{‰Ć’{ŠÇ—Šw‰ďE‰ž—p“Ž•¨s“ŽŠw‰ď2018”N“xt‹G‡“ŻŒ¤‹†”­•\‰ď (2018/3/30), “Œ‹ž, Animal Behaviour and Management 201; 54: p.28.


•úŽËü‰ČŠw (‰ć‘œf’fŠw)

[Šwp˜_•ś]

110328. [Œ´’˜] CT dose modulation using automatic exposure control in whole-body PET/CT: effects of scout imaging direction and arm positioning. Inoue Y1, Nagahara K2, Kudo H2, Itoh H2: Am J Nucl Med Mol Imaging 2018/4; 8 (2): 143-52. (ˆäă—D‰î1, ‰iŒ´˜aŒ›2, H“ĄŠ°Žq2, ˆÉ“ĄŠ°‘×2: 1•úŽËü (‰ć‘œ), 2•úŽËü•”)

110329. [Œ´’˜] The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Akai H, Yasaka K, Kunimatsu A, Nojima M, Inoue Y1, Abe O, Ohtomo K, Kiryu S: Eur Radiol 2018/10; 28 (10): 4128-33. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

110330. [Œ´’˜] Attentional bias modification alters intrinsic functional network of attentional control: A randomized controlled trial. Hakamata Y, Mizukami S, Komi S, Sato E, Moriguchi Y, Motomura Y, Maruo K, Izawa S, Kim Y, Hanakawa T, Inoue Y1, Tagaya H: J Affect Disord 2018/10; 238: 472-81. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

110331. [Œ´’˜] Super-early images of brain perfusion SPECT using 123I-IMP for the assessment of hyperperfusion in stroke patients. Inoue Y1, Hara T1, Ikari T1, Takahashi K2, Miyatake H2, Abe Y2: Ann Nucl Med 2018/12; 32 (10): 695-701. (ˆäă—D‰î1, Œ´@•qŤ1, ’–Žë’m”ü1, ‚‹´Œc‘ž2, ‹{•”ä˜CŽ÷2, ˆ˘•”@–L2: 1•úŽËü (‰ć‘œ), 2•úŽËü•”)

110332. [Œ´’˜] Effects of the scan range on radiation dose in the computed tomography component of oncology positron emission tomography/computed tomography. Inoue Y1, Nagahara K2, Kudo H2, Itoh H2: Radiat Prot Dosimetry 2018/12. doi: 10.1093/rpd/ncy210. [Epub ahead of print] (ˆäă—D‰î1, ‰iŒ´˜aŒ›2, H“ĄŠ°Žq2, ˆÉ“ĄŠ°‘×2: 1•úŽËü (‰ć‘œ), 2•úŽËü•”)

110333. [Œ´’˜] Quantitative evaluation of display contrast of Gd-EOB-DTPA-enhanced magnetic resonance images: Effects of the flip angle and grayscale gamma value. Inoue Y1, Hata H2, Nakajima A2, Matsunaga K1, Ohzeki Y2, Hashimoto T2, Haradome H3: Radiol Res Pract 2019/1; 2019: 7630671. doi: 10.1155/2019/7630671. eCollection 2019. (ˆäă—D‰î1, `@”Ž•ś2, ’†“ˆ@—•2, ź‰iŒh“ń1, ‘ĺŠÖ—T‰î2, ‹´–{“N–ç2, Œ´—ŻOŽ÷3: 1•úŽËü (‰ć‘œ), 2•úŽËü•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă)

110334. [Œ´’˜] Clinical evaluation of CT radiation dose in whole-body 18F-FDG PET/CT in relation to scout imaging direction and arm position. Inoue Y1, Nagahara K2, Inoki Y3, Hara T1, Miyatake H2: Ann Nucl Med 2019/3; 33 (3): 169-76. (ˆäă—D‰î1, ‰iŒ´˜aŒ›2, ’––ě–Ř—F—˘3, Œ´@•qŤ1, ‹{•”ä˜CŽ÷2: 1•úŽËü (‰ć‘œ), 2•úŽËü•”, 3–k—˘‘ĺŠwˆăŠw•”)

120037. [Œ´’˜] Cone-beam CT‚É‚¨‚Ż‚éăŽˆ‚ĚˆĘ’u‚ĆŽB‰eđŒ‚̉掿‚ɑ΂ˇ‚é‰e‹ż. “Ąˆä@Š]1, ’Ë–ě@—D2, Œ´@•qŤ1, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ), 2•úŽËü•”): –k—˘ˆăŠw 2018/12; 48 (2): 97-104.

520019. [‘ŕ] ŠjˆăŠwŒŸ¸‚Ě’č—ĘŽw•W: ¸“x‚Ć”ť’č. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ŠjˆăŠw‹Zp 2019/1; 39 (1): 79-81.

521023. [‰đŕ] ˆă—Ă•úŽËü”í‚΂­‚ĚŒ’N‰e‹ż‚Ć’áŒ¸‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý (‰đŕ). ˆäă—D‰î (•úŽËü (‰ć‘œ)): _“ސěˆăŠw‰ďŽGŽ 2019/1; 46 (1): 6-9.

522179. [uŔ]y“ÁW: —Ť‚̉ş• •”’É: ‰ć‘œf’f‚ĆIVRz“ŕśBŠíŽîᇐŤ•a•Ď. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü(‰ć‘œ)): —Տ°‰ć‘œ2018/4; 34 (4): 400-11.

522180. [uŔ]y“ÁW: čň•”EŠç–Ę‚Ě‹~‹}ŽžŠł‚Ě‰ć‘œf’fzŠç–ʍœ (Šç–ʍœœÜ). •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‰ć‘œf’f 2018/6; 38 (8): 759-70.

522181. [uŔ]y“ÁW: ŠĚ‚Ě‰ć‘œf’fupdatezŠĚ×–E‘BŽî‚ĚˆŸ•Ş—Ţ‚ĆMRf’f. Œ´—ŻOŽ÷ (V˘‹Iˆă—ÁEć’[ˆă—Ă): ‰ć‘œf’f 2018/8; 38 (10): 1025-37.

522182. [uŔ]y“ÁW: čň•”EŠç–Ę‚Ě‹~‹}ŽžŠł‚Ě‰ć‘œf’fzŠç–ʍœ (Šç–ʍœœÜ). •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‰ć‘œf’f 2018/8; 38 (8): 759-70.

522183. [uŔ]y“ÁW: ‰ć‘œf’f‚Ě•Ę‚Ě–e|’č—ʉť‚Ɛłí’l‚Ě‚Ü‚Ć‚ß, “KłŽg—p‚Ć”í”˜zCT‚𒆐S‚Ć‚ľ‚˝ŠłŽŇ‚Ě”í”˜‚ɂ‚˘‚Ä. ˆäă—D‰î (•úŽËü (‰ć‘œ)): Ň’ŐҐ‘ƒWƒƒ[ƒiƒ‹ 2018/9; 31 (9): 831-5.

522184. [uŔ]y“ÁW: ‚ł‚Ü‚´‚Ü‚Č’°ŽžŠł‚Ě‰ć‘œf’fzŒeŽşÇEMeckelŒeŽş. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)): —Տ°‰ć‘œ 2018/10; 34 (10): 1171-82.

522185. [uŔ]y“ÁW: ˆă—Ă”í‚΂­‚̐ł“–‰ť‚ĆĹ“K‰ť‚ÉŒü‚Ż‚Ä qPart IIIr@ü—ĘŠÇ—‹`–ą‰ť‚Ě“ŽŒü‚Ćˆă—Ă‹@ŠÖ‚É‹‚ß‚ç‚ę‚é‘ΉžzI ü—ĘŠÇ—‹`–ą‰ť‚ÉŒü‚Ż‚˝‘“ŕ“ŽŒü‚ĆŠCŠO‚ĚŒťó@2. ‰ć‘œf’fŠÇ—‰ÁŽZ3‚Ć“ú–{ˆăŠw•úŽËüŠw‰ďƒKƒCƒhƒ‰ƒCƒ“‚ĚŠT—v. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ŒŽŠ§ƒCƒ“ƒi[ƒrƒWƒ‡ƒ“ 2019/2; 34 (3): 7-9.

[’˜@‘]

620144. [Šwp‘ (•Ş’SŽˇ•M)]y’m‚Á‚Ä‚¨‚Ť‚˝‚˘MRI‰ć‘œf’f‚ĚƒRƒc (—Տ°‰ć‘œ2018”N4ŒŽ‘Š§†)zŠe˜_@“Şčň•”, p. 113-20. •‚F—´‘ž˜Y(•úŽËü (‰ć‘œ)), Šé‰ćE•ŇW: ŒăŠŐ••F, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/4”­s.

620145. [Šwp‘ (•Ş’SŽˇ•M)]y“Ş•”‚̊ӕʐf’f‚Ěƒ|ƒCƒ“ƒg (‰ć‘œf’f2018”N‘Š§†)z‘ć12Í ÇŒó‚Š‚ç‚ĚƒAƒvƒ[ƒ`@‚ß‚Ü‚˘EŽ¨–‚̊ӕĘ, p.s216-21. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)), •Ň: Â–Ř–ÎŽ÷, ‘ĺę@—m, ŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2018/4”­s.

620146. [Šwp‘ (•Ş’SŽˇ•M)]y‹~‹}•úŽËüf’f‚Ö‚ĚƒAƒvƒ[ƒ` (—Տ°‰ć‘œ2018”N10ŒŽ‘Š§†)zVI.• •”@‹}Ť• Ç: f’f‚̐i‚ß•ű@”ń•ÂÇŤ’°ŠÔ–Œ‹•ŒŒ, p.188-9. •wl‰Č‹~‹}ŽžŠł, p.202-8. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)), Šé‰ć: ]Œ´@–Î, •Ň: …ŔmF, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2018/10”­s.

620147. [Šwp‘ (•Ş’SŽˇ•M)]y‹~‹}IVRŽč‹ZÚŕ with WEB “Ž‰ć (—Տ°•úŽËü2018”N11ŒŽ—ŐŽž‘Š§†)zĄŽč‹ZÚŕ•Ň [ŒŒŠÇIVR] with WEB “Ž‰ć@<• •”>@”ń•ÂÇŤ’°ŠÔ–Œ‹•ŒŒ, p. 1486-9. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)), ‹ŕŒ´o”Ĺ, “Œ‹ž, 2018/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712031. [Šw‰ď (‘Ű)] (ľ‘ҍu‰‰) ˆă—Ă•úŽËü‚Ě“KłŠÇ—‚ւ̐V‚˝‚ČŽć‚č‘g‚݂ɂ‚˘‚Ä. Inoue Y1: Bayer Lecture Conference in Chicago (RSNA 2018) (2018/11/26), Chicago, USA. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713157. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) fMRI constrained source analysis on stimulus-preceding negativity before face, word and symbol. Kotani Y, Ohgami Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: The 24th Annual Meeting of the Organization for Human Brain Mapping (2018/6/17-21), Singapore, Annual Meeting of the Organization of Human Brain Mapping, Abstract Book p. 54. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713158. [Šw‰ď (‘Ű)] (ˆę”ĘŒű‰‰) Functional dissociation of left and right anterior insula in anticipation. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: The 24th Annual Meeting of the Organization for Human Brain Mapping (2018/6/17-21), Singapore, Annual Meeting of the Organization of Human Brain Mapping, Abstract Book p. 54. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713159. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“) Different roles of left and right anterior insula in anticipation of behavioral information and reward information. Kotani Y, Ohgami Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: The 58th Annual Meeting of Society for Psychophysiological Research (2018/10/3-7), Quebec, Canada, Psychophysiology 2018/10; 55 (Suppl 1): S87. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713160. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“) Neural substrates of early and late SPN before face, word and symbol stimuli. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: The 58th Annual Meeting of Society for Psychophysiological Research (2018/10/3-7), Quebec, Canada, Psychophysiology 2018/10; 55 (Suppl 1): S113. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

722204. [Šw‰ď (‘S‘)] (Ç—á‹łˆçu‰‰) Ç—á‚Ĺ•R‰đ‚­“Şčň•”‰ć‘œf’f‚ĚƒRƒc`ƒGƒLƒXƒp[ƒg‚Š‚çŠw‚ԁ`. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‘ć77‰ń“ú–{ˆăŠw•úŽËüŠw‰ď‘‰ď (2018/4/12), ‰Ą•l, “ú–{ˆăŠw•úŽËüŠw‰ďŠwpW‰ď´˜^W 2018/2; 77: S117.

722205. [Šw‰ď (‘S‘)] (‹łˆç“WŽŚ) •ĄŽ‹: CT/MRI‚É‚¨‚Ż‚é‰ć‘œf’f. Žë–ě—m•ă1, •‚F—´‘ž˜Y1, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ)): ‘ć77‰ń“ú–{ˆăŠw•úŽËüŠw‰ď‘‰ď (2018/4/12-15), ‰Ą•l, “ú–{ˆăŠw•úŽËüŠw‰ďŠwpW‰ď´˜^W 2018/2; 77: 57.

722206. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒvEŒű‰‰”­•\) ‹~‹}‘Ήž@ŠOE”M, ŽY‰ČŠë‹@“IoŒŒ; •ę‘Ě‹~–˝‚Ě‚˝‚ß‚ĚIVR‚̐헪. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)): ‘ć43‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2018/6/23), “Œ‹ž, “ú–{ŠO‰ČŒn˜A‡Šw‰ďŽ 2018/6; 43 (3): 480.

722207. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) IVR‚̐i•ŕ‚Ş‚Ç‚Ě‚ć‚¤‚É–ĺ–Źˆł˜´iÇ‚ĚŽĄ—Ă‚đ•Ď‚Ś‚˝‚Ě‚Š? ˆÝtƒVƒƒƒ“ƒgˆČŠO‚Ě–ĺ–Ź‘̏zŠÂƒVƒƒƒ“ƒg‚ɑ΂ˇ‚éIVR. ‘ëě­˜a1, ˆäă“oŽm˜Y1, •˝ěk‘ž1, “cŒű’qŽq1, ‘ĺX’qŽq1, ó–ě—Y“ń1, “Ąˆä@Š]2 (1‘—§•a‰@‹@\‘Š–ÍŒ´•a‰@•úŽËü‰Č, 2•úŽËü (‰ć‘œ)): ‘ć25‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2018/9/20), ‘ĺă, “ú–{–ĺ–Źˆł˜´iÇŠw‰ďŽGŽ 2018/8; 24 (3): 84.

722208. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ŠjˆăŠwŒŸ¸‚Ě’č—ĘŽw•W: ¸“x‚Ć”ť’č. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ďE‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/16), ‰Ť“ę, ŠjˆăŠw‹Zp 2018/10; 38 (—\eW): 357.

722209. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) Šç–ʍœœÜ‚Ě3ŽŸŒłCT‘œ: —L—pŤ‚ĆŒŔŠE. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‘ćŽO‰ń“ú–{ƒƒfƒBƒJƒ‹ƒCƒ‰ƒXƒgƒŒ[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ďE‘‰ď (2018/12/2), “Œ‹ž.

722210. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) “ŞŠW’ę‚Ě‰ć‘œf’f: —Տ°“I‚ɏd—v‚Čƒ|ƒCƒ“ƒg‚𒆐S‚É. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‘ć42‰ń“ú–{”]_ŒoCIŠw‰ď‘‰ď (2019/3/1), “Œ‹ž, ƒvƒƒOƒ‰ƒ€E´˜^W 2019/3; p.75.

723785. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) —Տ°“IŽîᇌaƒJƒeƒSƒŠ[‚đl—ś‚ľ‚˝ƒZƒ“ƒ`ƒlƒ‹ƒŠƒ“ƒpßśŒŸ“K‰žÇ—á‚ĚŒŸ“˘. ‘ş“c@Œ’1, Œ´@“ÖŽq1, ‘ĺ•”@˝1, –î“ŕŒ´‹v1,2, óŔŽjŽ÷1, ˆ˘•”h‘ĺ1, –îě‰ëŽj1, ”—@—T”V1, —é–ŘŒcˆę1, ‘ĺěš‹`1, _’J‹I‹P1,3, ‹e’rŽj˜Y1,4, Îˆä—ǍK1,5, “n粏š•F1,5, ’r“c@ł1 (1–k—˘Œ¤‹†Š•a‰@, 2•úŽËü (‰ć‘œ), 3ŒÄ‹zŠíŠO, 44•a‰@˜AŒg‹łˆç, 5‰ş•”Á‰ťŠÇŠO): ‘ć118‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/4/7), “Œ‹ž, “ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď´˜^W 2018/4; 118: 2479.

723786. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”ńZŤ“űŠÇŠŕ‚Əp‘Of’f‚ł‚ę‚˝Ç—á‚É‚¨‚Ż‚éƒZƒ“ƒ`ƒlƒ‹ƒŠƒ“ƒpßśŒŸČ—ނɂ‚˘‚Ä‚ĚŒŸ“˘. ‘ş“c@Œ’1, Œ´@“ÖŽq1, ‘ĺ•”@˝1, –î“ŕŒ´‹v1,2, óŔŽjŽ÷1, ‹kě“ސś1, ”~“c”üç1, Ş–{“Ţ’Ă”ü1, ‹v•Ç’źŽq1, Ź“c“‡D1, ŽR“c—mŽq1, ’†“ˆƒŽq1, ’r“c@ł1 (1–k—˘Œ¤‹†Š•a‰@, 2•úŽËü (‰ć‘œ)): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s, “ú–{“űŠŕŠw‰ď‘‰ďƒvƒƒOƒ‰ƒ€´˜^W 2018/5; 26: 673.

723787. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 60ÎˆČă‚̏—Ť‚ɑ΂ˇ‚é“ű‘BƒGƒR[•š—pŒŸf‚Ě—L—pŤ‚ĚŒŸ“˘. ”~“c”üç1, ‘ş“c@Œ’1, ’†“ˆƒŽq1, Œ´@“ÖŽq1, ‘ĺ•”@˝1, –î“ŕŒ´‹v1,2, ‹kě“ސś1, ŽR“c—mŽq1, ‹v•Ç’źŽq1, Ź“c“‡D1, Ş–{“Ţ’Ă”ü1, ’r“c@ł1 (1–k—˘Œ¤‹†Š•a‰@, 2•úŽËü (‰ć‘œ)): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/18), ‹ž“s, “ú–{“űŠŕŠw‰ď‘‰ďƒvƒƒOƒ‰ƒ€´˜^W 2018/5; 26: 776.

723788. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠgŽU‹­’˛‘œ‚Ĺ–ž—Ä‚Č‚M†‚đŽŚ‚ľ, ‘˝ŒŒŤŠĚ“]ˆÚ‚ĆŠÓ•Ę‚É‹ę—ś‚ľ‚˝FNH like nodule‚Ě1—á. âZ@@1, Œ´—ŻOŽ÷2, “c“‡@O3, ˆäă‹vŽq4, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ), 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4•a—): ‘ć32‰ń“ú–{• •”•úŽËüŠw‰ď (2018/5/25-26), _“ސě.

723789. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Œ°’˜Ť‚¨‚ć‚эs“Ž“K‰ž‚ÉŠÖ‚ˇ‚é‘O•”“‡”玿‚Ě‹@”\“Iś‰Eˇ. Ź’J‘בĽ1, ‘ĺăi”ü1, ‹g“c‹X´2, š ź@‘2, ‹Ëś@–Î3, ˆäă—D‰î4 (1“Œ‹žH‹Ć‘ĺŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ¤‹†‹łˆç‰@, 2“Œ‹ž‘ĺŠwˆă‰ČŠwŒ¤‹†Š, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠwˆăŠw•”, 4•úŽËü (‰ć‘œ)): ‘ć36‰ń“ú–{ś—S—Šw‰ď‘ĺ‰ď (2018/5/26), •Ÿ‰Ş, ‘ć36‰ń“ú–{ś—S—Šw‰ď‘ĺ‰ďƒvƒƒOƒ‰ƒ€E—\eW 2018/5; 2018: P-30b.

723790. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) fMRI§ŒŔƒ\[ƒX•ŞÍ‚É‚ć‚éSPN ‘OŠúŹ•Ş‚ĆŒăŠúŹ•Ş‚Ě”­śŒš‚Ě“Ż’č. ‘ĺăi”ü1, Ź’J‘בĽ1, ‹g“c‹X´2, š ź@‘2, ‹Ëś@–Î3, ˆäă—D‰î4 (1“Œ‹žH‹Ć‘ĺŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ¤‹†‹łˆç‰@, 2“Œ‹ž‘ĺŠwˆă‰ČŠwŒ¤‹†Š, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠwˆăŠw•”, 4•úŽËü (‰ć‘œ)): ‘ć36‰ń“ú–{ś—S—Šw‰ď‘ĺ‰ď (2018/5/27), •Ÿ‰Ş, ‘ć36‰ń“ú–{ś—S—Šw‰ď‘ĺ‰ďƒvƒƒOƒ‰ƒ€E—\eW 2018/5; 2018, P-60d.

723791. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Indocyanine Green‚đ—p‚˘‚˝Gd-EOB-DTPA‚ĚŠĚƒgƒ‰ƒ“ƒXƒ|[ƒ^[‚ւ̉e‹ż‚ĚŒŸ“˘. ÔˆäGs1, ‹Ëś@–Î2, ”ލâkˆę˜Y1, ‘ź@‘1, ˆäă—D‰î3, ‘ĺ—F@–M4, ˆ˘•”@C5 (1“Œ‹ž‘ĺŠwˆă‰ČŠwŒ¤‹†Š•úŽËü‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw•a‰@•úŽËü‰Č, 3•úŽËü (‰ć‘œ), 4‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 5“Œ‹ž‘ĺŠwˆăŠw•”•úŽËü‰Č): ‘ć13‰ń“ú–{•ŞŽqƒCƒ[ƒWƒ“ƒOŠw‰ď‘‰ďEŠwpW‰ď (2018/5/31), “Œ‹ž, “ú–{•ŞŽqƒCƒ[ƒWƒ“ƒOŠw‰ď‹@ŠÖŽ (JSMI Report) 2018/5; 11 (2): 94.

723792. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) Źl‚Ě–Tˆô“ŞŠÔŒ„‚ɐś‚ś‚˝‘ŮŽ™Œ^‰Ą–ä‹Ř“÷Žî‚Ě1—á. Žë–ě—m•ă1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, •Äˇ@ŠŠ2, Ź“‡—E‹M2, ‹g“c˜N•F3 (1•úŽËü (‰ć‘œ), 2‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@“ű‘BEŽîᇓŕ‰Č, 3“Ż•a—‰Č): ‘ć54‰ń“ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď (2018/10/6), •Ÿ‰Ş, “ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď´˜^W 2018/9; 54: S536.

723793. [Šw‰ď (‘S‘)] (Œű“Ş”­•\) 123I-IMP”]ŒŒ—ŹSPECT’´‘Šú‘œ‚Ě”]‘˛’†ŠłŽŇ‚É‚¨‚Ż‚鍂ŒŒ—Ź‚Ě•]‰ż. ’–Žë’m”ü1, ˆäă—D‰î1, Œ´@•qŤ1, ‚‹´Œc‘ž2, ‹{•”ä˜CŽ÷2, ˆ˘•”@–L2 (1•úŽËü (‰ć‘œ), 2•úŽËü•”): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ďE‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/16), ‰Ť“ę, ŠjˆăŠw 2018/11; 55 (Suppl): S206.

723794. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) ăŠ{“´‚ĚŒÇ—§ŤüˆŰŤŽîá‡. ˆŔ’B‚Ý‚¸‚Ů1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, —é–Ř—§r2, ŽR‰ş@‘ń2, H’JšŽj3, “Ąě’ź–ç2 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“ŞčňŠO, 3•a—): ‘ć38‰ń“ú–{‰ć‘œˆăŠw‰ďŠwpW‰ď (2019/3/8), “Œ‹ž, “ú–{‰ć‘œˆăŠw‰ďŽGŽ 2019/3; 37 (1): 88.

731105. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŔ‘H“IŠjˆăŠw“ljeuŔ|PACS‚đŠˆ—p‚ľ‚ā|. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ŠjˆăŠw“lje•×‹­‰ď (2019/3/16), “Œ‹ž.

732108. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆç‰‰‘č) ‚˝‚Ü‚É–Ú‚É‚ˇ‚éu‚ą‚ń‚ȏŠŒŠ‚Ş‘ľ‚Ś‚΂قړ–‚˝‚čv‚Ě“Şčň•”ŽžŠł. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‘ć540‰ńNR§˜b‰ď (2018/6/9), “Œ‹ž.

732109. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒnƒCƒhƒƒQƒ‹ƒRƒCƒ‹‚Ě—L—pŤ‚ɂ‚˘‚Ä. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)): AZUR”­”„5Žü”N‹L”Ou‰‰‰ď (2018/10/10), “Œ‹ž.

732110. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) CT‚É‚ć‚é•úŽËü”í‚΂­‚Ě’áŒ¸: “ú–{Šwp‰ď‹c‚Ě’ńŒž‚đŽó‚Ż‚Ä. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘Š–ÍŒ´‘˘‰eÜƒZƒ~ƒi[ 3rd stage (2018/10/30), _“ސě.

732111. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ˆă—Ă•úŽËü”í‚΂­‚ĚŒ’N‰e‹ż‚Ć’áŒ¸‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘ć60‰ń_“ސěˆăŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2018/11/23), _“ސě.

732112. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŠĚŽî᎐Ť•a•Ď‚ĚMRI‰ć‘œf’f|“ljeEŠÓ•Ę‚Ěƒ|ƒCƒ“ƒg‚ĆĹ‹ß‚Ě˜b‘č|. Œ´—ŻOŽ÷1 (1V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć35‰ń‘˝–€‰ć‘œˆăŠwƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/1/19), “Œ‹ž.

732113. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŽY•wl‰Č‹~‹}ŽžŠł‚Ě‰ć‘œf’f. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ)): 5th Radiology Today in Setouchi (2019/2/9), ‰ŞŽR.

733269. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “Ž–ŹŠÇŠJ‘ś‚É‚ć‚éEisenmengerÇŒóŒQ‚É‚¨‚Ż‚é”xŒŒ—ŹƒVƒ“ƒ`ƒOƒ‰ƒ€. ŽOˆäN•˝1, ƒEƒbƒhƒnƒ€ƒX—ćŽq1, •‚F—´‘ž˜Y1, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ)): ‘ć89‰ń“ú–{ŠjˆăŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2018/7/14), “Œ‹ž, ŠjˆăŠw 2018/12; 55 (1): 107.

733270. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ”]oŒŒ‹}ŤŠú‚Ě“Ş•”MRIŠgŽU‹­’˛‘œ‚Ĺ‹}ŤŠú”][Ç‚Ě“ŻŽž‡•š‚đ”F‚ß‚˝3—á. Šâč仉l1, Œ´@•qŤ1, ’–Žë’m”ü1, ŽOˆäN•˝1, ˆŔ’B‚Ý‚¸‚Ů1, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ)): 2018”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ď‹y‚Ń‘ć59‰ń—á‰ď (2018/10/20), ‰Ą•l, 2018”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ďE‘ć59‰ń—á‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.6.

733271. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) 18F-FDG PET/CT‚É‚¨‚Ż‚éCT”í‚΂­ü—Ę‚Ě—Ő°“IŒŸ“˘. ’––ě–Ř—F—˘1, ˆäă—D‰î2, Œ´@•qŤ2, ‰iŒ´˜aŒ›3, ‹{•”ä˜CŽ÷3 (1–k—˘‘ĺŠwˆăŠw•”, 2•úŽËü (‰ć‘œ), 3•úŽËü•”): ‘ć90‰ń“ú–{ŠjˆăŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2019/1/26), “Œ‹ž, ŠjˆăŠw 2019/1; 56 (1): 36.


•úŽËü‰ČŠw (•úŽËüŽîᇊw)

[Šwp˜_•ś]

110335. [Œ´’˜] Risk factors for radiotherapy incidents: a single institutional experience. Ishiyama H1, Shuto N2, Terazaki T2, Noda S2, Ishigami M2, Yogo K, Hayakawa K1: Med Dosim 2019 Spring; 44 (1): 26-9. doi: 10.1016/j.meddos.2017.12.006. Epub 2018 Feb 1. (ÎŽR”ŽžŠ1, Žń“Ąéş2, Ž›č„Žj2, –ě“c–Η˜2, Îă@–Ť2, ‘ě˜ad1: 1•úŽËü (Žîá‡), 2•úŽËü•”)

[Šw‰ďEŒ¤‹†‰ď“™]

723795. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Output characteristics of Cerenkov emission for a quality assurance tool in HDR brachytherapy. Yogo K, Tatsuno Y, Narusawa T, Shimo T, –ěŕVääť‰Ô1, Ozawa S, ÎŽR”ŽžŠ1, Nagata Y, ‘ě˜ad1 (1•úŽËü (Žîá‡): ‘ć115‰ń“ú–{ˆăŠw•¨—Šw‰ďŠwp‘ĺ‰ď (2018/4/14), ‰Ą•l, ˆăŠw•¨— 2018/4; 38 (1): 38.

723796. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)yŽi‰ďzÎŽR”ŽžŠ (•úŽËü (Žîá‡)): “ú–{•úŽËüŽîᇊw‰ďĽŹüŒšŽĄ—Ă•”‰ď‘ć‘ć20‰ńŠwp‘ĺ‰ď (2018/6/23), ˆďé.

723797. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒ‰ƒWƒIƒ~ƒNƒX“Á”÷—Ę‚đ—p‚˘‚˝œ“]ˆÚ‚đ—L‚ˇ‚é‘O—§‘BŠŕŠłŽŇ‚Ě—\Œă—\‘Ş. ÎŽR”ŽžŠ1, ‹´–{Ź˘2, “n糗S‰î2, ěăłŒĺ1, “c”¨Œ’ˆę3, ’Ă‘şGN3, Šâ‘şłŽk3, ’ˇ’Jě’q”V2 (1•úŽËü (Žîá‡), 2ˆă—ÉqśŠw•”, 3”ĺ”AŠí): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/11), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/9; p.344.

723798. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘O—§‘BŠŕ‰i‹v‘}“ü–§••ŹüŒš‚É‚¨‚Ż‚é•Ň‚ÝŽ…•tüŒš‚Ě—L—pŤ. ěăłŒĺ1, ÎŽR”ŽžŠ1, ’Ă‘şGN2, ŠÖŒűˆŠˆß1, “c”¨Œ’ˆę2, ‘“c@Ši1, ‘ě–L˜a1, –ěŕVääť‰Ô1, Ž”Ŕ‘ě˜N1, Šâ‘şłŽk2 (1•úŽËü (Žîá‡), 2”ĺ”AŠí): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/12), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/9; p.381.

723799. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘O—§‘BŠŕ‰i‹v‘}“ü–§••ŹüŒš—Ă–@Œă‚̍ś¸”XÄ”­‚ɑ΂ľ’čˆĘ•úŽËüŽĄ—Ă‚đŽ{s‚ľ‚˝ˆę—á. Ž”Ŕ‘ě˜N1, ěăłŒĺ1, ŠÖŒűˆŠˆß1, “c”¨Œ’ˆę2, ’Ă‘şGN2, Šâ‘şłŽk2, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”ĺ”AŠí): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/12), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/9; p.386.

723800. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) IŠú”xŠŕ‚ɑ΂ˇ‚é‘ĚŠ˛•”’čˆĘ•úŽËüŽĄ—Ă‚ĚŽĄ—ÐŹŃ. ‘ě–L˜a1, ‘“c@Ši1, ŠÖŒűˆŠˆß1, ěăłŒĺ1, —P–؍Ž•F2, ˛“Ą”Vr3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2ŒÄ‹zŠí“ŕ, 3ŒÄ‹zŠíŠO): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/12), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/9; p.396.

723801. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’ቿŠi3DƒXƒLƒƒƒi[‚đ—p‚˘‚˝‘Ě•\ŠłŽŇˆĘ’uĆ‡–@‚ĚƒZƒbƒgƒAƒbƒvƒGƒ‰[ŒŸo¸“x‚ɂ‚˘‚Ä. ‘“c@Ši1, ŽR–{˜ał2, Žń“Ąéş2, Žç“cŒ›’3, ŠÖŒűˆŠˆß1, ěăłŒĺ1, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2•úŽËü•”, 3ˆă—ÉqśŠw•”): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/13), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/9; p.321.

733272. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰)yŽi‰ďzÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘ć20‰ńƒˆƒE‘f125ƒV[ƒhüŒš‰i‹v‘}“ü‚É‚ć‚é‘O—§‘BŠŕ–§••ŹüŒš—Ă–@‹ZpuK‰ď (2018/7/21), “Œ‹ž.

733273. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 3ŽŸŒłƒXƒLƒƒƒi[‚đ—p‚˘‚˝Žîᇌa‘Ş’č‚ÉŠÖ‚ˇ‚錤‹†: ’†ŠÔ•ń. ‘“c@Ši1, ěăłŒĺ1, ŠÖŒűˆŠˆß1, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡): 2018”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ď (2018/10/20), ‰Ą•l, 2018”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ďĽ‘ć59‰ń—á‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.7.

733274. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘O—§‘BŠŕ‰i‹v‘}“ü–§••ŹüŒšŽĄ—ĂŒă‚b‚s‰ć‘œ‚Š‚ç’Šo‚ľ‚˝Radiomics“Á’Ľ—Ę‚Ě—\Œă—\‘ވöŽq‚Ć‚ľ‚Ẳ”\Ť. ěăłŒĺ (•úŽËü (Žîá‡)): ‘ć15‰ń‘O—§‘BŠŕ–§••ŹüŒš‰i‹v‘}“üŽĄ—ĂŒ¤‹†‰ď (2019/1/20), “Œ‹ž, ‘ć15‰ń‘O—§‘BŠŕ–§••ŹüŒš‰i‹v‘}“üŽĄ—ĂŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€ 2019; p.3.

733275. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰)yŽi‰ďzÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘ć66‰ń‰Ą•l•úŽËüŽĄ—ͧ˜b‰ď (2019/2/18), ‰Ą•l.

733276. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “Şčň•”IMRT‚É‚¨‚Ż‚éDVH‚ĆQOL‚ĚŠÖŒW. ‘ě–L˜a1, ‘“c@Ši1, ŠÖŒűˆŠˆß1, ěăłŒĺ1, Ž”Ŕ‘ě˜N1, ‹{–{r•ă2, ŽR‰ş@‘ń2, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2Ž¨•@ˆôAE“Şčň•”ŠO): ‘ć66‰ń‰Ą•l•úŽËüŽĄ—ͧ˜b‰ď (2019/2/18), ‰Ą•l.

733277. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) IIIŠú”ńŹ×–E”xŠŕ‚ɂ‚˘‚Ä. ‘“c@Ši (•úŽËüŽîá‡): –k—˘‘ĺŠw•a‰@ŒÄ‹zŠí“ŕ‰Čŕ–ž‰ď (2019/3/4), _“ސě.

733278. [Šw‰ď (’n•űŠw‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰)yŽi‰ďzÇ—áƒfƒBƒXƒJƒbƒVƒ‡ƒ“. ‘“c@Ši (•úŽËü (Žîá‡)): Pneumonitis Management Academy`PACIFIC ƒŒƒWƒƒ“‚É‚¨‚Ż‚é”x‘Ÿ‰Š‚đŠw‚ԁ` (2019/3/15), _“ސě.


–ƒŒ‰ČŠw

[Šwp˜_•ś]

110006. [Œ´’˜] Pallidin is a novel interacting protein for cytohesin]2 and regulates the early endosomal pathway and dendritic formation in neurons. Ito A1, Fukaya M2, Saegusa S, Kobayashi E, Sugawara T2, Hara Y2, Yamauchi J, Okamoto H3, Sakagami H2: J Neurochem 2018/10; 147 (2): 153-77. (ˆÉ“Ą—@Žq1, [’JšO2, ›Œ´Œ’”V2, Œ´@–FL2, ‰Ş–{_Žk3, ăă—ms2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰đ–U, 3–ƒŒ)

110336. [Œ´’˜] Short-term results of intrathecal injection of low-dose bupivacaine in outpatients with chronic low back and lower extremity pain. Kanai A1,2, Okamoto T, Hayashi N2, Shimao J2, Nagahara Y, Fujii K3: Eur Spine J 2019/2; 28 (2): 250-8. (‹ŕˆäş•ś1,2, —с@Œol2, “ˆ”ö~Žq2, “Ąˆä@Š]3: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ, 3•úŽËü (‰ć‘œ))

220008. [€Œ´’˜]y—Տ°ŒoŒąz“Ť‚Ş‚ńŤáu’ÉŠłŽŇ‚ɑ΂ˇ‚é‹ÇŠ–ƒŒ–ň‚É‚ć‚éŇ‘‚­‚ŕ–Œ‰ş’Á’É‚Ě—L—pŤ. ‹ŕˆäş•ś1,2, —с@Œol2, “ˆ”ö~Žq2, ŻŽR—LG, ‰Í‘ş’źŽ÷2, r@Ť’q2, •s•ˇˆę‹M2, Šâ–{ƒŽq (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): –ƒŒ 2019/1; 68 (1): 52-9.

310027. [Ç—á•ń] Postobstructive pulmonary edema complicated by transient cardiac dysfunction in a young woman. Otsuka T1, Nishizawa Y1, Yoshino K2, Tanaka K1, Sakai M1, Arai M1,3, Okamoto H1, Kuroiwa M1: Kitasato Med J 2018/9; 48 (1): 128-31. (‘ĺ’Ë’q‹v1, źŕV‹`”V1, ‹g–ě˜a‹v2, “c’†ˆęś1, ăˆä䝗LŽq, VˆäłN1,3, ‰Ş–{_Žk1, •Šâ­”V1: 1–ƒŒ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

320036. [Ç—á•ń]y—Տ°ŒoŒąz“Ť‚Ş‚ńŤáu’ÉŠłŽŇ‚ɑ΂ˇ‚é‹ÇŠ–ƒŒ–ň‚É‚ć‚éŇ‘‚­‚ŕ–Œ‰ş’Á’É‚Ě—L—pŤ. ‹ŕˆäş•ś1,2, —с@Œol2, “ˆ”ö~Žq2, ŻŽR—LG2, ‰Í‘ş’źŽ÷2, r@Ť’q2, •s•ˇˆę‹M2, Šâ–{ƒŽq3 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ, 3–k—˘‘ĺŠw•a‰@ŠÉ˜aƒPƒAŽş): –ƒŒ 2019/1; 68 (1): 52-9.

320037. [Ç—á•ń] ‘Sg–ƒŒŠoÁŒă‚Ě’áŽ_‘f. ŽR‰ş@“Ö1, —с@Œol1, ‘ĺ’Ë’q‹v1, ź“cO”ü1, ‰Ş–{_Žk1 (1–ƒŒ): ŹŽ™ŠO‰Č 2019/3; 51 (3): 303-7.

522186. [uŔ]y“ÁW: ’É‚˘‚Ů‚Ç‚ć‚­‚í‚Š‚é!@–Ťáu’ÉŽĄ—Ă–ň‚ĚƒLƒzƒ“z–Ťáu’ÉŽĄ—Ă–ň‚Ě‘I‚Ń•ű, Žg‚˘•ű@
EƒIƒsƒIƒCƒh’Á’É–ň. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ŒŽŠ§–ňŽ– 2018/4; 60 (5): 45-9.

522187. [uŔ]y“ú–{—Տ°–ƒŒŠw‰ď‘ć37‰ń‘ĺ‰ď ‹łˆçu‰‰zĂ–ŹŒŒđÇđÇUp-to-date|’áŽ_‘fŤŒŒŠÇ“ŕ”ńáŠQ‚â’SŠŕŠłŽŇ‚Ě‰Č‹ĂŒĹó‘ԂȂǂɂ‚˘‚ā|. •Šâ­”V (–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ďŽ 2018/9; 38 (5): 615-21.

[Šw‰ďEŒ¤‹†‰ď“™]

713161. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Effect of tranexamic acid on surgical bleeding: Does it works for adolescent idiopathic scoliosis surgery? Matsuda H1, Okamoto H1: The 15th Conference of Asian Society of Paediatric Anaesthesiologists (ASPA 2018) (2018/8/19), Bangkok, Thailand. (ź“cO”ü1, ‰Ş–{_Žk1: 1–ƒŒ)

713162. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Increase in itraocular pressure during robotic laparoscopic prostatectomy performed in head down position. Sugimura K1, Takenami T1, Suzuki T, Ikeda T, Tabata K, Okamoto H1: American Society of Anesthesiologists 2018 (2018/10/14), San Francisco, USA. (™‘şŒ›—ş1, ’|˜Q–Ż]1, ‰Ş–{_Žk1: 1–ƒŒ)

713163. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Effect of sub-tenon's block for post-operative analgesia after pediatric strabismus surgery. "A Comparison Between 2% Lidocaine and 0.75% Ropivacaine". Nakazawa A1, Suzuki S1, Matsuda H1, Goseki T2, Okamoto H1, Ishikawa H3: Anesthesiology2018 (American society of Anesthesiologist) (2018/10/16), San Francisco, USA. (’†ŕVˆş”T1, —é–؍š—R”ü1, ź“cO”ü1, ŒăŠÖ—˜–ž2, ‰Ş–{_Žk1, Îě@‹Ď3: 1–ƒŒ, 2Šá‰Č, 3ˆă—ÉqśŠw•”)

721023. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‚Ş‚ńƒTƒoƒCƒo[‚ɑ΂ˇ‚éƒIƒsƒIƒCƒh“Š—^‚ĚŒœ”O‚Ć‘Îô. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć40‰ń“ú–{áu’ÉŠw‰ď (2018/6/15), ’ˇč.

721024. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚̍čl. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/19), “Œ‹ž.

721025. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚éƒIƒsƒIƒCƒh‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć48‰ń“ú–{–Ťáu’ÉŠw‰ď (2019/2/15), Šň•Œ.

722211. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽŸ˘‘ă‚ĚŠë‹@ŠÇ—`–ƒŒ‰Čˆă‚Í‚˘‚Š‚ɉ@“ŕŠë‹@ŠÇ—‚ÉŠÖ—^‚ľ‚čs‚­‚ׂŤ‚Š`Rapid Response System‚Ö‚ĚŠÖ—^. •Šâ­”V (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/17), ‰Ą•l.

722212. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽüpŠúƒ‚ƒjƒ^[‚̐i•ŕ‚Í—\Œă‚đ‰ü‘P‚ľ‚˝‚Š?: ŒŒ‰t‹ĂŒĹƒ‚ƒjƒ^[. •Šâ­”V (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/18), ‰Ą•l.

722213. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yL•ńˆĎˆő‰ď: ˆăŠwśE—Տ°Œ¤Cˆă (‰Šú) ľ‘ŇŠé‰ćzPBLD ”xŒŒđÇđÇ. •Šâ­”V (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/18), ‰Ą•l.

722214. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ÇŠ–ƒŒ–ň‚̐_Œo“ŐŤ. ’|˜Q–Ż] (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/19), ‰Ą•l.

722215. [Šw‰ď (‘S‘)] (‹łˆçƒVƒ“ƒ|ƒWƒEƒ€) uĂ–ŹŽžŠł: ƒKƒCƒhƒ‰ƒCƒ“‚Ɖ䂪‘‚ĚƒGƒrƒfƒ“ƒXv“ú–{–ƒŒ‰ČŠw‰ď•ń: ŽüpŠú”xÇđÇ. •Šâ­”V (–ƒŒ): ‘ć38‰ń“ú–{Ă–ŹŠw‰ď‘‰ď (2018/6/15), ‰Ą{‰ę.

722216. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‚Ş‚ńƒTƒoƒCƒo[‚ɑ΂ˇ‚éƒIƒsƒIƒCƒh“Š—^‚ĚŒœ”O‚Ć‘Îô. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć40‰ń“ú–{áu’ÉŠw‰ď (2018/6/15), ’ˇč.

722217. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰@“ŕ‹}•Ď‚𖢑R‚É–h‚ŽRapid Response Systemv“–‰@‚É‚¨‚Ż‚éRRSŠĹŒěŽt‚Ě–đŠ„. •Šâ­”V (–ƒŒ): ‘ć14‰ń“ú–{ƒNƒŠƒeƒBƒJƒ‹ƒPƒAŠĹŒěŠw‰ďŠwpW‰ď (2018/6/30), “Œ‹ž.

722218. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚̍čl. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ):“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/19), “Œ‹ž.

722219. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y‘I‘đŽˆ‚ŞŠg‘ĺ‚ľ‚˝‚Ş‚ńáu’ɂɑ΂ˇ‚éƒIƒsƒIƒCƒh’Á’É–ň|—L—p‚ɂ‚Š‚¤‚˝‚ß‚Ě”éŒ|z1) ‚Ş‚ńŤ’ÉŠłŽŇ‚ɑ΂ˇ‚éƒgƒ‰ƒ}ƒh[ƒ‹‚Ě—L—pŤ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/21), “Œ‹ž.

722220. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –ƒŒŠÇ—‚ĆTEE. ‰Ş–{_Žk (–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ď‘ć38‰ń‘ĺ‰ď (2018/11/2), –k‹ăB.

722221. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –ƒŒ‰Čˆă‚Ě—§ę‚Š‚ç|MICSŠłŽŇ‚ĚˆŔ‘S‚ȏTpŠúŠÇ—|. ‰Ş–{_Žk (–ƒŒ): ‘ć44‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2018/11/10), ‹ŕ‘ň.

722222. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y‚˘‚Ü‚ł‚畡‚Ż‚Č‚˘‹Ů‹}‹C“šŠÇ—í—ށz‘˝EŽí‚Š‚ç‚̖ڐü‚Ĺ—lX‚ČŽć‚č‘g‚Ý‚đĐ‰î` ‹Ů‹}‹C“šŠÇ—‚ÉŠÖ‚ˇ‚éĹV‚Ě’mŒŠ‚đ“Ľ‚Ü‚Ś‚˝Žć‚č‘g‚݁`. •Šâ­”V (–ƒŒ): ‘ć13‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2018/11/24), –źŒĂ‰Ž.

722223. [Šw‰ď (‘S‘)] (ƒXƒC[ƒcƒZƒ~ƒi[) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚éƒIƒsƒIƒCƒh‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć48‰ń“ú–{–Ťáu’ÉŠw‰ď (2019/2/15), Šň•Œ.

722224. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “–‰@‚Ĺ‚Ěˆ’uE’ÁĂŽž‚É‚¨‚Ż‚éRRS‹N“ŽÇ—á‚ĚŒŸ“˘. •Šâ­”V1, źŕV‹`”V1, Ź’r•üF2,3, XˆŔŒbŽŔ2, ‘ĺ’JŽ–ç2,3, ‘şź–ž“ú1, —é–Ř—D‘ž˜Y1, ăˆä䝗LŽq1, ‘ĺ’Ë’q‹v1, VˆäłN1,4 (1–ƒŒ, 2ŠĹŒě•”, 3RSTERRTŽş, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s.

723802. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”­Ç3‚ŠŒŽˆČ“ŕ‚Ě‘Ńóáv]ŠÖ˜A’ÉŠłŽŇ‚É‚¨‚Ż‚é_ŒoƒuƒƒbƒN‚Ě–Ť’É—\–hŒř‰Ę. ‰iˆäˆŸˆË1, ‹ŕˆäş•ś1,2, —с@Œol1, “ˆ”ö~Žq1, ‰Í‘ş’źŽ÷1, r@Ť’q1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/17), ‰Ą•l.

723803. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć“VŤSŽžŠł‚đ‡•š‚ľ‚˝ŹŽ™‚É‚¨‚Ż‚é”ńS‘ŸŽčpŽž‚ĚŽüpŠú‹ô”­Ç‚ĚŒă•űŽ‹“IŒŸ“˘. “V–ě–ž’ĂŽŃ1, —é–؍š—R”ü1, ź“cO”ü1, ŽR‰ş@“Ö1, –x]ĘD1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/17), ‰Ą•l.

723804. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şŽčp—pƒƒ{ƒbƒg‚đ—p‚˘‚˝‘O—§‘B“Eœp‚ĚŠáˆł•Ď‰ť. Ź—ѐç‰Ä1, ’|˜Q–Ż]1, r@Ť’q1, “c’†ˆęś1, —é–Ř’mŽq, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/18), ‰Ą•l.

723805. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”­Ç3‚ŠŒŽˆČ“ŕ‚Ě‘Ńóáv]ŠÖ˜A’ÉŠłŽŇ‚É‚¨‚Ż‚é_ŒoƒuƒƒbƒN‚Ě–Ť’É—\–hŒř‰Ę. ‰iˆäˆŸˆË1, ‹ŕˆäş•ś1,2, —с@Œol1, “ˆ”ö~Žq1, ‰Í‘ş’źŽ÷1, r@Ť’q1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ď‘ć65‰ńŠwpW‰ď (2018/5/18), ‰Ą•l.

723806. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒsƒIƒCƒh—U”­Ť•Ö”éÇŽĄ—Ă–ňƒiƒ‹ƒfƒƒWƒ“‚Ě—LŒřŤ‚ÉŠÖ‚ˇ‚錤‹†. ‹ŕˆäş•ś1,2, •“š—Á•˝3, –{ŠÔ‰ëŽm3, ‘ž“c’q”Ž3, •˝’ËŒö–¤3, •˝ŽR•Ži3, —с@Œol1, Œú“cKˆę˜Y3 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3–ňÜ•”): ‘ć12‰ń“ú–{ŠÉ˜aˆă—Ă–ňŠw‰ď”N‰ď (2018/5/26), “Œ‹ž.

723807. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť‚Ş‚ńŤáu’ÉŠłŽŇ‚ɑ΂ˇ‚é‹ÇŠ–ƒŒ–ň‚É‚ć‚éŇ‘‚­‚ŕ–Œ‰ş’Á’É‚Ě—L—pŤ. ‚‹´—Cˆę˜N1, ‹ŕˆäş•ś1,2, —Ń Œol1, “ˆ”ö~Žq1, ŻŽR—LG1, ‰Í‘ş’źŽ÷1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/20), “Œ‹ž.

723808. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‘ą˜•”d–ŒŠOƒuƒƒbƒN‚Ş—L—p‚Ĺ‚ ‚Á‚˝Stiff-personÇŒóŒQ‚Ě1—á. ‰Í‘ş’źŽ÷1, ‹ŕˆäş•ś1,2, —с@Œol1, “ˆ”ö~Žq1, ŻŽR—LG1, ‚‹´—Cˆę˜N1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/20), “Œ‹ž.

723809. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘nˆ’u’ɂɑ΂ˇ‚éƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ě—L—pŤ. —с@Œol1, ‹ŕˆäş•ś1,2, ŻŽR—LG1, ‰Í‘ş’źŽ÷1, ‚‹´—Cˆę˜N1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/20), “Œ‹ž.

723810. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘яóáv]ŠÖ˜A’É‚đ—L‚ˇ‚鍂—îŽŇ‚Ě”F’m‹@”\‚Ě’ˇŠúŠĎŽ@. ŻŽR—LG1, ‹ŕˆäş•ś1,2, —с@Œol1, “ˆ”ö~Žq1, r@Ť’q1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă):“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/20), “Œ‹ž.

723811. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˜•”Žčp—đ‚Ě‚ ‚鍘‰şŽˆ’ÉŠłŽŇ‚ɑ΂ˇ‚éŇ‘‚­‚ŕ–Œ‰şƒuƒƒbƒN‚Ě—L—pŤ. ’|’†~Œĺ1, ‹ŕˆäş•ś1,2, —с@Œol1, “ˆ”ö~Žq1, ŻŽR—LG1, ‰Í‘ş’źŽ÷1, ‚‹´—Cˆę˜N1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‘ć52‰ń‘ĺ‰ď (2018/7/20), “Œ‹ž.

723812. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ź‘ĺŒŒŠÇ‰EŽş‹NŽnÇ‚ĚŽčp’†‚ɐlHS”x‰ń˜H‚ÉŒŒđ•ÂÇ‚𐜂ś‚˝ˆę—á. ’†ŕVˆş”T1, ě’[ääťŽq1, ˆŔ“ĄŽőŒb1, ź“cO”ü1, ŒË“c‰ë–ç1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ď‘ć23‰ńŠwp‘ĺ‰ď (2018/9/14), “Œ‹ž.

723813. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒoƒ‹ƒTƒ‹ƒo“´“Ž–ŹáŽ”j—ô‚É‚ć‚é‘ĺ“Ž–Ź-‰E–[á‘2Ç—á‚Ě–ƒŒŒoŒą. —é–Ř›’Žk1, ŒË“c‰ë–ç1, ‚‹´—Cˆę˜N1, ŽR‰ş@“Ö1, ™‘şŒ›—ş1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ď‘ć23‰ńŠwp‘ĺ‰ď (2018/9/15), “Œ‹ž.

723814. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŠłŽŇ‚É‚¨‚Ż‚é’´‰š”gƒKƒCƒh‰ş_ŒoƒuƒƒbƒN‚̍H•v. –x]ĘD1, ‹{ŕV“TŽq, ŽR’n–FO, ” Ş‰ëŽq, ź“cO”ü1, ‰Ş–{_Žk1, ź•”Lˆę (1–ƒŒ): “ú–{ŹŽ™–ƒŒŠw‰ď‘ć24‰ń‘ĺ‰ď (2018/10/20), _ŒË.

723815. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VśŽ™‚̏Á‰ťŠÇ•Â˝ÇŽčp‚É‚¨‚Ż‚é• ’ź‹ŘâƒuƒƒbƒN‚Ě—L—pŤ‚ĚŒŸ“˘. –x]ĘD1, ‹{ŕV“TŽq, _“ĄŒd—ć, ˆäăˆť”T, ˛X–Ř—C•ă, ’ˇ“céŽq, ’şŽg‰ÍŒ´ˆť–ě, ź“cO”ü1, ‰Ş–{_Žk1, ź•”Lˆę (1–ƒŒ): “ú–{ŹŽ™–ƒŒŠw‰ď‘ć24‰ń‘ĺ‰ď (2018/10/20), _ŒË.

723816. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}‘Ź‚ɐis‚ˇ‚éă‹C“š‹ˇó‚ɑ΂ľ‚Đş–ĺăƒfƒoƒCƒX‚đ—p‚˘‚Ä‹CŠÇ‘}ŠÇ‚đs‚Á‚˝ˆęÇ—á. —é–؍š—R”ü1, ź“cO”ü1, ˆÉ“Ą—@Žq2, ’†ŕVˆş”T1, “Ą–ěŽŃ‹M1, ŽÂŒ´ŒcŽq1, ‰Ş–{_Žk1 (1–ƒŒ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{ŹŽ™–ƒŒŠw‰ď‘ć24‰ń‘ĺ‰ď (2018/10/21), _ŒË.

723817. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚“xŒŒŠÇ•a•Ď‚đ—L‚ˇ‚鍂ˆŔ•a‡•š”D•w‚ɑ΂ˇ‚é’鉤ŘŠJp‚Ě–ƒŒŒoŒą. r@Ť’q1, ×ěKŠó1, ”˘•űhŽq1, ‰Á“Ą—˘ŠG1,2, ‰œ•xr”V1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{—Տ°–ƒŒŠw‰ď‘ć38‰ń‘ĺ‰ď (2018/11/2), –k‹ăB.

723818. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äB”^ᇂɂć‚épŒă”sŒŒÇŤƒVƒ‡ƒbƒN‚ɑ΂ľ‚ÄPMX-DHP‚Ş’˜Œř‚ľ‚˝ˆę—á. ŽR–{^–ç1, źŕV‹`”V1, —é–Ř—D‘ž˜Y1, ˆŔ’B@Œ’1, ‘ĺ’Ë’q‹v1, •Šâ­”V1, VˆäłN1,2, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{—Տ°–ƒŒŠw‰ď‘ć38‰ń‘ĺ‰ď (2018/11/2), –k‹ăB.

723819. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŒƒ{ƒuƒsƒoƒJƒCƒ“‚ĆƒƒsƒoƒJƒCƒ“‚đ—p‚˘‚˝d–ŒŠO–ƒŒŒă‚É‘J‰„ŤŠ´ŠoáŠQ‚ƉşŽˆ‚̋ؗ͒ቺ‚đ—ˆ‚ľ‚˝1Ç—á. –{“c’h1, m–Ř—L—Žq1, •s•ˇˆę‹M1, _“c‰Â“ŢŽq1, ˆÉ“Ą‘s•˝1, ’|˜Q–Ż]1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ď‘ć38‰ń‘ĺ‰ď (2018/11/2), –k‹ăB.

723820. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) d–ŒŠO—pƒJƒe[ƒeƒ‹‚đ—p‚˘‚˝ˆÓŽŻ‰şƒtƒ@ƒCƒo[‘}ŠÇ. ě’[ääťŽq1, —é–Ř—D‘ž˜Y1, ’|˜Q–Ż]1, ’Ă—Ż˘—˘2, ‰Ş–{_Žk1 (1–ƒŒ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{—Տ°–ƒŒŠw‰ď‘ć38‰ń‘ĺ‰ď (2018/11/3), –k‹ăB.

723821. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´‰š”g‰ć‘œf’f‘•’u‚É‚ć‚éICU“üŽşŠłŽŇ‚̍œŠi‹Ř“ÁŤ•]‰ż|ICU-AWE—\Œă‚Ć‚ĚŠÖŒW|. •Šâ­”V1, Ź’r•üF2,3, ŒŠˆä“c˜ał4, _’JŒ’‘ž˜Y5, ŕ_čL–ž4, VˆäłN1,6 (1–ƒŒ, 2RSTERRTŽş, 3ŠĹŒě•”, 4ƒŠƒnƒrƒŠ•”, 5ˆă—ÉqśŠw•”, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/1), ‹ž“s.

723822. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}Ť‘ĺ“Ž–Ź˜¨—Ł (Stanford A) ŠłŽŇ‚É‚¨‚Ż‚ép‘OD’†‹…/ƒŠƒ“ƒp‹…”ä‚ƏTpŠú‡•šÇ‚ĚŠÖ˜A‚ĚŒŸ“˘. ™‘şŒ›—ş1, VˆäłN1,2, •Šâ­”V1, ‘ĺ’Ë’q‹v1, ˆŔ’B@Œ’1, źŕV‹`”V1, ăˆä䝗LŽq1, —é–Ř—D‘ž˜Y1, ‹g–ě˜a‹v3, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/1), ‹ž“s.

723823. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Rapid Response System‹N“ŽŠłŽŇ‚Ö‚ĚŽĄ—Éî“ü‚Ć—\Œă. •Šâ­”V1, VˆäłN1,2, Ź’r•üF3,4, XˆŔŒbŽŔ3, ‘ĺ’JŽ–ç3,4, ăˆä䝗LŽq1, —é–Ř—D‘ž˜Y1, źŕV‹`”V1, ˆŔ’B@Œ’1, ™‘şŒ›—ş1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ŠĹŒě•”, 4RSTERRTŽş): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/3), ‹ž“s.

723824. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Rapid Response System‹N“Ž”‚Ş—\Šú‚š‚ʉ@“ŕŽ€–S‚É‹y‚Ú‚ˇŒř‰Ę. •Šâ­”V1, ăˆä䝗LŽq1, VˆäłN1,2, Ź’r•üF3,4, XˆŔŒbŽŔ3, ‘ĺ’JŽ–ç3,4, ‘ĺ’Ë’q‹v1, źŕV‹`”V1, ˆŔ’B@Œ’1, ™‘şŒ›—ş1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ŠĹŒě•”, 4RSTERRTŽş): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/3), ‹ž“s.

723040. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RAMP1 signaling in immune cells regulates lymphangiogenesis in the diaphragm during peritonitis. ’Ă—Ż˘—˘1, ˆÉ“Ą‹`–ç2, ×–ě‰Á“ŢŽq2, ź“cO”ü3, ‘ dçŠG3, ˆäă’qm1, ’†–{CŽi1, ‘ĺ‚Žjš1, ‰Ş–{_Žk3, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–ƒŒ): ‘ć92‰ń“ú–{–ň—Šw‰ď”N‰ď (2019/3/14), ‘ĺă.

723825. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒLƒVƒRƒhƒ“™•úů‚É‚ć‚éƒIƒsƒIƒCƒh—U”­Ť•Ö”é‚ɑ΂ˇ‚éƒiƒ‹ƒfƒƒWƒ“ƒgƒVƒ‹Ž_‰–‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚錤‹†. ‹ŕˆäş•ś1,2, •˝ŽR•Ži3, •“š—Á•˝3, —é–؁@ˆ¨, •˝’ËŒö–¤3, ‘ž“c’q”Ž3, –{ŠÔ‰ëŽm3, —с@Œol1, Œú“cKˆę˜Y3 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3–ňÜ•”): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď 2019 (2019/3/23), ŽD–y.

731106. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‹}Ť’É‚Ć–Ť’É‚ĚƒIƒsƒIƒCƒh‘Ήž. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘Š–ÍŒ´Žs‘ĺ˜aŽsŽŒ`ŠO‰Čˆă‰ď‡“ŻŠwpu‰‰‰ď (2018/4/14),‘Š–ÍŒ´.

731107. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): •˝’Ë–Ťáu’ɍu‰‰‰ď (2018/4/26), •˝’Ë.

731108. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): Œú–ŘŽs–ňÜŽt‰ďŠwpu‰‰‰ď (2018/5/23), Œú–Ř.

731109. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‚Ş‚ńƒTƒoƒCƒo[‚ɑ΂ˇ‚éƒIƒsƒIƒCƒh“Š—^‚ĚŒœ”O‚Ć‘Îô. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć53‰ń_“ސě—Տ°ŠO‰ČˆăŠw‰ď‘‰ď (2018/5/26), ‰Ą•l.

731110. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): –ÎŒ´’ˇśŒQˆăŽt‰ďu‰‰‰ď (2018/5/29), ç—tŒ§’ˇśŒS.

731111. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚éƒIƒsƒIƒCƒh‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć48‰ńŠÖźƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ďŠwpW‰ď (2018/6/2), ‘ĺă.

731112. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): –Ťáu’ɃZƒ~ƒi[ (2018/7/6), ěč.

731113. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‰Ą•lŽsáu’ÉŒ¤‹†‰ď (2018/7/20), ‰Ą•l.

731114. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): “ŒŠ‹–k•”Ň’ĹŽžŠłŒ¤‹†‰ď (2018/7/27), ”.

731115. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒIƒsƒIƒCƒh‚đăŽč‚ÉŽg‚¤|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ß‚˝—Տ°Žg—p|. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‚Ş‚ńŠłŽŇ‚Ěƒg[ƒ^ƒ‹ƒPƒA‚đl‚Ś‚é‰ď (2018/8/1), ’Ź“c.

731116. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒIƒsƒIƒCƒh‚đăŽč‚ÉŽg‚¤|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ß‚˝—Տ°Žg—p|. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“Šwpu‰‰‰ďinĂ“ě (2018/9/11), “Ą‘ň.

731117. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒZƒbƒVƒ‡ƒ“1u‚Ş‚ńŠłŽŇ‚ɑ΂ˇ‚é‹ÇŠ–ƒŒ–ň‚É‚ć‚éŇ‘‚­‚ŕ–Œ‰ş–ƒŒ–@v, ƒZƒbƒVƒ‡ƒ“2uƒIƒsƒIƒCƒh’Á’É–ň‚̍ŐV—p–@|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ށ|v. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ’É‚Ý‚đl‚Ś‚éin‘Š–ÍŒ´ (2018/9/26), ‘Š–ÍŒ´.

731118. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ý‘î‚Ĺ‚ŕŽ{Ý‚Ĺ‚ŕu–ƒ–ňv‚đˆŔ‘S‚ÉŽg‚¨‚¤. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć5‰ńu’nˆćˆă—Ă˜AŒg‚̉ďv (2018/11/15), `–ě.

731119. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‹ÇŠ–ƒŒ–ň‚É‚ć‚é— ‹Z‚Ć— ˜b. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć5‰ń–k—˘‚݂炢‚̐ŽŒ`ŠO‰ČŒ¤‹†‰ď (2018/11/24), ‰Ą•l.

731120. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) S‘ŸŒŒŠÇ–ƒŒ‚ĚTopics. ‰Ş–{_Žk (–ƒŒ): ˆ¤“†–ƒŒŒ¤‹†‰ď (2018/12/1), “Œ‹ž.

731121. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒIƒsƒIƒCƒh’Á’É–ň‚̍ŐV—p–@|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ށ|. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‚Ş‚ńáu’ɊɘaƒPƒAƒZƒ~ƒi[ (2019/3/5), ‘Š–ÍŒ´.

731122. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚é’Á’É–ň‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć36‰ńˆó×ŽsŒSŽŒ`ŠO‰Čˆă‰ď (2019/3/7), ˛‘q.

732114. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ’É‚Ý‚Ě\‘˘‚ōl‚Ś‚éƒIƒsƒIƒCƒh‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć48‰ńŠÖźƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ďŠwpW‰ď (2018/6/2), ‘ĺă.

732115. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (śŠUŠwKƒZƒ~ƒi[) ‚Ş‚ńŠłŽŇ‚É‚¨‚Ż‚é’ɂ݂̐f’f‚Ć–ň•¨‚Ě‘I‘đ. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): •˝Ź30”N“x–k—˘‘ĺŠw–ňŠw•”śŠUŠwKƒZƒ~ƒi[ (2018/6/30), “Œ‹ž.

732116. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒIƒsƒIƒCƒh’Á’É–ň‚̍ŐV—p–@|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ށ|. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): ‘ć11‰ń‘Š–ÍŒ´’n‹ćˆă—Ă˜AŒg•×‹­‰ď (2018/11/16), ‘Š–ÍŒ´.

732117. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒIƒsƒIƒCƒh’Á’É–ň‚̍ŐV—p–@|V–ňƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚đŠÜ‚ށ|. ‹ŕˆäş•ś1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2–ƒŒ): Phrmacy Director Conference in ‘Š–ÍŒ´@Œ§‰›ƒGƒŠƒA (2019/3/4), ‘Š–ÍŒ´.

733279. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Dual puncture epidural–@‚É‚ć‚éd–ŒŠO–ł’É•Ş•Ř‚đs‚Á‚˝Shone complex‡•š”DP‚Ě1Ç—á. ”˘•űhŽq1, ×ěKŠó1, r@Ť’q1, ‰Á“Ą—˘ŠG1,2, ‰œ•xr”V1, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ďŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć58‰ń‡“ŻŠwpW‰ď (2018/9/1), “Œ‹ž.

733011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • –Œ‰Šƒ}ƒEƒX‚̉ĄŠu–ŒƒŠƒ“ƒpŠÇVś‚đ‘‹­‚ˇ‚éŽó—e‘ĚŠˆŤ’˛ß’`”’1 (RAMP1) ‚Ě–đŠ„. ’Ă—Ż˘—˘1, ˆÉ“Ą‹`–ç2, ˆäă’qm1, ×–ě‰Á“ŢŽq2, ź“cO”ü3, ‘ dçŠG3, ’†–{CŽi1, ‘ĺ‚Žjš1, •ž•”‹żŽq4, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–ƒŒ, 4ŽY‰Č): ‘ć139‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2018/10/20), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-722001. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽüpŠúĂ–ŹŒŒđÇđÇup-to-date. •Šâ­”V (–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ď‘ć37‰ń‘ĺ‰ď (2017/11/4), “Œ‹ž.

H29-732004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ŽüpŠú”xŒŒđÇđÇ. •Šâ­”V (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ďŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć57‰ń‡“ŻŠwpW‰ď (2017/9/2), “Œ‹ž.


—Տ°ŒŸ¸f’fŠw

[’˜@‘]

620148. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚éz”A”äd, p.16. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620149. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒAƒ‹ƒuƒ~ƒ“’č—Ę (”A), p.21. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620150. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒgƒ‰ƒ“ƒXƒtƒFƒŠƒ“ (”A), p.22. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620151. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézIVŒ^ƒRƒ‰[ƒQƒ“ (”A), p.23. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620152. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒVƒ…ƒEŽ_ (”A), p.24. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620153. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézD’†‹…ƒ[ƒ‰ƒ`ƒi[ƒ[Œ‹‡ŤƒŠƒ{ƒJƒŠƒ“ (NGAL) (”A), p.24. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620154. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézIgE’萍 (—܉t), p.30. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620155. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒ}ƒCƒNƒƒoƒuƒ‹ƒeƒXƒg, p.E30. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620156. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézIIŒ^ƒvƒƒRƒ‰[ƒQƒ“-C-ƒvƒƒyƒvƒ`ƒh (ƒRƒ“ƒhƒƒJƒ‹ƒVƒ“ ) (ŠÖß‰t), p.31. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620157. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒJƒ‹ƒvƒƒeƒNƒ`ƒ“ (•ł•Ö), p.181. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620158. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézäNă÷“ŕˆł‘Ş’č, p.256. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620159. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚éz”A—Ę‘Ş’č, p.257. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620160. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézŠ‡–ń‹Ř‹Ř“d}, p.257. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620161. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚éz…—˜”AŽŽŒą, p.304. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.

620162. [Šwp‘ (•Ş’SŽˇ•M)]yĹVŒŸ¸E‰ć‘œf’fŽ–“T <2018-19”N”Ĺ>|•ŰŒŻż‹E“K‰žŽžŠł‚Ş‚ˇ‚ׂĂ킊‚ézƒˆ[ƒhƒJƒŠŽŽŒą, p.305. Žë–ě—Lě (—ŐŒŸŠw), •Ň’˜: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2018/4”­s.


—AŒŒE×–EˆÚAŠw

[Šwp˜_•ś]

110337. [Œ´’˜] The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants. Ishida T1, Miyazaki K1, Okina S2, Miyata T2, Hayama K2, Higashihara M2, Suzuki T2: Hematology 2019/12; 24 (1): 49-51. doi: 10.1080/10245332.2018.1507883. Epub 2018 Aug 20. (Î“c@—˛1, ‹{ř“_“ń1, ‰Ľ@‘c˝2, ‹{“c’m”ü2, ‰HŽRŒdˆČ2, “ŒŒ´ł–ž2, —é–Ř—˛_2: 1—AŒŒE×–EˆÚA, 2ŒŒ‰t“ŕ)

522188. [uŔ] “ďaÇ—á‚Š‚çŠw‚Ԑf—Ă‚ĚƒGƒbƒZƒ“ƒX (8)@ŒŒ—F•aŒyÇ—á‚ɃCƒ“ƒqƒrƒ^[”­ś. ‹{ř“_“ń (—AŒŒE×–EˆÚA): “ú–{ˆăŽ–V•ń 2018/5: 4909: 12-3.

522189. [uŔ] “ďaÇ—á‚Š‚çŠw‚Ԑf—Ă‚ĚƒGƒbƒZƒ“ƒX (17)@Š´–`‚ĆŽv‚˘‚Ť‚âˆŤŤƒŠƒ“ƒpŽî. ‹{ř“_“ń (—AŒŒE×–EˆÚA): “ú–{ˆăŽ–V•ń 2018/7; 4918: 12-3.

522190. [uŔ] “ďaÇ—á‚Š‚çŠw‚Ԑf—Ă‚ĚƒGƒbƒZƒ“ƒX (26)@œ‘üˆŰÇ‚ɃNƒŠƒvƒgƒRƒbƒJƒXŠ´őÇ•š”­. ‹{ř“_“ń (—AŒŒE×–EˆÚA): “ú–{ˆăŽ–V•ń 2018/9: 4927: 10-1.

522191. [uŔ]y“ÁW: —AŒŒ2018|ŒŔ‚č‚ ‚鎑Œš‚đˆŔ‘S‚É, —LŒř‚ÉŠˆ—p‚ˇ‚é‚˝‚߂Ɂz@ŒŒŹ””ZŒú‰t. ‹{ř“_“ń (—AŒŒE×–EˆÚA): “ŕ‰Č 2018/10; 122 (4): 735-9.

522192. [uŔ]yĄŒŽ‚Ě“ÁW2: Ĺ‹ß‚Ě—AŒŒE×–EˆÚA‚đ‚ß‚Ž‚Á‚āz—AŒŒŠÖ˜A‚Ě”F’莑Ši. ‘ĺ’JTˆę (—AŒŒE×–EˆÚA): —Տ°ŒŸ¸ 2018/12; 62 (12): 1628-31.

540041. [‚ť‚Ě‘ź]yPicture in Clinical Hematology No.121zIbrutinib“Š—^’†‚É’ÜŽüˆÍ‰Š‚Ć“÷‰čŒ`Ź‚đŒJ‚č•Ô‚ľ”­Ç‚ľRśÜŽĄ—Âʼnü‘P‚ľ‚˝–ŤƒŠƒ“ƒpŤ”’ŒŒ•a. Î“c@—˛1, ‹{__“ń1, ‰HŽRŒdˆČ2, –x]—Lję3, —é–Ř—˛_2 (1—AŒŒE×–EˆÚA, 2ŒŒ‰t“ŕ, 3ˆă—ÉqśŠw•”): —Տ°ŒŒ‰t 2019/3; 60 (3): 153.

[Šw‰ďEŒ¤‹†‰ď“™]

713164. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Analysis of anti-thrombopoietin receptor antibodies in patients with immune thrombocytopenia. Satoh T, Miyazaki K1, Horie R: 23rd Annual Congress of European Hematology Association (2018/6/16), Stockholm, Sweden. (‹{ř“_“ń1: 1—AŒŒE×–EˆÚA)

713165. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Analysis of anti-thrombopoietin receptor antibodies in patients with immune thrombocytopenia. Satoh T, Miyazaki K1, Horie R: The 10th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis (2018/6/29), Sapporo, Japan. (‹{ř“_“ń1: 1—AŒŒE×–EˆÚA)

722225. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •a‰@î•ńƒVƒXƒeƒ€5”NŠÔ‚Ě•ŕ‚Ý. ‘ĺ’JTˆę (—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/25), ‰F“s‹{.

723826. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —AŒŒˆă—Ă‚É‚¨‚Ż‚éƒgƒŒ[ƒTƒrƒŠƒeƒBŠm•Ű‚ÉŠÖ‚ˇ‚éƒpƒCƒƒbƒgƒXƒ^ƒfƒB. ź‰Ş˛•ŰŽq, ’r•Ó‰r”ü, ’†ŽR‹œ”V, ‘ĺ’JTˆę1, –kŕV~ˆę, ‹I–ěCˆę, •lŒű@Œ÷ (1—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/24), ‰F“s‹{.

723827. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •a‰@î•ńƒVƒXƒeƒ€‚̏Ť—ˆ‘œ. ‘ĺ’JTˆę (—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/25), ‰F“s‹{.

723828. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ôňŒŒŹ”ťÜ‚ĚŽg—p‚¨‚ć‚Ń•›”˝‰ž’ጸŒř‰Ę‚ÉŠÖ‚ˇ‚錟“˘. ’r•Ó‰r”ü, ź‰ŞŽu•ŰŽq, ’†ŽR‹œ”V, ‘ĺ’JTˆę1, –kŕV~ˆę, ‰Á“Ą‰hŽj, •lŒű@Œ÷ (1—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/25), ‰F“s‹{.

723829. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚é—AŒŒŠÖ˜AƒCƒ“ƒVƒfƒ“ƒg‚ɂ‚˘‚Ä. Ź–{”ü“Ţ1, ł–ŘˆÇ“Ţ1, “c•”—T“ń1, ŠâŘ•śŽq1, ŽR•Ó°”ü1, ‚–ě”g—Ż”ü1, “ŕ“cˆęO1,2, ‘ĺ’JTˆę3, ‹{ř“_“ń3 (1—AŒŒ•”, 2—ŐŒŸ•”, 3—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/25), ‰F“s‹{.

723830. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚é—AŒŒ•›ě—p‚ĚŒťó. ŠâŘ•śŽq1, —L”n˜a“Ţ1, ł–ŘˆÇ“Ţ1, “c•”—T“ń1, ŽR•Ó°”ü1, ‚–ě”g—Ż”ü1, Ź–{”ü“Ţ1, “ŕ“cˆęO1,2, ‘ĺ’JTˆę3, ‹{ř“_“ń3 (1—AŒŒ•”, 2—ŐŒŸ•”, 3—AŒŒE×–EˆÚA): ‘ć66‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ď‘‰ď (2018/5/26), ‰F“s‹{.

731123. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŒŒŹ”—AŒŒ|“KłŽg—p‚ĆĹ‹ß‚Ě˜b‘č|. ‹{ř“_“ń (—AŒŒE×–EˆÚA): ‘ć147‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ďŠÖ“ŒbM‰zŽx•”—á‰ď (2019/2/23), ‘Š–ÍŒ´.

733280. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ÔŒŒ‹…ťÜ‚Ě“Kł‚ČÝŒÉŠÇ—‚ɂ‚˘‚Ä. ł–ŘˆÇ“Ţ1, —L”n˜a“Ţ1, “c•”—T“ń1, ŽR•Ó°”ü1, ‚–ě”g—Ż”ü1, ŠâŘ•śŽq1, Ź–{”ü“Ţ1, “ŕ“cˆęO1, ‘ĺ’JTˆę2, ‹{ř“_“ń2 (1—AŒŒ•”, 2—AŒŒE×–EˆÚA): ‘ć147‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ďŠÖ“ŒbM‰zŽx•”—á‰ď (2019/2/23), ‘Š–ÍŒ´.


‹~–˝‹~‹}ˆăŠw

[Šwp˜_•ś]

110338. [Œ´’˜] Creating a new index to evaluate imbalance in medical demand and supply when disasters occur. Takahashi K, Morimura N, Takeuchi I, Abe T, Toida C, Hattori J1, Hattori K2, Honda H, Uchiyama M, Matsuda K, Nakagawa Y, Asari Y1: Acute Med Surg 2018/7; 5 (4): 329-36. (•ž•”@1, •ž•”‹żŽq2, ó—˜@–ő1: 1‹~–˝, 2ŽY‰Č)

110339. [Œ´’˜] The Imbalance in Medical Demand and Supply for Pediatric Victims in an Earthquake. Toida C, Takeuchi I, Abe T, Hattori J1, Hattori K2, Takahashi K, Uchiyama M, Honda H, Nakagawa Y, Matsuda K, Asari Y1, Morimura N: Disaster Med Public Health Prep 2018/12: 1-5. (•ž•”@1, •ž•”‹żŽq2, ó—˜@–ő1: 1‹~–˝, 2ŽY‰Č)

522193. [uŔ]y“ÁW: Ř‚Á‚ďW‚ß‚Ä, ŽŠ•Ş‚ž‚Ż‚Ěƒm[ƒg‚đ‚‚­‚낤!@ƒ|ƒCƒ“ƒg‚ž‚Ż‚đ‚Ü‚Ć‚ß‚˝ŽŒ`ŠO‰ČŽžŠłƒtƒ@ƒCƒ‹ ‰şŽˆ•Ňz(4) ‘ĺ‘ڍœ“]Žq•”œÜ. ‰Í‘ş@’ź, •ôŒ´Gš1 (1‹~–˝): ŽŒ`ŠO‰ČŠĹŒě 2018/4; 23: 128-32.

522194. [uŔ]y“ÁW: ‚ą‚Ě1ű‚ĹˆŔS! ”ĺ”AŠí‰Č“–’źˆăƒ}ƒjƒ…ƒAƒ‹ <“ü‰@•Ň>zpŒăƒRƒ“ƒp[ƒgƒƒ“ƒgÇŒóŒQ. •ôŒ´Gš1, ź‰YWł2, ‰Í‘ş@’ź (1‹~–˝, 2ŽŠO), —Տ°”ĺ”AŠí‰Č 2018/4; 72 (5): 370-5.

522195. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß`ŽžŠłEŽĄ—ÁEƒPƒA`z(5) ‘ĺ‘ڍœœŠ˛•”œÜ. •ôŒ´Gš (‹~–˝): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 768-9.

522196. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇŠÖß `ŽžŠłEŽĄ—ÁEƒPƒA`z(14) ‘ĺ‘ڍœœŠ˛•”œÜ‚̍œÚ‡p. •ôŒ´Gš (‹~–˝): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 795-7.

[’˜@‘]

620163. [Šwp‘ (–|–ó)]yAO–@œÜŽĄ—Á@Hand (Manual of Fracture Management Hand)z•ôŒ´Gš (‹~–˝), ŠÄ–ó: “c’†@ł, –óŽŇ‘ă•\: ‹ŕ’J•ś‘Ľ, ŕVŒű@‹B, ˆăŠw‘‰@, “Œ‹ž, 2018/4”­s.

620164. [Šwp‘ (•Ş’SŽˇ•M)]yŠOŽčpŽč‹ZƒAƒgƒ‰ƒX (Atlas of Surgical Techniques in Trauma)zSection 10 ŽŒ`ŠO‰Č“Iƒ_ƒ[ƒWƒRƒ“ƒgƒ[ƒ‹@39. ŽŒ`ŠO‰Č“Iƒ_ƒ[ƒWƒRƒ“ƒgƒ[ƒ‹, p.379-92. •ôŒ´Gš (‹~–˝), ŠÄ–ó: ‘ĺ—FN—T, •Ň–ó: X‰şKŽĄ, ź“‡ˆę‰p, ‚ρ[‚ť‚ń‘–[, “Œ‹ž, 2018/7”­s.

620165. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj 2019”N”Łz1. ‹~‹}ˆă—Á@“Ý“I• •”ŠO, p.65. •Đ‰Ş—Sˆę (‹~–˝), ‘•ŇW: •ŸˆäŽŸ–î ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2019/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711018. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Surgical treatment of unstable fractures of the distal clavicle without bridging over the AC joint using SCORPIONŇ NEO. Minehara H1: 44th Annual Meeting of the Korean Fracture Society (2018/4/27), Gwangju, Korea. (•ôŒ´Gš1: 1‹~–˝)

711019. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Treatment of diaphyseal/metaphyseal nonunions. Minehara H1: AOTrauma Advances Course: Sydney (2019/3/6), Sydney, Australia. (•ôŒ´Gš1: 1‹~–˝)

721026. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‘˝”­ŠO‚ĚŽĄ—Ă Early total care VS Damage control orthopaedics. •ôŒ´Gš (‹~–˝): AO Spine Seminar (2018/11/11), “Œ‹ž.

723831. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇ‘˝”­ŠO‚ɑ΂ˇ‚é•ďŠ‡“Iƒ`[ƒ€ˆă—Ă‚É‚ć‚éPICS‘΍ô. •Đ‰Ş—Sˆę1, •ž•”@1, ‹{č“š‹P2, ŒŠˆä“c˜ał2, ó—˜@–ő1 (1‹~–˝, 2ƒŠƒnƒrƒŠ•”): ‘ć32‰ń“ú–{ŠOŠw‰ď‘‰ďEŠwpW‰ď (2018/6/21), ‹ž“s.

723832. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) e‘nŠO‚Ě‹~–˝ŽĄ—Ñ̐§`p’†S’âŽ~‚Š‚ç‹~–˝‚ľ“ž‚˝e‘n‚É‚ć‚éS”x‘šÇ—á‚đ’Ę‚ś‚ā`. •Đ‰Ş—Sˆę1, ‰Ô“‡@Ž‘1, ‰–ŒŠ@˜a2, ó—˜@–ő1 (1‹~–˝, 2ŒÄ‹zŠíŠO): ‘ć32‰ń“ú–{ŠOŠw‰ď‘‰ďEŠwpW‰ď (2018/6/22), ‹ž“s.

723833. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇŠO‚ɑ΂ˇ‚é‹Ů‹}Žčp‚Əp’†IVR‚É‚ć‚éƒnƒCƒuƒŠƒbƒhŽĄ—Ă. •Đ‰Ş—Sˆę1, Š~ŒŠ•śŽ}1, ‰Ô“‡@Ž‘1, ŠŰ‹´Fş1, ŽR’J—§‘ĺ1, •ž•”@1, ó—˜@–ő1 (1‹~–˝): ‘ć32‰ń“ú–{ŠOŠw‰ď‘‰ďEŠwpW‰ď (2018/6/22), ‹ž“s.

723834. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŠw•a‰@‚É‚¨‚Ż‚éacute care surgery. •Đ‰Ş—Sˆę1, ‰Ô“‡@Ž‘1, Ź—с@ŒM1, ó—˜@–ő1 (1‹~–˝): ‘ć46‰ń“ú–{‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/11/21), ‰Ą•l.

723835. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇ‹~‹}ŠłŽŇ‚ɑ΂ˇ‚é•ďŠ‡“Iƒ`[ƒ€ˆă—Ă‚É‚ć‚éW’†ŽĄ—ĂŒăÇŒóŒQ (PICS) ‘΍ô. •Đ‰Ş—Sˆę1, •ž•”@1, ˆîŠ_‘דl1, ’†’JŒ¤“l1, ó—˜@–ő1 (1‹~–˝): ‘ć46‰ń“ú–{‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/11/21), ‰Ą•l.

723836. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝”­Šç–ʍœœÜ‚É‚¨‚Ż‚é‘Ň‹@“I—֏óbó‹ŘŠÔ–ŒŘŠJ‚Ě—L—pŤ. ŒFŕVŒ›ˆę1, •Šâ­”V2, ’†‘şGŒő3, ó—˜@–ő1, •“c@Œ[3 (1‹~–˝, 2–ƒŒ, 3Œ`ŹE”üŠO): ‘ć24‰ń“ú–{Œ`ŹŠO‰ČŽčpŽč‹ZŠw‰ď (2019/2/23), ‰Ą•l.

723837. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹~–˝‹~‹}EĐŠQˆă—ĂƒZƒ“ƒ^[‚É‚¨‚Ż‚éŠç–Ę‘˝”­œÜŽĄ—Á`ŽŠŒą—á‚Š‚猊‚˝ŽĄ—Ă‚ĚH•v`. ŒFŕVŒ›ˆę (‹~–˝): ‘ć24‰ń“ú–{Œ`ŹŠO‰ČŽčpŽč‹ZŠw‰ď (2019/2/23), ‰Ą•l.

723838. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇ‹~‹}ŠłŽŇ‚̉h—{•]‰ż‚̏d—vŤ. •Đ‰Ş—Sˆę1, ó—˜@–ő1 (1‹~–˝): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s.

723839. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚ł̐[ÝŤäX‘š‚ɑ΂ˇ‚éf’f‚ĆŽĄ—Ă–@‚ĚŒŸ“˘. •Đ‰Ş—Sˆę1, ‰Ô“‡@Ž‘1, ó—˜@–ő1 (1‹~–˝): ‘ć55‰ń“ú–{• •”‹~‹}ˆăŠw‰ď‘‰ď (2019/3/7), ĺ‘ä.

731124. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) “–‰@‚É‚¨‚Ż‚éL”͈͔M‚ĚŽĄ—Ð헪`Œťó‚Ć–â‘č“_`. ŒFŕVŒ›ˆę1, ’†‘şGŒő2, ”–ؐT–ç2, Ş–{@[2, •“c@Œ[2 (1‹~–˝, 2Œ`ŹE”üŠO): ‘ć26‰ńVh”MƒtƒH[ƒ‰ƒ€ (2018/8/31), “Œ‹ž.


‘‡f—ĂˆăŠw

[Šwp˜_•ś]

520020. [‘ŕ] –Ť“Ž–Ź•ÂÇÇ‚̐f’fˆÓ‹`‚ĆŒŒŠÇVśŽĄ—Âɂ‚˘‚Ä. ÂŽR’ź‘P (‘‡f—Ă): –k—˘ˆăŠw 2018/6; 48 (1): 11-7.


ˆăŠw•”•‘ŽˆăŠw‹łˆçŒ¤‹†ŠJ”­ƒZƒ“ƒ^[

ˆăŠw‹łˆçŒ¤‹†•”–ĺ

[Šwp˜_•ś]

110340. [Œ´’˜] Identification of Topics Explained by Home Doctors to Family Caregivers with Cancer Patients Died at Home: A Quantitative Text Analysis of Actual Speech in All Visits. Chiba H1, Ogata T, Ito M, Kaneko S: The Tohoku Journal of Experimental Medicine 2018/8; 245 (4): 251-61. (ç—tG‹B1: 1ˆăŠw‹łˆç)

[Šw‰ďEŒ¤‹†‰ď“™]

721027. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‹ŘˆŢkŤ‘¤őd‰ťÇ (ALS) ŠłŽŇ‚ĚƒAƒhƒoƒ“ƒXƒ‰ƒCƒtƒvƒ‰ƒ“ƒjƒ“ƒO. ˆÉ“Ą“šĆ, ”öŒ`—Ď–ž, ç—tG‹B1 (1ˆăŠw‹łˆç): “ú–{Ý‘îˆăŠw‰ď‘ć20‰ń‹L”O‘ĺ‰ď (2018/4/29), “Œ‹ž.

723840. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ŘˆŢkŤ‘¤őd‰ťÇ (ALS) ŠłŽŇ‚̏Z‚Ü‚˘•ű‚ÉŠÖ‚ˇ‚鎿“IŒ¤‹†. ˆÉ“Ą“šĆ, ”öŒ`—Ď–ž, ç—tG‹B1 (1ˆăŠw‹łˆç): ‘ć56‰ń“ú–{ˆă—ÁE•a‰@ŠÇ—Šw‰ďŠwp‘‰ď (2018/10/27), •Ÿ“‡.

723841. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) uƒGƒ“ƒhƒIƒuƒ‰ƒCƒtEƒPƒA‰‡•ŽŇ—{ŹŠî‘buŔv‚Ě‹łˆçŒř‰Ę‚ÉŠÖ‚ˇ‚é•]‰żŒ¤‹†ƒŠˆ“Ž•ń„: Œ¤‹†‚ĚŒo‰ß‚ɂ‚˘‚Ä. ç—tG‹B1, ”öŒ`—Ď–ž, ŽOŕVm•˝, ‚˝‚çŕV–M’j, X’JAŒc (1ˆăŠw‹łˆç): ˆę”ĘŽĐ’c–@lƒGƒ“ƒhƒIƒuƒ‰ƒCƒtEƒPƒA‹Ś‰ďÝ—§3Žü”NƒVƒ“ƒ|ƒWƒEƒ€ (2018/4/14), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723013. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) kĐ’nˆć‚ĚÝ‘î—Ă—{Žx‰‡f—ÏŠ‚É‚¨‚Ż‚éŠĹŽć‚č‚Ě‘Łi—vˆö2|‘˝EŽí˜AŒg‚ĆŠĹŽć‚č‚Ěó‹ľ|. ”öŒ`—Ď–ž, ŽOŕVm•˝, ç—tG‹B1, ‚˝‚çŕV–M’j, X’JAŒc (1ˆăŠw‹łˆç): ŠĹŒěŒoĎE­ôŒ¤‹†Šw‰ď‘ć8‰ńŠwpW‰ď (2017/10/28), ‰Ą•l.


ŠwKŽx‰‡Œ¤‹†•”–ĺ


ˆăŠwŒ´˜_Œ¤‹†•”–ĺ


ˆă—ĂŠÇ—ŠwŒ¤‹†•”–ĺ

ŚuÁ‰ťŠí“ŕ‰ČŠwv‚đŽQĆ


ˆă—Ă‹Zp‹łˆçŒ¤‹†•”–ĺ

Śut‘Ÿ“ŕ‰ČŠwv‚đŽQĆ


ˆă—Ïî•ń‹łˆçŒ¤‹†•”–ĺ

Śuś‰ťŠw (ä’PˆĘ)v‚đŽQĆ


“Œ—mˆăŠw‹łˆçŒ¤‹†•”–ĺ

[Šwp˜_•ś]

110341. [Œ´’˜] Possible anti-inflammatory role of Zingiberis processum rhizoma, one component of the Kampo formula daikenchuto, against neutrophil infiltration through muscarinic acetylcholine receptor activation. Endo M1, Hori M, Ozaki H, Oikawa T1, Odaguchi H1,2, Hanawa T1: J Pharmacol Sci 2018/8; 137 (4): 379-86. (‰““Ą^—1, ‹yě“N˜Y1, Ź“cŒű_1,2, ‰Ô—Öšć•F1: 1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç)

110342. [Œ´’˜] A Double-Blind, Randomized, Crossover Comparative Study for Evaluating the Clinical Safety of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE). Odaguchi H1,2, Sekine M2, Hyuga S2, Hanawa T2, Hoshi K3, Sasaki Y, Aso M, Yang J, Hyuga M, Kobayashi Y4, Hakamatsuka T, Goda Y, Kumagai Y5: Evid Based Complement Alternat Med 2018/8; 2018: 4625358. doi: 10.1155/2018/4625358. eCollection 2018. (Ź“cŒű_1,2, ŠÖŞ–ƒ—Žq2, “úŒü{”üŽq2, ‰Ô—Öšć•F2, Ż@‰Ŕ–F3, Ź—Ń‹`“T4, ŒF’J—YŽĄ5: 1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3‰qś, 4–ňŠw•”, 5—Տ°Œ¤‹†EŠé‰ć^ƒvƒƒWƒFƒNƒg)

320038. [Ç—á•ń] ‹@”\ŤÁ‰ťŠÇáŠQ‚ÉŠ°’†“’‚Ş‘tŒř‚ľ‚˝2—á. Ż–ě‘ě”V1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/4; 65 (4): 404-8.

320039. [Ç—á•ń] ’f—Ÿ“’‚Ĺ—}‚¤‚Â, •sˆŔÇó‚މü‘P‚ľ‚˝ˆę—á. Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): Šż•ű‚Ě—Ő° 2018/5; 65 (5): 505-7.

320040. [Ç—á•ń] Ť“]ŠˇŽčpŒă‚̓Ť–Ť• –Œ‰ŠÇó‚Ş‘ĺ‰Š‰˛’O”ç“’‚ɂĉü‘P‚ľ‚˝1Ç—á. ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/6; 65 (6): 604-8.

320041. [Ç—á•ń] ‹“Ž™Šó–]‚đŽĺ‘i‚ÉŠż•űŠO—ˆ‚đŽóf‚ľ‚˝ŠłŽŇ‚ĚŒŸ“˘. X—T‹IŽq1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/7; 65 (7): 687-94.

320042. [Ç—á•ń] ‚—îŽŇ‚ĚƒƒjƒG[ƒ‹•a‚ɑ΂ľŠż•űŽĄ—Ă‚Ş—L—p‚Ĺ‚ ‚Á‚˝3Ç—á. Î–Ń’B–ç1, ‹yě“N˜Y1, Žá™ˆŔŠó”T1, ŠÖŞ–ƒ—Žq1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): “ú–{“Œ—mˆăŠwŽGŽ 2018/7; 69 (3): 266-74.

320043. [Ç—á•ń] ’ńăčŽU‚Şăč–ĺ’ɂ𔺂¤“தŠj’Eăč‚É—LŒř‚Ĺ‚ ‚Á‚˝1—á. Â–Ř‚ä‚Š‚č1, ‹yě“N˜Y1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): “ú–{“Œ—mˆăŠwŽGŽ 2018/7; 69 (3): 287-90.

320044. [Ç—á•ń] ‹żş”j“JŠŰ—ż‚ĚŽg—pŒoŒą. ‹yě“N˜Y1, Ż–ě‘ě”V1, Î–Ń’B–ç1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/8; 65 (8): 803-6.

320045. [Ç—á•ń] ’°ăřx‘щŠ‚É”ş‚¤•G’ɂɔޕ¨~‰ş“’‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á. ě“çˆÉW1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/9; 65 (9): 900-4.

320046. [Ç—á•ń] •S‡ŒĹ‹ŕ“’‚ŞŒűŠŁ‚Ć–éŠÔ•p”A‚É’˜Œř‚ľ‚˝ˆęÇ—á. ‰““Ą‘ĺ•ă1, ‹yě“N˜Y1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2018/12; 65 (12): 1366-72.

540042. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)] Œ¤‹†‰Ű‘č: ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX (EFE) ‚đ—p‚˘‚˝Šż•ű–ň‚ĚŠJ”­‚Ɗ֐ߒɎĄ—Âւ̉ž—p. ‰Ô—Öšć•F1, Ź“cŒű_1,2, “úŒü{”üŽq1, Ź—Ń‹`“T3, ŒF’J—YŽĄ4 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç, 3–ňŠw•”, 4—Տ°Œ¤‹†EŠé‰ć^ƒvƒƒWƒFƒNƒg): •˝Ź27”N“x`•˝Ź29”N“x@–k—˘‘ĺŠwAKPS‹¤“ŻŒ¤‹†Ź‰Ę•ń‘ 2018.7.

[Šw‰ďEŒ¤‹†‰ď“™]

722226. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€Eƒpƒlƒ‹) Šż•űf—Ă (Žlf) ‚ɂ‚˘‚Ä‹c˜_‚ľ‚悤. Ź“cŒű_1,2, Žá™ˆŔŠó”T2, ŠÖŞ–ƒ—Žq2, ‰Ô—Öšć•F2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

722227. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€Eƒpƒlƒ‹) W’†ŽĄ—Ă—Ěˆć‚Ě×‹ŰŤ”x‰Š—\–h‚đ–ÚŽw‚ľ‚˝•â’†‰v‹C“’‚ĚŠ´ő§ŒäŒř‰Ę‚ĚŒ¤‹†. o–ě’qŽj1, ůś–ëŽq1, “c’†—y—F, źˆä‰p‘Ľ, ŠŰŽROŽq, ‰iˆä—˛”V2, ŠÖ@”ŽŽu, ‰Ô—Öšć•F2, Ź“cŒű_2,3, Xč@_, ´Œ´Š°Í2 (1‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/1), Šň•Œ.

723842. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ó’JŒŠ‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ƒWƒXƒgƒjƒA‚Ć’x”­ŤƒWƒXƒLƒlƒWƒA‚̍‡•šÇ—á. ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć67‰ń‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď@‘ĺă‘ĺ‰ď (2018/6/2), ‘ĺă.

723843. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒĂ“Tˆă‘‚É‹LÚ‚ł‚ę‚˝ŠďŒŠ‚ɂ‚˘‚Ä. ÎŒ´@•1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć67‰ń‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď@‘ĺă‘ĺ‰ď (2018/6/3), ‘ĺă.

723844. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —אڂˇ‚é•a‰@‚Ć‚Ě“‡ˆă—Ă‚Ć‚ľ‚ÄŽŔŽ{‚ł‚ę‚˝čI‹„‚Ěó‹ľ‚Ć‚ť‚̉ۑč. •Šâ“ށXŽq1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć67‰ń‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď@‘ĺă‘ĺ‰ď (2018/6/3), ‘ĺă.

723845. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹Č’ŕ”n‹Ő‚ĚˆăŠwŠĎ‚ĆˆăŽŇ‚Ć‚ĚŒđ—Ź. ‰Á”¨‘Žq1, Ż–ě‘ě”V1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć119‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2018/6/2), Ž­Ž™“‡.

723846. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ěCˆÁwˆę–{“°–ň‘Ix‚̐Ź—§‰ß’ö. Ż–ě‘ě”V1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć119‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2018/6/3), Ž­Ž™“‡.

723847. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ß‹ň—ŹčI–@‚ɂ‚˘‚Ä. Žü–hˆę•˝1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć119‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2018/6/3), Ž­Ž™“‡.

723848. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–Ž{Ý‚É‚¨‚Ż‚éŽl‹tŽU‚̏ˆ•űŽŔ‘Ô‚ĚŒŸ“˘. ‰““Ą‘ĺ•ă1, ‹yě“N˜Y1, Ż–ě‘ě”V1, ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723849. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Á”­Ť•‚Žî‚ɉz›X‰ÁžQ“’‚Ş‘tŒř‚ľ‚˝1—á. ˆÉ“ŒGŒ›1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723850. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’°ăřx‘щŠ‚É”ş‚¤•G’ɂɔޕ¨~‰ş“’‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á. ě“çˆÉW1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723851. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–Ž{Ý‚É‚¨‚Ż‚銿•űƒhƒbƒNŽófŽŇ‚ÉŠÖ‚ˇ‚錟“˘. —é–Ř–M•F1, Î–Ń’B–ç1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723852. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) škŠoáŠQ‚ɑ΂ˇ‚éčI‹„ŽĄ—Ă‚đs‚Á‚˝14—á‚ĚŒŸ“˘. ˆä“c„l1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723853. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘Ť‘ć3E‘ć4ćäŠÔŒ„‚ĚŠďŒŠ (Ó’J) ‚đ—p‚˘‚˝čI‹„ŽĄ—Ă‚Ş—LŒř‚Ĺ‚ ‚Á‚˝’x”­ŤƒWƒXƒLƒlƒWƒA‚Ě1Ç—á. ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723854. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ĄŒă—Տ°‰ž—p‚đ–ÚŽw‚ˇƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX (EFE) ‚ĚˆŔ‘SŤ‚đŒŸŘ‚ˇ‚é—Տ°ŽŽŒą. Ź“cŒű_1,2, ŠÖŞ–ƒ—Žq2, “úŒü{”üŽq2, —k@‹ŕˆÜ, “úŒüšŽi, Ź—Ń‹`“T3, ŒŃ’ˍ‚Žu, ŒF’J—YŽĄ4, ‰Ô—Öšć•F2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3–ňŠw•”, 4—Տ°Œ¤‹†EŠé‰ć^ƒvƒƒWƒFƒNƒg): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723855. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šż•űˆ•ű‘I‘đƒTƒ|[ƒgƒVƒXƒeƒ€‚Ě‚˝‚ß‚ĚƒXƒp[ƒX‰ťƒjƒ…[ƒ‰ƒ‹ƒlƒbƒgƒ[ƒN‚Ć‚ť‚̊ӕʐ¸“x‚ĚŒŸŘ. ˆÉ“Ą—Yˆę1, Î–Ń’B–ç1, ě“çˆÉW1, ŠÖŞ–ƒ—Žq1, Žá™ˆŔŠó”T1, ˆÉ“Ą@„1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/9), ‘ĺă.

723856. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹“Ž™Šó–]‚đŽĺ‘i‚ÉŠż•űŠO—ˆ‚đŽóf‚ľ‚˝ŠłŽŇ‚ĚŒŸ“˘. X—T‹IŽq1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723857. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹żş”j“JŠŰ—ż‚ĚŽg—pŒoŒą. ‹yě“N˜Y1, Ż–ě‘ě”V1, Î–Ń’B–ç1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723858. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–Ž{Ý‚É‚¨‚Ż‚鏗_ŽUˆ•űÇ—á‚ĚŒŸ“˘. X@‰lŽq1, ‹yě“N˜Y1, —é–Ř–M•F1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723859. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠćŒĹ‚Č“ŞŒz•”‚̏D‘i‚ɑ΂ˇ‚é‘ĺŽÄŒÓ“’‹Ž‘削‚ĚŽg—pŒoŒą. Î–Ń’B–ç1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723860. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ë”­Ť“ď’Ž‚É‚¨‚Ż‚éčIŽĄ—Ă‚Ě‘Šú‰î“ü‚ʼnü‘P‚Ş‚Ý‚ç‚ę‚˝1Ç—á. ‹ß“ĄˆŸš1, Î–Ń’B–ç1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723861. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰^“ŽčI‚Ě‹NŒš‚ɂ‚˘‚Ä. Žü–hˆę•˝1, ˛”Œ’ź–ç1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723862. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)w“Vš“şlŒŽ™`ŒŠčI‹„}Œoœb˝x‚ÉŒŠ‚ç‚ę‚ég‘Ě•”ˆĘ–źĚ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‰Á”¨‘Žq1, Ż–ě‘ě”V1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć69‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2018/6/10), ‘ĺă.

723863. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ź‰ÄŒú–p“’ˆ•űÇ—á‚É‚¨‚Ż‚銿•űˆăŠw“IŠŒŠ“™‚ĚŒŸ“˘. ‹yě“N˜Y1, ‰ĄŽR“ÖŽm, —é–ؐ’•ś, Žá™ˆŔŠó”T1, ŠÖŞ–ƒ—Žq1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/1), Šň•Œ.

723864. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •â’†‰v‹C“’‚ÉŠÜ—L‚ł‚ę‚éƒIƒŠƒS“œ‚ɑ΂ˇ‚郂ƒfƒ‹ƒIƒŠƒS“œ—Ţ‚ĚƒpƒCƒGƒ‹”‚¨‚ć‚Ń––˝–ƉuŒn’˛ßě—p‚̉đÍ. ’†‘ş—F‹I1, oŒ´–ƒ—R, ‰iˆä—˛”V2, ‰Ô—Öšć•F2, Ź“cŒű_2,3, ´Œ´Š°Í2 (1‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/1), Šň•Œ.

723865. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šż•űŠî–{ˆ•ű‚ĚŠö”­ŤŹ•Ş‚̉đÍ. ‘ĺ“c•°Ž÷1, ‰iˆä—˛”V2, ˆÉ“Ą’źŽ÷2, â“cKŽĄ2, •űçH2, ŠÖŞ–ƒ—Žq2, Žá™ˆŔŠó”T2, Ź—Ń‹`“T3, Ź“cŒű_2,4, ´Œ´Š°Í2, •˝–{’‰_ (1‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3–ňŠw•”, 4“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/1), Šň•Œ.

723866. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) c-Met‘jŠQě—p‚đ—L‚ˇ‚é–ƒ‰ŠƒGƒLƒX‚Ćc-Met‘jŠQÜSU11274‚̍ě—p—lŽŽ‚Ě”äŠr. “úŒü{”üŽq1, “úŒüšŽi, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/2), Šň•Œ.

723867. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) WăË-”’žQ”z‡•â’†‰v‹C“’‚ĚTƒŠƒ“ƒp‹…‰îÝŤ‘Sg‰ŠÇ‹y‚яŹ’°”S–Œ‰ŠÇƒ‚ƒfƒ‹ƒ}ƒEƒX‚ɑ΂ˇ‚é‰ü‘Pě—p‚ĚŒŸ“˘. ‰““Ą^—1, ´Œ´Š°Í1, ‹yě“N˜Y1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/2), Šň•Œ.

723868. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˜V‰ť‘Łiƒ}ƒEƒX‚đ—˜—p‚ľ‚˝–˘•a“Ž•¨ƒ‚ƒfƒ‹‚Ć‚ľ‚Ẳ”\Ť. ˆÉ“Ą’źŽ÷1, ’|Œł—T–ž2, ’ˇ’Jěˆť“ß3, ™ŽRç‰Ŕ2, ‰iˆä—˛”V1, Ź—Ń‹`“T2, ´Œ´Š°Í1, ‹yě“N˜Y1, Ź“cŒű_1,4 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2–ňŠw•”, 3‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 4“Œ—mˆăŠw‹łˆç): ‘ć35‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2018/9/2), Šň•Œ.

723869. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –ƒ‰Š‚ĚŽY’n‚Ěˆá‚˘‚𔽉f‚ˇ‚é”ńƒAƒ‹ƒJƒƒCƒh (2). ‘ĺ“ˆ’ź_, ŽR‰ş’‰r, “úŒü{”üŽq1, “V‘q‹gÍ, “úŒüšŽi, ’†Xr•ă2, “ŕŽR“Ţ•äŽq, —k@‹ŕˆÜ, ˆÉ“ŒG”V, Ź—Ń‹`“T2, ŒŃ’ˍ‚Žu, Ź“cŒű_1,3, ‡“cKL (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2–ňŠw•”, 3“Œ—mˆăŠw‹łˆç): “ú–{ś–ňŠw‰ď‘ć65‰ń”N‰ď (2018/9/16), L“‡.

723870. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŒš’†“’‚̍\Źś–ňEŠŁ›I‚Ěƒ}ƒEƒXpŒă’°ŠÇ–ƒáƒ‰ü‘PŒř‰Ę`D’†‹…Z—}§Œř‰Ę‚Ć‚ť‚̍ě—p‹@˜‚ɂ‚˘‚ā`. ‰““Ą^—1, –x@ł•q, ”öč@”Ž, ‹yě“N˜Y1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć20‰ń“ú–{_ŒoÁ‰ťŠí•aŠw‰ď (2018/10/5), ˆ¤’m.

723871. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •›ě—pŹ•Ş‚đœ‹Ž‚ľ‚˝ˆŔ‘SŤ‚̍‚‚˘ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX (EFE). “úŒü{”üŽq1, ’†Xr•ă2, ’|Œł—T–ž2, “úŒüšŽi, Ź—Ń‹`“T2, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_1,3, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2–ňŠw•”, 3“Œ—mˆăŠw‹łˆç): NPO–@l ƒZƒ‹ƒtƒƒfƒBƒP[ƒVƒ‡ƒ“„i‹Ś‹c‰ď@ŠwpƒtƒH[ƒ‰ƒ€2018 (2018/10/13), ‹{é.

723872. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –ƒ‰Š‚ÉŠÜ‚Ü‚ę‚éƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚ĚŽŠ”­‰^“Ž”\‚ɑ΂ˇ‚éě—p‚̉đÍ. ‰Š@á’O1, ˆŔ“Ą^‹I, ”ö–ěéDĆ, ’Ł@—t—Ô, “úŒü{”üŽq2, ’|Œł—T–ž1, ŽR‰ş’‰r, —k@‹ŕˆÜ, “ŕŽR“Ţ•äŽq, “úŒüšŽi, ‘ĺ“ˆ’ź_, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T1 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć139”N‰ď (2019/3/21), ç—t.

723873. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX (EFE) ‚É‚ć‚éCFA—U”­ŠÖß‰Šƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ě‹@ŠBŽhŒƒ‚ɑ΂ˇ‚銴ŽóŤ‚̒ቺ. ‹{“ˆ’ź‹I, ’†Xr•ă1, “úŒü{”üŽq2, “ě@‰ÂŒb, —k@‹ŕˆÜ, “ŕŽR“Ţ•äŽq, “úŒüšŽi, ‘ĺ“ˆ’ź_, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T1 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć139”N‰ď (2019/3/23), ç—t.

733281. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}ŤŠúŒÄ‹zŠíŠ´őÇ‚ĚœëŠł—\–h‚É‚¨‚Ż‚é•â’†‰v‹C“’‚Ě—L—pŤ‚̉đÍ. ůś–ëŽq1, o–ě’qŽj1, ‰iˆä—˛”V2, ‰Ô—Öšć•F2, Ź“cŒű_2,3, ´Œ´Š°Í2 (1‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “V‘R–ň•¨Œ¤‹†•ű–@˜_ƒAƒJƒfƒ~[‘ć21‰ńŒ¤‹†W‰ď (2018/9/3), ˆ¤’m.

733282. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–Œ¤‹†Š‚É‚¨‚Ż‚铝‡Ž¸’˛ÇŠłŽŇ‚ɑ΂ˇ‚銿•űŽĄ—Ă‚ĚŒŸ“˘. ‰““Ą‘ĺ•ă1, Î–Ń’B–ç1, ‹yě“N˜Y1, ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć75‰ń“ú–{“Œ—mˆăŠw‰ďŠÖ“ŒbM‰zŽx•”ŠwpW‰ď (2018/9/23), ŽR—œ.

733283. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šá¸”ć˜J‚𔺂¤X”NŠúáŠQ‚É䨗čŠĂ‘“’‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1Ç—á. X@‰lŽq1, ‹yě“N˜Y1, Ż–ě‘ě”V1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć28‰ńŠż•űŽĄ—ĂŒ¤‹†‰ď (2018/10/7), •Ÿ‰Ş.

733284. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •S‡ŒĹ‹ŕ“’‚ŞŒűŠŁ‚Ć–éŠÔ•p”A‚É’˜Œř‚ľ‚˝ˆęÇ—á. ‰““Ą‘ĺ•ă1, ‹yě“N˜Y1, ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć28‰ńŠż•űŽĄ—ĂŒ¤‹†‰ď (2018/10/7), •Ÿ‰Ş.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-110026. [Œ´’˜] Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, Has No Adverse Effects Such as Excitation, Insomnia, and Arrhythmias. Takemoto H1, Takahashi J, Hyuga S2, Odaguchi H2,3, Uchiyama N, Maruyama T, Yamashita T, Hyuga M, Oshima N, Amakura Y, Hakamatsuka T, Goda Y, Hanawa T2, Kobayashi Y1: Biol Pharm Bull 2018/1; 41: 247-53. (’|Œł—T–ž1, “úŒü{”üŽq2, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T1: 1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç)

H29-320005. [Ç—á•ń] 3Ç—á‚đ’Ę‚ś‚˝ŒÜĎŽUŒűŒ‚̍lŽ@. Ź“cŒű_1,2, Ż–ě‘ě”V2, ‰Ô—Öšć•F2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): Šż•ű‚Ě—Ő° 2018/1; 65 (1): 119-23.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-723014. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĐ‰ď“IƒXƒgƒŒƒX—U”­‚¤‚—ls“Ž‚ɑ΂ˇ‚銿•ű•űÜu‘hŽUv‚ƍR‚¤‚–ň‚Ě•š—p‚É‚ć‚鎥—ĂŒř‰Ę. ˆÉ“Ą’źŽ÷1, œAŁ‰hŽĄ, ’ˇ’Jěˆť“ß2, ‰iˆä—˛”V1, ´Œ´Š°Í1, ‹yě“N˜Y1, Ź“cŒű_1,3 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2‘ĺŠw‰@Š´ő§Œä‰ČŠw•{, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć138”N‰ď (2018/3/27), Îě.


4•a‰@˜AŒg‹łˆçŒ¤‹†•”–ĺ

Śu‰ş•”Á‰ťŠÇŠO‰ČŠwv‚đŽQĆ


ˆă—ĂˆŔ‘SŠwŒ¤‹†•”–ĺ

ŚuS‘ŸŒŒŠÇŠO‰ČŠwv‚đŽQĆ


—Տ°‰đ–U‹łˆç‹†•”–ĺ

[Šwp˜_•ś]

110343. [Œ´’˜] Distribution and co-localization of diversified natriuretic peptides in the eel heart. Takei Y, Nemoto N, Kameya T, Tamaki H1, Katsumata O, Hyodo S, Kusakabe M: Cell and Tissue Research 2018/8; 373 (2): 367-77. (‹Ę–؉p–ž1: 1—Տ°‰đ–U)


ˆăŠw•”•‘Ž—Տ°Œ¤‹†ƒZƒ“ƒ^[

Šé‰ćŠJ”­•”–ĺ

[Šwp˜_•ś]

110344. [Œ´’˜] Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial. Kumagai Y1, Amano H2, Sasaki Y3, Nakagawa C3, Maeda M3, Oikawa I, Furuie H: Br J Clin Pharmacol 2018/10; 84 (10): 2393-404. (ŒF’J—YŽĄ1, “V–ě‰pŽ÷2, ˛X–Ř‘PM3, ’†ě’qŽ}3, ‘O“cŽŔ‰Ô3: 1—Տ°Œ¤‹†EŠé‰ć, 2–ň—, 3–ňÜ•”)

110345. [Œ´’˜] Effects of zolpidem/triazolam on cognitive performance 12 hours after acute administration. Matsunaga Y1, Tagaya H2, Fukase Y2, Hakamata Y, Murayama N, Kumagai Y3, Kuroyama M4: Sleep Med 2018/12; 52: 213-8. (ź‰i—S•ă1, “cƒ–’J_–M2, [Ł—TŽq2, ŒF’J—YŽĄ3, •ŽR­ˆę4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3—Տ°Œ¤‹†EŠé‰ć, 4“Œ•a‰@–ňÜ•”)

110346. [Œ´’˜] Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study? Chen R, Chen X, Wang H, Zhong W, Oh ES, Park MS, Kumagai Y1, Zhou L, Nagahama F, Hu P: Int J Clin Pharmacol Ther 2019/1; 57 (1): 24-31. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EŠé‰ć)

110347. [Œ´’˜] Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. Kumagai Y1, Ose A, Tanaka K, Sugimoto T: Clin Pharmacol Drug Dev 2019/3. doi: 10.1002/cpdd.687. [Epub ahead of print] (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EŠé‰ć)

521024. [‰đŕ] “Á•ĘŠńe: ƒqƒg‰‰ń“Š—^ŽŽŒą (FIHŽŽŒą) ‚đŠÜ‚Ţ‘Šú—Տ°ŽŽŒą‚Ěƒ`ƒFƒbƒNƒŠƒXƒg. ŒF’J—YŽĄ1, –ƒś‰ëŽq, Ź“cŘŒ\ˆę, Ö“Ą‰Ă˜N, ˆŔ•y—˘], ˜@Ŕ’qŽq2, œAŁ@˝ (1—Տ°Œ¤‹†EŠé‰ć, 2—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): —Տ°–ň— 2018/9; 49 (5): 183-94.

522197. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€10: ŽĄŒąR¸ˆĎˆő‰ďE—Ď—R¸ˆĎˆő‰ď‚̐R¸‚ĚŽżŒüă‚Ě‚˝‚ß‚ĚŽć‚č‘g‚Ý Šé‰ćˆÓ}‚Ƃ܂Ƃ߁zŽĄŒąR¸ˆĎˆő‰ďŽ––ą‹Ç‚Ě—§ę‚Š‚ç. “n糒B–ç (—Տ°Œ¤‹†EŠé‰ć): –ň—‚ĆŽĄ—Ă 2018/6; 46 (6): 961-4.

522198. [uŔ]y“ÁW: —Տ°–ň—ŠwUPDATEz[V‹Kˆă–ň•iŠJ”­‚Ć—Ő°Œ¤‹†] V–ňŠJ”­‚ĚƒXƒeƒbƒv‚Ćƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`. ŒF’J—YŽĄ (—Տ°Œ¤‹†EŠé‰ć): ˆăŠw‚Ě‚ ‚ä‚Ý 2018/11; 267 (5): 387-92.

[Šw‰ďEŒ¤‹†‰ď“™]

713166. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Drug-drug interaction between TAS-303 and simvastatin /midazolam in healthy subjects. Kumagai Y1, Fujita T, Aso M, Amano H, Sasaki Y, Kawai M, Takenaka T, Nagaoka M, Hoashi K: 18th World Congress of Basic and Pharmacology (2018/7/3), Kyoto, Japan. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EŠé‰ć)

722228. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žwj‚Ć–@‚Ě‹ˇŠÔ‚É‚ ‚ég—Տ°Œ¤‹†h‚ÉŠÖ‚ˇ‚é‘Š’kŽ–€. “n糒B–ç (—Տ°Œ¤‹†EŠé‰ć): ‘ć18‰ńCRC‚Ć—Ő°ŽŽŒą‚Ě‚ ‚č•ű‚đl‚Ś‚é‰ď‹c2018in•xŽR (2018/9/16), •xŽR.

722229. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) TBSƒhƒ‰ƒ}uƒuƒ‰ƒbƒNƒyƒAƒ“v‚ɑ΂ˇ‚é“ú–{—Տ°–ň—Šw‰ď‚̑Ήž. ŒF’J—YŽĄ (—Տ°Œ¤‹†EŠé‰ć): ‘ć18‰ńCRC‚Ć—Ő°ŽŽŒą‚Ě‚ ‚č•ű‚đl‚Ś‚é‰ď‹c2018in•xŽR (2018/9/17), •xŽR.

722230. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —Տ°Œ¤‹†–@Œł”N`ˆă—Ă‹@ŠÖ‚Ě—§ę‚Š‚ç`. “n糒B–ç (—Տ°Œ¤‹†EŠé‰ć): ‘ć24‰ń“ú–{–ňÜ‰uŠw‰ďŠwp‘‰ď (2018/10/13), ‹{é.

723874. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĄŒąŽQ‰Á’†‚Ě”íŒąŽŇ‚Ě“ď•aˆă—Ï•Ź§“x‚̍XVŽć‚艺‚°‚ɑ΂ˇ‚éŽć‚č‘g‚Ý. ‰Ş“cˆť‰Ŕ, ŕ_“c‚Š‚Č‚Ś, –ΊїmŽq, ‹T“c—LŠóŽq, “n糒B–ç1, ’|“ŕ@C, ŽŒ´@~, ˜@Ŕ’qŽq2 (1—Տ°Œ¤‹†EŠé‰ć, 2—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘ć18‰ńCRC‚Ć—Ő°ŽŽŒą‚Ě‚ ‚č•ű‚đl‚Ś‚é‰ď‹c2018in•xŽR (2018/9/16), •xŽR.

732118. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) FIHŽŽŒąƒvƒƒgƒRƒ‹‚Ěƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg. ŒF’J—YŽĄ (—Տ°Œ¤‹†EŠé‰ć^ƒvƒƒWƒFƒNƒg): ‘ć22‰ń–ň•¨“Ž‘Ô’k˜b‰ďƒZƒ~ƒi[ (2018/8/22), •{’†.

732119. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒƒfƒBƒJƒ‹ƒAƒtƒFƒA[ƒYv‚đ’m‚é ƒƒfƒBƒJƒ‹ƒAƒtƒFƒA[ƒY‚ÉŠú‘Ň‚ˇ‚é‚ą‚Ɓ|ˆă—ĂŠÖŒWŽŇ‚Ě—§ę|. ŒF’J—YŽĄ (—Տ°Œ¤‹†EŠé‰ć): ‘ć62‰ń“ú–{–ňŠw‰ďŠÖ“ŒŽx•”‘ĺ‰ď (2018/9/15), ’†–ě.

732120. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚ĆŠĚ‹@”\ŒŸ¸. ŒF’J—YŽĄ (—Տ°Œ¤‹†EŠé‰ć): ‹{ŒĂ’n‹ćƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“Šwpu‰‰‰ď (2018/11/22), ‹{ŒĂ“‡.

ƒvƒƒWƒFƒNƒgŽŔŽ{•”–ĺ

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H28-110002. [Œ´’˜] The growth factor midkine may play a pathophysiological role in rheumatoid arthritis. Shindo E, Nanki T, Kusunoki N, Shikano K, Kawazoe M, Sato H, Kaneko K, Muraoka S, Kaburaki M, Akasaka Y, Shimada H, Hasunuma T1, Kawai S: Mod Rheumatol 2017/1; 27 (1): 54-9. (˜@Ŕ’qŽq1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)


ƒoƒCƒIƒGƒVƒbƒNƒX•”–ĺ


‘n–ňƒV[ƒYŒ¤‹†ŠJ”­•”–ĺ


ˆăŠw•”•‘ŽV˘‹Iˆă—ĂŠJ”­ƒZƒ“ƒ^[

ć’[ˆă—Ă—ĚˆćŠJ”­•”–ĺ

(“c糁@‘)
ŚuÁ‰ťŠí“ŕ‰ČŠwv‚đŽQĆ

(’ˇŔ‰p–ž)
ŚuŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠwv‚đŽQĆ

(“c’†@Œ‰)
Śuˆę”ʁEŹŽ™EŠĚ’_äXŠO‰ČŠwv‚đŽQĆ

(‹g“cˆęŹ)
Śu”ĺ”AŠí‰ČŠwv‚đŽQĆ

(Œ´—ŻOŽ÷)
Śu•úŽËü‰ČŠwi‰ć‘œf’fŠwjv‚đŽQĆ

(ćčG–ž)
ŚuŹŽ™‰ČŠwv‚đŽQĆ

(’†źG•F)
ŚuŹŽ™‰ČŠwv‚đŽQĆ

(‰Á“Ą—˘ŠG)
Śu–ƒŒ‰ČŠwv‚đŽQĆ


‰Ą’f“Iˆă—Ă—ĚˆćŠJ”­•”–ĺ

(˛X–ŘŽĄˆę˜Y)
ŚuŒÄ‹zŠí“ŕ‰ČŠwv‚đŽQĆ

(‹ŕˆäş•ś)
Śu–ƒŒ‰ČŠwv‚đŽQĆ

(VˆäłN)
Śu–ƒŒ‰ČŠwv‚đŽQĆ

(ŽR‰şŒpŽj)
Śuă•”Á‰ťŠÇŠO‰ČŠwv‚đŽQĆ

(–Ř‘ş‘ô–)

[Šwp˜_•ś]

522199. [uŔ]y“ÁW: Ý‘îˆă—Ă‚ĚŠC}‚Ć—…j”Ձz[•a‰@‚Ć’nˆć‚đ‚‚ȂŽ] Ý‘îˆă—Ă‚É‚¨‚Ż‚éu“ńlŽĺŽĄˆă§v‚Ć‚˘‚¤ŠT”O. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): Ý‘îV—Ă0-100 2018/4; 3 (4): 310-3.

522200. [uŔ]y“ÁW: —AŒŒ2018|ŒŔ‚č‚ ‚鎑Œš‚đˆŔ‘S‚É, —LŒř‚ÉŠˆ—p‚ˇ‚é‚˝‚߂Ɂz<“ÁŽę‚Čó‹ľ‚Ĺ‚Ě—AŒŒ> Ý‘îˆă—Ă‚É‚¨‚Ż‚é—AŒŒ.–Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ŕ‰Č 2018/10; 122 (4): 813-7.

522201. [uŔ]y“ÁW: Ý‘îˆă—Ă‚đŽn‚ß‚é!@ŽŔ‘H‚ˇ‚é!@˜AŒg‚ˇ‚é!z<‘˜_> Ý‘îˆă—Âʼn˝‚đ‚Ý‚é‚Š. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ŕ‰Č 2018/11; 122 (5): 888-92.

522202. [uŔ]y“ÁW: Ý‘îˆă—Ă‚đŽn‚ß‚é!@ŽŔ‘H‚ˇ‚é!@˜AŒg‚ˇ‚é!z<Ý‘îˆă—Ă‚ĚƒRƒc> Ý‘ŽŇ‚Ě‹}‚ȏó‘ԕωťŽž‚ÉŠO—ˆf—Ă‚ĆÝ‘îˆă—Ă‚đ—ź—§‚ˇ‚éƒRƒc. âV“Ą—Y”V, –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ŕ‰Č 2018/11; 122 (5): 911-6.

522203. [uŔ]y“ÁW: ‚—îŽŇf—Ă‚ĚƒgƒsƒbƒNzI. ˜V”NÇŒóŒQ‚ƍ‚—îŽŇ‘‡“I‹@”\•]‰ż. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{“ŕ‰ČŠw‰ďŽGŽ 2018/12; 107 (12): : 2420-9.

522204. [uŔ]y“ÁW: ƒRƒ“ƒTƒ‹ƒg‚Ě”üŠwzĄŽ{ÝŠÔ˜AŒg‚É‚¨‚Ż‚éî•ń‚ĚŽó‚Ż“n‚ľ@•a‰@‚Š‚çf—ÏŠE—Ă—{Ž{Ý‚Č‚Ç‚Ö‚ĚĐ‰î. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ŽĄ—Ă 2019/1; 101 (1): 97-102.

522205. [uŔ]y“ÁW: ŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠłzĄŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠł‚Ć‚˘‚¤‘O‚Ɂ@–Ť•Ö”é‚ւ̐f’f“IƒAƒvƒ[ƒ`. ]Œű’‰Žu, –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ŽĄ—Ă 2019/2; 101 (2): 146-50.

522206. [uŔ]y“ÁW: ŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠłzĄŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíŽžŠł‚Ö‚ĚƒAƒvƒ[ƒ`@‚—îŽŇ‚Ě–Ť•Ö”é‚ւ̐śŠˆŽw“ą. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ŽĄ—Ă 2019/2; 101 (2): 183-7.

522207. [uŔ]y“ÁW: ŒŸ¸‚ĹˆŮí‚Ş‚Č‚˘Á‰ťŠíÇóEŽžŠłzĄŒŽ‚ĚŽ‹“_: ‘‡f—Ăˆă‚É‹‚ß‚ç‚ę‚é“KŘ‚Čƒ}ƒlƒWƒƒ“ƒg. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ŽĄ—Ă 2019/2; 101 (2): 232.

[’˜@‘]

620166. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—ĂƒoƒCƒuƒ‹ <‘ć2”Ĺ>zI. ‰Ć’ëˆă—ĂŠwEÝ‘îˆă—Ă‘˜_@13. ‘˝EŽí‹Ś“­, p.90-5. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: ě‰zł, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2018/5”­s.

620167. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—ĂƒoƒCƒuƒ‹ <‘ć2”Ĺ>zI. ‰Ć’ëˆă—ĂŠwEÝ‘îˆă—Ă‘˜_@14. “ńlŽĺŽĄˆă§, p.96-101. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: ě‰zł, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2018/5”­s.

620168. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—ĂƒoƒCƒuƒ‹ <‘ć2”Ĺ>zIV. Ý‘îˆă—ĂŠe˜_E§“x@1. Ý‘îˆă—Ă‚É‚¨‚Ż‚éŠeŽíƒJƒe[ƒeƒ‹‚ĚŒđŠˇ‚ĆŠÇ—, p.502-10. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: ě‰zł, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2018/5”­s.

620169. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—Ăƒ}ƒlƒWƒƒ“ƒgQ&Az‘ć9Í Ý‘îˆă—Ă‚ĚƒXƒLƒ‹ƒAƒbƒv@Q98 Ý‘îˆă—Ă‚É•K—v‚ČƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹‚Ć‚Í, p.146. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ŠÄC: ‘ž“cGŽ÷, ˜a“c’‰Žu, •ŇW‹Ś—Í: “ú–{Ý‘îƒPƒAƒAƒ‰ƒCƒAƒ“ƒX, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2018/5”­s.

620170. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—Ăƒ}ƒlƒWƒƒ“ƒgQ&Az‘ć9Í Ý‘îˆă—Ă‚ĚƒXƒLƒ‹ƒAƒbƒv@Q197 Ý‘î‚É‚¨‚Ż‚é’†SĂ–Ź‰h—{‚ĚŠÇ—‚Ć’ˆÓ“_‚Í, p.291-2. VX‰Á“ŢŽq, –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ŠÄC: ‘ž“cGŽ÷, ˜a“c’‰Žu, •ŇW‹Ś—Í: “ú–{Ý‘îƒPƒAƒAƒ‰ƒCƒAƒ“ƒX, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2018/5”­s.

620171. [Šwp‘ (•ŇW)]yŽ–—á‚ĹŠw‚ԍݑîˆă—Ă‚ĚƒRƒc‚ĆƒsƒbƒgƒtƒH[ƒ‹z–@‘ń, –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), “ě]“°, 2018/6”­s.

620172. [Šwp‘ (•Ş’SŽˇ•M)]yŽ–—á‚ĹŠw‚ԍݑîˆă—Ă‚ĚƒRƒc‚ĆƒsƒbƒgƒtƒH[ƒ‹z‘ć1Í f’f@Case2 ć‚Ş“Ç‚ß‚Č‚˘, p.8-13. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: –@‘ń, –Ř‘ş‘ô–1, “ě]“°, “Œ‹ž, 2018/6”­s.

620173. [Šwp‘ (•Ş’SŽˇ•M)]yŽ–—á‚ĹŠw‚ԍݑîˆă—Ă‚ĚƒRƒc‚ĆƒsƒbƒgƒtƒH[ƒ‹zƒRƒ‰ƒ€1@”ń‚Ş‚ń‚É‚¨‚˘‚Ä—\Œă•s—Ç‚đŽŚ´‚ˇ‚é—Տ°ŠŒŠ‚Ć‚Í?, p.14. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: –@‘ń, –Ř‘ş‘ô–1, “ě]“°, “Œ‹ž, 2018/6”­s.

620174. [Šwp‘ (•Ş’SŽˇ•M)]yŽ–—á‚ĹŠw‚ԍݑîˆă—Ă‚ĚƒRƒc‚ĆƒsƒbƒgƒtƒH[ƒ‹z‘ć4Í ŠłŽŇE‰Ć‘°‚Ć‚ĚƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“@Case14 ‚ť‚ę‚Í’N‚ĚˆÓŒü?, p.86-9. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: –@‘ń, –Ř‘ş‘ô–1, “ě]“°, “Œ‹ž, 2018/6”­s.

620175. [Šwp‘ (•Ş’SŽˇ•M)]yŽ–—á‚ĹŠw‚ԍݑîˆă—Ă‚ĚƒRƒc‚ĆƒsƒbƒgƒtƒH[ƒ‹z‘ć6Í@ŠĹŽć‚č@Case29 g–„‘ h–ƒ–ň”­ŒŠ, p.175-6. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: –@‘ń, –Ř‘ş‘ô–1, “ě]“°, “Œ‹ž, 2018/6”­s.

620176. [Šwp‘ (•Ş’SŽˇ•M)]y‘‡f—Ðę–ĺˆăƒVƒŠ[ƒY5 •a‰@‚Ĺ‹P‚­‘‡f—ĂˆăzÇ—á•Ę‚É‚ć‚é7‚‚ĚCase@Case 1 1-2. ‰fŠO—ˆ‚Š‚ç“ü‰@: ”A˜HŠ´őÇ@u‘‡f—Ăˆăv‚Ć‚ľ‚Ä“ü‰@ŠłŽŇ‚֐śŠˆ‚đ”O“Ş‚É’u‚˘‚˝ƒPƒA‚đ’ń‹Ÿ‚ˇ‚é‚˝‚ß‚É, p.28-9. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •ŇWŽĺŠ˛: ‘ę“SŽü, ę–ĺ•ŇW: ě“‡“ÄŽu, ’†ŽR‘“X, “Œ‹ž, 2018/6”­s.

620177. [Šwp‘ (•Ş’SŽˇ•M)]yƒf[ƒ^‚Ĺ’T‚ˇ•a‰@‚Ě‘I‚Ń•ű2019z•a‰@‘I‚Ń‚Ě“üŒű@‚Š‚Š‚č‚‚Żˆă‚Ě’T‚ľ•ű, p.6-9. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ˆă—ÐV•ˇŽĐ, “Œ‹ž, 2018/10”­s.

620178. [Šwp‘ (•Ş’SŽˇ•M)]yƒWƒFƒlƒ‰ƒŠƒXƒg‹łˆçƒRƒ“ƒ\[ƒVƒAƒ€11 consortium vol.11z3. •a‰@‘‡ˆă‚̍L”Í‚Č‹@”\@3. •a‰@‚đŽĺ‚ČŠˆ“Ž‚̏ę‚Ć‚ˇ‚éu‘‡f—Ăˆăv‚Ě ’nˆć•ďŠ‡ƒPƒA‚É‚¨‚Ż‚é–đŠ„, p.54-7. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: ‘吟O‚, “ĄŔNŽ÷, ƒJƒC‘—Ń, ‚ł‚˘‚˝‚ÜŽs, 2018/11”­s.

620179. [Šwp‘ (•Ş’SŽˇ•M)]y‹­‚Ý‚ĆŽă‚Ý‚Š‚ç‚Ý‚˝@Ý‘îŠĹŒě‰ß’öz‘ć2Í Œ’NáŠQ•ĘŠĹŒě‰ß’ö@[2 “ď•a]@12. ‘˝”­Ťd‰ťÇ, p.211-25. X@hŽq, –Ř‘ş‘ô–1, —§Î—eŽq (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: ‰Í–ě‚ ‚ä‚Ý, •ŇW‹Ś—Í: ‘ę“SŽü, ˆăŠw‘‰@, “Œ‹ž, 2018/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713167. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Guide to reflection on the palliative care approach for family medicine residents. Hamano J, Haruta J, Ishimaru N, Otsuka T, Den N, Sakato K, Kimura T1, Yamamoto R: The 22nd WONCA World Conference of Family Doctors (Wonca 2018) (2018/10/18), Seoul, Korea. (•l–ě@~, t“c~Žu, ÎŠŰ’źl, ‘ĺ’Ë‹M”Ž, “c@’źŽq, âŒËŒcˆę˜Y, –Ř‘ş‘ô–1, ŽR–{@—ş: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

72231. [Šw‰ď (‘S‘)] (ƒZƒbƒVƒ‡ƒ“) ‚ą‚ę‚Š‚ç‚Ě‘‡f—Ă. ěKGş, –Ř‘ş‘ô–1, ‘ę“SŽü, ě“‡“ÄŽu (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{Ý‘îˆăŠw‰ď‘ć20‰ń‹L”O‘ĺ‰ď (2018/4/29), “Œ‹ž.

722232. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) multimorbidity‚—îŽŇf—ĂƒKƒCƒhƒ‰ƒCƒ“‚đ‚Ç‚¤‚˘‚Š‚ˇ‚ŠH âŒËŒcˆę˜Y, –Ř‘ş‘ô–1, ”~Š_Gs, ’|‰Ž@‘× (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć60‰ń“ú–{˜V”NˆăŠw‰ďŠwpW‰ď (2018/6/14), ‹ž“s.

722233. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠłŽŇEˆăŽt‚ĚƒWƒFƒ“ƒ_[‚ŞÝ‘îˆă—Ă‚É‚¨‚Ż‚éˆă—Öʐڂ֗^‚Ś‚é‰e‹ż. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć12‰ń“ú–{ŤˇˆăŠwEˆă—ĂŠw‰ďŠwpW‰ď (2019/1/19), ‘ĺ‹{.

723875. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)uÝ‘Šˆ‚đ”O“Ş‚É‚¨‚˘‚˝’SŠŕŠłŽŇv‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ĚƒS[ƒ‹Ý’č‚ÉŠÖ‚ˇ‚éU‚č•Ô‚č. ŽR–{—Žq, –Ř‘ş‘ô–1, X@hŽq, Îěƒ–ç, â@Ë•˝, ‹v•Ű“c”ü‰Ä2, ⨍F‘ž˜Y, ›–ě“N–ç3, ůŔG”N, ŠÖ—LŽq (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2‘‡f—Ă, 3’nˆć‘‡ˆă—Ă): “ú–{Ý‘îˆăŠw‰ď‘ć20‰ń‹L”O‘ĺ‰ď (2018/4/29), “Œ‹ž.

723876. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Vę–ĺˆă§“xg‘‡f—Ðę–ĺˆăh‚đŽuŒü‚ˇ‚é:u•a‰@‚ɋΖą‚ˇ‚é‘ŸŠíE—Ěˆć“ŕ‰Čę–ĺˆăv‚ĚÝ‘îˆă—ĂŒ¤C‚ÉŠÖ‚ˇ‚é”FŽŻ. –Ř‘ş‘ô–1, –ě‘ş‹ąŽq, ě‰zł•˝, ˜aŔˆęO, VX‰Á“ŢŽq, Ą‰iŒő•F (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{Ý‘îˆăŠw‰ď‘ć20‰ń‹L”O‘ĺ‰ď (2018/4/29), “Œ‹ž.

723877. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) uÝ‘îˆă—Ă‚É‚¨‚˘‚Ä‹Ů‹}“d˜b‚Ĺ‚â‚č‚Ć‚č‚Ş‚Ĺ‚Ť‚Č‚˘ŠłŽŇv‚ɑ΂ˇ‚é‘Ήž‚̐U‚č•Ô‚č. X@hŽq, –Ř‘ş‘ô–1, ŽR–{—Žq, Îěƒ–ç, â@Ë•˝, ‹v•Ű“c”ü‰Ä2, ⨍F‘ž˜Y, ›–ě“N–ç3, ůŔG”N, ŠÖ—LŽq (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2‘‡f—Ă, 3’nˆć‘‡ˆă—Ă): “ú–{Ý‘îˆăŠw‰ď‘ć20‰ń‹L”O‘ĺ‰ď (2018/4/29), “Œ‹ž.

723878. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Vę–ĺˆă§“xu‘‡f—Ðę–ĺˆăv‚Ě—Ő°‹Ć–ąE“Á’Ľ‚ÉŠÖ‚ˇ‚éf—ÏŠˆăŽt‚Ć•a‰@ˆăŽt‚Ě”FŽŻ‚̍ˇˆá. –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć9‰ń“ú–{ƒvƒ‰ƒCƒ}ƒŠEƒPƒA˜A‡Šw‰ďŠwp‘ĺ‰ď (2018/6/16), ’Ă.

723879. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Cłƒfƒ‹ƒtƒ@ƒC–@‚É‚ć‚鑍‡f—ÐęUˆă‚đ‘ÎŰ‚Ć‚ľ‚˝ŠÉ˜aƒPƒAEƒAƒvƒ[ƒ`‚̐U‚č•Ô‚čƒKƒCƒh‚ĚŠJ”­. t“c~Žu, •l–ě@~, ŽR–{@—ş, ÎŠŰ’źl, ‘ĺ’Ë‹M”Ž, “c@’źŽq, âŒËŒcˆę˜Y, –Ř‘ş‘ô–1 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć50‰ń“ú–{ˆăŠw‹łˆçŠw‰ď‘ĺ‰ď (2018/8/4), “’“‡.

733285. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) śŠˆKŠľ•a‚̐fŽ@‚É‚¨‚Ż‚鑍‡f—ÂƐSgˆăŠw‚̐ړ_. –Ř‘ş‘ô– (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń_“ŢěŒ§SgˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/4/21), ‰Ą•l.

(Ź—ѐ´“T)
ŚuÁ‰ťŠí“ŕ‰ČŠwv‚đŽQĆ

(‚ŽR—zŽq)
Śu–k—˘‘ĺŠw•a‰@Š´őŠÇ—Žşv‚ŕŽQĆ

[Šw‰ďEŒ¤‹†‰ď“™]

713168. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Immunochromatography for rapid detection of Streptococcus agalactiae in pregnant women. Takayama Y1, Unno N2, Hanaki H3: XXII FIGO World Congress of Gynecology and Obstetrics (FIGO 2018) (2018/10/16), Rio de Janeiro, Brazil. (‚ŽR—zŽq1, ŠC–ěM–ç2, ‰Ô–؏G–ž3: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ŽY‰Č, 3–k—˘‘ĺŠw–k—˘ś–˝‰ČŠwŒ¤‹†Š)

732121. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) g‹ß‚Čƒ[ƒ‹ƒ‚ƒfƒ‹. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć67‰ń“ú–{Š´őÇŠw‰ď“Œ“ú–{’n•ű‰ďŠwpW‰ď/‘ć65‰ń“ú–{‰ťŠw—Ă–@Šw‰ď“Œ“ú–{Žx•”‘‰ď ‡“ŻŠw‰ď (2018/10/25), “Œ‹ž.

732122. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Menace of Infectious Diseases of Multi Drug Resistant Bacteria -Current Status of Japan and Activities of Antibiotic Stewardship in Our Hospital-. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): 15th Joint Symposium Robert Koch Institute and Kitasato University (‘ć15‰ńƒ[ƒxƒ‹ƒgEƒRƒbƒzŒ¤‹†Š/–k—˘Œ¤‹†ŠE–k—˘‘ĺŠw‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) (2018/11/14), ‘Š–ÍŒ´.

732123. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹GßŤƒCƒ“ƒtƒ‹ƒGƒ“ƒUEƒmƒƒEƒCƒ‹ƒX‚É‚ć‚éˆÝ’°‰Š‚Ć‚ť‚Ě‘Îô. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ŠÂ‹ŤŠ´őŠw‰ďŽĺĂ ’nˆćƒZƒ~ƒi[ (2018/11/18), ěč.


ˆăŠw•”‹łˆçŒn‹ZpEˆő

Œ`‘ÔŒn

[Šw‰ďEŒ¤‹†‰ď“™]

723059. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žq‹{“ŕ–ŒŠŕ‚ĚƒvƒƒQƒXƒeƒƒ“ (MPA) —Ă–@‚É‚¨‚Ż‚éLEFTY‚Ě‹@”\‰đÍ. ‹´‘ş”ü‹I1, –Ř“‡‘ĺ‹P, ‹´–{䝎Ŕ, ŹŒINŽq1, ŽOŽ}@M2 (1Œ`‘ÔŒn, 2•a—): ‘ć107‰ń“ú–{•a—Šw‰ď‘‰ď (2018/6/21), ŽD–y.


ś•¨•¨—Œn

[Šw‰ďEŒ¤‹†‰ď“™]

723094. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ˆ˘•”@Šw, ě‘ş–źŽq, ꎓĄ“މp, Ź“c‰Ŕ“ŢŽq, ěŠÔćŕ–@, “ŕŽRŸ, ˆ˘•”ŒőŽő, “c’†@–Ť, ŽR–{”ü‹u, _•ŰKO, ˛“ĄrĆ2, “ĄŕVM‹`, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž): ‘ć41‰ń“ú–{_Œo‰ČŠw‘ĺ‰ď (2018/7/26), _ŒË.

723095. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ꎓĄ“މp, •Ÿ“cŽľ•ä, ˆ˘•”@Šw, ě‘ş–źŽq, Ź“c‰Ŕ“ŢŽq, ˛“ĄrĆ2, “ĄŕVM‹`, ŽRŒű@u, “cˆä’†ˆę‹M, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž): ‘ć41‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2018/11/30), ‰Ą•l.

733023. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) D1/D2ƒh[ƒpƒ~ƒ“Žó—e‘ĚƒRƒ“ƒfƒBƒVƒ‡ƒiƒ‹”­Œťƒ}ƒEƒX‚É‚ć‚é‰^“Ž§Œä‹@\‚̉đ–ž. ů‰Şr–M, ˛“Ą’ŠŽq1, ’mŒŠ‘”ü, ‘ĺ‹v•Ű’ź2, ꎓĄ“މp, •Ÿ“cŽľ•ä, ˆ˘•”@Šw, ě‘ş–źŽq, Ź“c‰Ŕ“ŢŽq, ˛“ĄrĆ2, ‰Ş–{_Žk3, “ĄŕVM‹`, č‘şŒšŽi, “ě•”@“Ä (1ś•¨•¨—Œn, 2ŽŔ“Ž, 3–ƒŒ): ‘ć59‰ńVŠƒś‰ťŠw§˜b‰ď (2018/6/2), ’ˇ‰Ş.


•a‘ԁEf—ĂŒn

[Šwp˜_•ś]

110215. [Œ´’˜] Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens. Matsuo Y1, Yoshida T2, Yamashita K3, Satoh Y4: Cancer Cytopathol 2018/12; 126 (12): 1011-21. (ź”ö—R‹IŽq1, ‹g“c@Œ÷2, ŽR‰ş˜a–ç3, ˛“Ą”Vr4: 1•a‘ԁEf—ĂŒn, 2•a—, 3•a—•”, 4ŒÄ‹zŠíŠO)

120014. [Œ´’˜] ”S‰tŤ—‘‘ƒŽîᇂɂ¨‚Ż‚éRac•sŠˆ‰ťˆöŽqFilGAP”­Œť‚Ć—\Œă‚Ć‚ĚŠÖ˜A‚ĚŒŸ“˘. ˛“ĄŠG—˘“Ţ1, ŽOŽ}@M2, ‹´‘ş”ü‹I3, Œ´@“ÖŽq4, ‰““Ą^ˆę5, ŒĂěł‹`5, “cŽG—L‹I5, ‚“c‹ąb5, VˆäłG5, ŠâŁtŽq5, ‘ž“cˆŔ—˛6, ‰ś“c‹MŽu4 (1•a‘ԁEf—ĂŒn, 2•a—, 3Œ`‘ÔŒn, 4–k—˘Œ¤‹†Š•a‰@, 5•wl, 6—Šw•”): –k—˘ˆăŠw 2018/12; 48 (2): 121-9.

[Šw‰ďEŒ¤‹†‰ď“™]

723055. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŠŕLBCŒŸ‘Ě‚Ěˆâ“`ŽqŒŸ¸‰ž—p‚ÖŒü‚Ż‚˝ŒŸ“˘|”|—{×–E‚đ—p‚˘‚˝‰đÍ|. ź”ö—R‹IŽq1, ‹g“c@Œ÷2, ŽR‰ş˜a–ç3, ŽOŒEŤŽj4, “ŕ“Ą‰ëm4, ŕV–ěáÁ—Žq, ‘ş‰_–FŽ÷2, ˛“Ą”Vr4 (1•a‘ԁEf—ĂŒn, 2•a—, 3•a—•”, 4ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/3), ŽD–y.


—\–hˆăŠwŒn


•ŞŽqˆă‰ČŠwE§ŒäŒn


“Œ•a‰@Œ¤‹†Œn


‘gD”|—{ƒZƒ“ƒ^[


DNAŽŔŒąƒZƒ“ƒ^[


ˆâ“`Žq‚ŽŸ‹@”\‰đÍƒZƒ“ƒ^[


ƒoƒCƒIƒCƒ[ƒWƒ“ƒOŒ¤‹†ƒZƒ“ƒ^[


Œ’NŠÇ—ƒZƒ“ƒ^[

[Šwp˜_•ś]

110348. [Œ´’˜] Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic Nephropathy. Doi T, Moriya T1, Fujita Y, Minagawa N, Usami M, Sasaki T, Abe H, Kishi S, Murakami T, Ouchi M, Ichien G, Yamamoto K, Ikeda H, Koezuka Y, Takamatsu N, Shima K, Mauer M, Nagai K, Tominaga T: Diabetes 2018/5; 67 (5): 986-93. doi: 10.2337/db17-1043. Epub 2018 Feb 28. (Žç‰Ž’B”ü1: 1Œ’NŠÇ—ƒZ)

110349. [Œ´’˜] Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. Oshima M1, Toyama T1, Haneda M1, Furuichi K1, Babazono T1, Yokoyama H1, Iseki K1, Araki S1, Ninomiya T1, Hara S1, Suzuki Y1, Iwano M1, Kusano E1, Moriya T1,2, Satoh H1, Nakamura H1, Shimizu M1, Hara A1, Makino H1, Wada T1 (1Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan): PLoS One 2018/8; 13 (8): e0201535. (Žç‰Ž’B”ü1,2: 2Œ’NŠÇ—ƒZ)

120038. [Œ´’˜]u‚ą‚ą‚ë‚ĚŒ’N’˛¸v‚đ—p‚˘‚˝S—Žx‰‡ƒj[ƒY‚đ—L‚ˇ‚éŠwś‚ĚŒ@‚č‹N‚ą‚ľ‚Ć“d˜bE–ʐڂɂć‚éƒAƒEƒgƒŠ[ƒ`Œ^Žx‰‡‚ĚŽŽ‚Ý. ŽR“c—TŽq1, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): Campus Health 2018/5; 55 (2): 70-6.

120039. [Œ´’˜] ‘Š’k‚ˇ‚é‚ą‚Ć‚É”ńŽĺ‘Ě“I‚ȏó‘Ô‚Ĺ—ˆ’k‚ˇ‚éŠwś‚Ö‚ĚŽx‰‡ƒ‚ƒfƒ‹‚ĚŒŸ“˘: ”ńŽĺ‘Ě“I—ˆ’kŠwśŽ–—á‚Ěƒƒ^•ŞÍ‚É‚ć‚鎿“IŒŸ“˘. ‘ĺ’Ź’m‹v1, “c‘ş—Fˆę, ŽR“c—TŽq1, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): Šwś‘Š’kŒ¤‹† 2018/7; 39 (1): 25-38.

540043. [‚ť‚Ě‘ź (•ń‘)] –k—˘‘ĺŠw‚É‚¨‚Ż‚éABCŒŸf‚Ě–âf•[•ĎX‚É‚ć‚鐸–§ŒŸ¸‘ÎŰŽŇ‚Ě“IŠm‚ČƒXƒNƒŠ[ƒjƒ“ƒO. ‹g“c—F‹I1, ‰HŽRŒdˆČ, źŒ´‚Ü‚Ç‚Š1, ‘ź (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH 2018; 55 (1): 263-5. (‘ć55‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď•ń‘)

540044. [‚ť‚Ě‘ź (•ń‘)]uS‚ĚŒ’N’˛¸v‚Š‚ç‚í‚Š‚éS—Žx‰‡‚đ—v‚ˇ‚é‰Â”\Ť‚ލ‚‚˘Šwś‚Ě“Á’Ľ. ŽR“c—TŽq1, Î’ˏš•Ű1, ‘ĺ’Ź’m‹v1, “c’†‚ ‚ä‚Ý, ‰ÍŒ´‹v”üŽq, ˆäăŽ‘ă, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH 2018; 55 (1): 352. (‘ć55‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď•ń‘)

540045. [‚ť‚Ě‘ź (”N•ń)] 2017”N“x‚đU‚č•Ô‚Á‚Ä. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): –k—˘‘ĺŠwŒ’NŠÇ—ƒZƒ“ƒ^[”N•ń 2018; ‘ć2†: 13-4.

[’˜@‘]

620180. [Šwp‘ (•Ş’SŽˇ•M)]y‘˝•ś‰ť‹¤ś‚Ě’nˆć“ú–{Œę‹łŽş‚đ‚ß‚´‚ľ‚ā^‹ęŠ‚Ă‚­‚č‚ĆŽQ‰ÁŒ^ŠwK‹łŢz‘ć2Í‘˝•ś‰ťŽĐ‰ďŒ^‹ęŠŠ´ŽÚ“x‚Ć’nˆć“ú–{Œę‹łˆç‚Ĺ‚ĚŠˆ—p–@@1. S—Šw‚É‚¨‚Ż‚éu‹ęŠv‚Š‚çu‘˝•ś‰ťŽĐ‰ďŒ^‹ęŠŠ´ŽÚ“xv‚Ö, p.17-24. 2D‹ęŠŠ´’˛¸‚Ě•ŞÍ•ű–@‚ĆŒ‹‰Ę‚Ě“Ç‚Ý‰đ‚Ť•ű, p.25-34. Î’ˏš•Ű (Œ’NŠÇ—ƒZ), •Ň: CINGA’nˆć“ú–{ŒęŽŔ‘HŒ¤‹†‰ď, ź”ŽĐ, “Œ‹ž, 2018/6”­s.

620181. [Šwp‘ (•Ş’SŽˇ•M)]y‰Ć‘°S—Šwƒnƒ“ƒhƒuƒbƒNzVI. ŒÂ•Ę—Ěˆć‚É‚¨‚Ż‚é‰Ć‘°Žx‰‡3. ‘ĺŠw‚Ĺ‚ĚŠwś‘Š’k‚É‚¨‚Ż‚é‰Ć‘°Žx‰‡, p.304-11. ‘ĺ’Ź’m‹v (Œ’NŠÇ—ƒZ), •Ň: ‰Ć‘°S—Šw‰ď, ‹ŕŽq‘–[, “Œ‹ž, 2019/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713169. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Impact of Vitamin B6 Intake on the Risk of Diabetic Retinopathy?Analysis from Multicenter Prospective Study of Japanese Patients with Type 2 Diabetes. Horikawa C, Aida R, Tanaka S, Yoshimura Y, Kawasaki R, Moriya T1, Araki A, Sone H: American Diabetes Association 78th Scientific Sessions (2018/6/22-26), Orlando, USA. (Žç‰Ž’B”ü1: 1Œ’NŠÇ—ƒZ)

713170. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Higher Dietary Intake of VitaminD Is Associated with Lower Incidence of Diabetic Nephropa thy in Japanese Patients with Type 2 Diabetes. Horikawa C, Aida R, Tanaka S, Tanaka S, Kamada C, Yoshimura Y, Aaraki A, Moriya T1, Katayama S, Sone H: American Diabetes Association 78th Scientific Sessions (2018/6/22-26), Orlando, USA. (Žç‰Ž’B”ü1: 1Œ’NŠÇ—ƒZ)

713171. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The accurate measurement of eGFR is different between each albuminuria grade in patients with type 2 diabetes. Moriya T1, Matsubara M1, Ouchi M: American Diabetes Association 78th Scientific Sessions (2018/6/22-26), Orlando, USA. (Žç‰Ž’B”ü1, źŒ´‚Ü‚Ç‚Š1: 1Œ’NŠÇ—ƒZ)

722234. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒVƒ“ƒ|ƒWƒEƒ€12: ut‘Ÿ•aE“œ”A•a—ĚˆćƒRƒz[ƒgŒ¤‹†‚̍ŐV’mŒŠv(“ú–{“œ”A•aŠw‰ď‡“ŻŠé‰ć) Japan Diabetes Complications Study (JDCS) ‚É‚¨‚Ż‚ét‘Ÿ•aE“œ”A•a—Ěˆć‚ĚŒ‹‰Ę. Žç‰Ž’B”ü1, ‘]Ş”Žm (1Œ’NŠÇ—ƒZ): ‘ć61‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2018/6/8-10), VŠƒ.

723880. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•aŠłŽŇ‚ĚƒAƒ‹ƒuƒ~ƒ“”AŠú‚É‚ć‚萄ŽZGFR (eGFR) ŽŽ‚đŽg‚˘•Ş‚Ż‚é•K—v‚Ş‚ ‚é. Žç‰Ž’B”ü1, źŒ´‚Ü‚Ç‚Š1, ‹g“c—F‹I1, ‘ĺ“ŕŠîŽi (1Œ’NŠÇ—ƒZ): ‘ć61‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2018/5/24-26), “Œ‹ž.

723881. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw‘Š–ÍŒ´ƒLƒƒƒ“ƒpƒX‚É‚¨‚Ż‚é‹łEˆő‚Ě‹Ö‰Œ‚ɑ΂ˇ‚éˆÓŽŻ‚̐„ˆÚ. źŒ´‚Ü‚Ç‚Š1, ‹g“c—F‹I1, ^čN”Ž, Šâ‘şłŽk2, ‚‹´–ž‹`, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ, 2”ĺ”AŠí): ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď (2018/10/3-4), •iě, ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‰ď´˜^W 2018; p.72.

723882. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŠwś‚Ě‚â‚š‚ɑ΂ˇ‚錒NŠÇ—ƒZƒ“ƒ^[‚Ě—LŒř‚ČŠČˆŐ‰î“ü‘̐§‚̍\’z. ‹g“c—F‹I1, ŕVŽRŒb”g2, źŒ´‚Ü‚Ç‚Š1, ‘ź (1Œ’NŠÇ—ƒZ, 2¸_): ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď (2018/10/3-4), •iě.

723883. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) uS‚ĚŒ’N’˛¸v‚Š‚ç‚í‚Š‚éS—Žx‰‡‚đ—v‚ˇ‚é‰Â”\Ť‚ލ‚‚˘Šwś‚Ě“Á’Ľ. ŽR“c—TŽq1, Î’ˏš•Ű1, ‘ĺ’Ź’m‹v1, ‰ÍŒ´‹v”üŽq, “c’†‚ ‚ä‚Ý, ˆäăŽ‘ă, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď (2018/10/3-4), •iě.

723884. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šwś‘Š’k‚É‚¨‚Ż‚鍢“—á‚Ĺ‚ ‚é”íŽĺ‘Ě“I—ˆ’kŠwś‚Ö‚Ě—‰đ‚ƑΉž‚ÉŠÖ‚ˇ‚é‘S‘’˛¸. ‘ĺ’Ź’m‹v1, ŽR“c—TŽq1, Î’ˏš•Ű1, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): ‘ć56‰ń‘S‘‘ĺŠw•ŰŒ’ŠÇ—Œ¤‹†W‰ď (2018/10/3-4), •iě.

723885. [Šw‰ď (‘S‘)] (Šw‰ď’ˇ) Žç‰Ž’B”ü (Œ’NŠÇ—ƒZ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l.

723886. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”DP’†‚ĚA1C‚Í“SŒ‡–Ró‘Ô‚Ě‚˝‚ß‚ÉŽ‘ąŒŒ“œ‘Ş’č‚Ĺ“ž‚ç‚ę‚˝•˝‹ĎŒŒ“œ‚ɔ䂾‹U‚’l‚đŽŚ‚ˇ. ŒĂ‰ęłŽj, ’š–{Œjˆę, ‰Ş“c—m‰E, źŒ´‚Ü‚Ç‚Š1, Žç‰Ž’B”ü1 (1Œ’NŠÇ—ƒZ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/23-24), ‰Ą•l.


–k—˘‘ĺŠw•a‰@

ŠĹŒě•”

[Šwp˜_•ś]

120040. [Œ´’˜] ‘ĺ’°“ŕŽ‹‹žŒŸ¸‚É‚¨‚Ż‚錟¸‘Ň‚żŽžŠÔ‚ĚŒťó‚Ć‘Ň‚żŽžŠÔ’Zk‚ÉŒü‚Ż‚Ä‚ĚŽć‚č‘g‚Ý. “Ą“c–ƒ”üŽq1, ŽOŽ}Ž–1 (1ŠĹŒě•”): “ú–{ŠĹŒěŠw‰ď˜_•śW: ŠĹŒěŠÇ— 2018/4; 48: 31-4.

320047. [Ç—á•ń] ‘˝EŽíŒŸ“˘‰ď‚É‚ć‚é–éŠÔŠO—ˆ‚ÉŒJ‚č•Ô‚ľŽóf‚ˇ‚銳ŽŇ‚ɑ΂ˇ‚éŒÂ•Ę“IŽx‰‡‚ĚŽŽ‚Ý. Î‘q@ˆ¤1, ÂŽR’ź‘P2, ’†‘şŒł”ü3, ě’JOŽq4, ś‰E“c“N4, “c糁@‘5 (1ŠĹŒě•”, 2‘‡f—Ă, 3¸_, 4–k—˘‘ĺŠw•a‰@ˆă—ĂŽx‰‡•”, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ďŽGŽ 2018/6; 19 (1): 11-5.

522208. [uŔ]y˜AÚ: ŒoŒűŰŽć‚đ–ÚŽw‚ˇ@ŰHš‹‰şŠłŽŇ‚ĚŠĹŒě (‘ć4‰ń)zˆŔ‘S‚ČŒoŒűŰŽć‚ÉŒü‚Ż‚˝ƒAƒvƒ[ƒ`. Î‘q@ˆ¤ (ŠĹŒě•”): ”]‚ĚŠĹŒěŽŔ‘H 2018/4; 3 (6): 82-8.

522209. [uŔ]y“ÁW: Äśˆ—‚Ć’P‰ńŽg—pŠíŢ (SUD) ‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒgzĄBig topics@’P‰ńŽg—pŠíŢ (SUD)@3) ŒoŒą ’P‰ńŽg—pŠíŢ (SUD) “ą“ü‚ĚŽć‚č‘g‚Ý‚Ć‚ť‚ĚŒř‰Ę|Žčp—pƒŠƒlƒ“‚É‚¨‚Ż‚錟“˘. ‚é—R”üŽq1,2, [–xMŽq1,2, ŔŠÔO˜a3 (1ŠĹŒě•”, 2Š´őŠÇ—Žş, 3Ž––ą•”): Š´ő‘΍ôICTƒWƒƒ[ƒiƒ‹ 2018/4; 13 (2): 162-7.

522210. [uŔ]y˜AÚ: ŽŔ‘H! ƒXƒLƒ“ƒPƒAEƒeƒNƒjƒbƒN@—Տ°ƒi[ƒX‚ލs‚¤ƒXƒLƒ“ƒPƒA (‘ć5‰ń)zIAD‚Ě”­ÇƒƒJƒjƒYƒ€‚Š‚ç‚Ý‚˝—\–hƒPƒA‚̏d—vŤ|Ž¸‹ÖŠÖ˜A”畆‰Š (IAD) ‚Ö‚ĚƒXƒLƒ“ƒPƒA|. ´‹{”ü‰r (ŠĹŒě•”): Expert Nurse 2018/6; 34 (8): 125-8.

522211. [uŔ]y˜AÚ: Margaret Newman‚ĚŒ’N‚Ě—˜_‚É“ą‚Š‚ę‚˝‚Ć‚Ť, ‚ ‚Č‚˝‚Ě‚Ş‚ńŠĹŒěŽŔ‘H‚Í‚ł‚ç‚ÉŠJ‚Š‚ę‚é`‚Ş‚ńŠłŽŇE‰Ć‘°‚Ć‚ĚƒPƒAƒŠƒ“ƒOƒp[ƒgƒi[ƒVƒbƒv‚đ‘ĚŒą‚ľ‚悤 (‘ć2‰ń)zNewman—˜_‚É“ą‚Š‚ę‚˝ƒPƒAƒŠƒ“ƒOEƒp[ƒgƒi[ƒVƒbƒv‚Ě•ű–@˜_‚Ć‚ť‚ĚˆÓ–Ą. ŽOŽŸ^—1, ˛“Ą–FŒb2, çř“”ü“oŽq2 (1•‘ –ě‘ĺŠwŠĹŒěŠw•”, 2ŠĹŒě•”): ‚Ş‚ńŠĹŒě 2018/11; 23 (7): 708-11.

522212. [uŔ]y“ÁW: ŹŽ™ŠO‰Č—Ěˆć‚É‚¨‚Ż‚éŽq‚Ç‚ŕŽĺ‘Ě‚ĚŽüpŠúƒvƒƒOƒ‰ƒ€z[’m‚Á‚Ä‚¨‚Ť‚˝‚˘’mŽŻ]@…EpŒă‚Ě’É‚Ý‚Ěƒ}ƒlƒWƒƒ“ƒg‚ĆƒhƒŒ[ƒ“ŠÇ—. ‘ĺ’JŽ–ç1,2, ‹ŕ„Ž›‚Ü‚čŽq1 (1ŠĹŒě•”, 2/RSTERRTŽş): ŹŽ™ŠĹŒě 2018/12; 41 (13): 1654-61.

522213. [uŔ]y˜AÚ: Margaret Newman‚ĚŒ’N‚Ě—˜_‚É“ą‚Š‚ę‚˝‚Ć‚Ť, ‚ ‚Č‚˝‚Ě‚Ş‚ńŠĹŒěŽŔ‘H‚Í‚ł‚ç‚ÉŠJ‚Š‚ę‚é`‚Ş‚ńŠłŽŇE‰Ć‘°‚Ć‚ĚƒPƒAƒŠƒ“ƒOƒp[ƒgƒi[ƒVƒbƒv‚đ‘ĚŒą‚ľ‚悤 (‘ć3‰ń)zNewman—˜_‚É“ą‚Š‚ę‚˝ŠĹŒěŽŔ‘H‚đ’Ę‚ľ‚ăi[ƒX‚Ć‚ľ‚Đi‰ťEŹ’ˇ‚ˇ‚é‰ß’ö. Ž™‹Ę”ü—R‹I1, Ź‘ň@1 (1ŠĹŒě•”): ‚Ş‚ńŠĹŒě 2019/1; 24 (1): 61-4.

540046. [‚ť‚Ě‘ź (Šw‰ď´˜^)]y‘ć26‰ń“ú–{”MŠw‰ďŠÖ“Œ’n•ű‰ďzˆę”ʍu‰‰OR-5. Šů‘ś‚ĚŒĹ’čŠĎ”O‚ÉŽú‚í‚ꂸ, ƒ[ƒƒx[ƒXŽvl‚ʼnü’ů‚ľ‚˝ICU”Mƒ}ƒjƒ…ƒAƒ‹ěŹ‚ĚŽć‚č‘g‚݁|Š´őŠÇ—Žş‚Č‚Ç‘ź•”–ĺ‚đŠŞ‚Ťž‚ń‚Ł|. Ž…’؁@Œb1, ‰Í“cˆ¤Žq1, ŒN“ˆ@“Œ1, ‹AŽRˆęŽu1, ’J@Kˆę1, ‘“cł˜a1 (1ŠĹŒě•”): ”M 2018/6; 44 (2): 98-9.

540047. [‚ť‚Ě‘ź (Šw‰ď´˜^)]y‘ć44‰ń“ú–{”MŠw‰ď‘‰ďEŠwpW‰ďzƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2udÇ”MŠĹŒě‚ĚŠ´ő—\–h, ƒŠƒlƒ“ˆ’u, ”p•¨ˆ’u‚ĚŽŔŰvPD2-7. ICU”Mƒ}ƒjƒ…ƒAƒ‹ěŹ‚ĆŽü’mŠˆ“Ž‚ĚŽć‚č‘g‚Ý. Ž…’؁@Œb1, ŒN“ˆ@“Œ1, ‹AŽRˆęŽu1, ’J@Kˆę1, ‘“cł˜a1 (1ŠĹŒě•”): ”M 2018/11; 44 (4): 173.

[’˜@‘]

620182. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…E‚Ş‚ń‚̒ɂ݂ɑ΂ˇ‚éƒPƒA\’É‚Ý‚ŞŒy‚­‚Č‚ę‚Î, ”ň–ô“I‚ÉQOL‚ŕŒüă, p.26-7. źŒ´’mŽ}1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620183. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…F–ň•¨—Ă–@‚ŞŒř‚Ť‚É‚­‚­‚Č‚Á‚Ä‚Ť‚˝‚ç, p.28-9. ”ԏ ÍŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620184. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…G‚Ş‚ńŠłŽŇŽŠg‚É‚ć‚鎥—ĂŒˆ’č‚ĚƒTƒ|[ƒg‚Ě‚˝‚ß‚É, p.30-1. Ž™‹Ę”ü—R‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620185. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…IR‚Ş‚ń–ň‚ĚŽćˆľ‚˘‚͐Td‚É, p.36-7. ˆÉ“Ą‚Ś‚čŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620186. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…Jˆă—ĂŽŇŽŠg‚̍R‚Ş‚ń–ň”˜˜I|Ž–ŒĚ‚Š‚çˆă—ĂŽŇŽŠg‚đŽç‚é‚˝‚ß‚É, p.38-9. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620187. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…@“Şčň•”‚Ş‚ń: Cmab + RT—Ă–@, p.42-3. –]ŒŽ”ü•ä1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620188. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…AH“š‚Ş‚ń: DCF—Ă–@, p.44-6. ‚‹´‚Š‚¨‚é1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620189. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…B”x‚Ş‚ń: ƒAƒtƒ@ƒ`ƒjƒu’PÜ—Ă–@, p.47-9. …–ě‰Ŕ“s”ü1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620190. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…C“ű‚Ş‚ń: ƒyƒ‹ƒcƒYƒ}ƒu + ƒgƒ‰ƒXƒcƒYƒ}ƒu + DOC—Ă–@, p.50-1. ’ˇ“c^—R”ü1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620191. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…DˆÝ‚Ş‚ń: CapeOX—Ă–@, p.52-3. Ź‰€“ŢŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620192. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…EäX‚Ş‚ń: GEM + nab-PTX—Ă–@, p.54-6. ‚‹´‚Š‚¨‚é1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620193. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…F’_“š‚Ş‚ń: GEM + CDDP—Ă–@, p.58-9. ‚‹´‚Š‚¨‚é1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620194. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…Gt×–E‚Ş‚ń: ƒXƒjƒ`ƒjƒu’PÜ—Ă–@, p.60-1. ÂúĺGş1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620195. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…H—‘‘ƒ‚Ş‚ń: TC + BEV—Ă–@, p.62-3. ˛“Ą”ü‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620196. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…I‘O—§‘B‚Ş‚ń: DOC’PÜ—Ă–@, p.64-5. ÂúĺGş1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620197. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…J‘ĺ’°‚Ş‚ń: FOLFOX{Pmab—Ă–@, p.66-8. Ź‘ň@1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620198. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…K‹}Ťœ‘Ť”’ŒŒ•a (AML): IDR + Ara-C—Ă–@, p.70-1. ŽO’Ă‹´—œŠG1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620199. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…L-1 CD20—zŤ‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EŤƒŠƒ“ƒpŽî: R-CHOP—Ă–@, p.72-4. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620200. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…L-2 ƒtƒBƒ‰ƒfƒ‹ƒtƒBƒAőF‘Ě—zŤ‹}ŤƒŠƒ“ƒpŤ”’ŒŒ•a (ALL): JALSG Ph(+)ALL202ƒŒƒWƒƒ“ (Źl), p.75-7. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620201. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz3 ‚Ş‚ń–ň•¨—Ă–@‚ĚƒƒU‚đ’m‚é|ƒŒƒWƒƒ“‚Ş•Ş‚Š‚ę‚΃PƒA‚ĚŽd•ű‚Ş‚Ý‚Ś‚Ä‚­‚é@…M‘˝”­Ťœ‘Žî: BD—Ă–@, p.78-9. Žt‰ŞŒbŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620202. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…@“Ë‘RŒť‚ę‚é•›ě—p|ŽĄ—Ă’†‚Ɂu‚ ‚Á!v‚ĆŽv‚Á‚˝‚ç, p.82-9. ˛“Ą‹vŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620203. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@1 œ‘—}§E”­”MŤD’†‹…Œ¸­Ç, p.90-1. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620204. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@2 ‹}Ť”xáŠQEŠÔŽżŤ”x‰Š, p.92-3. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620205. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@3 ˆŤSEšq“f, p.94-6. ”Ş–öçt1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620206. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@4 S‹@”\áŠQE‚ŒŒˆł, p.97-9. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620207. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@5 ”ć˜JEŒ‘‘ÓŠ´, p.100-2. •Đ‰–@K1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620208. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@6 ”畆áŠQ (”ç]^Žč‘ŤÇŒóŒQ), p.104-7. ´‹{”ü‰r1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620209. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@7 Œűo”S–ŒáŠQEŒűo”S–Œ‰Š, p.108-9. ˆÉ“Ą—FŒb1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620210. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@8 ––˝_ŒoáŠQ, p.110-2. ‚”ö^‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620211. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@9 ’܈͉Š, p.114-5. ´‹{”ü‰r1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620212. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@10 Ť‹@”\áŠQ, p.116-7. ˛“Ą”ü‹I1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620213. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@11 ’E–Ń, p.118-20. ‚‹´‚Š‚¨‚é1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620214. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@12 •Ö”é, p.121-3. Ź‘ň@1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620215. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz4 ‚Ş‚ń–ň•¨—Ă–@‚Ě•›ě—pŠÇ—|‚ť‚ĚŽĄ—Ă‚đŠŽ‹‚ł‚š‚é‚˝‚ß‚ĚƒRƒc@…A—\‘Ş‚ł‚ę‚é•›ě—p|u‚ť‚Ě•›ě—pŠÇ—‚Č‚ç”C‚š‚āv‚ĆŒž‚Ś‚é‚悤‚É‚Č‚é‚˝‚߂Ɂ@13 ‰ş—Ÿ, p.124-7. Ź‘ň@1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620216. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz5 ŠłŽŇ‚Ě‚˝‚ß‚É, ŒJ‚č•Ô‚ˇ|•Ş‚Š‚Á‚Ä‚ŕ‚炤ŠłŽŇŽw“ą@…@Ý‘—Ă‚đ–ł—‚Č‚­ˆŔ‘S‚ɍs‚¤‚˝‚ß‚É, ŕ–ž‚ˇ‚é‚ą‚Ć, p.130-1. â‰ş’qŽěŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620217. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz5 ŠłŽŇ‚Ě‚˝‚ß‚É, ŒJ‚č•Ô‚ˇ|•Ş‚Š‚Á‚Ä‚ŕ‚炤ŠłŽŇŽw“ą@…B‚ˇ‚Ž‚É•a‰@‚ɘA—‚ˇ‚ׂŤę‡‚ɂ‚˘‚Ä‚ĚƒAƒhƒoƒCƒX, p.134-5. ŒK–źŽő”ü1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620218. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz6 ŠłŽŇE‰Ć‘°‚đ‚Ů‚Á‚Ć‚ł‚š‚éˆęŒž|ŠÉ˜a‘Š’kEŽx‰‡@…@‚Ş‚ńŠłŽŇ‚Ě‘Ě’˛‚ÉŠÖ‚í‚éƒtƒHƒ[‚ĆƒAƒhƒoƒCƒX|g‘Ě“IŽx‰‡, p.138-9. Šâ–{ƒŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620219. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz6 ŠłŽŇE‰Ć‘°‚đ‚Ů‚Á‚Ć‚ł‚š‚éˆęŒž|ŠÉ˜a‘Š’kEŽx‰‡@…A‚Ş‚ńŠłŽŇ‚Ě‚ą‚ą‚ë‚ÉŠÖ‚í‚éƒtƒHƒ[‚ĆƒAƒhƒoƒCƒX|¸_“IŽx‰‡, p.140-2. ”’ˆä‹łŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620220. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz6 ŠłŽŇE‰Ć‘°‚đ‚Ů‚Á‚Ć‚ł‚š‚éˆęŒž|ŠÉ˜a‘Š’kEŽx‰‡@…B‚Ş‚ńŠłŽŇ‚̐śŠˆ‚ÉŠÖ‚í‚éƒtƒHƒ[‚ĆƒAƒhƒoƒCƒX|ŽĐ‰ď“IŽx‰‡^A˜JŽx‰‡, p.143-5. ‹ß“Ą‚Ü‚ä‚Ý1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620221. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz6 ŠłŽŇE‰Ć‘°‚đ‚Ů‚Á‚Ć‚ł‚š‚éˆęŒž|ŠÉ˜a‘Š’kEŽx‰‡@…C‚Ş‚ńŠłŽŇ‚̊‹Ť‚ÉŠÖ‚í‚éƒtƒHƒ[‚ĆƒAƒhƒoƒCƒX|ƒsƒAƒTƒ|[ƒg, p.146-7. Žt‰ŞŒbŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620222. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz6 ŠłŽŇE‰Ć‘°‚đ‚Ů‚Á‚Ć‚ł‚š‚éˆęŒž|ŠÉ˜a‘Š’kEŽx‰‡@…D‰Ć‘°‚́u‘rŽ¸Š´v‚ւ̑Ήž|ƒOƒŠ[ƒtƒPƒA, p.148-9. çř“”ü“oŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620223. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz7 ƒ`[ƒ€‚Ĺ“Ž‚­‚ą‚Ć‚Ě‘ĺŘ‚ł|ˆă—Ă‚đ‚‚ȂŽ‚Ě‚É•K—v‚Č‚ą‚Ɓ@…@•”ŠÔ‚Ĺ‚Ěˆă—Ă˜AŒg|Ĺ‚ŕg‹ß‚ȏꏩ‚ł́uƒ`[ƒ€ˆă—Áv‚Š‚çŽn‚߂悤, p.152-4. ‹ß“Ą‚Ü‚ä‚Ý1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620224. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz7 ƒ`[ƒ€‚Ĺ“Ž‚­‚ą‚Ć‚Ě‘ĺŘ‚ł|ˆă—Ă‚đ‚‚ȂŽ‚Ě‚É•K—v‚Č‚ą‚Ɓ@…AEŽíŠÔ‚Ĺ‚Ěˆă—Ă˜AŒg|‘˝EŽíŠÔ‚Ě˜AŒg‚đ‚ć‚č–§‚É‚ˇ‚é‚É‚Í, p.156-7. ’–ˆäÍŽq1 (1ŠĹŒě•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018/10”­s.

620225. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@4. Žg—p‚ĚŽŔŰ@Q58. lHŒÄ‹zŠí‚Ě‘•’…Žž‚Ě’ˆÓ“_‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. Q59. lHŒÄ‹zŠí‘•’…’†‚ĚŠĎŽ@‚Ěƒ|ƒCƒ“ƒg‚͉˝‚Ĺ‚ˇ‚Š, p.93-6. “ŕ“ĄˆŸŽ÷1, XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620226. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@4. Žg—p‚ĚŽŔŰ@Q60. PaO2‚𒲐Ž‚ˇ‚é‚ɂ͂ǂ̂悤‚É‚ˇ‚ę‚΂悢‚Ĺ‚ˇ‚Š. Q61. PaCO2‚𒲐Ž‚ˇ‚é‚ɂ͂ǂ̂悤‚É‚ˇ‚ę‚΂悢‚Ĺ‚ˇ‚Š, p.97-100. XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620227. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@4. Žg—p‚ĚŽŔŰ@Q62. PEEP‚͂ǂ̂悤‚ÉŒˆ’股‚ę‚΂悢‚Ĺ‚ˇ‚Š. Q63. EIP‚͂ǂ̂悤‚ÉŒˆ’股‚ę‚΂悢‚Ĺ‚ˇ‚Š@4. Žg—p‚ĚŽŔŰ, p.101-3. ‘ĺ’JŽ–ç1,2, XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620228. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@4. Žg—p‚ĚŽŔŰ@Q64. ‹CŠÇƒ`ƒ…[ƒu‚ĚƒJƒtˆł‚ĚŠÇ—‚Í‚Ç‚¤‚ˇ‚ę‚΂悢‚Ĺ‚ˇ‚Š. Q65. ‘}ŠÇ‚ľlHŒÄ‹zŠí‚đŽg—p‚ľ‚Ä‚˘‚銳ŽŇ‚Ě‘ĚˆĘ•ĎŠˇ‚đs‚¤Ű‚Ě’ˆÓ“_‚͉˝‚Ĺ‚ˇ‚Š, p.104-11. ꎓĄk•˝1, XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620229. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@7. lHŒÄ‹z’†‚ĚŠłŽŇŠÇ—@Q88. ‹CŠÇ‹zˆř‚Ě“K‰žE•ű–@E’ˆÓ“_‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘. Q89. ŠłŽŇ‚ƐlHŒÄ‹zŠí‚Ć‚Ě”ń“Ż’˛‚ĚŒ´ˆö‚ƑΉž‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.153-8. –x]çŒbŽq1, XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620230. [Šwp‘ (•Ş’SŽˇ•M)]yV ME‘‚í‚Š‚čQ&A@3. ŒÄ‹z—Ă–@‘•’uzI. lHŒÄ‹zŠí@7. lHŒÄ‹z’†‚ĚŠłŽŇŠÇ—@Q90.nasal CPAP‚Ě“K‰ž‚ĆŽg—pă‚Ě’ˆÓ“_‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.158-60. ‘ĺ’JŽ–ç1,2, XˆŔŒbŽŔ1,2 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş), •Ň:uV ME‘‚í‚Š‚čQ&Av•ŇWˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2018/10”­s.

620231. [Šwp‘ (•Ş’SŽˇ•M)]y‘Šú‚Š‚çŽn‚ß‚éS•s‘S‚Ěƒg[ƒ^ƒ‹ƒPƒA@’ˇŠú‚Ě—Ă—{‚đŽx‚Ś, ĹŠú‚Ü‚ĹQOL‚đˆŰŽ‚ˇ‚é‚˝‚ß‚ĚŠĹŒě (ŠĹŒě‹Zp2018”N10ŒŽ‘Š§†)z‘ć6Í Ž–—á‚É‚Ý‚éS•s‘SŠłŽŇ‚Ě—Ă—{Žx‰‡@3. ”F’m‹@”\’ቺ‚Ě‚ ‚鍂—îŽŇ, p.1267-74. 傖ź—R‰Á—˘1 (1ŠĹŒě•”), •Ň: áÁŠ‚Ý‚ä‚Ť2 (2ŠĹŒěŠw•”), ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽĐ, “Œ‹ž, 2018/10”­s.

620232. [Šwp‘ (•Ş’SŽˇ•M)]yƒ`ƒFƒbƒNƒV[ƒg‚ĹŠĹŒěƒŒƒxƒ‹‚đŠm”F@ƒi[ƒX‚Ě–đŠ„‚Ş‚ľ‚Á‚Š‚č‚Ý‚Ś‚é&ƒ`[ƒ€‚Ě’†‚Ĺ“Ž‚Ż‚é@‚ˇ‚˛‚­‚í‚Š‚é!@S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO 2018H‹G‘Š§)z‘ć3Í ‚ł‚ , ƒJƒeŽş‚É“ü‚낤!@(1) €”ő@1 ƒJƒeŽş‚É“ü‚éƒi[ƒX‚̐S“ž‚Í?@ƒJƒe’†‚Í‚Ç‚ą‚É‚˘‚ę‚΂˘‚˘‚Ě?, p.134-7. •˝@KŒb1 (1ŠĹŒě•”), ŠÄC: ˆ˘ŒĂĆ2 (2zŠÂŠí“ŕ), ƒƒf˛ƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620233. [Šwp‘ (•Ş’SŽˇ•M)]yƒ`ƒFƒbƒNƒV[ƒg‚ĹŠĹŒěƒŒƒxƒ‹‚đŠm”F@ƒi[ƒX‚Ě–đŠ„‚Ş‚ľ‚Á‚Š‚č‚Ý‚Ś‚é&ƒ`[ƒ€‚Ě’†‚Ĺ“Ž‚Ż‚é@‚ˇ‚˛‚­‚í‚Š‚é!@S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO 2018H‹G‘Š§)z[‘ć3Í ‚ł‚ , ƒJƒeŽş‚É“ü‚낤!]@(1) €”ő@3 ƒJƒeŽş‚̏€”ő‚Ĺ‚Í, ‰˝‚đ‚ľ‚Ä‚¨‚Ż‚΂˘‚˘?, p.141-7. Œ´“c–ž“ú1 (1ŠĹŒě•”), ŠÄC: ˆ˘ŒĂĆ2 (2zŠÂŠí“ŕ), ƒƒf˛ƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620234. [Šwp‘ (•Ş’SŽˇ•M)]yƒ`ƒFƒbƒNƒV[ƒg‚ĹŠĹŒěƒŒƒxƒ‹‚đŠm”F@ƒi[ƒX‚Ě–đŠ„‚Ş‚ľ‚Á‚Š‚č‚Ý‚Ś‚é&ƒ`[ƒ€‚Ě’†‚Ĺ“Ž‚Ż‚é@‚ˇ‚˛‚­‚í‚Š‚é!@S‘ŸƒJƒe[ƒeƒ‹ (ƒn[ƒgƒi[ƒVƒ“ƒO 2018H‹G‘Š§)z[‘ć3Í ‚ł‚ , ƒJƒeŽş‚É“ü‚낤!]@(1) €”ő@4 ƒJƒeŽĄ—Ă‘O‚ĚŠłŽŇ‚ł‚ń‚̏€”ő‚Í?, p.148-53. Îă”ü‹M1 (1ŠĹŒě•”), ŠÄC: ˆ˘ŒĂĆ2 (2zŠÂŠí“ŕ), ƒƒf˛ƒJo”Ĺ, ‘ĺă, 2018/10”­s.

620235. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK II ‚Ş‚ńƒTƒoƒCƒo[‚Ş’ź–Ę‚ˇ‚é‰Ű‘č‚ĆŽx‰‡@1 ƒZƒ‹ƒtƒAƒhƒ{ƒJƒV[‚đ‚‚ß‚éŽx‰‡, p.14-9. ‹ß“Ą‚Ü‚ä‚Ý1 (1ŠĹŒě•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620236. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK III ‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv‚É‚ŕ‚Ć‚Ă‚­Žx‰‡, p.79-88. ‹ß“Ą‚Ü‚ä‚Ý1 (1ŠĹŒě•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620237. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK IV ‚Ş‚ńƒTƒoƒCƒo[‚Ě“Á’Ľ‚ɉž‚ś‚˝Žx‰‡@3 ”x‚Ş‚ń‘ĚŒąŽŇ, p.105-12. ‰äČF‘Ľ1, Ž™‹Ę”ü—R‹I2, ‹v•ŰŒÜŒŽ3 (1‹ŕ‘ňˆă‰Č‘ĺŠw•‘Ž•a‰@ŠĹŒě•”, 2ŠĹŒě•”, 3ŠĹŒěŠw•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý2, ‹v•ŰŒÜŒŽ3, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620238. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK IV ‚Ş‚ńƒTƒoƒCƒo[‚Ě“Á’Ľ‚ɉž‚ś‚˝Žx‰‡@5 “Şčň•”‚Ş‚ń‘ĚŒąŽŇ, p.120-6. –]ŒŽ”ü•ä1 (1ŠĹŒě•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620239. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK IV ‚Ş‚ńƒTƒoƒCƒo[‚Ě“Á’Ľ‚ɉž‚ś‚˝Žx‰‡@8 •wl‰Č‚Ş‚ń‘ĚŒąŽŇ, p.140-6. ˛“Ą”ü‹I1 (1ŠĹŒě•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620240. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK IV ‚Ş‚ńƒTƒoƒCƒo[‚Ě“Á’Ľ‚ɉž‚ś‚˝Žx‰‡@9 ”ĺ”AŠí‰Č‚Ş‚ń‘ĚŒąŽŇ, p.147-53. ÂúĺGş1 (1ŠĹŒě•”), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620241. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”ŁzBOOK IV ‚Ş‚ńƒTƒoƒCƒo[‚Ě“Á’Ľ‚ɉž‚ś‚˝Žx‰‡@15 AYA˘‘ă‚Ě‚Ş‚ńƒTƒoƒCƒo[, p.189-94. ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2, “c‘şŒb”ü3 (1ŠĹŒě•”, 2ŠĹŒěŠw•”, 3é‹ĘŒ§—§ŹŽ™ˆă—ĂƒZƒ“ƒ^[), •Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

620242. [Šwp‘ (•Ş’SŽˇ•M)]ywith@NEO•Ęű@‚é‚éNEO@ć”yƒi[ƒX‚ĚŽ‹“_‚Ş‚í‚Š‚é@VśŽ™ƒPƒA‚Ě‚Ť‚Ů‚ń@‚Ü‚¸‚͉Ÿ‚ł‚Ś‚˝‚˘20‚Ěƒ|ƒCƒ“ƒgz2Í Ô‚ż‚á‚ń‚Ě“úí‚ĚƒPƒAE‚Ü‚¸‰Ÿ‚ł‚Ś‚˝‚˘20‚Ěƒ|ƒCƒ“ƒg@<Ô‚ż‚á‚ń‚Ě“úí‚ĚƒPƒA>@(12) •ę“űˆçŽ™Žx‰‡, p.133-40. •˝—Ń“Ţ•c1 (1ŠĹŒě•”), •Ň: –L“‡–œŠóŽq2, ’†–ěKŽq1, ŒĂ“s”ü’qŽq3 (2_“ŢěŒ§—§Žq‚Ç‚ŕˆă—ĂƒZƒ“ƒ^[, 3‰Ą•l˜JĐ•a‰@), ƒƒfƒBƒJo”Ĺ, , 2019/3”­s.

620243. [Šwp‘ (•Ş’SŽˇ•M)]ywith@NEO•Ęű@‚é‚éNEO@ć”yƒi[ƒX‚ĚŽ‹“_‚Ş‚í‚Š‚é@VśŽ™ƒPƒA‚Ě‚Ť‚Ů‚ń@‚Ü‚¸‚͉Ÿ‚ł‚Ś‚˝‚˘20‚Ěƒ|ƒCƒ“ƒgz2Í Ô‚ż‚á‚ń‚Ě“úí‚ĚƒPƒAE‚Ü‚¸‰Ÿ‚ł‚Ś‚˝‚˘20‚Ěƒ|ƒCƒ“ƒg@<Ô‚ż‚á‚ń‚Ě“úí‚ĚƒPƒA>@(13) šM“ű•rŽö“ű‚Ě‰î•, p.141-5. •˝—Ń“Ţ•c1 (1ŠĹŒě•”), •Ň: –L“‡–œŠóŽq2, ’†–ěKŽq1, ŒĂ“s”ü’qŽq3 (2_“ŢěŒ§—§Žq‚Ç‚ŕˆă—ĂƒZƒ“ƒ^[, 3‰Ą•l˜JĐ•a‰@), ƒƒfƒBƒJo”Ĺ, , 2019/3”­s.

621001. [Šwp‘ (•ŇW)]y‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv@‚Ş‚ń‚Ć‚Ć‚ŕ‚ɐś‚Ť‚él‚Ń‚Ć‚Ö‚ĚŠĹŒěƒPƒA ‘ć2”Łz•Ň: ‹ß“Ą‚Ü‚ä‚Ý1, ‹v•ŰŒÜŒŽ2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/2”­s.

621002. [Šwp‘ (•ŇW)]ywith@NEO•Ęű@‚é‚éNEO@ć”yƒi[ƒX‚ĚŽ‹“_‚Ş‚í‚Š‚é@VśŽ™ƒPƒA‚Ě‚Ť‚Ů‚ń@‚Ü‚¸‚͉Ÿ‚ł‚Ś‚˝‚˘20‚Ěƒ|ƒCƒ“ƒgz•Ň: –L“‡–œŠóŽq1, ’†–ěKŽq2, ŒĂ“s”ü’qŽq3 (1_“ŢěŒ§—§Žq‚Ç‚ŕˆă—ĂƒZƒ“ƒ^[, 2ŠĹŒě•”, 3‰Ą•l˜JĐ•a‰@), ƒƒfƒBƒJo”Ĺ, , 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713171. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A meta-analysis on attitudes towards organ donation of undergraduate nurse students. Tsubaki M1, Tougo S, Kobayashi M, Arakawa S1, Ito Y, Yoshida K2,3, Yokomizo I1: 55th ERA-EDTA Congress (2018/5/26), Copenhagen, Denmark. (’Ö”ü’q”Ž1, rě@‘1, ‹g“cˆęŹ2,3, ‰Ąaˆç”ü1: 1ŠĹŒě•”, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3”ĺ”AŠí)

721028. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ˆÚAˆă—Ă‚É‚¨‚Ż‚éŠĹŒě‚̐ę–名‚đƒLƒƒƒŠƒAƒ‰ƒ_[‚ōl‚Ś‚é. •Ę•{çŒb (ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.12.

722235. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ICU”Mƒ}ƒjƒ…ƒAƒ‹ěŹ‚ĆŽü’mŠˆ“Ž‚ĚŽć‚č‘g‚Ý. Ž…’؁@Œb1, ŒN“ˆ@“Œ1, ‹AŽRˆęŽu1, ’J@Kˆę1, ‘“cł˜a1 (1ŠĹŒě•”): ‘ć44‰ń“ú–{”MŠw‰ď‘‰ďEŠwpW‰ď (2018/5/17), “Œ‹ž, ‘ć44‰ń“ú–{”MŠw‰ď‘‰ďEŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/5; p.79.

722236. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv)u–ž“ú‚Š‚ç‚Ĺ‚Ť‚é‚Ť‚傤‚ž‚˘Žx‰‡\ŽĄ—ʋŤEŽ{Ý‚É‚ć‚é“Á’Ľ‚đ’m‚é‚ą‚Ć‚Š‚çŽn‚߂悤\vŹŽ™W’†ŽĄ—ĂŽş‚É‚¨‚Ż‚é‚Ť‚傤‚ž‚˘Žx‰‡. ˆÉ“ĄFŽq (ŠĹŒě•”): “ú–{ŹŽ™ŠĹŒěŠw‰ď‘ć28‰ńŠwpW‰ď (2018/7/21), –źŒĂ‰Ž.

722237. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) ‘ŸŠí’ń‹Ÿ‚Ć‘ŸŠíˆÚA‚Ě—Ő°Œťę‚É‚¨‚˘‚ÄŠĹŒě‚đŽx‚Ś‚é‹łˆç ’ń‹Ÿ‚ĚˆÓŽv‚đŽx‚Ś‚éŠĹŒě\ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‹łˆç‚ĚŽć‚č‘g‚Ý. ă‘ş—RŽ— (ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.23.

722238. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) RTC‚Ě“­‚Ť•ű‰üŠv. –ěŒű•ś”T (ŠĹŒě•”): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/15), ‘ĺă, ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/12; p.103.

722239. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) “–‰@‹~–˝‹~‹}ƒZƒ“ƒ^[‚É‚¨‚Ż‚éƒVƒ“ƒoƒCƒIƒeƒBƒNƒX—Ă–@. ‹{‰ş’mŽq1, Î‘q@ˆ¤1, –x˛‰lŽq1, âV“Ą—Ú“Ţ1, ‘“cł˜a1, ˛“ĄĆŽq2, [‘ň˛ŒbŽq2, Žç‰Ž—˘š2, ‰““ĄŹŽq2, _@ˆę–˛3, •˝ˆä”ü”T—˘3, ŽO‰Y–F“T4, ł–ŘˆÇ“Ţ4, •Đ‰Ş—Sˆę5 (1ŠĹŒě•”, 2‰h—{•”, 3–ňÜ•”, 4—ŐŒŸ•”, 5‹~–˝): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/15), “Œ‹ž.

723884. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) f’fŽžŠú‚É‚ ‚é“ű‚Ş‚ńŠłŽŇ‚Ě•ř‚Ś‚é‹ę’É‚ĆŠĹŒě‰î“ü‚ĚŽŔŰ`‹ę’ɃXƒNƒŠ[ƒjƒ“ƒO‚đ—p‚˘‚˝ŠĹŒě–Ę’k‚đU‚č•Ô‚Á‚ā`. X“c—zŽ}1, ”–ؐ́1, ‹g“c—R”üŽq1, ŁŒË–qŽq1, ’[ŽR˜a”ü1, “c’†—eŽq1, Ž™‹Ę”ü—R‹I1, ĺÎ‹I•F2, Źâ–ůŒŤ2, ‹e’r^—Žq2 (1ŠĹŒě•”, 2“ű‘BEbó‘BŠO): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/16), ‹ž“s, ‘ć26‰ń“ú–{“űŠŕŠw‰ď‘‰ďƒvƒƒOƒ‰ƒ€´˜^W 2018/5; p.599.

723885. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ű‚Ş‚ńpŒă“ŤƒŠƒ“ƒp•‚Žî‚ĚÇ—á•ń. ŁŒË–qŽq1, ‹g“c—R”üŽq1 (1ŠĹŒě•”): ‘ć26‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2018/5/17), ‹ž“s, ‘ć26‰ń“ú–{“űŠŕŠw‰ď‘‰ďƒvƒƒOƒ‰ƒ€´˜^W 2018/5; p.552.

723886. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™W’†ŽĄ—ĂŽş (PICU) ‚É‚¨‚Ż‚éƒOƒŠ[ƒtƒPƒA‚ĚŽć‚č‘g‚Ý. •äĎŘ•ä1, ˛X–Ř”ü˜aŽq1, ˆÉ“ĄFŽq1, ˆŔ“Ą@Žő2 (1ŠĹŒě•”, 2ŹŽ™): ‘ć32‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2018/6/2), ˆďé, “ú–{ŹŽ™‹~‹}ˆăŠw‰ďŽGŽ 2018/4; 17 (2): 310.

723887. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™ŠÖ˜A•a“‚É‚¨‚Ż‚éRSTę]ŽŇ‚Ć‚ľ‚Ä‚ĚŠˆ“Ž. ‘ĺ’JŽ–ç1,2, VˆäłN3, XˆŔŒb”ü1, Ź’r•üF1, ’†–ěKŽq1, ˆÉ“ĄFŽq1 (1ŠĹŒě•”, 2RST^RRTŽş, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć5‰ń“ú–{CNSŠĹŒěŠw‰ď (2018/6/2), “Œ‹ž.

723888. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) A‘ĺŠw•a‰@‚Ĺ‚Ě‹~‹}ŠO—ˆŽófŠłŽŇ‚Ěˆâ‘°‚ɑ΂ˇ‚é, ƒOƒŠ[ƒtƒJ[ƒh”z•z‚ĚŽć‚č‘g‚݁|ŠO—ˆŽ€–S‚Ěˆâ‘°, ‘SÇ—á‚ɑ΂ľ‚ā|. ěă‘ĺ•ă1, ‚‹´@Œb1, •Đ‰Ş—Sˆę2, ó—˜@–ő2 (1ŠĹŒě•”, 2‹~–˝): ‘ć21‰ń“ú–{—Տ°‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/6/2), ˆ¤’m, “ú–{—Տ°‹~‹}ˆăŠw‰ďŽGŽ 2018/4; 21 (2): 362.

723889. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹~‹}ICU‚É‚¨‚Ż‚éŽčŽwÁ“ŏ…Žç‚ĚŒüă‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý‚ĚŒŸ“˘. Ž…’؁@Œb1, ‹AŽRˆęŽu1, ’†–ě—R‹IŽq1, ‘“cł˜a1 (1ŠĹŒě•”): ‘ć21‰ń“ú–{—Տ°‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2018/6/2), ˆ¤’m, “ú–{—Տ°‹~‹}ˆăŠw‰ďŽGŽ 2018/4; 21 (2): 434.

723890. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™‹s‘Ň–hŽ~ˆĎˆő‰ď‚É‚ć‚é‹s‘Ň’mŽŻ•‹y‚ÉŒü‚Ż‚˝•×‹­‰ď‚މ@“ŕŠO‚Ö‹y‚Ú‚ľ‚˝‰e‹ż. ˛“Ą@—ƒ1, ŽÄ“cƒŽq1, ˆÉ“ĄFŽq1, Š@L–ç2, Îˆäł_2 (1ŠĹŒě•”, 2ŹŽ™): ‘ć32‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2018/6/3), ˆďé, “ú–{ŹŽ™‹~‹}ˆăŠw‰ďŽGŽ 2018/4; 17 (2): 317.

723891. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒAƒhƒoƒ“ƒXEƒPƒAEƒvƒ‰ƒ“ƒjƒ“ƒO‚̐„iƒvƒƒWƒFƒNƒg‚ĚŠˆ“Ž•ń|Ž–—ጟ“˘‰ď‚ĚŽQ‰ÁŽŇ‚Ě”˝‰ž‚â•Ď‰ť‚ÉĹ“_‚đ‚ ‚Ä‚Ä|. Šâ–{ƒŽq1, Ž™‹Ę”ü—R‹I1, â‰ş’qŽěŽq1, ‹ß“Ą‚Ü‚ä‚Ý1, ăžŠ^Žq2, ’Ă‘şGN3, Źâ–ůŒŤ4, ˛X–ŘŽĄˆę˜Y5 (1ŠĹŒě•”, 2ˆă—ĂŽx‰‡•”, 3”ĺ”AŠí, 4“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć23‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď (2018/6/15), _ŒË, Palliative Care Research 2018/6; 13 (S): S473.

723892. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒ‰t“§Í“ą“üƒNƒŠƒjƒJƒ‹ƒpƒXěŹ‚ĚŽŽ‚Ý. âV“Ą@Œb1, Œă“Ą (ě‘ş) ‹vŽ}1, ‰ĄŽR—˜1, Š™“c^—Žq2, “cč—R‰Ŕ3 (1ŠĹŒě•”, 2t‘Ÿ“ŕ, 3f—Ïî•ńŠÇ—Žş): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/6/29), _ŒË, “ú–{“§ÍˆăŠw‰ďŽGŽ 2018/5; 51 (suppl 1): 483.

723893. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™Šú‚ɐś‘ĚŠĚˆÚA‚đŽó‚Ż‚˝ŠłŽŇ‚Ş‘¨‚Ś‚Ä‚˘‚é‰Ć‘°‚Ě—l‘Š|—Ă—{śŠˆ‚ɂ‚˘‚Ä‚ĚŒę‚č‚Š‚ç|. ź“ŕ‰ŔŽq1, Ź“‡‚Đ‚ĹŽq2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): “ú–{ŹŽ™ŠĹŒěŠw‰ď‘ć28‰ńŠwpW‰ď (2018/7/22), –źŒĂ‰Ž, “ú–{ŹŽ™ŠĹŒěŠw‰ď‘ć28‰ńŠwpW‰ďu‰‰W 2018/6; p.184.

723894. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —Տ°‚Ĺ‚Ě‘nˆÓH•v‚đ”­–ž‚ɂ‚ȂŽ|“Á‹–“o˜^‚Ü‚Ĺ‚ĚŽć‚č‘g‚݁|. ˆÉ“Ą‚Ý‚¸‚Ů1, ź“ŕ‰ŔŽq1 (1ŠĹŒě•”): “ú–{ŹŽ™ŠĹŒěŠw‰ď‘ć28‰ńŠwpW‰ď (2018/7/22), –źŒĂ‰Ž, “ú–{ŹŽ™ŠĹŒěŠw‰ď‘ć28‰ńŠwpW‰ďu‰‰W 2018/6; p.210.

723895. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) A•a‰@‚É‚¨‚Ż‚éŠĹŒěŽt‚đ‘ÎŰ‚Ć‚ľ‚˝ĐŠQ‘Ήž‚ÉŠÖ‚ˇ‚錤C‚ɂ‚˘‚Ä‚Ě•ń. ŹŽR–ž—˘1, ’–Žë—ÉŽq1, ŠŽR˜a”ü1 (1ŠĹŒě•”): “ú–{ĐŠQŠĹŒěŠw‰ď‘ć20‰ń”NŽŸ‘ĺ‰ď (2018/8/10), •şŒÉ, “ú–{ĐŠQŠĹŒěŠw‰ďŽ 2018/6; 20 (1): 150.

723896. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĹŒěŽt’ˇ‚̐E–ąƒXƒgƒŒƒX‚ĆƒR[ƒsƒ“ƒO, Eęƒ\[ƒVƒƒƒ‹ƒTƒ|[ƒg‚ĚŠÖ˜A. ’JŒű—zŽq1, “c’†KŽq2 (1ŠĹŒě•”/ŠĹŒěŒ¤CE‹łˆçƒZƒ“ƒ^[, 22“Œ‹žŽœŒb‰ďˆă‰Č‘ĺŠw‘ĺŠw‰@): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/24), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.318.

723897. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒLƒƒƒŠƒA’†ŠúŠĹŒěŽt‚Ě‘gDƒRƒ~ƒbƒgƒƒ“ƒg‚ƐEęƒ\[ƒVƒƒƒ‹EƒTƒ|[ƒg‚Ć‚ĚŠÖ˜A`—Տ°ŽŔ‘H—Í‚É’…–Ú‚ľ‚ā`. ŒÜ“Ą—zŽq (ŠĹŒě•”): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/25), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.263.

723898. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠĹŒěŠÇ—‚ÉŠÖ‚ˇ‚é•a‰@“ŕ•śŒŁ´“ljď‚ɂ‚˘‚Ä‚Ě•ń. ŽOŽ}Ž–1, ŹŽR–ž—˘1, ŽR–{‰Ŕ“1, Â–öG–ž1, ‚‹´N‰î1, “Ą“c—ş‰î1, ç–ؗǓމ›1, ]“cˆęd1 (1ŠĹŒě•”): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/25), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.265.

723899. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •śŒŁ´“ljď‚ĚŠJĂ‚É‚¨‚Ż‚éŒř‰Ę‚Ɖۑč‚ÉŠÖ‚ˇ‚é•śŒŁŒŸ“˘. ŽR–{‰Ŕ“1, ŽOŽ}Ž–1 (1ŠĹŒě•”): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/25), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.269.

723900. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒZƒNƒVƒ‡ƒ“”z’u‚̐ę–ĺŠĹŒěŽtE”F’čŠĹŒěŽt‚Ö‚ĚŠĹŒěŠÇ—ŽŇ‚ĚŠÖ‚í‚č‚ɂ‚˘‚Ä. ‹TÎ—çŽq1, ‹ß“Ą‚Ü‚ä‚Ý1, â‰ş’qŽěŽq1, ’†“‡ßŽq1, ŽR–ě•Ó‚Ý‚żŽq1 (1ŠĹŒě•”): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/25), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.275.

723901. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠĹŒěŽŔ‘H‚ĚŒę‚č‚É‚¨‚Ż‚éƒRƒ“ƒsƒeƒ“ƒV[‚ĚŽŠŒČ•]‰ż‚ŞŠĹŒěŽt‚ĚŽŠŒČ—‰đ‚Ć–Ú•WÝ’č‚É‹y‚Ú‚ˇ‰e‹ż. ‹g•”Œb—Žq1, ŒÜ“Ą—zŽq1, ’†ŽR‰hƒ2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2018/8/25), •şŒÉ, ‘ć22‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2018/7; p.275.

723902. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œëš‹E’‚‘§ƒŠƒXƒN‚đ‰ń”đ‚ˇ‚éŽć‚č‘g‚݁|“–‰@‚Ě‚Ť‚´‚ݐH”pŽ~‚Ö‚ĚŠˆ“Ž|. Î‘q@ˆ¤1, ˆÉ“Ą—FŒb1, ´‰Ć—R”üŽq2, “’–{@“ľ3, —é–Ř—§r4 (1ŠĹŒě•”, 2‰h—{•”, 3ƒŠƒnƒrƒŠ•”, 4Ž¨•@ˆôAE“ŞčňŠO): ‘ć24‰ń“ú–{ŰHš‹‰şƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwp‘ĺ‰ď (2018/9/8), ‹{é.

723903. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇS•s‘SŠłŽŇ‚̎Љď“I–đŠ„‚đ‘¸d‚ľ‚˝ˆÓŽuŒˆ’čŽx‰‡‚É‚¨‚Ż‚閝ŤS•s‘SŠĹŒě”F’čŠĹŒěŽt‚Ě–đŠ„. ™–썁“ŢŽq1, ŒÜ\—’ˆŸŠóŽq1, ‰Í–ě^—1, ꎓĄŒ\Žq1, …ă‚˘‚Ă‚Ý1 (1ŠĹŒě•”): ‘ć22‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2018/10/12), “Œ‹ž, ‘ć22‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€´˜^ 2018; p.452.

723904. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A•a‰@‹~‹}ŠO—ˆ‚É‚¨‚Ż‚éŠĹŒěŽt‚ĚƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg“ŻČŽž‚Ě‹L˜^‚ÉŠÖ‚ˇ‚éŒťó. ˆäăˆş—F”ü1, ’Ö”ü’q”Ž1, ‹Ë–{çŒb”ü1, ’ˇ–ě—F‹IŽq1 (1ŠĹŒě•”): ‘ć20‰ń“ú–{‹~‹}ŠĹŒěŠw‰ďŠwpW‰ď (2018/10/20), ˜a‰ĚŽR, “ú–{‹~‹}ŠĹŒěŠw‰ďŽGŽ 2018/10; 20 (3): 261.

723905. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ŸŠíˆÚA‘Ň‹@ŠúŠÔ‚É‚¨‚Ż‚éˆÓŽvŒˆ’čŽx‰‡‚ƏI––ŠúƒPƒA‚Ě•Ŕs`”]Ž€‰şŠĚ‘ŸŹ’°“ŻŽžˆÚA‚đ‘I‘đ‚ľ‚˝ŠłŽŇE‰Ć‘°‚Ö‚ĚŠĹŒěŽŔ‘H‚̍lŽ@`. œA“Ąt˘1, ź“ŕ‰ŔŽq1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.28.

723906. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŽOŽŸ‹~‹}”Ŕ‘—ŠłŽŇ‚Ě‘ŸŠí’ń‹Ÿ‚ÉŠÖ‚ˇ‚éˆÓŽv‚É‚¨‚Ż‚é‰ń“š•Ď‰ť‚ĚŒŸ“˘|ŽOŽŸ’˛¸•[‚Ć“ü‰@Žžî•ń’ń‹Ÿ—pŽ†‚Ě‹LÚ“ŕ—e‚Š‚ç|. ”W–{—łĆ1, ă‘ş—RŽ—1, ‚‹´@Œb1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.32.

723907. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ŸŠí’ń‹ŸŠó–]‚Ş‚ ‚銳ŽŇ‰Ć‘°‚̏I––Šú‚ĚƒvƒƒZƒX|ŠłŽŇE‰Ć‘°‚É‘ŸŠí’ń‹ŸŠó–]‚Ş‚ ‚Á‚˝‚Ş’ń‹Ÿ‚ÉŽŠ‚ç‚Č‚Š‚Á‚˝Ç—á|. ŽR–{@Œ›1, ]ě˜aŠě1, ‘“cł˜a1, ‚‹´@Œb1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.36.

723908. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰@“ŕƒhƒi[ƒR[ƒfƒBƒl[ƒ^[‚Ě–đŠ„”­Šö‚ÉŒü‚Ż‚˝‹łˆç‚ĚŽć‚č‘g‚Ý. ŠÖ@ˆę”n1, ă‘ş—RŽ—1, ‚‹´@Œb1, rě–@Žq1, ‰Ąa@Žq1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.37.

723909. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •â•lHS‘Ÿ“K‰žŠłŽŇ‚Ě‘ă—ˆÓŽvŒˆ’čŽx‰‡@—Տ°—Ď—ŒŸ“˘ƒV[ƒg‚ĚŠˆ—p. ‰Hś“c—I1, ‹{‰ş’mŽq1, ]ě˜aŠě1, ’†“‡ßŽq1, ‘“cł˜a1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.40.

723910. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™dÇS•s‘S‚Ě‹Ů‹}•â•lHS‘ŸŽĄ—Ă‚đ–Ú“I‚Ć‚ľ‚˝“]‰@”Ŕ‘—|lHŒÄ‹zŠí‚âcentral ECMO‚Ȃǂ̐ś–˝ˆŰŽ‘•’u‘•’…‰ş‚Ě”Ŕ‘—ŒoŒą|. ŒĂŽs‘ĽŒő1, ‹{“‡@Œd1, ‰Ąa@Žq1, ź“ŕ‰ŔŽq1, ’†“‡ßŽq1, ěă‘ĺ•ă1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.41.

723911. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ŸŠí’ń‹Ÿ‚ÉŠÖ‚ˇ‚éŠĹŒěŽt‹łˆç‚Ö‚ĚŽć‚č‘g‚݁|•×‹­‰ďŽŔŽ{‘OŒă‚Ĺ‚ĚŠĹŒěŽt‚ĚˆÓŽŻ•Ď‰ť|. ˛ě”ü—˘1, ŽR–{@Œ›1, ”W–{—łĆ1, ň@•śŘ1, ‚‹´@Œb1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.44.

723912. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) tˆÚAƒ`[ƒ€‚Ć‚ľ‚Ä‚ĚŠO—ˆŠĹŒěŽt‚Ě–đŠ„‚Ć‚Í|ŽŠŒČŠÇ—Šm—§‚ÉŒü‚Ż‚˝ŠĹŒě–Ę’k‚đŠJŽn‚ľ‚Ä•Ş‚Š‚Á‚˝‚ą‚Ɓ|. ˆä‘ş—[•P1, Â–öˆŸ”ü1, –ěŒű•ś”T1, ‹g“c—R”üŽq1 (1ŠĹŒě•”): ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ď (2018/11/10), ‘Š–ÍŒ´, ‘ć14‰ń“ú–{ˆÚAEÄśˆă—ĂŠĹŒěŠw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/10; p.46.

723913. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚—ŽŇ“™‚Ě–Í‹[‘ĚŒą‚É‚ć‚é‰@“ŕƒ‰ƒEƒ“ƒh‚̉ü‘PŒř‰Ę. ě’JOŽq1,2, —é–Ř”üŽ}Žq1, Â–Ř—”ü1,2 (1ŠĹŒě•”, 2ˆă—ĂŽx‰‡•”): ‘ć13‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2018/11/24), –źŒĂ‰Ž, ˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŽ 2018/10; 13 (Suppl): 366.

723914. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚“x‹}ŤŠú•a‰@‚É‚¨‚Ż‚éf—ĂŠĹŒěŽt (NP) ‚Ě–đŠ„‚Ć‰Ű‘č|ˆăŽt, ŠĹŒě•”’ˇ, “Ż—ťŠĹŒěŽt‚ĚŽ‹“_‚Š‚ç|. ‰F“cě”ü‹I1, •ĘŠ—VŽq2, ‘ŠÔ•üŽq2 (1ŠĹŒě•”, 2“Œ‹žˆă—Ă•ŰŒ’‘ĺŠw‘ĺŠw‰@): ‘ć4‰ń“ú–{NPŠw‰ďŠwpW‰ďE‘‰ď (2018/11/24), ĺ‘ä, ‘ć4‰ń“ú–{NPŠw‰ďŠwpW‰ďE‘‰ď´˜^W 2018/11; p.133.

723915. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)y“dŽqƒJƒ‹ƒeExpo 2018z‘ź‰@‚ĚŽ–—á‚Š‚çŠw‚Ô:u‰^—pE•ŰŽçv Œř‰Ę“IEŒř—Ś“I‚ČŠĹŒě‰ß’ö‚Ě“WŠJ‚đ–ÚŽw‚ľ‚˝ƒVƒXƒeƒ€‰^—p‚̍č\’z. ´…›’“ (ŠĹŒě•”): ‘ć38‰ńˆă—Ïî•ńŠw˜A‡‘ĺ‰ď (‘ć19‰ńˆă—Ïî•ńŠw‰ďŠwp‘ĺ‰ď) (2018/11/25), •Ÿ‰Ş, ‘ć38‰ńˆă—Ïî•ńŠw˜A‡‘ĺ‰ď˜_•śW 2018/11; p.92-3.

723916. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ŸŠí’ń‹Ÿ‚Ö‚Ě‘Ô“x‚Ö‰e‹ż‚ˇ‚é—vˆö‚ÉŠÖ‚ˇ‚éƒiƒ‰ƒeƒBƒuƒŒƒrƒ…[. ’Ö”ü’q”Ž1, rě@‘1, “ĄŒăG•ă2, Ź—ŃŠ˛h3, ‰Ąaˆç”ü1 (1ŠĹŒě•”, 2ş˜a‘ĺŠw“Ą‚Ş‹u•a‰@ŠĹŒě•”, 3‘ĺŠw‰@ŠĹŒěŠwŒ¤‹†‰Č): ‘ć38‰ń“ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ď (2018/12/15), ˆ¤•Q, “ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ďu‰‰W 2018/12; 38: P1-3-55.

723917. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚—î‘ĺ’°ŠŕŠłŽŇ‚̏pŒă—Ł°‚É‚¨‚Ż‚銈“Ž—ʂƉşŽˆ‹Ř—Í‚Ć‚ĚŠÖ˜A. ŒHěL•˝1, ’†ŽR‰hƒ2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ‘ć38‰ń“ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ď (2018/12/16), ˆ¤•Q, “ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ďu‰‰W 2018/12; 38: O55-1.

723918. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠO—ˆ‰ťŠw—Ă–@‚đŽó‚Ż‚Ä‚˘‚é‚Ş‚ńŠłŽŇ‚ޏA˜JŒp‘ą‚É•K—v‚Ć‚ˇ‚éŠĹŒěŽt‚ĚŽx‰‡. ŽRč‹ąŽq1, Ź‘ň@2, ”Ş–Ř—Ú”ü2, ”ԏ ÍŽq2 (1’é‹ž‘ĺŠwˆă—Ă‹ZpŠw•”ŠĹŒěŠw‰Č, 2ŠĹŒě•”): ‘ć38‰ń“ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ď (2018/12/16), ˆ¤•Q, “ú–{ŠĹŒě‰ČŠwŠw‰ďŠwpW‰ďu‰‰W 2018/12; 38: P2-10-33.

723919. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) CKDƒ`[ƒ€ˆă—Ă˜AŒg‚ĆRTC‚̉@ŠOŠˆ“Ž`–ÚŽw‚šƒGƒLƒXƒp[ƒgRTC`. –ěŒű•ś”T1, ’r“cŹ]2, ˆä‘ş—[•P1, rě–@Žq1, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3 (1ŠĹŒě•”, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/13), ‘ĺă, ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/12; p.200.

723920. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠO—ˆŠĹŒěŽt‚Š‚ç‚Ý‚˝ ŽŠŒČŠÇ—Šm—§‚É‚¨‚Ż‚éRTC‚Ě–đŠ„. ˆä‘ş—[•P1, Â–öˆŸ”ü1, –ěŒű•ś”T1, ‹g“c—R”üŽq1, ’r“cŹ]2, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3 (1ŠĹŒě•”, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/13), ‘ĺă, ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2018/12; p.200.

723921. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A•a‰@‚ĹŠO—ˆ‰ťŠw—Ă–@‚đŽó‚Ż‚é‚Ş‚ńŠłŽŇ‚̏A˜Jó‹ľ‚Ɖۑč (‘ć2•ń)|A˜JŒp‘ą‚ɉe‹ż‚đ—^‚Ś‚é—vˆö‚̏A˜Jó‹ľ‚É‚ć‚éˆá‚˘|. ”ԏ ÍŽq1,2, Ź‘ň@1, ”Ş–Ř—Ú”ü1, ŽRč‹ąŽq3 (1ŠĹŒě•”, 2ŠĹŒěŒ¤CE‹łˆçƒZƒ“ƒ^[, 3’é‹ž‘ĺŠwˆă—Ă‹ZpŠw•”ŠĹŒěŠw‰Č): ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2019/2/23), •Ÿ‰Ş, ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ďW 2019/1; 33 (S): 221.

723922. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A•a‰@‚ĹŠO—ˆ‰ťŠw—Ă–@‚đŽó‚Ż‚é‚Ş‚ńŠłŽŇ‚̏A˜Jó‹ľ‚Ɖۑč (‘ć3•ń)|A˜JŒp‘ą‚Ě‚˝‚ß‚É•K—v‚ČŠĹŒěŽt‚ĚŽx‰‡‚ɂ‚˘‚ā|. ”Ş–Ř—Ú”ü1, Ź‘ň@1, ”ԏ ÍŽq1, ŽRč‹ąŽq2 (1ŠĹŒě•”, 2’é‹ž‘ĺŠwˆă—Ă‹ZpŠw•”ŠĹŒěŠw‰Č): ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2019/2/23), •Ÿ‰Ş, ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ďW 2019/1; 33 (S): P27-313.

723923. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A•a‰@‚ĹŠO—ˆ‰ťŠw—Ă–@‚đŽó‚Ż‚é‚Ş‚ńŠłŽŇ‚̏A˜Jó‹ľ‚Ɖۑč (‘ć4•ń)|A˜JŒp‘ąŽŇ‚ƑސEŽŇ‚̏A˜J‚ÉŠÖ‚ˇ‚éŽv‚˘|. Ź‘ň@1, ”Ş–Ř—Ú”ü1, ”ԏ ÍŽq1, ŽRč‹ąŽq2 (1ŠĹŒě•”, 2’é‹ž‘ĺŠwˆă—Ă‹ZpŠw•”ŠĹŒěŠw‰Č): ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2019/2/23), •Ÿ‰Ş, ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ďW 2019/1; 33 (S): P27-314.

723924. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰ťŠw—Ă–@‚đŽó‚Ż‚Ä‚˘‚éisäX‚Ş‚ńŠłŽŇ‚Ě—Ă—{śŠˆ‚É‚¨‚Ż‚é‘ĚŒą (‘ć2•ń)|Řœ•s”\‰ťŠw—Ă–@ŠJŽnŒă6ƒ•ŒŽ–˘–ž‚ĚŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚ā|. çř“”ü“oŽq (ŠĹŒě•”): ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2019/2/24), •Ÿ‰Ş, ‘ć33‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ďW 2019/1; 33 (S): O32-349.

723925. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚í‚Ş‘‚Ě‹~‹}ˆă—Ă‚É‚¨‚Ż‚éˆâ‘°ƒPƒA‚ĚŒťó‚Ɖۑč‚ÉŠÖ‚ˇ‚é‘S‘’˛¸. ˆÉ“Œ—RN1, ”ö‰Ô”üK2, ěă‘ĺ•ă3, ‘şă“TŽq4, âŒűKO5 (1ŠÖźŠw‰@‘ĺŠw‘ĺŠw‰@, 2‰Ą•lŽs—§Žs–Ż•a‰@, 3ŠĹŒě•”, 4_ŒËÔ\Žš•a‰@S—Ă“ŕ‰Č, 5ŠÖźŠw‰@‘ĺŠw): ‘ć1‰ń“ú–{ƒOƒŠ[ƒt&ƒrƒŠ[ƒuƒƒ“ƒgŠw‰ď‘‰ď‚¨‚ć‚ŃŠwpW‰ď (2019/2/24), ‹ž“s.

723926. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PICU‚É‚¨‚Ż‚éŠJSpŒă“üŽşƒVƒƒƒh[ƒCƒ“ƒO‚ĚŽć‚č‘g‚Ý. Źł]—˘“Ţ1, ˆÉ“ĄFŽq1, •äĎŘ•ä1, ”’ˆäçt1 (1ŠĹŒě•”): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.P74-3.

723927. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒ‹[ƒg—ŢŽŠŒČ”˛‹ŽÇ—á‚Š‚ç‚Ý‚˝‹CŠÇ‘}ŠÇŠłŽŇ‚ɑ΂ˇ‚ég‘Ě—}§‰đœƒtƒ[‚ĚŒŸ“˘. ˆŔdŽľ‰Ä1, ꎓĄk•˝1, XˆŔŒbŽŔ2, “ŕ“ĄˆŸŽ÷1, ‰Ąa@Žq1 (1ŠĹŒě•”, 2W’†ŽĄ—ĂƒZƒ“ƒ^[RSTERRTŽş): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.O122-4.

723928. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ICU‚É‚¨‚Ż‚éU‚č•Ô‚莖—á‚ōs‚¤‘˝EŽí—Ď—ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ĚˆÓ–Ą`ƒ`[ƒ€‚ĹŠłŽŇ‚ĚˆÓŽvŒˆ’č‚đŽx‚Ś‚˝1Ç—á`. —é–؁@šá1, “ŕ“ĄˆŸŽ÷1 (1ŠĹŒě•”): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.P47-5.

723929. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’ŽË–ň—^–ňŽž‚ÉŠÖ‚ˇ‚éƒ_ƒuƒ‹ƒ`ƒFƒbƒN‚ĚŽć‚č‘g‚Ý. ŒN“ˆ@“Œ1, ‹Ë–{çŒb”ü1, ŠÖ–îq•˝1, “y‰ŽŽu•Ű1, ‘“cł˜a1 (1ŠĹŒě•”): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ď (2019/3/2), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.O81-5.

723930. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŠÖ˜A•a“‚É‚¨‚Ż‚éRRS‚Ć‚ľ‚Ä‚Ě‚Š‚Š‚í‚č|ƒvƒƒAƒNƒeƒBƒuƒ‰ƒEƒ“ƒh‚đ’Ę‚ľ‚ÄŒŠ‚Ś‚Ä‚Ť‚˝‚ŕ‚́|. ‘ĺ’JŽ–ç1,2, Ź’r•üF1,2, XˆŔŒbŽŔ1, ˆÉ“ĄFŽq1, ˆŔ“Ą@Žő3, •Šâ­”V4, VˆäłN4,5 (1ŠĹŒě•”, 2RSTERRTŽş, 3ŹŽ™, 4–ƒŒ, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s.

723931. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PICU‚É‚¨‚Ż‚鎥—ĂƒfƒoƒCƒXŠÇ—‚đ–Ú“I‚Ć‚ľ‚˝g‘Ě—}§‚ĚŽżŒüă‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý. ŸŽR”ü—˘1, Ź—Ń—R‰Ŕ—1, ˆÉ“ĄFŽq1, Źł]—˘“Ţ1, ˛X–Ř”ü˜aŽq1, ‘şă”üŒb1 (1ŠĹŒě•”): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/3), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.P99-4.

723932. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‹~–˝‹~‹}ƒZƒ“ƒ^[‚É‚¨‚Ż‚éƒOƒŠ[ƒtƒPƒAŠˆ“Ž‚ĚŒťó•ń. ă‘ş—RŽ—1, ‚‹´@Œb1,2, ěă‘ĺ•ă1, ‹Ë–{çŒb”ü1, ‰Ąaˆç”ü1, ‘“cł˜a1, •Đ‰Ş—Sˆę3, ó—˜@–ő3 (1ŠĹŒě•”, 2ˆÚAˆă—ĂŽx‰‡Žş, 3‹~–˝): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/3), ‹ž“s, ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď´˜^WƒAƒvƒŠ 2019/2; p.O138-5.

723933. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”]‘˛’†‹}ŤŠú‚É‚¨‚Ż‚éÁ‰ťŠí‡•šÇ‚ĚŒŸ“˘. ź“cŒb”ü1, ‹”ö”üš1, ‰““Ą—fŽq1, ‚‹´‚Š‚¨‚č1, ‹TÎ—çŽq1, ˛“Ą@—I2, –k‘ş‰p“ń2, ˆ˘‹v’Ă“ń•v2, źŽR˜a—˜2 (1ŠĹŒě•”, 2_Œo“ŕ): ‘ć44‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď (2019/3/23), _“ސě.

723934. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DOAC“ŕ•ž‚Ě—L–ł‚É‚ć‚éS–[×“ŽƒAƒuƒŒ[ƒVƒ‡ƒ“’†‚ĚŠĹŒě‹Ć–ą‚É‹y‚Ú‚ˇ‰e‹ż‚ÉŠÖ‚ˇ‚錟“˘. ‹Ęě’źŽq1, •˝@KŒb1, ‹yě@~2, [’J‰p•˝2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1ŠĹŒě•”, 2zŠÂŠí“ŕ): ‘ć83‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2019/3/29), _“ސě.

731125. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •ďŠ‡“It‘ă‘Ö—Ă–@‚ĆRTC‚Ě–đŠ„`CKDƒ`[ƒ€ˆă—Ă‚đŒq‚Žt•s‘SŠĹŒě`. –ěŒű•ś”T1, ’r“cŹ]2, ˆä‘ş—[•P1, rě–@Žq1, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3 (1ŠĹŒě•”, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć20‰ń“§ÍŠłŽŇ‚̍‡•šÇ‚đl‚Ś‚é‰ď (2018/11/27), é‹Ę.

732124. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ŇŒű‰‰) t•s‘SŠĹŒě‚ÍCKDŠłŽŇ‚̊‹Ť‚đ‚‚ȂŽ`CKDƒ`[ƒ€ˆă—Ă‚ĆRTC‚Ě–đŠ„`. –ěŒű•ś”T1, ’r“cŹ]2, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3 (1ŠĹŒě•”, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć7‰ńĂ“쓧ÍŒ¤‹†‰ď (2018/5/8), _“ސě.

732125. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) dÇ‹~‹}ŠłŽŇ‚̉h—{ŠJŽnŽžŠú‚ĚŒŸ“˘. ‹{‰ş’mŽq1, ’J@Kˆę1, Î‘q@ˆ¤1, •Đ‰Ş—Sˆę2, ˛“ĄĆŽq3, Žç‰Ž—˘š3, ‰““ĄŹŽq3, [‘ň˛œ¨Žq3, Ž›ź—m”ü4, ŽO‰Y–F“T5, Ź–ě—Ç‘ž5, ł–ŘˆÇ“Ţ5 (1ŠĹŒě•”, 2‹~–˝, 3‰h—{•”, 4–ňÜ•”, 5—ŐŒŸ•”): ‘ć10‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď (2018/6/2), “Œ‹ž.

732126. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ś‚Ť‚é‹ę”Y‚ĆŠě‚Ń, Šó–]‚đŽx‚Ś‚éŠĹŒě. ”’ˆä—R‹MŽq1, “cŒű^“Ţ”ü2, –kŽR•śŽq3, ‰F“cě”ü‹I4 (1‘Šˆ¤•a‰@, 2‘Š–ÍŒ´—Ăˆç‰€, 3ƒ[ƒNƒZƒ“ƒ^[‚ꂡ‚Ć, 4ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.21-5.

732127. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) Œđ—ŹW‰ď…A@‰z‹Ť“IŠwK‚ĚŽ‹“_‚đŽć‚č“ü‚ę‚˝V‚˝‚ČŠwK‚̏ę‚̍\’z‚ÉŒü‚Ż‚˝’§í. ŽOŽ}Ž–1, –{’Jş”Ž2, ŹŽR–ž—˘1 (1ŠĹŒě•”, 2ƒRƒjƒJƒ~ƒmƒ‹ƒ^Š”ŽŽ‰ďŽĐ): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.29-30.

732128. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) Œđ—ŹW‰ď…B@ŠĹŒěŠwś‚Š‚çƒXƒ^[ƒg‚ˇ‚éŠĹŒěE‚̐lŢˆçŹ. –]ŒŽ”ü•ä1, ’†“‡éş1, –ö“cŒ’–ž1, ‹{–{ŠG”ü1, ç–ؗǓމ›1, ŹěŠě”üŽq1, źŒ´N”ü2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.31-32.

733286. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™W’†ŽĄ—ĂŽş‚É‚¨‚Ż‚éŒo•@‘}ŠÇƒ`ƒ…[ƒu‚̐V‚˝‚ČŒĹ’č•ű–@‚ƍĄŒă‚̉ۑč. ‘ĺ‹v•Ű‘t”ü1, ˆÉ“ĄFŽq1, {ě’qŹ1 (1ŠĹŒě•”): “ú–{W’†ŽĄ—ĂˆăŠw‰ď‘ć2‰ń“ŒŠC–k—¤Žx•”ŠwpW‰ď (2018/6/9), Îě.

733287. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™W’†ŽĄ—ĂŽş‚É‚¨‚Ż‚éŠĹŒěŽt‚Ě“üŽş‘O–K–â‚ĚŽć‚č‘g‚Ý. ˆÉ“ĄFŽq1, •äĎŘ•ä1 (1ŠĹŒě•”): “ú–{W’†ŽĄ—ĂˆăŠw‰ď‘ć2‰ń“ŒŠC–k—¤Žx•”ŠwpW‰ď (2018/6/9), Îě.

733288. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹~–˝‹~‹}ƒZƒ“ƒ^[‚É‚¨‚Ż‚é‰h—{ŠÖ˜A‚ĚƒCƒ“ƒVƒfƒ“ƒg‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‘ž“cŽĄ˘1, ”’Î—LŽŃ1, ă‘ş—RŽ—1, ’†‰Ž—˘š2, [‘ň˛ŒbŽq2, ŽO‰Y–F“T3, _@ˆę–˛4, •Đ‰Ş—Sˆę5 (1ŠĹŒě•”, 2‰h—{•”, 3—ŐŒŸ•”, 4–ňÜ•”, 5‹~–˝): ‘ć5‰ń_“ސě‹}ŤŠú‰h—{ŠÇ—Œ¤‹†‰ď (2018/6/16), _“ސě, “ú–{Ă–ŹŒo’°‰h—{Šw‰ďŽGŽ 2018/10; 33 (4): 86 (“dŽq”Ĺ).

733289. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) dÇ‹~‹}ŠłŽŇ‚Ě”r•ÖƒRƒ“ƒgƒ[ƒ‹‚Ć‚ľ‚Ä‚ĚƒvƒŒƒoƒCƒIƒeƒBƒNƒX‚ĚŒř‰Ę‚ÉŠÖ‚ˇ‚錟“˘. âV“Ą—Ú“Ţ1, –x˛‰lŽq1, Î‘q@ˆ¤1, ‘“cł˜a1, •Đ‰Ş—Sˆę2, ó—˜@–ő2, Žç‰Ž—˘š3 (1ŠĹŒě•”, 2‹~–˝, 3‰h—{•”): ‘ć5‰ń_“ސě‹}ŤŠú‰h—{ŠÇ—Œ¤‹†‰ď (2018/6/16), _“ސě, “ú–{Ă–ŹŒo’°‰h—{Šw‰ďŽGŽ 2018/10; 33 (4): 86 (“dŽq”Ĺ).

733290. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠłŽŇ‚Ć‹¤‚ÉŽć‚č‘g‚ń‚ž”r•ÖƒRƒ“ƒgƒ[ƒ‹. ˛–쐐”ż1, ]ě˜aŠě1, ‘“cł˜a1, ŒFŕVŒ›ˆę2 (1ŠĹŒě•”, 2‹~–˝): ”MƒtƒH[ƒ‰ƒ€ (2018/8/29), “Œ‹ž.

733291. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) PICU‚É‚¨‚Ż‚éECMO‘˝EŽí˜AŒgƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ƒgƒŒ[ƒjƒ“ƒO‚ĚŽć‚č‘g‚Ý. ‹ŕ„Ž›‚Ü‚čŽq1, –ŠCSŒő1, ˆÉ“ĄFŽq1 (1ŠĹŒě•”): ‘ć26‰ńŹŽ™W’†ŽĄ—Ăƒ[ƒNƒVƒ‡ƒbƒv (2018/10/13), ‹ž“s.

733292. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –ŤŠúŠĹŒěŠwŽŔK‚É‚¨‚Ż‚é—Տ°‹łˆő§“x“ą“ü‚Ě•]‰ż. ç–ؗǓމ›1, –]ŒŽ”ü•ä1, ’†“‡éş1, –ö“cŒ’–ž1, ‹{–{ŠG”ü1, ‹v•ŰŒÜŒŽ2, źŒ´N”ü2, ˆÉ“ĄT–ç2, ’JŒű—zŽq1 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.38.

733293. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) —Տ°‹łˆő’S“–‚Ě—Ő’nŽŔK‚É‚¨‚Ż‚é•a“ŠĹŒěŽt‚ĚŽŔKŽw“ą‚ÉŠÖ‚ˇ‚é”FŽŻ‚Š‚ç‚ĚˆęlŽ@. –ö“cŒ’–ž1, ’†“‡éş1, –]ŒŽ”ü•ä1, ‹{–{ŠG”ü1, ç–ؗǓމ›1, ’JŒű—zŽq1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.39.

733294. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒZƒNƒVƒ‡ƒ“”z’u‚̐ę–ĺŠĹŒěŽtE”F’čŠĹŒěŽt‚Ö‚ĚŠĹŒěŠÇ—ŽŇ‚ĚŠÖ‚í‚č‚ɂ‚˘‚Ä. ‹TÎ—çŽq1, ŽR–ě•Ó‚Ý‚żŽq1, ’†“‡ßŽq1, ‹ß“Ą‚Ü‚ä‚Ý1, â‰ş’qŽěŽq1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.40.

733295. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) Vl‹łˆç’S“–ŽŇ‚Ě–đŠ„”­Šö‚É‚ć‚鐏’ˇ‚ÉŠÖ‚ˇ‚éˆęlŽ@`‰Ę‚˝‚ľ‚˝Ź‰ĘÓ”C‚ĆŠˆ—p‚ľ‚˝ƒRƒ“ƒsƒeƒ“ƒV[‚̕ωť‚ć‚č`. ”ԏ ÍŽq1,2, ŽR–{]gŽq1,2, –x]çŒbŽq1,2, ’ˇŕV­Žu1,2, ŽĹ“c’q‘ăŽq1,2, ’JŒű—zŽq1,2, ’r“c—ćŽq1 (1ŠĹŒě•”, 2ŠĹŒěŒ¤CE‹łˆçƒZƒ“ƒ^[): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.41.

733296. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒLƒƒƒŠƒA’†ŠúŠĹŒěŽt‚Ě‘gDƒRƒ~ƒbƒgƒƒ“ƒg‚ƐEęƒ\[ƒVƒƒƒ‹EƒTƒ|[ƒg‚Ć‚ĚŠÖ˜A`—Տ°ŽŔ‘H—Í‚É’…–Ú‚ľ‚ā`. ŒÜ“Ą—zŽq (ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.42.

733297. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽOŽŸ‹~‹}‚É‚¨‚Ż‚éI––ŠúŠŕŠłŽŇ‚ĚˆÓŽvŒˆ’čŽx‰‡. Žáś“Ţ’ĂŽ÷1, “Ą‰Ş—Ú—ž1, ’ˇ–ě—F‹IŽq1, ‰Ąaˆç”ü1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.45.

733298. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”ť’f”\—͂̒ቺ‚ľ‚˝–ŤŽžŠł‚—îŽŇ‚ĚˆÓŽvŒˆ’čŽx‰‡‚đs‚¤ă‚Ĺ‚ĚŠĹŒěŽt‚̍˘“`“ŕ•Ş”ĺ‘ăŽÓŽžŠł‚đ‚ŕ‚ŠłŽŇ‚ÉĹ“_‚đ‚ ‚Ä‚Ä`. ’†Şt”ü1, ‚ŒŠ‹IŽq1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.46.

733299. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) g‘Ě—}§’†‚ĚƒhƒŒ[ƒ“Eƒ‹[ƒg”˛‹Ž–hŽ~‚ÖŒü‚Ż‚˝Œťó•ŞÍ‚ƍĄŒă‚ĚŽć‚č‘g‚Ý. ‹AŽRˆęŽu1, ‘“cł˜a1, _“cW—D1, ˛“Ąç–ž1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.47.

733300. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) š‹‰şáŠQŠłŽŇ‚É‚¨‚Ż‚éš‹‰şŒP—űŽŔŽ{‚ĚŒťó•ń. ŽÄ“c^Šó1, ”’Î—LŽŃ1, ‘ž“cŽĄ˘1, ă‘ş—RŽ—1, ‰Ąaˆç”ü1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.48.

733301. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽčŽw‰qśŽŔŽ{‰ń”Œüă‚đ–ÚŽw‚ľ‚˝Žć‚č‘g‚݁`ŽčŽw‰qś„iŽŇ‚Ć‚ľ‚Ă̐„iŠˆ“Ž`. ˛“Ąˆş‰Ä1, “n糁@•ŕ1, ‰iˆäD1, ”’’š—FŠî1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.49.

733302. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠÖ˜A•”ŠÔ‚ŏî•ń‹¤—L‚Ĺ‚Ť‚é‹L˜^‚̐Ž”ő`‰ż’l‚đś‚Ţî•ń‚Əî•ńƒvƒ‰ƒCƒoƒV[‚Ö‚Ě”z—ś`. ”Ş–öçt (ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.50.

733303. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŒÂ•ĘŤ‚Ě‚ ‚éŠĹŒěŽŔ‘H‚đ–Ú“I‚Ć‚ľ‚˝ƒJƒ“ƒtƒ@ƒŒƒ“ƒXŠJĂ‚Ö‚ĚŽć‚č‘g‚Ý. ‘ŠŕV‚ꂢ‚Š (ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.51.

733304. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) •Ş•Ř‰î•ŽŔK‚É‚ć‚鏕ŽYŠwś‚́g•Ş•Řh‚ɑ΂ˇ‚éƒCƒ[ƒW‚̕ωť`FĘŰ’ĽƒeƒXƒg‚đ—p‚˘‚ā`. ŽR‘şD1, Žć—mŽq2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.54.

733305. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‚ ‚éˆŤŤƒŠƒ“ƒpŽîŠłŽŇ‚Ş, yŽ„‚ç‚ľ‚­ś‚Ť‚éz‚˝‚ß‚ĚˆÓŽvŒˆ’čŽx‰‡`wˆÓŽv‚Ě•śÍ‰ťx‚ĚŒř‰Ę`. ‚”ö^‹I1, ]“Ş”üŽ÷1, ŽR–ě•Ó‚Ý‚żŽq1 (1ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^ 2018/11; p.55.

733306. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) Žqˆç‚Т‘ă‚ĚÄ”­‚ľ‚˝“ű‚Ş‚ńŠłŽŇ‚Ş•ř‚­Žq‚Ç‚ŕ‚Ö‚ĚŽv‚˘`Žq‚Ç‚ŕ‚Ć‚ĚŠÖ‚í‚č‚𒆐S‚Ɂ`. Ź“‡‚Đ‚ĹŽq1, Ž™‹Ę”ü—R‹I2, –ű’J˜aŽq3 (1ŠĹŒěŠw•”, 2ŠĹŒě•”, 3“Œ•a‰@ŠĹŒě•”): ‘ć42‰ń“ú–{Ž€‚Ě—Ő°Œ¤‹†‰ď”NŽŸ‘ĺ‰ď (2018/12/9), VŠƒ, ‘ć42‰ń“ú–{Ž€‚Ě—Ő°Œ¤‹†‰ďƒvƒƒOƒ‰ƒ€E—\eW 2018/12; p.390.

733307. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) A•a“‚É‚¨‚Ż‚éŒoŒąŠwK‚ÉŠî‚Ă‚˘‚˝ƒŠ[ƒ_[ˆçŹ‚ĚŽć‚č‘g‚݁`‘ć2•ń`. –ě”ŇŒb”üŽq1, Â–ŘŒŞŽĄ1, ˆ˘•”^—R”ü1, ’†“‡éş1, ‰ĄŽR—˜1 (1ŠĹŒě•”): 2018”N“x_“ŢěŒ§ŠĹŒě‹Ś‰ď‘Š–ÍŒ´Žx•”ŠĹŒěŒ¤‹†”­•\‰ď (2019/1/18), _“ސě, 2018”N“x_“ŢěŒ§ŠĹŒě‹Ś‰ď‘Š–ÍŒ´Žx•”ŠĹŒěŒ¤‹†”­•\‰ďW˜^W 2019/1; p.13-6.

733308. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘ĚŠOŽŽ–ŒŒ^lH”x (ECMO) ‚đ‘•’…‚ľ‚˝_ŒoŤ‚â‚šÇŠłŽŇ‚̐ś—“I—~‹‚̏[‘Ť‚ÉŒü‚Ż‚˝ƒAƒvƒ[ƒ`. •Ÿ“ˆšD1, ź“cGˆę1, Î‘q@ˆ¤1, ‘“cł˜a1, ŠŰ‹´Fş2, ó—˜@–ő2 (1ŠĹŒě•”, 2‹~–˝): ‘ć69‰ń“ú–{‹~‹}ˆăŠw‰ďŠÖ“Œ’n•ű‰ďŠwpW‰ďE‘ć56‰ń‹~‹}‘ŕˆőŠwpŒ¤‹†‰ď (2019/2/2), ˆďé, “ú–{‹~‹}ˆăŠw‰ďŠÖ“Œ’n•ű‰ďŽGŽ 2019/2; 40 (1): 140.

733309. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘ĚŠOŽŽ–ŒŒ^lH”x‚đ‘•’…‚ľ‚˝_ŒoŤ‚â‚šÇŠłŽŇ‚ɑ΂ˇ‚éŰHš‹‰şáŠQŠĹŒě. Î‘q@ˆ¤1, •Ÿ“ˆšD1, ź“cGˆę1, ‘“cł˜a1, ŠŰ‹´Fş2, ó—˜@–ő2 (1ŠĹŒě•”, 2‹~–˝): ‘ć69‰ń“ú–{‹~‹}ˆăŠw‰ďŠÖ“Œ’n•ű‰ďŠwpW‰ďE‘ć56‰ń‹~‹}‘ŕˆőŠwpŒ¤‹†‰ď (2019/2/2), ˆďé, “ú–{‹~‹}ˆăŠw‰ďŠÖ“Œ’n•ű‰ďŽGŽ 2019/2; 40 (1): 140.

733310. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”][Ç‹}ŤŠúÄŠJ’Ę—Ă–@‚É‚¨‚Ż‚é‘˝EŽíƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ĚŽć‚č‘g‚Ý. ź“cGˆę1, ’ˇ–ě—F‹IŽq1, ‰Ąaˆç”ü1, ˆä“‡‘ĺ•ă2, ŽR–{‘ĺ•ă3 (1ŠĹŒě•”, 2_Œo“ŕ, 3”]ŠO): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď@‘ć18‰ń_“ސěŽx•”ŠwpW‰ď (2019/3/9), _“ސě.

733311. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”]Ž€‰şŠĚ‘ŸŹ’°“ŻŽžˆÚA‚đ‘I‘đ‚ľ‚˝ˆęÇ—á‚Ö‚ĚŽx‰‡‚đU‚č•Ô‚Á‚Ä. ź“ŕ‰ŔŽq1, ’†“‡ßŽq1 (1ŠĹŒě•”): ‘ć31‰ń“ú–{Ź’°ˆÚAŒ¤‹†‰ď (2019/3/9), “Œ‹ž.

H29”N“xˆČ‘O•Ş

[Šwp˜_•ś]

H29-120003. [Œ´’˜] isäX‚Ş‚ńŠłŽŇ‚Ć‚ť‚̉Ƒ°‚Ě—Ă—{‘ĚŒą‚Ě•Ď—e|ŠĹŒěŽt‚Ć‚Ěƒp[ƒgƒi[ƒVƒbƒv‚̉ߒö‚É‚¨‚Ż‚é‘ŠŒÝsˆ×‚ÉĹ“_‚𓖂Ăā|. çř“”ü“oŽq (ŠĹŒě•”): “ú–{‚Ş‚ńŠĹŒěŠw‰ďŽ 2018/1; 32: 159-69.

[Šw‰ďEŒ¤‹†‰ď“™]

H29-733009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”r”AŽŠ—§Žw“ą—żŽZ’č‚ĚŽć‚č‘g‚݁|•a“ŠĹŒěŽt‚ĚŽ‹“_‚Š‚ç|. Ż–ě@Œ’1, ŒŃ“cŤŽk1 (1ŠĹŒě•”): ‘ć14‰ń‘O—§‘BŠŕ–§••ŹüŒš‰i‹v‘}“üŽĄ—ĂŒ¤‹†‰ď (2018/1/21), “Œ‹ž, ‘ć14‰ń‘O—§‘BŠŕ–§••ŹüŒš‰i‹v‘}“üŽĄ—ĂŒ¤‹†‰ď‹L˜^W 2018; p.29.


—Տ°ŒŸ¸•”

[Šwp˜_•ś]


120041. [Œ´’˜] VśŽ™’ŽŠoƒXƒNƒŠ[ƒjƒ“ƒO‚Ě“KłđŒ‚¨‚ć‚Ń’ˆÓ“_‚ÉŠÖ‚ˇ‚錟“˘|–k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŽŔŽ{ó‹ľ, ŒŸ¸Œ‹‰Ę‚Š‚ç|. ŽÂŒ´—ş‘ž1, Ź”Ś@i1, –ź–؁@‰1, –F“c‚Đ‚Ć‚Ý1, –Ń—˜’m—ĺ1, –ł‘ž˜Y1, “•űLˆę1, Vˆä—œˆß“ß1,2, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): –k—˘ˆăŠw2018/12; 48 (2): 113-20.

120042. [Œ´’˜] lHŠÖßŠ´őÇ‚É‚¨‚Ż‚ép’†ŒŸ‘Ě‚đ—p‚˘‚˝×‹Űˆâ“`ŽqŒŸ¸‚Ě—L—pŤ‚ɂ‚˘‚Ä. ŸNˆäŒc‘˘1, ˆŔ–{—´”n1, ’†čM•F1, “•űLˆę1, “ŕŽRŸ•ś2, Žë–ě—Lě3 (1—ŐŒŸ•”, 2ŽŠO, 3—ŐŒŸ•”): ˆăŠwŒŸ¸ 2018; 67 (5): 660-7.

310028. [Ç—á•ń] Evoked potential studies for predicting functional recovery in a case of acute necrotizing encephalopathy. Onozawa Y1, Iwasaki T2, Iizuka T3, Nonoda Y2, Toki T2, Obata S1, Munekata S1, Kanoh Y4: Clin Case Rep 2018/5; 6 (5): 813?6. (Ź–ěŕV—T–ç1, Šâčr”V2, ”Ń’Ë‚_3, –ěX“c–L2, “yŠň@•˝2, Ź”Ś@i1, “•űLˆę1, Žë–ě—Lě4: 1—ŐŒŸ•”, 2ŹŽ™, 3_Œo“ŕ, 4—ŐŒŸŠw)

[Šw‰ďEŒ¤‹†‰ď“™]

721029. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) —Ő’nŽŔK‚ĚÝ‚č•ű`‹‚ß‚ç‚ę‚é—Ő’nŽŔK‚Ƃ́`. ŽO‰Y–F“T (—ŐŒŸ•”): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12), •lź, ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 35.

723935. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) XNƒVƒŠ[ƒY‚É‚¨‚Ż‚éBFƒ‚[ƒh‚đ—p‚˘‚˝‹CŠÇŽx”x–Eôň‰t (BALF) ‚Ě‘Ş’č‚ÉŠÖ‚ˇ‚錟“˘. Ź–ě—Ç‘ž1, ăŒ´—R‰Ŕ—1, ’†ź@ŒO1, ˆ˘•”—L1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12), •lź, ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 60.

723936. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) tŒŒŠÇ‹ŘŽ‰–bŽî”j—ô‚Ĺ”F‚ß‚˝–Œ•”č÷—ąŹ•Ş‹ĂWó’Eƒwƒ‚ƒOƒƒrƒ“ÔŒŒ‹…‚Ć‚ť‚Ě—Ő°“IˆÓ‹`. ”Ń’Ë‚ś1, “y•M’qť1, ˆÉ“ĄˆŸ–퍁1, ꠓc˜a•ä1, ŽO‰Y–F“T1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/13), •lź, ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 74.

723937. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒv[ƒ‹ŒŒŸ÷Eƒv[ƒ‹ŒŒ´‚đ—p‚˘‚˝BNP-proBNP‚ĚŠO•”¸“xŠÇ—’˛¸. Ž}ź´—˛1, ’†‘ş‘ž˜Y2, ˆÉ“Œ•ü”ü3, ‘şă’źŽ÷4, ŽR‰şăđž5, ŽÄ“c^ˆßŽq6, —é–ؐç•ä7, “y•M’qť8 (1“Ą‘ňŽs–Ż•a‰@, 2ˆÉ¨Œ´‹Ś“Ż•a‰@, 3“Œ–źŒú–Ř•a‰@, 4‰Ą•lŽs—§‘ĺŠw•t‘Žˆă—ĂƒZƒ“ƒ^[•a‰@, 5šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw•a‰@LSI, 6“ŒŠC‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 7_“ŢěŒ§—\–hˆăŠw‹Ś‰ď, 8—ŐŒŸ•”): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12-13), •lź, “ú–{ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 92.

723938. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 2Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éÉŽq‰~’Œ‚Ě—Ő°“IˆÓ‹`. “y•M’qť1, ”Ń’Ë‚ś1, ˆÉ“ĄˆŸ–퍁1, ŽÂŒ´—ş‘ž1, ŽO‰Y–F“T1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12-13), •lź, “ú–{ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 386.

723939. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷ŠŕŠłŽŇ‚Ě”A’†‚Ƀwƒ}ƒgƒCƒWƒ“Œ‹ť‚đ”F‚ß‚˝1Ç—á. ˆÉ“ĄˆŸ–퍁1, “y•M’qť1, ”Ń’Ë‚ś1, ꠓc˜a•ä1, ŽO‰Y–F“T1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12-13), •lź, “ú–{ˆăŠwŒŸ¸Šw‰ďŽ 2018; 67 (•Ęű): 392.

723940. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) tÇ”­Ç‘O‚Ě“œ”A•aƒ‰ƒbƒg‚É‚¨‚Ż‚éƒ~ƒgƒRƒ“ƒhƒŠƒAƒ^ƒ“ƒpƒNŽż‚Ě”A’†”rŸ•‚ɂ‚˘‚Ä. Ź“‡@”Ł1, ’r‰iGŽ÷2, ŹŽ›‹`’j3, ˆä–{–ž”ü1,4, •čËŽj1,4, “y•M’qť5, Ź”Ś@i5,6, —é–؉p–ž7, ‰Ąęł“T1,4, Žsě‘¸•ś1,4, ’|’†P•v8, •Đ‹Ë^l1,4, Îˆä’źm1,4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—Ă–@lšˆă‰ď, 3–k—˘‘ĺŠw—Šw•”•t‘ŽŽžŠłƒvƒƒeƒIƒ~ƒNƒXƒZƒ“ƒ^[, 4ˆă—ÉqśŠw•”, 5—ŐŒŸ•”, 6“Œ•a‰@—ŐŒŸ•”, 7–k—˘‘ĺŠw•ŰŒŻ‰qśę–ĺŠw‰@, 8‘Űˆă—Ă•ŸŽƒ‘ĺŠwŽR‰¤•a‰@t‘Ÿ“ŕ‰Č): ‘ć58‰ń“ú–{—Տ°‰ťŠw‰ď”NŽŸŠwpW‰ď (2018/8/24-26), –źŒĂ‰Ž, —Տ°‰ťŠw 2018/10; 47 (suppl 1): 257.

723941. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) _—Ő‹ZƒT[ƒxƒC‚ĹŠm”F‚ľ‚˝“ú–{‘“ŕ‚ĹŽg—p‚ł‚ę‚Ä‚˘‚éBNPŽŽ–ňŠÔˇ‚ɂ‚˘‚Ä. Ž}ź´—˛1, “y•M’qť2, ŽR‰şăđž3, ‘şă’źŽ÷4, ŽRŒű—El1 (1“Ą‘ňŽs–Ż•a‰@, 2—ŐŒŸ•”, 3šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw•a‰@LSI, 4‰Ą•lŽs—§‘ĺŠw•t‘Žˆă—ĂƒZƒ“ƒ^[•a‰@): ‘ć58‰ń“ú–{—Տ°‰ťŠw‰ď”NŽŸŠwpW‰ď (2018/8/24-26), –źŒĂ‰Ž, —Տ°‰ťŠw 2018/10; 47 (suppl 1): 303.

723942. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠ“Ž×–EŒŸo‘•’u (DI60) ‚Ěƒ‹[ƒ`ƒ“ŒŸ¸‚É‚¨‚Ż‚é‰^—p‚ɂ‚˘‚Ä. ˆ˘•”—L1, ăŒ´—R‰Ŕ—1, ’†ź@ŒO1, “ŕ“cˆęO1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‘ć50‰ń‘ĺ‰ď (2018/10/11), _ŒË, “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‰ďŽ 2018/10; 43 (4): 425.

723943. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ELFƒXƒRƒA‚É‚ć‚éŠĚ‘@ˆŰ‰ť‚Ě•]‰ż‚¨‚ć‚Ń—Ő°“IŒŸ“˘. ’†čLŽq1, ŹŽRhŽq1, “y•M’qť1, “Ą‘ş‘Ps1, “ŕ“cˆęO1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‘ć50‰ń‘ĺ‰ď (2018/10/11-13), _ŒË, “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‰ďŽ 2018/10; 43 (4): 481.

723944. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) HBVŠ´őÇ‚ĚƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚É‚¨‚Ż‚éuƒGƒNƒ‹[ƒVƒXŽŽ–ňHBsAgII(S300)v‚̐Ť”\•]‰ż. ‰Ş“c—R‹I1, ŹŽRhŽq1, “y•M’qť1, ’†čLŽq1, “ŕ“cˆęO1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‘ć50‰ń‘ĺ‰ď (2018/10/11-13), _ŒË, “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‰ďŽ 2018/10; 43 (4): 482.

723945. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ÔŒŒ‹…“ŕŹ•ŞASTELDHEK‚É‚¨‚Ż‚éŒÂ‘̍ˇ‚ɂ‚˘‚Ä. —L”n˜a“Ţ1, “y•M’qť1, “Ą‘ş‘Ps1, ˆ˘•”—L1, ’†čLŽq1, Ź–{”ü“Ţ1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‘ć50‰ń‘ĺ‰ď (2018/10/11-13), _ŒË, “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‰ďŽ 2018/10; 43 (4): 485.

723946. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) HBsR‘Ě‚Ě•W€‰ť‚ĚŒťó‚Ć–â‘č“_|_“ŢěŒ§¸“xŠÇ—’˛¸Œ‹‰Ę‚̉đÍ|. “y•M’qť1, ’†‘ş‘ž˜Y2, ‰Á“ĄŽ‡”T3, ‘şă’źŽ÷4, ˆÉ“Œ•ü”ü5, ŽÄ“c^ˆßŽq6, ŽR‰şăđž7, —é–ؐç•ä8, Ž}ź´—˛9 (1—ŐŒŸ•”, 2ˆÉ¨Œ´‹Ś“Ż•a‰@, 3’é‹ž‘ĺŠwˆăŠw•”•t‘ŽaŒű•a‰@, 4‰Ą•lŽs—§‘ĺŠw•t‘Žˆă—ĂƒZƒ“ƒ^[•a‰@, 5Ă“ěŒú–Ř•a‰@, 6“ŒŠC‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 7šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠwź•”•a‰@LSI, 8_“ŢěŒ§—\–hˆăŠw‹Ś‰ď, 9“Ą‘ňŽs–Ż•a‰@): “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‘ć50‰ń‘ĺ‰ď (2018/10/11-13), _ŒË, “ú–{—Տ°ŒŸ¸ŽŠ“Ž‰ťŠw‰ď‰ďŽ 2018/10; 43 (4): 486.

723947. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LHON“ď•a”F’čŠî€‚̐f’f‹ć•Ş‚É‚ć‚éƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`ŽqŒŸ¸‚ĚŒŸ“˘. ŸNˆäŒc‘˘1, ˆŔ–{—ł”n1, Îě@‹Ď2, ŽRă–žŽq, Žá‘q‰ë“o, Vˆä—œˆß“ß3, Žë–ě—Lě1,3 (1—ŐŒŸ•”, 2ˆă—ÉqśŠw•”, 3—ŐŒŸŠw): ‘ć65‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďŠwpW‰ď (2018/11/17), “Œ‹ž.

723948. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œz•””^ᇊłŽŇ‚Š‚猟o‚ľ‚˝Actinomyces oris‚Ě1—á. ˆŔ’B@÷1, “ń–{–öL2, ŹŠŃ’q‘ă1, ˆŔ–{—´”n1, ’†čM•F1, ŸNˆäŒc‘˘1, “•űLˆę1, Žë–ě—Lě1,3 (1—ŐŒŸ•”, 2Š´őŠÇ—Žş, 3—ŐŒŸŠw): ‘ć30‰ń“ú–{—Տ°”÷ś•¨Šw‰ď‘‰ďEŠwpW‰ď (2019/2/1-3), “Œ‹ž, ‘ć30‰ń“ú–{—Տ°”÷ś•¨Šw‰ď‘‰ďEŠwpW‰ď´˜^ 2019/2; 29: 448.

732129. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) “œ”A•a‚Ć”A’žŸÔ. “y•M’qť (—ŐŒŸ•”): ‘ć35‰ń“ú–{—Տ°‰ťŠw‰ďŠÖ“ŒŽx•”—á‰ď (2018/12/8), ‘Š–ÍŒ´, ‘ć35‰ń“ú–{—Տ°‰ťŠw‰ďŠÖ“ŒŽx•”—á‰ďƒvƒƒOƒ‰ƒ€ 2018/12; p.7.

733312. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚“x—zˆł‘¤‚Ƀs[ƒN‚đŽŚ‚ľ‚˝ƒeƒBƒ“ƒpƒmƒOƒ‰ƒ€‚Ě—Ő°“I”wŒi‚ÉŠÖ‚ˇ‚錟“˘. Ź”Ś@i1, Šâ|‹Ô‰›1, –ł‘ž˜Y1, ˛‹´‹v”üŽq1, “•űLˆę1, Îˆä’źm2, Vˆä—œˆß“ß3, Žë–ě—Lě1,3 (1—ŐŒŸ•”, 2ˆă—ÉqśŠw•”, 3—ŐŒŸŠw): ‘ć29‰ń_“ŢěŒ§—Տ°ŒŸ¸ˆăŠw‰ď‘ĺ‰ď (2018/6/2), _“ސě.

733313. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆŮí”]”g. Ź–ěŕV—T–ç (—ŐŒŸ•”): ŠÖ“Œ_Œoś—ŒŸ¸‹ZpŒ¤‹†‰ďƒXƒLƒ‹ƒAƒbƒv”]”guK‰ď (2018/9/9), “Œ‹ž.

733314. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽŠ“Ž×–EŒŸo‘•’u (DI60) ‚Ěƒ‹[ƒ`ƒ“ŒŸ¸‚É‚¨‚Ż‚é‰^—p‚ɂ‚˘‚Ä. ˆ˘•”—L1, ăŒ´—R‰Ŕ—1, ’†ź@ŒO1, “ŕ“cˆęO1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć8‰ń–k—˘‘ĺŠw4•a‰@—Տ°ŒŸ¸•”ŠwpW‰ď (2018/11/4), ”’‹ŕ, ‘ć8‰ń–k—˘‘ĺŠw4•a‰@—Տ°ŒŸ¸•”ŠwpW‰ďƒvƒƒOƒ‰ƒ€´˜^W 2018/11; p.7.

733315. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –@“I”]Ž€”ť’č‚ĚŽŔŰ. Ź–ěŕV—T–ç (—ŐŒŸ•”): _“ŢěŒ§Œ’Nˆă—Ă‹Ç (2018/12/6), ‰Ą•l.

733316. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Çó‚Š‚çl‚Ś‚é’´‰š”gf’f@—Ť‚̉ş• •”—Ěˆć. ‰FŽĄ‹´‘PŸ (—ŐŒŸ•”): “ú–{’´‰š”gŒŸ¸Šw‰ďŠÖ“ŒbM‰z‘ć40‰ń’n•ű‰ďŒ¤C‰ď (2018/12/9), ’ˇ–ě, ’´‰š”g‹Zp 2019/4; 42 (2): 284-5

733317. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™”]”g‚Ě“Á’Ľ. Ź–ěŕV—T–ç (—ŐŒŸ•”): Œő“dƒtƒFƒAinˇ‰Ş (2019/2/2), ˇ‰Ş.

733318. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘˝—l‚ČŽ‹“_‚Ĺ—‰đ‚ˇ‚é”]”g•ŠŠˆ–@vol.1. Ź–ěŕV—T–ç (—ŐŒŸ•”): ŠÖ“Œ_Œoś—ŒŸ¸‹ZpŒ¤‹†‰ď“ú—juK‰ď (2019/2/3), “Œ‹ž

733319. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œz•””^ᇊłŽŇ‚Š‚猟o‚ľ‚˝Actinomyces oris‚Ě1—á. ˆŔ’B@÷1, “ń–{–öL2, ŹŠŃ’q‘ă1, ˆŔ–{—´”n1, ’†čM•F1, ŸNˆäŒc‘˘1, “•űLˆę1, Žë–ě—Lě1,3 (1—ŐŒŸ•”, 2Š´őŠÇ—Žş, 3—ŐŒŸŠw): ‘ć85‰ń_“ŢěŒ§Š´őÇˆăŠw‰ď (2019/3/9), ‰Ą•l, ‘ć85‰ń_“ŢěŒ§Š´őÇˆăŠw‰ď´˜^ 2019/3; p.13.


•úŽËü•”

[Šwp˜_•ś]

110201. [Œ´’˜] Automated source tracking with a pinhole imaging system during high-dose-rate brachytherapy treatment. Watanabe Y1, Muraishi H1, Takei H, Hara H1, Terazaki T2, Shuto N2, Shimono T1, Nozawa M3, Ishiyama H3, Hayakawa K3, Gomi T1: Phys Med Biol 2018/7; 63 (14): 145002. (“n糗S‰î1, ‘şÎ@_1, Œ´@G„1, Ž›č„Žj2, Žń“Ąéş2, ‰ş–ě“N”Í1, –ěŕVääť‰Ô3, ÎŽR”ŽžŠ3, ‘ě˜ad3, ŒÜ–Ą@•×1: 1ˆă—ÉqśŠw•”, 2•úŽËü•”, 3•úŽËü (Žîá‡))

110202. [Œ´’˜] Attentional bias modification alters intrinsic functional network of attentional control: A randomized controlled trial. Hakamata Y, Mizukami S1, Komi S2, Sato E, Moriguchi Y, Motomura Y, Maruo K, Izawa S, Kim Y, Hanakawa T, Inoue Y3, Tagaya H1: J Affect Disord 2018/10; 238: 472-81. (…ăT–ç1, ŹŒŠł‘ž˜Y2, ˆäă—D‰î3, “cƒ–’J_–M1: 1ˆă—ÉqśŠw•”, 2•úŽËü•”, 3•úŽËü (‰ć‘œ))

110203. [Œ´’˜] Reliability of 3D arterial spin labeling MR perfusion measurements: The effects of imaging parameters, scanner model, and field strength. Tanaka Y1, Inoue Y2, Abe Y1, Miyatake H1, Hata H1: Clin Imaging 2018/11-12; 50: 23-7. (“c’†’ől1, ˆäă—D‰î2, ˆ˘•”@–L1, ‹{•”ä˜CŽ÷1, `@”Ž•ś1: 1•úŽËü•”, 2•úŽËü (‰ć‘œ))

[Šw‰ďEŒ¤‹†‰ď“™]

723949. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Cone Beam CT‚É‚¨‚Ż‚éăŽˆ‚ĚˆĘ’u‚ĆŽB‰eđŒ‚̉掿‚ɑ΂ˇ‚é‰e‹ż. ’Ë–ě@—D1, ˆäă—D‰î2, “Ąˆä@Š]2, Œ´@•qŤ2, í–Ř•Žm1, ‘ŠŕV@^1, _‹{ŽiŒö“ń1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć74‰ń“ú–{•úŽËü‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/4/12), ‰Ą•l, “ú–{•úŽËü‹ZpŠw‰ď‘ć75‰ń‘‰ďŠwp‘ĺ‰ď—\eW 2018; p.191.

723950. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‘SgPET/CT‚É‚¨‚Ż‚éˆŮ‚Ȃ鎊“Ž˜Io‹@\‚đ—p‚˘‚˝CTü—Ę•Ď’˛. ‰iŒ´˜aŒ›1, H“ĄŠ°Žq1, ˆÉ“ĄŠ°‘×1, ˆäă—D‰î2 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć74‰ń“ú–{•úŽËü‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/4/14), ‰Ą•l, “ú–{•úŽËü‹ZpŠw‰ď‘ć75‰ń‘‰ďŠwp‘ĺ‰ď—\eW 2018; p.349.

723951. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 3D cine Phese Contrast MRI‚É‚¨‚Ż‚éˆŮ‚Č‚ék‹óŠÔ[“U–@‚đ—p‚˘‚˝ƒiƒrƒQ[ƒ^ƒGƒR[–@‚Ě”äŠr. ŹŒŠł‘ž˜Y1, `@”Ž•ś1, ˆäă—D‰î2, ‘ĺŠÖ—T‰î1, “n糂 ‚ä‚Ý1, ŒĂ‰ę—_Žj1, ‚“Ą—D‹P1, ‹{•”ä˜CŽ÷1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć46‰ń“ú–{ŽĽ‹C‹¤–ˆăŠw‰ď‘ĺ‰ď (2018/9/7), ‹ŕ‘ň, “ú–{ŽĽ‹C‹¤–ˆăŠw‰ďŽGŽ 2018; 38 (Suppl): 254.

723952. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Gd-EOB-DTPA‘˘‰eMRI‚É‚¨‚Ż‚é‰ć‘œ•\ŽŚƒXƒP[ƒ‹‚ĚƒKƒ“ƒ}’l•âł‚É‚ć‚éƒRƒ“ƒgƒ‰ƒXƒg‹­’˛–@‚ĚŒŸ“˘. ’†“ˆ@—•1, ˆäă—D‰î2, `@”Ž•ś1, ź‰iŒh“ń2, ‘ĺŠÖ—T‰î1, ‹´–{“N–ç1, Œ´—ŻOŽ÷3 (1•úŽËü•”, 2•úŽËü (‰ć‘œ), 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć46‰ń“ú–{ŽĽ‹C‹¤–ˆăŠw‰ď‘ĺ‰ď (2018/9/7), ‹ŕ‘ň, “ú–{ŽĽ‹C‹¤–ˆăŠw‰ďŽGŽ 2018; 38 (Suppl): 314.

723953. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]ŒŒ‰tzŠÂ—Ę‚É‚ć‚éV‚˝‚Č‘ĚŠiŽw•W‚Ě“ą“ü‚É‚¨‚Ż‚é“Ş•”CTAđŒ‚ĚĹ“K‰ť. Œ@’C–ç1, Œ´@G„2, …ăT–ç2, ˛“Ą@˝1, ‰Žˆä—Y‰î1, ’†“ˆ@—•1, ”nę‹MŽm2 (1•úŽËü•”, 2ˆă—ÉqśŠw•”): ‘ć46‰ń“ú–{•úŽËü‹ZpŠw‰ďH‹GŠwp‘ĺ‰ď (2018/10/4), ĺ‘ä, “ú–{•úŽËü‹ZpŠw‰ďŽGŽ 2018; 74 (9): 972.

723954. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “Ş•”CTA‚É‚¨‚Ż‚éV‚˝‚Č‘ĚŠiŽw•W‚đ“ą“ü‚ľ‚˝“Ž–ŹáŽ‚¨‚ć‚Ń–•ÁŒŒŠÇ‚Ě•`o•]‰ż. ‰Žˆä—Y‰î1, Œ´@G„2, …ăT–ç2, Œ@’C–ç1, ˛“Ą@˝1, ”nę‹MŽm2, ’†“ˆ@—•1 (1•úŽËü•”, 2ˆă—ÉqśŠw•”): ‘ć46‰ń“ú–{•úŽËü‹ZpŠw‰ďH‹GŠwp‘ĺ‰ď (2018/10/4), ĺ‘ä, “ú–{•úŽËü‹ZpŠw‰ďŽGŽ 2018; 74 (9): 972.

723955. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĚŠ˛•”• ”w•űŒü‚ĚƒZƒbƒgƒAƒbƒv‚É‚¨‚Ż‚éCouch Height–@‚Ě—L—pŤ. ŽR–{˜ał1, Îă@–Ť1, Ž›č„Žj1, Žń“Ąéş1, ÎŽR”ŽžŠ2 (1•úŽËü•”, 2•úŽËü (Žîá‡)): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/13), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/10; p.312.

723956. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Gafcromic EBT3 film‚đ—p‚˘‚˝‚ü—Ęˆćü—Ę•Ş•zŒŸŘ‚ĚŽŔs‰Â”\Ť. –ě“c–Η˜1, ŽR–{˜ał1, Žń“Ąéş1, Ž›č„Žj1, “n粗S‰î2, Îă@–Ť1, ÎŽR”ŽžŠ3 (1•úŽËü•”, 2ˆă—ÉqśŠw•”, 3•úŽËü (Žîá‡)): “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď (2018/10/13), ‹ž“s, “ú–{•úŽËüŽîᇊw‰ď‘ć31‰ńŠwp‘ĺ‰ď•ń•śW 2018/10; p.411.

723957. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒgƒŒ[ƒTƒuƒ‹Na-22“_óü‚É‚ć‚éPET‘•’u‚̉ˇ“xˆË‘śŤ‚ĚŠm”F. ‹{•”ä˜CŽ÷1, ’ˇ’Jě’q”V2, ˆ˘•”@–L1, ‹e’r@Œh1, _‹{ŽiŒö“ń1, ˆäă—D‰î3 (1•úŽËü•”, 2ˆă—ÉqśŠw•”, 3•úŽËü (‰ć‘œ)): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď/‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/15), ‰Ť“ę, “ú–{ŠjˆăŠw‹ZpŠw‰ďŽ 2018; 38 (Suppl): 408.

723958. [Šw‰ď (‘S‘)] (Œű“Ş”­•\) ƒgƒŒ[ƒTƒuƒ‹“_óüŒš‚Ćƒtƒ@ƒ“ƒgƒ€‚đ‘g‚ݍ‡‚í‚š‚é’č—ʐŤ•]‰ż–@. ‰Ş–{”ü÷1, ’ˇ’Jě’q”V2, ‹{•”ä˜CŽ÷3, ‹e’r@Œh3, ˆäă—D‰î4, ‰äČ@Œd5, D“c@Œ\6, ˜a“cNO7 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3•úŽËü•”, 4•úŽËü (‰ć‘œ), 5Œ’N’ˇŽőˆă—ĂƒZƒ“ƒ^[Œ¤‹†Š, 6–kŠC“š‰ČŠw‘ĺŠw, 7—‰ťŠwŒ¤‹†ŠEś–˝‹@”\‰ČŠwŒ¤‹†ƒZƒ“ƒ^[): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď/‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/15), ‰Ť“ę, ŠjˆăŠw‹Zp 2018/10; 38 (Suppl): 411.

723959. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]SPECT‚É‚¨‚Ż‚錸Žă•âł‚ĚŠî‘b“IŒŸ“˘. ‚‹´Œc‘ž1, ˆäă—D‰î2, ‹{•”ä˜CŽ÷1, ˆ˘•”@–L1, _‹{ŽiŒö“ń1, ‹e’r@Œh1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď/‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/15), ‰Ť“ę, “ú–{ŠjˆăŠw‹ZpŠw‰ďŽ 2018; 38 (Suppl): 418.

723960. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) PET/CT‚É‚¨‚Ż‚éCT‚ĚŽB‰e”͈͂ޔí‚΂­ü—Ę‚É‹y‚Ú‚ˇ‰e‹ż‚ɂ‚˘‚Ä. H“ĄŠ°Žq1, ˆäă—D‰î2, ‰iŒ´˜aŒ›1, ˆÉ“ĄŠ°‘×1, ‹e’r@Œh1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď/‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/15), ‰Ť“ę, “ú–{ŠjˆăŠw‹ZpŠw‰ďŽ 2018; 38 (Suppl): 466.

723961. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 123I-IMP”]ŒŒ—ŹSPECT’´‘Šú‘œ‚̍č\Ź•ű–@‚ÉŠÖ‚ˇ‚錟“˘. ‚‹´Œc‘ž1, ˆäă—D‰î2, ‹{•”ä˜CŽ÷1, ˆ˘•”@–L1, _‹{ŽiŒö“ń1, ‹e’r@Œh1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): ‘ć58‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď/‘ć38‰ń“ú–{ŠjˆăŠw‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2018/11/15), ‰Ť“ę, “ú–{ŠjˆăŠw‹ZpŠw‰ďŽ 2018; 38 (Suppl): 468.

733320. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) 3T‘•’u‚É‚¨‚Ż‚éƒ`ƒ‹ƒg‹@”\Žg—pŽž‚ĚŠgŽU‹­’˛‰ć‘œ‚Ě˜c‚Ý‚É—^‚Ś‚é‰e‹ż‚ɂ‚˘‚Ä. ‘ĺŠÖ—T‰î1, `@”Ž•ś1, ’†“ˆ@—•1, ŹŒŠł‘ž˜Y1, ‹{•”ä˜CŽ÷1 (1•úŽËü•”): Œö‰vŽĐ’c–@l “ú–{•úŽËü‹ZpŠw‰ď ŠÖ“ŒE“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018 (2018/12/15), é‹Ę, ŠÖ“ŒĽ“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018´˜^W 2018; p.75.

733321. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆę”ĘŽB‰eƒGƒŠƒA‚É‚¨‚Ż‚éŽčŽw‰qśŠˆ“Ž„i‚É‚ć‚é‰@“ੴő‘΍ô‚ĚŽć‚č‘g‚Ý. “n糓šŽq1, “că‘”ü1, —é–Řˆ¤Žq1, ‹e’r@Œh1 (1•úŽËü•”): Œö‰vŽĐ’c–@l “ú–{•úŽËü‹ZpŠw‰ď ŠÖ“ŒE“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018 (2018/12/15), é‹Ę, ŠÖ“ŒĽ“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018´˜^W 2017/11; p.85.

733322. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) đŒ•t‚ŤMRI‘Ήž“dŽqƒfƒoƒCƒX‚ĚMRIŒŸ¸‚ɂ‚˘‚Ä. `@”Ž•ś (•úŽËü•”): Œö‰vŽĐ’c–@l “ú–{•úŽËü‹ZpŠw‰ď ŠÖ“ŒE“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018 (2018/12/16), é‹Ę, ŠÖ“ŒĽ“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018´˜^W 2017/11; p.65.

733323. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ’´’áŽü”g‹­’˛ˆ—‚đ—p‚˘‚˝“üŽË•\–ʐü—Ę’áŒ¸‚ĚŒŸ“˘. œAŁ’B–ç1, ŽR›˝‰ëŽj1, ŠÖ@ŤŽu1 (1•úŽËü•”): Œö‰vŽĐ’c–@l “ú–{•úŽËü‹ZpŠw‰ď ŠÖ“ŒE“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018 (2018/12/16), é‹Ę, ŠÖ“ŒĽ“Œ‹žŽx•”‡“ŻŒ¤‹†”­•\‘ĺ‰ď2018´˜^W 2017/11; p.101.


–ňÜ•”

[Šwp˜_•ś]

120043. [Œ´’˜] ƒ^ƒyƒ“ƒ^ƒh[ƒ‹‚ĚŽg—pŒoŒą|ƒ^ƒyƒ“ƒ^ƒh[ƒ‹‚Ö‚ĚƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚É‚ć‚éŒř‰Ę‚¨‚ć‚Ń—LŠQ”˝‰ž‚ĚŒŸ“˘|. –{ŠÔ‰ëŽm1, ‘•ŞG–ç2, —с@Œol3, ‹ŕˆäş•ś4, Œú“cKˆę˜Y1,5 (1–ňÜ•”, 2“Œ‹ž–ň‰Č‘ĺŠw, 3–ƒŒ, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5–ňŠw•”): Šŕ‚ƉťŠw—Ă–@ 2018/7; 45 (7): 1081-6.

522214. [uŔ]y˜AÚ: “œ”A•a–ň‚Ćˆę‚ÉŽg‚í‚ę‚é–ň‚ĚƒLƒzƒ“z…’Ž (‘Ť”’á) ‚Ě–ň|–ňÜŽt‚ĚŽ‹“_‚Š‚ç. Ÿ˜C”ü1, Œú“cKˆę˜Y1 (1–ňÜ•”): DxM 2018/5; 20: 8-9.

522215. [uŔ]y“ÁW: ‚˘‚ÜŒŠ’ź‚ľ‚Ä‚¨‚Ť‚˝‚˘! pŒăƒCƒxƒ“ƒg‚Ě–ňŠw“IŠÇ—ŽŔ‘Hƒ|ƒCƒ“ƒgzŒŒđ ([•”Ă–ŹŒŒđÇ, ”xŒŒđÇđÇ, Ă–ŹŒŒđÇđÇ). •yŕV@~1 (1–ňÜ•”): ŒŽŠ§–ňŽ– 2018/7; 60 (9): 1609-14.

522216. [uŔ]y˜AÚ: “œ”A•a–ň‚Ćˆę‚ÉŽg‚í‚ę‚é–ň‚ĚƒLƒzƒ“z_ŒoˆöŤäNă÷‚Ě–ň|–ňÜŽt‚ĚŽ‹“_‚Š‚ç. Ÿ˜C”ü1, Œú“cKˆę˜Y1 (1–ňÜ•”): DxM 2018/8; 21: 8-9.

522217. [uŔ]y˜AÚ: –ňÜŽt‚É‚ć‚鏈•űÝŒv <68>z‚Ş‚ń‰ťŠw—Ă–@‚É‚¨‚Ż‚éƒvƒƒgƒRƒ‹‚ÉŠî‚Ă‚­–ň•¨ŽĄ—ĂŠÇ—. ˆî–ě@Š°1 (1–ňÜ•”): ˆă–ňƒWƒƒ[ƒiƒ‹ 2018/10; 54 (10): 155-62.

522218. [uŔ]y˜AÚ: “œ”A•a–ň‚Ćˆę‚ÉŽg‚í‚ę‚é–ň‚ĚƒLƒzƒ“zŽ‰ŽżˆŮíÇ‚Ě–ň|–ňÜŽt‚ĚŽ‹“_‚Š‚ç. Ÿ˜C”ü1, Œú“cKˆę˜Y1 (1–ňÜ•”): DxM 2018/12; 22: 8-9.

540048. [‚ť‚Ě‘ź] “ú–{•a‰@–ňÜŽt‰ďVlŒ¤C‚đŽóu‚ľ‚Ä. “Ą–ě‰i从q (–ňÜ•”): “ú–{•a‰@–ňÜŽt‰ďŽGŽ 2018/9; 54 (9): 1139-40.

540049. [‚ť‚Ě‘ź (•ń)] —DG˜_•śÜ (‘ĺ“ú–{Z—Fť–ňÜ) ‚đŽóÜ‚ľ‚Ä uLinezolid‚ĚŒŒ’†”Z“xŠÇ—‚ÉŠÖ‚ˇ‚é•śŒŁŒŸő‚đ’Ę‚ľ‚āv. Źź•q˛1,2 (1–ňÜ•”, 2Š´őŠÇ—Žş): TDMŒ¤‹† 2018; 35 (3): 85-8.

540050. [‚ť‚Ě‘ź (Œ¤‹†•ń)]ŠOŠłŽŇ‚É‚¨‚Ż‚éĂ–ŹŒŒđÇđÇ—\–h“IR‹ĂŒĹ–ň‚Ě“KłŽg—p‚ÉŠÖ‚ˇ‚é‘˝EŽí˜AŒg‚Ĺ‚ĚŽć‚č‘g‚Ý. •yŕV@~1, ŠŰ‹´Fş2, •ž•”@2, Ž›ź—m”ü1, _@ˆę–˛1, Ź—яšG1, ‹ß“Ą—Ż”üŽq1, •Đ‰Ş—Sˆę2, ó—˜@–ő2, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2‹~–˝, 3–ňŠw•”): “ú–{—Տ°‹~‹}ˆăŠw‰ďŽ 2019/2; 22 (1): 20-6.

[’˜@‘]

620244. [Šwp‘(•Ş’SŽˇ•M]yƒT[ƒtƒ‰ƒCƒtƒZ[ƒrƒ“ƒO‹ł–{zƒAƒ“ƒ`ƒh[ƒsƒ“ƒO, p.11. rˆäG˜a1, ÎěmŒ›2, ˆîŠ_—T”ü1, ă–ě^G3, ‰““Ą‘ĺĆ4, ’b–č—L“o5, ‰Á“Ą“š•v6, ‹e’r@‘ž4, Źź—R‹I4,7, ’†’ËŒ’‘ž˜Y8, ’†ŒŠ—˛’j4,9, [ŽRŒł—Ç10 (1—Ź’ĘŒoĎ‘ĺŠwƒXƒ|[ƒcŒ’N‰ČŠw•”, 2‹ZpŽm, 3“ú–{ƒ‰ƒCƒtƒZ[ƒrƒ“ƒO‹Ś‰ď, 4NPO–@lƒoƒfƒB–`ŒŻ’c, 5ŠÝ˜a“c“żB‰ď•a‰@‹~–˝‹~‹}ƒZƒ“ƒ^[, 6(Š”) ƒT[ƒtƒŒƒWƒFƒ“ƒh, 7–ňÜ•”, 8“ż“‡‘ĺŠw‘ĺŠw‰@ŽŇŽĐ‰ďŽY‹Ć—HŠwŒ¤‹†•”, 9JLAƒ‰ƒCƒt, 10éź‘Ű‘ĺŠwŒo‰cî•ńŠw•”), •Ň: “ú–{ƒ‰ƒCƒtƒZ[ƒrƒ“ƒO‹Ś‰ď, ‘ĺCŠŮ‘“X, “Œ‹ž, 2018/4”­s.

620245. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č–ň•¨—Ă–@ƒ}ƒjƒ…ƒAƒ‹z‘ć3Í Œü¸_–ň‚ĚŠî‘b–ň—@3. R‚¤‚–ň, p.P169-86. ’Ł@@’ (–ňÜ•”), ŠÄC: ˆę”ĘŽĐ’c–@l “ú–{•a‰@–ňÜŽt‰ď, •Ň: ˆę”ĘŽĐ’c–@l “ú–{•a‰@–ňÜŽt‰ď ¸_‰Čę–ĺ–ňÜŽtŽŽŒąˆĎˆő‰ď, “ěŽR“°, “Œ‹ž, 2018/7”­s.

620246. [Šwp‘ (•Ş’SŽˇ•M)]y•a‹C‚Ć–ň•¨—Ă–@@ “ŕ•Ş”厞Šł^‘ăŽÓŽžŠłzĄ‘ăŽÓŽžŠł •Ň@Chapter1 “œ”A•a, p.78-111. ˆî–ě@Š°1 (1–ňÜ•”), ŠÄC: Œú“cKˆę˜Y1,2 (2–ňŠw•”), •Ň: Œú“cKˆę˜Y1,2 ‘O“c’čH, źŒ´@”Ł2, ƒI[ƒ€ŽĐ, “Œ‹ž, 2018/9”­s.

620247. [Šwp‘ (•Ş’SŽˇ•M)]y|‚í‚Š‚č‚₡‚˘–ňÜî•ń’ń‹Ÿ‚Ě‚˝‚߂́|ŽĘ^•t/•ž–ňŽw“ą CD-ROM (2018”N9ŒŽ”Ĺ)zŒú“c Kˆę˜Y1 (1–ňÜ•”), •Ň: ŠłŽŇŒü‚Żˆă–ň•iî•ńCD‰ť•ŇWˆĎˆő‰ď, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620248. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…Dƒp[ƒLƒ“ƒ\ƒ“•aŽĄ—Ă–ň, p.48-57. •˝ŽR•Ži1, ‚‹´”ü—R‹I2, •ŽR­ˆę3 (1–ňÜ•”, 2Œł“Œ•a‰@–ňÜ•”, 3“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę3, •ŇW‹Ś—Í: ě–ěçq3, Žć—S‰î3, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620249. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒzŒoŒű–ň‚đ—p‚˘‚銳ŽŇ‚Ö‚ĚŽw“ą, p.132-3. ˛X–ŘŽőŽq1 (1–ňÜ•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK3 (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3˜aňŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018”N/10”­s.

620250. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒě@‚ˇ‚Ž‚ÉŠw‚Ń‚˝‚˘ƒPƒA‚ĚƒAƒŒƒRƒŒz2u‚Ş‚ń–ň•¨—Ă–@‚ĚŠĹŒěvƒRƒR‚Ş•Ş‚Š‚é‚Ć, ƒXƒLƒ‹‚Şă‚Ş‚é@…CDose Intensity‚Ě•ŰŽ‚ĆŒ¸—ĘŠî€, p.22-3. ›Œ´[L1 (1–ňÜ•”), ŠÄC: ˛X–ŘŽĄˆę˜Y2, ‰v“c“TK3 (2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3˜aňŽs—§‘‡ˆă—ĂƒZƒ“ƒ^[), ƒ”ƒ@ƒ“ƒƒfƒBƒJƒ‹, “Œ‹ž, 2018”N/10”­s.

620251. [Šwp‘ (•Ş’SŽˇ•M)]y–ň•¨—Ă–@–â‘čW ƒRƒ‚ƒ“‚Č50ŽžŠłE150‘č‚ĹŽŔ—͂ނ‚­! (ŒŽŠ§–ňŽ–2018”N10ŒŽ—ŐŽž‘Š§†)z16. ƒp[ƒLƒ“ƒ\ƒ“•a, p.96-9. ’Ł@@’1 (1–ňÜ•”), •ŇW‘ă•\: Źě—łˆę, •Ň: ‘ĺ–ě”\”V, ’Ł@@’1, ’ҁ@‘ĺŽ÷, ‰Ôˆä—Y‹M, •y‰Ćr–í, –xˆä„Žj2, ‘O“cŠ˛L, ŒŠ–ě–őW, ‹{–{NŒh (2–ňŠw•”), ‚ś‚Ů‚¤, “Œ‹ž, 2018/10”­s.

620252. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń‰ťŠw—Ă–@‚ĚƒŒƒWƒƒ“44@‚â‚ł‚ľ‚­‚܂ȂׂéBOOK|ŽĄ—Ă‚ŕŽdŽ–‚ŕƒTƒ|[ƒg‚ľ‚Ü‚ˇ! ‚܂邲‚Ć•›ě—pƒPƒA (YORi-SOU‚Ş‚ńƒi[ƒVƒ“ƒO2018”N‘Š§)zBld—Ă–@, Dld—Ă–@, p.180-2. ŒËŞ“Ţ’ĂŽq1 (1–ňÜ•”), ŠÄC: ‰ŞŒł‚é‚ÝŽq, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2018”N/12”­s.

620253. [Šwp‘ (•Ş’SŽˇ•M)]yŽüpŠú‚Ě–ňŠwŠÇ—@‰ü’ů2”ŁzŠ´őŠÇ—`R‹Ű–ň, p.92-109. mini lecture ’źÚ“Ž–Źˆł‘Ş’č–@‚ĆƒwƒpƒŠƒ“‰Áś—H‰–‰t, p.138. ‚Í‚ś‚ß‚Ä‚ĚŽčpŽş (ŽčpŽş‚̊‹Ť, ŽčpŽş‚Ĺ“­‚­ˆă—ĂƒXƒ^ƒbƒt, Žčp\‚ľž‚Ý‚Š‚ç‘ŢŽş‚Ü‚Ĺ‚Ě—Ź‚ę), p.168-73. mini lecture ŒŒŠÇ•Ť‡Žž‚ĚƒpƒpƒxƒŠƒ“‚ĆƒIƒ‹ƒvƒŠƒmƒ“‚Ě‹ÇŠŽg—p, p.186. pŽŽ‚˛‚Ć‚ĚŠm”FŽ–€ (”]ŽîᇓEop, Œo•@“I‰ş‚‘ĚŽîᇓEop, ŠĽ“Ž–ŹƒoƒCƒpƒXˆÚAp, p.188-97. ‹Ř’oŠÉ–ň”äŠr•\, p.260-6. ŽčpŽşÁ“Ĺ–ňˆę——, p.273. •yŕV@~1 (1–ňÜ•”), ŠÄC: ˆę”ĘŽĐ’c–@l “ú–{•a‰@–ňÜŽt‰ď, “ěŽR“°, “Œ‹ž, 2018/12”­s.

620254. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—ĂĺZƒnƒ“ƒhƒuƒbƒN2019z“œ”A•aŽĄ—Ă–ň, p.657-86. Ž‰ŽżˆŮíŽĄ—Ă–ň, p.695-706. ‚”AŽ_ŒŒÇ, ’É•—ŽĄ—Ă–ň, p.712-5. Œú“c Kˆę˜Y1 (1–ňÜ•”), ŠÄC: ‚‹vŽj–›, •Ň: –x@ł“ń, ›–ěŒ’‘ž˜Y, –ĺ˜e@F, ŠŁ@ŒŤˆę, —с@š—m, ‚ś‚Ů‚¤, “Œ‹ž, 2019/1”­s.

620255. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2019@–ňÜ‘I‘đ‚Əˆ•ű‚Ěƒ|ƒCƒ“ƒgz“ŻŒř–ň”äŠr•\, p.24-6. p.59. p.85. p.110. p.143. p.160. p.199. p.321. p.374-7. p.464-5. p.488. p.533-4. p.632. p.656. p.694. p.775. p.810. p.825. p.931-2. p.1137. p.1152. p.1185-6. p.1237. p.1291. •˝ŽR•Ži1, ”ň“c—[‹I2, ě–ěçq2, •ŽR­ˆę2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), ŠÄC: ‚‹vŽj–›, •Ň: –xł@“ń, ›–ěŒ’‘ž˜Y, –ĺ˜e@F, ŠŁ@ŒŤˆę, —с@š—m, ‚ś‚Ů‚¤, “Œ‹ž, 2019/1”­s.

620256. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj2019”N”Ł@Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚éz•ž–ňŽw“ą, p.723-4. •ž–ňŽw“ą, p.728-9. Œú“c Kˆę˜Y1 (1–ňÜ•”), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2019/1”­s.

620257. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz7. ƒCƒ“ƒXƒŠƒ“ťÜ, p.113`132. •˝ŽR•Ži1, ’ߐě•S‡2 (1–ňÜ•”, 2Œł“ú–{ˆă‰Č‘ĺŠw•‘Ž•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę3 (3“Œ•a‰@–ňÜ•”), ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620258. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz8. œ‘e頏ǎĄ—Ă–ň (ŒoŒűƒrƒXƒzƒXƒzƒl[ƒgťÜ), p.133-48. ‘O“cŽŔ‰Ô1, •ŽR­ˆę2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620259. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz11. ƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłŽĄ—Ă–ň (“_Šá–ň), p.183-92. •˝ŽR•Ži1, ŹŒ´”ü]2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620260. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz14. —ΓŕáŽĄ—Ă–ň (“_Šá–ň), p.235-48. •˝ŽR•Ži1, ŹŒ´”ü]2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620261. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz16. RCŒ^ŠĚ‰ŠƒEƒCƒ‹ƒX–ň, p.265-84. ‘ž“c’q”Ž1, •˝ŽR•Ži1 (1–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2 (2“Œ•a‰@–ňÜ•”), ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713172. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) The impact of implementing a medication algorithm for drug-na?ve patients with type 2 diabetes mellitus in an academic teaching hospital in Japan. Iwasawa M1, Suzuki A1, Hayashi T2, Atsuta K1,3: ASHP Midyear Clinical Meeting 2018 (2018/12/4), Anaheim, CA, USA, ASHPƒ~ƒbƒhƒCƒ„[ƒ~[ƒeƒBƒ“ƒO2018”N—vŽ| 2018/12; online. (ŠâŕV^‹IŽq1, —é–ŘˆťŠG1, —с@“N”Í2, Œú“cKˆę˜Y1,3: 1–ňŠw•”, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3–ňÜ•”)

723962. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒIƒsƒIƒCƒh—U”­Ť•Ö”éÇŽĄ—Ă–ňƒiƒ‹ƒfƒƒWƒ“‚Ě—LŒřŤ‚ÉŠÖ‚ˇ‚錤‹†. •“š—Á•˝1, –{ŠÔ‰ëŽm1, ‘ž“c’q”Ž1, •˝’ËŒöŒČ1, •˝ŽR•Ži1,2, —с@Œol3, ‹ŕˆäş•ś4, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3–ƒŒ‰ČŠw, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć12‰ń“ú–{ŠÉ˜aˆă—Ă–ňŠw‰ď”N‰ď (2018/5/26), “Œ‹ž, ‘ć12‰ń“ú–{ŠÉ˜aˆă—Ă–ňŠw‰ď”N‰ďƒvƒƒOƒ‰ƒ€W 2018/5; p.53.

723963. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eˆő’čŠúŒ’Nf’f‚ĚŒŒ‰tŒŸ¸ƒf[ƒ^‚Š‚ç“ž‚ç‚ę‚˝—Տ°‰h—{Šw“I‰đŽß‚̐EˆőŒ’NŠÇ—‚ւ̉ž—p. ‹ß“Ą—Ż”üŽq1, Žç‰Ž’B”ü2, “y•M’qť3, Žç‰Ž—˘š4, Œú“cKˆę˜Y1 (1–ňÜ•”, 2Œ’NŠÇ—ƒZ, 3—ŐŒŸ•”, 4‰h—{•”): ‘ć18‰ń“ú–{R‰Á—îˆăŠw‰ď‘‰ď (2018/5/25-27), ‘ĺă, “ú–{R‰Á—îˆăŠw‰ď‘‰ďƒvƒƒOƒ‰ƒ€ 2018/5; p.225.

723964. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š”­Ç—\–h‚ɑ΂ˇ‚éƒAƒgƒoƒRƒ“‚ĚŒă•űŽ‹“IŒŸ“˘. ŁŒË—Ç‹ł1, Ź—яšG1,2, â‘q’qŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć66‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď (2018/5/31), ‰ŞŽR, ‘ć66‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď“ÁW† 2018/4; 66 (Suppl A): 222.

723965. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) H“šŠŕ‚đ‘ÎŰ‚Ć‚ľ‚˝DTX + CDDP + 5FU—Ă–@‚É‚¨‚Ż‚éƒGƒŒƒ“ƒ^[ƒ‹”z‡“ŕ—pÜ‚Ě—LŠQŽ–ŰŒyŒ¸Œř‰Ę‚ÉŠÖ‚ˇ‚郉ƒ“ƒ_ƒ€‰ť”äŠrŽŽŒą. ›Œ´[L1, Œ˜“ce—˜2, ‚‹´‚Š‚¨‚é3, ‚‹´ˆŸ‹IŽq3, [‘ň˛ŒbŽq4, â–{‘×—5, Źň˜aŽO˜Y2, Œú“cKˆę˜Y1,6 (1–ňÜ•”, 2Á‰ťŠí“ŕ, 3ŠĹŒě•”, 4‰h—{•”, 5—Տ°Œ¤‹†EŠé‰ć, 6–ňŠw•”): ‘ć16‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2018/7/19), _ŒË, ‘ć16‰ń“ú–{—Տ°Žîᇊw‰ď—vŽ| 2018; p.141.

723966. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ˆÝ‚Ş‚ńŠłŽŇ‚ɑ΂ˇ‚郉ƒ€ƒVƒ‹ƒ}ƒu’PÜ—Ă–@‚ĆƒpƒNƒŠƒ^ƒLƒZƒ‹•š—p—Ă–@‚É‚¨‚Ż‚é’`”’”A”­Œť—Ś‚Ě”äŠr. ‹{â—Dl1, ŹŒ`D1, ™‰Y•‡—uŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć12‰ń“ú–{t‘Ÿ•a–ň•¨—Ă–@Šw‰ďŠwpW‰ďE‘‰ď2018 (2018/10/20), •lź.

723967. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) [•”Ă–ŹŒŒđÇ—\–h‚Ě‚˝‚ß‚Ě‘ĺ‘ڐÖŹŒŒ—Ź‚ɑ΂ˇ‚é‘ŤŠÖßŽŠ“Ž‰^“Ž’†‚ĚŠÔŸ[“I‹ó‹Cˆł”—‚ĚŒř‰Ę. âˆäŒ’‘ž1, ‚•˝ŽL2, ’Ă“cWŽi1, Ô—䑏•F3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3–ňÜ•”): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/26), –źŒĂ‰Ž, ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ď—vŽ| 2018; p.490.

723968. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) [•”Ă–ŹŒŒđÇ—\–h‚ɑ΂ˇ‚é‘ŤŠÖß‰^“Ž‚ɘA“Ž‚ľ‚ĉş‘Ú‚đ‹ó‹Cˆł”—‚ˇ‚é‘•’u‚ĚŠJ”­‚ƉşŽˆ[•”Ă–ŹŒŒ—Ź‚É‹y‚Ú‚ˇ‰e‹ż. âˆäŒ’‘ž1, ‚•˝ŽL2, ’Ă“cWŽi1, Ô—䑏•F3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3–ňÜ•”): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/27), –źŒĂ‰Ž, ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ď—vŽ| 2018; p.491.

723969. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) lHŒŇŠÖß’uŠˇp‚É‚¨‚Ż‚éƒZƒtƒ@ƒ]ƒŠƒ“‚ĚŒŒ’†”Z“x‚Ć‹Ř–Œ‚Ě‘gD”Z“x‚Ć‚ĚŠÖŒWŤ?•”ˆĘ“ÁˆŮ“IPK-PD‰đÍ‚đ“Ľ‚Ü‚Ś‚ā`. Źź•q˛1,2, ‰Ä–Ú—Sˆß3, â”Vă˜aŽŔ3, ě‘ş[Žj3, —F“c‹g‘Ľ3, ’r“cM‰î4, “ŕŽRŸ•ś4, ‚ŽR—zŽq1,5, Œú“cKˆę˜Y2,3 (1Š´őŠÇ—Žş, 2–ňÜ•”, 3–ňŠw•”, 4ŽŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/23), _ŒË.

723970. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) äNă÷ŠŕGN—Ă–@‚É‚¨‚Ż‚ét‹@”\•ĘNedaplatin“Š—^—Ę‚ĚŒŸ“˘. ŽR–{—IŽ÷1, ˆî–ě@Š°1, •ÄŽR‘ĺŽu1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/24), _ŒË.

723971. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‚Ş‚ń‰ťŠw—Ă–@ŠłŽŇ‚̐§“fŽĄ—Ă‚É‚¨‚Ż‚é”ń’čŒ^R¸_•a–ň (ƒIƒ‰ƒ“ƒUƒsƒ“) ‚ĚŽg—pŽŔ‘Ô‚ÉŠÖ‚ˇ‚é’˛¸. â‘q’qŽq1, ŠâŕV^‹IŽq2, –öŕV—D—˘2, ŁŒË—Ç‹ł1, ’Ł@@’1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/24), _ŒË.

723972. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]‘š‚ވŸ‰”‚Ě‘Ě“ŕ“Ž‘Ô‚É‹y‚Ú‚ˇ‰e‹ż. •yŕV@~1, •Đ‰Ş—Sˆę2, ‹ß“Ą—Ż”üŽq1, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2‹~–˝, 3–ňŠw•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/24), _ŒË.

723973. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŹŽ™W’†ŽĄ—ĂŽş‚É‚¨‚Ż‚钍ŽË–ň‚Ě“KłŽg—p‚ÉŠÖ‚ˇ‚éŽć‚č‘g‚Ý. Ź–쎛‚Ý‚ł‚Ť1, Źě—˛O1, ‰Ô“‡—ćŽq1, –{ŠÔ‰ëŽm1, Ź—яšG1,2, â‘q’qŽq1, ‹ß“Ą—Ż”üŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/24), _ŒË.

723974. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Šż•ű–ň’†‚̐ś–ňŹ•Ş‚ÉŠÖ‚ˇ‚錤‹† (11) |‘ĺŒš’†“’‚Ě“œ—Ţ‚Ě’č—Ę‚ĆKK-Ayƒ}ƒEƒX‚ĚŒŒ“œ’l‚ւ̉e‹ż‚ɂ‚˘‚ā|. ’Ł@@’1,2, •Ä‘q–GÎ1, ź”ö˜ĐŠóŽq1, •“c–ž•˝1, ˆî—t“ń˜N1, ŽOŠŞË_1 (1“Œ‹ž–ň‰Č‘ĺŠw–ňŠw•”, 2–ňÜ•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/25), _ŒË, ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ďŠw‰ď—vŽ|W 2018; p.169.

723975. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “dŽqƒJƒ‹ƒeƒVƒXƒeƒ€‚É‚¨‚Ż‚é–ňÜƒAƒŒƒ‹ƒM[“o˜^‚ĚŽŔ‘Ô’˛¸. ŁŒË—Ç‹ł1, â‘q’qŽq1, ›Œ´[L1, ‹ß“Ą—Ż”üŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/25), _ŒË.

723976. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •Ą”‚Ěˆă—Ăƒ`[ƒ€‚Ĺ‹Ś“­ŠÇ—‚ľ‚˝HIVŠ´őŽŇ‚̐tˆÚA. ˆî–ě@Š°1, Ź—яšG1,2, ‹{â—Dl1, ŽR–{—IŽ÷1, •“š—Á•˝1, ˜a“c’B•F3, Îˆä‘ĺ•ă4, ‹g“cˆęŹ4,5, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3äPŒ´•aĽŠ´ő“ŕ, 4”ĺ”AŠí, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/14), ‘ĺă, ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2019/1; p.48.

723977. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‹~–˝‹~‹}ƒZƒ“ƒ^[‰h—{ŠÇ—‚Ŕɗp‚ł‚ę‚éˆă–ň•i‚̍Ź‡‚É‚ć‚éŒo’°‰h—{Ü‚̐Ťó•Ď‰ť‚ÉŠÖ‚ˇ‚錟“˘. •˝ˆä”ü”T—˘1, _@ˆę–˛1, Œ´“c”ü1, •Đ‰Ş—Sˆę2, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2‹~–˝, 3–ňŠw•”): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/14), “Œ‹ž.

723978. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒGƒmƒLƒTƒpƒŠƒ““Š—^ŠłŽŇ‚É‚¨‚Ż‚éĂ–ŹŒŒđÇđÇ—\–hŽŔŽ{•[‚đ—p‚˘‚˝ŒŒđ”­śƒŠƒXƒNƒXƒRƒA‚ĚƒJƒbƒgƒIƒt’l‚ĚŽZo. Ô—䑏•F1, ‚•˝ŽL2, •yŕV@~1, ÎŽR—I4, ’Ă“cWŽi3, âˆäŒ’‘ž3, ‚‹´‰Ŕô3, •Šâ­”V5, Œú“cKˆę˜Y1,4 (1–ňÜ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4–ňŠw•”, 5–ƒŒ): “ú–{–ňŠw‰ď‘ć139”N‰ď (2019/3/21), –‹’Ł, “ú–{–ňŠw‰ď‘ć139”N‰ď—vŽ| (DVD).

723979. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒIƒLƒVƒRƒhƒ“™•úů‚Š‚çƒtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚Ö‚ĚƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚É‚ć‚é•Ö”éŒyŒ¸Œř‰Ę‚ÉŠÖ‚ˇ‚錟“˘. ‘ž“c’q”Ž1, •˝ŽR•Ži1,2, ŽRč‚ŕ‚ŕ2, –{ŠÔ‰ëŽm1, •˝’ËŒöŒČ1, •“š—Á•˝1, —с@Œol3, ‹ŕˆäş•ś3,4, Œú“cKˆę˜Y11,2 (1–ňÜ•”, 2–ňŠw•”, 3–ƒŒ, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2019 (2019/3/23), ŽD–y, “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2019u‰‰—vŽ|W 2019/3; p.184.

723980. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) H“šŠŕ‰ťŠw—Ă–@Ž{sÇ—á‚É‚¨‚Ż‚é‚Ş‚ń‰ťŠw—Ă–@—U”­ŤˆŤS‚¨‚ć‚Ńšq“f‚Ě”­Œť‚ÉŠÖ‚ˇ‚郊ƒXƒNˆöŽq‰đÍ. –Ń—˜‡ˆę1,2, Œ˜“ce—˜3, –ԁ@‹ĹŽj1, ’†ŽR–G”ü1,2, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”, 3Á‰ťŠí“ŕ): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2019 (2019/3/23), ŽD–y, “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2019u‰‰—vŽ|W 2019/3; p.191.

733324. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –k—˘‘ĺŠw‚É‚¨‚Ż‚é–ňÜŽtŠCŠOŒ¤C. Ô—䑏•F1, ‹{XˆŸ‹IŽq2, ŽR–{—IŽ÷1, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3–ňŠw•”): ‘ć71‰ńˆă—Ă–ňŠwŒöŠJƒVƒ“ƒ|ƒWƒEƒ€ (2018/10/27), ‘Š–ÍŒ´.

733325. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) _“ŢěŒ§•a‰@–ňÜŽt‰ď‹Ć–ą’˛¸ƒAƒ“ƒP[ƒg‚ĚŒ‹‰Ę•ń`ƒ|ƒŠƒtƒ@[ƒ}ƒV[‚Ö‚ĚŠÖ‚í‚č‚ĆŽŽQ–ň‚ĚŽg—pó‹ľ‚ɂ‚˘‚ā`. ˛X–ŘŽőŽq1,2, ”ZŔ­”ü3, ˆî—tŒ’“ń˜Y1, ”Ń“cƒˆę1, ˆ°’Ë‘ń–ç1, ‘ë–{@~1, ‰ÍŒ´‰pŽq1, ]“‡T‘ž˜Y1, Ź‹ř‹ť•˝1, ”č—F‹I]1, ”’’šç•ä1, ŒĂě‘ĺ•ă1, “n粔ü’q—Ż1, ›–ě@_1, ‹ŕ“cŒőł1, ˛“Ą@“§1 (1Œö‰vŽĐ’c–@l _“ŢěŒ§•a‰@–ňÜŽt‰ď ‹Ć–ąŒŸ“˘ˆĎˆő‰ď, 2–ňÜ•”, 3’é‹ž•˝Ź‘ĺŠw–ňŠw•”): ‘ć17‰ń‚Š‚Č‚Ş‚í–ňÜŽtŠwp‘ĺ‰ď (2019/1/20), ‰Ą•l.


ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”

[Šwp˜_•ś]

110204. [Œ´’˜] SARC-F questionnaire identifies physical limitations and predicts post discharge outcomes in elderly patients with cardiovascular disease. Tanaka S1, Kamiya K2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Icinosawa Y1, Harada M1, Nakamura T1, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Masuda T2, Ako J4: JCSM Clinical Reports 2018/4; 3 (1): 1-11. (“c’†L–í1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, ź‘ň—Ç‘ž3, –ěčN•˝3, Žs–ě‘ň—R‘ž1, Œ´“cˆ¤‰i1, ’†‘şŠxŽj1, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ‘“c@‘ě2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110205. [Œ´’˜] Asymptomatic peripheral artery disease and mortality in patients on hemodialysis. Harada M1, Matsuzawa R2, Aoyama N3, Uemura K, Horiguchi Y, Yoneyama J, Hoshi K4, Yoneki K, Watanabe T1, Shimoda T1, Takeuchi Y5, Naito S5, Yoshida A, Matsunaga A6: Renal Replacement Therapy 2018/4; 17. https://rrtjournal.biomedcentral.
com/articles/10.1186/s41100-018-0159-6. (Œ´“cˆ¤‰i1, ź‘ň—Ç‘ž2, ÂŽR’ź‘P3, Ż@‰Ŕ–F4, “n粍F–ž1, ‰ş“c—˛‘ž1, ’|“ŕN—Y5, “ŕ“Ął‹g5, ź‰i“Ä•F6: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3‘‡f—Ă, 4‰qś, 5t‘Ÿ“ŕ, 6ˆă—ÉqśŠw•”)

110206. [Œ´’˜] Excessive SBP elevation during moderate exercise discriminates patients at high risk of developing left ventricular hypertrophy from hypertensive patients. Tanaka S1, Masuda T2, Kamada Y, Hamazaki N3, Kamiya K2, Ogura MN2, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Ako J4: J Hypertens 2018/6; 36 (6): 1291-8. (“c’†L–í1, ‘“c@‘ě2, ŕ_čL–ž3, _’JŒ’‘ž˜Y2, Ź‘q@Ę2, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110207. [Œ´’˜] Prognostic usefulness of arm circumference and nutritional screening tools in older patients with cardiovascular disease. Nakamura T1, Kamiya K2, Matsunaga A2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Tanaka S1, Yamashita M1, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Masuda T2, Ako J4: Nutr Metab Cardiovasc Dis 2018/7; 28 (7): 743-8. (’†‘şŠxŽj1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2, ŕ_čL–ž3, ź‘ň—Ç‘ž3, –ěčN•˝3, “c’†L–í1, ŽR‰ş^Ži1, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ‘“c@‘ě2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110208. [Œ´’˜] Utility of Regular Management of Physical Activity and Physical Function in Hemodialysis Patients. Yamamoto S1, Matsuzawa R2, Abe Y, Hoshi K3, Yoneki K, Harada M1, Watanabe T1, Shimoda T1, Suzuki Y, Matsunaga Y, Kamiya K4, Yoshida A, Matsunaga A4: Kidney Blood Press Res 2018/10; 43 (5): 1505-15. (ŽR–{Ž•˝1, ź‘ň—Ç‘ž2, Ż@‰Ŕ–F3, Œ´“cˆ¤‰i1, “n粍F–ž1, ‰ş“c—˛‘ĺ1, _’JŒ’‘ž˜Y4, ź‰i“Ä•F4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3‰qś, 4ˆă—ÉqśŠw•”)

110209. [Œ´’˜] Incremental Value of Objective Frailty Assessment to Predict Mortality in Elderly Patients Hospitalized for Heart Failure. Tanaka S1, Kamiya K2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Matsunaga A2, Masuda T2, Ako J4: J Card Fail 2018/11; 24 (11): 723-32. (“c’†L–í1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, ź‘ň—Ç‘ž3, –ěčN•˝3, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ‘“c@‘ě2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110210. [Œ´’˜] Electromyographic analysis of infraspinatus and scapular muscles during external shoulder rotation with different weight loads and positions. Sasaki S1, Kenmoku T2, Otera A3, Miyajima G, Nagura N1, Nakawaki M, Nakazawa T2, Takaso M2, Fukuda M4, Takahira N4: J Orthop Sci 2019/1; 24 (1): 75-80. (˛X–؏Gˆę1, ŒŠ–Ú’q‹I2, ‘厛ˆŸ—R”ü3, –ź‘q’źd1, ’†ŕVr”V2, ‚‘ŠťŽm2, •Ÿ“c—Ď–ç4, ‚•˝ŽL4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ƒŠƒnƒrƒŠ•”, 4ˆă—ÉqśŠw•”)

110211. [Œ´’˜] Office-Based Physical Assessment in Patients Aged 75 Years and Older with Cardiovascular Disease. Matsuzawa R1, Kamiya K2, Hamazaki N1, Nozaki K1, Tanaka S3, Maekawa E4, Matsunaga A2, Masuda T2, Ako J4: Gerontology 2019; 65 (2): 128-35. doi: 10.1159/000493527. Epub 2019 Jan 16. (ź‘ň—Ç‘ž1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, –ěčN•˝1, “c’†L–í3, ‘OěŒb”ü4, ź‰i“Ä•F2, ‘“c@‘ě2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†, 4zŠÂŠí“ŕ)

110212. [Œ´’˜] Respiratory muscle weakness increases dead-space ventilation ratio aggravating ventilation-perfusion mismatch during exercise in patients with chronic heart failure. Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Maekawa E3, Noda C3, Yamaoka-Tojo M2, Ako J3: Respirology 2019/2; 24 (2): 154-61. (ŕ_čL–ž1, ‘“c@‘ě2, _’JŒ’‘ž˜Y2, ź‘ň—Ç‘ž1, –ěčN•˝1, ‘OěŒb”ü3, –ě“cçt3, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ3: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ)

110213. [Œ´’˜] Pupillary Light Reflex as a New Prognostic Marker in Patients With Heart Failure. Nozaki K1, Kamiya K2, Matsue Y, Hamazaki N1, Matsuzawa R1, Tanaka S3, Maekawa E4, Kishi T, Matsunaga A2, Masuda T2, Izumi T, Ako J4: J Card Fail 2019/3; 25 (3): 156-63. (–ěčN•˝1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, ź‘ň—Ç‘ž1, “c’†L–í3, ‘OěŒb”ü4, ź‰i“Ä•F2, ‘“c@‘ě2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

110214. [Œ´’˜] Prognostic value of sarcopenic obesity estimated by computed tomography in patients with cardiovascular disease and undergoing surgery. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4, Matsuzawa R4, Nozaki K4, Tanaka S1, Nakamura T1, Maekawa E5, Masuda T2, Ako J5, Miyaji K3: J Cardiol 2019/9; 74 (3): 273-8. doi: 10.1016/j.jjcc.2019.02.010. Epub 2019 Mar 28. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2, –k‘ş@—Ľ3, ŕ_čL–ž4, ź‘ň—Ç‘ž4, –ěčN•˝4, “c’†L–í1, ’†‘şŠxŽj1, ‘OěŒb”ü5, ‘“c@‘ě2, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ)

120044. [Œ´’˜] •ĎŒ`ŤŒŇŠÖßÇŠłŽŇ‚É‚¨‚Ż‚鐜Šˆ‹óŠÔ‚̐§ŒŔ‚É‚Í•ŕs‘Ź“x‚ŞŠÖ˜A‚ˇ‚é. “ě—˘—C‘ž1, ‹{é‚ľ‚Ů1, …–ěŒö•ă1, ‘q’Ř—ş‘ž1, “ŕŽRŸ•ś2, •Ÿ“‡Œ’‰î2, X’JŒőr2, ‚•˝ŽL3 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): Hip Joint 2018/9; 44 (2): S141-5.

120045. [Œ´’˜] Œ¨äF”Â’f—ôC•œpŒăŠłŽŇ‚É‚¨‚Ż‚épŒă1”N‚Ü‚Ĺ‚Ě—ŠwŠŒŠ‚ĆŠłŽŇ—§‹rŒ¨ŠÖß•]‰ż–@Shoulder36‚Ě”äŠr. ˛X–؏Gˆę1, ‘厛ˆŸ—R”ü2, ŒŠ–Ú’q‹I3, Ź—ŃˆŸ—˘2, –ź‘q’źd1, ’†˜e[Í3, “cŕV@—Č3, ‚•˝ŽL4, ‚‘ŠťŽm3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“Œ•a‰@ƒŠƒnƒrƒŠ•”, 3ŽŠO, 4ˆă—ÉqśŠw•”): _“ސěě‹Ć—Ă–@Œ¤‹† 2019/3; 9 (1): 7-12.

522219. [uŔ]y“ÁW: —Šw—Ă–@‚É‚¨‚Ż‚é‘SgŠÇ—‚ĚŽw•W‚Ě—‰đz—Šw—Ă–@‚É‚¨‚Ż‚éu‘̉ˇv‚Ě—‰đ‚Ěƒ|ƒCƒ“ƒg. –ěčN•˝1, _’JŒ’‘ž˜Y2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): —Šw—Ă–@ 2018/6; 35 (6): 510-5.

522220. [uŔ]y“ÁW: ƒI[ƒ‹ƒCƒ“ƒƒ“ ŒŇ ŠÖ ß `ŽžŠłEŽĄ—ÁEƒPƒA`z(20) ŒŇŠÖßŽžŠł‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ŕF’J^ (ƒŠƒnƒrƒŠ•”): ŽŒ`ŠO‰ČŠĹŒě 2018/8; 23 (8): 812-6.

[’˜@‘]

620262. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@1. ƒoƒCƒ^ƒ‹ƒTƒCƒ“@6) Œo”ç“IŽ_‘f–O˜a“x, p.8-11. Ź—ŃŽĺŒŁ1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620263. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@2) •s‰¸E’ÁĂó‘ԁE‚š‚ń–Ď, p.13-7. ŕ_čL–ž1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620264. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@8) Œ`‘Ô, p.38-48. Š™“c—TŽŔ1, _’JŒ’‘ž˜Y2 (1‘Š•‘äƒj[ƒŒƒ“ƒNƒŠƒjƒbƒN, 2ˆă—ÉqśŠw•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2, •śŒő“°, “Œ‹ž, 2018/7”­s.

620265. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@9) ”F’m, p.49-55. Ź—ŃŽĺŒŁ1, ź‘ň—Ç‘ž1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620266. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@10) áu’É, p.56-8. “ě—˘—C‘ž1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620267. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@1. ˆę”Ę“I‚ȏŠŒŠ@12) ‹Ř—Í, p.61-5. ŕF’J^1, –ěčN•˝1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620268. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@2. ŽžŠł“ÁˆŮ“I‚ȏŠŒŠ@1) ŒÄ‹zŠíŽžŠł‚̐g‘̏ŠŒŠ, p.130-9. ŕ_čL–ž1, Ź—ŃŽĺŒŁ1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620269. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@2. ŽžŠł“ÁˆŮ“I‚ȏŠŒŠ@2) SŽžŠł‚̐g‘̏ŠŒŠ, p.140-6. _’JŒ’‘ž˜Y1 (1ˆă—ÉqśŠw•”), •Ň: ź‰i“Ä•F1, _’JŒ’‘ž˜Y1, •śŒő“°, “Œ‹ž, 2018/7”­s.

620270. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zI •]‰ż•Ň@2. g‘̏ŠŒŠ@2. ŽžŠł“ÁˆŮ“I‚ȏŠŒŠ@3) ––˝“Ž–ŹŽžŠł‚̐g‘̏ŠŒŠ, p.147-50. ź‘ň—Ç‘ž1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620271. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zII “ŕ•”áŠQŒnŽĺ—vŒŸ¸@6. ƒXƒpƒCƒƒƒgƒŠ[, p.195-9. Ź—ŃŽĺŒŁ1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620272. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zIII ŽžŠł•Ę‰^“Ž—Ă–@•Ň@1. SŒŒŠÇŽžŠł@A. S•s‘S, p.208-19. _’JŒ’‘ž˜Y1 (1ˆă—ÉqśŠw•”), •Ň: ź‰i“Ä•F1, _’JŒ’‘ž˜Y1, •śŒő“°, “Œ‹ž, 2018/7”­s.

620273. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zIII ŽžŠł•Ę‰^“Ž—Ă–@•Ň@4. tŽžŠł@A. –Ťt‘Ÿ•a (•Ű‘śŠú), p.329-6. ź‘ň—Ç‘ž1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620274. [Šwp‘ (•Ş’SŽˇ•M)]y‰^“Ž—Ă–@ƒGƒrƒfƒ“ƒXƒŒƒrƒ…[zIII ŽžŠł•Ę‰^“Ž—Ă–@•Ň@5. śŠˆKŠľ•a@B. Ž‰ŽżˆŮíÇ, p.356-65. –ěčN•˝1 (1ƒŠƒnƒrƒŠ•”), •Ň: ź‰i“Ä•F2, _’JŒ’‘ž˜Y2 (2ˆă—ÉqśŠw•”), •śŒő“°, “Œ‹ž, 2018/7”­s.

620275. [Šwp‘ (•Ş’SŽˇ•M)]yƒGƒLƒXƒp[ƒg—Šw—Ă–@3@PDCA—˜_‚ĹŠw‚Ô“ŕ•”áŠQ—Šw—Ă–@|SŒŒŠÇŽžŠłE“ŕ•Ş”ĺ‘ăŽÓŽžŠłEtŽžŠł•Ňz‘ćIIÍ PDCA—˜_‚ĹŠw‚ԐSŒŒŠÇŽžŠł—Šw—Ă–@@[‚ć‚­–Ŕ‚˘‹ę‚ľ‚Ţ“ďaÇ—á‚̍U—Ş]@3. ƒtƒŒƒCƒ‹‚đ—L‚ˇ‚éSŽžŠłÇ—á, p.86-97. ŕ_čL–ž1, _’JŒ’‘ž˜Y2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”), Ó”C•ŇW: X‘ň’m”V3, –ě‘ş‘쐜4 (3•şŒÉˆă—Ă‘ĺŠw 4,ŠÖź•ŸŽƒ‰ČŠw‘ĺŠw), ƒqƒ…[ƒ}ƒ“ƒvƒŒƒX, ‰Ą•l, 2019/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713173. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Increased respiratory muscle strength contributes to improvement of exercise tolerance following cardiac rehabilitation in patients with chronic heart failure. Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Tanaka S3, Ichikawa T1, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Ako J4: EuroPrevent 2018 (2018/4/19-21), Ljubljana, Slovenia. (ŕ_čL–ž1, ‘“c@‘ě2, _’JŒ’‘ž˜Y2, ź‘ň—Ç‘ž1, –ěčN•˝1, “c’†L–í3, Žsě‹M•ś1, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

713174. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) (Best Moderated Poster Award ŽóÜ‰‰‘č) Respiratory muscle weakness predicts all-cause mortality in chronic heart failure patients with preserved left ventricular ejection fraction. Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Tanaka S3, Tabata M, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Ako J4: EuroPrevent 2018 (2018/4/19-21), Ljubljana, Slovenia. (ŕ_čL–ž1, ‘“c@‘ě2, _’JŒ’‘ž˜Y2, ź‘ň—Ç‘ž1, –ěčN•˝1, “c’†L–í3, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

713175. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) PHYSICAL PERFORMANCE, PHYSICAL ACTIVITY AND QUALITY OF LIFE BEFORE AND AFTER KIDNEY TRANSPLANTATION. Matsuzawa R1, Yoshid K2,3, lshii D3, Noguchi F4, Ikeda M3, Takeuchi Y5, Matsunaga A6: 55th ERA-EDTA Congress (2018/5/26), Copenhagen, Denmark. (ź‘ň—Ç‘ž1, ‹g“cˆęŹ2,3, Îˆä‘ĺ•ă3, –ěŒű•ś”T4, ’r“cŹ]3, ’|“ŕN—Y5, ź‰i“Ä•F6: 1ƒŠƒnƒrƒŠ•”, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3”ĺ”AŠí, 4ŠĹŒě•”, 5t‘Ÿ“ŕ, 6ˆă—ÉqśŠw•”)

722240. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚA‚Ɛt‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ź‘ň—Ç‘ž1, ‹g“cˆęŹ2,3, Îˆä‘ĺ•ă3, ’|“ŕN—Y4 (1ƒŠƒnƒrƒŠ•”, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3”ĺ”AŠí, 4t‘Ÿ“ŕ): ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2018/10/4), “Œ‹ž, ‘ć54‰ń“ú–{ˆÚAŠw‰ď‘‰ď—ŐŽž† 2018; 53 (—ŐŽž†): 262.

722241. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) Ň’ŒƒAƒ‰ƒCƒƒ“ƒg‚Ć‹Ř—Í‚ŞŇ’Œ•ĎŒ`‚đ—L‚ˇ‚銳ŽŇ‚Ěáu’É‚Ć•ŕs”\—Í‚É‹y‚Ú‚ˇ‰e‹ż. “ě—˘—C‘ž1, źŠŰƒ‰Ŕ1, ŕF’J^1, ‹{éłs2, ˆäă@Œş2, ’†ŕVr”V2, ˆä‘ş‹M”V2, Ö“Ą@˜j2, ”’ŕV‰hŽ÷2, ‚‘ŠťŽm2 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO): ‘ć9‰ń“ú–{ŹlŇ’Œ•ĎŒ`Šw‰ď (2019/3/2), “Œ‹ž.

723981. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ęŽwCMŠÖßÇ‚ɑ΂ˇ‚é–k—˘ŽŽ‹@”\“IƒXƒvƒŠƒ“ƒg‚É‚ć‚é‘•‹ď—Ă–@‚ĚŒř‰Ę. ˛X–؏Gˆę1, ŹŔŒŤŽĄ2, •ě_Žm2, ŒŠ–Ú’q‹I2, ‚‘ŠťŽm2, ‚•˝ŽL3 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć30‰ń“ú–{ƒnƒ“ƒhƒZƒ‰ƒsƒBŠw‰ďŠwpW‰ď (2018/4/28-29), “Œ‹ž.

723982. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ‘ڍœŠ°œ‰PƒCƒ“ƒsƒ“ƒWƒƒ“ƒg‚ɑ΂ˇ‚éŒŇŠÖß‹žŽ‹‰şŽčp‚̏pŒă3ƒ–ŒŽŽž‚Ěáu’É‚É‚ÍŽčp‘O‚̋ؗ͒ቺ‚Ćƒoƒ‰ƒ“ƒX‹@”\’ቺ‚ŞŠÖ˜A‚ˇ‚é. “ě—˘—C‘ž1, “ŕŽRŸ•ś2, •Ÿ“‡Œ’‰î2, ‚•˝ŽL3 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{ŠÖß‹žE•GEƒXƒ|[ƒcŽŒ`ŠO‰ČŠw‰ď (JOSKAS2018) (2018/6/14-16), •Ÿ‰Ş.

723983. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •aŽŻŒ‡”@‚ɑ΂ľ‘˝EŽíî•ń‹¤—L‚É‚ć‚萜ŠˆKŠľ‰ü‘P‚đŽŽ‚Ý‚˝‹´’†S‘â•ö‰óÇ‚ĚˆęÇ—á. ŠĄ’J‰p‹I1, “ú”ä—mŽq2, ‰Í‘Š‚ä‚˝1, “J“c–ƒ—F1, —é–Ř—Ç˜a1, “Ą‹´‹Is1, •˝–ě“ÄŽj1, ě’[—ÇŽĄ1, ‰“Œ´^ˆę1, •˝‰ę‚ć‚ľ‚Ý3, •Ÿ“c—Ď–ç4 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2“Œ•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Č, 3ƒŠƒnƒrƒŠ•”, 4ˆă—ÉqśŠw•”): ‘ć55‰ń“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆăŠw‰ďŠwpW‰ď (2018/6/28-7/1), •Ÿ‰Ş.

723984. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œy“x•Đ–ƒáƒŠłŽŇ‚É‚¨‚Ż‚錨ŠÖßŠOů‹Ř—Í‚ÍăŽˆŽg—p•p“x‚ÉŠÖ˜A‚ˇ‚é. ˛X–؏Gˆę1, ŒŠ–Ú’q‹I2, Ź—ŃˆŸ—˘1, ‘ş”öç‰ŘŽq1, ŸNˆä”üšŽ÷1, ‰Í‘Š‚ä‚˝1, ŠĄ’J‰p‹I1, “ú”ä—mŽq3, ł–Řꢎq3, ‚•˝ŽL3, •Ÿ“c—Ď–ç4 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3“Œ•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Č, 4ˆă—ÉqśŠw•”): ‘ć55‰ń“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆăŠw‰ďŠwpW‰ď (2018/6/28-7/1), •Ÿ‰Ş.

723985. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) (International Session Award ŽóÜ‰‰‘č) Inspiratory muscle strength as a predictor of all-cause mortality in heart failure patients with preserved ejection fraction. ŕ_čL–ž1, ‘“c@‘ě2, _’JŒ’‘ž˜Y2, ź‘ň—Ç‘ž1, –ěčN•˝1, Žsě‹M•ś1, “c’†L–í3, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ): AsiaPRevent2018 (‘ć24‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď) (2018/7/14-15), ‰Ą•l.

723986. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ľE‘ÎŒő”˝‰žŽw•W‚Ćƒmƒ‹ƒAƒhƒŒƒiƒŠƒ“‚ĚŠÖŒW. –ěčN•˝1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, ź‘ň—Ç‘ž1, “c’†L–í3, ’†‘şŠxŽu3, ŽR‰ş^Ži3, ‘OěŒb”ü4, –ě“cçt4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ‘“c@‘ě2, ˆ˘ŒĂĆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ): ‘ć24‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2018/7/14-15), ‰Ą•l.

723987. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŒŒŠÇŽžŠłŠłŽŇ‚É‚¨‚Ż‚é•ŕs‘Ź“x‚̒ቺ‚͐ś–˝—\Œă‚Ě—\‘ވöŽq‚Ć‚Č‚é. Žsě‹M•ś1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, ź‘ň—Ç‘ž1, –ěčN•˝1, “c’†L–í3, ŒÜ\—’ˆŸŠóŽq4, ™–썁“ŢŽq4, ‘OěŒb”ü5, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ‘“c@‘ě2, ˆ˘ŒĂĆ5 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ŠĹŒě•”, 5zŠÂŠí“ŕ): ‘ć24‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2018/7/14-15), ‰Ą•l.

723988. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) (English Session Best Presentation Award ŽóÜ‰‰‘č) Increased respiratory muscle strength as a contributor to improvement of exercise tolerance following cardiac rehabilitation in patients with chronic heart failure. ŕ_čL–ž1, _’JŒ’‘ž˜Y2, ź‘ň—Ç‘ž1, –ěčN•˝1, “c’†L–í3, Žsě‹M•ś1, ‘OěŒb”ü4, ‘“c@‘ě2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ): ‘ć2‰ń“ú–{ŒÄ‹zESŒŒŠÇE“œ”A•a—Šw—Ă–@Šw‰ď‡“ŻŠwp‘ĺ‰ď (2018/7/16), ‰Ą•l.

723989. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ń•œŠúƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a“‚É‚¨‚Ż‚éŒz’ŏǐŤŇ‘ÇpŒăŠłŽŇ‚ĚˆÚ“Ž”\—ÍŽŠ—§“x‚ɉe‹ż‚ˇ‚éˆöŽq‚ĚŒŸ“˘. ˛X–؏Gˆę1, ăo’źl2, —é–ŘŒb—˜1, ŒŠ–Ú’q‹I3, ’†ŕVr”V3 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3ŽŠO): ‘ć52‰ń“ú–{ě‹Ć—Ă–@Šw‰ď (2018/9/7-9), –źŒĂ‰Ž.

723990. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ˇŠúlHŒÄ‹zŠÇ—’†‚Ě“ű—cŽ™‚ɑ΂ˇ‚é‰^“Ž”­’B‚đl—ś‚ľ‚˝—Šw—Ă–@‚ĚŽŽ‚Ý. –ě‘ş—DŽq1, ‰ĄŽR”ü˛Žq2, ă“cN‹v, …–ěŒö•ă1, ‹ŕŽq’‰O3, ”~Œ´@ŽŔ, •Ÿ“c—Ď–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723991. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰Á‘Ź“xƒZƒ“ƒT‚đ—p‚˘‚˝lHŒÄ‹zŠÇ—’†‚Ě“ű—cŽ™‚É‚¨‚Ż‚éÝ‘î‚Ĺ‚ĚŽp¨”cˆŹ‚ĚŽŽ‚Ý. …–ěŒö•ă1, ‰ĄŽR”ü˛Žq2, ă“cN‹v, –ě‘ş—DŽq1, ‹ŕŽq’‰O3, ”~Œ´@ŽŔ, •Ÿ“c—Ď–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3ŹŽ™): ‘ć51‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2018/9/28-29), ŽD–y.

723992. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O’ág‘Ě‹@”\‚̐lHŒŇŠÖß’uŠˇpŒăŠłŽŇ‚É‚¨‚Ż‚鎊‘î‘މ@‚ɉe‹ż‚đ‹y‚Ú‚ˇˆöŽq‚ĚŒŸ“˘. ŕF’J^1, ‹{é‚ľ‚Ů1, “ě—˘—C‘ž1, •Ÿ“‡Œ’‰î2, “ŕŽRŸ•ś2, ‚•˝ŽL3 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/26-27), –źŒĂ‰Ž.

723993. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŒŇŠÖß‘S’uŠˇpŠłŽŇ‚É‚¨‚Ż‚épŒă•ŕsŽŠ—§“ú‚ƏpŒă14“úˆČ“ŕ‚ĚŽŠ‘î‘މ@‰Â”Ű‚Ć‚ĚŠÖ˜A. “ě—˘—C‘ž1, ‹{é‚ľ‚Ů1, ŕF’J^1, “ŕŽRŸ•ś2, •Ÿ“‡Œ’‰î2, ‚•˝ŽL3 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć45‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2018/10/26-27), –źŒĂ‰Ž.

723994. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtŒ¤‹†—DGÜztˆÚAŒă‰^“Ž—Ă–@‚͐t‹@”\‚ɈŤ‰e‹ż‚đ—^‚Ś‚¸‚ɐg‘Ě‹@”\‚đ‰ü‘P‚ˇ‚é. ŽR–{Ž•˝1, ź‘ň—Ç‘ž2, Îˆä‘ĺ•ă3, –ěŒű•ś”T4, ź‰i“Ä•F5, ‹g“cˆęŹ3,6 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3”ĺ”AŠí, 4ŠĹŒě•”, 5ˆă—ÉqśŠw•”, 6V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/14), ‘ĺă.

723995. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Potential benefits of acute-phase cardiac rehabilitation in the intensive care unit for patients with cardiovascular disease -A retrospective observational study-. ŕ_čL–ž1, ź‘ň—Ç‘ž1, –ěčN•˝1, Žsě‹M•ś1, _’JŒ’‘ž˜Y2, ŒŠˆä“c˜ał1, Ź’r•üF3, ‘OěŒb”ü4, VˆäłN5,6, ‘“c@‘ě2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3ŠĹŒě•”, 4zŠÂŠí“ŕ, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 6–ƒŒ): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/1-3), ‹ž“s.

723996. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚š‚ń–Ď‚đ”­Ç‚ľ‚˝”sŒŒÇŠłŽŇ‚É‚¨‚Ż‚鎊‘î‘މ@—\‘ވöŽq‚ĚŒŸ“˘. ‹{č“š‹P1, ŒŠˆä“c˜ał1, ’†–ěŠěŒb1, _•Ű•‘Ľ1, •Šâ­”V2, VˆäłN2,3, •Đ‰Ş—Sˆę4, ó—˜@–ő4, “cƒ–’J_–M5 (1ƒŠƒnƒrƒŠ•”, 2–ƒŒ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‹~–˝, 5ˆă—ÉqśŠw•”): ‘ć46‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2019/3/2), ‹ž“s.

723997. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒ‰t“§ÍŠłŽŇ‚É‚¨‚Ż‚éModified Creatinine Index‚đ—p‚˘‚Ä•]‰ż‚ľ‚˝œŽ‰–b—Ę‚ĚŒo”N•Ď‰ť‚Ɛś–˝—\Œă. —é–Ř—T‘ž1, ź‘ň—Ç‘ž2, _’JŒ’‘ž˜Y3, Ż@‰Ŕ–F4, Œ´“cˆ¤‰i1,5, “n粍F–ž1,5, ‰ş“c—˛‘ĺ1, ŽR–{Ž•˝1, ˆé•”—F—S1, Ą‘şŒcŒá1, ź‰i—S•ă1, ‹g“c@ŕˆ5, ź‰i“Ä•F3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3ˆă—ÉqśŠw•”, 4‰qś, 5‚ł‚Ş‚ÝzŠÂŠíƒNƒŠƒjƒbƒN): ‘ć9‰ń“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2019/3/10), ‘ĺ•Ş.

732130. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) zŠÂŠíŽžŠł‚ɑ΂ˇ‚éW’†ŽĄ—ĂŽş‚Š‚ç‚Ě‘ŠúƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ ’ˇŠúW’†ŽĄ—Ă‚Ş•K—v‚ȐSŽžŠłŠłŽŇ‚ɑ΂ˇ‚鑁ŠúƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ĚŽŔŰ. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć3‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2018/11/23), “Œ‹ž.

732131. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) zŠÂŠí—Ěˆć‚É‚¨‚Ż‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ě–đŠ„|”x‚ŒŒˆłÇ‚ɑ΂ˇ‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̉”\Ť|. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć17‰ńCardiovascular P ƒZƒ~ƒi[ (2019/2/1), ’Ź“c.

733326. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œy“x•Đ–ƒáƒŠłŽŇ‚ĚăŽˆ‹@”\‚Ć“™ŽÚŤŒ¨ŠÖßŠOů‹Ř—Í‚Ć‚ĚŠÖ˜AŤ. ˛X–؏Gˆę1, ŒŠ–Ú’q‹I2, ’|“ੰl1, _•Ű•‘Ľ1, –ź‘q’źd2, ’†˜e[Í2, •Ÿ“c—Ď–ç3, ‚•˝ŽL3, ‚‘ŠťŽm2 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć15‰ńŒ¨‚̉^“Ž‹@”\Œ¤‹†‰ď (2018/10/19-20), ‘ĺă.

733327. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) RA•ęŽwZ•ĎŒ`‚ɑ΂ˇ‚é–k—˘ŽŽ‹@”\“IƒXƒvƒŠƒ“ƒg‚ĚŒř‰Ę‚ĚŒŸŘ|ˆłƒZƒ“ƒT‚đ—p‚˘‚˝’č—Ę“I•ŞÍ|. ˛X–؏Gˆę1, ŹŔŒŤŽĄ2, •ě_Žm2, ‘ĺ’|—IĆ2, ŒŠ–Ú’q‹I2, ’|“ੰl1, _•Ű•‘Ľ1, ‚•˝ŽL3, ‚‘ŠťŽm2 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć20‰ńƒŠƒEƒ}ƒ`EƒŠƒnƒPƒAŒ¤‹†‰ď (2019/1/26), ‰Ą•l.


‰h—{•”

[Šwp˜_•ś]

120046. [Œ´’˜] ‘˝EŽí‰î“ü‚Í“œ”A•atÇŠłŽŇ‚Ě“§Í“ą“üŽž‚Ě•a‘Ô‚ÉŠÖ˜A‚Ş‚ ‚é‚Š? lŒŠ–ƒ”üŽq1, ˛“ĄĆŽq1, ‘ĺŠŃŒbŽq2, â–{”~Žq2, Ÿ˜C”ü3, ŽO‰Y–F“T4, Žç‰Ž’B”ü5 (1‰h—{•”, 2ŠĹŒě•”, 3–ňÜ•”, 4—ŐŒŸ•”, 5Œ’NŠÇ—ƒZ): “œ”A•a 2018/8; 61 (8): 537-43.

522221. [uŔ]y“ÁW: ŠÇ—‰h—{Žm‚́gƒXƒS‹Zh‹ł‚Ś‚Ü‚ˇ! –Ú‚Š‚çƒEƒƒR‚̐HŽ–—Ă–@Žw“ąp ƒ_ƒEƒ“ƒ[ƒh‚ľ‚ÄŠłŽŇ‚É“n‚š‚é‚Š‚ń‚˝‚ńƒŒƒVƒs‚‚Ťz<2 ŠÇ—‰h—{Žm‚́gƒXƒS‹Zh‚đ“`Žó ƒP[ƒX•ĘHŽ–Žw“ąp> 1 “œ”A•a‚Ć‚Í‚˘‚í‚ę‚˝‚Ż‚ę‚Ç, H‚ׂˇ‚Ź‚đ‚â‚ß‚ç‚ę‚Č‚˘. lŒŠ–ƒ”üŽq (‰h—{•”): “œ”A•aƒPƒA 2019/1; 16 (1): 20-4.

[Šw‰ďEŒ¤‹†‰ď“™]

713176. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Multidisciplinary Predialyis Team education for patients with Diabetes Nephropathy reduced cost for admission at the induction of hemodialysis and subsequent mortality. Hitomi M1, Sato T1, Moriya T2: The American Diabetes Association's 78th Scientific Sessions (2018/6/22-26), Orlando, Florida, Diabetes 2018/7; 1: A174. (lŒŠ–ƒ”üŽq1, ˛“ĄĆŽq1, Žç‰Ž’B”ü2: 1‰h—{•”, 2Œ’NŠÇ—ƒZ)

722242. [Šw‰ď (‘S‘)] (—v–]‰‰‘č) ŠÔÚ”M—Ę‘Ş’č‚ÉŠî‚Ă‚­dÇ‹~‹}ŠłŽŇ‚ĚŽŠ“K“Š—^ƒGƒlƒ‹ƒM[—Ę‚ĚŒŸ“˘. Žç‰Ž—˘š1, •Đ‰Ş—Sˆę2, ‰““ĄŹŽq1, [‘ň˛ŒbŽq1, ‹yě‚ ‚¸‚ł1, –î•”hŽu3, ‘ž“cŽĄ‘ă3, ‹{‰ş˜aŽq3, _@ˆę–˛4, ˛“ĄĆŽq1 (1‰h—{•”, 2‹~–˝, 3ŠĹŒě•”, 4–ňÜ•”): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ď (2019/2/15), “Œ‹ž, ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ďŠwpW‰ďƒvƒƒOƒ‰ƒ€W 2019/1; 34: Y07-07.

723998. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ`[ƒ€ˆă—Ă‚Ě’†‚ĹŠÇ—‰h—{Žm‚ލs‚¤H“šŠŕpŒă‚̐V‚˝‚ȉh—{ŠÇ—‚ĚŽć‚č‘g‚Ý. ‹e’r“Ţ•äŽq1, [‘ň˛ŒbŽq1, Ź‰€“ŢŽq2, ‚‹´N‰î2, X’JGŒő3, ŽR‰şŒpŽj3,4, “n粏š•F5 (1‰h—{•”, 2ŠĹŒě•”, 3ă•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5‰ş•”Á‰ťŠÇŠO): ‘ć72‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2018/6/28), ‰F“s‹{.

723999. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) V‹KˆŰŽ“§Í“ą“üŽž‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Ž{sŠłŽŇ‚̉h—{ŠÇ—‚̉ۑč. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2, “Ąˆä䝎Ŕ1, ł–Ř‹M‹ł2, Š™“c^—Žq2, “ŕ“Ął‹g2, ˛–ě@—˛2, ’|“ŕN—Y2 (1‰h—{•”, 2t‘Ÿ“ŕ): ‘ć63‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2018/7/1), _ŒË, ‘ć63‰ń“ú–{“§ÍˆăŠw‰ď´˜^W 2018/6; p.662.

7231000. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž‚𔺂¤”DP“œ”A•aŠłŽŇ‚ɑ΂ˇ‚é‘˝EŽí‰î“ü‚ĚŒř‰Ę. lŒŠ–ƒ”üŽq1, Žç‰Ž’B”ü2 (1‰h—{•”, 2Œ’NŠÇ—ƒZ): ‘ć34‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2018/11/24), ‰Ą•l, “œ”A•a”DPŠw‰ď 2018/11; 18 (3): S-114.

7231001. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) H“šŠŕ‚đ‘ÎŰ‚Ć‚ľ‚˝DCF—Ă–@‚É‚¨‚Ż‚鐏•Ş‰h—{ÜƒGƒŒƒ“ƒ^[ƒ‹‚̉h—{ŽxŽ—Ă–@‚ÉŠÖ‚ˇ‚錟“˘. [‘ň˛ŒbŽq1, ‘ž“c—TŽq1, Œ˜“ce—˜2, ‚‹´‚Š‚¨‚é3, ‚‹´ˆŸ‹IŽq3, ›Œ´[L4, â–{‘×—5, ˛“ĄĆŽq1, Źň˜aŽO˜Y2 (1‰h—{•”, 2Á‰ťŠí“ŕ, 3ŠĹŒě•”, 4–ňÜ•”, 5—Տ°Œ¤‹†EŠé‰ć): ‘ć22‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2019/1/11), ‰Ą•l, ‘ć22“ú–{•a‘Ô‰h—{Šw‰ď´˜^W 2019/1; 22: S25.

7231002. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) p‘OOGTT‚Ĺ‘Ď“œ”\ˆŮí‚đŽŚ‚ľ‚˝tˆÚAƒŒƒVƒsƒGƒ“ƒg‚͏pŒă‚Ě‘Ěd‘‰Á—Ę‚Ş‘˝‚˘. ‹g“c•üŽq1, —с@“N”Í2, Îˆä‘ĺ•ă3, –ěŒű•ś”T4, ˆä‘ş—[•P4, “Ąˆä䝎Ŕ1, X‰Ş—DŽq1, Žľ—˘áÁ‹`2, ‹g“cˆęŹ3,5 (1‰h—{•”, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3”ĺ”AŠí, 4ŠĹŒě•”, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć22‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2019/1/12), ‰Ą•l, ‘ć22“ú–{•a‘Ô‰h—{Šw‰ď´˜^W 2019/1; 22: S56.

7231003. [Šw‰ď (‘S‘)] (ˆę”ʉ‰‘č) tˆÚA‘O‚ĚBMI•Ę‚É‚Ý‚˝ˆÚAŒă‚Ě‘Ěd‚âHŽ–ŠÇ—‚̉ۑč. ‹g“c•üŽq1, Îˆä‘ĺ•ă2, –ěŒű•ś”T3, ˆä‘ş—[•P3, ’r“cŹ]2, ‹g“cˆęŹ2,4 (1‰h—{•”, 2”ĺ”AŠí, 3ŠĹŒě•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć52‰ń“ú–{—Տ°tˆÚAŠw‰ď (2019/2/15), ‘ĺă, ‘ć52‰ń—Տ°tˆÚAŠw‰ď´˜^W 2019/2; p.278.

7231004. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) dÇ‹~‹}ŠłŽŇ‚̉h—{•]‰ż‚Ć—\Œă‚Ć‚ĚŠÖŒW‚ÉŠÖ‚ˇ‚é—Տ°“IŒŸ“˘. ‰““ĄŹŽq1, •Đ‰Ş—Sˆę2, Žç‰Ž—˘š1, [‘ň˛ŒbŽq1, –î•”hŽu3, ‹{‰ş’mŽq3, ‘ž“cŽĄ˘3, Ź–ě—Ç‘ž4, ˛“ĄĆŽq1 (1‰h—{•”, 2‹~–˝, 3ŠĹŒě•”, 4—ŐŒŸ•”): ‘ć34‰ń“ú–{Ă–ŹŒo’°‰h—{Šw‰ď‘‰ď (2019/2/15), “Œ‹ž.

733328. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “œ”A•aŽĄ—Ă‚Ö“ďF‚đŽŚ‚ˇŠłŽŇ‚ւ̑Ήž. lŒŠ–ƒ”üŽq (‰h—{•”): ‘ć85‰ń‚ł‚Ş‚Ý“œ”A•aƒJƒ“ƒtƒ@ƒŒƒ“ƒX(2018/4/20), _“ސě.

733329. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺŠw•a‰@‚É‚¨‚Ż‚éf—Ă‰Č•ĘƒTƒeƒ‰ƒCƒgŒ^NSTŠˆ“Ž‚ɂ‚˘‚Ä. ˛“ĄĆŽq1, •Đ‰Ş—Sˆę2, ‹g“c•üŽq1, —é–Ř—§r3, Œ´“cŒbŽq4, ŹěK—Y5, ŽO‰Y–F“T6 (1‰h—{•”, 2‹~–˝, 3Ž¨•@ˆôAE“ŞčňŠO, 4ŠĹŒě•”, 5–ňÜ•”, 6—ŐŒŸ•”): ‘ć21‰ń_“ސěNSTƒtƒH[ƒ‰ƒ€(2018/10/20), _“ސě, ‘ć21‰ń_“ސěNSTƒtƒH[ƒ‰ƒ€´˜^W 2018; p.11.


•a‰@•a—•”

[Šw‰ďEŒ¤‹†‰ď“™]

722243. [Šw‰ď (‘S‘)] (ƒXƒC[ƒcƒZƒ~ƒi[) ŽĄ—Ă‚đ’S‚¤ •a—ŒŸ¸‚Ě•W€‰ť. ŽR‰ş˜a–ç (•a—•”): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/12), •lź.

722244. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”xŠŕ‚É‚¨‚Ż‚é×–Ef•W–{‚ĚŒŠ•ű. Š`ŔœA–M1, âŒű@”E1, ŽR‰ş˜a–ç1, “ŕ“Ą‰ëm2, ŽOŒEŤŽj2, ˛“Ą”Vr2, Š“cç”ü”T3, ‹g“c@Œ÷3, ‘ş‰_–FŽ÷3, ŽOŽ}@M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—): ‘ć57‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2018/11/17), ‰Ą•l, “ú–{—Տ°×–EŠw‰ďŽ 2018; 57 (2): 524.

7231005. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) …—nŤƒpƒ‰ƒtƒBƒ“‚đ—p‚˘‚˝ƒuƒƒbƒNƒJƒo[‚Ě—L—pŤ‚ĚŒŸ“˘. ’ˇ’Jě—S“ń1, ŽR‰ş˜a–ç1, ‹g“c@Œ÷2, ‘ş‰_–FŽ÷2 (1•a—•”, 2•a—): ‘ć67‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2018/5/13), •lź, ˆăŠwŒŸ¸ 2018/5; 67 (•Ęű): 223.

7231006. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒÄ‹zŠí×–Ef‚É‚¨‚Ż‚é‰tó‰ťŒŸ‘Ě×–Ef‚Ě“W–] ”ńŹ×–E”xŠŕLBC•W–{‚É‚¨‚Ż‚éEGFRˆâ“`Žq‰đÍ‚Ě“ÁŤ‚ɂ‚˘‚Ä. ŽR‰ş˜a–ç1, ‹g“c@Œ÷2, ‹vę@Ž÷1, ź”ö—R‹IŽq3, ŽOŽ}@M2, ˛“Ą”Vr4, ‘ş‰_–FŽ÷2, ŕV–ě^—Žq (1•a—•”, 2•a—, 3•a‘ԁEf—ĂŒn, 4ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/2), ŽD–y, “ú–{—Տ°×–EŠw‰ďŽGŽ 2018/4; 57 (1): 143.

7231007. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Žq‹{čň•”Z‚𔺂¤‘Ě•”Œ´”­Large cell neuroendocrine carcinoma‚Ě1—á. ‘ş“c从Ń1, âŒű@”E1, Š`ŔœA–M1, Œ˘Ž”@‰~2, ŽR‰ş˜a–ç1, ‹g“c@Œ÷2, ŽOŽ}@M2, ‘ş‰_–FŽ÷2 (1•a—•”, 2•a—): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/2), ŽD–y, “ú–{—Տ°×–EŠw‰ďŽGŽ 2018/4; 57 (1): 185.

7231008. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńŹ×–E”xŠŕLBC•W–{‚É‚¨‚Ż‚éEGFRˆâ“`Žq‰đÍ‚Ě“ÁŤ‚ɂ‚˘‚Ä. ŽR‰ş˜a–ç1, ‹g“c@Œ÷2, ‹vę@Ž÷1, ź”ö—R‹IŽq3, ŽOŽ}@M2, ‘ş‰_–FŽ÷2, ŕV–ěáÁ—Žq, ˛“Ą”Vr4 (1•a—•”, 2•a—, 3•a‘ԁEf—ĂŒn, 4ŒÄ‹zŠíŠO): ‘ć59‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2018/6/2), ŽD–y.

731126. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•ĘŒű‰‰) ˆâ“`ŽqŒŸ¸‚ĚŠî‘b (‘gDŒŸ‘ĚŽć‚čˆľ‚˘‚đŠÜ‚ß‚˝). ŽR‰ş˜a–ç (•a—•”): •˝Ź30”N“x”F’č•a—ŒŸ¸‹ZŽt§“xŽw’čuK‰ď (2018/7/7), “Œ‹ž, Žw’čuK‰ďƒeƒLƒXƒg (•˝Ź30”N“x”Ĺ) 2018/7.

733330. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) p‘O‚ĚäX‘ŸEUS-FNA‚É‚ć‚čf’f‚ľ‚Ś‚˝č÷—ą×–EŽî‚Ě1—á. âŒű@”E1, Š`ŔœA–M1, ‘ž“c˝Žq1, ŽR‰ş˜a–ç1, Œ˘Ž”@‰~2, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—): ‘ć37‰ń_“ŢěŒ§—Տ°×–EŠw‰ďŠwpW‰ď (2018/10/6), _“ސě, _“ŢěŒ§—Տ°×–EŠw‰ďŽ 2018/9; 23 (2): 19.

H29”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

H29-732005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ”xŠŕf’f‚É‚¨‚Ż‚é•W–{ěť‚Ěpitfall. ŽR‰ş˜a–ç (•a—•”): ’č”ń‰c—˜Šˆ“Ž–@l“ú–{•a—¸“x•ŰŘ‹@\‹łˆçEŒ¤C‰ď (2018/3/18), “Œ‹ž.


ME•”

[Šwp˜_•ś]

120047. [Œ´’˜] ˆă—Ă‹@Ší’†‰›ŠÇ—‚É‚¨‚Ż‚éˆă—Ă‹@Ší‰Ň“­—Ś‚ĚŒŸ“˘|ˆă—Ă‹@ŠíŠÇ—‚É—L—p‚ȉғ­—Ś‚Ě•]‰ż–@|. “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, –؉şt“Ţ1, •“cÍ”1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ˆă—Ă‹@ŠíŠw 2018/10; 88 (5): 549-57.

120048. [Œ´’˜] ƒWƒ‡ƒuƒ[ƒe[ƒVƒ‡ƒ“ŽŔŽ{Ž{Ý‚É‚¨‚Ż‚éVl‹łˆç‚ÉŠÖ‚ˇ‚錟“˘|ƒvƒŠƒZƒvƒ^[§“x‚Ě“ą“ü‚ĚŒř‰Ę|. “ŒžŠŒ\ˆę1, ŠC˜VŞ’q‘ă1, •˝–ö@Œő1, ŒKŒ´ŽŃˆß1, ě“‡Ę‰Ř1, •“cÍ”1, –؉şt“Ţ1, “ĄˆäłŽŔ1, ”’ˆä“ÖŽj1, ŒĂ•˝@‘1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): _“ŢěŒ§—Տ°HŠw‹ZŽm‰ďŽ 2018/12; 30: 45-7.

120049. [Œ´’˜] lH”x‚Ö‚Ě‹C–Aˆř‚Ťž‚Ý‚ĚŽŔŒą“IŒŸ“˘. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, •“cÍ”1, —L”n@Ži1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ĚŠOzŠÂ‹Zp 2019/3; 46 (1): 12-8.

220009. [€Œ´’˜] “–‰@‚É‚¨‚Ż‚éÝ‘îˆă—Ă‚Ě‹łˆçŽžŠÔ‚ÉŠÖ‚ˇ‚錟“˘. •x‰išÍ1, “ŒžŠŒ\ˆę1, ”’ˆä“ÖŽj1, ”Ń“‡Œő—Y1 (1ME•”): _“ŢěŒ§—Տ°HŠw‹ZŽm‰ďŽ 2018/12; 30: 1-2.

220010. [€Œ´’˜] ƒWƒ‡ƒuƒ[ƒe[ƒVƒ‡ƒ“ŽŔŽ{Ž{Ý‚É‚¨‚Ż‚éVl‹łˆç‚ÉŠÖ‚ˇ‚錟“˘|ƒvƒŠƒZƒvƒ^[§“x‚Ě“ą“ü‚ĚŒř‰Ę|. “ŒžŠŒ\ˆę1, ŠC˜VŞ’q‘ă1, •˝–ö@Œő1, ŒKŒ´ŽŃˆß1, ě“‡Ę‰Ř, •“cÍ”1, –؉şt“Ţ1, “ĄˆäłŽŔ1, ”’ˆä“ÖŽj1, ŒĂ•˝@‘1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): _“ŢěŒ§—Տ°HŠw‹ZŽm‰ďŽ 2018/12; 30: 45-7.

220011. [€Œ´’˜]y‹Zp•ńzlH”x‚Ö‚Ě‹C–Aˆř‚Ťž‚Ý‚ĚŽŔŒą“IŒŸ“˘. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, •“cÍ”1, —L”n@Ži1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ĚŠOzŠÂ‹Zp 2019/3; 46 (1): 12-8.

522222. [uŔ]y“ÁW: —Տ°HŠw•”–ĺ‚Ě‘gD‚Ě‚ ‚č•ű‚ɂ‚˘‚čl‚Ś‚ézŽ„—§‘ĺŠw•a‰@‚Ě—á. “ŒžŠŒ\ˆę (ME•”): Clinical Engineering 2018/11; 29 (12): 1019-27.

522223. [uŔ]y˜AÚ (ƒVƒŠ[ƒY\Ź: X›‰‰ëŽi)z‚Ś?’m‚ç‚Č‚˘‚Ě?”]E‘gD‹ÇŠŽ_‘fƒ‚ƒjƒ^[. ŒĂ•˝@‘ (ME•”): Intensivist 2019/1/1; 11 (1): 220-7.

[Šw‰ďEŒ¤‹†‰ď“™]

722245. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) zŠÂŠíŽüpŠúŠłŽŇ‚Ěƒ‚ƒjƒ^[‚ĆˆŔ‘SŠÇ—. –؉şt“Ţ (ME•”): ‘ć29‰ń“ú–{—Տ°ƒ‚ƒjƒ^[Šw‰ď‘‰ď (2018/4/21), ‰Ą•l, —Տ°ƒ‚ƒjƒ^[ 2018/3; 29 (suppl): 28.

722246. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰)y•a‰@‚đ‚‚­‚é (ě‚é, ‘˘‚é, ‘n‚é)z‹ZŽm‚Ě—§ę‚Š‚ç: “Á’č‹@”\•a‰@‚đ‚‚­‚é. “ŒžŠŒ\ˆę (ME•”): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/27), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 100.

722247. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) —Տ°HŠw‹ZŽm‚̐lŢˆçŹ|“ž’B“x•]‰ż‚𒆐S‚Ć‚ľ‚˝‹łˆçŒ¤CƒVƒXƒeƒ€‚đ—p‚˘‚ā|. ŒĂ•˝@‘ (ME•”): ‘ć20‰ń“ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ďŠwp‘‰ď (2018/6/8), ŽD–y, “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ďŽGŽ 2018/5; 19 (suppl): 123.

7231009. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éÝ‘îˆă—Ă‚Ě‹łˆçŽžŠÔ‚ÉŠÖ‚ˇ‚錟“˘. •x‰išÍ1, “ŒžŠŒ\ˆę1, ”’ˆä“ÖŽj1, ”Ń“‡Œő—Y1 (1ME•”): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/26), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 146.

7231010. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é’…—pŒ^ŽŠ“Žœ×“ŽŠí‚ĚŽć‚č‘g. •“cÍ”1, “ŒžŠŒ\ˆę1, ˛“Ą@“ě1 (1ME•”): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/26), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 158.

7231011. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘MACT (monitor alarm control team) ‚É‚¨‚Ż‚é—Տ°HŠw‹ZŽm‚Ě–đŠ„. “ĄˆäłŽŔ1, “ŒžŠŒ\ˆę1, –؉şt“Ţ1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/27), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 181.

7231012. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽčpŽş‚Ě‹@Šíƒgƒ‰ƒuƒ‹‚É‚ć‚銳ŽŇ‚ւ̉e‹ż‚Ě’áŒ¸‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý‚ĚŒŸ“˘. —§–ě@‘1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1 (1ME•”): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/27), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 183.

7231013. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒWƒ‡ƒuƒ[ƒe[ƒVƒ‡ƒ“ŽŔŽ{Ž{Ý‚É‚¨‚Ż‚éVl‹łˆç‚ÉŠÖ‚ˇ‚錟“˘|ƒvƒŠƒZƒvƒ^[§“x‚Ě“ą“ü‚ĚŒř‰Ę|. “ŒžŠŒ\ˆę1, ‹{“c‚ł‚â‚Š1, ŠC˜VŞ’q‘ă1, ‚‹´@Œő1, ŒKŒ´ŽŃˆß1, –؉şt“Ţ1, “ĄˆäłŽŔ1, ”’ˆä“ÖŽj1, ŒĂ•˝@‘1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/27), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 186.

7231014. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹zˆř‚¨‚ć‚Ń•Ů‚Ćƒ|ƒ“ƒv‚É‚¨‚Ż‚éˆł•Â“x’˛Ž•ű–@‚̍lˆÄ. —L”n@Ži1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, ‘哇O”V1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆß1 (1ME•”): ‘ć28‰ń“ú–{—Տ°HŠw‰ď‹y‚Ń•˝Ź30”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2018/5/27), ‰Ą•l, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2018/4; 63: 197.

7231015. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆă—Ă‹@Ší’†‰›ŠÇ—‚É‚¨‚Ż‚éˆă—Ă‹@Ší‰Ň“­—Ś‚ĚŒŸ“˘. “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, –؉şt“Ţ1, •“cÍ”1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć93‰ń“ú–{ˆă—Ă‹@ŠíŠw‰ď‘ĺ‰ď (2018/6/2), ‰Ą•l, ˆă—Ă‹@ŠíŠw 2018/4; 88 (2): 158.

7231016. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŠJSp‚É‚¨‚Ż‚élH”xŒÄ‹CˆęŽ_‰ť’Y‘f”Z“x‚ƏpŒă‹}ŤtáŠQ‚ÉŠÖ‚ˇ‚錟“˘. ŒĂ•˝@‘1, •Ÿź‘ô^2, –L“c^Žő2, ‹{–{—˛Ži2, ’šˆäWŽO2,3, –k‘ş@—Ľ2, Ź—ŃŒ’‰î2, “Ą‰Şrˆę˜Y2, –x‰z—m2, ’†‘ş—D”ň2, źˆäŒŞ‘ž2, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO, 3ˆă—ĂˆŔ‘S): ‘ć71‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2018/10/3-6), “Œ‹ž, “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2018/10; suppl: p.217.

7231017. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽčpŽş‚É‚¨‚Ż‚é‹@Šíƒgƒ‰ƒuƒ‹”­ś•p“x‚ĚŒŸ“˘. —§–ě@‘1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, “ĄˆäłŽŔ1, ě“‡Ę‰Ř1 (1ME•”): ‘ć40‰ń“ú–{ŽčpˆăŠw‰ď‘‰ď (2018/10/12), “Œ‹ž, “ú–{ŽčpˆăŠw‰ďŽ 2018/9; 39 (suppl): 103.

7231018. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ŠJSp‚É‚¨‚Ż‚élHS”x’†‚̍D’†‹…/ƒŠƒ“ƒp‹…”ä‚ƏpŒă‹}ŤtŠQ‚ÉŠÖ‚ˇ‚錟“˘. ŒĂ•˝@‘1, ‘哇O”V1, —L”n@Ži1, •“cÍ”1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆË1, “ŒžŠŒ\ˆę1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć44‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2018/11/10), ‹ŕ‘ň, ‘ĚŠOzŠÂ‹Zp 2018/10; 45 (3): 273.

7231019. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éĂ–Ź’EŒŒ|“ŽĂ–Ź“ŻŽž‘—ŒŒ (V-VA ECMO) ‚ĚŒoŒą. “c‘ş”üš‹I1, “ŒžŠŒ\ˆę1, –؉şt“Ţ1, ’†‘ş‹ąŽq1, ‹{“c‚ł‚â‚Š1, •˝–ö@Œő1 (1ME•”): ‘ć44‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2018/11/10), ‹ŕ‘ň, ‘ĚŠOzŠÂ‹Zp 2018/10; 45 (3): 274.

7231020. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lH”x‚Ö‚Ě‹C–Aˆř‚Ťž‚Ý‚ĚŽŔŒą“IŒŸ“˘. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, •“cÍ”1, —L”n@Ži1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć44‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2018/11/10), ‹ŕ‘ň, ‘ĚŠOzŠÂ‹Zp 2018/10; 45 (3): 284.

7231021. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĚŠOzŠÂ‹łˆç•ű–@‚ĚŒŸ“˘|‘ĚŠOzŠÂ‹łKŽč’ ‚ĚŠˆ—p|. —L”n@Ži1, “ŒžŠŒ\ˆę1, ŒĂ•˝@‘1, •“cÍ”1, ‘哇O”V1, ŠC˜VŞ’q‘ă1, ŒKŒ´ŽŃˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć44‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2018/11/11), ‹ŕ‘ň, ‘ĚŠOzŠÂ‹Zp 2018/10; 45 (3): 295.

732132. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) Še•Ş–ě‚Ĺ‚Ě“`ł|W’†ŽĄ—ÁE•â•zŠÂ‹Ć–ą‚Ě“`ł|. “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, –؉şt“Ţ1, “c‘ş”üš‹I1, ’†‘ş‹ąŽq1, •˝–ö@Œő1 (1ME•”): ‘ć9‰ńŠÖ“Œ—Տ°HŠw‰ď (2018/10/27), ç—t, ‘ć9‰ńŠÖ“Œ—Տ°HŠw‰ď´˜^W 2018/9; 28.


—Տ°ŽŽŒąƒZƒ“ƒ^[


ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş


Š´őŠÇ—Žş

[Šwp˜_•ś]

522224. [uŔ]y˜AÚ: —Տ°ŒŸ¸‚ĚƒsƒbƒgƒtƒH[ƒ‹zƒRƒAƒOƒ‰[ƒ[ŽŽŒą‚ĚŠî–{‚Ćƒsƒbƒgƒz[ƒ‹. “ń–{–öL1,2 (1Š´őŠÇ—Žş, 2—ŐŒŸ•”): ŒŸ¸‚Ć‹Zp 2018/7; 46 (7): 786-9.

540049. [‚ť‚Ě‘ź (•ń)] —DG˜_•śÜ (‘ĺ“ú–{Z—Fť–ňÜ) ‚đŽóÜ‚ľ‚āuLinezolid‚ĚŒŒ’†”Z“xŠÇ—‚ÉŠÖ‚ˇ‚é•śŒŁŒŸő‚đ’Ę‚ľ‚āv. Źź•q˛1,2 (1Š´őŠÇ—Žş, 2–ňÜ•”): TDMŒ¤‹† 2018; 35 (3): 85-8.

[’˜@‘]

620276. [Šwp‘ (•Ş’SŽˇ•M)]yÝ‘îˆă—ÁE‰îŒě‚É‚¨‚Ż‚銴őŠÇ—ƒnƒ“ƒhƒuƒbƒNz[I. ‘˜_] Š´őŠÇ—‚ĚŠî‘b’mŽŻ@3. •aŒ´‘Ě‚ĚŠî‘b‚ĆŠ´őŠÇ—, p.26-46. “ń–{–öL1,2 (1Š´őŠÇ—Žş, 2—ŐŒŸ•”), ŠÄC: Y’J’źl, •Ň: ‚‹´•ôŽq, —é–؍‚O, Ž˝“°o”Ĺ, “Œ‹ž, 2018/5”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

7231022. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŒŇŠÖß’uŠˇp‚É‚¨‚Ż‚éƒZƒtƒ@ƒ]ƒŠƒ“‚ĚŒŒ’†”Z“x‚Ć‹Ř–Œ‚Ě‘gD”Z“x‚Ć‚ĚŠÖŒWŤ`•”ˆĘ“ÁˆŮ“IPK-PD‰đÍ‚đ“Ľ‚Ü‚Ś‚ā`. Źź•q˛1,2, ‰Ä–Ú—Sˆß3, â”Vă˜aŽŔ3, ě‘ş[Žj3, —F“c‹g‘Ľ3, ’r“cM‰î4, “ŕŽRŸ•ś5, ‚ŽR—zŽq1,6, Œú“cKˆę˜Y2,3 (1Š´őŠÇ—Žş, 2–ňÜ•”, 3–ňŠw•”, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5ŽŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/23), _ŒË.

731127. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŹŽ™‚Ş‚ńŒoŒąŽŇ‚Ě‘S‘ƒlƒbƒgƒ[ƒN‚Š‚çŽĐ‰ď‚É“`‚Ś‚˝‚˘‚ą‚Ć. Źź•q˛1,2 (1Š´őŠÇ—Žş, 2–ňÜ•”): ‘Űˆă—Ă•ŸŽƒ‘ĺŠwŒöŠJuŔ (2019/1/16), “Œ‹ž.

733331. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ASTŠˆ“Ž‚ĚŒťó‚Ɖۑč. Źź•q˛1,2 (1Š´őŠÇ—Žş, 2–ňÜ•”): ‘Š–ÍŒ´Š´őÇƒZƒ~ƒi[ (2018/11/9), ‘Š–ÍŒ´.

H29”N“xˆČ‘O•Ş

[’˜@‘]

H29-620028. [Šwp‘ (•Ş’SŽˇ•M)]yup-to-date Žq‚Ç‚ŕ‚ĚŠ´őÇz”÷ś•¨ABC: ‰ŠFƒuƒhƒE‹…‹Ű‚Ě×‹ŰŠw“I“Á’Ľ, p.48-52. “ń–{–öL1-3, ‰Ô–؏G–ž3 (1Š´őŠÇ—Žş, 2—ŐŒŸ•”, 3ś–˝‰ČŠwŒ¤‹†ŠŠ´ő§ŒäŒ¤‹†ƒZƒ“ƒ^[), ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ, “Œ‹ž, 2018/1”­s.


f—Ïî•ńŠÇ—Žş


—Տ°S—Žş


ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZƒ“ƒ^[


ŠÉ˜aƒPƒAŽş


ˆÚAˆă—ĂŽx‰‡Žş


–k—˘‘ĺŠw“Œ•a‰@

“Œ•a‰@ŠĹŒě•”

[Šwp˜_•ś]

522225. [uŔ]y“ÁW: ˆę•ŕć‚đ–ÚŽw‚ľ‚čĕ]‰ż@‚ą‚ę‚Š‚ç‚ĚMRSAŠ´ő‘΍ôzĄPrevention MRSAŠ´ő‘΍ô‚̍ŐVƒGƒrƒfƒ“ƒX@2) •W€—\–hô‚ƐڐG—\–hô‚Ěƒoƒ‰ƒ“ƒX|ŠCŠO‚Ĺ‚Ěl‚Ś•ű‚đŠÜ‚ß‚Ä. “Ą–Ř‚­‚ÉŽq1,2 (1“Œ•a‰@ŠĹŒě•”, 2Š´őŠÇ—Žş): Š´ő‘΍ôICTƒWƒƒ[ƒiƒ‹2018/10; 13 (4): 289-93.

[’˜@‘]

620277. [Šwp‘ (•Ş’SŽˇ•M)]yƒAƒZƒXƒƒ“ƒg‚É‹­‚­‚Č‚éŠĹŒěf’f@Ž–—á‚Ĺ‚í‚Š‚é ’†”͈͗˜_‚Ĺ‚í‚Š‚é ŠÄ¸‚ĚŽ‹“_‚Ĺ‚í‚Šz‘ć2Í Ž–—á‚ĹŠw‚ÔƒAƒZƒXƒƒ“ƒg@6. I––ŠúŽ–—á…@, p.126-43. Źˆä”ü•ä (“Œ•a‰@ŠĹŒě•”), •Ň: •“c—TŽq, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2018/10”­s.

620278. [Šwp‘ (•Ş’SŽˇ•M)]yNANDA-I-NIC-NOC‚ĚŠî–{‚đ—‰đ‚ˇ‚é@ĹV‚Ě“ŽŒü‚ĆŠĹŒěŒv‰ć‚Ö‚ĚŠˆ—p‚ĚŽd•ű (‘ć2”Ĺ)zIV. ŠĹŒěŒv‰ć‚ÉNANDA-I-NIC-NOC‚đ‚ǂ̂悤‚ÉŽg‚¤‚Ě‚Š@2. Ž–—á‚ĚŠĹŒěŒv‰ć‚ÉNANDA-I-NIC-NOC‚đŠˆ—p‚ˇ‚é@I––Šú‚ĚŽ–—á, p.232-58. Źˆä”ü•ä (“Œ•a‰@ŠĹŒě•”), •Ň: •“c—TŽq, ˆăŠw‘‰@, “Œ‹ž, 2019/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

7231023. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ALSFRS-R‚É•R•t‚Ż‚ľ‚˝–âf•\‚Ć‘˝EŽí‹Ś“­‚É‚ć‚éƒPƒAƒ}ƒbƒv‚̍쐬. –ě“c—ÁŽq1, ‚‹´—R”ü1, ‰iˆä^‹MŽq2, •x‰i“Ţ•Ű”ü2, ˜a‰Ć•‚Šó1, âV“Ą^Žě1, V•á’mŒb1, ´…’G2, ě˜Q@•ś2, —é–Ř—Ç˜a3, Œy•”“ÖŽq3, ˆŔ“cŘ•ä3, źŽR˜a—˜2 (1“Œ•a‰@ŠĹŒě•”, 2_Œo“ŕ, 3“Œ•a‰@ƒŠƒnƒrƒŠ•”): ‘ć59‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2018/5/25), ŽD–y.

7231024. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) dÇSgáŠQŽ™‚ĚƒVƒ‡[ƒgƒXƒeƒB—˜—p‚É”ş‚¤‰Ć‘°‚̐śŠˆ‚̕ωť. “cK–žŽq1, ˆÉĽ–źŽáŘ1 (1“Œ•a‰@ŠĹŒě•”): ‘ć44‰ń“ú–{dÇSgáŠQŠw‰ďŠwpW‰ď (2018/9/28), “Œ‹ž, ‘ć44‰ń“ú–{dÇSgáŠQŠw‰ďŽ 2018/8; p.266.

7231025. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŰHš‹‰şáŠQƒPƒAŒüă‚Ö‚ĚŽć‚č‘g‚݁`‘ź—Ěˆć‚Ě”F’čŠĹŒěŽt‚Ć‘˝EŽí‚Ć‚Ě‹Ś“­`. ŒşŠC‘׎q1, ˛“Ą—ÇŽq1 (1“Œ•a‰@ŠĹŒě•”): NPO–@l“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ŠĹŒěŠw‰ď‘ć30‰ńŠwp‘ĺ‰ď (2018/11/23), •xŽR, “ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ŠĹŒěŠw‰ď‘ć30‰ńŠwpW‰ď´˜^ 2018/11; p.98.

733332. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆÓ—~‚đŽć‚č–ß‚ľ‚˝”F’mÇŠłŽŇ‚Ö‚ĚŠĹŒěŽŔ‘H`ƒp[ƒ\ƒ“EƒZƒ“ƒ^[ƒhEƒPƒA‚̉ˆ‚Á‚˝U‚č•Ô‚č`. “ĄŽ}@K1, –Ń’Ë—R”üŽq1, ŒşŠC‘׎q1 (1“Œ•a‰@ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), _“ސě, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€´˜^ 2018/12; 43.

733333. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠłŽŇ‚ĆŠĹŒěŽt‚̐M—ŠŠÖŒW\’z‚̉ߒö‚É‚¨‚Ż‚éŠĹŒěŽt‚Ě–đŠ„`ƒyƒvƒƒE‚ĚŠĹŒě—˜_‚đ—p‚˘‚˝ŠĹŒě‚̐U‚č•Ô‚č`. ź“c”üç (“Œ•a‰@ŠĹŒě•”): ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2018/12/8), _“ސě, ‘ć18‰ń–k—˘ŠĹŒěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€´˜^ 2018/12; 44.

733334. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆă—Ă‚Ć•ŸŽƒ‚đ•š‚šŽ‚Â’†ŠÔŽ{Ý‚Ĺ‚ĚŽć‚č‘g‚݁`dÇSgáŠQŽ™‚ĚƒVƒ‡[ƒgƒXƒeƒC—˜—p‚É”ş‚¤‰Ć‘°‚̐śŠˆ‚̕ωť‚ÉĹ“_‚đ‚ ‚Ä‚Ä`. “cK–žŽq1, ˆÉĽ–źŽáŘ1 (1“Œ•a‰@ŠĹŒě•”): _“ŢěŒ§ŠĹŒě‹Ś‰ď‘Š–ÍŒ´Žx•”ŽĺĂŠĹŒěŒ¤‹†”­•\‰ď (2019/1/18), _“ސě, 2018”N“xŠĹŒěŒ¤‹†W˜^W 2019/1; 28.


“Œ•a‰@—Տ°ŒŸ¸•”

[Šwp˜_•ś]

320048. [Ç—á•ń] ‚“x—zˆł‘¤‚Ƀs[ƒN‚đŽŚ‚ľ‚˝ƒeƒBƒ“ƒpƒmƒOƒ‰ƒ€‚Ě—Ő°“I”wŒi‚ÉŠÖ‚ˇ‚錟“˘. Ź”Ś@i1, Šâ|‹Ô‰›1, –ł‘ž˜Y1, ˛‹´‹v”üŽq, “•űLˆę1, Îˆä’źm2, Žë–ě—Lě3 (1—ŐŒŸ•”, 2ˆă—ÉqśŠw•”, 3—ŐŒŸŠw): ˆăŠwŒŸ¸ 201/10; 67 (5): 791-6.

[Šw‰ďEŒ¤‹†‰ď“™]

733335. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚“x—zˆł‚đŽŚ‚ľ‚˝Tympanogram‚Ě—Ő°“I”wŒi‚ɂ‚˘‚Ä. Ź”Ś@i1,2, Šâ|‹Ô‰›1, –ł‘ž˜Y1, “•űLˆę1,2, Žë–ě—Lě1,3, Îˆä’źm4,5 (1—ŐŒŸ•”, 2“Œ•a‰@—ŐŒŸ•”, 3—ŐŒŸŠw, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5ˆă—ÉqśŠw•”): ‘ć29‰ń_“ŢěŒ§—Տ°ŒŸ¸ˆăŠw‰ď‘ĺ‰ď (2018/6/2), ‰Ą•l, —Տ°ŒŸ¸ˆăŠw‰ď (—Տ°•a—) ‘ć29‰ń_“ŢěŒ§—Տ°ŒŸ¸ˆăŠw‰ď, ‘ĺ‰ď´˜^W 2018; p.13.

733336. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) tÇ”­Ç‘O“œ”A•aƒ‰ƒbƒg‚Ě”A’†ƒ~ƒgƒRƒ“ƒhƒŠƒAƒ^ƒ“ƒpƒNŽż‚ɂ‚˘‚Ä. Ź“‡@”Ł1, ˆä–{–ž”ü2, •čËŽj2, ‰Ąęł“T2, “y•M’qť3, Ź”Ś@i3,4, —é–؉p–ž5, Žsě‘¸•ś2, •Đ‹Ë^l2, Îˆä’źm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3—ŐŒŸ•”, 4“Œ•a‰@—ŐŒŸ•”, 5–k—˘‘ĺŠw•ŰŒŻ‰qśę–ĺŠw‰@): ‘ć31‰ń–k—˘‘ĺŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€/‘ć21‰ń–k—˘”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2018/8/8-9), ‘Š–ÍŒ´.


“Œ•a‰@–ňÜ•”

[Šwp˜_•ś]

110215. [Œ´’˜] Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy. Iizuka N1, Morita A1, Kawano C1, Mori A1, Sakamoto K1, Kuroyama M1,2, Ishii K1, Nakahara T1: J Pharmacol Sci 2018/11; 138 (3): 203-8. (•ŽR­ˆę1,2: 1–ňŠw•”, 2“Œ•a‰@–ňÜ•”)

[’˜@‘]

620279. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…@‡–°–ň, p.12-9. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620280. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…AR¸_•a–ň, p.20-9. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620281. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…BR‚¤‚–ň, p.30-7. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620282. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…CR‚Ä‚ń‚Š‚ń–ň, p.38-47. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620248. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…Dƒp[ƒLƒ“ƒ\ƒ“•aŽĄ—Ă–ň, p.48-57. •˝ŽR•Ži1, ‚‹´”ü—R‹I2, •ŽR­ˆę3 (1–ňÜ•”, 2Œł“Œ•a‰@–ňÜ•”, 3“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę3, •ŇW‹Ś—Í: ě–ěçq3, Žć—S‰î3, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620283. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…ER”F’mÇ–ň, p.58-63. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620284. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…F’Á’É–ň, p.64-71. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620285. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…G~ˆł–ň, p.72-9. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620286. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…H‹•ŒŒŤSŽžŠłŽĄ—Ă–ň, p.80-5. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620287. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…IR•sŽ–Ź–ň, p.86-93. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620288. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…J—˜”A–ň, p.94-101. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620289. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…KÁ‰ťŤ’×ᇎĄ—Ă–ň, p.102-9. Ô—ä‚ż‚Š]1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620290. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…L“œ”A•aŽĄ—Ă–ň, p.110-9. ”ň“c—[‹I1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620291. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…MRŒŒđ–ň, p.120-9. Žć—S‰î1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620292. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…N’{”AáŠQE”r”AáŠQŽĄ—Ă–ň, p.130-7. Ô—ä‚ż‚Š]1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620293. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚̍ě—p‚ŞŽč‚ÉŽć‚é‚悤‚É‚í‚Š‚é–{@ŠG‚ĹŒŠ‚é–ň—Šwz…Obó‘B‹@”\ˆŮíŽĄ—Ă–ň, p.138-44. ”ň“c—[‹I1, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, •ŇW‹Ś—Í: ě–ěçq1, Žć—S‰î1, ‚ś‚Ů‚¤, “Œ‹ž, 2018/9”­s.

620294. [Šwp‘ (•Ş’SŽˇ•M)]y‘ąˆá‚˘‚Ş•Ş‚Š‚éI“ŻŽíE“ŻŒř–ň@‰ü’ů‘ć2”Łz3Í ƒp[ƒLƒ“ƒ\ƒ“•aŽĄ—Ă–ň, p.33-49. ‚‹´”ü—R‹I1, •ŽR­ˆę2 (1Œł“Œ•a‰@–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę2, ‘ĺ’J“š‹P3 (3ˆÇ‰_“°•a‰@), “ě]“°, “Œ‹ž, 2018/10”­s.

620295. [Šwp‘ (•Ş’SŽˇ•M)]y‘ąˆá‚˘‚Ş•Ş‚Š‚éI“ŻŽíE“ŻŒř–ň@‰ü’ů‘ć2”Łz4Í “‡Ž¸’˛ÇŽĄ—Ă–ň, p.50-67. •ŽR­ˆę1, Ô—ä‚ż‚Š]1 (1“Œ•a‰@–ňÜ•”), •Ň: •ŽR­ˆę1, ‘ĺ’J“š‹P2 (2ˆÇ‰_“°•a‰@), “ě]“°, “Œ‹ž, 2018/10”­s.

620296. [Šwp‘ (•Ş’SŽˇ•M)]y‘ąˆá‚˘‚Ş•Ş‚Š‚éI“ŻŽíE“ŻŒř–ň@‰ü’ů‘ć2”Łz5Í R”F’mÇ–ň, p.68-78. ”ň“c—[‹I1, •˝ŽR•Ži2 (1“Œ•a‰@–ňÜ•”, 2–ňÜ•”), •Ň: •ŽR­ˆę1, ‘ĺ’J“š‹P3 (3ˆÇ‰_“°•a‰@), “ě]“°, “Œ‹ž, 2018/10”­s.

620297. [Šwp‘ (•Ş’SŽˇ•M)]yPocket Drugs 2019zŠŕ@RˆŤŤŽîᇖň (‘ăŽÓhR–ň), p.479-91. ‰Ş–{Œb”üŽq1, Źň˜aŽO˜Y2 (1“Œ•a‰@–ňÜ•”, 2Á‰ťŠí“ŕ), ŠÄC: •ŸˆäŽŸ–î3 (3š˜H‰Á‘Ű•a‰@), •Ň: ŹźNG4, “n糗TŽi5 (4ŒQ”n‘ĺŠw‘ĺŠw‰@, 5•lźˆă‰Č‘ĺŠw/‘—§‘Űˆă—ĂŒ¤‹†ƒZƒ“ƒ^E—Տ°Œ¤‹†ƒZƒ“ƒ^[), ˆăŠw‘‰@, “Œ‹ž, 2019/1”­s.

620298. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2019@–ňÜ‘I‘đ‚Əˆ•ű‚Ěƒ|ƒCƒ“ƒgz–ňÜƒŠƒXƒg. •ŽR­ˆę1, ‘ź41–ź (1“Œ•a‰@–ňÜ•”), ŠÄC: ‚‹vŽj–›2 (2ŽŠŽĄˆă‰Č‘ĺŠw), •Ň: –xł@“ń3, ›–ěŒ’‘ž˜Y2, –ĺ˜e@F4, ŠŁ@ŒŤˆę5, —с@š—m6 (3‘ĺă‘ĺŠw, 4“Œ‹ž‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č, 5‹ž“s–ň‰Č‘ĺŠw, 6ŒŐ‚Ě–ĺ•a‰@), ‚ś‚Ů‚¤, “Œ‹ž, 2019/1”­s.

620255. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2019@–ňÜ‘I‘đ‚Əˆ•ű‚Ěƒ|ƒCƒ“ƒgz“ŻŒř–ň”äŠr•\, p.24-6. p.59. p.85. p.110. p.143. p.160. p.199. p.321. p.374-7. p.464-5. p.488. p.533-4. p.632. p.656. p.694. p.775. p.810. p.825. p.931-2. p.1137. p.1152. p.1185-6. p.1237. p.1291. •˝ŽR•Ži1, ”ň“c—[‹I2, ě–ěçq2, •ŽR­ˆę2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), ŠÄC: ‚‹vŽj–›3 (3ŽŠŽĄˆă‰Č‘ĺŠw), •Ň: –xł@“ń4, ›–ěŒ’‘ž˜Y3, –ĺ˜e@F5, ŠŁ@ŒŤˆę6, —с@š—m7 (4‘ĺă‘ĺŠw, 5“Œ‹ž‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č, 6‹ž“s–ň‰Č‘ĺŠw, 7ŒŐ‚Ě–ĺ•a‰@), ‚ś‚Ů‚¤, “Œ‹ž, 2019/1”­s.

620299. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2019@–ňÜ‘I‘đ‚Əˆ•ű‚Ěƒ|ƒCƒ“ƒgzR‹Ű–ň“K‰ž‹ŰŽíˆę——, •t2-15. •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”), ŠÄC: ‚‹vŽj–›2 (2ŽŠŽĄˆă‰Č‘ĺŠw), •Ň: –xł@“ń3, ›–ěŒ’‘ž˜Y2, –ĺ˜e@F4, ŠŁ@ŒŤˆę5, —с@š—m6 (3‘ĺă‘ĺŠw, 4“Œ‹ž‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č, 5‹ž“s–ň‰Č‘ĺŠw, 6ŒŐ‚Ě–ĺ•a‰@), ‚ś‚Ů‚¤, “Œ‹ž, 2019/1”­s.

620300. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz“ŻŒř–ň‚đ”äŠr‚ˇ‚邤‚Ś‚Ĺ‚Ť‚ż‚ń‚Ć—‰đ‚ľ‚Ä‚¨‚Ť‚˝‚˘8‚Â‚ĚƒL[ƒ[ƒh, p.125. p.207. p.243. p.257. p.275. ě–ěçq1, ”ň“c—[‹I1 (1“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620301. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz1. Á‰ťŤ’×ᇎĄ—Ă–ň, p.1-22. ‚‹´”ü—R‹I1, ‘ŠŕV­–ž2, •ŽR­ˆę3 (1Œł–k—˘‘ĺŠw“Œ•a‰@–ňÜ•”, 2‘Š–Í‘ä•a‰@, 3“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę3, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620302. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz2. 5-HT3Žó—e‘̝hR§“f–ň, p.23-32. Ô—ä‚ż‚Š]1, •ŽR­ˆę1, ě–ěçq1 (1“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620303. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz4. ‰ßŠˆ“ŽäNă÷ŽĄ—Ă–ň, p.57-70. •ŽR­ˆę1, ‚‹´”ü—R‹I2, Ô—ä‚ż‚Š]1, •˝ŽR•Ži3, Vˆä–œ—Žq1 (1“Œ•a‰@–ňÜ•”, 2Œł“Œ•a‰@–ňÜ•”, 3–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620304. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz5. ‘O—§‘B”ě‘ĺÇE”r”AáŠQŽĄ—Ă–ň (ƒż1ŽŐ’f–ň), p.71-82. •ŽR­ˆę1, ‚‹´”ü—R‹I2, •˝ŽR•Ži3, Vˆä–œ—Žq1 (1“Œ•a‰@–ňÜ•”, 2Œł“Œ•a‰@–ňÜ•”, 3–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620258. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz8. œ‘e頏ǎĄ—Ă–ň (ŒoŒűƒrƒXƒzƒXƒzƒl[ƒgťÜ), p.133-48. ‘O“cŽŔ‰Ô1, •ŽR­ˆę2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620305. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz10. ƒAƒŒƒ‹ƒM[ŤŽžŠłŽĄ—Ă–ň (ƒƒfƒBƒG[ƒ^[Žó—e‘̝hR–ň), p.167-82. _‹{’źŽq1, •˝ŽR•Ži2 (1“Œ•a‰@–ňÜ•”, 2–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620259. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz11. ƒAƒŒƒ‹ƒM[ŤŒ‹–ŒŽžŠłŽĄ—Ă–ň (“_Šá–ň), p.183-92. •˝ŽR•Ži1, ŹŒ´”ü]2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620260. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz14. —ΓŕáŽĄ—Ă–ň (“_Šá–ň), p.235-48. •˝ŽR•Ži1, ŹŒ´”ü]2 (1–ňÜ•”, 2“Œ•a‰@–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę2, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620306. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚŠłŽŇE‚ą‚ĚÇ—á‚É‚˘‚ż‚΂ń“KŘ‚Č–ňÜ‚Ş‘I‚ׂé@“ŻŒř–ň”äŠrƒKƒCƒh2 ‘ć2”Łz15. ƒjƒ…[ƒLƒmƒƒ“ŒnR‹Ű–ň, p.249-64. ŹŒ´”ü]1, •˝ŽR•Ži2 (1“Œ•a‰@–ňÜ•”, 2–ňÜ•”), •ŇW‘ă•\: •ŽR­ˆę1, ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

620307. [Šwp‘ (’P’˜)]yŽžŠł‚Ć–ň‚̍ě—p‚Ş‚Đ‚Ć–Ú‚Ĺ‚í‚Š‚é ‘ć2”Ł@‰‚ß‚Ěˆę•ŕ‚ÍŠG‚ĹŠw‚Ô–ň—Šwz•ŽR­ˆę1, Žć—S‰î1 (1“Œ•a‰@–ňÜ•”), ‚ś‚Ů‚¤, “Œ‹ž, 2019/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

7231026. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “ŕˆöŤƒJƒ“ƒWƒ_Šá“ŕ‰Š‚Ě”­ÇŠëŒŻˆöŽq‚ÉŠÖ‚ˇ‚錤‹†. ăŕ_•ü—m1, Žć—S‰î2, ”ň“c—[‹I1,2, ě–ěçq1,2, •˝ŽR•Ži1,3, Žs糋`Í4, •ŽR­ˆę1,2 (1–ňŠw•”, 2“Œ•a‰@–ňÜ•”, 3–ňÜ•”, 4_“ސ쎕‘ĺ): ˆă—Ă–ňŠwƒtƒH[ƒ‰ƒ€2018/‘ć26‰ńƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (2018/6/24), “Œ‹ž, ˆă—Ă–ňŠwƒtƒH[ƒ‰ƒ€2018@‘ć26‰ńƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€u‰‰—vŽ|W 2018/6; p.253

7231027. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) •a‰@ŽŔ–ąŽŔK‚ÉŒü‚Ż‚˝Ž–‘OŠwKuÇ—á‚ÉŠî‚Ă‚­–ň•¨ŽĄ—Ă‚Ě•]‰żv‚ÉŠÖ‚ˇ‚éŽŔK‚Ě—L—pŤ. ”ň“c—[‹I1,2, •˝ŽR•Ži1,3, ě–ěçq1,2, Œú“cKˆę˜Y1,3, •ŽR­ˆę1,2 (1–ňŠw•”, 2“Œ•a‰@–ňÜ•”, 3–ňÜ•”): ‘ć28‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2018/11/23), _ŒË.

733336. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “d‹C‚Ż‚˘‚ę‚ń—Ă–@“Kł‰ť‚ÉŒü‚Ż‚˝–ňÜŽt‚É‚ć‚éŽć‚č‘g‚Ý. ”ň“c—[‹I1, ÎŽRËŽq2, Ô—ä‚ż‚Š]2, ‹ß“ĄĂ1, Ä“Ą”ü—é1, ě–ěçq1, ‹{‰Ş@“™3, •ŽR­ˆę1 (1“Œ•a‰@–ňÜ•”, 2–ňÜ•”, 3¸_): –k—˘‘ĺŠw4•a‰@–ňÜ•”‡“ŻŒ¤‹†‰ď (2018/6/9), ‘Š–ÍŒ´.

733337. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ¸_‰Č–ň•¨—Ă–@‚É‚¨‚Ż‚é•ž–ňŽw“ą‚Ěƒ|ƒCƒ“ƒg‚Ć–ňÜŽt‚ĚŠÖ‚í‚č. ”ň“c—[‹I1,2 (1“Œ•a‰@–ňÜ•”, 2–ňŠw•”): –k—˘‘ĺŠw–ňŠw•”śŠUŠwKƒZƒ~ƒi[ (2018/6/16), ”’‹ŕ.

733338. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) f—Ă•ńV‰ü’č‚É”ş‚¤¸__Œo‰Č“ü‰@Ç—á‚̍R‚¤‚–ňˆ•űŽŔ‘Ô. ŽáŽR”ü•ä1, ”ň“c—[‹I1,2, •˝ŽR•Ži1,3, ‹{‰Ş@“™4, •ŽR­ˆę1,2 (1–ňŠw•”, 2“Œ•a‰@–ňÜ•”, 3–ňÜ•”, 4¸_): “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć48‰ńŠwp‘ĺ‰ď (2018/8/25), ‰F“s‹{, “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć48‰ńŠwp‘ĺ‰ďu‰‰—vŽ|W 2018/8; p.248.

733339. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) R¸_•a–ň‚ĚŽí—Ţ‚ĆŒëš‹Ť”x‰Š‚Ě”­Çó‹ľ‚ÉŠÖ‚ˇ‚é’˛¸. ŽR‰ş^—R1, ě–ěçq1,2, ”ň“c—[‹I1,2, Žć—S‰î2, ŹŒ´”ü]2, ‘ęŕV‹B–î3, ‘ĺÎ@’q3, ‹{‰Ş@“™3, •ŽR­ˆę1,2 (1–ňŠw•”, 2“Œ•a‰@–ňÜ•”, 3¸_): “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć48‰ńŠwp‘ĺ‰ď (2018/8/25), ‰F“s‹{, “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć48‰ńŠwp‘ĺ‰ďu‰‰—vŽ|W 2018/8; p.248.

733340. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “‡Ž¸’˛Ç‚Ě–ň‚ɂ‚˘‚Ä’m‚č‚Ü‚ľ‚傤. ”ň“c—[‹I1,2 (1“Œ•a‰@–ňÜ•”, 2–ňŠw•”): •˝Ź30”N“x¸_á‚Ş‚˘‰Ć‘°‹łŽş (2018/10/17), “Ą‘ň.

733341. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) R¸_•a–ň‚ĆŒëš‹Ť”x‰Š‚ÉŠÖ‚ˇ‚é’˛¸. ě–ěçq1,2, ”ň“c—[‹I1,2, •ŽR­ˆę1,2 (1“Œ•a‰@–ňÜ•”, 2–ňŠw•”): ‘ć41‰ń”’‹ŕƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/18), “Œ‹ž.


“Œ•a‰@—Տ°S—Žş

[Šwp˜_•ś]

120050. [Œ´’˜] ŹlASD‚É‚¨‚Ż‚éP-FƒXƒ^ƒfƒB‚đ—p‚˘‚˝W’cˆę’v“x (GCR) ‚ĆASD“ÁŤ‚Ć‚ĚŒŸ“˘. •űŒcŽO˜Y1, ˆäăŸ•v2, ‘ęŕV‹B–î2, ˛ŽR‰p”ü2, ’Ăř“S–ç3, Aź”ü”ż1, ‹{‰Ş@“™1,2,3 (1“Œ•a‰@—Տ°S—Žş, 2¸_, 3—Տ°S—Žş): ¸_ˆăŠw 2019/2; 61 (2): 205-12.

310029. [Ç—á•ń] The Effectiveness of Cognitive Behavioral Therapy With Mindfulness and an Internet Intervention for Obesity: A Case Series. Ogata K1,2, Koyama KI2,3, Amitani M2, Amitani H2, Asakawa A2, Inui A2: Front Nutr 2018/6; 5: 56. (•űŒcŽO˜Y1,2, ŹŽRŒ›ˆę˜Y2,3, –Ô’J^—Œb2, –Ô’J“Œ•ű2, óě–žO2, ŠŁ@–ž•v2: 1“Œ•a‰@—Տ°S—Žş, 2Ž­Ž™“‡‘ĺŠw‘ĺŠw‰@, 3•Ÿ‰ŞŒ§—§‘ĺŠw)

[’˜@‘]

620308. [Šwp‘ (•Ş’SŽˇ•M)]y¸_‰Č—Տ°144‚ĚQ•A (¸_‰ČŽĄ—ĂŠw33ŠŞ‘Š§†)z‘ć11Í: ŒŸ¸@Q94. S—ŒŸ¸‚ĚŒ‹‰Ę‚𕡂˘‚˝ŠłŽŇ‚ł‚ń‚Ş, •”‰Ž‚É–ß‚Á‚Ä‚Š‚獆‹ƒ‚ł‚ę‚Ä‚˘‚˝‚ť‚¤‚Ĺ‚ˇ. ‚ą‚ĚŒă‚ĚƒtƒHƒ[‚͂ǂ̂悤‚É‚ˇ‚ę‚΂悢‚Ĺ‚ľ‚傤‚Š? p.218-9. •űŒcŽO˜Y1 (1“Œ•a‰@—Տ°S—Žş), •Ň:u¸_‰ČŽĄ—ĂŠwv•ŇWˆĎˆő‰ď, •ŇW‹Ś—Í: ‘ĺÎ@’q2, ‰ęŒĂ—E‹P, ’†‘O@‹M (2¸_), Ż˜a‘“X, “Œ‹ž, 2018/11”­s.